Henoch-Schonleln Purpura: HTTQSJL

AR01431
3. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and

BNT162b2 mRNA vaccines in a patient with multiple sclerosis treated with
teriflunomide: https;//pubmed.ocbi.olm,nih,goy/34696248/
Henoch-Schonleln Purpura
Affects the small blood vessels of the skin, joints, intestines and kidneys. It's most common
before the age of seven but can affect anyone. A disorder causing inflammation and
bleeding in the small blood vessels.
1. A rare case of Henoch-Sch0nlein purpura after a case report of COVID-19 vaccine:

htlps:/Jpubmed .ncbi.nlm .n ih. gov/34518812/
2. Henoch-Sch0nlein purpura occurring after vaccination with COVID-19: https://
pubmed.ncbi,nlm,nih,qov/34247902/-
3. Henoch-Sch0nlein purpura following the first dose of COVID-19 viral vector vaccine:
case report: https://pubmed.ncbi.nlm.nih.qov/34696186/.
Bleeding episodes
Major episodes include most joint bleeds, bleeding into large muscles, muscle bleeds with
signs of compartment syndrome, life-threatening bleeds, and surgery. These usually
require a 70% - 100% correction and more than one infusion. The exact dose will depend
on the individual and on HTC policy.
1. Blood clots and bleeding episodes after BNT162b2 and ChAdOx1 nCoV-19
vaccination: analysis of European data: https:llwww.sciencedirect.com/scjeoce/
article/pii/S0896841121 000937
2. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large
population-based cohort study: httos:l/pubmed,ncbi,nlm,nih,gov/34479760/.
3. Association between ChAdOx1 nCoV-19 vaccination and bleeding episodes: large
population-based cohort study: https://pubmed.ncbi.nlm.nih.qov/34479760/.
Cutaneous Adverse Effects
Also known as toxidermia, are skin manifestations resulting from systemic drug
administration. These reactions range from mild erythematous skin lesions to much more
severe reactions such as Lyell's syndrome.
~-------------------------------------~----
1. Cutaneous adverse effects of available COVID-19 vaccines: httQsJL
oubmed.ncbi.nlm.nih,qovf34518015/
2. Rare cutaneous adverse effects of COVID-19 vaccines: a case series and review of
the literature: https:/Jpubmed.ncbi.nlm.nih.qov/34363637/
3. Cutaneous adverse reactions of 35,229 doses of COVID-19 Sinovac and
AstraZeneca vaccine COVID-19: a prospective cohort study in health care workers:
https://pubmed.ncbi.nlm.nih.gov/34661934/
AR01432
Skin Reactions
An allergic reaction can cause rash, itching, burning, redness, bumps, hives, and swelling.
1. A case series of skin reactions to COVID-19 vaccine in the Department of

Dermatology at Loma Linda University: httos·J/pubmed,ocbi,olm,oib,goy/34423106/
2. Skin reactions reported after Modema and Pfizer's COVID-19 vaccination: a study
based on a registry of 414 cases: https://pubmed,ncbi.nlm.nih.gov/33838206/
3. Skin reactions after vaccination against SARS-COV-2: a nationwide Spanish cross-
sectional study of 405 cases: bttps:l/pubroed.ncbi.nlm.nib.gov/34254291/
Coagulopathles (Includes term: Prothrombotic)
Is often broadly defined as any derangement of hemostasis resulting in either excessive

bleeding or clotting, although most typically it is defined as impaired clot fom,ation.
1. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of

SARS-CoV-2 spike protein and adenovirus vector-activated signaling pathways:
https:1/oubmed .ocbi,olm.nih .goY134639132/
2. Diffuse prothrombotic syndrome after administration of ChAdOx1 nCoV-19 vaccine:
case report: https:{lpybmed.ncbi.nlm,nih,qov/34615534/
3. Calcaterra, G., Bassareo, P. P., Barilla, F., Romeo, F., & Mehta, J. L. (2022).
Concerning the unexpected prothrombotic state following some coronavirus disease
2019 vaccines. J Cardiovasc Med (Hagerstown), 23(2), 71-74. doi:10.2459/JCM,
0000000000001232. httos://www.ncbi-nlm.nih.gpv/pybmed/34366403
Multlsystem Inflammatory Syndrome (includes terrri: Autoantibody Release)
A condition where different body parts can become inflamed, including the heart, lungs,
kidneys, brain, skin, eyes, or gastrointestinal organs .
.. ------------------------~
1. Post-vaccination multisystem inflammatory syndrome in adults without evidence of

prior SARS-CoV-2 infection: https://pubmed.ncbi.nlm.nih.gov/34852213/
2. Buchhorn, R., Meyer, C., Schulze-Forster, K., Junker, J., & Heidecke, H. (2021).
Autoantibody Release in Children after Corona Virus mRNA Vaccination: A Risk
Factor of Multisystem Inflammatory Syndrome? Vaccines (Basel), 9(11 ). doi:10.3390/
vaccines9111353. https://www.ncbi.nlm.nih.gov/pubmed/34835284
AR01433
3. Chai, Q., Nygaard, U., Schmidt, R. c., Zaremba, T., Moller, A. M., & Thorvig, C. M.
(2022). Multisystem inflammatory syndrome in a male adolescent after his second
Pfizer-BioNTech COVID-19 vaccine.Acts Paediatr, 111(1).125-127. doi:10.1111/apa.
16141.
Vogt-Koyanagi-Harada syndrome
A rare disorder of unknown origin that affects many body systems, including as the eyes,
ears, skin, and the covering of the brain and spinal cord (the meninges). The most
noticeable symptom is a rapid loss of vision.
1. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19

(AZD1222) vaccination: https:llpubroed,ncbi,nlm,oih,gov/34462013/.
2. Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years,
after anti-SARS-CoV-2 vaccination: https://pubmed.ncbi.nlm.nih.gov/34224024/
Capillary l,.eak Syndrome (Includes Term: Systemic Capillary Extravasation

Syndrome)
A rare disorder by acute and severe recurrent attacks associated with a rapid fall in blood
pressure as a result of fluid leaks from smaller vessels called capillaries. Attacks often last
several days and require emergency care. They are sometimes life threatening. SCLS
occurs most often in adults and the disease is very rare in children.
------ --·· --- - . --- -· - - - - - - - - - - - - - - - -
1. Fatal systemic capillary leak syndrome after SARS-COV-2 vaccination in a patient
with multiple myeloma: https://pubmed.ncbi,nlm,oih,goy/34459725/
2. Systemic capillary extravasation syndrome following vaccination with ChAdOx1
nCOV-19 (Oxford-AstraZeneca): bttps://pubmed,ncbi,nlm,nih,gov/3436272V
Systemic Lupus Erythematosus
An autoimmune disease in which the immune system attacks its own tissues, causing
widespread inflammation and tissue damage in the affected organs. It can affect the joints,
skin, brain, lungs, kidneys, and blood vessels. Treatment can help, but this condition can't
be cured.
~-------------------------- - ------ ----~---·-- -
1. Induction and exacerbation of subacute cutaneous lupus erythematosus

erythematosus after mRNA- or adenoviral vector-based SARS-CoV-2 vaccination:
https;//pubmed.ncbi.nlm.nih.gov/34291477/
2. Ntouros, P.A., Vlachogiannis, N. I., Pappa, M., Nezos, A., Mavragani, C. P.,
Tektonidou, M. G., ... Sfikakis, P. P. (2021 ). Effective DNA damage response after
acute but not chronic immune challenge: SARS-CoV-2 vaccine versus Systemic
Lupus Erythematosus. Clin lmmunol, 229, 108765. doi:10.1016fj.clim.2021.108765.
httos:llwww,ocbi,olm,nih.aov/pubmed/34089859
IPetechl~a (also includes: Petechial rash)

AR01434
Tiny purple, red, or brown spots on the skin. They usually appear on your arms, legs,
stomach, and buttocks. You might also find them inside your mouth or on your eyelids.
These pinpoint spots can be a sign of many different conditions - some minor, others
serious. They can also appear as a reaction to certain medications. Though petechiae look
like a rash, they're actually caused by bleeding under the skin.
1. Petechiae and peeling of fingers after immunization with BTN162b2 messenger RNA
(mRNA)-based COVID-19 vaccine: httos://oubroed,ocbi.nlm.nih,govi34513435/
2. Petechial rash associated with CoronaVac vaccination: first report of cutaneous side
effects before phase 3 results: https://ejhp.bmj.com/contenVearly/2021/05/23/
eihpharm-2021-002194
Purpura Annularls Telanglectodes
An uncommon pigmented purpuric eruption, which is characterized by symmetrical,

purpuric, telangiectatic, and atrophic patches with a predilection for the lower extremities
and buttocks.
·····-----·----------- ··----------------
1. Purpuric rash and thrombocytopenia after mRNA-1273 (Modem) COVID-19 vaccine:
https://www.ncbi.nlm.nih.goyJpmcJarticles/PMC7996471/
2. Generalized purpura annularis telangiectodes after SARS-CoV-2 mRNA vaccination:
httos:f{Qubmed. ncbi .aim .a ih,aov/3423671 Zf
Pulmonary Embolism
Pulmonary embolism is a blockage in one of the pulmonary arteries in your lungs. In most
cases, pulmonary embolism is caused by blood clots that travel to the lungs from deep
veins in the legs or, rarely, from veins in other parts of the body (deep vein thrombosis).
Because the clots block blood flow to the lungs, pulmonary embolism can be life-
threatening.
1. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson

& Johnson COVID-19 vaccine: httos:/Joubmed.ncbi.nlm.nih,aovi34261635f
2. A case of acute pulmonary embolism after immunization with SARS-CoV-2 mRNA:
https://pubmed.ncbi.nlm.nih.gov/344520281
Psoriasis
A chronic autoimmune condition that causes the rapid buildup of skin cells. This buildup of
cells causes scaling on the skin's surface. Inflammation and redness around the scales is
fairly common. Typical psoriatic scales are whitish-silver and develop in thick, red patches.
Sometimes, these patches will crack and bleed.
1. Onset I outbreak of psoriasis after Corona virus ChAdOx1 nCoV-19 vaccine (Oxford-
AstraZeneca I Covishield): report of two cases: httos:1/oubmed,ocbi,olm,nih,govi
34350668/
2. Exacerbation of plaque psoriasis after COVID-19 inactivated mRNAand BNT162b2
vaccines: report of two cases: bttps;l/pubmed,ncbLnlm.nib,qoy/34427024/
AR01435
MIiier Fisher Syndrome
A rare acquired neive disease related to Guillain-Barre syndrome (GBS). Features include
weakness of the eye muscles causing difficulty moving the eyes; impaired limb
coordination and unsteadiness; and absent tendon reflexes.
1. Miller Fisher syndrome after Pfizer COVID-19 vaccine: h11l2§iL

pubmed,ocbi.olm,oib,goy/3481772V.
2. Miller Fisher syndrome after 2019 BNT162b2 mRNAcoronavirus vaccination:~

pubmed.ncbi.nlm.nih.gov/34789193/.
Nephrotlc· Syndrome
Kidney disorder that causes your body to pass too much protein in your urine. Nephrotic
syndrome is usually caused by damage to the clusters of small blood vessels in your
kidneys that filter waste and excess water from your blood
1. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: b1tR§;Lt:

pubmed.ncbi.nlm.nib.gov/34250318/.
2. New-onset nephrotic syndrome after Janssen COVID-19 vaccination: case report
and literature review: http5://oubmed.ncbi.nlm.nih.gov/34342187/
Macroscopic Hematuria
Visible blood in the urine causing it to be discoloured pink, red, brownish-red or tea-
coloured.
1. Hematuria, a generalized petechlal rash and headaches after Oxford AstraZeneca

ChAdOx1 nCoV-19 vaccination: https://pubmed.ncbi.nlm.nih.gov/34620638/
2. A case of outbreak of macroscopic hematuria and lgA nephropathy after SARS-

CoV-2 vaccination: https:flpubmed.ocbi.nlm,oih,gov/33932458/
Bullolls Drug Eruption
Refers to adverse drug reactions that result in fluid-filled blisters or bullae. Blistering may
be localised and mild, or widespread and severe, even life-threatening.
1. Bullous drug eruption after the second dose of COVID-19 mRNA-1273 (Modems)
vaccine: Case report: bttps:l/www.sciencedirect,com/science/article/pii/
S1876034121001878.
AR01436
2. Widespread fixed bullous drug eruption after vaccination with ChAdOx1 nCoV-19:
https://pubmed.ncbi.nlm.nih.gov/34482558/
Hemophagocytlc lymphohlstlocytosls
An aggressive and life-threatening syndrome of excessive immune activation. It most

frequently affects infants from birth to 18 months of age, but the disease is also observed
in children and adults of all ages.
1. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19:

https:/Jpubmed.ncbi.nlm.nih.gov/34406660/.
2. Hemophagocytic lymphohistiocytosis following COVID-19 vaccination (ChAdOx1
nCoV-19): httos:lloubmed .ncbi.nlm.nih,gov/34862234/
Pulmonary Embolism
Pulmonary embolism is a blockage in one of the pulmonary arteries in your lungs. In most
cases, pulmonary embolism is caused by blood clots that travel to the lungs from deep
veins in the legs or, rarely, from veins in other parts of the body (deep vein thrombosis).
Because the clots block blood flow to the lungs, pulmonary embolism can be life-
threatening.
1. Isolated pulmonary embolism after COVID vaccination: 2 case reports and a review
of acute pulmonary embolism complications and follow-up: .!:lnR§;[L
oubmed.ocbi, nlm.nih,gov/34804412/
2. Myocardial infarction, stroke, and pulmonary embolism after BNT162b2 mRNA
COVID-19 vaccine in persons aged 75 years or older: https://
pubmed.ncbi.nlm,nih,qov/34807248/
Neuromyelitis Optica
also called NMO or Devic's disease, is a rare yet severe demyelinating autoimmune
inflammatory process affecting the central nervous system. It specifically affects the
myelin, which is the insulation around the nerves
----- -- - - - - - - ------- - - - - - - - ---- ···---·----
1. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated

virus for COVID-19: https://pubmed.ncbi.nlm.nih.gov/34189662/
2. Neuromyelitis optica in a healthy woman after vaccination against severe acute

respiratory syndrome coronavirus 2 mRNA-1273: bttps;//pubmed.ncbi-nlm.nib,qovt
34660149/
Shingles (Includes term: Herpes zoster)
a reactivation of the chickenpox virus in the body, causing a painful rash.

AR01437
1. Shingles-like skin lesion after vaccination with AstraZeneca for COVID-19: a case
report: bttps://pubmed.ncbi.nlm-nih,goy/34631069/
2. Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria
on cyclosporine treatment -A report of 3 cases: bttps;l/pubmed.ocbLnlm.nih,goyJ
34510694/
Blood Clots
A gelatinous mass of fibrin and blood cells formed by the coagulation of blood.
1. Blood clots and bleeding after BNT162b2 and ChAdOx1 nCoV-19 vaccination: an
analysis of European data: bttps;//pubroed.ncbLnlm.nib,goy/34174723/
Thrombophllla
A blood disorder that makes the blood in your veins and arteries more likely to clot. This is
also known as a "hypercoagulablen condition because your blood coagulates or clots more
easily.
1. Antiphospholipid antibodies and risk ofthrombophilia after COVID-19 vaccination:

the straw that breaks the camel's back?: https:1/docs,gooale,com/documeot/d/
1XzajasOBVMMnC3CdxSBKks1 o7ki0LXEO
ITTP episode
A rare, life-threatening thrombotic microangiopathy caused by severe ADAMTS13 (a

disintegrin and metalloproteinase with thrombospondin motifs 13) deficiency, recurring in
30-50% of patients.
1. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based

anti-COVID-19 vaccine: https://pubmed.ncbi,nlm.nih,gov/34105244/
Refractory Status Epilepticus
Can be defined as status epilepticus (seizures) that continues despite treatment with
benzodiazepines and one antiepileptic drug. RSE should be treated promptly to prevent
morbidity and mortality; however, scarce evidence is available to support the choice of
specific treatments.
1. New-onset refractory status epilepticus after chadox1 ncov-19 vaccination: https://

www.sciencedirect.com/science/artide/pii/s0165572821 001569
Central Serous Retlnopathy
A medical condition where fluid builds up behind the retina in the eye. It can cause sudden
or gradual vision loss as the central retina detaches. This central area is called the macula.
AR01438
1. Acute-onset central serous retinopathy after Immunization with COVJD-19 mRNA

vaccine: . httQs:[lwww.§gjgaggdjmgt,coml§Qgag§:lif!tligJelgji£$2~51993§2 j 001 ~56.
Cutaneous Reactions
A group of potentially lethal adverse drug reactions that involve the skin and mucous
membranes of various body openings such as the eyes, ears, and inside the nose, mouth,
and lips.
--- ------ - - - - - - - ---
1. Late cutaneous reactions after administration of COVID-19 mRNA vaccines: ~

www.sciencedirect.com/science/articlell:l:ii/S22132198210079~6
Prion Disease
Prion diseases comprise several conditions. A prion is a type of protein that can trigger
normal proteins in the brain to fold abnormally. Prion diseases or transmissible spongiform
encephalopathies (TSEs) are a family of rare progressive neurodegenerative disorders
that affect both humans and animals. They are distinguished by long incubation periods,
characteristic s pon g iform chan ges associated with neuronal loss, and a failure to induce
inflammatory
1. COVID-19 RNA-based vaccines and the risk of prion disease:~

sdvisionoub.com/pdfs/covid 19ma-based-vaccines-aod-the-dsk-of-pdon-dis
ease-1503.pdf
!regnant Woman
See below studies.
1. This study notes that 115 pregnant women lost their babies, out of 827 who
participated in a study on the safety of covid-19 vaccines: https;//www,oejro.org/doi/
lull/10.1056/NEJMoa2104983.
Process-Related Impurities
See below studies.
1. Process-related impurities in the ChAdOx1 nCov-19 vaccine: https://

www.researchsauare.com/articie/rs-4V964/v1
CNS Inflammation
A disease that causes inflammation of the small arteries and veins in the brain and/or
spinal cord. The brain and spinal cord make up the CNS. Intense interest in inflammation
in the CNS has arisen from its potential role in diseases including acute brain injury, stroke,
epilepsy, multiple sclerosis, motor neurone disease, movement disorders and Alzheimer's
disease, and more recently some psychiatric disorders.
1. COVID-19 mRNA vaccine causing CNS inflammation: a case series: https:Jf

link,springer.com/articJef1 0, 1007/s0Q415-021-101ao-z
AR01439
CNS Deriiyeliilation
a demyelinating disease is any condition that results in damage to the protective covering
(myelin sheath) that surrounds nerve fibers in your brain, optic nerves and spinal cord.
When the myelin sheath is damaged, nerve impulses slow or even stop, causing
neurological problems.
1. A systematic review of cases of CNS demyelination following COVID-19 vaccination:

httos://pubmed,ocbi.nlm.nih,aoYi34839149/
Orofaclal
An orofacial myofunctional disorder (OMD) is when there is an abnormal lip, jaw, or tongue
position during rest, swallowing or speech.
1. Reported orofacial adverse effects from COVID-19 vaccines: the known and the
unknown: https://pubmed.ncbi.nlm.nih.gov/33527524/
Brain Haemorrhage (Includes Term: Lobar Hemorrhage)
An emergency condition in which a ruptured blood vessel causes bleeding inside the brain.
1. Fatal brain haemorrhage after COVID-19 vaccine: https://pubroed.ocbi.olm nib gay/

33928772/
Varlcella Zoster Virus
The varicella-zoster virus r,JZV) is so named because it causes two distinct illnesses:
varicella (chickenpox), following primary infection, and herpes zoster (shingles), following
reactivation of latent virus. Varicella is a highly contagious infection with an incubation
period of 10-21 days, most commonly 14-16 days, after which a characteristic rash
appears. Acute varicella may be complicated by secondary bacterial skin infections,
haemorrhagic complications, cerebellitis, encephalitis, and viral and bacterial pneumonia.
1. Acute retinal necrosis due to varicella zoster virus reactivation after vaccination with
BNT162b2 COVID-19 mRNA: httos;//pubmed,ocbi.nlro,nih,goy/34851795/.
-Nerve And Muscle Adverse Events
Many different possible neurologic adverse events including encephalitis, myelopathy,

aseptic meningitis, meningoradiculitis, Guillain-Barr0-like syndrome, peripheral neuropathy
(including mononeuropathy, mononeuritis multiplex, and polyneuropathy) as well as
myasthenic syndrome.
1. Nerve and muscle adverse events after vaccination with COVID-19: a systematic
review and meta-analysis of clinical trials: https:1/pubmed.ncbi,nlm.nih.gov/
34452064/.
IOculomo_tor Paralysis
AR01440
Defines the decreased strength of a muscle, which produces a reduced rotational

movement of the eyeball in the direction corresponding to the paralysed muscle. Partial
deficit is called paresis, while full deficit is called paralysis.
1. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine

for SARS-CoV-2 diplopia after COVID-19 vaccine: https:llpubroed,ocbi,nlro,nih,gov/
34369471/
Parsonage-Turner Syndrome
An neurological disorder characterized by rapid onset of severe pain in the shoulder and
arm. This acute phase may last for a few hours to a few weeks and is followed by wasting
and weakness of the muscles (amyotrophy) in the affected areas.
------------------------------~
1. Parsonage-Turner syndrome associated with SARS-CoV-2 or SARS-CoV-2
vaccination. Comment on: ~Neuralgic amyotrophy and COVID-19 infection: 2 cases
of accessory spinal nerve palsy" by Coll et al. Articular Spine 2021; 88: 10519:
https:l/pubmed.ncbi.nlm.nih.goW34139321/.
Acute Macular Neuroretlnopathy
A rare, acquired retinal disorder characterised by transient or permanent visual impairment

accompanied by the presence of reddish-brown, wedge-shaped lesions in the macula, the
apices of which tend to point towards the fovea.
1. Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: https:J/

oubmed.ncbi.nlm.nih,qoy1342B7612/
Lipschutz ulcers (Vaginal ulcers)
Acute genital ulceration, also known as "Lipsch0tz ulcer" or "ulcus vulvae acutum," is an
uncommon, self-limited, nonsexually transmitted condition characterized by the rapid onset
of painful, necrotic ulcerations of the vulva or lower vagina.
1. Lipsch0tz ulcers after AstraZeneca COVID-19 vaccination: .b.tlpsJl

pubmed,ncbi.nlm.nih.gov/34366434/.
IAmyotrophlc Neuralgia
AR01441
A disorder characterized by episodes of severe pain and muscle wasting (amyotrophy) in

one or both shoulders and arms. Neuralgic pain is felt along the path of one or more
neives and often has no obvious physical cause.
- - - - - - - - - - - - - - - - - - - - --- .. ----- --------
1. Arnyotrophic Neuralgia secondary to Vaxzevri vaccine (AstraZeneca) COVID-19:
https://pubmed.ncbi.nlm.nih.goyf3433067V
Polyarthralgla
Pain in multiple joints. Symptoms may include pain, tenderness, or tingling in the joints and 1
reduced range of motion. Polyarthralgia is similar to polyarthritis, but it doesn't cause ·
inflammation. Lifestyle changes, home remedies, and medication can help manage the i
symptoms. I
1. Polyarthralgia and myalgia syndrome after vaccination with ChAdOx1 nCOV-19:
httos:l/oubmed-ncbi.nlm.nih,oPY/34463066/
Thyroid Ills
The swelling, or inflammation, of the thyroid gland and can lead to over- or under-
production of thyroid hormone. A thyroid storm - or thyroid crisis - can be a life-
threatening condition. It often includes a rapid heartbeat, fever, and even fainting.
Symptoms may include pain in the throat, feeling generally unwell, swelling of the thyroid
gland and, sometimes, symptoms of an overactive thyroid gland or symptoms of an
underactive thyroid gland.
1. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination

ASIA syndrome: https:/fpubmed.ncbi.nlm.nih.qov/34043800/.
Keratolysls (also termed: corneal melting)
A common prelude to the development of corneal perforation. This process occurs from
conditions such as infections, sterile inflammation, or surgical/chemical injury to the
cornea. Collectively, these conditions are a significant cause for blindness world-wide.
1. Bilateral immune-mediated keratolysls after immunization with SARS-CoV-2

recombinant viral vector vaccine: https;/lpubmed.ncbi.nlm.nih.goy/34483273/.
Arthritis
The swelling and tenderness of one or more joints. The main symptoms of arthritis are joint 1
pain and stiffness, which typically worsen with age. The most common types of arthritis are !
osteoarthritis and rheumatoid arthritis. I
1. Reactive arthritis after COVID-19 vaccination: https://pybmed,ocbj.nlm.nih.gov/
34033732/.
AR01442
Thymlc hyperplasia
A condition in which the thymus gland is inflamed. It isoften accompanied by autoimmune

diseases such as systemic lupus erythematosus, myasthenia gravis and rheumatoid
arthritis.
1. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: ~

oubmed.ncbi.nlm,oih,qov/3446264V
Tolosa-Hunt syndrome
A rare disorder characterized by severe periorbital headaches, along with decreased and
painful eye movements (ophthalmoplegia). Symptoms usually affect only one eye
(unilateral). In most cases, affected individuals experience intense sharp pain and
decreased eye movements.
1. Tolosa-Hunt syndrome occurring after COVID-19 vaccination: https:1/

oubmed,ncbi,nlm.nih,ggv/34513398/
Halley-Halley disease
Also known as benign chronic pemphigus, is a rare skin condition that usually appears in
early adulthood. The disorder is characterized by red, raw, and blistered areas of skin that
occur most often in skin folds, such as the groin, armpits, neck, and under the breasts.
1. Hailey-Hailey disease exacerbation after SARS-CoV-2 vaccination: b:l:b;2s;il

pubmed.ncbi.nlm.nih.gov/34436620/
Acute )ympholysls
The destruction of lymph cells.
1. Rituximab-induced acute lympholysis and pancytopenia following vaccination with

COVID-19: https://pubmed,ocbi,nlm.nih,qov/34429981/
Interstitial lung disease
Describes a large group of disorders, most of which cause progressive scarring of lung
tissue. The scarring associated with interstitial lung disease eventually affects your ability
to breathe and get enough oxygen into your bloodstream.
1. Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccine:

https://pubmed, ncbi ,nlm ,oih,goy/3451 0014/.
IVeslculobullous cutaneous reactions

AR01443
A vesiculobullous lesion of the skin encompasses a group of dermatological disorders with

protean clinicopathological features. They usually occur as a part of the spectrum of
various infectious, inflammatory, drug-induced, genetic, and autoimmune disorders.
1. Vesiculobullous cutaneous reactions induced by COVJD-19 mRNA vaccine: report of

four cases and review of the literature: bttps:llpubmed,ocbi,olm,oib,goy/34236711/
Hematologlc condltlbns
Disorders of the blood and blood-forming organs.

i
'
1. Collection of complement-mediated and autoimmune-mediated hematologic
conditions after SARS-CoV-2 vaccination: httos://ashoublications,ora/bloodadvances/
artide/5/13/2794/476324/Autoimmuoe-and-complement-mediated-hematolooic
Hemolysls
The destruction of red blood cells.
1. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal

hemoglobinuria: httos:/lashpublicalions.org/blood/article/13m6/3670!475905/
COVID-19-vaccines-induce-severe-hemolysis-in
I:::::~:: papera.____________ _______________

1. Headache attributed to COVI0-19 (SARS-CoV-2 coronavirus) vaccination with the
~
ChAdOx1 nCoV-19 (AZD1222) vaccine: a multicenter observational cohort study:
httos://pubmed,ocbj .nlm.nih.gov/34313952/
Acute Coronary Syndrome
Any condition brought on by a sudden reduction or blockage of blood flow to the heart.
~---------------------·- ------------------
1. Mrna COVID vaccines dramatically increase endothelial inflammatory markers and

risk of Acute Coronary Syndrome as measured by PULS cardiac testing: a caution:
https:/lwww.abajourna1s.org/doi/1 Q,1161 /circ.144.suppl 1.10712
IANCA Glomerulonephrltls
AR01444
is the term we use when ANCA vasculitis has affected or involved the kidneys, and when
this happens there is inflammation and swelling in the kidney filters, meaning that the
body's own immune system injures its cells and tissues.
-- ·------· ·- .,_., ____ --- - - - ·--
1. ANCA glomerulonephritis following Modem COVID•19 vaccination:~
12ubm~d. □cbi, □ lm,□ ib,gov/3~Q8:l~Bl
Neurologlc Phantosmia
is an olfactory hallucination perceived when no odorants are present. Both the olfactory
distortions are typically described as unpleasant.
1. Unique imaging findings of neurologic phantosmia after Pflzer-BioNtech COVID-19

vaccination: a case report: bttgs;llgy!;m:uiQ,acbi.alm,Dib,ggv/34Q968:96l
UveltlS (includes temis: bilateral}
is a form of eye inflammation. It affects the middle layer of tissue in the eye wall (uvea).
Uveitis warning signs often come on suddenly and get worse quickly. They include eye
redness, pain and blurred vision.
1. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report: https:f/
www.sdencedirect.com/science/article/oiVS1201971221007797
Pathophyslologic Alterations
Deranged function in an individual or an organ due to a disease. For example, a

pathophysiologic alteration is a change in function as distinguished from a structural
defect.
1. Extensive investigations revealed consistent pathophysiologic alterations after

vaccination with COVID-19 vaccines: htt125·llwww, □ ature corn/articles/
s41421-021-00329-3
Gross Hematuria (Includes term: Acral Hemorrahge)
produces pink, red or cola-colored urine due to the presence of red blood cells. It takes
little blood to produce red urine, and the bleeding usually isn't painful. Passing blood clots
in your urine, however, can be painful. Bloody urine often occurs without other signs or
symptoms.
1. Gross hematuria after severe acute respiratory syndrome coronavirus 2 vaccination

in 2 patients with lgA nephropathy: bttps-/lpubmed ocbi.olm,oib,gpy/33771584/
AR01445
Inflammatory Myosltls
inflammatory myopathies aare a group of diseases that involve chronic (long-standing)

muscle inflammation, muscle weakness, and, in some cases, muscle pain. Myopathy is a
general medical term used to describe a number of conditions affecting the muscles. All
myopathies cause muscle weakness.
1. Inflammatory myositis after vaccination with ChAdOx1: https://

pubmed,ncbi,nlm.nih,gov/34585145/
Still's Disease
is a rare type of inflammatory arthritis that features fevers, rash and joint pain. Some
people have just one episode of adult Still"s disease. In other people, the condition persists
or recurs. This inflammation can destroy affected joints, particularly the wrists.
1. An outbreak of Still's disease after COVID-19 vaccination in a 34-year-old patient:

https;//pubmed,ncbi,nlm.nih.gov/34797392/
Pityi'lasls ROsea
a skin rash that sometimes begins as a large spot on the chest, abdomen or back,
followed by a pattern of smaller lesions.
1. Case report: Pityriasis rosea-like rash after vaccination with COVID-19: ~

pubmed.ncbi.nlm.nih.qov/34557507/
Acute Eosinophillc Pneumonia
is the acute-onset form of eosinophilic pneumonia, a lung disease caused by the buildup of
eosinophils, a type of white blood cell, in the lungs. It is characterized by a rapid onset of
shortness of breath, cough, fatigue, night sweats, and weight loss.
1. Acute eosinophilic pneumonia associated with anti-COVID-19 vaccine AZD1222:

https:/lpubmed.ocbi.nlm.nih ,gov/34812326/.
Sweet's Syndrome
is an uncommon skin condition marked by a distinctive eruption of tiny bumps that enlarge
and are often tender to the touch. They can appear on the back, neck, arms or face.
Sweat's syndrome, also called acute febrile neutrophilic dermatosis, is an uncommon skin
condition.
1. Sweet's syndrome after Oxford-AstraZeneca COVID-19 vaccine (AZD1222) in an

elderly woman: httpg:l/pubmed.ncbi.nlm.nih.gov/3459039V
AR01446
Sensorlneural Hearing Loss
Hearing loss caused by damage to the inner ear or the nerve from the ear to the brain.
Sensorineural hearing loss is permanent.
1. Sudden sensorineural hearing loss after COVID-19 vaccination: l!1m§;lL

pubmed.ncbLnlm,nih.goy/34670143/.
Serious Adverse Events Among Health· Care Professionals
See below paper.
1. Prevalence of serious adverse events among health care professionals after

receiving the first dose of ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in
Togo, March 2021: https://pubmed.ncbi.nlro,nib,qov/34819146/.
Toxic Epidennal Necrolysls
A life-threatening skin disorder characterized by a blistering and peeling of the skin. This
disorder can be caused by a drug reaction-often antibiotics or anticonvulsives.
1. A case of toxic epidermal necrolysis after vaccination with ChAdOx1 nCoV-19

(AZD1222): httos:lloubmed.ocbi.olm-nih.goy/347514291.
Ocular Adverse Events
The majority of ocular immune-related adverse events (irAEs) are mild, low-grade, non-
sight threatening, such as blurred vision, conjunctivitis, and ocular surface disease.
1. Ocular adverse events following COVID-19 vaccination: bttps1l

Depression
A common and serious medical illness that negatively affects how you feel, the way you
think and how you act. Depression causes feelings of sadness and/or a loss of interest in
activities you once enjoyed.
1. Depression after ChAdOx1-S / nCoV-19 vaccination:~

pubmed.ocbi,nlro,oih,gov/34608345/-
Pancreas Allograft Rejection
the body's blood cells identify the pancreas as foreign and begin mounting an army of
cells to attack the transplanted organ. Although acute rejection can happen at any time,
about 15 to 25% of pancreas acute rejection occurs within the first three months after
transplant.
AR01447
1. Pancreas allograft rejection after ChAdOx1 nCoV-19 vaccine: https://

oubmed,ocbi,nlm,nih,qov/34781027/
Acute Hemlchorea-Hemlballsmus
Hemiballismus is characterized by high amplitude, violent, flinging and flailing movements

confined to one side of body and hemichorea is characterized by involuntary random-
appearing irregular movements that are rapid and non-patterned confined to one side of
body.
1. Acute hemichorea-hemibalismus after COVID-19 (AZD1222) vaccination: htt(;m.:il

pubmed,ncbi.nlm.nih.gov/34581453/
Alopecia Areata
Sudden hair loss that starts with one or more circular bald patches that may overlap.
Alopecia areata occurs when the immune system attacks hair follicles and may be brought
on by severe stress.
---~ ·····---·---
1. Recurrence of alopecia areata after covid-19 vaccination: a report of three cases in

Italy: bttps:1/pubmed .ncbLnlm. nib.gov1347415831
Graves' Disease
is an autoimmune disorder that causes hyperthyroidism, or overactive thyroid. With this

disease, your immune system attacks the thyroid and causes it to make more thyroid
hormone than your body needs. The thyroid is a small, butterfly-shaped gland in the front
of your neck. Thyroid hormones control how your body uses energy, so they affect nearly
every organ in your body-even the way your heart beats. If left untreated,
hyperthyroidism can cause serious problems with the heart, bones, muscles, menstrual
cycle, and fertility. During pregnancy, untreated hyperthyroidism can lead to health
'
problems for the mother and baby. Graves' disease also can affect your eyes and skin.
i
~-------·----··----- ---------- ... --------- - ... -- ----- I
1. Two cases of Graves' disease after SARS-CoV-2 vaccination: an autoimmune /

inflammatory syndrome induced by adjuvants: httos:llpubmed,ncbi.nlm.nib.goy/
33858208/
Cardiovascular Events
refer to any incidents that may cause damage to the heart muscle.
1. Cardiovascular, neurological, and pulmonary events after vaccination with

BNT162b2, ChAdOx1 nCoV-19, and Ad26.COV2.S vaccines: an analysis of
European data: bttps:1/puhmed □chi nlm,nib,goy/34710832/
Metabolic Syndrome
A cluster of conditions that increase the risk of heart disease, stroke and diabetes.
AR01448
1. Change in blood viscosity after COVID-19 vaccination: estimation for persons with
underlying metabolic syndrome: bttps;l/pubmed.ocbi,nlm,nih,goy/34868465/
Eoslnophlllc Dermatosis
Eosinophilic skin diseases, commonly termed as eosinophilic dermatoses, refer to a broad

spectrum of skin diseases characterized by eosinophil infiltration and/or degranulation in
skin lesions, with or without blood eosinophilia. The majority of eosinophilic dermatoses lie
in the allergy-related group, including allergic drug eruption, urticaria, allergic contact
dermatitis, atopic dermatitis, and eczema.
1. Eosinophilic dermatosls after AstraZeneca COVID-19 vaccination: btulSJ1

pubmed.ncbi,nlm.nih.gov/34753210/.
Hypercoagulability
the tendency to have thrombosis as a result of certain inherited and/or acquired molecular
defects. Clinical manifestations of hypercoagulability can be devastating and even lethal
----- ----------·---·---·
1. COVI0-19 vaccine in patients with hypercoagulability disorders: a clinical
perspective: httos:llpubroed.ocbi,nlm nib,aov/34786893/
Neurolmaglng Findings In Post COVID-19 Vaccination
see paper below.
1. Spectrum of neuroimaging findings in post-CoVID-19 vaccination: a case series and

review of the literature: https:l/pubmed,ncbi.nlm,nib,goy/34842783/
Urtlcaria
A rash of round, red welts on the skin that itch intensely, sometimes with dangerous
swelling, caused by an allergic reaction.
1. Increased risk of urticaria/angioedema after BNT162b2 mRNA COVID-19 vaccination

in health care workers taking ACE inhibitors: https://pubmed.ncbi.nlm.nih.gov/
34579248(
Central Vein Occlusion
Is a blockage of this vein that causes the vein to leak blood and excess fluid into the retina.
This fluid often collects in the area of the retina responsible for central vision called the
macula. When the macula is affected, central vision may become blurry. The second eye
will develop vein occlusion in 6-17% of cases. There's no cure for retinal vein occlusion.
Your doctor can't unblock the retinal veins. What they can do is treat any complications
and protect your vision.
1. Central retinal vein occlusion after vaccination with SARS-CoV-2 mRNA: case report:
https://pubmed.ncbi.nlm.nih.gov/345716531.
AR01449
Thrombophlebllls
A condition in which a blood clot in a vein causes inflammation and pain.
1. Idiopathic external jugular vein thrombophlebitis after coronavirus disease

vaccination (COVID-19): httos://oubmed,ocbi.nlm.nih,goy/33624509/.
Squamous Cell Carcinoma
A slow-growing type of lung cancer.

I
1. Squamous cell carcinoma of the lung with hemoptysis following vaccination with
tozinameran (BNT162b2, Pfizer-BioNTech): https:1/pubmed.ncbi.nlm.nih.qgv/
34612003/
1. Chest pain with abnormal electrocardiogram redevelopment after injection of

COVID-19 vaccine manufactured by Moderna: https:f/pybmed,ncbi,nlm,nih,qov/
34866106/
Acute Inflammatory Neuropathles
Encompass groups of heterogeneous disorders characterized by pathogenic immune-

mediated hematogenous leukocyte infiltration of peripheral nerves, nerve roots or both,
with resultant demyelination or axonal degeneration or both, and the pathogenesis of
these disorders remains elusive.
1. Reporting of acute inflammatory neuropathies with COVID-19 vaccines: subgroup

disproportionality analysis in VigiBase: https://pubmed.ncbi.nlm.nih.qov/34579259/
Brain Death
Irreversible cessation of all functions of the entire brain, including the brain stem. A person
who is brain dead is dead.
1. Brain death in a vaccinated patient with COVID-19 infection: b.1um.i!

IKounls Syndrome
AR01450
is the concurrence of acute coronary syndromes with conditions associated with mast cell
activation, such as allergies or hypersensitivity and anaphylactic or anaphylactoid insults
that can involve other interrelated and interacting inflammatory cells behaving as a 'ball of
thread'.
1. Kounis syndrome type 1 induced by inactivated SARS-COV-2 vaccine: https:1/

oubmed.ocbi.nlro,oih,goy/34148TT2/
Angloimmunoblastlc T-cell Lymphoma
is a type of peripheral T-ceH lymphoma. It is a high grade (aggressive) lymphoma that

affects blood cells called T cells. High grade lymphomas tend to grow more quickly than
low grade lymphomas. AITL usually affects older people, typically around the age of 70, is
typically aggressive with a median survival of fewer than 3 years, even with intensive
treatment.
1. Rapid progression of angioimmunoblastic T-cell lymphoma after BNT162b2 mRNA

booster vaccination: case report: https;//www.trontiersin.orq/articles/1 0,3389/fmed.
2021.798095/
Gastroparesis
A condition that affects the stomach muscles and prevents proper stomach emptying.
1. Gastroparesis after Pfizer-BioNTech COVID-19 vaccination: https://

pybmed. ncbi.nlm.oih .gov/34187985/
Asthma
a condition in which a person's airways become inflamed, narrow and swell and produce
extra mucus, which makes it difficult to breathe. Asthma can be minor or it can interfere
with daily activities. In some cases, it may lead to a life-threatening attack.
1. Colaneri, M., De Filippo, M., Licari, A., Marseglia, A., Maiocchi, L., Ricciardi, A., ...
Bruno, R. (2021 ). COVID vaccination and asthma exacerbation: might there be a
link? lnt J Infect Dis, 112, 243-246. doi:10.1016/j.ijid.2021.09.026. https://
www.ncbi.nlro,nih.gov/pubmed/34547487
Safety In Adolescents
see below paper
1. Dimopoulou, □., Spyridis, N., Vartzelis, G., Tsolia, M. N., & Maritsi, D. N. (2021).
Safety and tolerability of the COVID-19 mRNA-vaccine in adolescents with juvenile
idiopathic arthritis on treatment with TNF-inhibitors. Arthritis Rheumatol. doi:10.1002/
art.419TT. https·/Jwww ocbi aim nib gov[pubmed/34492161
AR01451
2. Hause, A. M., Gee, J., Baggs, J., Abara, W. E., Marquez, P., Thompson, D., ... Shay,
D. K. (2021). COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years- United
States, December 14, 202Q..July 16, 2021. MMWR Morb Mortal Wkly Rep, 70(31),
1053-1058. doi:10.15585/mmwr.mm7031e1. https·Jlwww ocbi nlm,nih,goy/pubmed/
34351881
Safety Monitoring of the ·Janssen Vaccine
see below paper
1. Shay, D. K., Gee, J., Su, J. R., Myers, T. R., Marquez, P., Liu, R., ... Shimabukuro, T.
T. (2021). Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine
-United States, March-April 2021. MMWR Morb Mortal Wkly Rep, 70(18), 680-684.
doi:10.15585/mmwr.mm7018e2. https://www.ncbi,nlm.nih.gov/pµbmed/33956784
Myocardial Injury
refers to the cell death of cardiomyocytes and is defined by an elevation of cardiac

troponin values. It is not only considered a prerequisite for the diagnosis of myocardial
infarction but also an entity in itself and can arise from non-ischaemic or non-cardiac
conditions.
1. Acute myocardial injury after COVI0-19 vaccination: a case report and review of
current evidence from the Vaccine Adverse Event Reporting System database:
https:1/pubmed.ncbi ,nlm,nih,ggv/34219532/
2. Deb, A., Abdelmalek, J., lwuji, K., & Nugent, K. (2021 ). Acute Myocardial Injury
Following COVID-19 Vaccination: A Case Report and Review of Current Evidence
from Vaccine Adverse Events Reporting System Database. J Prim Care Community
Health, 12, 21501327211029230. doi:10.1177/21501327211029230. https://
www.ncbi.nlm.nih,goYlpubmed/34219532
Autoimmune Inflammatory Rheumatic Diseases
Rheumatic diseases are autoimmune and inflammatory diseases that cause your immune
system to attack your joints, muscles, bones and organs. Rheumatic diseases are often
grouped under the term "arthritis~ - which is used to describe over 100 diseases and
conditions. :
--------~· ~-·- ---------~
!
1. Furer, V., Eviatar, T., Zisman, D., Peleg, H., Paran, D., Levartovsky, D., ... Elkayam,
0. (2021 ). lmmunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in
adult patients with autoimmune inflammatory rheumatic diseases and in the general
population: a multicentre study.Ann Rheum Dis, 80(10), 1330-1338. doi:10.1136/
annrheumdis-2021-220647. https://www.ncbi.nlm.nih.gov/pubmed/34127481
INeurological Autoimmune Diseases

7
AR01452
If you have a neurological autoimmune disease, your immune system may be overly active
and mistakenly attack healthy cells. These include central nervous system demyelinating
disorders such as multiple sclerosis and neuromyelitis optica, paraneoplastic, and other
autoimmune encephalomyelitis and autoimmune inflammatory myositis and demyelinating
neuropathies.
1. Neurological autoimmune diseases after SARS-CoV-2 vaccination: a case series:

https;//pubmed.ncbi,□ tm.nih,aov/34668274/.
V REPP
0
vaccine-related eruption of papules and plaques.

----- - ----- - -····----------------~
1. Clinical and pathologic correlates of skin reactions to COVID-19 vaccine, including V-

REPP: a registry-based study: https://www.sciencedirect.com/science/article/pii/
S0190962221024427
Herpes Simplex Virus
A virus causing contagious sores, most often around the mouth or on the genitals.
1. Varicella zoster virus and herpes simplex virus reactivation after vaccination with
COVJD-19: review of 40 cases in an international dermatologic registry: https://
oubmed,ocbi.nlm,oib.goy/34487581/
AR01453
This is BB referred to in the Affidavit of Karl Harrison sworn March 11, 2022
:·'J;,;. .
·~
6.
Commissioner for Taking Affidavits
Sam A. Presvelos
AR01454
Cl[
BC Centre for Disease Control
-------- - --
- - --- - - - - - - - - -
-------------- - - . - -
•
AR01455
You're pregnant. breastfeeding or thinking about getting pregnant.

Should you get a COVID-19 vaccine?
- - - - - - - - - - - - - -- - - - -
•
AR01456
•
AR01457
-- ---- -----------
---------------- -- ---- -
•
AR01458
'
c•v10-19
Vaccination after COVID-19
.
, crt:
· · ·· :-:- - ·
Wha1 lsunmuruty' Should I gei V.Monate-d after J haw h.:ld

COVID·l9 1
~•Plbaltfl ...,tof'rlllCG'WW~OCtlA
.,;,.n'P6tiod'r1S.-,(IQl,ldtoadil,Nw~such•• ...-. ii )OJ h.M Nd COYIO- 9. 12' Ulea _,,,, tMn
vna ~ n • .,._~ to«~ IMUWf 1A~h:ifll~1'c-'la10. . h-wctl"ft
-
~ . . . . . , _ , . YQ/t•~toaew1d DIICWIOtft'OITIINUSVl()M~~drfWIC'.OOnOI
•~ClfpwnO,a~ ~o,p'IVII~ CC>.011klr#l~ptf1101'1#'01vdft.,..
~•bft"""" twoal'ldl'Mtcim«1hilfw hl'low
.,,_
~ ~ Yca.n.dffCIJf'apoMO IO
fi..i.drenhiconoJ(OJ'O,Wba-.«D'1Md~1111hai
..,..co.,,o,,.,._
.,...,..,,.,haCIPf'N,.,p.#lfflfft.!Nlw,:... 1111'
Pf'0IM- ~ttiam.ldt.thfdt,Nl,fVf/1.1..,...,,..,.._,
¥H'fthll•nwnor,..,_,'1)0'.,.ftocad101hfwme
cra...,,.IIITlibrd.-.i,,ct-..~4-'ffiadws;i,rTW
to
--·-------
ri-WCIOVll>-IW
---
nOOCM1.Alehmot•q..icfdftndhfjpfif!'.Cdfh~,o,
ffl,lttlf.-.,~~fllOl'flr.abn .... ~)1011
Do I hnt,pro<rction altor hmngCOYID•l9'

~0....(.lr,lftf'-(CM019~•100ft•)Q.lfl(lft~
-"'t011),ph.M-to~ Flf"dQA~topt.t.0-.
,...,au- bcak:.u,t1,ut1h-r!f
~
CIMCJ-1..toWl- t ~DIW-.ijdOiiliw. al•bllil)
lfMMnnlC Nldil'tltmml0'1Jl1J111dJ,o,,a-(.a"ft'l'IICn
Yr ~lhrN•~tp,,.idP""'i!ICtCll'I-.,~
hllhlCSCQY0.19 ~'Nittl.,.,.,,ffllld«~
·~
.....,.,.....,. -~
vouunW.tdrit.owll~cnftCOI0- 19 ~
,.,
~ro~~Haalonp,ocl.ce1bMrfflft'UWI
mpcr,wSbxNl~NUf9f'Cltltnd . . . d ~
.,,,..h.M,cCOV0-19 ~ . . . __, ........ ~
~v.Jht,--to~C0.,,.19,pn
An: na:tnes bo11<r II provldlnalmmuruiy>

T~IOC...,fflltV\4:,b,lf'(t: COW)..19!1~IO
.,ca,..:acahn~'l(ll.l•)Q.lca,pa~cn.CO,O.tt
ancaatMflOI.II ~lll'ffl~ir.11~
'PJlcs_,--..-ldtwndNt!L
---......
~ a•IIM!\ 1M - , a ~ ....,10 dlMicp
ffi'l'llil'IC'(to COW). IQ,• c ,_,, pcutit ~IJ!I Co-tO-lt
_,,,..,,
•
AR01459
•
•
•
AR01460
•
•
•
•
•
•
•
•
•
•
AR01461
•
•
•
AR01462
•
•
•
•
•
AR01463
•
•
•
• -------- --------- ------ ---- .
•
•
•
•
AR01464
• -------- -- --- -- ------
• ----------------------- ----- -- - - - -
•
•
•
•
•
•
•
AR01465
•
AR01466
This is CC referred to in the Affidavit of Karl Harrison sworn March 11, 2022

Sam A. Presvelos
AR01467
0 | RECOMMENDATION ON THE USE OF COVID-19 VACCINES IN THE CONTEXT OF
MYOCARDITIS AND PERICARDITIS FOLLOWING VACCINATION
An Advisory Committee
Statement (ACS)
National Advisory Committee
on Immunization (NACI)
Rapid response: Updated recommendation on the use of
authorized COVID-19 vaccines in individuals aged 12 years
and older in the context of myocarditis and pericarditis
reported following mRNA COVID-19 vaccines
Published: December 3, 2021
PROTECTING AND EMPOWERING CANADIANS TO IMPROVE THEIR HEALTH
l♦I
Public Health
Agency of Canada
Agence de la sante
publique du Canada Canada
AR01468
PREAMBLE
The National Advisory Committee on Immunization (NACI) is an External Advisory Body that
provides the Public Health Agency of Canada (PHAC) with independent, ongoing and timely
medical, scientific, and public health advice in response to questions from PHAC relating to
immunization.
In addition to burden of disease and vaccine characteristics, PHAC has expanded the mandate
of NACI to include the systematic consideration of programmatic factors in developing evidence-
based recommendations to facilitate timely decision-making for publicly funded vaccine programs
at provincial and territorial levels.
The additional factors to be systematically considered by NACI include: economics, ethics, equity,
feasibility, and acceptability. Not all NACI Statements will require in-depth analyses of all
programmatic factors. While systematic consideration of programmatic factors will be conducted
using evidence-informed tools to identify distinct issues that could impact decision -making for
recommendation development, only distinct issues identified as being specific to the vaccine or
vaccine-preventable disease will be included.
This statement contains
upon the best current available scientific knowledge. This document is being disseminated for
information purposes. People administering the vaccine should also be aware of the contents of
the relevant product monograph. Recommendations for use and other information set out herein
may differ from that set out in the product monographs of the Canadian manufacturers of the
vaccines. Manufacturer(s) have sought approval of the vaccines and provided evidence as to its
safety and efficacy only when it is used in accordance with the product monographs. NACI
s Policy on
Conflict of Interest, including yearly declaration of potential conflict of interest .
AR01469
INTRODUCTION
Cases of myocarditis/pericarditis have rarely been reported following mRNA COVID-19 vaccines
globally, including in Canada, and the National Advisory Committee on Immunization (NACI) has
been closely monitoring this vaccine safety signal.
Post-market safety surveillance on mRNA COVID-19 vaccines identified that when myocarditis
and/or pericarditis occurs, it occurs usually within a week following vaccination, most frequently
in adolescents and young adults (12 to 29 years of age), more frequently in males compared to
females, and more frequently after the second dose as compared to the first.
METHODS
On November 16, 2021, NACI reviewed the recent evidence on myocarditis/pericarditis following
COVID-19 vaccination including data from Canada, Israel, the United States (US), France, and
Nordic countries (Denmark, Finland, Norway, Sweden). NACI discussed this recent ev idence
while considering data on the epidemiology of COVID-19 infection, safety, immunogenicity,
efficacy/effectiveness of COVID-19 vaccines as well as ethics, equity, feasibility, and
acceptability.
Following a comprehensive review, NACI updated and approved its recommendations on the use
of the COVID-19 vaccines authorized for use among individuals aged 12 years and older in the
context of myocarditis and pericarditis following vaccination on November 16, 2021. NACI
continues to review the evidence on the use of COVID-19 vaccines. Recommendations on re-
vaccination of individuals aged 12 years and older with a history of myocarditis/pericarditis
following a previous dose of an mRNA COVID-19 vaccine is not covered in this document but will
be addressed in future updates. Refer to this link for the full NACI Recommendations on the use
of COVID-19 vaccines among individuals aged 12 years and older, and other NACI statements
including Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10mcg) in
children 5 to 11 years of age.
Details of NACI's evidence-informed recommendation development process can be found

elsewhere (1, 2).
AR01470
RECOMMENDATIONS
The previous NACI recommendation continues to be maintained:
1. NACI preferentially recommends that a complete series with an mRNA COVID-19

vaccine should be offered to individuals 12 years and older without
contraindications to the vaccine. (Strong NACI Recommendation)
In addition, NACI now recommends that:
1.a. For individuals aged 12 to 29 years receiving an mRNA COVID-19 vaccine primary
series:
The use of Pfizer-BioNTech Comirnaty (30 mcg dose ) is preferred to Moderna

Spikevax (100 mcg dose) to start or continue the mRNA primary vaccine series.
The second dose of mRNA vaccine should be provided 8 weeks after the first
dose as a longer interval between doses is associated with higher vaccine
effectiveness and potentially lower risk of myocarditis/pericarditis.
1.b. For individuals aged 18 to 29 years who are eligible to receive a booster dose of
vaccine*:
The use of Pfizer-BioNTech Comirnaty booster dose (30 mcg dose) may be
preferred to Moderna Spikevax booster dose (50 mcg dose).
The booster dose should be provided at least six months after completing the
primary vaccine series.
1.c. For individuals aged 30 years or older receiving an mRNA COVID-19 vaccine primary
series or booster dose:
Either of the mRNA COVID-19 vaccines (Moderna Spikevax or Pfizer-BioNTech

Comirnaty) should be used.
The second dose of mRNA vaccine should be provided 8 weeks after the first
dose as a longer interval between doses is associated with higher vaccine
effectiveness and potentially lower risk of myocarditis/pericarditis.
The booster dose should be provided at least six months after completing the
primary vaccine series.
*The use of mRNA booster doses is not currently authorized among individuals aged less than
18 years.
NACI will continue to review the evidence as it emerges and update the recommendations as
needed.
AR01471
Rationale and additional considerations

NACI has reviewed the recent evidence and continues to strongly recommend the
preferential use of mRNA COVID-19 vaccines instead of viral vector COVID-19 vaccines
in all authorized age groups, due to better effectiveness of mRNA vaccines and the rare
risk of other serious adverse events with viral vector vaccines, such as vaccine-induced
immune thrombotic thrombocytopenia (VITT).
The known risks of COVID-19 illness (including complications like myocarditis/pericarditis)
outweigh the potential harms of having an adverse reaction following mRNA vaccination,
including the rare risk of myocarditis or pericarditis which despite hospitalization, is
relatively mild and resolves quickly in most individuals.
In a context of sufficient vaccine supply and in order to maximize the benefits while
minimizing the risks associated with vaccine; among individuals aged 12 to 29 years, the
use of the Pfizer-BioNTech vaccine is preferred to the Moderna vaccine because of a
lower reported rate of myocarditis/pericarditis following the Pfizer-BioNTech (30 mcg)
compared to the Moderna (100 mcg) vaccine. The Pfizer-BioNTech COVID-19 vaccine
(30 mcg) should be used to start or complete the mRNA primary vaccine series.
For the booster dose, the use of the Pfizer-BioNTech 30 mcg booster dose may be
preferred to the Moderna 50 mcg (i.e. half of the dose used in the primary series) booster
dose among eligible individuals aged 18 to 29 years as a precaution due to the lower
reported rate of myocarditis/pericarditis following the Pfizer-BioNTech 30mcg vaccine
compared to the Moderna 100 mcg vaccine but data specific to the lower Moderna 50 mcg
booster dose are limited. Further data will be assessed as it emerges.
The use of mRNA booster doses is not currently authorized among individuals aged less
than 18 years.
Moderately and severely immunocompromised individuals may benefit from the slightly
higher antibody levels generated and slightly higher vaccine effectiveness provided by the
Moderna 100mcg vaccine compared to the Pfizer-BioNTech 30mcg vaccine. Given this
potential benefit, administration of a Moderna vaccine may be considered in some
immunocompromised individuals aged 12 to 29 years based on clinical judgement. For
additional details, consult the NACI Recommendations on the use of COVID-19 vaccines
and Rapid response on the additional dose of COVID-19 vaccine in immunocompromised
individuals following a 1- or 2-dose primary series.
Individuals aged 12 to 29 years who have already received the Moderna 100mcg vaccine
do not need to be concerned, as the risk of myocarditis/pericarditis with this vaccine is
rare and events usually occur within a week following vaccination.
Among individuals aged 30 years or older, either mRNA vaccines (Pfizer-BioNTech or
Moderna) should be used to start or continue the mRNA vaccine series (primary series or
booster dose) given that this age group has a lower risk of vaccine-associated
myocarditis/pericarditis. Furthermore, in older age groups, COVID-19 infection is
associated with a higher risk of complications (including myocarditis/pericarditis) and older
adults may benefit from the slightly higher antibody titres observed with the Moderna
100mcg vaccine compared to the Pfizer-BioNTech 30mcg vaccine. Limited data suggests
that protection from Moderna 100mcg may also be more durable compared to Pfizer-
BioNTech 30mcg but more research is required.
AR01472
Refer to the NACI updated guidance on booster COVID-19 vaccine doses in Canada
(December 3, 2021) for more information.
Further data on the safety, immunogenicity and effectiveness of mRNA boosters will be
assessed as it emerges.
In all authorized individuals aged 12 years and older, the subsequent vaccine doses
(second dose, additional dose among eligible immunocompromised individuals or booster
dose among eligible individuals aged 18 years or older) should be provided in accordance
with the NACI recommended intervals between doses. For additional details, consult the
NACI publications and statements which include: Recommendations on the use of
COVID-19 vaccines, NACI rapid response: Booster dose of COVID-19 vaccine in long-
term care residents and seniors living in other congregate settings and NACI rapid
response: Additional dose of COVID-19 vaccine in immunocompromised individuals
following a 1- or 2-dose primary series
Summary of Evidence
There are many potential causes of myocarditis and pericarditis, including both infectious
and non-infectious causes, and disease severity can be variable (3).
Myocarditis can occur as a complication of COVID-19 infection. In Israel, COVID-19
infection has been estimated to cause myocarditis at a rate of 11.0 events per 100,000
persons among individuals aged 16 years and older (4). A retrospective study from the US
found myocarditis (or pericarditis or myopericarditis) rates after primary COVID-19
infection to be as high as 45 cases per 100,000 patients in young males aged 12 to 17
years (5).
Further analyses of Canadian data continue to show that with the primary series, the
incidence of myocarditis is rare with either mRNA vaccines, but higher following the
Moderna 100 mcg vaccine compared to the Pfizer-BioNTech 30mcg vaccine (6). The
product-specific risk is highest following the second dose and among males aged 12 to 29
years. Similar trends were observed in other countries including US (7-9), France (10) and
Nordic countries (unpublished data from Denmark, Finland, Norway and Sweden) (11). In
Canada, as of November 12, 2021, the overall reported rate of myocarditis/pericarditis
was 3.0 per 100,000 doses administered following any dose of the Moderna 100 mcg
vaccine compared to 1.9 per 100,000 doses administered following any dose of the Pfizer-
BioNTech 30 mcg vaccine. The reported rates of myocarditis/pericarditis among males 18
to 29 years after the second vaccine dose were of 15.9 per 100,000 for the Moderna 100
mcg vaccine and 2.6 per 100,000 for the Pfizer-BioNTech 30 mcg vaccine. To date, there
has been one case of myocarditis/pericarditis following vaccination with the Moderna 100
mcg vaccine within the 12 to 17 year age group. The reporting rate among males 12 to 17
years after the second vaccine dose was 8.6 per 100,000 for the Pfizer -BioNTech 30 mcg.
Preliminary unpublished analyses of Canadian data suggest that longer intervals between
the first and second vaccine doses of mRNA vaccines are associated with lower reported
rates of myocarditis/pericarditis compared to shorter intervals.
Preliminary data from the US based on assessments by health care providers (n=47)
indicate that by 3 months after vaccination, 91% of individuals with myocarditis following
AR01473
mRNA COVID-19 vaccination had fully (74%) or probably fully (17%) recovered. However,
2% had the same cardiac status as at initial diagnosis and 6% had improved but not fully
recovered. Long-term follow up of patients with myocarditis and/or pericarditis following
mRNA COVID-19 vaccination is ongoing in the US and in other countries and new data
will be assessed as they emerge.
In Israel where the Pfizer-BioNTech vaccine primary series has usually been administered
at a 21-day interval between doses 1 and 2; preliminary results on the safety of a booster
dose of Pfizer-BioNTech 30mcg vaccine (usually administered at least 5 months after the
primary series) among individuals aged 12 years and older suggest that the incidence of
myocarditis after the third dose is lower compared to after the second dose but higher
compared to after the first dose. After the booster dose, the highest incidence of
myocarditis/pericarditis continues to be reported in males aged 12 to 29 years. As noted
above, there are currently limited data on the safety of the Moderna 50 mcg booster dose
and the risk of myocarditis/pericarditis with this booster dose is unknown.
Clinical trial data available to date have shown that both authorized mRNA COVID-19
-19
disease in the short term (12, 13). New evidence suggests slightly higher vaccine
effectiveness against SARS-CoV-2 infection and/or COVID-19-related hospitalization with
the Moderna 100 mcg vaccine compared to the Pfizer-BioNTech 30 mcg primary vaccine
series (14-20). Emerging evidence is also suggestive of a more durable immune response
being mounted in recipients of the Moderna 100 mcg vaccine (21-29). Studies investigating
differences between these two mRNA COVID-19 vaccines are ongoing and new
effectiveness and immunogenicity data will be assessed as they emerge.
Unknowns:
The risk of recurrence of myocarditis/pericarditis following receipt of additional doses of

any of the authorized COVID-19 vaccines is unknown at this time. Very few cases of
revaccination in these individuals have been described in published studies (30-32).
Investigations into the possible mechanisms of action, risk of recurrence, long -term
outcomes, risk following booster doses and identification of potential risk factors of these
cases of myocarditis and/or pericarditis continue in Canada and abroad. NACI will
continue to review the evidence as it emerges and update the recommendations as
needed.
For additional details on myocarditis/pericarditis following COVID-19 vaccination among

individuals aged 12 years and older, refer to the Recommendations on the use of COVID-19
vaccines and Recommendation on the use mRNA COVID-19 vaccines in adolescents 12 to 17
years of age statements from NACI.
AR01474
ACKNOWLEDGMENTS
This statement was prepared by: J Zafack, B Warshawsky, M Salvadori, E Abrams, R Krishnan,
R Pless, M Tunis, K Young, S Ismail, S Ogunnaike-Cooke, R Harrison, and S Deeks on behalf of
NACI.
NACI gratefully acknowledges the contribution of: K Farrah, K Ramotar, N St-Pierre, and the
NACI Secretariat.
NACI Members: S Deeks (Chair), R Harrison (Vice-Chair), J Bettinger, N Brousseau, P De Wals,

E Dubé, V Dubey, K Hildebrand, K Klein, J Papenburg, A Pham-Huy, C Rotstein, B Sander, S
Smith, and S Wilson.
Liaison representatives: L Bill (Canadian Indigenous Nurses Association), LM Bucci (Canadian

Public Health Association), E Castillo (Society of Obstetricians and Gynaecologists of Canada),
A Cohn (Centers for Disease Control and Prevention, US), L Dupuis (Canadian Nurses
Association), D Fell (Canadian Association for Immunization Research and Evaluation), S Funnell
(Indigenous Physicians Association of Canada), J Hu / N Ivers (College of Family Physicians of
Canada), M Lavoie (Council of Chief Medical Officers of Health), D Moore (Canadian Paediatric
Society), M Naus (Canadian Immunization Committee), and A Ung (Canadian Pharmacists
Association).
Ex-officio representatives: V Beswick-Escanlar (National Defence and the Canadian Armed

Forces), E Henry (Centre for Immunization and Respiratory Infectious Diseases [CIRID], PHAC),
M Lacroix (Public Health Ethics Consultative Group, PHAC), C Lourenco (Biologic and
Radiopharmaceutical Drugs Directorate, Health Canada), D MacDonald (Vaccine Safety, PHAC),
S Ogunnaike-Cooke (CIRID, PHAC), G Poliquin (National Microbiology Laboratory, PHAC), K
Robinson (Marketed Health Products Directorate, HC), and T Wong (First Nations and Inuit Health
Branch, Indigenous Services Canada).
NACI Vaccine Safety Working Group
Members: J Bettinger (Chair), N Brousseau, E Castillo, D Danoff, V Dubey, D Fell, K Hildebrand,

G Lacuesta, A Pham-Huy, B Seifert, K Top, S Wilson.
PHAC Participants: N Abraham, N Dayneka, C Jensen, R Krishnan, R Pless, A Shaw, N St

Pierre, B Warshawsky and J Zafack.
AR01475
TABLES
Table 1. Strength of NACI Recommendations
Strength of NACI STRONG DISCRETIONARY
Recommendation
based on factors not isolated to

strength of evidence
(e.g., public health need)
Wording should/should not be may/may not be
Known/anticipated advantages Known/anticipated advantages

outweigh known/anticipated are closely balanced with
known/anticipated
Rationale disadvantages, OR uncertainty
OR Known/anticipated in the evidence of advantages
disadvantages outweigh and disadvantages exists
known/anticipated advantages
A strong recommendation
applies to most A discretionary recommendation
populations/individuals and may/may not be offered for
Implication should be followed unless a some populations/individuals in
clear and compelling rationale some circumstances. Alternative
for an alternative approach is approaches may be reasonable.
present.
AR01476
ABBREVIATIONS
Abbreviation Term
COVID-19 Coronavirus disease 2019
mcg microgram
mRNA Messenger Ribonucleic Acid
NACI National Advisory Committee on Immunization
PHAC Public Health Agency of Canada
US United States
VITT Vaccine-induced immune thrombotic thrombocytopenia
REFERENCES
1. Ismail SJ, Langley JM, Harris TM, Warshawsky BF, Desai S, FarhangMehr M. Canada's
National Advisory Committee on Immunization (NACI): Evidence-based decision-making on
vaccines and immunization. Vaccine. 2010;28:A58,63. doi: 10.1016/j.vaccine.2010.02.035.
2. Ismail SJ, Hardy K, Tunis MC, Young K, Sicard N, Quach C. A framework for the systematic
consideration of ethics, equity, feasibility, and acceptability in vaccine program
recommendations. Vaccine. 2020 Aug 10;38(36):5861,5876. doi:
10.1016/j.vaccine.2020.05.051.
3. Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis--diagnosis, treatment

options, and current controversies. Nat Rev Cardiol. 2015 Nov;12(11):670,680. doi:
10.1038/nrcardio.2015.108.
4. Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the

BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021 Sep
16;385(12):1078,1090. doi: 10.1056/NEJMoa2110475.
5. Singer ME, Taub IB, Kaelber DC. Risk of myocarditis from COVID-19 infection in people
under age 20: A population-based analysis. medRxiv. 2021 Jul 27. doi:
10.1101/2021.07.23.21260998.
6. Public Health Agency of Canada. Reported side effects following COVID-19 vaccination in
Canada [Internet]. Ottawa (ON): Government of Canada; 2021 Nov [cited 2021 Nov 5].
Available from: https://health-infobase.canada.ca/covid-19/vaccine-safety/.
AR01477
7. Su J.R. Myopericarditis following COVID-19 vaccination: Updates from the Vaccine Adverse
Event Reporting System (VAERS) [slides presented at Advisory Committee on Immunization
Practices (ACIP) meeting on October 21, 2021] [Internet]. Atlanta (GA): Centers for Disease
Control and Prevention (CDC); 2021 Oct [cited 2021 Nov 26]. Available from:
https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/07-COVID-Su-
508.pdf.
8. Klein N. Myocarditis analyses in the Vaccine Safety Datalink: Rapid cycle analyses and
-to- Advisory Committee on Immunization
Practices (ACIP) meeting October 21, 2021] [Internet]. Atlanta (GA): Centers for Disease
Control and Prevention (CDC); 2021 Oct [cited 2021 Nov 26]. Available from:
https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-10-20-21/08-COVID-Klein-
508.pdf.
9. Oster, M. mRNA COVID-19 vaccine-associated myocarditis [slides presented at Advisory

Committee on Immunization Practices (ACIP) meeting November 2, 2021] [Internet]. Atlanta
(GA): Centers for Disease Control and Prevention (CDC); 2021 Nov [cited 2021 Nov 10].
Available from: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-2-3/04-
COVID-Oster-508.pdf.
10. Myocardite et péricardite après la vaccination Covid-19 [Internet]. Saint-Denis (France): EPI-
PHARE; 2021 Nov 8 [cited 2021 Nov 26]. Available from: https://www.epi-phare.fr/rapports-
detudes-et-publications/myocardite-pericardite-vaccination-covid19/.
11. COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety
(GACVS): updated statement regarding myocarditis and pericarditis reported with COVID-19
mRNA vaccines [Internet]. Geneva: World Health Organization (WHO); 2021 Oct 27 [cited 2021
Nov 26]. Available from: https://www.who.int/news/item/27-10-2021-gacvs-statement-
myocarditis-pericarditis-covid-19-mrna-vaccines-updated.
12. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and
efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec
31;383(27):2603,2615. doi: 10.1056/NEJMoa2034577.
13. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and safety of
the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 Feb 4;384(5):403,416. doi:
10.1056/NEJMoa2035389.
14. Pawlowski C, Lenehan P, Puranik A, Agarwal V, Venkatakrishnan AJ, Niesen MJM, et al.
FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized
across a multi-state health system. Med (N Y). 2021 Aug 13;2(8):979,992.e8. doi:
10.1016/j.medj.2021.06.007.
15. Puranik A, Lenehan PJ, Silvert E, Niesen MJM, Corchado-

Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and
Delta variant prevalence. medRxiv. 2021 Aug 9. doi: 10.1101/2021.08.06.21261707.
16. Nasreen S, Chung H, He S, Brown KA, Gubbay JB, Buchan SA, et al. Effectiveness of
mRNA and ChAdOx1 COVID-19 vaccines against symptomatic SARS-CoV-2 infection and
AR01478
severe outcomes with variants of concern in Ontario. medRxiv. 2021 Sep 30. doi:
10.1101/2021.06.28.21259420.
17. Self WH, Tenforde MW, Rhoads JP, Gaglani M, Ginde AA, Douin DJ, et al. Comparative
effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in
preventing COVID-19 hospitalizations among adults without immunocompromising conditions -
United States, March-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep
24;70(38):1337,1343. doi: 10.15585/mmwr.mm7038e1.
18. Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Khatib HAA, et al.
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta (B.1.617.2)
variant in Qatar. medRxiv. 2021 Aug 11. doi: 10.1101/2021.08.11.21261885.
19. Higdon MM, Wahl B, Jones CB, Rosen JG, Truelove SA, Baidya A, et al. A systematic
review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and
disease. medRxiv. 2021 Sep 25. doi: 10.1101/2021.09.17.21263549.
20. Robles Fontán MM, Nieves EG, Gerena IC, Irizarry RA. Time-varying effectiveness of three
Covid-19 vaccines in Puerto Rico. medRxiv. 2021 Oct 20. doi: 10.1101/2021.10.17.21265101.
21. Steensels D, Pierlet N, Penders J, Mesotten D, Heylen L. Comparison of SARS-CoV-2

antibody response following vaccination with BNT162b2 and mRNA-1273. JAMA. 2021 Aug 30.
doi: 10.1001/jama.2021.15125.
22. Richards NE, Keshavarz B, Workman LJ, Nelson MR, Platts-Mills TAE, Wilson JM.
Comparison of SARS-CoV-2 antibody response by age among recipients of the BNT162b2 vs
the mRNA-1273 vaccine. JAMA Netw Open. 2021 Sep 1;4(9):e2124331. doi:
10.1001/jamanetworkopen.2021.24331.
23. Barbeau DJ, Martin JM, Carney E, Dougherty E, Doyle JD, Dermody TS, et al. Comparative
analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2,
mRNA-1273, or Ad26.COV2.S. medRxiv. 2021 Sep 23. doi: 10.1101/2021.09.21.21262927.
24. Kaplonek P, Cizmeci D, Fischinger S, Collier A, Suscovich T, Linde C, et al. Subtle

immunological differences in mRNA-1273 and BNT162b2 COVID-19 vaccine induced Fc-
functional profiles. bioRxiv. 2021 Aug 31. doi: 10.1101/2021.08.31.458247.
25. Markewitz R, Pauli D, Dargvainiene J, Steinhagen K, Engel S, Herbst V, et al. The temporal
course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273. Clin
Microbiol Infect. 2021 Sep 20. doi: 10.1016/j.cmi.2021.09.006.
26. Montoya JG, Adams AE, Bonetti V, Deng S, Link NA, Pertsch S, et al. Differences in IgG
antibody responses following BNT162b2 and mRNA-1273 Vaccines. bioRxiv. 2021 Jun 19. doi:
10.1101/2021.06.18.449086.
27. Kaiser RA, Haller MC, Apfalter P, Kerschner H, Cejka D. Comparison of BNT162b2 (Pfizer -
BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis
patients. Kidney Int. 2021 Sep;100(3):697,698. doi: 10.1016/j.kint.2021.07.004.
AR01479
28. Stumpf J, Siepmann T, Lindner T, Karger C, Schwöbel J, Anders L, et al. Humoral and
cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A
prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine.
Lancet Reg Health Eur. 2021 Jul 23. doi: 10.1016/j.lanepe.2021.100178.
29. Wu AHB, Nguyen ED, Ong CM, Yun C, Lynch KL. Rate of serum SARS-CoV-2 antibody
decline for two mRNA vaccines. J Appl Lab Med. 2021 Oct 14. doi: 10.1093/jalm/jfab137.
30. Diaz GA, Parsons GT, Gering SK, Meier AR, Hutchinson IV, Robicsek A. Myocarditis and
pericarditis after vaccination for COVID-19. JAMA. 2021 Sep 28;326(12):1210,1212. doi:
10.1001/jama.2021.13443.
31. Albert E, Aurigemma G, Saucedo J, Gerson DS. Myocarditis following COVID-19

vaccination. Radiol Case Rep. 2021 Aug;16(8):2142,2145. doi: 10.1016/j.radcr.2021.05.033.
32. Tano E, San Martin S, Girgis S, Martinez-Fernandez Y, Sanchez Vegas C. Perimyocarditis

in adolescents after Pfizer-BioNTech COVID-19 vaccine. J Pediatric Infect Dis Soc. 2021 Nov
11;10(10):962,966. doi: 10.1093/jpids/piab060.
AR01480
This is DD referred to in the Affidavit of Karl Harrison sworn March 11, 2022

Sam A. Presvelos
AR01481
From: Karl Harrison

Sent: February 9, 2022 9:32 PM
To: monika
Subject: Moderna - SpikeVax
Hi Monika
Can you please confirm what due diligence you personally undertook in relation to Moderna and its
Chief Executive Officer, Stephane Bancel. On what information did you rely before deciding that
Moderna’s product would be “safe and effective” for millions of people in British Columbia? Moderna,
of course, has never previously had any other product authorised for use. The same is true of BioNTech.
Those that trade in the financial markets have followed Moderna, and the effervescent career of Mr
Bancel, for some years. I would undertake considerable due diligence before buying Moderna stock let
alone deciding to advise everyone over the age of 12 in British Columbia that a the Moderna product
was “safe and effective” to inject into their bodies. A reasonable person would certainly expect Dr
Henry to undertake due diligence before going on TV virtually every day for months and unreservedly
advising British Columbians, regardless of the circumstances of their personal health, to “get
vaccinated”. The government of BC has seen fit, like many others Canada and around the world, to
publish on websites its concerns and reservations about the Moderna product (and others), but with
little obvious intention of drawing people’s attention to that published information.
In Gregory Zuckerman’s book, “A Shot to Save the World” I’m led to believe that the co-founder of
Moderna – a Canadian scientist, Derrick Rossi – says of Mr Bancel “He was asking me to steal from a
hospital that treats children. Stephane is someone without a moral compass.” As a responsible person
and a loving parent, and one experienced in recognising where ethics might be compromised by the
profit motive, I would think that a moral compass might be the sort of strong characteristic for which
any Provincial Health Officer would look in the supplier of experimental drugs intended to end up in the
arms of the people of our great province.
Please read this link for an article from 2017 as a simple example of basic due diligence which would
raise questions in the mind of most readers. I expect it would raise concerns in the mind of any health
official.
https://www.statnews.com/2017/01/10/moderna-trouble-mrna/
Mr Bancel is considered to be a smart salesman. Having sold his product to countries like Canada in vast
quantities his company’s share price rose from $20 in February 2020 to a peak of over $400 and settling
today around $165. He is billions of dollars richer for his activities. I expect that Moderna will have
sought to transfer its risk and liability to those whose job it was to decide whether to recommend the
use of his mRNA. It is possible that Mr Bancel may be able to claim that he was asked to apply for the
EUA’s that permitted his products to be initially used in Canada. He may be able to point to warnings he
gave to Health Canada.
British Columbians are concerned about health risks, such as myocarditis, arising from the Moderna
product which was, according to filings with Nasdaq up until a recent definition change, classed by the
FDA as a “gene therapy”. We are keen to understand what our health officials knew; when then knew
it and how they acted upon that knowledge. In your email of December 8th you confirm you were aware
AR01482
of risks. It appears however that little or no attention has been drawn to the risks, despite the multitude
of daily oral announcements made to British Columbians, and the radio commercials. Instead
information, reservations and cautionary tones are buried in websites to which the people of British
Columbia are not regularly, or at all, referred.
Whilst I’m specifically referring here to the Moderna product, there are evolving issues arising also in
relation to the BioNTech product.
There is a growing body of evidence suggesting that public health policy around SARS-CoV-2 has been
mis-handled. A bungled application of public policy made under the influence of, or in connection with,
corporate lobbying has ended many careers. Accountability is routinely handed down the ranks. In BC
the Premier may blame the Minister of Health,, who might blame the Provincial Health Officer, who
might in turn blame the Director of the CDC.
The potential liability issues here are substantial and the full extent may not be known for some
years. We are just starting to see the damage that has been wrought on our communities by ill-
considered and, some would say, experimental public policy initiatives imposed by people who may
have been ill-qualified to implement them. Those years ahead may see legal proceedings brought
against those who made decisions leading to the loss of businesses, jobs, health and lives.
I believe that an opportunity remains for health officials to speak out. To raise concerns that many will
have had, and of which many may have been fearful of speaking. Some are already speaking out. Public
health policy during the SARS-CoV-2 pandemic may have undermined confidence in the medical
profession and in health officials. The short term offers the opportunity to come together, to broaden
the dialogue and to lessen the risk of legal and public recrimination.
I look forward to your thoughts and hope, in due course, to be able to discuss some of these issues with
you.
Regards
Karl
Karl Harrison
AR01483
From: Naus, Monika [BCCDC]

Sent: December 8, 2021 7:56 AM
To: Karl Harrison
Cc: hlth.minister@gov.bc.ca; Henry, Bonnie [EXT]
Subject: RE: Moderna - SpikeVax - urgent
Hello Mr. Harrison
The issue of the differential risk of peri/myocarditis associated with the two mRNA COVID-19 vaccines
in use has been recognized and discussed at the advisory table that makes recommendations for the
COVID-19 immunization program in BC, most recently on Monday following the release of the NACI
statement on Friday December 3th.
Our updated pages supporting immunizers with the use of these two vaccines were released yesterday,
and are located at this link under COVID-19, for the Pfizer and Moderna products. These do recommend
preferential use of Pfizer vaccine as possible, although we do allow for use of Moderna in specific
circumstances in this age group including immunocompromised individuals and those who specifically
request this product, despite the higher risk of this adverse event compared to its occurrence following
the Pfizer vaccine. This will be primarily relevant to the booster dose program, given where we are in
the rollout of this immunization program.
Our reports of adverse events following immunization with the COVID-19 vaccines, including the
myocarditis reports (numbers and rates) are updated regularly and located here. As you know these
events are based on temporal relationship to vaccination, given that there is not a specific diagnostic
tool to differentiate these events by cause unless a specific alternate cause is identified.
Thank you,
Monika
................................
Monika Naus MD FRCPC
Medical Director, Communicable Diseases & Immunization Service
Medical Head, Immunization Programs & Vaccine Preventable Diseases
BC Centre for Disease Control
Tel 604.707.2540
Cell 604.219.4524
Assistant: Jessica Taylor (Monday - Wednesday) and Esther Cummings
(Thursday/Friday) mnds.assist@bccdc.ca Tel 604 707 2519
I gratefully acknowledge that I live on the territory of the Coast Salish Peoples.
AR01484
From: Karl Harrison

Sent: Tuesday, December 07, 2021 8:34 PM
To: Naus, Monika [BCCDC] ; Henry, Bonnie [EXT]
Cc: hlth.minister@gov.bc.ca
Subject: Moderna - SpikeVax - urgent
EXTERNAL SENDER. If you suspect this message is malicious, please forward to spam@phsa.ca and do not open
attachments or click on links.
Dr Naus and Dr Henry
No more Moderna doses for young men, after millions already given - The Western Standard
(westernstandardonline.com)
As per the above example it is being reported that Dr Teresa Tam and the National Advisory Committee
on Immunization (“NACI”) have advised (further to Dr Dina Hinshaw’s earlier adoption of a similar
position) that Canadians between the ages of 12 and 29 years should not be given shots of the Moderna
SpikeVax gene therapy.
There has been an abundance of prior and high level information widely available to indicate that
myocarditis, now accepted by NACI as at least 15.9 incidences per 100,000 of otherwise healthy young
people, could occur. Many health authorities, some superior in expertise to yours, have cautioned
about the use of unproven mRNA products in young people. Several have stopped the use of an mRNA
product for specific cohorts of their population.
You will be aware that the UK’s Joint Committee on Vaccination and Immunisation (“JCVI”) advised the
UK government against use of mRNA products for some young people. I’ve attached a helpful quote
from Professor Jeremy Brown of University College London and a member the JCVI. It was published in
the New York Times on 9th of October 2021. Professor Brown, an expert in respiratory diseases,
highlights that the great majority of our young people remain, fortunately, unaffected by the etiological
agent which may lead to development of the symptomatic disease now called ‘Covid-19’. He expresses
the myocarditis risk in explicit language and further says that “You don’t vaccinate a 15 year old to
prevent them infecting other adults – that’s not morally, ethically the right thing to do”. It may not
have been a “safe and effective” thing to do either.
Please can you provide, as matter of urgency, your government’s updated advice in relation to
SpikeVax. All I can find so far on your website is this,COVID-19_mRNA_Vaccine_mRNA-
1273_Moderna.pdf (bccdc.ca) and which appears to offer no caution to British Columbians of the kind
now being advised to Canadians by the NACI, and to Albertans by Dr Hinshaw.
I look forward to hearing from you shortly.
Regards
Karl Harrison
+
AR01485
This is EE referred to in the Affidavit of Karl Harrison sworn March 11, 2022

Sam A. Presvelos
AR01486
moderna· Menu
For healthcare providers ➔
~ .k
V\A sp1 evax™
' - / elasomeran
mRNA vaccine
mo_g~~Q_g· invites you to meet SPIKEVAX

•
(elasomeran mRNA vaccine)
Vaccination for prevention of coronavirus

disease 2019 (COVID-19) caused by the SARS-
CoV-2 virus for individuals 12 years and older.
AR01487
<Plow to aet vaccinated

AR01488
nearyou
Looking for the SPIKEVAX COVID-19 vaccine?
Use your provincial health website to find a location

near you and make an appointment.
Find where to get vaccinated
Patient medication
information
Download the document below to read about safe and effective use of SPIKEVAX.
SPIKEVAX patient medication information 71

AR01489
AR01490
AR01491
Booster information and more

Here are some helpful resources to learn more about vaccination with SPIKEVAX and COVID-19.
What is a booster? Why is it recommended? 71
Which booster is right for me? 71
~ t causes viruses to mutate? 71

~
AR01492
The science behind mRNA and SPIKEVAX
The Moderna story 71
How mRNA science works 71
Learn about messenger RNA (mRNA), and how we turned it into a vaccine to protect
against COVID-19.
a
AR01493
Moderna lipid nanoparticles explainer video

August 9, 2021 / 2 mins
Call us at
1 866 663-3762
+1-866-MODERNA
www.ModernaTX.com
Medinfo@modernatx.com
Available in English and French
8:00AM to 8:00PM EST
Monday - Friday (not including holidays)
AR01494
~ ay up to date
AR01495
- ■
Sign up to receive the latest Moderna news, events and updates.
Full name
Email
C I consent to receiving Moderna marketing communications via

email. I understand that I can always opt out at any time.
By submitting your information, you agree to Moderna's Terms and Conditions. You also
acknowledge that your information will be processed in accordance with
Moderna's PrivacY. PolicY..
This site is protected by reCAPTCHA and the Google PrivacY. PolicY. and Terms of Service
apply.
Subscribe to Moderna updates
Privacy Policy
Terms and Conditions
Important Safety Information
CA-COV-2200004 02/2022
© 2022 Moderna, Inc.

AR01496
AR01497
This is FF referred to in the Affidavit of Karl Harrison sworn March 11, 2022

Sam A. Presvelos
AR01498
BC COVID-19
STRATEGIC RESEARCH
ADVISORY COMMITTEE
Knowledge gaps relevant to

COVID-19 vaccine rollout in BC
January 29, 2021

AR01499
BC COVID-19
STRATEGIC RESE..O.RCH
ADVISORY CO"'liMITTEE
Table of Contents
Introduction .................................................................................................................................... 1
Process and Themes ....................................................................................................................... 1
Themes and Questions ................................................................................................................... 2
Appendix: Vaccine Evaluation and Research Group {VERG) Terms of Reference ..........................
1
January 29, 2021
Knowledge gaps relevant to COVI0-19 vaccine rollout in BC

AR01500
· COVID-19
STRATEGIC RESEARCH
ADVISORY COMMITTEE
Introduction
What are the most critical questions research must answer to optimize the safety, speed and
impact of a COVID-19 vaccine program rollout? This document, produced by the BC COVID-19
Strategic Research Advisory Committee (SRAC), summarizes a rapid gap analysis in late 2020
towards determining these questions.
The document will be used by SRAC to advise on research related to vaccine rollout in BC,
including through the SRAC Vaccine Evaluation Working Group (VERG - see appendix for terms
of reference), established to advise the Immunize BC Operations Centre Committee (IBCOC).
IBCOC provides oversight and governance for the planning, implementation and administration
of the COVID-19 mass immunization campaign and reports to the Deputy Minister of Health and
the Provincial Health Officer with ultimate accountability to the Minister of Health and the
Premier.
Use of the document, which is posted to the SRAC website, is also encouraged by the research
community, including funders who aim to support research that will assist in BC's vaccine rollout,
and researchers applying to funding opportunities.
SRAC recognizes this document was created at one point in time in a rapidly evolving
environment. Therefore, readers are encouraged to visit the BC Academic Health Science
Network Inventory of COVID-19 Research for a listing of research underway, and/or to visit t he
SRAC webpage for updates or to contact us with questions.
Process and Themes

To create the gap ana lysis, input was sought in late 2020 from public health practitioners,
the Immunize BC Operations Committee, and the BC Provincial Health Officer. In addition,
a Twitter consultation was conducted, as well as review a of the National Advisory Committee
on Immunization (NACI) Research Priorities for COVID-19 Vaccines to Support Public Health
Decisions statement1 and the BC COVID-19 Strategic Research Advisory Committee's (SRAC)
BC COVID-19 Strategic Research Framework. 2
Six themes were developed from the input and reviews
• Vaccine effectiveness - preventing illness and infection

• Vaccine effectiveness - reducing transmission
• Vaccine immunogenicity
• Monitoring for adverse effects
• Concerns of British Columbians
• Equitable access
January 29, 2021
Knowledge gaps relevant to COVID-19 vaccine rollout in BC 1

AR01501
BC COVID-19
STRATEGIC RESE.ARCH
ADVISORY COMMITTEE:
In addition to the vaccine-specific themes, SRAC notes there is also an opportunity to study t he
effectiveness of the vaccine rol lout itself. For example, to what extent did it prevent mortality
and morbidity in the BC population; were the right popu lations prioritized; was t he plan -
includ ing logistics, communications and strategies to encourage uptake - well-execut ed, an d
more. Additional questions w ill arise from the rollout as wel l, for example, the role of vaccine use
in the control of clusters and outbreaks pending full population coverage, or the need for
mandatory vaccinat ion of workers who expose others to risk.
As stakeholders review and prepare to act on the themes and questions in the next section, SR C
advises careful consideration of:
• What needs to be studied in t he BC popu lation vs. what can be learned from stud ies in
other jurisdictions?
• What would idea lly be studied as part of a Canada-wide or at least multi-province effort?
• What evidence needs to be generated through research vs. being rapidly gathered and
synthesized?
• What are immediate and urgent questions vs. important but less immediate?
• What is needed to ensure research evide nee is not just generated, but put into action
(e.g. working with policy makers and other 'end users' from the beginning)?
Themes and Questions

1. What is the effectiveness of the vaccine in preventing illness and infection?
o Comparative effectiveness of the various vaccine products in the BC population

real-time effectiveness evaluat ions.
o Effectiveness in populations not represented in clinical trials (e.g. pregnant
women, children and immunocompromised people).
o Impact of prior infection with COVID-19 or seasonal coronaviruses on vaccine
effectiveness and impact of vaccination on future infection wit h coronaviruses.
o Effectiveness of immunization for those who receive only the first dose of a
two- dose series.
o Exploration of any risk of antibody-dependent disease enhancement.
2. What is the effectiveness of the vaccine in reducing transmission?
o Determine if immunization also prevents asymptomatic infection and onward

transmission.
January 29, 2021

AR01502
BC COVID-19
STRATEGIC RESEARCH
ADVISORY COMMITTE
3. What is the immunogenicity of the vaccine?
o Characterize the humeral and cell-mediated protective immunity elicited by the

vaccine products.
o Understand correlates of protection following vaccination.
o Explore the impact of prior infection with COVID-19 or seasonal coronaviruses on
humoral and cell-mediated immunity and impact of vaccination on future
infection with coronaviruses.
4. How do we monitor for adverse effects following immunization {AEFI)?
o Assess the rate of AEFls with vaccine rollout across all vaccine products
(and how they compare to the background rates of these symptoms) .
o The rate of AEFls in children, imnnunocompromised individuals, pregnant and
breastfeeding individuals and others excluded from the t rials.
o Vaccine safety data for groups excluded from the trials.
5. What concerns do British Columbians have about the vaccine?
o Establish which groups of people have which concerns.

o Where do these groups of people get their health-related information and whom
do they trust?
o How can trusted community leaders be supported to provide information and
address concerns?
o How can social media networks be used to distribute information and address
concerns?
o How can existing institutions (e.g. schools) and their programs be used to inform
specific groups (e.g. youth) and encourage conversation about vaccines and the
COVID-19 vaccination?
6. How do we deliver equitable access to vaccination?
o How can equitable access to vaccination be ensured for racialized communities

that have been disproportionately affected by COVID-19 in BC?
o How can vaccine best be provided to persons with mobility issues or who live in
rural/remote locations (in the context of storage/distribution challenges)?
o How can cu lturally-safe vaccine rollout be best established for Indigenous peoples
identified to be most at risk of severe COVID-19 infection?
o How can ongoing monitoring of VE and AEFI among Indigenous peoples who are
vaccinated be culturally-safe?
January 29, 2021

AR01503
BC COVID-19
STRATEGIC RESEARCH
ADVISORY COMMITTEE
1
NACI. Research Priorities for COV/0-19 Vaccines to Support Public Health Decisions. Available
from: ht tps://www.canada.ca/en/public-health/services/immunization/national-advisory-
committee-on-immunization-naci/research-priorities-covid-19-vaccines.html
2 BC COVID-19 SRAC (Dec 2020). BC COV!D-19 Strategic Research Framework: An Evolving Guid,
for Decision-Makers and Researchers (Issue 2). Available from:
https://www.msfhr.org/sites/default/fi1es/SRAC%20Framework%20lssue2 dec4.pdf
January 29, 2021
'
.~ Knowledge gaps relevant to COVID-19 vaccine rollout in BC 4
AR01504
BC COVID-19
STRATEGIC RESEARCH
ADVISORY COMMITTEE
Appendix: Vaccine Evaluation and Research Group (VERG)

Terms of Reference
Purpose
The purpose of this Working Group is to identify and support research activities that can inform a
fast, safe, and effect ive mass COVID-19 immunization for the citizens of British Columbia.
Term
The Working Group was formed on December 9, 2020 and will continue at the call of the BC
COVID-19 Strategic Research Advisory Committee and the Immunize BC Operations Centre
Committee.
Structure and membership

The Working Group
The Working Group reports to t he BC COVID-19 Strategic Research Advisory Committee and will
provide advice to the Immunize BC Operations Centre Committee through the Director/Incident
Commander, Dr. Ross Brown.
Dr. David Patrick is the Chair of the Working Group.
The Working Group is supported by the BC COVID-19 Strategic Research Advisory Committee.
Secretariat
Secretariat support w ill be provided by the BC COVID-19 Strategic Research Advisory Committee.
Judith Hutson is the Project Manager/Secretariat for this Working Group.
Meetings and meeting frequency

Meetings wi ll be chaired by Dr. David Patrick and wil l be schedu led twice a week.
January 29, 2021
Knowledge gaps relevant to COVI0-19 vaccine rollout in BC 5

AR01505
BC COVID- 19
STRATEGIC RESEARCH
ADVISORY COMMITTff
M embership
M embers Organization
David M. Patrick (Chair)

Director of Research and M edical Epidemiology Lead for i
BCCDC
Antimicrobial Resistance
Co-Chair BC COVID-19 Strategic Research Advisory Comm ittee
Judith Hutson (Secretariat)

BC COVID-19
Project Manager/ Secretariat BC COVID-19 Strategic Research
SRAC
Advisory Committee
Victoria Schuckel
Executive Director, Research and Technology BC MOH
Member, BC COVID-19 Strategic Research Advisory Committee
Monika Naus
Medical Director, Communicable Diseases & Immunization
BCCDC
Service/ Medical Head, Immunization Programs & Vaccine
I
Preventable Diseases
Brent Gabel I
Research Analyst, Communicable Diseases and Immunization BCCDC
Service
Danuta Skowronski
Epidemiology Lead, Influenza & Emerging Respiratory Pathogens, BCCDC
BCCDC
Mel Krajden
Medica l Director, BCCDC Public Health Laboratory BCCDC
Medical Head, Hepatitis - Clinical Prevention Services, BCCDC
Michael Otterst atter

BCCDC
Senior Scientist and Epidemiologist, BCCDC
Kate Smolina
Director of the BC Observatory for Population & Public Health, BCCDC
BCCDC
Gina Ogilvie
BCCDC
Senior Public Hea lth Scientist, BCCDC
January 29. 2021
Knowledge gaps relevant to COVI0-19 vaccine rollout in BC 6

AR01506
BC COVID-19
STRA l EGIC RESl::ARC H
ADVISORY COMMITTEE
Members Organization
Hannah Lishman, PhD

Postdoctoral Research Fellow, UBC School of Population and Public
BCCDC
Health, BC Centre for Disease Control - Community Antimicrobial
Stewardship
Manish Sadarangani BC Children's

Director, Vaccine Evaluation Center, BC Children's Hospital Hospita l Research
Research Institute Institute
Julie Bettinger BC Children' s

Vaccine Safety Scientist, Vaccine Evaluation Center, BC Children's Hospital Research
Hospital Research Institut e Institute
Alice Virani
Director, Ethics Service, Provincial Health Services Authorit y PHSA
Member, BC COVID-19 Strategic Research Advisory Committ ee
Martin T Schechter
Professor, Faculty of Medicine, School of Population and Public
UBC
Health, UBC
M ember, BC COVID-19 St rategic Research Advisory Committee
January 29, 2021
l<nowledge gaps relevant to COVID-19 vaccine rollout in BC 7

AR01507
AR01508
This is GG referred to in the Affidavit of Karl Harrison sworn March 11, 2022

Sam A. Presvelos
AR01509
FDA-CBER-2021-5683-0000054
AR01510
FDA-CBER-2021-5683-0000055
AR01511
FDA-CBER-2021-5683-0000056
AR01512
FDA-CBER-2021-5683-0000057
AR01513
“Monthly safety reports primarily focus on events that occurred during the reporting interval
and include information not relevant to a BLA submission such as line lists of adverse events
by country. We are most interested in a cumulative analysis of post-authorization safety data
to support your future BLA submission. Please submit an integrated analysis of your
cumulative post-authorization safety data, including U.S. and foreign post-authorization
experience, in your upcoming BLA submission. Please include a cumulative analysis of the
Important Identified Risks, Important Potential Risks, and areas of Important Missing
Information identified in your Pharmacovigilance Plan, as well as adverse events of special
interest and vaccine administration errors (whether or not associated with an adverse event).
Please also include distribution data and an analysis of the most common adverse events. In
addition, please submit your updated Pharmacovigilance Plan with your BLA submission.”
FDA-CBER-2021-5683-0000058
AR01514
■
(b) (4)
-
(b) (4)
-
(b) (4)
FDA-CBER-2021-5683-0000059
AR01515
FDA-CBER-2021-5683-0000060
AR01516
Ge neral diso rde rs
Neivous system
Musrnloskeletal
Gas troin tes tinal
Res piratory
Injury/procedural co mpl ica tions

lnfoc tions
Invesligations
Cardiac
Psychiatric _
Blood & lymphatic lJ
Eye E
Immune I
Ear & labyrinth I
Metabolis m & nutrition
Product iss ues
Re nal & urinary
Re prod uctive & breas t I
Social cire wns lances

FDA-CBER-2021-5683-0000061
HeJX1 lob iIiary

Neo plas ms
Pregnancy iii
Endocrine -
onge nital & ge netic
Surg ical & medical procedures 1 1 1 1 1 1 '-'<!..JI

AR01517
FDA-CBER-2021-5683-0000062
AR01518
Total
FDA-CBER-2021-5683-0000063
AR01519
FDA-CBER-2021-5683-0000064
AR01520
•
•
FDA-CBER-2021-5683-0000065
AR01521
•
•
•
•
•
•
•
o
o
o
•
o
FDA-CBER-2021-5683-0000066
AR01522
Lack of efficacy cases

•
Drug ineffective cases (1649)

•
•
o
o
o
•
o
o
o
•
o
o
o
•
o
o
o
FDA-CBER-2021-5683-0000067
AR01523
Vaccination failure cases (16)

•
•
•
o
o
FDA-CBER-2021-5683-0000068
AR01524
Search criteria: Anaphylactic

reaction SMQ (Narrow and Broad,
with the algorithm applied),
selecting relevant cases according
to BC criteria
•
Search criteria: PTs Acute
myocardial infarction;
Arrhythmia; Cardiac failure; •
Cardiac failure acute;
Cardiogenic shock; Coronary
artery disease; Myocardial
infarction; Postural orthostatic
tachycardia syndrome; Stress
cardiomyopathy; Tachycardia
•
•
• <
FDA-CBER-2021-5683-0000069
AR01525
•
Search criteria: Covid-19 SMQ
(Narrow and Broad) OR PTs
Ageusia; Anosmia •
•
•
• >
•
Search criteria: PT Chillblains;
Erythema multiforme
•
•
•
•
FDA-CBER-2021-5683-0000070
AR01526
• <
•
Search criteria: Leukopenias NEC
(HLT) (Primary Path) OR •
Neutropenias (HLT) (Primary
Path) OR PTs Immune
thrombocytopenia
Thrombocytopenia OR SMQ
Haemorrhage terms (excl
laboratory terms
•
•
• <
•
Search criteria: Liver related
investigations, signs and symptoms •
(SMQ) (Narrow and Broad) OR
PT Liver injury
•
•
FDA-CBER-2021-5683-0000071
AR01527
• <
•
Search criteria: PTs Facial
paralysis, Facial paresis •
•
•
•
•
FDA-CBER-2021-5683-0000072
AR01528
Search criteria: Immune- •

mediated/autoimmune disorders
(SMQ) (Broad and Narrow) OR
Autoimmune disorders HLGT
(Primary Path) OR PTs Cytokine
release syndrome; Cytokine storm; •
Hypersensitivity •
•
Search criteria: PTs Arthralgia;
Arthritis; Arthritis bacterial ; •
Chronic fatigue syndrome;
Polyarthritis; Polyneuropathy;
Post viral fatigue syndrome;
Rheumatoid arthritis
•
•
FDA-CBER-2021-5683-0000073
AR01529
Search criteria: Convulsions •

(SMQ) (Broad and Narrow) OR
Demyelination (SMQ) (Broad and
Narrow) OR PTs Ataxia;
Cataplexy; Encephalopathy •
Fibromyalgia; Intracranial •
pressure increased; Meningitis; •
Meningitis aseptic; Narcolepsy
•
•
Search criteria: Herpes viral
infections (HLT) (Primary Path)
OR PTs Adverse event following •
immunisation; Inflammation;
Manufacturing laboratory
analytical testing issue;
Manufacturing materials issue;
Manufacturing production issue;
MERS-CoV test; MERS-CoV test
negative; MERS-CoV test positive;
Middle East respiratory syndrome; •
Multiple organ dysfunction •
syndrome; Occupational exposure
to communicable disease; Patient
FDA-CBER-2021-5683-0000074
AR01530
isolation; Product availability •

issue; Product distribution issue;
Product supply issue; Pyrexia; •
Quarantine; SARS-CoV-1 test;
SARS-CoV-1 test negative; SARS-
CoV-1 test positive
Search criteria: PTs Amniotic Use in Pregnancy and While Breast Feeding
cavity infection; Caesarean
section; Congenital anomaly;
Death neonatal; Eclampsia;
Foetal distress syndrome; Low
birth weight baby; Maternal
exposure during pregnancy;
Placenta praevia; Pre-eclampsia;
Premature labour; Stillbirth;
Uterine rupture; Vasa praevia
•
Search criteria: PTs Acute kidney
injury; Renal failure. •
•
•
•
•
• <
•
Search criteria: Lower respiratory
tract infections NEC (HLT)
FDA-CBER-2021-5683-0000075
AR01531
(Primary Path) OR Respiratory •

failures (excl neonatal) (HLT)
(Primary Path) OR Viral lower
respiratory tract infections (HLT)
(Primary Path) OR PTs: Acute •
respiratory distress syndrome; •
Endotracheal intubation; Hypoxia;
Pulmonary haemorrhage; •
Respiratory disorder; Severe acute
respiratory syndrome •
•
Search criteria: Embolism and
thrombosis (HLGT) (Primary •
Path), excluding PTs reviewed as
Stroke AESIs, OR PTs Deep vein
thrombosis; Disseminated
intravascular coagulation;
Embolism; Embolism venous; •
Pulmonary embolism •
•
• >
•
Search criteria: HLT Central
nervous system haemorrhages and •
cerebrovascular accidents
FDA-CBER-2021-5683-0000076
AR01532
(Primary Path) OR HLT

Cerebrovascular venous and sinus
thrombosis (Primary Path)
•
•
•
• >
o
•
Search criteria: Vasculitides HLT
•
•
•
•
•
• <
FDA-CBER-2021-5683-0000077
AR01533
FDA-CBER-2021-5683-0000078
AR01534
FDA-CBER-2021-5683-0000079
AR01535
FDA-CBER-2021-5683-0000080
AR01536
FDA-CBER-2021-5683-0000081
AR01537
FDA-CBER-2021-5683-0000082
AR01538
FDA-CBER-2021-5683-0000083
AR01539
FDA-CBER-2021-5683-0000084
AR01540
FDA-CBER-2021-5683-0000085
AR01541
FDA-CBER-2021-5683-0000086
AR01542
FDA-CBER-2021-5683-0000087
AR01543
FDA-CBER-2021-5683-0000088
AR01544
FDA-CBER-2021-5683-0000089
AR01545
FDA-CBER-2021-5683-0000090
AR01546
FDA-CBER-2021-5683-0000091
AR01547
This is HH referred to in the Affidavit of Karl Harrison sworn March 11, 2022

Sam A. Presvelos
AR01548
English translation
BKK ProVita
The health insurance for life
BKK ProVita 85217 Bergkirchen
Paul-Ehrlich-lnstitut Prof.
Dr. Klaus Cichutek
Paul-Ehrllch-Str. 51-
63225 Langen
You are attended to by

Andreas SchOfbeck
MUnchner Weg 5
85232 Bergkirchen
T 08131/6133-1000
F 08131/6133-91000
Andreas.Schoefbeck@bkk-provita.de
21.02.2022
Severe warning signal of coded vaccination side effects after Corona vaccination
Dear Prof. Dr. Cichutek,
The Paul Ehrlich Institute has announced via press release that 244,576 suspected cases for
vaccination side effects after Corona vaccination were reported for the calendar year 2021.
The data available to us give us reason to believe that there is a very significant under-reporting of
suspected cases of vaccine adverse events following Corona vaccination. I am enclosing an evaluation
of this in my letter.
The data basis for our evaluation is physician billing data. Our sample is from the anonymized data
set of the company health insurance funds. The sample comprises 10,937,716 insured persons. So
far, we have the physicians' billing data for the first half of 2021 and approximately half for the third
quarter of 2021. Our query includes valid ICD codes for vaccination adverse events. This analysis has
shown, although we do not yet have the complete data for 2021, that based on the available figures
we now already assume 216,695 treated cases of vaccination side effects after Corona vaccination
from this sample. If these figures are extrapolated to the whole year and to the population in
Germany, probably 2.5-3 million people in Germany have received medical treatment for vaccination
side effects after Corona vaccination.
We regard this as a considerable alarm signal that must be taken into account in the further use of
vaccines. In our view, the figures can be validated relatively easily and also in the short term by
asking the other types of health insurance funds (AOKs (General Local Health Insurances),
Ersatzkrankenkassen (substitute health insurance funds), etc.) for a corresponding evaluation of the
AR01549
data available to them. Extrapolated to the number of vaccinated people in Germany, this means
that about 4-5% of vaccinated people received medical treatment for vaccination side effects.
In our opinion, there Is a considerable underreporting of vaccination side effects. It is an important

concern to identify the causes for this in the short term. Our first guess is that, since no remuneration
is paid for reporting vaccine adverse events, reporting to the Paul Ehrlich Institute Is often not done
because of the great expense involved. Physicians have reported to us that reporting a suspected
vaccine adverse event takes about half an hour. This means that 3 million suspected cases of vaccine
adverse events require about 1.5 million working hours of physicians. That would be almost the
annual workload of 1,000 physicians. This should be clarified in the same short term. A copy of this
letter will therefore also be sent to the Bundesiirztekammer (German Medical Association) and the
Kassenarrtliche Bundesvereinigung (Federal Association of Statutory Health Insurance Physicians).
The GKV-Spitzenverband (Central association of statutory health insurers)will also receive a copy of
this letter with the request to obtain corresponding data analyses from all health insurance
companies.
Since danger to human life cannot be ruled out, we request that you provide feedback on the
measures initiated by 22.2.2022 18.00 hrs.
Yours sincerely
Signature
Andreas SchOfbeck Executive Board
This letter should also be sent in writing to:

GKV-Spitzenverband (Central association of statutory health insurers)
Bundesarztekammer (German Medical Association)
Kassenarztliche Bundesvereinigung {Federal Association of Statutory Health Insurance Physicians)
Standige lmpfkommission (Permanent Vaccination Commission)
BKK Dachverband (BKK umbrella organization)
GKV-Spitzenverband
Translated with www.Deepl.com/Translator {free version)

AR01550
BKK ProVita
Die Kasse fOrs Leben
BKK ProVita 85217 Bergkirchen
Paul-Ehrlich-lnstitut Prof.
Dr. Klaus Cichutek
Paul-Ehrllch-Str. 51 -
63225 Langen
Es betreut Sie
Andreas SchOfbeck
MOnchner Weg 5
85232 Bergkirchen
T 08131/6133-1000
F 08131/6133-91000
Andreas.Schoefbeck@bkk-provita.de
21.02.2022
Heftiges Warnsignal bei codlerten lmpfnebenwlrkungen nach Corona lmpfung
Sehr geehrter Herr Prof. Dr. Cichutek,
Das Paul-Ehrlich-lnstitut hat mittels Pressemitteilung bekannt gegeben, dass fUr das Kalenderjahr
2021244.576 Verdachtsfalle tor lmpfnebenwlrkungen nach Corona lmpfung gemeldet wurden.
Die unserem Haus vorliegenden Oaten geben uns Grund zu der Annahme, dass es elne sehr
erhebliche Untererfassung von Verdachtsfallen for lmpfnebenwirkungen nach Corona lmpfung gibt.
Dazu fOge ich meinem Schreiben eine Auswertung bei.
Datengrundlage for unsere Auswertung sind die Abrechnungsdaten der Arzte. Unsere Stichprobe
erfolgt aus dem anonymisierten Datenbestand der Betriebskrankenkassen. Die Stichprobe umfasst
10.937.716 Versicherte. Uns liegen bisher die Abrechnungsdaten der Arzte fOr das erste Halbjahr
2021 und circa zur Haltte fur das drltte Quartal 2021 var. Unsere Abfrage beinhaltet die gultigen ICD-
Codes tor lmpfnebenwirkungen. Diese Auswertung hat ergeben, obwohl uns noch nicht die
kompletten Oaten fiir 2021 vorliegen, dass wir anhand der vorliegenden Zahlen jetzt schon van
216.695 behandelten Fallen van lmpfnebenwirkungen nach Corona lmpfung aus dieser Stichprobe
ausgehen. Wenn diese Zahlen auf das Gesamtjahr und auf die BevOlkerung in Deutschland
hochgerechnet werden, sind vermutlich 2,5-3 Millionen Menschen in Deutsch land wegen
lmpfnebenwirkungen nach Corona lmpfung in arztlicher Behandlung gewesen.
Das sehen wir als erhebliches Alarmsignal an, das unbedlngt beim weiteren Einsatz der lmpfstoffe
berOcksichtigt werden muss. Die Zahlen kOnnen in unseren Au gen relativ leicht und auch kurzfristig
validiert werden, indem die anderen Kassenarten (AO Ken, Ersatzkrankenkassen etc) um eine
entsprechende Auswertung der Ihnen vorliegenden Oaten gebeten werden. Hochgerechnet auf die
Anzahl der geimpften Menschen in Deutsch land bedeutet dies, dass circa 4-5 % der geimpften
Menschen wegen lmpfnebenwirkungen in arztlicher Behandlung waren.
AR01551
In unseren Augen liegt eine erhebliche Untererfassung der lmpfnebenwirkungen var. Es ist ein
wichtiges Anliegen die Ursachen hierfUr kurzfristig auszumachen. Unsere erste Vermutung ist, da, da
keine VergUtung fUr die Meldung van lmpfnebenwirkungen bezahlt wird, eine Meldung an das Paul
Ehrlich lnstitut wegen des groBen Aufwandes vielfach unterbleibt. Arzte haben uns berichtet, dass
die Meldung eines lmpfschadenverdachtsfalls circa eine halbe Stunde Zeit in Anspruch nimmt. Das
bedeutet, dass 3 Millianen Verdachtsfalle auf lmpfnebenwirkungen circa 1,5 Millianen
Arbeitsstunden van Arztinnen und Arzten erfardern. Das ware nahezu die j8hrllche Arbeitsleistung
van 1000 A.rztinnen und A.rzten. Dies sallte ebensa kurzfristig geklart werden. Deshalb ergeht eine
Durchschrift dieses Schreibens auch an die Bundesarztekammer und die Kassen.lirztliche
Bundesvereinigung.
Der GKV-Spitzenverband erhalt ebensa eine Abschrift dieses Schreibens mlt der Bltte entsprechende
Datenanalysen bei samtlichen Krankenkassen einzuhalen.
Da Gefahr fiir das Leben van Menschen nicht ausgeschlassen werden kann, bitten wir Sie um eine
RUckauBerung Uber die veranlassten MaBnahmen bis 22.2.2022 18.00 Uhr.
Mit freundlichen GrUBen
Unterschrift
Andreas Schofbeck Vorstand
Das Schreiben ergeht durchschriftlich ebensa an:

GKV-Spitzenverband
Bundesarztekammer
Kassenarztliche Bundesvereinigung
Standige lmpfkammissian
BKK Dachverband
AR01552
This is II referred to in the Affidavit of Karl Harrison sworn March 11, 2022

Sam A. Presvelos
AR01553
l♦I
Statistics
Canada
Statistique
Canada
Canada
AR01554 The Daily, Monday, December 6, 2021
2 Component of Statistics Canada catalogue no. 11-001-X

AR01555
This is KK referred to in the Affidavit of Karl Harrison sworn March 11, 2022

Sam A. Presvelos
AR01556
Video Title: Federal health officials provide COVID-19 update

Dated March 4, 2022
Link: https://www.youtube.com/watch?v=7FZWbEJLGzk
AR01557
This is Exhibit “LL” referred to in the Affidavit of Karl Harrison sworn March 11, 2022

Sam A. Presvelos
AR01558
AR01559
SHAUN RICKARD AND - and - HER MAJESTY THE QUEEN, as represented by the ATTORNEY
KARL HARRISON GENERAL OF CANADA and TRANSPORT CANADA
Applicants Respondents
Court File No.: T-1991-21-ID
FEDERAL
COURT OF CANADA
Proceeding Commenced at Toronto, Ontario
AFFIDAVIT OF KARL HARRISON

VOLUME 2 OF 2
PRESVELOS LAW LLP

141 Adelaide Street West, Suite 1006
Toronto, Ontario
M5H 3L5
Sam A. Presvelos (LSO #:

Tel:
Email:
Evan A. Presvelos (LSO #: )

Tel:
Email:
Lawyers for the Applicants

AR01560
TAB 8
AR01561
Court File No.: T-1991-21
FEDERAL COURT OF CANADA
BETWEEN:
SHAUN RICKARD AND KARL HARRISON

Applicants
- and -
HER MAJESTY THE QUEEN, as represented by ATTORNEY GENERAL OF

CANADA and TRANSPORT CANADA
Respondents
AFFIDAVIT OF SHAUN RICKARD
1. I, Shaun Rickard, of the City of Pickering in the Province of Ontario, MAKE OATH AND SAY
AS FOLLOWS:
2. I have been personally involved in the matters to which I herein depose. Where my knowledge and
information is based on other sources, I have stated the source of such knowledge and information
and verily believe it to be true.
3. My name is Shaun Rickard. I am 54 years of age and I live in Pickering, Ontario.
4. I was born in Bournemouth in the south of England and lived in the UK until I officially moved to
Canada in 1999.
5. I originally came to Canada in 1989 for a vacation. I was 20 years old at the time and excited to
explore this beautiful country. I immediately fell in love with all that Canada had to offer, and I
knew the moment I set foot in Ontario that I would one day make Canada my new home. As an
outdoorsman and sport fisherman, I was in awe at the seemingly infinite wilderness destinations,
pristine lakes, and open spaces there were to explore and adventure in.
AR01562
6. For 10 years I travelled back and forth between the UK and Canada. I then met my partner, and
subsequently my wife, and made the permanent move to Canada. Although my wife and I have
since divorced, I have remained a permanent resident of Canada since June 12th, 1999.
7. Currently, I own and operate my own contracting business called ‘Home Doctor’, which
specializes in the replacement of exterior siding and eaves for private homeowners. I founded the
business 10 years ago and since then it has grown to employ multiple sub-contractors and
installation crews during peak season. Home Doctor has also consistently received awards and
top reviews for the quality of our work.
Travelling is an Important Part of My Life and Identity
8. The ability to travel to other countries has been an extremely important right in my life.
9. I have a 90-year-old father back in England who has advanced Alzheimer’s, so it is important that
I visit him as much as I can, especially considering he could pass away at any time. I love my
father and the thought of being unable to visit him considering his age and condition is
heartbreaking.
10. I also travel with my partner of 7 years, Jodi, as well as with my brother, John, whenever time
permits. Travel is an opportunity for us to spend quality time together, build new memories and
share experiences. My entire family still reside in the UK, including my brother John, so we always
put at least 2 weeks aside each year to either visit one another or travel and spend important family
time together.
11. Traveling during the Winter months is extremely helpful for me because my business very rarely
allows allow me to take time off during our incredibly busy Spring, Summer and Fall work season.
12. Put simply, traveling is an important aspect of my social and family life as well as my mental well-
being.
2
AR01563
13. As a result of the federal government’s travel ban announced by Prime Minister Trudeau, I can no
longer leave this country. This means I cannot see my father, who is in a very frail condition. In
fact, on account of the pandemic, I have not seen my father in over 2 years. I also cannot travel
with my partner and her children for the annual family vacations we take between December and
February each year. This year they travelled without me. I also have been unable to see my brother
John for over 2 years now. Being unable to spend time with my family in this way has had a
significant impact on my morale and happiness. It has put a strain on my entire family.
14. I also own and operate Euro Canadian Outfitters Inc, a small fishing and outdoor video production
company which I created and launched just prior to the pandemic.
15. In late 2020 I was invited to Oman to shoot fishing videos to promote the world class fishing that
the country has to offer for sports fishermen and tourists from around the world. Oman was looking
to create an online presence and boost tourism for its country specifically in this category.
16. The person who contacted me wanted to hire myself and a small film crew to come out for three
weeks to shoot promotional videos. These videos were going to be released on several social media
sites. Months of planning and the assembling of a skilled crew followed… but sadly in February
of 2021 we were forced to reschedule the trip until February 2022 due to the high Covid case
numbers in Oman. Given the Prime Minister’s travel ban, this project will no longer happen.
Losing this unique opportunity has impacted my ability to grow this business.
17. In addition to the Oman trip, I also had several trips planned to the Caribbean to shoot videos for
my own YouTube channel, which I started prior to the pandemic. These videos would help to
promote fishing in Caribbean regions. As I am legally prohibited from leaving my country due to
my vaccination status, these trips were also cancelled. This has resulted in lost future income and
a loss of exposure these opportunities would have provided for my fledgling business.
3
AR01564
18. Because of Canada’s travel restrictions, I literally feel like a prisoner in my own country. The
effects of this policy – which were introduced at a time when most Canadians were vaccinated -
seemed vindictively motivated. It has taken a heavy toll in my mental health, and I would imagine
on the mental health of many Canadians in my position.
COVID-19 and My Decision not to get Vaccinated
19. I have received many vaccines throughout my life. I am not against vaccines and never will be.
However, I was never forced into taking any of these vaccines and I always consulted with my
doctors and did my own research before deciding to be vaccinated.
20. As a citizen living in a democracy, I believe I have an obligation and right to be informed of matters
that directly affect my welfare. I take seriously the opportunity to look through relevant
information from several sources when making major decisions in my life. I do not simply rely
on authority as a basis to uncritically accept certain advice, recommendations or statements as
necessarily being true and correct. To be clear, I am not saying that I know better than experts in
any given field, but only that I am capable of considering information from several experts, sources
and data in making any informed decisions. I believe that this is the essence of informed consent.
21. Consider, for instance, the following excerpt on informed consent by the Canadian Medical
Protective Association’s handbook, Consent: A guide for Canadian physicians:
For consent to treatment to be considered valid, it must be an "informed" consent. The

patient must have been given an adequate explanation about the nature of the proposed
investigation or treatment and its anticipated outcome as well as the significant risks
involved and alternatives available. The information must be such as will allow the patient
to reach an informed decision. In situations where the patient is not mentally capable, the
discussion must take place with the substitute decision maker.
22. This handbook also discussed a corollary concept of “informed refusal”:
When patients decide against recommended treatment, particularly urgent or medically

necessary treatment, discussions about their decision must be conducted with some
sensitivity. While recognizing an individual's right to refuse, physicians must at the same
time explain the consequences of the refusal without creating a perception of coercion in
4
AR01565
seeking consent. Refusal of the recommended treatment does not necessarily constitute
refusal for all treatments. Reasonable alternatives should be explained and offered to the
patient.
Attached hereto as Exhibit “A” is a true copy of the CMPA’s Consent: A Guide for Canadian
physicians updated April 2021.
23. There is no question that Covid-19 has been terrible, resulting in the deaths and hospitalizations
of many people around the world. At the onset of the pandemic, I was frightened as to the virus’
capability and trajectory over the next several months and years. I felt compelled to do something.
24. At the outset of the pandemic PPE shortages for our local long term care facilities and adult day
care programs in Durham Region was a huge problem. These items simply were not readily
available for these organizations to purchase and were incredibly expensive due to the surge in
demand. To help protect our local LTC workers, nurses, and staff, I set up a fundraiser to source
and buy as much PPE equipment as I could get my hands on. I raised money through a GoFundMe
page which I then used to purchase face masks, surgical gowns, face shields, hand sanitizer and
surgical gloves from all over the world. After contacting organizations such as Community Care
Durham and others, I began distributing these items to all their staff. Words cannot express how
powerful this experience was for me. These organizations were so grateful to have the protection
and peace of mind they needed and deserved.
25. However, as the pandemic continued to evolve, I started to realize that some things did not add up
for me and that our understanding of the virus, and the vaccine that was developed, was incomplete
to a worrying degree.
26. For example, there has and continues to be a sweeping focus over Covid-19 as a health risk to our
community at the exclusion of almost all other important health risks. I wondered how
proportionate the media and other attention that was given to Covid-19 was with what we were
observing from this virus. To illustrate, the cumulative deaths associated with Covid-19 since early
2020 across Canada is estimated at 37,039. In contrast, expected deaths from cancer in 2021, alone,
5
AR01566
was 84,600 with 1 in 4 Canadians expected to die from cancer. Deaths caused by heart disease
during the same time was 106,988. Attached hereto as Exhibit “B” is a true copy of Statistics
Canada report, Covid-19 Pandemic in Canada: year-end update on Social and Economic Impacts;
attached hereto as Exhibit “C” is a true copy of Canadian Cancer Statistics 2021 published by the
Canadian Cancer Statistics Advisory Committee; attached hereto as Exhibit “D” is a true copy of
Statistics Canada webpage on the leading causes of death, total population, by age group.
27. Some statistics that I found interesting and relevant in understanding the risk of Covid-19 include
the following:
a. 47% of men who died because of Covid-19 were over the age of 85.
b. 94% of those who died of Covid-19 were over the age of 65, of which 89% had one co-
morbidity and 46% had three or more comorbidities.
Attached hereto as Exhibit “E” is a true copy of Statistics Canada’s report, Provisional Death
Counts and Excess Mortality January 2020 to February 2021.
28. Notably, according to Statistics Canada, between March 2020 and May 2021 (during which time
very little of our population was vaccinated) there were approximately 19,884 or 5% excess deaths
that, “were largely occurring among seniors and were mostly attributable to COVID-19.” From
this figure and during this same period, a significant number of deaths (estimated at 6,946) were
due to opioid use.
29. As an aside, sadly, one of the negative impacts of the Covid-19 pandemic, and the measures
implemented to address the pandemic, has been an increase in substance abuse. For example:
c. 30% of people increased their alcohol consumption and 40% increased cannabis use.
d. Opioid-related harms increased by 36% for emergency departments and 30% for
hospitalizations.
e. There was an 88% increase in Opioid toxicity deaths.
6
AR01567
Attached hereto as Exhibit “F” is a true copy of the report, Unintended Consequences of
Covid-19: Impact on harms caused by substance use, self-harm and accidental falls published
by Canadian Institute for Health Information.
30. These statistics helped me begin to understand the risk of death from Covid-19, which is important
in assessing whether to take a vaccine. Add to this the fact that this vaccine had be rapidly
developed with mRNA technology that had never been available for human use - I was
understandably cautious.
31. Statements made by public health authorities throughout the pandemic have also given me cause
for concern. Some of these key statements, as highlighted in Mr. Karl Harrison’s affidavit, proved
to be untrue. One example is Dr. Theresa Tam’s early statement on masking, when she remarked
that individuals who are not sick and have not been around someone with a confirmed case of
Covid-19 should not wear a mask. She subsequently corrected her position and claimed that masks
play an important role in controlling the spread of Covid-19. Attached hereto as Exhibit “G” is a
true copy of the Globe and Mail article, Dr. Tam’s about-face on masks damages trust at a crucial
time.
32. Interestingly, Dr. Anthony Fauci made a similar statement about masks at the beginning of the
Covid-19 pandemic:
There’s no reason to be walking around with a mask. When you’re in the middle of an
outbreak, wearing a mask might make people feel a little bit better and it might even block
a droplet, but it’s not providing the perfect protection that people think that it is. And, often,
there are unintended consequences — people keep fiddling with the mask and they keep
touching their face.
Attached hereto as Exhibit “H” is a true copy of an article from Reuters, Fact check: Outdated
video of Fauci saying “there’s no reason to be walking around with a mask”.
7
AR01568
33. Both Dr. Fauci and Dr. Tam revised their position on masking. In fact, in October 2020, Dr. Tam
acknowledged the government had been providing inconsistent messaging with respect to Covid-
19 measures, which she attributed to the fact that the science was “evolving”. Attached hereto as
Exhibit “I” is a true copy of the article, Evolving science reason for inconsistent messaging on
COVID-19: Tam from CP24 (originally published by the Canadian Press).
34. A further example of a complete reversal on policy was Canada’s Minister of Health, Patty Hajdu,
stating that closing our borders was “not effective”. She specifically said that shutting down the
border makes it hard to detect where people are coming from during the pandemic and that this
measure was “not effective at all”. To the contrary, she believed that open borders foster
transparency and cooperation between countries. Attached hereto as Exhibit “J” is a true copy of
a link to the YouTube video of Minister Hajdu’s press conference hosted on Global News
YouTube Channel.
35. While I appreciate that health experts have imperfect knowledge of a new virus, as a member of
the public who is being asked to trust the medical experts, it is concerning that absolute and
sweeping statements are made before all relevant facts are known.
36. There have also been other developments which, to me, cast some doubt on the idea that vaccines
are as safe as Canadian public health authorities have declared them to be. For example, a group
of doctors made a Freedom of Information Request for Pfizer to release the data the U.S. Federal
Drug Administration had relied upon to license its COVID-19 vaccine. Pfizer responded by
claiming that that they could only release 500 pages per month over the course of 75 years. U.S.
District Judge Mark Pittman ordered the FDA and Pfizer to expedite the release of information so
that it would be publicly available by the end of summer 2022. Attached hereto as Exhibit “K” is
a true copy of the article, “Paramount importance”” Judge orders FDA to hasten release of Pfizer
docs. Attached hereto as Exhibit “L” is a true copy of the decision by the United States District
Court, Northern District of Texas.
8
AR01569
37. At the beginning of the pandemic, the British Medical Journal (“BMJ”), a peer-reviewed medical
journal in the UK, criticized the lack of transparency in the vaccine trials, stating that “none of the
current trials are designed to detect a reduction in any serious outcome such as hospitalization,
intensive care use, or deaths.”. Attached hereto as Exhibit “M” is a true copy of the BMJ article,
Covid-19 vaccine trials cannot tell us if they will save lives.
38. Recently, the BMJ’s editor called upon the release and availability of Covid-19 vaccine and
treatment data:
Today, despite the global rollout of covid-19 vaccines, the participant level data underlying
the trials for these new products remain inaccessible to doctors, researchers, and the public
– and are likely to remain that way for years to come,” they write. “This is morally
indefensible for all trials, especially those involving major public health interventions.”
We are left with publications but no access to the underlying data upon reasonable request,”
write the editors. “This is worrying for trial participants, researchers, clinicians, journal
editors and the public.
Attached hereto as Exhibit “N” is a true copy of the BMJ article, Editors call for COVID-19
vaccine and treatment data to be available for public scrutiny in the BHMJ dated January 19th,
2022.
39. Of course, I do not know what information will be shown through these documents. However, I
believe it is rational to be concerned about the fact that the pharmaceutical companies which are
trusted with the welfare of, literally, humanity have not been proactive in disclosing the scientific
documents that would show how the single most important tool to fight the Covid-19 virus has
been tested and assessed. These companies have a moral obligation to be outstanding corporate
citizens. Concerned individuals, such as myself, should not have to sue pharmaceutical companies
to share data that directly relates to the health of everyone who was strongly encouraged,
persuaded, and indirectly coerced into to get vaccinated. I hope this much is common sense.
9
AR01570
40. Equally concerning is the fact that on February 20, 2022, the New York Times published an article
detailing how the CDC had not shared “large portions” of data it collects on Covid-19. Below is
an example of information that the CDC – a publicly funded organization trusted to protect the
public welfare - withheld:
When the C.D.C. published the first significant data on the effectiveness of boosters in
adults younger than 65 two weeks ago, it left out the numbers for a huge portion of that
population: 18- to 49-year-olds, the group least likely to benefit from extra shots, because
the first two doses already left them well-protected.
Attached hereto as Exhibit “O” is a true copy of the New York Times article, The C.D.C. Isn’t
Publishing Large Portions of the Covid Data It Collects.
41. This was not the first time the CDC withheld crucial information from the public. In 2020, it
decided to not track breakthrough infections in vaccinated Americans, instead focusing “only on
individuals who became ill enough to be hospitalized or die. The agency presented that information
as risk comparisons with unvaccinated adults, rather than provide timely snapshots of hospitalized
patients stratified by age, sex, race, and vaccination status.”. I still cannot understand why the CDC
would ignore breakthrough infection numbers in vaccinated Americans and I have been unable to
find a response from the CDC suggesting this information would be irrelevant or unhelpful in
assessing vaccine efficacy or in formulating an appropriate response to the Covid-19 pandemic.
42. The CDC offered several reasons for withholding such data, including ensuring that its data is
accurate and actionable (what does this even mean?) and because of fears that its data, if made
public, might be “misinterpreted as the vaccines being ineffective”. The idea that information
could be withheld on the presumption that that information might be misinterpreted is anathema
to the concept of informed consent and, frankly, an assault on democracy. As far as I am concerned,
such decisions only heighten suspicions as to, and undermine confidence in, public health
measures when the opposite should be happening.
10
AR01571
43. In October 2021, Dr. Patty Daly, Chief Medical Officer of Health for Vancouver Coastal Health,
acknowledged vaccine passports were not directly about health but rather to incentivize higher
vaccination rates. Statements like these, coupled with the earlier issues I highlighted, have caused
me to significantly doubt the mainstream messaging and vaccination advice by our public health
officials. Attached hereto as Exhibit “P” is a true copy of the article, Top Vancouver doc caught
admitting vax passports are merely ‘incentive’ program which appeared in LifeSite.
Personal Impacts of Covid-19
44. Covid-19 has touched me personally. Several weeks ago, my partner’s 19-year-old son was rushed
to hospital after complaining of severe chest pains. He was panicking and thought he would die.
After waiting in the emergency for hours and undergoing several diagnostic tests, doctors told him
he had Myocarditis resulting from his Covid-19 vaccine. His doctor recommended that Jodi
purchase a defibrillator for her home, “just in case”. This is not something a healthy 19-year-old
should ever experience.
45. Jodi’s son is not alone. I personally know two other parents whose children are being treated for
Myocarditis following their vaccination.
46. Due to my involvement on this legal challenge, I am fortunate to have access to some of Canada’s
best doctors so, for now, medical help and advice is only a phone call away as Jodi and I work on
getting her son the treatment he needs. Many Canadians, however, are not so lucky, and some we
have spoken to have been brushed off and have had their child’s conditions significantly
downplayed.
47. Finally, as it pertains to my own Infection Fatality Risk, as referenced in the affidavit of Karl
Harrison, according to the Lancet article, Variation in the COVID-19 infection-fatality ratio by
age, time, and geography during the pre-vaccine era: a systematic analysis, my risk of dying of
COVID-19 is 0.576%; this figure is an over-estimation as it was calculated during the most virulent
11
AR01572
period of the pandemic. Using the Canada’s Covid-19 weekly Epidemiology Report published by
the Public Health Agency of Canada, my risk of hospitalization due to Covid-19 is 0.065%. This
is a risk I am prepared to live with until I am confident in the longer-term effects of the vaccines.
Attached hereto as Exhibit “Q” is a true copy of Canada’s weekly epidemiology report from
February 20 and 26, 2022.
48. The past two years of this pandemic have been incredibly hard and challenging for all Canadians
to deal with, from a financial, social, and mental health perspective. None have suffered and
sacrificed more than our elderly and young children.
49. However, what I have personally struggled with and have found to be the most unconscionable
and objectionable aspects of how this pandemic has been managed, is the unnecessary hateful,
vindictive and divisive behavior that I have witnessed from neighbors, friends, family members,
colleagues and our government. The words and action of our government, which has entrenched
policies based on vaccination status, without reflecting the risk of those unvaccinated, is far from
the warm, caring, and thoughtful Canada I remember living in.
50. Prime Minister Trudeau’s domestic and international travel ban for unvaccinated Canadians was
the catalyst for me to stand and up and do something. I knew when the Prime Minister invoked
the travel vaccine mandate, at a time when publicly safety was at its lowest risk level, that it was
not about ‘keeping Canadians safe’, it was about punishing anyone who did not comply with the
government’s objective of increasing vaccination uptake. On this day, I decided to do whatever I
could to challenge and overturn this mandate, which is a blatant disregard of my Charter rights,
rendering me immobile and trapped within my own country – simply for being cautious about a
health choice with unknown long-term consequences which are irreversible.
12
AR01573
Sworn before me )
by videoconference )
at the City of Toronto, )
in the Province of Ontario, )
this 11th day of March, 2022 )
~-
A Commissioner for taking Affidavits
, within the Province of Ontario
Sam A. Presvelos
13
AR01574
This is Exhibit “A” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
A Commissioner for Taking Affidavits
SAM A. PRESVELOS
CMPA - Consent: A guide for Canadian physicians 2022-03-10, 9:49 PM
AR01575
Consent: A guide for Canadian physicians

Fourth edition: May 2006 / Updated: April 2021
Table of contents
■ Introduction
■ Before we begin: Two important issues
■ Emergency treatment
■ Assault and battery
■ Types of consent
■ Implied consent
■ Expressed consent
■ Requirements for valid consent
■ Voluntary consent
■ Capacity to consent
■ Informed consent
■ Disclosure of information
■ Standard of disclosure
■ Patient comprehension
■ Consent disclosure in research and experimentation
■ Informed refusal
■ Informed discharge
■ Some practical considerations about informed consent
■ Consent forms — Documentation of consent
■ A consent form itself is not consent

■ Basic elements
■ Handouts and materials supplemental to consent explanations
■ Treatment in Canada of U.S. and other foreign residents
Which form do you use?

https://www.cmpa-acpm.ca/en/advice-publications/handbooks/consent-a-guide-for-canadian-physicians Page 1 of 20
AR01576
■ Which form do you use?
Introduction
In the shorter Oxford dictionary, consent is defined as "the voluntary agreement to or acquiescence in what
another person proposes or desires; agreement as to a course of action."
In the medical context and as the law on consent to medical treatment has evolved, it has become a basic
accepted principle that "every human being of adult years and of sound mind has the right to determine
what shall be done with his or her own body." Clearly physicians may do nothing to or for a patient without
valid consent. This principle is applicable not only to surgical operations but also to all forms of medical
treatment and to diagnostic procedures that involve intentional interference with the person.
That consent to treatment was lacking or inadequate continues to be a frequent claim against physicians.
Obviously it is important therefore that physicians be aware of their legal obligations in obtaining consent
from patients. It is hoped this booklet will assist in strengthening this awareness. It is not intended as a
legal treatise on the subject of consent but rather as a practical guide for physicians in their day-to-day
dealings with patients.
Before we begin: Two important issues

Emergency treatment
To the general rule that consent must always be obtained before any treatment is administered, there is an
important exception. In cases of medical emergency when the patient (or substitute decision maker) is
unable to consent, a physician has the duty to do what is immediately necessary without consent. For the
physician to declare any clinical situation an emergency for which consent is not required, there must be
demonstrable severe suffering or an imminent threat to the life or health of the patient. It cannot be a
question of preference or convenience for the health care provider; there must be undoubted necessity to
proceed at the time. Further, under medical emergency situations, treatments should be limited to those
necessary to prevent prolonged suffering or to deal with imminent threats to life, limb or health.
Even when unable to communicate in medical emergency situations, the known wishes of the patient must
be respected. Therefore, before proceeding, the physician will want to be satisfied there has been no
indication in the past by way of Advance Directive or otherwise that the patient does not want the proposed
treatment. Further, as soon as the patient is able to make decisions and regains the ability to give consent,
a proper and "informed" consent must then be obtained from the patient for additional treatment.
In some provinces, legislation permits the designation of substitute decision-makers to provide or refuse
consent on behalf of the incapacitated patient. If the substitute decision-maker is immediately available
emergency treatment should proceed only with the consent of that individual.
In urgent situations, it may be necessary or appropriate to initiate emergency treatment while steps are
taken to obtain the informed consent of the patient or the substitute decision-maker, or to determine the
availability of advance directions. However, the instructions as to whether to proceed or not must be
AR01577
availability of advance directions. However, the instructions as to whether to proceed or not must be
obtained as quickly as practicably possible.
When an emergency dictates the need to proceed without valid consent from the patient or the substitute
decision-maker, a contemporaneous record (at the time) should be made explaining the circumstances
which forced the physician's hand. If the circumstances are such that the urgency might be questioned at a
later date, arranging a second medical opinion would be prudent if possible.
The bottom line:
■ When the patient or substitute decision maker is unable to consent and there is demonstrable severe
suffering or an imminent threat to the life or health of the patient, a doctor has the duty to do what is
immediately necessary without consent. Emergency treatments should be limited to those necessary to
prevent prolonged suffering or to deal with imminent threats to life, limb or health. Even when he/she is
unable to communicate, the known wishes of the patient must be respected.
Assault and battery

Most legal actions against physicians concerning consent are based on negligence and raise allegations as
to the adequacy of the consent discussion with the patient. A claim of assault and battery may, however, be
alleged in specific circumstances. A physician may be liable in assault and battery when no consent was
given at all or when the treatment went beyond or deviated significantly from that for which the consent was
given. Allegations of assault and battery might also be made if consent to treatment was obtained through
serious or fraudulent misrepresentation in what was explained to the patient.
Thus, as has happened in various legal actions, it was seen as an assault and battery to carry out an
amputation without having received consent to do so; to administer an intravenous anaesthetic agent into
the left arm when the patient had specifically forbidden it; to sterilize a patient when consent had been
given for a Caesarean section only; to operate on the patient's back when consent had been given only for
a procedure on the toe.
In each of these examples, the physicians knew they were proceeding in the medical best interests of the
patients and took measures which were clearly medically indicated. However, our courts have repeatedly
affirmed that good intentions of the physician cannot be substituted for the will of the patient.
The bottom line:
■ A physician may be liable in assault and battery when no consent was given at all, when the treatment
went beyond or deviated significantly from that for which the consent was given, or if consent to
treatment was obtained through serious or fraudulent misrepresentation in what was explained to the
patient.
Types of consent
Consent to treatment may be implied or it may be specifically expressed either orally or in writing. The
AR01578
clinical situation determines the approach required.
Implied consent
Much of a physician's work is done on the basis of consent which is implied either by the words or the
behaviour of the patient or by the circumstances under which treatment is given. For example, it is common
for a patient to arrange an appointment with a physician, to keep the appointment, to volunteer a history, to
answer questions relating to the history and to submit without objection to physical examination. In these
circumstances consent for the examination is clearly implied. To avoid misunderstanding, however, it may
be prudent to state to the patient an intention to examine the breasts, genitals or rectum.
The foregoing notwithstanding, in many situations the extent to which consent was implied may later
become a matter of disagreement. Physicians should be reasonably confident the actions of the patient
imply permission for the examinations, investigations and treatments proposed. When there is doubt, it is
preferable the consent be expressed, either orally or in writing.
Expressed consent
Expressed consent may be in oral or written form. It should be obtained when the treatment is likely to be
more than mildly painful, when it carries appreciable risk, or when it will result in ablation of a bodily
function.
Although orally expressed consent may be acceptable in many circumstances, frequently there is need for
written confirmation. As physicians have often observed, patients can change their minds or may not recall
what they authorized; after the procedure or treatment has been carried out, they may attempt to take the
position it had not been agreed to or was not acceptable or justified. Consent may be confirmed and
validated adequately by means of a suitable contemporaneous notation by the treating physician in the
patient's record.
Expressed consent in written form should be obtained for surgical operations and invasive investigative
procedures. It is prudent to obtain written consent also whenever analgesic, narcotic or anaesthetic agents
will significantly affect the patient's level of consciousness during the treatment.
Requirements for valid consent

For consent to serve as a defence to allegations of either negligence or assault and battery, it must meet
certain requirements. The consent must have been voluntary, the patient must have had the capacity to
consent and the patient must have been properly informed.
Voluntary consent
Patients must always be free to consent to or refuse treatment, and be free of any suggestion of duress or
coercion. Consent obtained under any suggestion of compulsion either by the actions or words of the
physician or others may be no consent at all and therefore may be successfully repudiated. In this context
physicians must keep clearly in mind there may be circumstances when the initiative to consult a physician
AR01579
was not the patient's, but was rather that of a third party, a friend, an employer, or even a police officer.
Under such circumstances the physician may be well aware that the patient is only very reluctantly
following the course of action suggested or insisted upon by a third person. Then, physicians should be
more than usually careful to assure themselves patients are in full agreement with what has been
suggested, that there has been no coercion and that the will of other persons has not been imposed on the
patient.
The bottom line:
■ Consent obtained under any suggestion of compulsion either by the actions or words of the doctor or
others may be no consent at all and therefore may be successfully repudiated.
Capacity to consent
An individual who is able to understand the nature and anticipated effect of proposed medical treatment
and alternatives, and to appreciate the consequences of refusing treatment, is considered to have the
necessary capacity to give valid consent. However, there are special circumstances to which particular
attention must be given.
Age of consent
The legal age of majority has become progressively irrelevant in determining when a young person may
consent to his or her medical treatment. As a result of consideration and recommendations by law reform
groups as well as the evolution of the law on consent, the concept of maturity has replaced chronological
age. The determinant of capacity in a minor has become the extent to which the young person's physical,
mental, and emotional development will allow for a full appreciation of the nature and consequences of the
proposed treatment, including the refusal of such treatments.
Legislation in a number of provinces and the territories has codified the law on consent, including the
reliance on maturity in assessing a young person's capacity to consent to or refuse medical treatment. Only
the Province of Quebec has established a fixed age of 14 years, below which the consent of the parent or
guardian or of the court is necessary for the purposes of proposed treatment.
Generally, where the minor patient lacks the necessary capacity, the parents or guardian are authorized to
consent to treatment on the minor's behalf. In doing so, the parents or guardian must be guided by what is
in the best interests of the minor. This consideration becomes all the more important when the parent or
guardian seeks to refuse treatment the physician regards as medically necessary. In these circumstances,
there is an obligation on the part of physicians to report the matter to child protection authorities.
Patients must be at least 18 years of age to consent to medical assistance in dying. A minor patient’s
parents or guardian cannot consent to assistance in dying on the minor’s behalf.
The bottom line:
■ The determinant of capacity in a minor has become the extent to which the young person's physical,
AR01580
mental, and emotional development will allow for a full appreciation of the nature and consequences of
the proposed treatment, including the refusal of such treatments.
■ Generally, where the minor patient lacks the necessary capacity, the parents or guardian are authorized
to consent to treatment on the minor's behalf, and must be guided by what is in the best interests of the
minor.
Mental incapacity / Substitute decision-making

It is well accepted that a person who is incapable to make decisions regarding certain matters might still
have sufficient mental capacity to give valid consent to medical treatment. Again, it depends on whether the
patient is able to appreciate adequately the nature of the proposed treatment, its anticipated effect and the
alternatives. Therefore, many individuals who may be mentally infirm or who have been committed to a
psychiatric facility continue to be capable of controlling and directing their own medical care, including the
right to consent to treatment or to refuse treatment. It is beyond the scope of this general discussion to
comment on the various legal requirements pursuant to mental health legislation, but physicians should be
generally familiar with the applicable mental health legislation in their jurisdiction, particularly with reference
to formal capacity assessments necessary to declare the patient incapable of consent and the appeal
process available to the patient.
In circumstances where it has been determined that a patient is incapable of consenting to a particular
medical treatment, the question as to who is authorized to make the decision will arise. It is now possible in
the majority of provinces for a patient to execute an Advance Directive as to future care in the event that
the patient becomes incapacitated or is unable to communicate his or her wishes. Advance Directives are
sometimes referred to as living wills. Advance Directives may contain explicit instructions relating to
consent or refusal of treatment in specified circumstances. In some provinces, Advance Directives may be
contained in Powers of Attorney for personal care. An Advance Directive may also be used to appoint or
designate an individual who will be authorized to make substitute decisions about consent or refusal of
treatment in the event that the patient becomes incapacitated. Again, physicians will want to be generally
familiar with any applicable legislation in their particular jurisdiction. Consent to medical assistance in dying
cannot be given by way of Advance Directives.
In limited circumstances, a patient can waive the requirement that their consent to medical assistance in
dying be confirmed at the time it is administered. Before losing capacity, patients who meet all eligibility
criteria and safeguards for MAID and for whom natural death is reasonably foreseeable may make advance
arrangements in writing with their medical or nurse practitioner. The advance agreement will be invalided if
the person subsequently refuses or demonstrates resistance to MAID in their words, sounds, or gestures.
A number of provinces have also enacted legislation for substitute decision-makers which sets out and
ranks a list of individuals, usually family members, who are authorized to give or refuse consent to
treatment on behalf of an incapable person. The specific legislation in the jurisdiction will generally set out
the principles that should guide the substitute decision-maker's treatment decision. Generally speaking,
substitute decision-makers must act in compliance with any prior capable wish of the patient, where
possible. Consideration of such factors as the individual's current wishes and his or her known beliefs and
AR01581
values may also be required, depending on the jurisdiction. It is clear that the substitute decision-maker
should always be guided by the patient's best interests. Substitute consent, including that of a parent for a
child, cannot be utilized for proposed treatment which might be regarded as non-therapeutic, such as non-
therapeutic sterilization. Physicians will want to be alert to other circumstances that might raise unique
issues such as substitute consent in the context of clinical research. It is also important to remember that a
substitute decision-maker cannot consent to MAID on behalf of an incapable patient.
The determination of the patient's best interests, or whether a proposed treatment is "therapeutic" or not
can be difficult, and, in circumstances where there are questions or doubts, physicians are encouraged to
consult with other physicians and legal counsel. There may be circumstances where an ethical consult
would be prudent. Physicians should also be aware that there are legal mechanisms available to address
circumstances where concerns exist that a substitute decision-maker may not be acting in the patient's best
interests.
In the absence of a valid Advance Directive or duly authorized substitute decision-maker, strictly speaking
only the court or someone appointed by the court may properly consent to or refuse medical treatment
where the patient lacks the requisite capacity to make the decision. Unfortunately, the legal procedure for
the appointment of a guardian of the patient can be lengthy and expensive. As a result, and from a practical
standpoint, physicians have often proceeded on the basis of the family's approval where the medical
treatment is clearly required, where the patient's condition may deteriorate if not treated promptly, and the
treatment is determined to be in the patient's best interests. Should there be any disagreement among
family members, or if the proposed treatment carries significant risks, then specific legal advice should
probably be sought about that situation.
The bottom line:
■ Many individuals who may be mentally infirm or who have been committed to a psychiatric facility
continue to be capable of controlling and directing their own medical care, including the right to consent
to treatment or to refuse treatment; legal requirements vary with jurisdiction, so physicians should be
generally familiar with the applicable mental health legislation in their jurisdiction.
■ In circumstances where there are questions or doubts about what is in the patient's best interests or
whether a proposed treatment is "therapeutic" or not, physicians are encouraged to consult with other
physicians and, when warranted, legal counsel.
Informed consent
Disclosure of information
For consent to treatment to be considered valid, it must be an "informed" consent. The patient must have
been given an adequate explanation about the nature of the proposed investigation or treatment and its
anticipated outcome as well as the significant risks involved and alternatives available. The information
must be such as will allow the patient to reach an informed decision. In situations where the patient is not
mentally capable, the discussion must take place with the substitute decision maker.
AR01582
The obligation to obtain informed consent must always rest with the physician who is to carry out the
treatment or investigative procedure. This obligation may be delegated in appropriate circumstances (to a
PGY trainee for example) but before assigning this duty to another, the treating physician should be
confident the delegate has the knowledge and experience to provide adequate explanations to the patient.
In special circumstances, an obligation of pre-treatment disclosure may fall to more than one physician
involved in the care. For example, a radiologist carrying out an invasive diagnostic procedure would likely
be seen as responsible for explaining how the test will be done and the risks attendant upon it. The
physician who ordered the test might also be expected to tell the patient, in general terms, about the nature
and purpose of the test and alternatives which might be employed.
The bottom line:
■ The patient must have been given an adequate explanation about the nature of the proposed
investigation or treatment and its anticipated outcome as well as the significant risks involved and
alternatives available.
■ The obligation to obtain informed consent must always rest with the physician who is to carry out the
treatment or investigative procedure.
Standard of disclosure
Although obtaining a valid consent from patients has always involved explanations about the general
nature of the proposed treatment and its anticipated effect, the Supreme Court of Canada, over two
decades ago, imposed a more stringent standard of disclosure upon physicians. The adequacy of consent
explanations is to be judged by the "reasonable patient" standard, or what a reasonable patient in the
particular patient's position would have expected to hear before consenting.
The Supreme Court of Canada has set out in general terms the scope of the physician's duty in informing
patients before treatment as follows:
"In summary, decided cases appear to indicate that in obtaining the consent of a patient for the
performance upon him of a surgical operation, a surgeon, generally, should answer any specific questions
posed by the patient as to the risks involved and should, without being questioned, disclose to him the
nature of the proposed operation, its gravity, any material risks and any special or unusual risks attendant
upon the performance of the operation. However, having said that, it should be added that the scope of the
duty of disclosure and whether or not is has been breached are matters which must be decided in relation
to the circumstances of each particular case."
In a subsequent decision, the court extended the obligation of disclosure as follows:
"... a surgeon must also, where the circumstances require it, explain... alternative means of treatment and
their risks."
The foregoing does provide physicians with a general basis for deciding the nature and extent of the pre-
AR01583
The foregoing does provide physicians with a general basis for deciding the nature and extent of the pre-
treatment information which should be given to patients but it can be difficult to apply legal generalizations
to specific clinical situations. Therefore, some comment about several of the points raised in these
precedent-setting judgments may be helpful.
Throughout these and other legal judgments which have been rendered in more recent years, there is
repeated reference to the need to disclose "material" risks to patients. However, there can be some
understandable uncertainty as to what in fact does constitute a "material" risk. One court has defined it as
follows:
"A risk is thus material when a reasonable person in what the physician knows or should know to be the
patient's position would be likely to attach significance to the risk or cluster of risks in determining whether
or not to undergo the proposed therapy."
Thus the particular circumstances of the patient are an important determinant of materiality.
It is clear that the materiality of a risk is influenced as well both by the frequency of the possible risk and
also by its seriousness should it occur. Generally speaking, the more frequent the risk, the greater the
obligation to discuss it beforehand. Further, even uncommon risks of great potential seriousness should be
disclosed. In this context the Supreme Court of Canada indicated that even if a risk is "a mere possibility"
yet it carries with it serious consequences such as paralysis or death, it should be regarded as material and
therefore requires disclosure.
The bottom line:
■ The adequacy of consent explanations is judged by the "reasonable patient" standard, or what a
reasonable patient in the particular patient's position would have expected to hear before consenting.
■ Recent legal judgments repeatedly refer to the need to disclose "material" risks to patients. Generally
speaking, the more frequent the risk, the greater the obligation to discuss it beforehand. Further, even
uncommon risks of great potential seriousness should be disclosed.
Patient comprehension
It has been suggested that not only must the physician provide the necessary details about the nature,
consequences and material risks of the proposed treatment in order to obtain informed consent, but also
the physician has the duty to ensure the patient has understood the information. This interpretation of the
case law goes too far and would place an unfair and unreasonable burden on the physician. In
rejecting this obligation, the court, in a recent Scottish case, commented that such an onus upon the
physician could only be discharged through "vigorous and inappropriate cross-examination" of the patient.
There is no doubt, however, that the physician does have a duty to take reasonable steps so as to be
relatively satisfied that the patient does understand the information being provided, particularly where there
may be language difficulties or emotional issues involved. What amounts to "reasonable steps" will very
much depend on the individual facts and circumstances of the particular situation.
AR01584
It seems clear that by engaging in personal dialogue with the patient, the physician will be placed in the
best possible position to be reasonably comfortable the patient understands the consent explanation.
Personal attendance permits the physician the opportunity to observe the patient's reaction for signs of
apparent comprehension or confusion. As well, the ability of the patient to ask questions will often assist
the physician to assess the level of patient understanding.
The bottom line:
■ Physicians have a duty to take reasonable steps so as to be relatively satisfied that the patient does
understand the information being provided, particularly where there may be language difficulties or
emotional issues involved.
Consent disclosure in research and experimentation

The issue of consent merits careful consideration by those physicians who may become involved in any
research work in which patients or human volunteers are asked to participate.
In terms of the extent to which risks must be disclosed, there is now less distinction between "therapeutic"
and "non-therapeutic" research than in earlier years when requirements for informed consent were less
stringent. These days, for any treatment or procedure that is innovative or that could be perceived as
experimental, anything which may be interpreted as going beyond the need for prophylaxis, diagnosis or
therapy, an element of "research" should be assumed. In such circumstances a standard of full disclosure
may be applicable when obtaining consent. The concept of therapeutic privilege is inappropriate and no
information about a project or clinical trial may be hidden from a patient on the ground that disclosure would
result in undue worry or anxiety. As well, researchers must recognize the potential for what might later
appear to have been duress or coercion. This is a particularly important consideration if the subject has a
physician-patient relationship with a member of the research team.
A fair explanation must always be given about what is proposed, its risks and discomforts, what, if any,
benefits might accrue and, if applicable, what appropriate alternative treatments or procedures might be
offered. If a blind study is involved, patients must be aware they could stand to derive no benefit at all.
Researchers should offer and make themselves available to answer enquiries about what is proposed and
should emphasize to patients or subjects they are free to withdraw consent and discontinue participation in
the project at any time without prejudice.
It might be argued that minors or adults with mental disability do not have the capacity to consent when
research or experimentation figure to any significant extent in clinical management. Physicians should
exercise a great deal of caution in dealing with such situations.
The bottom line:
■ When it comes to research and experimentation, a fair explanation must be given about what is
proposed, its risks and discomforts, what if any benefits might accrue and, if applicable, what
appropriate alternative treatments or procedures might be offered. If a blind study is involved, patients
AR01585
appropriate alternative treatments or procedures might be offered. If a blind study is involved, patients
must be aware they could stand to derive no benefit at all.
Informed refusal
Our courts have reaffirmed repeatedly a patient's right to refuse treatment even when it is clear treatment is
necessary to preserve the life or health of the patient. Justice Robins of the Ontario Court of Appeal
explained:
"The right to determine what shall, or shall not, be done with one's own body, and to be free from non-
consensual medical treatment, is a right deeply rooted in our common law. This right underlines the
doctrine of informed consent. With very limited exceptions, every person's body is considered inviolate,
and, accordingly, every competent adult has the right to be free from unwanted medical treatment. The fact
that serious risks or consequences may result from a refusal of medical treatment does not vitiate the right
of medical self-determination. The doctrine of informed consent ensures the freedom of individuals to make
choices about their medical care. It is the patient, not the physician, who ultimately must decide if treatment
— any treatment — is to be administered."
However, difficulty may arise if it should later be claimed the refusal had been based on inadequate
information about the potential consequences of declining what had been recommended. In the same way
as valid consent to treatment must be "informed," so it may be argued a refusal must be similarly
"informed." Physicians thus may be seen to have the same obligations of disclosure as when obtaining
consent, that is, disclosure of the risk to be accepted.
When patients decide against recommended treatment, particularly urgent or medically necessary
treatment, discussions about their decision must be conducted with some sensitivity. While recognizing an
individual's right to refuse, physicians must at the same time explain the consequences of the refusal
without creating a perception of coercion in seeking consent. Refusal of the recommended treatment does
not necessarily constitute refusal for all treatments. Reasonable alternatives should be explained and
offered to the patient.
As when documenting the consent discussion, notes should be made about a patient's refusal to accept
recommended treatment. Such notes will have evidentiary value if there is any controversy later about why
treatment was not given.
The bottom line:
■ Our courts have reaffirmed repeatedly a patient's right to refuse treatment even when it is clear
treatment is necessary to preserve the life or health of the patient. Physicians must at the same time
explain the consequences of the refusal without creating a perception of coercion in seeking consent.
Informed discharge
Although not strictly an element of the pre-operative consent process, the courts have recently elaborated
on the duty or obligation of physicians to properly inform patients in the post-operative or post-discharge
period. Thus a physician must conduct a discussion with a patient of the post-treatment risks or
AR01586
period. Thus a physician must conduct a discussion with a patient of the post-treatment risks or
complications, even statistically remote ones that are of a serious nature. The purpose is to inform the
patient of clinical signs and symptoms that may indicate the need for immediate treatment such that the
patient will know to visit the physician or return to the hospital/facility.
The bottom line:
■ Physicians have an obligation to properly inform patients in the post-operative or post-discharge period,
most specifically about clinical signs and symptoms that may indicate the need for immediate treatment.
Some practical considerations about informed consent

The law on consent will continue to evolve. However, current interpretation of legal judgements dealing with
"informed consent" will allow some suggestions which may be of practical assistance to physicians in their
attempt to meet the legal standards:
1. Insofar as may be possible, tell the patient the diagnosis. If there is some uncertainty about the
diagnosis mention this uncertainty, the reason for it and what is being considered.
2. The physician should disclose to the patient the nature of the proposed treatment, its gravity, any
material risks and any special risks relating to the specific treatment in question. Even if a risk is a
mere possibility which ordinarily might not be disclosed, if its occurrence carries serious
consequences, as for example paralysis or death, it must be regarded as a material risk requiring
disclosure.
3. A physician must answer any specific questions posed by the patient as to the risks involved in the
proposed treatment. Always the patient must be given the opportunity to ask questions.
4. The patient should be told about the consequences of leaving the ailment untreated. Although there
should be no appearance of coercion by unduly frightening patients who refuse treatment, our courts
now recognize there is a positive obligation to inform patients about the potential consequences of
their refusal.
5. The patient should be told about available alternative forms of treatment and their risks. There is no
obligation to discuss what might be clearly regarded as unconventional therapy but patients should
know there are other accepted alternatives and why the recommended therapy has been chosen.
6. Physicians must be alert to a patient's individual concerns about the proposed treatment and deal with
them. It must be remembered that any particular patient's special circumstances might require
disclosure of potential although uncommon hazards of the treatment when ordinarily these might not
be seen as material. Courts have made it clear that the duty of disclosure extends to what the
physician knows or should know the particular patient deems relevant to a decision whether or not to
undergo treatment.
AR01587
7. Although any particular patient may waive aside all explanations, may have no questions, and may be
prepared to submit to the treatment whatever the risks may be without any explanatory discussion,
physicians must exercise cautious discretion in accepting such waivers.
8. When, because of emotional factors, the patient may be unable to cope with pre-treatment
explanations, the physician may be justified in withholding or generalizing information which otherwise
would be required to be given. This so-called "therapeutic privilege" should be exercised with great
discretion and only when there are compelling reasons dictated by clinical circumstances.
9. In obtaining consent for cosmetic surgical procedures or for any type of medical or surgical work which
might be regarded as less than entirely necessary to the physical health of the patient, physicians must
take particular care in explaining fully the risks and anticipated results. As in experimental research
situations, courts may impose on physicians a higher standard of disclosure in such circumstances.
10. Encouragement about optimistic prospects for the results of treatment should not allow for the
misinterpretation that results are guaranteed.
11. Where a part or all of the treatment is to be delegated, patients have a right to know about this and
who will be involved in their care. Consent explanations should include such information.
12. A note by the physician on the record at the time of consent explanations can later serve as important
confirmation that a patient was appropriately informed, particularly if the note refers to any special
points which may have been raised in the discussion.
Consent forms — Documentation of consent

A consent form itself is not consent
Consideration of a consent form to be signed by the patient should not obscure the important fact that the
form itself is not the "consent." The explanation given by the physician, the dialogue between physician and
patient about the proposed treatment, is the all important element of the consent process. The form is
simply evidentiary, written confirmation that explanations were given and the patient agreed to what was
proposed. A signed consent form will be of relatively little value later if the patient can convince a court the
explanations were inadequate or, worse, were not given at all.
Apart from providing evidence that a patient consented to proposed treatment, there is another important
reason for having consent forms signed. In many Canadian jurisdictions it has become a legal requirement
that such a document must be completed before any surgical procedure is undertaken in a hospital.
The bottom line:
■ The explanation given by the physician, the dialogue between physician and patient about the proposed
AR01588
treatment, is the all important element of the consent process.
■ The consent form itself is not the "consent." It is simply evidentiary, written confirmation that the
explanations were given and that the patient agreed to what was proposed.
■ In many Canadian jurisdictions it has become a legal requirement that such a document must be
completed before any surgical procedure is undertaken in a hospital.
Basic elements
On the basis of experience in advising and defending its members on matters of consent, the Canadian
Medical Protective Association believes a satisfactory consent form, adaptable to most situations, should
be a relatively simple document, such as the prototype suggested below.
Basic elements of a consent form:

Consent to investigation, treatment or operative procedure
(1) I,_________________________________ , hereby consent to undergo the investigation,
treatment or operative procedure, _____________________________, ordered by or to be
performed by Dr._____________________.
(2) The nature and anticipated effect of what is proposed including the significant risks and
alternatives available have been explained to me. I am satisfied with these explanations and I have
understood them.
(3) I also consent to such additional or alternative investigations, treatments or operative procedures
as in the opinion of Dr.________________________ are immediately necessary.
(4) I further agree that in his or her discretion, Dr._______________________ may make use of the
assistance of other surgeons, physicians, and hospital medical staff (including trainees) and may
permit them to order or perform all or part of the investigation, treatment, or operative procedure, and
I agree that they shall have the same discretion in my investigation and treatment as Dr.
_____________________.
Dated_______________________
day / month / year
Patient______________________
Witness_____________________
Identification and acknowledgement of explanations

The form should name the patient and in general terms the nature of the investigation, treatment or
AR01589
operation. It should name the physician who is to carry out the treatment. There should be included an
acknowledgement by the patient that explanations have been given about the nature of the treatment and
its anticipated effect, and about any material risks and special or unusual risks. Mention should be made
also of the patient's acknowledgement that alternative forms of treatment or investigation have been
discussed. The form should allow for acknowledgement by the patient that he or she is satisfied with the
explanations and has understood them.
Anaesthesia
Again, as a result of its experience with negligence litigation against physicians, the Canadian Medical
Protective Association continues to believe that specific consent, except where required by a statute, is
unnecessary for the administration of anaesthesia for surgery. The need for written consent for anaesthesia
is seen as limited because ordinarily it should be implicit in the documentation of the pre-anaesthetic
examination by the anaesthetist that the patient was properly informed. The pre-anaesthetic visit by the
anaesthetist or the anaesthetist's delegate provides an opportunity for discussion about alternative forms of
anaesthesia which might be offered, any exclusions imposed by the patient and any particular risks which
the examining anaesthetist feels may be appropriate to mention in the particular case.
Although usually the record of the pre-anaesthetic examination will adequately confirm the dialogue which
occurred between anaesthetist and patient, if specific consent for anaesthesia is included on a form, care
should be taken to avoid provision on the document inviting exclusions to be stated by the patient. Any
such exclusions should have been agreed upon at the pre-anaesthetic examination. Failing such
discussion and decision, and particularly with a form that offers opportunity for the patient to stipulate
exclusions, there is greater risk the patient could impose last minute restrictions on the anaesthetist with
the possibility that these might be overlooked.
Added or alternative procedures

The clause in the prototype form authorizing additional or alternative procedures requires some special
comment. In their pre-operative explanations to patients, surgeons will always attempt to anticipate in
advance what various conditions might be encountered and what alternative procedures might have to be
added during the operation. However, not infrequently, circumstances arise which compel the physician to
consider an extension of the procedure, something which could not have been anticipated and which was
not mentioned to the patient beforehand.
In these situations, the physician may exceed the mandate given by the patient only if failure to take the
additional or alternative steps would render ineffective the procedure for which the consent was given or
would pose a significant risk to the health or life of the patient. If there arises need to proceed with
something wholly different from that to which the patient has given consent and if it be reasonable and not
harmful to delay, the patient should be allowed to regain consciousness. Then additional explanations can
be given and consent sought for the different procedure. Only when something additional or alternative is
immediately necessary and vital to the health and life of the patient, not merely a matter of convenience,
should a physician proceed without expressed consent.
Delegation to others
AR01590
Delegation to others
The final paragraph of the prototype consent form is deemed necessary because of two sets of
circumstances which are common in practice. The first is the situation where a number of physicians work
as a group and where for various reasons work may be delegated to another member of the same group.
The other circumstances are those found in teaching hospitals where PGY trainees and others participate
in the care of patients. Delegation of work and responsibility to these post-graduate trainees is essential.
They must have assigned to them increasing responsibility for reaching decisions and for carrying out
progressively more difficult and complex treatments and procedures once they have shown evidence of
ability.
Patients must be informed about the involvement of trainees in their care. At the same time they should be
reassured about the quality of that care and the measure of supervision which will be exercised. If patients
in teaching hospitals are told that other physicians may be involved in their care, if they are given
appropriate reassurances and especially if they have already met the other members of the medical team
looking after them, patients will likely accede to the proposals and, most important, can never claim they
did not know work might be delegated to someone else.
Some clinical teachers may still have concern that if all of this is done routinely and such
acknowledgements are set out on a consent form, some patients might refuse to allow the management to
be delegated, insisting that their own attending physician provide it all. This, of course, is the patient's
prerogative. If there must be difficulty, better it be resolved beforehand than to be faced later with a patient
who thinks the result of treatment is less than ideal and who then claims if it had been known the treatment
was to be delegated, consent would have been withheld. Under such circumstances both physician and
post-graduate trainee might be relatively defenceless.
Signatures and witnesses

Remembering that consent forms are simply documentary confirmation of consent explanations and the
patient's willingness to proceed with what has been proposed, it is preferable to arrange for a patient's
signature on the form as contemporaneously as possible with the pre-treatment discussions. Sometimes it
is convenient to accomplish this in a physician's office or at the bedside with the physician present. More
often, however, the signing may occur as an administrative step during the process of admission to hospital
or as part of a hospital ward administrative routine. The patient should be given ample opportunity to
consider what he or she is signing and be given adequate opportunity to consider the implications of that to
which they are consenting.
Because of the varying circumstances under which consent forms are frequently signed, nurses or other
hospital personnel may be asked to witness the signing. It should be remembered that in witnessing a
signature the witness simply confirms the identity of the patient who signed the document and that the
person's mental state at the time appeared to allow for an understanding of what was signed. The role of
the witness has no other legal significance. Most important, the witness to a signature on a consent form
should not feel he or she has any obligation whatsoever to provide pre-treatment explanations which, in
signing the form, the patient acknowledges having received. A nurse or other person witnessing a patient's
AR01591
signing the form, the patient acknowledges having received. A nurse or other person witnessing a patient's
signature on a consent form does in no way attest to the adequacy of explanations which have been given
by the physician. However, if a patient implies or states that he or she has been inadequately informed
about the nature of the proposed treatment, a person witnessing the signature or others present should not
press for the signature and the treating physician should be notified.
Some consent forms require the signature of the treating physician who, by signing, acknowledges that
consent explanations have been given. Clearly, the purpose of this signature is to direct the physician's
attention to his or her legal obligations. Although the purpose of the treating physician's signature may be
commendable, having regard to some of the practical considerations in arranging for the completion of
consent forms, it may be preferable that this requirement not be contained on the form and imposed. On
most occasions the physician will have held the required discussions with the patient previously and may
not be readily available at the time when the form is prepared for the patient's signature. Then, if through an
administrative failure the physician's signature fails to appear on the form, its absence might be more
harmful to the physician's legal interest than if the form did not call for his or her signature in the first place.
Notes in the medical record

A signed consent form has undoubted evidentiary value and is a specific legal requirement in many
situations. However, when an informed consent is called into question, a physician's note on the record
may be of equal or even greater usefulness for defence purposes. Courts rely heavily on progress notes if
it is clear they were made contemporaneously with the events they record.
At the time when consent explanations are given it is a relatively simple matter for the physician to note
briefly some of the significant points raised in conversation with the patient. Such notations, particularly if
they identify questions or special concerns expressed by the patient, can serve to validate the consent
process better than any other documentation.
The note need not be voluminous or time consuming. If it records on the office or hospital chart something
relevant to the discussion with the particular patient, it will be much more credible in evidence than the
recollections of any of the parties involved in a lawsuit. The contemporaneous progress note about consent
can be invaluable and is highly recommended.
Consent forms and medical assistance in dying

In addition to amendments to the Criminal Code, all regulatory authorities (Colleges) have developed
guidelines for physicians concerning MAID. Physicians should be familiar with the requirements concerning
written consent in the Criminal Code and the College guidelines, including the requirements concerning
witnessing the request for MAID, and other information that must be attested to.
Handouts and materials supplemental to consent explanations

Because the essential element of consent is the dialogue and sharing of information between physician
and patient, anything which can conveniently facilitate this process is desirable. The pre-treatment consent
discussions with the patient are most important and should not be replaced; however, sometimes these
AR01592
discussions can be more informative if they are supplemented by printed or other recommended materials
which are given to the patient in advance and can be reviewed at leisure by the patient.
For relatively standardized treatments, investigative or therapeutic procedures, background information

about what is being proposed may be provided in the form of, for example, information sheets, printed
brochures or electronic resources. This material should outline the nature of the proposed treatment or
procedure, its purpose and intended outcome, and should mention significant risks and potential
complications which might be of relevance to most patients. Such information resources should invite
questions from the patient about the treatment and it should be clear that opportunity will be given for such
questioning and for further discussion after the resource has been reviewed.
Information sheets, brochures, and similar materials may not be applicable in many circumstances under
which consent is obtained but when they are used should be seen only as an adjunct and not a substitute
to consent discussions. Frequently consent explanations must be tailored to the particular circumstances of
the individual patient.
Because of the wide variety of circumstances under which consent forms are signed, it is preferable that
the information sheet or similar document not be an integral part of the consent form. The signing of a
consent form, the acknowledgement that appropriate information has already been given, is often simply an
administrative step which does not allow for adequate review of information on which patients must base
their decisions for or against treatment. Documents supplementary to consent explanations should be
provided well in advance of signing. From time to time when commenting about consent procedures, courts
have made it clear, except in urgent and pressing circumstances, patients must be given adequate
opportunity to consider the implications of that to which they are consenting.
Consent explanations are sometimes added to in a more elaborate fashion by a videotape recording of the
discussion about the proposed treatment or procedure. This adjunct is probably most applicable for
cosmetic surgery but may be suitable also in other circumstances.
Regardless of what supplementary methods are employed to provide patients with information prior to
consent, it must again be emphasized they can only supplement and not replace dialogue with the patient.
For evidentiary purposes, a contemporaneous notation should be made confirming that the supplementary
material had been provided and that after reviewing it the patient was given an opportunity to ask questions
about it before consenting.
Since legal actions often arise many years after clinical treatment, it is wise to keep older versions of
information sheets or other materials in an archive file, with the dates noted of when these were in use,in
case they are required during medico-legal difficulties that arise after they are no longer in use.
The bottom line:
■ Handouts and materials should be supplemental to consent explanations; the essential element of
consent is the dialogue and sharing of information between physician and patient.
Supplementary documents should be provided well in advance of signing the consent form so that
AR01593
■ Supplementary documents should be provided well in advance of signing the consent form so that
patients have adequate opportunity to consider the implications of that to which they are consenting.
■ It is wise to keep older versions of materials in an archive file.
Treatment in Canada of U.S. and other foreign residents

It is not unusual that physicians practising in Canada are called upon to provide professional services to
patients who are not ordinarily resident in Canada. Many such patients are visitors or tourists who become
ill and require urgent or emergent care. Increasingly, however, such patients are individuals, mostly United
States residents, who have travelled to Canada specifically to receive elective medical care, perhaps
attracted by comparative cost benefits.
Every Canadian physician should appreciate that any foreign patient who brings a legal action because of
dissatisfaction with the medical care received in Canada may very well seek to bring that legal action back
home where the patient resides. The risk of a foreign action is very important to physicians, as there may
very well be limitations on the legal assistance or protection available from, for example, CMPA to member
physicians or insurers to other health professionals in connection with such actions.
When a foreign patient brings a legal action against a Canadian physician, one of the principal issues to be
determined is whether the foreign court should accept jurisdiction or defer such that the legal action must
be brought in Canada. There is a greater likelihood the foreign court will permit the legal action to proceed
in the patient's home jurisdiction:
■ the more it appears that a foreign resident was encouraged or invited to attend in Canada for medical
care or attention,
■ the more it appears that arrangements for such care were initiated while the patient was in the foreign
jurisdiction,
■ the more elective the care or treatment provided was, or
■ the more it appears foreign funding was involved.
Canadian physicians attending foreign patients in Canada should take steps to encourage that any
subsequent medico-legal action be brought in Canada. Before treating a foreign patient (with the
exception of emergency cases), all physicians and health care organizations should make
reasonable efforts to ensure a Governing Law and Jurisdiction Agreement is completed. These
forms are designed to assist in establishing Canadian jurisdiction for any potential legal actions that may
result from care or treatment provided by Canadian physicians or health care organizations to non-
residents.
Which form do you use?

■ Physicians who provide treatment in their private office should ensure the patient completes the form for
use by physicians in private practice.
■ Physicians working in a health care organization setting are specifically included in the health care
organization form, and are not required to also have the physician in private practice form completed.
AR01594
Either the physician or a representative of the health care organization can have the patient complete
and sign the form; it is not intended that separate forms be obtained by both parties.
■ In Québec, the Direction des programmes d'assurance du Réseau de la santé et des services sociaux
will recommend the use of the form for health care organizations be integrated in the administrative
process relating to the examination, treatment and in-hospital stay of all non-residents of Canada. Until
this form is in use, the CMPA recommends physicians who treat non-residents of Canada in a Québec
public health care institution use the physician in private practice form.
■ Physicians who work at a health care organization that is not a HIROC or a Direction des programmes
d'assurance subscriber should check with the administration of the facility before using the form for
health care organizations.
■ Physicians who practice in a clinic or facility that is a recognized legal entity should use the form for
health care organizations. This advice does not apply if the entity is simply the physician's personal
professional corporation. In such cases, the physician should use the form for a physician in private
practice.
The bottom line:
■ Any foreign patient who brings a legal action because of dissatisfaction with the medical care received in
Canada may very well seek to bring that legal action back home where the patient resides. There may
be limitations on the legal assistance or protection available from the CMPA or insurers in connection
with foreign actions.
■ Before treating a foreign patient (with the exception of emergency cases), all physicians and health care
organizations should make reasonable efforts to ensure a Governing Law and Jurisdiction Agreement is
completed.
Click here to view:
■ Governing Law and Jurisdiction Agreement (for Health Care Organizations) [PDF]
■ Governing Law and Jurisdiction Agreement (for Physician in Private Practice) [PDF]
AR01595
This is Exhibit “B” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
SAM A. PRESVELOS
AR01596
COVID-19 in Canada: Year-end Update on Social

and Economic Impacts
December 22, 2021
\\1ERS
..."'-
~ c::-
~
.......
-,,.
t-.
CANAOA'SBfST
DIVERSITY EMPLOYERS
Delivering insight through data for a better Canada Catalogue no. 11-631-X
ISBN 978-0-660-41224-5
l♦I
Statistics
Canada
Statistique
Canada Canada
AR01597
COVID-19 in Canada: Year-end Update on Social and Economic Impacts
Statistics Canada has long had the privilege of serving Canadians by providing them with high-quality information that
helps shape their view of our society and economy. The pandemic has strengthened our commitment to provide new,
timely information that provides insights on how COVID-19 has impacted Canadian households and businesses.
This presentation provides an update of selected highlights from COVID-19 in Canada: A One-year Update on Social and
Economic Impacts released on March 11, 2021 to mark the first year of the pandemic. This review reflects work that the
Agency has undertaken, and continues to undertake, using existing and new data sources to provide critical insights into
the social and economic impacts of COVID-19 on Canadians. The year-in-review compendium updates and extends our
analysis of the pandemic’s early impacts, building on The Social and Economic Impacts of COVID-19: A Six-month Update
and reflecting the many analytical releases in COVID-19: A data perspective.
While continuing to document the current impacts of the pandemic remains important, we are turning our attention to
trends and measures that may be pointing to potential longer-term changes in the economic and social lives of
Canadians.
-Anil Arora, Chief Statistician of Canada
...
l♦ I Stat1st1cs
Canada
Stat1sflque
Canada Delivering insight through data for a better Canada Canada
AR01598
Summary of contents
• Vaccination and unintended health impacts of COVID-19
• More Canadians get vaccinated as provinces introduce passports, but vaccination rates are uneven across the
country.
• Stress levels remain high as the pandemic continues to challenge Canadians’ mental health.
• The pandemic has resulted in more deaths than would be expected, but they are not all from COVID-19—poisonings
and opioid overdoses are contributing to excess mortality.
• Demographic Impacts
• Increased deaths, decreased immigration and delayed family planning due to the pandemic will change the
demographic make up of Canada.
• These demographic changes will impact employment and interprovincial migration.
• Assessing the economic recovery
• Economic activity remains below pre-pandemic levels and the recovery is uneven across industries.
• Employment rebounded to pre-COVID levels but high job vacancies reveal a mismatch between labour supply and
demand.
• Rising prices put pressure on businesses and consumers as input costs increase and consumer inflation accelerates at
the fastest pace since 2003, outpacing wage growth.
...
l♦ I Stat1st1cs
Canada
Stat1sflque
AR01599
Vaccination and unintended health impacts of

COVID-19
...
l♦ I Stat1st1cs
Canada
Stat1sflque
AR01600
Vaccination efforts continue across the country as jurisdictions opt for vaccine passports
• Vaccination rates have risen recently as Cumulative percentage of people who received at least one dose of a COVI 0 - 19 vaccine in Canada,
by age group and sex, Decembe r 4th 2021
provinces issued vaccination passport percent
requirements for non-essential services.

100
90
80
• As of December 4th,
89.6% of Canadians aged 12 70
and older had received at least one dose and 60
86.7% were fully vaccinated. so

40
• At 85%, Newfoundland and Labrador has the 30
highest proportion of its total population fully

20
10
vaccinated. Saskatchewan, Northwest Territories 0
and Nunavut had rates at or below 70%. 5- 11 12 - 17 1 8-29 30 -39 40-4 9

Age Group
50-59 60 -6 9 70-79 80+
■ Fe m ale □ Male
Source: Government of Canada . Public Health Agency of Canada . COVI D- 19 vaccination in canada .
...
l
♦
I
$1at,shcs
Canada
Stabsbque
Canada Delivering insight through data for a better Canada Can']!,d a
et.:
AR01601
Excess mortality among those under 65 years of age due in part to unintentional poisonings and overdoses
• The pandemic has resulted in excess deaths in Canada –

that is, more deaths occurring than what would be
expected if there was no pandemic. Estimated percentages o f e xcess and COVID-19 deaths, by age group and period, Canada, March 28,
20 20 t o May 15, 2021
• Overall, from March 2020 to May 2021, there were an 0 to 44 y ear s-

estimated 19,884 excess deaths in Canada, or over 5%
more deaths than what would be expected were there
no pandemic. 45 to 64 y ear s
• Early on in the pandemic, excess deaths were largely 65 to 84 y ear s
occurring among seniors and were mostly attributable

to COVID-19. Later on, excess deaths rose among 85 y ear s and
younger Canadians. older
0 10 20 30 40 so 60
• Between March 2020 and May 2021, approximately percent
35% of excess deaths occurred among those less than

D COVID- 19 Deaths ■ Ex cess Deaths
Source: I mpact of the COVID- 19 pandemic or Canadian senior s.
65 years of age compared with approximately 7% of

COVID-19 related deaths. Excess deaths were partially
due to unintentional poisonings and overdoses.
6
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01602
Increases in opioid overdoses during the pandemic are occurring mostly among young Canadians
and those living in British Columbia, Alberta or Ontario
• According to the Public Health Agency of Canada, 6,946

apparent opioid toxicity deaths occurred between April 2020
C rude rates ( pe r 1001 000 po pulatio n ) of t ot a l apparent opioid t oxicity deaths, Canada
r ate per 100,000
and March 2021 — representing an 88% increase from the

same time period prior to the pandemic (April 2019 to March
2020 – 3,691 deaths).
• Between January and March 2021, 1,772 apparent opioid

toxicity deaths occurred — approximately 20 deaths per day —
representing a 65% increase compared to January to March
2020 (1,073 deaths).
• 90% of all opioid toxicity deaths occurred in British
Columbia, Alberta or Ontario.
• The majority of deaths were among individuals aged 20 to
49 years.
• 75% of accidental apparent opioid toxicity deaths
20 16 20 17 20 18 20 19 20 20 2021 (Jd ll lo Md f)
S o urce: Go ve mme r t of Car ada . Opio id - a nd S tinu a nt- rela te d ~a rms in Can ada, Septe mbe r 202 1.
occurred among males.
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01603
Generally, those experiencing opioid overdoses represent diverse groups – many disadvantaged
and impacted by the pandemic
• A national study of individuals experiencing opioid poisoning-related In the year before experiencing
hospitalizations revealed higher rates among those…
Socio-economic an overdose, 38% of individuals
• with lower levels of income and education
• who were unemployed or out of the labour force characteristics of were employed.
• who self-identify as Indigenous individuals experiencing

• who live in lone parent households an opioid overdose in MALES
• who spend more than 50% of their income on housing (Carriere et al., Simcoe Muskoka prior to were employed, of whom
2018).
the pandemic one-third worked
in construction.
• Studies that examined the socio-economic conditions facing individuals who
experienced an opioid overdose in British Columbia and parts of Ontario Of the individuals who
prior to the pandemic revealed… experienced an overdose, half
• higher rates of unemployment received social .assistance
were employed, of whom
• among those who were employed, many were in construction and one-q,uarter worked in
services (52%). accommodations and
• approximately half received social assistance food services.
• between 30% and 40% had at least one police contact in the two years
prior.
Sources: Statistics Canada. Carriere G et al. Social and economic characteristics of those experiencing hospitalizations due to opioid poisonings , October 2018; Carriere G et al. Understanding the socioeconomic
profile of people who experienced opioid overdoses in British Columbia, 2014 to 2016, February 2021; Statistics Canada. Understanding opioid overdoses in Simcoe Muskoka, Ontario. October 2021 8
...
l♦ I S1at1St1cs
Canada
StatlShque
Canada Delivering insight through data for a better Canada Canad a
AR01604
The pandemic also continues to cause high levels of stress among Canadians
Proportion of Canadians who reported that the amount of stress in life, most days, was somewhat or
much worse compared to before the COVID- 19 pandemic, by selected characteristics, Canada, April
to June 2021
• In the spring of 2021, one-quarter of
Canadians reported experiencing high Men
levels of stress most days. Women
• Nearly 50% of Canadians considered that 15 to 24 years
their stress levels were somewhat or much 25 to 34 years
worse than prior to the pandemic. Rates 35 to 44 years
were higher among… 45 to 54 years

55 to 64 years
• women 65 years or older
• those age 35 to 44
LGBTQ2+ (Yes)
• LGBTQ+ and LGBTQ2+ ( No)
• those living with children less than

15 years of age. I n a couple
Not in a couple
• Many of these groups experience more
challenges related to mental health in Living with childr en under age 15
general. Not Living with children under age 15
0 10 20 30 40 50 60
percent
Sou rce: Statistics Canada, Canadian Social Survey - COVI D- 19 and Well -being, 2021. 9
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01605
Despite the impacts of the pandemic, many Canadians are optimistic for the future
Proportion reporting t hat they think their life opportunities will improve or stay the same in the
next year among those 15 years of age and older, Canada, March to April 2021
• Between March and April 2021, 42% of
Canadians aged 15 and older reported that 15 to 24
they think their life will improve in the next 25 to 34
year. 35 to 44
45 to 54
• Rates were highest among… 55 to 64
• those 15 to 24 years of age (64%) 65 and older
• males (45%) compared with females

(38%)
Female
• visible minority groups (49%) compared
with non-visible minority groups (39%). Visi bl e minority
• Almost half (48%) think their life will remain Non-visibl e m inority
the same — highest rate among those 65 years 0 10 20 30 40 50 60 70 80 90 100
of age (61%).
percent
■ Better o Stay the same
Sou rce: Portrait of Canadian Society · Experiences During the Pandem ic, 2021.
10
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01606
Social cohesion during the pandemic: Selected crime and calls for police service are up in the
second quarter of 2021 compared with 2020
• Selected crime was up 7% in the second Selected police- reported crime and calls for service during the COVID- 19 pandemic, monthly, 2020 and
quarter of 2021 compared with the same 2021
period a year earlier. Both violent and non-
number
violent crimes contributed to the increase.

80,000
Q2
Crime levels throughout the pandemic

70,000
remain lower than pre-pandemic levels from

60,000
2019. 50,000
First full
40,000 pandemic
• Selected calls for service were 3% higher in

. --·-------------
-
month
the second quarter of 2021 compared with

30,000
20,000
. .----....--------·--------- ..
2020, particularly responding to overdoses
(+25%), general wellness checks (+17%), and
10,000
mental health-related calls such as a person

0
Jon -20 Feb-20 Mor-20 Apr-20 Moy-20 Jun-20 Jul-20 Aug-20 Sep-20 Oct-20 Nov-20 Oec-20 Jon-21 Feb-2 1 Mor-21 Apr-21 Moy-21 Jun-2 1
in emotional crisis or an attempted suicide - Total selected criminal incidents Total selected calls for service
(+8%). Since the start of the pandemic Notes: I nformation presented in this cha rt r epresents data r eported by a sample of 19 police services acr oss canada. Calls for service information w as
reported by 14 of these police services, as at the time of this release, the Mont r eal Police Se rivce, SUrete du Quebec, Royal cana dian Mounted Police,
period, monthly counts of calls for police Edmonton Police Service and the Winnipeg Police Servic-e were unable to provide calls for service data . Due to incomplete covera ge, only data up to
a nd including June 2021 wer e available. Data for this project continue to be oollected on a monthly basis a nd re leased r egula rly.
service have been higher in comparison to Source: Statistics canada, Special police-reported crime statistics• Specia l COVIO-19 r eport to Statistics Ca nada.
pre-pandemic levels reported in 2019.

11
...
l
♦
I
$1at,shcs
Canada
Stabsbque
Canada Delivering insight through data for a better Canada Can']!,d a et.:
AR01607
Looking forward…
• Canadians will continue to have to contend with COVID-19 with the introduction of the new omicron variant
with increased transmissibility which may lead to new restrictions as case counts increase.
• Continued efforts are required to increase vaccination rates and the uptake of booster shots.
• Pressures on healthcare systems and healthcare workers due to COVID-19 will likely continue resulting in
reduced capacity and access to other healthcare services including cancer care. Modelling results are
predicting increases in cancer rates and mortality for colorectal and breast cancer.
• While the direct impacts of COVID-19 remain front and centre, strategies are also required to support those
facing indirect impacts including mental health and substance use and abuse.
12
...
l♦ I Stat1st1cs
Canada
Stat1sflque
AR01608
Impact on Demographic trends
13
...
l♦ I Stat1st1cs
Canada
Stat1sflque
AR01609
Demographic changes due the pandemic will have implications for Canada’s society and economy
• Canada, like other developed countries, is
experiencing demographic changes due to the Factors of annual population growth, Canada, 2010 to 2021
pandemic. persons
• Population growth in 2020 fell to levels not 600,000
seen in 75 years.
500,000
• Annual population growth in 2020 was 0.4%

(+149,461):
400,000 -
• Lowest growth since 1945 (in number)
and 1916 (in percent)
• Only one-quarter of the growth that
300,000 /
✓
200,000
occurred in 2019 (+575,038).
• • • •
• Deaths in 2020 surpassed 300,000 (309,893) for
the first time in Canadian history, up 7% from
100,000
0
• • • • • • • ..
2019: 2010 201 1 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
• Natural increase (births minus deaths) fell - -Population Growth - - Natural Increase Migratory Increase
to its lowest level since at least 1922. So urce: Statistics Canada, Centre for Demography.
• The Public Health Agency of Canada

reported 15,651 COVID-19 related deaths.
14
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01610
Low levels of immigration during the pandemic will have implications for employment
• The contribution of international migration to population
growth fell to 58% in 2020. Number of new immigrants admitted t o Canada and net non-permanent residents (NPRs), Canada,
• It had accounted for three quarters of growth since 2019 t o 2021
2016. 150.000
• The pandemic’s largest impact on population growth in 2020 100,000
reflected lower international migration, specifically, net non-

permanent residents.
50,000
• In 2020, immigration was at just over half (184,624) of 0

Immigration, Refugees and Citizenship Canada’s pre-
pandemic target of 341,000. -50,000
• Canada experienced the largest net loss of non-

permanent residents (NPR) since at least 1972 (-86,535), - lUU,UUU
Ql Q2 Q3 Q4 Ql Q2 Q3 Q4 Ql
due mostly to declines in student and work permit 2019 2020 2021
holders. - - Immigra nts - - rlet non-perrranent r eside ,ts
• Canada also saw the lowest level of net emigration

Sou rce : Demogr a:>hic Estimates Pr ogr am , Centr e :or Demography.
(11,462) since comparable records have been available.
• Immigration numbers in 2021 are recovering to pre-pandemic

15
levels.
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01611
The pandemic has affected Canadians' intentions to have children which will have longer lasting fertility
impacts
• Nearly 20% of Canadians aged 25 to 44 want of the COVJU-19 pandemic

Wants to have a baby later than previously planned because Wants to have fewer children than previously planned
b ecause ot the COVID-19 pandemic
to have children later as a result of the

pandemic — 23% among those who were not
married or in a common-law relationship
compared with 15% of those in a couple.
• 14% reported wanting fewer children than

before — 18% among those not in a couple
compared with 12% of those who were a v e.c
married.
■ I.Jo
Source: St.:,tis:ics C.ino :l.1, Con:1di:1n S-ocid ~.1rvcy COVI O 19 O "l d 'Ne I b:in ;i, ~021. Sou rce: S-to:is t ics C:ln.:ico, C:in.:di.:n Socio l SLrtcy COV JD 1e:• .ird V/cll bcin~, 2021.
• Some Canadians reported the opposite — 7% of Canadians aged 25 to 44 now want to have children sooner, while 4% want
to have more children than prior to the pandemic.
16
...
l
♦
I
$1at,shcs
Canada
Stabsbque
AR01612
Strong interprovincial migration toward British Columbia and Atlantic Canada – which will have social and
economic implications for these regions
Population growth rate, 2019/ 2020and 2020/ 2021, Canada, provinces and territories
• Interprovincial migration has also begun canada
to return to pre-pandemic levels. Newfoundland and Labrador
-
Prince Edward Island
• British Columbia saw the largest

Nova Scotia
New Brunswick
increase in interprovincial migration Quebec
(+34,277) nationally in 2020/2021. This Ontario
was also the largest increase

Manitoba
Saskatchewan
-
~
since 1993/1994. Alberta

British Columbia
Yukon
• Conversely, Ontario reported the largest Northwest Territories
net loss (-17,085) in interprovincial Nunavut
migration. ·l 0 1
Growth rate (%)
2 3
■ 20 19/2020 □ 2020/2021
Source : Statistics Canada, Table 17·10·0009·01.

17
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01613
Looking forward…
• Short-term, COVID-19 will have implications on labour shortages, supply of goods and services, housing, and downtowns.
• The significant drop in the net immigration level will have implications for population growth, labour, since most new
immigrants are concentrated in the working age population, and regional distribution of the population since most live in
large urban areas.
• Before the pandemic, immigrants and temporary foreign workers (TFW) filled gaps in Canada’s labour force helping
employers respond to vacancies in various sectors including agriculture, accommodation and food services and
professional, scientific and technical services sectors. With the cut by half in inflows of new immigrants and TFWs during
the pandemic, those sectors are likely aligned with where labour shortages are more acute.
• Fertility was already at record low levels in 2020—1.4 children per woman—and in some parts of the country such as the
Atlantic, natural increase is already at a negative. This means that for so many regions of the country, positive population
growth can only be generated through immigration.
• Longer-term, while harder to predict, we may see higher population growth in the Atlantic, which can be seen to some
extent as the “winners”, and slower population growth in the Prairies, in particular in Alberta with the slowdown related to
oil.
18
...
l♦ I Stat1st1cs
Canada
Stat1sflque
AR01614
Assessing the economic recovery
19
...
l♦ I Stat1st1cs
Canada
Stat1sflque
AR01615
Overall economic activity remains below pre-pandemic levels
• Real gross domestic product rose 1.3% Percentage change m economic activity, selected expenditure components, Q4 2019 to Q3 2021
in the third quarter, but remained percent
1.4% below pre-pandemic levels. 15

11.0
10
• Spurred by strong demand and
higher incomes, household s
spending fueled output growth 0.5
along with rebounding exports.

0
-0.2
-1.4
-5
• Non-residential business -6.3
investment remained subdued, - 10
- 10.9
and was almost 11% below pre- - 15
pandemic levels.
-20
• Despite declines in recent

Household final Investment in housing Non-res idential Goods exports Goods imports Real gross domestic
consumption business investment product at market
quarters, outlays on housing expend itu re pr ices

Source: Statistics Canada , Table 36- 10- 0104- 01.
remained elevated compared to
pre-COVID levels.
20
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01616
As economy-wide output continues to recover, employment rebounded to pre-COVID levels in the

wake of third wave restrictions
• Economy-wide output strengthened as third wave

Cumulative percentage decline in output and employment since February 2020
per cent
restrictions eased and consumers spent more on out-of- 5
the-home purchases.
0
• Employment growth during the late spring and summer -5

months was led by gains in accommodation and food
services as activity levels in hard-to-distance sectors - 10
rallied.
- 15
• Total employment recovered to pre-pandemic levels in -20
September, while full-time employment among both

Mar . A pr . May. Jun . Jui. A ug . Sep . Od:. Nov. Dec . Jan. Feb . Mar . A pr . May. Jun . Jui . A ug . Sep . Oct. Nov.
2020 202 1
core-age men and women had recovered by October. ■ Real gr oss domestic pr oduct a Employ ment
Sou rces: S ta tistics Canada, Tables36- 10-0434-0 1 a nd 14- 10-0287-01.
21
...
l
♦
I
$1at,shcs
Canada
Stabsbque
AR01617
The recovery remains uneven across industrial sectors as supply disruptions impact activity
• After the initial stages of the pandemic, Current output relative to pre-COVID levels (February 2020 to September 2021)
economic losses became increasingly Mining and quarrying
concentrated in lower-wage, high contact Offices of real estate agents
services. Residential bu ilding construction
--
Computer systems d~ign
Finance and insurance
• Professional services with high degrees of Wood product manufacturing

Food manufacturing
telework capacity recovered quickly, while Retail trade
supply disruptions continue to weigh on Oil and gas extraction

Rail transportation I
I
factory output. All industries ■

Food services and drinking places
Petroleum refineries
• As of September 2021, output levels in Non-r esidential building constr uction
' '
accommodation and food services remained

Accommodation services
Crop pr oduction
12% below pre-pandemic levels, while output Arts, entertainment and recreation
in arts, entertainment and recreation

Motor vehicles and parts manufacturing
-so - 40 -30 -20 - 10 0 10 20 30

industries remained about one third below. percent change
Source: Statistics Canada, Table 36- 10-0434-01.
22
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01618
Employment recovery varies markedly across industrial sectors

• Employment growth strengthened in the wake of third
wave restrictions in the spring. All of the cumulative gains
from May to August were in service industries, over half of Net employment ch an ge, by i ndustry (February 2020 to Octobe r 2021)
Professiona l, scie ntific a nd tedmical services
which reflected higher employment in accommodation Tota l employed, a ll indust ries
and food services. Public administra tion

Health care and social assistance
Finance, insurance, real estate, rental and leasing
• Over half the net employment increase during this three- Wholesale and retail trade
Educational se rvices
month period reflected higher employment among 15 to Informa tion, cult ure a nd recreation
24 year-olds, led by gains among young women. By Manufactur ing
Forest ry, fishing, mining, quarrying , oil a nd gas
August, the employment rate among youth had essentially utilities
returned to pre-pandemic levels. Transportation and warehousing

Business, building and other support services
Agricultur e
• Total employment returned to pre-pandemic levels in Construction

Othe r services (ex ce pt public a dministra tion)
September and, as of November, was one percent above Accommodation and food services
levels reported in February 2020 (+186,000). Substantial ·300 ·200 ·100 0 100 200 300
differences continue to persist across sectors. As of

thousands of persons
Sourc e: Statistics Canada, Table 14•10·0355·01.
November, net employment losses in accommodation and
food services since the start of the pandemic were
202,000, while employment in professional, scientific and
technical services has risen by 190,000.
23
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01619
Financial conditions in the household sector continue to be impacted by COVID

• Household wealth has risen by $2.8 trillion (+23.1%)
during the pandemic, bolstered by gains in equities
Percentage change in household net worth, Q2 2020 to Q2 2021
and housing. The household saving rate has been in
double-digit territory for six consecutive quarters,
while financial risk ratios, including those for low-
Highest wea lt h quintile
income and younger households, remain below pre-

pandemic levels. Fourth wea lth quintile
• Lower-wealth household and young families have

seen disproportionately large increases in their
Third wealth quintile
income and wealth.

Lowest and .second wealth quintiles
• The winding down of emergency support programs

may put strains on the inclusiveness of the recovery. pe rcent
Workers in the population groups designated as ■ Mortgag e debt D Non-mortgage d ebt ■ Financial assets D Real estate D Consumer goods
visible minorities were hit harder by the social,
economic and health impacts of the pandemic, were
So urce: Statistics canada, Table 36-10-0660-0l.
more likely to receive Canada Emergency Response

Benefit (CERB) payments, and are more financially
vulnerable as income supports wind down.
24
...
l
♦
I
$1at,shcs
Canada
Stabsbque
Canada Delivering insight through data for a better Canada Can']!,d aet.:
AR01620
The number of workers experiencing long-term unemployment remains above pre-COVID levels
• As of November 2021, long-term Long-term unemployment

unemployment was about three index of unemployed persons who have been sear ching for work or on temporary layoff for 27 weeks or more
quarters above levels reported prior to 400
the pandemic. 350

• 318,000 Canadians have been
searching for work or on 300
temporary layoff for 27 weeks or 250
more.
200
• In November, workers experiencing 150
long-term unemployment accounted 100

for 25.6% of all unemployed persons,
up from 15.6% prior to the pandemic. 50
l 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49
Months since beginning of downturn
• Over half of the net increase in long- - - - 1981/1982 recession - - 1990/1992 recession 2008/ 2009 rece!;Sion ----· COVID-19 recession
term unemployment reflects higher

Note : Index begins in the month of peak employment immediately prior to each economic downturn .
So urce: Statistics Canada, Table 14- 10-0342- 0l.
unemployment among core-aged

workers, led by increases among core-
age men. 25
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01621
Current business conditions: Significant pressures related to rising input costs and mismatches
between labour supply and demand cloud the business outlook
• Rising input costs related to labour, energy, Anticipated business obstacles over the next three months
capital or raw materials were identified as an Risi ng cost of in puts .

obstacle in late 2021 by over 40% of
businesses. Recruiti ng ski lled employees
Shortage of labour force '

• One third of businesses expect labour
shortages to be an obstacle, up from 30% Cost of insurance '
and 24% in the previous two quarters. Tr ansportation costs '
• One quarter of businesses expect difficulty Retaining ski lled employees '
sourcing inputs domestically, with another Fluctuations in consumer demand .

one fifth anticipating difficulties 0 5 10 15 20 25 30 35 40 45
internationally. In both cases, over one half percent of businesses
of those businesses expect these challenges ■ Q2 202 1 OQ3 2021 ■ Q4 2021
to persist for six months or more. Sources: Statist i cs canada, Tables 33·10·0364· 01, 33 · 10·0338·01 and 33·10·0400·1.
26
...
l
♦
I
$1at,shcs
Canada
Stabsbque
AR01622
Job vacancies remain elevated, highlighting potential mismatches between labour supply and
demand
Labour demand continues t o increase in accommodation and food services
• While high job vacancies can be an indicator of number of j ob v acancies and payr oll employ ees
growing employment, they can also be a signal of high 1,600,000
turnover, labour shortages or mismatches between 1,400,000
the characteristics of vacant positions and those of 1,200,000
available workers.
1,000,000
800,000
• Job vacancies were at record levels in the second 600,000
quarter and continued to rise into early fall. The job 400,000
vacancy rate was 6.0% in September.

lUU,UUU
0
Ql Q2 Q3 Q4 Oct, Nov, Dec, Jan , Feb, Mar , Apr , May, Jun , Jui , Aug , Sep ,
• Vacancies were highest in accommodation and food 2021 2021 2021 2021 2020 2020 2020 2021 2021 2021 2021 2021 2021 2021 2021 2021
Quarter ly s er ies Monthly ser ies
services, where employers were actively recruiting for ■ Payr oll employ ees □ Job vacancies
196,100 positions. By comparison, there were 76,600 Note: The data ar e not s easonally adjusted .
Sources : Job V acancy and Wage Survey (5217), tables 14- 10-0371-0 l and 14- 10-0326-0 L
vacancies in this sector during the third quarter of

2019.
27
...
l
♦
I
$1at,shcs
Canada
Stabsbque
Canada Delivering insight through data for a better Canada Can']!,d aet.:
AR01623
Consumer inflation accelerates at the fastest pace since 2003 as gasoline, shelter costs and
consumer durables put upward pressure on the headline rate
Consu mer p rice index
• While base effects have impacted index level
headline inflation in recent months, 146

consumer prices, measured month-over-
month, have increased steadily since the
144 January 20 20
Headline consumer inflation: 2 .4 %
beginning of 2021. 142
Price growth, excluding gasoline: 2 .0 %
\
• Higher prices for gasoline, shelter and
140
consumer durables have all contributed to 138
these recent increases as disruptions ...

,, ......, ,#....... ........., ___ , ,,' , ...' __,
136 ,,' '
continue to impact supply chains in many
No vemb er 20 21
,,' ,,- ~ - - .,,?I Headli ne consumer
,,' _.,,, /
sectors of the economy. ,~- ..........,,..., inflation: 4 .7 0/o
134 _____, •--•/ H ay 2020 Price growth, excluding
,,, , ' Headline consumer gasoline: 3 .60/o
132 ,, ~ - inflation: - 0 .4 0/o
• Food prices have also risen in recent _,,,,,,, Price growth, excluding
gasoline : 0 .7%
months, and were up 4.4%, year-over- 130
year, in November. 128

2018 2019 2020 2021
----· All-items - - - All-items excluding gasoline
So urce: Statistics canada, Table 18·10·0004·01.
28
...
l
♦
I
$1at,shcs
Canada
Stabsbque
AR01624
Consumer Inflation outpacing wage growth as supply disruptions contribute to rising prices
Average hourly wages (fixed weight, adjusted for composition) and consumer prices
• The pace of wage growth in the index
economy, measured year-over-

115
year, is running well behind the

113 Average hou rly wages ( Fixed weight), two-year change,
Novem ber 2019 to November 2021 : 2. 2 0/o
111
current rate of consumer 109
Consu mer prices, two-year change,
November 2019 to November 2021: 4 . 7 %
inflation. 107
105
• Average hourly wages (adjusted 103
for changes in workforce 101 ,-~ - -
composition due to the 99
pandemic) were up 2.8% in the 97
twelve months to November, 95

J FMAMJ JASON DJ F M A MJ J ASO N DJ FMA MJ J ASO NDJ FM A MJ JASON
while headline inflation was 4.7%. 20 18 2019 2020 202 1
...-. AV G HW ( fixed weight) - CPI

So u rce: Statistics canada , special tabulations .
29
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01625
Sustained increases in new home prices reflect strong demand and rising input costs, putting
pressures on affordability
• Nationally, new home prices rose 11.5% New ho me prices, percenta qe chanqe , month over month
year-over-year in October. i £ ~------------------------------------------------------~
• Prices were up in all 27 markets 2.0
surveyed, with the largest annual

increases in Kitchener–Cambridge–
Waterloo (+29.2%), Ottawa (+24.8%)
and Windsor (+21.9%). 1,C,
• Strong demand, rising input costs, and

limited housing supply has put upward
pressure on home prices across the
country.
o.o I I 11., I,.1. ,, Iu I..I.1.l 1•• 1.I1•.1••• I
I, 1,1 I 1°1 ■ 1•1 1 1• hh
-u., ' - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - '
• Many first-time homebuyers may face Je111 !~,I'' Jui Oe.;l J::111 Aj.11 Jui Oe.;l Jo11 Aµ · J .11 OL;l : du Aµ1 Jui OU. Je11 A~•r : ul 0 Ll Je111 Al" JLI Oe.:l J::111 !~,:,, Jui Oe.;l
significant financial challenges, especially

20 15 ~0 15 2 JLS 20 15 20 16 20 16 ~0 1.S 2 Jl6 20 1/ 20 17 2017 2017 2 JL8 20 1£ 20 18 ~0 18 2019 2 ) 19 20 19 20 19 ~020 2020 2020 2020 20~1 ~021 202 1 2 ) 2 1
s ou rce: ~tatistics c ar ad:1, able U:S- W ·L:lU:>· 01.
as borrowing and debt-servicing costs

begin to rise, while other potential
homeowners will be priced out of the
housing market.
30
...
l
♦
I
$1at,shcs
Canada
Stabsbque
AR01626
Labour market resilience: Job security will likely be higher among higher-paid and more educated
workers, who often hold triple-protected jobs
Percentaqe o f employees a qed 25 to G4 in s pe cit ic job types, by waqe d ecile, 2019
Job Is not tem porary Jvl, hd~ d lvw r i ~k vr e1ulv m~d ivn
per cent p-: rccnt
1 0() l)O
• Of employees aged 25 to 64 YU 90 -
who were in the top 10% of
••
;u
••
/0 -
-
the wage distribution in 2019,
bU 50
>U >O ,-
88% held triple-protected jobs '"

30
""
30 . - -
(not temporary, low risk of
nn
,u ;o
10 10
automation, and resilient to )

lst 2nd 3cc 4th S:h 61t ith St , 9th !Jth
0
1st 2nd 3r,j 4th S:h 5th 7th .3th ? :h !Jth
pandemics). wage ,j ed e
Job Is reslllent t o pandem i cs Job Is trlple- protected

per cc.nt 1•~11:~111
• The corresponding percentage

100 100
for their counterparts in the

90
00
70
..•o
70
bottom 10% of the wage 60 60
so
distribution was 14%.
50
•• ...
,.
30 so
20
lU LO
u
:i,:;t 2nd 3, d .... 5th 6t , ith 8:h 9th !Jth
0
1st 2id 2rd 4th S:h 5th 7th .3th ? :h !Jth
W.:,Jc de e le wage. d ecil:
Source: Fr cnctt: , \I . .:,nd ll. Mo r sscttc. 2 : 21 . ':oo s ccunt-1 1n the .:,; c ot,:,rt1·1c1.:, 1ntc111, crc: .:,nd pXCnb .:,I p.:,ndcn-1cs, • E,:ono m,c .:,rd ; oc1.:l 1lcports,
s :atiu. cc <..:ana d a <..:atal oaue r o. ::1t:.•:!l::l·UOUl.
...
l
♦
I
$1at,shcs
Canada
Stabsbque
U:
AR01627
The interconnectedness of the environment, the economy and society is more apparent than ever, and
will require policy makers to consider all three lenses to ensure effective decision-making
• Economic sectors like oil and gas extraction are Top 5 greenhouse gas emitting sectors in 2018, Canada
major emitters, but so are final consumption

activities from households, such as driving gasoline- Oil and gas extraction
powered vehicles.
Hous eholds : Motor fuels
• There are economic opportunities in responding to

and lubricants
climate change: The environmental and clean Crop and animal production
technology sector contributed 3.3% of GDP in 2020. (except cannabis)
The composition of that sector’s workforce in 2019

was still predominantly male (64%), and Indigenous
Electric power generation,
transmission and distribution
participation was focused in the 15- to 24-year age

group. Households : Electricity
and otherfue ls
• Expenditures on environmental protection 0 20,000 40,000 60,000 80,000 100, 000 120,000 140,000 160,000 180,000
increased by 15% between 2016 and 2018. Business Sou rc e : Statistics Canada, Table 38-10-0097-0 1.
kilo tonnes of CO,e
innovation strategies are increasingly focused on

environmental outcomes.
32
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01628
Looking forward…
The initial stages of the pandemic coincided with sharp increases in business productivity as businesses invested in digital
infrastructure while economic resources were transferred from lower productivity to higher productivity sectors. Productivity has
trended down in recent quarters as lower-wage services rebound.
• Are the productivity impacts of the pandemic, especially those related to investments in digital technology, likely to be short-
lived or long-lasting? How would a widespread shift to working from home, after most pandemic-related restrictions have eased,
affect the competitiveness of Canadian businesses?
Business innovation is becoming more focused on environmental outcomes—nearly half of businesses reported that they
experienced environmental benefits from innovating, with over one third indicating that the innovation had environmental benefits
for the consumer or end user.
• To what extent will investments in clean energy, clean technology and environmental products supplant traditional investments in
oil and gas? What are the implications of the clean energy transition for economic growth?
Housing prices have continued to rise steadily in recent months, while consumer inflation is at its highest level in over 18 years.
• How are emerging pressures related to affordability affecting the financial well-being of Canadian families? How will financial
conditions in the household sector evolve in the near term as income support programs wind down?
A key feature of the pandemic has been its unevenness—evidenced by the disproportionate social, economic and health impacts on
more vulnerable groups, including low wage workers, recent immigrants, young people and racialized communities.
• How will the pandemic affect job quality going forward—especially in lower paid sectors that were severely impacted by the
pandemic? What does this imply for the unevenness of the recovery over the longer-term?
33
...
l♦ I Stat1st1cs
Canada
Stat1sflque
AR01629
Statistics Canada – Areas of focus moving forward
• Disaggregated Data Action Plan: The Agency will further improve the quality and
availability of disaggregated data in support of the Government’s commitment to
evidence-based decision-making that takes into consideration the impacts of
policies on all Canadians to address systemic socio-economic inequities.
• Census of the Environment: Provide a detailed picture of Canada’s natural assets
that will enable informed decision-making regarding the impact of various
interventions that aim to protect, rehabilitate, enhance or sustain the country’s
natural environment.
• Quality of Life Framework: Working with Department of Finance to develop new
indicators to monitor the quality of life of Canadians.
• Develop new partnerships and tools, as well as data-collection and analysis
methods to monitor and report on trends in the well-being of Canadians,
particularly as the country moves from pandemic response to recovery.
34
...
l
♦
I
$1at,shcs
Canada
Stabsbque
et.:
AR01630
For more information and research from Statistics Canada on COVID-19 and other critical policy
issues, check out the following….
COVID-19: A data perspective

Canadian Economic Dashboard and COVID-19
COVID-19 in Canada: A One-year Update on Social and Economic Impacts
Interactive data visualizations related to COVID-19
Selected analytical and research publications: COVID-19

Health Reports A data perspective
Economic and Social Reports
Insights on Canadian Society
35
...
l♦ I Stat1st1cs
Canada
Stat1stique
Canada Delivering insight through data for a better Canada Canad a
AR01631
This is Exhibit “C” to the Affidavit of Shaun Rickard sworn March 11, 2022
-
~
-
v .•:
-
.
____________________________________
SAM A. PRESVELOS
AR01632
Canadian
Cancer Statistics
2021
Canadian
l♦I
Government Gouvernement
of Canada du Canada Cancer
Society
This publication was developed by the Canadian Cancer Statistics Advisory Committee in collaboration with the
Canadian Cancer Society, Statistics Canada and the Public Health Agency of Canada with data provided by the
provincial and territorial cancer registries.
cancer.ca/statistics
AR01633
Citation
Material appearing in this publication may be reproduced or
copied without permission. The following citation is
recommended: Canadian Cancer Statistics Advisory Committee in
collaboration with the Canadian Cancer Society, Statistics
Canada and the Public Health Agency of Canada. Canadian
Cancer Statistics 2021. Toronto, ON: Canadian Cancer Society;
2021.
Available at: cancer.ca/Canadian-Cancer-Statistics-2021-EN

(accessed [date]).
November 2021
ISSN 0835-2976
This publication is available in English and French on the

Canadian Cancer Society’s website at cancer.ca/statistics. Visit
the website for the most up-to-date version of this publication
and additional resources, such as individual figures from the
chapters and past editions.
The development of this publication over the years has benefited

considerably from the comments and suggestions of readers. The
Canadian Cancer Statistics Advisory Committee appreciates and
welcomes such comments. To offer ideas on how the publication
can be improved or to be notified about next year’s publications,
complete the evaluation form or email stats@cancer.ca.
Canadian Cancer Society • Canadian Cancer Statistics 2021 2

AR01634
Members of the Canadian Cancer

Statistics Advisory Committee
Darren Brenner, PhD (Co-chair) Hannah K. Weir, PhD
Departments of Oncology and Community Health Division of Cancer Prevention and Control,
Sciences, University of Calgary, Calgary, Alberta Centers for Disease Control and Prevention,
Atlanta, Georgia
Abbey Poirier, MSc (Co-chair)
Cancer Information and Policy, Canadian Cancer Ryan Woods, PhD
Society, Calgary, Alberta Cancer Control Research, BC Cancer, Vancouver,
British Columbia
Leah Smith, PhD (Co-chair)
Cancer Information and Policy, Canadian Cancer Analytic leads
Society, St. John’s, Newfoundland and Labrador
Alain Demers, PhD
Samina Aziz, MSc Centre for Surveillance and Applied Research,
Centre for Surveillance and Applied Research, Public Health Agency of Canada, Ottawa, Ontario
Public Health Agency of Canada, Ottawa, Ontario
Larry Ellison, MSc
Larry Ellison, MSc Centre for Population Health Data, Statistics
Centre for Population Health Data, Statistics Canada, Ottawa, Ontario
Canada, Ottawa, Ontario
Additional analysis
Natalie Fitzgerald, MA Jean-Michel Billette, PhD; Statistics Canada
Performance, Canadian Partnership Against Chunhe Yao, PhD; Statistics Canada
Cancer, Toronto, Ontario
Shary Xinyu Zhang, MSc; Statistics Canada
Nathalie Saint-Jacques, PhD
Nova Scotia Health Cancer Care Program, Project management
Nova Scotia Health, Halifax, Nova Scotia Monika Dixon, Canadian Cancer Society
Donna Turner, PhD Acknowledgments

Population Oncology, CancerCare Manitoba, The Canadian Cancer Sta ee
Winnipeg, Manitoba would like to acknowledge the following individuals
for their help developing this publica
Jean-Michel Billette, PhD; Statistics Canada
Yibing Ruan, MPH; Alberta Health Services

AR01635
Table of Contents
Executive summary Chapter 2
Notable new statistics . . . . . . . . . . . . . . . . . . . . . .7 How many people die from cancer in Canada?
About this publication Mortality by sex, age, geography and year
Purpose and intended audience . . . . . . . . . . . . . .8 Key findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .33
What is new or noteworthy? . . . . . . . . . . . . . . . . .9 Probability of dying from cancer . . . . . . . . . . . .34
Projected cancer deaths in 2021 . . . . . . . . . . . .34
Chapter 1
Mortality by sex . . . . . . . . . . . . . . . . . . . . . . . . . .35
How many people get cancer in Canada?
Mortality by age . . . . . . . . . . . . . . . . . . . . . . . . . .36
Incidence by sex, age, geography and year
Mortality by geographic region . . . . . . . . . . . . .38
Key findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10
Mortality over time. . . . . . . . . . . . . . . . . . . . . . . .39
Probability of developing cancer . . . . . . . . . . . .11
What do these statistics mean? . . . . . . . . . . . . .45
Projected new cancer cases in 2021 . . . . . . . . .11
Incidence by sex . . . . . . . . . . . . . . . . . . . . . . . . . .12 Chapter 3
Incidence by age . . . . . . . . . . . . . . . . . . . . . . . . .13 What is the probability of surviving cancer in
Incidence by geographic region . . . . . . . . . . . . .15 Canada? Net survival by sex, age, geography
Incidence over time . . . . . . . . . . . . . . . . . . . . . . .16 and over time
What do these statistics mean? . . . . . . . . . . . . .22 Key findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .56
Five- and 10-year net survival . . . . . . . . . . . . . .57
Survival by sex . . . . . . . . . . . . . . . . . . . . . . . . . . .58
Survival by age . . . . . . . . . . . . . . . . . . . . . . . . . . .58
Survival by geographic region . . . . . . . . . . . . . .60
Survival over time . . . . . . . . . . . . . . . . . . . . . . . .60
Conditional net survival . . . . . . . . . . . . . . . . . . .60
What do these statistics mean? . . . . . . . . . . . . .61

AR01636
Table of contents
Chapter 4 APPENDIX I
Cancer in context: The cancer burden in Canada Related resources
Cancer is the leading cause of death Additional cancer surveillance statistics . . . . .76
in Canada. . . . . . . . . . . . . . . . . . . . . . . . . . . . . .67 Chronic disease surveillance . . . . . . . . . . . . . . .77
Cancer is a complex disease . . . . . . . . . . . . . . . .68 Childhood cancer surveillance . . . . . . . . . . . . .77
Cancer outcomes in Canada are among Cancer system performance . . . . . . . . . . . . . . .78
the best in the world . . . . . . . . . . . . . . . . . . . .69
Cancer prevention . . . . . . . . . . . . . . . . . . . . . . . .78
Cancer outcomes are not evenly distributed
International cancer surveillance . . . . . . . . . 78
among Canadians . . . . . . . . . . . . . . . . . . . . . .69
Cancer has a substantial economic burden APPENDIX II
on Canadians and Canadian society . . . . . .69 Data sources and methods
Progress has been made but the challenge Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .79
continues . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .70
Data sources . . . . . . . . . . . . . . . . . . . . . . . . . . 79
How statistics can help guide cancer control . .72
Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .81
Data and methods issues . . . . . . . . . . . . . . . . . .87
Index of tables and figures . . . . . . . . . . . . . .92

Contact us . . . . . . . . . . . . . . . . . . . . . . . . . . . . .94

AR01637
Executive summary
Canadian Cancer Statistics is a publication that

provides comprehensive, up-to-date estimates of
the impact of cancer in Canada.
Cancer is the
...........
It is estimated that about 2 in 5 Canadians will
develop cancer in their lifetime, and about 1 in #1 2 in 5
4 Canadians will die from cancer. In 2021 alone, Canadians will
it is expected that 229,200 Canadians will be leading cause of develop cancer in
diagnosed with cancer and 84,600 will die from death in Canada their lifetime
the disease. Cancer is by far the leading cause of
death among Canadians.
Lung and bronchus (lung), breast, colorectal

and prostate cancers account for almost half of
all new cancer cases diagnosed. Lung cancer is
the leading cause of cancer death, responsible 229,200
for more cancer deaths among Canadians than Canadians will be diagnosed
the other three major cancer types (colorectal, with cancer in 2021
breast and prostate) combined. Despite this large
impact, there has been a substantial drop in the Five-year cancer 84,600
lung cancer death rate in males over the past 35 survival is about Canadians
will die from
years, which has contributed to a decline in the
death rate in males for all cancers combined. 64% cancer in 2021
Lung cancer death rates in females have also
recently started to decrease. As a result of the
progress made with lung and other cancers,
cancer death rates have decreased 37% in males
and 22% in females since their peak in 1988. 1 in 4
Canadians will die
Cancer survival has also increased. In the early from cancer
1990s, five-year net survival for all cancers
combined was only 55%, but current estimates
show that it has reached 64%. Survival varies
widely by the type of cancer. Some cancers
have very high five-year net survival, including

AR01638
Executive summary
thyroid cancer and testicular cancer (both 97%). affected by cancer and who may need support Reference
Other cancers have consistently low five-year net after their treatment has ended. 1. Statistics Canada [Internet]. Table 13-10-0394-01. Leading causes of death, total
survival, such as esophageal cancer (16%) and population, by age group. Available at: https://www150.statcan.gc.ca/t1/tbl1/en/tv.
action?pid=1310039401 (accessed April 2021).
pancreatic cancer (10%). The goal in providing cancer incidence and
mortality projections was to estimate the true
Cancer strikes males and females, young and old, underlying impact of cancer up to 2021. As such,
and those in different regions across Canada on a the projections presented in this publication
decidedly uneven basis. For example: do not account for any changes in diagnosis or
• Males are more likely to be diagnosed with cancer control due to the COVID-19 pandemic.
The effect of the pandemic on cancer diagnosis
cancer than females, and females are more
and control is an important issue that will need to
likely to survive cancer than males.
be explored when data are available.
• About 90% of cancer diagnoses occur among
Canadians who are at least 50 years of age, but We hope that our readers think critically about
its impact at a younger age can be particularly what these numbers mean and how they can be
devastating. In 2019, cancer was the leading used to reduce cancer incidence, improve survival
cause of disease-related death in children under and develop better overall care for those dealing
with cancer in Canada.
the age of 15 years.(1)
• Across Canada, cancer incidence and death
rates are generally higher in the east than in Notable new statistics
the west. Compared with the last full Canadian Cancer
Statistics publication in 2019, several new patterns
Measures of the cancer impact in Canada are have emerged. Notably:
vital for developing and evaluating health policy,
• Thyroid cancer incidence is decreasing, after
helping decision-makers assess the type and
amount of health resources needed and informing the rates increased for many years.
health research priorities. This information is also • The magnitude of the declining mortality rate
essential for informing and evaluating primary for lung cancer is now comparable between
and secondary cancer prevention activities and sexes for the first time since 1984.
assessing the impact of early detection and cancer • Death rates for colorectal cancer in both sexes
treatment on cancer outcomes. Moreover, these are decreasing, with the rate in females
statistics can be used to prioritize services to
decreasing more rapidly.
help Canadians and their families who have been

AR01639
About this publication
Canadian Cancer Statistics 2021 is the most recent Box 1 How these statistics can be used
in a series of publications that began in 1987
to describe the impact of cancer in Canada. It Cancer cases (incidence): Useful for Age-standardized mortality rates
was developed through a collaboration between determining the amount of diagnosis, (ASMR): Facilitate comparisons across
the Canadian Cancer Society, Statistics Canada treatment and support services needed. populations and over time; can reflect
and the Public Health Agency of Canada, who changes in incidence rates, show
Age-standardized incidence rates
brought together expertise from across the cancer where progress is being made in early
(ASIR): Facilitate comparisons across
surveillance and epidemiology community in the detection, diagnosis and treatment and
populations and over time; can reflect
form of the Canadian Cancer Statistics Advisory indicate where more progress is needed.
changes in risk factors and screening
Committee.
and show where progress is being made Annual percent change (APC): Useful for
(or not) in cancer prevention. examining trends in age-standardized
Purpose and intended audience incidence and mortality rates over time.
Cancer deaths (mortality): Useful
This publication provides the most current for determining the amount of Net survival: Facilitate comparisons
summary of key cancer surveillance indicators healthcare and support services needed, across populations and over time; useful
in Canada. It includes detailed information on particularly for those who are at the end for monitoring the effects of early
incidence, mortality, survival and other measures
of life. detection and diagnosis and treatment
of the impact of cancer for selected types of cancer
on cancer outcomes.
in Canada. This information is presented by sex,
age group, geographic region and time period.
These statistics are produced using the Canadian

Cancer Registry (CCR),(1) one of the highest
quality national population-based cancer registry
systems in the world,(2) as well as the national Vital
Statistics—Death Database (CVSD),(3) a census
of all deaths occurring in Canada each year.
Such comprehensive and reliable surveillance
information allows us to monitor cancer patterns
and identify where progress has been made and
where there is more to do. It is also important
for cancer control planning, healthcare resource
allocation and research. Box 1 describes some of
the ways in which the specific types of statistics in
this publication can be used.

AR01640
About this publication
Notably, this publication is the only source of Box 2 Projecting the cancer burden to 2021
national estimates of cancer incidence and
mortality projected to the current year (2021). This publication strives to provide the Important: Projected estimates are not
While projected estimates must be interpreted most up-to-date statistics. However, expected to be exact predictions. They are
with caution (Box 2), they provide a more up-to-date because time is required for reporting, used to give an indication of what might be
picture of the cancer burden in Canada than collating, verifying, analyzing and expected if the analytic assumptions were
would otherwise be available, which is important publishing surveillance data, the most to hold true over the projected time frame
for planning health services and allocating recent data available are several years based on the best available data.
resources. behind the publication year. For this
The projections presented here are based
publication, actual cancer incidence
This publication is designed to help health on quality historical data and reflect the
data up to 2017 and cancer death data
professionals, policy-makers and researchers underlying cancer incidence and mortality
up to 2019 (2018 for projections) were
make decisions and identify priorities for action in trends in the population, not the likely
used (except Quebec, where cancer
their respective areas. However, the information changes in diagnosis patterns due to
incidence data were available to 2010).
contained in this publication is relevant to a much COVID-19. It is expected that COVID-19 has
These historical data were used to
broader audience. As such, the media, educators impacted cancer diagnosis and potentially
project cancer incidence and cancer
and members of the public with an interest in cancer outcomes in Canada, which might
deaths to 2021.
cancer may also find this publication valuable. impact actual incidence and mortality data
for 2020 and 2021. This is discussed further
in Chapter 4.
What is new or noteworthy?
Continuous efforts are made to ensure this
publication best serves the needs of the cancer 2. Updated incidence, mortality and References
community and is based on the most up-to-date survival statistics 1. Statistics Canada [Internet]. Canadian Cancer Registry (CCR). Ottawa, ON: Statistics
Canada; 2021. Available at: https://www23.statcan.gc.ca/imdb/p2SV.
data and most appropriate methodology available. In the 2019 edition, estimates of cancer mortality pl?Function=getSurvey&SDDS=3207 (accessed April 2021).
To that end, many updates were made this year. were based on data to 2015. Statistics Canada 2. International Agency for Research on Cancer [Internet]. Cancer Registries: Why, what
and how? Geneva, Switzerland: Union for International Cancer Control. Available at:
Two are particularly noteworthy: recently released cancer mortality data up to https://www.uicc.org/sites/main/files/atoms/files/UICC%20Cancer%20Registries-%20
why%20what%20how.pdf (accessed April 2021).
2019, which has provided the opportunity to
1. New head and neck category examine more recent trends in cancer mortality
3. Statistics Canada [Internet]. Vital Statistics—Death Database (CVSD). Ottawa, ON;
2021. Available at: http://www23.statcan.gc.ca/imdb/p2SV.
A head and neck cancer grouping has been in Canada. These updated mortality statistics are pl?Function=getSurvey&SDDS=3233 (accessed April 2021).
added to this 2021 publication. This new grouping presented in detail in Chapter 2. The mortality
includes the combination of oral (oral cavity projections to 2021 were based on mortality data
and pharynx) and laryngeal cancers, which to 2018. In addition, incidence and survival data
were included as separate cancers in the 2019 up to 2015 and 2014, respectively, were used in
publication, as well as the nasal cavity sinuses. the 2019 edition. These data are now updated to
The head and neck grouping excludes thyroid, 2017 and are presented in detail in Chapters 1
which continues to be reported on separately. and 3.

AR01641 1
Chapter
How many people get cancer in Canada?

Incidence by sex, age, geography and year
The number and rate of new cases of Key findings

cancer diagnosed each year (incidence) • It is estimated that 43% of Canadians • The rate of new cancer cases increases
and over time are important measures will be diagnosed with cancer in their substantially with age. It is expected
of the cancer burden on the Canadian lifetime. that 93% of new cancer cases in males
population and healthcare system. This and 87% in females will be diagnosed
• 229,200 new cases of cancer are
information is essential for ensuring expected to be diagnosed in Canada
in Canadians 50 years of age and
that adequate screening, diagnosis, older.
in 2021. The number of cases
treatment and support services are expected in males (118,200) is slightly • The rate of melanoma skin cancer
available, as well as for directing future higher than in females (110,900). is still increasing although this is a
cancer prevention, control and research largely preventable cancer.
• Together, the four most frequently
programs. diagnosed cancers (lung, breast, • In general, cancer incidence rates
This chapter examines incidence by sex, colorectal and prostate cancers) are are lower in the western provinces
expected to account for 46% of all and the territories, and higher in
age and geographic region, as well as
cancers diagnosed in 2021. the central and eastern provinces.
over time, to better understand who is Newfoundland and Labrador is
affected by cancer in Canada and what • Overall, cancer rates have declined
expected to have the highest rate
can be done about it. -1.5% annually since 2011 for males
in Canada followed by Ontario and
and -1.2% annually since 2013 for
Nova Scotia.
females.
• The number of cancer cases
diagnosed each year has been
increasing because of the growing
and aging population. When the
effect of age and population size are
removed, the risk of cancer has been
decreasing.

Chapter 1 • How many people get cancer in Canada?
AR01642
Probability of developing cancer As shown in Table 1.1, the probability of Probability

developing cancer varies by cancer type. The chance of developing cancer
The probability of developing a specific type
of cancer depends on many factors, including • Canadians are more likely to be diagnosed with measured over a lifetime. The probability
age, sex, risk factors and life expectancy. This lung cancer than any other cancer. An estimated of developing cancer is expressed as a
probability reflects the average experience of 1 in 15 Canadians (7%) is expected to be percentage or as a chance (e.g., 20% or
people in Canada and does not take into account diagnosed with lung cancer in their lifetime. 1 in 5 people over a lifetime)
individual behaviours and risk factors; therefore, • 1 in 8 males (12%) is expected to be diagnosed
it should not be interpreted as an individual’s risk. with prostate cancer in their lifetime.
The numbers presented in this section reflect the
Projected new cancer cases
• 1 in 8 females (12%) is expected to be in 2021
likelihood at birth that Canadians will develop
cancer at some point during their lifetime. diagnosed with breast cancer in their lifetime.
The cancer incidence data used for this
• The lifetime probability of developing breast,
• About 2 in 5 (43%) of Canadians are expected publication were from 1984 to 2017 (1984 to
prostate, colorectal or lung cancer remains high, 2010 for Quebec). These were the most recent
to be diagnosed with cancer in their lifetime
but it is lower for other cancers. data available when the analyses began. Data
(Figure 1.1).
from 1993 onward were used to project rates
• The probability of developing cancer remains
and counts to 2021.
slightly higher in males (44%) than females (43%).
An estimated 229,200 new cases of cancer are
FIGURE 1.1 Lifetime probability of developing cancer, Canada (excluding Quebec*), 2017
expected to be diagnosed in Canada in 2021
(Table 1.2).
• Lung cancer is expected to be the most
Both sexes
tttt t ttttt 43%
(1 in 2.3)
commonly diagnosed cancer in Canada with an
estimated 29,600 cases expected in 2021. It is
followed by breast cancer (28,000), colorectal
cancer (24,800) and prostate cancer (24,000).
Males
iiii . iiiii 44%
(1 in 2.3)
• The four most commonly diagnosed cancers are
expected to account for about half (46%) of all
cancers diagnosed in 2021.
♦♦♦♦ ♦♦♦♦♦♦
Females 43%
(1 in 2.4)
Every hour in 2021,

26 Canadians are expected to
* Quebec is excluded because cases diagnosed in Quebec from 2011 onward had not been submitted to the Canadian Cancer Registry.
Note: The probability of developing cancer is calculated based on age- and sex-specific cancer incidence and mortality rates for Canada be diagnosed with cancer.
excluding Quebec in 2017. For further details, see Appendix II: Data sources and methods. The complete definition of the specific cancers
included here can be found in Table A1.
Analysis by: Centre for Surveillance and Applied Research, Public Health Agency of Canada
Data sources: Canadian Cancer Registry and Canadian Vital Statistics Death database at Statistics Canada

AR01643
Incidence by sex • The four most commonly diagnosed cancers

are expected to account for 46% of all cancers Incidence
Cancer affects males and females differently.
in 2021, which is less than in the previous The number of new cancer cases
This may be the result of biological differences,
or differences in risk factors or health behaviours. report, Canadian Cancer Statistics 2019 (48%). diagnosed in a given population during a
In general, cancer is more commonly diagnosed specific period of time, often a year.
in males than females (Table 1.2). FIGURE 1.2 Percent distribution of projected new cancer
cases, by sex, Canada,* 2021 Age-standardized incidence
• Slightly more males (118,200) than females rate (ASIR)
(110,900) are expected to be diagnosed with
The number of new cases of cancer per
cancer in 2021.
• The age-standardized incidence rate (ASIR) in
males (556 per 100,000) is expected to be about
15% higher than in females (485 per 100,000).
• The same number (14,800) of lung cancers are
expected to be diagnosed in males and females.
t
Prostate
Males
118,200
New cases
20.3%
t
Breast
Females
110,900
New cases
25.0%
100,000 people, standardized to the age
structure of the 2011 Canadian standard
population. In this publication, ASIR is also
referred to as “incidence rate.”
Projected incidence
Lung and bronchus 12.5% Lung and bronchus 13.3%
Actual cancer incidence data were available
• The rate at which cancer is diagnosed is Colorectal 11.6% Colorectal 10.0%
to 2017 for all provinces and territories
Bladder 8.0% Uterus (body, NOS) 7.2%
expected to be higher in males than in females except Quebec, for which data were
Non-Hodgkin lymphoma 5.2% Non-Hodgkin lymphoma 4.5%
for all cancer types except breast and thyroid Head and neck 4.6% Thyroid 4.4% available to 2010. Data from 1993 onward
cancers. Kidney and renal pelvis 4.4% Melanoma 3.6% were used to project cancer incidence
Melanoma 4.0% Bladder 2.7% to 2021.
Leukemia 3.4% Pancreas 2.7%
Figure 1.2 shows the expected distribution of
Pancreas 3.1% Ovary 2.7%
cancer cases in males and females in 2021.
Stomach 2.2% Leukemia 2.4%
• In males, prostate cancer is expected to be the Liver 2.2% Kidney and renal pelvis 2.3%
most commonly diagnosed cancer, accounting Multiple myeloma 1.9% Head and neck 1.8%
Esophagus 1.6% Multiple myeloma 1.4%
for about 1 in 5 (20%) of new cases. It is Brain/CNS 1.5% Cervix 1.3%
followed by lung cancer (13%), colorectal cancer Thyroid 1.5% Stomach 1.3% The most commonly
(12%), bladder cancer (8%) and non-Hodgkin Testis 1.0% Brain/CNS 1.2%
lymphoma (5%). Hodgkin lymphoma 0.5% Liver 0.7% diagnosed cancer in males is
• In females, breast cancer is expected to be the
Breast
All other cancers
0.2%
10.3%
Esophagus
Hodgkin lymphoma
0.5%
0.4%
prostate cancer and in females
most commonly diagnosed cancer, accounting All other cancers 10.5% is breast cancer.
for 1 in 4 (25%) of new cases. It is followed by
lung cancer (13%), colorectal cancer (10%), CNS=central nervous system, NOS=not otherwise specified
uterine cancer (7%) and non-Hodgkin * Quebec is included in the cases because of their importance in
determining the national total projected number. `
lymphoma (5%).
Note: The complete definition of the specific cancers included
here can be found in Table A1.
Analysis by: Centre for Population Health Data, Statistics Canada
Data source: Canadian Cancer Registry database at Statistics Canada

AR01644
Incidence by age Table 1.3 shows the projected number of cases by colorectal cancer cases will be diagnosed in
age group in 2021. people younger than 50 years of age.
Age is the most important risk factor for cancer.
Figure 1.3 shows the dramatic increase in cancer • 9 in 10 cancers are expected to be diagnosed in • It is expected that 38% of breast cancer cases
rates by age. Canadians aged 50 years and older. will be diagnosed in females aged 30 to 59
• Of all cancers diagnosed, a projected 4,050 years, which helps explain why overall cancer
• Cancer rates peak in males and females aged 85
(almost 2%) will be diagnosed in children and rates are higher in females than males in that
to 89 years.
young adults (0 to 29 years) and 143,900 (63%) age group.
• For both males and females, the highest number
will be diagnosed in seniors (65 years and
of new cancers is diagnosed between the ages The distribution of cancer type varies by age. In
older).
of 65 and 69 years. general, embryonal and hematopoietic cancers
• Almost all lung and prostate cancers (98% and
• Between the ages of 25 and 59 years, rates of are more common in children, while epithelial
99%, respectively) are expected to occur in
cancer are higher in females than males. In all tumours are more common in adults. Cancers
people 50 years of age or older. found in adolescents and young adults are a mix
other age groups, rates are higher in males.
• Over half (56%) of colorectal cancer cases are of childhood and adult tumours.
expected to occur in Canadians who fall within
the age covered by the screening guidelines
(50 to 74 years).(1) It is expected that 8% of
FIGURE 1.3 Percentage of new cases and age-specific incidence rates for all cancers, by age group and sex, Canada
(excluding Quebec*), 2015–2017
Percentage of new cases Age-specific incidence rate (per 100,000)
20 3,200
• Males
15 2,400 I Rate
-
Percentage ■
10 1,600
•
t
Females
Rate -
Percentage
■
5 800
0 0
( View data )
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85–89 90+
Age group (years)

AR01645
The most commonly diagnosed cancers in each FIGURE 1.4 Distribution of new cancer cases for selected cancers, by age group, Canada (excluding Quebec*), 2013–2017
age group are shown in Figure 1.4:
• In children aged 0 to 14 years, the most 100
commonly diagnosed cancers were leukemia Breast Colorectal

Thyroid (14%) Lung and bronchus (15%)
(35%), followed by central nervous system 90 (16%) Breast (17%)
cancers (17%), lymphoma (13%), neuroblastoma (23%)
Leukemia
and other peripheral nervous cell tumours (7%) 80
(35%) Prostate
Lung and bronchus
Testis (14%) Colorectal
and soft tissue sarcoma (7%). (13%) (13%)
(14%)
Thyroid
• Among youth and young adults (aged 15 to 29 70 (12%)
Hodgkin Lung and bronchus Breast
years), the most commonly diagnosed cancers lymphoma (12%) Prostate (9%)
were thyroid (16%), testicular (13%), Hodgkin (11%) (12%)
Percentage of cases
60 Colorectal (9%)
Bladder (7%)
lymphoma (11%), non-Hodgkin lymphoma Brain/CNS Non-Hodgkin
Colorectal
(17%) lymphoma (7%) Breast Prostate
(11%)
(7%), melanoma (6%), colorectal (6%) and Melanoma (7%) (9%) (7%)
50 Melanoma (6%)
leukemia (6%). Non-Hodgkin
lymphoma (5%) Uterus (body, NOS) (5%) Non-Hodgkin lymphoma (5%)
Bladder (7%)
Lymphoma Colorectal (6%)
• In Canadians aged 30 to 49 years, the most Kidney and renal pelvis (4%) Non-Hodgkin lymphoma (4%)
Pancreas (4%)
40 (13%)
Cervix (4%) Bladder (4%) Non-Hodgkin lymphoma (5%)
commonly diagnosed cancers were breast Leukemia (6%)
Uterus (body, NOS) (3%) Melanoma (3%)
Melanoma (4%)
Melanoma (4%) Leukemia (4%)
(23%), thyroid (12%), colorectal (9%) and Neuroblastoma Brain/CNS (5%) Head and neck (3%)
Head and neck (4%)
Pancreas (3%)
30 and other PNC (7%) Testi (3%) Stomach (3%)
Leukemia (3%)
melanoma (7%). Breast (4%) Lung and bronchus (3%) Kidney and renal pelvis (4%) Kidney and renal pelvis (3%)
Soft tissue (7%) Cervix (3%)
• Between the ages of 50 and 84 years, lung, Leukemia (3%) Thyroid (3%) Head and neck (3%)
20 Other malignant Leukemias (3%)
breast, colorectal and prostate cancers were the epithelial (5%) Other
(29%)
most commonly diagnosed cancers. In those Renal tumours (5%)
Other Other Other Other
10 (22%) (22%)
aged 85 years and older, bladder cancer ties Malignant bone (4%) (22%) (19%)
Germ cell tumours† (3%)
with prostate cancer as the fourth most Other (4%)
commonly diagnosed cancers, after colorectal, 0
0 –14 15 – 29 30 – 49 50 – 69 70 – 84 85+
lung and breast. (0.5%) (1.5%) (9.6%) (44.7%) (34.4%) (9.3%)
Age group, in years (percentages of all cancer cases‡)
CNS=central nervous system; PNC=peripheral nervous cell tumours; NOS=not otherwise specified
† Also includes trophoblastic tumours and neoplasms of gonads.
The most commonly ‡ The relative percentage is calculated based on the total number of cancer cases over five years (2013–2017) for each age group. Cases
aged 0–14 years not mapping to a main childhood cancer diagnostic group were excluded.
diagnosed types of cancers Note: Cancers diagnosed in children (aged 0–14 years) were classified according to the Surveillance, Epidemiology and End Results Program
(SEER) update to the International Classification of Childhood Cancer, Third Edition (ICCC-3).
vary between age groups. Cancers diagnosed in older individuals were classified according to the International Classification of Diseases for Oncology, Third Edition
(ICD-O-3). For further details, see Appendix II: Data sources and methods.The complete definition of the specific cancers included here can
be found in Table A1.
Analysis by: Centre for Surveillance and Applied Research, Public Health Agency of Canada; Centre for Population Health Data, Statistics Canada

AR01646
Incidence by geographic region within a region, age-standardized rates should • For both sexes combined, Newfoundland
be used when comparing across jurisdictions and Labrador is expected to have the highest
Figure 1.5 shows the expected distribution of
and populations. ASIR in 2021, closely followed by Ontario and
cancer across Canada in 2021. Estimates for
Quebec were not included because a different • In general, it is expected that cancer incidence Nova Scotia.
projection approach was used for Quebec, rates for 2021 will be highest in eastern and
meaning those rates are not comparable to the central Canada and lowest in western Canada Tables 1.4 and 1.5 show the projected number of
others. and the territories. Nova Scotia is expected to new cases and projected ASIR by cancer type for
have the highest ASIR in males (598.9 per each province and territory.
• The number of expected cancer cases in each
province and territory is largely a function of 100,000) and Newfoundland and Labrador the • Among males and females, the highest rates
the expected population size. While the number highest rate for females (542.9 per 100,000). of colorectal cancer are expected in
of cases is important for healthcare planning Newfoundland and Labrador (105.0 per 100,000
and 80.3 per 100,000, respectively), while the
■
■
■
ASIR ≥500 per 100,000
ASIR 475–499 per 100,000
ASIR <475 per 100,000
Excluded
-
Population distribution*
I
I
SK 3.2%
MB 3.6%
BC 13.5%
AB 11.9%
ON 38.8%
highest rates of lung cancer are expected in
New Brunswick for males (90.6 per 100,000)
and Nova Scotia for females (74.9 per 100,000).
• The rates of prostate cancer across the country
are expected to range from a low of 101.7 per
100,000 in Manitoba to a high of 127.8 per
QC 22.3% 100,000 in Prince Edward Island.
I NB 2.0% • Rates of breast cancer in females are expected
I NS 2.5% to be lowest in Manitoba (113.9 per 100,000)
415.1 per 100,000 IPE 0.4%
(170 new cases) and Prince Edward Island (114.0 per 100,000)
I NL 1.4%
ITerritories 0.3% and highest in Newfoundland and Labrador
480.9 per 100,000
(160 new cases)
358.2 per 100,000
(136.6 per 100,000).
(60 new cases)
~ Differences in cancer rates between provinces

457.7 per 100,000 and territories could be the result of different risk
(28,500 new cases)
559.8 per 100,000 factors (such as smoking and obesity), as well
(4,000 new cases)
485.8 per 100,000 as differences in diagnostic practices and data
(21,000 new cases)
483.6 per 100,000
(6,900 new cases)
† * Based on projected estimates of population size in 2021.
482.8 per 100,000
(6,000 new cases) 498.4 per 100,000
† Quebec is excluded because a different projection method was
545.9 per 100,000 (1,000 new cases) used for Quebec than the other regions, meaning the estimates are
(91,600 new cases) not comparable. For further details, see Appendix II: Data source
and methods.
Note: Rates are age-standardized to the 2011 Canadian standard
539.8 per 100,000
FIGURE 1.5 Geographic distribution of projected 508.9 per 100,000 (6,900 new cases) population.
new cancer cases and age-standardized (5,300 new cases) Analysis by: Centre for Population Health Data, Statistics Canada
incidence rates (ASIR), by province and Data sources: Canadian Cancer Registry database and Population projec-
territory, both sexes, 2021 tions for Canada, Provinces and Territories at Statistics Canada

AR01647
collection. For example, the dramatic variation FIGURE 1.6 New cases and age-standardized incidence rates (ASIR) for all cancers, Canada,* 1984–2021
in prostate cancer incidence across the country
is likely largely due to differences in the use of ASIR (per 100,000) New cases (in thousands)
prostate-specific antigen (PSA) testing. 700 120
t
Males
110 ASIR
Importantly, these estimates do not include a 600 New cases ■
100
measure of precision, such as confidence intervals
90
or p-values, so we cannot determine whether the
differences reported are statistically significant. 500 80
Also, estimates from less populous provinces and 70
the territories must be interpreted with caution as
Projected
400 60
they can vary considerably from year to year.
50
300 40
Incidence over time 30
200
Monitoring trends in incidence over time can 20
help identify emerging trends, where progress has 10
been made and where more needs to be done. View data )
(__
100 0
1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
Figure 1.6 shows the counts and rates for all Year
cancers combined, by sex. ASIR (per 100,000) New cases (in thousands)
--.
• In 1984, the age-standardized incidence rate 600 120
♦
Females
(ASIR) for all cancers combined in males was 110 ASIR
577.4 per 100,000 and is projected to be 556.3 New cases
100
per 100,000 in 2021 (-3.6% decrease). For
females, it was 423.6 in 1984 and is projected to
500
-----
...
90
80
be 484.9 per 100,000 in 2021, which is an 400 70
increase of 12.5%.
60
Projected
• The number of new cases diagnosed each year
300 50
rose steadily, from 46,700 in 1984 to a projected
40
118,200 in males in 2021 (an increase of 153%),
30
and from 42,500 to a projected 110,900 in 200
females (an increase of 161%). The steady 20
increase in the number of new cases diagnosed 10

each year is primarily due to the growing and 100 0
1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
aging Canadian population.(2,3) Year
* Quebec is included in the cases because of their importance in Note: Rates are age-standardized to the 2011 Canadian standard population. Actual data were available to 2017 for all provinces and
determining the national total projected number. Quebec is territories except Quebec, for which actual data were available to 2010, and projected thereafter.
excluded from the rates because a different projection method Analysis by: Centre for Population Health Data, Statistics Canada
was used for this province than for other regions. Data source: Canadian Cancer Registry database at Statistics Canada

AR01648
FIGURE 1.7 Most recent annual percent change (APC)† in age-standardized incidence rates (ASIR), by sex, Canada
Annual percent change (APC) (excluding Quebec‡), 1984–2017
The estimated change in the age- APC

3
standardized incidence rate per year over 2.5**
2.2**
■ I I III
Males
II I I I ■ ■ ■
a defined period of time in which there is 2
1.4** 1.3** 1.3**
no significant change in trend (i.e., no 1 0.6* 0.6** 0.5* 0.4
changepoint). It is reported as a percentage. 0
-1
• - • • -0.3 -0.4** -0.4** -0.5§
-1.0**
Reference year -2 -1.8*
The year corresponding to the first year of -3
-2.4 -2.6*
the APC segment.
-4 -3.8**
-4.3** -4.4**
-5
Statistical significance
-6
Refers to a result that is unlikely due to a a as sti
s a ck rs ea
st lvi
s
Liv
er
NS ma er ch us ro
id ia
hu
s tal te
om om cre om ne ce pe dd ma ag y em ec sta
yel lan Te ph an Br al n/C ho Bla ph Th uk nc or
chance, assuming there were no other le
m e Pan
lym a nd
e r c e n Br
ai
lym
p Sto Es
o Le b r o o l Pro
ltip
M in ad th dr an
d C
gk He lo an kin
sources of bias, given a predetermined Mu
-Hod Al
d n ey
Ho
dg
Lu
ng
No
n Ki
threshold (e.g., fewer than 1 out of 20 times,
which is expressed as p<0.05). APC
3
Confidence limits (CL)

Upper and lower values of a range
(confidence interval) that provide an
indication of the precision of an estimate.
Confidence intervals are usually 95%.
-1
-2
2
0
2.0**
111111. ______
1.6**
1.1** 1.0 0.9** 0.9**
0.3
0.1
-0.2* -0.4**
-0.5* -0.5** -0.6*
,,,,,,1
-1.2 §
-1.6*
-2.0**
♦
Females
-2.2
This means that upon repeated sampling -3
-3.1* -3.2
for a study, and assuming there were no -4
-3.4**
other sources of bias, 95% of the resulting -5

confidence intervals would contain the true -5.4**
-6
value of the statistic being estimated. ma ma s ) s k
ma as
t s h NS rvi
x
de
r
mi
a us ea
s
ar
y er
cta
l id
no lvi OS ma nc
er ec e gu ac /C ad ch cr Ov Liv ro
elo e y,N ho dn ph
o Br ph
a om Ce Bl uk
e
lor
e
Th
y
ela y lp d p ca n o St ain Le r on Pa
n
M em en
a
( bo lym he
r da lym Es Br db Co
ipl nd
r
us in lo
t
He
a
kin an
ult ya er gk Al dg ng
M e Ut H od Ho Lu
idn n-
CNS=central nervous system; NOS=not otherwise specified K No
* APC differs significantly from 0, p<0.05

‡ Quebec is excluded because cases diagnosed in Quebec from 2011 onward had not been submitted to the Canadian Cancer Registry.
** APC differs significantly from 0, p<0.001
§ The trend analysis for bladder cancer was performed using the Jump Model of the JoinPoint Regression Program to account for the
† The APC was calculated using the Joinpoint Regression Program artificial change in cancer counts introduced in 2010 when Ontario started to include in situ carcinomas of the bladder in their data
and rates age-standardized to the 2011 Canadian standard collection. For further details, see Appendix II: Data sources and methods.
population. If one or more significant changes in the trend of rates
was detected, the APC reflects the trend from the most recent Note: The reference year for each cancer is in Table 1.7. The range of scales differs widely between the figures. The complete definition
significant change (reference year) to 2017. Otherwise, the APC of the specific cancers included here can be found in Table A1.
reflects the trend in rates over the entire period (1984–2017). For Analysis by: Centre for Surveillance and Applied Research, Public Health Agency of Canada
further details, see Appendix II: Data sources and methods. Data sources: Canadian Cancer Registry and National Cancer Incidence Reporting System databases at Statistics Canada

AR01649
Recent trends FIGURE 1.8 Age-standardized incidence rates (ASIR) for selected* cancers, males, Canada (excluding Quebec†), 1984–2021
Table 1.6 provides details on trends between 1984
and 2017 for each cancer, by sex, as measured by ASIR (per 100,000)
annual percent change (APC).(4) Table 1.7 draws 200 200
...
i
Males
out the most recent trends for each cancer. These Colorectal
180 180
recent trends are depicted in Figure 1.7.
Projected
Lung and
160 160 bronchus
• In males, the most recent largest decreases Prostate
were for prostate (-4.4% per year), colorectal 140 140
(-4.3% per year) and lung (-3.8% per year) 120 120
cancers.
100 100
• In females, the largest significant decreases
were for thyroid (-5.4% per year), colorectal 80 80
(-3.4% per year) and ovarian (-3.1% per year). 60 60

• The biggest increases in males were for multiple
40 40
myeloma (2.5% per year) and melanoma (2.2%
per year). In females, melanoma (2.0% per year) 20 20
and multiple myeloma (1.6% per year) increased 0 0 ( __

View data ,)
the most. 1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
Year
• Compared to the results presented in Canadian
Cancer Statistics 2019,(5) prostate cancer shows ASIR (per 100,000)
30 30
i=
a slower decline and colorectal cancer shows a Males
more rapid decline in both males and females. Melanoma
Multiple
Trends in thyroid cancer for females and 25 25
myeloma
leukemia for both sexes are now decreasing. Leukemia
• Between 1984 and 2013, the rate of thyroid 20 . ·.;; ·.·· ·,·-·•,.,.-. . 20
cancer in both sexes was steeply rising. ..
Projected
However, there has been an annual decline 15 15
of -4.7% since then.
10 10
* Three most frequently diagnosed cancers among males and
cancers with a statistically significant change in incidence rate of
at least 2% per year, as measured by the most recent annual
percent change (see Table 1.7). 5 5
† Quebec is excluded because cases diagnosed in Quebec from 2011

onward had not been submitted to the Canadian Cancer Registry.
0 0
Note: Rates are age-standardized to the 2011 Canadian standard 1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
population. Actual incidence data were available to 2017 and Year
projected thereafter. The range of scales differs widely between the
figures. The complete definition of the specific cancers included Analysis by: Centre for Population Health Data, Statistics Canada
here can be found in Table A1. Data sources: Canadian Cancer Registry and National Cancer Incidence Reporting System databases at Statistics Canada

AR01650
• Leukemia is now significantly declining for both FIGURE 1.9 Age-standardized incidence rates (ASIR) for selected* cancers, females, Canada (excluding Quebec†), 1984–2021
sexes.
ASIR (per 100,000)
160 160
Long-term trends Females
Breast
Longer-term trends provide additional context for 140 140
Colorectal
understanding the achievements and challenges Lung and
in reducing cancer incidence. Table 1.6 shows 120 120 bronchus
trends in incidence rates between 1984 and 2017
Projected
100 100
by cancer type.
• The trend for all cancers combined in males 80 80
increased slowly from 1984 to 1992 (0.9% per
year), stabilized between 1992 and 2011 60 60
(-0.1% per year) and decreased after 2011

(-1.5% per year).
40 • • • .-! . ~
--------------
••••••••••••••••••• 40
• The trend for all cancers combined in females 20 20

increased slowly between 1984 and 2007 (0.3%
0 View data
per year), and then more steeply between 2007
1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
and 2013 (1.2% per year). Since 2013, the rate Year
has been decreasing in females (-1.2% per year).
ASIR (per 100,000)
30 30
Figures 1.8 and 1.9 show the ASIR over time Females
Ovary
(projected to 2021) for the most common cancers
Thyroid
in Canada and cancers that had a statistically
25 25 Melanoma
significant change in APC of at least 2% in the
most recent trend: melanoma in both sexes,
leukemia and multiple myeloma in males, and
20
... 20
ovarian and thyroid cancers in females.
15 15
:.. ....... ...... .....

* Three most frequently diagnosed cancers among females and
cancers with a statistically significant change in incidence rate of
at least 2% per year, as measured by the most recent annual
.
Projected
percent change (see Table 1.7). 10 ............. 10
† Quebec is excluded because cases diagnosed in Quebec from
2011 onward had not been submitted to the Canadian Cancer
Registry.
5 5
Note: Rates are age-standardized to the 2011 Canadian standard 1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
population. Actual incidence data were available to 2017 and Year
projected thereafter. The range of scales differs widely between the
figures. The complete definition of the specific cancers included Analysis by: Centre for Population Health Data, Statistics Canada
here can be found in Table A1. Data sources: Canadian Cancer Registry and National Cancer Incidence Reporting System databases at Statistics Canada

AR01651
A short discussion of trends (based on Table 1.6) programs were implemented. After 1991, Prostate cancer
for each of these notable cancers is presented incidence rates fluctuated with peaks around The prostate cancer incidence rate for males
below. The list does not include liver and 1999 and 2011. However, overall, rates have increased rapidly from 1984 to 1993 (5.6% per year),
pancreatic cancers in females and thyroid shown a small but statistically significant decline then levelled off, and then declined steeply from
cancer in males (APC=-3.2%, -2.2% and -2.4%, between 1991 and 2017 of -0.2% per year. 2007 to 2017 (-4.4% per year). The incidence
respectively) because the trends were not The reasons for these fluctuations are unclear. rate peaked in 1993 and 2001, which mirrored
statistically significant. They are likely due to continued participation intensified use of prostate-specific antigen (PSA)
in mammography screening and to long-term testing in Canada.(16) The US Preventive Services
Lung and bronchus (lung) cancer changes in hormonal factors, such as early age at Task Force advised against PSA screening in
menarche, breastfeeding, late age at menopause, men over 75 years of age in 2008, and then in
In males, the incidence rate for lung cancer was
oral contraceptive use and late age at full-term asymptomatic men of all ages in 2011. Canada
stable in the late 1980s and has been decreasing
pregnancy.(8) The slight decrease in incidence that released similar guidelines in 2014.(17,18) The
since 1990, though at different rates: steeply
occurred around 2002 may reflect the reduced considerable decline in prostate cancer following
from 1990 to 2003 (-2.2% per year), then less
use of hormone replacement therapy (HRT) changes in PSA testing guidelines has also been
steeply from 2003 to 2013 (-1.0% per year), and
among post-menopausal females at that time.(9,10) reported in the US.(7,11)
then more steeply after 2013 (-3.8% per year). In
Recent data from the US show a moderate
females, the lung cancer incidence rate increased
increase in female breast cancer rates over
significantly between 1984 and 1993 (2.9%). The
the last 10 years.(11)
Leukemia
increase continued, but more slowly, from 1993 to Trends in the incidence rate for leukemia have
2013 (0.9% per year). The lung cancer incidence been variable over the period from 1984 to
rate in females started to decrease in 2013 (-2.0% Colorectal cancer 2017. In males, the incidence rate for leukemia
per year). Overall, colorectal cancer incidence rates decreased -1.1% per year until 1994, increased
decreased between 1984 and 1995 (-1.1% per 0.9% per year until 2013, and has since declined
The differences in trends in lung cancer rates year), were stable between 1995 and 2001, and -2.6% annually. In females, the modest rate of
in males and females reflect past differences decreased slightly between 2001 and 2013 (-0.5% decrease seen until 2001 (-0.3% per year) was
in cigarette smoking, which is the main risk per year). Since 2013, colorectal cancer incidence followed by a 1.9% annual increase until 2010.
factor for this cancer. In males, a decrease in the rates have declined more steeply in males (-4.3% More recently, the rate has declined -1.6%
prevalence of daily smokers began in the mid- per year) and females (-3.4% per year). annually.
1960s in Canada, preceding the decrease in lung
cancer incidence by about 20 years.(6) In females, The recent decline in colorectal cancer rates is A similar trend in the incidence rate for leukemia
the drop in smoking was not until the mid-1980s, likely due in part to increased screening for the has been reported globally between 1990
and lung cancer rates have only recently started disease, which can identify treatable precancerous and 2017, though the rate of decline varies
to decrease. These results are similar to those polyps and reduce cancer incidence. Between between countries and leukemia subtypes.(19,20)
found in the United States (US).(7) 2007 and 2016, Yukon and every province in For example, the incidence of all types of
Canada (except Quebec) implemented organized leukemia decreased in Australia, whereas most
Breast cancer (female) colorectal cancer screening programs.(12,13) The countries have witnessed increases in chronic
decline in colorectal cancer incidence rates may lymphocytic leukemia (CLL) and acute myeloid
In Canada, the breast cancer incidence rate in
be confined to older adults as rates are reportedly leukemia (AML). Factors driving these trends
females rose between 1984 and 1991 by 2.0%
increasing among adults younger than 50 years of are not well understood, though some suggest
per year. This is attributable in part to increased
age in Canada and the US.(14,15) that changes in environmental exposures (e.g.,
opportunistic mammography screening that was
done before even the first organized screening benzene), lifestyle (e.g., smoking) and parental

AR01652
behaviours (e.g., increased intake of folate during Ovarian cancer recent studies also show an increase in late-
the preconception period and pregnancy) may be The incidence rate of ovarian cancer declined stage papillary tumours, suggesting that the
at play.(19,21) (-1.5% per year) between 1984 and 1997 and overall increase may not be entirely due to
then levelled off until 2013. It has since been over-diagnosis.(38)
Melanoma decreasing rapidly (-3.1% per year). In 2021, the
Between 1984 and 2017, the incidence rate for rate is projected to be 27% lower than in 1984. A
melanoma increased an average of 2.2% per year gradual decline in incidence rate has also been
reported in most European countries and in the
Average annual percent change
in males and 1.4% per year in females. Exposure
to ultraviolet (UV) radiation through sunlight, US.(31) Several factors could be contributing to (AAPC)
tanning beds and sun lamps is a well-established the favourable trend, including increased use The weighted average of the APCs in effect
risk factor for melanoma.(22, 23) Past increases in of oral contraceptives, changes in reproductive during a period of time, where the weights
sun exposure without corresponding increases and protective risk factors (e.g., older age at equal the proportion of time accounted
in sun safety behaviours likely accounts for the childbirth), decreased prevalence of smoking for by each APC in the interval. AAPC
continued rise in melanoma rates.(24) and changes in disease classifications (i.e., since summarizes the change in age-standardized
2000, ovarian neoplasms with borderline or low rates over a specified interval. It is reported
malignant potential are no longer considered as a percentage.
Multiple myeloma
malignant tumours).(31–33)
In males, the incidence rate for multiple myeloma
was stable until 2007, after which it began to
increase at about 2.5% per year. Similarly, in Thyroid cancer
Incidence rates for thyroid cancer increased
Average annual percent change
females, the rate was stable until 2005 and has
since been increasing at 1.6% per year. In the rapidly between 1984 and 2013. Between 2013 (AAPC)
US, the incidence rate for multiple myeloma and 2017, incidence rates have decreased Table 1.6 also shows the average annual percent
increased slowly (0.8% per year) until 2008, significantly in females (-5.4% per year) and non- change (AAPC) in cancers between 1984 and
and has been increasing more rapidly (1.8% per significantly in males (-2.4% per year). The rate of 2017. By summarizing changes in trends, the
year) since then.(4) Improved detection and case thyroid cancer is decreasing in the US.(34) AAPC enables the comparison of changes in
ascertainment has been reported to contribute to incidence across cancers for the same defined
some of the increase in multiple myeloma cases in It is suspected that a substantial portion of the time period. In both males and females, the
other countries.(25) increase in thyroid cancer incidence was due greatest increases were observed for thyroid
to the over-diagnosis as a result of increased (4.0% and 4.3% per year, respectively) and liver
The increased prevalence of obesity, a known risk use of improved diagnostic technologies such (3.3% and 2.2% per year, respectively). The
factor for multiple myeloma, could be contributing as ultrasound and fine needle aspiration.(35) greatest decrease was in stomach cancer (-1.8%
to the recent upward trend in the incidence rate.(26,27) A recent Canadian study found evidence to and -1.7% per year, respectively). Despite the
Elevated risk of multiple myeloma has also support the over-diagnosis hypothesis, including current decrease in prostate cancer incidence,
been linked with pesticide use and proximity to the confirmation of the central role played by the dramatic increases and decreases since 1984
contaminated bodies of water and rivers.(28,29) papillary thyroid cancer in past trends. It also have averaged to indicate virtually no change
From 1981 to 2011, the relative risk of water reported significant increases in medullary over the three time periods (AAPC=0.2%). AAPCs
contamination by pesticides across agricultural thyroid cancer.(36) should be interpreted with caution as they do not
areas in Canada has increased 50%.(30) necessarily reflect the most recent trends; the
Many other reports have found increases
APC should be used for the most recent trends.
primarily in small, indolent papillary cases with
no concurrent increase in mortality.(37) However,

AR01653
What do these statistics mean? each year, a trend that is expected to continue The overall incidence rate for both sexes
until at least the early 2030s.(41) With the rising combined has not changed dramatically over the
Cancer strikes males and females, young and number of new cancer cases, there will be a past 30 years, but trends in individual cancers
old, and those in different regions across Canada corresponding increase in the need for primary tell a different story about the progress that has
on an uneven basis. The statistics in this chapter prevention, screening, diagnosis, treatment and been made. For example, the recent decreases
can support informed decision-making to ensure support services, including palliative care. in thyroid and prostate cancers likely reflect the
that healthcare services meet the needs of success of evolving screening policies and the
specific populations. They can also help identify It is also important to recognize that the priorities decrease in lung cancer likely reflects success
opportunities for further prevention and cancer of people with cancer and their needs for services in tobacco control. Also, the decline in cervical
control initiatives. can vary at different points in the age continuum. cancer likely reflects the success of widespread
For example, females are more likely than males screening programs, and similar signs of progress
We estimate that approximately 43% of Canadians to be diagnosed with cancer in the prime of
will be diagnosed with cancer in their lifetime. are emerging for colorectal cancer. In contrast,
their lives (between the ages of 25 and 59 years), there are significant increases in some cancers,
This high number is attributable to several factors, which reflects patterns for specific cancers, such
including that the Canadian population has a such as melanoma and multiple myeloma.
as breast and thyroid. Also, approximately 2% Strategies to mitigate these increases must be
high life expectancy. It emphasizes the need for of cancers are diagnosed in children and young
support services for those diagnosed with cancer developed promptly.
adults (aged 0 to 29 years), but these cancers
and their caregivers. have a significant and lasting impact on both the
individuals and their caregivers.
Supplementary resources
In 2021 alone, a projected 229,200 people in Cancer.ca/statistics houses supplementary
Canada will be diagnosed with cancer. An Cancer incidence rates vary across the country, resources for this chapter. This includes:
increased focus on primary prevention efforts with generally higher rates in the east and lower
should be employed to minimize the risk of • Excel spreadsheets with the statistics used to
rates in the west. These data can help inform
developing cancer. Prevention efforts include create the figures
screening and support efforts. To better target
vaccination, sun exposure awareness, tobacco prevention activities, these differences in rates • Excel spreadsheets with supplementary
control and the promotion of healthy living can be correlated with the prevalence of risk statistics
such as physical activity, healthy eating and factors, such as tobacco and alcohol consumption, • PowerPoint images of the figures throughout
limiting alcohol consumption. In addition, a physical inactivity and obesity rates. this chapter
focus on screening and early detection should be
maintained to diagnose and treat cancer at
an earlier stage when treatments are more References
effective and more likely to be successful. 1. Canadian Task Force on Preventive Healthcare. Recommendations on screening for
colorectal cancer in primary care. CMAJ. 2016;188 340-8.
The biggest risk factor for cancer is age, and the 2. Statistics Canada [Internet]. Age and sex, and type of dwelling data: Key results from
the 2016 Census. The Daily: Statistics Canada; 2017. Available at: https://www150.
Canadian population is aging.(39) Like many other statcan.gc.ca/n1/en/daily-quotidien/170503/dq170503a-eng.pdf?st=li6F_zjZ (accessed
developed countries, Canada now has a greater April 2021).
3. Statistics Canada [Internet]. Population size and growth in Canada: Key results from
proportion of seniors (people who are 65 years the 2016 census. Ottawa, ON: The Daily; 2017. Available at: https://www150.statcan.
of age or older) than at any time in the past, and gc.ca/n1/daily-quotidien/170208/dq170208a-eng.htm (accessed April 2021).
seniors represent the fastest-growing age group 4. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al [Internet]. SEER
Cancer Statistics Review, 1975–2018. Bethesda, MD: National Cancer Insitute; 2021.
in Canada.(40) As a result, the number of people Available at: https://seer.cancer.gov/csr/1975_2018/ (accessed May 2021). [Based on
November 2020 SEER data submission.]
diagnosed with cancer is increasing in Canada

AR01654
5. Canadian Cancer Statistics Advisory Committee [Internet]. Canadian Cancer Statistics 24. National Skin Cancer Prevention Committee. Exposure to and Protection from the Sun
2019. Toronto, ON: Canadian Cancer Society; 2019. Available at: cancer.ca/ in Canada. A Report Based on the 2006 Second National Sun Survey. Toronto, ON:
Canadian-Cancer-Statistics-2019-EN (accessed April 2021). Canadian Partnership Against Cancer; 2010.
6. Organisation for Economic Co-operation Development (OECD) [Internet]. Daily 25. Velez R, Turesson I, Landgren O, Kristinsson SY, Cuzick J. Incidence of multiple
smokers (indicator); 2015. Available at: https://data.oecd.org/healthrisk/daily-smokers. myeloma in Great Britain, Sweden, and Malmo, Sweden: The impact of differences in
htm (accessed April 2021). case ascertainment on observed incidence trends. BMJ Open. 2016;6(1):e009584.
7. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 26. Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res.
2021;71(1):7–33. 2011;183:25–35.
8. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer 27. Twells LK, Gregory DM, Reddigan J, Midodzi WK. Current and predicted prevalence of
incidence trends. J Natl Cancer Inst Monogr. 2006(36):19–25. obesity in Canada: A trend analysis. CMAJ Open. 2014;2(1):E18–26.
9. De P, Neutel CI, Olivotto I, Morrison H. Breast cancer incidence and hormone 28. Kachuri L, Demers PA, Blair A, Spinelli JJ, Pahwa M, McLaughlin JR, et al. Multiple
replacement therapy in Canada. J Natl Cancer Inst. 2010;102(19):1489–95. pesticide exposures and the risk of multiple myeloma in Canadian men. Int J Cancer.
10. Neutel Ci, Morrison H. Could recent decreases in breast cancer incidence really be due 2013;133(8):1846–58.
to lower HRT use? Trends in attributable risk for modifiable breast cancer risk factors 29. Tsang M, Le M, Ghazawi FM, Cyr J, Alakel A, Rahme E, et al. Multiple myeloma
in Canadian women. Can J Public Health. 2010;101(5):405–9. epidemiology and patient geographic distribution in Canada: A population study.
11. Henley SJ, Ward EM, Scott S, Ma J, Anderson RN, Firth AU, et al. Annual Report to the Cancer. 2019;125(14):2435–44.
Nation on the status of cancer, part I: National cancer statistics. Cancer. 30. Canada Agriculture and Agri-Food Canada [Internet]. Pesticides indicator. 2016.
2020;126(10):2225–49. Available at: https://agriculture.canada.ca/en/agriculture-and-environment/
12. Cancer Care Ontario [Internet]. Colorectal cancer incidence increasing among agriculture-and-water/pesticides-indicator (accessed April 2021).
adolescents and young adults. Toronto, ON: Cancer Care Ontario; 2009. Available at: 31. Zhang Y, Luo G, Li M, Guo P, Xiao Y, Ji H, et al. Global patterns and trends in ovarian
http://www.cancercare.on.ca/cancerfacts (accessed April 2021). cancer incidence: Age, period and birth cohort analysis. BMC Cancer. 2019;19(1):984.
13. BC Cancer Registry [Internet]. Age-standardized cancer incidence rates, relative to 32. Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world:
1970, British Columbia, 1970–2016: Colorectal. Vancouver, BC: BC Cancer Agency; Epidemiology and risk factors. Int J Womens Health. 2019;11:287–99.
2019. Available at: http://www.bccancer.bc.ca/statistics-and-reports-site/ 33. Cabasag CJ, Arnold M, Butler J, Inoue M, Trabert B, Webb PM, et al. The influence of
Documents/2019_Colorectal_inc_trend_1970_2016_20190208.pdf birth cohort and calendar period on global trends in ovarian cancer incidence. Int J
(accessed April 2021). Cancer. 2020;146(3):749–58.
14. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. 34. Surveillance Research Program, National Cancer Institute [Internet]. SEER Explorer: An
Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–64. interactive website for SEER cancer statistics. Available at: https://seer.cancer.gov/
15. Brenner DR, Ruan Y, Shaw E, De P, Heitman SJ, Hilsden RJ. Increasing colorectal cancer explorer/ (accessed April 2021).
incidence trends among younger adults in Canada. Prev Med. 2017;105:345–9. 35. Vaccarella S, Dal Maso L, Laversanne M, Bray F, Plummer M, Franceschi S. The impact
16. LeBlanc AG, Demers A, Shaw A. Recent trends in prostate cancer in Canada. Health of diagnostic changes on the rise in thyroid cancer incidence: A population-based
Rep. 2019;30(4):12–7. study in selected high-resource countries. Thyroid. 2015;25(10):1127–36.
17. Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, Dickinson J, et al. 36. Ellison LF, Bushnik T. Changing trends in thyroid cancer incidence in Canada: A
Recommendations on screening for prostate cancer with the prostate-specific antigen histologic examination, 1992 to 2016. Health Rep. 2020;31(1):15–25.
test. CMAJ. 2014;186(16):1225–34. 37. Topstad D, Dickinson JA. Thyroid cancer incidence in Canada: A national cancer
18. Lin K, Croswell JM, Koenig H, Lam C, Maltz A. Prostate-specific antigen-based registry analysis. CMAJ Open. 2017;5(3):E612-E6.
screening for prostate cancer: An evidence update for the US Preventive Services Task 38. Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence
Force. Rockville, MD: Agency for Healthcare Research and Quality (US); 2011. and mortality in the United States, 1974–2013. JAMA. 2017;317(13):1338–48.
19. Dong Y, Shi O, Zeng Q, Lu X, Wang W, Li Y, et al. Leukemia incidence trends at the 39. Statistics Canada [Internet]. Annual Demographic Estimates: Canada, Provinces and
global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. Territories. Catalogue no. 91-215-x. Ottawa, ON: Statistics Canada; 2020. Available at:
2020;9:14. http://www.statcan.gc.ca/pub/91-215-x/91-215-x2016000-eng.pdf (accessed April
20. Ning L, Hu C, Lu P, Que Y, Zhu X, Li D. Trends in disease burden of chronic myeloid 2021).
leukemia at the global, regional, and national levels: A population-based 40. Statistics Canada [Internet]. Seniors. Ottawa, ON: Statistics Canada; 2018. Available
epidemiologic study. Exp Hematol Oncol. 2020;9(1):29. at: https://www150.statcan.gc.ca/n1/pub/11-402-x/2011000/chap/seniors-aines/
21. Public Health Agency of Canada [Internet]. Chapter 4: Cancer incidence in Canada: seniors-aines-eng.htm (accessed April 2021).
Trends and projections (1983–2032) – Leukemia. Health Promot Chronic Dis Prev Can. 41. Canadian Cancer Society’s Advisory Committee on Cancer Statistics [Internet].
Spring 2015 ;35 Suppl 1:2–186. Available at: https://www.Canada.ca/en/public-health/ Canadian Cancer Statistics 2015. Toronto, ON: Canadian Cancer Society; 2015.
services/reports-publications/health-promotion-chronic-disease-prevention-Canada- Available at: www.cancer.ca/Canadian-Cancer-Statistics-2015-EN (accessed April
research-policy-practice/vol-35-no-1-2015/supplement/page-17.html (accessed April 2021).
2021).
22. World Health Organization [Internet]. Artificial tanning sunbeds; risk and guidance.
World Health Organization; 2003. Available at: https://www.who.int/uv/publications/
en/sunbeds.pdf (accessed April 2021).
23. International Agency for Research on Cancer [Internet]. Exposure to artificial ultraviolet
light. Exposure to artificial UV radiation and skin cancer. Lyon, France. Available at:
https://publications.iarc.fr/_publications/media/download/4033/
c6dbb6ef039134a92cce28b4bfc7ce5d21ad9a8f.pdf (accessed April 2021).

AR01655
TABLE 1.1 Lifetime probability of developing cancer, Canada (excluding Quebec*), 2017
Lifetime probability of developing cancer

% One in:
Both sexes Males Females Both sexes Males Females
All cancers† 43.4 44.3 42.6 2.3 2.3 2.4
Lung and bronchus 6.7 6.8 6.6 15 15 15
Breast 6.1 0.1 12.1 16 934 8
Colorectal 5.7 6.1 5.3 18 16 19
Prostate — 11.9 — — 8 —
Bladder 3.0 4.6 1.4 34 22 73
Non-Hodgkin lymphoma 2.5 2.7 2.2 40 37 45
Melanoma 2.2 2.4 1.9 46 41 51
Uterus (body, NOS) — — 3.2 — — 31
Kidney and renal pelvis 1.5 2.0 1.1 65 51 92
Head and neck 2 2 0.9 66 46 114
Pancreas 1.5 1.5 1.4 68 67 69
Leukemia 1.5 1.8 1.3 65 55 80
Thyroid 1.2 0.6 1.7 85 158 58
Stomach 1.0 1.3 0.7 104 80 146
Multiple myeloma 0.9 1.0 0.8 111 95 131
Liver 0.6 0.9 0.3 159 109 299
Brain/CNS 1 1 0.6 155 137 178
Ovary — — 1.3 — — 79
Esophagus 0.6 0.9 0.3 169 113 329
Cervix — — 0.6 — — 161
Testis — 0.4 — — 237 —
Hodgkin lymphoma 0.2 0.3 0.2 448 392 525
— Not applicable; CNS=central nervous system; NOS=not otherwise specified
† “All cancers” includes in situ bladder cancer and excludes non-melanoma skin cancer (neoplasms, NOS; epithelial neoplasms, NOS; and
basal and squamous).
Note: The probability of developing cancer is calculated based on age-, sex- and cancer-specific incidence and mortality rates for Canada
excluding Quebec in 2017. For further details, see Appendix II: Data sources and methods. The complete definition of the specific cancers
included here can be found in Table A1.
Data sources: Canadian Cancer Registry and Canadian Vital Statistics Death databases at Statistics Canada

AR01656
TABLE 1.2 Projected new cases and age-standardized incidence rates (ASIR) for cancers, by sex, Canada,* 2021
New cases (2021 estimates) Cases per 100,000

Total† Males Females Both sexes Males Females
All cancers ‡
229,200 118,200 110,900 515.2 556.3 484.9
Lung and bronchus 29,600 14,800 14,800 59.5 62.0 57.9
Breast 28,000 260 27,700 66.5 1.2 126.8
Colorectal 24,800 13,700 11,100 54.9 64.1 46.6
Prostate 24,000 24,000 — — 117.9 —
Bladder 12,500 9,500 3,000 25.0 41.4 11.3
Non-Hodgkin lymphoma 11,100 6,200 5,000 25.7 30.3 21.8
Melanoma 8,700 4,700 4,000 22.9 26.1 20.7
Uterus (body, NOS) 8,000 — 8,000 — — 37.2
Kidney and renal pelvis 7,800 5,200 2,600 17.6 24.5 11.3
Head and neck 7,400 5,400 2,000 16.5 25.1 8.8
Pancreas 6,700 3,700 3,000 14.1 16.5 12.0
Leukemia 6,700 4,000 2,700 15.7 20.0 11.9
Thyroid 6,700 1,800 4,900 17.3 9.2 25.2
Stomach 4,000 2,600 1,400 8.7 12.3 5.7
Multiple myeloma 3,800 2,300 1,500 8.4 10.9 6.2
Liver 3,300 2,600 800 7.1 11.5 3.1
Brain/CNS 3,100 1,800 1,350 7.2 8.6 5.8
Ovary 3,000 — 3,000 — — 13.5
Esophagus 2,400 1,900 560 5.6 9.2 2.4
Cervix 1,450 — 1,450 — — 7.5
Testis 1,200 1,200 — — 6.5 —
Hodgkin lymphoma 1,050 600 460 2.7 3.0 2.4
All other cancers 23,800 12,200 11,600 50.8 56.0 46.9
* Quebec is included in the cases because of their importance in determining the national total projected number. Quebec is excluded
from the rates because a different projection method was used for this province than for other regions.
† Column totals may not sum to row totals due to rounding. See Rounding for reporting in Appendix II for more information on
rounding procedures.
‡ “All cancers” includes in situ bladder cancer and excludes non-melanoma skin cancer (neoplasms, NOS; epithelial neoplasms, NOS; and
basal and squamous).
Note: Rates are age-standardized to the 2011 Canadian standard population. The complete definition of the specific cancers included

AR01657
TABLE 1.3 Projected new cases for the most common cancers, by age group and sex, Canada,* 2021
All cancers† Lung and bronchus Breast Colorectal Prostate
Age Both sexes‡ Males Females Both sexes‡ Males Females Females Both sexes‡ Males Females Males
All ages 229,200 118,200 110,900 29,600 14,800 14,800 27,700 24,800 13,700 11,100 24,000
0–14 1,050 600 470 — — — — 5 — 5 —
15–29 3,000 1,450 1,500 20 10 10 140 210 100 110 —
30–39 6,200 2,100 4,100 95 30 65 1,150 490 240 250 5
40–49 13,200 4,500 8,700 540 220 320 3,400 1,200 630 590 290
50–59 32,800 15,100 17,700 2,800 1,300 1,450 5,900 3,400 1,950 1,450 3,300
60–69 63,000 34,700 28,300 8,300 4,100 4,200 7,500 6,400 3,900 2,600 9,500
70–79 64,900 36,300 28,600 10,700 5,500 5,200 6,200 7,300 4,200 3,100 7,500
80–89 36,000 19,400 16,600 5,900 3,100 2,900 2,700 4,600 2,300 2,300 2,900
90+ 9,100 4,100 5,000 1,200 550 650 730 1,150 410 730 590
50–74 131,400 69,800 61,600 16,700 8,300 8,400 17,000 13,800 8,200 5,600 17,300
65+ 143,900 78,900 65,000 22,500 11,500 11,000 13,500 16,500 9,000 7,500 16,200
— Fewer than 3 cases.
* Quebec is included in the cases because of their importance in determining the national total projected number. Quebec is excluded from the rates because a different projection method was used for this
province than for other regions.
† “All cancers” includes in situ bladder cancer and excludes non-melanoma skin cancer (neoplasms, NOS; epithelial neoplasms, NOS; and basal and squamous).
‡ Counts for both sexes may not sum to row totals due to rounding. See Rounding for reporting in Appendix II for more information on rounding procedures.
Note: The complete definition of the specific cancers included here can be found in Table A1.

AR01658
TABLE 1.4 Projected age-standardized incidence rates (ASIR) for selected cancers, by sex and province, Canada (excluding
Quebec*), 2021
Cases per 100,000
CA† BC AB SK MB ON QC* NB NS PE NL
Males
All cancers‡ 556.3 501.8 519.4 517.7 509.4 587.6 560.5 598.9 559.2 580.1
Prostate 117.9 115.7 116.7 108.8 101.7 120.7 116.4 122.1 127.8 105.2
Lung and bronchus 62.0 55.2 62.9 63.6 61.2 59.9 90.6 84.0 68.4 77.9
Colorectal 64.1 61.1 59.6 82.9 64.3 61.5 66.7 76.5 84.9 105.0
Bladder 41.4 41.7 41.8 39.0 36.1 41.5 43.7 44.1 39.4 39.4
Non-Hodgkin lymphoma 30.3 23.2 25.9 22.1 25.7 35.5 27.3 29.3 23.8 31.1
Head and neck 25.1 24.2 20.9 20.4 23.1 27.1 23.0 23.6 29.9 27.6
Kidney and renal pelvis 24.5 20.8 22.8 24.5 25.4 25.1 26.3 31.3 22.7 35.0
Melanoma 26.1 22.1 21.7 17.4 28.4 28.5 22.3 37.5 42.8 24.3
Leukemia 20.0 16.9 18.9 23.1 16.7 22.2 22.2 18.1 15.8 11.5
Pancreas 16.5 15.4 15.6 16.1 15.4 17.5 17.3 16.1 16.7 11.0
Stomach 12.3 9.6 9.7 12.0 12.7 14.0 13.3 9.1 12.9 16.0
Liver 11.5 13.6 11.2 9.2 8.9 11.8 6.0 10.0 8.4 6.1
Multiple myeloma 10.9 8.1 9.6 9.7 9.1 13.0 8.8 9.6 10.7 8.3
Esophagus 9.2 9.7 9.1 8.2 8.6 8.9 8.2 12.6 9.9 11.1
Brain/CNS 8.6 8.7 8.2 7.9 7.4 8.9 8.5 9.5 9.7 9.6
Thyroid 9.2 5.0 8.9 5.6 8.2 11.4 8.3 7.4 5.0 14.3
Testis 6.5 6.7 6.5 5.8 6.6 6.7 7.1 6.8 4.4 4.8
Hodgkin lymphoma 3.0 2.7 3.0 2.6 2.8 3.1 3.4 3.0 3.2 2.5
Breast 1.2 1.1 1.0 1.2 1.0 1.3 1.4 1.7 — 1.4
Females
All cancers‡ 484.9 421.5 459.6 456.6 467.7 517.2 468.3 493.1 448.9 542.9
Breast 126.8 116.4 131.5 119.7 113.9 131.3 119.2 124.4 114.0 136.6
Lung and bronchus 57.9 54.3 58.1 66.6 56.3 56.2 68.0 74.9 69.8 68.3
Colorectal 46.6 46.7 44.6 48.2 46.2 45.0 46.5 48.8 53.2 80.3
Uterus (body, NOS) 37.2 29.8 34.0 34.9 53.3 40.2 33.0 34.3 30.0 41.9 — Projected incidence rate based on fewer than 3 cases;
Non-Hodgkin lymphoma 21.8 16.6 17.1 18.7 18.8 25.7 20.5 18.9 16.6 22.8 CNS=central nervous system; NOS=not otherwise specified
Thyroid 25.2 12.8 19.4 13.1 21.5 33.4 19.5 18.3 8.9 32.0
* Quebec is excluded because a different projection method was
Melanoma 20.7 17.3 18.4 23.7 19.3 21.8 22.0 29.1 35.3 18.3
used for Quebec than the other regions, meaning the estimates
Bladder 11.3 9.8 10.1 10.6 10.1 12.2 11.8 12.4 11.6 13.8 are not comparable. For further details, see Appendix II: Data
Pancreas 12.0 12.0 12.4 11.7 13.2 11.9 12.3 12.0 11.3 9.9 source and methods.
Ovary 13.5 11.8 10.9 12.5 11.8 15.6 9.9 11.0 12.5 13.6
Leukemia 11.9 10.3 12.5 13.2 9.6 12.6 16.3 10.4 9.3 8.9 † Canada totals include provincial and territorial estimates, except
Kidney and renal pelvis 11.3 9.3 11.7 15.1 11.8 10.7 14.9 17.8 12.2 16.1 Quebec. Territories are not listed due to small numbers.
Head and neck 8.8 7.7 7.2 7.6 9.5 9.7 8.0 8.8 10.4 7.8 ‡ “All cancers” includes in situ bladder and excludes non-
Multiple myeloma 6.2 5.0 5.4 5.5 5.1 7.2 5.8 5.3 6.5 5.8 melanoma skin cancer (neoplasms, NOS; epithelial neoplasms,
Cervix 7.5 6.5 8.4 8.2 7.2 7.6 7.5 5.9 8.9 10.4 NOS; and basal and squamous).
Stomach 5.7 4.1 4.2 4.5 5.0 6.9 5.5 4.5 4.8 8.1 Note: Rates are age-standardized to the 2011 Canadian standard
Brain/CNS 5.8 5.7 5.4 5.6 5.2 6.0 5.9 6.2 4.6 6.4 population. The complete definition of the specific cancers includ-
Liver 3.1 3.7 2.8 2.2 2.9 3.4 1.6 1.9 2.8 2.2 ed here can be found in Table A1.
Esophagus 2.4 2.8 2.3 2.0 2.1 2.4 1.6 3.5 2.6 2.1 Analysis by: Centre for Population Health Data, Statistics Canada
Hodgkin lymphoma 2.4 2.0 2.0 2.1 2.3 2.7 2.5 2.5 — 2.5 Data source: Canadian Cancer Registry database at Statistics Canada

AR01659
TABLE 1.5 Projected new cases for selected cancers, by sex and province, Canada,* 2021
CA† BC AB SK MB ON QC‡ NB NS PE NL
Males
All cancers§ 118,200 15,100 10,700 3,100 3,500 46,600 30,100 2,800 3,600 540 2,000
Prostate 24,000 3,600 2,500 680 710 9,900 4,600 620 780 130 400
Lung and bronchus 14,800 1,700 1,250 380 420 4,800 4,800 470 520 70 280
Colorectal 13,700 1,800 1,250 500 430 4,800 3,600 340 470 85 370
Bladder 9,500 1,250 830 230 240 3,300 2,900 220 280 40 140
Non-Hodgkin lymphoma 6,200 680 530 130 170 2,800 1,450 130 170 20 100
Head and neck 5,400 710 440 120 160 2,100 1,500 110 150 25 95
Kidney and renal pelvis 5,200 610 480 150 170 1,950 1,350 130 190 20 120
Melanoma 4,700 650 440 100 190 2,200 640 110 220 40 85
Leukemia 4,000 490 390 140 110 1,700 900 110 110 15 40
Pancreas 3,700 460 310 95 110 1,400 1,050 85 100 15 40
Stomach 2,600 290 190 70 85 1,100 680 65 55 10 55
Liver 2,600 420 230 55 60 950 700 30 65 10 20
Multiple myeloma 2,300 240 200 55 65 1,050 610 45 60 10 30
Esophagus 1,900 290 190 50 60 710 420 40 75 10 40
Brain/CNS 1,800 240 180 50 50 680 470 40 55 10 30
Thyroid 1,800 140 200 35 55 850 400 35 40 5 45
Testis 1,200 170 150 35 45 490 240 25 30 5 10
Hodgkin lymphoma 600 70 65 15 20 230 160 15 15 5 5
Breast 260 30 20 10 5 100 65 5 10 — 5
Females
All cancers§ 110,900 13,500 10,300 2,900 3,400 45,100 27,400 2,500 3,300 480 1,950
Breast 27,700 3,600 2,900 730 820 11,000 6,700 610 780 120 490 — Fewer than 3 cases; CNS=central nervous system; NOS=not
Lung and bronchus 14,800 1,900 1,300 450 440 5,300 4,100 390 540 80 270 otherwise specified
Colorectal 11,100 1,550 1,000 320 340 4,100 2,800 260 340 60 300
* Canada totals include provincial and territorial estimates.
Uterus (body, NOS) 8,000 930 750 210 380 3,400 1,750 180 220 30 150
Territories are not listed due to small numbers.
Non-Hodgkin lymphoma 5,000 540 380 120 140 2,300 1,100 110 130 15 85
Thyroid 4,900 350 430 75 140 2,500 1,100 85 95 10 95 † Canadian counts may not sum to row totals due to rounding.
Melanoma 4,000 540 410 140 140 1,850 530 100 170 35 60 See Rounding for reporting in Appendix II for more information
Bladder 3,000 340 230 70 80 1,150 960 65 90 15 55 on rounding procedures.
Pancreas 3,000 410 280 80 100 1,150 820 75 85 15 40 ‡ Quebec projections are calculated differently from the other
Ovary 3,000 370 240 75 80 1,300 720 50 75 15 45 provinces and territories because actual data were only available
Leukemia 2,700 330 280 85 75 1,100 580 85 65 10 30 to 2010 for Quebec, whereas they were available to 2017 for the
Kidney and renal pelvis 2,600 300 260 95 85 940 650 80 120 15 60 other regions. For further details, see Appendix II: Data source and
Head and neck 2,000 250 160 50 70 850 500 45 60 10 25 methods.
Multiple myeloma 1,500 170 120 35 40 670 360 35 40 5 25 § “All cancers” includes in situ bladder cancer and excludes
Cervix 1,450 180 190 50 45 580 290 30 30 10 30 non-melanoma skin cancer (neoplasms, NOS; epithelial neoplasms,
Stomach 1,400 140 95 30 40 630 380 30 30 5 30 NOS; and basal and squamous).
Brain/CNS 1,350 170 120 35 35 510 360 30 40 5 20 Note: The complete definition of the specific cancers included
Liver 800 120 65 15 25 310 230 10 15 5 10 here can be found in Table A1.
Esophagus 560 95 55 15 15 230 120 10 25 5 10 Analysis by: Centre for Population Health Data, Statistics Canada
Hodgkin lymphoma 460 55 45 10 15 210 110 10 10 — 5 Data source: Canadian Cancer Registry database at Statistics Canada

AR01660
TABLE 1.6 Annual percent change (APC) and average annual percent change (AAPC) in age-standardized incidence rates (ASIR) for selected cancers, by sex, Canada (excluding
Quebec*), 1984–2017
Both sexes Males Females

AAPC (95% CL),
†
AAPC (95% CL),
†
AAPC† (95% CL),
Period APC† (95% CL) 1984–2017 Period APC† (95% CL) 1984–2017 Period APC† (95% CL) 1984–2017
All cancers 1984–2012 0.3 (0.2, 0.4) 1984–1992 0.9 (0.2, 1.6) 1984–2007 0.3 (0.2, 0.4)
2012–2017 -1.1 (-1.9, -0.2) 0.1 (-0.1, 0.2) 1992–2011 -0.1 (-0.3, 0.0) -0.1 (-0.4, 0.1) 2007–2013 1.2 (0.5, 1.8) 0.3 (0.1, 0.4)
2011–2017 -1.5 (-2.2, -0.8) 2013–2017 -1.2 (-2.1, -0.3)
Lung and bronchus 1984–1990 0.6 (-0.0, 1.3) 1984–1990 -0.7 (-1.4, 0.1) 1984–1993 2.9 (2.4, 3.5)
1990–2003 -0.8 (-1.0, -0.6) 1990–2003 -2.2 (-2.4, -1.9) 1993–2013 0.9 (0.8, 1.0)
-0.6 (-0.8, -0.4) -1.7 (-2.0, -1.5) 1.1 (0.9, 1.3)
2003–2013 -0.1 (-0.4, 0.2) 2003–2013 -1.0 (-1.4, -0.6) 2013–2017 -2.0 (-3.1, -1.0)
2013–2017 -2.8 (-3.7, -1.9) 2013–2017 -3.8 (-4.9, -2.7)
Breast 1984–1991 1.9 (0.8, 3.1) 1984–2017 0.5 (0.1, 0.9) 1984–1991 2.0 (0.9, 3.1)
0.2 (-0.1, 0.4) 0.5 (0.1, 0.9) 0.3 (0.0, 0.5)
1991–2017 -0.3 (-0.4, -0.2) 1991–2017 -0.2 (-0.3, -0.0)
Colorectal 1984–1995 -1.1 (-1.4, -0.8) 1984–2013 -0.3 (-0.4, -0.2) 1984–1994 -1.7 (-2.0, -1.4)
1995–2001 0.5 (-0.3, 1.3) 2013–2017 -4.3 (-5.8, -2.8) 1994–2000 0.4 (-0.5, 1.3)
-0.9 (-1.1, -0.7) -0.8 (-1.0, -0.6) -1.1 (-1.3, -0.8)
2001–2013 -0.5 (-0.7, -0.3) 2000–2013 -0.5 (-0.7, -0.3)
2013–2017 -3.6 (-4.5, -2.7) 2013–2017 -3.4 (-4.5, -2.4)
Prostate 1984–1993 5.6 (3.4, 7.8)
1993–2007 0.2 (-0.6, 1.1) 0.2 (-0.5, 0.9)
2007–2017 -4.4 (-5.5, -3.3)
Bladder‡ 1984–2007 -1.1 (-1.3, -0.8) 1984–2007 -1.2 (-1.4, -0.9) 1984–2008 -0.9 (-1.2, -0.5)
2007–2011 7.8 (2.9, 12.9) 0.1 (-0.5, 0.7) 2007–2011 7.8 (2.5, 13.3) -0.0 (-0.7, 0.7) 2008–2012 7.2 (-0.1, 15.0) 0.0 (-0.9, 1.0)
2011–2017 -0.2 (-1.5, 1.2) 2011–2017 -0.5 (-1.9, 1.0) 2012–2017 -1.2 (-3.9, 1.6)
Non-Hodgkin lymphoma 1984–1997 1.8 (1.4, 2.3) 1984–2017 1.3 (1.2, 1.4) 1984–1993 2.1 (1.2, 3.1)
1997–2007 0.5 (-0.1, 1.1) 1993–2017 0.9 (0.8, 1.1)
1.3 (0.9, 1.6) 1.3 (1.2, 1.4) 1.2 (1.0, 1.5)
2007–2013 2.2 (1.0, 3.5)
2013–2017 -0.0 (-1.6, 1.6)
Melanoma 1984–2017 2.0 (1.8, 2.1) 1984–2017 2.2 (2.1, 2.4) 1984–1994 0.2 (-0.9, 1.3)
2.0 (1.8, 2.1) 2.2 (2.1, 2.4) 1.4 (1.1, 1.8)
1994–2017 2.0 (1.8, 2.2)
Continued on next page

AR01661
Quebec*), 1984–2017

AAPC (95% CL), AAPC (95% CL), AAPC (95% CL),
Period APC (95% CL) 1984–2017 Period APC (95% CL) 1984–2017 Period APC (95% CL) 1984–2017
Uterus (body, NOS) 1984–1990 -1.5 (-3.1, 0.2)
1990–2005 0.4 (-0.0, 0.8)
0.7 (0.2, 1.1)
2005–2011 3.1 (1.5, 4.8)
2011–2017 1.0 (-0.0, 2.1)
Kidney and renal pelvis 1984–1989 4.1 (1.6, 6.6) 1984–1989 4.0 (1.3, 6.7) 1984–2017 1.1 (0.9, 1.2)
1989–1998 -0.4 (-1.4, 0.7) 1989–2003 0.1 (-0.4, 0.6)
1.4 (0.9, 1.9) 1.4 (0.9, 2.0) 1.1 (0.9, 1.2)
1998–2012 1.9 (1.5, 2.3) 2003–2012 2.7 (1.8, 3.6)
2012–2017 0.3 (-1.1, 1.7) 2012–2017 0.4 (-1.1, 1.8)
Head and neck 1984–2004 -2.0 (-2.2, -1.8) 1984–2004 -2.4 (-2.7, -2.2) 1984–2004 -1.1 (-1.4, -0.9)
-1.0 (-1.1, -0.8) -1.2 (-1.4, -1.0) -0.5 (-0.8, -0.3)
2004–2017 0.7 (0.3, 1.0) 2004–2017 0.6 (0.2, 1.0) 2004–2017 0.3 (-0.1, 0.8)
Pancreas 1984–2006 -0.7 (-0.9, -0.5) 1984–2002 -1.4 (-1.8, -1.0) 1984–2006 -0.3 (-0.5, -0.0)
0.0 (-0.4, 0.4)
2006–2013 2.7 (1.4, 3.9) -0.1 (-0.4, 0.3) 2002–2017 1.4 (1.0, 1.9) -0.1 (-0.4, 0.2) 2006–2013 2.2 (0.8, 3.7)
2013–2017 -1.6 (-3.6, 0.4) 2013–2017 -2.2 (-4.6, 0.2)
Leukemia 1984–1996 -0.7 (-1.2, -0.1) 1984–1994 -1.1 (-2.0, -0.2) 1984–2001 -0.3 (-0.6, 0.1)
1996–2013 1.1 (0.8, 1.4) -0.0 (-0.4, 0.3) 1994–2013 0.9 (0.6, 1.2) -0.1 (-0.6, 0.3) 2001–2010 1.9 (1.0, 2.9) 0.0 (-0.3, 0.4)
2013–2017 -2.8 (-4.9, -0.7) 2013–2017 -2.6 (-5.0, -0.2) 2010–2017 -1.6 (-2.6, -0.5)
Thyroid 1984–1998 3.7 (2.8, 4.5) 1984–1998 2.8 (1.5, 4.0) 1984–1998 4.0 (3.2, 4.8)
1998–2004 9.4 (6.6, 12.3) 1998–2013 7.0 (6.3, 7.8) 1998–2004 10.4 (7.6, 13.2)
4.2 (3.6, 4.9) 4.0 (3.3, 4.8) 4.3 (3.6, 5.0)
2004–2013 5.9 (5.0, 6.9) 2013–2017 -2.4 (-5.8, 1.1) 2004–2013 5.5 (4.6, 6.4)
2013–2017 -4.7 (-6.9, -2.4) 2013–2017 -5.4 (-7.6, -3.2)
Stomach 1984–2002 -2.6 (-2.8, -2.4) 1984–2002 -2.6 (-2.8, -2.3) 1984–2001 -2.8 (-3.2, -2.4)
-1.7 (-1.9, -1.5) -1.8 (-2.0, -1.6) -1.7 (-2.0, -1.5)
2002–2017 -0.7 (-0.9, -0.4) 2002–2017 -1.0 (-1.3, -0.6) 2001–2017 -0.5 (-0.9, -0.1)
Multiple myeloma 1984–2006 0.3 (0.0, 0.7) 1984–2007 0.3 (-0.0, 0.7) 1984–2005 0.2 (-0.2, 0.6)
0.9 (0.6, 1.2) 1.0 (0.6, 1.4) 0.7 (0.4, 1.1)
2006–2017 2.1 (1.4, 2.8) 2007–2017 2.5 (1.5, 3.4) 2005–2017 1.6 (0.9, 2.3)
Liver 1984–2004 3.0 (2.6, 3.5) 1984–2013 3.8 (3.5, 4.1) 1984–2005 1.9 (1.2, 2.6)
2004–2013 4.9 (3.8, 6.1) 3.0 (2.5, 3.5) 2013–2017 -0.3 (-3.5, 3.1) 3.3 (2.8, 3.8) 2005–2013 5.8 (3.5, 8.2) 2.2 (1.3, 3.1)
2013–2017 -1.7 (-4.3, 1.0) 2013–2017 -3.2 (-7.6, 1.4)
Brain/CNS 1984–2017 -0.4 (-0.5, -0.3) -0.4 (-0.5, -0.3) 1984–2017 -0.4 (-0.5, -0.2) -0.4 (-0.5, -0.2) 1984–2017 -0.5 (-0.6, -0.3) -0.5 (-0.6, -0.3)
Ovary 1984–1997 -1.5 (-1.9, -1.0)
1997–2013 -0.1 (-0.5, 0.2) -1.0 (-1.4, -0.7)
2013–2017 -3.1 (-5.3, -0.8)

AR01662
Quebec*), 1984–2017

Cancer Period APC (95% CL) 1984–2017 Period APC (95% CL) 1984–2017 Period APC (95% CL) 1984–2017
Esophagus 1984–2005 0.1 (-0.2, 0.4) 1984–2005 0.3 (0.0, 0.6) 1984–2017 -0.4 (-0.6, -0.2)
2005–2011 2.2 (0.3, 4.2) 0.2 (-0.2, 0.7) 2005–2011 2.8 (0.8, 4.8) 0.4 (-0.1, 0.8) -0.4 (-0.6, -0.2)
2011–2017 -1.4 (-2.7, -0.1) 2011–2017 -1.8 (-3.0, -0.5)
Cervix 1984–2005 -2.0 (-2.2, -1.8)
-1.5 (-1.7, -1.3)
2005–2017 -0.6 (-1.1, -0.1)
Testis 1984–2017 1.3 (1.1, 1.5) 1.3 (1.1, 1.5)
Hodgkin lymphoma 1984–2017 -0.2 (-0.3, -0.0) -0.2 (-0.3, -0.0) 1984–2017 -0.4 (-0.5, -0.2) -0.4 (-0.5, -0.2) 1984–2017 0.1 (-0.1, 0.3) 0.1 (-0.1, 0.3)
All other cancers 1984–2017 0.7 (0.6, 0.9) 0.7 (0.6, 0.9) 1984–2017 0.6 (0.5, 0.8) 0.6 (0.5, 0.8) 1984–2017 0.9 (0.8, 1.0) 0.9 (0.8, 1.0)
CL=confidence limits; CNS=central nervous system; NOS=not otherwise specified
† The APC and AAPC are calculated using the Joinpoint Regression Program and rates age-standardized to the 2011 Canadian standard population.
‡ The trend analysis for bladder cancer was performed using the Jump Model of the Joinpoint Regression Program to account for the artificial change in cancer counts introduced in 2010 when Ontario started
to include in situ carcinomas of the bladder in their data collection. For further details, see Appendix II: Data sources and methods.
Data sources: Canadian Cancer Registry and National Cancer Incidence Reporting System databases at Statistics Canada

AR01663
TABLE 1.7 Most recent annual percent change (APC) in age-standardized incidence rates (ASIR), by sex, Canada (excluding Quebec*), 1984–2017

Reference year APC† (95% CL) Reference year APC† (95% CL) Reference year APC† (95% CL)
All cancers ‡
2012 -1.1 (-1.9, -0.2) 2011 -1.5 (-2.2, -0.8) 2013 -1.2 (-2.1, -0.3)
Lung and bronchus 2013 -2.8 (-3.7, -1.9) 2013 -3.8 (-4.9, -2.7) 2013 -2.0 (-3.1, -1.0)
Breast 1991 -0.3 (-0.4, -0.2) 1984 0.5 (0.1, 0.9) 1991 -0.2 (-0.3, -0.0)
Colorectal 2013 -3.6 (-4.5, -2.7) 2013 -4.3 (-5.8, -2.8) 2013 -3.4 (-4.5, -2.4)
Prostate — — 2007 -4.4 (-5.5, -3.3) — —
Bladder§ 2011 -0.2 (-1.5, 1.2) 2011 -0.5 (-1.9, 1.0) 2012 -1.2 (-3.9, 1.6)
Non-Hodgkin lymphoma 2013 -0.0 (-1.6, 1.6) 1984 1.3 (1.2, 1.4) 1993 0.9 (0.8, 1.1)
Melanoma 1984 2.0 (1.8, 2.1) 1984 2.2 (2.1, 2.4) 1994 2.0 (1.8, 2.2)
Uterus (body, NOS) — — — — 2011 1.0 (-0.0, 2.1)
Kidney and renal pelvis 2012 0.3 (-1.1, 1.7) 2012 0.4 (-1.1, 1.8) 1984 1.1 (0.9, 1.2)
Head and neck 2004 0.7 (0.3, 1.0) 2004 0.6 (0.2, 1.0) 2004 0.3 (-0.1, 0.8)
Pancreas 2013 -1.6 (-3.6, 0.4) 2002 1.4 (1.0, 1.9) 2013 -2.2 (-4.6, 0.2)
Leukemia 2013 -2.8 (-4.9, -0.7) 2013 -2.6 (-5.0, -0.2) 2010 -1.6 (-2.6, -0.5)
Thyroid 2013 -4.7 (-6.9, -2.4) 2013 -2.4 (-5.8, 1.1) 2013 -5.4 (-7.6, -3.2)
Stomach 2002 -0.7 (-0.9, -0.4) 2002 -1.0 (-1.3, -0.6) 2001 -0.5 (-0.9, -0.1)
Multiple myeloma 2006 2.1 (1.4, 2.8) 2007 2.5 (1.5, 3.4) 2005 1.6 (0.9, 2.3)
Liver 2013 -1.7 (-4.3, 1.0) 2013 -0.3 (-3.5, 3.1) 2013 -3.2 (-7.6, 1.4)
Brain/CNS 1984 -0.4 (-0.5, -0.3) 1984 -0.4 (-0.5, -0.2) 1984 -0.5 (-0.6, -0.3)
Ovary — — — — 2013 -3.1 (-5.3, -0.8)
Esophagus 2011 -1.4 (-2.7, -0.1) 2011 -1.8 (-3.0, -0.5) 1984 -0.4 (-0.6, -0.2)
Cervix — — — — 2005 -0.6 (-1.1, -0.1)
Testis — — 1984 1.3 (1.1, 1.5) — —
Hodgkin lymphoma 1984 -0.2 (-0.3, -0.0) 1984 -0.4 (-0.5, -0.2) 1984 0.1 (-0.1, 0.3)
All other cancers 1984 0.7 (0.6, 0.9) 1984 0.6 (0.5, 0.8) 1984 0.9 (0.8, 1.0)
— Not applicable; CL=confidence limits; CNS=central nervous system; NOS=not otherwise specified
† The APC was calculated using the Joinpoint Regression Program and rates age-standardized to the 2011 Canadian standard population. If one or more significant changes
in the trend of rates from was detected, the APC reflects the trend from the most recent significant change (reference year) to 2017. Otherwise, the APC reflects the trend in
rates over the entire period (1984–2017). For further details, see Appendix II: Data sources and methods.
‡ “All cancers” includes in situ bladder cancer and excludes non-melanoma skin cancer (neoplasms, NOS; epithelial neoplasms, NOS; and basal and squamous).
§ The trend analysis for bladder cancer was performed using the Jump Model of the Joinpoint Regression Program to account for the artificial change in cancer counts
introduced in 2010 when Ontario started to include in situ carcinomas of the bladder in their data collection. For further details, see Appendix II: Data sources and methods.
Data sources: Canadian Cancer Registry and National Cancer Incidence Reporting System databases at Statistics Canada

AR01664 2
Chapter
How many people die from cancer in Canada?

Mortality by sex, age, geography and year
The number and rate of cancer deaths Key findings

that occur each year (mortality) and • It is estimated that 1 in 4 Canadians • In general, cancer mortality rates are
over time provide the ultimate measure will die from cancer. The lifetime lower in the western provinces and
of progress in cancer control: reduction probability of dying from cancer is Ontario, and higher in Quebec and
in cancer-related deaths. Mortality is slightly higher for males than females. the eastern provinces.
affected by the things that drive cancer • An estimated 84,600 Canadians are • The mortality rates for all cancers
incidence, such as risk factors and expected to die from cancer in 2021. combined peaked in 1988 and have
aging. It also reflects improvements in 1 in 4 of these deaths is expected to been decreasing ever since. However,
finding cancers early and treating them be caused by lung cancer. the number of cancer deaths continues
successfully. to increase each year due to the
• Pancreatic cancer is expected to be
growing and aging population.
This chapter examines mortality by sex, the third leading cause of cancer
age, geography and over time to better death in 2021 in Canada for both • The expected prostate cancer
sexes combined. mortality rate in 2021 represents a
understand who is dying from cancer
50% decline since the rate peaked
so cancer control services that address • Almost all (96%) cancer deaths in
in 1995.
the needs of specific populations can Canada are expected to occur in
be better directed. people 50 years of age and older.

Chapter 2 • How many people die from cancer in Canada?
AR01665
Probability of dying from cancer Canadians will die from lung cancer, followed • It is expected that lung cancer will continue to
by colorectal cancer (1 in 37; almost 3%) and be the leading cause of cancer death for both
The probability of dying from a specific type
pancreas (1 in 66; 1.5%). sexes, accounting for approximately 25% of all
of cancer depends on many factors, including
the probability of developing that cancer, the • 1 in 29 (4%) males is expected to die from cancer deaths in Canada.
treatments available and how the cancer responds prostate cancer. • Lung cancer is followed by colorectal cancer,
to treatment. The estimated probabilities are for • 1 in 34 (3%) females is expected to die from which will account for 11% of all cancer deaths
the general Canadian population and should not breast cancer. in Canada, and pancreatic cancer, which will
be interpreted as an individual’s risk. account for 7%.
• Approximately 1 in 4 Canadians is expected to Projected cancer deaths in 2021 • The five leading causes of cancer death (lung,
die from cancer (Figure 2.1). colorectal, pancreatic, breast and prostate
The cancer mortality data used for projections in
• The probability of dying from cancer is slightly this publication were from 1994 to 2018. These cancers) account for about 55% of all cancer
higher for males (26%) than females (22%). were the most recent data available when the deaths in Canada.
analyses began. The data were used to project
As shown in Table 2.1, the probability of dying rates and deaths to 2021.
from cancer varies by type of cancer.
An estimated 84,600 Canadians are expected to
• Canadians are more likely to die from lung and die from cancer in 2021 (Table 2.2).
bronchus (lung) cancer than any other type of Lung cancer is responsible
cancer. An estimated 1 in 19 (5%) of all
for 1 in 4 cancer deaths
FIGURE 2.1 Lifetime probability of dying from cancer, Canada (excluding Quebec), 2019 in Canada.
Both sexes
tt t ttttttt 23%
(1 in 4.3)
Males
ii . iiiiiii 26%
(1 in 3.9)
♦♦ ♦♦♦♦♦♦♦♦
Females 22%
(1 in 4.7)
Note: The probability of dying from cancer is calculated based on

age-, sex- and cause-specific mortality rates for Canada excluding
Quebec in 2019. For further details, see Appendix II: Data sources
Analysis by: Centre for Surveillance and Applied Research, Public Health Agency of Canada and methods. The complete definition of the specific cancers
Data source: Canadian Vital Statistics Death database at Statistics Canada included here can be found in Table A1.

AR01666
Mortality by sex FIGURE 2.2 Percent distribution of projected cancer deaths,
Table 2.2 shows the number and rate of cancer

by sex, Canada, 2021 Probability
deaths projected for males and females in 2021. The chance of dying from cancer measured
over a lifetime. The probability of dying
• For each cancer type except breast and thyroid,
a higher number of deaths is expected among
males than females.
Males
44,600 44,600
• 53% of all cancer deaths are expected to occur Deaths
among males.
• More males (44,600) than females (40,000) are
i Males
Deaths
Lung and bronchus 24.2%

t Females
40,000 40,000
Deaths
Lung and bronchus 25.8%

Females
Deaths
from cancer is expressed as a percentage
or as a chance (e.g., 20% or 1 in 5 people
over a lifetime).
Deaths
The number of cancer deaths in a given
Colorectal 11.9% Breast 13.5%
expected to die from cancer in 2021. Prostate 10.1% Colorectal 10.8% population during a specific period of time,
• The age-standardized mortality rate (ASMR) in Pancreas 6.5% Pancreas 6.8% often a year.
Bladder 4.3% Ovary 4.9%
males (217 per 100,000) is expected to be 33% Leukemia 4.0% Uterus (body, NOS) 3.5%
higher than in females (163 per 100,000). Esophagus 3.9% Leukemia 3.3% Age-standardized mortality rate
Non-Hodgkin lymphoma 3.7% Non-Hodgkin lymphoma 3.1% (ASMR)
Head and neck 3.4% Brain/CNS 2.6%
Figure 2.2 shows the expected distribution of The number of cancer deaths per 100,000
Brain/CNS 3.1% Stomach 1.9%
cancer deaths in males and females in 2021. people, standardized to the age structure of
Liver* 2.9% Bladder 1.8%
• For males, lung cancer is expected to be Kidney and renal pelvis 2.8% Multiple myeloma 1.7% the 2011 Canadian standard population. In
Stomach 2.8% Kidney and renal pelvis 1.7% this publication, ASMR is also referred to as
the most common cause of cancer death,
Multiple myeloma 2.1% Head and neck 1.4% “mortality rate” or “death rate.”
accounting for 24% of all cancer deaths, Melanoma 1.8% Esophagus 1.3%
followed by colorectal cancer (12%) and Thyroid 0.2% Melanoma 1.1%
prostate cancer (10%). Hodgkin lymphoma 0.1% Cervix 1.0%
Projected mortality
Breast 0.1% Liver* 0.8% Actual death data were available to 2019
• For females, lung cancer is expected to be the
Testis 0.1% Thyroid 0.3% for all provinces and territories except
leading cause of cancer death, accounting for All other cancers 12.1% Hodgkin lymphoma 0.1% Yukon, for which data were imputed for
26% of all cancer deaths, followed by breast All other cancers 12.8% 2017 through 2019. Data were used to
cancer (14%) and colorectal cancer (11%). project cancer mortality to 2021.
• Pancreatic cancer is expected to be the fourth CNS=central nervous system; NOS=not otherwise specified
most common cause of cancer death for each * Liver cancer mortality was underestimated because deaths from
liver cancer, unspecified (ICD-10 code C22.9), were excluded. For
sex, accounting for almost 7% of all cancer further details, see Appendix II: Data sources and methods.
deaths in both males and females. Note: The complete definition of the specific cancers included
Data source: Canadian Vital Statistics Death database at Statistics Canada

AR01667
Mortality by age • Almost half (48%) of breast cancer deaths are • 89% of pancreatic cancer deaths are expected
expected to occur among females who fall to occur among Canadians 60 years of age and
The number of cancer deaths increases
within the age covered by the screening older.
dramatically with age (Table 2.3).
guidelines (aged 50 to 74 years),(2) while 9% are
• 96% of cancer deaths are expected to occur in expected to occur among Canadians who are Patterns in cancer mortality by age differ for
people 50 years of age and older. younger than 50 years of age. males and females (Figure 2.3).
• The majority of deaths (78%) occur in • 88% of cancer deaths are expected to occur in • Between the ages of 30 and 54, the rate of
Canadians aged 65 years and older. However, people 60 years of age and older. cancer deaths is higher in females than males.
almost half (46%) of all cancer deaths occur in
• 91% of lung cancer deaths are expected to • From age 55 onward, the cancer death rate is
people aged 50 to 74 years. This is one reason
occur among Canadians 60 years of age and higher in males than females.
why cancer screening (which aims to reduce
older. Almost half of all lung cancer deaths are • The rate of cancer deaths is highest among
cancer mortality) is frequently focused on
in the age range proposed for lung cancer Canadians aged 90 years and older. In that age
people in these older age groups.
screening in Canada (aged 55 to 74 years with a group, the number of cancer deaths is higher in
• 42% of colorectal cancer deaths are expected 30 pack-year smoking history).(3) females than males (Table 2.3), despite a lower
to occur among Canadians who fall within the
• 86% of prostate cancer deaths are expected to age-specific rate.
age covered by the screening guidelines (aged
occur among Canadians 70 years of age and
50 to 74 years),(1) while 4% are expected to
older.
occur among Canadians who are younger
than 50 years of age.
FIGURE 2.3 Percentage of cancer deaths and age-specific mortality rates for all cancers, by age group and sex, Canada,
2017–2019
Percentage of deaths Age-specific mortality rate (per 100,000)
20 3,600
i
Males
Rate
Percentage ■
15 2,700
~- . . ...
♦
10 1,800 Females
...
/ ... ~ Rate
Percentage
■
5 i..,
~--... ... ~
900
• _ data____,)
(,___View
0 0
0–4 5–9 10–14 15–19 20–24 25–29 30–34 35–39 40–44 45–49 50–54 55–59 60–64 65–69 70–74 75–79 80–84 85–89 90+
Age group (years)

Data source: Canadian Vital Statistics Death Database at Statistics Canada

AR01668
Figure 2.4 shows the most common causes of

FIGURE 2.4 Distribution of cancer deaths for selected cancers by age group, Canada, 2015–2019
cancer death by age group.
• In the youngest age groups (0 to 14 years and 100
15 to 29 years), brain cancer, leukemia and
non-Hodgkin lymphoma are the most common Brain/CNS (17%) Breast Lung and bronchus
90 (17%) (18%)
causes of cancer death. In the 0 to 14 years age Lung and bronchus Lung and bronchus
group, these cancers make up 67% of all cancer (28%) (28%)
Brain/CNS
80 (41%)
deaths, yet they comprise only 39% of all cancer Colorectal
Leukemia (15%) Colorectal
deaths in the 15 to 29 years age group. This (13%) (14%)
70 Colorectal
older group had more deaths from “adult” Colorectal
Lung and bronchus (10%)
cancers (e.g., colorectal, breast and melanoma) Non-Hodgkin lymphoma (7%) (11%)
(9%)
Breast Prostate (10%)
and cancers of the reproductive system (e.g., 60
Colorectal (5%) (8%) Pancreas (7%)
Brain/CNS (9%)
% of deaths
testis). Breast (4%) Breast (7%)
50 Testis (3%) Pancreas (7%) Prostate (6%)
• In the 30 to 49 years age group, breast cancer is Leukemia
Pancreas (4%)
Pancreas (6%)
Melanoma (3%) Leukemia (4%) Brain/CNS (4%) Breast (5%)
the leading cause of cancer death and accounts (23%) Stomach (3%)
Esophagus (3%)
Head and neck (3%) Cervix (4%) Non-Hodgkin lymphoma (4%) Bladder (5%)
for 17% of all cancer deaths. Colorectal, lung 40
Ovary (4%)
Head and neck (3%)
Non-Hodgkin lymphoma (3%) Leukemia (4%) Leukemia (4%)
and brain cancers are the next most common, Non-Hodgkin lymphoma (3%)
Non-Hodgkin lymphoma (3%)
Ovary (3%) Bladder (3%) Non-Hodgkin lymphoma (4%)
Stomach (3%)
accounting for another 31% of cancer deaths in 30
Melanoma (3%)
Leukemia (3%)
Stomach (3%)
this age group. Head and neck (3%)
Prostate (3%)
Other
• In all older age groups (50 years of age and 20 Other (42%)
Other Other
older), the most common causes of cancer (32%)
Other Other (33%) (32%)
death are those associated with lung cancer, (24%) (23%)
10
followed by the other overall common cancer
deaths (colorectal, breast, pancreatic and, in the 0
oldest age groups, prostate cancer). 0–14 15–29 30–49 50–69 70–84 85+
(0.2%) (0.3%) (3%) (33%) (43%) (21%)
Age group, in years (percentage of all cancer deaths*)
CNS=central nervous system; NOS=not otherwise specified

* The relative percentage is calculated based on the total number of cancer deaths over five years (2015–2019) for each age group.

AR01669
Mortality by geographic region Projected 2021 rates (Table 2.4) and numbers • Mortality rates for stomach cancer are also
of deaths (Table 2.5) for selected cancer types projected to be highest in Newfoundland and
Figure 2.5 shows the expected distribution of by sex and province show that there are several Labrador.
cancer deaths across Canada in 2021. These geographic differences by cancer type.
estimates are based on the individual’s province • Prostate cancer mortality rates vary from about
or territory of residence at the time of death • Lung cancer mortality rates for males are 20 per 100,000 to 30 per 100,000 across regions.
rather than the place where the death occurred. generally highest in Quebec and the Atlantic
provinces. Differences in cancer mortality rates may
• Similar to incidence, the mortality rates for all
• Colorectal cancer mortality rates are highest correlate with differences in incidence due to
cancers combined are generally higher in the
in Newfoundland and Labrador for both males regional variations in modifiable risk factors
east and lower in the west.
and females. Newfoundland and Labrador also (Chapter 1), as well as differences in access to
has a high incidence rate of colorectal cancer cancer services, such as screening, diagnosis,
treatment and follow-up.(4,5)
(Table 1.4).
Importantly, these estimates do not include a
-
Population distribution* measure of significance, such as confidence
■
ASMR ≥ 215 per 100,000
intervals or p-values, so we cannot conclude if the
BC 13.5%
■ differences reported are statistically significant.
ASMR 195–214 per 100,000
AB 11.9%
ASMR < 195 per 100,000 Also, estimates from less populous provinces and
■ I SK 3.2%
the territories must be interpreted with caution as
I MB 3.6%
they can vary considerably from year to year.
ON 38.8%
QC 22.3%
205.0 per 100,000

I NB 2.0%
(70 deaths) I NS 2.5%
IPE 0.4%
189.6 per 100,000 I NL 1.4%
(50 deaths)
224.5 per 100,000
(30 deaths)
ITerritories 0.3% Cancer mortality rates are
~ generally higher in eastern
175.2 per 100,000
(11,300 deaths)
219.9 per 100,000
Canada and lower in the
173.3 per 100,000
(7,300 deaths)
(1,600 deaths)
western Canada.
196.1 per 100,000
(2,900 deaths)
189.0 per 100,000

(2,400 deaths) 200.9 per 100,000 197.2 per 100,000
177.6 per 100,000 (22,200 deaths) (420 deaths)
(31,100 deaths)
* Based on projected estimates of population size in 2021.
219.8 per 100,000
FIGURE 2.5 Geographic distribution of projected 196.0 per 100,000 (2,900 deaths) population.
cancer deaths and age-standardized mortality (2,200 deaths) Analysis by: Centre for Population Health Data, Statistics Canada
rates (ASMR), by province and territory, both Data sources: Canadian Vital Statistics Death database and Population
sexes, Canada, 2021 projections for Canada, Provinces and Territories at Statistics Canada

AR01670
Mortality over time FIGURE 2.6 Deaths and age-standardized mortality rates (ASMR) for all cancers, Canada, 1984–2021
Monitoring mortality over time can help identify

emerging trends, where progress has been made ASMR (per 100,000) Deaths (in thousands)
and where more needs to be done. 350 50
Males
ASMR
Figure 2.6 provides a high-level view of patterns Deaths
in mortality over time for all cancers combined. 280 40
• From 1984 to 2021, mortality rates for all
cancers combined decreased from 335.4 to an
210 30
estimated 216.9 per 100,000 in males, and from
203.9 to an estimated 162.6 per 100,000 in
females. Cancer death rates peaked in 1988 and
Projected
140 20
have since decreased 37% in males and 22% in
females.
• Over the same period, the number of cancer 70 10
deaths has increased from 24,900 to an
expected 44,600 in males, and from 19,900 to
0 0
an expected 40,000 in females. This increase is 1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
due primarily to the growing and aging Year
population.(6,7) ASMR (per 100,000) Deaths (in thousands)
The number of cancer deaths

350
280
50
40
t .- Females
ASMR
Deaths
210 30
in Canada continues to
increase each year.
140 20
Projected
70 10
0 0
( View data )
1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
Year
population. Actual mortality data were available to 2019; estimates Analysis by: Centre for Population Health Data, Statistics Canada
for 2020–2021 were projected based on data up to 2018. Data source: Canadian Vital Statistics Death database at Statistics Canada

AR01671
Recent trends . . . . . .
FIGURE 2.7 Most recent annual percent change (APC)† in age-standardized mortality rates (ASMR) for selected cancers,
. . . ~ ...
by sex, Canada, 1984–2019
Table 2.6 provides the complete picture of trends
APC
in cancer mortality rates between 1984 and 2019 4
Males
for males and females, as measured by an annual
I
2.8**
I■
percent change (APC).(8) Table 2.7 draws out the 2
I III I
most recent trends for each cancer. These recent 0.6*
0.2 0.2 0.1
trends are depicted in Figure 2.7.
IIIII
0
-2
- - - - - I I I -0.2* -0.3
-0.9* -1.0** -1.0** I
-1.2**
-1.6** -1.6** -1.8** -1.8* -1.9**
-2.3**
-2.5** -2.6*
Annual percent change (APC) -4
-3.0*
-3.4**
The estimated change in the age-

standardized mortality rate per year -6
over a defined period of time in which
s
er ‡
id
NS
as
ck
st
ia
tis
rs
ch
ers
tal
ma
er
s
lvi
gu
hu
om
tat
lom
om
ea
ce
em
ro
dd
cre
ma
s
rec
/C
nc
no
pe
Te
n
Liv
ha
nc
y
os
an
Br
ph
ph
Bla
uk
ain
Th
ye
ca
nd
Sto
lo
ela
ro
op
al
Pr
there is no significant change in trend
Pa
lc
lym
lym
em
Le
Co
da
db
ren
Br
er
Es
M
Al
th
in
ipl
an
in
nd
lo
He
gk
gk
ult
(i.e., no changepoint). It is reported as a
ya
ng
Al
od
d
M
Ho
Lu
ne
n-H
Kid
No
percentage. APC
t
4
Females
Reference year 2.2**
II I
2.0**
2
II - ■ ■ ■ I I I I II I II I II I
The year corresponding to the start year of
the APC. 0
- 0.1*
- 0.4** - 0.4 - 0.5**
- 0.8*
- 1.0** - 1.2** - 1.3** - 1.4** - 1.4** - 1.6**
Statistical significance
-2
- 2.0** - 2.0**
- 2.2**
- 2.8**
Refers to a result that is unlikely due to -4
- 3.2** - 3.2**
- 3.5**
- 3.8*
chance, assuming there were no other - 4.9*
sources of bias, given a predetermined -6
threshold (e.g., fewer than 1 out of 20 times,

er ‡
er
id
ary
st
ma
rs
rs
is
ch
tal
NS
ma
OS
rea
gu
hu
rvi
ec
i
om
om
elv
ea
ce
ce
em
yro
dd
ma
ec
Liv
/C
Ov
lo
no
dn
,N
ha
nc
Ce
an
an
nc
Br
ph
ph
p
Bla
uk
lor
ain
Th
ye
Sto
ela
which is expressed as p<0.05).
ro
op
dy
al
Pa
lc
an
lym
lym
Le
em
Co
db
Br
er
ren
bo
Es
M
Al
ad
th
ipl
s(
an
kin
kin
nd
lo
He
eru
ult
dg
dg
ng
ya
Al
M
Ut
Ho
Ho
Lu
ne
n-
Kid
No
Confidence limits (CL)
Upper and lower values of a range
* APC differs significantly from 0, p<0.05
(confidence interval) that provide an
** APC differs significantly from 0, p<0.001
indication of the precision of an estimate.
† The APC was calculated using the Joinpoint Regression Program and rates age-standardized to the 2011 Canadian standard population. If one
Confidence intervals are usually 95%. or more significant changes in the trend of rates was detected, the APC reflects the trend from the most recent significant change (reference year) to 2019.
This means that upon repeated sampling Otherwise, the APC reflects the trend in rates over the entire period (1984–2019). For further details, see Appendix II: Data sources and methods.
for a study, and assuming there were no ‡ Liver cancer mortality was underestimated because deaths from liver cancer, unspecified (ICD-10 code C22.9), were excluded. For further
details, see Appendix II: Data sources and methods.
other sources of bias, 95% of the resulting
Note: The reference year for each cancer is in Table 2.7. The range of scales differs between the figures. The complete definition of the
confidence intervals would contain the true
specific cancers listed here can be found in Table A1.
value of the statistic being estimated. Analysis by: Centre for Population Health Data, Statistics Canada

AR01672
• Mortality rates have declined for nearly all FIGURE 2.8 Age-standardized mortality rates (ASMR) for selected* cancers, males, Canada, 1984–2021
cancers in recent years.
• For both sexes and all cancers combined, ASMR (per 100,000)
mortality decreased at a rate of -1.9% per year 120 120
i
Males
since 2015. Colorectal
• In males, this decrease in mortality is largely
~.".':~.~ ,- ... _ ·~',·~·········· ........................................................ . Lung and
driven by decreases in lung (-3.4%), and

100 .. ···········:-:- , __ 100 bronchus
Prostate
colorectal (-2.3%) cancers, along with bladder \
Projected
(-3.0%), melanoma (-2.6%) and Hodgkin 80 ,--,
··························································~ - ;,;: ~ ·~ ·~ ·······
...................... . 80
lymphoma (-2.5%).
............
• In females, the decrease in mortality is largely ,-.
driven by decreases in lung (-3.5%) and 60 ························································································· ' ·,:,;,:~~·· ... 60
colorectal (-3.2%) cancers, along with

melanoma (-4.9%), brain/CNS (-3.8%), Hodgkin
40 40
lymphoma (-3.2), stomach (-2.8%), non-Hodgkin
lymphoma (-2.2%) and kidney and renal pelvis
(-2.0%). View data
20 20
1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
• The largest increases in mortality rates are for
Year
liver cancer in both males (2.8%) and females
(2.2%), as well as for uterine cancer (2.0%). ASMR (per 100,000)
i-
20 20
Males
Projected
Hodgkin
lymphoma
Melanoma
15 .................................................................. 15
Liver†
10 10
- Bladder
Pancreas
* Four most frequent causes of cancer death among males and

cancers with a statistically significant change in mortality rate of at
least 2% per year, as measured by the most recent annual percent
change (see Table 2.7). 5 5
† Liver cancer mortality was underestimated because deaths from
further details, see Appendix II: Data sources and methods.
Note: Rates are age-standardized to the 2011 Canadian standard 0 0
population. Actual mortality data were available to 2019; estimates 1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
for 2020–2021 were projected based on data up to 2018. The Year
range of scales differs widely between the figures. The complete
definition of the specific cancers included here can be found in Analysis by: Centre for Population Health Data, Statistics Canada
Table A1. Data source: Canadian Vital Statistics Death database at Statistics Canada

AR01673
Long-term trends FIGURE 2.9 Age-standardized mortality rates (ASMR) for selected* cancers, females, Canada, 1984–2021
Longer-term trends provide additional context
for understanding the success and challenges in ASMR (per 100,000)
reducing cancer mortality. Table 2.6 shows trends 50 50
Females
in mortality rates between 1984 and 2019 by
Breast
cancer type. Colorectal
40 .................................................. 40
• In males, the overall cancer mortality rate Lung
increased slightly (0.6% per year) from 1984 to

-- .... _ -~-,-- ;,;: Pancreas
Projected
1988, after which it started to decrease -0.9%
per year until 2001. Since 2001, the rate of
decline has doubled, with mortality decreasing
30
-....._,_ .......... -~ ............................... .
.... _.... _
------ -.... _
30
-1.8% annually. 20 20
• In females, the overall cancer mortality has
been decreasing at varying rates since 1984:
-0.2 % per year between 1984 and 2002; -1.1% 10 10
per year between 2002 and 2015; and -2.0 % per

year since 2015. View data
0 0
1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
Figures 2.8 and 2.9 show the ASMR over time Year
(projected to 2021) for the leading causes of
ASMR (per 100,000)
cancer death. They also show cancers that had 10 10
a statistically significant change of at least 2% in Females
Hodgkin
the most recent APC: Hodgkin lymphoma, liver
lymphoma
cancer and melanoma for both sexes; bladder
...
Projected
8 8 Liver†
cancer in males; and brain/CNS, kidney and renal Melanoma
pelvis, stomach and uterine cancers, as well as Kidney and
non-Hodgkin lymphoma, in females. 6 6 renal pelvis

.... Stomach
Brain/CNS
Non-Hodgkin
4 4
* Four most frequent causes of cancer death among females and lymphoma
cancers with a statistically significant change in mortality rate of at Uterus
least 2% per year, as measured by the most recent annual percent (body, NOS)
change (see Table 2.7). 2 2
† Liver cancer mortality was underestimated because deaths from
0 0
1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
population. Actual mortality data were available to 2019; estimates
Year
for 2020–2021 were projected based on data up to 2018. The range
of scales differs widely between the figures. The complete definition Analysis by: Centre for Population Health Data, Statistics Canada
of the specific cancers included here can be found in Table A1. Data source: Canadian Vital Statistics Death Database at Statistics Canada

AR01674
Lung and bronchus (lung) cancer Colorectal cancer Breast cancer (female)
The mortality rates for colorectal cancer have The breast cancer mortality rate in females has
In males, the mortality rate for lung cancer
declined significantly for both sexes between been declining since the 1980s. After its peak
was stable throughout the 1980s and has been
1984 and 2019. In males, the rate declined -1.0% in 1986, the ASMR has fallen 46%, from 42.7
declining since 1992. In females, the mortality
per year until 2004 and -2.3% afterwards. In deaths per 100,000 in 1986 to a projected rate of
rate continued to increase until 2006. While the
females, the rate initially declined -1.7% per year, 23.1 deaths per 100,000 in 2021. The downward
initial decline in females was slow (-0.7% between
but since 2014 the rate of decline has nearly trend was estimated at -2.4% per year between
2006 and 2015), the rate of decline for lung cancer
doubled, lowering mortality -3.4% per year. Part 1994 and 2011 and -1.4% per year between 2011
mortality is now comparable between sexes for
of this decline may be driven by the decrease in and 2019. The decline in breast cancer mortality
the first time since 1984 (-3.4% between 2011 and
incidence and improvements in treatment.(16,17) has been largely attributed to a combination of
2019 for males and -3.5% between 2015 and 2019
Given the strong connection between stage at increased mammography screening(25) and the use
for females).
diagnosis and survival for colorectal cancer,(18,19) of more effective and multidisciplinary therapies
The pattern in lung cancer mortality largely participation in colorectal cancer screening following breast cancer diagnosis.(26,27) A similar
mirrors that of lung cancer incidence, which programs may be an additional factor contributing decline has been observed in the US where the
reflects past tobacco smoking. Despite the to the more rapid rate of decline observed in breast cancer death rate decreased by -1.3%
observed downward trends, lung cancer continues colorectal cancer mortality in recent years.(20) per year between 2011 and 2017.(28) However,
to be the most commonly diagnosed cancer in breast cancer continues to be an important health
Canada and remains the leading cause of cancer Pancreatic cancer concern internationally. Many countries report
death. Efforts to control tobacco use are still increases in both prevalence and mortality rates(29)
Although it is not one of the most commonly
needed to further reduce the burden of lung and there continues to be high incidence and
diagnosed cancers, pancreatic cancer is expected
cancer(9,10) as approximately 15% of Canadians mortality rates in Canada.
to be the third leading cause of cancer death
continue to smoke on a daily basis.(11) Pilot in 2021. This is in part because the mortality
studies are currently underway to investigate rate for pancreatic cancer has stayed largely the Prostate cancer
the feasibility of implementing lung cancer same over the past 35 years, whereas that of The mortality rate for prostate cancer has been
screening programs for high-risk populations.(12) more common cancers, including lung, breast, decreasing since 1994. Initially, the rate declined
In 2020, British Columbia announced the prostate and colorectal, has declined considerably. -2.8% per year, and in 2012 the decline slowed
funding of the first province-wide organized For both sexes combined, there was a marginal to -1.6% per year. The decline likely reflects
lung screening program in Canada, and in April decrease in pancreatic cancer mortality rates improved treatment following the introduction of
2021 Ontario transitioned their four screening between 1984 and 2000 (-0.8% per year) and hormonal therapy for early and advanced stage
sites from their pilot study into the Ontario no significant change since 2000 (0.1%). The disease(30,31) and advances in radiation therapy.(32)
Lung Screening Program. Quebec launched a mortality rates for pancreatic cancer are almost The role of screening with the prostate-specific
three-year lung cancer screening demonstration as high as the incidence rates for this cancer due antigen (PSA) test in reducing mortality rate
project that began on June 1, 2021. The aim of to the low survival.(21–23) Between countries, trends remains unclear. In 2009, two large randomized
these programs is to detect disease at an earlier in pancreatic cancer mortality rates varied in the trials in the US and Europe reported conflicting
stage when it may respond better to treatment. past decade but have typically increased over results on the use of PSA testing in males older
Currently, about 70% of lung cancers are time.(24) than 55 years of age.(33,34) The Canadian Task
diagnosed at a late stage (stage III or IV),(13–15) Force on Preventive Health Care does not
so these programs may help further reduce lung For more discussion about the burden of recommend the use of the PSA test for screening
cancer mortality rates in the future. pancreatic cancer, see Canadian Cancer Statistics based on the current evidence.(35) A recent
2017 (Chapter 6: Pancreatic cancer).(22) study from the Public Health Agency of Canada

AR01675
reported no increase in mortality or diagnosis of primary CNS cancers consist of multidisciplinary Liver cancer
late-stage tumours in the five years following the approaches that combine biopsy or aggressive Trends in liver cancer mortality fluctuated
adoption of revised PSA screening guidelines. surgical resection with post-operative radiation considerably between 1984 and 2019, with recent
and chemotherapy, when appropriate.(40) patterns showing significant increases in mortality
Bladder for both sexes. In males, the rate increased 2.8%
In males, the bladder cancer mortality rate Hodgkin lymphoma per year since 1991. In females, it has increased
had historically decreased marginally (-0.4%). Hodgkin lymphoma mortality rates have been 2.2% per year since 1994. If these rates continue
However, since 2015, the rate of decline has been declining rapidly in both males and females to increase, mortality rates for 2021 are expected
rapid at -3.0% per year. In females, the decrease since 1984. For both sexes combined, the rate to be 150% higher in males and 75% higher in
in the mortality rate has been stable at -0.4% per declined -4.6% per year until 1997 and has since females compared to what they were in 1991
year since 1984. Similar patterns of decline have declined -2.5% per year. Based on these rates of and 1994, respectively. Similar trends have been
been reported in the United Kingdom (UK)(36) decline, mortality rates in 2021 are expected to reported in several countries, including the US
where males have also shown a faster reduction be 77% and 71% lower than in 1984 for males and UK.(48) Typically, trends in mortality mirror
in mortality rates than females in recent years. and females, respectively. The latest study of those of incidence because prognosis for liver
Globally, bladder cancer mortality has decreased global mortality for Hodgkin lymphoma reported cancer remains poor. However, the decline in liver
in most countries, except in those undergoing similar downward trends(41) though the magnitude cancer incidence rates noted in Chapter 1 has yet
rapid economic transition. As tobacco smoking is of decline in mortality varies by age group and a to translate into a downward shift in mortality.
the main risk factor for bladder cancer, accounting region’s sociodemographic index. The reduction Hepatitis C infection and alcohol use are the main
for about half of all bladder cancer cases in some in mortality has been largely attributed to risk factors for liver cancer in the high-income
populations, it is not surprising to see trends in improvements in treatment.(42,43) countries.(49–51)
bladder cancer incidence (see Chapter 1) and
mortality partially mirroring smoking histories in Kidney and renal pelvis Melanoma
Canada and elsewhere.(37) In males, the melanoma mortality rate increased
Kidney and renal pelvis cancer mortality rates
1.3% per year between 1984 and 2013. Since
have been declining since 1984 in both males and
Brain and central nervous system (CNS) then, it has decreased -2.6% annually. In females,
females. Recent trends show a -1.2% annual decline
In males, the mortality rate associated with the mortality rate increased marginally (0.4% per
in male mortality rate since 2004 and a -2.0%
cancer of the brain and CNS decreased -0.5% year) until 2015 and has since declined at a rapid
annual decline in female mortality since 2008.
per year between 1984 and 2003; it has since rate of -4.9% per year. This represents the fastest
Similar magnitude declines in kidney cancer
stabilized. In females, the mortality rate declined decline in mortality amongst all cancer types.
mortality have been reported in the US(44) and
-0.7% until 2006, increased 1.3% per year until Similar patterns have also been reported in the
globally, in high sociodemographic regions.(45)
2015 and has since decreased rapidly at -3.8 US(8) and Europe.(52) These decreases have largely
The interpretation of these trends remains
per year. Decreases in brain and CNS cancer been attributed to the introduction of improved
open to discussion. However, some researchers
mortality rates have been reported in several therapies and early diagnosis, as well as the
have suggested that a greater understanding
countries, though the magnitude of decline implementation of awareness programs.
of the molecular biology of the disease and
varies considerably between countries, sexes and improvements in diagnosis and treatment, as
sociodemographic index.(38,39) Sex differences well as downward trends in tobacco smoking, Non-Hodgkin lymphoma
in cancer risk and mortality are likely linked to may have played a role.(44–47) Non-Hodgkin lymphoma mortality rates increased
differences in fundamental mechanisms of tumour prior to 2000 but have declined subsequently
initiation, tumour promotion and therapeutic since then. In males, the rate decreased -2.4%
response. Currently, optimal treatment for per year between 2000 and 2010, and -0.9% per

AR01676
year thereafter. In females, the rate of decline has Uterine cancer (body, not otherwise mortality rate for lung cancer in females increased
been constant since 1999 at -2.2% per year. As specified [NOS]) marginally (AAPC=0.8%) between 1984 and
incidence rates continue to increase in both sexes 2019, it has decreased rapidly since 2015
The mortality rate for uterine cancer increased
combined (Table 1.6) declining mortality likely (APC=-3.5%). In Canada, the mortality rate
2.0% per year between 2005 and 2019, which
reflect recent improvements in treatment, such for all cancers combined has decreased by an
represents an increase of 35% over the entire 14-
as immunotherapy (e.g., rituximab). In addition, average of -0.9% per year since 1984.
year period. Comparatively, the incidence rate for
the introduction of highly active antiretroviral
uterine cancer increased rapidly through the mid-
therapy (HAART) in the late 1990s(53) for the
2000s, but it has slowed to a 1.0% increase per What do these statistics mean?
human immunodeficiency virus (HIV) resulted in
year since 2011. Similar trends have been reported
a decline of the aggressive forms of non-Hodgkin Encouragingly, the mortality rate for all cancers
in the US(56) and UK.(57) The past increase in
lymphoma attributable to HIV infection. combined has been decreasing since the late
uterine cancer incidence (and therefore mortality)
has been attributed, at least in part, to increases in 1980s. This is despite the fact that the incidence
Stomach cancer the prevalence of obesity, an important risk factor rate for all cancers combined has only been
Between 1984 and 2019, mortality rates for for the disease.(58–60) Currently, uterine cancer is declining in Canada since 2011.
stomach cancer declined for both sexes. In males, one of the few cancer types for which both the
A decrease in the mortality rate for a specific
the rate declined rapidly at -3.3% per year until mortality and incidence rates continue to increase
cancer can result from a decrease in the incidence
2012, and then -1.8% afterwards. In females, the in Canada.
rate. As a result, it is not surprising that the
rate of decline has been constant since 1984 at
patterns in mortality rates by sex, age and
-2.8% per year. In 2021, the mortality rate for Average annual percent change geographic region largely mirror the patterns for
females is expected to be less than half of what
it was in 1984. The trends in mortality rates have
(AAPC) incidence reported in Chapter 1. For example,
Table 2.6 also shows the average annual percent cancer mortality rates are generally higher
largely mirrored those in incidence. This pattern
change (AAPC) in cancers between 1984 and among males than females, most cancer deaths
was reported in several regions of the world.(54)
2019. By summarizing changes in trends, the occur at older ages and cancer mortality rates
Research suggests that diet modification and
AAPC enables the comparison of changes are generally higher in eastern Canada than in
changes in the prevalence of common risk
in mortality across cancers for the same western Canada.
factors, including Helicobacter pylori infections
and tobacco smoking, have contributed to the defined time period. Since 1984, the biggest
However, incidence is not the only factor that
reported trends.(54,55) improvements for both sexes combined were for
determines mortality. A decrease in the mortality
Hodgkin lymphoma and stomach cancer, while
rate for a specific cancer can also result from an
the biggest increase was for liver cancer.
improvement in early detection. This is because
Average annual percent change cancer stage at diagnosis has a significant impact
The AAPC also provides a measure of the
(AAPC) overall change in a cancer over a period of time. on cancer survival.(13) Improvements in treatments
The weighted average of the APCs in For example, despite the increase in prostate that increase the chances of survival also have an
eff e cancer mortality rate between 1984 and 1994 impact on mortality rates. As such, factors like access
the weights equal the pr (APC=1.3%), the mortality rate for this cancer to cancer control interventions (e.g., screening) or
ounted for by each APC in the has decreased overall since 1984 (AAPC=- variations in clinical practice patterns by province,
1.4%). AAPCs should be interpreted with caution age or sex also contribute to variations in mortality
interval. AAPC summarizes the change in
because they do not necessarily reflect the rates. There are likely also age and sex differences
age-standardized rates over a specified in the response to cancer treatment(61) that further
most recent trends; the APC should be used for
interval. It is reported as a percentage. contribute to variations in mortality rates.
the most recent trends. For example, while the

AR01677
Although the overall mortality rate continues to 8. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. [Internet]. SEER 27. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to
Cancer Statistics Review, 1975–2018. Bethesda, MD: National Cancer Insitute; 2021. the nation on the status of cancer, 1975–2002, featuring population-based trends in
decline in Canada, the actual number of cancer Available at: https://seer.cancer.gov/csr/1975_2018/ (accessed May 2021). [Based on cancer treatment. J Natl Cancer Inst. 2005;97(19):1407–27.
deaths continues to increase due to the growth November 2020 SEER data submission]. 28. American Cancer Society. Breast cancer facts & figures 2019–2020. Atlanta: American
9. Boer R, Moolgavkar SH, Levy DT. Chapter 15: Impact of tobacco control on lung cancer Cancer Society, Inc.; 2019.
and aging of the population. This has implications mortality in the United States over the period 1975–2000 — summary and limitations. 29. Azamjah N, Soltan-Zadeh Y, Zayeri F. Global trend of breast cancer mortality rate: A
for health policy and resource planning. Moreover, Risk Anal. 2012;32 Suppl 1:S190–201. 25-year study. Asian Pac J Cancer Prev. 2019;20(7):2015–20.
10. Fillon M. Tobacco control initiatives cut the number of lung cancer deaths in California
the mortality rate of some cancers, like liver by 28. CA Cancer J Clin. 2019;69(2):83–5.
30. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and
time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst.
cancer, continues to increase. Improving early 11. Statistics Canada [Internet]. Canadian Tobacco, Alcohol and Drugs Survey (CTADS): 2003;95(13):981–9.
detection and treatment for people diagnosed summary of results for 2017. Ottawa, ON: Health Canada; 2017. Available at: https:// 31. Meng MV, Grossfeld GD, Sadetsky N, Mehta SS, Lubeck DP, Carroll PR. Contemporary
www.Canada.ca/en/health-Canada/services/canadian-tobacco-alcohol-drugs- patterns of androgen deprivation therapy use for newly diagnosed prostate cancer.
with cancer and improving supports for people survey/2017-summary.html (accessed April 2021). Urology. 2002;60(3 Suppl 1):7–11.
living with and beyond cancer continues to be of 12. Canadian Partnership Against Cancer [Internet]. Lung Cancer Screening in Canada; 32. Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA. Improvement in
— Environmental Scan. Toronto, ON; 2018. Available at: https://s22457.pcdn.co/
the utmost importance. wp-content/uploads/2019/04/Lung-Cancer-Screening-Environmental-Scan_EN_2018_
relapse-free survival throughout the psa era in patients with localized prostate cancer
treated with definitive radiotherapy: Year of treatment an independent predictor of
final.pdf (accessed April 2021). outcome. Int J Radiat Oncol Biol Phys. 2003;57(3):629–34.
13. Canadian Cancer Statistics Advisory Committee [Internet]. Canadian Cancer Statistics
Supplementary resources 2018. Toronto, ON: Canadian Cancer Society; 2018. Available at: www.cancer.ca/
33. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, Church TR, et al. Mortality
results from a randomized prostate-cancer screening trial. N Engl J Med.
Canadian-Cancer-Statistics-2018-EN (accessed April 2021).
Cancer.ca/statistics houses supplementary 14. Bryan S, Masoud H, Weir H, et al. Cancer in Canada: Stage at diagnosis. Health Rep.
2009;360(13):1310–9.
34. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening
resources for this chapter. This includes: 2018;29(12):21-25. and prostate-cancer mortality in a randomized European study. N Engl J Med.
15. Canadian Cancer Statistics Advisory Committee [Internet]. Canadian Cancer Statistics: 2009;360(13):1320–8.
• Excel spreadsheets with the statistics used A special report on lung cancer. Toronto, ON: Canadian Cancer Society; 2020. 35. Canadian Task Force on Preventive Healthcare [Internet]. Prostate cancer — summary
Available at: cancer.ca/Canadian-Cancer-Statistics-2020-EN (accessed April 2021).
to create the figures of recommendations for clinicians and policy-makers. 2014. Available at: https://
16. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual canadiantaskforce.ca/guidelines/published-guidelines/prostate-cancer/ (accessed April
• Excel spreadsheets with supplementary report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer 2021).
trends and impact of interventions (risk factors, screening, and treatment) to reduce 36. Cancer Research UK [Internet]. Bladder cancer mortality statistics. 2015. Available at:
statistics future rates. Cancer. 2010;116(3):544–73. https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
17. National Cancer Institute [Internet]. Advances in colorectal cancer research. Bethesda, cancer-type/bladder-cancer/mortality (accessed April 2021).
• PowerPoint images of the figures used MD; 2019. Available at: https://www.cancer.gov/types/colorectal/research (accessed 37. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder cancer incidence
throughout this chapter April 2021). and mortality: A global overview and recent trends. Eur Urol. 2017;71(1):96–108.
18. White A, Joseph D, Rim SH, Johnson CJ, Coleman MP, Allemani C. Colon cancer 38. Patel A, Fisher J, Nichols E, Abd-Allah F, Abdela J, Abdelalim A, et al. Global, regional,
survival in the United States by race and stage (2001–2009): Findings from the and national burden of brain and other CNS cancer, 1990–2016: A systematic analysis
References CONCORD-2 study. Cancer. 2017;123 Suppl 24:5014–36. for the global burden of disease study 2016. Lancet Neurol. 2019;18:376–93.
1. Canadian Task Force on Preventive Healthcare. Recommendations on screening for 19. Joseph DA, Johnson CJ, White A, Wu M, Coleman MP. Rectal cancer survival in the 39. Sun T, Plutynski A, Ward S, Rubin JB. An integrative view on sex differences in brain
colorectal cancer in primary care. CMAJ. 2016;188 340–8. United States by race and stage, 2001 to 2009: Findings from the CONCORD-2 study. tumors. Cell Mol Life Sci. 2015;72(17):3323–42.
Cancer. 2017;123 Suppl 24:5037–58.
2. Klarenbach S, Sims-Jones N, Lewin G, Singh H, Theriault G, Tonelli M, et al. 40. Preusser M, Marosi C. Neuro-oncology in 2016: Advances in brain tumour classification
Recommendations on screening for breast cancer in women aged 40–74 years who 20. Levin TR, Corley DA, Jensen CD, Schottinger JE, Quinn VP, Zauber AG, et al. Effects of and therapy. Nat Rev Neurol. 2017;13(2):71–2.
are not at increased risk for breast cancer. CMAJ. 2018;190(49):E1441–51. organized colorectal cancer screening on cancer incidence and mortality in a large
41. Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, et al. Global, regional, and national
community-based population. Gastroenterology. 2018;155(5):1383–91 e5.
3. Canadian Task Force on Preventive Healthcare. Recommendations on screening for burden of Hodgkin lymphoma from 1990 to 2017: Estimates from the 2017 Global
lung cancer. CMAJ. 2016;188(6):425–32. 21. Hurton S, MacDonald F, Porter G, Walsh M, Molinari M. The current state of pancreatic Burden of Disease study. J Hematol Oncol. 2019;12(1):107.
cancer in Canada: Incidence, mortality, and surgical therapy. Pancreas.
4. Canadian Partnership Against Cancer [Internet]. Lung cancer and equity: A focus on 42. Koshy M, Fairchild A, Son CH, Mahmood U. Improved survival time trends in Hodgkin’s
2014;43(6):879–85.
income and geography. Toronto, ON; 2020. Available at: https://www. lymphoma. Cancer Med. 2016;5(6):997–1003.
partnershipagainstcancer.ca/lung-equity (accessed April 2021). 22. Canadian Cancer Society’s Advisory Committee on Cancer Statistics [Internet].
43. Ye X, Mahmud S, Skrabek P, Lix L, Johnston JB. Long-term time trends in incidence,
Canadian Cancer Statistics 2017. Toronto, ON: Canadian Cancer Society; 2017.
5. Saint-Jacques N, Dewar R, Cui Y, Parker L, Dummer TJ. Premature mortality due to survival and mortality of lymphomas by subtype among adults in Manitoba, Canada: A
Available at: http://www.cancer.ca/Canadian-Cancer-Statistics-2017-EN (accessed
social and material deprivation in Nova Scotia, Canada. Int J Equity Health. population-based study using cancer registry data. BMJ Open. 2017;7(7):e015106.
April 2021).
2014;13(1):94. 44. Saad AM, Gad MM, Al-Husseini MJ, Ruhban IA, Sonbol MB, Ho TH. Trends in renal-cell
23. Ellison LF. Progress in net cancer survival in Canada over 20 years. Health Rep.
6. Statistics Canada [Internet]. Age and sex, and type of dwelling data: Key results from carcinoma incidence and mortality in the United States in the last 2 decades: A
2018;29(9):10–18.
the 2016 Census. Ottawa, ON: The Daily; 2017. Available at: https://www150.statcan. SEER-based study. Clin Genitourin Cancer. 2019;17(1):46–57 e5.
gc.ca/n1/en/daily-quotidien/170503/dq170503a-eng.pdf?st=li6F_zjZ (accessed April 24. Rawla P, Sunkara T, Gaduputi V. Epidemiology of pancreatic cancer: Global trends,
45. Cai Q, Chen Y, Qi X, Zhang D, Pan J, Xie Z, et al. Temporal trends of kidney cancer
2021). etiology and risk factors. World J Oncol. 2019;10(1):10–27.
incidence and mortality from 1990 to 2016 and projections to 2030. Transl Androl
7. Statistics Canada [Internet]. Population size and growth in Canada: Key results from 25. Shields M, Wilkins K. An update on mammography use in Canada. Health Rep. Urol. 2020;9(2):166–81.
the 2016 census. Ottawa, ON: The Daily; 2017. Available at: https://www150.statcan. 2009;20(3):7–19.
46. Levi F, Ferlay J, Galeone C, Lucchini F, Negri E, Boyle P, et al. The changing pattern of
gc.ca/n1/daily-quotidien/170208/dq170208a-eng.htm (accessed April 2021). 26. Holford TR, Cronin KA, Mariotto AB, Feuer EJ. Changing patterns in breast cancer kidney cancer incidence and mortality in Europe. BJU Int. 2008;101(8):949–58.
incidence trends. J Natl Cancer Inst Monogr. 2006(36):19–25.
47. De P, Otterstatter MC, Semenciw R, Ellison LF, Marrett LD, Dryer D. Trends in incidence,
mortality, and survival for kidney cancer in Canada, 1986–2007. Cancer Causes
Control. 2014;25(10):1271–81.

AR01678
48. Wong MC, Jiang JY, Goggins WB, Liang M, Fang Y, Fung FD, et al. International
incidence and mortality trends of liver cancer: A global profile. Sci Rep. 2017;7:45846.
49. Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global
epidemiology of bladder cancer: A joinpoint regression analysis of its incidence and
mortality trends and projection. Sci Rep. 2018;8(1):1129.
50. Lin L, Yan L, Liu Y, Qu C, Ni J, Li H. The burden and trends of primary liver cancer
caused by specific etiologies from 1990 to 2017 at the global, regional, national, age,
and sex level results from the Global Burden of Disease study 2017. Liver Cancer.
2020;9(5):563–82.
51. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of
hepatocellular carcinoma: A global and regional perspective. Oncologist. 2010;15
Suppl 4:5–13.
52. Liszkay G, Kiss Z, Gyulai R, Olah J, Hollo P, Emri G, et al. Changing trends in melanoma
incidence and decreasing melanoma mortality in Hungary between 2011 and 2019: A
nationwide epidemiological study. Front Oncol. 2020;10:612459.
53. Pulte D, Gondos A, Brenner H. Ongoing improvement in outcomes for patients
diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century.
Arch Intern Med. 2008;168(5):469–76.
54. Balakrishnan M, George R, Sharma A, Graham DY. Changing trends in stomach cancer
throughout the world. Curr Gastroenterol Rep. 2017;19(8):36.
55. Chao A, Thun MJ, Henley SJ, Jacobs EJ, McCullough ML, Calle EE. Cigarette smoking,
use of other tobacco products and stomach cancer mortality in US adults: The Cancer
Prevention Study II. Int J Cancer. 2002;101(4):380–9.
56. Henley SJ, Miller JW, Dowling NF, Benard VB, Richardson LC. Uterine cancer incidence
and mortality — United States, 1999–2016. MMWR Morb Mortal Wkly Rep.
2018;67(48):1333–8.
57. Cancer Research UK [Internet]. Uterine cancer mortality statistics. 2015. Available at:
https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-
cancer-type/uterine-cancer/mortality (accessed April 2021).
58. Twells LK, Gregory DM, Reddigan J, Midodzi WK. Current and predicted prevalence of
obesity in Canada: A trend analysis. CMAJ Open. 2014;2(1):E18–26.
59. International Agency for Research on Cancer. IARC handbooks of cancer prevention:
Weight control and physical activity. Lyon, France: IARC; 2002.
60. Bancej C, Jayabalasingham B, Wall RW, Rao DP, Do MT, de Groh M, et al. Evidence
brief — trends and projections of obesity among canadians. Health Promot Chronic Dis
Prev Can. 2015;35(7):109–12.
61. Schmetzer O, Florcken A. Sex differences in the drug therapy for oncologic diseases.
Handb Exp Pharmacol. 2012(214):411–42.

AR01679
TABLE 2.1 Lifetime probability of dying from cancer, Canada (excluding Quebec), 2019
Lifetime probability of dying from cancer

% One in:
All cancers 23.4 25.6 21.5 4.3 3.9 4.7
Lung and bronchus 5.2 5.4 5.0 19 18 20
Colorectal 2.7 3.0 2.5 37 34 40
Pancreas 1.5 1.5 1.5 66 65 68
Breast 1.5 0.0 2.9 66 3,344 34
Prostate — 3.5 — — 29 —
Leukemia 0.8 1.0 0.7 118 102 140
Non-Hodgkin lymphoma 0.9 1.0 0.7 115 97 140
Bladder 0.8 1.1 0.4 131 90 225
Brain/CNS 0.6 0.7 0.4 181 149 227
Esophagus 0.6 1.0 0.3 156 101 329
Head and neck 0.5 0.7 0.3 194 133 337
Stomach 0.6 0.7 0.4 178 140 229
Kidney and renal pelvis 0.5 0.7 0.4 190 145 273
Ovary — — 1.0 — — 103
Multiple myeloma 0.5 0.6 0.4 213 181 263
Liver* 0.4 0.6 0.2 271 174 602
Melanoma 0.3 0.5 0.2 292 211 479
Uterus (body, NOS) — — 0.7 — — 137
Cervix — — 0.2 — — 486
Thyroid 0.1 0.1 0.1 1,258 1,580 995
Hodgkin lymphoma 0.0 0.0 0.0 2,825 2,500 7,463
Testis — 0.0 — — 6,667 —
— Not applicable; CNS=central nervous system; NOS=not otherwise specified; 0.0 indicates that value is less than 0.05
* Liver cancer mortality was underestimated because deaths from liver cancer, unspecified (ICD-10 code C22.9), were excluded.
For further details, see Appendix II: Data sources and methods.
Note: The probability of dying from cancer is calculated based on age-, sex- and cause-specific mortality rates for Canada excluding
Quebec in 2019. For further details, see Appendix II: Data sources and methods. The complete definition of the specific cancers included

AR01680
TABLE 2.2 Projected deaths and age-standardized mortality rates (ASMR) for cancers, by sex, Canada, 2021
Deaths (2021 estimates) Deaths per 100,000

Total* Males Females Both sexes Males Females
All cancers 84,600 44,600 40,000 185.9 216.9 162.6
Lung and bronchus 21,000 10,800 10,300 45.5 50.9 41.4
Colorectal 9,600 5,300 4,300 21.2 25.9 17.2
Pancreas 5,600 2,900 2,700 12.3 13.9 10.9
Breast 5,500 55 5,400 12.5 0.3 23.1
Prostate 4,500 4,500 — — 22.7 —
Leukemia 3,100 1,800 1,300 6.8 8.8 5.2
Non-Hodgkin lymphoma 2,900 1,650 1,250 6.5 8.2 5.0
Bladder 2,600 1,900 720 5.7 9.6 2.8
Brain/CNS 2,400 1,400 1,050 5.7 6.9 4.5
Esophagus 2,300 1,750 530 5.1 8.4 2.2
Head and neck 2,100 1,500 560 4.6 7.3 2.3
Stomach 1,950 1,250 740 4.4 6.0 3.0
Kidney and renal pelvis 1,950 1,250 660 4.3 6.2 2.6
Ovary 1,950 — 1,950 — — 8.1
Multiple myeloma 1,600 930 690 3.5 4.5 2.7
Liver† 1,600 1,300 330 3.6 6.0 1.4
Uterus (body, NOS) 1,400 — 1,400 — — 5.7
Melanoma 1,250 790 450 2.8 3.9 1.9
Cervix 380 — 380 — — 1.8
Thyroid 240 110 130 0.5 0.5 0.5
Hodgkin lymphoma 110 65 40 0.2 0.3 0.2
Testis 35 35 — — 0.2 —
All other cancers 10,500 5,400 5,100 23.0 26.6 20.1
* Column totals may not sum to row totals due to rounding. See Rounding for reporting in Appendix II for more information
on rounding procedures.
† Liver cancer mortality was underestimated because deaths from liver cancer, unspecified (ICD-10 code C22.9), were excluded. For
Note: Rates are age-standardized to the 2011 Canadian standard population. The complete definition of the specific cancers included

AR01681
TABLE 2.3 Projected deaths for the most common causes of cancer death, by age group and sex, Canada, 2021
All cancers Lung and bronchus Colorectal
Age Both sexes* Males Females Both sexes* Males Females Both sexes* Males Females
All ages 84,600 44,600 40,000 21,000 10,800 10,300 9,600 5,300 4,300
0–14 110 60 45 — — — — — —
15–29 230 130 100 5 — — 10 5 5
30–39 680 270 410 35 10 25 90 50 40
40–49 2,000 880 1,150 240 100 140 280 150 120
50–59 7,300 3,600 3,600 1,550 750 780 860 510 350
60–69 18,800 10,200 8,600 5,500 2,800 2,700 1,850 1,150 720
70–79 26,200 14,400 11,800 7,600 4,000 3,600 2,700 1,600 1,050
80–89 21,500 11,600 9,900 4,900 2,600 2,300 2,600 1,350 1,250
90+ 7,800 3,600 4,300 1,200 540 650 1,200 450 770
50–74 39,200 21,000 18,200 11,000 5,600 5,300 4,000 2,400 1,600
65+ 66,100 35,300 30,800 16,900 8,700 8,100 7,600 4,100 3,500
Pancreas Breast Prostate

Age Both sexes* Males Females Females Males
All ages 5,600 2,900 2,700 5,400 4,500
0–14 — — — — —
15–29 — — — 10 —
30–39 20 10 10 140 —
40–49 110 65 45 350 5
50–59 530 320 220 750 100
60–69 1,400 780 600 1,150 540
70–79 1,850 970 870 1,300 1,250
80–89 1,350 630 710 1,100 1,750
90+ 400 140 260 610 820
50–74 2,900 1,600 1,250 2,600 1,200
65+ 4,400 2,200 2,200 3,600 4,200
— Fewer than 3 deaths.
* Counts for both sexes may not sum to row totals due to rounding. See Rounding for reporting in Appendix II for more information on rounding procedures.

AR01682
TABLE 2.4 Projected age-standardized mortality rates (ASMR) for selected cancers, by sex and province, Canada,* 2021
CA BC AB SK MB ON QC NB NS PE NL
Males
All cancers 216.9 201.7 200.5 217.2 231.0 209.7 231.3 235.8 264.9 237.6 256.8
Lung and bronchus 50.9 42.0 44.1 49.2 48.3 45.0 64.7 65.2 60.4 58.0 65.7
Colorectal 25.9 24.6 23.3 27.8 29.1 23.0 28.7 26.9 35.9 33.7 42.8
Prostate 22.7 22.1 25.3 29.5 29.2 22.0 20.3 22.1 28.8 24.6 27.8
Pancreas 13.9 13.6 13.4 13.8 14.0 14.2 13.8 15.1 14.5 12.6 12.5
Bladder 9.6 9.8 6.6 9.6 10.5 9.2 10.7 10.3 10.8 9.5 10.2
Leukemia 8.8 8.1 8.1 10.8 10.3 8.5 9.6 10.1 10.5 7.2 7.6
Esophagus 8.4 9.5 8.1 10.5 9.1 8.3 7.1 9.7 11.9 9.7 8.6
Non-Hodgkin lymphoma 8.2 7.8 7.7 8.1 7.6 8.3 8.4 9.1 9.8 9.2 8.9
Head and neck 7.3 6.6 6.4 5.5 5.7 7.5 7.9 6.3 8.3 6.0 7.5
Brain/CNS 6.9 6.9 6.7 5.2 5.2 6.9 7.5 6.7 7.5 5.8 7.1
Liver† 6.0 7.7 5.6 3.1 5.0 6.5 5.4 4.1 6.4 6.0 3.4
Kidney and renal pelvis 6.2 5.7 5.3 7.3 8.9 5.6 6.6 8.3 8.9 7.7 9.1
Stomach 6.0 4.9 5.0 4.4 5.5 6.4 6.6 6.1 5.9 5.3 10.1
Multiple myeloma 4.5 4.6 4.3 4.4 5.3 4.4 4.8 4.3 4.5 6.7 4.7
Melanoma 3.9 3.4 3.2 2.9 3.2 4.9 3.1 3.3 5.9 5.2 3.1
Thyroid 0.5 0.7 0.5 0.5 0.6 0.6 0.5 — 0.7 — 0.7
Hodgkin lymphoma 0.3 0.3 0.4 — 0.4 0.4 0.4 — — — —
Breast 0.3 0.3 0.3 — 0.4 0.3 0.3 0.7 0.5 — —
Testis 0.2 0.2 0.1 — — 0.2 0.2 — — — —
Females
All cancers 162.6 154.3 153.3 167.9 170.1 153.7 178.7 165.8 185.9 164.4 190.7
Lung and bronchus 41.4 39.8 38.5 43.9 43.1 35.4 50.7 44.6 51.3 48.3 44.4
Breast 23.1 20.2 22.7 25.3 23.5 22.9 24.9 20.9 24.7 20.0 25.3
Colorectal 17.2 16.8 15.4 18.9 18.8 15.1 19.6 18.0 22.7 20.4 27.9
Pancreas 10.9 11.1 11.0 10.2 11.0 10.5 11.5 10.9 10.3 9.1 9.7
Ovary 8.1 9.4 7.3 8.9 9.0 7.8 7.9 7.8 9.1 9.6 9.3
Uterus (body, NOS) 5.7 5.1 5.4 4.9 6.5 6.0 5.8 5.1 6.8 4.3 5.8
Leukemia 5.2 5.3 4.4 5.2 5.5 5.1 5.7 5.7 5.2 4.4 5.9
Non-Hodgkin lymphoma 5.0 4.9 4.5 4.8 5.6 5.0 5.0 6.3 6.3 5.1 6.5 — ASMR based on fewer than 3 deaths; CNS=central nervous
Brain/CNS 4.5 4.4 4.1 4.3 4.0 4.4 5.3 4.3 4.2 4.5 6.2 system; NOS=not otherwise specified
Stomach 3.0 2.4 2.8 2.6 2.9 3.2 3.3 3.3 2.4 2.4 4.4
Bladder 2.8 2.8 2.4 2.5 2.6 2.7 3.2 2.7 2.7 2.7 2.8
Territories are not listed due to small numbers.
Multiple myeloma 2.7 2.7 2.3 3.0 3.2 2.6 3.0 3.4 3.1 3.3 3.5
Kidney and renal pelvis 2.6 2.2 2.2 3.5 3.5 2.4 3.0 3.4 3.8 2.9 4.6 † Liver cancer mortality was underestimated because deaths from
Head and neck 2.3 2.5 2.0 1.9 2.1 2.2 2.7 2.0 2.3 2.9 2.0 liver cancer, unspecified (ICD-10 code C22.9), were excluded. For
Esophagus 2.2 2.7 2.0 2.2 2.2 2.2 1.8 2.5 2.7 2.7 2.0 further details, see Appendix II: Data sources and methods.
Melanoma 1.9 1.6 1.7 1.7 1.5 2.1 1.9 2.4 2.3 3.3 1.7 Note: Rates are age-standardized to the 2011 Canadian standard
Cervix 1.8 1.6 1.9 2.8 2.0 1.8 1.7 1.7 1.8 2.9 3.1 population. The complete definition of the specific cancers listed
Liver† 1.4 1.8 1.5 0.7 1.4 1.4 1.3 1.0 1.1 — 1.2 here can be found in Table A1.
Thyroid 0.5 0.6 0.6 0.5 0.6 0.5 0.5 0.5 0.6 — 0.7 Analysis by: Centre for Population Health Data, Statistics Canada
Hodgkin lymphoma 0.2 0.2 0.2 — — 0.2 0.3 — — — — Data source: Canadian Vital Statistics Death Database at Statistics Canada

AR01683
TABLE 2.5 Projected deaths for selected cancers by sex and province, Canada,* 2021
CA† BC AB SK MB ON QC NB NS PE NL
Males
All cancers 44,600 6,000 3,800 1,300 1,550 16,400 11,600 1,200 1,600 230 860
Lung and bronchus 10,800 1,300 870 300 330 3,600 3,400 330 380 60 230
Colorectal 5,300 720 450 160 190 1,800 1,400 140 210 30 140
Prostate 4,500 640 440 170 180 1,700 980 100 160 20 85
Pancreas 2,900 410 260 80 95 1,150 710 75 90 10 45
Bladder 1,900 290 120 55 65 700 530 50 65 10 30
Leukemia 1,800 240 150 65 70 660 480 50 60 5 25
Esophagus 1,750 290 170 60 60 670 360 50 70 10 30
Non-Hodgkin lymphoma 1,650 230 140 45 50 650 420 45 55 10 30
Head and neck 1,500 200 130 35 40 600 400 30 50 5 25
Brain/CNS 1,400 200 140 30 35 530 370 30 45 5 25
Liver‡ 1,300 240 120 20 35 520 280 25 40 5 10
Kidney and renal pelvis 1,250 170 100 45 60 440 330 45 55 10 30
Stomach 1,250 140 95 25 35 500 330 30 35 5 35
Multiple myeloma 930 140 80 25 35 350 240 20 25 5 15
Melanoma 790 100 60 20 20 380 150 15 35 5 10
Thyroid 110 20 10 5 5 50 25 — 5 — 5
Hodgkin lymphoma 65 10 10 — 5 30 20 — — — —
Breast 55 10 5 — 5 25 15 5 5 — —
Testis 35 5 5 — — 15 10 — — — —
Females
All cancers 40,000 5,300 3,500 1,150 1,350 14,700 10,600 980 1,350 190 730
Lung and bronchus 10,300 1,400 880 300 350 3,400 3,000 270 380 60 170
Breast 5,400 680 510 170 180 2,100 1,400 120 170 20 90
Colorectal 4,300 590 350 140 160 1,500 1,200 110 170 25 110
Pancreas 2,700 390 250 70 90 1,050 690 65 75 10 40
Ovary 1,950 320 160 60 70 720 450 45 65 10 35
Uterus (body, NOS) 1,400 180 120 35 50 570 340 30 50 5 25 — Fewer than 3 deaths; CNS=central nervous system; NOS=not
Leukemia 1,300 180 100 35 45 490 340 35 40 5 20 otherwise specified
Non-Hodgkin lymphoma 1,250 170 100 35 45 490 310 35 45 5 25
Brain/CNS 1,050 140 95 25 30 390 280 20 30 5 20 Territories are not listed due to small numbers.
Stomach 740 80 60 20 25 300 200 20 15 5 15
Bladder 720 100 55 20 20 270 200 15 20 5 10 † Canadian counts may not sum to row totals due to rounding.
Multiple myeloma 690 95 55 20 25 250 190 20 25 5 15 See Rounding for reporting in Appendix II for more information
Kidney and renal pelvis 660 75 50 25 30 240 180 20 30 5 20 on rounding procedures.
Head and neck 560 85 45 15 15 210 160 10 15 5 5 ‡ Liver cancer mortality was underestimated because deaths from
Esophagus 530 95 45 15 20 210 110 15 20 5 5 liver cancer, unspecified (ICD-10 code C22.9), were excluded. For
Melanoma 450 50 40 10 10 200 100 15 15 5 5 further details, see Appendix II: Data sources and methods.
Cervix 380 50 40 15 15 150 80 10 10 5 10 Note: The complete definition of the specific cancers listed here
Liver‡ 330 60 35 5 10 140 80 5 5 — 5 can be found in Table A1.
Thyroid 130 20 15 5 5 50 30 5 5 — 5 Analysis by: Centre for Population Health Data, Statistics Canada
Hodgkin lymphoma 40 5 5 — — 15 15 — — — — Data source: Canadian Vital Statistics Death Database at Statistics Canada

AR01684
TABLE 2.6 Annual percentage change (APC) and average annual percent change (AAPC) in age-standardized mortality rates (ASMR) for selected cancers, by sex, Canada, 1984–2019

AAPC* (95% CL), AAPC* (95% CL), AAPC* (95% CL),
Period APC* (95% CL) 1984–2019 Period APC* (95% CL) 1984–2019 Period APC* (95% CL) 1984–2019
All cancers 1984–1992 -0.1 (-0.3, 0.2) 1984–1988 0.6 (-0.1, 1.4) 1984–2002 -0.2 (-0.3, -0.1)
1992–2002 -0.7 (-0.9, -0.5) 1988–2001 -0.9 (-1.0, -0.7) 2002–2015 -1.1 (-1.2, -0.9)
-0.9 (-1.0, -0.8) -1.1 (-1.3, -1.0) -0.7 (-0.8, -0.6)
2002–2015 -1.3 (-1.4, -1.2) 2001–2019 -1.8 (-1.8, -1.7) 2015–2019 -2.0 (-2.7, -1.4)
2015–2019 -1.9 (-2.4, -1.4)
Lung and bronchus 1984–1992 1.0 (0.5, 1.5) 1984–1992 -0.1 (-0.6, 0.5) 1984–1993 3.8 (3.2, 4.3)
1992–2007 -0.8 (-0.9, -0.6) 1992–2011 -2.1 (-2.3, -2.0) 1993–2006 1.2 (1.0, 1.5)
-0.9 (-1.1, -0.7) -2.0 (-2.1, -1.8) 0.8 (0.6, 1.1)
2007–2015 -1.7 (-2.1, -1.2) 2011–2019 -3.4 (-3.9, -3.0) 2006–2015 -0.7 (-1.1, -0.2)
2015–2019 -3.6 (-4.7, -2.6) 2015–2019 -3.5 (-4.6, -2.3)
Colorectal 1984–2005 -1.3 (-1.4, -1.2) 1984–2004 -1.0 (-1.2, -0.9) 1984–2014 -1.7 (-1.8, -1.6)
-1.7 (-1.7, -1.6) -1.6 (-1.7, -1.5) -1.9 (-2.1, -1.7)
2005–2019 -2.2 (-2.3, -2.0) 2004–2019 -2.3 (-2.5, -2.1) 2014–2019 -3.2 (-4.2, -2.1)
Pancreas 1984–2000 -0.8 (-1.1, -0.6) 1984–2000 -1.4 (-1.7, -1.1) 1984–2019 -0.1 (-0.2, 0.0)
-0.3 (-0.5, -0.2) -0.6 (-0.8, -0.4) -0.1 (-0.2, 0.0)
2000–2019 0.1 (-0.1, 0.2) 2000–2019 0.1 (-0.1, 0.3)
Breast 1984–1994 -0.6 (-0.9, -0.2) 1984–2019 -1.0 (-1.5, -0.5) 1984–1994 -0.7 (-1.1, -0.3)
1994–2012 -2.5 (-2.6, -2.3) -1.7 (-1.9, -1.6) -1.0 (-1.5, -0.5) 1994–2011 -2.4 (-2.6, -2.2) -1.7 (-1.8, -1.5)
2012–2019 -1.5 (-2.1, -0.9) 2011–2019 -1.4 (-1.9, -0.9)
Prostate 1984–1994 1.3 (0.7, 1.8)
1994–2012 -2.8 (-3.0, -2.6) -1.4 (-1.6, -1.2)
2012–2019 -1.6 (-2.3, -0.9)
Leukemia 1984–2019 -0.9 (-1.0, -0.8) -0.9 (-1.0, -0.8) 1984–2019 -1.0 (-1.1, -0.9) -1.0 (-1.1, -0.9) 1984–2019 -1.0 (-1.1, -0.9) -1.0 (-1.1, -0.9)
Non-Hodgkin lymphoma 1984–2000 1.6 (1.3, 1.9) 1984–2000 1.8 (1.5, 2.2) 1984–1999 1.5 (1.0, 2.0)
2000–2010 -2.5 (-3.1, -1.9) -0.3 (-0.6, -0.1) 2000–2010 -2.4 (-3.0, -1.7) -0.1 (-0.4, 0.2) 1999–2019 -2.2 (-2.4, -1.9) -0.6 (-0.9, -0.4)
2010–2019 -1.2 (-1.8, -0.7) 2010–2019 -0.9 (-1.6, -0.3)
Bladder 1984–2015 -0.3 (-0.4, -0.2) 1984–2015 -0.4 (-0.6, -0.3) 1984–2019 -0.4 (-0.6, -0.3)
-0.5 (-0.8, -0.2) -0.7 (-1.0, -0.4) -0.4 (-0.6, -0.3)
2015–2019 -2.0 (-4.5, 0.6) 2015–2019 -3.0 (-5.4, -0.4)
Brain/CNS 1984–2005 -0.6 (-0.8, -0.4) 1984–2003 -0.5 (-0.8, -0.2) 1984–2006 -0.7 (-1.0, -0.5)
2005–2015 0.8 (0.2, 1.4) -0.4 (-0.7, -0.1) 2003–2019 0.2 (-0.1, 0.5) -0.2 (-0.4, 0.0) 2006–2015 1.3 (0.3, 2.3) -0.6 (-1.0, -0.2)
2015–2019 -2.1 (-3.9, -0.3) 2015–2019 -3.8 (-6.4, -1.1)
Esophagus 1984–1999 0.7 (0.4, 1.1) 1984–2000 0.9 (0.5, 1.3) 1984–2019 -0.5 (-0.7, -0.3)
0.2 (0.0, 0.4) 0.3 (0.1, 0.5) -0.5 (-0.7, -0.3)
1999–2019 -0.2 (-0.4, 0.0) 2000–2019 -0.2 (-0.4, 0.0)
Head and neck 1984–2010 -2.1 (-2.3, -1.9) 1984–1991 -0.6 (-2.0, 0.8) 1984–2019 -1.3 (-1.5, -1.0)
2010–2019 -0.3 (-1.2, 0.7) -1.6 (-1.9, -1.3) 1991–2009 -2.8 (-3.1, -2.4) -1.7 (-2.0, -1.3) -1.3 (-1.5, -1.0)
2009–2019 -0.3 (-1.1, 0.4)
Stomach 1984–2010 -3.1 (-3.2, -3.0) 1984–2012 -3.3 (-3.4, -3.2) 1984–2019 -2.8 (-2.9, -2.6)
-2.8 (-3.0, -2.6) -3.0 (-3.2, -2.8) -2.8 (-2.9, -2.6)
2010–2019 -2.0 (-2.6, -1.3) 2012–2019 -1.8 (-2.8, -0.7)
Kidney and renal pelvis 1984–2008 -0.3 (-0.5, -0.1) 1984–2004 -0.1 (-0.4, 0.3) 1984–2008 -0.5 (-0.8, -0.1)
-0.7 (-0.9, -0.4) -0.6 (-0.8, -0.3) -0.9 (-1.3, -0.6)
2008–2019 -1.5 (-2.1, -0.9) 2004–2019 -1.2 (-1.6, -0.8) 2008–2019 -2.0 (-2.9, -1.1)

AR01685
TABLE 2.6 Annual percentage change (APC) and average annual percent change (AAPC) in age-standardized mortality rates (ASMR) for selected cancers, by sex, Canada, 1984–2019
Period APC (95% CL) 1984–2015 Period APC (95% CL) 1984–2015 Period APC (95% CL) 1984–2015
Ovary 1984–2003 -0.6 (-0.9, -0.2)
-0.9 (-1.1, -0.6)
2003–2019 -1.2 (-1.6, -0.9)
Multiple myeloma 1984–1994 0.7 (-0.3, 1.6) 1984–1995 1.0 (0.0, 2.1) 1984–2002 -0.1 (-0.6, 0.5)
1994–2019 -0.9 (-1.1, -0.7) -0.4 (-0.7, -0.2) 1995–2008 -1.6 (-2.4, -0.9) -0.2 (-0.7, 0.2) 2002–2019 -1.4 (-1.9, -1.0) -0.8 (-1.1, -0.4)
2008–2019 0.2 (-0.5, 1.0)
Liver† 1984–1996 -1.1 (-2.3, 0.1) 1984–1991 -2.7 (-5.8, 0.4) 1984–1989 3.1 (-2.3, 8.8)
1996–2015 3.2 (2.7, 3.7) 1.4 (0.8, 2.0) 1991–2019 2.8 (2.5, 3.1) 1.7 (1.0, 2.3) 1989–1994 -8.0 (-14.6, -0.8) 0.8 (-0.5, 2.1)
2015–2019 0.6 (-2.7, 4.0) 1994–2019 2.2 (1.8, 2.5)
Uterus (body, NOS) 1984–2005 -0.8 (-1.1, -0.5)
0.3 (0.1, 0.6)
2005–2019 2.0 (1.5, 2.4)
Melanoma 1984–2013 0.9 (0.7, 1.2) 1984–2013 1.3 (1.0, 1.6) 1984–2015 0.4 (0.1, 0.6)
0.3 (0.0, 0.6) 0.6 (0.1, 1.1) -0.2 (-0.8, 0.3)
2013–2019 -2.7 (-4.3, -0.9) 2013–2019 -2.6 (-5.0, -0.2) 2015–2019 -4.9 (-9.2, -0.4)
Cervix 1984–2006 -2.8 (-3.2, -2.5)
-2.1 (-2.4, -1.7)
2006–2019 -0.8 (-1.6, 0.0)
Thyroid 1984–2019 0.0 (-0.4, 0.3) 0.0 (-0.4, 0.3) 1984–2019 0.6 (0.0, 1.1) 0.6 (0.0, 1.1) 1984–2019 -0.4 (-0.8, 0.1) -0.4 (-0.8, 0.1)
Hodgkin lymphoma 1984–1997 -4.6 (-5.8, -3.4) 1984–1996 -5.2 (-6.6, -3.8) 1984–2019 -3.2 (-3.6, -2.9)
-3.3 (-3.9, -2.8) -3.4 (-4.0, -2.8) -3.2 (-3.6, -2.9)
1997–2019 -2.5 (-3.2, -1.9) 1996–2019 -2.5 (-3.1, -1.9)
Testis 1984–2019 -1.6 (-2.1, -1.0) -1.6 (-2.1, -1.0)
All other cancers 1984–2002 1.6 (1.2, 2.0) 1984–2003 1.7 (1.3, 2.2) 1984–2002 1.4 (1.0, 1.8)
0.0 (-0.2, 0.3) 0.0 (-0.3, 0.3) -0.1 (-0.3, 0.2)
2002–2019 -1.6 (-2.0, -1.3) 2003–2019 -1.9 (-2.4, -1.5) 2002–2019 -1.6 (-1.9, -1.3)
CL=confidence limits; CNS=central nervous system; NOS=not otherwise specified
* The APC and the AAPC are calculated using the Joinpoint Regression Program and rates age-standardized to the 2011 Canadian standard population.
† Liver cancer mortality was underestimated because deaths from liver cancer, unspecified (ICD-10 code C22.9), were excluded. For further details,
see Appendix II: Data sources and methods.
Note: The complete definition of the specific cancers listed here can be found in Table A1.

AR01686
TABLE 2.7 Most recent annual percent change (APC) in age-standardized mortality rates (ASMR) for selected cancers, by sex, Canada, 1984–2019

Reference year APC* (95% CL) Reference year APC* (95% CL) Reference year APC* (95% CL)
All cancers 2015 -1.9 (-2.4, -1.4) 2001 -1.8 (-1.8, -1.7) 2015 -2.0 (-2.7, -1.4)
Lung and bronchus 2015 -3.6 (-4.7, -2.6) 2011 -3.4 (-3.9, -3.0) 2015 -3.5 (-4.6, -2.3)
Colorectal 2005 -2.2 (-2.3, -2.0) 2004 -2.3 (-2.5, -2.1) 2014 -3.2 (-4.2, -2.1)
Pancreas 2000 0.1 (-0.1, 0.2) 2000 0.1 (-0.1, 0.3) 1984 -0.1 (-0.2, 0.0)
Breast 2012 -1.5 (-2.1, -0.9) 1984 -1.0 (-1.5, -0.5) 2011 -1.4 (-1.9, -0.9)
Prostate — — 2012 -1.6 (-2.3, -0.9) — —
Leukemia 1984 -0.9 (-1.0, -0.8) 1984 -1.0 (-1.1, -0.9) 1984 -1.0 (-1.1, -0.9)
Non-Hodgkin lymphoma 2010 -1.2 (-1.8, -0.7) 2010 -0.9 (-1.6, -0.3) 1999 -2.2 (-2.4, -1.9)
Bladder 2015 -2.0 (-4.5, 0.6) 2015 -3.0 (-5.4, -0.4) 1984 -0.4 (-0.6, -0.3)
Brain/CNS 2015 -2.1 (-3.9, -0.3) 2003 0.2 (-0.1, 0.5) 2015 -3.8 (-6.4, -1.1)
Esophagus 1999 -0.2 (-0.4, 0.0) 2000 -0.2 (-0.4, 0.0) 1984 -0.5 (-0.7, -0.3)
Head and neck 2010 -0.3 (-1.2, 0.7) 2009 -0.3 (-1.1, 0.4) 1984 -1.3 (-1.5, -1.0)
Stomach 2010 -2.0 (-2.6, -1.3) 2012 -1.8 (-2.8, -0.7) 1984 -2.8 (-2.9, -2.6)
Kidney and renal pelvis 2008 -1.5 (-2.1, -0.9) 2004 -1.2 (-1.6, -0.8) 2008 -2.0 (-2.9, -1.1)
Ovary — — — — 2003 -1.2 (-1.6, -0.9)
Multiple myeloma 1994 -0.9 (-1.1, -0.7) 2008 0.2 (-0.5, 1.0) 2002 -1.4 (-1.9, -1.0)
Liver† 2015 0.6 (-2.7, 4.0) 1991 2.8 (2.5, 3.1) 1994 2.2 (1.8, 2.5)
Uterus (body, NOS) — — — — 2005 2.0 (1.5, 2.4)
Melanoma 2013 -2.7 (-4.3, -0.9) 2013 -2.6 (-5.0, -0.2) 2015 -4.9 (-9.2, -0.4)
Cervix — — — — 2006 -0.8 (-1.6, 0.0)
Thyroid 1984 0.0 (-0.4, 0.3) 1984 0.6 (0.0, 1.1) 1984 -0.4 (-0.8, 0.1)
Hodgkin lymphoma 1997 -2.5 (-3.2, -1.9) 1996 -2.5 (-3.1, -1.9) 1984 -3.2 (-3.6, -2.9)
Testis — — 1984 -1.6 (-2.1, -1.0) — —
All other cancers 2002 -1.6 (-2.0, -1.3) 2003 -1.9 (-2.4, -1.5) 2002 -1.6 (-1.9, -1.3)
— Not applicable; CL=confidence limits; CNS=central nervous system; NOS=not otherwise specified
* The APC was calculated using the Joinpoint Regression Program and rates age-standardized to the 2011 Canadian standard population. If one or more significant changes
in the trend of rates was detected, the APC reflects the trend from the most recent significant change (reference year) to 2019. Otherwise, the APC reflects the trend in rates
over the entire period (1984–2019). For further details, see Appendix II: Data sources and methods.
† Liver cancer mortality was underestimated because deaths from liver cancer, unspecified (ICD-10 code C22.9), were excluded. For further details, see Appendix II: Data
sources and methods.
Note: The complete definition of the specific cancers listed here can be found in Table A1.

AR01687 3
Chapter
What is the probability of surviving cancer in Canada?

Net survival by sex, age, geography and over time
Population-based cancer survival Key findings Net survival

includes all people diagnosed with • For 2015 to 2017, the predicted The percentage of people diagnosed
cancer in a defined geographic area five-year net survival for all cancers with a cancer who survive a given period
(such as a province) regardless of their of time past their diagnosis, assuming
combined was 64%. This was up
that the cancer of interest is the only
age, health status or access to health from 55% in the early 1990s.
possible cause of death. Net survival
insurance and medical care. It provides • The highest five-year net survival is the preferred method for comparing
useful “average” estimates of survival was for cancers of the thyroid cancer survival in population-based cancer
and does not reflect any individual’s (97%) and testis (97%). It was studies because it adjusts for the fact that
prognosis. Along with incidence and lowest for cancers of the pancreas different populations may have different
mortality data, population-based (10%) and esophagus (16%). levels of background risk of death. It can
cancer survival is a key metric by which be measured over various timeframes but,
• Net survival is generally higher as is standard in other reports, five years
to evaluate cancer care and screening among females (66%) than among has been chosen as the primary duration of
initiatives in the population.(1,2) males (62%). analysis for this publication.
• Net survival generally decreased Predicted survival
with advancing age.
Predicted (period) survival provides a
• 84% of children diagnosed with more up-to-date estimate of survival by
cancer survived at least five years. exclusively using the survival experienced
by cancer cases during a recent period
Predicted five-year • Some of the biggest increases in (e.g., 2015–2017). When there is an
net survival have been for blood-
net survival is 64%. related cancers. There has been no
increasing trend in survival, predicted
estimates provide a more up-to-date,
improvement in survival for uterine though typically conservative, measure of
cancer since the early 1990’s. recent survival.(3,4)

Chapter 3 • What is the probability of surviving cancer in Canada?
AR01688
Five- and 10-year net survival • For colorectal cancer, net survival declined from • There appears to be a plateau in the long-term
84% to 72% between one and three years after survival curve for prostate, colorectal and
Population-based net cancer survival provides a
diagnosis, and then more gradually three to 10 pancreatic cancer, but not for female breast and
measure of the prognosis for a cancer. Table 3.1
shows the predicted five- and 10-year net survival years after diagnosis, at which point survival lung cancer.
by sex for people diagnosed with cancer at ages was 61%.
15–99 years. • For lung cancer and pancreatic cancer, net
• For all cancers combined, adjusted net survival survival declined sharply during the first three
is 64% at five years and 58% at 10 years. years after diagnosis (to 29% and 13%,
respectively) and more gradually thereafter.
• Five- and 10-year net survival were highest for
cancers of the thyroid (97%, 97%) and testis
(97%, 96%).
• Five- and 10-year net survival is lowest for
pancreatic (10%, 8%) and esophageal (16%,
13%) cancers. Although not presented in this
publication, five-year survival is also low for FIGURE 3.1 Predicted net survival for leading causes of cancer death by survival duration, ages 15–99, Canada
mesothelioma (9%).(5,6) (excluding Quebec*), 2015–2017
• Where feasible, estimates of survival were also

100 97 100
provided for individual cancers (e.g., colon
-
.....
94
91
cancer and rectum cancer) within a group of 90 ..'!I.,...... .
97
93
88
90
..... Colorectal
cancers (e.g., colorectal cancer). This was done

80
', 89
80 -+
Female breast
Lung and bronchus
84
because survival can vary considerably within a 82
group. For example, five-year survival is 70

."',.~~<·-:;:..:~--
72 c; ~ ·;.: :;·~ ~ ·~~·~~.~.-CC,.~.~.=-·-·• ·.... 70 --- Pancreas
Prostate
Net survival (%)
significantly lower for acute myeloid leukemia 60

67
60
(23%) than for chronic lymphocytic leukemia 48
61
50 50
(86%), while survival for all leukemias combined
is 61%. 40 40
29
30 30
Cancer survival generally decreases with time, 31 22
particularly in the first few years following a 20 15 20
diagnosis. Figure 3.1 shows the predicted net 10 13 10

survival up to 10 years after diagnosis for selected 10
8
0 0
cancers. 1 3 5 10
Survival duration (years)
• For prostate cancer and female breast cancer,
net survival declined relatively gradually over *Quebec is excluded because cases diagnosed in Quebec from 2011 onward had not been submitted to the Canadian Cancer Registry.
the first 10 years, though less gradually for Note: The complete definition of the specific cancers listed here can be found in Table A1.
breast cancer.
Data sources: Canadian Cancer Registry death linked file (1992–2017) and life tables at Statistics Canada

AR01689
Survival by sex The higher net survival among females is • Survival for breast cancer is relatively high (≥85%)
mirrored by the observation that females have a among females diagnosed before 85 years of age,
Cancer survival can vary between sexes. In significantly lower excess risk of dying from their after which survival drops to about 73%.
addition to results for both sexes combined, cancer than males, particularly for people younger
Table 3.1 also presents estimates for males and • For both sexes combined, survival for lung
than 55 years of age.(8)
females separately. The following points pertain cancer is twice as high (43%) among Canadians
to five-year net survival. diagnosed between 15 and 44 years of age than
• For all cancers combined, females had higher Survival by age it is among those diagnosed between 75 and 84
adjusted survival (66%) than males (62%). years of age (19%) and between 85 and 99 years
For most cancers diagnosed in adults, net survival
decreases with advancing age at diagnosis.(5,6) of age (11%).
• In terms of percentage point differences, the
largest advantages for females relative to males Table 3.2 shows predicted five-year net survival
were observed for breast cancer, chronic by age group.
myeloid leukemia, lung cancer and melanoma. • Survival for prostate cancer is consistently high
• Five-year net survival was lower in females than (≥94%) among males diagnosed before 75 years
males for acute lymphocytic leukemia (42% vs. of age and lowest (52%) among males aged 85 Survival is typically lower
51%), bladder cancer (75% vs. 77%), cancers of years and older. among males than females.
the central nervous system (59% vs. 61%) and
pancreatic cancer (9% vs. 10%), but these
differences were not statistically significant.
Age-standardized net survival All cancers combined
• For bladder cancer, the 10-year prognosis
favoured females (69% vs. 65%). A previous The net survival that would have occurred if Non-age-standardized survival estimates
the age distribution at diagnosis of the group of for all cancers combined (Table 3.1) were
study using Canadian Cancer Registry data
people with the cancer under study had been calculated as a weighted average of estimates
found that the survival advantage for males was
the same as that of the standard population. for individual cancer and sex combinations.
significant for only the first 12 to 18 months post For childhood cancer (Table 3.3), main
For each cancer, the standard population was
diagnosis.(8) One partial explanation is that based on persons diagnosed with that cancer diagnostic groups were used in place of
bladder cancer diagnoses among females may in Canada (excluding Quebec) from 2010 to 2014. individual cancers. To facilitate comparison of
be more delayed due to the rarity of this cancer This facilitates the comparison of net survival net survival for all cancers combined over time
in females relative to males.(9) between geographic areas and over time. (Figure 3.2), a net cancer survival index was
constructed by additionally adjusting for age
Confidence interval (CI) group at diagnosis.(7) The index is unaffected
A range of values that provides an indication by changes in the age, sex or cancer type
of the precision of an estimate. Confidence (case-mix) distribution of cancer cases over
Observed survival intervals are usually 95%. This means that time. In this case, the index represents the net
The proportion of people with cancer who upon repeated sampling for a study, and survival from cancer that would have occurred
are alive after a given period of time (e.g., five assuming there were no other sources of bias, if the age, sex and cancer type distribution of
years) following diagnosis. In this publication, 95% of the resulting confidence intervals cancers under study had been the same as the
observed survival is only used to describe would contain the true value of the statistic distribution of cancers in Canada (excluding
cancer in children (aged 0–14 years). being estimated. Quebec) from 2010 to 2014.

AR01690
• There is a considerable difference in survival FIGURE 3.2 Predicted five-year age-standardized net survival for selected cancers by time period, ages 15–99, Canada
among those diagnosed with pancreatic cancer (excluding Quebec*), 2015–2017 versus 1992–1994
between 15 and 44 years of age (43%) and 30
those diagnosed between 75 and 84 years of 25.2
25 23.1 23.3
age (6%) or older (2%). 20.9
20
Change (percentage points)

Childhood cancer survival 17.0
15 13.1
Cancer in children (under the age of 15 years) 12.4 12.7
11.3
10.5 10.0
is uncommon (Table 1.3), and deaths due to
1_1.l lll ...1ll1l.11

10 8.6 9.2
7.1 6.5
cancer are even more uncommon (Table 2.3). 6.0 6.4
4.6 5.3
6.4
5.0
4.6
In general, cancer survival is relatively high for
many of the most commonly diagnosed cancers
in this age group. Table 3.3 shows one- and five-
5
0 li.lll 1.7
-1.2
3.5 2.2
year predicted observed survival for children by -5

childhood cancer diagnostic group and selected -10 -7.8
subgroups.(10,11)
s†
id
tis
te
a
ast
ia
S)
er
ix
lvis
m
lon
tem
ia
ary
ch
ia
er
in
us
s
chu
ea
Fem nom
om
om
mi
ocy yelom
cer
erv
kem
kem
kem
yro
Bra
NO
ctu
sta
dd
Liv
ag
ma
Tes
bre
Ov
Co
pe
ncr
e
sys
ph
ph
Bla
ron
can
ph
C
k
Pro
Th
Re
Sto
• For all childhood cancers combined, one-year
la
dy,
leu
leu
leu
leu
al
Pa
ale
ym
lym
lym iple m
Eso
Me
ic m ous
db
ren
bo
All
tic
oid
tic
id
l
s(
rv
an
kin
in
elo
survival is 93% and five-year survival is 84%.
ocy
nd
yel
ne
gk
eru
lt
dg
ng
my
ya
Mu
ph
ph
od
al
Ut
Ho
Lu
ne
ntr
ym
n-H
ute
• Five-year survival exceeds 95% among children
ron
Kid
Ce
ic l
Ac
No
ute
Ch
ron
diagnosed with Hodgkin lymphoma,
Ac
Ch
View data
nephroblastoma and other non-epithelial renal
NOS=not otherwise specified
tumours, and malignant gonadal germ cell tumours.
* Quebec is excluded because cases diagnosed in Quebec from 2011 onward have not been submitted to the Canadian Cancer Registry.
• Five-year survival is lowest for acute myeloid † Estimates for all cancers combined were calculated as a weighted average of sex-specific, age-standardized estimates. For further
leukemia (65%), rhabdomyosarcomas (69%), details, see Appendix II: Data sources and methods.
intracranial and intraspinal embryonal tumours Note: Estimates were age-standardized using the Canadian Cancer Survival Standard weights. For further details, see Appendix II: Data
sources and methods. The complete definition of the specific cancers listed here can be found in Table A1.
(71%), malignant bone tumours (72%) and Analysis by: Centre for Population Health Data, Statistics Canada
hepatic tumours (72%). Data sources: Canadian Cancer Registry death linked file (1992–2017) and life tables at Statistics Canada.
• One-year survival was 80% or higher for all

childhood cancers considered and was 95% or
higher for seven of the 12 diagnostic groups.
A recently published study reported statistically

significant increases in both one- and five-
year survival (2.7 and 7.5 percentage points,
respectively) for all childhood cancers combined
from 1992–1996 to 2013–2017.(12) Most of this
improvement occurred in the first half of this time
span and increases since the 2003–2007 period
were not found to be statistically significant.

AR01691
Survival by geographic region • Very modest improvements were observed for five-year survival. Stomach and lung cancers
testicular and brain cancer. While survival for were associated with the next largest differences
Table 3.4 shows age-standardized five-year net
testicular cancer has been at or above 95% for at 26 and 24 percentage points, respectively.
survival for selected cancers by province (except
Quebec). some time, the prognosis for individuals • In contrast, since the potential for improvement
diagnosed with brain cancer remains relatively is limited for cancers that have a good prognosis
• Five-year net survival is fairly uniform among very poor. at diagnosis, there was little difference between
the provinces for female breast cancer and
• The largest increases between the two time five-year net survival and five-year conditional
thyroid cancer. There is also little provincial
periods were for chronic myeloid leukemia net survival for these cancers. For example,
variation in five-year survival for prostate cancer
(25 percentage points), acute lymphocytic given the high one-year net survival for breast
with the exception of a relatively low predicted
leukemia (23 percentage points) and multiple cancer (97%), there was only a 2-point
estimate for Saskatchewan (86%).
myeloma (23 percentage points), followed difference between the five-year net survival
• There is more variation in survival estimates by non-Hodgkin lymphoma (21 percentage (88%) and the five-year conditional net survival
for certain cancers. Colorectal cancer estimates points) and chronic lymphocytic leukemia (91%) for this cancer.
range from 62% (Nova Scotia) to 68% (17 percentage points).
(Newfoundland and Labrador). Lung cancer
estimates range from 18% (Saskatchewan)
Conditional net survival Conditional net survival
to 24% (Ontario). Pancreatic cancer A measure that reflects improvements in
estimates range from 7% (British Columbia) Conditional survival is often more meaningful for prognosis for people who have already
to 12% (Ontario). clinical management and prognosis than the five- survived a given number of years (e.g., one
year survival measured from the date of diagnosis.(14) year) since diagnosis. This is measured in
• Some of this variation may reflect variations Since the risk of death due to cancer is often
in the stage at which cancers are typically the hypothetical situation where the cancer
greatest in the first few years after diagnosis of interest is the only possible cause of death.
diagnosed in different provinces.(13) (Figure 3.1), prognosis can substantially improve
among people surviving one or more years.
Survival over time For these people, the five-year net survival
measured at diagnosis (Table 3.1) no longer
Examining trends in net survival alongside trends
applies. Table 3.5 shows the five-year predicted
in incidence and mortality can give important
conditional net survival, which is calculated from
information about progress in cancer treatment
the date of cancer diagnosis among people who
and control. Figure 3.2 shows the predicted
have survived the first year after their cancer
change in five-year age-standardized net survival
diagnosis. It also presents one-year predicted net
since the 1992–1994 period.
survival.
• Survival for all cancers combined rose by 9
• Typically, the largest differences between
percentage points, from 55% in 1992–1994 to
five-year net survival and five-year conditional
64% in 2015–2017.
net survival were for cancers with a relatively
• Survival has increased for most cancers but has low one-year survival. The largest difference
remained virtually unchanged for uterine cancer. was observed for acute myeloid leukemia, for
which the five-year conditional survival was
51%, 28 percentage points higher than the

AR01692
What do these statistics mean? Nonetheless, lung cancer survival has improved References
in recent years(7) with advances in treatment, 1. Coleman MP. Cancer survival: Global surveillance will stimulate health policy and
Survival statistics are important indicators of the including the increasing use of targeted therapy improve equity. Lancet. 2014;383(9916):564–73.
effectiveness of cancer detection and treatment. drugs, playing a role.(17) This improvement has
2. Dickman PW, Adami HO. Interpreting trends in cancer patient survival. J Intern Med.
2006;260(2):103–17.
A number of factors influence survival, including been identified as a key factor in the recent 3. Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more
sex (females have better survival than males), age improvement in survival for all cancers combined.(7) up-to-date estimates of long-term survival rates: Empirical evaluation among 370,000
cancer patients in Finland. Int J Epidemiol. 2002;31(2):456–62.
(survival typically decreases with age) and access The anticipated introduction of lung cancer 4. Brenner H, Gefeller O, Hakulinen T. Period analysis for “up-to-date” cancer survival
to quality care (which can vary between regions). screening programs in Canada in the near future data: Theory, empirical evaluation, computational realisation and applications. Eur J
Cancer. 2004;40(3):326–35.
Fortunately, we are making progress. Cancer may increase early detection of the disease, 5. Statistics Canada [Internet]. Cancer survival statistics, 2020 update. Ottawa, ON; 2020.
survival has improved for most cancers over the potentially leading to further improvements in Available at: https://www150.statcan.gc.ca/n1/daily-quotidien/201127/dq201127b-
eng.htm (accessed April 2021).
last 20 to 25 years in Canada. The most notable survival. With pancreatic cancer, research in
6. Ellison LF. Progress in net cancer survival in Canada over 20 years. Health Rep.
improvements have been for blood-related improving early detection and treatment is key 2018;29(9):10–8.
cancers, including leukemia and non-Hodgkin to improving survival. 7. Ellison LF. The cancer survival index: Measuring progress in cancer survival to help
evaluate cancer control efforts in Canada. Health Rep. 2021; 32(9):14–26.
lymphoma, which can be largely attributed to Continuing to monitor cancer survival by sex, age, 8. Ellison LF. Differences in cancer survival in Canada by sex. Health Rep. 2016;27(4):
19–27.
improvements in treatment.(15,16) geography and time helps point to areas where 9. Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JW. Competing mortality in
While colorectal cancer survival has also greater efforts are required to detect, diagnose patients diagnosed with bladder cancer: Evidence of undertreatment in the elderly and
female patients. Br J Cancer. 2013;108(7):1534–40.
improved, its five-year survival is still only 67%. and treat cancer, or where more research is 10. National Cancer Institute [Internet]. International Classification of Childhood Cancer
This likely reflects that fact that almost 50% of needed to develop better treatments. (ICCC) Recode ICD-0-3/WHO 2008. Bethesda, MD: Surveillance Epidemiology, and End
Results Program (SEER); 2008. Available at: https://seer.cancer.gov/iccc/iccc-who2008.
colorectal cancers are diagnosed at stage III html (accessed April 2021).
or IV.(13) However, population-based colorectal Supplementary resources 11. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of
Childhood Cancer, third edition. Cancer. 2005;103(7):1457–67.
cancer screening programs exist across the Cancer.ca/statistics houses supplementary 12. Ellison LF, Xie L, Sung L. Trends in paediatric cancer survival in Canada, 1992 to 2017.
country. With increased participation in these resources for this chapter. This includes: Health Rep. 2021;32(2):3–15.
13. Canadian Cancer Statistics Advisory Committee [Internet]. Canadian Cancer Statistics
programs, it is expected that more cancers will be
• Excel spreadsheets with the statistics used to 2018. Toronto, ON: Canadian Cancer Society; 2018. Available at: www.cancer.ca/
diagnosed early and colorectal cancer survival will Canadian-Cancer-Statistics-2018-EN (accessed April 2021).
create the figures 14. Ellison LF, Bryant H, Lockwood G, Shack L. Conditional survival analyses across cancer
increase. This is based on cancers such as female sites. Health Rep. 2011;22(2):21–5.
breast, where most cases are diagnosed early(13) • Excel spreadsheets with supplementary 15. Ellison LF. Increasing survival from leukemia among adolescents and adults in Canada:
and survival is high, which likely reflects the statistics. For example, in order to help A closer look. Health Rep. 2016;27(7):19–26.
16. Awad K, Dalby M, Cree IA, Challoner BR, Ghosh S, Thurston DE. The precision
success of well-established screening programs. facilitate international comparison of survival medicine approach to cancer therapy: Part 2 — haematological malignancies. The
estimates with Canada, online Table S3.1 Pharmaceutical Journal. 2020.
Despite these notable successes, there remains presents sex-specific survival estimates for 17. Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, et al. The effect
of advances in lung-cancer treatment on population mortality. N Engl J Med.
a lot of room for improvement because some
selected cancers that were age-standardized 2020;383(7):640–9.
cancers continue to have low net survival. These 18. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age
using both the Canadian Standard Weights
include lung cancer — the most commonly standardising survival ratios. Eur J Cancer. 2004;40(15):2307–16.
diagnosed cancer and leading cause of cancer and the International Cancer Survival Standard
death in Canada — and pancreatic cancer, (ICSS) weights.(18)
which is a less commonly diagnosed cancer • PowerPoint images of the figures used
but is projected to be the third leading cause of throughout this chapter
cancer death in Canada in 2021. The low survival
probabilities for these cancers are largely reflected
in the late stage at which they are diagnosed.(13)

AR01693
TABLE 3.1 Predicted five- and 10-year net survival for selected cancers by sex, ages 15–99, Canada (excluding Quebec*),
2015–2017
5-year net survival (%) (95% CI) 10-year net survival (%) (95% CI)
All cancers† 64 (64–64) 62 (62–62) 66 (66–66) 58 (57–58) 55 (55–56) 60 (59–60)
Thyroid 97 (97–98) 95 (93–96) 98 (98–99) 97 (96–98) 93 (91–95) 99 (98–99)
Testis — 97 (96–98) — — 96 (95–97) —
Prostate — 91 (91–92) — — 88 (87–88) —
Melanoma 89 (88–90) 86 (85–88) 92 (91–93) 85 (84–87) 82 (79–84) 90 (87–92)
Breast 89 (88–89) 76 (70–81) 89 (88–89) 82 (81–83) 60 (50–69) 82 (82–83)
Hodgkin lymphoma 85 (83–87) 84 (81–86) 86 (84–89) 81 (79–83) 80 (76–82) 82 (79–85)
Uterus (body, NOS) — — 82 (82–83) — — 80 (79–81)
Bladder‡ 77 (76–77) 77 (76–78) 75 (73–77) 66 (64–68) 65 (63–67) 69 (66–72)
Cervix — — 74 (72–75) — — 68 (67–70)
Kidney and renal pelvis 73 (72–74) 73 (71–74) 73 (71–74) 64 (63–66) 64 (62–66) 64 (62–66)
Non–Hodgkin lymphoma 69 (69–70) 68 (67–69) 71 (70–73) 61 (60–62) 59 (57–60) 64 (62–65)
Colorectal 67 (66–67) 66 (66–67) 67 (66–68) 61 (60–61) 60 (59–61) 61 (60–62)
Rectum 67 (67–68) 67 (66–68) 69 (67–70) 60 (59–62) 59 (57–60) 64 (61–66)
Colon 66 (66–67) 66 (65–67) 66 (65–67) 61 (60–62) 62 (60–63) 60 (59–62)
Head and neck 64 (63–65) 64 (63–65) 65 (63–67) 56 (55–57) 56 (54–57) 57 (54–60)
Leukemia 61 (60–62) 60 (59–62) 61 (60–63) 52 (50–53) 51 (49–53) 53 (50–56)
Chronic lymphocytic leukemia 86 (85–88) 84 (82–86) 89 (86–91) 73 (70–76) 70 (67–74) 77 (72–82) — Not applicable; CI=confidence interval; CNS=central nervous
Chronic myeloid leukemia 58 (56–61) 55 (52–59) 63 (59–67) 49 (46–53) 46 (42–51) 54 (49–59) system; NOS=not otherwise specified
Acute lymphocytic leukemia 47 (42–51) 51 (44–57) 42 (35–48) 41 (36–46) 44 (38–51) 37 (29–45) * Quebec is excluded because cases diagnosed in Quebec from
2011 onward had not been submitted to the Canadian Cancer
Acute myeloid leukemia 23 (22–25) 22 (19–24) 26 (23–29) 20 (19–22) 19 (17–21) 23 (20–25) Registry.
Ovary — — 44 (43–45) — — 35 (33–36)
† Estimates for all cancers combined were calculated as a
Multiple myeloma 50 (49–52) 50 (48–52) 51 (48–53) 30 (28–32) 28 (26–31) 32 (29–35) weighted average of sex–specific estimates for individual cancers.
Stomach 29 (28–30) 27 (26–29) 32 (30–34) 25 (24–27) 23 (21–25) 29 (26–32) For further details, see Appendix II: Data sources and methods.
Lung and bronchus 22 (22–23) 19 (18–19) 26 (25–26) 15 (15–16) 13 (12–13) 18 (17–19) ‡ Ten year net survival for bladder cancer does not include in situ
cases for Ontario diagnosed prior to 2010 because they were not
Liver 22 (21–23) 22 (21–23) 22 (20–25) 16 (15–18) 16 (14–18) 18 (15–21)
submitted to the Canadian Cancer Registry.
Brain/CNS 22 (21–23) 21 (20–22) 23 (21–24) 17 (16–18) 16 (15–17) 18 (16–20)
Note: Estimates associated with a standard error > 0.05 and
CNS 61 (54–67) 61 (51–70) 59 (49–67) 51 (44–58) 50 (40–60) 51 (41–60) ≤ 0.10 are italicized. The complete definition of the specific
Brain 20 (19–21) 19 (18–21) 20 (19–22) 15 (14–16) 14 (13–16) 16 (14–17) cancers listed here can be found in Table A1.
Esophagus 16 (15–18) 16 (15–18) 17 (15–20) 13 (11–14) 12 (11–14) 14 (12–17) Analysis by: Centre for Population Health Data, Statistics Canada
Data sources: Canadian Cancer Registry death linked file (1992–2017)
Pancreas 10 ( 9–10) 10 ( 9–11) 9 ( 9–10) 8 ( 7– 9) 8 ( 7– 9) 8 ( 7– 9)
and life tables at Statistics Canada

AR01694
TABLE 3.2 Predicted five-year net survival for selected cancers by age group, Canada (excluding Quebec*), 2015–2017
Net survival (%) (95% CI)
Age group Breast Lung and
(years) Prostate (female) Colorectal bronchus Thyroid Melanoma
15–44 94 (88–97) 88 (87–89) 74 (73–76) 43 (38–47) 100 (99–100) 95 (94–96)
45–54 96 (95–97) 91 (91–92) 73 (72–74) 29 (28–31) 99 (98–99) 94 (92–95)
55–64 97 (96–97) 91 (90–91) 71 (70–72) 26 (25–27) 98 (97–98) 91 (89–92)
65–74 95 (95–96) 91 (90–92) 70 (69–71) 24 (24–25) 95 (93–96) 90 (89–92)
75–84 85 (84–86) 85 (83–86) 62 (61–63) 19 (18–20) 92 (86–95) 83 (81–86)
85–99 52 (49–56) 73 (70–77) 50 (47–52) 11 ( 9–12) 57 (41–70) 75 (68–80)

Age group Uterus Kidney and Non–Hodgkin
(years) (body, NOS) Bladder renal pelvis lymphoma Pancreas
15–44 91 (88–93) 91 (87–93) 92 (90–94) 86 (84–87) 43 (37–49)
45–54 88 (87–90) 86 (84–88) 85 (84–87) 83 (82–85) 21 (18–23)
55–64 88 (87–89) 83 (82–85) 77 (76–79) 78 (77–80) 12 (10–13)
65–74 81 (79–82) 81 (79–82) 73 (71–75) 72 (70–73) 9 ( 8–10)
75–84 69 (67–72) 74 (72–75) 59 (57–62) 56 (55–58) 6 ( 5–7)
85–99 56 (49–63) 58 (54–62) 33 (27–38) 42 (38–46) 2 ( 1–4)
CI=confidence interval; NOS=not otherwise specified
* Quebec is excluded because cases diagnosed in Quebec from 2011 onward had not been submitted to the
Canadian Cancer Registry.
Note: Estimates associated with a standard error > 0.05 and ≤ 0.10 are italicized. The complete definition of the
specific cancers listed here can be found in Table A1.

AR01695
TABLE 3.3 Predicted one- and five-year observed survival proportions by diagnostic group
and selected subgroups, ages 0–14 at diagnosis, Canada (excluding Quebec*), 2013–2017
OSP (%) (95% CI)
Diagnostic group †
1-year 5-year
All groups‡ 93 (92–93) 84 (83–85)
I. Leukemias, myeloproliferative diseases, and myelodysplastic diseases 95 (93–96) 88 (87–90)
a. Lymphoid leukemias 97 (96–98) 93 (92–95)
b. Acute myeloid leukemias 81 (74–86) 65 (57–71)
II. Lymphomas and reticuloendothelial neoplasms 96 (94–97) 92 (89–94)
a. Hodgkin lymphomas 99 (95–100) 99 (95–100)
b. Non-Hodgkin lymphomas (except Burkitt lymphoma) 93 (89–96) 84 (78–89)
c. Burkitt lymphoma 97 (89–99) 94 (84–98)
III. CNS and miscellaneous intracranial and intraspinal neoplasms 84 (81–87) 72 (69–75)
b. Astrocytomas 88 (84–91) 82 (78–86)
c. Intracranial and intraspinal embryonal tumours 85 (79–90) 71 (64–78)
IV. Neuroblastoma and other peripheral nervous cell tumours 96 (92–97) 84 (79–88)
V. Retinoblastoma 100 ( ..– ..) 94 (85–98)
VI. Renal tumours 98 (95–99) 96 (91–98)
a. Nephroblastoma and other non-epithelial renal tumours 98 (95–99) 96 (92–98)
VII. Hepatic tumours 84 (71–92) 72 (58–82)
VIII. Malignant bone tumours 97 (92–99) 72 (64–78)
IX. Soft tissue and other extraosseous sarcomas 90 (85–93) 70 (64–76)
a. Rhabdomyosarcomas 92 (85–96) 69 (60–77)
X. Germ cell tumours, trophoblastic tumours, and neoplasms of gonads 92 (86–96) 91 (85–95)
b. Malignant extracranial and extragonadal germ cell tumours 91 (75–97) 91 (75–97)
c. Malignant gonadal germ cell tumours 97 (83–100) 97 (83–100)
XI. Other malignant epithelial neoplasms and malignant melanomas 96 (92–98) 92 (86–95)
XII. Other and unspecified malignant neoplasms 80 (55–92) 80 (55–92)
.. estimate cannot be calculated; OSP=observed survival proportion; CI=confidence interval;
CNS=central nervous system
* Quebec is excluded because cases diagnosed in Quebec from 2011 onward had not been submitted
to the Canadian Cancer Registry.
† Cancers were classified according to the Surveillance, Epidemiology, and End Results Program (SEER)
update of the International Classification of Childhood Cancer, Third Edition (ICCC-3).(11) Only selected
subgroups within each diagnostic group are listed.
‡ Estimates for all childhood cancers combined were calculated as a weighted average of sex- and
diagnostic group–specific estimates. For further details, see Appendix II: Data sources and methods.
Note: Estimates associated with a standard error >0.05 and ≤0.10 are italicized.
Data source: Canadian Cancer Registry death linked file (1992–2017). Adapted from Table 2 in Ellison LF, Xie L,
Sung L. Trends in paediatric cancer survival in Canada, 1992 to 2017. Health Reports 2021; Feb 17; 32(2):3–15.

AR01696
TABLE 3.4 Predicted five-year age-standardized net survival for selected cancers by province, ages 15–99, Canada (excluding Quebec*), 2015–2017
Breast Lung and Uterus
Province Prostate Colorectal Thyroid Melanoma
(female) bronchus (body, NOS)
Canada* 91 (91–92) 89 (88–89) 66 (66–67) 22 (22–23) 98 (97–98) 89 (88–90) 83 (82–83)
British Columbia (BC) 91 (90–92) 88 (87–89) 67 (66–68) 21 (20–21) 95 (93–96) 90 (88–91) 83 (81–85)
Alberta (AB) 91 (90–92) 89 (88–90) 67 (65–68) 22 (20–23) 97 (95–98) 88 (85–90) 83 (81–85)
Saskatchewan (SK) 86 (84–88) 88 (86–89) 64 (62–67) 18 (17–20) 95 (91–97) 87 (82–91) 87 (83–91)
Manitoba (MB) 91 (89–93) 88 (86–89) 64 (61–67) 22 (20–24) 97 (93–99) 90 (84–94) 85 (82–88)
Ontario (ON) 92 (92–93) 89 (88–89) 67 (66–67) 24 (23–24) 98 (98–99) 89 (88–90) 82 (81–83)
New Brunswick (NB) 91 (88–93) 88 (86–91) 63 (60–65) 21 (20–23) 98 (93–99) 93 (87–96) 83 (78–87)
Nova Scotia (NS) 90 (88–92) 89 (86–90) 62 (60–64) 20 (18–22) 95 (91–97) 91 (86–94) 77 (73–81)
Prince Edward Island (PE) 88 (82–93) 90 (84–94) 67 (60–73) .. 91 (62–98) 82 (72–88) 79 (67–87)
Newfoundland and Labrador (NL) 91 (87–93) 89 (85–91) 68 (65–71) 23 (20–26) 97 (93–98) 87 (78–92) 88 (82–92)

Kidney and Non-Hodgkin
Province Bladder Pancreas
renal pelvis lymphoma
Canada* 77 (76–77) 72 (72–73) 69 (69–70) 10 ( 9–10)
British Columbia (BC) 75 (73–77) 69 (67–72) 69 (67–71) 7 ( 6– 8)
Alberta (AB) 77 (74–80) 71 (68–74) 70 (67–72) 9 ( 8–11)
Saskatchewan (SK) 73 (68–77) 65 (60–69) 70 (65–74) 9 ( 7–12)
Manitoba (MB) 72 (67–77) 66 (62–70) 69 (65–73) 11 ( 9–15)
Ontario (ON) 77 (76–78) 76 (75–77) 70 (69–71) 12 (11–13)
New Brunswick (NB) 75 (70–80) 71 (66–75) 70 (65–74) ..
Nova Scotia (NS) 77 (72–82) 69 (65–73) 66 (62–70) 9 ( 7–12)
Prince Edward Island (PE) 68 (55–78) .. 67 (52–78) ..
Newfoundland and Labrador (NL) 82 (73–88) 70 (64–75) 69 (63–75) ..
.. estimate can not be calculated as one or more of the age-specific estimates are undefined; CI=confidence interval; NOS=not otherwise specified
* Quebec is excluded because cases diagnosed in Quebec from 2011 onward have not been submitted to the Canadian Cancer Registry.
Note: Estimates were age-standardized using the Canadian Cancer Survival Standard weights. For further details, see Appendix II: Data sources and methods. The complete
definition of the specific cancers listed here can be found in Table A1. Estimates associated with a standard error > 0.05 and ≤ 0.10 are italicized.

AR01697
TABLE 3.5 Predicted net survival for one year and for five years from diagnosis (conditional on having survived one year),
for selected cancers, by sex, ages 15–99, Canada (excluding Quebec*), 2015–2017
1-year net survival (%) (95% CI) 5-year conditional net survival (%) (95%CI)
Both Sexes Males Females Both sexes Males Females
Thyroid 98 (98–98) 96 (96–97) 99 (98–99) 99 (99–100) 98 (97–99) 100 (99–100)
Testis — 98 (98–99) — — 98 (97–99) —
Prostate — 97 (97–98) — — 94 (93–94) —
Breast 97 (97–97) 96 (92–98) 97 (97–97) 91 (91–92) 79 (73–84) 91 (91–92)
Melanoma 97 (96–97) 96 (95–96) 98 (97–98) 92 (91–93) 90 (89–91) 94 (93–95)
Uterus (body, NOS) — — 93 (92–93) — — 89 (88–90)
Hodgkin lymphoma 91 (90–92) 90 (88–91) 93 (91–94) 93 (92–95) 93 (91–95) 93 (91–95)
Bladder 89 (89–90) 91 (90–91) 85 (84–86) 86 (85–87) 85 (84–86) 88 (87–90)
Cervix — — 89 (88–90) — — 82 (81–84)
Kidney and renal pelvis 85 (85–86) 86 (85–87) 85 (83–86) 85 (84–86) 85 (83–86) 86 (85–88)
Colorectal 84 (83–84) 84 (84–85) 83 (82–83) 80 (79–80) 79 (78–79) 81 (80–82)
Rectum 87 (87–88) 88 (87–88) 87 (86–88) 77 (76–78) 76 (75–77) 79 (78–81)
Colon 82 (81–82) 83 (82–83) 81 (81–82) 81 (80–82) 80 (79–81) 82 (81–83)
Head and neck 83 (83–84) 84 (83–85) 82 (81–84) 77 (76–78) 76 (75–78) 79 (77–81)
Non–Hodgkin lymphoma 81 (81–82) 81 (80–82) 82 (81–83) 85 (84–86) 84 (83–85) 87 (86–88)
Multiple myeloma 80 (78–81) 79 (78–81) 80 (78–81) 63 (62–65) 63 (61–66) 64 (61–66)
Ovary — — 76 (75–77) — — 57 (56–59)
Leukemia 75 (74–76) 76 (75–77) 74 (73–75) 81 (80–82) 80 (78–81) 83 (81–84)
Chronic lymphocytic leukemia 94 (94–95) 94 (93–95) 95 (93–96) 91 (90–93) 90 (87–91) 94 (91–96)
Chronic myeloid leukemia 81 (79–83) 79 (76–82) 83 (80–86) 72 (69–75) 70 (66–74) 76 (71–80)
Acute lymphocytic leukemia 67 (63–71) 69 (64–74) 64 (58–70) 70 (64–75) 73 (65–79) 65 (56–72)
Acute myeloid leukemia 46 (44–48) 45 (43–48) 46 (44–49) 51 (48–54) 48 (43–52) 56 (51–60)
Stomach 53 (52–54) 53 (51–54) 53 (51–55) 55 (53–57) 52 (50–54) 61 (57–64) —not applicable; CI=confidence interval; CNS=central nervous
system; NOS=not otherwise specified
Liver 50 (48–51) 51 (49–52) 47 (44–49) 45 (42–47) 44 (41–46) 48 (43–52)
* Quebec is excluded because cases diagnosed in Quebec from
Brain/CNS 49 (48–50) 49 (47–50) 50 (47–52) 44 (42–46) 43 (40–46) 45 (42–48)
2011 onward have not been submitted to the Canadian Cancer
CNS 79 (73–84) 81 (73–87) 76 (67–83) 77 (70–82) 76 (65–84) 77 (67–84) Registry.
Brain 48 (46–49) 47 (46–49) 48 (46–50) 41 (39–43) 41 (38–43) 42 (39–45) Note: The complete definition of the specific cancers listed here
Lung and bronchus 48 (48–49) 44 (43–44) 53 (52–53) 46 (45–47) 43 (42–44) 49 (48–50) can be found in Table A1.
Esophagus 45 (44–47) 46 (44–47) 43 (40–46) 37 (34–39) 36 (33–38) 40 (35–45) Analysis by: Centre for Population Health Data, Statistics Canada
Data sources: Canadian Cancer Registry death linked file (1992–2017)
Pancreas 31 (30–32) 32 (31–33) 30 (29–32) 32 (30–33) 32 (29–35) 31 (29–34)
and life tables at Statistics Canada

AR01698 4
Chapter
Cancer in context: The cancer burden in Canada
Cancer is the leading cause of FIGURE 4.1 Proportion of deaths due to cancer and other causes, Canada, 2019
death in Canada
Cancer poses an enormous burden on both the
health of Canadians and the Canadian healthcare
system. This publication shows that 43% of
Canadians are expected to be diagnosed with Other Cancer
cancer in their lifetime and about one-quarter 29.4% 28.2%
are expected to die from the disease. In recent
years, the proportion of Canadians that die from
cancer has gone up compared to other causes of Kidney disease 1.3%
death. In fact, a significantly higher proportion of
Suicide 1.4%
Canadians die from cancer (28.2%) than any of
Alzheimer's disease 2.2% Heart disease
the other leading causes of death, including heart
18.5%
disease (18.5%), cerebrovascular diseases and Influenza and pneumonia 2.4%
accidents (4.8% each) (Figure 4.1). Diabetes 2.4%
Chronic lower respiratory diseases 4.5%

Cerebrovascular diseases 4.8%
Accidents 4.8%
Note: The total of all deaths in 2019 in Canada was 284,082

Data source: Statistics Canada. Table 13-10-0394-01 Leading causes of death, total population, by age group
(accessed November 26, 2020)

Chapter 4 • Cancer in context: The cancer burden in Canada
AR01699
Cancer is also the leading cause of premature FIGURE 4.2 Selected causes of death* and their associated potential years of life lost (PYLL), Canada, 2017–2019
death in Canada, which means that people
are dying from cancer at younger ages than
t
Males
the average age of death from other causes. Cancer
Premature mortality is often reported in terms
Accidents
of potential years of life lost (PYLL). PYLL is
an estimate of the additional number of years
♦
Heart disease Females
a person would have lived if they had not died
prematurely (e.g., before the age of 75). For Suicide
example, if a person dies from cancer at 60 years
of age, they have lost 15 potential years of life, Respiratory disease
while dying at 70 years of age results in 5 years
of life lost. During the period from 2017 to 2019, Cerebrovascular diseases * See Appendix II: Data sources
the PYLL for all cancers combined was about and methods for definitions of
HIV causes of death.
1,347,600 (Figure 4.2), which was considerably
Note: Causes are displayed in
higher than any of the other leading causes of 800 600 400 200 0 200 400 600 800 decreasing order of total PYLL
premature death in Canada. for males and females
PYLL (in thousands) combined.
Cancer is a complex disease Data sources: Canadian Vital Statistics Death Database at Statistics Canada
Cancer is a complex disease that is influenced

by many factors, including the environment,
lifestyle and genetics. Cancer is not just one
disease, but a group of more than 100 different cancer type and they are used to help determine cancer cells, the location of the primary tumour,
diseases characterized by uncontrolled growth of prognosis and plan treatment. The detailed how long it has been in the body, and the type
abnormal cells that have the propensity to invade categorization of cancer and the related cell types and effectiveness of available treatments. Once
nearby tissues. This abnormal cell growth can is essential for effective clinical management of a cancer has spread, it is more difficult to treat.
begin almost anywhere in the body, and it can different types of cancers. Some types of cells This can lead to lower survival rates for certain
behave differently depending on the origin. have a greater tendency to become cancerous cancers. For example, almost half of all lung
than others, leading to higher incidence rates for cancer cases diagnosed in Canada are stage IV
those cancers. This is one reason cancer in the (cancer has spread)(1) and, as a result, its survival
How cancers are categorized
breast, for example, is much more common than rate is very low.
Cancers are categorized based on the organ, cancer in the liver.
tissue or body system in which they originate
(primary site) and their cellular characteristics
How cancer is detected
(histology). Some cancer cells tend to grow
How cancer spreads Detecting cancer at an early stage can improve
and spread more slowly and look like normal Any type of cancer can spread (metastasize) from outcomes. Our ability to detect a cancer early
cells (low-grade cancer cells). Others look very the organ it originated in to another site in the depends on the availability and effectiveness
different from normal cells and tend to grow body. Whether or not and to what extent a cancer of screening and early detection tools, or on
and spread quickly (high-grade cancer cells). spreads will depend on several factors, such as the location and depth of the tumour and when
A different grading system is used for each the type of cancer, the aggressiveness of the symptoms become noticeable. This helps explain

AR01700
why cancer of the pancreas, which resides deep in subgroup rates and meaningfully compare the Cancer has a substantial
the body and is generally asymptomatic in early differences within the population are limited
stages, is detected so much later than cancer of or lacking. The collaborators involved in this
economic burden on Canadians
the testes.(1) Cancers that are more likely to be publication and other members of the cancer and Canadian society
detected early, such as breast cancer, have a much control community are investing in efforts to Cancer is a costly illness, which means that it
higher chance of survival than cancers that tend increase data collection and availability to address has major implications for people diagnosed
to be detected late, as is the case with lung cancer. these crucial gaps. For example, the Canadian with cancer, their families and Canadian society
Cancer Society is currently co-leading a pan- as a whole. It is difficult to obtain reliable
Canadian cancer data strategy with the Canadian measures of the true economic cost of cancer,
Cancer outcomes in Canada are Partnership Against Cancer (CPAC) that focuses and different approaches can produce a wide
among the best in the world on enhancing data collection, integration and range of estimates. A report in 2012 noted that
use to improve cancer control and outcomes for the costs of cancer care in Canada rose steadily
Comparable measures of cancer burden for
all people in Canada. The 2019–2029 Canadian over the period studied, from $2.9 billion in 2005
different countries can be found through various
Strategy for Cancer Control includes several to $7.5 billion in 2012.(9) Similarly, a study in the
international resources, such as those provided in
key investments in building capacity for data US estimated that the cost of cancer care would
Appendix I.(2–6) These resources generally indicate
collection by partners, including partners that increase by 27% between 2010 and 2020.(10) Given
that Canada compares favourably to other
have a focus on First Nation, Inuit and Métis the increasing number of cancer cases diagnosed
countries on several measures, including survival
populations. The Public Health Agency of Canada each year in Canada,(11) the cost of cancer care is
rates. For example, the recent International
and Statistics Canada are focused on better also likely to continue to rise for the foreseeable
Cancer Benchmarking Partnership (ICBP) study
integrating socio-economic and ethno-cultural future.
showed that Canada’s cancer survival rate ranks
data with cancer and outcome data in addition
among the highest in the world.(7) Ongoing
to recently launching important data collection The financial hardship of cancer in Canada goes
exploratory research through the ICBP is focused
initiatives. The Canadian Institute for Health beyond the physical and emotional challenges
on understanding why cancer outcomes vary
Information (CIHI) endorsed the collection of related to the disease because people with cancer
between countries. Areas of investigation include
race-based and ethnicity data in a publication also face significant financial pressures following
differences in access to diagnostics, optimal
from 2020 that outlines proposed standards the cancer diagnosis.(12–15) New research in Canada
treatments and healthcare system structures.(6)
of data collection to facilitate better reporting has shed light on the financial burden faced by
of population groups that typically experience many people with cancer and their families.(16)
Cancer outcomes are not evenly disparate access and outcomes. Together the The national survey, administered in 20 cancer
cancer control community is working to address centres across Canada, found that one-third of
distributed among Canadians these important gaps in data so that we can better survey respondents noted “somewhat, large,
Despite comparatively positive population-level identify disparities in outcomes for increased or worst possible” financial burden. They also
cancer outcomes in Canada, incidence, mortality attention and investment.(8) reported spending an average of 34% of their
and survival vary across socio-economic status, monthly income on cancer-related costs. This
racial, ethnic and under-represented population was particularly experienced by those with lower
groups. The comprehensive national estimates incomes. These challenges can result from a loss
included in this publication would require of income after diagnosis and an increase in day-
systematically collected and complete data to to-day costs caused by unforeseen expenses, such
provide the same detail of estimates by these as medical equipment, childcare, homecare and
and other important groups. At this time, the transportation fees.
data needed to rigorously estimate population

AR01701
Progress has been made but the For example, research shows that new and long- Research data also highlight some of the
term immigrant Canadians of racialized groups disparities in cancer survival for First Nations,
challenge continues have lower screening uptake and adherence to Inuit and Métis people. First Nations had poorer
There is no doubt that a lot of progress has been recommendations even in the presence of funded, survival than the general population in Canada
made in the fight against cancer, despite the high population-based screening programs.(21) for 14 of the 15 most common cancers, and this
burden of the disease. Today, more is known These screening disparities also follow socio- disparity could not be explained by income and
about what causes cancer, how it develops and economic and racial divisions within cities and rurality.(18,20,25) Data from the territories can also
how best to prevent and treat it. This progress towns, with lower uptake in neighbourhoods with shed some light on the experience of people who
is reflected by decreases in incidence rates over lower socio-economic status and higher numbers live in northern Canada, many of whom are First
time and even more so in trends in mortality of Black people and other racialized groups.(22) Nations, Inuit and Métis often at a great distance
rates, which have decreased more than 35% in Structural barriers that lower screening rates and to cancer care. Delivering healthcare services in
males and 20% in females since the cancer death access to appropriate care have also been noted remote areas like Nunavut can be challenging for
rate peaked in 1988 (Figure 4.3). for LGBTQ2S+ populations, which can potentially several reasons, including the size of the territory,
lead to differential outcomes.(23,24) dispersion of the small population, weather and
However, in addition to the continued high
burden of cancer, new challenges continue to ...................................................................................................................................................
arise. For example, colorectal cancer rates among FIGURE 4.3 Age-standardized incidence and mortality rates for all cancers combined, by sex, Canada,* 1984–2021
younger people are rising.(17) The reasons for
Rate (per 100,000)
this remain unclear and research is needed to
understand how we can mitigate this increase.
Addressing gaps in cancer control

Inequities in terms of access to care and
outcomes are also a challenge in Canada. For
700
600
500
•·
700
600
500
t .. Both sexes
Incidence
Mortality
i
Males
example, people in Canada with a lower income
Projected
400 400 Incidence
are more likely to be diagnosed with lung cancer,
more likely to be diagnosed with advanced stage 300 .......................'..'.'. '·" '·"·· ..·····.,., ............................ ..
; 300
Mortality
.::: ::::--:-~: ~ :..:::::::: ::::::::::::::::::~:::::::c:::::::::::::::::::

(stage III or IV) disease and less likely to survive
lung cancer.(18) Inequities in cancer outcomes can
be further exacerbated by the increasing costs of
emerging cancer treatments, some of which are
paid out of pocket. Limited data have shown that
some racialized groups face additional barriers
to accessing cancer care and experience worse
200
100
0
1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
200
100
0
t
(
Females
Incidence
Mortality
View data )
outcomes.(19,20) As noted above, systematically Year
collected racial and ethnicity-specific surveillance * Age-standardized incidence rates exclude data from Quebec.
data are lacking in Canada, creating a challenge Note: Rates are age-standardized to the 2011 Canadian standard population. Projected rates are based on long-term historic data and
to comprehensively quantify the cancer outcomes may not always reflect recent changes in trends. Incidence excludes non-melanoma skin cancer (neoplasms, NOS; epithelial neoplasms, NOS;
experienced in under-served communities. and basal and squamous). Actual incidence data were available to 2017 and projected thereafter. Actual mortality data were available to
2019; estimates for 2020–2021 were projected based on data up to 2018. For further details, see Appendix II: Data sources and methods.
However, data from targeted provincial analyses
Analyses by: Centre for Population Health Data, Statistics Canada
or research studies do provide some insights. Data sources: Canadian Cancer Registry, National Cancer Incidence Reporting System and Canada Vital Statistics Death Database at Statistics Canada

AR01702
reliance on air transportation. The territory’s FIGURE 4.4 Trends in new cases and deaths (in thousands) for all cancers and ages, attributed to changes in cancer risk and
25 communities are isolated and spread across cancer control practices, population growth and aging population, Canada, 1984–2021
the largest territory or province in Canada.
(26,27)
People living in Inuit Nunangat (Inuvialuit Incidence
New cases (in thousands)
Settlement Region, Nunavut, Nunavik and 250 250
Number of cancer cases or deaths
Nunatsiavut) are more than twice as likely to be that would have occurred if the
diagnosed with lung cancer than people living in 200 200
cancer risk, population size and age
structure remained the same as they
the rest of Canada.(27) Furthermore, individuals were in 1984.
in these communities must travel extensive
distances to access treatment not available locally. 150 Aging population 150 Number of new cancer cases or
cancer deaths that would have
To help drive needed changes in outcomes occurred if the population size and
Population growth
and experiences for all First Nations, Inuit and 100 100 age distribution remained the same
as they were in 1984.
Métis, the Canadian Strategy for Cancer Control (1984 cancer count) Changes in cancer risk
includes three Peoples-specific self-identified and cancer control practices
Projected
Number of new cancer cases or
priorities: culturally appropriate care closer to 50 50 cancer deaths that would have
occurred if the age distribution
home; peoples-specific, self-determined cancer remained the same as it was in 1984.
care; First Nations- Inuit- or Métis-governed 0 0
research and data systems. 1984 1988 1992 1996 2000 2004 2008 2012 2016 2020 Actual number of new cases and
Year deaths that occurred. Reflects impact
of changes in cancer risk and cancer
The challenge of a growing and Mortality
control practices, population growth
Deaths (in thousands) and aging population.
aging population 100 100
As presented in this publication, the total number

of new cases of cancer and the number of cancer 80 80
deaths continues to increase each year in Canada,
Aging population
a phenomenon that can largely be explained by
60 60
the aging and growing population.
Population growth
Figure 4.4 illustrates how the number of new 40

40
cases of cancer and deaths from cancer each year (1984 cancer death)
Changes in cancer risk
are affected by changes in cancer risk factors and and cancer control practices
Projected
cancer control practices, the aging population 20 20
and population growth. Since 1984, changes in
cancer risks and cancer control practices have 0
0
had a small influence on reducing the overall 1984 1988 1992 1996 2000 2004 2008 2012 2016 2020
number of cancer cases diagnosed. But they have Year
had a more meaningful influence on reducing Note: New cases exclude non-melanoma skin cancer (neoplasms, NOS; epithelial neoplasms, NOS; and basal and squamous).
the number of Canadians who die from cancer. Actual incidence data was available to 2017 for all provinces and territories except Quebec and mortality data to 2019 for all
provinces and territories except Yukon. For further details, see Appendix II: Data sources and methods. The range of scales differs
Unfortunately, this progress has been outweighed between the graphs.
by the impact of population aging, followed Analyses by: Centre for Surveillance and Applied Research, Public Health Agency of Canada
by population growth, both of which have Data sources: Canadian Cancer Registry, National Cancer Incidence Reporting System and Canadian Vital Statistics Death Database at Statistics Canada
contributed to a dramatic increase in the number

AR01703
of cancer cases and cancer deaths each year. FIGURE 4.5 Summary of key cancer control and outcome characteristics by cancer type
Because the Canadian population is continuing Preventability Detectability Incidence Survival Mortality
to grow and age,(28) the average annual number Lung and bronchus
of cancer cases is projected to be 79% higher Breast
in 2028–2032 than it was in 2003–2007.(11,29) Colorectal
As a result, the Canadian healthcare system is Prostate
expected to continue to face increasing demand Bladder
for cancer services, including diagnostics,
Non-Hodgkin lymphoma
treatment and palliative care.
Melanoma
In addition, an increasing percentage of
Canadians are surviving their cancer diagnosis,
meaning there is an increasing number of cancer
survivors in the population. Individuals who
-----!- __
Head and neck
Pancreas
-
Uterus (body, NOS)
Kidney and renal pelvis
- - -
survive a cancer diagnosis often go on to live
productive and rewarding lives, but the cancer
experience presents many physical, emotional,
spiritual and financial challenges that can persist
long after the disease is treated.(30) This growing
population of survivors will require continued
------------J-
_
Leukemia_ _ _ _
Thyroid
Stomach
Multiple myeloma
Liver
Brain/CNS
,
support and services.

Ovary
Esophagus
How statistics can help guide Cervix
cancer control Testis
Hodgkin lymphoma
The wide variation we observe in incidence,
mortality and survival across cancers reflects the CNS=central nervous system; NOS=not otherwise specified
complexity of the disease. But additional factors Preventability — Relative ratings are assigned to each cancer site based primarily on the population attributable risk reported by Canadian
must also be taken into account when assessing Population Attributable Risk of Cancer (ComPARe) study. Green represents cancers for which it is estimated that at least 50% of cancers are
preventable or for which screening programs can detect treatable precancerous lesions, yellow where 25%–49% are preventable and red
how to address the ongoing burden of cancer in
where less than 25% are preventable. Where information was not available through ComPARe, Cancer Research UK was used.
Canada. For example, prevention, screening and
Detectability — Relative ratings were assigned as green if organized screening programs are available in Canada, yellow if opportunistic
early detection, treatment and survivorship all early detection is available and red if no organized screening and limited early detection procedures are available.
play an important role in the fight against cancer. Incidence — Relative ratings were assigned as green if there were less than 5,000 cases, yellow if there were less than 15,000 cases and
red if there at least 15,000 cases in 2021 (Table 1.2).
Figure 4.5 presents a simplified approach to Survival — Relative ratings are assigned based on predicted five-year net survival probabilities listed in Table 3.1. Red represents a survival of
categorizing cancers based on their relative less than 50%, yellow represents 50%–79% and green represents 80% or more.
burden in Canada and the extent to which Mortality — Relative ratings were assigned as green if there were less than 1,000 deaths, yellow if there were 1,000–4,000 deaths and red if
there were more than 4,000 deaths in 2021 (Table 2.2).
they can be prevented and detected early. The
figure displays a relative rating for the most
commonly diagnosed cancer types in relation

AR01704
to their preventability, detectability, incidence, Cervical cancer is almost entirely preventable Because of additional prevention opportunities
survival and mortality using the statistics in this through human papillomavirus (HPV) vaccination. that currently exist through HPV vaccination and
publication and information about modifiable risk The World Health Organization’s goal to eliminate further improvements in screening, many believe
factors and early detection programs. cervical cancer this century has been widely this cancer could be virtually eradicated in some
adopted globally. Canada has set an ambitious countries.(38)
It is recognized that other measures, such as the target to eliminate cervical cancer by 2040
PYLL and economic impacts described earlier, through coordinated efforts to improve HPV
must be considered when assessing the cancer
Incidence, survival and mortality
vaccination rates and replace traditional Pap
burden. Also, this approach does not take into There are many cancers with low to medium
testing with HPV primary screening.(36) The Action
account the fact that less common cancers and incidence rates that are considered medium to
Plan to Eliminate Cervical Cancer in Canada,
pediatric cancers can still have a devastating high burden because they do not have definitively
2020–2030, describes how a broad group of
impact on people with cancer and their families. preventable risk factors, are not easily detected
partners, experts and stakeholders, including the
Despite these limitations, Figure 4.5 aims to through current diagnostic modalities and do not
Public Health Agency of Canada, as well as First
illustrate that, when assessed together, the have noticeable early symptoms. As a result, these
Nations, Inuit and Métis organizations and people
statistics reported in this publication can be used cancers tend to be diagnosed at a later stage, have
with cancer, plan to close the gaps in equitable
to highlight gaps and opportunities in population- limited treatment options and have low survival.
access to immunization, screening and follow-up
based cancer control strategies and identify Examples include brain and pancreatic cancers.
of abnormal screening results.
priority areas for clinical and health services It is important to note that the development
research. and progression of these cancers are not as
Detectability well understood as other cancers because the
Detecting cancer early (e.g., through screening short survival time makes it difficult to conduct
Preventability tests) and being treated for precancerous meaningful clinical research. Nevertheless, there
The World Health Organization suggests that conditions can significantly reduce the burden is a need to intensify efforts to better understand
prevention offers the most cost-effective, long- of some cancers. Organized screening programs the etiology of these diseases and identify more
term strategy for controlling cancer and other exist in most provinces and territories for breast, effective diagnostic and treatment strategies to
non-communicable diseases.(31) Research suggests cervical and colorectal cancers, which is reducing reduce the burden.
that a large number of cancers can be prevented the burden of these diseases. Lung cancer
through reductions in exposure to adverse screening for high-risk populations has been On the other side of the spectrum are thyroid and
environmental, behavioural and infectious explored in several provinces through pilots and prostate cancers, which have high incidence rates
factors.(32) Efforts to reduce cancer risk through research trials demonstrating that it is feasible, but good survival. However, both of these cancers
the implementation of prevention programs scalable and cost-effective in reducing lung have come under scrutiny for over-diagnosis.(39,40)
targeted at both the individual and the population cancer mortality. It is expected that provinces will Given the significant toll each diagnosis takes
level can have a substantial impact on the future begin to roll out these programs over the coming on individuals and the healthcare system, when
cancer burden in Canada. For example, the years. The widespread adoption of population- and how cancers are diagnosed and treated must
Canadian Cancer Society and Cancer Partnership based screening has had a meaningful impact on always be taken into careful consideration.
Against Cancer have collaborated on a national the incidence and mortality of several common
smoking cessation initiative targeting First cancers in Canada. For example, cervical
Nations, Inuit and Metis communities, which cancer once had high incidence and mortality
have significantly higher rates of smoking than rates.(37) But due to the success of widespread
non-Indigenous populations.(33–35) cervical cancer screening, it now has a moderate
incidence rate and relatively low mortality rate.

AR01705
The impact of COVID-19 on cancer Summary References

statistics Despite the limitations of the approach taken 1. Canadian Cancer Statistics Advisory Committee [Internet]. Canadian Cancer Statistics
2018. Toronto, ON: Canadian Cancer Society; 2018. Available at: www.cancer.ca/
Throughout the COVID-19 pandemic, cancer in generating Figure 4.5, it is an example of Canadian-Cancer-Statistics-2018-EN (accessed April 2021).
control efforts across the spectrum have been an exercise that can help focus cancer control 2. International Agency for Research on Cancer [Internet]. Global Cancer Observatory
(GCO). Available at: http://gco.iarc.fr/ (accessed April 2021).
impacted. Given the disproportionate impact efforts. It also helps reinforce that measures of 3. Forman D, Bray F, Brewster DH, Gombe Mbalawa C, Kohler B, Pineros M, et al.
of the pandemic on Black people and people of cancer burden must be assessed in a variety of [Internet]. Cancer Incidence in Five Continents, vol. X (electronic version). IARC; 2013.
Available at: http://ci5.iarc.fr/ (accessed April 2021).
colour,(41,42) it is likely they have also experienced ways and alongside each other. They also need 4. Ferlay J, Colombet M, Bray F [Internet]. Cancer Incidence in Five Continents, CI5plus.
greater access challenges and adverse outcomes. to be examined in relation to the extent to which Lyon, France: IARC; 2018. Available at: http://ci5.iarc.fr (accessed April 2021).
The projections in this publication do not account we are currently able to reduce the burden 5. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. [Internet].
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of
for any changes in diagnosis or cancer control through improved primary prevention, timely individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322
due to COVID-19 as they are based on data up to and effective early detection and screening, and population-based registries in 71 countries. 2018 [updated Jan 30]. Available at: http://
www.ncbi.nlm.nih.gov/pubmed/29395269 (accessed April 2021).
2017 for incidence and 2018 for mortality. Several evidence-based and person-centred diagnosis and 6. Cancer Research UK [Internet]. International Cancer Benchmarking Partnership (ICBP).
initiatives are underway at the provincial and treatment. Such comprehensive assessments can London, UK: Cancer Research UK. Available at: https://www.cancerresearchuk.org/
health-professional/data-and-statistics/international-cancer-benchmarking-partnership-
national levels to understand the impacts. help take the statistics reported in this publication icbp (accessed April 2021).
to the next level by highlighting gaps and 7. Arnold M, Rutherford MJ, Bardot A, Ferlay J, Andersson TM, Myklebust TA, et al.
International efforts suggest that the diagnoses of opportunities in population-based cancer control Progress in cancer survival, mortality, and incidence in seven high-income countries
1995–2014 (ICBP SURVMARK-2): A population-based study. Lancet Oncol.
cancers were reduced by 40% between March 9 strategies and identifying priority areas for clinical 2019;20(11):1493–505.
and May 17, 2020, compared to diagnoses and health services research. 8. Abdillahi I, Shaw A. Social determinants and inequities in health for Black Canadians:
A snapshot. Ottawa, ON: Public Health Agency of Canada; 2020.
averaged over the same time period in 2018 and 9. de Oliveira C, Weir S, Rangrej J, Krahn MD, Mittmann N, Hoch JS, et al. The economic
2019.(43) In terms of screening, we expect that Supplementary resources burden of cancer care in Canada: A population-based cost study. CMAJ Open.
2018;6(1):E1–E10.
interruptions to programs will have an impact
Cancer.ca/statistics houses supplementary 10. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer
in future cancer survival. These impacts will be care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–28.
resources for this chapter. This includes:
picked up in future analyses. Early reports from 11. Canadian Cancer Society’s Advisory Committee on Cancer Statistics [Internet].
Canadian Cancer Statistics 2015. Toronto, ON: Canadian Cancer Society; 2015.
provincial analyses suggest that biopsies, surgical • Excel spreadsheets with the statistics used to Available at: www.cancer.ca/Canadian-Cancer-Statistics-2015-EN (accessed April
referrals and even emergency department visits create the figures 2021).
12. Canadian Cancer Action Network and Canadian Cancer Society [Internet]. Five-year
were lower for a number of months. Data from • PowerPoint images of the figures used action plan to address the financial hardship of cancer in Canada: A call for action.
CIHI show a 25% reduction in diagnostic imaging throughout this chapter Toronto, ON; 2010. Available at: http://www.cancer.ca/~/media/cancer.ca/MB/get%20
involved/take%20action/financial%20hardship%20of%20cancer%20in%20Canada/
and a 20% reduction in the number of cancer financialhardshipofcancer-MB-EN.pdf?la=en (accessed May 2021).
surgeries in the first six months of the pandemic.(44) 13. Iragorri N, de Oliveira C, Fitzgerald N, Essue B. The out-of-pocket cost burden of
Importantly, COVID-19 has impacted some cancer care: A systematic literature review. Curr Oncol. 2021;28(2):1216–48.
14. Iragorri N, de Oliveira C, Fitzgerald N, Essue B. The indirect cost burden of cancer care
populations more than others, exacerbating the in Canada: A systematic literature review. Appl Health Econ Health Policy.
inequities faced by many, including Indigenous 2021;19(3):325–341.
peoples, people of colour, LGBTQ2S+ and others. 15. Essue BM, Iragorri N, Fitzgerald N, de Oliveira C. The psychosocial cost burden of
cancer: A systematic literature review. Psychooncology. 2020;29(11):1746–60.
16. Longo CJ, Fitch MI, Loree JM, Carlson LE, Turner D, Cheung WY, et al. Patient and
family financial burden associated with cancer treatment in Canada: A national study.
Support Care Cancer. 2021; un;29(6):3377–3386.
17. O’Sullivan DE, Hilsden RJ, Ruan Y, Forbes N, Heitman SJ, Brenner DR. The incidence of
young-onset colorectal cancer in Canada continues to increase. Cancer Epidemiol.
2020;69:101828.
18. Canadian Partnership Against Cancer [Internet]. Lung cancer and equity: A focus on
income and geography. Toronto, ON; 2020. Available at: https://www.
partnershipagainstcancer.ca/lung-equity (accessed April 2021).

AR01706
19. Nnorom O, Findlay N, Lee-Foon NK, Jain AA, Ziegler CP, Scott FE, et al. Dying to Learn: 38. Hall MT, Simms KT, Lew JB, Smith MA, Brotherton JM, Saville M, et al. The projected
A Scoping Review of Breast and Cervical Cancer Studies Focusing on Black Canadian timeframe until cervical cancer elimination in Australia: A modelling study. Lancet
Women. J Health Care Poor Underserved. 2019;30(4):1331–59. Public Health. 2019;4(1):e19–e27.
20. Withrow DR, Pole JD, Nishri ED, Tjepkema M, Marrett LD. Cancer Survival Disparities 39. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide
Between First Nation and Non-Aboriginal Adults in Canada: Follow-up of the 1991 thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med.
Census Mortality Cohort. Cancer Epidemiol Biomarkers Prev. 2017;26(1):145–51. 2016;375(7):614–7.
21. Kiran T, Glazier RH, Moineddin R, Gu S, Wilton AS, Paszat L. The impact of a 40. Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, Dickinson J, et al.
population-based screening program on income- and immigration-related disparities in Recommendations on screening for prostate cancer with the prostate-specific antigen
colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2017;26(9):1401–10. test. CMAJ. 2014;186(16):1225–34.
22. Buchman S, Rozmovits L, Glazier RH. Equity and practice issues in colorectal cancer 41. Public Health Agency of Canada. [Internet] The Chief Public Health Officer of Canada’s
screening: Mixed-methods study. Can Fam Physician. 2016;62(4):e186–93. Report on the State of Public Health in Canada 2020. Ottawa, ON: Public Health
23. Giblon R, Bauer GR. Health care availability, quality, and unmet need: A comparison of Agency of Canada; 2020. Available at: https://www.canada.ca/en/public-health/
transgender and cisgender residents of Ontario, Canada. BMC Health Serv Res. corporate/publications/chief-public-health-officer-reports-state-public-health-canada/
2017;17(1):283. from-risk-resilience-equity-approach-covid-19.html (accessed April 2021).
24. D’Souza G, Rajan SD, Bhatia R, Cranston RD, Plankey MW, Silvestre A, et al. Uptake 42. Etowa J, Hyman I. Unpacking the health and social consequences of COVID-19
and predictors of anal cancer screening in men who have sex with men. Am J Public through a race, migration and gender lens. Can J Public Health. 2021;112(1):8–11.
Health. 2013;103(9):e88–95. 43. De Vincentiis L, Carr RA, Mariani MP, Ferrara G. Cancer diagnostic rates during the
25. Mazereeuw MV, Withrow DR, Nishri ED, Tjepkema M, Vides E, Marrett LD. Cancer 2020 “lockdown,” due to COVID-19 pandemic, compared with the 2018–2019: An
incidence and survival among Métis adults in Canada: Results from the Canadian audit study from cellular pathology. J Clin Pathol. 2021;74(3):187–9.
census follow-up cohort (1992–2009). CMAJ. 2018;190(11):E320–6. 44. Canadian Institute for Health Information. Wait Times for Priority Procedures in
26. Health Care Services_Nunavut [Internet]. 2017 march report of the auditor general of Canada, 2021: Focus on the First 6 Months of the COVID-19 Pandemic. Ottawa,
Canada health care services—Nunavut. 2017. Available at: https://assembly.nu.ca/sites/ ON; 2021.
default/files/TD-270-4(3)-EN-OAG-2017-Report-on-Health-Care-Services-in-Nunavut.
pdf (accessed April 2021).
27. Carriere GM, Tjepkema M, Pennock J, Goedhuis N. Cancer patterns in Inuit Nunangat:
1998–2007. Int J Circumpolar Health. 2012;71:18581.
28. Statistics Canada [Internet]. Population Projections for Canada (2018 to 2068),
Provinces and Territories (2018 to 2043) (Catalogue no. 91-520-x). Ottawa, ON:
Statistics Canada; 2019. Available at: https://www150.statcan.gc.ca/n1/en/
pub/91-520-x/91-520-x2019001-eng.pdf?st=AtOO8q7u (accessed April 2021).
29. Xie L, Semenciw R, Mery L. Cancer incidence in Canada: Trends and projections
(1983–2032). Health Promot Chronic Dis Prev Can. 2015;35 Suppl 1:2–186.
30. Canadian Partnership Against Cancer [Internet]. Living with Cancer: A Report on the
Patient Experience. Toronto, ON: Canadian Partnership Against Cancer; 2018. Available
at: https://www.systemperformance.ca/report/living-with-cancer-patient-experience/
(accessed April 2021).
31. World Health Organization [Internet]. Cancer Prevention. Geneva, Switzerland.
Available at: http://www.who.int/cancer/prevention/en/ (accessed April 2021).
32. Poirier AE, Ruan Y, Volesky KD, King WD, O’Sullivan DE, Gogna P, et al. The current
and future burden of cancer attributable to modifiable risk factors in Canada:
Summary of results. Prev Med. 2019;122:140–7.
33. Statistics Canada [Internet]. Aboriginal peoples survey. Ottawa, ON: Statistics Canada;
2017. Available at: https://www150.statcan.gc.ca/n1/en/catalogue/89-653-X (accessed
April 2021).
34. Statistics Canada [Internet]. Aboriginal peoples survey, 2012: Social determinants of
health for the off-reserve First Nations population, 15 years of age and older, 2012.
Ottawa, ON; 2016. Available at: https://www150.statcan.gc.ca/n1/pub/89-653-x/89-
653-x2016010-eng.htm (accessed April 2021).
35. Statistics Canada [Internet]. Table 13-10-0096-01. Health characteristics, annual
estimates. Available at: https://www150.statcan.gc.ca/t1/tbl1/en/cv.
action?pid=1310009601.
36. Canadian Partnership Against Cancer [Internet]. Action plan for the elimination of
cervical cancer in Canada 2020–2030. Available at: https://s22438.pcdn.co/
wp-content/uploads/2020/11/Elimination-cervical-cancer-action-plan-EN.pdf (accessed
April 2021).
37. Dickinson JA, Stankiewicz A, Popadiuk C, Pogany L, Onysko J, Miller AB. Reduced
cervical cancer incidence and mortality in Canada: National data from 1932 to 2006.
BMC Public Health. 2012;12:992.

AR01707
APPENDIX I
Related resources
Additional cancer surveillance Table number Title and description

statistics 13-10-0111-01 Number and rates of new cases of primary cancer, by cancer type, age group and sex
Provides counts of new cancer cases and crude incidence rates (and 95% confidence intervals) for Canada and provinces
Statistics Canada offers a series of online tables of and territories by cancer type, age group, sex and year
aggregate statistics that can be manipulated to the 13-10-0747-01 Number of new cases and age-standardized rates of primary cancer, by cancer type and sex
user’s specifications. The tables were previously Provides counts of new cancer cases and age-standardized incidence rates (and 95% confidence intervals) for Canada and
provinces and territories by cancer type, sex and year
referred to as CANSIM.
13-10-0761-01 Number and rates of new primary cancer cases, by stage at diagnosis, selected cancer type and sex
Provides counts of new cancer cases and crude incidence rates (and 95% confidence intervals) by stage at diagnosis for
Statistics Canada also offers a series of online Canada, the provinces and the territories, by selected cancer type, age group, sex and year
data tables that provide the public with fast and 13-10-0762-01 Number of new cases and age-standardized rates of primary cancer, by stage at diagnosis, selected cancer type
easy access to the latest statistics available in and sex
Canada relating to demography, health, trade, Provides counts of new cancer cases and age-standardized incidence rates (and 95% confidence intervals) by stage at
diagnosis for Canada, the provinces and the territories, by selected cancer type, sex and year
education and other key topics. This includes a
13-10-0109-01 Cancer incidence, by selected sites of cancer and sex, three-year average, Canada, provinces, territories and
number of tables related to cancer. These tables
health regions (2015 boundaries)
can be accessed from the Statistics Canada Provides counts of new cancer cases and crude age-standardized incidence rates (and 95% confidence intervals) for
website at https://www150.statcan.gc.ca/n1/en/ Canada, the provinces and the territories by cancer type, sex, geography and year
type/data. 13-10-0112-01 Cancer incidence, by selected sites of cancer and sex, three-year average, census metropolitan areas
Provides cancer cases and crude and age-standardized cancer rates (and confidence intervals) for metropolitan areas, by sex
Users can browse available data tables by topic and cancer site for 2001/2003 to 2013/2015
or search by keywords or a table number. Users 13-10-0142-01 Deaths, by cause, Chapter II: Neoplasms (C00 to D48)
Provides the annual number of cancer deaths for Canada by cancer cause of death, age group, sex and year
can generate customized statistical summaries
13-10-0392-01 Deaths and age-specific mortality rates, by selected grouped causes
of tables using some of the data functions Provides the annual number of deaths and crude mortality rates for Canada by cause of death, age group, sex and year
(e.g., “Add/Remove data”). Final summaries 13-10-0800-01 Deaths and mortality rate (age-standardization using 2011 population), by selected grouped causes
can be exported using the download function. Provides the annual number of deaths and the crude and age-standardized mortality rates for Canada, the provinces or the
territories by sex, year and cause of death
17-10-0005-01 Population estimates on July 1st, by age and sex
Provides population counts for Canada, the provinces and the territories by age, year and sex
13-10-0158-01 Age-specific five-year net survival estimates for primary sites of cancer, by sex, three years combined
Provides estimates of age-specific five-year net survival (and 95% confidence intervals) for Canada (with and without
Quebec) by cancer type, sex and overlapping three-year time periods
13-10-0159-01 Age-specific five-year net survival estimates for selected cancers with age distributions of cases skewed to older
ages, by sex, three years combined
Provides estimates of age-specific five-year net survival (and 95% confidence intervals) for Canada (with and without
Quebec) by selected cancers with age distributions of cases skewed to older ages, by sex and overlapping three-year time
periods

Appendix I • Related resources
AR01708
Which tables are relevant and how Table number Title and description
do I use them? 13-10-0160-01 Age-standardized five-year net survival estimates for primary sites of cancer, by sex, three years combined
Provides estimates of age-standardized five-year net survival (and 95% confidence intervals) for Canada (with and without
The table on the right contains a list of tables Quebec) by cancer type, sex and overlapping three-year time periods
most relevant to this publication. Many have 13-10-0161-01 Age-standardized and all-ages five-year net survival estimates for selected primary sites of cancer, by sex, three
been referenced in this publication. This is not years combined, by province
a complete list of all tables available. Additional Provides estimates of all-ages and age-standardized five-year net survival (and 95% confidence intervals) for provinces by
selected cancers, sex and overlapping three-year time periods
tables can be found by browsing the Statistics
13-10-0790-01 Predicted age-standardized and all ages five-year net survival estimates for selected primary types of cancer, by
Canada website. sex, three years combined
A detailed description of how to access, modify Provides estimates of age-standardized and all ages five-year net survival (and 95% confidence intervals) for Canada
(excluding Quebec) for selected cancers by sex for the 2015 to 2017 time period
and download these data tables is provided online.
13-10-0791-01 Predicted age-specific five-year net survival estimates for selected primary types of cancer, by sex, three years
of cases
What if I need statistics that are Provides estimates of age-specific five-year net survival (and 95% confidence intervals) for Canada (excluding Quebec) for
selected cancers by sex for the 2015 to 2017 time period
not available in the tables? 13-10-0751-01 Number of prevalent cases and prevalence proportions of primary cancer, by prevalence duration, cancer type,
Custom tabulations are available on a cost- attained age group and sex
recovery basis upon request from Statistics Provides prevalence counts and proportions (and 95% confidence intervals) by prevalence duration for Canada, the
provinces and the territories, by cancer type, sex, attained age group and index date
Canada. Analytical articles appear regularly in
Health Reports, Statistics Canada, Catalogue
no. 82-003. Chronic disease surveillance infographics on cancer in Canada
(https://www.canada.ca/en/public-health/
Other information about the data Statistics The Public Health Agency of Canada hosts a services/chronic-diseases/cancer.html).
Canada offers is available through their website series of online interactive tools, including data
(statcan.gc.ca). tools, indicator frameworks and data blogs,
on their Public Health Infobase, which allows Childhood cancer surveillance
users to access and view public health data.
Why do some statistics in this The Public Health Agency of Canada funds and
This includes the Canadian Cancer Data Tool
publication differ from the (CCDT), which provides data on the incidence manages the Cancer in Young People in Canada
statistics in these tables? and mortality of cancer in Canada over time by (CYP-C) program, which is a national, population-
age and sex for 22 different cancer types and all based surveillance system studying all children
Users of Statistics Canada’s data tables should be and youth with cancer in Canada. This program
aware that there are some differences between cancers combined. Other resources in the Public
Health Infobase include the Canadian Chronic is a partnership with the C17 Council, the
the data compiled for this publication and those network of all 17 children’s cancer hospitals
used in Statistics Canada’s tables. For additional Disease Surveillance System (CCDSS) data
tool, which is a comprehensive pan-Canadian across Canada. CYP-C products include the
details on those data, users should review the Cancer in Young People in Canada (CYP-C) Data
footnotes provided under each table on the resource on the burden of chronic diseases and
associated determinants, as well as the Canadian Tool, a full report(1) and fact sheets. The CYP-C
Statistics Canada website. The information in Data Tool, located on the Public Health Infobase,
those footnotes can be compared to the details Chronic Disease Indicators (CCDI). Among
other indicators, the CCDI provides the rate provides pan-Canadian surveillance data on
provided in Appendix II of this publication. children and youth with cancer to inform research
of cancer incidence, mortality, prevalence and
screening practices over time and by sex, age and and planning for cancer control efforts.
province or territory. The Public Health Agency
of Canada also regularly publishes fact sheets and

Appendix I • Related resources
AR01709
Cancer system performance International cancer surveillance References

1. Public Health Agency of Canada [Internet]. Cancer in Young People in Canada: A
The Canadian Partnership Against Cancer is Comparable cancer indicators for different Report from the Enhanced Childhood Cancer Surveillance System. Ottawa, ON: Public
Health Agency of Canada; 2017. Available at: https://www.Canada.ca/content/dam/
an independent organization funded by the countries can be found through various hc-sc/documents/services/publications/science-research-data/cancer-young-people-
federal government to accelerate action on international resources. Those listed below Canada-surveillance-2017-eng.pdf (accessed April 2021).
cancer control for all Canadians. As part of that represent reputable resources for that 2. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. [Internet].
Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): Analysis of
work, they produce cancer system performance information. individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322
data to see how jurisdictions compare and to • The Global Cancer Observatory (GCO) is an
population-based registries in 71 countries. 2018 [updated Jan 30]. Available at:
http://www.ncbi.nlm.nih.gov/pubmed/29395269. (accessed April 2021).
identify gaps in care. This includes information
interactive web-based platform that focuses on
related to prevention, screening, diagnosis,
the visualization of cancer statistics to show the
treatment, the person-centred perspective and
research. Online tools and reports are available changing scale, epidemiologic profile and
at partnershipagainstcancer.ca/performance- impact of the disease worldwide.
reports. • The Cancer Incidence in Five Continents series
provides comparable data on cancer incidence
from a range of geographical locations.
Cancer prevention
• The Cancer in North America (CiNA)
The Canadian Cancer Society maintains up-to- publications are produced annually to provide
date, accurate information on cancer prevention. the most current incidence and mortality
This includes It’s My Life, which is an online, statistics for the US and Canada.
interactive tool designed to teach the public how
different risk factors affect the risk of getting • The International Cancer Benchmarking
cancer and what can be done to reduce the risk. Partnership (ICBP) quantifies international
differences in cancer survival and identifies
In 2019, the Canadian Population Attributable factors that might influence observed variations.
Risk of Cancer (ComPARe) study was released. It • CONCORD is a program for worldwide
quantified the number and percentage of cancers
surveillance of cancer survival. The most recent
in Canada, now and in the future, attributable
CONCORD publication is CONCORD-3.(2)
to modifiable risk factors. All results from that
study are available through a data dashboard at
prevent.cancer.ca. Using the dashboard, users can
select the cancer and risk factor of interest and
investigate the data by age, sex and year.

AR01710
APPENDIX II
Data sources and methods
Summary • Survival analyses were based on a Canadian Data sources

Cancer Registry death-linked analytic file that
Who was involved? covered the period from 1992 to 2017. Incidence data: The Canadian
The Centre for Population Health Data at • Additional sources of data included population Cancer Registry (CCR)
Statistics Canada and the Centre for Surveillance life tables, population estimates and forecasts Actual cancer incidence data used in this
and Applied Research at the Public Health Agency on population growth. publication cover the period of 1984 to 2017
of Canada conducted the analyses that are (except Quebec, for which data from 1984 to
presented in this publication. The provincial and 2010 were used). Data for 1992 to 2017 were
territorial cancer registries were consulted in the Which analytic approaches were obtained from the CCR Tabulation Master File,(6)
preparation of the cancer incidence and mortality used? released January 29, 2020 (see Data methods
projections for their jurisdictions. The Canadian and issues). Data for years that precede the CCR
• Estimates of the lifetime probability of
Cancer Statistics Advisory Committee advised (before 1992) were retrieved from its predecessor,
on the methodology and interpretation of results developing and dying from cancer were
the National Cancer Incidence Reporting System
and wrote the accompanying text. The Canadian estimated using DevCan.(1)
(NCIRS). The NCIRS is a fixed, tumour-oriented
Cancer Society coordinated the production of this • Cancer incidence and mortality projections database containing cases diagnosed between
publication and the work of the committee. were estimated using CANPROJ.(2) 1969 and 1991.
• Joinpoint analysis was applied to estimate • Incidence data originate with the provincial
What data were used? trends in incidence(3) and mortality(4) over time. and territorial cancer registries (PTCR), which
• Actual cancer incidence data used for this • Net survival was calculated using the Pohar provide data annually to Statistics Canada for
publication were for the period 1984 to 2017 Perme estimator.(5) inclusion in the CCR.
(except for Quebec, for which data were • The CCR is a person-oriented database that
available to 2010). includes clinical and demographic information
• Actual cancer mortality data covered the period about residents of Canada diagnosed with new
from 1984 to 2019. primary cases of cancer.
• Cancer incidence and mortality projections • Incidence estimates are based on the
up to 2021 were generally based on the most individuals’ province or territory of residence
recent 25 years of data available. However, at the time of diagnosis, which may differ from
the mortality projections were based on data the jurisdiction in which the diagnosis occurred.
from 1994 to 2018 as the projection analysis • The Centre for Population Health Data at
commenced prior to the release of the 2019 Statistics Canada maintains the CCR. An annual
mortality data by Statistics Canada. process is in place to identify and remove

Appendix II • Data sources and methods
AR01711
duplicate person and tumour records. Records • The CVSD includes information on • All population estimates include non-permanent
from Quebec have not been de-duplicated demographics and cause of death for all deaths residents and are adjusted for net census
within or between provinces since the last in Canada. Prior to the 2010 reference year, undercoverage and Canadians returning from
provincial process, which was completed for some data were also collected on Canadian abroad.
cases diagnosed to December 31, 2008. residents who died in American states within
• Cancer diagnoses are classified according to the US. Deaths of non-residents of Canada are
not included in the calculation of mortality
Survival data
the International Classification of Diseases for
Oncology, 3rd Edition (ICD-O-3) from 1992 statistics in this publication. • Survival analyses were conducted using the
onward.(7) Cancer diagnoses in the NCIRS • Mortality estimates are based on the individuals’ CCR death-linked analytic file created by
(i.e., prior to 1992) were classified according province or territory of residence at the time Statistics Canada in their Social Data Linkage
to the International Statistical Classification of of death rather than the place where the death Environment.(14) Specifically, the CCR tabulation
Diseases and Related Health Problems, Ninth occurred. file released January 29, 2020, was linked to
Revision (ICD-9).(8) mortality information complete through
• Cause of death is classified according to the
December 31, 2017.
• The International Agency for Research on ninth and 10th revisions of the International
Cancer (IARC) rules(9) for multiple primaries Statistical Classification of Diseases and Related • In addition to pre-existing mortality information
were used for cases from the CCR (see Data Health Problems (ICD): ICD-9(8) from 1979 to on the CCR itself, mortality information were
and methods issues) from 1992 onward for all 1999 and ICD-10 from 2000 onward.(11) also obtained from the CVSD(10) and from the T1
provinces except Ontario which had slightly Personal Master Files (as reported on tax
• Cancer deaths are those for which some form
more conservative IARC rules until the 2010 returns). The use of death information
of cancer, as certified by a physician, is the
diagnosis year. During the period covered by appearing on tax returns permitted the
primary underlying cause of death.
the NCIRS, registries other than Quebec and identification of additional deaths events that
Ontario used multiple primary rules that may not have been included in the CVSD (e.g.,
allowed a small percentage of additional cases. Population data: Census of the deaths occurring outside Canada).(15)
population • The analytic file follows the multiple primary
coding rules of IARC.(9)
Mortality data: The Canadian Vital • Population estimates for 1984 to 2019 were
obtained from Statistics Canada.(12) These • Survival time was measured in days from the
Statistics—Death database (CVSD) date of diagnosis to the date of death, where
estimates are final intercensal up to 2015, final
The actual mortality data used in this publication applicable; otherwise to the end of 2017.
postcensal for 2016, updated postcensal for 2017
cover the period of 1984 to 2019 and were • For more precise matching of obtained age and
to 2018 and preliminary postcensal for 2019.
obtained from the Canadian Vital Statistics— obtained calendar year to expected survival
Death Database (CVSD).(10) • Projected population estimates are used for
2020 and 2021, as prepared by Statistics Canada probabilities in the follow-up experience of
• Death records originate with the provincial individual people with cancer, the CCR death-
under assumptions of medium growth (scenario
and territorial registrars of vital statistics and linked analytic file includes variables for age at
M1).(13) Scenario M1 incorporates medium
are provided regularly to Statistics Canada for diagnosis and diagnosis year measured to three
growth and historical trends (1991/1992 to
inclusion in the CVSD. decimal places.
2016/2017) of interprovincial migration.
• The Centre for Population Health Data at
Statistics Canada maintains the CVSD.

AR01712
• More information on the linkage process and on previously reported categories of oral (i.e., lip, 2011 Canadian standard population
the resulting death-linked analytic file is oral cavity and pharynx) and laryngeal cancer. It
Standard
supplied in the User Guide to this file, which is additionally includes cancers of the nasal cavity, Age group Population
weight
available upon request. middle ear and accessory sinuses, which were 0–4 1,899,064 0.055297
previously included in the “all other cancers” 5–9 1,810,433 0.052717
category. The head and neck cancers group 10–14 1,918,164 0.055853
Expected survival does not include thyroid cancer, which remains 15–19 2,238,952 0.065194
• Expected survival probabilities necessary for the as its own independent category. 20–24 2,354,354 0.068555
calculation of net survival were mostly obtained • For Figure 1.4 and Table 3.3, new cancers for
25–29 2,369,841 0.069006
from sex-specific, complete, annual national or children (aged 0–14 years) were classified and
30–34 2,327,955 0.067786
provincial life tables.(16) 35–39 2,273,087 0.066188
reported according to the Surveillance, 40–44 2,385,918 0.069474
• As complete life tables were not available for Epidemiology and End Results Program (SEER) 45–49 2,719,909 0.079199
Prince Edward Island or the territories, update(19) of the International Classification of 50–54 2,691,260 0.078365
expected survival for these jurisdictions were Childhood Cancer, Third Edition (ICCC-3).(20) The 55–59 2,353,090 0.068518
derived, up to the age of 99 years, from update was in response to new morphology 60–64 2,050,443 0.059705
abridged life tables for Canada and the affected codes introduced by the World Health 65–69 1,532,940 0.044636
jurisdictions(17) and from complete Canadian life Organization.(21) The classification system is 70–74 1,153,822 0.033597
tables(16) using a method suggested by Dickman more appropriate for reporting childhood 75–79 919,338 0.026769
et al.(18) For ages 100 to 109, where this was not 80–84 701,140 0.020416
cancers because it acknowledges the major
85–89 426,739 0.012426
possible for these jurisdictions, complete differences between cancers that develop 90+ 216,331 0.006299
Canadian life values were directly used. during childhood and those that occur later in Total 34,342,780 1.000000
life. Non-malignant tumours were excluded.
Note: The Canadian population distribution is based on the final
Cancer definitions postcensal estimates of the July 1, 2011, Canadian population,
Methods adjusted for census undercoverage.
• Cancer cases were defined according to ICD-9(8) Data source: Census and Demographics Branch, Statistics Canada
prior to 1992 and ICD-O-3(7) thereafter. Cancer Incidence and mortality rates
deaths were defined according to ICD-9(8) prior calculations of age-standardized rates and for
• Records from each province or territory were projections beyond the most recent year of
to 2000 and ICD-10(11) thereafter. Table A1
extracted from the relevant incidence or actual data.
outlines the ICD-9, ICD-O-3 and ICD-10 codes
mortality files and then classified by year of
used to identify cancer cases and deaths by • Age-standardized rates were calculated using
diagnosis or death and by sex, five-year age
cancer type for this publication. the direct method, which involves weighting the
group (e.g., 0–4, 5–9, …, 85–89, 90+ years) and
• Some definitions have changed slightly over age-specific rates for each five-year age group
cancer type.
time. Changes occurring since the 2004 edition according to the age distribution of the 2011
• Rates for each category were calculated by Canadian standard population (see table above).
of this publication are outlined in Tables A2-1
dividing the number of cases or deaths in each Unlike previous editions of this publication prior
and A2-2.
category (i.e., sex, age group, year, cancer type to 2020, all age-standardized rates were based
• A new cancer grouping — head and neck and province or territory) by the corresponding
cancers — has been included with this edition on 19 age groups.
population figure. These formed the basis for
of the publication. This group subsumes the

AR01713
Figure 4.4 (in Chapter 4: Cancer in context) shows Nordpred model when the Poisson distribution CANPROJ-selected model looked problematic
the relative number of new cases and deaths is used; the age-cohort model; the hybrid models (e.g., the estimates were at least 10% different
that can be attributed to changes in cancer risk that incorporate age and period effects (age- than what would be expected), an alternate
and cancer control practices, population size and specific or one common trend for all ages); model was selected and approved through
aging of the population. the hybrid model that incorporates only age group consensus.
(equivalent to a long-term average); and the five-
The series shown in Figure 4.4 were calculated as • The proposed estimates (counts and age-
year average method.
follows: standardized rates) were sent to the provincial
• Uppermost series (red) — The actual and CANPROJ is equipped with a decision tree that and territorial cancer registries for approval.
determines which of these options is the most • In instances where the province or territory
projected annual number of Canadian cancer
suitable for projecting the data based on the disagreed with an estimate based on in-house
cases or deaths for both sexes combined
significance of the variables that are included in
• Next-to-uppermost series (orange) — Annual projections, knowledge of local trends or access
the AdPC model (age, drift, period and cohort).
total population multiplied by the annual to more recent data, they had the opportunity to
age-standardized rate, using the 1984 population Age was included in all models as a factor. The provide this information to the committee for
distribution for males and females as the number of age groups used has been increased consideration.
standard weights from 18 to 19 this year with the disaggregation • If the committee approved the rationale, they
of the 85+ plus age group into 85 to 89 and 90+ recommended an alternate model to the
• Next-to-baseline series (green) — The 1984 age groups. Trends in age-specific incidence and
total population multiplied by the annual registry.
mortality rates were extrapolated to 2021. The
age-standardized rate, using the 1984 population projected numbers of cancer cases and deaths
distribution for males and females as the in 2021 were calculated by multiplying these Through this consultation process, the “best”
standard weights extrapolated rates by the sex-, age- and province- model was selected. All cancer-specific provincial
specific projected population figures for 2021. and territorial projections reported in this
• Baseline (dotted line) — The observed number publication were approved by a representative
of Canadian cancer cases or deaths during 1984 from the respective cancer registry as well as
for both sexes combined. Selection of “best” projections by the Canadian Cancer Statistics Advisory
The process for selecting the “best” projected Committee.
counts and rates by sex, cancer type and
Projection of incidence and geography went as follows: Quebec incidence projections
mortality rates and counts for 2021 • The CANPROJ package decision tree was used Because cancer incidence data were only
The CANPROJ R-package was used to produce to select the model that best suited the actual available for Quebec to 2010, an alternative
annual incidence and mortality projections of data, according to the statistical tests performed projection method was used to estimate
rates and counts. Six options are available in Quebec-specific cases and rates for 2011–2021.
within CANPROJ. When counts were small, the
CANPROJ, including four regression models and Specifically:
five-year average projection was used. This
two average methods. All regression models are
based on a Power5 linked function (although happened more often in the territories and • Sex-, age- and cancer-specific correction factors
this option can be changed), and a negative Prince Edward Island, as well as in rare cancer were calculated as the ratio of sex-, age- and
binomial distribution is used instead of a Poisson types. cancer-specific rate estimates for Quebec
distribution when there is overdispersion. The • Figures created with the CANPROJ-selected relative to Canada (excluding Quebec) for the
projection options available are: the age-drift- models were visually inspected for face validity 2006–2010 years.
period-cohort (AdPC) model, also known as the by a review committee. In instances where the

AR01714
• Actual (2011–2017) and projected (2018–2021) cancer-specific projections, and “both sexes” was Annual percent change (APC) and
Canada rates that excluded Quebec by year, sex calculated as the sum of male and female counts.
Projections for Canada as a whole were computed
average annual percent change
and five-year age group were applied to the
2011 to 2021 Quebec population to estimate as sums of the projections for the individual (AAPC) in cancer incidence and
preliminary Quebec-specific counts. provinces and territories. mortality rates
• The correction factors were applied to the • Using Joinpoint,(4) the APC was calculated for
preliminary Quebec-specific counts to produce Rounding for reporting each cancer type by fitting a piecewise linear
the counts and rates used for this publication. Projected estimates of incidence and mortality regression model, assuming a constant rate of
presented in this publication have been rounded change in the logarithm of the annual age-
as follows: standardized rates in each segment. The models
This method assumes the ratio of rates between
Quebec and the rest of Canada remained • Numbers between 0 and 99 were rounded to the incorporated estimated standard errors of the
constant over time, which may not be the case. nearest 5. age-standardized rates. The tests of significance
Given the assumptions made for this analysis, • Numbers between 100 and 999 were rounded to used a Monte Carlo Permutation method. The
extra caution should be taken when interpreting the nearest 10. estimated slope from this model was then
Quebec projected data. Limitations involving the transformed back to represent an annual
• Numbers between 1,000 and 1,999 were
under-reporting of melanoma and prostate cancer percentage change in the rate.
in Quebec(22) noted in previous editions of this rounded to the nearest 50.
• Numbers greater than or equal to 2,000 were • Joinpoint analysis was applied to annual
publication were addressed in a simple manner
rounded to the nearest 100. age-standardized rates (1984 to 2017 for
for the 2021 projections. The magnitude of the
under-reporting for these cancers was estimated incidence, and 1984 to 2019 for mortality) to
using the preliminary Quebec counts for 2011 determine years in which the APC changed
Age-specific and sex-specific numbers were
(available from: http://publications.msss.gouv. combined before rounding, so it is possible that significantly. Such years are referred to as
qc.ca/msss/fichiers/2017/17-902-36W.pdf ). totals in the tables do not add exactly. However, changepoints.
The methodology described above was applied any such discrepancies are within the precision of • After consultation, 1984 was chosen as the start
and the resulting counts were multiplied by an the rounding units described above. year because the quality of the data is
additional correction factor corresponding to the considered good for all the provinces and
2011 Quebec Cancer Registry to 2010 CCR count Throughout the publication, actual incidence and
territories from that year onward.
ratio for all imputed years (2011 to 2021). mortality frequencies are randomly rounded up or
down to a multiple of 5. • Data from Quebec were excluded from the
In this publication, cases were reported analysis of incidence trends because cases
for Quebec because of their importance in diagnosed from 2011 onward had not been
Precision of 2021 projections
determining the national total projected number submitted to the CCR. Imputed cancer
of cancer cases. However, age-standardized rates The precision of a projection depends primarily
incidence rates for Quebec for 2011 to 2017
were not reported for Quebec since they were on the number of observed cases and the
population size for each combination of cancer were not used as a replacement for the
estimated differently than other regions and missing data.
therefore should not be compared. type, age, sex and province or territory. Therefore,
caution must be taken when interpreting • The minimum time span on which to report a
differences in counts or rates, particularly for trend was set at five years. Thus, the most
Combined projections the smaller provinces and territories, as these recent possible trend period in this study was
For each province or territory, the “all cancers” differences may not be statistically significant. 2013 to 2017 for incidence, and 2015 to 2019 for
projection was calculated as the sum of the

AR01715
mortality. A maximum of five joinpoints was cancers are in situ carcinomas, the trend analysis Probability of developing cancer
allowed. An uncorrelated error model was for bladder cancer incidence was performed Age-, sex- and cancer-specific case and death
selected for the autocorrelated errors options using the “jump” model to account for the counts, age- and sex-specific all-cause death
and the permutation test was used for the model artificial increase in rates that occurred between counts and population estimates for Canada
selection. 2009 and 2010. Specifically, the “jump” model (excluding Quebec) in 2017 were calculated using
• The year corresponding to the most recent has an additional parameter that allows direct 20 age groups (0 to <1, 1–4, 5–9, 10–14,…, 85–89
changepoint detected (reference year) and the estimation of trends in situations where there is and 90+ years). Quebec could not be included
a “jump” in rates caused by systematic scaled because incidence data were only available to
APC for the years beyond the changepoint are
change, but it is assumed that the “jump” does 2010. Input death counts were rounded to a base
reported in Tables 1.6 and 2.6, as well as
5 for both the probability of developing cancer
Figures 1.7 and 2.7. In the absence of a not affect the underlying trend.(23)
and of dying from cancer (below) to fulfill the data
changepoint, the reference year is 1984. sharing agreement between Statistics Canada and
• For each sex, cancers that demonstrated a Probability of developing or dying PHAC.
statistically significant APC of at least 2% since
from cancer • The lifetime probability of developing cancer
the reference year, as well as the four most was calculated by dividing the total number of
Crude probabilities of developing or dying
commonly diagnosed cancers (for incidence) cancers occurring over the complete life
from cancer were calculated using the software
and the five leading causes of cancer death (for (age 0–90+) by the hypothetical cohort of
application DevCan.(1) Using cross-sectional data
mortality), are highlighted in the text. The on cancer diagnoses, cancer deaths, all deaths 10,000,000 live births. This calculation does not
trends for these notable cancers are depicted in and population estimates, DevCan employs assume that an individual lives to any particular
Figures 1.8 and 1.9 for incidence and Figures statistical modelling to compute the probability age.
2.8 and 2.9 for mortality. of developing a first-time cancer during an age • Probabilities were calculated for all cancers
• To summarize the trend(s) over specified interval, conditioned on being alive and cancer
combined and by cancer type, by sex.
periods, the average annual percent change free at the beginning of the age interval, as well as
(AAPC) was calculated for the entire time period the probability of dying from cancer.(1)
(1984 to 2017 or 1984 to 2019) and the most Probability of dying from cancer
Estimates of the probability of developing or
recent 10 years (2008 to 2017 or 2010 to 2019). dying from cancer are based on a hypothetical Age, sex- and cancer-specific death counts,
The AAPC is computed as a weighted average cohort of 10,000,000 live births and the age- and sex-specific all-cause death counts
of the APCs in effect during the specified period assumption that the current incidence and and population estimates for Canada in 2019
with the weights equal to the proportion of the mortality rates at each age stay constant (excluding Quebec) were calculated using 20
period accounted for by each APC. throughout each age interval. Since this age groups (0 to <1, 1–4, 5–9, 10–14,…, 85–89
assumption may not be true, the probabilities and 90+ years).
• Bladder cancer incidence included in situ
carcinomas, which are considered invasive may only regarded as approximations. Further,
the estimated probabilities are for the general
for the purpose of incidence reporting for all
Canadian population and should not be
provinces and territories. At the time of analysis,
interpreted as an individual’s risk.
data on in situ carcinomas of the bladder for
Ontario were limited to 2010 to 2017. Because a
large proportion of Canadians live in Ontario
and since a significant proportion of bladder

AR01716
• The lifetime probability of dying from cancer is Survival that would otherwise not have been mapped to
the total number of cancer deaths occurring a diagnostic group, the histology code was
over the complete life (age 0–90+) divided by Inclusions and exclusions edited to 9508 (atypical teratoid rhabdoid
the hypothetical cohort of 10,000,000 live births. • New primary cancers diagnosed in individuals tumour) and the cases included in diagnostic
This calculation does not assume that an aged 15 to 99 years at diagnosis were initially subgroup IIIc. The same exclusions noted above
individual lives to any particular age. included. Cases were defined based on the apply. In addition, 15 remaining malignant
• Probabilities were calculated for all cancers International Classification of Diseases for cancer cases that did not map to a diagnostic
combined and by cancer type, by sex. Oncology, Third Edition(7) and classified using group were excluded.
Surveillance, Epidemiology, and End Results
(SEER) Program grouping definitions.(24)
Potential Years of Life Lost (PYLL) Observed and net survival
• Cases from the province of Quebec were
PYLL was calculated by taking the exact age of • Observed survival proportions were reported
excluded because cancer incidence data from
each person dying before the age of 75 years and for the analysis of childhood cancers. Otherwise,
this province had not been submitted to the
subtracting that from 75 to calculate individual net survival probabilities were reported. Both
CCR since the 2010 data year. Next, cases for
years lost. The sum of all these values represents statistics were expressed as percentages.
which the diagnosis had been established
the total PYLL. • Unstandardized (crude) survival analysis
through autopsy only or death certificate only,
Figure 4.2 presents the total PYLL for people aged or for which a death had been established but estimates were derived using an algorithm(29)
0–74 for the years 2017 to 2019 combined using the year of death was unknown, were excluded. that has been augmented by Ron Dewar of the
data from the CVSD. Nova Scotia Cancer Care Program (Dewar R,
• The data set was then further restricted to first
2020, email communication, 22nd June) to
The following ICD-10 codes were used to create primary cancers per person per individual
include the Pohar Perme estimator of net
the categories presented in Figure 4.2. cancer, or per cancer group when individual
survival(5) using the hazard transformation
cancers are grouped for reporting purposes
approach.
ICD-10 cause (e.g., colorectal cancers, head and neck cancers,
Category of death ICD-10 Codes leukemias, and brain and other nervous systems • Cases with the same date of diagnosis and
terminology
cancers), diagnosed from 1992 to 2017.(25–28) death (not including those previously excluded
Cancer All malignant C00-C97 because they were diagnosed through autopsy
neoplasms • Childhood cancer survival analyses were
only or death certificate only) were assigned
Accidents Unintentional injuries V01-X59, Y85-Y86 conducted separately on new malignant primary
one day of survival because the program
Heart disease Ischaemic heart I20-I25 cancers in children aged 0 to 14 years at
diseases automatically excludes cases with zero days of
diagnosis. Cases were classified according to the
Suicide Suicides and self- X60-X84, Y87.0 survival. Exclusion of these cases would have
Surveillance, Epidemiology and End Results
inflicted injuries biased estimates of survival upward.
Respiratory disease Respiratory diseases J00-J99
Program (SEER) update(19) of the International
Classification of Childhood Cancer, Third Edition • For five-year survival, three-month subintervals
Cerebrovascular Cerebrovascular I60-I69
diseases diseases (ICCC-3).(20) The update was in response to new were used for the first year of follow-up, then
HIV Human B20-B24 morphology codes introduced by the World six-month subintervals for the remaining four
immunodeficiency
Health Organization.(21) For 19 cases with a years, for a total of 12 subintervals. Where the
virus (HIV) disease
histology code of 8963 (malignant rhabdoid analysis was extended to 10 years, one-year
tumour) and a topography code of C71 (brain) subintervals were used for the sixth through
10th years.

AR01717
• Estimating net survival in a relative survival survival estimates for those diagnosed in the • A comparison of five-year net survival estimates
framework requires that the non-cancer most recent period derived using the cohort age-standardized using the CCSS weights
mortality rate in a group of people diagnosed method will not be known for some time. described above and, alternatively, weights
with cancer is the same as that in the • The underlying methodology between the developed from data collected for the
population-based life table.(30) To better satisfy cohort and period approaches is essentially the EUROCARE-2 study(42) is provided as online-
this assumption, expected survival data used in same. The exception is that the follow-up only supplementary data (Table S3.1).
the calculation of net survival for colorectal, information used in the period method • Standard errors for age-standardized estimates
prostate and female breast cancer were adjusted necessarily does not relate to a fixed cohort of were estimated by taking the square root of the
for cancer-specific mortality rates in the general people. Rather, estimates of period survival are sum of the squared, weighted, age-specific
population.(31–33) In each case, the proportion of based on the assumption that persons standard errors.
deaths among Canadian residents due to the diagnosed in the period of interest will
specific cancer, by sex, five-year age group and experience the most recently observed
year of death, was used for the adjustment. conditional survival probabilities.
All cancers combined
Provincial-specific mortality estimates were • In the analysis of cancer survival for all cancers
• Empirical evaluations of period analysis have
used for those aged 55 to 59 and older age combined, age-standardized net survival
shown that this method provides estimates that
groups. Otherwise, national estimates were estimates for both sexes combined were
closely predict the survival that is eventually
used.(34) calculated as the weighted sum of the
observed for people diagnosed in the period of
• Conditional five-year net survival(35,36) was unrounded sex- and cancer-specific age-
interest, particularly when survival is fairly
calculated as per five-year net survival using standardized net survival estimates. These
constant.(38–40) When survival is generally
only the data of people who had survived at estimates are referred to as net cancer survival
increasing (or decreasing), a period estimate
least one year after diagnosis. That is, the index (CSI) estimates.(43)
tends to be a conservative prediction of the
survival estimates for an additional four years survival that is eventually observed.(39,41) • Sex-specific net CSI estimates were calculated
among people who had already survived one separately as the weighted sum of the
• The cohort method was used to derive non-
year. unrounded cancer-specific age-standardized net
predictive (actual) estimates of survival for
• Survival estimates associated with standard survival estimates for each sex.
1992–1994.
errors greater than 0.10 were omitted. Estimates • The weights used in the calculation of net CSIs
associated with standard errors greater than are provided elsewhere.(43)
0.05, but less than or equal to 0.10, were Age-standardization • For this publication, 55 cancers were considered
italicized. • Age-standardized estimates for each cancer — the cancers traditionally reported on for
group were calculated using the direct method cancer incidence, survival and prevalence by
as a weighted average of age-specific estimates Statistics Canada with the exception that the
Predicted survival for that particular cancer. For individual cancers, categories corresponding to the corpus uteri
• Predicted survival estimates for the most recent the Canadian Cancer Survival Standard (CCSS) and uterus not otherwise specified were
period — typically 2015–2017, but 2013–2017 weights were used.(34) For the five cancer groups combined.
for childhood cancer — were derived using appearing in this publication, the weights were • The CSI is superior to age-standardization alone
period analysis.(37) The period approach to derived in the same manner as for the CCSS in measuring progress in survival for all cancers
survival analysis provides up-to-date predictions weights and are provided as online-only combined because it additionally adjusts for
of cancer survival(38) because actual long-term supplementary data (Table S3.2).

AR01718
changes in the sex and cancer type distribution these cases had not been submitted to the expected with the inclusion of pathology
of cancer cases over time. Canadian Cancer Registry. reports starting with 2011 data (these data are
• Non–age-standardized net survival estimates for • Benign and borderline tumours and carcinomas not yet available).
all cancers combined (Table 3.1) were similarly in situ are not routinely captured or reported • At the time of publication, no death certificate
calculated as the weighted sum of the except for in situ carcinomas of the bladder, only (DCO) cases had been reported to the CCR
unrounded sex- and cancer-specific net survival which are considered invasive for the purpose from Ontario for 2017, from Manitoba for 2013
estimates (both sexes) or as the weighted sum of incidence reporting for all provinces and to 2017 and from Quebec for 2010. DCO cases
of the unrounded cancer-specific net survival territories. At the time of analysis, data on in situ for Ontario were imputed by randomly
estimates for each sex (sex-specific). carcinomas of the bladder for Ontario were assigning DCO cases diagnosed in 2014 to 2016
• Observed survival estimates for all childhood limited to 2010 to 2017. to the time period 2017 to 2019 and keeping
cancers combined were calculated as a • In previous editions of this publication, it was only 2017. DCO cases in Manitoba were
weighted average of sex and diagnostic group- noted that data from Newfoundland and estimated by using the DCO cases diagnosed in
specific estimates. The weights used were based Labrador (NL) were potentially affected by 2008 to 2012 and randomly assigning them to
on the sex and diagnostic group case-mix under-reporting of cases due to incomplete the time period 2013 to 2017. DCOs for Quebec
distribution of people aged 0 to 14 diagnosed linkage of cancer and vital statistics information. were imputed by randomly assigning DCO
with cancer in Canada, excluding Quebec, from The NL Cancer Registry has implemented cases diagnosed in 2007 to 2009 to the time
2010 to 2014.(15) death clearance processes to improve case period 2010 to 2012 and keeping only 2010.
• Case-mix standard weights are applicable to ascertainment and have also improved the These DCO cases were all assumed to be first
both crude and age-standardized estimates for reporting of cases from subprovincial regions cancer diagnoses when calculating the
all cancers combined. that previously under-reported cases. As a probability of developing cancer.
result of the enhancements to the NL Cancer • In October 2014, Ontario implemented a new
Data and methods issues Registry, case ascertainment is improved in the cancer reporting system. The new system has
2006 data onward. However, under-reporting several enhancements that permit the
Incidence persists in this province in years prior to 2006. identification of cancer cases that previously
Although the Canadian Council of Cancer For example, the total number of cases reported went unrecorded. These include the use of
Registries and its standing Data Quality and to the CCR by NL for 2005 is 21% lower than more liberal rules for counting multiple primary
Management Committee make every effort to the corresponding count for 2006. sites, the use of additional source records and
achieve uniformity in defining and classifying • Because the Quebec registry relied primarily on the inclusion of records that were previously not
new cancer cases, reporting procedures and hospital data for the period included in the included. The new system has applied these
completeness still vary across the country. The present publication, the numbers of cases of changes retrospectively to the 2010 diagnosis
standardization of case-finding procedures, year onward. The relative number of cases of
some cancers are underestimated, particularly
including linkage to provincial or territorial certain types of cancer — including bladder,
for those where pathology reports represent the
mortality files, has improved the registration of
main source of diagnostic information. Prostate non-Hodgkin lymphoma, leukemia, multiple
cancer cases and comparability of data across the
cancer, melanoma and bladder cancer are myeloma, melanoma and stomach — reported
country. Some specific issues remain:
affected in particular.(44) The 2021 projections for to the CCR from Ontario increased considerably
• The analytic file used for cancer incidence following this implementation, while for many
these cancer types may be an underestimate
analyses does not include cases diagnosed in other cancers studied in this publication there
because an increase in cases in the registry is
the province of Quebec from 2011 onward as was little change.

AR01719
• Non-melanoma skin cancers (neoplasms, NOS; Since this publication uses historical data, data • Liver cancer mortality statistics in this
epithelial neoplasms, NOS; basal and squamous) were collapsed into the IARC rules for all publication exclude liver, unspecified (C22.9).
are not included since most PTCRs do not regions. Consequently, cancer counts for some This decision was based on unpublished
collect incidence data on this type of cancer. provinces may appear lower in this publication analyses performed by the Public Health
These cancers are difficult to register because than cancer counts in provincial cancer reports. Agency of Canada indicating a consequential
they may be diagnosed and/or treated in a The magnitude of difference between the two number of CCR decedents without a registered
variety of settings that do not report to the systems varies by province, cancer, sex and primary liver cancer had C22.9 as their
PTCRs, including dermatologist offices. diagnosis year. For example, analyses performed underlying cause of death. In other words,
• Some PTCRs experience delays in submitting all by the Public Health Agency of Canada using C22.9 likely includes a substantial number of
cases for a reference period to Statistics Canada CCR data showed British Columbia would deaths from cancers that metastasized to the
due to timing of collection and/or reporting report approximately 6% more female breast liver. Nevertheless, given C22.9 also contains
within their own registry systems.(6) Cases cancer cases under the SEER rules compared primary liver cancer deaths, its exclusion from
delayed for one data submission are often with the IARC rules for diagnosis year 2010.(45) the liver cancer mortality definition used in this
reported in the next submission year and the For melanoma among males in British publication results in underestimated liver
missing cases are added to their appropriate Columbia, the number of new cases in 2010 cancer deaths. The impact of adding liver,
diagnosis year. Generally, the reporting delay for under the SEER rules would be about 8% unspecified (C22.9) to the current liver cancer
the most recent year ranges between 2% and higher than under the IARC rules. A recent mortality definition would be substantial,
3% nationally, which may impact the estimates paper from the US based on data from the increasing the number of liver cancer deaths in
in this publication. SEER program reported similar differences Canada in 2012 by about 45.9% (from 1,059 to
between statistics based on SEER and IARC 1,545 deaths). Therefore, the method of defining
rules(46) and also examined the impact of the liver cancer mortality should be acknowledged
Multiple primaries rules on reported trends. when comparing estimates across sources. For
• There are two common systems of rules used to example, code C22.9 is included in the
determine when a second or subsequent cancer presentation of liver and intrahepatic bile duct
should be considered a new primary cancer, as
Mortality cancer mortality statistics in the annual SEER
opposed to a relapse or duplicate of a previously Although procedures for registering and allocating Cancer Statistics in Review publication.(24) It is
cause of death have been standardized both also included in the presentation of liver cancer
registered cancer: one from the International
nationally and internationally, some lack of
Agency for Cancer Research (referred to as the mortality statistics in the annual Cancer in
specificity and uniformity is inevitable. The
“IARC rules”) and one from the Surveillance, North America (CINA) publication.(47) The
description of cancer type provided on the death
Epidemiology, and End Results Program certificate is usually less accurate than that Canadian Cancer Statistics Advisory Committee
(referred to as “SEER rules”). IARC rules tend to obtained by the cancer registries from hospital will continue to examine this issue when
yield lower total case counts than the SEER and pathology records. Although there have been deciding on the definition to use for future
rules because IARC rules generally do not numerous small changes in definitions over the publications.
permit multiple cancers to be diagnosed at the years (see Tables A2-1 and A2-2), there are a few
same site within a single individual. of note:
• Although all provinces and territories now
register cancers according to the SEER rules for
multiple primaries, historically, some did not.

AR01720
• The analytic file used for the mortality analysis 12. Statistics Canada [Internet]. Annual Demographic Estimates: Canada, Provinces and 33. Hinchliffe SR, Dickman PW, Lambert PC. Adjusting for the proportion of cancer deaths
Territories. Catalogue no. 91-215-x. Ottawa, ON: Statistics Canada; 2020. Available at: in the general population when using relative survival: A sensitivity analysis. Cancer
did not include deaths from Yukon for the 2017 http://www.statcan.gc.ca/pub/91-215-x/91-215-x2016000-eng.pdf (accessed April Epidemiol. 2012;36(2):148–52.
2021).
to 2019 period as this data had yet to be 34. Ellison LF. Progress in net cancer survival in Canada over 20 years. Health Rep.
13. Statistics Canada [Internet]. Population Projections for Canada (2018 to 2068), 2018;29(9):10–8.
reported to the CVSD at the time of file release. Provinces and Territories (2018 to 2043). Catalogue no. 91-520-x). Ottawa, ON: 35. Ellison LF, Bryant H, Lockwood G, Shack L. Conditional survival analyses across cancer
Statistics Canada; 2019. Available at: https://www150.statcan.gc.ca/n1/en/
This necessitated the imputation of cancer pub/91-520-x/91-520-x2019001-eng.pdf?st=AtOO8q7u (accessed April 2021).
sites. Health Rep. 2011;22(2):21–5.
36. Henson DE, Ries LA. On the estimation of survival. Semin Surg Oncol. 1994;10(1):2–6.
deaths in Yukon for these three data years. 14. Statistic Canada [Internet]. Social data linkage environment. Available at: https://www.
37. Ellison LF, Gibbons L. Survival from cancer — up-to-date predictions using period
statcan.gc.ca/eng/sdle/index (accessed April 2021).
This was accomplished by randomly assigning 15. Ellison LF, Xie L, Sung L. Trends in paediatric cancer survival in Canada, 1992 to 2017.
analysis. Health Rep. 2006;17(2):19–30.
38. Ellison LF. An empirical evaluation of period survival analysis using data from the
cancer deaths in this jurisdiction from the 2012 Health Rep. 2021;32(2):3–15.
Canadian Cancer Registry. Ann Epidemiol. 2006;16(3):191–6.
16. Statistics Canada [Internet]. Life Tables, Canada, Provinces and Territories, 2016 to
to 2016 period to the 2017 to 2021 period and 2018 (Catalogue no. 84-537). Ottawa, ON: Statistics Canada. Available at: https://
39. Brenner H, Soderman B, Hakulinen T. Use of period analysis for providing more
up-to-date estimates of long-term survival rates: Empirical evaluation among 370,000
then retaining only the data for 2017 to 2019. www150.statcan.gc.ca/n1/en/catalogue/84-537-X (accessed April 2021).
cancer patients in Finland. Int J Epidemiol. 2002;31(2):456–62.
17. Statistics Canada. Special request tabulation completed by demography division.
40. Talback M, Stenbeck M, Rosen M. Up-to-date long-term survival of cancer patients: An
Ottawa, ON: Statistics Canada; 2020.
evaluation of period analysis on Swedish Cancer Registry data. Eur J Cancer.
18. Dickman PW, Auvinen A, Voutilainen ET, Hakulinen T. Measuring social class 2004;40(9):1361–72.
Survival differences in cancer patient survival: Is it necessary to control for social class
differences in general population mortality? A Finnish population-based study. J
41. Brenner H, Gefeller O, Hakulinen T. Period analysis for “up-to-date” cancer survival
data: Theory, empirical evaluation, computational realisation and applications. Eur J
Survival analyses do not include data from Epidemiol Community Health. 1998;52(11):727–34.
Cancer. 2004;40(3):326–35.
Quebec because cases diagnosed in this province 19. National Cancer Institute [Internet]. International Classification of Childhood Cancer
42. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age
(ICCC) Recode ICD-0-3/WHO 2008. Bethesda, MD: Surveillance Epidemiology, and End
from 2011 onward have not been submitted to the Results Program (SEER); 2008. Available at: https://seer.cancer.gov/iccc/iccc-who2008.
standardising survival ratios. Eur J Cancer. 2004;40(15):2307–16.
html (accessed April 2021). 43. Ellison LF. The cancer survival index: Measuring progress in cancer survival to help
Canadian Cancer Registry. evaluate cancer control efforts in Canada. Health Rep. 2021;32(9):14–26.
20. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of
Childhood Cancer, Third edition. Cancer. 2005;103(7):1457–67. 44. Brisson J, Major D, Pelletier E. Evaluation of the completeness of the fichier des
tumeurs due Quebec. Quebec, QC: Institut National de la Santé Publique du Quebec;
References 21. Swerdlow SH, Campo E, Harris NL. WHO Classification of Tumours of Haematopoietic
and Lymphoid Tissues. Geneva, Switzerland: World Health Organization; 2008.
2003.
1. National Cancer Institute. DevCan: Probability of developing or dying of cancer 45. Zakaria D. The impact of multiple primary rules on cancer statistics in Canada, 1992 to
22. Gouvernement du Québec [Internet]. Registre québécois du cancer incidence du
software, Version 6.7.4. Surveillance Research Program, Statistical Methodology and 2012. J Registry Manag. 45(1):8–20.
cancer au Québec pour l’année 2011 : Données préliminaires et considérations
Applications; 2012. 46. Weir HK, Johnson CJ, Ward KC, Coleman MP. The effect of multiple primary rules on
méthodologiques. Quebec, QC; 2018. Available at: http://publications.msss.gouv.qc.
2. Qiu Z, Hatcher, J. CANPROJ—The R package of cancer projection methods based on ca/msss/fichiers/2017/17-902-36W.pdf (accessed April 2021). cancer incidence rates and trends. Cancer Causes Control. 2016;27(3):377–90.
generalized linear models for age, period, and/or cohort. Alberta: Alberta Health 47. Sherman R, Firth R, Charlton M, al e. Cancer in North America: 2013–2017.
23. Chen HS, Zeichner S, Anderson RN, Espey DK, Kim HJ, Feuer EJ. The joinpoint-jump
Services: Technique Report for Cancer Projections Network (C-Proj); 2011. Springfield, IL: North American Association of Central Cancer Registries.
and joinpoint-comparability ratio model for trend analysis with applications to coding
3. Joinpoint Regression Program. Version 4.7.0.0. Statistical Methodology and changes in health statistics. J Off Stat. 2020;36(1):49–62.
Applications Branch, Surveillance Research Program. National Cancer Institute; 2019.
24. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. [Internet], SEER
4. Joinpoint Regression Program. Version 4.6.0.0. Statistical Methodology and cancer statistics review, 1975–2018. Bethesda, MD: National Cancer Insitute; 2021.
Applications Branch, Surveillance Research Program. National Cancer Institute; 2019. [Based on November 2020 SEER data submission]. Available at: https://seer.cancer.gov/
5. Perme MP, Stare J, Estève J. On estimation in relative survival. Biometrics. csr/1975_2018/ (accessed April 2021).
2012;68(1):113–20. 25. Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Grande E, et al.
6. Statistics Canada [Internet]. Canadian Cancer Registry. Ottawa, ON: Statistics Multiple tumours in survival estimates. Eur J Cancer. 2009;45(6):1080–94.
Canada; 2021. Available at: http://www23.statcan.gc.ca/imdb/p2SV. 26. Brenner H, Hakulinen T. Patients with previous cancer should not be excluded in
pl?Function=getSurvey&SDDS=3207 (accessed April 2021). international comparative cancer survival studies. Int J Cancer. 2007;121(10):2274–8.
7. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin D, et al (eds). 27. Ellison LF. Measuring the effect of including multiple cancers in survival analyses using
International Classification of Disease for Oncology, Third edition, First revision. data from the Canadian Cancer Registry. Cancer Epidemiol. 2010;34(5):550–5.
Geneva, Switzerland: World Health Organization; 2013.
28. Ellis L, Woods LM, Esteve J, Eloranta S, Coleman MP, Rachet B. Cancer incidence,
8. World Health Organization. International Classification of Diseases, Ninth revision. survival and mortality: Explaining the concepts. Int J Cancer. 2014;135(8):1774–82.
Volume 1 and 2 Geneva, Switzerland: World Health Organization; 1977.
29. Dickman PW [Internet]. Estimating and modelling relative survival using SAS. Available
9. International Agency for Research on Cancer [Internet]. International Rules for Multiple at: http://www.pauldickman.com/software/sas/ (accessed April 2021).
Primary Cancers (ICD-O Third Edition). Lyon, France: IARC; 2004.
30. Lambert PC, Dickman PW, Rutherford MJ. Comparison of different approaches to
10. Statistics Canada [Internet]. Canadian Vital Statistics—Death Database (CVSD). estimating age standardized net survival. BMC Med Res Methodol. 2015;15:64.
Ottawa, ON: Statistics Canada; 2021. Available at: http://www23.statcan.gc.ca/imdb/
31. Ellison LF. Adjusting relative survival estimates for cancer mortality in the general
p2SV.pl?Function=getSurvey&SDDS=3233 (accessed April 2021).
population. Health Rep. 2014;25(11):3–9.
11. World Health Organization. International Statistical Classification of Disease and
32. Talback M, Dickman PW. Estimating expected survival probabilities for relative survival
Related Health Problems, Tenth revision. Volumes 1 to 3. Geneva, Switzerland: World
analysis — exploring the impact of including cancer patient mortality in the
Health Organization; 1992.
calculations. Eur J Cancer. 2011;47(17):2626–32.

AR01721
TABLE A1 Cancer definitions

ICD-O-3 Site/type ICD-9 ICD-10 ICD-9
Cancer
Incidence (1992–2017) Incidence (1984–1991) Mortality (2000–2019) Mortality (1984–1999)
Head and neck C00–C14, C30-C32.9 140-149, 160, 161 C00–C14, C30–C32 140-149, 160, 161
Esophagus C15 150 C15 150
Stomach C16 151 C16 151
Colorectal C18–C20, C26.0 153, 159.0, 154.0, 154.1 C18–C20, C26.0 153, 159.0, 154.0, 154.1
Liver C22.0 155.0 C22.0, C22.2–C22.4, C22.7 155.0
Pancreas C25 157 C25 157
Lung and bronchus C34 162.2–162.5 162.8, 162.9 C34 162.2, 162.3, 162.4, 162.5, 162.8, 162.9
Melanoma C44 (Type 8720–8790) 172 C43 172
Breast C50 174, 175 C50 174, 175
Cervix C53 180 C53 180
Uterus (body, NOS) C54–C55 179, 182 C54–C55 179, 182
Ovary C56.9 183.0 C56 183.0
Prostate C61.9 185 C61 185
Testis C62 186 C62 186
Bladder (including in situ for incidence) C67 188, 233.7 C67 188
Kidney and renal pelvis C64.9, C65.9 189.0, 189.1 C64–C65 189.0, 189.1
Brain/CNS C70–C72 191, 192 C70–C72 191, 192
Thyroid C73.9 193 C73 193
Hodgkin lymphoma* Type 9650–9667 201 C81 201
Non-Hodgkin lymphoma* Type 9590–9597, 9670–9719, 9724–9729, 200, 202.0–202.2, 202.8, 202.9 C82–C86 200, 202.0–202.2, 202.8, 202.9
9735, 9737, 9738
Type 9811-9818, 9823, 9827, 9837 all
sites except C42.0, C42.1, C42.4
Multiple myeloma* Type 9731, 9732, 9734 203.0, 238.6 C90.0, C90.2, C90.3 203.0, 238.6
Leukemia* Type 9733, 9742, 9800–9801, 9805-9809, 204.0, 204.1, 205.0, 207.0, 207.2, 205.1, C91–C95, C90.1 204.0, 204.1, 205.0, 207.0, 207.2, 205.1,
9820, 9826, 9831–9836, 9840, 9860– 202.4, 204.2, 204.8, 204.9, 205.2, 205.3, 202.4, 204.2, 204.8, 204.9, 205.2, 205.3,
9861, 9863, 9865–9867, 9869–9876, 205.8, 205.9, 206.0, 206.1, 206.2, 206.8, 205.8, 205.9, 206.0, 206.1, 206.2, 206.8,
9891, 9895–9898, 9910, 9911, 9920, 206.9, 203.1, 207.1, 207.8, 208.0, 208.1, 206.9, 203.1, 207.1, 207.8, 208.0, 208.1,
9930–9931, 9940, 9945–9946, 9948, 208.2, 208.8, 208.9 208.2, 208.8, 208.9
9963–9964
Type 9811-9818, 9823, 9827, 9837 sites
C42.0, C42.1, C42.4
All other cancers All sites C00–C80 not listed above All sites 140-209 not listed above All sites C00–C80 not listed above, C97 All sites 140-209 not listed above
All cancers All invasive sites All invasive sites All invasive sites All invasive sites
* For incidence, histology types 9590–9992 (leukemia, lymphoma and multiple myeloma), 9050–9055 (mesothelioma) and 9140 (Kaposi sarcoma) are excluded from other specific organ sites.
Note: ICD-O-3 refers to the International Classification of Diseases for Oncology, Third Edition.(7) ICD-10 refers to the International Statistical Classification of Diseases and Related Health Problems, Tenth
Revision.(11) ICD-9 refers to the International Statistical Classification of Diseases and Related Health Problems, Ninth Revision.(8)

AR01722
TABLE A2-1 Recent cancer definition changes in incidence
New definition Year changed Old definition

Bladder ICD-O-3 C67 (including in situ cancers, 2006 ICD-O-3, C67
except for Ontario which did not report in situ (not including in situ cancers)
bladder cancer cases prior to 2010)
Colorectal ICD-O-3 C18–C20, C26.0 2011 ICD-O-3 C18–C21, C26.0
Kidney and renal pelvis ICD-O-3 C64–C65 2008 ICD-O-3 C64–C66, C68
Lung and bronchus ICD-O-3 C34 2008 ICD-O-3 C33–C34 (before 2006)
ICD-O-3 C34 (in 2006)
ICD-O-3 C33–C34 (in 2007)
Ovary ICD-O-3 C56 2006 ICD-O-3 C56, C57.0–C57.4
Note: Bladder, colorectal, kidney, lung and ovary cancers exclude histology types 9590–9992 (leukemia, lymphoma and multiple
myeloma), 9050–9055 (mesothelioma) and 9140 (Kaposi sarcoma). ICD-O-3 refers to the International Classification of Diseases for
Oncology, Third Edition.(7)
Note: As of 2021, this publication reports on a new cancer category: head and neck cancers include cancers of the lip, oral cavity and
pharynx previously associated with the “oral cancers” category, those of the larynx (which previously had their own category), as well
as cancers of the nasal cavity and middle ear, and cancers of the accessory sinuses (which were previously part of the “all other cancers”
category).
TABLE A2-2 Recent cancer definition changes in mortality
New definition Year changed Old definition

Colorectal ICD-10 C18–C20, C26.0 2012 ICD-10 C18–C21, C26.0
Kidney and renal pelvis ICD-10 C64–C65 2008 ICD-10 C64–C66, C68
Leukemia ICD-10 C91–C95, C90.1 2008 ICD-10 C91–C95
Liver ICD-10 C22.0, C22.2–C22.7 2007 ICD-10 C22 (before 2006)
ICD-10 C22.0, C22.2–C22.9 (in 2006)
Lung and bronchus ICD-10 C34 2008 ICD-10 C33–C34 (before 2006)
ICD-10 C34 (in 2006)
ICD-10 C33–C34 (in 2007)
Multiple myeloma ICD-10 C90.0, C90.2 2008 ICD-10 C88, C90 (before 2007)
ICD-10 C90 (in 2007)
Ovary ICD-10 C56 2006 ICD-10 C56, C57.0–C57.4
All other and unspecified ICD-10 C44, C46, C76–C80, C88,C96.0– 2007 ICD-10 C44, C46, C76–C80,C96.0–C96.2,
cancers C96.2, C96.7–C96.9, C97 C96.7–C96.9, C97
Note: ICD-10 refers to the International Statistical Classification of Disease and Related Health Problems, Tenth Revision.(11)
Note: As of 2021, this publication reports on a new cancer category: head and neck cancers include cancers of the lip, oral cavity and
pharynx previously associated with the “oral cancers” category, those of the larynx (which previously had their own category), as well
as cancers of the nasal cavity and middle ear, and cancers of the accessory sinuses (which were previously part of the “all other cancers”
category).

Index of tables and figures
AR01723
Tables 2.6 Annual percentage change (APC) and average annual Appendix tables
percent change (AAPC) in age-standardized mortality
1.1 Lifetime probability of developing cancer, Canada A1 Cancer definitions . . . . . . . . . . . . . . . . . . . . . . . 90
rates (ASMR) for selected cancers, by sex, Canada,
(excluding Quebec), 2017 . . . . . . . . . . . . . . . . . . . 24 A2-1 Recent cancer definition changes in incidence . . . . 91
1984–2019 . . . . . . . . . . . . . . . . . . . . . . . . . 53, 54
1.2 Projected new cases and age-standardized incidence A2-2 Recent cancer definition changes in mortality . . . . 91
2.7 Most recent annual percent change (APC) in age-
rates (ASIR) for cancers, by sex, Canada, 2021 . . . . 25
standardized mortality rates (ASMR) for selected
1.3 Projected new cases for the most common cancers, by cancers, by sex, Canada, 1984–2019. . . . . . . . . . . 55
age group and sex, Canada, 2021 . . . . . . . . . . . . . 26
3.1 Predicted five- and 10-year net survival for selected
1.4 Projected age-standardized incidence rates (ASIR) for cancers by sex, ages 15–99, Canada (excluding
selected cancers, by sex and province, Canada Quebec), 2015–2017 . . . . . . . . . . . . . . . . . . . . . . 62
(excluding Quebec), 2021 . . . . . . . . . . . . . . . . . . . 27
3.2 Predicted five–year net survival for selected cancers
1.5 Projected new cases for selected cancers, by sex and by age group, Canada (excluding Quebec),
province, Canada, 2021 . . . . . . . . . . . . . . . . . . . . 28 2015–2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
1.6 Annual percent changes (APC) and average annual 3.3 Predicted one- and five-year observed survival
percent change (AAPC) in age-standardized incidence proportions by diagnostic group and selected
rates (ASIR) for selected cancers, by sex, Canada subgroups, ages 0–14 at diagnosis, Canada
(excluding Quebec), 1984–2017 . . . . . . . . . . . . . . 29 (excluding Quebec), 2013–2017 . . . . . . . . . . . . . . 64
1.7 Most recent annual percent change (APC) in age- 3.4 Predicted five-year age-standardized net survival
standardized incidence rates (ASIR), by sex, Canada for selected cancers by province, ages 15–99,
(excluding Quebec), 1984–2017 . . . . . . . . . . . . . . 32 Canada (excluding Quebec), 2015–2017 . . . . . . . . 65
2.1 Lifetime probability of dying from cancer, Canada 3.5 Predicted net survival for one year and for five years
(excluding Quebec), 2019 . . . . . . . . . . . . . . . . . . . 48 from diagnosis (conditional on having survived one
2.2 Projected deaths and age-standardized mortality rates year), for selected cancers, by sex, ages 15–99,
(ASMR) for cancers, by sex, Canada, 2021 . . . . . . . 49 Canada (excluding Quebec), 2015–2017 . . . . . . . . 66
2.3 Projected deaths for the most common causes of
cancer death, by age group and sex, Canada, 2021 50
2.4 Projected age-standardized mortality rates (ASMR)
for selected cancers, by sex and province, Canada,
2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
2.5 Projected deaths for selected cancers by sex and
province, Canada, 2021 . . . . . . . . . . . . . . . . . . . . 52

AR01724
Figures 2.6 Deaths and age-standardized mortality rates (ASMR)

for all cancers, Canada, 1984–2021 . . . . . . . . . . . 39
1.1 Lifetime probability of developing cancer, Canada
(excluding Quebec), 2017 . . . . . . . . . . . . . . . . . . . 11 2.7 Most recent annual percent change (APC) in age-
standardized mortality rates (ASMR) for selected
1.2 Percent distribution of projected new cancer cases, by
cancers, by sex, Canada, 1984–2019. . . . . . . . . . . 40
sex, Canada, 2021 . . . . . . . . . . . . . . . . . . . . . . . . 12
2.8 Age-standardized mortality rates (ASMR) for
1.3 Percentage of new cases and age-specific incidence
selected cancers, males, Canada, 1984–2021 . . . . . 41
rates for all cancers, by age group and sex, Canada
(excluding Quebec), 2015–2017 . . . . . . . . . . . . . . 13 2.9 Age-standardized mortality rates (ASMR) for
selected cancers, females, Canada, 1984–2021 . . . 42
1.4 Distribution of new cancer cases for selected
cancers, by age group, Canada (excluding Quebec), 3.1 Predicted net survival for leading causes of cancer
2013–2017 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 death by survival duration, ages 15–99, Canada
(excluding Quebec), 2015–2017 . . . . . . . . . . . . . . 57
1.5 Geographic distribution of projected new cancer
cases and age-standardized incidence rates (ASIR), 3.2 Predicted five-year age-standardized net survival
by province and territory, both sexes, 2021. . . . . . . 15 for selected cancers by time period, ages 15–99,
Canada (excluding Quebec), 2015–2017 versus
1.6 New cases and age-standardized incidence rates
1992–1994 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
(ASIR) for all cancers, Canada, 1984–2021 . . . . . . 16
4.1 Proportion of deaths due to cancer and other causes,
1.7 Most recent annual percent change (APC) in
Canada, 2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . 67
age-standardized incidence rates (ASIR), by sex,
Canada (excluding Quebec), 1984–2017 . . . . . . . . 17 4.2 Selected causes of death and their associated
potential years of life lost (PYLL), Canada,
1.8 Age-standardized incidence rates (ASIR) for selected
2017–2019 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
cancers, males, Canada (excluding Quebec),
1984–2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 4.3 Age-standardized incidence and mortality rates for
all cancers combined, by sex, Canada, 1984–2021 70
1.9 Age-standardized incidence rates (ASIR) for selected
cancers, females, Canada (excluding Quebec), 4.4 Trends in new cases and deaths (in thousands) for all
1984–2021 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 cancers and ages, attributed to changes in cancer risk
and cancer control practices, population growth and
2.1 Lifetime probability of dying from cancer, Canada
aging population, Canada, 1984–2021 . . . . . . . . . 71
(excluding Quebec), 2019 . . . . . . . . . . . . . . . . . . . 34
4.5 Summary of key cancer control and outcome
2.2 Percent distribution of projected cancer deaths,
characteristics by cancer type . . . . . . . . . . . . . . . . 72
by sex, Canada, 2021. . . . . . . . . . . . . . . . . . . . . . 35
2.3 Percentage of cancer deaths and age-specific
mortality rates for all cancers, by age group and sex,
Canada, 2017–2019 . . . . . . . . . . . . . . . . . . . . . . 36
2.4 Distribution of cancer deaths for selected cancers by
age group, Canada, 2015–2019 . . . . . . . . . . . . . . 37
2.5 Geographic distribution of projected cancer deaths and
age-standardized mortality rates (ASMR), by province
and territory, both sexes, Canada, 2021 . . . . . . . . . 38

AR01725
Contact us
Collaborators Canadian Council of Cancer Vital Statistics Council for Canada

Registries Mortality data are supplied to Statistics Canada
Canadian Cancer Society by the provincial and territorial Vital Statistics
Cancer incidence data are supplied to Statistics
For general information about cancer (such as Canada by provincial and territorial cancer Registrars to form the Canadian Vital Statistics—
cancer prevention, screening, diagnosis, treatment registries to form the Canadian Cancer Registry Death Database (CVSD). The Canadian Vital
or care), contact the Canadian Cancer Society’s (CCR). The CCR is governed by the Canadian Statistics System is governed by the Vital
Cancer Information Helpline at 1-888-939- Council of Cancer Registries (CCCR), a Statistics Council for Canada (VSCC) since 1945.
3333 or visit cancer.ca. For questions about this collaboration between the 13 provincial and The VSCC is a collaboration between the 13
publication, email: stats@cancer.ca. territorial cancer registries and the Centre provincial and territorial Vital Statistics Registrars
for Population Health Data Statistics Canada. and the federal government represented by the
Public Health Agency of Canada Information about the CCR and CCCR can be Centre for Population Health Data of Statistics
(PHAC) found on Statistics Canada’s Canadian Cancer Canada. Detailed information on the VSCC and
Registry (CCR) website. Detailed information the CVSD can be found on Statistics Canada’s
For information on chronic diseases including
regarding the statistics for each province or Vital Statistics—Death Database (CVSD).
cancer, their determinants, and their risk and
territory is available from the relevant registry:
protective factors in Canada, please refer to
https://www.canada.ca/en/public-health.html Newfoundland and Labrador
(select “Chronic Diseases”) or email: phac.chronic. Prince Edward Island
publications-chronique.aspc@canada.ca. Nova Scotia
New Brunswick
Statistics Canada Quebec
More detailed information on the methodology Ontario
used in this publication is available from the Manitoba
Centre for Population Health Data at Statistics Saskatchewan
Canada, National Enquiries Line (1-800-263- Alberta
1136) or through Client Services at the Centre for British Columbia
Population Health Data (statcan.hd-ds.statcan@ Nunavut
canada.ca or 613-951-1746). Northwest Territories
Yukon
Statistics Canada

AR01726
Questions about cancer?

When you want to know more about cancer, call the
Canadian Cancer Society’s Cancer Information Helpline.
1-888-939-3333 Monday to Friday

-
cancer.ca
Canadian
Cancer
Society
AR01727
This is Exhibit “D” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
SAM A. PRESVELOS
AR01728
l♦I
Statistics Statistique
Canada Canada
..,
..,
[ D
-r
I -I
--1 ·- - ·
--- I I I I I I
-
-
AR01729
-r
-I
--1
I ---
I --- I
1--
1-
1- 1 AR01730
AR01731
-r
-I
--1
I ---
AR01732
1 -f
-I
--1
I --- I I
- - 1-_ - 1---------------------
- - - - - - - - - -
►
AR01733
This is Exhibit “E” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
SAM A. PRESVELOS
AR01734
Statistics Statistique
l♦I Canada Canada
Canada
AR01735 The Daily, Friday, May 14, 2021
□ ■
■

.--
f-------1
I--,
□ ■
■ □
Component of Statistics Canada catalogue no. 11-001-X 3


Component of Statistics Canada catalogue no. 11-001-X 5

AR01739
·t·,..·.·. .-
This is Exhibit “F” to the Affidavit of Shaun Rickard sworn March 11, 2022
·•'
•.
\'"·
____________________________________
SAM A. PRESVELOS
Unintended consequences of COVID-19: Impact on harms caused by substance use, self-harm and accidental falls | CIHI 2022-03-10, 9:59 PM
AR01740
Unintended consequences of COVID-19: Impact

on harms caused by substance use, self-harm and
accidental falls
The following page discusses suicide and self-harm. Help is available 24/7 if yo
need it:
• 9-1-1
• Your local crisis centre
• Kids Help Phone ! : 1-800-668-6868
• Crisis Text Line powered by Kids Help Phone:
0 Adults can text 741741

0 Youth can text 686868
• First Nations and Inuit Hope for Wellness Help Line ! : 1-855-242-3310
• 1-866-APPELLE (Quebec residents)
• Crisis Services Canada ! : 1-833-456-4566
December 9, 2021 — Canadians are experiencing prolonged public health measures during the
COVID-19 pandemic. While these measures are intended to restrict the spread of COVID-19, they
may also be leading to unintended consequences. Surveys have found declining mental health amon
Canadians during the pandemic due to high levels of anxiety and loneliness, and changes to the care
they were able to access.1, 2 (#ref1) Many of those surveyed reported that their substance use
increased, with 30% reporting increased alcohol consumption and 40% reporting increased cannab
use. As well, at least 5% reported seriously considering suicide.3 (#ref3) This analysis tells the story of
3 selected unintended consequences of the pandemic: harms caused by substance use, self-harm
behaviours and accidental falls that require care at a hospital (emergency department or inpatient
care).
Hospitalizations increased for harms caused by

substance use
https://www.cihi.ca/en/covid-19-resources/impact-of-covid-19-on-canadas-health-care-systems/unintended-consequences Page 1 of 8
AR01741
While hospitalizations for most other conditions declined during the first 16 months of the pandemic
period (March 2020 to June 2021), hospitalizations for harms caused by substance use rose by 9%.
The increase, totalling more than 16,000 additional hospitalizations, was largest in the later stages o
the pandemic period (October 2020 to June 2021). Overall, there were about 190,000
hospitalizations for harms caused by substance use during the entire pandemic period.
Change in hospitalizations for harms caused by substance

use, March 2020 to June 2021
--+- All hospitalizations --o-- Hospitalizations for substance use
30%
20%
en
~
0
N
10%
E
......0
t
C:
0%
ni
~
(.)
-10%
t
...
ni
C:
-20%
QI
...
(.)
QI
Q.
-30%
-40%
Show text version +
Notes
Substances included in this analysis are alcohol, opioids, cannabis, cocaine, other central nervous system
stimulants (e.g., amphetamines), other central nervous system depressants (e.g., benzodiazepines), other
substances, and unknown and multiple substances.
Quebec data is not available for hospitalizations.
Discharge Abstract Database and National Ambulatory Care Reporting System: Data for March 2020 to March
2021 is closed. Data for April to June 2021 is provisional and is subject to change; this data should be interpreted
with caution. Learn about how to use CIHI’s provisional health data (/en/access-data-and-reports/how-to-use-
cihis-provisional-health-data).
Ontario Mental Health Reporting System (OMHRS): Provisional data submitted as of September 1, 2021.
Emergency department data was used to validate harms caused by substance use in the OMHRS data set. See
notes to readers in the data tables for more information.
AR01742
Sources
Discharge Abstract Database, National Ambulatory Care Reporting System and Ontario Mental Health Reporting
System, January to December 2019 (pre-pandemic baseline data) and March 2020 to June 2021 (pandemic data),
Canadian Institute for Health Information.
There are known social inequities related to harms from substance use. In a typical year, people from
the lowest-income neighbourhoods experience more harms from substance use than people from
the highest-income neighbourhoods. This inequity has been more pronounced during the COVID-19
pandemic, with hospitalizations for harms caused by substance use increasing the most in the
lowest-income communities (13%) compared with the highest-income communities (5%). These
findings may reflect the uneven burden of the pandemic on those who use substances.4 (#ref4)
In contrast, emergency department visits due to harms caused by substances remained similar to
pre-pandemic (2019) levels, while overall emergency department visits declined. One of the notable
exceptions is for alcohol harms, where a marked decrease in emergency department visits was
observed.
Patterns of care for alcohol harms changed for youth

and middle-aged adults
Emergency department visits for alcohol harms dropped by 9% during the pandemic period. The
decreases were most pronounced among younger age groups, dropping 36% among those age 10 t
19 and 18% among those age 20 to 29. These decreases may be due to closures of bars and
restaurants, reductions in social interactions and parties, and youth being at home under parental
supervision.5 (#ref5)
In contrast, hospitalizations due to alcohol harms rose by 10% during the pandemic. The increase wa
more pronounced among middle-aged adults (22% increase for those age 30 to 39). Furthermore,
hospitalizations increased more for conditions that can be attributed to chronic alcohol use. For
example, there were almost 4,300 additional hospital stays for chronic medical conditions related to
alcohol, such as liver diseases, and almost 8,000 additional hospitalizations for mental and
behavioural disorders due to alcohol use.
Increases in opioid- and cannabis-related harms

differed by gender
From October 2020 to June 2021, opioid-related harms showed a notable increase — up 36% for
emergency department visits and 30% for hospitalizations. During the pandemic period, men
AR01743
experienced a larger increase in harms from opioids — 33% more hospitalizations compared with a
5% increase for women. It should be noted that our data includes only those who sought or survived
to receive care in hospital. The Public Health Agency of Canada reported an 88% increase in opioid
toxicity deaths from April 2020 to March 2021 relative to the same period prior to the
pandemic.6 (#ref6) This has been attributed to an increasingly toxic drug supply; increased feelings of
isolation, stress and anxiety; and limited availability of or access to services.
From October 2020 to June 2021, there was a notable increase in cannabis-related emergency
department visits and hospitalizations (14% each). In total, there were about 25,000 hospitalizations
for cannabis-related harms from March 2020 to June 2021. Increases in emergency department
visits for cannabis harms were higher for women (21%) compared with men (6%).
Change in emergency department visits and hospitalizations

for opioid and cannabis harms, by gender, March 2020 to
June 2021
■ Male ~ Female
Opioids Cannabis
35%
30%
25%
20%
15%
10%
5%
0%
Emergency Hospitalizations Emergency Hospitalizations
department visits department visits
Show text version +
Notes
For emergency department data, full regional coverage is available for Quebec, Ontario, Alberta and Yukon. Partial
regional coverage is available for Prince Edward Island, Nova Scotia, Saskatchewan and British Columbia.
AR01744
Emergency department data was used to validate harms caused by substance use in the OMHRS data set. See
notes to readers in the data tables for more information.
Sources
Increases in care for self-harm for young females
The pandemic has also impacted patterns of hospital care for self-harm. There were decreases in
emergency department visits (7%) and in hospitalizations (6%) for self-harm from March 2020 to
June 2021, compared with before the pandemic, with larger decreases in the first few months.
The impact of the pandemic on those requiring care for self-harm varied by age and gender. Females
age 10 to 24 saw overall increases in care for self-harm, mostly in the later months of the pandemic
period, with a 10% increase in emergency department visits and a 12% increase in hospitalizations
from October 2020 to June 2021. These young females also represented the largest group seeking
care for self-harm during the pandemic, accounting for almost 40% of all emergency department
visits and more than 30% of all hospitalizations overall.
Change in emergency department visits and hospitalizations

for self-harm, females age 10 to 24, March 2020 to June
2021
AR01745
-+- Emergency department visits -o-- Hospitalizations
50%
40%
...
en
0 30%
N
E
......
0 20%
miC: 10%
Cl!
.s::
(.)
0%
mi
....C:Cl! -10%
QI
~
QI -20%
a.
-30%
-40%
Show text version +
Notes
For emergency department data, full regional coverage is available for Ontario, Alberta and Yukon. Partial regional
coverage is available for Prince Edward Island, Nova Scotia and Saskatchewan.
Emergency department data was used to validate self-harm in the OMHRS data set. See notes to readers in the
data tables for more information.
Sources
It is important to remember that, for self-harm, our data does not capture deaths that occur outside
of hospital or care provided in the community. This analysis provides a high-level indication of
whether Canadians are getting access to the mental health care they need during the pandemic.
Changes in self-harm hospitalizations and emergency department visits, particularly among young
adults, will need to continue to be monitored.
AR01746
The third story of unintended consequences of the pandemic is about accidental falls. Overall, there
was a decrease in emergency department visits (22%) and hospitalizations (4%) for accidental falls
during the pandemic period compared with pre-pandemic levels in 2019. The largest decreases wer
seen for those age 5 to 19. For more information about accidental falls, please see the data tables.
What we don’t know from this information
• Were supervised consumption sites 7 and other harm reduction programs able to continue
operating during the pandemic?
• Are the changes in care for self-harm linked to changes in suicide rates during the pandemic?
Featured resources
Impact of COVID-19 Impact of COVID-19 Impact of COVID-19

on Harms Caused on Self-Harm on Accidental Falls
by Substance Use Behaviour in Canada
These data tables contain These data tables contain These data tables contain
information on emergency information on emergency information on emergency
department (ED) visits and department (ED) visits and department (ED) visits and
hospitalizations from 2 hospitalizations from 2 hospitalizations from 2
periods: pre-pandemic and periods: pre-pandemic and periods: pre-pandemic and
pandemic, to help understand pandemic, to help understand pandemic, to help understand
the impact of COVID-19 on the impact of COVID-19 on the impact of COVID-19 on
harm caused by substance use intentional self-harm in accidental falls in Canada.
in Canada. Canada.
Download data tables (XLSX)
Download data tables (XLSX) Download data tables (XLSX) (https://www.cihi.ca/sites/def
(https://www.cihi.ca/sites/defa (https://www.cihi.ca/sites/defa ult/files/document/impact-
ult/files/document/impact- ult/files/document/impact- covid-19-accidental-falls-
covid-19-harms-caused- covid-19-self-harm-behaviour- march-2020-to-june-2021-
substance-use-march-2020- march-2020-to-june-2021- data-tables-en.xlsx)
to-june-2021-data-tables- data-tables-en.xlsx)
en.xlsx)
Additional resources
AR01747
• Unintended consequences of COVID-19: Impact on harms caused by substance use (May 2021
• Unintended consequences of COVID-19: Impact on self-harm behaviour (May 2021)
• Impact of COVID-19 on accidental falls in Canada (July 2021)
• Webinar: Substance use during COVID-19: How health systems responded ! (May 2021)
• COVID-19 resources
Related resources
• Overview: COVID-19’s impact on Canada’s health care systems
• COVID-19’s impact on emergency departments
• COVID-19’s impact on hospital services
• COVID-19’s impact on physician services
• COVID-19’s impact on long-term care
• COVID-19’s impact on home care
References
1. " Statistics Canada. Survey on COVID-19 and Mental Health, February to May 2021. 2021.
2. " Organisation for Economic Co-operation and Development. Tackling the mental health impact of the COVID-1
crisis: An integrated,-
whole-of-society
- - - - - - - -response.
- - - - Accessed October 13, 2021.
3. " Canadian Centre on Substance Use and Addiction, Mental Health Commission of Canada. Mental Health and
Substance Use During COVID-19 — Summary Report. 2020.
4. " Canadian Centre on Substance Use and Addiction, Mental Health Commission of Canada. Mental Health and
Substance Use During-
COVID-19
----- —-
Summary
- - - -Report
---- 3:-
Spotlight on Income, Employment, Access. 2021.
- - -------
5. " Canadian Centre on Substance Use and Addiction. Boredom and Stress Drives Increased Alcohol Consumptio
During COVID-19: NANOS Poll Summary Report. 2020.
6. " Government of Canada. Opioid- and stimulant-related harms in Canada (September 2021). Accessed October
13, 2021.
7. " Government of Canada. Supervised consumption sites and services.. Accessed December 2, 2021.
AR01748
~
This is Exhibit “G” to the Affidavit of Shaun Rickard sworn March 11, 2022
It<
____________________________________
SAM A. PRESVELOS
AR01749 SUBSCRIBE REGISTER LOG IN AdChoices
FROM $1.99/WK
CANADA WORLD BUSINESS INVESTING OPINION POLITICS SPORTS LIFE ARTS DRIVE REAL ESTATE PODCASTS WATCHLIST
m
Greater possibilities
for the future.
~Invesco
OPINION
Trending
Dr. Tam’s about-face on masks 1 Russian forces appear to take
heavy losses as troops continue
damages trust at a crucial time advance toward Kyiv
OPINION
ROBYN URBACK 2
A
)
PUBLISHED APRIL 7, 2020 A message to Conservatives:

Smarten up – serious times need
This article was published more than 1 year ago. Some information may no longer be current. serious leaders
993 COMMENTS ,. SHARE BOOKMARK 3 Russia-Ukraine live updates:

Protecting Canada’s Arctic key
LISTEN TO ARTICLE V
priority as Russia reoccupies
abandoned Cold War bases,
defence chief says
Last week, Canada’s top doctor said that if we’re not sick, or haven’t been around someone
with a confirmed case of COVID-19, we shouldn’t wear a mask. “Putting a mask on an
Canadian Tire spending $3.4-
asymptomatic person is not beneficial, obviously if you’re not infected,” she said. 4 billion over four years to expand
products, bolster operations
This week, Dr. Theresa Tam did a complete about-face: actually, the use of non-medical
masks can help to control the spread of COVID-19, she said. “Wearing a non-medical mask,
Leaders of truck convoy protests
even if you have no symptoms, is an additional measure that you can take to protect others 5 sought to overthrow government,
around you in situations where physical distancing is difficult to maintain, such as in public
national security adviser says
transit or maybe in the grocery store.”
In normal times, a week is not a long time for a public health official to totally reverse a
previous policy recommendation. But when the world is in the midst of a deadly pandemic,
when a cough from one unknowingly infected person can lead to exponential numbers of
infections, a week is a painfully long time.
Countless Canadians have been taking transit, working essential jobs or stopping into stores
for necessary food and medicine – all with their mouths and noses uncovered, heeding what
was then the advice of Canada’s Chief Public Health Officer. There’s no way of knowing
how much virus was shed during that time.
Dr. Tam’s earlier contention that masks are useless on asymptomatic people was outdated
the moment she said it. (To be fair, the World Health Organization still maintains masks are
only necessary for healthy people when taking care of a sick person.)
A letter published by a group of physicians in Germany in late January outlined a case of

apparent transmission during the incubation period. A case study from February chronicled
an asymptomatic 20-year-old Wuhan woman who infected five of her relatives without
ever developing symptoms. Research published in March suggested that undocumented
infections (meaning not-yet-diagnosed, mildly symptomatic or asymptomatic carriers)
were the source of nearly 80 per cent of documented COVID-19 cases. All of that material
was published before Dr. Tam said, in late March, that “there is no need to use a mask for
well people.”
The purpose of a mask on an asymptomatic person is less to protect the wearer from
everyone else than it is to protect everyone else from the wearer. That’s why, in a public
health emergency, widespread adoption of masks is so important. It’s also why other
countries, including Austria, South Korea, Slovakia, Czech Republic, to name a few, began
coupling physical distancing directives with recommendations to wear masks in public
weeks or months ago.
There are handfuls of studies of varying scopes and methods that suggest that even
homemade masks (which, importantly, preserve medical masks for front line personnel)
offer some benefit in mitigating viral shedding. And while it is true that precise
characteristics of the virus is not yet fully understood, a weighing of available evidence – on
the nature of COVID-19 spread, on the efficacy of masks and on our recent proclivity toward
adopting as many preventative measures as possible – should have made a
recommendation for face masks in Canada a no-brainer.
When pressed by journalists Monday, Dr. Tam attributed her reversal to a review of
evolving evidence. Yet it is unclear to which precise evidence she refers, and why that
evidence was more compelling than the collection of previous published research.
There may have been some concern from public health authorities that recommending
masks for general use would have sent people snapping up medical masks, depleting
supply. Dr. Tam also alluded to the idea that masks can confer a sense of invincibility; that
mask-wearers might feel “protected” enough to ease up physical distancing guidelines. But
both issues can be neutered with clear, unequivocal public health instructions: Here’s how
you wear your mask. Here’s how you take it off. Here’s what you don’t do while wearing a
mask. And please, homemade masks only.
STORY CONTINUES BELOW ADVERTISEMENT
In a time of crisis, the public’s faith in those calling the shots is absolutely critical. Health
authorities are asking a lot of people – to stay home, to avoid seeing friends and family, to
eliminate so many simple, easy pleasures. If people can’t trust the individuals issuing the
directives, they will be far less inclined to follow their instructions.
Dr. Tam has backtracked before – on the risk posed to Canadians by COVID-19, on the
usefulness of travel restrictions and, now, on the efficacy of masks for asymptomatic
individuals. And while we can’t expect health authorities to be omniscient, we can expect
them to be direct, to explain their work, to produce their evidence and to offer some
humility when they get things wrong. That can go a long way in establishing, or repairing,
trust. Dr. Tam has some work to do.
Keep your Opinions sharp and informed. Get the Opinion newsletter. Sign up today.
Your Globe
Follow Robyn Urback on Twitter: @RobynUrback Build your personal news feed
Report an error More info V
Editorial code of conduct

Follow the author of this article:
ROBYN URBACK FOLLOW

Comments L _ I_ _ I
READ OR POST COMMENTS (993) V

Follow topics related to this article:
CORONAVIRUS FOLLOW
Related articles
Check Following for new articles
Theresa Tam issues new guidance on the wearing of masks, but says
there are some caveats to keep in mind
APRIL 6, 2020
OPINION
The moral obligations of our health care workers in a pandemic

'ii
APRIL 3, 2020 I
OPINION
The only exit from this pandemic is through science. We must fund it
APRIL 6, 2020
Boost your financial confidence

Get access to valuable investor tools $1.99 PER WEEK
FOR 24 WEEKS
SUBSCRIBE NOW
AR01750
~
This is Exhibit “H” to the Affidavit of Shaun Rickard sworn March 11, 2022
ttf·:.,
____________________________________
SAM A. PRESVELOS
Discover Thomson Reuters Directory of sites Login Contact Support
AR01751
World Business Markets Breakingviews Video More
EVERY THINGNEWS OCTOBER 8, 2020 / 11:31 AM / UPDATED A YEAR AGO
Fact check: Outdated video of Fauci saying

“there’s no reason to be walking around with a
mask”
By Reuters Staff 5 MIN READ
A video circulating on social media shows Dr Anthony Fauci, director of the

ADVERTISEMENT
National Institute of Allergy and Infectious Diseases (NIAID) at the National
Institutes of Health (NIH), saying “there’s no reason to be walking around with a
mask.” Fauci’s remarks were made on March 8, 2020 and do not represent his
current stance on face coverings nor the updated guidance issued by the Centers
for Disease Control and Prevention (CDC).
Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, wears a Washington
Nationals protective mask during a House Select Subcommittee on the Coronavirus Crisis hearing in
Washington, D.C., U.S., July 31, 2020. Kevin Dietsch/Pool via REUTERS
A post made on Oct. 2 featuring this old video is visible here .
In the clip, Dr Fauci says “There’s no reason to be walking around with a mask.
When you’re in the middle of an outbreak, wearing a mask might make people
feel a little bit better and it might even block a droplet, but it’s not providing the
perfect protection that people think that it is. And, often, there are unintended
consequences — people keep fiddling with the mask and they keep touching their
face.”
Fauci made this comment on an interview with 60 Minutes on March 8, during

the early stages of the novel coronavirus outbreak in the United States. A longer
extract of the interview is visible youtu.be/PRa6t_e7dgI (see 30-second mark).
The interview predates the CDC’s updated guidance on the use of face coverings. TRENDING STORIES
On April 3, 2020, the CDC updated its previous advice and recommended people
EU leaders to make room for more
wear cloth face coverings “in public settings when around people outside their spending over Ukraine, no new
household, especially when social distancing measures are difficult to maintain.” joint debt seen
ADVERTISEMENT Russian military convoy northwest of Kyiv has

dispersed, redeployed -Maxar
Third Point takes stake in Cano

Health, pushes for company sale
Russia says U.S. has biolabs with

plague and anthrax in Ukraine,
U.S. calls claim absurd
Pfizer begins COVID pill study in

high-risk children aged 6-17
CDC’s latest guidance on face coverings is visible here . As of this fact check’s
publication, the CDC recommendation remains almost the same. They ADVERTISEMENT
note children under the age of 2, people who have trouble

breathing, are unconscious or incapacitated should not wear a mask (
archive.vn/wip/TY8JR ).
As Fauci told the Washington Post here , at the beginning of the COVID-19
pandemic, masks were not recommended for the general public, as authorities
were trying to prevent a mask shortage for health workers and the extent of
asymptomatic spread was unknown.
As more information became available about SARS-CoV-2, the virus that causes
COVID-19, health authorities and organizations around the world have changed
their stance towards the impact of face masks and the spread of the disease (
here ).
As of the publishing of this fact check, Fauci is encouraging people to wear face
coverings. Fauci has reaffirmed this stance on interviews on Sept. 21, Aug. 10 and
Aug. 5 that are visible here ( bit.ly/3dbpHsA , bit.ly/36GS9Bz , bit.ly/2GKAw94 )
ADVERTISEMENT
Ad
Secure Your Cloud with Code

The nature of the cloud miscon5guration problem
Fugue.co Open
Reuters has fact-checked outdated medical guidance being shared as if current

and misleading people, examples are visible here , here , here , here .
VERDICT
Partly false. Video shows Fauci’s remarks at early stages of the COVID-19 REUTERS NEWS NOW
pandemic when masks were not yet recommended by the government. As of the Subscribe to our daily curated newsletter to
publishing of this check, Fauci recommends the use of face masks. receive the latest exclusive Reuters coverage
delivered to your inbox.
This article was produced by the Reuters Fact Check team. Read more about our Enter email address
work to fact-check social media posts here .
Submit
Our Standards: The Thomson Reuters Trust Principles.
MORE FROM REUTERS
00:00 00:10
PAID PROMOTIONAL LINKS Promoted

by Dianomi
ADVERTISEMENT
-40%
Surprising trends in the Canadian and U.S. The Huge Electric Vehicle Story Everyone's
labour markets Missing
The Globe and Mail Empire Financial Research
NOUVEAU
Make an executive decision How Far Does $1 Million Last Enbridge Stock Report - Tells
to push your career forward. After 65? you if ENB is a buy or sell. No
Learn more. Fisher Investments Canada Guessing
Harvard Business School VectorVest -10%
MORE FROM REUTERS
Chaussures SoftMoc
SoftMoc Shoes
Philippine mobile wallet GCash raises over $175 Analysis: Cancel your weekends! Bitcoin doesn't rest,
million in new capital and neither...
11 Jan 11 Jan
Bitcoin hits one-week low as rising Russia says China refuses to Russian tourists in Indonesia
U.S. yields dent rally supply Russian airlines with without cash as sanctions bite
11 Jan aircraft... 10 Mar
10 Mar

by Dianomi
Positive results for your client and everyone’s planet. 5 SaaS metrics essential to your organization’s
Learn More. growth
Sponsored by Desjardins Sponsored by Sage
Where leaders go, learning follows. Explore the The Huge Electric Vehicle Story Everyone's Missing
newest programs. Sponsored by Empire Financial Research
Sponsored by HBS Executive Education
ADVERTISEMENT
How Far Does $1 Million Last After 65? Let our experts advise you on a tailored financing
Sponsored by Fisher Investments Canada plan.
-40%
Sponsored by BDC
NOUVEAU
Nio Stock Report - Tells you if NIO is a buy or sell. No File today with TurboTax
Guessing Sponsored by TurboTax®
Sponsored by VectorVest
-10%
Chaussures SoftMoc
SoftMoc Shoes
Buy Alert: This Stock Could Be Like Surprising trends in the Canadian You help others, we help you - with
Buying Facebook In 2012 and U.S. labour markets tailored business insurance advice
Sponsored by The Motley Fool Canada Sponsored by The Globe and Mail Sponsored by Desjardins Insurance
MORE FROM REUTERS
Smelling blood, Huawei's Chinese mobile rivals look Putin ally Chemezov says Russia will be the victor
to capitalise... 10 Mar
23 Nov
Commentary: Ukraine's neo-Nazi Nuclear war? Russia's Lavrov says:

problem 0.82- I don't believe so
19 Mar 0.84%-- 10 Mar
07 Mar

by Dianomi
Attract top talent in a tight labour market Make an executive decision to push your
through automation. career forward. Learn more.
The Globe and Mail Harvard Business School
Nio Stock Report - Tells you The Huge EV Story How Far Does $1 Million Last
if NIO is a buy or sell. No Everyone's Missing After 65?
Guessing Empire Financial Research Fisher Investments Canada
VectorVest
Apps Newsletters Advertise with Us Advertising Guidelines Cookies Terms of Use Privacy
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2022 Reuters. All Rights Reserved.
AR01752
This is Exhibit “I” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
SAM A. PRESVELOS
WATCH LIVE
AR01753
NEWS WEATHER TRAFFIC VIDEO CP24 BREAKFAST LIFESTYLE MORE
Advertisement
Evolving science reason for inconsistent messaging

on COVID-19: Tam
Advertisement
MOST READ
Ontario reports 20 net new

Chief Public Health Officer Dr. Theresa Tam speaks during a press conference during the COVID pandemic in Ottawa on
COVID-19 deaths on Thursday;
Tuesday, Oct. 13, 2020. THE CANADIAN PRESS/Sean Kilpatrick 489 'incidental' deaths from tally
removed
SHARE: Tweet Reddit Share 0 TEXT: El B
Maan Alhmidi, The Canadian Press

Published Thursday, October 22, 2020 3:20PM EDT
Last Updated Thursday, October 22, 2020 4:51PM EDT
OTTAWA - Canada's chief public health officer says messages on how to keep safe during Goodbye to masks, symptom
the COVID-19 pandemic might seem inconsistent, but that's because the epidemiology is screening, self-isolation in most
different across the country and the science on the virus has evolved. circumstances under new
Ontario rules
“We have been criticized as public health professionals for changing our advice over time,”
Dr. Theresa Tam said Thursday.
“We have been doing so because the science is evolving.”

ADVERTISEMENT
The full list of COVID-19

restrictions that will be lifted in
Ontario
Ford defends lifting mask

mandate this month as
Mississauga's mayor raises
concerns about timing of move
Speaking at a journalism conference at Carleton

University in Ottawa, Tam said public health officials RELATED STORIES
had to change their advice regarding wearing non- Fake news creates serious issues
medical masks when epidemiologists came to for battling pandemic, Tam says TDSB holds special meeting on
understand that asymptomatic people can transmit the masks amid confusion around
virus that causes COVID-19. who will get final say on lifting
mandate in classrooms
“This kind of change, I think, is to be expected,” she said. “Science is playing out in real time
in front of TVs and the internet.”
Scientists don't have the luxury of debating things behind closed doors and in peer-reviewed
journals as every event related to COVID-19 is being reported to the public in real time, Tam
said.
When an adverse event happens during a clinical trial of a vaccine candidate, it gets reported
right away, she said. HELP US IMPROVE YOUR
ONLINE EXPERIENCE.
“Normally, you actually had a very thoughtful process of evaluating of these things and then
communicating it,” she said. “That is extremely challenging.” START SURVEY >
Tam said the core public health messages haven't changed, including practising physical
distancing, washing hands, wearing a mask, staying at home when you're sick and avoiding
overcrowded rooms with poor ventilation.
MOST WATCHED
Public health officials have to make their messages clear because if they don't people will
have their own intuitive views on what makes sense and they will make their own decisions
on how to behave under certain circumstances, Tam said.
She said messaging and advice can appear inconsistent because the pandemic is different in
different parts of the country and authorities apply responses to match.
“We are living in a more challenging period right now - to convince people who are fatigued to Everyone has already made up
stick to sustainable habits or public health practices.” minds on masks
Tam said misinformation can travel faster than the virus on the internet, making it more
challenging for public health officials to communicate.
“We needs to sharpen our social media skills, if we're going to combat misinformation in that
sphere,” she said.
The rapidly evolving situations during COVID-19 pandemic have also created fertile ground
for conspiracy theories to grow, Tam said, adding that the problem is not a lack of
information, but too much of it, making it hard for people to know what is credible.
CP24 Breakfast Live Stream
“It's like information junk food,” she said.
People should really either spend a lot of time doing research, or rely on credible sources
who can provide in-depth analysis that translate complex scientific information, Tam said. a
Unreliable sources usually cherry-pick bits of information that fit their narrative, she said,
while scientists and journalists present each side of the argument and tell you what is known
and unknown.
Unrealistic expectations are also making communicating with the public during the pandemic
more difficult.
LIVE4 Digital Channel
“We've never said that the vaccine was going to be 100 per cent effective,” she said. “Even
when a vaccine is safe, effective, we're going to use it, it means it's not going to be 100 per
cent effective. It's just another layer of protection.”
This report by The Canadian Press was first published Oct. 22, 2019.
This story was produced with the financial assistance of the Facebook and Canadian Press
How students feel about end of
News Fellowship.
mask mandates
SHARE: Tweet Reddit Share 0 News Tips Report Errors
TOP VIDEOS
Dr. Kieran Moore defends plan

to end masking
Travel industry continues push Poll: Majority believes COVID Jussie Smollett sentenced to 150
for end of testing pulled people apart days in jail
LOCAL NEWS WORLD NEWS REAL ESTATE NEWS
Ford says Ontario working to ‘cut

Toronto Pearson expecting Russians keep pressure on red tape’ on housing
busiest travel day since start of Mariupol; massive convoy developments as home prices
pandemic Friday for March Break outside Kyiv breaks up rise
• TDSB holds special meeting on • North Korea testing new ICBMs, US • GTA home prices up 28% from last
masks amid confusion around who says, warns more coming year as supply remains hampered:
will get final say on lifting mandate in TRREB
classrooms • U.S. VP Harris embraces call for war
crimes probe of Russia
• Interest rate hike won't cool
• Ford defends lifting mask mandate Canada's housing market, say
this month as Mississauga's mayor experts
raises concerns about timing of move
SPORTS NEWS ENTERTAINMENT NEWS LIFESTYLE NEWS
Maple Leafs No. 1 goaltender

Jack Campbell out at least two 'Black Panther' director mistaken U.S. extends mask rule for travel
weeks with rib injury for bank robber in Atlanta while weighing new approach
• Play ball! MLB players reach deal, • UPDATED Former 'Empire' actor • Health workers prescribe radical
salvage 162-game season changes to health care to treat
Jussie Smollett sentenced to 150
pandemic burnout
• Sanctions on Abramovich see
restrictions placed on Chelsea
days in jail in fake attack
• This tale wags the dog: 'Rescued by • U.S. man who got 1st pig heart
transplant dies after 2 months
Ruby' tells K-9's story
CP24 on Twitter
Tweets by CP24
Home Careers Privacy Policy Terms and Conditions Contact Us About Us Political Ads Registry Advertise on CP24
Toronto News World News Weather Sports News Entertainment News
@ii'?
..,,. BNN CP
8 DT 2 NEWS NEWS
CHANN&:L
Bloomberg
==
Use of this Website assumes acceptance of Terms & Conditions and Privacy Policy
© 2021 BellMedia All rights reserved.

AR01754
~
This is Exhibit “J” to the Affidavit of Shaun Rickard sworn March 11, 2022
It::-:.,
____________________________________
SAM A. PRESVELOS
AR01755
Coronavirus outbreak: Canada's health minister says shutting down borders 'not effective'
https://www.youtube.com/watch?v=L3O1EBQXl6U.
AR01756
This is Exhibit “K” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
SAM A. PRESVELOS
AR01757 World Business Legal Markets Breakingviews Technology Investigations Sports More Sign In Register
Commentary Legal Action by Jenna Greene
January 7, 2022 Health COVID-19 Public Policy

12:51 PM EST
Last Updated 2 months
‘Paramount importance’:
ago
Judge orders FDA to hasten

release of Pfizer vaccine docs Report ad
By Jenna Greene
My View Legal
4 minute read Antitrust Appellate
Attorney Analysis Bankruptcy
Capital Markets Civil Rights
Class Actions & Multi-district Litigation
Competitive Intelligence
Construction
Corporate Counsel
Apply
A vial and sryinge are Companies Law firms Related documents

seen in front of a
displayed Pfizer and
Biontech Pfizer Inc
logo.REUTERS/Dado
Ruvic/Illustration
The company and law firm names shown above are generated automatically based on the text of the
article. We are improving this feature as we continue to test and develop in beta. We welcome feedback,
Register now for which you can provide using the feedback tab on the right of the page.
FREE unlimited
access to
Jan 7 - Score one for transparency.
Reuters.com
Register A federal judge in Texas on Thursday ordered the Food and Drug
Administration to make public the data it relied on to license Pfizer’s COVID-
19 vaccine, imposing a dramatically accelerated schedule that should result
in the release of all information within about eight months.
That’s roughly 75 years and four months faster than the FDA said it could
take to complete a Freedom of Information Act request by a group of doctors
and scientists seeking an estimated 450,000 pages of material about the
vaccine.
The court “concludes that this FOIA request is of paramount public

importance,” wrote U.S. District Judge Mark Pittman in Fort Worth, who was
appointed to the bench by former President Donald Trump in 2019.
The FDA didn’t dispute it had an obligation to make the information public
but argued that its short-staffed FOIA office only had the bandwidth to
review and release 500 pages a month. Latest In Health
Health
While Pittman recognized “the ‘unduly burdensome’ challenges that this Must Medicaid cover trans
teen’s surgery? Too soon to say
FOIA request may present to the FDA,” in his four-page order, he
- 9th Circ
resoundingly rejected the agency’s suggested schedule.
COVID-19
United Airlines to let
Rather than producing 500 pages a month — the FDA's proposed timeline —
unvaccinated employees
he ordered the agency to turn over 55,000 a month. That means all the return to jobs March 28 -memo
Pfizer vaccine data should be public by the end of the summer rather than,
COVID-19
say, the year 2097.
9th Circ signals may need help
with 'take-home' COVID
Even if the FDA may not see it this way, I think Pittman did the agency — and liability question
the country — a big favor by expediting the document production.
Legal Industry
4th Circ. may back West
I’ve been chronicling this fight since November and have heard from of Virginia's limits on attorney
readers who said they felt something was suspicious, even nefarious, in the drug ads
FDA’s proposed slo-mo timeline. Making the information public as soon as

possible may help assuage the concerns of vaccine skeptics and convince
them the product is safe.
Pittman in his order nodded to this as well, including a quote from the late
senator John McCain, who said that excessive administrative secrecy “feeds
conspiracy theories and reduces the public’s confidence in the government.”
Still, the FDA is likely to be hard-pressed to process 55,000 pages a month.
The office that reviews FOIA requests has just 10 employees, according to a
declaration filed with the court by Suzann Burk, who heads the FDA’s Division
of Disclosure and Oversight Management. Burk said it takes eight minutes a
page for a worker “to perform a careful line-by-line, word-by-word review of
all responsive records before producing them in response to a FOIA request.”
At that rate, the 10 employees would have to work non-stop 24 hours a day,
seven days a week to produce the 55,000 pages a month (and would still fall
a bit short).
But as lawyers for the plaintiffs Public Health and Medical Professionals for
Transparency pointed out in court papers, the FDA as of 2020 had 18,062
employees. Surely some can be dispatched to pitch in at the FOIA office.
Aaron Siri of Siri & Glimstad, who represents the plaintiffs, in an email said
the decision "came down on the side of transparency and accountability."
His clients — a group that includes more than 200 doctors, scientists,
professors and public health professionals, including some who have publicly
questioned the efficacy of lockdown policies, mask mandates and the vaccine
itself — have pledged to publish all the information they receive from the
FDA on their website.
The Justice Department, which represented the FDA in the litigation, did not
immediately respond to a request for comment on Thursday evening. Pfizer,
not a party to the suit, also did not immediately respond to a request for
comment.
Pittman in his order made clear that the FOIA request, even if burdensome,
has to be a priority for the FDA.
Quoting from remarks made during the hearing before him on December 14,
he wrote that “there may not be a ‘more important issue at the Food and
Drug Administration . . . than the pandemic, the Pfizer vaccine, getting every
American vaccinated," and assuring the public that the vaccine was not
"'rush[ed] on behalf of the United States.'"
Read more:
Wait what? FDA wants 55 years to process FOIA request over vaccine data
My View
Register now for FREE unlimited Register
access to Reuters.com
Following
Our Standards: The Thomson Reuters Trust Principles.
Saved
Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the
Trust Principles, is committed to integrity, independence, and freedom from bias.
Jenna Greene
Jenna Greene writes about legal business and culture, taking a
broad look at trends in the profession, faces behind the cases, and
quirky courtroom dramas. A longtime chronicler of the legal
industry and high-profile litigation, she lives in Northern California.
Reach Greene at jenna.greene@thomsonreuters.com
More from Reuters Daily Docket

Sign up to our legal newsletter for a smart
Humanitarian corridors look at the day's headlines concerning the
into Russia 'absurd' practice of law.
idea -Blinken
Sign up
Kyiv governor calls fight

for city 'Judgement Day'
Supplying combat
aircraft to Ukraine is
'high risk' -Pentagon
Daily Briefing
Trial over Michigan
governor kidnapping Subscribe to our newsletter to get all the
plot begins news you need to start your day.
U.S. says attack on Sign up

Ukraine children's
hospital 'barbaric'
Sponsored Content
Make an executive decision to push The Huge EV Story Everyone's Attract top talent in a tight labour How Far Does $1 Million Last After
your career forward. Learn more. Missing market through automation. 65?
Sponsored by Harvard Business School Sponsored by Empire Financial Research Sponsored by The Globe and Mail Sponsored by Fisher Investments Canada
Industry Insight
Industry Insight Industry Insight Industry Insight Industry Insight

Boosting retention: Tips to build social How small and midsize accounting firms How professional service firms can recruit For law firms relying on increasing
connections in hybrid work environments can deliver advisory services without & retain top talent in an overheated labor compensation, economics says you lose
12:17 PM EST disrupting their businesses market March 2, 2022
March 7, 2022 March 7, 2022
Sponsored Content
How Far Does $1 Million Last After Transform your company into an AI- Talk to an agent for business File today with TurboTax
65? first leader with this new program. insurance advice that's tailored to
you
Sponsored by Fisher Investments Canada Sponsored by HBS Executive Education Sponsored by Desjardins Insurance Sponsored by TurboTax®
Sponsored Content
Barely anyone knows this Canadian What is the latest on ETFs? Positive results for your client and How to attract and retain talent in a
EV maker… here’s why you should. everyone’s planet. Learn More. worker’s market
Sponsored by The Motley Fool Canada Sponsored by MarketViews Sponsored by Desjardins Sponsored by The Globe and Mail
Sponsored Content
The latest news on commodity Get expert advice to help you keep 5 ways CFOs can keep their The Huge EV Story Everyone's
markets from leading experts moving your business forward. organizations on track in the COVID Missing
era
Sponsored by MarketViews Sponsored by BDC Sponsored by Sage Sponsored by Empire Financial Research
Latest Browse Media About Reuters

Home World Videos About Reuters
Business Pictures Careers
Legal Graphics Reuters News Agency
Markets Brand Attribution Guidelines
Breakingviews Reuters Leadership
Technology Reuters Fact Check
Investigations Reuters Diversity Report
Lifestyle
Stay Informed
Download the App
Newsletters
Information you can trust Follow Us

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia
news provider, reaching billions of people worldwide every day. Reuters provides business,
financial, national and international news to professionals via desktop terminals, the world's
media organizations, industry events and directly to consumers.
Thomson Reuters Products Refinitiv Products

Feedback
Westlaw Onesource Checkpoint Refinitiv Workspace Refinitiv Data Catalogue Refinitiv World-Check
Build the strongest argument The most comprehensive The industry leader for online Access unmatched financial Browse an unrivalled portfolio Screen for heightened risk
relying on authoritative solution to manage all your information for tax, data, news and content in a of real-time and historical individual and entities
content, attorney-editor complex and ever-expanding accounting and finance highly-customised workflow market data and insights from globally to help uncover
expertise, and industry tax and compliance needs. professionals. experience on desktop, web worldwide sources and hidden risks in business
defining technology. and mobile. experts. relationships and human
networks.
Advertise With Us Advertising Guidelines Cookies Terms of Use Privacy Digital Accessibility Corrections Site Feedback
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays. © 2022 Reuters. All rights reserved
AR01758
This is Exhibit “L” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
SAM A. PRESVELOS
AR01759
Case 4:21-cv-01058-P Document 26 Filed 12/07/21 Page 1 of 30 PageID 697
UNITED STATES DISTRICT COURT

NORTHERN DISTRICT OF TEXAS
PUBLIC HEALTH AND MEDICAL

PROFESSIONALS FOR TRANSPARENCY,
Plaintiff, Civil Action No. 4:21-cv-01058-P

-against-
FOOD AND DRUG ADMINISTRATION,
Defendant.
BRIEF IN SUPPORT OF TIMELY PRODUCTION

AR01760
TABLE OF CONTENTS
TABLE OF AUTHORITIES ...................................................................................................... iii
PRELIMINARY STATEMENT ................................................................................................. 1
BACKGROUND ........................................................................................................................... 6
A. The Need for the Transparency as Promised by Pfizer, White House, and FDA ............ 6
B. PHMPT Formed to Disseminate the Promised Vaccine Data.......................................... 8
C. FDA Approval of the Pfizer Vaccine ............................................................................... 8
D. Mandates Abound While the FDA Hides the Data .......................................................... 9
E. If the Above Is Not Enough, the Federal Government Granted Pfizer Immunity ......... 10
F. PHMPT’s FOIA Request ............................................................................................... 10
G. FDA Proposes to Process the Documents Over the Next 55-plus Years ....................... 11
ARGUMENT ............................................................................................................................... 12
I. THE REQUEST QUALIFIES FOR EXPEDITED REVIEW AND PRODUCTION ... 12
1. The Standard For Reviewing Requests to Expedite ................................................... 13
2. PHMPT’s Request Must be Expedited ....................................................................... 14
i. Urgent Need for Independent Review of Pfizer Vaccine Data ............................... 15
ii. The Value of Independent Review is Lost if Not Done Forthwith ......................... 17
iii. The FDA’s Approval of the Pfizer Vaccine is Government Activity ..................... 20
II. THE FDA’S POSITION IS IRRATIONAL AND HIGHLY CONCERNING ............. 20
1. The FDA Has the Resources to Expeditiously Produce all Responsive Documents .. 20
2. Even Absent the Current Exigency, Courts Regularly Order Agencies to Produce
Large Volumes of Documents in Short Periods of Time ............................................ 22
3. The FDA is Dramatically Overemphasizing the Risk of Inadvertent Disclosure ....... 24
4. The FDA’s Regulations Require Immediate Production ............................................ 25
CONCLUSION ........................................................................................................................... 25
Page ii
AR01761
TABLE OF AUTHORITIES
Cases
Al-Fayed v. C.I.A.,
254 F.3d 300 (D.C. Cir. 2001) .................................................................................................. 14
Avondale Indus., Inc. v. N.L.R.B.,

90 F.3d 955 (5th Cir. 1996) ...................................................................................................... 13
Batton v. Evers,
598 F.3d 169 (5th Cir 2010) ..................................................................................................... 12
Bloomberg, L.P. v. United States Food and Drug Admin.,

500 F. Supp. 2d 371 (S.D.N.Y. 2007)........................................................................... 13, 14, 19
Citizens for Responsibility and Ethics in Washington v. U.S. Dept. of Justice,

436 F. Supp. 3d 354 (D.D.C. 2020) .......................................................................................... 13
Clemente v. Fed. Bur. of Investigation,

71 F. Supp. 3d 262 (DDC 2014) ............................................................................................... 24
Colbert v. FBI,
No. 16 Civ. 1790 (DLF), 2018 WL 6299966 (D.D.C. Sept. 3, 2018) ...................................... 22
Dep’t of the Air Force v. Rose,

425 U.S. 352 (1976) .................................................................................................................. 12
Diocesan Migrant & Refugee Services, Inc. v. United States Immigration and Customs Enf’t,
No. EP-19-CV-00236-FM, 2021 WL 289548 (W.D. Tex. Jan. 28, 2021) ......................... 20, 22
Freedom Watch v. Bureau of Land Mgmt.,

No. 16 Civ. 2320 (D.D.C.) ........................................................................................................ 21
Huddleston v. Fed. Bur. of Investigation,

No. 4:20-CV-447, 2021 WL 327510 (E.D. Tex. Feb. 1, 2021) ................................................ 12
Inst. for Justice v. Internal Revenue Serv.,

1:18-CV-01477 (CJN), 2021 WL 4935536 (D.D.C. July 8, 2021) .......................................... 22
NRDC v. Dep’t of Energy,

191 F. Supp. 2d 41 (D.D.C. 2002) ............................................................................................ 23
Open Soc’y. Justice Initiative v. Cent. Intelligence Agency,

399 F. Supp. 3d 161 (S.D.N.Y. 2019)........................................................................... 12, 20, 23
Page iii
AR01762
Payne Enterprises v. United States,

837 F.2d 486 (D.C. Cir. 1988) .................................................................................................. 12
Pub. Citizen Health Research Group v. F.D.A.,

964 F. Supp. 413 (D.D.C. 1997) ............................................................................................... 12
Seavey v. Dept. of Justice,

266 F. Supp. 3d 241 (D.D.C. 2017) .......................................................................................... 22
Seife v. FDA,
492 F. Supp. 3d 269 (S.D.N.Y. 2020)................................................................................. 22, 23
Treatment Action Group v. FDA,

Case No. 15-cv-00976-VAB (D. Conn. 2016) ................................................................... 22, 23
United States Dept. of Justice v. Reporters Committee,

489 U.S. 749 (1989) .................................................................................................................. 13
Statutes and Regulations

21 C.F.R. § 20.44 .............................................................................................................. 13, 14, 19
21 C.F.R. § 601.51 ................................................................................................................. passim
21 C.F.R. § 20.63 .......................................................................................................................... 24
5 U.S.C. § 552 ................................................................................................................... 11, 13, 14
Page iv
AR01763
Plaintiff, Public Health and Medical Professionals for Transparency (“PHMPT”), by and
through its attorneys, Siri & Glimstad LLP, respectfully submits this brief in support of prompt
and timely production of the documents submitted by Pfizer Inc. (“Pfizer”) to the U.S. Food and
Drug Administration (the “FDA”) to license its COVID-19 vaccine (the “Pfizer vaccine”).
PRELIMINARY STATEMENT
A minimum of 20,010 days (54 years and 10 months). That is how long the FDA
proposes to take, at a rate of 500 pages per month, to produce only a portion of the documents in
its file for the COVID-19 Pfizer vaccine that PHMPT requested pursuant to the Freedom of
Information Act (the “FOIA Request”) and 21 C.F.R. § 601.51(e). But when it came to reviewing
those same documents to license this product so that Pfizer could freely sell it to the public, the
FDA took just 108 days. It took the FDA’s parent department even less time to grant Pfizer
complete immunity to liability for injuries from this product, and it took a stroke of the President’s
pen to mandate this product for federal employees, the private sector and military personnel.
The federal government mandating that millions of people be injected with a liability-free
vaccine requires complete government transparency – not the government’s suppression of
information. PHMPT is comprised of independent scientists working at some of our nation’s
premier institutions, and all they are seeking is the data the FDA has already reviewed concerning
the Pfizer vaccine in order to provide the necessary peer review. The FDA knows that they, and
other independent scientists, cannot properly analyze that data until it is all released. Yet, the FDA
wants to wait until most of those scientists are long since dead to fully release the data. News
outlets, politicians, and scientists have called the FDA’s position “outrageous.” They are correct.
The entire purpose of FOIA is government transparency. In multiple recent cases, in
upholding the FOIA’s requirement to “make the records promptly available,” courts have required
Page 1
AR01764
agencies, including the FDA, to produce 10,000 or more pages per month, and those cases did not
involve a request nearly this important – i.e., the data underlying licensure of a liability-free
product that the federal government requires nearly all Americans to receive. As the present
pandemic rages on, independent review of these documents by outside scientists is urgently needed
to assist with addressing the shortcomings and issues with the response to the pandemic to date.
The context surrounding PHMPT’s FOIA request is truly unprecedented, and the request
should be treated as such. Historically, there has been no consumer product that the federal
government has mandated Americans to receive. Now, it has mandated Pfizer’s vaccine to private
sector employees, federal employees, the military, and more. States have done the same at the
urging of the federal government, extending mandates for people to enter schools, universities,
restaurants, and public venues, among other places. A majority of Americans are now mandated
to receive this product under penalty of losing a job or worse. This is truly unparalleled in the
nation’s past. There has never been such a large-scale mandate of any product for society, let
alone one that is injected into people. Even school mandates under state laws have almost always
included an easy to obtain exemption. The current inability to say “no” to injecting a product into
one’s body absent serious consequences dictated by the government is truly unprecedented.
Making this even more unprecedented is that Americans, if injured, cannot sue Pfizer and
otherwise have no recourse. There is virtually no other product where a consumer is prohibited
from suing the company that manufactures, markets, and profits from the product. Decoupling a
company’s profit interest from its interest in safety is a moral hazard, and a departure from
centuries of product liability doctrine. Yet we find ourselves in this truly extraordinary
circumstance where not only must Americans take this product under penalty of expulsion from
work, school, the military and civil life, but they cannot sue Pfizer for any resulting injuries.
Page 2
AR01765
And who has created this unprecedented situation? The Executive Branch, normally with
little or no input from the other branches. It has granted the immunity, licensed the product, and
aggressively implemented or demanded mandates. This therefore requires unprecedented
transparency. When Americans cannot say “no” and cannot sue Pfizer for harm, then the FDA
should also not be able to say “no” to forthwith releasing the Pfizer vaccine data. If the
administration wants Americans to be subject to its mandates, Americans must at least be granted
the dignity of access to the data supposedly supporting the safety and efficacy of Pfizer’s liability-
free vaccine so that independent scientists can conduct a timely review.
Even President Joe Biden, when truth was original to him as candidate Joe Biden, on
January 28, 2020, told the American people that, “You’ve got to make all of it [the vaccine data]
available to other experts across the nation so they can look and see, so there’s a consensus
this is a safe vaccine.” (App000338 ¶ 2.) On September 7, 2020, on national television, he stated:
I get asked the question, if … President [Trump] announced

tomorrow we have a vaccine, would you take it? Only if it was
completely transparent and other experts in the country could
look at it. Only if we knew all of what went into it.
(App000338 ¶ 3.) And then he again said to the American people that we need “total
transparency so scientists outside the government know exactly what is being approved.”
(App000339 ¶ 4.) Fifteen U.S. Senators, all caucusing Democrats, similarly stated as follows in a
letter to the FDA:
Full transparency throughout the review and authorization

process is thus essential to countering real or perceived
politicization and building public confidence in any approved
vaccine. … In addition to the efforts FDA has already made to
publish its recommendations regarding data needed for clinical
development and licensure of vaccines, a transparent review
process will require that FDA … make the data generated by
clinical trials and supporting documents submitted to the FDA
by developers available to the public.
Page 3
AR01766
(App000339 ¶ 8.) Numerous Republicans have also demanded immediate release of the
documents. For example, Congressman Ralph Norman recently stated:
The FDA’s only priority should be the health and safety of

consumers. The agency has compromised its integrity by delaying
information that belongs to the public. Since the Biden
administration is hell-bent on forcing these vaccine mandates on us,
the public has every right to know how this vaccine was approved,
especially in such a short amount of time. After all, the FDA
managed to consider all 329,000 pages of data and grant emergency
approval of the Pfizer vaccine within just 108 days. So it’s hard to
rationalize why it now needs 55 years to fully release that
information to the public.
(App000339 ¶ 9.) Senator Ted Cruz called the FDA’s position “Completely outrageous.”
(App000340 ¶ 10.)
The transparency sought by politicians is consistent with well-established norms in the
scientific community and with the purpose of FOIA; but that purpose will be utterly frustrated
unless the data is released now, in its entirety, to the public. Releasing this data, so independent
scientists can review it, is akin to getting a second opinion from a doctor, or a peer review of a
scientific paper. Every day that passes without this data’s release is another day that the American
people are deprived of this basic transparency and review.
The FDA does not dispute that it should produce these documents. Rather, it proposes
doing so at a rate so slow that the documents will not be fully produced until almost all of the
scientists, attorneys, and most of the Americans that received Pfizer’s product, will have died of
old age. The FDA’s excuse? It cries it does not have the resources. Considering how many
taxpayer dollars this administration has spent on its COVID-19 response, the FDA cannot now
claim it lacks the money to timely conduct its review. This excuse is a red herring that just adds
insult to the liberty-crushing approach the FDA and administration have taken with this product.
Page 4
AR01767
The Executive Branch gave Pfizer $1.95 billion in taxpayer funds to promote development
of its vaccine through an advance-purchase agreement. (App000340 ¶ 11.) It then paid Pfizer
more than $15.7 billion collected from the American people to purchase that product.
(App000340-App000341 ¶¶ 12-16.) Thereafter, it spent $18.75 billion more of the American
people’s money promoting that product. (App000341 ¶¶ 17-19.) Yet, when it comes to being
transparent with those same American people, the FDA claims it cannot muster the resources to
timely produce the same documents it reviewed for licensure in 108 days. Just as the government
found the resources for Operation Warp Speed, it must now do the same to produce these critical
documents with the same warp speed. How about the federal government spend just 0.1% of the
taxpayer money it has given Pfizer – that would be at least $17.6 million – a pittance compared to
the billions given to Pfizer and more than sufficient to hire enough reviewers to timely produce
the documents. Companies in private litigation produce hundreds of thousands of pages per month
in discovery, reviewing each document for privilege, etc. But yet the vast federal government, on
an issue this important, claims it cannot find the resources. A product the administration says
everyone must take under penalty of exclusion from American life and for which they cannot even
sue Pfizer if injured! Whose interests is the executive branch protecting, the American people or
its own?
Reflecting that the FDA can, in fact, produce documents at a far greater rate than 500 pages
per month, on December 1, 2021, in an effort to avoid the hearing with this Court, it offered to
produce approximately 12,658 pages, 4 .txt files, and 4 SAS files within a period of 61 days if
PHMPT would agree to thereafter only receive 500 pages per month. (App000341 ¶ 20.) The FDA
does not appear to recognize the gravity of its ethical breach to the American people in playing
these games.
Page 5
AR01768
The pandemic is continuing to spiral. Despite over 83% of adults having received a
COVID-19 vaccine (App000341 ¶ 21), cases are on the rise in the most vaccinated states
(App000342 ¶ 22), variants that evade vaccine immunity are rising (App000342 ¶ 24), the
CDC has admitted the COVID-19 vaccines do not prevent transmission (App000342 ¶ 23),
the number of breakthrough cases is increasing exponentially (App000342 ¶ 25), and boosters
are now needed for everyone and will likely continue to be required every six months, if not
more frequently (App000342 ¶ 26), among numerous other issues with the vaccine program.
America has some of the greatest institutions of learning and research the world has
ever known. We need all these hands on deck, both inside and outside the government, to
address these serious, ongoing issues, and failings within the vaccine program. Locking out
independent scientists from addressing these issues is dangerous, irresponsible, and
unethical. The FDA, in both the prior and current administration, has never been free of political
pressure when conducing its work and it has also been widely promoting this vaccine to the public,
including before it was licensed. This all raises questions about the licensure process and whether
the FDA will admit mistakes or failings of the same product, mistakes and failings that will only
be identified through outside review. America needs independent scientists, like the ones from
our premier universities and medical centers comprising Plaintiff, to review this data and assist
with offering solutions and addressing these issues. Not 55 years from now or longer. But today.
BACKGROUND
A. The Need for the Transparency as Promised by Pfizer, White House, and FDA
Pfizer itself acknowledges the need for “Transparency in Clinical Trials.” (App000342 ¶
27 (Pfizer’s policy statement from December 2019 explaining its “commitment to openness and
transparency” including in “all aspects of research and development behind our products, including
clinical trials.”). See also App000342 – App000343 ¶ 28.) Similarly, the U.S Institute of Medicine
Page 6
AR01769
consensus study emphasized “that verification and replication of investigators claims [in clinical
trials] were essential to the scientific process” and results in “numerous benefits to … patients,
their physicians and researchers.” (Id. (internal quotations eliminated).)
Likewise, as quoted supra, numerous U.S. Representatives and Senators, and the White
House and FDA leadership, have all called for transparency; as Presidential candidate Joe Biden,
told the American people: “You’ve got to make all of it [the vaccine data] available to other experts
across the nation so they can look and see.” (App000338 – App000340 ¶¶ 2-4, 8-10.)
These call for transparency is consistent with well-established norms in the scientific
community. As explained by a PHMPT member who is also a member of the World Health
Organization’s COVID-19 Infection Prevention and Control Working Group:
The importance of independent review of data in science cannot be

overstated. Science is never static. … Censorship and lack of
transparency have always been the enemies of progress. … Given
the insufficient and hurried testing and the culture of secrecy, it is
arguable whether any informed consent is valid prior to making
public all of the documents the FDA has in Pfizer’s COVID-19 file.
(App000108 ¶ 17.) As explained by another PHMPT member, a full professor of epidemiology at
Yale School of Public Health and Yale School of Medicine, Dr. Harvey Reich: “Absent an
independent review, the nation is dependent on one body’s review,” that of the FDA. (App000008
¶ 10.) He explains this is concerning because the FDA was “under tremendous political pressure
[to license the Pfizer vaccine], which shortened the typical review process, making it impossible
to carry out all analyses that are typically carried out.” (Id.) Hence, he continues, “[a]llowing the
Pfizer vaccine data to be made available to independent scientists and healthcare professionals is
akin to a peer review process and is critical to ensure the accuracy of the conclusions reached.”
(App000009 ¶ 12.)
Dr. Reich continues that: “Independent scientists and epidemiologist … need this data
Page 7
AR01770
sooner rather than later… We are still in a pandemic, the vaccines are failing, children are starting
to be vaccinated, we are moving to boosters for all eligible Americans and so we need to have as
complete an understanding of these vaccines and their efficacy, or lack thereof, as soon as possible
so that we can learn how to properly manage things moving forward… Time is of the essence.
Collective efforts of all scientists in the United States will produce more insights at a quicker pace
than if the FDA hoards data, prohibiting others from getting involved.” (App000011 ¶ 16.)
B. PHMPT Formed to Disseminate the Promised Vaccine Data
PHMPT is a not-for-profit with more than 75 members, including professors at major
universities, public health professionals, medical doctors, scientists, and journalists, and current
and former WHO and HHS COVID-19 advisory group members. (App000002 ¶ 3.)
PHMPT exists for the sole purpose of making public the data in the biological product files
for each licensed COVID-19 vaccine. (App000003 ¶ 5.) Many of its members, who include
journalists, are primarily engaged in disseminating information to the public. (App000002 ¶ 4.)
Through its members and website, PHMPT intends to disseminate to the public all records it
receives. (App000003 ¶ 7.)
C. FDA Approval of the Pfizer Vaccine
On August 23, 2021, the FDA approved the Pfizer vaccine. (App000343 ¶ 29). Despite
the promise of transparency, not a single page submitted by Pfizer to the FDA was released to the
public. (App.000008 ¶ 10.) This is hindering the nation’s response to the pandemic and, as
President Biden and others predicted, has led to skepticism regarding this product.
On the one hand, prominent figures in the media, politics, and public health fields have
sought to reassure the public that the data evaluated by the FDA was sufficient for licensure. For
example, Dr. Peter Marks, the Director of FDA’s biologics/vaccine division stated that
[the FDA’s] scientific and medical experts conducted an incredibly
Page 8
AR01771
thorough and thoughtful evaluation of [the Pfizer vaccine]. We

evaluated scientific data and information included in hundreds of
thousands of pages, conducted our own analyses of [the Pfizer
vaccine’s] safety and effectiveness, and performed a detailed
assessment of the manufacturing processes, including inspections of
the manufacturing facilities[.]
(App000343 ¶ 29.). Dr. Marks further stated that “although [the FDA] approved [the Pfizer
vaccine] expeditiously, it was fully in keeping with [the FDA’s] existing high standards for
vaccines.” (Id.)
On the other hand, numerous prominent scientists have questioned the sufficiency of the
data submitted by Pfizer and the adequacy of the FDA’s review to license its vaccine. For example,
on June 1, 2021, a group of 27 clinicians and scientists, including professors from Harvard Medical
School, and members of PHMPT, filed a Citizen Petition with the FDA claiming that the available
evidence for licensure of the Pfizer vaccine “is simply not mature enough at this point to adequately
judge whether clinical benefits outweigh the risks in all populations.” (App000343 ¶¶ 30-31.)
Similarly, Professor Peter Doshi, a senior editor at The British Medical Journal and a PHMPT
member, has publicly questioned the adequacy of the data the FDA relied on for licensure and the
lack of transparency in the vaccine approval process. (App000343 ¶¶ 32-33.)
Incredibly, the FDA even denied the public the opportunity to hear discussion about the
data and to offer public comment by not convening its public advisory committee, the Vaccines
and Related Biological Products Advisory Committee, to discuss licensure. (App000343 ¶ 34.)
D. Mandates Abound While the FDA Hides the Data
While hiding Pfizer’s data from the public, the federal executive has pushed an agenda to
make it impossible to participate in American society without receiving the Pfizer vaccine. This
includes mandates by the federal executive for private sector employees, public sector employees,
health care professionals, federal contractor employees, military personnel, and certain air
Page 9
AR01772
travelers. (See, e.g., App000344 ¶¶ 35-37.) Mandates have also been instituted by state and local
governments at the urging of the federal government on university students, customers at retail
stores, diners at restaurants, and virtually dozens of other everyday locations visited in the normal
affairs of American life. (See, e.g., App000344 ¶¶ 38-39.) Many more are expected to follow suit.
(See, e.g., App000344 – App000345 ¶ 40.)
Some mandates now require three doses of Pfizer’s vaccine, and the number of doses
Americans must receive to simply keep their job and otherwise engage in civil society is only
expected to increase over time. (App000342 ¶ 26.) What makes this all the more incredible is
that Pfizer’s vaccine does not prevent infection and transmission. (App000342 ¶ 23.) Meaning,
at best, Pfizer’s vaccine provides personal protection, akin to taking statins. We may want people
to take their heart medicine, but we don’t mandate them to do so. That is simply authoritarian.
E. If the Above Is Not Enough, the Federal Government Granted Pfizer Immunity
While hiding Pfizer’s data from the public, the federal government granted Pfizer, and
anyone associated with administering its vaccine, complete legal immunity for any injury caused
by its vaccine. 42 U.S.C. § 247d-6d (providing that any “manufacturer” of “any vaccine, used to
… prevent or mitigate COVID-19” shall be “immune from suit and liability under Federal and
State law with respect to all claims … resulting from … [its] use by an individual”). Pfizer is even
immune from liability for willful misconduct unless the federal government, which promoted and
licensed this product, first brings this claim. Id. So, to be clear, Americans are forced to receive
Pfizer’s product, but if injured, they cannot sue anyone associated with this vaccine, yet the
government is refusing to permit outside scientists to review the data supporting its safety.
F. PHMPT’s FOIA Request
On August 27, 2021, just four days after the FDA approved the Pfizer vaccine, PHMPT
submitted the FOIA Request to the agency, seeking the following documents:
Page 10
AR01773
All data and information for the Pfizer vaccine enumerated in 21

C.F.R. § 601.51(e) with the exception of publicly available reports
on the Vaccine Adverse Events Reporting System.
(App000345 ¶ 41.) 21 C.F.R. § 601.51(e) lists the “data and information in the biological product
file” that is supposed to be “immediately available for public disclosure” after the FDA licenses
a vaccine. (emphasis added). That data and information includes, inter alia, “[a]ll safety and
effectiveness data and information[,]” “[a] protocol for a test or study” of the vaccine, “[a]dverse
reaction reports,” and “[a]ll correspondence and written summaries of oral discussions relating to
the biological product file[.]” 21 C.F.R. § 601.51(e)(1)-(8). On August 31, 2021, the FDA
assigned the FOIA Request case number 2021-5683. (App000345 ¶ 43.)
As part of its FOIA request, PHMPT requested expedited professing pursuant to 5 U.S.C.
§ 552 (a) (6)(E)(v)(II). On September 9, 2021, the FDA denied PHMPT’s request (the “Denial
Letter”). In the Denial Letter, the FDA stated in relevant part:
I have determined that your request for expedited processing does

not meet the criteria under the FOIA. You have not demonstrated a
compelling need that involves an imminent threat to the life or
physical safety of an individual. Neither have you demonstrated that
there exists an urgency to inform the public concerning actual or
alleged Federal Government activity. Therefore, I am denying your
request for expedited processing. (App000345 ¶ 44).
G. FDA Proposes to Process the Documents Over the Next 55-plus Years
On November 15, 2021, the parties submitted a Second Joint Report to the Court. (Dkt.
No. 20.) Therein, the FDA reported “that there are more than 329,000 pages potentially responsive
to Plaintiff’s FOIA request.” (Id. at p. 3.) This page count does not include other files, “typically
containing data in a format similar to a spreadsheet.” (Id.). In order to produce those responsive
documents, the “FDA propose[d] to process and produce the non-exempt portions of responsive
records at a rate of 500 pages per month.” (Id. at p. 4.) At that rate, it will take the FDA at least
54 years and 10 months to produce all the responsive documents – not exactly meeting the FOIA
Page 11
AR01774
statute’s requirement that the agency “shall make the records promptly available.” 5 U.S.C.
§ 552(a)(3)(A). The FDA’s proposed schedule is tantamount to a denial of the FOIA Request.
PHMPT therefore asked the Court to direct the FDA to produce all responsive documents
by no later than March 3, 2022. (Dkt. No. 20 p. 9.) “This 108-day period [from the date the Joint
Report was filed] is the same amount of time it took the FDA to review the responsive documents
for the far more intricate task of licensing Pfizer’s Covid-19 vaccine.” (Id.) In response, the Court
ordered a scheduling conference for December 14, 2021, and directed the parties to file briefs or
appendices that could “assist the Court in its preparation for the” conference. (Dkt. No. 21.)
In the more than three months since PHMPT submitted the FOIA request, the FDA has
produced only an index of documents, 1 txt file, 1 xpt file, and 339 pages of information, most of
which concerned the principal investigators for the Pfizer vaccine trials, information that was
already publicly available on the clinicaltrials.gov website. Counsel for the FDA has also recently
advised PHMPT’s counsel that in addition to the 329,000+ pages, there are an additional
“approximately 39,000 pages” plus “ten of thousands of additional pages” plus hundreds of
spreadsheets and the FDA will treat each twenty lines in each spreadsheet as one page.
(App000345 ¶ 45.) Meaning, the FDA’s position is that the independents scientists can review the
data but they will just have to wait until long after they are all dead.
ARGUMENT
I. THE REQUEST QUALIFIES FOR EXPEDITED REVIEW AND PRODUCTION
“The FOIA was enacted to ‘pierce the veil of administrative secrecy and to open agency
action to the light of public scrutiny.’” Batton v. Evers, 598 F.3d 169, 175 (5th Cir 2010)
(quoting Dep’t of the Air Force v. Rose, 425 U.S. 352, 361 (1976)). And courts have long
acknowledged that “‘stale information’ produced pursuant to FOIA requests ‘is of little value.’”
Huddleston v. Fed. Bur. of Investigation, No. 4:20-CV-447, 2021 WL 327510, at *3 (E.D. Tex.
Page 12
AR01775
Feb. 1, 2021) (quoting Payne Enterprises v. United States, 837 F.2d 486, 494 (D.C. Cir. 1988)).
See also Open Soc’y., 399 F. Supp. 3d at 164 (“Congress has long recognized that ‘information is
often useful only if it is timely’ and that, therefore ‘excessive delay by the agency in its response
is often tantamount to denial.’” (quoting H.R. Rep. No. 93-876, at 6271 (1974)). That is why
Congress amended the FOIA statute in 1996 to mandate expedited processing of important FOIA
requests.
Here, PHMPT is unquestionably entitled to the information sought in the FOIA Request
because the FDA’s own regulations require the information to be “immediately available” to the
public. 21 C.F.R. § 601.51(e). See also Pub. Citizen Health Research Group v. F.D.A., 964 F.
Supp. 413, 414 (D.D.C. 1997) (finding that data submitted for drug licensure had to be disclosed
under FOIA because “[o]nce an approval letter has been sent, certain data and information are
immediately available for disclosure”). The question is how quickly the FDA will produce those
documents. Given the clear national importance, this Court should direct that all responsive
documents be produced within 108 days of November 15, 2021.
1. The Standard For Reviewing Requests to Expedite
FOIA provides for “expedited processing of request for records” when there is a
“compelling need.” 5 U.S.C. § 552 (a)(6)(E). The statute states that a compelling need includes:
“with respect to a request made by a person primarily engaged in disseminating information,
urgency to inform the public concerning actual or alleged Federal Government activity.”
Bloomberg, L.P. v. United States Food and Drug Admin., 500 F. Supp. 2d 371, 376-77 (S.D.N.Y.
2007) (quoting 5 U.S.C. § 552 (a)(6)(E)(v)); Citizens for Responsibility and Ethics in Washington
v. U.S. Dept. of Justice, 436 F. Supp. 3d 354, 358 (D.D.C. 2020) (applying the same standard).
The FDA’s regulations contain the same definition of when a compelling need exists. 21 C.F.R.
§ 20.44 (a). “‘Unlike the review of other agency action that must be upheld if supported by
Page 13
AR01776
substantial evidence and not arbitrary or capricious, the FOIA expressly places the burden on the
agency to sustain its action and directs the district courts to determine the matter de
novo.’” Avondale Indus., Inc. v. N.L.R.B., 90 F.3d 955, 958 (5th Cir. 1996) (quoting United States
Dept. of Justice v. Reporters Committee, 489 U.S. 749, 755 (1989)). See also Bloomberg, L.P.,
500 F. Supp. 2d at 374 (“The Court reviews agency decisions, including those regarding expedited
processing of FOIA requests, de novo.”).
2. PHMPT’s Request Must be Expedited
There is no question PHMPT is “primarily engaged in disseminating information” because,
as explained on its website, it “exists solely to obtain and disseminate the data relied upon by the
FDA to license COVID-19 vaccines” and that “[a]ny data received will be made public on this
website.” (App000003 ¶¶ 5, 7.) See also Bloomberg, L.P., 500 F. Supp. 2d at 378 (holding that
the “inability of the general public to understand the raw data submitted by the drug
manufacturers” has no bearing on the urgent need to produce that data).
As for showing an “urgency to inform the public concerning actual or alleged Federal
Government activity,” PHMPT’s request easily meets this standard. 5 U.S.C. § 552 (a)(6)(E)(v).
In answering this question, “[c]ourts must consider at least the following three factors …:
(1) ’whether the request concerns a matter of exigency to the American public; (2) whether the
consequences of delaying a response would compromise a significant recognized interest; and (3)
whether the request concerns federal government activity.’” Bloomberg, L.P., 500 F. Supp. 2d at
377 (quoting Al-Fayed v. C.I.A., 254 F.3d 300, 310 (D.C. Cir. 2001)). The FDA’s FOIA
regulations present a similar tripartite analysis, and ask whether: (1) “[t]here is an urgent need for
the requested information[,]” (2) the information “has a particular value that will be lost if not
obtained and disseminated quickly[,]” and (3) “[t]he request … specifically concerns identifiable
operations or activities of the Federal Government.” 21 C.F.R. § 20.44(c)(2)-(3). PHMPT’s FOIA

Page 14
AR01777
Request satisfies both of these tests.
i. Urgent Need for Independent Review of Pfizer Vaccine Data
Independent review of Pfizer’s vaccine data is a matter of current “exigency to the
American public.” Bloomberg, L.P., 500 F. Supp. 2d at 377. There can be no question that the
FDA’s approval of Pfizer’s vaccine, and its safety and efficacy, is one of the most covered news
stories of the last decade. The need for rapid independent review of the data Pfizer submitted to
the FDA is central to this story, and disseminating this data is PHMPT’s raison d’etre.
As discussed above, there exists unanimity from all quarters for the need for transparency
and independent review of the clinical trial data. Pfizer has made fostering transparency with
regard to clinical trial data part of its corporate policy, as have U.S. and European pharmaceutical
trade organizations. (App000342 – App000343 ¶¶ 27-28.) The U.S. Institute of Medicine has
made the same endorsement. (App000342 – App000343 ¶ 28) As has the FDA itself, when it
acknowledged not only the need to disclose data relied upon for licensure, but that it be released
straightaway. That is why FDA regulations provide that “[a]fter a license has been issued, the …
data and information in the biological product file are immediately available for public
disclosure unless extraordinary circumstances are shown. . . .” 21 C.F.R. § 601.51(e) (emphasis
added).
With respect to the Pfizer vaccine in particular, as quoted supra, numerous politicians have
called for greater transparency concerning the FDA’s approval of the Pfizer vaccine. As noted,
even the current President of the United States has repeatedly urged the government to “make all
of it [the vaccine data] available to other experts across the nation.” (See App000338 ¶ 2
(emphasis added).) Nor has the President retreated from this rhetoric, imploring during a “Global
COVID-19 Summit” in September 2021 that the nations of the world must “exercise transparency
to build vital public trust in these lifesaving tools.” (App000339 ¶ 6.)

Page 15
AR01778
Transparency is critical because “[i]ndependent review is essential to scientific integrity.”
(App000163 ¶ 25.) “Professionals working in the scientific and healthcare professions all seek
second opinions.” (App000009 ¶ 12.) Likewise, the “[c]ollective efforts of all scientists in the
United States will produce more insights at a quicker pace than if the FDA hoards data, prohibiting
others from getting involved.” (App000011 ¶ 16.) With regard to the Pfizer vaccine, the need for
peer review is even more acute because of the “drastically shorted regulatory approval process”
that the FDA undertook to rush the Pfizer vaccine to licensure. (App000009 – App000010 ¶ 14.)
“It is nearly impossible that the FDA could have done everything it typically does in its review of
a vaccine in the short time period within which Pfizer’s vaccine was reviewed and approved.” (Id.)
For true independent analysis to occur, half-measures will not do. “Scientists and
healthcare professionals need all of the documents submitted by Pfizer to conduct a proper
analysis” since missing even a single dataset could throw off any analysis. (App000162 ¶ 21. See
also App000008 ¶ 10.) This is because “[a]ll scientific analyses rely on complete sets of
information[.]” (App000162 ¶ 21.) “Attempting to recreate analyses on efficacy or safety without
all the relevant data – data already limited by the short time period of the [Pfizer vaccine] trials –
would prove useless.” (App000009 ¶ 11.) As such, even though the FDA proposes a rolling
production, that will do nothing to expedite the independent review.
The urgent need for the FDA to release the data sought by PHMPT can be seen from the
media’s shocked reaction to the FDA’s request in this case to take 55 years to respond to the FOIA
Request. For example, Reuters published an article titled: “Wait what? FDA wants 55 years to
process FOIA request over vaccine data,” and other media outlets have expressed similar surprise
and often outrage that it would take so long to release the Pfizer data. (App000339 ¶ 7.)
Furthermore, the shock was not confined to domestic media.
Page 16
AR01779
Independent review of the data is precisely what PHMPT is seeking here. It filed the FOIA
Request within days of the FDA approving the Pfizer vaccine. The organization’s website states
that it “takes no position on the data other than that it should be made publicly available to allow
independent experts to conduct their own review and analyses.” (App000003 ¶ 5.) To achieve
this goal, the site states that “[a]ny data received will be made public on this website.”
ii. The Value of Independent Review is Lost if Not Done Forthwith
Time is of the essence with regard to reviewing the data sought in the FOIA Request.
(App000011 ¶ 16.) Governments, employers, and individuals are making decisions every day
regarding the Pfizer vaccine. The longer it takes the FDA to produce documents responsive to the
FOIA Request, the more of those decisions will be made without the benefit of any independent
review of the Pfizer data. The best way to improve decision making and otherwise reassure
Americans about the decisions being made is to have independent review of the Pfizer data. Thus,
the value of the information decreases every day that the FDA delays in producing the full data
set.
In many ways, what is occurring is unprecedented. “An estimated 9.5 billion doses [of the
COVID-19 vaccines] have been administered thus far making it the largest medical intervention
in the history of humankind.” (App000107 ¶ 14.) Not only are the COVID-19 vaccines
unparalleled in scale, the way in which that scale has been achieved is also unprecedented. There
is no other consumer product that the federal government has ever mandated that millions of
Americans receive in order to earn a living.
The unprecedented nature of these mandates have been met with skepticism and protests.
According to a tracking poll by Morning Consult, as of mid-November 2021, 27% of the
respondents in the United States were either uncertain or unwilling to be vaccinated. Of those
respondents, 48% were skeptical about being vaccinated because they were either “worried the
Page 17
AR01780
clinical trials moved too fast” (29%), do not “think the vaccine will be effective” (9%), or do not
“trust the companies making vaccines” (10%). Having multiple trusted independent authorities
review the safety and effectiveness data sought in the FOIA Request, which is what PHMPT
intends, will almost certainly play a role in how these people evaluate their vaccine decisions. (See
App000342 ¶ 27 (Pfizer policy statement noting that transparency of clinical trial data “fosters
trust”); App000342 – App000343 ¶ 28 (“In a time of increasing public scrutiny, transparency of
regulatory decision making leading to the approval of … vaccines for COVID-19 is important to
ensure patient and stakeholder trust.”).)
Furthermore, skepticism regarding the Pfizer vaccine is not unfounded, nor is it confined
to the general populous. Prominent members of the scientific community have raised serious
concerns regarding its clinical trials, its safety and efficacy, and the FDA’s drastically abbreviated
licensing process. “There has never been a vaccine approved [by the FDA] in such a short time
period.” (App000009 – App000010 ¶ 14.) The abbreviated schedule led researchers to question
everything from the adequacy of the data the FDA relied on to whether the FDA permitted Pfizer
to use fewer test subjects than would normally be required. In an article published last month in
the medical journal “BMJ Evidence-Based Medicine,” its five authors noted that there “are issues
in COVID-19 vaccine trials that merit scrutiny” and then went on to discuss some of those
unresolved issues in detail. (App000342 – App000343 ¶ 28.) Other scientists have noted that
adverse reactions in VAERS and other data signal tremendous issues with the safety of the Pfizer
vaccine. (See, e.g., App000162 – App000163 ¶ 23 (“The combined failure of COVID-19 vaccine
protection to last even six months and the catastrophic number of serious adverse events reported
have created an urgent need for the scientific community to study and the public to understand what
has gone wrong in the United States and how we can remedy the public COVID-19 vaccine program
Page 18
AR01781
currently being administered by the CDC/FDA.”).)
Further contributing to the unprecedented nature of the situation is that Americans, if
injured, cannot sue Pfizer, the FDA, or the doctors that administer the vaccines. 42 U.S.C. § 247d-
6d. There is almost no other product where an injured consumer cannot sue the company that
makes, sells, and profits from the product. Thus, consumers, who in many cases are being
mandated by the government to receive the COVID-19 vaccines, have no way to be compensated
if they are injured nor do they have any way to force the manufacturer to improve the safety of the
product.
This extraordinary state of affairs leads to an unprecedented need for transparency. See
Bloomberg, L.P., 500 F. Supp. 2d at 378 (holding that the need for the public to have information
collected by the FDA disseminated widely and reviewed by independent experts was a major factor
in the need for expedited production). Currently, the only entities that have reviewed the full data
are Pfizer and the FDA, both of which are immune from suit and are under enormous political
pressure to deliver vaccines quickly. If Americans cannot say no and cannot sue for harm, then
the safety and efficacy of the vaccines must be put through the most rigorous review possible. In
the scientific and healthcare fields, rigorous review means independent peer review.
Nevertheless, peer review will be meaningless if it cannot happen for another 55 years.
Even if delayed one year from now, the value of the review will be lost because the pandemic and
technology will have moved on. That is why rapid production of all the documents within 108
days, at most, even if unprecedented, is necessary. Governments, employers, and individuals are
making decisions about the vaccines every day and the data can potentially shape how we move
forward in continuing to combat an ongoing global pandemic.
Page 19
AR01782
iii. The FDA’s Approval of the Pfizer Vaccine is Government Activity
The FOIA Request also meets the third factor required for a showing of urgent need
because the information PHMPT seeks concerns actual federal government activity. It involves
the sufficiency and accuracy of the review the FDA conducted to license the Pfizer vaccine, and
more broadly, the central role HHS – FDA’s parent department – played in developing, testing,
and promoting Pfizer’s vaccine. As such, there is no reasonable argument that PHMPT’s FOIA
Request seeks anything other than documents concerning “identifiable operations or activities of
the Federal Government.” 21 C.F.R. § 20.44 (c)(2)-(3).
II. THE FDA’S POSITION IS IRRATIONAL AND HIGHLY CONCERNING
The FDA claims it has identified over 329,000+ pages of documents, in addition to data,
that are responsive to the FOIA Request. (Dkt. No. 20 p. 3.) Nevertheless, it proposes to produce
just 500 pages every month for nearly 55 years before it will fully produce the documents. None
of the FDA’s arguments for this position in the parties Second Joint Report justifies its patently
irrational proposal to produce documents over the course of the next five decades! And none of its
arguments acknowledge the most obvious factor: the importance and unprecedented nature of the
documents at issue. Each of the FDA’s arguments are addressed in turn.
1. The FDA Has the Resources to Expeditiously Produce all Responsive Documents
The FDA’s first argument for wanting to take decades to produce is that its FOIA office
does not have the capacity to produce the documents any faster. This argument is specious on
numerous levels. First, while the FOIA office itself may only have a few employees, the FDA has
18,062 employees as of 2020. (App000339 ¶ 5.) For expedited productions, courts regularly
instruct agencies to redirect resources, or to acquire new resources, in order to expeditiously
produce documents. E.g., Diocesan Migrant & Refugee Services, Inc. v. United States
Immigration and Customs Enf’t, No. EP-19-CV-00236-FM, 2021 WL 289548, at *4 (W.D. Tex.
Page 20
AR01783
Jan. 28, 2021) (nothing that by using software programs, and reassigning personnel to the task,
ICE was able to review 86,000 potentially responsive documents within four months in order to
meet the court’s production deadline); Open Soc’y. Justice Initiative v. Cent. Intelligence Agency,
399 F. Supp. 3d 161, 169 (S.D.N.Y. 2019) (requiring the Department of Defense to produce
documents at a rate of 5,000 pages a month, “even if meeting this demand calls upon DOD to
augment, temporarily or permanently, its review resources, human and/or technological”).
Furthermore, the FDA’s claimed lack of resources rings hollow in the face of the fact that
the public has paid enormous sums to develop, manufacture, and market the Pfizer vaccine, and
the public is statutorily entitled to see what it is getting for its money. This includes giving Pfizer
$1.95 billion of taxpayer money to promote development of its vaccine and then an additional
$15.7 billion of taxpayer money to purchase this product. Beyond the money directly handed to
Pfizer, federal health authorities spent $18.75 billion of taxpayer money promoting this product.
Thus, federal health authorities have had no issue with rapidly spending in total at least $35 billion
of American taxpayer money supporting Pfizer’s vaccine. Even if one just takes the $17.6 billion
given directly to Pfizer, that amounts to giving the company over $48 million in taxpayer money
every day for over a year, plus spending more than that amount per day promoting Pfizer’s product.
Given this, these same federal health authorities cannot claim that they are incapable of meeting
their statutory requirements to produce documents due to a lack of resources.
As noted, there is near universal agreement that transparency and independent review are
extremely valuable for society. The FDA must therefore explain why it could not use a fraction
of the billions of taxpayer dollars it has given to Pfizer for its vaccine in order to ensure a timely
production of the documents the FDA used to approve the vaccine’s licensure.
Page 21
AR01784
2. Even Absent the Current Exigency, Courts Regularly Order Agencies to Produce
Large Volumes of Documents in Short Periods of Time
The FDA further tries to justify its incredulous request to produce just 500 page per month
by arguing this rate has been adopted by other courts, even when the production would take years
to complete. The FDA’s claim is highly misleading.
First, the FDA cites sixteen cases in the November 11, 2021 Joint Report where it says the
court directed the agency to produce documents at a rate of 500 per month. (Dkt. No. 20 pp. 4 n.3,
7-8.) However, in none of those cases did the Court or agency decide that the production qualified
for expedited processing. See, e.g., Freedom Watch v. Bureau of Land Mgmt., No. 16 Civ. 2320
(D.D.C.), Minute Order of June 13, 2017 (plaintiff failed to show any reasons for expediting). In
other cases cited by the FDA, the requester never even questioned the rate of production or sought
expedited production. See, e.g., Judicial Watch, Inc. v. U.S. Dep’t of State, No. 15 Civ. 687
(D.D.C.), Minute Order of April 4, 2017; Citizens United v. U.S. Dep’t of State, No. 15 Civ. 1720
(D.D.C.), Dkt. 11 ¶ 10. In other cases, the underlying acts that the FOIA request concerned
occurred years or even decades before the requests were made, meaning that there was no urgency
to the requests. See, e.g., Colbert v. FBI, No. 16 Civ. 1790 (DLF), 2018 WL 6299966, at *3
(D.D.C. Sept. 3, 2018) (seeking documents concerning the D.B. Cooper incident in 1971).
Likewise, in none of those cases did the Court contemplate a production schedule that
would last over five decades. To the contrary, most courts reviewing expedited productions seek
to ensure productions are completed expeditiously. See, e.g., Diocesan Migrant & Refugee
Services, Inc., 2021 WL 289548, at *4 (setting a goal for the agency to produce documents within
four months); Inst. for Justice v. Internal Revenue Serv., 1:18-CV-01477 (CJN), 2021 WL
4935536, at *7 (D.D.C. July 8, 2021) (“it would be inappropriate for productions to extend over
multiple years”); Seavey v. Dept. of Justice, 266 F. Supp. 3d 241, 248 (D.D.C. 2017) (rejecting
Page 22
AR01785
FBI proposal to produce 500 pages per month over the course of 17 years).
Instead, where expedited processing is warranted and an agency refuses to timely produce,
courts regularly require production at many times the FDA’s proposed 500 pages per month. The
following are samples of production rates endorsed by such courts before and during the pandemic:
• In Diocesan Migrant, 2021 WL 289548, to meet the court’s deadline, ICE produced
86,000 pages in four months, for an average rate of 21,500 pages per month.
• In Treatment Action Group v. FDA, Case No. 15-cv-00976-VAB (D. Conn. 2016) the
FDA produced 82,668 pages and 1,045 electronic files in approximately 7 months for
an average production rate of approximately 11,800 pages per month.
• In Seife v. FDA, 492 F. Supp. 3d 269, 273 (S.D.N.Y. 2020), the FDA agreed to produce
45,000 pages in approximately four months for an average of 10,000 pages per month.
• In Open Soc’y Justice Initiative v. CIA, 399 F. Supp. 3d 161 (S.D.N.Y. 2019), the CIA
produced 288,000 pages at the rate of around 8,000 pages per month.
• In NRDC v. Dep’t of Energy, 191 F. Supp. 2d 41, 43 n.5 (D.D.C. 2002) the court
ordered the Department of Energy to produce around 7,500 pages in a month.
Even with these large production numbers, none of these cases involved documents as
consequential to American life as the documents PHMPT seeks here. The Seife v. FDA matter
presents an apt example. There the plaintiff sought “documents and records regarding the testing
and approval process for eteplirsen … a drug … for the treatment of Duchenne Muscular
Dystrophy …, a rare neuromuscular disease.” 492 F. Supp. 3d at 271, 273. In 2016 the FDA
granted “accelerated approval” of eteplirsen. Id. at 272. Nevertheless, the next year the FDA
produced tens of thousands of pages of documents concerning eteplirsen, most of which were
substantially similar to those at issue in this case, many requiring redactions. Id. at 273. Seife
Page 23
AR01786
concerned a product rarely used by a small fraction of the population, but the FDA was able to
timely produce all the responsive documents. Id. at 271. This fact raises serious questions here
about why, where PHMPT seeks similar documents concerning a liability-free vaccine mandated
by the government for use by millions of Americans, the FDA has proposed a monthly production
rate 20 times slower than it produced in Seife. Similarly, Treatment Action Group concerned the
approval of two Hepatitis C drugs, again drugs that are not mandated nor used by nearly the same
number of people who will receive the Pfizer vaccine, but still the FDA could produce documents
similar to those sought in the instant case at an average rate of nearly 12,000 pages per month, at
one point even producing 25,000 pages, with redactions, in just six weeks. Case No. 15-cv-00976-
VAB (D. Conn. 2016) Dkt. No. 87 pp. 4-5.
In addition, the FDA has simply proposed producing 500 pages per month regardless of
whether those pages contain exempt material or are otherwise easily producible. “The D.C. Circuit
has found that unreasonable delays in disclosing non-exempt documents violate the intent and
purpose of the FOIA, and the courts have a duty to prevent [such] abuses.” Clemente v. Fed. Bur.
of Investigation, 71 F. Supp. 3d 262, 269 (DDC 2014) (internal quotations omitted). Given this
goal, the FDA’s one size fits all approach is inappropriate, and a higher rate of production for at
least some of the documents is achievable and necessary.
The FDA also tries to argue that its proposed 55+-year production schedule is PHMPT’s
fault for requesting too many documents. This is a red herring. PHMPT merely requested the
documents that are supposed to be publicly available under 21 C.F.R. § 601.51(e), and as explained
above, all of those documents are required for a true independent evaluation of the data.
3. The FDA is Dramatically Overemphasizing the Risk of Inadvertent Disclosure
The FDA also claims that an expedited production of documents could risk the inadvertent
disclosure of personal privacy information. This concern, however, is unfounded and greatly
Page 24
AR01787
overblown because the FDA’s own regulations require that “[t]he names and other information
which would identify patients or research subjects should be deleted from any record before it is
submitted to the Food and Drug Administration.” 21 C.F.R § 20.63(b) (emphasis added).
Thus, the documents submitted by Pfizer, which are the subject of the FOIA Request, would have
already been anonymized, and therefore, the risk of disclosing such information is minimal.
4. The FDA’s Regulations Require Immediate Production
The FDA further argues that even though 21 C.F.R. § 601.51(e) states that the agency must
make “the biological product file … immediately available for public disclosure” that has no
bearing on its over 55-year production schedule. This claim makes a mockery of the regulation.
It is hard to see how anyone could interpret “immediately available” as being intended to mean
that the documents would be made available to the public over 55 years after the vaccine was
licensed. The FDA further asserts that the regulation does not actually require production of
anything to the public and, instead, requires that the public make a separate FOIA request in order
for those documents to actually become public. A wholistic reading of the regulation reflects the
opposite. In the paragraph preceding paragraph (e), the regulation instructs that the “FDA will
make available to the public upon request” other documents concerning pre-licensure applications,
and specifically states that “[p]ersons wishing to request this information shall submit a request
under” FOIA. 21 C.F.R. § 601.51 (d)(2) (emphasis added). In contrast, paragraph (e) says nothing
about a member of the public needing to make a specific request in order to view the information
listed in that paragraph regarding vaccine licensure applications. This difference in language
should reflect that paragraph (e) obligates the FDA to make those documents (i.e., the documents
sought in the FOIA Request) “immediately available” just as it says.
CONCLUSION
For the foregoing reasons, during the upcoming scheduling conference, the Court should
Page 25
AR01788
order the FDA to produce all documents responsive to the PHMPT’s FOIA Request on or before
March 3, 2022, which is 108 days from the parties Second Joint Report to the Court.
Dated: December 7, 2021
SIRI & GLIMSTAD LLP
__________________________
Aaron Siri, NY Bar No. 4321790
Elizabeth A. Brehm, NY Bar No. 4660353
Gabrielle G. Palmer, CO Bar No. 48948
200 Park Avenue
New York, New York 10166
Tel: (212) 532-1091
Fax: (646) 417-5967
aaron@sirillp.com
ebrehm@sirillp.com
gpalmer@sirillp.com
HOWIE LAW, PC
John Howie
Texas Bar Number: 24027239
2608 Hibernia Street
Dallas, Texas 75204
Tel: (214) 622-6340
jhowie@howielaw.net
Attorneys for Plaintiff
Page 26
AR01789
This is Exhibit “M” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
SAM A. PRESVELOS
%
AR01790
WHO WE ARE WHAT WE DO PRODUCTS & SERVICES NEWSROOM WORK AT BMJ CONTACT US &
Covid-19 vaccine trials cannot tell us if

they will save lives
BMJ / Newsroom / Newsroom / Covid-19 vaccine trials cannot tell us if they will save lives
Covid-19 vaccine trials cannot tell us if BMJ EXPERT MEDIA PANEL
they will save lives If you are a journalist needing to speak to an

expert, please click here.
None of the current trials are designed to detect a reduction in any serious outcome
such as hospitalisations, intensive care use, or deaths
Vaccines are being hailed as the solution to the covid-19 pandemic, but the vaccine B RO W S E O U R E X P E R T M E D I A PA N E L
trials currently underway are not designed to tell us if they will save lives, reports Peter
Doshi, Associate Editor at The BMJ today.
Several covid-19 vaccine trials are now in their most advanced (phase 3) stage, but
what will it mean exactly when a vaccine is declared “effective”? BMJ IN THE NEWS
Many may assume that successful phase 3 studies will mean we have a proven way of
keeping people from getting very sick and dying from covid-19. And a robust way to Latest coverage of BMJ in the national and
interrupt viral transmission. international media
Yet the current phase 3 trials are not actually set up to prove either, says Doshi.
SEE BMJ IN THE NEWS
“None of the trials currently underway are designed to detect a reduction in any
serious outcome such as hospitalisations, intensive care use, or deaths. Nor are the
vaccines being studied to determine whether they can interrupt transmission of the
virus,” he writes.
JOIN OUR MEDIA LIST
He explains that all ongoing phase 3 trials for which details have been released are
evaluating mild, not severe, disease - and they will be able to report final results once
around 150 participants develop symptoms. If you are a journalist who would like to
receive our press releases, please provide
In Pfizer and Moderna’s trials, for example, individuals with only a cough and positive
your details.
lab test would bring those trials one event closer to their completion.
Yet Doshi argues that vaccine manufacturers have done little to dispel the notion that G E T T H E L AT E S T P R E S S R E L E A S E S
severe covid-19 was what was being assessed.
Moderna, for example, called hospitalisations a “key secondary endpoint” in

statements to the media. But Tal Zaks, Chief Medical Officer at Moderna, told The BMJ
that their trial lacks adequate statistical power to assess that endpoint. CONTACT OUR MEDIA RELATIONS
TEAM
Part of the reason may be numbers, says Doshi. Because most people with
symptomatic covid-19 infections experience only mild symptoms, even trials involving
30,000 or more patients would turn up relatively few cases of severe disease. Email the UK media relations team for more
information.
“Hospitalisations and deaths from covid-19 are simply too uncommon in the population
being studied for an effective vaccine to demonstrate statistically significant differences
in a trial of 30,000 people,” he adds. “The same is true regarding whether it can save C O N TAC T U S TO DAY
lives or prevent transmission: the trials are not designed to find out.”
Zaks confirms that Moderna’s trial will not demonstrate prevention of hospitalisation
because the size and duration of the trial would need to be vastly increased to collect
the necessary data. “Neither of these I think are acceptable in the current public need
for knowing expeditiously that a vaccine works,” he told The BMJ.
Moderna’s trial is designed to find out if the vaccine can prevent covid-19 disease,
says Zaks. Like Pfizer and Johnson and Johnson, Moderna has designed its study to
detect a relative risk reduction of at least 30% in participants developing lab-confirmed
covid-19, consistent with FDA and international guidance.
Zaks also points to influenza vaccines, saying they protect against severe disease
better than mild disease. “To Moderna, it’s the same for covid-19: if their vaccine is
shown to reduce symptomatic covid-19, they will feel confident it also protects against
serious outcomes,” Doshi writes.
But Doshi raises another important issue - that few or perhaps none of the current
vaccine trials appear to be designed to find out whether there is a benefit in the elderly,
despite their obvious vulnerability to covid-19.
If the frail elderly are not enrolled into vaccine trials in sufficient numbers to determine
whether there is a reduction in cases in this population, “there can be little basis for
assuming any benefit against hospitalisation or mortality,” he warns.
Doshi says that we still have time to advocate for changes to ensure the ongoing trials
address the questions that most need answering.
For example, why children, immunocompromised people, and pregnant women have
largely been excluded; whether the right primary endpoint has been chosen; whether
safety is being adequately evaluated; and whether gaps in our understanding of how
our immune system responds to covid-19 are being addressed.
“The covid-19 vaccine trials may not have been designed with our input, but it is not
too late to have our say and adjust their course. With stakes this high, we need all
eyes on deck,” he argues.
[Ends]
21/10/2020
Feature: Will covid-19 vaccines save lives? Current trials are not designed to tell us
Journal: The BMJ
Funding: None
Link to Academy of Medical Sciences press release labelling

system: https://press.psprings.co.uk/AMSlabels.pdf
Peer reviewed? Yes
Evidence type: Feature
Subjects: Covid-19 vaccine trials
Who we are What we do BMJ resource centre Contact us

Addressing the gender pay gap BMJ impact report 2021 Select Product London, UK head office
Support for start ups For advertisers and sponsors
How green is The BMJ? For BMA members
Our story For entrepreneurs
Newsroom London, UK head office
BMJ
Our values For individuals BMA House
Open access at BMJ For institutions Work at BMJ Tavistock Square
Research integrity For funders London WC1H 9JR
For recruiters United Kingdom
Switchboard: +44 (0)203 655 5997

Customer Service: +44 (0) 20 7111 1105
Email: support@bmj.com
! ! " # $
© BMJ Publishing Group Ltd. 2022 Cookie settings Accessibility Modern slavery statement Privacy & cookie policy Terms and conditions Select Language ▼
AR01791
This is Exhibit “N” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
SAM A. PRESVELOS
AR01792
l♦I
of Canada du Canada
Updated: March 10, 2022, 9 am EST
Summary of COVID-19 cases across Canada and over time. Contains detailed data about the spread of the
virus over time and in different regions of the country. Includes breakdowns by age and sex or gender.
Provides an overview of hospitalizations and deaths, testing, variants of concern and exposures.
Cases today Total cases Active cases Total resolved Deaths today Total deaths
Total tests performed Daily percent positive (last 7 days) Daily tests per 100,000 population (last 7 days)
• We update these sections Monday to Friday at 9:00 AM EST: Key updates, Current situation and National
overview. Laboratory data represents specimens received by labs up to March 7, 2022 to allow time to
process results.
• We update these sections every Friday: COVID-19 variants in Canada, Epidemic curve, Demographics,
How people were exposed, and Severe illness and outcomes.
• The Cases following vaccination section is updated every Tuesday.
• Of the 11 jurisdictions reporting updates, no new cases were reported in 0 provinces and territories in the
past 24 hours.
• Of the 11 jurisdictions reporting updates, no new deaths were reported in 3 provinces and territories in the
past 24 hours.
• Due to changes in COVID-19 testing policies in many jurisdictions starting in late December 2021, case
counts will under estimate the total burden of disease.
• Resulting from the delays in data entry caused by the recent high number of cases, Nova Scotia issued a
press release on December 10 indicating that they would begin announcing the daily number of new
cases using laboratory test results, not data from Panorama (their public health disease information
system) on the Nova Scotia COVID-19 Dashboard. These reporting changes are expected to be
temporary. In the absence of Panorama data, we will report Nova Scotia’s cumulative cases up until
December 9 and add the daily lab positive cases reported. We will use the estimated number of active
AR01793
cases from Nova Scotia’s updates to calculate the number of recoveries as of December 10. Once Nova
Scotia resumes reporting case data from Panorama, our data will be retroactively corrected.
• As of February 7, 2022, Saskatchewan is reporting COVID-19 epidemiological information weekly on
Thursdays. Their reporting week runs from Sunday to Saturday. As a result, statistics for the most recent
5-11 days are not available for Saskatchewan. Indicators for the last 7 days and the last 14 days are
presented as “not available” or “NA”. Cumulative case and death indicators reflect Saskatchewan data
from the most recent Weekly COVID-19 Situation Report.
• As of March 7, 2022, Nova Scotia is reporting COVID-19 epidemiological information weekly on
Thursdays. The Thursday updates will reflect data up until Wednesday. As a result, statistics for the most
recent 1-7 days are not available for Nova Scotia. Indicators for the last 7 days and the last 14 days are
presented as “not available” or “NA”. Cumulative case and death indicators reflect Nova Scotia data from
the most recent Nova Scotia COVID-19 Dashboard.
• The national count displayed represents the most recent data publicly available for all 13 provinces and
territories. This count may exceed the sum of the individual provincial and territorial counts displayed in
the maps for the last 1, 7, and 14 days.
AR01794
V
[
[ V
Canada 37,510
...
...
... ,. Count of cases (last 7 days) of
COVID-19
10,000 and higher

5,000 to 9,999
500 to 4,999
50 to 499
25 to 49 c=J
1 to 24 D
60 0 □
393
246
on First Nations
2,789
reserves
2,202
3,173 3,322
1,102
7,867
N/A 12,293
3,638
N/A
2,499
The count of cases (last 7 days) of COVID-19 in Canada was 37,510 as of March 9, 2022.
a. This information is based on data our provincial and territorial partners published on cases, deaths,
and testing daily, and are current as of the day they are published. Today’s numbers are current as of
March 9, 2022. For the most up to date data for any province, territory or city, please visit their
website. The number of cases or deaths reported on previous days may differ slightly from those on
the provincial and territorial websites as these websites may update historic case and death counts
as new information becomes available.
AR01795
b. Due to changes in COVID-19 testing policies in many jurisdictions starting in late December 2021,
case counts will under estimate the total burden of disease.
c. Resulting from the delays in data entry caused by the recent high number of cases, Nova Scotia
issued a press release on December 10 indicating that they would begin announcing the daily
number of new cases using laboratory test results, not data from Panorama (their public health
disease information system) on the Nova Scotia COVID-19 Dashboard. These reporting changes are
expected to be temporary. In the absence of Panorama data, we will report Nova Scotia’s cumulative
cases up until December 9 and add the daily lab positive cases reported. We will use the estimated
number of active cases from Nova Scotia’s updates to calculate the number of recoveries as of
December 10. Once Nova Scotia resumes reporting case data from Panorama, our data will be
retroactively corrected.
d. As of February 7, 2022, Saskatchewan is reporting COVID-19 epidemiological information weekly on
Thursdays. Their reporting week runs from Sunday to Saturday. As a result, statistics for the most
recent 5-11 days are not available for Saskatchewan. Indicators for the last 7 days and the last 14
days are presented as “not available” or “NA”. Cumulative case and death indicators reflect
Saskatchewan data from the most recent Weekly COVID-19 Situation Report.
e. As of March 7, 2022, Nova Scotia is reporting COVID-19 epidemiological information weekly on
Thursdays. The Thursday updates will reflect data up until Wednesday. As a result, statistics for the
most recent 1-7 days are not available for Nova Scotia. Indicators for the last 7 days and the last 14
days are presented as “not available” or “NA”. Cumulative case and death indicators reflect Nova
Scotia data from the most recent Nova Scotia COVID-19 Dashboard.
f. The national count displayed represents the most recent data publicly available for all 13 provinces
and territories. This count may exceed the sum of the individual provincial and territorial counts
displayed in the maps for the last 1, 7, and 14 days.
AR01796
Areas in Canada with cases of COVID-19 as of March 9, 2022
Moving Moving
average tests average
Cases last 7 Deaths last 7 Total tests performed last positivity
Total cases days Active cases Resolved Deaths days performed 7 days last 7 days
Location Count Rate* Count Rate* Count Rate* Count Count Rate* Count Rate* Count Count Rate* Percent
British Columbia 351,415 6,739 2,202 42 37,953 728 310,533 2,929 56 46 0.9 5,706,144 5,330 102 7.8%
Alberta 529,736 11,923 3,173 71 6,878 155 518,872 3,986 90 47 1.1 6,857,117 2,382 54 19.4%
Saskatchewan 128,289 10,873 N/A N/A N/A N/A N/A 1,135 96 N/A N/A 1,490,479 1,040 88 14.5%
Manitoba 132,295 9,561 1,102 80 7,903 571 122,689 1,703 123 21 1.5 1,467,488 962 70 13.9%
Ontario 1,117,439 7,537 12,293 83 16,206 109 1,088,615 12,618 85 140 0.9 23,081,303 13,940 94 10.9%
Quebec 932,176 10,834 7,867 91 13,068 152 904,982 14,126 164 110 1.3 16,548,317 11,545 134 9.2%
Newfoundland 28,103 5,399 3,322 638 3,697 710 24,334 72 14 6 1.1 590,263 1,387 267 31.3%
and Labrador
New Brunswick 40,654 5,151 2,499 317 3,859 489 36,482 313 40 7 0.9 745,091 1,417 180 25.7%
Nova Scotia 47,089 4,747 N/A N/A N/A N/A N/A 212 21 N/A N/A 1,783,998 1,696 171 20.3%
Prince Edward 18,905 11,505 3,638 2,214 4,893 2,978 13,996 16 10 0 0.0 256,841 40 24 13.0%
Island
Yukon 3,533 8,219 60 140 45 105 3,466 22 51 0 0.0 9,129 N/A N/A N/A
Northwest 9,400 20,658 393 864 362 796 9,018 20 44 1 2.2 40,279 11 24 33.3%
Territories
Nunavut 3,200 8,121 246 624 472 1,198 2,723 5 13 0 0.0 37,029 151 383 23.3%
Canada 3,342,247 8,739 37,510 98 112,117 293 3,192,973 37,157 97 384 1.0 58,613,554 39,900 104 12.4%
* Rate per 100,000 population

Moving average of cases (last 7 days) Moving average of cases (last 7 days) Moving average of cases (last 7 days)
0
5k
10k
15k
20k
25k
30k
35k
40k
0
5k
10k
15k
20k
25k
30k
35k
40k
0
5k
15k
20k
25k
30k
35k
40k
_,
_,
_,
10k _,
01 01 01
Ap Ap Ap
r' r' r '2
20 20 0
01 01 01
Ju Ju Ju
l '2 l '2 l '2
01 0 01 0 01 0
O O O
[
ct ct ct
' 20 '2 '2
0 0
-,-------,----------,----
01 01 01
Ja Ja Ja
n n n
AR01797
'2 '2 '2

01 1 01 1 01 1
Ap Ap Ap
r' r' r '2
21 21 1
01 01 01
Canada
Quebec
Ju Ju Ju
Reporting date
Reporting date
Reporting date
l '2 l '2 l '2
1 1 1
Saskatchewan
01 01 01
O O O
ct ct ct
' 21 '2 '2
01 01 1 01 1
Ja Ja Ja
n n n
T
'2 '2 '2
2 2 2
V
0
5k
10k
15k
20k
25k
30k
35k
40k
0
5k
10k
15k
20k
25k
30k
35k
40k
0
5k
10k
15k
20k
25k
30k
35k
40k
01 01 01
Ap Ap Ap
r' r' r '2
20 20 0
01 01 01
Ju Ju Ju
l '2 l '2 l '2
01 0 01 0 01 0
O O O
ct ct ct
' 20 '2 '2
01 01 0 01 0
Ja Ja Ja
n n n
'2 '2 '2
01 1 01 1 01 1
Ap Ap Ap
r
-----,
r' r' '2
21 21 1
01 01 01
Ju Ju Manitoba Ju
Reporting date
Reporting date
Reporting date
l '2 l '2 l '2

01 1 01 1 01 1
O O O
British Columbia
ct ct ct
' '2 '2
.--------.
01 21 01 1 01 1
Ja Ja Ja
n n n
'2 '2 '2
Newfoundland and Labrador

2 2 2
0
5k
10k
15k
20k
25k
30k
35k
40k
0
5k
10k
15k
20k
25k
30k
35k
40k
0
5k
10k
15k
20k
25k
30k
35k
40k
01 01 01
Ap Ap Ap
r' r' r '2
20 20 0
01 01 01
Ju Ju Ju
l '2 l '2 l '2
01 0 01 0 01 0
O O O
ct ct ct
' 20 '2 '2
01 01 0 01 0
Ja Ja Ja
n n n
'2 '2 '2
01 1 01 1 01 1
Ap Ap Ap
r' r' r '2
21 21 1
Alberta
Ontario
01 01 01
Ju Ju Ju
Reporting date
Reporting date
Reporting date
l '2 l '2 l '2

01 1 01 1 01 1
O
ct New Brunswick O
ct
O
ct
' 21 '2 '2
1 1
same for each figure. This allows you to compare the provinces and territories on the same timescale.
01 01 01
Ja Ja Ja
n n n
'2 '2 '2
V
2 2 2
The figures below show cases over time. The range of dates (January 31st, 2020 - present date) is the
AR01798
Moving average of cases (last 7 days) Nova Scotia Prince Edward Island Yukon
Moving average of cases (last 7 days)

1 J
40k 40k 40k
35k 35k 35k

~
30k 30k 30k

1
25k 25k 25k

~
20k 20k 20k

~
15k 15k 15k

1
10k 10k 10k

~
5k 5k 5k
0 0 0
j
-I
2
0
1
0
1
0
1
'2
'2
'2
'2
'2
'2
'2
'2
'2
'2
'2
'2
'2
'2
'2
'2
'2
'2
l '2
l '2
l '2
l '2
l '2
l '2
n
n
ct
ct
ct
ct
ct
ct
r
r
Ap
Ju
Ap
Ju
Ap
Ju
Ap
Ju
Ap
Ju
Ap
Ju
Ja
Ja
Ja
Ja
Ja
Ja
O
O
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
Reporting date Reporting date Reporting date
Northwest Territories Nunavut


~·
40k 40k
35k 35k
1
30k 30k
1
25k 25k
~
20k 20k
1
15k 15k
1
10k 10k
~
5k 5k
0 0
j
1
2
0
1
20
21
20
21
0
1
'2
'2
'2
'2
'2
'2
'2
'2
l '2
l '2
l '2
l '2
r'
r'
r'
r'
n
n
ct
ct
ct
ct
Ap
Ju
Ap
Ju
Ap
Ju
Ap
Ju
Ja
Ja
Ja
Ja
O
O
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
01
Reporting date Reporting date
a. Due to changes in COVID-19 testing policies in many jurisdictions starting in late December 2021,
b. This information is based on data from our provincial and territorial partners. Data about cases was
last updated on March 9, 2022. Laboratory data includes specimens received by labs up to March 7,
2022. For the most up to date data for any province, territory or city, please visit their web site.
c. The 7-day moving average is the total of the daily numbers for the previous 7 days (up to and
including the day of the last update), divided by the number of days for which data is available. We
go back and update the moving averages as provinces and territories submit more data. We
calculate the national 7-day moving average by summing the 7-day moving average from the
provinces and territories then dividing by the national population if a rate is calculated.
d. Resulting from the delays in data entry caused by the recent high number of cases, Nova Scotia
AR0179910. Once Nova Scotia resumes reporting case data from Panorama, our data will be
December
e. As of February 7, 2022, Saskatchewan is reporting COVID-19 epidemiological information weekly on
f. As of March 7, 2022, Nova Scotia is reporting COVID-19 epidemiological information weekly on
g. The national count displayed represents the most recent data publicly available for all 13 provinces
Downloadable data (in .csv format).
Due to changes in COVID-19 testing policies in many jurisdictions starting in late December 2021, case
counts will under estimate the total burden of disease.
Note: Out of the total number of people tested, 76 were repatriated travellers, of which 13 were cases.
AR01800
There have been over 58,613,554 COVID-19 tests performed in Canada or 1,532,536 tests per 1 million
people. For information about testing trends, please see the Detailed weekly epidemiological report (PDF).
Table 1. Daily* change in the number of cases, deaths and tests performed, by province or
territory, as of March 9, 2022 (Last data update March 10, 2022, 9 am EST)
Location New cases New deaths Tests performed
British Columbia 274 14 4,028
Alberta 552 7 2,210
Saskatchewan N/A N/A 919
Manitoba 206 3 928
Ontario 1,947 27 11,128
Quebec 1,426 6 12,594
Newfoundland and Labrador 596 4 1,407
New Brunswick 342 1 1,158
Nova Scotia N/A N/A 1,334
Prince Edward Island 577 0 56
Yukon 9 0 N/A
Northwest Territories 75 1 16
Nunavut 30 0 225
Canada 6,034 63 36,003
1. * The new cases, deaths and tests reflect the difference between a province or territory's current
report and their last report. Some provinces and territories do not update daily.
2. N/A means that no daily update was provided by the province or territory.
3. Due to changes in COVID-19 testing policies in many jurisdictions starting in late December 2021,
4. Resulting from the delays in data entry caused by the recent high number of cases, Nova Scotia
AR01801
December 10. Once Nova Scotia resumes reporting case data from Panorama, our data will be
5. As of February 7, 2022, Saskatchewan is reporting COVID-19 epidemiological information weekly on
6. As of March 7, 2022, Nova Scotia is reporting COVID-19 epidemiological information weekly on
7. The national count displayed represents the most recent data publicly available for all 13 provinces
AR01802
All viruses, including COVID-19, change over time. These changes are called mutations, and result in variants
of the virus. Not all mutations are of concern. Most do not cause more severe illness. However, some
mutations result in variants of concern or variants of interest.
A variant of concern has mutations that are significant to public health. Before a variant of interest is
considered one of concern, scientists and public health professionals must determine if the mutations result in
an actual change in the behaviour of the virus. For example, it might:
• spread more easily

• cause more severe illness
• require different treatments, or
• reduce vaccine effectiveness
There are several variants of interest that have mutations similar to variants of concern, but we don’t yet know
if they pose a higher risk to public health.
The Public Health Agency of Canada (PHAC) works with provincial and territorial partners and the Canadian
COVID-19 Genomics Network (CanCOGeN) to sequence a percentage of all positive COVID-19 test results.
Sequencing reveals the genetic code of the virus, which tells us which variant is involved in a specific case of
COVID-19. We report the proportion of COVID-19 variants in Canada every week.
We collect evidence to determine if new variants meet the definition for a variant of concern or a variant of
interest. Many variants are being tracked across Canada and around the world. Variants of concern now
represent a majority of COVID-19 cases in Canada.
Current variants of concern in Canada include:
• Alpha (B.1.1.7)
• Beta (B.1.351)
• Gamma (P.1)
• Delta (B.1.617.2)
• Omicron (B.1.1.529)
New variants will continue to appear. We must remain vigilant and take all available measures to limit spread.
AR01803
The graphic shows the percentage mix of COVID-19 variants detected in Canada through whole genome
sequencing, by week of sample collection. You can see the numbers for each date by hovering over, tabbing
to, or long-pressing any of the bars. To see a specific variant or variant grouping, click or press return. Repeat
to restore the complete graph. Sublineages or offshoots for some variants can be revealed or hidden by
clicking on the name of the variant in the legend.
Accumulating data
Variants of concern
Delta
100%
.• ►. .
Omicron
• BA.1
• BA.1.1
Percentage of samples sequenced
80%
• BA.2
Variants of interest
60% 0 Mu
Other variants
Other
40%
20%
0%
1
2
02
02
02
02
02
02
02
02
02
02
,2
,2
,2
,2
,2
,2
,2
,2
,2
,2
12
19
26
02
09
16
23
30
06
13
ec
ec
ec
b
Ja
Ja
Ja
Ja
Ja
Fe
Fe
D
Week of sample collection
This information is based on whole genome sequencing from surveillance testing in all provinces and territories. In addition to
sequencing done by the National Microbiology Laboratory in Winnipeg, data is included from provincial and territorial
laboratories.
Sequencing takes from 1 to 3 weeks to complete, so the proportions for recent weeks may change as more data are added.
Surveillance in each province or territory is organized and prioritized according to local needs and may change from time to
time. Because of differences in local sampling and reporting, the percentages illustrate trends rather than precise
measurements.
AR01804
Percentage of COVID-19 cases identified through whole genome sequencing, presented by variant and
by week of sample collection.
Dec 12, Dec 19, Dec 26, Jan 02, Jan 09, Jan 16, Jan 23, Jan 30, Feb 06, Feb 1
Variant 2021 2021 2021 2022 2022 2022 2022 2022 2022 2022
Grouping (n=8,023) (n=9,056) (n=9,598) (n=8,984) (n=6,627) (n=5,269) (n=5,684) (n=5,531) (n=4,246) (n=78
Variants 99.8% 99.9% 100.0% 99.9% 100.1% 100.1% 100.0% 100.1% 100.0% 100.0
of
concern
Delta 42.6% 15.2% 5.6% 3.8% 2.7% 1.5% 1.1% 0.6% 0.3% 0.2%
AY.103 3.5% 1.1% 0.4% 0.3% 0.2% 0.1% 0.1% 0.1% 0.0% -
AY.25.1 22.9% 9.0% 3.2% 2.2% 1.6% 0.8% 0.7% 0.3% 0.1% 0.1%
AY.27 1.8% 0.9% 0.2% 0.2% 0.1% 0.1% 0.1% 0.1% 0.1% -
AY.74 1.0% 0.1% 0.1% 0.0% 0.1% 0.0% 0.0% 0.0% - -
AY.93 0.2% 0.2% 0.1% - - 0.0% - - - -
Other 13.2% 3.9% 1.6% 1.1% 0.7% 0.5% 0.2% 0.1% 0.1% 0.1%
Delta
Omicron 57.2% 84.7% 94.4% 96.1% 97.4% 98.6% 98.9% 99.5% 99.7% 99.8%
BA.1 41.7% 58.8% 56.4% 49.4% 46.1% 39.2% 36.1% 33.5% 31.0% 29.2%
BA.1.1 15.5% 25.9% 37.6% 45.4% 49.0% 53.7% 54.3% 56.7% 59.8% 59.6%
BA.2 - 0.0% 0.4% 1.3% 2.3% 5.7% 8.5% 9.3% 8.9% 11.0%
Variants - - - - - - 0.0% - - -
of
interest
Mu - - - - - - 0.0% - - -
B.1.621 - - - - - - 0.0% - - -
Other 0.1% 0.0% 0.0% 0.0% 0.0% - 0.0% 0.0% 0.0% -

variants
Other 0.1% 0.0% 0.0% 0.0% 0.0% - 0.0% 0.0% 0.0% -
Note: The shaded columns on the right represent a period of accumulating data.
• Saskatchewan - Roy Romanow Provincial Laboratory (RRPL)

• Public Health Ontario (PHO)
AR01805 and Labrador - Eastern Health
• Newfoundland
• New Brunswick – Vitalité Health Network
• Manitoba Cadham Provincial Laboratory
• Laboratoire de santé publique du Québec (LSPQ)
• BCCDC Public Health Laboratory
• Alberta Precision Labs - Edmonton (APL)
• National Microbiology Laboratory (NML) - supplemental sequencing for all provinces and territories
The tables and figures below reflect detailed case information provided to the Public Health Agency of Canada
(PHAC) by health authorities in the provinces and territories. This data is updated every week. It may change
as we get more information about cases.
Updated: March 4, 2022, 8 am EST
As of March 4, 2022, 8 am EST, PHAC has received detailed case report data on 3,219,741 cases. Both
exposure and symptom onset date were available for 2,088,555 (64.9%) cases 1.
The shaded area on the far right of Figure 3 represents a period of accumulating data. This is the period of
time (1 to 2 weeks) before the latest cases are reported to PHAC. This delay is a result of the time required to
seek health care, get tested and receive results. It also takes time for public health authorities to gather
information on cases. We update this information as it becomes available.
Number of reported cases
15
-J
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
50,000
55,000
02 an
-F -20
e
23 b-2
-F 0
e
15 b-2
-M 0
a
05 r-2
-A 0
p
26 r-2
-A 0
AR01806
17 pr-
-M 20
a
07 y-2
-J 0
u
28 n-2
-J 0
u
19 n-2
-J 0
09 ul-2
-A 0
u
30 g-2
-A 0
u
20 g-2
-S 0
e
11 p-2
-O 0
01 ct-2
-N 0
22 ov-2
-N 0
13 ov-2
-D 0
e
03 c-2
-J 0
an
24 -2
-J 1
a
14 n-2
-F 1
e
07 b-2
-M 1
Date
28 ar-2
-M 1
a
18 r-2
-A 1
09 pr-
-M 21
30 ay-
-M 21
a
20 y-2
-J 1
un
11 -21
-J
01 ul-2
-A 1
u
22 g-2
-A 1
u
12 g-2
-S 1
e
03 p-2
-O 1
24 ct-2
-O 1
14 ct-2
-N 1
05 ov-2
-D 1
26 ec-2
-D 1
e
16 c-2
-J 1
a
06 n-2
-F 2
e
27 b-2
-F 2
eb
-2
2
Number of reported cases Number of reported cases
15 15
-J -J
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
50,000
55,000
0
2,000
4,000
6,000
8,000
10,000
12,000
14,000
16,000
18,000
20,000
22,000
24,000
26,000
28,000
30,000
02 an 02 an
-F -20 -F -20
e e
23 b-2 23 b-2
■
-F 0 -F 0
e e
15 b-2 15 b-2
-M 0 -M 0
80+
a a
0-11
12-19
20-29
30-39
40-49
50-59
60-69
70-79
05 r-2 05 r-2
-A 0 -A 0
p p
26 r-2 26 r-2
-A 0 -A 0
AR01807
17 pr- 17 pr-
-M 20 -M 20
a a
07 y-2 07 y-2
-J 0 -J 0
u u
Information pending
Domestic - Unknown
28 n-2 28 n-2
-J 0 -J 0
u u
19 n-2 19 n-2
-J 0 -J 0
Travelled outside of Canada
09 ul-2 09 ul-2
-A 0 -A 0
u u
30 g-2 30 g-2
Domestic - Contact with a traveller
-A 0 -A 0
u u
20 g-2 20 g-2
Domestic - Contact with a COVID case
-S 0 -S 0
e e
11 p-2 11 p-2
-O 0 -O 0
01 ct-2 01 ct-2
-N 0 -N 0
22 ov-2 22 ov-2
-N 0 -N 0
13 ov-2 13 ov-2
-D 0 -D 0
e e
03 c-2 03 c-2
-J 0 -J 0
an an
24 -2 24 -2
-J 1 -J 1
a a
14 n-2 14 n-2
-F 1 -F 1
e e
07 b-2 07 b-2
-M 1 -M 1
Date
Date
28 ar-2 28 ar-2
-M 1 -M 1
a a
18 r-2 18 r-2
-A 1 -A 1
09 pr- 09 pr-
-M 21 -M 21
30 ay- 30 ay-
-M 21 -M 21
a a
20 y-2 20 y-2
-J 1 -J 1
un un
11 -21 11 -21
-J -J
01 ul-2 01 ul-2
-A 1 -A 1
u u
22 g-2 22 g-2
-A 1 -A 1
u u
12 g-2 12 g-2
-S 1 -S 1
e e
03 p-2 03 p-2
-O 1 -O 1
24 ct-2 24 ct-2
-O 1 -O 1
14 ct-2 14 ct-2
-N 1 -N 1
05 ov-2 05 ov-2
-D 1 -D 1
26 ec-2 26 ec-2
-D 1 -D 1
e e
16 c-2 16 c-2
-J 1 -J 1
a a
06 n-2 06 n-2
-F 2 -F 2
e e
27 b-2 27 b-2
-F 2 -F 2
eb eb
-2 -2
2 2
Number of reported cases
15
-J
0
5,000
10,000
15,000
20,000
25,000
30,000
35,000
40,000
45,000
50,000
55,000
02 an
-F -20
e
23 b-2
-F 0
e
15 b-2
-M 0
a
80+
0-19
20-39
40-59
60-79
05 r-2
-A 0
p
26 r-2
-A 0
AR01808
17 pr-
-M 20
a
07 y-2
-J 0
u
28 n-2
-J 0
u
19 n-2
-J 0
09 ul-2
-A 0
u
30 g-2
-A 0
u
20 g-2
-S 0
e
11 p-2
-O 0
01 ct-2
-N 0
22 ov-2
-N 0
13 ov-2
-D 0
e
03 c-2
-J 0
an
24 -2
-J 1
a
14 n-2
-F 1
e
07 b-2
-M 1
Date
28 ar-2
-M 1
a
18 r-2
-A 1
09 pr-
-M 21
30 ay-
-M 21
a
20 y-2
-J 1
un
11 -21
-J
01 ul-2
-A 1
u
22 g-2
-A 1
u
12 g-2
-S 1
e
03 p-2
-O 1
24 ct-2
-O 1
14 ct-2
-N 1
05 ov-2
cases and jurisdictions have not all consistently reported exposure history to PHAC throughout the pandemic.
-D 1
26 ec-2
-D 1
e
16 c-2
-J 1
a
06 n-2
-F 2
e
27 b-2
-F 2
This figure may underestimate the total number of cases among returning travelers. Exposure history is not available for all
eb
-2
2
AR01809
We have detailed case report data from 3,219,741 cases. We know the age of patients in 99.97% of cases,
and both age and gender in 99.71% of cases.
Of the cases reported in Canada so far, 52.6% were female and 36.8% were between 20 and 39 years old
(Figure 4).
0-11 360,218 (11.2%)
12-19 290,746 (9.0%)
20-29 616,334 (19.1%)

Age group (years)
30-39 567,639 (17.6%)
40-49 486,842 (15.1%)
50-59 393,681 (12.2%)
60-69 236,418 (7.3%)
70-79 123,128 (3.8%)
80+ 143,613 (4.5%)
0 100,000 200,000 300,000 400,000 500,000 600,000 700,000

Number (Proportion (%))
Male ■ Female □ Other ■

0-11 187,580 (52.2%) 171,870 (47.8%) 21 (0.0%)
12-19 141,872 (48.9%) 148,052 (51.1%) 15 (0.0%)
20-29 288,003 (46.9%) 326,097 (53.1%) 34 (0.0%)

Age group (years)
30-39 259,383 (45.8%) 306,773 (54.2%) 33 (0.0%)
40-49 221,301 (45.6%) 264,423 (54.4%) 18 (0.0%)
50-59 188,881 (48.1%) 203,911 (51.9%) 16 (0.0%)
60-69 120,280 (51.0%) 115,618 (49.0%) 10 (0.0%)
70-79 62,088 (50.5%)60,801 (49.5%) 2 (0.0%)
80+ 53,521 (37.3%) 89,833 (62.7%) 0 (0.0%)
0 100,000 200,000 300,000 400,000 500,000 600,000 700,000

AR01810
Age by gender 4 distribution of COVID-19 cases (n=3,218,619 1) in Canada, March 4, 2022,

8 am EST
Age Number of cases with Number of male Number of other

group case reports cases Number of female cases
(years) (percentage) (percentage) cases (percentage) (percentage)
0-11 360,218 (11.2%) 187,580 (12.3%) 171,870 (10.2%) 21 (14.1%)
12-19 290,746 (9.0%) 141,872 (9.3%) 148,052 (8.8%) 15 (10.1%)
20-29 616,334 (19.1%) 288,003 (18.9%) 326,097 (19.3%) 34 (22.8%)
30-39 567,639 (17.6%) 259,383 (17.0%) 306,773 (18.2%) 33 (22.1%)
40-49 486,842 (15.1%) 221,301 (14.5%) 264,423 (15.7%) 18 (12.1%)
50-59 393,681 (12.2%) 188,881 (12.4%) 203,911 (12.1%) 16 (10.7%)
60-69 236,418 (7.3%) 120,280 (7.9%) 115,618 (6.9%) 10 (6.7%)
70-79 123,128 (3.8%) 62,088 (4.1%) 60,801 (3.6%) 2 (1.3%)
80+ 143,613 (4.5%) 53,521 (3.5%) 89,833 (5.3%) 0 (0.0%)
Total 3,218,619 (100%) 1,522,909 (100%) 1,687,378 (100%) 149 (100%)
In Canada V , detailed case report data were provided for 3,219,741 cases. We have
exposure history for 2,088,555 (64.9%) cases. The probable exposure setting of these cases 1 are:
• any exposure that occurred in Canada: 1,583,841 (75.8%), including

0 from contact with a known COVID case: 836,735 (40.1%)
0 from contact with a traveller: 9,980 (0.5%)
0 from an unknown source: 737,126 (35.3%)
• currently unknown (information pending): 487,640 (23.3%)
• travelled outside of Canada: 17,074 (0.8%)
AR01811
Data extracted on March 04, 2022 for cases from December 14, 2020 up until February 20, 2022.
While the COVID-19 vaccines are highly effective at preventing severe outcomes, a percentage of the
population who are vaccinated may become infected with COVID-19 if they are exposed to the virus that
causes it. This means that even with high vaccine effectiveness, a percentage of people who are vaccinated
against COVID-19 will still get sick and some may be hospitalized or die.
It is also possible that a person could be infected just before or just after vaccination and still get sick. It
typically takes about two weeks for the body to build protection after vaccination, so a person could get sick if
the vaccine has not had enough time to provide protection.
As the majority of Canadians are now vaccinated, counts will inherently be higher within this population,
compared to the unvaccinated population. However, risk among this population may be lower, despite higher
case counts.
Due to the rapid increase in cases starting December 2021, delays in data entry, and changes in COVID-19
testing policies in many jurisdictions, case counts will under estimate the total burden of disease, and may
over-represent people at risk of severe disease. Data should be interpreted with caution.
Since the start of the vaccination campaign on December 14, 2020, PHAC received case-level vaccine history
data for 72.3% (n=1,841,797) of COVID-19 cases aged 5 years or older.
Of these cases:
• 916,475 (49.8%) were unvaccinated at the time of their episode date

• 51,466 (2.8%) were not yet protected by the vaccine
-- --------
• 87,698 (4.8%) were only partially vaccinated
• 647,438 (35.2%) were fully vaccinated
• 138,720 (7.5%) were fully vaccinated with an additional dose
AR01812
Cases Hospitalizations Deaths
100% 100% 100%
90% 90% 90%
Percentage of cases
Percentage of cases
Percentage of cases
80% 80% 80%
70% 70% 70%
63.8% 63.4%
60% 60% 60%
50% 49.8% 50% 50%
40% 35.2% 40% 40%
30% 30% 30%
---•- •
20% 20% 19.0% 20% 16.5%
■
10% 7.5% 10% 7.1% 10% 8.8%
4.8% 4.3% 5.8% 5.4% 5.9%
2.8%
0% 0% 0% < ... 1111!11
ated cted ated ated an
th e ate
d
cte
d
ate
d
ate
d an
th e ate
d
cte
d
ate
d
ate
d an
th e
ccin ote
r cinc cin c d wi dos ccin rote ccin c cin d wi dos ccin rote ccin c cin d wi dos
a p a a e l va tp va va e l va tp va va e l
Un
v et v v at na Un ye
t a
Un ye
t a
ty lly lly cin itio ot
lly lly ina ion ot
lly lly ina ion
no rtia Fu ac add n rtia Fu cc dit n rtia Fu cc dit
s P a v es Pa va ad es Pa va ad
se lly s lly s lly
Ca Fu Ca Fu Ca Fu
Vaccination status Vaccination status Vaccination status
AR01813
Characteristics and severe outcomes associated unvaccinated, partially vaccinated and

fully vaccinated confirmed cases reported to PHAC, as of February 20, 2022
Status Cases Hospitalizations Deaths
Unvaccinated 49.8% 63.8% 63.4%
Cases not yet protected 2.8% 4.3% 5.4%
Partially vaccinated 4.8% 5.8% 5.9%
Fully vaccinated 35.2% 19.0% 16.5%
Fully vaccinated with an additional dose 7.5% 7.1% 8.8%
Among the twelve jurisdictions that have reported case-level vaccine history data to PHAC, a total of 24.9
million people have received at least one dose of the COVID-19 vaccine as of February 20, 2022.
Of these people:
• 24.9 million achieved partial vaccination status, of which 87,698 (0.35%) were diagnosed with COVID-19
while partially vaccinated
• 23.4 million achieved full vaccination status, of which 647,438 (2.77%) were diagnosed with COVID-19
while fully vaccinated
• 12.2 million achieved full vaccination with an additional dose status, of which 138,720 (1.13%) were
diagnosed with COVID-19 while fully vaccinated with an additional dose
Based on detailed case information reported to PHAC from provinces and territories, cases following
vaccination were reported more frequently among females (Table 2). This may be the result of higher
vaccination coverage in Canada among females due to the prioritization of healthcare workers as part of the
vaccine rollout.
Table 2. Characteristics and severe outcomes among unvaccinated, partially vaccinated, fully
vaccinated, and fully vaccinated with additional dose confirmed cases reported to PHAC, as
of February 20, 2022
Fully
vaccinated
Cases not with an
yet Partially Fully additional
Unvaccinated protected vaccinated vaccinated dose Total cases
(n=916,475) (n=51,466) (n=87,698) (n=647,438) (n=138,720) (n=1,841,797)
Gender* Male 467,714 25,187 42,679 288,179 51,218 (5.9%) 874,977

(53.5%) (2.9%) (4.9%) (32.9%) (100%)
AR01814 Fully
vaccinated
Cases not with an
yet Partially Fully additional
Unvaccinated protected vaccinated vaccinated dose Total cases
(n=916,475) (n=51,466) (n=87,698) (n=647,438) (n=138,720) (n=1,841,797)
Female 445,365 26,199 44,837 357,179 87,059 (9.1%) 960,639

(46.4%) (2.7%) (4.7%) (37.2%) (100%)
Hospitalizations 47,710 3,220 4,370 14,210 5,320 (7.1%) 74,830

(63.8%) (4.3%) (5.8%) (19.0%) (100%)
Deaths 9,240 (63.4%) 786 (5.4%) 857 (5.9%) 2,397 1,286 (8.8%) 14,566
(16.5%) (100%)
Source: Detailed case information received by PHAC from provinces and territories, since December 14, 2020
Note:
0 Twelve of thirteen provinces and territories have reported case-level vaccine history data to PHAC as part
of the national COVID-19 dataset.
■ Eight of these provinces and territories have reported data on cases fully vaccinated with an
additional dose. In provinces and territories that have not yet reported additional dose data, cases are
classified as fully vaccinated if they are fully vaccinated or fully vaccinated with an additional dose.
0 A data cut-off of February 20, 2022 was used to account for routine reporting delays associated with
vaccine history information.
0 Data on cases fully vaccinated with an additional dose are limited to the eligible population aged 12 years
or older.
0 Beginning February 6, 2022, cases following vaccination analyses are updated with data up to and
including the previous Sunday to align with changes in vaccination coverage reporting. To account for this
change in reporting, data for the week ending January 30, 2022 contains an extra day of case-level
vaccine history data for most provinces and territories. This change will not be implemented retroactively.
0 *Where available, gender data was used; when gender data was unavailable, sex data was used. Cases
with missing gender and sex data were excluded from the gender analysis. Reliable data on gender
diverse respondents are unavailable due to small counts.
Individuals fully vaccinated and fully vaccinated with an additional dose who were diagnosed with COVID-19
were significantly protected from severe outcomes. From January 23, 2022 to February 20, 2022, compared to
fully vaccinated cases, unvaccinated cases were 4 times more likely to be hospitalized and 5 times more likely
to die as a result of their illness. Compared to cases fully vaccinated with an additional dose, unvaccinated
cases were 11 times more likely to be hospitalized and 15 times more likely to die as a result of their illness,
during this same 4-week period (Table 3).
TableAR01815
3. Risk of severe outcomes among unvaccinated cases, compared to fully
vaccinated cases and cases fully vaccinated with an additional dose, January 23, 2022 to
February 20, 2022
4-week age standardized* rate 4-week age standardized* rate ratio,

Severe ratio, unvaccinated compared to unvaccinated compared to fully vaccinated
Outcome fully vaccinated with an additional dose
Hospitalizations 4 11
Deaths 5 15
*Age-standardized using July 2021 Canadian population estimates

Source: Detailed case information received by PHAC from provinces and territories
Note:
0 Rate ratio calculations were based on data from nine provinces and territories that have reported
complete case-level vaccine history data to PHAC during the 4-week period of analysis.
Data for this analysis is extracted from the COVID-19 national data set, which contains detailed case-level
information received by PHAC from all provinces and territories. Note that a data cut-off of February 20,
2022 was used to account for any reporting delays associated with vaccine history information. There are
currently twelve jurisdictions reporting case-level vaccine history data to PHAC as part of the national
COVID-19 dataset.
PHAC monitors cases following vaccination using the following categories:
Unvaccinated cases: include those who were unvaccinated at the time of their episode date.
Cases not yet protected from vaccination include those whose episode date occurred less than 14
days after their first dose of the vaccine.
Partially vaccinated cases include those whose episode date occurred 14 days or more after their first
vaccine dose or less than 14 days after their second dose of the vaccine.
Fully vaccinated cases include those whose episode date occurred 14 days or more after receipt of a
second dose in a two-dose series or 14 days or more after receipt of one dose of a one-dose vaccine
series,, and, if an additional (i.e., third or booster) dose was received, 0 to <14 days after receipt of the
additional dose.
Fully vaccinated cases with an additional dose include those whose episode date occurred 14 days or
more following the receipt of at least one additional dose (e.g., third or booster) of a COVID-19 vaccine
product, after being fully vaccinated.
Note: A COVID-19 vaccine product includes vaccines authorized by Health Canada and vaccines
accepted by the Government of Canada for the purpose of travel to and within Canada.
AR01816
When symptom onset date is unavailable or the case is asymptomatic, episode date uses the following dates
as a proxy for classification: laboratory specimen collection date, or laboratory testing date.
For more information on cases following vaccination, please see the Weekly epidemiology report (PDF)
available on the Government of Canada’s COVID-19 data trends page.
Total patients hospitalized

11,000
10,000
9,000
8,000
7,000
Number
6,000
5,000
4,000
3,000
2,000
1,000
0
ril
ly
er
21
ril
ly
er
22
Ju
Ju
Ap
Ap
ob
ob
20
20
ct
ct
O
O
Patients in non-ICU Patients in ICU Patients mechanically vented
11,000 11,000 11,000
10,000 10,000 10,000
9,000 9,000 9,000
8,000 8,000 8,000
7,000 7,000 7,000
6,000 6,000 6,000
5,000 5,000 5,000
4,000 4,000 4,000
3,000 3,000 3,000
2,000
1,000
0
2,000
1,000
0
-- •• • ft
2,000
1,000
0
--- -·
ril
ly
er
21
ril
ly
er
22
ril
ly
er
21
ril
ly
er
22
ril
ly
er
21
ril
ly
er
22
Ju
Ju
Ju
Ju
Ju
Ju
Ap
Ap
Ap
Ap
Ap
Ap
ob
ob
ob
ob
ob
ob
20
20
20
20
20
20
ct
ct
ct
ct
ct
ct
O
Between February 21, 2022 and February 28, 2022:
• the total number of hospital beds occupied by COVID-19 patients decreased from 6,175 to 5,136 beds.
• the number of non-ICU beds occupied by COVID-19 patients decreased from 5,504 to 4,566 beds.
• the number of ICU beds occupied by COVID-19 patients decreased from 671 to 570 beds.
• the number of COVID-19 patients who were mechanically vented decreased from 361 to 291.
We have detailed case report data with hospitalization status for 3,219,734 cases:
• AR01817
134,279 cases (4.2%) were hospitalized, of whom:
0 23,020 (17.1%) were admitted to the ICU
The provinces and territories provided detailed case report forms for 36,326 deaths related to COVID-19.
Male Female Other ■

0-11 n = 2,916 (2.2%)
12-19 n = 1,620 (1.2%)
20-29 n = 6,459 (4.8%)

Age group (years)
30-39 n = 10,174 (7.6%)
40-49 n = 11,549 (8.6%)
50-59 n = 17,688 (13.2%)
60-69 n = 22,981 (17.1%)
70-79 n = 26,077 (19.4%)
80+ n = 34,642 (25.8%)
0 5,000 10,000 15,000 20,000 25,000 30,000 35,000

Male Female Other

0-11 n = 278 (1.2%)
12-19 n = 167 (0.7%)
20-29 n = 705 (3.1%)

Age group (years)
30-39 n = 1,445 (6.3%)
40-49 n = 2,383 (10.4%)
50-59 n = 4,469 (19.4%)
60-69 n = 5,981 (26.0%)
70-79 n = 5,172 (22.5%)
80+ n = 2,384 (10.4%)
0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 4,500 5,000 5,500 6,000 6,500
AR01818
0-11 n = 22 (0.1%)
Male ■ Female
• Other ■
12-19 n = 11 (0.0%)
20-29 n = 108 (0.3%)

Age group (years)
30-39 n = 260 (0.7%)
40-49 n = 585 (1.6%)
50-59 n = 1,631 (4.5%)
60-69 n = 3,880 (10.7%)
70-79 n = 7,694 (21.2%)
80+ n = 22,053 (60.8%)
0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 16,000 18,000 20,000 22,000 24,000
Data note: Figure 7 includes COVID-19 cases hospitalized, admitted to ICU, and deceased for which age and
gender information were available. Therefore, some COVID-19 hospitalizations, ICU admissions, and deaths
may not be included in Figure 7.
AR01819
Age and gender 4 distribution of COVID-19 cases hospitalized in Canada as of March 4,

2022, 8 am EST (n=134,106 1)

0-11 2,916 (2.2%) 1,650 (1.2%) 1,265 (0.9%) 1 (0.0%)
12-19 1,620 (1.2%) 694 (0.5%) 926 (0.7%) 0 (0.0%)
20-29 6,459 (4.8%) 2,437 (1.8%) 4,021 (3.0%) 1 (0.0%)
30-39 10,174 (7.6%) 4,287 (3.2%) 5,887 (4.4%) 0 (0.0%)
40-49 11,549 (8.6%) 6,539 (4.9%) 5,010 (3.7%) 0 (0.0%)
50-59 17,688 (13.2%) 10,595 (7.9%) 7,093 (5.3%) 0 (0.0%)
60-69 22,981 (17.1%) 13,537 (10.1%) 9,444 (7.0%) 0 (0.0%)
70-79 26,077 (19.4%) 14,756 (11.0%) 11,321 (8.4%) 0 (0.0%)
80+ 34,642 (25.8%) 16,623 (12.4%) 18,019 (13.4%) 0 (0.0%)
Age and gender 4 distribution of COVID-19 cases admitted to ICU in Canada as of March
4, 2022, 8 am EST (n=22,984 1)

0-11 278 (1.2%) 149 (0.6%) 129 (0.6%) 0 (0.0%)
12-19 167 (0.7%) 93 (0.4%) 74 (0.3%) 0 (0.0%)
20-29 705 (3.1%) 377 (1.6%) 328 (1.4%) 0 (0.0%)
30-39 1,445 (6.3%) 834 (3.6%) 611 (2.7%) 0 (0.0%)
40-49 2,383 (10.4%) 1,467 (6.4%) 916 (4.0%) 0 (0.0%)
50-59 4,469 (19.4%) 2,942 (12.8%) 1,527 (6.6%) 0 (0.0%)
60-69 5,981 (26.0%) 3,835 (16.7%) 2,146 (9.3%) 0 (0.0%)
70-79 5,172 (22.5%) 3,283 (14.3%) 1,889 (8.2%) 0 (0.0%)
80+ 2,384 (10.4%) 1,396 (6.1%) 988 (4.3%) 0 (0.0%)

AR01820
Age and gender 4 distribution of COVID-19 cases deceased in Canada as of March 4,
2022, 8 am EST (n=36,244 1)

0-11 22 (0.1%) 9 (0.0%) 13 (0.0%) 0 (0.0%)
12-19 11 (0.0%) 6 (0.0%) 5 (0.0%) 0 (0.0%)
20-29 108 (0.3%) 68 (0.2%) 40 (0.1%) 0 (0.0%)
30-39 260 (0.7%) 162 (0.4%) 98 (0.3%) 0 (0.0%)
40-49 585 (1.6%) 370 (1.0%) 215 (0.6%) 0 (0.0%)
50-59 1,631 (4.5%) 1,003 (2.8%) 628 (1.7%) 0 (0.0%)
60-69 3,880 (10.7%) 2,469 (6.8%) 1,411 (3.9%) 0 (0.0%)
70-79 7,694 (21.2%) 4,645 (12.8%) 3,049 (8.4%) 0 (0.0%)
80+ 22,053 (60.8%) 10,197 (28.1%) 11,856 (32.7%) 0 (0.00%)

AR01821
For more information, please refer to provincial or territorial COVID-19 webpages:
• British Columbia
• Alberta
• Saskatchewan
• Manitoba
• Ontario
• Quebec
• Newfoundland and Labrador
• New Brunswick
• Nova Scotia
• Prince Edward Island
• Yukon
• Northwest Territories
• Nunavut
• World Health Organization
• Centers for Disease Control and Prevention
• European Centre for Disease Control and Prevention
1 This figure is based on cases for which a case report form was received by the Public Health
Agency of Canada from provincial or territorial partners.
2 The shaded area represents a period of accumulating data where it is expected that cases have
occurred but have not yet been reported nationally. The earliest of the following dates were used as
an estimate: Onset date, Specimen Collection Date, Laboratory Testing Date, Date Reported to
Province or Territory, or Date Reported to PHAC.
3 Exposure information may not be available for all cases. Some jurisdictions haven’t consistently
reported to PHAC how people were exposed throughout the pandemic. As a result, this may
underestimate the total number of cases by different exposures, especially among returning
travelers.
4 Where available, gender data was used; when gender data was unavailable, sex data was used.
Reliable data on gender diverse respondents are unavailable due to small counts.
Date modified:
2022-03-10
AR01822
~
This is Exhibit “O” to the Affidavit of Shaun Rickard sworn March 11, 2022
· ft?>
____________________________________
SAM A. PRESVELOS
AR01823
AR01824
AR01825
AR01826
This is Exhibit “P” to the Affidavit of Shaun Rickard sworn March 11, 2022
t
.
.
____________________________________
SAM A. PRESVELOS
"
AR01827
$ USA LIFE SITE SUBSCRIBE READ WATCH DONATE #
NEWS
Top Vancouver doc caught admitting vax

passports are merely ‘incentive’ program
It's all about higher vaccination rates and not limiting the spread of COVID, Dr. Patty Daly of
Vancouver Coastal Health divulged during a meeting.
_.........
...
ensemblenous
pouvonsSTOPPI
leVIHetleSI
VIH
Dr. Patty Daly is the chief medical officer for Vancouver Coastal Health. Twitter
Tue Oct 19, 2021 - 3:43 pm EDT

Kennedy
Hall
LifeSiteNews has produced an extensive COVID-19 vaccines resources page. View it here.
VANCOUVER, British Columbia (LifeSiteNews) – Dr. Patty Daly, chief medical officer
% of health for Vancouver Coastal Health, acknowledged in a recorded virtual meeting that
vaccine passports in her region are not about health but about creating an “incentive to get
& higher vaccinate rates.”
'
( MOST POPULAR
) Abp. Viganò: Globalists have fomented

1
* war in Ukraine to establish the tyranny of
the New World Order
+ 2 Babies could be killed 28 days after birth

under proposed Maryland law, attorney
0 A video posted by Action4Canada shows a recorded clip taken from a “Build Back Better and
,
9
warns
COVID-19” forum. The site page for the event was taken down after the public health
gaffe was released. Pope Francis abruptly removes faithful
3 bishop who opposed COVID vaccine
mandates
Technocrats behind the Great Reset are

4 pushing ahead with digital IDs
How much does the LGBT agenda have to

5 do with the conflict in Ukraine?
SUBSCRIBE TO DAILY HEADLINES »
ADV nsr rNr

In the meeting, Daly was asked by a participant: “We aren’t allowing unvaccinated people
into restaurants, but they are still allowed to visit patients in acute care (ICU, etc). Is this
true? If so, what are the risks?”
The Vancouver doctor responded by saying the point of vaccine passports was to incentivize
people to get vaccinated, not to stop the spread of COVID.
“Maybe I can answer this question briefly,” she said. “The vaccine passport requires people
be vaccinated to do certain discretionary activities such as go to restaurants, movies, gyms
not because these places are high risk. We’re not actually seeing COVID transmission in these
settings.”
After she acknowledged that the vaccine passport is required for settings where there is no
statistically relevant risk of transmitting the virus, she stated clearly that the system is all
about getting people to take the jab.
“It’s really to create incentive to improve our vaccine coverage,” she said. “The vaccine
passport is for non-essential opportunities and it is really to create incentive to get higher
vaccination rates.”
She then explained that those who visit loved ones in a hospital but are not vaccinated will be
screened and given a medical mask upon entry. She also said they are “not seeing” any
notable spreading of COVID by visitors who are unvaccinated in hospital settings but that
most cases come from health care workers, who by now are largely vaccinated. She said
visitors are “actually a lower risk than staff.”
Daly’s job description according to Vancouver Coastal Health is to “improve the health of the
population that Vancouver Coastal Health serves.” In the clip taken from the meeting, she did
not suggest that the health of Vancouverites would be improved by higher vaccination rates,
and made it clear that there was no reason to impose a vaccine segregation policy on citizens
other than to increase the jab rate.
ADVE""RTISE""MENT
She also did not mention growing evidence of the disastrous consequences from the mass-
vaccination program, especially as talk of kids getting jabbed with the experimental drugs
intensifies.
TOPICS
Freedom Politics - Canada
TAGGED AS
Action4Canada Covid-19 patty daly Vaccine Passports
vancouver coastal health
SHARE
% & ' ( ) * + , 9 Comments
Keep this news available to you and millions more

Your gift will spread truth, defeat lies, and save lives
$ 35.00 ! Donate Now
News Opinion Blogs Shows About

Subscribe
USA USA John-Henry Westen The John-Henry Westen Show
Advertise
Canada Canada Steve Jalsevac The Van Maren Show
Reprint Permissions
Catholic Catholic Doug Mainwaring Mother Miriam Live
Privacy
Abortion Today’s Opinion Jonathon Van Maren The Bishop Strickland Show
Legal
Faith Editorials Dorothy Cummings McLean LSNTV
Technical Support
Family Maike Hickson Ladies of LifeSite
Contact
Today’s News Peter Kwasniewski Faith & Reason
Donate
Last 10 Days Steven Mosher
Video © 1997-2022 LifeSiteNews.com.
Stephen Kokx
All Rights Reserved.
Video Home
Most Watched
Latest Videos
Shows
AR01828
This is Exhibit “Q” to the Affidavit of Shaun Rickard sworn March 11, 2022
____________________________________
SAM A. PRESVELOS
COVID-19 IN CANADA -~;.!t"t :1-
,..;.· . .., .J. ·•
AR01829
.. ~~ :~ ,. 0
C "t, •· • ::,
CANADA COVID-19 WEEKLY EPIDEMIOLOGY REPORT

20 FEBRUARY TO 26 FEBRUARY 2022 (WEEK 08)
Published: 04 March 2022

I • II • I
40 644 ( 12%) 459 ( 33%)
New cases reported in the last 7 daysa New deaths reported in the last 7 daysa
I • II • I
5 806 ( 12%) 66 ( 33%)
Average number of cases reported daily in the last 7 daysa Average number of deaths reported daily in the last 7 daysa
I • 11 • I
48 204 ( 5%) 11.0% ( 0.8)

Average number of tests performed daily in the last 7 daysb Average percentage of positive tests in the last 7 daysb
a
Source: Provincial and Territorial Ministry of Health (MOH) websites as of 26 February 2022
b
Source: National Microbiology Laboratory (NML) data for laboratory analyses as of 26 February 2022
Note: The percentages are calculated based on the difference in the total number of cases, deaths, or tests in the past 7 days compared to the prior
7 days, divided by the number of cases, deaths, or tests in the prior 7 days. The change in the percentage of positive tests is based on the difference
in percentage points compared to the previous week.
Note: Due to the rapid increase in cases starting December 2021, delays in data entry, and changes in COVID-19 testing policies in many
jurisdictions, case counts will under estimate the total burden of disease. Depending on the jurisdiction, positive rapid antigen test results may not be
captured in case reporting without access to confirmatory PCR testing. Data should be interpreted with caution as case counts are underreported.
KEY MESSAGES
• There was an average of 5 806 new cases reported daily during week 08, a decrease compared to the
previous week. Following a decrease since late-September 2021, the number of daily reported cases
have been increasing since early November 2021, with a rapid increase in cases in mid-December 2021,
aligning with an increase in Omicron cases in Canada. The number of new reported cases should be
interpreted with caution due to changes in testing policies across jurisdictions resulting in
underestimation beginning in mid January 2022.
• During week 08, 12 provinces and territories reported new cases. The weekly number of new cases
decreased for British Columbia, Alberta, Manitoba, Ontario, Quebec, Nova Scotia and Northwest
Territories compared to the previous week. The weekly number of new cases increased for Prince
Edward Island, Newfoundland and Labrador, and New Brunswick compared to the previous week. The
weekly number of new cases remained similar for Nunavut and Yukon compared to the previous week.
• Outbreaks have been a significant source of COVID-19 spread in Canada and point to vulnerabilities in
closed and crowded settings. Outbreaks in long-term care facilities, congregate living and acute care
follow a similar trend to case incidence over time. Beginning in early December 2021, the number of
outbreaks in these settings increased substantially. Since early January 2022, the number of outbreaks
has decreased following declines in case incidence.
• During week 08, an average of 48 204 tests were performed daily for COVID-19 across Canada. The
weekly percentage of tests positive was 11.0%, a decrease compared to the previous week.
• Variants of concern (VOCs) represent the majority of reported COVID-19 cases. Of the cases with a
genomic sequencing or screening result, Omicron accounts for 97% of all cases, Delta accounts for <1%
of all cases, and 2% of cases were of VOC undetermined lineage. Please note that these data now
include screening results with known lineage; therefore, more cases have been identified as “VOC
undetermined lineage”.
1|Page
Week 08 (20 February to 26 February 2022 Public Health Agency of Canada
COVID-19 IN CANADA
AR01830
• Beginning early-December 2021, incidence rates increased sharply among both unvaccinated
individuals and fully vaccinated individuals. As of early-January 2022, the incidence rate among fully
vaccinated individuals has decreased to a lower rate than that of unvaccinated individuals.
Hospitalization rates among unvaccinated individuals continue to be higher than those fully vaccinated.
The hospitalization rates among both unvaccinated and fully vaccinated cases increased between mid-
December 2021 and early-January 2022, and have declined since mid-January 2022.
• There were 459 deaths reported during week 08, representing a 33% decrease compared to the
previous week.
• During week 08, the number of hospitalizations and ICU admissions decreased compared to the
previous week. On 26 February 2022, 4 971 hospitalizations and 617 cases in ICU, representing a
15.3% decrease in the seven-day moving average of hospitalized cases, and a 16.7% decrease in ICU
admissions, compared to one week prior.
2|Page
COVID-19 IN CANADA
AR01831
NATIONAL DEMOGRAPHICS AND TRENDS
NATIONAL TRENDS IN CASES

• During week 08, a total of 40 644 cases of COVID-19 were reported in Canada, an average of 5 806
cases per day; a 12% decrease compared to week 07 (Figure 1).
• Following a decrease since late-September 2021, the number of daily reported cases increased in early-
November 2021, with a rapid increase in cases in mid-December 2021, aligning with an increase in
Omicron cases in Canada. Since mid January 2022, new reported cases has been declining. The
number of new cases should be interpreted with caution due to changes in testing policies across
jurisdictions.
Figure 1. Daily number of reported COVID-19 cases in Canada (and 7-day moving average), as of 26
February 2022 (n=3 282 427)
48000 Daily reported cases
- - - 7-day moving average
44000
40000
36000
f/)
a,
f/) 32000
"'0 28000
0
24000
]
E 20000
::,
z 16000
12000
8000
4000
0
08Mar 18Apr 29May 09Jul 19Aug 29Sep 09Nov 20Dec 30Jan 12Mar 22Apr 02Jun 13Jul 23Aug 03Oct 13Nov 24Dec 03Feb
Report Date
Source: Provincial and Territorial MOH websites, as of 26 February 2022. The graph includes data from twelve of Canada’s thirteen provinces and
territories that provide daily reporting from provincial and territorial websites
Note: The 7-day moving average is a trend indicator that captures the arithmetic mean of the daily reported cases over the previous seven days. The
moving average helps smooth out day-to-day variability in reporting, filtering out the “noise” of short-term fluctuations. Fluctuations can be attributed
to retrospective data, non-reporting on the weekends or provinces or territories reporting cases at a reduced frequency. Spikes in cases may be due
to regular reporting variations (e.g., lower reporting on weekends or holidays), or periodic reporting of previous cases by provinces and territories.
Due to the rapid increase in cases starting December 2021, delays in data entry, = and changes in COVID-19 testing policies in many jurisdictions,
case counts will under estimate the total burden of disease. Depending on the jurisdiction, positive rapid antigen test results may not be captured in
case reporting without access to confirmatory PCR testing. Data should be interpreted with caution as case counts are underreported.
Twelve provinces and territories reported new cases during week 08 (Table 1):
• The weekly number of new cases remained similar in Yukon and Nunavut compared to the previous
week.
• The weekly number of new cases increased for Prince Edward Island, Newfoundland and Labrador and
New Brunswick compared to the previous week.
• The weekly number of new cases decreased for British Columbia, Alberta, Manitoba, Ontario, Quebec,
Nova Scotia and Northwest Territories compared to the previous week.
• Cases decreased by 13% in Ontario, and by 26% in Québec compared to the previous week; these
provinces accounted for 56.5% of the cases reported during week 08.
3|Page
COVID-19 IN CANADA
AR01832
Table 1. Trends of new reported cases in Canada and by province or territory, during week 08 (20 February
to 26 February 2022)
Average Weekly number of cases

Weekly
number of reported a
Percent incidence rate
cases 13 February to 20 February to
Province/Territory change per 100,000
reported 19 February 26 February
(%)a population
daily 2022 2022
(Week 08)
(Week 08) (Week 07) (Week 08)
British Columbia 495 5 046 3 467 -31% 66.5
Alberta 598 5 805 4 188 -28% 94.3
Saskatchewan* N/A N/A N/A N/A N/A
Manitoba 257 2 642 1 800 -32% 130.1
Ontario 1 882 15 063 13 177 -13% 88.9
Québec 1 399 13 230 9 794 -26% 113.8
Newfoundland and Labrador 261 1 659 1 830 10% 351.5
New Brunswick 323 1 915 2 263 18% 286.7
Nova Scotia 172 1 612 1 204 -25% 122.9
Prince Edward Island 284 1 523 1 987 30% 1209.2
Yukon 10 67 67 0% 155.9
Northwest Territories 80 703 563 -20% 1237.3
Nunavut 43 282 304 8% 771.5
Canadab 5 806 46 219 40 644 -12% 106.3
Source: Provincial and Territorial MOH websites. Rates calculated using July 1, 2021, post-census population estimate.
Note: Recent case data corrections impacting cases that occurred prior to the last two weeks are excluded from weekly counts in this table. Due to
the rapid increase in cases starting December 2021, delays in data entry, and changes in COVID-19 testing policies in many jurisdictions, case
counts will under estimate the total burden of disease. Depending on the jurisdiction, positive rapid antigen test results may not be captured in case
reporting without access to confirmatory PCR testing. Data should be interpreted with caution as case counts are underreported. The number of new
reported cases for Canada includes twelve provinces and territories for which data was available.
* Data could not be calculated as data were not reported on the provincial or territorial MOH website prior to the analysis being completed.
a
The percentage is calculated based on the difference in the total number of cases in the past 7 days compared to the prior 7 days divided by the
number of cases in the prior 7 days. Note that for provinces/territories with low case counts, an increase or decrease of only a few cases leads to a
large percentage change. If the denominator is zero, the percent change cannot be calculated.
b
Includes 13 cases identified in repatriated travelers (Grand Princess Cruise ship travelers) who were under quarantine in Trenton in March 2020 .
Age-standardized rates take into account the differences in population size and age structure between
provinces and territories to allow for reliable comparisons of COVID-19 spread in Canada.
Table 2 presents the age-standardized incidences rate by province or territory for week 08 based on date
reported to PHAC.
• Prince Edward Island reported the highest age-standardized incidence rate (977.5 cases per 100 000
population).
• The second and third highest age-standardized incidence rates were reported by Nova Scotia (219.2
cases per 100 000 population) and Alberta (195.5 cases per 100 000 population).
4|Page
COVID-19 IN CANADA
AR01833
Table 2. Age-standardized incidence rates by province or territory for week 08 (20 February to 26 February
2022)
Age-standardized incidence rate per 100 000
Province/Territory
for week 08
British Columbia 70.9
Alberta 195.5
Saskatchewan 95.5
Manitoba 127.7
Ontario 89.5
Québec 143.3
Newfoundland and Labrador N/A*
New Brunswick N/A*
Nova Scotia 219.2
Prince Edward Island 977.5
Yukon 111.5
Northwest Territories N/A*
Nunavut N/A*
Canada 116.0**
Source: Detailed case information received by PHAC from provinces and territories, standardized to the July 1, 2021, post-census population
estimate.
Note: Data are analyzed based on date reported to PHAC. Note that there is a period of time (accumulating data period) where it is expected that
cases have occurred but have not yet been reported nationally. Therefore, COVID-19 cases reported to PHAC during Week 08 may include cases
that occurred (based on date of illness onset, or lab related dates) in previous weeks. Due to the rapid increase in cases starting December 2021,
delays in data entry, and changes in COVID-19 testing policies in many jurisdictions, case counts will under estimate the total burden of disease.
Depending on the jurisdiction, positive rapid antigen test results may not be captured in case reporting without access to confirmatory PCR testing.
Data should be interpreted with caution as case counts are underreported.
*Age-standardized incidence could not be calculated as data were either not reported to PHAC during Week 08 or were not included in the national
dataset prior to the analysis being completed.
**The age-standardized incidence rate for Canada only includes provinces and territories for which data was available for Week 08.
Table 3 outlines the total number of new reported cases, resolved cases, and deaths reported during week
08.
• Newfoundland and Labrador, New Brunswick, Prince Edward Island, and Yukon reported more new
cases than new resolved cases during week 08.
Table 3. Summary of new COVID-19 reported cases, resolved cases, and deaths reported in Canada, and
by province or territory, during Week 08 (20 February to 26 February 2022)
Province/Territory New cases New resolved cases New deaths

British Columbia 3 467 N/A 61
Alberta 4 188 9 615 62
Saskatchewan N/A N/A N/A
Manitoba 1 800 5 034 25
Ontario 13 177 16 467 169
Québec 9 794 16 204 128
Newfoundland and Labrador 1 830 1 503 3
New Brunswick 2 263 2 246 4
Nova Scotia 1 204 1 628 5
Prince Edward Island 1 987 1 283 0
Yukon 67 61 1
Northwest Territories 563 661 1
Nunavut 304 325 0
Canada 40 644 55 027 459
Source: Provincial and Territorial MOH websites
Note: Recent case data corrections impacting cases that occurred prior to the last two weeks are excluded from weekly counts in this table. Due to
the rapid increase in cases starting December 2021, delays in data entry, and changes in COVID-19 testing policies in many jurisdictions, case
counts will under estimate the total burden of disease. Depending on the jurisdiction, positive rapid antigen test results may not be captured in case
reporting without access to confirmatory PCR testing. Data should be interpreted with caution as case counts are underreported.
* New reported or resolved cases/deaths could not be calculated as data were not available prior to the analysis being completed.
** The number of resolved cases for Canada includes twelve provinces and territories for which data was available.
5|Page
COVID-19 IN CANADA
AR01834
DEMOGRAPHIC DISTRIBUTIONa
a
Detailed case information received by PHAC from provinces and territories
Note: Data are analyzed based on PHAC report date.
• Cases for which PHAC received detailed case-level information during week 08 (20 February to 26
February 2022) (n=44 412) ranged in age from less than one year to over 100 years of age. The median
age was 38 years, same as the median age of 38 for week 07.
• Table 4 presents a summary of the age and gender distribution of COVID-19 cases reported to PHAC
during week 08:
o Fifty-two (52%) of cases were under 40 years of age
o The highest proportions of cases by age group were observed among those aged 30-39 (19.9%),
followed by those 40-49 years (17.1%).
o The highest age-specific incidence rates were observed among those aged 80 years and older
(203.8 cases per 100 000 population).
Table 4. Age, gender distribution, and rate of COVID-19 cases reported to PHAC, during week 08 (20
February to 26 February 2022)
Age Female Male Totala
groups n % Rate n % Rate n % Rate
<5 834 3.2 93.9 949 5.3 101.5 1 783 4.0 97.8
5-11 1 141 4.3 84.0 1 206 6.8 84.8 2 347 5.3 84.4
12-19 1 915 7.3 122.2 1 649 9.3 101.2 3 564 8.1 111.5
20-29 4 171 15.9 176.0 2 247 12.7 87.6 6 418 14.6 130.1
30-39 5 775 22.0 224.7 2 981 16.8 113.4 8 756 19.9 168.4
40-49 4 725 18.0 198.6 2 798 15.8 119.6 7 523 17.1 159.4
50-59 2 882 11.0 116.4 2 143 12.1 87.6 5 025 11.4 102.1
60-69 1 697 6.5 71.6 1 438 8.1 63.5 3 135 7.1 67.7
70-79 994 3.8 63.1 1 103 6.2 77.8 2 097 4.8 70.0
80+ 2 127 8.1 217.1 1 235 7.0 184.3 3 362 7.6 203.8
Total 26 261 100.0 136.5 17 749 100.0 93.4 44 010 100.0 119.4
Source: Detailed case information received by PHAC from provinces and territories. Rates are presented per 100 000 individuals in the given age
group based on the 1 July 2021 post-census population estimate.
Note: This table includes data from the nine of Canada’s thirteen provinces and territories that reported case-level information to the Public Health
Agency of Canada (PHAC). Data are analyzed based on date reported to PHAC. Note that there is a period of time (accumulating data period) where
it is expected that cases have occurred but have not yet been reported nationally. Therefore, COVID-19 cases reported to PHAC during week 08 may
include cases that occurred (based on date of illness onset, or lab related dates) in previous weeks. Due to the rapid increase in cases starting
December 2021, delays in data entry, and changes in COVID-19 testing policies in many jurisdictions, case counts will under estimate the total
burden of disease. Depending on the jurisdiction, positive rapid antigen test results may not be captured in case reporting without access to
confirmatory PCR testing. Data should be interpreted with caution as case counts are underreported.
Note: Cases with missing gender or age were excluded. Where available, gender data was used; when gender data was unavailable, sex data was
used. Reliable data on gender diverse respondents are unavailable due to small counts.
a
Cases not identified as male, or female were removed from the total due to small numbers.
6|Page
COVID-19 IN CANADA
AR01835
Figure 2 presents cases by date of illness onset, stratified by gender, and adjusted for population at the
national level. The figure illustrates the following trends for data up to 26 February 2022. Preliminary data
(shaded area) suggests:
• Daily rates of cases per 100 000 population are decreasing in all age groups since an increase in
early November 2021.
• Daily rates of cases are highest among the 20-39 and 80 plus age groups for females, surpassing the
rates among the 5-11 year age group in mid-December 2021, while the 80 plus group has surpassed
this age group in males.
• Daily rates of cases remain the lowest among individuals aged 60 years or older for both males and
females.
Figure 2. Daily rate of reported cases per 100 000 population, by age and gender, from 1 June 2020 to 26
February 2022
Male
m~ moo m~ m~ m~ m~ 01Aug 01Oct 01Dec 01Feb

Date•
- <5 - 12 to 19 - 40 to 59 - 80 plus
- 5101 1 20to39 - 60to79
Female
200
0
0
o ~
0 Q)
~ ~ 150
~ Q)
Q) >
C.. Ol
en Cl
Q) C
gi ·;; 100
'-' 0
-0 E
>,
~~
Et::.. 50
::,
z
O~Jun 01Aug 010ct 01Dec 01Feb 01Apr 01Jun 01Aug 010ct 01Dec 01Feb
Date*
- <5 - 12 to 19 - 40 to 59 - 80 plus
- 5 to 11 20 to 39 - 60 to 79
Source: Detailed case information received by PHAC from provinces and territories. Rates are calculated based on the 1 July 2021 post-census
population estimate.
Note: The shaded area represents a period of time (accumulating data period) where it is expected that cases have occurred but have not yet been
reported nationally. Where available, gender data was used; when gender data was unavailable, sex data was used. Reliable data on gender diverse
respondents are unavailable due to small counts. This graph includes data from the nine of Canada's thirteen provinces and territories that reported
case-level information to the Public Health Agency of Canada (PHAC).
* The earliest of the following dates were used as an estimate: Symptom onset date, Laboratory specimen collection date, Laboratory testing date,
Date reported to province or territory, or Date reported to PHAC.
7|Page
COVID-19 IN CANADA
AR01836
TRANSMISSION
TEMPORAL DISTRIBUTION BY EXPOSURE CATEGORYa
a
Detailed case information received by PHAC from provinces and territories
During week 08 (20 February to 26 February 2022), exposure and date of illness onset information was
available for 15 807 cases. Of these:
• 5 757 cases (36%) reported exposure in Canada to a known COVID-19 case;
• 9 946 cases (63%) reported exposure in Canada to an unknown source;
• 90 cases (<1%) reported having travelled outside of Canada during the exposure period; and
• 14 cases (<1%) reported exposure to a traveller.
Jurisdictions update exposure status on an ongoing basis as case investigations are completed and may
result in changes to the percent distributions by exposure type for previous weeks (Figure 3).
Of the 1 594 566 cases submitted as of 26 February 2022 with information on the source of exposure and
date of illness onset provided to date:
• 833 573 cases (52%) reported exposure in Canada to a known COVID-19 case;
• 734 048 cases (46%) reported exposure in Canada to an unknown source;
• 16 967 cases (1%) reported having travelled outside of Canada during the exposure period; and
• 9 978 cases (<1%) reported exposure to someone who had travelled.
Figure 3. Number of reported COVID-19 cases in Canada, by date of illness onset* and exposure category
as of 26 February 2022 (n=1 594 566)
35000
Pending or missing data

30000
International travel
Domestic acquisition - Contact with traveler

25000
Domestic acquisition - Contact of COVID

Number of Cases
case
20000
Domestic acquisition - Unknown source
15000
10000
5000
0
08-May
18-May
28-May
03-May
13-May
23-May
09-Mar
19-Mar
29-Mar
04-Mar
14-Mar
24-Mar
08-Feb
18-Feb
28-Feb
06-Aug
16-Aug
26-Aug
04-Nov
14-Nov
24-Nov
02-Feb
12-Feb
22-Feb
01-Aug
11-Aug
21-Aug
31-Aug
29-Nov
08-Apr
18-Apr
28-Apr
07-Jun
17-Jun
27-Jun
05-Sep
15-Sep
25-Sep
03-Apr
13-Apr
23-Apr
02-Jun
12-Jun
22-Jun
10-Sep
20-Sep
30-Sep
09-Nov
19-Nov
07-Feb
17-Feb
15-Jan
27-Jan
07-Jul
17-Jul
27-Jul
03-Jan
13-Jan
23-Jan
05-Oct
15-Oct
25-Oct
02-Jul
12-Jul
22-Jul
08-Jan
18-Jan
28-Jan
10-Oct
20-Oct
30-Oct
04-Dec
14-Dec
24-Dec
09-Dec
19-Dec
29-Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb
2020 2021 2022
Date of Illness Onset*
Note: Data from the nine of Canada’s thirteen provinces and territories were available for week 08. The shaded area represents a period of time
(accumulating data period) where it is expected that cases have occurred but have not yet been reported nationally. There is missing information for
exposure variables from several provinces and territories. Due to the rapid increase in cases starting December 2021, delays in data entry, and
changes in COVID-19 testing policies in many jurisdictions, case counts will under estimate the total burden of disease. Depending on the jurisdiction,
positive rapid antigen test results may not be captured in case reporting without access to confirmatory PCR testing. Data should be interpreted with
caution as case counts are underreported.
* The earliest of the following dates were used as an estimate: Symptom onset date, Laboratory specimen collection date, Laboratory testing date,
Date reported to province or territory, or Date reported to PHAC.
8|Page
COVID-19 IN CANADA
AR01837
OUTBREAKS
• During the Omicron surge, many jurisdictions reached public health diagnostic and response capacity.
The total number of cases reported to PHAC is underestimated, as is the number of outbreaks.
Decreased laboratory capacity and the increased transmissibility with the Omicron variant provide
rationale for more targeted testing approaches (i.e. priority populations) and reduced contact tracing.
These changes effectively decrease the ability of jurisdictions to detect and report outbreaks in most
settings. As such, we expect outbreak numbers reported from settings not prioritized for PCR testing to
be under-ascertained.
• Settings with vulnerable and high-risk populations (e.g., long-term care facilities, congregate living,
acute care) continue to be prioritized for PCR testing, resulting in consistent reporting of outbreaks from
these settings during the Omicron surge.
• Outbreaks in LTCF, congregate living and acute care follow a similar trend to case incidence over time
(Figure 4).
• Beginning in early December 2021, the number of outbreaks in these settings increased substantially.
Since early January 2022, the number of outbreaks has decreased following declines in case incidence
(Figure 4).
Figure 4. Number of reported outbreaks in long-term care facilities, congregate living settings and acute care
settings as of 26 February 2022
Number of outbreaks in long-term care facilities

800
600
400
20
: ~ -·-· -- -- -- -_-
Jan 03 Feb 07
_ -_-_-~--- _- _- _
Mar 14
- -_-
Apr 18
_ -_ -_ -_-_-_- _
May 23
~
Jun 27
_ -_ -_-_-_- _- _- _- _- -
Aug 01 Sep 05
_ -
_ -_ -~-
Oct 10
- - _- _- _-_- _- _
Nov 14
___
Dec 19
.~l_l_1_1_1_■_-___
Jan 23
Number of outbreaks in congregate living setting
800
::: ~-·-·-·-·---·-----------•-•_■_■_•_■_•_-_____________ __-_-_-_-_-______________________________._I_____

o
1111I_I_■_-__
Jan 03 Feb 07 Mar 14 Apr 18 May 23 Jun 27 Aug 01 Sep 05 Oct 10 Nov 14 Dec 19 Jan 23
Number of outbreaks in acute care
800
600
400
20: ~ -· -· -· -- -- -- -_ -_-_- ~- -- _- __ __ _ ~
_ _ __ __ _________ __ __
__ ~---_-_-_-_--_-_-~---_-_-_-_-_-_--_■~·-'-'-I_I_■_•__
Jan 03 Feb 07 Mar 14 Apr 18 May 23 Jun 27 Aug 01 Sep 05 Oct 10 Nov 14 Dec 19 Jan 23
Source: Provinces and Territories submitted outbreak data
Note: See Technical Notes for more information on interpretation and data limitations. The shaded area represents a period of time (accumulating
data period) of two weeks where it is expected that outbreaks have occurred but have not yet been reported nationally.
9|Page
COVID-19 IN CANADA
AR01838
LABORATORY-CONFIRMED COVID-19 DETECTION
LABORATORY TESTS AND PERCENT POSITIVITY

During week 08 (20 February to 26 February 2022), an average of 48 204 tests were performed daily,
reflecting a rate of 126.0 tests performed daily per 100 000 population across Canada. The weekly
percentage of tests positive was 11.0% during week 08, a decrease compared to the previous week (Table
5).
Table 5. Summary of COVID-19 tests performed in Canada, by province or territory, for week 08 (20
February to 26 February 2022)
Week 08
Cumulative (20 February to 26 February 2022)
number of tests
Number of tests Number of tests Percentage of
performed
Province/Territory performed daily performed daily per tests positive
as of 26
(7-day moving 100 000 population (7-day moving
February 2022
average1) (7-day moving average1) average1)
British Columbia 5 656 911 7 239.0 138.8 7.8%
Alberta 6 836 545 2 701.9 60.8 22.1%
Saskatchewan 1 481 412 1 119.0 94.8 18.0%
Manitoba 1 458 738 989.6 71.5 18.0%
Ontario 22 958 517 16 352.3 110.3 9.7%
Québec 16 425 387 15 380.9 178.8 8.3%
Newfoundland and Labrador 578 233 1 393.4 267.7 20.3%
New Brunswick 732 209 1 246.9 158.0 26.5%
Nova Scotia 1 769 098 1 602.3 161.5 13.3%
Prince Edward Island 256 482 37.7 23.0 6.4%
Yukon2 9 129 NA NA NA
Northwest Territories 40 185 12.7 27.9 20.2%
Nunavut 35 659 128.9 327.0 31.7%
Canada 3 58 238 505 48 204.4 126.0 11.0%
Source: National Microbiology Laboratory (NML) Data for laboratory analyses, standardized to the July 1, 2021, post-census population estimate.
Note: Laboratory testing numbers may be an underestimate due to reporting delays, changes in testing practises, and may not include additional
sentinel surveillance or other testing conducted in the province or territory.
1
The 7-day moving average is the total of the daily numbers for the previous 7 days (up to and including the day of the last update), divided by the
number of days for which data is available.
2
Laboratory data for this territory has been unavailable since week 18 (2021).
3
The number of tests performed and the weekly percentage of tests positive for Canada only include provinces and territories for which data was
available for Week 08. The national 7-day moving average number of tests performed is calculated by summing the 7-day moving average from the
provinces and territories.
10 | P a g e
COVID-19 IN CANADA
AR01839
The mean time from symptom onset to lab specimen collection is 1.84 days for early February 2022, a
decrease compared to the mean of 2.24 days in January 2022 (Figure 5).
Figure 5. Onset date to laboratory collection date for cases reported to PHAC as of 26 February 2022
Aug 1 to 31; Sept 1 to 30; Oct 1 to 31; Nov 1 to 30; Dec 1 to 31; Jan 1 to 31; Feb 1 to 13;
Mean=3.09 Mean=2.96 Mean=2.81 Mean=2.85 Mean=2.79 Mean=2.24 Mean=1.84
12 days days
20 000
days days days days days
19 000
U) 11 18 000
~ 10 17 000
(J)
e, 16 000 I-
0::
z 9 15 000
14 000 0
0 Cl.
~
8 13 000 UJ
u 12 000
0::
UJ 7 UJ
...J 11 000 Cf)
...J <{
0 6 10 000
u
u 9 000 u..
II) 5 8 000 0
<{
...J
4 7 000 0::
0 6 000 UJ
II)
I-
I-
3 5 000 ~
UJ 4 000 ::>
(J) 2 3 000
z
z
0 2 000
1 000
0 0
01Mar 03May 05Jul 06Sep 08Nov 10Jan 14Mar 16May 18Jul 19Sep 21Nov 23Jan
ONSET DATE
- - Days (left axis) Number of case reports (right axis)
Note: This graph includes data from nine of Canada's thirteen provinces and territories that reported case-level information to the Public Health
Agency of Canada (PHAC). Date of symptom onset to date of specimen collection intervals of >15 days are deemed outliers, and not included in this
figure
VARIANTS OF CONCERN
All viruses, including COVID-19, change, or mutate, over time. Not all mutations are of concern. However,
some changes result in variants of concern (VOC). A VOC has changes that are significant to public health.
For example, they might:
• spread more easily
• cause more severe illness
• require different treatments, or
• not respond the same to current vaccines
VOCs represent the majority of reported COVID-19 cases.

• The proportion of cases with genomic sequencing data classified as a VOC has remained near 100%
since early June 2021.
o Of the cases with a genomic sequencing or screening result, Omicron accounts for 97% of all
cases, Delta accounts for <1% of all cases, and 2% of cases were of undetermined lineage.
Source: Detailed case information received by PHAC from provinces and territories, the national genomic sequencing database, and the border
genomic surveillance system.
Note: Data are analyzed based on specimen collection date. Variant identification requires additional laboratory testing which results in an expected
delay between case reporting and updates on variant status. Differences in jurisdictional strategies for variant identification and reporting affect the
interpretation of national trends and may limit the comparability between jurisdictions and over time. Not all variants can be detected through
screening or sequencing in each jurisdiction.
Data as of 28 February 2022, using data up until 5 February, 2022.
11 | P a g e
COVID-19 IN CANADA
AR01840
CASES FOLLOWING VACCINATION

Data extracted on 25 February 2022 for cases from 19 December 2020 up until 13 February 2022.
While the COVID-19 vaccines are highly effective at preventing severe outcomes, a percentage of the
population who are vaccinated may become infected with COVID-19 if they are exposed to the virus that
causes it. This means that even with high vaccine effectiveness, a percentage of the population who are
vaccinated against COVID-19 will still get sick and some may be hospitalized or even die as a result of their
illness. It is also possible that a person could be infected just before or just after vaccination and still get sick.
It typically takes about two weeks for the body to build protection after vaccination, so a person could get
sick if the vaccine has not had enough time to provide protection.
As the majority of Canadians are now vaccinated, counts of COVID-19 outcomes will inherently be higher
within this population, compared to the unvaccinated population. However, risk among this population may
be lower, despite higher case counts. The rate of fully vaccinated cases may also increase because
individual protection from the vaccine may decrease over time and emergence of new variants may
decrease vaccine effectiveness. Due to the rapid increase in cases starting December 2021, delays in data
entry, and changes in COVID-19 testing policies in many jurisdictions, case counts will under estimate the
total burden of disease, and may over-represent people at risk of severe disease. Data should be interpreted
with caution.
Incidence and Hospitalization Rates by Vaccination Status

Based on data from 12 provinces and territories for the eligible population 5 years or older, incidence and
hospitalization rates have varied by vaccine status in recent weeks (Figure 6). In early-December 2021,
incidence rates increased sharply among both unvaccinated individuals and fully vaccinated individuals, and
incidence rates were highest among fully vaccinated individuals between mid-December 2021 and the
beginning of January 2022. However, since early-January 2022, incidence rates in all vaccine status groups
have decreased, whereby the incidence rates are highest among unvaccinated individuals. In the most
recent report week ending February 13, 2022, the incidence rate among those fully vaccinated and those
fully vaccinated with an additional dose have converged. Hospitalization rates among both unvaccinated and
fully vaccinated cases increased between mid-December 2021 and early-January 2022, and have declined
since mid-January 2022. Though declining, hospitalization rates continue to be highest among unvaccinated
individuals, and are lowest among individuals fully vaccinated with an additional dose. Since early-January
2022, hospitalization rates among individuals fully vaccinated with an additional dose has been low and
stable.
12 | P a g e
COVID-19 IN CANADA
AR01841
Figure 6. National weekly COVID-19 age-standardized incidence and hospitalization rate by vaccination
status, data as of 13 February 2022
National weekly COVID-19 age-standardized incidence rate in Canada by vaccination status
(age 5+)
700
600
Incidence per 100,000
500
400
300
200
100
Week
Unvaccinated Fully Vaccinated Fully vaccinated with an additional dose
National weekly COVID-19 age-standardized hospitalization rate in Canada by vaccination

status (age 5+)
80
70
Hospitalizations per 100,000
60
50
40
30
20
10
Week
Unvaccinated Fully vaccinated Fully vaccinated with an additional dose
Source: Detailed case information received by PHAC from provinces and territories as of 25 February 2022 using data up to 13 February 2022.
Vaccination coverage data were collected from the Canadian COVID-19 Vaccination Coverage Surveillance System on 20 February 2022, using data
up to 13 February 2022. Denominator data were provided by Statistics Canada and include population size estimates by age, sex, and province or
territory as of 1 July 2021.
Note: Twelve of thirteen provinces and territories have reported case-level vaccine history data to PHAC as part of the national COVID-19 dataset.
Nine provinces and territories have reported complete case-level vaccine history data to PHAC in the four most recent report weeks. Seven of these
provinces and territories have reported data on cases fully vaccinated with an additional dose. In provinces and territories that have not yet reported
additional dose data, cases are classified as fully vaccinated if they are fully vaccinated or fully vaccinated with an additional dose. Data on cases fully
vaccinated with an additional dose are limited to the eligible population aged 12 years or older. Beginning February 6, 2022, cases following
vaccination analyses are updated with data up to and including the previous Sunday to align with changes in vaccination coverage reporting. To
account for this change in reporting, data for the week ending January 30, 2022 contains an extra day of case-level vaccine history data for most
provinces and territories. This change will not be implemented retroactively. A data cut-off of 13 February, 2022 was used to account for routine
reporting delays associated with vaccine history information. Cases with missing vaccination information are excluded from analysis. When symptom
onset date is unavailable or the case is asymptomatic, episode date uses the following dates as a proxy for classification: laboratory specimen
collection date, or laboratory testing date.
13 | P a g e
COVID-19 IN CANADA
AR01842
Based on data from nine provinces and territories for the eligible population 5 years or older, for the period of
16 January to 13 February 2022, adjusting for age, the rate of new COVID-19 cases among fully vaccinated
and unvaccinated individuals was similar. The incidence rate was 2 times higher among unvaccinated
individuals than those fully vaccinated with an additional dose. The rate of COVID-19 hospitalized cases
among unvaccinated individuals was 4 times higher than in fully vaccinated individuals, and 12 times higher
than those fully vaccinated with an additional dose. However, there are differences observed between age
groups. From 16 January to 13 February 2022, adjusting for age, comparisons of hospitalization rates
indicate that:
• Among youth and adults aged 12 to 59 years, unvaccinated people were 3 times more likely to
be hospitalized with COVID-19 than fully vaccinated people, and 6 times more likely to be
hospitalized than people fully vaccinated with an additional dose.
• Among older adults aged 60 years or older, unvaccinated people were 4 times more likely to be
hospitalized with COVID-19 than fully vaccinated people, and 14 times more likely to be
hospitalized than people fully vaccinated with an additional dose.
For more information on cases following vaccination with cumulative data, please see the Daily
Epidemiology Report available on the Government of Canada’s COVID-19 data trends page.
14 | P a g e
COVID-19 IN CANADA
AR01843
SEVERITY INDICATORS
HOSPITALIZATIONS, INTENSIVE CARE, AND DEATHS
Following a sharp increase starting late-December 2021, the number of COVID-19 cases in hospital and
ICU, are now decreasing. During week 08, the number of hospitalizations and ICU admissions decreased
compared to the previous week. On 26 February 2022, there were 4 971 hospitalizations and 617 cases in
ICU, representing a 15.3% decrease in the seven-day moving average of hospitalized cases, and a 16.7%
decrease in ICU admissions, compared to one week prior. The average number of hospitalizations and ICU
admissions have decreased to 5 806 and 696 cases, respectively.
Figure 7. Number of COVID-19 cases in hospital and ICU daily in Canada, as of 26 February 2022
Canada
10,000
8,000
rn
Q)
rn
6,000
rn
u
4,000
2,000
0
01Apr 20May 08Jul 26Aug 14Oct 02Dec 20Jan 10Mar 28Apr 16Jun 04Aug 22Sep 10Nov 29Dec 16Feb
Date
- - Total hospitalizations - - Total ICU
Source: Provincial and Territorial MOH websites. Hospitalization and ICU data for each province or territory are based on the date of last report.
Note: The data included in this figure represents the number of cases currently hospitalized and/or in ICU on a given reporting date and does not
represent the number of new hospitalizations or ICU admission over time. Cases admitted to the ICU are included in the hospitalization counts; these
categories are not mutually exclusive. The numbers of cases in hospital and ICU are not available for the Northwest Territories. As a result, the
Northwest Territories are not included in analyses of daily cases in hospital or ICU.
During week 08 (20 February to 26 February 2022), detailed case information on hospitalization status was
available for 44 412 cases. Among these cases:
• 2 044 (5%) were hospitalized (including ICU admission), of whom:
o 217 (11%) were admitted to ICU.
Among the total number of hospitalizations reported during week 08 for which age information was available,
15% (n=301/2 044) were 40 to 59 years of age, 35% (n=723/2 044) were 60 to 79 years of age, and 28%
(n=580/2 044) were 80 years and older (Table 6).
As of 26 February 2022, case information on hospitalization status was available for 3 192 369 cases,
where:
• 132 909 (4%) were hospitalized (including ICU admission), of whom:
o 22 865 (17%) were admitted to ICU.
In the most recent week, the majority of cases were among those ages 30-39 years, followed by those ages
40-49 years (Table 4), however, hospitalization counts were highest in those ages 60-79 years, followed by
those aged 80 years and older and ICU admissions were highest in those ages 60-79, followed by those 40-
59 years.
15 | P a g e
COVID-19 IN CANADA
AR01844
Table 6. Number of COVID-19 cases hospitalized, and admitted to ICU, overall and by gender and age
group, and proportion of total cases hospitalized reported to PHAC during Week 08a (20 February to 26
February 2022)
I Age groups I Hospitalized – non-ICU Hospitalized - ICU i
' Female J Male J Total Female J Male I Total
' <5 41 54 95 3 7 10
' 5-11 12 9 21 3 0 3
12-19 28 16 44 2 4 6
I
' 20-39 184 63 247 9 5 14

' 40-59 125 123 248 17 36 53
' 60-79 251 372 623 40 60 100
80+ 292 257 549 9 22 31
I
Total 933 894 1 827 83 134 217

I
L J l l J J J J
Note: Non-ICU hospitalizations and ICU counts are mutually exclusive. Cases with missing gender, sex or age were excluded. Where available,
gender data were used; when gender data were unavailable, sex data were used. Reliable data on gender diverse respondents are unavailable due
to small counts.
a
Data are analyzed based on date reported to PHAC. Note that there is a period of time (accumulating data period) where it is expected that cases
have occurred but have not yet been reported nationally. Therefore, COVID-19 cases reported to PHAC during week 08 may include cases that
occurred (based on date of illness onset, or lab related dates) in previous weeks.
Based on detailed case information provided to PHAC, the overall cumulative hospitalization rate (including
ICU admissions) is 350 cases per 100 000 population, with the highest rates observed in those 80 years of
age and older (2 014 cases per 100 000 population). For week 08, the highest rates were observed in those
80 years of age and older (35 cases per 100 000 population), with hospitalization rates decreasing with
younger age groups.
16 | P a g e
COVID-19 IN CANADA
AR01845
Figure 8. Number of COVID-19 hospitalizations per 100 000 population, by age, from 1 June 2020 to 26
February 2022
OqJun 01Aug 010ct 01Dec 01 Feb 01Apr 01Jun 01Aug 010ct 01Dec 01 Feb O 31Jan 07Feb 14Feb 21Feb
Date* Date*
<5 12 to 19 40 to 59 - 80 plus
5 to 11 20 to 39 60 to 79
Source: Detailed case information received by PHAC from provinces and territories. Rates are calculated based on the 1 July 2021 post-census
population estimate.
Note: The shaded area represents a period of time (accumulating data period) where it is expected that cases have occurred but have not yet been
reported nationally. This graph includes data from the nine of Canada’s thirteen provinces and territories that provide detailed age information to
PHAC. *The earliest of the following dates were used as an estimate: Symptom onset date, Laboratory specimen collection date, Laboratory testing
date, Date reported to province or territory, or Date reported to PHAC.
During week 08, there were 459 COVID-19 related deaths were reported in Canada.
• This represents a 14% decrease compared to the previous week.
• This amounts to an average of 66 deaths reported per day, compared to 76 deaths per day reported in
the previous week.
Of the deaths reported from week 08, jurisdictions submitted individual-level information to PHAC for 101
deaths, of which 36 (36%) were ages 60-79 and 52 (51%) were aged 80 and older. To date, deaths are the
highest in those 80 years of age and older (Table A4 in the annex, cumulative counts).
Figure 9. Daily number of COVID-19 related deaths reported in Canada (and 7-day moving average), as of
26 February 2022 (N=36 500)
300 - - - Daily reported deaths
- - - 7-day moving average
250
(/)
.c 200
'"
Q)
i::,
'o 150
~
E
::,
z 100
50
0
08Mar 17Apr 27May 06Jul 15Aug 24Sep 03Nov 13Dec 22Jan 03Mar 12Apr 22May 01Jul 10Aug 19Sep 29Oct 08Dec 17Jan 26Feb
Report Date
Source: Provincial and Territorial MOH websites. This graph includes data from twelve of Canada’s thirteen provinces and territories that provide daily
reporting from provincial and territorial websites.
Note: The 7-day moving average is a trend indicator that captures the arithmetic mean of the daily reported deaths over the previous seven days.
The moving average helps smooth out day-to-day variability in reporting, filtering out the “noise” of short-term fluctuations. Fluctuations can be
attributed to retrospective data or provinces or territories reporting cases at a reduced frequency.
17 | P a g e
COVID-19 IN CANADA
AR01846
MODELLING
Estimates of transmission rates in Canada: Effective reproductive rate (Rt)
Rt is the time variable reproduction rate, representing the average number of newly infected people for each
infected person. If Rt is less than 1 at a particular time (t), than the average number of people infected by
one infected person is less than one, so the epidemic is being brought under control. If Rt is greater than 1,
the average number of people infected by one infected person is greater than one, and the epidemic is
growing. A value of Rt above 1 indicates that there is active community transmission, meaning that the
disease will continue to spread in the population. The higher the Rt value, the faster the disease is
spreading, which leads to an increase in the incidence of new cases.
However, there are some limitations to consider. As the epidemic continues, the Rt may not capture the
current state of the epidemic with low case burden and the value must be interpreted based on the current
landscape. The Rt can easily fluctuate when case numbers are low. It is also an average Rt for a population
and does not point to local outbreaks driving case counts. Since the method used to calculate Rt is highly
sensitive to the reported number of new cases, community outbreaks within specific provinces and territories
will cause the estimated Rt value in that respective region to be higher, which may not always accurately
depict overall transmission in the province or territory as a whole.
Figure 10 shows the Rt over time.

• In 2020, the reproductive rate was hovering under 1 in May and early June, followed by fluctuations
in July. In early August, the Rt increased until the end of September when it decreased to just above
1. Between October 2020 and January 2021, the Rt fluctuated just above 1 with a slight increase in
early November and early January.
• Starting in mid-January 2021, the Rt decreased to below 1, indicating that the epidemic was reducing
nationally. From February to mid-April 2021, the Rt gradually increased, surpassing 1 in mid-March
2021. From May to June 2021 the national Rt decreased, and then started increasing in July. Since
mid-August 2021, the national Rt had a decreasing trend, decreasing below 1 in late-September
2021. Since early December 2021, the Rt has been above 1 associated with Omicron transmission
however, the recent decline in Rt in late December 2021 early January 2022 may be in part due to
changes in testing practices; Rt value of 0.79 as of 19 February 2022.
Figure 10. Reproductive rate in Canada based on date of case report
Canada Rt = 0. 79 (0. 73 ; 0.86)
Source: Calculated from detailed case information received by PHAC from provinces and territories
Note: Fluctuations are attributed to provincial and territorial reporting delays and non-reporting on the weekends
18 | P a g e
COVID-19 IN CANADA
AR01847
TECHNICAL NOTES
The data in the report are based on information from various sources described below. The information
presented for case-based analyses, trend analyses and laboratory analyses are available as of 19 February
2022 at 4 p.m. EDT.
DATA SOURCES AND DATA CAVEATS
Epidemiological data received by PHAC

Some of the epidemiological data for this report are based on detailed case information on the total
confirmed and probable cases received by PHAC from provinces/territories (P/Ts). This information is
housed in the PHAC COVID-19 database. Case counts and level of detail in case information submitted to
PHAC varies by P/T due to:
• Possible reporting delay between time of case notification to the P/T public health authority and when
detailed information is sent/received by PHAC.
• Preliminary data may be limited, and data are not complete for all variables.
• Data on cases are updated on an ongoing basis. The current report reflects data most recently
received by PHAC and are subject to change.
• Variation in approaches to testing and testing criteria over time within and between P/Ts.
• Variants of concern (VOC) identification requires additional laboratory testing which results in an
expected delay between case reporting and updates on VOC status. PHAC’s national case
definitions, classifications and public health actions for VOCs can be found here:
https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-
professionals/testing-diagnosing-case-reporting/sars-cov-2-variants-national-definitions-
classifications-public-health-actions.html f11
• The accumulating data period from illness onset to PHAC report date is approximately two weeks
and data within this period is subject to change.
• Case attribution of COVID-19 infection to a province or territory is determined by the individual's
place of residence and captured as reported by provincial and territorial health partners.
Note: Missing data for hospitalizations, ICU admissions, and deceased were not included in calculations.
Unless calculations were broken down by age and gender, cases with missing values for age and gender
were included. P/Ts may define gender differently and some may be referring to biological sex. Case
severity is likely underestimated due to underreporting of related variables, as well as events that may have
occurred after the completion of public health reporting, and therefore is not captured in the case report
forms. Transmission data should be interpreted with caution as information on exposure are missing from
several provinces and territories.
Provincial and territorial case counts

P/T information on case counts, resolved cases, and deaths associated with COVID-19 are collected from
publicly available P/T websites, generally from the P/T ministry of health. Case definitions may vary by P/T.
• National COVID-19 case definitions are provided by PHAC for the purpose of standardized case
classification and reporting. PHAC’s national case definitions can be found here:
https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-
professionals/national-case-definition.html
• Only cases and deaths meeting P/T’s definition for case classification are reported. For details on
case definitions, please consult each P/T ministry of health website.
19 | P a g e
COVID-19 IN CANADA
AR01848
• Case attribution of COVID-19 infection to a province or territory is determined by the individual's

place of residence and captured as reported by provincial and territorial health partners.
• The number of cases or deaths reported during previous weeks may differ slightly from those
reported on provincial and territorial websites as these websites may update historic case and death
counts as new information becomes available.
• For the most up to date information, please refer to the provincial and territorial MOH websites.
• As of February 7, 2022, Saskatchewan is reporting COVID-19 epidemiological information weekly on
recent 5-11 days are not available for Saskatchewan. Indicators for the last 7 days are presented as
“not available” or “N/A”. Cumulative case and death indicators reflect Saskatchewan data from the
most recent Weekly COVID-19 Situation Report.
Laboratory information
Data on the number of tests conducted in each P/T are received from the National Microbiology Laboratory
(NML).
• Laboratory testing numbers may be an underestimate due to reporting delays and may not include
additional sentinel surveillance or other testing performed. They are subject to changes as updates are
received.
Cases following vaccination

Twelve of thirteen provinces and territories have reported case-level vaccine history data to PHAC as part of
the national COVID-19 dataset. Nine provinces and territories have reported case-level vaccine history data
to PHAC in the four most recent report weeks. Seven of these provinces and territories have reported data
on cases fully vaccinated with an additional dose. In provinces and territories that have not yet reported
additional dose data, cases are classified as fully vaccinated if they are fully vaccinated or fully vaccinated
with an additional dose. Data on cases fully vaccinated with an additional dose are limited to the eligible
population aged 12 years or older. A data cut-off of 13 February 2022 was used to account for routine
reporting delays associated with vaccine history information.
Beginning February 6, 2022, cases following vaccination analyses are updated with data up to and including
the previous Sunday to align with changes in vaccination coverage reporting. To account for this change in
reporting, data for the week ending January 30, 2022 contains an extra day of case-level vaccine history
data for most provinces and territories. This change will not be implemented retroactively.
Vaccination coverage data were collected from the Canadian COVID-19 Vaccination Coverage Surveillance
System on 20 February 2022, using data up to 13 February 2022. Denominator data were provided by
Statistics Canada and include population size estimates by age, sex, and province or territory as of 1 July
2021. Estimates were derived from 2016 Census of Population counts adjusted for Census net
undercoverage and growth. Note that starting the week of 10 to 15 October, 2021 the national analysis of
cases following vaccination is based on updated population estimates from July 1, 2021 (formerly: July 1,
2020). The 2021 population denominators were retrospectively applied to all data in Figure 7. The number of
people unvaccinated is obtained by subtracting the population estimate and the number of people who have
received at least one dose of a COVID-19. However, the 2021 population size estimates by age, sex, and
province and territory, for the provinces and Nunavut, were provided by Stats Can and are derived from the
2016 Census of population counts. As a result, in certain age groups and provinces and territories, the
number of people vaccinated is higher the denominator. In that case, we put the number and proportion of
people unvaccinated as “0” (instead of the negative value). PHAC monitors cases following vaccination using
the following categories:
20 | P a g e
COVID-19 IN CANADA
AR01849
• Unvaccinated cases include those who were unvaccinated at the time of their episode date.
• Cases not yet protected from vaccination include those whose episode date occurred less than 14
days after their first dose of the vaccine.
• Partially vaccinated cases include those whose episode date occurred 14 days or more after their
first vaccine dose or less than 14 days after their second dose of the vaccine.
• Fully vaccinated cases include those whose episode date occurred 14 days or more after receipt of
a second dose in a two-dose series or 14 days or more after receipt of one dose of a one-dose
vaccine series, and, if an additional (i.e., third or booster) dose was received, 0 to <14 days after
receipt of the additional dose.
• Fully vaccinated with an additional dose cases include those whose episode date occurred 14
days or more following the receipt of at least one additional dose (e.g., third or booster) of a COVID-
19 vaccine product, after being fully vaccinated.
Note: A COVID-19 vaccine product includes vaccines authorized by Health Canada and vaccines accepted
by the Government of Canada for the purpose of travel to and within Canada. Note: When symptom onset
date is unavailable or the case is asymptomatic, episode date uses the following dates as a proxy for
classification: laboratory specimen collection date, or laboratory testing date.
Outbreak data
Reporting delays and gaps in information that are available at the federal level present difficulties in
reporting on local outbreaks. Data on COVID-19 outbreaks at the federal level is on P/T submitted
outbreak data. There are several important limitations to these data:
• Data on COVID-19 outbreaks at the federal level is based on P/T submitted outbreak data.
• As of January 17, 2022, web-scraped outbreak data from media and P/T public health authority
websites are no longer included.
• P/T submission only included data from January 3, 2021 onward.
• All data only include outbreaks with a reported case count of two or more in line with the national
outbreak definition.
• During the Omicron surge, many jurisdictions reached public health diagnostic and response
capacity. The total number of cases reported to PHAC is underestimated, as is the number of
outbreaks. Decreased laboratory capacity and the increased transmissibility with the Omicron
variant provide rationale for more targeted testing approaches (i.e. priority populations) and
reduced contact tracing. These changes effectively decrease the ability of jurisdictions to detect
and report outbreaks in most settings. As such, we expect outbreak numbers reported from
settings not prioritized for PCR testing to be under-ascertained.
Population data
• Canadian population data from Statistics Canada Population estimates on 1 July 2021 are used for
age-standardized and age-specific rate calculations.
• Note that starting the week of October 31 to November 6, 2021 the national analysis of cases has
been updated to include population estimates from July 1, 2021 (previously July 1, 2020 population
estimates). The 2021 population denominators were retrospectively applied to all data in Table 2,
Table 4, Table A2, Table A3, and hospitalization related text (see Severity Indicators section). As
expected, the increase in the 2021 population denominator has resulted in a decrease in age
standardized incidence rates per 100 000.
21 | P a g e
COVID-19 IN CANADA
AR01850
ANNEX
Table A1. Cumulative number of COVID-19 reported cases, resolved cases, and deaths reported in
Canada by province or territory, as of 26 February 2022
Crude incidence
Total resolved
Province/Territory Total cases Total deaths rate per 100 000
cases
population
British Columbia 347 702 310 533 2 848 6667.6
Alberta 524 975 510 371 3 890 11816.1
Saskatchewan 127 187 113 023 1 091 10780.0
Manitoba 130 065 115 445 1 672 9399.4
Ontario 1 098 667 1 067 714 12 410 7410.3
Québec 919 994 886 721 13 969 10692.0
Newfoundland and Labrador 23 443 20 992 65 4503.5
New Brunswick 36 772 32 734 302 4659.3
Nova Scotia 45 230 42 827 193 4618.4
Prince Edward Island 13 606 10 642 15 8280.3
Yukon 3 428 3 362 21 7974.7
Northwest Territories 8 622 8 155 19 18947.8
Nunavut 2 723 2 299 5 6910.6
Canada a 3 282 427 3 124 831 36 500 8582.4
Source: Provincial and Territorial MOH websites
a
Includes 13 cases identified in repatriated travelers (Grand Princess Cruise ship travelers) who were under quarantine in Trenton in March
2020. Update on their status is not available.
Table A2. Age-standardized incidence rates of reported COVID-19 cases, by province or territory, as of
26 February 2022
Cumulative age-standardized incidence rates
Province/Territory
(Per 100 000 population)
British Columbia 6 681.8
Alberta 11 497.4
Saskatchewan 10 632.2
Manitoba 9 276.6
Ontario 7 357.2
Québec 10 755.8
Newfoundland and Labrador 2 984.2
New Brunswick 355.6
Nova Scotia 1 864.1
Prince Edward Island 7 349.1
Yukon 7 682.1
Northwest Territories 5 876.8
Nunavut 2 535.3
Canada 8 344.8
Source: Detailed case information received by PHAC from provinces and territories, standardized to the July 1 2020 post-census population
estimate
Note: Data from the nine of Canada’s thirteen provinces and territories were available for week 08. Data are analyzed based on date reported
to PHAC.
22 | P a g e
COVID-19 IN CANADA
AR01851
Table A3. Cumulative age and gender distribution of COVID-19 cases reported to PHAC, as of 26
February 2022
Age l Female Male l Totala 7
group r n I % l Rate n I % I Rate I n I % l Rate

- -
<5 l 55 351 3.3 I 6 034.9 60 993 4.0 I 6 318.0 l 116 344 3.7 I 6 180.1
I 5-11 I 115 219 6.9 I 8 190.0 125 008 8.3 I 8 490.7 I 240 227 7.5 I 8 343.8
I 12-19 I 146 937 8.8 I 9 044.3 140 802 9.3 I 8 335.4 I 287 739 9.0 I 8 682.9
r 20-29
30-39
I 323 648 19.4 I 13 232.5 286 447 18.9 I 10 821.8 I 610 095 19.2 I 11 979.5
-
i I 303 554 18.2 I 11 441.3 257 489 17.0 I 9 496.9 I 561 043 17.6 I 10 458.6
i 40-49 I 261 650 15.6 I 10 599.7 219 519 14.5 I 9 049.8 I 481 169 15.1 I 9 831.5
50-59 I 202 128 12.1 I 7 830.5 187 439 12.4 I 7 352.8 I 389 567 12.2 I 7 593.1
60-69 I 114 653 6.9 I 4 632.3 119 316 7.9 I 5 043.4 I 233 969 7.3 I 4 833.2
-
70-79 I 60 151 3.6 I 3 648.7 61 430 4.1 I 4 135.3 I 121 581 3.8 I 3 879.3
-
80+ I 88 586 5.3 I 8 708.6 52 794 3.5 I 7 579.9 I 141 380 4.4 I 8 249.9
-
Total I 1 671 877 I 100.0 I 8 690.4 I 1 511 237 I 100.0 I 7 950.6 I 3 183 114 I 100.0 I 8 322.7_J
-
a
Cases not identified as male or female were removed from the total due to small numbers.
Note: Data from the nine of Canada’s thirteen provinces and territories were available for week 08. Cases with missing gender, sex or age
were excluded. Where available, gender data was used; when gender data was unavailable sex data was used. Reliable data on gender
diverse respondents are unavailable due to small counts.
Table A4. Cumulative age and gender distribution of COVID-19 deaths reported to PHAC, as of 26
February 2022
Age group Female Male Totala
<5 9 3 12
5-11 4 6 10
12-19 5 6 11
20-39 138 229 367
40-59 838 1 366 2 204
60-79 4 440 7 081 11 521
80+ 11 819 10 151 21 970
Total 17 253 18 842 36 095
a
Note: Cases with missing gender, sex or age were excluded. Where available, gender data was used; when gender data was unavailable, sex
data was used. Reliable data on gender diverse respondents are unavailable due to small counts.
23 | P a g e
COVID-19 IN CANADA
AR01852
Table A5. Cumulative age and gender distribution of cases hospitalized and admitted to ICU reported
to PHAC, as of 26 February 2022
Hospitalized – non-ICU Hospitalized – ICU
Age groups
Female Male Total Female Male Total
<5 817 1 081 1 898 80 99 179
5-11 283 362 645 46 46 92
12-19 827 590 1 417 74 93 167
20-39 8 875 5 475 14 350 934 1 202 2 136
40-59 9 575 12 647 22 222 2 438 4 390 6 828
60-79 16 573 20 989 37 562 4 019 7 075 11 094
80+ 16 869 15 081 31 950 984 1 385 2 369
Total 53 819 56 225 110 044 8 575 14 290 22 865
a
Note: Cases with missing gender, sex or age were excluded. Where available gender data was used; when gender data was unavailable, sex
data was used. Reliable data on gender diverse respondents are unavailable due to small counts.
Table A6. Cumulative number of COVID-19 cases, hospitalizations, ICU admissions and deaths, by
age group, reported to PHAC as of 26 February 2022
Cumulative I
-
Hospitalized – I
Age groups Cases Hospitalized – ICU Deaths
r I non-ICU I -
<5
~
116 599 I 2 082 (1.8%) 179 (0.2%) I 12 (<0.1%)
5-11 ..__ 240 711 I 737 (0.3%) 92 (<0.1%) I 10 (<0.1%)
I 12-19 288 552 I 1 587 (0.6%) 167 (0.1%) 11 (<0.1%)
l
r 20-39
40-59
1 174 875
872 664
I 16 507 (1.4%)
29 075 (3.3%)
2 137 (0.2%)
6 834 (0.8%)
I 375 (<0.1%)
I 2 212 (0.3%) -
~
,__ I >--
60-79 356 226 I 48 691 (13.7%) 11 102 (3.2%) I 11 537 (3.2%)
-- -
80+ 141 637 l 34 352 (24.3%) 2 373 (1.7%) 22 013 (15.5%)
l
Total 3 191 264 133 031 (4.2%) I 22 884 (0.8%) I 36 170 (1.1%) J
C I I
Source: Detailed case information received by PHAC from provinces and territories.
24 | P a g e
AR01853
SHAUN RICKARD AND - and - HER MAJESTY THE QUEEN, as represented by the ATTORNEY
FEDERAL
COURT OF CANADA
AFFIDAVIT OF SHAUN RICKARD
PRESVELOS LAW LLP

Toronto, Ontario
M5H 3L5

Tel: (
Email: s
Evan A. Presvelos (LSO

Tel:
Email:

AR01854
TAB 9
AR01855
Court p·1 e No.: T-1991-21

BETWEEN:

Applicants
- and-
HER MAJESTY THE QUEEN, as represented by ATTORNEY GENE L OF

Respondents
SUPPLEMENTARY AFFIDAVIT OF SHAUN RICKARD
1. I, Shaun Rickard, in the City of Pickedng, in the Province of Ontario, MAKE ATH AND SAY
AS FOLLOWS:
2. I am one of the named Applicants in this matter and, as such, have personal kno ledge of the facts
and matters contained in this affidavit.
3. On March 11, 2022, I swore an affidavit in support of this Application (the "M rch Affidavit").
4. At various points in my March Affidavit, I refer to, among other things, public available media
reports, scientific studies, literature and/or journal articles, statements made! by public health
officials, foreign Court decisions, and/or Statistics Canada publications. F example, these
materials are referenced and described in paragraphs: 26, 27, 28, 29, 30, 31, 2, 33, 34, 36, 37,
38, 40, 41, 42, 43, 46, 47.
5. To the extent it is not already apparent from the overall tone and content ofmy arch Affidavit, I
wish to clarify that I refer to this information not for the truth of its content, bu ecause:
134
AR01856
a. it is information that was available to me and that I relied on, and con nue to rely on, to
inform my personal decision-making process in deciding whether not to undergo
vaccination for Covid-19;
b. it is important context to understand the impact the challenged , ransport Canada
Ministerial Orders have on my Section 6 and Section 7 Charter rights: ' d,
c. it highlights the type of information available to Canadian citizens or p . manent residents
who are interested in informing themselves and applying a critical lens o the information
their government has shared over the course of the pandemic.
6. For example, in paragraphs 26 to 28, I relied on statistical information pre • red by Statistics
Canada to subjectively understand the health risks of Covid-19.
7. Similarly, I considered statements made by prominent public health officials su • as, Dr. Anthony
I
Fauci and Dr. Theresa Tam, to assess their advice as it pertained to the pande ic and associated
public health measures being promoted at the time. The changes in their positio on certain public
health measures, as reported to the public, caused me concern about the reliability of the
information public officials were relying on to inform health policy decisions a . any given time.
8. The following are additional illustrative examples ofinformation referred to in~ March Affidavit
I
and which played an important part ofmy decision against receiving a Covid-1: vaccine:
a. Through online media sources, I became aware that a U.S. Court ordere '. Pfizer to disclose
I
information the company had relied upon to license its Covid-19 vacc· e. I reviewed the
1
!
I
Court's decision and found it to be of interest to me because Pfizer is o e of the two main
vaccines approved for use in Canada and their involvement in this legal hallenge attracted
my attention and, frankly, my concern (further details are found at p · agraph 36 of the
March Affidavit); and,
b. I also came across an online article published in the British Medi al Journal which
criticized an atleged lack of transparency in how Covid-19 vacci trials had been
135
I
[
AR01857
conducted by Pfizer and Modema. While I am unable comment on the 8-curacy and merits
1
!
of the authors' remarks, or on vaccine trials, generally, I personally ~ und the authors'
comments concerning and it gave me reason to be cautious about thel manner in which
I
Pfizer and Modema vaccines had been tested (further details are foun•. at paragraphs 37
and 38 of the March Affidavit). I

I
9. I do not profess to be an expert about any of the matters contained in the aforem .i tioned materials.
I am also not suggesting that I possess the necessary qualifications required to rovide an expert
opinion on the medical and scientific facts concerning the pandemic, public h Ith and/or any of
the Covid• 19 vaccines.
10. In short, and as discussed in my March Affidavit, the materials I discussed are , mply to illustrate
I
the type of information I used to form, and continue to form, an important part 4; my deliberations
and medical decision making insofar as it relates to being vaccinated against cJiii id•l9. Relatedly,
I,
my intention in highlighting some seemingly conflicting information was to r :veal the dilemma
1
!
before me; namely deciding between taking a vaccine I that am uncomfortable w: h or being unable
to travel within Canada or to leave Canada.
11. I swear this affidavit in support of this Application and for no other or imprope purpose.
Sworn before me )
at the City of Toronto, )
in the Province of Ontario, )
this J" ~of May, 2022 )
A Commissioner for taking Affidavits

within the Province of Ontario
Sam A. Presvelos
136
SHAUN RICKARD AND - and- HER MAJESTY THE QUEEN, as represented by the ATTORNEY
FEDERAL
COURT OF CANADA
SUPPLEMENTARY AFFIDAVIT OF
SHAUN RICKARD
PRESVELOS LAW LLP

Toronto, Ontario
M5H 3L5

Tel:
Email:
Evan A. Presvelos (LSO #:

Tel: (
Email:

AR01858
AR01859
TAB 10
AR01860
Court File No.: T-1991-21
BETWEEN:

Applicants
- and-
HER MAJESTY THE QUEEN, as represented by the ATTORNEY GENERAL OF

Respondents
AFFIDAVIT OF KARL HARRISON
1. I, Karl Harrison, in the City of Vancouver, in the Province of British Columbia, MAKE
OATH AND SAY AS FOLLOWS:
2. I am one of the named Applicants in this matter and, as such, have personal knowledge of
the facts and matters contained in this affidavit.
3. On March 11, 2022, I swore an affidavit in support of this Application (the "March
Affidavit").
4. At various points in my March Affidavit, I refer to public documents published by
Canadian and UK government authorities, scientific articles, media articles, public filings
of pharmaceutical companies and statements made to the media by public health officials.
These materials are referenced and described in the following paragraphs: 9, 24, 25, 27,
28,29,30,31,32,35,39,40,41,42,43,44,45,46,4 7,48,50,52,52,60,61,62,63,64,
66, 67, 69.
139
AR01861
5. To the extent it was unclear in my March Affidavit, I never intended to rely on subh
materials for the truth of its content. I wish to clarify that I referred to such informatirl n
because:
a. 1
it is information that was available to me and that I relied on, and continue to r1 ly
on, to inform my personal decision-making process in deciding whether or not to
undergo vaccination for Covid-19; ;
b. it is important context to understand the impact the challenged Transport Canakia
Ministerial Orders have on my Section 6 and Section 7 Charter rights: and, j

c. it highlights the type of information available to Canadian citizens or perman .nt
residents who are interested in informing themselves and applying a critical lens to
the information their government has shared over the course of the pandemic.
6. I, obviously, do not possess the medical or scientific qualifications and experience to lb e
able to assess the accuracy of the various sources of information I reviewed and highligh~ed
in my March Affidavit. Nonetheless, these are sources which I subjectively reviewed ld

II
considered as relevant to making an informed decision about my personal bod1·1y
autonomy, namely my decision against receiving a Covid-19 vaccine.
7. As discussed in the March Affidavit, the information I considered from several sour es
I
impacted how I assessed the risk/benefits of the Covid-19 vaccine. Some of the informat ·6n
that informed my decision-making included:
140
AR01862
a. Media articles from Canada and the U.S. as well as public security filings from
Moderna concerning the history and previous applications of mRNA technology
(this can be found in paragraphs 27 to 32 in the March Affidavit);
b. Information from scientific periodicals, like The Lancet, which I reviewed to
subjectively understand the effectiveness of Covid-19 vaccines in preventing
infection against Covid-19 and/or transmission of Covid-19 to others (this can be
found in paragraph 42 of the March Affidavit);
c. A letter, I found interesting, from Vancouver Coastal Health advocating for the end
of Covid-19-related policies including why such policies should be discontinued
(this can be found in paragraphs 43 -46 of the March Affidavit);
d. A report prepared by British Columbia's Covid-19 Strategic Research Advisory
Committee concerning "knowledge gaps" (a term used by the authors of the report)
about the effects of Covid-19 vaccines. I found this report helpful in thinking
through and understanding the possible risks that other people have raised and
considered regarding the Covid-19 vaccine (this can be found at paragraphs 60 and
61 of the March Affidavit); and,
e. Reports from Statistics Canada that I reviewed and subjectively considered to
understand the risk of fatalities associated with Covid-1 9 which, in tum, informed
my decision as to the benefits of being vaccinated against Covid-19 (this can be
found at paragraph 64 of the March Affidavit).
8. I acknowledge that I am unable to determine the ultimate correctness of the information I
reviewed and considered. However, as a curious and informed citizen in a Western
141
AR01863
democracy, I am explaining the information and sources of information I relied upon •n
exercising a personal and private decision against a certain medical procedure.
9. Although I highlighted conflicting and critical information about Covid-19 vaccinati n
and/or Canadian public health policy, I did not intend to present any argument or expert
opinion on such information or to present the information as necessarily accurate; rather! I

I
intended to illustrate the conflicting infonnation I am presented with, includit g
reservations I have regarding vaccination against Covid-19. I hope that such information
will allow this Court to appreciate the difficult decision I am faced with - compromise i y
bodily integrity and autonomy or remain unable to travel across and/or outside my count.
I 0. I swear this affidavit in support of this Application and for no other or improper purpos~.
Sworn before me )
at the City of Toronto,
in the Province of Ontario,
this 4•h day o May, 2022
)
)
)
(~
)/~~-------
A Commissioner for taking Affidavits KARL HARRISON
within the Province of Ontario
Sam A. Presvelos
LSO#
142
SHAUN RICKARD AND - and- HER MAJESTY THE QUEEN, as represented by the ATTORNEY
FEDERAL
COURT OF CANADA
SUPPLEMENTARY AFFIDAVIT OF
KARL HARRISON
PRESVELOS LAW LLP

Toronto, Ontario
M5H 3L5
Sam A. Presvelos (LSO #: )

Tel: (
Email:
Evan A. Presvelos (LSO #: )

Tel: (
Email:

AR01864
AR01865
TAB 11
e-document T-168-22-ID 25
AR01866 F
I FEDERAL1COURT
D
É
L COUR FÉDÉRALE P
E O
D S
March 11, 2022 É
COURT FILE NO: T-168-22-ID 12022
11 mars
FEDERAL COURT Kevin Lemieux
BETWEEN:
CAL
I 13
THE HONOURABLE A. BRIAN PECKFORD, LEESHA NIKKANEN,

KEN BAIGENT, DREW BELOBABA, NATALIE GRCIC,
AND AEDAN MACDONALD
Applicants
and
THE MINISTER OF TRANSPORT AND ATTORNEY GENERAL OF CANADA
Respondents
AFFIDAVIT OF KENNETH B. BAIGENT

(Sworn March 10, 2022)
I, Kenneth B. Baigent, of the City of Yellowknife, in the Territory of the Northwest Territories,
SWEAR AND SAY THAT:
1. I am one of the Applicants herein, and as such have a personal knowledge of matters
hereinafter deposed to, except where they are based on information and belief, in which
case I verily believe them to be true.
Background Personal Information
2. I am 57 years old Canadian citizen. I am married to my lovely wife Elizabeth, and we are
proud parents to our son, Jakob. We are a Christian family with long held and sincere
religious beliefs, and our trust in God has guided our lives including our health and healing.
3. In 2012, I was recruited to work in Yellowknife as an Energy Management Specialist with

my employer, the Arctic Energy Alliance. My wife and son joined me in Yellowknife in
AR01867 2
2013, where we all lived full-time. Due to a severe medical condition with my mother-in-
law, my wife & son returned to Ontario in late 2014 to support her eldercare.
4. I was faced with the challenge of how to accommodate my career in Yellowknife and still
have a good quality family life. I had many meetings with my Executive Director.
Ultimately, a creative accommodation was made that would allow me to continue full-
time employment, where I could work rotationally between Yellowknife, NWT
(performing work that required onsite work) and from Jordan, ON (completing client
analyses, reports & other required projects).
5. My rotational work schedule has continued from 2015 to the present. Typically, I fly eight
to 12 times per year with WestJet between Ontario and the Northwest Territories. Even
under these circumstances, I have continuously proven my ability to deliver a high volume
of work and have been assigned to manage various programs & projects, earning a
promotion to Senior Energy Management Specialist.
6. When Covid-19 arrived in Canada in March of 2020, my employer suggested I fly back to
Ontario a bit earlier than scheduled. There was a concern that air travel may soon be
temporarily suspended in Canada and my employer wanted me to be with my family
during this period of lockdown.
7. Air travel started to open in June, and I flew back to Yellowknife on July 6, 2020. During
the Covid-19 pandemic, I flew business class with WestJet 13 times between Ontario and
the Northwest Territories during which time I followed all the required public health and
safety guidelines of the airline industry both in the airport and on the airplane (health
screening, temperature checks, sanitizing, masking, physical distancing). I was proud to
do my part and believe the combined efforts of the airlines and passengers resulted in the
very low risk of Covid-19 transmission that is highlighted on Transport Canada’s website.
Attached hereto and marked as Exhibit “A” to this my Affidavit is a printout of Transport
Canada’s website.
8. In addition to the airline travel health & safety requirements, the Northwest Territories
Health, and Social Services Authority (NTHSSA) banned all non-resident travel to the
AR01868 3
-
Northwest Territories and implemented a self-isolation policy for all returning residents.
With my rotational work schedule, I completed eight self-isolation plans, for a total of 102
days (14.6 weeks, or 28% of a year) in self-isolation between July 6, 2020, and February
22, 2022. My employer was very accommodating of my situation, and I appreciated his
support in these unusual circumstances and government-mandated restrictions.
9. My office has about 25 staff and we all follow Northwest Territories Workers’ Safety &
Compensation Commission (WSCC) Covid-19 Health & Safety guidelines and workplace
practices. Covid-19 vaccinations in the Northwest Territories commenced on December
30, 2020 and were initially listed on the NTHSSA website as being voluntary.
10. After the Federal Government introduced the concept of a vaccine mandate for Federal
Employees on August 13, 2021 (and rolled it out in late September), the Government of
the Northwest Territories (GNWT) followed suit in September to introduce a vaccination
policy of Staff that would require all GNWT Staff to be fully vaccinated by November 30,
2021 or submit to regular rapid testing & additional use of PPE. For GNWT Staff, there
would be no requirement to apply for an exemption to the policy or suffer being placed on
a Leave of Absence without pay – the alternative option was to wear the personal
protective equipment and submit to the regular rapid testing.
11. I have been proactive in personally informing my Executive Director about my long-held
and sincere religious beliefs and that I would not be taking the Covid-19 vaccine. I follow
all required Covid-19 health and safety protocols in the respective region I am in Canada
and for my airline travel back & forth.
12. I believe my Charter rights are being violated. I cannot travel freely for work, my religious
beliefs, my medical freedoms, and my privacy rights are not being respected, and I feel as
though I am being discriminated against just for being unvaccinated.
13. In order to be fit for work and ensure that I am not a risk to my colleagues, I voluntarily
complete three rapid antigen self-tests per week. I contacted Levitt Safety in October 2021
and ordered my own “Health Canada” approved test kits (a 25-test kit package of the
AR01869 4
-
Abbott Panbio Ag Nasal tests) at a personal cost of about $275 per box. I could do the
same for boarding an airplane to ensure that I am not a risk to other passengers.
Federal Travel Ban
14. On August 13, 2021 (2 days before the federal election was called), I heard the Federal
Government announce they were planning to restrict unvaccinated Canadians from
federally regulated domestic air, rail and marine transport in Canada, commencing by the
end of October 2021.
15. Following the election results on September 20, 2021, another announcement was issued
on October 6, 2021, to confirm the domestic travel restrictions would be implemented
commencing October 30, 2021. From October 30 through November 29, 2021, passengers
could board by either being fully vaccinated or by providing a negative Covid-19
molecular test conducted within 72 hours of travel. Commencing November 30, 2021,
only the fully vaccinated would be allowed to travel. Attached hereto and marked as
Exhibit “B” to this my Affidavit is a copy of the website on the Government of Canada
travel mandate.
16. I understand that in the fall of 2021, the Federal Government announced that they had
enacted Interim Order Respecting Certain Requirements for Civil Aviation Due to
COVID-19 (the “Travel Ban”). It is my understanding that the Federal Government is
constantly changing the Travel Ban. I am having a hard time understanding the constantly
changing laws and requirements and how it will affect my ability to travel for work and
return home to visit my family.
17. Following the Federal Government’s announcement, I knew I needed to travel by air to
work and wanted to book the following three flights:
a) The first week of December 2021 from YZF to YYC;

b) The first week of February 2022 from YYC to YZF; and
c) The first week of April 2022 from YZF to YYC.
AR01870 5
-
18. I have been a patron with WestJet for over 25 years and am currently a Gold Rewards
member. With very little information coming from the Federal Government about how the
Travel Ban will affect me and my ability to work, I finally saw a CTV News article on
October 15, where Andrew Gibbons, VP of Government Relations and Regulatory Affairs,
was quoted saying: “Ultimately verifying the legitimacy of people’s vaccination records
should reside with government.” Attached hereto and marked as Exhibit “C” to this my
Affidavit is a copy of the CTV News Article.
19. Details from the Federal Government regarding the exemption program to the Travel
Mandate were minimal. I send a letter to Ed Simms, President and CEO of WestJet, and
copied Andrew Gibbons regarding how to submit a request for an exemption. Mr. Gibbons
responded to me within one week and has been very kind; however, he stated that he had
no details on the process to request an exemption at that time. Attached hereto and marked
as Exhibit “D” to this my Affidavit is a copy of my letter.
20. From what I could gather that was made public regarding the Travel Ban, the new domestic
travel restriction was supposed to accommodate long held and sincere religious beliefs via
an exemption application & approval process; however, the specific application details
were not being made available.
21. From October 15 – November 22, 2021, I have been contacting WestJet, my Northwest
Territories MP (Michael MacLeod), and the Federal Minister of Transport (Omar
Alghabra) numerous times in order to get some direction and clarity on how to apply for
a religious exemption. Attached hereto and marked as Exhibit “E” to this my Affidavit is
a copy of my emails.
22. On November 22, 2021, Wendy Nixon, Director General, Aviation Security at Transport
Canada wrote the following:
For domestic and outbound travel from Canadian airports, airlines and
railways will administer the process for considering a traveller’s medical
inability to be vaccinated, essential medical services and treatment, sincere
religious beliefs, and emergency/urgent travel (including for urgent
medical reasons). Travellers who think they may be eligible for one of
AR01871 6
-
these exemptions should contact their airline or railway company to obtain

the necessary form and submit it in accordance with their carrier’s
approval process (forms available starting November 30, 2021). Travellers
may need to adjust their travel plans in the weeks following November 30
to allow time for their air carrier to process their exemption request. Please
note that travellers who are exempted from the vaccination requirement
will require a valid COVID-19 molecular test result before boarding.
A copy of that correspondence is attached hereto and marked as Exhibit “F” to this my
Affidavit.
23. The content of Ms. Nixon’s email made it clear that my religious beliefs exemption
application & approval would not be completed in time for me to fly to Ontario during the
first week of December. I then made the difficult decision that, to see my wife and son in
December, I would need to drive 5000 km from Yellowknife, NWT to Jordan, ON. This
required me to book off a week of vacation from work and drive across Northern &
Remote Arctic Canada in extreme cold, snow and ice-covered roads during a time of year
with very little daylight. I do not have the financial means to pay to fly by private chartered
aircraft to visit family or travel for work.
24. On November 30, 2021, and upon arrival in Ontario, I could see the WestJet Airlines
website had been updated with the process to apply for a religious beliefs exemption for
domestic travel. I completed and submitted my application on December 2, 2021.
Attached hereto and marked as Exhibit “G” to this my Affidavit is a copy of my WestJet
religious exemption request application form.
25. On November 19, 2021, I completed and submitted a religious exemption application to
the NWT Office of the Chief Public Health Officer (NWT CPHO). Attached hereto and
marked as Exhibit “H” to this my Affidavit is a copy of my religious exemption
application to the NWT CPHO.
26. I also received a religious exemption from the City of Yellowknife Council for the City
of Yellowknife Proof of Vaccine Policy.
AR01872 7
-
27. On the evening of Friday, December 3, 2021, my religious exemption application was
approved by the NWT CPHO. Attached hereto and marked as Exhibit “I” to this my
Affidavit is a copy of the approval letter from NWT CPHO. I provided a copy of the
approval letter from NWT CPHO to WestJet to add to my religious exemption application.
I also provided a copy to the City of Yellowknife Council to confirm my approved
exemption to their Proof of Vaccine Policy. Attached hereto and marked as Exhibit “J”
to this my Affidavit is a copy of my religious exemption request to WestJet and my
updated religious exemption request of December 4, 2021.
28. I was informed that the WestJet religious beliefs exemption process would take about 3
weeks, and I expected a response by December 23, 2021. In the interim, I saw some
concerning information regarding the process:
a) A December 12, 2021, article in the Globe and Mail where WestJet and Air
Canada both state that the airlines should not be the ones to evaluate
exemptions applications for religious beliefs.
b) A December 16, 2021, video that includes Andrew Gibbons, VP of

Government Relations and Regulatory Affairs WestJet, talking about Federal
Government airline travel restrictions not being based on science and data.
Attached hereto and marked as Exhibit “K” and “L” respectively, are copies of those
articles.
29. On December 23, 2021, I received a notice from WestJet indicating that my religious
beliefs exemption application had been declined and there was no appeal process. I was in
shock and disbelief. Attached hereto and marked as Exhibit “M” to this my Affidavit is a
copy of the denial from WestJet.
30. Between Christmas and New Year’s, I considered applying for a religious exemption with
Air Canada. However, the Air Canada website had been updated and the religious beliefs
exemption application (which I had previously downloaded) was removed. The updated
Air Canada website said:
AR01873 8
Passengers who are entitled to be accommodated on the basis of their sincerely

held religious beliefs. The government has asked air carriers to administer these
exemption requests, indicating that they must be submitted 21 days in advance of
travel. However, we have carefully considered this reason for an exemption, the
interests of all parties involved, and other factors relating to the accommodation of
sincere religious beliefs, and do not anticipate being able to accommodate any
exemption request on this basis in the present circumstances.
31. The Air Canada website page referenced above was found at
https://www.aircanada.com/ca/en/aco/home/book/travel-news-and-
updates/2021/travellers-vaccine-rules.html#/ but has since been removed, and a copy of
that page, which was accessed on December 29, 2021, is attached hereto and marked as
Exhibit “N” to this my affidavit.
32. As a result of the Travel Ban and the difficulty in obtaining a religious exemption from
WestJet or Air Canada, I was left with no other option than to drive 5,000 km back to
Yellowknife during early February, again facing extremely dangerous driving conditions.
I am now uncertain if my employer will have the patience to continue accommodating my
position if I am unable to resume flights for my work within the NWT. We have 32
northern remote communities outside of Yellowknife and many of them can only be
accessed by flights from Yellowknife (our hub community). Because of my vaccination
status, I cannot board a plane out of Yellowknife to any of our remote northern
communities so that I can perform the fieldwork required of my job.
Restricting My Rights and Freedoms
33. I cannot take the Covid-19 vaccination because it contradicts my long-held and sincere
religious beliefs that are to be protected under Section 2 of the Charter.
34. I am a Christian who has accepted my Lord, our God, Jesus Christ as my creator and
savior. Through my personal and prayerful relationship with Him, Jesus teaches me
through the Bible (both the Old & New Testaments), how great His love for me truly is
and to fully trust in Him. His teachings through the Bible are rock solid to those who truly
AR01874 9
-
believe and trust in Him. I know that Jesus guides me, protects me, loves me
unconditionally, and provides for my health & healing.
35. I have fully outlined my beliefs in my religious exemption application requests to:
a) The Northwest Territories Office of the Chief Public Health Officer (CPHO)
• Exemption from October 22, 2021 Proof of Vaccination restrictions

• Application submitted November 21, 2021
• Approval received December 3, 2021
b) WestJet Airlines Ltd.
• Exemption from the November 30, 2021 Domestic Travel Ban

• Application submitted December 2, 2021
i. Updated on December 4, 2021, to include the CPHO Approval
Letter
• Declination received December 23, 2021
The information contained in both applications is the same, however, WestJet decided to
go against the decision rendered by my Territorial Chief Public Health Officer. Based on
the concern the airline industry raised on December 12, 2021 (stating they should not be
the ones to evaluate exemptions applications for religious beliefs), I suspect Transport
Canada may have intervened. Air Canada updated their website between Christmas and
New Year’s to remove the ability for anyone to apply for a religious exemption to the
Travel Ban.
36. I do not believe the process regarding the application for a religious exemption has been
transparent or genuine. I believe the Federal Government (Transport Canada) has no
sincere interest in recognizing the Charter Rights of Canadians in relation to the Travel
Ban against the unvaccinated. They have obviously not established the Travel Ban, based
on Covid-19 science and data:
AR01875 10
a. By following the airport & airline Covid-19 health and safety procedures, there has
been no significant risk of Covid-19 transmission onboard planes;
b. During the month of November 2021, unvaccinated Canadians could only board an
airplane, by providing a negative PCR test conducted within 72 hours prior to
boarding (making these folks the safest ones on the planes); and
c. Effective November 30, 2021, only the fully vaccinated (still defined as two
vaccines) and children under 12 can freely board domestic airplanes. It is known
that even the vaccinated are catching and transmitting Covid-19 infections from
November 30, 2021, to the present.
37. Based on my own understanding and conscience and after an extensive review of the
scientific research and medical data, I will not be taking the Covid-19 vaccine.
38. The Travel Ban is infringing on my Charter rights, human rights, and is a violation of the
Nuremberg Code. I am disappointed in the Government of Canada, how it has treated
Canadians in a divisive and disrespectful manner. I have always been a law-abiding
Christian and I have been vilified, shamed, and discriminated against like a criminal by my
own government.
39. I swear this affidavit bona fide in support of the within application and for no improper
purpose.
SWORN BEFORE ME by Ken Baigent, of the )

City of Yellowknife, in the Territory of the )
Northwest Territories, before me at the City of )
Brampton, in the Province of Ontario, this 10th )
day of March 2022 in accordance with O. Reg. )
431/20 Administering Oath or Declaration )
Remotely )
) KENNETH B. BAIGENT
)
)
)
)
A Notary Public in and )
for the Province of Ontario )
Barrister & Solicitor
AR01876
11
This is Exhibit “A” referred to in the Affidavit

of Kenneth B. Baigent sworn before me
virtually this 10 day of March, 2022.
r
r
________________________________
Barrister and Solicitor in the
Province on Ontario
2/1/22, 4 :28 PM RISK OF COVID-19 TRANSMISSION ABOARD AIRCRAFT
AR01877
12
OPENING REMARKS SCENARIO NOTE TRAN BIOGRAPHIES
SUPPLEMENTARY MANDATE LETTER COMMITMENTS - KEY MESSAGES
MINISTER OF TRANSPORT SUPPLEMENTARY MANDATE LETTER
MANDATE LETTER COMMITMENTS - KEY MESSAGES MINISTER OF TRANSPORT MANDATE LETTER
COVID-19 IMPACTS ON TRANSPORTATION SECTOR
HOT ISSUES
Appearance at TRAN: Supplemental Mandate Letter and on the pre-

entry testing requirements
RISK OF COVID-19 TRANSMISSION ABOARD
AIRCRAFT
ISSUE
1. What is the risk of passenger-to-passenger COVID-19 transmission aboard an
aircraft?
BACKGROUND AND DISCUSSION

2. Media reports and scientific journal articles have conveyed both concerning and
reassuring messages about the risk of COVID-19 transmission aboard aircraft.
3. While it is true that air travel can result in the importation of passengers with COVID-
19,.[11 the risk of spread of COVID-19 amongst passengers while traveling aboard
aircraft appears to be low.
a. The European Centre for Disease Prevention and Control (ECDC) has commented
on the risk of COVID-19 transmission on aircraft: "The risk of being infected on an
airplane cannot be excluded, but is currently considered to be low for an individual
traveller. ".[il
b. IATA press release stated: "The risk of a passenger contracting COVID-19 while
on board appears very low. With only 44 identified potential cases of flight-related
transmission among 1.2 billion travelers, that's one case for every 27 million
travelers. We recognize that this may be an underestimate but even if 90% of the
cases were un-reported, it would be one case for every 2.7 million travelers.".[2]
file :/1/C:/Users/asexton/Justice Centre for Constitutional Freedoms/Legal Team - Documents/01 Vaccination Mandates/Litigation/Federal Travel Vaccin ... 1/5
2/1/22, 4:28 PM RISK OF COVID-19 TRANSMISSION ABOARD AIRCRAFT
AR01878 13
c. A recent study conducted by Defence Advanced Research Projects Agency
(DARPA) for the United States Transport Command (TRANSCOM) investigated
aerosol dispersion aboard Boeing 767 /777 aircraft.[4]
i. Reported findings include:
1. 99.7% reduction of from aerosolized exposure in nearby seat with the
highest measured exposure level
2. Average of 99.99% reduction from aerosolized exposure across the
approximately 40 other seats nearby the simulated infected passenger
3. "Transmission model calculations with a 4,000 viruses/hour shedding rate
and 1,000 virus infectious dose show a minimum 54 flight hours required
to produce inflight infection from aerosol transmission."
ii. Report limitations:
1. Defence Advanced Research Projects Agency (DARPA) scientists
emphasized the study limitations and their focus on aerosol exposure
(rather than disease transmission) during a recent teleconference 22
October 2020.
2. The COVID-19 infectious dose (required number of virions) is unknown in
humans and estimates vary in multiple orders of magnitude. The number
of virions shed by an infectious person is also unknown and variable.
3. Testing did not incorporate large droplets. Large droplets co-release with
aerosols when talking, sneezing or coughing. They may result in
transmission directly or via surfaces. Risk of contamination via large
droplets is likely increased in lavoratories and other common areas.
4. Human behavior, such as conversations and moving around the aircraft
were not simulated (testing mannequin remained facing forward).
d. The true rate of COVID-19 transmission during flight is difficult to ascertain due
to the low percentage of passengers tested, limited contact tracing, and difficulty
proving transmission occurred during a flight.
4. A number of interacting factors aboard an aircraft are likely responsible for the
relatively low risk of spread of COVID-19 amongst passengers, even in circumstances
where physical distance between passengers is reduced, including:
a. Air quality.
i. Overall, the United States Centers for Disease Control (CDC) states that
"[m]ost viruses and other germs do not spread easily on flights because of
file:///C:/Users/asexton/Justice Centre for Constitutional Freedoms/Legal Team - Documents/01 Vaccination Mandates/Litigation/Federal Travel Vaccin... 2/5
2/1/22, 4:28 PM RISK OF COVID-19 TRANSMISSION ABOARD AIRCRAFT
AR01879 14
how air circulates and is filtered on airplanes.",[~l
ii. Airflow direction described by recent JAMA publication states: "Air enters the
cabin from overhead inlets and flows downwards toward floor-level outlets.
Air enters and leaves the cabin at the same seat row or nearby rows. There is
relatively little airflow forward and backward between rows, making it less
likely to spread respiratory particles between rows.".[§] (see figure 1 below).
iii. Air exchange rate in modern jet airliners is much higher than a typical home
and even higher than recommended design specifications for modern
hospital operating and patient isolation rooms.4
iv. Air filtration in many modern jet airliners uses highly effective HEPA filters.
11Rick for covid aircraft en
Figure 1 Aircraft air circulation,[§]
b. Face masks. The addition of mask-wearing adds a further and significant layer of
protection. TRANSCOM/DARPA study reported "application of a mask provided
significant protection against micron diameter droplets released during the
cough simulations and reductions greater than 90% were measured." Lack of
transmission in the CMAJ case was partly attributed to masking in April 2020.[Z]
Masks are mandatory for air travelers and crew under the current Interim Order.
c. Cabin characteristics: Other features of aircraft interiors may reduce the
likelihood of COVID-19 transmission, including: seat backs serving as physical
barriers, reduced face-to-face interactions, and limited passenger mixing when
seated.HH
d. Additional measures: Airports and airlines have implemented a multi-layered
approach to reduce COVID-19 transmission. In addition to those described above,
measures include symptom screening; temperature screening; enhanced
cleaning and disinfection; increased use of contactless boarding/baggage
processing; use of physical barriers and sanitization in airports; physical
distancing in airports and during boarding; adjustment of food and beverage
service to reduce contact; control of access to aisles and bathrooms to minimize
contact.
ASSESSMENT
file:///C:/Users/asexton/Justice Centre for Constitutional Freedoms/Legal Team - Documents/01 Vaccination Mandates/Litigation/Federal Travel Vaccin... 3/5
2/1/22, 4 :28 PM RISK OF COVID-19 TRANSMISSION ABOARD AIRCRAFT
AR01880
5. Available evidence suggests that the likelihood of passenger-to-passenger 15
transmission aboard aircraft appears to be low. However, accurate estimation is

difficult due to limited passenger testing, contact tracing, and difficulty proving
transmission aboard an aircraft.
DATE PREPARED: 4 NOVEMBER 2020
REFERENCES
.[11 Adiga A, et al. Evaluating the impact of international airline suspensions on the early
global spread of COVID-19. medRxiv preprint doi:
httP-s://doi.org/10.1101 /2020.02.20.20025882.this version posted March 2, 2020 .
.[~l httP-s: //www.ecdc.eu roP-a.eu /en/ covid-19 /facts/g uestions-a nswers-travel

.[Jl IATA press release 8 October 2020: Research Points to Low Risk for COVID-19
Transmission Inflight
,[4] Silcott et al. TRANSCOM/AMC Commercial Aircraft Cabin Aerosol DisP-ersion Tests
.[21 https://www.cdc.gov/coronavirus/2019-ncov/travelers/faqs.html#Air-or-Cruise-
Travel
,[§]JAMA. 2020;324(17):1798. doi:10.1001/iama.2020.19108
.[Zl Schwartz Ket al. Lack of COVID transmission aboard and international flight.
Canadian Medical Association Journal. April 14, 2020 192 ( 15) E41 O; DOI:
httP-s://doi.org/10.1503/cmaj.75015
HH IATA press release 8 October 2020: Research Points to Low Risk for COVID-19
Transmission Inflight
< Previous
l
Home
l
Next>
l
Date modified:
2021-09-09
file :/1/C:/Users/asexton/Justice Centre for Constitutional Freedoms/Legal Team - Documents/01 Vaccination Mandates/Litigation/Federal Travel Vaccin ... 4/5
AR01881
16
This is Exhibit “B” referred to in the Affidavit

r
r
________________________________
Province on Ontario
2/1/22, 4 :29 PM Mandatory COVID-19 vaccination requirements for federally regulated transportation employees and travellers - Canada.ea
AR01882 17
l♦I
of Canada du Canada
Canada.ea > TransP-ort Canada
Mandatory COVID-19 vaccination

requirements for federally regulated
transportation employees and travellers
From: TransP-ort Canada
Backgrounder
October 6, 2021
Vaccinations are our best line of defense against COVID-19 and its variants.
On August 13, 2021, the Government of Canada announced its intent to

reguire COVID-19 vaccination for employees in the federally regulated air, rail,
and marine transportation sectors and its travellers.
On October 6, Prime Minister Justin Trudeau and DeP-UtY. Prime Minister

hill,Y.stia Freeland announced that, as of October 30, the Government of
Canada will require employers in the federally regulated air, rail, and marine
transportation sectors to establish vaccination policies for their employees.
Also effective October 30, travellers departing from Canadian airports, and
travellers on VIA Rail and Rocky Mountaineer trains, will be required to be fully
vaccinated in order to travel. To allow travellers time to become fully
vaccinated, there will be a short transition period where they will be able to
travel if they show a valid COVID-19 molecular test within 72 hours of travel as
https://www.canada.ca/en/transport-canada/news/2021 /1 0/mandatory-covid-19-vaccination-requirements-for-federally-regulated-transportation-employ... 1/5

2/1/22, 4:29 PM Mandatory COVID-19 vaccination requirements for federally regulated transportation employees and travellers - Canada.ea
AR01883 18
an alternative to providing proof of full vaccination. If travellers have not
already started the vaccination process, or do not start soon, they risk not
qualifying for travel as of November 30.
The Government of Canada is committed to keeping the transportation sector,

including employees and travellers, safe and secure. Mandatory vaccination
for the federally regulated air, rail, and marine sectors helps limit the risk of
spreading COVID-19 and helps prevent against future outbreaks.
Vaccine requirements for employees in the federally regulated

transportation sector
As of October 30, employers in the federally regulated air and rail, and as of
November 1, marine transportation sectors will be required to establish
vaccination policies for their organizations. Specifically, the vaccination
requirement will apply to:
• airlines and airports, and other organizations who have employees who
enter restricted areas of airports, such as concession and hospitality
workers
• federally regulated railways, and their rail crew and track employees
• marine operators with Canadian vessels that operate with 12 or more
crew
Transport Canada will use its specific regulatory and oversight authorities
related to operations of federally regulated air, rail, and marine transportation
service providers to ensure that the transportation system and these
workplaces are safe through vaccination mandates. Each organization will be
required to implement a rigorous policy, which must:
• Include a provision for employee attestation/declaration of their

vaccination status;

AR01884 19
• Include a description of consequences for employees who do not comply
or who falsify information; and
• Meet standards consistent with the approach taken by the Government of
Canada for the Core Public Administration.
After a short phase-in period, each organization is required to guarantee

employees are fully vaccinated or they will be unable to work.
The Government of Canada is engaged with industry and labour groups to

discuss the details to ensure an effective implementation of the requirements.
Vaccine requirements for travellers

Effective October 30, air passengers departing from Canadian airports,
travellers on VIA Rail and Rocky Mountaineer trains, and travellers on non-
essential passenger vessels on voyages of 24 hours or more, such as cruise
ships, will need to be vaccinated.
Effective October 30, travellers will need to be fully vaccinated in order to

board. Specifically, the vaccination requirement will apply to all travellers 12
years of age and older who are:
• Air passengers flying on domestic, transborder or international flights

departing from airports in Canada
• Rail passengers on VIA Rail and Rocky Mountaineer trains
For travellers who are in the process of being vaccinated, there will be a short
transition period where they will be able to travel if they can show a valid
COVID-19 molecular test within 72 hours of travel. By November 30, all
travellers must be fully vaccinated, with very limited exceptions to address
specific situations such as emergency travel, and those medically unable to be
vaccinated.

AR01885 20
In addition, this vaccination mandate will include specific accommodation to
recognize the unique needs of travellers from small, remote communities
(some of which are not accessible by road) to ensure they will be able to travel
to obtain essential services in support of their medical, health, or social well-
being, and return safely to their homes. This accommodation will be informed
by engagement with Indigenous organizations and provinces and territories in
the coming days.
Enforcement
Transport Canada will oversee compliance by means of inspections and
enforcement tools-including Administrative Monetary Penalties-using
oversight systems in place for each mode.
For those who falsify information or otherwise fail to comply, there will be
serious consequences. For example:
• Railway companies could be subjected to compliance actions up to

$250,000 per violation, per day, under the Railway Saf_gJy_Act
• In the air sector, individuals-either travellers or employees-could be
fined up to $5,000 per violation under the Aeronautics Act, and operators
could be fined up to $25,000 per violation
• In the marine sector, employees and travellers could be fined for being
non-compliant with the obligation to provide proof of vaccination up to
$250,000 per violation, per day, and operators could be fined up to
$250,000 per violation, per day, for non-compliance to the Interim Order
made pursuant to the Canada ShiP-P-,ing Act, 2001
Pan-Canadian Proof of Vaccination

AR01886 21
A pan-Canadian, secure, and standardized proof of vaccination for
international travel was announced on August 11, 2021, and is being
developed in partnership with provinces and territories. This document, which
will be available to travellers in digital formats, will be easily recognized and
trusted.
This credential will make it easy and quick for travellers to provide
transportation operators and border officials in other countries with their
validated COVID-19 vaccination history needed to facilitate travel.
Vaccination is one of the most effective ways to fight COVID-19 and the
Government of Canada will continue to take action to get as many Canadians
vaccinated as possible.
Search for related information by keyword: Coronavirus diseases I Safecy.

measures I TransP-ort Canada I Canada I TransP-ort and infrastructure I
Health risks and safety I general P-Ublic I backgrounders I Hon. Chcy.stia
Freeland I Right Hon. Justin P. J. Trudeau I Hon. Omar Alghabra
Date modified:
2021-10-15

AR01887 22
This is Exhibit “C” referred to in the Affidavit

r
f
________________________________
Province on Ontario
AR01888 23
CORONAVIRUS I News
Ottawa eyes charging airport security with vaccine

verification for travellers
C hristophe r Reynold s
The Canad ian Press Staff

Contact
Pub lis he d Frid ay. Octo ber 15. 20214:24AM E DT

Last Up d ate d Frid ay, Octo be r 15. 20 212:53 PM E DT
CTV National News for Sunday, October 10, 2021

A look at what w inter travel will look like
for Canadians booking getaways: and
the intensifying tensions between
China and Taiwan.
CTV National News: Vaccine travel passports

As Creeson Agecoutay reports. it could
be a few months until Canadians can
access a singular vaccine passport for
inte rnational trave l.
CTV National News: The impending flu season

Thanks to public health measures.
influenza was almost non-existent last
season. but doctors warn the numbers
could be worse this w inter.
1 2 3 >
AR01889
The federa l giove rnment is im ulling handing responsibility for verifying passengers 1
24
vaccination status to a ir · ort office rs, rathe r t ha n a ir ines - which hope to skip the
headache..
Canadian ca rriers received three consu ltation pa pers from Tra nsport Canada this w eek
asking for feedback on putting an agency in cha rge of t he proof of-vaccine volidation
proc ess, accord ing to hree sources w ho spoke on cond ition of anonymity because t hey
we re ot outhorized to d iscuss the matter public ly.
· Newsletter sign-up: Get The COVI D-19 Brief sent to your

CORONAV RIUS inbox
COVERAGE
T he Ca1nadian A ir Tra nsport Secu ri y Autho rity, t he Crown
• Tracking every case of COVID-119 corporation known as CATSA that oversees passenger
in Canada
andl baggage screening at a irports, wou ld talke on the
• Goronavirus vacci na tion tracker:
How many people in Ca nada additiona l ro le in ba:relytwo weeks if t he p lan goes ahead
have received shots? fo llowing industry feedback.
• New York cong1ressman Higgins
urges Cana1da to drop COVID-19 Prime Ministe r J ustin Trudeau said last week that as of
trave~test before Nov. 8 Oct. 30 a ll a ir, t ra in a:nd boat travellers ,aged 12 or o lder
• Ontario premier reveals new m us be fullyvacc inated ..a nd have the documentation to
deta:Us on prov:ince s reopen ing
1
plan p rove it.

• Hundreds of samplles from
But o veil of uncertainty lingers over how that requiremen
Onta ri,o groce ry stores exam ined
for coronavirus; a lll test. negative will unfold, with corriers dem anding onswers on t he
• Study suggests correlation patchwork of provincia l system s a nd who will ha ndle
between COVID-l Q ra 1tes a nd
- - - - ,._, - - -
quara ntine for vaccinated

AR01890
traveUers 25
A irlines have been lobbyi g for CATSA to take he reins
• Cross-border travel in questio n on vac c ine c hecks ot o irports in what wou ld am1ount o a
for Canadia ns with mixed shift fro m the current health protocol w he re ca rriers a re
v,a ccines
responsib le fo r c hec king passengers COVID-19 test
1
• Saskatchewan a nd COVID-19:
How did its fo urth wave death resu lts ..
rate become the highest j n
Canada?
11
U ltim1ately, verifying he leg it im acy of people's vaccination
1
• What you need to know if you records shou ld reside w i h government." A ndy Gibbons.
wa nt to cross the U.S. land border head of government rela tio ns and regu la o ry a ffa irs at
• Transplant programs reviewing West.Jet A irlines, sa id in a n in erview.
policy on reci pients being
v,a ccinated aga inst COVID-19 11
11 can see the Ca1lgary a irpo rt from he re. You have fou r
• Resta urants may not survive
without extension of COVID-19
entry p oints fo r CATSA, a nd you have 90-so me -odld gates
benefits, group warns ac ross however m1any o irlines,' odded WestJ e t
11
'
• Expect vacci ne p,a ssports for spokesima n Ric ha rd Ba rtre1m.

travel 'in the next couple of
m1onth s': LeBla nc 11
lt is a much mo re effic ient p rocess a nd gets -t into t he
• Full coverage at ha nds of ,g overnme nt agenc ies ve rsus us as the airline to
CTV News.ca/Coro navirus
be verifying t hat."
T he ,g overn me nt continues to sort out how to knit together

13 d iffe rent p rovincia l a nd te rrito ria l docum entation reg1im1es into a single passport-like
ce rt ificate. comp lete w ith a OR code t hat con be scree ne d across t he country.
11
T he "techn ica l odm,inist ratio n of a domestic va:ccinotion document available in d ig ita l
11
We a re wo rking ve ry closely w ith t he p rovinces and te rrito ries to im plement t hat
AR01891 26
requ irement. but t he requ irement is clea r, and p eop le need to plan t heir lives accordingly,"
she to ld reporte rs in Washington.
Transport Ca nada is co-ord inating w ith government pa rt ne rs and stakeho lders to

11
develop the operationa l model for va lidating proof of vaccination fo r t ravellers,''
spokeswoma n Sa u Sau Li u sa id in an email.
A t Flair A irlines, chief executive Step he n J ones' development team is working on how to
upload p roof of vaccination as pa rt of t he booking and check-in process, in case CATSA
does not assu me sole responsibility - or only does so until the d ig ita l vaccine passport
e nters the picture. 11 But that is yet to be completed. 11 he said of t he upload pla ns.
11
Th is is a federa l mandate a nd that's a fede ra lly run process, and so it wou ld make sense
to have it at t hat (secu rity) point. Because failing that you ca n have p eop le wande ring
a round on t he secure side of the a irpo rt with out having had their vacc inatio n status
checked, 11 Jones sa id in a n inte rview.
11
Healt h is run provincia lly, so I recog nize t hat t he re a re comp lexities to it. 11
Comp lications to bot h the eventua l d igita l, sing le-sou rce proof of vaccinat ion and the
more scattershot p rocess of va lidating vaccine documents from va rious jurisdictions that
w ill kick off Oct. 30 incl ude fa ctors like records for shots received in t he U.S. as well as
d ifferences in provincia lly app roved vaccines.
Nova Scotia a nd A lb erta, for examp le, recog nize any vacc ine a ut horized by the World
Health Organizat ion, such as Sinovac, wh ile other p rovinces and Health Canada have a
shorter list.
Discrepancies exist between count ries as well.

AR01892
'''It would 27
be very im portant for Canada to agree on the kind of proof that can be used fer
vaccination o r fo r tests with as many countries as possib le." sa id Transat vice-p resident
Ch ristophe Hennebellle. stress ing the government•s ro le in vaccine checks.
'''The more help we can giet in p lonn ing and impllementing that. the better fo r us."
The secto r is a lso hoping to see the government a llow more a irpo rts to accept
interna1tiona l flights. Ten cu rrently e joy tha1t status. expanded from fou r when OttaIwa fi rst
introduced the rest ricfon in February-as pa rt of o move to d iscou rage non-essentia l trips,
slow t he spreod of COVIID-19 va riain sand concentrate t he location of quarantine hotels.
A irpo rts in cities such as V ictoria, Kelowno, B.C., and Ham1illt on, Ont.. hat wou d typicollly
book flights bound for the U.S. a nd Ca ri bbean destinations as w inter app roaches now
face a "b ig competitive concern.''' w hich a lso a:f fects a irlines. sa id CanadIio n A irports
Council p resident Danie l-Robert ,G ooch.
'''Many of t hese a irpo rts have fli,g hts that are scheduled. aind t hose · lights are at risk o f
being cance lled,"'' he sa id. adding that some co rriers have a lready be,g un to scrap flig:hts.
llronsport Ca nada sa id it will consider authorizingi more airport s based on demand.

operationa l capacity a nd Canada11s "epidemio log ica l situation. 11
This report by The Canadian Press was first published Oct. 15, 2021.
AR01893 28
This is Exhibit “D” referred to in the Affidavit

r
r
________________________________
Province on Ontario
AR01894 29
November 26, 2021
Andrew Gibbons
VP Government Relations & Regulatory Affairs
Westjet Airlines Ltd.
22 Aerial Place NE
Calgary, AB T2E 3Jl
Via Email:
Hello Andrew:
Re: Proof of Covid-19 Vaccination Requirement - November 30, 2021

Religious Exemption/Accommodation Request - Ken Baigent
Westjet Rewards Gold Member #601126573
I had first approached Westj et back on Oct. 15 (copy of letter attached) and you personally took
the initiative on Oct. 20 to reply to me, indicating that I would need Transport Canada to confirm
the exemption process for their new vaccination requirement for commercial travel in Canada. I
received a response on Nov. 22 from Wendy Nixon (Director General, Aviation Security@
Transport Canada) confirming the exemption process (including for sincere religious beliefs)
would be handled by each airline. I have forwarded you that email & a copy is attached.
I am therefore submitting my religious exemption request for continued commercial air travel
with Westjet, as my sincere and long-held religious beliefs are protected grounds within Human
Rights legislation.
I am a Christian who has accepted my Lord, our God, Jesus Christ as my creator and savior.
Through my personal and prayerful relationship with Him, Jesus teaches me through the Bible
(both the Old & New Testaments) how great His love for me truly is and to fully trust in Him.
His teachings through the Bible are rock solid to those who truly believe & trust in Him. I know
that Jesus guides me, protects me, loves me unconditionally, and He provides for my health &
healing.
My wife Elizabeth and I have a consistent Christian view on God's health and healing, and we
have been living this way long before Covid-19 came on the scene. Here are a few examples of
our commitment to God for our health & healing:
We have not received any form of vaccines for 30+ years

We do not take any prescription phatmaceuticals
We have not had a family physician in the past 15 years.
Our son Jakob (now almost 21) has never been vaccinated - this was our parental choice
initially, and he has maintained this decision once obtaining the age to decide for himself.
We have been through numerous vaccination exemption applications (with 100% of them
AR01895 30
2
being approved) for Jakob (for the 4 schools he has attended (in Ontario & the NWT) and
with the Canadian Forces for his Air Cadet training & deployments (in Ontario, the NWT
& Alberta).
My wife & I regularly attend Church services of various Christian Churches, with our current
attendance being most closely aligned with the Yellowknife Vineyard Church. It is important for
you to lmow that we do not consider ourselves "members" of any one Church or subscribe to the
authority or direction of any one Pastor ........ we are members of the greater Body of Christ and
lean into Him personally & communally with our prayers for guidance, including matters related
to health & healing. This personal relationship was created when Christ was crucified, and the
veil of the temple was torn ... eliminating old covenant beliefs regarding separation from God.
Our religious beliefs & associated health decisions regarding immunizations far pre-dates our
current attendance at any Church we may attend - it is God who personally guides us !
I would like to reference a few of the many scriptures that we hold near as we trust God with our
health & healing:
James 5: 13-16 (NKJV): " 13 Is anyone among you suffering? Let him pray. Is anyone cheer.fit!?
Let him sign psalms. 141s anyone among you sick? Let him call for the elders of the church, and
let them pray over him, anointing him with oil in the name of the Lord. 15And the prayer offaith
-will save the sick, and the Lord will raise him up. And, if he has committed sins, he will be
forgiven. 16Confess your trespasses to one another, and pray for one another, that you may be
healed. The effective, fervent prayer of a righteous man avails much. "
Psalms 23: 1-6 (NKJV): " 1The Lord is my shepherd; I shall not want. 2He makes me to lie davvn
in green pastures; He leads me beside the still waters. 3He restores my soul; He leads me in the
paths of righteousness for His name's sake. 4 Yea, though I walk through the valley of the shadow
of death, I will fear no evil;for You are ·with me; Your rod and Your staff, they comfort me. 5 You
prepare a table before me in the presence ofmy enemies; You anoint my head with oil; my cup
runs over. 6Surely goodness and mercy shall follow me all the days of my life; and I will dwell in
the house of the Lordforever.
As outlined within this letter, I am a man of conviction to my faith in God and I (and my family)
am/are paii of the greater Body of Christ, together with many who share my/our beliefs. I request
Westjet honour my religious beliefs exemption from having to take a Covid-19 vaccine in order
continue flying commercially with Westjet within Canada.
I will obviously continue to support the use and application of all required public health
measures in the airport and while on-board the plane. As required by Transport Canada, I agree
to provide a negative PCR test result that has been obtained within 72 hours prior to each flight
with Westjet. Please confirm if Westjet has a preferred (discounted?) PCR testing provider,
similar to what Air Canada recently announced.
AR01896 31
3
Thank you Andrew for reviewing my request & I look forward to your approval.
~t-~
Kenneth B. Baigent
I make the foregoing statements conscientiously believing them to be true and knowing that it is
of the same force and effect as if made under oath.
SWORN BEFORE ME at the City of )

Yellowknife, in th orthwest Territories, this )
26
th
day of ,· we b ·, 2:~;- )
)
)
A Notar{ Public in nd for the N01ihwest ) Kenneth B. Baigent

Territories . )
My appointment expires: not, being a solicitor
Qlothy P. Wiest
NollfY Public In and for the NorthWNt
T ~ My appointment doN not
uplre being a Solicitor.
D:ENRQCHE & ASSOCIATES

Bartl:$ters;_Solicitors·an~·No.tari'8
Slf>7'- 53rd.Stfdt·
Yellowknife, NT XlA 1V7
AR01897 32
This is Exhibit “E” referred to in the Affidavit

r
f
________________________________
Province on Ontario
RE: Westjet - October 30, 2021 Covid-19 Vaccination Requirements mailbox:///C:/Personal/Personal/Personal%20Email/pop.cogeco.c...
AR01898 33
Subject: RE: Westjet - October 30, 2021 Covid-19 Vaccina on Requirements

From: KEN BAIGENT <
Date: 2021-11-22, 12:33 p.m.
To: "Nixon, Wendy" >, Andrew.Gibbon
CC:
Thank You Wendy for this informa on.
Andrew ............ it looks like this has come full circle back to Westjet again - please review Wendy's
response below.
I am s ll looking to book the following 3 flights with Westjet:

- Flight 1 required December 3, 2021 YZF to YYZ
- Flight 2 required February 1, 2022 YYZ to YZF
- Flight 3 required April 1, 2022 YZF to YYZ
It sounds like the exemp on applica on form (for my long-standing & sincere religious beliefs) that I
will need to submit to Westjet may not even be available un l Nov. 30, so it may be a challenge for me
to catch that Dec. 3 flight.
Andrew, I look forward to your response !!!
Thank You,
Ken Baigent
Yellowknife
On 11/22/21, "Nixon, Wendy" < wrote:
UNCLASSIFIED / NON CLASSIFIÉ
Hello Ken,
On November 19, 2021, the Government of Canada released addi onal informa on regarding
Canada’s border measures and exemp ons, which is available at the following link: Adjustments
to Canada’s border and travel measures - Canada.ca. The COVID-19 Boarding flights and trains in
Canada – Travel.gc.ca website has also been updated with the latest informa on (see sec on on
‘Exemp ons to the vaccine requirement’).
1 of 9 2021-11-23, 6:40 a.m.

AR01899 34
For domes c and outbound travel from Canadian airports, airlines and railways will administer
the process for considering a traveller’s medical inability to be vaccinated, essen al medical
services and treatment, sincere religious beliefs, and emergency/urgent travel (including for
urgent medical reasons). Travellers who think they may be eligible for one of these exemp ons
should contact their airline or railway company to obtain the necessary form and submit it in
accordance with their carrier’s approval process (forms available star ng November 30, 2021).
Travellers may need to adjust their travel plans in the weeks following November 30 to allow me
for their air carrier to process their exemp on request. Please note that travellers who are
exempted from the vaccina on requirement will require a valid COVID-19 molecular test result
before boarding.
Thank you,
Wendy Nixon
Director General, Avia on Security
Transport Canada
From: Ken Baigent

Sent: Tuesday, November 16, 2021 8:09 PM
To: Nixon, Wendy
Cc: Andrew Gibbons
Subject: Re: Westjet - October 30, 2021 Covid-19 Vaccina on Requirements
Hi Wendy:
Just following up. I don't see anything posted yet regarding the Exemp on Process for travel. I
no ced in this news ar cle yesterday that over 3,100 Federal Government workers were able to
apply for & receive an exemp on ......... and the guidelines around domes c travel were supposed
to mirror the Federal Gov't employee policy. So I'm assuming if the Feds have figured it out for
your own employees, it must also be ready for the rest of us?
- --
h ps://www.ctvnews.ca/poli
- . ------------ cs/unvaccinated-federal-employees-not-granted-exemp ons-to-
be-put-on-unpaid-leave-monday-1.5666451
I outlined the 3 flights I'm trying to book with Westjet and I am losing hope that the exemp on
process will be announced in me for me to have everything in place in me for my Dec. 3 flight.
My alterna ve is to drive 5000 kms through Arc c & Northwestern Canada in the height of winter
- pu ng myself at great risk when I should be able to safely fly.
2 of 9 2021-11-23, 6:40 a.m.

AR01900 35
The fully vaccinated and kids <12 can both be infected & spread Covid-19, however they can
freely board a plane. I have already indicated that I have no problems providing a nega ve PCR
test before each flight to ensure that I am not boarding any flights & transpor ng Covid-19 around
Canada. I just need my Religious Beliefs exemp on in place so that I can con nue do my part.
Wendy, is there anything further you can share regarding the process I need to follow?
Thank You,
Ken Baigent
Yellowknife, NT
On 2021-11-09 5:13 p.m., Ken Baigent wrote:
Thank You Wendy for the update:
I am anxiously trying to figure out how I am going to get to see my wife & son on Dec
3, 2021 as the process to obtain an Exemp on for "In-Canada" Travel is s ll yet
undefined. I can appreciate your indica on that the process & details should be
released within the upcoming weeks, and yet I am less than 4 weeks from when I need
to fly out of Yellowknife to Toronto ....... or be stranded 5000 kms away from my family
for the foreseeable future.
I am a 25 year supporter of Westjet and currently a Gold Member patron who flies
Execu ve Class with them 10-12 mes per year .......... even during Covid. The next 3
flights I need to book are:
My family has long standing )30+ years) & sincere Religious Beliefs about our personal
healthcare and I understand the Federal Gov't employee Vaccine Mandate Policy (the
same founda on as the domes c Canada travel policy is based upon) includes an
exemp on process for protected grounds under the Canadian Charter of Rights
(includes Religious Beliefs). So ....... I just need to understand the exemp on
applica on process & then quickly maneuver it so that I can fly out of Yellowknife on
Dec. 3, 2021 with Westjet.
FYI - I always follow all Air Terminal & airline in-flight health safety protocol. In
addi on, I am offering to provide a nega ve PCR test before each future flight I take.
As one step further (as an illustra on of how much I care about this) I even complete
self-administered rapid an gen tes ng 3 days/week (at my own expense) using one of
the Health Canada approved self-test units. Transport Canada & Westjet should be
thrilled to have someone like me con nuing to fly a er Nov. 30th - especially when
3 of 9 2021-11-23, 6:40 a.m.

AR01901 36
60% - 75% of all posi ve Covi-19 cases across Canada are now coming from "double
vaccinated" or children <12 and both of these groups can s ll board planes a er Nov.
30 without any tes ng at all.
The airlines have par cipated in many studies to confirm that in-flight transmission of
Covid-19 is one of the lowest of any public ac vity - and these studies were all
completed before the new airline travel restric ons were recently implemented. Have
a look at #3b in the following Government of Canada website, that confirms the risk of
contrac ng Covid-19 on a plane as 1 in 2.7 million passengers:
- --
h ps://tc.canada.ca/en/binder/risk-covid-19-transmission-aboard-aircra
- . ---------
Air Canada offers the following & I'm sure Westjet has something similar:
- --
h ps://www.aircanada.com/content/dam/aircanada/portal/documents/PDF/en
- . -------------- ------ ------- - ---- ---------
/Onboard_Transmission_FactSheet_en.pdf
It is obvious that in-flight transmission is not the problem .......... Transport Canada
must be more concerned about le ng infected people board the planes. Please let
me do my part by obtaining my Exemp on & providing a nega ve PCR test for the
future flights I take.
Thank You,
Ken Baigent
On 2021-11-08 8:57 a.m., Nixon, Wendy wrote:
Dear Ken Baigent,
Thank you for your e-mail of October 20, 2021, to the Minister of Transport regarding
COVID-19 vaccina on requirements.
Informa on pertaining to the federal vaccina on mandate for travelers, which includes
the requirements for air travel from remote communi es, is publically available at the
web links below:
1. ----------
h ps://travel.gc.ca/travel-covid/travel-restric ons/domes c-
travel
2. ----
h ps://travel.gc.ca/travel-covid/travel-restric
------ ons/domes c-
travel#enter-transi on
Transport Canada is currently finalizing the exemp on process for travel, the details of
which should be released in the upcoming weeks. For the most recent informa on
regarding COVID-19 travel requirements for Canada, please con nue to check
h ps://travel.gc.ca/travel-covid.
--- ----- ---------
4 of 9 2021-11-23, 6:40 a.m.

AR01902 37
For addi onal informa on pertaining to legisla on and other measures that have been
adopted in response to COVID-19 can be found here: Government of Canada’s
response to COVID-19 (jus ce.gc.ca).
Thank you,
Wendy Nixon
Transport Canada
From: KEN BAIGENT

Sent: October 20, 2021 11:31 AM
To: Andrew Gibbons >; McLeod, Michael - M.P.
Alghabra, Omar - M.P.
Cc:
Thank You Andy for your prompt response & guidance - very much
appreciated !
Michael, can you please proceed to engage Transport Canada regarding

the regula ons & exemp ons applica on process.
As it stands now, we are only 10 days away from the new guidelines
becoming effec ve & I am 5,000 kms away from my wife & son. My
current work schedule in the NWT extends to December 3 - at which me I
need to fly with Westjet to Ontario.
I also need to book 2 more business flights with Westjet in early 2022.
Michael - there are many commercial transporta on issues for our NWT
remote communi es, so I assume you are likely in regular contact with
Transport Canada and your federal colleague - Transport Minister Omar
Alghabra.
I look forward to your response & direc on.
Thank You,
Ken Baigent
On 10/20/21, Andrew Gibbons wrote:
Hi Mr. Baigent,
Thank you for your kind words about WestJet and your
5 of 9 2021-11-23, 6:40 a.m.

AR01903 38
patronage since our founding in 1996. We appreciate your
business and look forward to welcoming you on board. With
respect to your ques ons on exemp ons, I recommend your
local MP engage Transport Canada who is developing the
regula ons and will soon be publishing the criteria for
exemp ons. These are federal government regula ons for which
WestJet will be complying with. Discre on of individual airlines
will be limited and the mandate is expected to be
comprehensive.
This is the very best path for your to ar culate your concerns and
seek clarity.
Take Care and Thank you
Andy Gibbons
WestJet
From: Ken Baigent >

Sent: Tuesday, October 19, 2021 9:52 PM
To: Andrew Gibbons
michael.mcleod
- -
Subject: Re: Westjet - October 30, 2021 Covid-19 Vaccina on
Requirements
EXTERNAL: Do not click links or open attachments
I unless you recognize the sender and know the content is

safe.
I
For your considera on:
In my ini al le er, I was asking if the new air travel restric ons
were being ini ated because:
1. Trying to reduce the # of Covid-19 posi ve infected individuals
boarding the plane (and transpor ng the infec ous disease
elsewhere in Canada)
2. In addi on to #1, is there a concern about transmission during
the in-flight experience (Which Teresa Tam previously said was
VERY low, because the airlines are doing a great job).
I know all the airlines are working together on this current

ini a ve, so I thought I would share what Air Canada offers on
their website:
--h-ps://www.aircanada.com/ca/en/aco/home/about/media
- -- --
6 of 9 2021-11-23, 6:40 a.m.

AR01904 39
/media-features/science-based-alterna ve.html
In the top right side of their website, they provide a link to an

October 8, 2021 document that specifically highlights on Pages
1-3 that the risk of in-flight transmission of Covid-19 is s ll very
low. Congratula ons to Westjet, Air Canada and others for a job
well done !!
- --
h ps://www.iata.org/globalassets/iata/programs/covid/restart
-- - --------- ------- --- - -- ---- ---- -----
/covid-public-health-meausures-evidence-doc.pdf
So ............. the risk trying to be mi gated when the new

domes c travel guidelines are launched Oct. 30 must be focused
on reducing the # of Covid-19 posi ve individuals boarding the
plane.
I am pleased to do my part by providing a PCR nega ve test in

advance of each flight. I am, however, concerned that (with
"waning immunity" of the fully vaxxed folks ages 12+) and the
<12 kids s ll being allowed to board planes on/a er Oct. 30
............ there will s ll be a significant risk of transpor ng
Covid-19 throughout Canada.
Have a look at this recent news release from NB, where they say
anyone Age 65+ who is double jabbed should now be considered
unvaccinated - but each one of them can s ll get on a Westjet
flight on/a er October 30, 2021.
- --
h ps://www.cbc.ca/news/canada/new-brunswick/most-deaths-
-- - ---------
are-unvaccinated-1.6212234
I am hoping that one of you (Andrew or Michael) can help me

out to maneuver how I am to apply for my Exemp on & provide
a nega ve PCR test for my flights once the new rules are
launched.
As a 27-year passenger of Westjet & a current gold travel

member ........... I definitely need your help to secure my future
flights !!
Thank You,
Ken Baigent
7 of 9 2021-11-23, 6:40 a.m.

AR01905 40
Hello:
- Andrew Gibbons (Westjet VP Government Rela ons
& Regulatory Affairs)
- Michael McLeod (my Liberal MP for the NT)
I am following up to the email I sent on Friday,

reaching out to you both as perhaps the most likely
contacts to help me understand the changes coming
on October 30, 2021.
We are now 11 days away from the new Covid

screening rules coming into effect, and I am not sure
if the airlines & the Federal Gov't have yet
determined who is taking on the role of Covid
vaccina on screening & where I am to apply for an
Exemp on Request ?
As men oned in my le er, I have no problem

providing a nega ve PCR test within 72 hours of the
flight, in addi on to all of the other airport & airline
health/safety measures that I do.
Based on current Covid Tes ng in Canada & abroad,

there are now numerous reports that 50%+ of fully
vaccinated folks age 12+ and kids <12 are tes ng
posi ve .......... and both of these groups will s ll be
able to freely board planes a er Oct. 30. I do believe
it would be prudent to have everyone boarding the
plane provide a nega ve test (perhaps the rapid
an gen tests that the Federal and
Provincial/Territorial Governments, many Canadian
employers and Universi es/Colleges are using). This
issue is secondary to what I am currently needing
your help with.
Can one or both of you please help me understand

who is in control of the rollout & administra on of
the new Vaccine Mandate for commercial airline
travel in Canada? I would like to get started on my
Exemp on Request (I accept the PCR Nega ve Tes ng
requirement) so that I can proceed to book my next 3
business flights with Westjet.
Thank You,
8 of 9 2021-11-23, 6:40 a.m.

AR01906 41
Ken Baigent
Yellowknife
Good A ernoon Mr. Sims:
I am a long- me passenger with Westjet

(all the way back to those first regional
flights in 1994) and I con nue to fly with
Westjet many mes each year. I am
reaching out to Westjet today to help
steer me through the process of
managing my Exemp on
Applica on/Approval so I can proceed to
book my flights beyond October 30, 2021.
I have prepared a detailed le er
(a ached) so no need to reiterate
anything further in this email.
It appears that Randy Antoniuk & Andrew

Gibbons are heavily involved in the new
policy, so I have copied them as well. I am
a Yellowknife Resident - in case the new
policy will ul mately be managed by the
Federal Government (airport security as
per the CTV news ar cle today that
Andrew was quoted in), I have included
our NWT Liberal MP (Michael McLeod),
and our GNWT Premier (Caroline
Cochrane).
Thank you Ed & congratula ons on your

re rement at the end of this year.
Ken Baigent
9 of 9 2021-11-23, 6:40 a.m.

AR01907 42
This is Exhibit “F” referred to in the Affidavit

r
f
________________________________
Province on Ontario
AR01908 43

From: KEN BAIGENT
Date: 2021-11-22, 12:33 p.m.
To: "Nixon, Wendy" < >, Andrew.Gibbons
CC:
Thank You Wendy for this informa on.
Andrew ............ it looks like this has come full circle back to Westjet again - please review Wendy's
response below.
I am s ll looking to book the following 3 flights with Westjet:

It sounds like the exemp on applica on form (for my long-standing & sincere religious beliefs) that I
will need to submit to Westjet may not even be available un l Nov. 30, so it may be a challenge for me
to catch that Dec. 3 flight.
Andrew, I look forward to your response !!!
Thank You,
Ken Baigent
On 11/22/21, "Nixon, Wendy" > wrote:
Hello Ken,
On November 19, 2021, the Government of Canada released addi onal informa on regarding
Canada’s border measures and exemp ons, which is available at the following link: Adjustments
to Canada’s border and travel measures - Canada.ca. The COVID-19 Boarding flights and trains in
Canada – Travel.gc.ca website has also been updated with the latest informa on (see sec on on
‘Exemp ons to the vaccine requirement’).
1 of 9 2021-11-23, 6:40 a.m.

AR01909 44
For domes c and outbound travel from Canadian airports, airlines and railways will administer
the process for considering a traveller’s medical inability to be vaccinated, essen al medical
services and treatment, sincere religious beliefs, and emergency/urgent travel (including for
urgent medical reasons). Travellers who think they may be eligible for one of these exemp ons
should contact their airline or railway company to obtain the necessary form and submit it in
accordance with their carrier’s approval process (forms available star ng November 30, 2021).
Travellers may need to adjust their travel plans in the weeks following November 30 to allow me
for their air carrier to process their exemp on request. Please note that travellers who are
exempted from the vaccina on requirement will require a valid COVID-19 molecular test result
before boarding.
Thank you,
Wendy Nixon
Transport Canada
From: Ken Baigent

Sent: Tuesday, November 16, 2021 8:09 PM
To: Nixon, Wendy
Cc: Andrew Gibbons >
Hi Wendy:
Just following up. I don't see anything posted yet regarding the Exemp on Process for travel. I
no ced in this news ar cle yesterday that over 3,100 Federal Government workers were able to
apply for & receive an exemp on ......... and the guidelines around domes c travel were supposed
to mirror the Federal Gov't employee policy. So I'm assuming if the Feds have figured it out for
your own employees, it must also be ready for the rest of us?
- --
h ps://www.ctvnews.ca/poli
- . ------------ cs/unvaccinated-federal-employees-not-granted-exemp ons-to-
be-put-on-unpaid-leave-monday-1.5666451
I outlined the 3 flights I'm trying to book with Westjet and I am losing hope that the exemp on
process will be announced in me for me to have everything in place in me for my Dec. 3 flight.
My alterna ve is to drive 5000 kms through Arc c & Northwestern Canada in the height of winter
- pu ng myself at great risk when I should be able to safely fly.
2 of 9 2021-11-23, 6:40 a.m.

AR01910 45
This is Exhibit “G” referred to in the Affidavit

r
r
________________________________
Province on Ontario
AR01911 46
WESTJETf/'J,
GUEST REQUEST FOR TEMPORA R Y EXEMPTION :

COVID-19 NON-VACCINATION BA S ED ON RELIGIOUS GROUNDS
This form must be completed in its entirety by WestjeUSwoop guests seeking a temporary exemption on religious grounds
with respect to Transport Canada's Covid-19 vaccination requirement. All pages must be reviewed and completed by the
person to be exempted and/or the requester, as well as by the required Commissioner of Oaths. Incomplete exemption
requests will not be considered. This form must be completed in full and submitted to the Westjet Group for approval
no less than 21 days prior to departure.
Approved temporary exemptions are valid for a three month period with WestJet or Swoop. Guests are required to submit
a new request for a temporary exemption on religious grounds for any new trips beyond this period. Approved tempo rary
exemptions are applicable on WestJet and Swoop flights only, and do not extend to travel w ith any other airline. Westjet and
Swoop guests are responsible for keeping their own record of any approved exemptions, and must carry a copy of WestJet's
approval, together with this completed form, for the duration of their trip.
This form is interactive. You can type your information into the form and then print before you sign. If you fill it in by hand,
be sure to print legibly; this will help avoid processing delays. Submit completed forms to Westjet by e-mail to
religious.exemptjon@westjet,com.
WestJet approves exemptions at it s sole discretion. WestJet's decision to approve or decline an exemption request is final
and not subject to appeal. Please note that WestJet or Swoop does not provide refunds for trips cancelled because of an
accommodation request t hat is not approved.
Fees for vaccination exemptions, including any costs associated with the services of a Commission of Oaths or for
obtaining a Covid-19 molecular test, are the responsibility of the applicant.
GUEST AND TRAVEL INFORMATION
Last name (provide name exact!Y as slloiv11 on travel ide11tificatio11) First name Middle name
Baigent Kenneth B.
Birthdate
1964
MM/DD/YYYY J Gender
0 Female @ Male
E-mail I Contact number

~
Address Town/City
--------------
Province/State Postal code/ZIP Country
Ontario Canada
Existing Westjet OP Number (ifyou llad a pievious acco111moda11011 app1oval) I WestJet Rewards ID (oprional but will aide in our provisio11 ofsome services)
N/IA J 6
Intended date of travel MM/DD/YYYY I Flight origin Flight destination
February 1, 2022 ~ onto Yellowknife
Page 1 of4 v1.0

AR01912 47
Guest name
WESTJETf/>'
Kenneth B. Baigent
PREVIOUS EXEMPTION REQUESTS
Has a previous temporary exemption request been made for this

0 No @ Yes
person on WestJet or any other carrier/airline?
If yes, please provide details.
With Andrew Gibbons (VP Government Relations & Regulatory Affairs - Westjet) - submitted ab Exemption Request Nov. 27/21.
Date MM/DD/YYYY Name of carrier/airline
27/11/2021 Westjet Airlines Ltd.
Was the temporary exemption approved? @ No 0 Yes
REQUESTER INFORMATION
Complete if requester is different than person seeking temporary exe mption.
Last name (provide name exacc/y as slloivn 011 n-avel ide11lifica1io11) First name Middle name
E-mail Contact number
Address Town/City
Province/State Postal code/ZIP Country
PRIVACY AGREEMENT
Kenneth B. Baigent
I, - - - - - - - -- - - ~ consent to the collection and retention of the personal information on this form and
contained in any documentation I have provided for the purposes of adjudicating my exem pt ion request and facilitati ng
travel, with the understanding that this information will be kept confid ential in accordance with WestJet's Privacy Policy.
Page2of4 v1.0
AR01913 48
Guest name
WESTJET'i/',
Kenneth B. Baigent
CONDITIONS OF ACCOMMODATION
Kenneth B. Baigent
I, - - -- - -- - - -- ~ understand that if approved, WestJet will provide appropriate accommodations to me. I
agree to abide by the terms of any religious accommodation, including a requirement that I present WestJet with Covid-19
molecular test results taken:
Within 72 hours of my scheduled departure time, where the result is negative, or
At least 14 days before but not more than 180 days prior to my scheduled departu re t ime, where the result is positive
Kenneth B. Baigent
I, - - - - - -- - - - -~ understand that any accommodation provided by WestJet is for the purpose of t ravel
within or out of Canada, and I will st ill be subject to all border entry requirements including quarantine requirements
imposed under the Quarantine Act.
QUESTIONNAIRE
Please note that leaders and members of a number of religions and religious denominations (Islam, Roman Cathol ic,
Judaism, Greek Orthodox, Mennonites,Jehovah's Witnesses, Christian Science) have released public statements indicating
their support of COVID-19 vaccines in the interest of public health.
With what religion/religious denomination do you identify?
See attached Response #1
Describe how you are a practicing member of this religion/religious denomination
Explain the connection between your religious beliefs and your inability to receive a Covid-19 vaccine
- - - - - - - - - - - -- - -- - - - - - - - - - - - - - -- - - -- - - - -- - - - - - - - - -
What specific religious beliefs or authorities do you rely upon to demonstrate that your religion/religious denomination precludes you
from receiving a Covid-19 vaccine?
Page 3 af4 v1 .0
AR01914 49
Guest name
WESTJET,;f,
Kenneth B. Baigent
Do your religious beliefs preclude you from receiving other vaccines or medications? If yes, please provide examples. If no, please explain
why not.
Can you provide documentation from religious leaders or other practitioners of your faith that explain the connection between your
religious beliefs and your objection to the vaccine, and the accommodation you are seeking? If yes, please attach documentation. If no,
please explain why documentation cannot be provided.
DECLARATION
I hereby make oath or solemnly affirm and say:

I am unable to be vaccinated against Covid-19 because of my sincere religious belief;
I am requesting a temporary exemption from Transport Canada's requirement to be fully vaccinated for air travel, on the basis of
religion;
The information provided In support of this application is accurate and truthful;
I acknowledge that it is an offence under section 131 of the Criminal Code to make a false statement under oath or solemn affirmation,
knowing that the statement is false; and
I acknowledge that it is an offence under section 366 of the Criminal Code to make a false document, knowing it to be false.
Signature Full name
Kenneth B. Baigent
Date MM/DD/YYYY Location
12/02/2021 Jordan, ON, Canada
SIGNATURE OF COMMISSIONER OF OATHS
SWORN or SOLEMNLY AFFIRMED before me at (Municipality) In (Province or State, Ca1111t1y) On (date)
Yellowknife Northwest Territories, Canada December 2, 2021
Signature AJnl ~ Full name
Geoffrey P. Wiest
Page4of4 vl.O
AR01915 50
Westjet Religious Exemption Form – Kenneth B. Baigent – December 2, 2021

Outlined below are the full responses to the 6 Questions in the Westjet Religious Exemption Form, as the
“Fillable Form” does not allow adequate space to respond.
Response #1
I am a Christian who has accepted my Lord, our God, Jesus Christ as my creator and personal savior.
Through my personal and prayerful relationship with Jesus, He teaches me through the Bible (both the
Old & New Testaments) how great His love for me truly is and to fully trust in Him. His teachings through
the Bible are rock solid to those who truly believe & trust in Him. I know that Jesus guides me, protects
me, loves me unconditionally, and He provides for my health & healing.
Response #2
My wife & I regularly attend Church services of various Christian Churches, with our current attendance
being most closely aligned with the Yellowknife Vineyard Church. It is important for you to know that we
do not consider ourselves “members” of any one Church or subscribe to the authority or direction of any
one Pastor .……. we are members of the greater Body of Christ and lean into Him personally &
communally with our prayers for guidance, including matters related to health & healing. This personal
relationship was created when Christ was crucified, and the veil of the temple was torn … eliminating
old covenant beliefs regarding separation from God. Our religious beliefs & associated health decisions
regarding immunizations & pharmaceuticals far pre-dates our current attendance at any Church we may
attend – it is God who personally guides us !
Response #3
Our religious beliefs & associated health decisions regarding immunizations & pharmaceuticals far pre-
dates our current attendance at any Church we may attend – it is God who personally guides us. I would
like to reference a few of the many scriptures that we hold near as we trust God with our health &
healing:
James 5: 13-16 (NKJV): “13Is anyone among you suffering? Let him pray. Is anyone cheerful? Let him
sign psalms. 14Is anyone among you sick? Let him call for the elders of the church, and let them pray
over him, anointing him with oil in the name of the Lord. 15And the prayer of faith will save the sick, and
the Lord will raise him up. And, if he has committed sins, he will be forgiven. 16Confess your trespasses
to one another, and pray for one another, that you may be healed. The effective, fervent prayer of a
righteous man avails much.”
Psalms 23: 1-6 (NKJV): “1The Lord is my shepherd; I shall not want. 2He makes me to lie down in green
pastures; He leads me beside the still waters. 3He restores my soul; He leads me in the paths of
righteousness for His name’s sake. 4Yea, though I walk through the valley of the shadow of death, I will
fear no evil; for You are with me; Your rod and Your staff, they comfort me. 5You prepare a table before
me in the presence of my enemies; You anoint my head with oil; my cup runs over. 6Surely goodness
and mercy shall follow me all the days of my life; and I will dwell in the house of the Lord forever.
Page 1 of 2
AR01916 51
Westjet Religious Exemption Form – Kenneth B. Baigent – December 2, 2021

Outlined below are the full responses to the 6 Questions in the Westjet Religious Exemption Form, as the
“Fillable Form” does not allow adequate space to respond.
Response #4
As outlined in the responses above & below this question, my sincere & long-held Religious Beliefs are
not focused specifically against a Covid-19 vaccine. Through our 30+ year trust in the Lord for our health
& healing, we are not taking any vaccinations or pharmaceuticals – and our actions for many decades is
proof of our sincerity.
Response #5
My wife Elizabeth and I have a consistent Christian view on God’s health and healing, and we have been
living this way long before Covid-19 came on the scene. Here are a few examples of our commitment to
God for our health & healing:
- We have not received any form of vaccines for 30+ years

- We do not take any prescription pharmaceuticals
- We have not had a family physician in the past 15 years
- Our son Jakob (now almost 21) has never been vaccinated – this was our parental choice
initially, and he has maintained this decision once obtaining the age to decide for himself. We
have been through numerous vaccination exemption applications (with 100% of them being
approved) for Jakob (for the 4 schools he has attended (in Ontario & the NWT) and with the
Canadian Forces for his Air Cadet training & deployments (in Ontario, the NWT & Alberta).
Response #6
As per my responses to the first two questions, my wife & I do not consider ourselves “members” of any
one Church or subscribe to the authority or direction of any one Pastor - we are members of the greater
Body of Christ and lean into Him personally & communally with our prayers for guidance, including
matters related to health & healing. I can provide a letter from the Pastor of the Yellowknife Vineyard
Church that reinforces this relationship and the sincerity of my personal relationship with God.
Page 2 of 2
AR01917 52
This is Exhibit “H” referred to in the Affidavit

________________________________
Province on Ontario
AR01918 53
November 21, 2021
Office of the Chief Public Health Officer (OCPHO)

Department of Health and Social Services
P.O. Box 1320
Yellowknife, NT X1A 2L9
Via
Attn: Sami:
Re: GNWT Proof of Vaccination

NWT Public Health Order – October 22, 2021
Religious Exemption Request – Ken Baigent
Thank you Sami for confirming that my religious beliefs exemption request from the Proof of
Vaccination, for the purpose of the Oct. 22, 2021 NWT Public Health Order, will be managed
through the OCPHO. Attached is a copy of your November 19, 2021 email outlining the
information the CPHO requires from me.
I am submitting my religious exemption request, as my sincere and long-held religious beliefs

are protected grounds within Human Rights legislation.
I am a Christian who has accepted my Lord, our God, Jesus Christ as my creator and savior.
Through my personal and prayerful relationship with Him, Jesus teaches me through the Bible
(both the Old & New Testaments) how great His love for me truly is and to fully trust in Him.
His teachings through the Bible are rock solid to those who truly believe & trust in Him. I know
that Jesus guides me, protects me, loves me unconditionally, and He provides for my health &
healing.
My wife Elizabeth and I have a consistent Christian view on God’s health and healing, and we
have been living this way long before Covid-19 came on the scene. Here are a few examples of
our commitment to God for our health & healing:
- We have not received any form of vaccines for 30+ years

- We do not take any prescription pharmaceuticals
- We have not had a family physician in the past 15 years.
- Our son Jakob (now almost 21) has never been vaccinated – this was our parental choice
initially, and he has maintained this decision once obtaining the age to decide for himself.
We have been through numerous vaccination exemption applications (with 100% of them
being approved) for Jakob (for the 4 schools he has attended (in Ontario & the NWT) and
with the Canadian Forces for his Air Cadet training & deployments (in Ontario, the NWT
& Alberta).
My wife & I regularly attend Church services of various Christian Churches, with our current
attendance being most closely aligned with the Yellowknife Vineyard Church. It is important for
you to know that we do not consider ourselves “members” of any one Church or subscribe to the
AR01919 54
authority or direction of any one Pastor .……. we are members of the greater Body of Christ and
lean into Him personally & communally with our prayers for guidance, including matters related
to health & healing. This personal relationship was created when Christ was crucified, and the
veil of the temple was torn … eliminating old covenant beliefs regarding separation from God.
Our religious beliefs & associated health decisions regarding immunizations far pre-dates our
current attendance at any Church we may attend – it is God who personally guides us !
I would like to reference a few of the many scriptures that we hold near as we trust God with our
health & healing:
James 5: 13-16 (NKJV): “13Is anyone among you suffering? Let him pray. Is anyone cheerful?
Let him sign psalms. 14Is anyone among you sick? Let him call for the elders of the church, and
let them pray over him, anointing him with oil in the name of the Lord. 15And the prayer of faith
will save the sick, and the Lord will raise him up. And, if he has committed sins, he will be
forgiven. 16Confess your trespasses to one another, and pray for one another, that you may be
healed. The effective, fervent prayer of a righteous man avails much.”
Psalms 23: 1-6 (NKJV): “1The Lord is my shepherd; I shall not want. 2He makes me to lie down
in green pastures; He leads me beside the still waters. 3He restores my soul; He leads me in the
paths of righteousness for His name’s sake. 4Yea, though I walk through the valley of the shadow
of death, I will fear no evil; for You are with me; Your rod and Your staff, they comfort me. 5You
prepare a table before me in the presence of my enemies; You anoint my head with oil; my cup
runs over. 6Surely goodness and mercy shall follow me all the days of my life; and I will dwell in
the house of the Lord forever.
As outlined within this letter, I am a man of conviction to my faith in God and I (and my family)
am/are part of the greater Body of Christ (together with many who share my/our beliefs). I
request that the OCPHO honour my religious beliefs exemption from having to take a Covid-19
vaccine (or any vaccine) & remove the restrictions the October 22, 2021 Public Health Order
places upon me.
I will obviously continue to support the use and application of all other required public health
measures that are non-invasive to my body. I am specifically referring to wearing a mask,
sanitizing, physical distancing, self-isolating (if I’m ever not feeling well) and even regular rapid
antigen testing (as part of granting my exemption). As community spread in the NWT & Canada
is occurring from both the non-vaccinated & the fully vaccinated, I should not be restricted from
society based upon my vaccination status.
Thank you for reviewing my request & I look forward to your approval.
Sincerely,
Ken Baigent
AR01920 55
4811a
54th Ave
Yellowknife
X1A 1H5
21 November 2021
PRIVATE AND CONFIDENTIAL
Dear Sir / Madam
Subject: Religious Exemption from vaccination for Ken Baigent
Ken Baigent has been part of the Yellowknife Vineyard Church community for ten years. As his pastor, he has
informed me that he faces the loss of freedom to fly or travel by means of any public transport within the borders
of Canada from 30 November 2021, unless he can show proof of Covid-19 vaccination. I write to assist him state
his objections to the requirement and to request exemption on the grounds of his religious objection to the
same.
I share my belief as a local pastor, ethicist and theologian. There is diversity of opinion and practice within the
Association of Vineyard Churches. We are not a prescriptive Christian movement, who insist on groupthink, or
group practice. As a denomination, we do not determine for people what they need to think or believe about
any matter that is secondary to matters of faith.
The traditional Christian ethical foundation is that every individual must act and live within the constraints of
their own moral / religious conscience and be free to make their own moral and ethical choices before God. If,
for Ken the requirement to take the vaccine runs against his religious conscience, then for Ken, that decision is
indeed grounds for religious objection and exemption.
For many within Vineyard churches the vaccine is not an issue that offends their moral conscience, and we affirm
their freedom to take the vaccinations within the guidance of their own moral conscience. For others within
Vineyard, it is an issue that offends conscience. Similarly, Vineyard affirms their religious freedom not to take
the vaccines. We would only ask and urge each person to act within the guidance and constraints of their own
religious conscience. The term ‘conscience’ appears often in the New Testament. It always ‘causes people to act
in a certain way.’ Ro 14:1-8; 1 Co 6:19,20; 1 Co 3:16,17; Acts 23:1; 24:16; 1 Tim. 1:5, 19; 3:9; 2 Tim. 1:3; Heb.
13:18; 1 Pet. 3:16, 21; Heb. 9:9, 14; 10:22.
I trust that Ken and the Federal Government and / or airlines can come to an agreement that is in line with
current general health guidelines that allow for COVID testing as an alternative to vaccine passports. Freedom
of movement within Canada as a citizen of Canada is an inalienable right. Ken is comfortable to provide a
negative COVID test whenever he needs to use public transportation or fly.
I confirm that the choice Ken has made, is well within the guidelines of what the Scriptures teach. Individual
freedom of choice is grounds for religious exemption according to both the Freedom Charter and the Canadian
constitution. I hope and trust that common ground for freedom of movement might be found.
Sincerely,
.
-~.,· vineyardcanada
Melt van der Spuy
MTh (Stellenbosch) DMin (Fuller Seminary)
Regional Team Leader Vineyard Churches: Prairies & North (NWT, Nunavut, Alberta, Manitoba,
Yukon & Saskatchewan)
AR01921 56
This is Exhibit “I” referred to in the Affidavit

r
f
________________________________
Province on Ontario
AR01922 57
Government of Gouvernement des

Northwest T rritories T rritoires du Nord-Ou st
Issue Number: E-3328

Date Issued: December 3, 2021
Expiry Date: March 31, 2022
Ken Baigent:
Exemption from Proof of Vacciantion Requirement
I acknowledge receipt of your request for an exemption from COVID-19 proof of vaccination requirements
within the Northwest Territories pursuant to Public Health Order – NORTHWEST TERRITORIES COVID-19
GATHERINGS ORDER (effective October 22, 2021) (hereinafter the “October 22, 2021 order”). I, as Chief Public
Health Officer, may take certain actions including issuing directions or orders for the purpose of protecting the
public health under the authority of the Public Health Act, S.N.W.T. 2007, c.17. As a result of the COVID-19
pandemic, gatherings within the NWT are currently restricited, in accordance with the October 22, 2021 order.
I have considered your request for an exemption from from the application of Section 2(d) of the October 22,
2021 order, including your specific circumstances and the documentation included as part of your request.
You are hereby exempted from the requirement at Section 2(d)of the October 22, 2021 order which requires
persons to be fully vaccinated against COVID-19 in order to enter an indoor or outdoor location in which a
person, business, organization or facilty has in place a proof of vaccination program at their location. Please
keep and show this letter to any person, business, organization or facility that has in place a proof of vaccination
program in order to seek entry at their location.
In accordance with the October 22, 2021 Order, this exemption is subject to the following conditions:
• for each week that you will be attending gatherings/establishments that would otherwise have
required proof of vaccination, you must follow whichever of the following is applicable said week:
o If there are no active cases in your community and a negative (defined as “No Detection”) or
trace wastewater signal is being detected, you are not required to receive a COVID-19 test;
o If there are active COVID-19 cases in your community and an anticipated wastewater signal
detection, you are required to receive a Health Canada authorized COVID-19 test once a week;
and
o If there is community spread of COVID-19 or an unexpected wastewater signal in your
community, you are required to take a Health Canada authorized COVID-19 test twice a week
(at least 72 hours apart).
• immediately self-isolate away from other persons, contact a health care provider and comply with any
further directions provided by the Chief Public Health Officer if you test POSITIVE for COVID-19;
• self-monitor and immediately self-isolate away from other persons, contact a health care provider and
comply with any further directions provided by the Chief Public Health Officer if you exhibit any
symptoms of COVID-19, including fever, new or worsening cough, shortness of breath or difficulty
breathing, generally feeling unwell, chills, muscle aches, fatigue or weakness, sore throat, congestion or
runny nose, headache, diarrhoea, nausea or vomiting, abdominal pain, loss of appetite, loss of sense of
taste, loss of sense of smell, skin changes or rashes;
P.O. Box 1320, Yellowknife NT X1A 2L9 www.gov.nt.ca C. P. 1320, Yellowknife NT X1A 2L9
AR01923 58
Government of Gouvern ement des

Northwest Territories Territoires du Nord-Quest
• immediately self-isolate from other persons and contact a local health care provider and comply with
any further directions provided by the Chief Public Health Officer if anyone in your household displays
any Symptoms of COVID-19; and
• immediately self-isolate, contact a health care provider and comply with any further directions
provided by the Chief Public Health Officer if you have been made aware that you (a) are a contact of a
known COVID-19 positive case; or (b) have been part of a COVID-19 outbreak.
For the purposes of this exemption:
• a “week” is determined to be a 7 day period beginning on Monday and terminating on Sunday;

• a list of Health Canada authorized COVID-19 tests can be found here. It is your responsibility for
accessing the appropriate testing services through private industry to meet the above requirement;
• “community transmission” is considered to be active COVID-19 cases in your community that are not
linked to out-of-territory travel. Please visit here for announcements from the Office of the Chief Public
Health Officer on the COVID-19 situation in the NWT; and
• Current NWT wastewater signals can be viewed here. Please select the “Wastewater” tab at the top of
the webpage.
If at any time you are unsure what condition is applicable, please reach out to the Office of the Chief Public
Health Officer for guidance by emailing CPHO@gov.nt.ca.
Please be advised that you are still required to follow all other public health orders in place, which include but
are not limited to, requirements to:
• Isolate or self-isolate in certain circumstances;

• Wear a face mask mask while in public indoor spaces; and
Please go to https://www.gov.nt.ca/covid-19/en/current-public-health-orders for up-to-date information on all

current public health orders in place in the Northwest Territories. We appreciate you continuing to follow the
public health orders and guidance, and protecting yourself, our families and our communities.
It is an offence pursuant to s.49 of the Public Health Act for a person to fail to comply with the Public Health Act,
its regulations or an order or direction made by the Chief Public Health Officer.
If you require any additional information, please contact Protect NWT toll-free at 1-833-378-8297 or by email
at protectnwt@gov.nt.ca from 8:00 am - 6:00 pm MT.
Sincerely,
Kami Kandola, MD, MPH, CCFP, FCFP, ACBOM,

DTM&H, ABPM
Chief Public Health Officer
AR01924 59
This is Exhibit “J” referred to in the Affidavit

r
f
________________________________
Province on Ontario
Re: Westjet - October 30, 2021 Covid-19 Vaccination Requirements mailbox:///C:/Personal/Personal/Personal%20Email/pop.cogeco.c...
AR01925 60
From: Ken Baigent <
Date: 2021-12-04, 9:08 a.m.
To: Jared Mikoch-Gerke Andrew Gibbons >, Religious Exemp on
<religious.exemp on@westjet.com>
Just a quick update Jared:
I received my Religious Beliefs Exemp on Approval last night from the Chief Public Health Officer of the NWT (copy a ached). I provided
the CPHO with all of the same informa on that was contained in my applica on to Westjet.
A posi ve step forward !!
Have a great weekend,
Ken Baigent
On 2021-12-02 12:42 p.m., Jared Mikoch-Gerke wrote:

Hi Ken,
Thank you very much, and appreciate you taking the me to complete the forms that are required through the Transport Canada guidelines.
The team responsible for reviewing these has began to process as they come in, and will respond directly to you when the assessment is complete.
Best,
Jared
Jared Mikoch-Gerke
Senior Manager, Government Rela ons & Regulatory Affairs
WestJet Airlines | P. 403.444.2294 | M: 403.618.7637
22 Aerial Place NE, Calgary, AB, T2E 3J1
From: Ken Baigent >

Sent: Thursday, December 2, 2021 10:28 AM
To: Jared Mikoch-Gerke ; Andrew Gibbons ; Religious Exemp on
<religious.exemp on@westjet.com>
Thank You Jared & Andrew:
This email represents my formal applica
I appreciate the tough & changing posi on we are all in & I thank you for your prompt and courteous responses.
As I started this conversa on 6 weeks ago with Andrew, I have a regular flight schedule for work/family that takes me many mes per year between Toronto
or Hamilton & Yellowknife. My next 3 flights were to be:
I had submi ed a Religious Exemp on request to Westjet last Friday (with a Commission of Oaths) from Yellowknife. Knowing that it would be highly
unlikely that we would get this sorted out in me for me to board a Dec. 3 flight, I drove 5000 kms across Canada in 4 days (Nov 27 - 30 inclusive) - a
horrible & dangerous drive that I hope to never do again.
Based on the new form you provided, I completed it this morning (with the same informa on that was in the le er I sent last Friday) and arranged a virtual
mee ng with my lawyer (the same Commissioner of Oaths who signed the le er I submi ed on the Nov 26). So ........... everything is consistent !! So this
email represents
- - - - my
- -official
- - -submission
- - - - - -to-Westjet
- - - -for- my
- -Religious
- - - -Exemp
- - on Request.
With the 21 day turnaround, I'm glad I drove here & didn't wait to see if we could figure out my Dec. 3 flight. My applica on is therefore focused towards
my next flight to Yellowknife on Feb. 1, 2022. As this exemp on is deemed "temporary" and renewable every 3 months, I am praying that I won't get caught
in a "renewal delay" that causes me to miss my April 1, 2022 flight to Toronto. We'll just take this one step at a me & work together.
NOTE: the fillable form on your website does not allow room in the "ques onnaire response" boxes to enter the informa on required, so my lawyer
indicated that I should include them in a separate document to a ach. He reviewed them both & then met with me this morning to take my Oath.
Thank You All,
Ken Baigent
1 of 8 2022-01-16, 2:41 p.m.

AR01926 61
Government of Gouvernement des

Northwest T rritories T rritoires du Nord-Ou st
Issue Number: E-3328

Date Issued: December 3, 2021
Expiry Date: March 31, 2022
Ken Baigent:
Exemption from Proof of Vacciantion Requirement
I acknowledge receipt of your request for an exemption from COVID-19 proof of vaccination requirements
within the Northwest Territories pursuant to Public Health Order – NORTHWEST TERRITORIES COVID-19
GATHERINGS ORDER (effective October 22, 2021) (hereinafter the “October 22, 2021 order”). I, as Chief Public
Health Officer, may take certain actions including issuing directions or orders for the purpose of protecting the
public health under the authority of the Public Health Act, S.N.W.T. 2007, c.17. As a result of the COVID-19
pandemic, gatherings within the NWT are currently restricited, in accordance with the October 22, 2021 order.
I have considered your request for an exemption from from the application of Section 2(d) of the October 22,
2021 order, including your specific circumstances and the documentation included as part of your request.
You are hereby exempted from the requirement at Section 2(d)of the October 22, 2021 order which requires
persons to be fully vaccinated against COVID-19 in order to enter an indoor or outdoor location in which a
person, business, organization or facilty has in place a proof of vaccination program at their location. Please
keep and show this letter to any person, business, organization or facility that has in place a proof of vaccination
program in order to seek entry at their location.
In accordance with the October 22, 2021 Order, this exemption is subject to the following conditions:
• for each week that you will be attending gatherings/establishments that would otherwise have
required proof of vaccination, you must follow whichever of the following is applicable said week:
o If there are no active cases in your community and a negative (defined as “No Detection”) or
trace wastewater signal is being detected, you are not required to receive a COVID-19 test;
o If there are active COVID-19 cases in your community and an anticipated wastewater signal
detection, you are required to receive a Health Canada authorized COVID-19 test once a week;
and
o If there is community spread of COVID-19 or an unexpected wastewater signal in your
community, you are required to take a Health Canada authorized COVID-19 test twice a week
(at least 72 hours apart).
• immediately self-isolate away from other persons, contact a health care provider and comply with any
further directions provided by the Chief Public Health Officer if you test POSITIVE for COVID-19;
• self-monitor and immediately self-isolate away from other persons, contact a health care provider and
comply with any further directions provided by the Chief Public Health Officer if you exhibit any
symptoms of COVID-19, including fever, new or worsening cough, shortness of breath or difficulty
breathing, generally feeling unwell, chills, muscle aches, fatigue or weakness, sore throat, congestion or
runny nose, headache, diarrhoea, nausea or vomiting, abdominal pain, loss of appetite, loss of sense of
taste, loss of sense of smell, skin changes or rashes;
AR01927 62
Government of Gouvern ement des

Northwest Territories Territoires du Nord-Quest
• immediately self-isolate from other persons and contact a local health care provider and comply with
any further directions provided by the Chief Public Health Officer if anyone in your household displays
any Symptoms of COVID-19; and
• immediately self-isolate, contact a health care provider and comply with any further directions
provided by the Chief Public Health Officer if you have been made aware that you (a) are a contact of a
known COVID-19 positive case; or (b) have been part of a COVID-19 outbreak.
For the purposes of this exemption:
• a “week” is determined to be a 7 day period beginning on Monday and terminating on Sunday;

• a list of Health Canada authorized COVID-19 tests can be found here. It is your responsibility for
accessing the appropriate testing services through private industry to meet the above requirement;
• “community transmission” is considered to be active COVID-19 cases in your community that are not
linked to out-of-territory travel. Please visit here for announcements from the Office of the Chief Public
Health Officer on the COVID-19 situation in the NWT; and
• Current NWT wastewater signals can be viewed here. Please select the “Wastewater” tab at the top of
the webpage.
If at any time you are unsure what condition is applicable, please reach out to the Office of the Chief Public
Health Officer for guidance by emailing CPHO@gov.nt.ca.
Please be advised that you are still required to follow all other public health orders in place, which include but
are not limited to, requirements to:
• Isolate or self-isolate in certain circumstances;

• Wear a face mask mask while in public indoor spaces; and
Please go to https://www.gov.nt.ca/covid-19/en/current-public-health-orders for up-to-date information on all

current public health orders in place in the Northwest Territories. We appreciate you continuing to follow the
public health orders and guidance, and protecting yourself, our families and our communities.
It is an offence pursuant to s.49 of the Public Health Act for a person to fail to comply with the Public Health Act,
its regulations or an order or direction made by the Chief Public Health Officer.
If you require any additional information, please contact Protect NWT toll-free at 1-833-378-8297 or by email
at protectnwt@gov.nt.ca from 8:00 am - 6:00 pm MT.
Sincerely,
Kami Kandola, MD, MPH, CCFP, FCFP, ACBOM,

DTM&H, ABPM
AR01928 63
This is Exhibit “K” referred to in the Affidavit

r
r
________________________________
Province on Ontario
AR01929 64
THE
GWBE
AND
MAIL•
Approving religious exemptions for vaccine rules

should fall to government, airlines say
ERIC ATKINS > TRANSPORTATION REPORTER
PUBLISHED DECEMBER 12, 2021
Air Canada plane takes off from Montreal Trudeau Airport in Montreal on Dec. 5.
GRAHAM HUGHES/THE CANADIAN PRESS
Canada's airlines are urging the federal government to relieve them of the responsibility for approving passenger applications for
religious exemptions to COVID-19 vaccination requirements.
In a letter to members of Parliament, the National Airlines Council of Canada says the government - not private companies -
should be in charge of approving or rejecting faith-based travel requests from people who are not vaccinated against the deadly
virus.
"Individual companies in the private sector should not be responsible for determining whether a person's religious beliefs are
'sufficient' to merit an exemption from a federally mandated obligation related to public health, nor do companies have the means
to evaluate a person's religious convictions," says the letter, a copy of which was obtained by The Globe and Mail.
The airlines are reacting to a new federal rule, effective as of Nov. 30, that requires all air and rail passengers older than 11 who are
travelling within Canada or leaving the country to show proof they are fully vaccinated. The rule is intended to slow the spread of
AR01930 65
COVID-19, as the Omicron variant threatens to strain hospital capacity and spurs fears of new lockdowns.
Travellers whose "sincere religious belief' prevents them from being vaccinated are exempt from the rule. Exemptions also apply
to other groups, including people who need to fly in order to access essential medical services, people who are travelling to and
from remote Canadian communities, and people who are catching connecting flights in Canada on their way to other countries.
Passengers seeking religious exemptions must apply to their airlines three weeks before travelling, and they have to present
negative COVID-19 test results before boarding. "Your request to your airline or railway must clearly demonstrate your sincere
religious belief, how it prevents you from being vaccinated, and be signed by a Commissioner of Oaths," the government says on
its website.
The airlines say they are in no position to judge whose beliefs prevent them from getting their shots.
"Only the state itself can fulfill that responsibility, a responsibility that by definition gives rise to Charter and privacy issues," the
National Airlines Council says in its letter. "If nothing else, it demands a consistency of process and application across the country
that can only be provided by a single federal entity and decision-making body."
The council lobbies on behalf of Air Canada, WestJet Airlines and other airlines.
Peter Fitzpatrick, a spokesperson for Air Canada, said the airline has had about 100 requests for religious exemptions since Dec. 1.
Many of those were for more than one person, he said. "And we expect more."
Air Transat has received about 20 requests, according to spokesperson Christophe Hennebelle. "It's too early to comment on the
acceptation or rejection rate," he said.
It is not clear which religions and their followers are opposed to vaccinations, and on what grounds. The federal government's
website links to messages of support for vaccines from several religious organizations, including those representing Islam, Roman
Catholics, Mennonites and Christian Science.
The heads of the Mennonite Church Canada told adherents in October the group supports getting vaccinated. "We wish to clarify
that there is nothing in the Bible, in our historic confessions of faith, in our theology or in our ecclesiology that justifies granting a
religious exemption from vaccinations against COVID-19," the leaders said in a statement. "We have heard concerns from some
members of our constituency regarding the vaccines. However, we do not believe these concerns justify an exemption from
COVID-19 vaccinations on religious grounds from within a Mennonite faith tradition."
Sau Sau Liu, a spokesperson for Transport Canada, did not address a question about why airlines are responsible for administering
the exemptions. "Transport Canada continues to engage with industry on the ... requirements and provide them with the
necessary guidance," she said by e-mail.
The National Airlines Council and WestJet did not respond to requests for comment.
Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or
evening. Sign up today.
AR01931 66
This is Exhibit “L” referred to in the Affidavit

r
f
________________________________
Province on Ontario
AR01932 67
TRANSCRIPTION
WestJet says feds' non-essential travel advisory is 'not based on science and data'
Date: December 16, 2021
Speaker: Andy Gibbons: WestJet's vice-president of government relations
News Source: CBC News

Website: https://www.youtube.com/watch?v=c3ZsZ_URl4I
Paul, Anchorman: “Federal Government says now is not the time to travel internationally, it is
advising Canadians to re-think their holiday vacation plans and WestJet is not happy about that.
The airline said in a statement the advisory is quote “not based on science and data” Andy
Gibbons is the vice-president of government relations for WestJet and he’s in Ottawa. Thanks
for Joining us today to talk about this.”
Andy Gibbons: “Thank you Paul, nice to see you.”
Paul, Anchorman: “Likewise, um so why is WestJet so against this updated advisory? Given
what we currently know about the spread about this variant.”
Andy Gibbons: “I think it’s primarily based on past experience with advisories Paul. Canada had
a ban, had an advisory on non-essential travel up until early October and during those months
Canadians travelled across the continent and the globe, so it is, our main issue is frustration
that we are sliding back into blanket policies, whereas other Countries have more tailored
travel guidance that is dependant on the country you are visiting, the type of travel you’re
thinking about. So, the promise of vaccinations and the promise of testing was so that we
wouldn’t have blanket travel advisors anymore that we fundamentally don’t think serve the
travelling public.”
Paul, Anchorman: “I wonder if many Canadians thinking back to earlier days in the pandemic
would recall that initially, it spread through travel and that the first cases detected in this
country of Omicron were in people who recently travelled. Thus, some might think it might be a
good idea to limit non-essential travel to curb the spread. So, you disagree with that?”
Andy Gibbons: “Well I think that the fact that Covid can come through travel is why we became
a fully vaccinated airline and why in partnering with the Government we’ve delivered on that
mandate, and that’s why we’ve been a voice for testing, so it’s in recognition of that Paul, that
we’ve had such a strong safety and health record with respect to Covid. But also remember,
you know if we are going down memory lane – last winter we cancelled all flights to sun
destinations and we did so in partnership with the Federal Government and while travel was
completely cancelled, we had a third wave. So, the main for us in the point of our statement,
it is a tough statement but the main process that we are asking the Federal Government to
1
AR01933 68
produce and be transparent about the data and science that’s behind these measures. What
are the Covid rates by country when it comes to travel? How many tests are needed? All of
these questions um you know, really have come to light given the fact that they have re-
introduced the advisory.”
Paul, Anchorman: “Does WestJet have its own data um underlining the safety in WestJet’s view
of travel, especially a regards Omicron?”
Andy Gibbons: “Well the data is recorded by the Public Health Agency of Canada. So, for
example, Paul all the Canadian press reported yesterday that the positivity rate from inbound
travellers for the last two weeks in November was 0.17 and since July it’s been 0.20. So that is
an incredible record and we’ve said in our statement that air travel is the most tested consumer
activity in Canada. You know I’m not picking on the Toronto Raptors - I love the Toronto
Raptors, but they had a home match last night – No one has a mandatory PCR when they leave
the Scotia Bank arena or Canadian Tire Centre, but every single guest on our airline before they
step foot in a Canadian airport coming home has a mandatory PCR. So you know that is
something that we’ve achieved with the Government and I think that’s something that needs to
be recognized in Federal Policy.”
Paul, Anchorman: “Um you know, obviously you are making the case on behalf of WestJet, but
what is your concern about the threat to the Canadian economy broadly with this advisory?”
Andy Gibbons: “We’ll have to see; I mean it hasn’t even been maybe 24 hours since the
announcement and we’ll have to assess those impacts. There are so many communities we in
Canada rely on our investments. Many communities in Canada and their local airports’ reliance
on flying to keep their local economy going in the winter, and if we see major cancellations, it’s
possible that we may have to consolidate some of those investments. It’s too early to tell right
now, but obviously, that’s the last thing we ever want to do. What we want to do is fly
Canadians safely, um and to so with proper measures in place given the fact that we are
partners in health.”
Paul, Anchorman: “Um, I guess lastly I will just ask, what would you suggest? Are you talking
about wide-open international travel? What like as everyone is trying to figure out Omicron,
um, you know, what should the government be doing in your view?”
Andy Gibbons: “No one is asking for wide-open travel. You know airlines are very unique in the
Covid equation because we are a safety business. Uh, and if we don’t have a strong safety and
health record we aren’t in business. So, we are very different in that regard. What we are
advocating for is travel guidance based on science and data and for the Government to
present that. That is the fundamental premise and what has been lacking for the past 20
months. We continue to call for that, but at the same time Paul, we are working with the
government to implement arrivals testing. We are working with them right now to put that in
place across Canada and we are proud to partner with them to do that. But at the same time,
given that we are 20 months in we do require a greater focus on how these policies are
2
AR01934 69
developed and what is going to be achieved by them, and um you know we think these are
legitimate questions to ask and I think the response to our statement yesterday you know has
been overwhelmingly positive and people have appreciated our frankness, uh and hopefully
some of those answers will come from our statement.”
Paul, Anchorman: “And just very quickly, did you have any heads up on this or did it hit you the
same way it hit the rest of our country?”
Andy Gibbons: “We were notified that they intended to proceed with an alteration to the travel
advisory. That is the information they gave us before the announcement.”
Paul, Anchorman: “Alright, thank you, Andy Gibbons, WestJet. I appreciate your time.
Andy Gibbons: “Paul, thank you.”
https://en.videoencontexto.com/2021/11/westjet-says-feds-non-essential-travel-advisory-is-
not-based-on-science-and-data_c3zsz_url4i/
3
AR01935 70
This is Exhibit “M” referred to in the Affidavit

r
f
________________________________
Province on Ontario
Not approved for a COVID-19 Vaccine Exemption on Religious Grounds mailbox:///C:/Personal/Personal/Personal%20Email/pop.cogeco.c...
AR01936 71
Subject: Not approved for a COVID-19 Vaccine Exemp on on Religious Grounds
From: Religious Exemp on <religious.exemp on@westjet.com>
Date: 2021-12-23, 3:53 p.m.
To:
Thank you for considering WestJet for your travel plans.
To ensure you receive emails from WestJet, please add us to your contacts.
Hello Ken Baigent,
Not approved for a COVID-19 Vaccine Exemp on on Religious Grounds
We have reviewed your request for a temporary exemp on to the COVID-19 vaccina on requirement on religious grounds. The
informa on you have provided does not meet Transport Canada’s requirements for this exemp on. Your request for an exemp on to the
COVID-19 vaccina on requirement for air travel with WestJet is not approved.
This determina on is based on our review of your request form and any addi onal materials you provided. The result cannot be appealed
and WestJet will not respond to further inquiries with respect to this applica on.
As per the Government of Canada regula ons, as of October 30th 2021, all passengers the age of 12 years plus 4 months, or older, must be
fully vaccinated in order to board domes c or interna onal flights depar ng from most airports in Canada. Therefore, you are currently
restricted from travel with WestJet, WestJet Encore and Swoop.
If you have current travel booked with WestJet, you may cancel your booking at no charge and receive a full refund to original form of
payment, if a flexible fare was purchased that includes this. For all other fares, you will receive a full refund to travel bank in the event of
cancella on.
Kind regards,
Regulatory Guest Rela ons Team

Privileged and confiden al
loYeWbririt
WESTJET 'l'Wf•r;.;o,ng
This electronic message and any a ached documents are intended only for the named addressee(s). This communica on from WestJet may contain informa on that is privileged, confiden al or otherwise protected from disclosure and it must not
be disclosed, copied, forwarded or distributed without authoriza on. If you have received this message in error, please no fy the sender immediately and delete the original message. Thank you.
1 of 1 2022-01-16, 2:37 p.m.

AR01937 72
This is Exhibit “N” referred to in the Affidavit

r
f
________________________________
Province on Ontario
Travel Ready hub | Air Canada https://www.aircanada.com/ca/en/aco/home/book/travel-news-and-updat...
AR01938 73
TRAVEL READY
How to prepare for travel

Review the latest COVID-19 travel requirements
and find answers to your freQuently asked
questions.
Health and safety

Learn about how we are helping keep you safe with Air Canada CleanCare+.
Face coverings
For the safety of our customers and crew, it's crucial to comply with face covering
guidelines.
Exemption to vaccine requirements due to medical reasons

Find out if you are eligible for an exemption to vaccine requirements due to medical
reasons.
Exemption to vaccine requirements based on other reasons

Find out if you are eligible for an exemption to vaccine requirements based on other
reasons.
There are a number of grounds for exemption that the Government of Canada has set out. There is no
1 of 3 2021-12-29, 9:15 a.m.
assurance that such an exemption might be considered or available; if it were, it would be your
AR01939
responsibility to ensure you satisfy and abide by all requirements relating to your travel, including in 74
respect of any available exemption .
These potential grounds for exemption are as follows:
■ A person who has a medical inability to be vaccinated or is traveling to receive essential medical services
and treatment. To find out how to apply, open up the tab above titled "Exemption to vaccine requirements
due to medical reasons".
■ A person who must travel due to an emergency situation or an urgent medical reason and there is an
immediate threat to their safety.
■ A person who qualifies for a National Interest Exemption from Transport Canada. These exemptions are
administered by Transport Canada. For additional information, visit https://vaccine-
exemption.tc.canada.ca/ 121 .
■ A person may apply to the Minister ofTransport for a public interest exemption under section 5.9(2) of the
Aeronautics Act. For more information, you may em ai l Transport Canada at: questions@tc.gc.ca . Th is is a
general discretionary power that the Minister may ch oose to use where he be li eves the publ ic interest
requires it.
In addition, the government of Canada has indicated that certain persons may be exe mpt from the
vaccine requirement to travel in the following cases:
■ A person who is only transiting through Canada .
■ Foreign nationals who do not reside in Canada and are departing Canada before February 28, 2022 .
■ Canadians returning to Canada and not traveling with in Canada by air or rai l upon arriva l.
■ Passengers traveling from a remote community, und er certai n co nditions.
■ Passengers who are entitled to be accommodated on th e ba sis of the ir si ncerely held rel igious be liefs. Th e
government has asked air carriers to administer these exemption reque sts, stating th is type of exemption
was anticipated to be granted "very rarely''. Indeed, we have carefully considered th is reason for an
exemption, the interests of all parties involved, and other factors relating to the accommodat io n of si ncere
religious beliefs, and do not anticipate being able to accommodate any exemption request on thi s basis in
the present circumstances.
Finally, please note that with any exemption, a traveller will remain subject to other conditions and other
measures such as being required to present a valid proof of a valid COVI D-19 molecular test result at the
time of boarding and to wear a suitable mask, covering their nose and mouth, at all times when on board
our aircraft or in an airport with no exception, except for brief periods of time when eating, drinking, and
taking oral medication.
Health and safety measures

With Air Canada CleanCare+, we've enhanced our health and safety measures at every stage
of your journey.
On-board transmission facts

Find out why the transmission of communicable diseases inside an aircraft are very rare.
2 of 3 2021-12-29, 9:15 a.m.

AR01940 75
Contact tracing protocol

What does Air Canada do if a passenger is identified as having travelled with COVID-19 post
flight?
Back to top
To assist you, our Travel Ready hub is a guide to help you understand some of the key requirements in order for you to travel on your
intended itinerary. However, especially as the requirements continue to change quickly, this information does not replace the specific
information provided by government and other relevant authorities. Air Canada has partnered with Sherpa to bring this information
to you for reference only, and while Sherpa makes best efforts to keep the information updated, due to fast-changing government
mandates and restrictions which may be affected by numerous factors (for example, point of origin, age, final destination, purpose or
duration of travel, state of vaccination), as well as due to interpretation by the applicable local government officials, Air Canada is not
responsible for the completeness and accuracy of this information; neither Air Canada, nor any of its employees or agents may under
any circumstances be held responsible or liable in any way for any claim, loss, damage, cost, expense or liability whatsoever that may
result from your access to, or reliance on, information provided on this page. It is your responsibility to ensure that you meet all entry
requirements and have all the valid travel documents necessary to enter in, exit from or transit through, each country/region on your
itinerary regardless of if the flight is operated by Air Canada or another carrier. We strongly recommend that you contact the
government of each country on your itinerary for detailed, up-to-date information on health, passport, visa, and other entry
requirements applicable to your case, as they may vary based on country of nationality and other factors. The final determination of
entry in or transit through is the decision of the government and officials of the country to which you are travelling. For this we
recommend reviewing the IATA Travel Centre IZl prior to travelling.
3 of 3 2021-12-29, 9:15 a.m.

AR01941
TAB 12
AR01942 F
I FEDERAL1COURT
D
É
L COUR FÉDÉRALE P
E O
D S
March 11, 2022 É
11 mars 2022
COURT FILE NO: T-168-22-ID-1

Kevin Lemieux
BETWEEN:
CAL
I 18

AND AEDAN MACDONALD
Applicants
-and-
THE MINISTER OF TRANSPORT and

THE ATTORNEY GENERAL OF CANADA
Respondents
APPLICATION UNDER ss. 18 and 18.1 of the Federal Courts Act, RSC 1985, c F-7 and Rules
300(a) and 317 of the Federal Courts Rules, SOR/98-106
AFFIDAVIT OF NATALIE GRCIC

(Sworn March 10th, 2022)
I, Natalie Grcic, of the City of Gatineau, in the Province of Quebec, SWEAR AND SAY THAT:
1. I am one of the Applicants herein, and as such have a personal knowledge of the matters
2. I am a 38-year-old married mother of one who immigrated to Canada with my husband in

August 2016 from South Africa. I am a permanent resident of Canada. Before coming to
Canada, I attended law school and was qualified as an attorney. I worked as an Executive
Assistant in Montreal from 2020 to 2021 before relocating from Montreal to Gatineau in
June 2021, where we currently reside. Presently, I am a stay-at-home mom and
homemaker. We lead a relatively quiet and secluded lifestyle.
1
AR01943 2
-
3. I have not been vaccinated for Covid-19, but I am also not an "anti-vaxxer." I willingly
received all my vaccinations and took my infant daughter for her Canadian recommended
vaccinations. I am deeply distraught and have been negatively impacted due to elected
officials and other government officials negatively labelling, shaming, and discriminating
against people who have chosen not to or are unable to receive the Covid-19 vaccine. I
vehemently oppose such labels and mischaracterization, particularly from influential
people who portray me as a bad mother, stupid and anti-science. Specifically, on August
31, 2021, the Prime Minister of Canada stated publicly:
So the folks out there tonight shouting, the anti-vaxxers, they’re wrong.
They’re wrong about how we get through this pandemic, and more than
just being wrong – cause everyone’s entitled to their opinions – they are
putting at risk their own kids, and they’re putting at risk our kids as well.
That’s why we’ve been unequivocal. If you want to get on a plane or a
train in the coming months, you're gonna have to be fully vaccinated so
families with their kids don't have to worry that someone is going to put
them in danger, in the seat next to them or across the aisle.
Attached hereto and marked as Exhibit "A" to this Affidavit is a transcript of Prime
Minister Trudeau's public speech on August 31, 2021.
4. I have observed the Prime Minister also publicly call unvaccinated Canadians "misogynist
and racist.” I am offended by the Prime Minister's labelling of me and other Canadians in
this disparaging way especially because I have a deep interest in well-tested and
established vaccination, medical advancement, and science. Attached hereto and marked
as Exhibit “B” to this my Affidavit is a translated transcript of the Prime Minister making
these comments.
5. On October 6, 2021, I learned that the Federal Government was preparing to make a law
that restricted unvaccinated Canadians from travelling by air and rail within and outside
of Canada.
2

AR01944 3
-
6. I believe that on October 29, 2021, the Federal Government announced that they had
enacted Interim Order Respecting Certain Requirements for Civil Aviation Due to COVID-
19, No. 43 (the "Travel Ban"). Attached hereto and marked as Exhibit "B" to this my
Affidavit is copy of that Order. It is my understanding that the Travel Ban is amended
often and that as of today’s date, the Travel Ban currently in force is Interim Order
Respecting Certain Requirements for Civil Aviation Due to COVID-19, No. 56 which was
enacted on February 28, 2022. Attached hereto and marked as Exhibit "C" to this my
Affidavit is a copy of that Order.
7. I have had a hard time understanding the constantly changing Covid laws and
requirements. Attached hereto and marked as Exhibit "D" to this my Affidavit is a table
outlining all of the amendments to the Travel Ban and the dates the changes were made.
8. As a result of the constant changes to the Travel Ban and uncertainty about the Covid laws
in Canada, I have experienced a lot of undue anxiety and stress, especially because these
laws restrict my freedom of movement and choice about what I consent to being put into
my body as well as the personal medical information that I have to share.
My Concerns Regarding the Covid-19 Vaccine
9. I have done extensive personal research into the various vaccines and have genuine
concerns about taking the Covid-19 vaccines. I have discussed my concerns with medical
professionals that are entrusted with helping me make decisions regarding my health. The
vaccines currently being offered to Canadians/Permanent Residents have a limited long-
term safety and efficacy profile. It is my view that until long-term safety trials are complete,
a vaccine is still experimental. I have declined to be a part of the experiment.
10. From my life experience, I have observed the normal amount of time for vaccine
development. I know that they can take years to develop. I believe the Covid 19 vaccine
development and rollout was rushed. One of the published articles that I have read
regarding safety assessments of vaccines was from the College of Physicians and Surgeons
in Philadelphia where it states: "Vaccine development is a long, complex process, often
3

AR01945 4
-
lasting 10-15 years and involving a combination of public and private involvement."
Attached hereto and marked as Exhibit "E" to this my Affidavit is an article from the
College of Physicians and Surgeons in Philadelphia.
11. I would like to have another child, and I have legitimate concerns and fears over the risks
a vaccine that has not completed long-term testing and the impact it may have on my
reproductive health.
12. I am a healthy, relatively young woman, who is careful about what I put into my body,
including what I eat. My health, and the health of my family is of paramount importance,
so I undertake extensive personal research before committing to medicines, supplements,
treatments, vaccinations, and other personal health decisions. Furthermore, I know that
sometimes pharmaceutical companies and drug approval agencies make mistakes and I
have not forgotten the horrors of the drug Thalidomide. In high school, I completed a study
and essay on this drug, the horrific impacts to women and babies and the regulatory system
that allowed that to happen. While the true impacts of Thalidomide have been known now
for 60 years there is no way to correct the deformed and dead babies that the drug caused
many years ago.
13. Given my legal background, I am analytical and assess the supporting data. This has caused
me to critically assess information that I am receiving and not simply accept without
question what the pharmaceutical companies or government officials are saying.
14. I am also concerned that governments have shielded the pharmaceutical companies from
liability or responsibility for me or my family if we suffer an adverse effect from one of
the Covid-19 vaccines. I believe that if the pharmaceutical companies have no liability it
can reduce the incentive for them to produce a safe product.
15. I read the report in The British Medical Journal where it is documented that an internal
Pfizer researcher made a public interest disclosure on data integrity issues in Pfizer's Covid-
19 vaccine trial. Attached hereto and marked as Exhibit "F" to this my Affidavit is a copy
4

AR01946 5
-
of that report. This increases the risk that the safety of the Pfizer vaccine has not been
properly assessed and informs my decision to decline this vaccine.
16. My understanding is that none of the Covid-19 vaccines offered in Canada have been given
full approval and are still under "emergency use authorization.". Given my efforts to inform
myself, I do not consent to this vaccine being put into my body. Therefore, forcing or
coercing me or my family members into taking the Covid-19 vaccine is an assault and
amounts to a violation of the Nuremberg Code.
17. I personally have observed how the vaccine is not effective at stopping people from
catching and spreading Covid-19. My fully vaccinated sister-in-law, my mother-in-law and
her husband contracted Covid-19. I also know many other vaccinated and unvaccinated
people who caught Covid-19 and recovered from it.
18. Given the known risks with the Covid-19 vaccines and continued transmissibility of the
virus despite vaccination, as a healthy young woman of childbearing age, I am more
comfortable exercising my choice over bodily autonomy than exposing myself to the risk
of taking this vaccine.
19. As an immigrant to Canada, aside from a cousin on the other side of Canada, in Victoria,
British Columbia, my entire extended family is overseas. The Travel Ban bars me from
leaving Canada to travel to my home country for any reason, such as bereavement, or to
assist my family should they need my help. This is extremely distressing to me as I am a
family-oriented person, and my parents are now very elderly and require assistance and
may pass soon.
20. I also fear that this will negatively impact my three-year-old child and her relationship
with my family as she will not be able to form relationships with my family because I
5

AR01947 6
-
cannot take her to see them. I do not have the financial means to pay to fly by private
chartered aircraft to visit family.
21. As a result of the Federal Government announcement on October 6, 2021 about its plan to
implement travel bans, I quickly made plans for me and my daughter to leave Canada prior
to November 30, 2021 (the effective date of the ban, as I understood it). I had been
previously planning to return to South Africa for the Christmas Holidays due to concerns
about my elderly father's health and in hopes of having him connect with his grandchild
while we were able to.
22. My husband was unable to travel with us because of work commitments but he hoped that
reason would prevail and that the ban would somehow be stopped before Christmas so that
he could join us. Since the Travel Ban remained in place, my husband was forced to spend
Christmas in a new home, in a new city, alone and isolated from his family as he is
unvaccinated and was not able to board an airplane. He was also prevented from travelling
to South Africa to see his mother and family.
23. I had an especially hard time when I arrived in South Africa without my husband and I
just suffered from a miscarriage, potentially due to the stress while travelling without him,
together with the stress caused by this Travel Ban and other COVID-19 measures.
24. I also understand that while Canada is one of the largest by land mass, it is the only Country
that prevented domestic air and rail travel to unvaccinated individuals. Attached hereto
and marked as Exhibit "G" to this my Affidavit is my review of travel restrictions due to
Covid-19 around the world.
25. Based on my own understanding and conscience and after an extensive review of the
scientific research and medical data, I am unable to take the Covid-19 vaccine at this time.
I believe that taking the Covid-19 vaccine at this time would be a real and significant risk
to my current, and especially future, health and wellbeing.

6

AR01948 7
-
26. I believe that the Travel Ban is infringing on my Charter rights, human rights and the
Nuremburg code and is an attempt to coerce me to take a medical treatment that I consider
experimental, at this stage, just to be able to leave the country and visit my family overseas.
I feel like I am being discriminated against, and that there is no basis for it, based on the
evidence that both vaccinated and unvaccinated travellers pose a risk of transmitting
Covid-19.
27. We are not criminals or dirty Canadians but that is how we have been painted by our
elected officials and rhetoric about being labeled "anti-vaxxers". Living through this time
was incredibly hard emotionally, physically, and spiritually. It is my belief that the
government and media messaging about the unvaccinated caused people to turn on each
other. My friends and family turned on each other and on us and are divided over the issue
of one's Covid-19 vaccination status. We have lost numerous close friendships and my
father-in-law (who lives in Montreal) has refused to see us or his granddaughter. This is
not the Canada I dreamed about and came to.
28. I am simply a person who wishes to visit my home country and visit my family if and so
when the need arises. I am asking to be able to go home and see my family if and when I
need or want to do so. I do not want to be trapped in Canada and discriminated against for
exercising a personal medical choice.
7
AR01949 8
purpose.
SWORN REMOTELY by Natalie Grcic of )

the City of Gatineau in the Regional )
Municipality of Outaouais in the Province of )
Quebec before me at the City of Brampton in )
the Regional Municipality of Peel in the )
Province of Ontario on March 10th, 2022, in )
accordance with O.Reg 431/20, ) NATALIE GRCIC
Administering Oath or Declaration Remotely. )
Rosy Rajni B. Rumpal

Barrister, Solicitor & Notary Public
103 – 60 Queen St. E
Brampton, ON
L6V 1A9
8
AR01950 9

of atali cic sworn before me virtually
this 10 day of ar , 2022.
7
________________________________
\
arr r an
r n n
l r n
n ar
AR01951 10
1 to 4
1 2
· ·1· ·(AUDIO BEGINS)
· ·2· ·JUSTIN TRUDEAU:· · · · · So the folks out there tonight
· ·3· ·shouting, the anti-vaxxers, they're wrong.
· ·4· ·(UNREPORTABLE SOUNDS)
· · · · · · · · · · · ·AUDIO TRANSCRIPTION ·5· ·JUSTIN TRUDEAU:· · · · · They're wrong about how we get
· ·6· ·through this pandemic, and more than just being
· ·7· ·wrong -- 'cause everyone's entitled to their
· ·8· ·opinions -- they are putting at risk their own kids,
· ·9· ·and they're putting at risk our kids as well.· That's
· 10· ·why we've been unequivocal.· If you want to get on a
· 11· ·plane or a train in the coming months, you're gonna
· 12· ·have to be fully vaccinated so families with their kids
· 13· ·don't have to worry that someone is gonna put them in
· 14· ·danger in the seat next to them or across the aisle.
· · ·_______________________________________________________ 15· · · · And we know that the way to get through this as
· · · TRUDEAU CONDEMNS ANTI-VAX PROTESTERS, ACCUSES THEM OF 16· ·well is to make sure that people can go into
· · · · · · · · · · · ·ENDANGERING OTHERS 17· ·nonessential businesses and feel safe that they're not
· · · · · · · · · · · · ·AUGUST 31, 2021 18· ·gonna get -- caught -- catch COVID from someone next to
· · ·_______________________________________________________ 19· ·them.· And that means we're gonna work with provinces
· 20· ·and territories who want to move forward on vaccination
· 21· ·certifications, on vaccination passports, so that
· 22· ·everyone can be safe.· And what's more, the federal
· 23· ·government has announced we're gonna pay for the
· 24· ·development of those privileges that you get once you
· 25· ·get vaccinated because everyone needs to get
· 26· ·vaccinated, and those people are putting us all at
· 27· ·risk.
3 4
·1· ·(UNREPORTABLE SOUNDS) ·1· ·CERTIFICATE OF TRANSCRIPT:
·2· ·JUSTIN TRUDEAU:· · · · · Canadians made incredible ·2
·3· ·sacrifices over the past year and a half, and Erin ·3· · · · I, Jolina Hale, certify that the foregoing pages
·4· ·O'Toole is siding with them instead of with Canadians ·4· ·are a complete and accurate transcript of the audio
·5· ·who did their part and stepped up.· He's talking about ·5· ·recording, taken down by me in shorthand and
·6· ·personal choice.· What about my choice to keep my kids ·6· ·transcribed from my shorthand notes to the best of my
·7· ·safe? ·7· ·skill and ability.
·8· ·(UNREPORTABLE SOUNDS) ·8· · · · Dated at the City of Medicine Hat, Province of
·9· ·JUSTIN TRUDEAU:· · · · · What about our choices to make ·9· ·Alberta, this 8th day of March 2022.
10· ·sure we're getting through this pandemic as quickly as 10
11· ·we can?· That's the choice we've all made.· Canadians 11
12· ·have shown it in being there for each other. 12
13· · · · And I am not gonna back down, no matter how many 13· ·________________________________
14· ·of them show up to try and shout us down from what I 14· ·Jolina Hale
15· ·know to be true, what science tells us, what Canadians 15· ·Official Court Reporter
16· ·have told me, which is people are willing to do their 16
17· ·part to get through this pandemic, and that's what we 17
18· ·will do together. 18
19· ·(UNREPORTABLE SOUNDS) 19
20· ·JUSTIN TRUDEAU:· · · · · So shame on you, Erin O'Toole. 20
21· ·You need to condemn those people.· You need to correct 21
22· ·them.· You need to use your voice and actually add it 22
23· ·to those of us who understand that vaccinations are the 23
24· ·way through this pandemic and listen to the almost 24
25· ·80 percent of Canadians who know that too. 25
26· ·(AUDIO CONCLUDES) 26
27· ·_______________________________________________________ 27
Dicta Court Reporting Inc.

403-531-0590 YVer1f
AR01952 11
This is Exhibit “. ” referred to in the Affidavit

________________________________
arr r an l r n
r n n n ar
AR01953 12
l • •Is 111ml ft::....,, l'u - 11M __,,,

'll1MV · ---• ,,., •• ,,..,....,,.. -.4n11:,tu 1s;,
Tm I • • I -,1 --. · . ....... ._,,_.,_,_,,.._,.,1111ldlal
f/•IIQ' I JJnp llnf&t- ■ J,,J,,..
.-.lllL'
a MIii r<M • . . , f ii 1-, JI.
AR01954 13
*https://rumble.com/vrof7e-fascist-psychopath-justin-trudeau-calls-the-unvaccinated-racist-and-
misogyn.html*
Line# Timestamp Speaker Transcription

1 0:00-0:03 Justin Trudeau Oui, on va s’en sortir de cette pandémie par la vaccination.
2 0:03-0:09 Justin Trudeau On en connaît des gens qui sont en train
3 d’hésiter un petit peu, qu’on réussis de convaincre,
4 0:09-0:13 Justin Trudeau mais aussi des gens farouchement opposés à la vaccination…
5 0:13-0:14 Journaliste Qui sont extrémistes.
6 0:14-0:16 Justin Trudeau …qui ne croient pas dans la science,
7 0:16-0:24 Justin Trudeau qui sont souvent misogynes, souvent racistes…
8 c’est un petit groupe, mais qui prend de la place.
9 0:24-0:28 Justin Trudeau Et là il faut faire un choix,
10 en tant que leader, en tant que pays -
11 0:28-0:31 Justin Trudeau est-ce qu’on tolère ces gens-là ou est-ce qu’on dit :
12 0:31 -0:36 Justin Trudeau voyons… la plupart des gens, parce que
13 80% des Québécois ont fait ce qu’il fallait faire,
14 0:37-0:40 Justin Trudeau se sont fait vacciner, on veut revenir aux choses qu’on aime faire,
15 0:40-0:43 Justin Trudeau c’est ces gens-là qui vont nous bloquer maintenant…
403-648-3010 Toll Free: 1-888-556-5541 'I @languagesim #300, 404 6th Ave SW Calgary, AB, T2P 0R9 www.languagesim.com
AR01955 14

________________________________
arr r an l r n
r n n n ar
AR01956 15
Repealed - Interim Order Respecting
Certain Requirements for Civil Aviation
Due to COVID-19, No. 43
From: Transgort Canada
Whereas the annexed Interim Order Respecting Certain Requirements for Civil
Aviation Due to COVID-19, No. 43 is required to deal with a significant risk,
direct or indirect, to aviation safety or the safety of the public;
Whereas the provisions of the annexed Order may be contained in a

regulation made pursuant to sections 4.719. and 4.9.b., paragraphs 7.6(1 )(a)~
and (b)9 and section 7.7~oftheAeronauticsActf;
• g_S.C.2004,c. 15,s.5
• .b.s.c. 2014, c. 39, s. 144
• ~s.C.2015,c.20,s. 12
• !!s.C. 2004,c. 15,s. 18
• ~s.c.2001,c.29,s. 39
• fR.S., c. A-2
And whereas, pursuant to subsection 6.41 (1.2}9 of that Act, the Minister of
Transport has consulted with the persons and organizations that that
Minister considers appropriate in the circumstances before making the
annexed Order;
• 95.C. 2004, c. 15, s. 11 (1)
Therefore, the Minister of Transport, pursuant to subsection 6.41 (1 )9 of the

Aeronautics Actf, makes the annexed Interim Order Respecting Certain
Requirements for Civil Aviation Due to COVID-19, No. 43.
Ottawa, October 29, 2021
Le ministre des Transports,
Omar Alghabra
Minister of Transport
Interpretation
Definitions
• 1 (1) The following definitions apply in this Interim Order.
aerodrome property
AR01957 16
aerodrome property means, in respect of an aerodrome listed in Schedule
2, any air terminal buildings, restricted areas or facilities used for
activities related to aircraft operations that are located at the
aerodrome. (terrains de !'aerodrome)
aerodrome security personnel

aerodrome security personnel has the same meaning as in section 3 of the
Canadian Aviation Security Regulations, 2012. (personnel de sGrete de
!'aerodrome)
air carrier
air carrier means any person who operates a commercial air service
under Subpart 1, 3, 4 or 5 of Part VII of the Regulations. (transporteur
aerien)
COVID-19
COVID-19 means the coronavirus disease 2019. (COVID-19)
COVID-19 molecular test

COVID-19 molecular test means a COVID-19 screening or diagnostic test
carried out by an accredited laboratory, including a test performed using
the method of polymerase chain reaction (PCR) or reverse transcription
loop-mediated isothermal amplification (RT-LAMP). (essai moleculaire
relatif a la COVID-19)
foreign national
foreign national means a person who is not a Canadian citizen or a
permanent resident and includes a stateless person. (etranger)
non-passenger screening checkpoint

non-passenger screening checkpoint has the same meaning as in section 3
of the Canadian Aviation Security Regulations, 2012. (point de controle des
non-passagers)
passenger screening checkpoint

passenger screening checkpoint has the same meaning as in section 3 of
the Canadian Aviation Security Regulations, 2012. (point de controle des
passagers)
peace officer
peace officer has the same meaning as in section 3 of the Canadian
Aviation Security Regulations, 2012. (agent de la paix)
Regulations
Regulations means the Canadian Aviation Regulations. (Reglement)
restricted area
restricted area has the same meaning as in section 3 of the Canadian
Aviation Security Regulations, 2012. (zone reglementee)
screening authority
AR01958 17
screening authority means a person responsible for the screening of
persons and goods at an aerodrome set out in the schedule to the CATSA
Aerodrome Designation Regulations or at any other place designated by
the Minister under subsection 6(1.1) of the Canadian Air Transport Security
Authority Act. (administration de controle)
screening officer
screening officer, except in section 2, has the same meaning as in section
2 of the Canadian Air Transport Security Authority Act. (agent de controle)
• Interpretation
(2) Unless the context requires otherwise, all other words and
expressions used in this Interim Order have the same meaning as in the
Regulations.
• Conflict
(3) In the event of a conflict between this Interim Order and the
Regulations or the Canadian Aviation Security Regulations, 2012, the
Interim Order prevails.
• Definition of face mask
(4) For the purposes of this Interim Order, a face mask means any mask,
including a non-medical mask that meets all of the following
requirements:
0 (a) it is made of multiple layers of tightly woven materials such as

cotton or linen;
o (b) it completely covers a person's nose, mouth and chin without

gaping;
o (c) it can be secured to a person's head with ties or ear loops.
• Face masks - lip reading
(5) Despite paragraph (4)(a}, the portion of a face mask in front of a

wearer's lips may be made of transparent material that permits lip
reading if
o (a) the rest of the face mask is made of multiple layers of tightly
woven materials such as cotton or linen; and
o (b) there is a tight seal between the transparent material and the rest
of the face mask.
• Definition of fully vaccinated person
(6) For the purposes of this Interim Order, afullyvaccinated person

means a person who completed, at least 14 days before the day on which
they access aerodrome property or a location where NAV CANADA
AR01959 18
provides civil air navigation services, a COVID-19 vaccine dosage regimen
if
o (a) in the case of a vaccine dosage regimen that uses a COVID-19

vaccine that is authorized for sale in Canada,
■ (i) the vaccine has been administered to the person in accordance

with its labelling, or
■ {ii) the Minister of Health determines, on the recommendation of

the Chief Public Health Officer appointed under subsection 6(1) of
the Public Health Agency of Canada Act, that the regimen is suitable,
having regard to the scientific evidence related to the efficacy of
that regimen in preventing the introduction or spread of COVID-19
or any other factor relevant to preventing the introduction or
spread of COVID-19; or
o (b) in all other cases,
■ (i) the vaccines of the regimen are authorized for sale in Canada or
in another jurisdiction, and
■ {ii) the Minister of Health determines, on the recommendation of

the Chief Public Health Officer appointed under subsection 6(1) of
the Public Health Agency of Canada Act, that the vaccines and the
regimen are suitable, having regard to the scientific evidence
related to the efficacy of that regimen and the vaccines in
preventing the introduction or spread of COVID-19 or any other
factor relevant to preventing the introduction or spread of COVID-
19.
• Interpretation - fully vaccinated person
(7) For greater certainty, for the purposes of the definition fully vaccinated
person in subsection (6), a COVID-19 vaccine that is authorized for sale in
Canada does not include a similar vaccine sold by the same manufacturer
that has been authorized for sale in another jurisdiction.
Notification
Federal, provincial and territorial measures
• 2 (1) A private operator or air carrier operating a flight between two

points in Canada or a flight to Canada departing from any other country
must notify every person boarding the aircraft for the flight that they
may be subject to measures to prevent the spread of COVID-19 taken by
AR01960 19
the provincial or territorial government with jurisdiction where the
destination aerodrome for that flight is located or by the federal
government.
• Suitable quarantine plan
(2) A private operator or air carrier operating a flight to Canada

departing from any other country must notify every person before the
person boards the aircraft for the flight that they may be required, under
an order made under section 58 of the Quarantine Act, to provide, before
boarding the aircraft, to the Minister of Health, a screening officer or a
quarantine officer, by the electronic means specified by that Minister, a
suitable quarantine plan or, if the person is not required under that order
to provide the plan and the evidence, their contact information. The
private operator or air carrier must also notify every person that they
may be liable to a fine if this requirement applies to them and they fail to
comply with it.
• Vaccination

boarding the aircraft or before entering Canada, to the Minister of
Health, a screening officer or a quarantine officer, by the electronic
means specified by that Minister, information related to their COVID-19
vaccination and evidence of COVID-19 vaccination. The private operator
or air carrier must also notify every person that they may be denied
permission to board the aircraft and may be liable to a fine if this
requirement applies to them and they fail to comply with it.
• False confirmation
(4) A private operator or air carrier operating a flight between two points
in Canada or a flight to Canada departing from any other country must
notify every person boarding the aircraft for the flight that they may be
liable to a monetary penalty if they provide a confirmation referred to in
subsection 3(1) that they know to be false or misleading.
• Definitions
(5) The following definitions apply in this section.
quarantine officer
quarantine officer means a person designated as a quarantine officer
under subsection 5(2) of the Quarantine Act. (agent de quarantaine)
screening officer
AR01961 20
screening officer has the same meaning as in section 2 of the Quarantine
Act. (agent de controle)
Confirmation
• 3 (1) Before boarding an aircraft for a flight between two points in

Canada or a flight to Canada departing from any other country, every
person must confirm to the private operator or air carrier operating the
flight that they understand that they may be subject to a measure to
prevent the spread of COVID-19 taken by the provincial or territorial
government with jurisdiction where the destination aerodrome for that
flight is located or by the federal government.
(2) A person must not provide a confirmation referred to in subsection

(1) that they know to be false or misleading.
• Exception
(3) A competent adult may provide a confirmation referred to in

subsection (1) on behalf of a person who is not a competent adult.
Prohibition
4 A private operator or air carrier operating a flight between two points in

Canada or a flight to Canada departing from any other country must not
permit a person to board the aircraft for the flight if the person is a
competent adult and does not provide a confirmation that they are required
to provide under subsection 3(1 ).
Foreign Nationals
Prohibition
5 A private operator or air carrier must not permit a foreign national to

board an aircraft for a flight that the private operator or air carrier operates
to Canada departing from any other country.
Exception
6 Section 5 does not apply to a foreign national who is permitted to enter

Canada under an order made under section 58 of the Quarantine Act.
Health Check
Non-application
AR01962 21
7 Sections 8 to 10 do not apply to either of the following persons:
• (a) a crew member;
• (b) a person who provides a medical certificate certifying that any

symptoms referred to in subsection 8(1) that they are exhibiting are not
related to COVID-19.
Health check
• 8 (1) A private operator or air carrier must conduct a health check of

every person boarding an aircraft for a flight that the private operator or
air carrier operates by asking questions to verify whether they exhibit
any of the following symptoms:
o (a) a fever;
o (b) a cough;
o (c) breathing difficulties.
• Notification
(2) A private operator or air carrier must notify every person boarding an
aircraft for a flight that the private operator or air carrier operates that
the person may be denied permission to board the aircraft if
o (a) they exhibit a fever and a cough or a fever and breathing

difficulties, unless they provide a medical certificate certifying that
their symptoms are not related to COVID-19;
o (b) they have, or suspect that they have, COVID-19;
o (c) they have been denied permission to board an aircraft in the

previous 14 days for a medical reason related to COVID-19; or
0 (d) in the case of a flight departing in Canada, they are the subject of a
mandatory quarantine order as a result of recent travel or as a result
of a local or provincial public health order.
• Confirmation
(3) Every person boarding an aircraft for a flight that a private operator
or air carrier operates must confirm to the private operator or air carrier
that none of the following situations apply to them:
0 (a) the person has, or suspects that they have, COVID-19;
o (b) the person has been denied permission to board an aircraft in the
previous 14 days for a medical reason related to COVID-19;
o (c) in the case of a flight departing in Canada, the person is the

subject of a mandatory quarantine order as a result of recent travel or
as a result of a local or provincial public health order.
AR01963 22
• False confirmation - obligation of private operator or air carrier
(4) The private operator or air carrier must advise every person that they
may be liable to a monetary penalty if they provide answers, with respect
to the health check or a confirmation, that they know to be false or
misleading.
• False confirmation - obligations of person
(5) A person who, under subsections (1) and (3), is subjected to a health
check and is required to provide a confirmation must
o (a) answer all questions; and
o (b) not provide answers or a confirmation that they know to be false

or misleading.
• Exception
(6) A competent adult may answer all questions and provide a

confirmation on behalf of a person who is not a competent adult and
who, under subsections (1) and (3), is subjected to a health check and is
required to give a confirmation.
• Observations - private operator or air carrier
(7) During the boarding process for a flight that the private operator or
air carrier operates, the private operator or air carrier must observe
whether any person boarding the aircraft is exhibiting any symptoms
referred to in subsection (1 ).
Prohibition
9 A private operator or air carrier must not permit a person to board an

aircraft for a flight that the private operator or air carrier operates if
• (a) the person's answers to the health check questions indicate that they
exhibit
o (i) a fever and cough, or
0 (ii) a fever and breathing difficulties;
• (b) the private operator or air carrier observes that, as the person is
boarding, they exhibit
o (ii) a fever and breathing difficulties;
• (c) the person's confirmation under subsection 8(3) indicates that one of
the situations described in paragraphs 8(3)(a), (b) or (c) applies to that
person; or
AR01964 23
• (d) the person is a competent adult and refuses to answer any of the
questions asked of them under subsection 8(1) or to give the
confirmation under subsection 8(3).
Period of 14 days
10 A person who is not permitted to board an aircraft under section 9 is not

permitted to board another aircraft for a period of 14 days after the denial,
unless they provide a medical certificate certifying that any symptoms
referred to in subsection 8(1) that they are exhibiting are not related to
COVID-19.
COVID-19 Molecular Test - Flights to

Canada
Application
• 11 (1) Sections 12 to 17 apply to a private operator or air carrier

operating a flight to Canada departing from any other country and to
every person boarding an aircraft for such a flight.
• Non-application
(2) Sections 12 to 17 do not apply to persons who are not required under
an order made under section 58 of the Quarantine Act to provide evidence
that they received a result for a COVID-19 molecular test.
Notification
12 A private operator or air carrier must notify every person who intends to
that the person may be denied permission to board the aircraft if they are
unable to provide evidence that they received a result for a COVID-19
molecular test.
Evidence - result of test
• 13 (1) Before boarding an aircraft for a flight, every person must provide
to the private operator or air carrier operating the flight evidence that
they received either
o (a) a negative result for a COVID-19 molecular test that was

performed on a specimen collected no more than 72 hours before the
aircraft's initial scheduled departure time; or
o (b) a positive result for such a test that was performed on a specimen
collected at least 14 days and no more than 180 days before the
aircraft's initial scheduled departure time.
• Evidence - location of test

AR01965 24
(2) For the purposes of subsection (1 }, the COVID-19 molecular test must
have been performed in a country or territory that is not listed in
Schedule 1.
Evidence - elements
14 Evidence of a result for a COVID-19 molecular test must include
• (a) the person's name and date of birth;
• (b) the name and civic address of the laboratory that administered the
test;
• (c) the date the specimen was collected and the test method used; and
• (d) the test result.
False or misleading evidence
15 A person must not provide evidence of a result for a COVID-19 molecular

test that they know to be false or misleading.
Notice to Minister
16 A private operator or air carrier that has reason to believe that a person
has provided evidence of a result for a COVID-19 molecular test that is likely
to be false or misleading must notify the Minister as soon as feasible of the
person's name and contact information and the date and number of the
person's flight.
Prohibition

aircraft for a flight that the private operator or air carrier operates if the
person does not provide evidence that they received a result for a COVID-19
molecular test in accordance with the requirements set out in section 13.
Vaccination or COVID-19 Molecular Test -

Flights Departing from an Aerodrome in
Canada
Application
• 17.1 (1) Beginning on October 30, 2021 at 3:00:59 a.m. Eastern daylight
time, sections 17.2 to 17.17 apply to all of the following persons:
o (a) a person boarding an aircraft for a flight that an air carrier

operates departing from an aerodrome listed in Schedule 2;
o (b) a person entering a restricted area at an aerodrome listed in

Schedule 2 from a non-restricted area to board an aircraft for a flight
that an air carrier operates;
AR01966 25
0 (c) an air carrier operating a flight departing from an aerodrome
listed in Schedule 2;
o (d) a screening authority at an aerodrome listed in Schedule 2.
• Non-application
(2) Sections 17.2 to 17.17 do not apply to any of the following persons:
0 (a) a child who is less than 12 years and four months of age;
o (b) a crew member;
o (c) a person who arrives at an aerodrome from any other country on

board an aircraft in order to transit to another country and remains in
a sterile transit area, as defined in section 2 of the Immigration and
Refugee Protection Regulations, of the aerodrome until they leave
Canada;
o (d) a person who arrives at an aerodrome on board an aircraft

following the diversion of their flight for a safety-related reason, such
as adverse weather or an equipment malfunction, and who boards an
aircraft for a flight not more than 24 hours after the arrival time of the
diverted flight.
Notification
17.2 An air carrier must notify every person who intends to board an aircraft
for a flight that the air carrier operates that they
• (a) are prohibited from boarding the aircraft unless they are a fully
vaccinated person, have received a result for a COVID-19 molecular test
or are a person referred to in paragraph 17.4(2)(a) or (b);
• (b) will be required to confirm to the air carrier that they are a fully
vaccinated person, have received a result for a COVID-19 molecular test
or are a person referred to in paragraph 17.4(2)(a) or (b);
• (c) may be required to provide to the air carrier evidence of COVID-19

vaccination demonstrating that they are a fully vaccinated person,
evidence that they have received a result for a COVID-19 molecular test
or evidence that they are a person referred to in paragraph 17.4(2)(a) or
(b);
• (d) may be denied permission to board the aircraft if a requirement

referred to in paragraph (b) or (c) applies to them and they fail to comply
with it, and, in the case of the requirement referred to in paragraph (c),
may be denied permission to board any other aircraft for a flight
departing from Canada for a period of 72 hours after the first denial; and
AR01967 26
• (e) may be liable to a monetary penalty if they provide a confirmation
referred to in section 17.3 that they know to be false or misleading.
Confirmation
• 17.3 (1) Before boarding an aircraft for a flight, every person must
confirm to the air carrier operating the flight that they
o (a) are a fully vaccinated person;
o (b) have received a result for a COVID-19 molecular test; or
o (c) are a person referred to in paragraph 17.4(2)(a) or (b).
• Exception

• Exception - person less than 16 years of age
(3) Subsection (1) does not apply to a person who is less than 16 years of
age and who is travelling alone.
Prohibition - person
• 17.4 (1) A person is prohibited from boarding an aircraft for a flight or

entering a restricted area unless
o (a) they are a fully vaccinated person; or
o (b) they have received a result for a COVID-19 molecular test.
• Exception
(2) Subsection (1) does not apply to a person who
o (a) is boarding the aircraft for a flight to an aerodrome in Canada if

the initial scheduled departure time of that flight is not more than 24
hours after the departure time of a flight taken by the person to
Canada from any other country; or
o (b) is boarding the aircraft for a flight
■ (i) only to become a crew member on board another aircraft that

an air carrier operates under Subpart 1 of Part VII of the
Regulations,
■ (ii) after having been a crew member on board an aircraft that an

air carrier operates under Subpart 1 of Part VII of the Regulations,
or
■ (iii) to participate in mandatory training required by an air carrier

that operates a commercial air service under Subpart 1 of Part VII
of the Regulations in relation to the operation of an aircraft, if the
AR01968 27
person will be required to return to work as a crew member.
Request for evidence - air carrier
• 17.5 (1) Before permitting a certain number of persons, as specified by

the Minister and selected on a random basis, to board an aircraft for a
flight that the air carrier operates, the air carrier must request that each
of those persons provide
o (a) evidence of COVID-19 vaccination demonstrating that they are a

fully vaccinated person;
o (b) evidence that they have received a result for a COVID-19 molecular
test; or
o (c) evidence that they are a person referred to in paragraph 17.4(2)(a)

or (b).
• Person less than 16 years of age
(2) An air carrier must request that every person described in subsection
17.3(3) provide, before they board an aircraft for a flight that the air
carrier operates, the evidence referred to in paragraph (1 )(a}, (b) or (c).
Request for evidence - screening authority
17.6 Before permitting a certain number of persons, as specified by the

Minister and selected on a random basis, to enter a restricted area, the
screening authority must request that each of those persons, when they
present themselves for screening at a passenger screening checkpoint,
provide the evidence referred to in paragraph 17.5(1)(a}, (b) or (c).
Provision of evidence
17.7 A person must, at the request of an air carrier or a screening authority,

provide to the air carrier or screening authority the evidence referred to in
paragraph 17.5(1 )(a}, (b) or (c).
Evidence of vaccination - elements
• 17.8 (1) Evidence of COVID-19 vaccination must be evidence issued by the

government or the non-governmental entity that is authorized to issue it
in the jurisdiction in which the vaccine was administered and must
contain the following information:
o (a) the name of the person who received the vaccine;
o (b) the name of the government or of the non-governmental entity;
o (c) the brand name or any other information that identifies the
vaccine that was administered; and
AR01969 28
0 (d) the dates on which the vaccine was administered or, if the
evidence is one document issued for both doses and the document
specifies only the date on which the most recent dose was
administered, that date.
• Evidence of vaccination - translation
(2) The evidence of COVID-19 vaccination must be in English or French

and any translation into English or French must be a certified translation.
Evidence of COVID-19 molecular test - result
• 17.9 (1) A result for a COVID-19 molecular test is a result described in

paragraph 13(1 )(a) or (b).
• Evidence of COVID-19 molecular test - elements
(2) Evidence of a result for a COVID-19 molecular test must include the
elements set out in paragraphs 14(a) to (d).
Evidence - persons referred to in subsection 17.4(2)
17.10 Evidence that the person is a person referred to in paragraph 17.4(2)

(a) or (b) means
• (a) in the case of paragraph 17.4(2)(a), a travel itinerary or boarding pass

that confirms that the initial scheduled departure time of the person's
flight to an aerodrome in Canada is not more than 24 hours after the
departure time of a flight taken by the person to Canada from any other
country; and
• (b) in the case of paragraph 17.4(2)(b),
o (i) a statement from the person that they are a person referred to in
paragraph 17.4(2)(b) if they provide a piece of identification issued by
the air carrier or if they are in uniform, or
o (ii) a document from the air carrier demonstrating that they are a
person referred to in paragraph 17.4(2)(b).
False or misleading confirmation or evidence
17.11 A person must not provide a confirmation or evidence that they know
to be false or misleading.
Notice to Minister
17.12 An air carrier or screening authority that has reason to believe that a
person has provided a confirmation or evidence that is likely to be false or
misleading must notify the Minister of the person's name and contact
information and the date and number of the person's flight not more than
72 hours after the provision of the confirmation or evidence.
AR01970 29
Prohibition - air carrier
• 17.13 (1) An air carrier must not permit a person to board an aircraft for a
flight that the air carrier operates if
o (a) the person is a competent adult and does not provide a

confirmation that they are required to provide under section 17.3; or
o (b) the person does not provide the evidence they are required to
provide under section 17.7.
• Notification to person
(2) An air carrier that denies a person permission to board an aircraft

under paragraph (1 )(b) must notify the person that
o (a) they are not permitted to board an aircraft for a flight departing
from Canada for a period of 72 hours after the denial; and
o (b) the Minister will be informed of the denial.
Prohibition - screening authority
• 17.14 (1) A screening authority must not permit a person to enter a

restricted area if the person does not provide the evidence they are
required to provide under section 17.7.
• Notification to person
(2) A screening authority that denies a person entry to a restricted area

under subsection (1) must notify the person that
o (a) they are not permitted to enter a restricted area at any aerodrome
in Canada for a period of 72 hours after the denial; and
o (b) the Minister will be informed of the denial.
• Notification to air carrier
(3) If a screening authority denies a person entry to a restricted area, the

screening authority must notify the air carrier operating the flight that
the person has been denied entry and provide the person's name and
flight number to the air carrier.
• Air carrier requirements
(4) An air carrier that has been notified under subsection (3) must ensure
that the person is escorted to a location where they can retrieve their
checked baggage, as defined in section 3 of the Canadian Aviation Security
Regulations, 2012, if applicable.
Prohibition - boarding an aircraft

AR01971 30
• 17.15 (1) A person who is denied permission to board an aircraft under
paragraph 17.13(1 )(b) is not permitted to board an aircraft for a flight
departing from Canada for a period of 72 hours after the denial.
• Prohibition - entry to restricted area
(2) A person who is denied entry to a restricted area under subsection

17.14(1) is not permitted to enter a restricted area at any aerodrome in
Canada for a period of 72 hours after the denial.
Record keeping - air carrier
• 17.16 (1) An air carrier must keep a record of the following information in
respect of each instance that a person was denied permission to board
an aircraft under paragraph 17.13(1 )(b):
o (a) the person's name, date of birth and contact information,

including the person's home address, telephone number and email
address;
o (b) the date and flight number; and
o (c) the reason why the person was denied permission to board the
aircraft.
• Informing Minister
(2) The air carrier must inform the Minister of any record referred to in
subsection (1) not more than 72 hours after it is created.
• Retention period
(3) The air carrier must retain a record referred to in subsection (1) for a
period of at least 12 months after the date of the flight.
• Ministerial request
(4) The air carrier must make a record referred to in subsection (1)
available to the Minister on request.
Record keeping - screening authority
• 17.17 (1) A screening authority must keep a record of the following

information in respect of each instance that a person was denied entry to
a restricted area under subsection 17.14(1 ):
o (a) the person's name;
o (b) the date and flight number; and
o (c) the reason why the person was denied entry to the restricted area.
• Informing Minister
AR01972 31
(2) The screening authority must inform the Minister of any record
referred to in subsection (1) not more than 72 hours after it is created.
(3) The screening authority must retain a record referred to in subsection

(1) for a period of at least 12 months after the day on which the record is
created.
(4) The screening authority must make a record referred to in subsection

(1) available to the Minister on request.
[17.18 to 17.49 reserved]
Policy Respecting Mandatory Vaccination

Application
17.50 Beginning on October 30, 2021 at 3:00:59 a.m. Eastern daylight time,
sections 17.51 to 17.55 apply to
• (a) the operator of an aerodrome listed in Schedule 2;
• (b) an air carrier operating a flight departing from an aerodrome listed in

Schedule 2, other than an air carrier that operates a commercial air
service under Subpart 1 of Part VII of the Regulations; and
• (c) NAV CANADA.
Definition of relevant person
• 17.51 (1) For the purposes of sections 17.52 to 17.55, relevant person
means, in respect of an entity referred to in section 17.50, a person
whose duties involve an activity described in subsection (2) and who is
o (a) an employee of the entity;
o (b) an employee of the entity's contractor, agent or mandatary;
o (c) a person hired by the entity to provide a service;
o (d) the entity's lessee or an employee of the entity's lessee, if the

property that is subject to the lease is part of aerodrome property; or
o (e) a person permitted by the entity to access aerodrome property or,

in the case of NAV CANADA, a location where NAV CANADA provides
civil air navigation services.
• Activities
(2) For the purposes of subsection (1 }, the activities are

AR01973 32
o (a) conducting or directly supporting activities that are related to
commercial flight operations - such as aircraft refuelling services,
aircraft maintenance and repair services, baggage handling services,
supply services for the operator of an aerodrome, an air carrier or
NAV CANADA, runway and taxiway maintenance services or de-icing
services - and that take place on aerodrome property or at a location
where NAV CANADA provides civil air navigation services;
o (b) interacting in-person on aerodrome property with a person who

intends to board an aircraft for a flight;
o (c) engaging in tasks, on aerodrome property or at a location where

NAV CANADA provides civil air navigation services, that are intended
to reduce the risk of transmission of the virus that causes COVID-19;
and
o (d) accessing a restricted area at an aerodrome listed in Schedule 2.
Comprehensive policy - operators of aerodromes
• 17.52 (1) The operator of an aerodrome must establish and implement a

comprehensive policy respecting mandatory COVID-19 vaccination in
accordance with subsection (2).
• Policy - content
(2) The policy must
o (a) subject to paragraph (b}, require that as of November 15, 2021, a

person who is 12 years and four months of age or older, other than a
person who intends to board an aircraft for a flight, be a fully
vaccinated person before accessing aerodrome property;
o (b) provide for a procedure for granting an exemption to a person

referred to in paragraph (a) from the requirement to be a fully
vaccinated person if the person
■ (i) has not completed a COVID-19 vaccine dosage regimen due to a

medical contraindication or their sincerely held religious beliefs, or
■ {ii) received the first dose of a COVID-19 vaccine dosage regimen

before November 15, 2021;
o (c) provide for a procedure for issuing a document to a person who

has been granted an exemption referred to in paragraph (b) that
confirms the granting of the exemption;
o (d) provide for a procedure that ensures that a person who has been
granted an exemption referred to in paragraph (b) is tested for
COVID-19 at least twice every week;
AR01974 33
0 (e) provide for a procedure that ensures that a person who receives a
positive result for a COVID-19 test, other than a COVID-19 molecular
test, under the procedure referred to in paragraph (d) receives a
result for a COVID-19 molecular test;
o (f) provide for a procedure that ensures that a person who receives a
positive result for a COVID-19 molecular test under the procedure
referred to in paragraph (d) or (e) is prohibited from accessing
aerodrome property for a period of 14 days after the result was
received or until the person is not exhibiting any of the symptoms
referred to in subsection 8(1 ), whichever is later; and
o (g) provide for a procedure that ensures that a person referred to in

paragraph (f) is exempt from the requirement referred to in
paragraph (d) for a period of 180 days after the person received a
positive result for a COVID-19 molecular test.
• Medical contraindication
(3) For the purposes of subparagraph (2)(b){i), the policy must provide
that an exemption is to be granted to a person on the basis of a medical
contraindication only if the person provides a medical certificate from a
medical doctor or nurse practitioner certifying that the person cannot be
vaccinated due to a medical condition.
• Canadian Human Rights Act
(4) For the purposes of subparagraph (2)(b){i), in the case of an employee

of the operator of an aerodrome or a person hired by the operator of an
aerodrome to provide a service, the policy must provide that an
exemption is to be granted to a person on the basis of their sincerely
held religious beliefs only if the operator of the aerodrome is obligated to
accommodate them on the basis of this ground under the Canadian
Human Rights Act by providing such an exemption.
• Applicable legislation
(5) For the purposes of subparagraph (2)(b){i), in the following cases, the
policy must provide that an exemption is to be granted to a person on
the basis of their sincerely held religious beliefs only if they would be
entitled to such an exemption as an accommodation on the basis of this
ground under applicable legislation:
o (a) in the case of an employee of the operator of an aerodrome's

contractor, agent or mandatary; and
AR01975 34
0 (b) in the case of an employee of the operator of an aerodrome's
lessee, if the property that is subject to the lease is part of aerodrome
property.
Comprehensive policy - air carriers and NAV CANADA
17.53 Section 17.54 does not apply to an air carrier or NAV CANADA if that
entity
• (a) establishes and implements a comprehensive policy respecting

mandatory COVID-19 vaccination in accordance with paragraphs 17.54(2)
(a) to (g) and subsections 17.54(3) to (5); and
• (b) has procedures in place to ensure that while a relevant person is

carrying out their duties related to commercial flight operations, no in-
person interactions occur between the relevant person and an
unvaccinated person who has not been granted an exemption referred
to in paragraph 17.54(2)(b) and who is
o (i) an employee of the entity,
o (ii) an employee of the entity's contractor, agent or mandatary,
o {iii) a person hired by the entity to provide a service, or
o (iv) the entity's lessee or an employee of the entity's lessee, if the

property that is subject to the lease is part of aerodrome property.
Targeted policy - air carriers and NAV CANADA
• 17.54 (1) An air carrier or NAV CANADA must establish and implement a
targeted policy respecting mandatory COVID-19 vaccination in
(2) The policy must
o (a) subject to paragraph (b), require that as of November 15, 2021, a

relevant person be a fully vaccinated person before accessing
aerodrome property or, in the case of NAV CANADA, a location where
NAV CANADA provides civil air navigation services;
o (b) provide for a procedure for granting an exemption to a relevant

person from the requirement to be a fully vaccinated person if the
relevant person
■ (i) has not completed a COVID-19 vaccine dosage regimen due to a

medical contraindication or their sincerely held religious beliefs, or
■ {ii) received the first dose of a COVID-19 vaccine dosage regimen

before November 15, 2021;
AR01976 35
o (c) provide for a procedure for issuing a document to a relevant
person who has been granted an exemption referred to in paragraph
(b) that confirms the granting of the exemption;
o (d) provide for a procedure that ensures that a relevant person who
has been granted an exemption referred to in paragraph (b) is tested
for COVID-19 at least twice every week;
o (e) provide for a procedure that ensures that a relevant person who
receives a positive result for a COVID-19 test, other than a COVID-19
molecular test, under the procedure referred to in paragraph (d)
receives a result for a COVID-19 molecular test;
o (f) provide for a procedure that ensures that a relevant person who
receives a positive result for a COVID-19 molecular test under the
procedure referred to in paragraph (d) or (e) is prohibited from
accessing aerodrome property for a period of 14 days after the result
was received or until the relevant person is not exhibiting any of the
symptoms referred to in subsection 8(1 ), whichever is later;
o (g) provide for a procedure that ensures that a relevant person

referred to in paragraph (f) is exempt from the requirement referred
to in paragraph (d) for a period of 180 days after the relevant person
received a positive result for a COVID-19 molecular test;
o (h) set out procedures for reducing the risk that a relevant person will
be exposed to the virus that causes COVID-19 due to an in-person
interaction occurring on aerodrome property or at a location where
NAV CANADA provides civil air navigation services with an
unvaccinated person who has not been granted an exemption under
paragraph (b) and who is a person referred to in subparagraph
17.53(b)(i), (ii), {iii) or (iv), which may include protocols related to
■ (i) the vaccination of persons, other than relevant persons, who

access aerodrome property or a location where NAV CANADA
provides civil air navigation services,
■ {ii) physical distancing and the wearing of face masks, and
■ {iii) reducing the frequency and duration of in-person interactions;
o (i) establish a procedure for collecting the following information with

respect to an in-person interaction related to commercial flight
operations between a relevant person and a person referred to in
subparagraph 17.53(b){i), {ii), {iii) or (iv) who is unvaccinated and has
not been granted an exemption under paragraph (b) or whose
vaccination status is unknown:
AR01977 36
■ (i) the time, date and location of the interaction, and
■ (ii) contact information for the relevant person and the other
person;
o 0) establish a procedure for recording the following information and

submitting it to the Minister on request:
■ (i) the number of relevant persons who are subject to the entity's
policy,
■ (ii) the number of relevant persons who require access to a

restricted area,
■ (iii) the number of relevant persons who
■ (A) are fully vaccinated persons,
■ (B) have received the first dose of a COVID-19 vaccine dosage

regimen, and
■ (C) are unvaccinated persons,
■ (iv) the number of hours during which relevant persons were

unable to fulfill their duties related to commercial flight operations
due to COVID-19,
■ (v) the number of relevant persons who have been granted an

exemption referred to in paragraph (b), the reason for granting
the exemption and a confirmation that the relevant persons have
submitted evidence of COVID-19 tests in accordance with the
requirements referred to in paragraphs (d) and (e),
■ (vi) the number of relevant persons who refuse to comply with a

requirement referred to in paragraph (a), (d), (e) or (f),
■ (vii) the number of relevant persons who were denied entry to a

restricted area because of a refusal to comply with a requirement
referred to in paragraph (a), (d), (e) or {f),
■ (viii) the number of persons referred to in subparagraphs 17.53(b)

(i) to (iv) who are unvaccinated and who have not been granted an
exemption under paragraph (b), or whose vaccination status is
unknown, who have an in-person interaction related to
commercial flight operations with a relevant person and a
description of any procedures implemented to reduce the risk that
a relevant person will be exposed to the virus that causes COVID-
19 due to such an interaction, and
AR01978 37
■ (ix) the number of instances in which the air carrier or NAV Canada
is made aware that a person with respect to whom information
was collected under paragraph (i) received a positive result for a
COVID-19 test, the number of relevant persons tested for COVID-
19 as a result of this information, the results of those tests and a
description of any impacts on commercial flight operations; and
o (k) require the air carrier or NAV CANADA, as applicable, to keep the
information referred to in paragraph U) for a period of at least 12
months after the date that the information was recorded.
(3) For the purposes of subparagraph (2)(b){i), the policy must provide
that an exemption is to be granted to a relevant person on the basis of a
medical contraindication only if the relevant person provides a medical
certificate from a medical doctor or nurse practitioner certifying that the
relevant person cannot be vaccinated due to a medical condition.
(4) For the purposes of subparagraph (2)(b){i), in the case of an employee

of an entity or a person hired by an entity to provide a service, the policy
must provide that an exemption is to be granted to a relevant person on
the basis of their sincerely held religious beliefs only if the entity is
obligated to accommodate the relevant person on the basis of this
ground under the Canadian Human Rights Act by providing such an
exemption.
(5) For the purposes of subparagraph (2)(b){i), in the following cases, the
policy must provide that an exemption is to be granted to a relevant
person on the basis of their sincerely held religious beliefs only if they
would be entitled to such an exemption as an accommodation on the
basis of this ground under applicable legislation:
0 (a) in the case of an employee of an entity's contractor, agent or

mandatary; and
o (b) in the case of an employee of an entity's lessee, if the property

that is subject to the lease is part of aerodrome property.
Ministerial request - policy
• 17.55 (1) The operator of an aerodrome, an air carrier or NAV CANADA

must make a copy of the policy referred to in section 17.52, 17.53 or
17.54, as applicable, available to the Minister on request.
• Ministerial request - implementation

AR01979 38
(2) The operator of an aerodrome, an air carrier or NAV CANADA must
make information related to the implementation of the policy referred to
in section 17.52, 17.53 or 17.54, as applicable, available to the Minister on
request.
Face Masks
Non-application
• 18 (1) Sections 19 to 24 do not apply to any of the following persons:
o (a) a child who is less than two years of age;
o (b) a child who is at least two years of age but less than six years of
age who is unable to tolerate wearing a face mask;
o (c) a person who provides a medical certificate certifying that they are
unable to wear a face mask for a medical reason;
o (d) a person who is unconscious;
o (e) a person who is unable to remove their face mask without

assistance;
o (f) a crew member;
o (g) a gate agent.
• Face mask readily available
(2) An adult responsible for a child who is at least two years of age but
less than six years of age must ensure that a face mask is readily
available to the child before boarding an aircraft for a flight.
• Wearing of face mask
(3) An adult responsible for a child must ensure that the child wears a
face mask when wearing one is required under section 21 and complies
with any instructions given by a gate agent under section 22 if the child
o (a) is at least two years of age but less than six years of age and is
able to tolerate wearing a face mask; or
o (b) is at least six years of age.
Notification
that the person must
• (a) be in possession of a face mask before boarding;

AR01980 39
• (b) wear the face mask at all times during the boarding process, during
the flight and from the moment the doors of the aircraft are opened until
the person enters the air terminal building; and
• (c) comply with any instructions given by a gate agent or a crew member
with respect to wearing a face mask.
Obligation to possess face mask
20 Every person who is at least six years of age must be in possession of a

face mask before boarding an aircraft for a flight.
Wearing of face mask - persons
• 21 (1) Subject to subsections (2) and (3), a private operator or air carrier
must require a person to wear a face mask at all times during the
boarding process and during a flight that the private operator or air
carrier operates.
• Exceptions - person
(2) Subsection (1) does not apply
o (a) when the safety of the person could be endangered by wearing a

face mask;
o (b) when the person is drinking or eating, unless a crew member

instructs the person to wear a face mask;
o (c) when the person is taking oral medications;
o (d) when a gate agent or a crew member authorizes the removal of

the face mask to address unforeseen circumstances or the person's
special needs; or
o (e) when a gate agent, a member of the aerodrome security

personnel or a crew member authorizes the removal of the face mask
to verify the person's identity.
• Exceptions - flight deck
(3) Subsection (1) does not apply to any of the following persons when
they are on the flight deck:
o (a) a Department of Transport air carrier inspector;
o (b) an inspector of the civil aviation authority of the state where the
aircraft is registered;
o (c) an employee of the private operator or air carrier who is not a crew
member and who is performing their duties;
o (d) a pilot, flight engineer or flight attendant employed by a wholly

owned subsidiary or a code share partner of the air carrier;
AR01981 40
0 (e) a person who has expertise related to the aircraft, its equipment or
its crew members and who is required to be on the flight deck to
provide a service to the private operator or air carrier.
Compliance
22 A person must comply with any instructions given by a gate agent, a

member of the aerodrome security personnel or a crew member with
respect to wearing a face mask.
Prohibition - private operator or air carrier

• (a) the person is not in possession of a face mask; or
• (b) the person refuses to comply with an instruction given by a gate

agent or a crew member with respect to wearing a face mask.
Refusal to comply
• 24 (1) If, during a flight that a private operator or air carrier operates, a
person refuses to comply with an instruction given by a crew member
with respect to wearing a face mask, the private operator or air carrier
must
o (a) keep a record of
■ (i) the date and flight number,
■ {ii) the person's name, date of birth and contact information,

including the person's home address, telephone number and
email address,
■ {iii) the person's seat number, and
■ (iv) the circumstances related to the refusal to comply; and
o (b) inform the Minister as soon as feasible of any record created

under paragraph (a).
(2) The private operator or air carrier must retain a record referred to in
paragraph (1)(a) for a period of at least 12 months after the date of the
flight.
(3) The private operator or air carrier must make a record referred to in
paragraph (1 )(a) available to the Minister on request.
Wearing of face mask - crew member

AR01982 41
must require a crew member to wear a face mask at all times during the
carrier operates.
• Exceptions - crew member
o (a) when the safety of the crew member could be endangered by

wearing a face mask;
o (b) when the wearing of a face mask by the crew member could
interfere with operational requirements or the safety of the flight; or
o (c) when the crew member is drinking, eating or taking oral

medications.
• Exception - flight deck
(3) Subsection (1) does not apply to a crew member who is a flight crew
member when they are on the flight deck.
Wearing of face mask - gate agent
must require a gate agent to wear a face mask during the boarding
process for a flight that the private operator or air carrier operates.
• Exceptions
o (a) when the safety of the gate agent could be endangered by

wearing a face mask; or
0 (b) when the gate agent is drinking, eating or taking oral medications.
• Exception - physical barrier
(3) During the boarding process, subsection (1) does not apply to a gate
agent if the gate agent is separated from any other person by a physical
barrier that allows the gate agent and the other person to interact and
reduces the risk of exposure to COVID-19.
Deplaning
Non-application
• 27 (1) Section 28 does not apply to any of the following persons:

AR01983 42

assistance;
o (f) a person who is on a flight that originates in Canada and is

destined to another country.
face mask when wearing one is required under section 28 if the child
Wearing of face mask - person
28 A person who is on board an aircraft must wear a face mask at all times
from the moment the doors of the aircraft are opened until the person
enters the air terminal building, including by a passenger loading bridge.
Screening Authority
Non-application

assistance;
o (f) a member of emergency response provider personnel who is

responding to an emergency;
o (g) a peace officer who is responding to an emergency.

AR01984 43
face mask when wearing one is required under subsection 30(2) and
removes it when required by a screening officer to do so under
subsection 30(3) if the child
Requirement - passenger screening checkpoint
• 30 ( 1) A screening authority must notify a person who is subject to

screening at a passenger screening checkpoint that they must wear a
face mask at all times during screening.
• Wearing of face mask - person
(2) Subject to subsection (3), a person who is the subject of screening

referred to in subsection (1) must wear a face mask at all times during
screening.
• Requirement to remove face mask
(3) A person who is required by a screening officer to remove their face

mask during screening must do so.
• Wearing of face mask- screening officer
(4) A screening officer must wear a face mask at a passenger screening

checkpoint when conducting the screening of a person if, during the
screening, the screening officer is two metres or less from the person
being screened.
Requirement - non-passenger screening checkpoint
• 31 (1) A person who presents themselves at a non-passenger screening

checkpoint to enter into a restricted area must wear a face mask at all
times.
• Wearing of face mask- screening officer
(2) Subject to subsection (3), a screening officer must wear a face mask at
all times at a non-passenger screening checkpoint.
• Exceptions
o (a) when the safety of the screening officer could be endangered by

wearing a face mask; or
o (b) when the screening officer is drinking, eating or taking oral

medications.
AR01985 44
Exception - physical barrier
32 Sections 30 and 31 do not apply to a person, including a screening officer,

if the person is two metres or less from another person and both persons
are separated by a physical barrier that allows them to interact and reduces
the risk of exposure to COVID-19.
Prohibition - passenger screening checkpoint
• 33 (1) A screening authority must not permit a person who has been
notified to wear a face mask and refuses to do so to pass beyond a
passenger screening checkpoint into a restricted area.
• Prohibition - non-passenger screening checkpoint
(2) A screening authority must not permit a person who refuses to wear a
face mask to pass beyond a non-passenger screening checkpoint into a
restricted area.
Designated Provisions
Designation
• 34 (1) The provisions of this Interim Order set out in column 1 of

Schedule 3 are designated as provisions the contravention of which may
be dealt with under and in accordance with the procedure set out in
sections 7.7 to 8.2 of the Act.
• Maximum amounts
(2) The amounts set out in column 2 of Schedule 3 are the maximum
amounts of the penalty payable in respect of a contravention of the
designated provisions set out in column 1.
• Notice
(3) A notice referred to in subsection 7.7(1) of the Act must be in writing

and must specify
o (a) the particulars of the alleged contravention;
o (b) that the person on whom the notice is served or to whom it is sent
has the option of paying the amount specified in the notice or filing
with the Tribunal a request for a review of the alleged contravention
or the amount of the penalty;
o (c) that payment of the amount specified in the notice will be

accepted by the Minister in satisfaction of the amount of the penalty
for the alleged contravention and that no further proceedings under
Part I of the Act will be taken against the person on whom the notice
in respect of that contravention is served or to whom it is sent;
AR01986 45
0 (d) that the person on whom the notice is served or to whom it is sent
will be provided with an opportunity consistent with procedural
fairness and natural justice to present evidence before the Tribunal
and make representations in relation to the alleged contravention if
the person files a request for a review with the Tribunal; and
o (e) that the person on whom the notice is served or to whom it is sent
will be considered to have committed the contravention set out in the
notice if they fail to pay the amount specified in the notice and fail to
file a request for a review with the Tribunal within the prescribed
period.
Repeal
35 The Interim Order Respecting Certain Requirements for Civil Aviation
Due to COVID-19, No. 42, made on October 19, 2021, is repealed.
SCHEDULE 1(Subsection 13(2))

Countries and Territories
Item Name
1 India
2 Morocco
SCHEDULE 2(Subsections 1(1) and 17.1(1)

and paragraphs 17.SO(a) and (b) and 17.51(2)
(d))
Aerodromes
ICAO Location
Name Indicator
Abbotsford International CYXX
Alma CYTF
Bagotville CYBG
Baie-Comeau CYBC
Bathurst CZBF
Brandon Municipal CYBR
Calgary International CYYC

AR01987 46
ICAO Location
Name Indicator
Campbell River CYBL
Castlegar (West Kootenay Regional) CYCG
Charle CYCL
Charlottetown CYYG
Chibougamau/Chapais CYMT
Churchill Falls CZUM
Comox CYQQ
Cranbrook (Canadian Rockies International) CYXC
Dawson Creek CYDQ
Deer Lake CYDF
Edmonton International CYEG
Fort McMurray CYMM
Fort St. John CYXJ
Fredericton International CYFC
Gander International CYQX
Gaspe CYGP
Goose Bay CYYR
Grande Prairie CYQU
Greater Moncton International CYQM
Halifax (Robert L. Stanfield International) CYHZ
Hamilton Uohn C. Munro International) CYHM
Iles-de-la-Madeleine CYGR
Iqaluit CYFB
Kamloops CYKA
Kelowna CYLW
Kingston CYGK
Kitchener/Waterloo Regional CYKF
La Grande Riviere CYGL

AR01988 47
ICAO Location
Name Indicator
Leth bridge CYQL
Lloyd minster CYLL
London CYXU
Lourdes-de-Blanc-Sablon CYBX
Medicine Hat CYXH
Mont-Joli CYYY
Montreal (Montreal - Pierre Elliott Trudeau CYUL

International)
Nanaimo CYCD
North Bay CYYB
Ottawa (Macdonald-Cartier International) CYOW
Penticton CYYF
Prince Albert (Glass Field) CYPA
Prince George CYXS
Prince Rupert CYPR
Quebec Uean Lesage International) CYQB
Quesnel CYQZ
Red Deer Regional CYQF
Regina International CYQR
Riviere-Rouge/Mont-Tremblant International CYFJ
Rouyn-Noranda CYUY
Saint John CYSJ
Samia (Chris Hadfield) CYZR
Saskatoon Uohn G. Diefenbaker International) CYXE
Sault Ste. Marie CYAM
Sept-lies CYZV
Smithers CYYD
St. Anthony CYAY
St. John's International CYYT

AR01989 48
ICAO Location
Name Indicator
Stephenville CYJT
Sudbury CYSB
Sydney U.A. Douglas Mccurdy) CYQY
Terrace CYXT
Thompson CYTH
Thunder Bay CYQT
Timmins (Victor M. Power) CYTS
Toronto (Billy Bishop Toronto City) CYTZ
Toronto (Lester B. Pearson International) CYYZ
Toronto/Buttonville Municipal CYKZ
Val-d'Or CYVO
Vancouver International CYVR
Victoria International CYYJ
Wabush CYWK
Whitehorse (Erik Nielsen International) CYXY
Williams Lake CYWL
Windsor CYQG
Winnipeg Uames Armstrong Richardson CYWG

International)
Yellowknife CYZF
SCHEDULE 3{Subsections 34(1) and

{2))Designated Provisions
Column 1 Column 2
Designated Provision Maximum Amount of Penalty{$)
Individual Corporation
Subsection 2(1) 5,000 25,000
Subsection 2(2) 5,000 25,000

AR01990 49
Column 1 Column 2
Subsection 2(3) 5,000 25,000
Subsection 2(4) 5,000 25,000
Subsection 3(1) 5,000
Section 4 5,000 25,000
Section 5 5,000 25,000
Subsection 8(1) 5,000 25,000
Subsection 8(2) 5,000 25,000
Subsection 8(4) 5,000 25,000
Subsection 8(7) 5,000 25,000
Section 9 5,000 25,000
Section 10 5,000
Section 12 5,000 25,000
Section 15 5,000
Section 16 5,000 25,000
Section 17 5,000 25,000
Section 17.2 25,000
Subsection 17.3(1) 5,000
Section 17.6 25,000
Section 17.7 5,000
Section 17.11 5,000

AR01991 50
Column 1 Column 2
Section 17.12 25,000
Subsection 17.13(1) 25,000
Subsection 17.13(2) 25,000
Subsection 17.14(1) 25,000
Subsection 17.14(2) 25,000
Subsection 17.14(3) 25,000
Subsection 17.14(4) 25,000
Subsection 17.16(1) 25,000
Subsection 17.16(2) 25,000
Subsection 17.16(3) 25,000
Subsection 17.16(4) 25,000
Subsection 17.17(1) 25,000
Subsection 17.17(2) 25,000
Subsection 17.17(3) 25,000
Subsection 17.17(4) 25,000
Section 17.52 25,000
Section 17.54 25,000
Subsection 17.55(1) 25,000
Subsection 17.55(2) 25,000
Section 19 5,000 25,000
Section 20 5,000
Subsection 21 (1) 5,000 25,000
Section 22 5,000
AR01992 51
Column 1 Column 2
Section 23 5,000 25,000
Subsection 24(1) 5,000 25,000
Subsection 24(2) 5,000 25,000
Subsection 24(3) 5,000 25,000
Subsection 25(1) 5,000 25,000
Subsection 26(1) 5,000 25,000
Section 28 5,000
Subsection 31 (1) 5,000
C, Transport Canada is closely monitoring the COVID-19 situation. In response, we have issued
some transP-ortation-related measures and guidance. Please check if any of these
measures apply to you.
You may experience longer than usual wait times or partial service interruptions. If you
cannot get through, please contact us bY. email.
For information on COVID-19 updates, please visit Canada.ca/coronavirus.
Date modified:
2021-10-29
AR01993 52
-
AR01994 53

________________________________
arr r an l r n
r n n n ar
AR01995 54
Interim Order Respecting Certain
Requirements for Civil Aviation Due to
COVID-19, No. 56

regulation made pursuant to sections 4.719. and 4.9.b., paragraphs 7.6(1 )(a)~
and (b)9 and section 7.7~oftheAeronauticsActf;
• g_S.C.2004,c. 15,s.5
• .b.s.c. 2014, c. 39, s. 144
• ~s.C.2015,c.20,s. 12
• 2s.C. 2004,c. 15,s. 18
• ~s.c.2001,c.29,s. 39
• fR.S., c. A-2
annexed Order;
• 9S.C. 2004, c. 15, s. 11 (1)
Therefore, the Minister of Transport, pursuant to subsection 6.41 (1 )9 of the

Ottawa, February 28, 2022
Omar Alghabra
Interpretation
Definitions
accredited person
AR01996 55
accredited person means a foreign national who holds a passport that
contains a valid diplomatic, consular, official or special representative
acceptance issued by the Chief of Protocol for the Department of Foreign
Affairs, Trade and Development. (personne accreditee)
aerodrome property
aerodrome property means, in respect of an aerodrome listed in
Schedule 1, any air terminal buildings or restricted areas or any facilities
used for activities related to aircraft operations or aerodrome operations
that are located at the aerodrome. (terrains de /'aerodrome)

aerodrome security personnel has the same meaning as in section 3 of
the Canadian Aviation Security Regulations, 2012. (personnel de surete de
/'aerodrome)
air carrier
aerien)
Canadian Forces
Canadian Forces means the armed forces of Her Majesty raised by
Canada. (Forces canadiennes)

Chief Public Health Officer means the Chief Public Health Officer
appointed under subsection 6( 1) of the Public Health Agency of Canada
Act. (administrateur en chef)
COVID-19
COVID-19 antigen test

COVID-19 antigen test means a COVID-19 screening or diagnostic
immunoassay that
o (a) detects the presence of a viral antigen indicating the presence of
COVID-19;
o (b) is authorized for sale or distribution in Canada or in the
jurisdiction in which it was obtained;
o (c) if the test is self-administered, is observed and whose result is
verified
■ (i) in person by an accredited laboratory or testing provider, or
■ (ii) in real time by remote audiovisual means by the accredited
laboratory or testing provider that provided the test; and
o (d) if the test is not self-administered, is performed by an accredited
laboratory or testing provider. (essai antigenique relatif aJa COVID-19)

AR01997 56
COVID-19 molecular test means a COVID-19 screening or diagnostic test,
including a test performed using the method of polymerase chain
reaction (PCR) or reverse transcription loop-mediated isothermal
amplification (RT-LAMP), that
o (a) if the test is self-administered, is observed and whose result is
verified
laboratory or testing provider that provided the test; or
o (b) if the test is not self-administered, is performed by an accredited
laboratory or testing provider. (essai moleculaire relatif ala COVID-19)
document of entitlement
document of entitlement has the same meaning as in section 3 of the
Canadian Aviation Security Regulations, 2012. (document d'autorisation)
foreign national
foreign national has the same meaning as in subsection 2(1) of the
Immigration and Refugee Protection Act. (etranger)

non-passenger screening checkpoint has the same meaning as in section
3 of the Canadian Aviation Security Regulations, 2012. (point de controle des
non-passagers)
operator of an aerodrome
operator of an aerodrome means the person in charge of an aerodrome
where activities related to civil aviation are conducted and includes an
employee, agent or mandatary or other authorized representative of that
person. (exploitant)

passagers)
peace officer
Regulations
restricted area
screening authority
AR01998 57
screening officer
testing provider
testing provider means
o (a) a person who may provide COVID-19 screening or diagnostic
testing services under the laws of the jurisdiction where the service is
provided; or
o (b) an organization, such as a telehealth service provider or
pharmacy, that may provide COVID-19 screening or diagnostic testing
services under the laws of the jurisdiction where the service is
provided and that employs or contracts with a person referred to in
paragraph (a). (fournisseur de services d'essais)
variant of concern
variant of concern means a variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) that is designated as a variant of concern by
the World Health Organization. (variant preoccupant)
• Interpretation
Regulations.
• Conflict
• Definition of mask
(4) For the purposes of this Interim Order, a mask means any mask,
including a non-medical mask, that meets all of the following
requirements:
o (a) it is made of multiple layers of tightly woven materials such as

cotton or linen;

gaping;

AR01999 58
• Masks - lip reading
(5) Despite paragraph (4)(a), the portion of a mask in front of a wearer's

lips may be made of transparent material that permits lip reading if
o (a) the rest of the mask is made of multiple layers of tightly woven
materials such as cotton or linen; and
of the mask.
(6) For the purposes of this Interim Order, a fully vaccinated person
if


■ (ii) the Minister of Health determines, on the recommendation of

the Chief Public Health Officer, that the regimen is suitable, having
regard to the scientific evidence related to the efficacy of that
regimen in preventing the introduction or spread of COVID-19 or
any other factor relevant to preventing the introduction or spread
of COVID-19; or

the Chief Public Health Officer, that the vaccines and the regimen
are suitable, having regard to the scientific evidence related to the
efficacy of that regimen and the vaccines in preventing the
introduction or spread of COVID-19 or any other factor relevant to
preventing the introduction or spread of COVID-19.
AR02000 59
Notification

government.

comply with it.
• Vaccination

AR02001 60
• Definitions

agent de quarantaine
agent de controle
Confirmation


• Exception

Prohibition

to provide under subsection 3( 1).
Foreign Nationals
Prohibition

Exception
AR02002 61
Health Check
Non-application

Health check

o (a) a fever;
o (b) a cough;
• Notification

o (b) they have, or have reasonable grounds to suspect they have,

COVID-19;

previous 1O days for a medical reason related to COVID-19; or
o (d) in the case of a flight departing in Canada, they are the subject of a
• Confirmation
AR02003 62
0 (a) the person has, or has reasonable grounds to suspect that they
have, COVID-19;

misleading.

or misleading.
• Exception

whether any person boarding the aircraft is exhibiting any of the
symptoms referred to in subsection (1 ).
Prohibition

exhibit

AR02004 63
the situations described in paragraphs 8(3)(a}, (b) or (c) applies to that
person; or
Period of 1O days

permitted to board another aircraft for a period of 1O days after the denial,
COVID-19.
COVID-19 Tests - Flights to Canada

Application

• Non-application
that they received a result for a COVID-19 molecular test or a COVID-19
antigen test.
Notification
molecular test or a COVID-19 antigen test.
AR02005 64
0 (a) a negative result for a COVID-19 molecular test that was
flight's initial scheduled departure time;
o (b) a negative result for a COVID-19 antigen test that was performed
on a specimen collected no more than one day before the flight's
initial scheduled departure time; or
o (c) a positive result for a COVID-19 molecular test that was performed
on a specimen collected at least 1O days and no more than 180 days
before the flight's initial scheduled departure time.
• Location of test - outside Canada
(1.1) The COVID-19 tests referred to in paragraphs (1 )(a) and (b) must be
performed outside Canada.
(2) For the purposes of paragraphs (1 )(a) and (b) and subsection (1.1 },
the COVID-19 molecular test or COVID-19 antigen test must not have
been performed in a country where, as determined by the Minister of
Health, there is an outbreak of a variant of concern or there are
reasonable grounds to believe that there is an outbreak of such a variant.
Evidence - alternative testing protocol
13.1 Despite subsections 13(1) and (1.1), a person referred to in section 2.22
of the Order entitled Minimizing the Risk of Exposure to COVID-19 in Canada
Order (Quarantine, Isolation and Other Obligations) must, before boarding an
aircraft for a flight, provide to the private operator or air carrier operating
the flight evidence of a COVID-19 molecular test or a COVID-19 antigen test
that was carried out in accordance with an alternative testing protocol
referred to in that section.
Evidence - molecular test
• 14 (1) Evidence of a result for a COVID-19 molecular test must include
0 (a) the name and date of birth of the person from whom the
specimen was collected for the test;
o (b) the name and civic address of the accredited laboratory or the
testing provider that performed or observed the test and verified the
result;
o (c) the date the specimen was collected and the test method used;
and
o (d) the test result.
• Evidence - antigen test

AR02006 65
(2) Evidence of a result for a COVID-19 antigen test must include
o (a) the name and date of birth of the person from whom the
result;
and

test or a COVID-19 antigen test that they know to be false or misleading.
Notice to Minister
has provided evidence of a resu It for a COVID-19 molecular test or a COVID-
19 antigen test that is likely to be false or misleading must notify the
Minister as soon as feasible of the person's name and contact information
and the date and number of the person's flight.
Prohibition

molecular test or a COVID-19 antigen test in accordance with the
requirements set out in section 13 or 13.1.
Vaccination - Flights Departing from an

Aerodrome in Canada
Application
• 17.1 (1) Sections 17.2 to 17.17 apply to all of the following persons:


o (c) an air carrier operating a flight departing from an aerodrome

listed in Schedule 1.
AR02007 66
• Non-application
o (a) a child who is less than 12 years and four months of age;
o (c) a person entering a restricted area at an aerodrome listed in

operated by an air carrier
■ (i) only to become a crew member on board another aircraft

operated by an air carrier,
■ (ii) after having been a crew member on board an aircraft

operated by an air carrier, or

in relation to the operation of an aircraft, if the person will be
required to return to work as a crew member;
o (d) a person who arrives at an aerodrome from any other country on

Canada;
o (e) a person who arrives at an aerodrome on board an aircraft

diverted flight.
Notification
for a flight that the air carrier operates that
• (a) they must be a fully vaccinated person or a person referred to in any

of paragraphs 17.3(2)(a) to (c) or any of subparagraphs 17.3(2)(d)(i) to
(iv) or (e)(i) to (vii);
• (b) they must provide to the air carrier evidence of COVID-19 vaccination
demonstrating that they are a fully vaccinated person or evidence that
they are a person referred to in any of paragraphs 17.3(2)(a) to (c) or any
of subparagraphs 17.3(2)(d)(i) to (iv) or (e)(i) to (vii); and
• (c) if they submit a request referred to in section 17.4, they must do so

within the period set out in subsection 17.4(3).
AR02008 67
entering a restricted area unless they are a fully vaccinated person.
• Exception
(2) Subsection (1) does not apply to
o (a) a foreign national, other than a person registered as an Indian

under the Indian Act, who is boarding the aircraft for a flight to an
aerodrome in Canada if the initial scheduled departure time of that
flight is not more than 24 hours after the departure time of a flight
taken by the person to Canada from any other country;
o (b) a permanent resident who is boarding the aircraft for a flight to an

taken by the person to Canada from any other country for the
purpose of entering Canada to become a permanent resident;
o (c) a foreign national who is boarding an aircraft for a flight to a

country other than Canada or to an aerodrome in Canada for the
purpose of boarding an aircraft for a flight to a country other than
Canada and who has received either
■ (i) a negative result for a COVID-19 molecular test that was

performed on a specimen collected no more than 72 hours before
the flight's initial scheduled departure time,
■ (ii) a negative result for a COVID-19 antigen test that was

performed on a specimen collected no more than one day before
the flight's initial scheduled departure time, or
■ (iii) a positive result for a COVID-19 molecular test that was

performed on a specimen collected at least 1O days and no more
than 180 days before the flight's initial scheduled departure time;
o (d) a person who has received a result for a COVID-19 molecular test
or a COVID-19 antigen test described in subparagraph (c)(i}, (ii) or (iii)
and who is
■ (i) a person who has not completed a COVID-19 vaccine dosage

regimen due to a medical contraindication and who is entitled to
be accommodated on that basis under applicable legislation by
being permitted to enter the restricted area or to board an aircraft
without being a fully vaccinated person,
■ (ii) a person who has not completed a COVID-19 vaccine dosage

regimen due to a sincerely held religious belief and who is entitled
to be accommodated on that basis under applicable legislation by
AR02009 68
■ (iii) a person who is boarding an aircraft for a flight for the purpose
of attending an appointment for an essential medical service or
treatment, or
■ (iv) a competent person who is at least 18 years old and who is

boarding an aircraft for a flight for the purpose of accompanying a
person referred to in subparagraph {iii) if the person needs to be
accompanied because they
■ (A) are under the age of 18 years,
■ (B) have a disability, or
■ (C) need assistance to communicate; or
o (e) a person who has received a result for a COVID-19 molecular test
or a COVID-19 antigen test described in subparagraph (c)(i), (ii) or {iii)
and who is boarding an aircraft for a flight for a purpose other than
an optional or discretionary purpose, such as tourism, recreation or
leisure, and who is
■ (i) a person who entered Canada at the invitation of the Minister of

Health for the purpose of assisting in the COVID-19 response,
■ {ii) a person who is permitted to work in Canada as a provider of

emergency services under paragraph 186(t) of the Immigration and
Refugee Protection Regulations and who entered Canada for the
purpose of providing those services,
■ (iii) a person who entered Canada not more than 90 days before
the day on which this Interim Order came into effect and who, at
the time they sought to enter Canada,
■ (A) held a permanent resident visa issued under subsection

139( 1) of the Immigration and Refugee Protection Regulations,
and
■ (B) was recognized as a Convention refugee or a person in

similar circumstances to those of a Convention refugee within
the meaning of subsection 146(1) of the Immigration and
Refugee Protection Regulations,
■ (iv) a person who has been issued a temporary resident permit
within the meaning of subsection 24( 1) of the Immigration and
Refugee Protection Act and who entered Canada not more than 90
AR02010 69
days before the day on which this Interim Order came into effect
as a protected temporary resident under subsection 151.1 (2) of the
Immigration and Refugee Protection Regulations,
■ (v) an accredited person,
■ (vi) a person holding a D-1, 0-1 or C-1 visa who entered Canada to
take up a post and become an accredited person, or
■ (vii) a diplomatic or consular courier.
Persons - subparagraphs 17.3(2)(d)(i) to (iv)
• 17.4 (1) An air carrier must issue a document to a person referred to in

any of subparagraphs 17.3(2)(d)(i) to (iv) who intends to board an aircraft
for a flight that the air carrier operates or that is operated on the air
carrier's behalf under a commercial agreement if
o (a) in the case of a person referred to in any of subparagraphs 17.3(2)

(d)(i) to (iii), the person submits a request to the air carrier in respect
of that flight in accordance with subsections (2) and (3) or such a
request is submitted on their behalf;
o (b) in the case of a person referred to in subparagraph 17.3(2)(d)(i) or

(ii), the air carrier is obligated to accommodate the person on the
basis of a medical contraindication or a sincerely held religious belief
under applicable legislation by issuing the document; and
0 (c) in the case of a person referred to in subparagraph 17.3(2)(d)(iv),

the person who needs accompaniment submits a request to the air
carrier in respect of that flight in accordance with subsections (2) and
(3) or such a request is submitted on their behalf.
• Request - contents
(2) The request must be signed by the requester and include the
following:
o (a) the person's name and home address and, if the request is made
by someone else on the person's behalf, that person's name and
home address;
o (b) the date and number of the flight as well as the aerodrome of
departure and the aerodrome of arrival;
o (c) in the case of a person described in subparagraph 17.3(2)(d)(i),
■ (i) a document issued by the government of a province confirming

that the person cannot complete a COVID-19 vaccination regimen
due to a medical condition, or
AR02011 70
■ (ii) a medical certificate signed by a medical doctor or nurse
practitioner who is licensed to practise in Canada certifying that
the person cannot complete a COVID-19 vaccination regimen due
to a medical condition and the licence number issued by a
professional medical licensing body to the medical doctor or nurse
practitioner;
o (d) in the case of a person described in subparagraph 17.3(2)(d)(ii), a

statement sworn or affirmed by the person before a person
appointed as a commissioner of oaths in Canada attesting that the
person has not completed a COVID-19 vaccination regimen due to a
sincerely held religious belief, including a description of how the belief
renders them unable to complete such a regimen; and
o (e) in the case of a person described in subparagraph 17.3(2)(d)(iii), a

document that includes
■ (i) the signature of a medical doctor or nurse practitioner who is

licensed to practise in Canada,
■ (ii) the licence number issued by a professional medical licensing

body to the medical doctor or nurse practitioner,
■ (iii) the date of the appointment for the essential medical service
or treatment and the location of the appointment,
■ (iv) the date on which the document was signed, and
■ (v) if the person needs to be accompanied by a person referred to

in subparagraph 17.3(2)(d)(iv), the name and contact information
of that person and the reason that the accompaniment is needed.
• Timing of request
(3) The request must be submitted to the air carrier
o (a) in the case of a person referred to in subparagraph 17.3(2)(d)(i) or

(ii), 21 days before the day on which the flight is initially scheduled to
depart; and
o (b) in the case of a person referred to in subparagraph 17.3(2)(d)(iii)

or (iv), 14 days before the day on which the flight is initially scheduled
to depart.
• Special circumstances
(4) In special circumstances, an air carrier may issue the document

referred to in subsection (1) in response to a request submitted after the
period referred to in subsection (3).
• Content of document
AR02012 71
(5) The document referred to in subsection (1) must include
o (a) a confirmation that the air carrier has verified that the person is a
person referred to in any of subparagraphs 17.3(2)(d)(i) to (iv); and
departure and the aerodrome of arrival.
Record keeping
• 17.5 (1) An air carrier must keep a record of the following information:
o (a) the number of requests that the air carrier has received in respect
of each exception referred to in subparagraphs 17.3(2)(d)(i) to (iv);
o (b) the number of documents issued under subsection 17.4(1 ); and
o (c) the number of requests that the air carrier denied.
• Retention
(2) An air carrier must retain the record for a period of at least 12 months
after the day on which the record was created.
(3) The air carrier must make the record available to the Minister on
request.
Copies of requests
• 17.6 (1) An air carrier must keep a copy of a request for a period of at
least 90 days after the day on which the air carrier issued a document
under subsection 17.4(1) or refused to issue the document.
(2) The air carrier must make the copy available to the Minister on
request.
17.7 Before permitting a person to board an aircraft for a flight that the air
carrier operates, the air carrier must request that the person provide
• (a) evidence of COVID-19 vaccination demonstrating that they are a fully

vaccinated person;
• (b) evidence that they are a person referred to in paragraph 17.3(2)(a) or

(b); or
• (c) evidence that they are a person referred to in paragraph 17.3(2)(c) or

any of subparagraphs 17.3(2)(d)(i) to (iv) or (e)(i) to (vii) and that they
have received a result for a COVID-19 molecular test or a COVID-19
antigen test.
AR02013 72
[17.8 reserved]
17.9 A person must, at the request of an air carrier, provide to the air carrier
the evidence referred to in paragraph 17.7(a), (b) or (c).
• 17.10 (1) Evidence of COVID-19 vaccination must be evidence issued by a

non-governmental entity that is authorized to issue the evidence of
COVID-19 vaccination in the jurisdiction in which the vaccine was
administered, by a government or by an entity authorized by a
government, and must contain the following information:
o (b) the name of the government or of the entity;
0 (c) the brand name or any other information that identifies the
o (d) the dates on which the vaccine was administered or, if the

Resu It of COVID-19 test
• 17.11 (1) A result for a COVID-19 molecular test or a COVID-19 antigen

test is a result described in subparagraph 17.3(2)(c){i), {ii) or (iii).
• Evidence - molecular test
elements set out in paragraphs 14(1 )(a) to (d).
(3) Evidence of a result for a COVID-19 antigen test must include the
elements set out in paragraphs 14(2)(a) to (d).
Person - paragraph 17.3(2)(a)
• 17.12 (1) Evidence that the person is a person referred to in paragraph

17.3(2)(a) must be
AR02014 73
0 (a) a travel itinerary or boarding pass that shows that the initial
scheduled departure time of the flight to an aerodrome in Canada is
not more than 24 hours after the departure time of a flight taken by
the person to Canada from any other country; and
o (b) their passport or other travel document issued by their country of

citizenship or nationality.
• Person - paragraph 17.3(2}{b)
(2) Evidence that the person is a person referred to in paragraph 17.3(2)

(b) must be
o (a) a travel itinerary or boarding pass that shows that the initial
not more than 24 hours after the departure time of the flight taken by
0 (b) a document entitled "Confirmation of Permanent Residence"

issued by the Department of Citizenship and Immigration that
confirms that the person became a permanent resident on entry to
Canada after the flight taken by the person to Canada from any other
country.
• Person - paragraph 17.3(2)(c)

(c) must be
o (a) a travel itinerary or boarding pass that shows that the person is
boarding an aircraft for a flight to a country other than Canada or to
an aerodrome in Canada for the purpose of boarding an aircraft for a
flight to a country other than Canada; and

• Person - subparagraphs 17.3(2)(d)(i) to (iv)
(4) Evidence that the person is a person referred to in any of

subparagraphs 17.3(2)(d)(i) to (iv) must be a document issued by an air
carrier under subsection 17.4(1) in respect of the flight for which the
person is boarding the aircraft or entering the restricted area.
• Person - subparagraph 17.3(2)(e)(i)
(5) Evidence that the person is a person referred to in subparagraph

17.3(2)(e)(i) must be a document issued by the Minister of Health that
indicates that the person was asked to enter Canada for the purpose of
assisting in the COVID-19 response.
AR02015 74
• Person - subparagraph 17.3(2)(e)(ii}

17.3(2)(e)(ii) must be a document from a government or non-
governmental entity that indicates that the person was asked to enter
Canada for the purpose of providing emergency services under
paragraph 186(t) of the Immigration and Refugee Protection Regulations.
• Person - subparagraph 17.3(2)(e)(iii)

17.3(2)(e)(iii) must be a document issued by the Department of
Citizenship and Immigration that confirms that the person has been
recognized as a Convention refugee or a person in similar circumstances
to those of a Convention refugee within the meaning of subsection
146(1) of the Immigration and Refugee Protection Regulations.
• Person - subparagraph 17.3(2)(e)(iv)

17.3(2)(e)(iv) must be a document issued by the Department of
Citizenship and Immigration that confirms that the person entered
Canada as a protected temporary resident under subsection 151.1 (2) of
the Immigration and Refugee Protection Regulations.
• Person - subparagraph 17.3(2)(e)(v)

17.3(2)(e)(v) must be their passport containing a valid diplomatic,
consular, official or special representative acceptance issued by the Chief
of Protocol for the Department of Foreign Affairs, Trade and
Development.
• Person - subparagraph 17.3(2)(e)(vi)

17.3(2)(e)(vi) must be the person's D-1, 0-1 or C-1 visa.
• Person - subparagraph 17.3(2)(e)(vii)

17.3(2)(e)(vii) must be
o (a) in the case of a diplomatic courier, the official document

confirming their status referred to in Article 27 of the Vienna
Convention on Diplomatic Relations, as set out in Schedule I to the
Foreign Missions and International Organizations Act; and
AR02016 75
o (b) in the case of a consular courier, the official document confirming
their status referred to in Article 35 of the Vienna Convention on
Consular Relations, as set out in Schedule II to that Act.
False or misleading information
• 17.13 (1) A person must not submit a request referred to in section 17.4
that contains information that they know to be false or misleading.
• False or misleading evidence
(2) A person must not provide evidence that they know to be false or
misleading.
Notice to Minister - information
• 17.14 (1) An air carrier that has reason to believe that a person has
submitted a request referred to in section 17.4 that contains information
that is likely to be false or misleading must notify the Minister of the
following not more than 72 hours after receiving the request:
o (a) the person's name and contact information;
o (b) the date and number of the person's flight; and
o (c) the reason the air carrier believes that the information is likely to
be false or misleading.
• Notice to Minister - evidence
(2) An air carrier that has reason to believe that a person has provided
evidence that is likely to be false or misleading must notify the Minister
of the following not more than 72 hours after the provision of the
evidence:
o (c) the reason the air carrier believes that the evidence is likely to be
false or misleading.
17.15 An air carrier must not permit a person to board an aircraft for a flight
that the air carrier operates if the person does not provide the evidence they
are required to provide under section 17.9.
[17.16 reserved]

AR02017 76
respect of a person each time the person is denied permission to board
an aircraft for a flight under section 17.15:
o (a) the person's name and contact information, including the person's
home address, telephone number and email address;
o (b) the date and flight number;
0 (c) the reason why the person was denied permission to board the
aircraft; and
o (d) whether the person had been issued a document under

subsection 17.4(1) in respect of the flight.
• Retention
(2) The air carrier must retain the record for a period of at least 12
months after the date of the flight.
request.
[17.18 and 17.19 reserved]

Application
17.20 Sections 17.21 to 17.25 apply to

Schedule 1, other than an air carrier who operates a commercial air
• (c) NAV CANADA.
• 17.21 (1) For the purposes of sections 17.22 to 17.25, relevant person, in
respect of an entity referred to in section 17.20, means a person whose
duties involve an activity described in subsection (2) and who is
o (b) an employee of the entity's contractor or agent or mandatary;
0 (d) the entity's lessee or an employee of the entity's lessee, if the

AR02018 77
• Activities
(2) For the purposes of subsection (1 ), the activities are

aerodrome operations or commercial flight operations - such as
aircraft refuelling services, aircraft maintenance and repair services,
baggage handling services, supply services for the operator of an
aerodrome, an air carrier or NAV CANADA, fire prevention services,
runway and taxiway maintenance services or de-icing services - and
that take place on aerodrome property or at a location where NAV
CANADA provides civil air navigation services;


and

(2) The policy must
o (a) require that a person who is 12 years and four months of age or
older be a fully vaccinated person before accessing aerodrome
property, unless they are a person
■ (i) who intends to board an aircraft for a flight that an air carrier
operates,
■ {ii) who does not intend to board an aircraft for a flight and who is
accessing aerodrome property for leisure purposes or to
accompany a person who intends to board an aircraft for a flight,
■ {iii) who is the holder of an employee identification document

issued by a department or departmental corporation listed in
Schedule 2 or a member identification document issued by the
AR02019 78
Canadian Forces, or
■ (iv) who is delivering equipment or providing services within a

restricted area that are urgently needed and critical to aerodrome
operations and who has obtained an authorization from the
operator of the aerodrome before doing so;
o (b) despite paragraph (a), allow a person who is subject to the policy
and who is not a fully vaccinated person to access aerodrome
property if the person has not corn pleted a COVID-19 vaccine dosage
regimen due to a medical contraindication or their sincerely held
religious belief;
o (c) provide for a procedure for verifying evidence provided by a

person referred to in paragraph (b) that demonstrates that the
person has not completed a COVID-19 vaccine dosage regimen due to
a medical contraindication or their sincerely held religious belief;
o (d) provide for a procedure for issuing to a person whose evidence

has been verified under the procedure referred to in paragraph (c) a
document confirming that they are a person referred to in paragraph
(b);
o (e) provide for a procedure that ensures that a person subject to the
policy provides, on request, the following evidence before accessing
aerodrome property:
■ (i) in the case of a fully vaccinated person, the evidence of COVID-

19 vaccination referred to in section 17.10, and
■ (ii) in the case of a person referred to in paragraph (d), the

document issued to the person under the procedure referred to in
that paragraph;
o (f) provide for a procedure that allows a person to whom sections

17.31 to 17.40 apply- other than a person referred to in subsection
17.34(2)-who is a fully vaccinated person or a person referred to in
paragraph (b) and who is unable to provide the evidence referred to
in paragraph (e) to temporarily access aerodrome property if they
provide a declaration confirming that they are a fully vaccinated
person or that they have been issued a document under the
procedure referred to in paragraph (d);

paragraph (d) is tested for COVID-19 at least twice every week;
AR02020 79
0 (h) provide for a procedure that ensures that a person who receives a
positive result for a COVID-19 test taken under the procedure referred
to in paragraph (g) is prohibited from accessing aerodrome property
until the end of the period for which the public health authority of the
province or territory in which the aerodrome is located requires them
to isolate after receiving a positive result; and
o (i) provide for a procedure that ensures that a person referred to in

paragraph (h) who undergoes a COVID-19 molecular test is exempt
from the procedure referred to in paragraph (g) for a period of 180
days after the person received a positive result from that test.
(3) For the purposes of paragraphs (2)(c) and (d), the policy must provide
that a document is to be issued to a person confirming that they did not
complete a COVID-19 vaccine dosage regimen on the basis of a medical
contraindication only if they provide a medical certificate from a medical
doctor or nurse practitioner who is licensed to practise in Canada
certifying that the person cannot complete a COVID-19 vaccination
regimen due to a medical condition and specifying whether the condition
is permanent or temporary.
• Religious belief
complete a COVID-19 vaccine dosage regimen on the basis of their
sincerely held religious belief only if they submit a statement sworn or
affirmed by them attesting that they have not completed a COVID-19
vaccination regimen due to their sincerely held religious belief.
(5) For the purposes of paragraphs (2)(c) and (d), in the case of an
employee of the operator of an aerodrome or a person hired by the
operator of an aerodrome to provide a service, the policy must provide
that a document is to be issued to the employee or person confirming
that they did not complete a COVID-19 vaccine dosage regimen on the
basis of their sincerely held religious belief only if the operator of the
aerodrome is obligated to accommodate them on that basis under the
Canadian Human Rights Act by issuing such a document.
(6) For the purposes of paragraphs (2)(c) and (d), in the following cases,
the policy must provide that a document is to be issued to the employee
confirming that they did not complete a COVID-19 vaccine dosage
AR02021 80
regimen on the basis of their sincerely held religious belief only if they
would be entitled to such an accommodation on that basis under
applicable legislation:

contractor or agent or mandatary; and
o (b) in the case of an employee of the operator of an aerodrome's

property.
entity

(a) to (h) and subsections 17.24(3) to (6); and

unvaccinated person who has not been issued a document under the
procedure referred to in paragraph 17.24(2)(d) and who is
0 (ii) an employee of the entity's contractor or agent or mandatary,

(2) The policy must
0 (a) require that a relevant person, other than the holder of an

employee identification document issued by a department or
departmental corporation listed in Schedule 2 or a member
identification document issued by the Canadian Forces, be a fully
vaccinated person before accessing aerodrome property or, in the
case of NAV CANADA, a location where NAV CANADA provides civil air
navigation services;
AR02022 81
o (b) despite paragraph (a), allow a relevant person who is subject to
the policy and who is not a fully vaccinated person to access
NAV CANADA provides civil air navigation services, if the relevant

relevant person referred to in paragraph (b) that demonstrates that
the relevant person has not completed a COVID-19 vaccine dosage
religious belief;
o (d) provide for a procedure for issuing to a relevant person whose

evidence has been verified under the procedure referred to in
paragraph (c) a document confirming that they are a relevant person
referred to in paragraph (b);
o (e) provide for a procedure that ensures that a relevant person

subject to the policy provides, on request, the following evidence
before accessing aerodrome property:

■ {ii) in the case of a relevant person referred to in paragraph (d),

the document issued to the relevant person under the procedure
referred to in that paragraph;
o (f) provide for a procedure that ensures that a relevant person

referred to in paragraph (d) is tested for COVID-19 at least twice every
week;
o (g) provide for a procedure that ensures that a relevant person who
receives a positive result for a COVID-19 test under the procedure
referred to in paragraph (f) is prohibited from accessing aerodrome
property until the end of the period for which the public health
authority of the province or territory in which the aerodrome is
located requires them to isolate after receiving a positive test result;
o (h) provide for a procedure that ensures that a relevant person

referred to in paragraph (g) who undergoes a COVID-19 molecular
test is exempt from the procedure referred to in paragraph (f) for a
period of 180 days after the relevant person received a positive result
from that test;
AR02023 82
o (i) set out procedures for reducing the risk that a relevant person will
interaction, occurring on aerodrome property or at a location where
NAV CANADA provides civil air navigation services, with an
procedure referred to in paragraph (d) and who is a person referred
to in any of subparagraphs 17.23(b)(i) to (iv), which procedures may
include protocols related to

■ {ii) physical distancing and the wearing of masks, and
o 0) establish a procedure for collecting the following information with

operations between a relevant person and a person referred to in any
of subparagraphs 17.23(b)(i) to (iv) who is unvaccinated and has not
been issued a document under the procedure referred to in
paragraph (d) or whose vaccination status is unknown:
■ {ii) contact information for the relevant person and the other
person;
o (k) establish a procedure for recording the following information and

policy,
■ {ii) the number of relevant persons who require access to a

restricted area,
■ {iii) the number of relevant persons who are fully vaccinated

persons and those who are not,

due to COVID-19,
■ (v) the number of relevant persons who have been issued a

document under the procedure referred to in paragraph (d), the
reason for issuing the document and a confirmation that the
relevant persons have submitted evidence of COVID-19 tests taken
in accordance with the procedure referred to in paragraph (f),
AR02024 83
requirement referred to in paragraph (a), (f) or (g),

referred to in paragraph (a), (f) or (g),

(i) to (iv) who are unvaccinated and who have not been issued a
document under the procedure referred to in paragraph (d), or
whose vaccination status is unknown, who have an in-person
interaction related to commercial flight operations with a relevant
person and a description of any procedures implemented to
reduce the risk that a relevant person will be exposed to the virus
that causes COVID-19 due to such an interaction, and
■ (ix) the number of instances in which the air carrier or NAV

CANADA, as applicable, is made aware that a person with respect
to whom information was collected under paragraph U) received a
positive result for a COVID-19 test, the number of relevant persons
tested for COVID-19 as a result of this information, the results of
those tests and a description of any impacts on commercial flight
operations; and
o (I) require the air carrier or NAV CANADA, as applicable, to keep the
information referred to in paragraph (k) for a period of at least 12
that a document is to be issued to a relevant person confirming that they
did not complete a COVID-19 vaccine dosage regimen on the basis of a
medical contraindication only if they provide a medical certificate from a
medical doctor or nurse practitioner who is licensed to practise in
Canada certifying that the relevant person cannot complete a COVID-19
vaccination regimen due to a medical condition and specifying whether
the condition is permanent or temporary.
did not complete a COVID-19 vaccine dosage regimen on the basis of
their sincerely held religious belief only if they submit a statement sworn
or affirmed by them attesting that they have not completed a COVID-19
AR02025 84
employee of an entity or a relevant person hired by an entity to provide a
service, the policy must provide that a document is to be issued to the
employee or the relevant person confirming that they did not complete a
COVID-19 vaccine dosage regimen on the basis of their sincerely held
religious belief only if the entity is obligated to accommodate the
relevant person on that basis under the Canadian Human Rights Ad by
issuing such a document.
o (a) in the case of an employee of an entity's contractor or agent or

mandatary; and



request.
Vaccination - Aerodromes in Canada

Application
o (a) subject to paragraph (c), a person entering a restricted area at an

aerodrome listed in Schedule 1 from a non-restricted area for a
reason other than to board an aircraft for a flight operated by an air
AR02026 85
carrier;
o (b) a crew member entering a restricted area at an aerodrome listed

in Schedule 1 from a non-restricted area to board an aircraft for a
flight operated by an air carrier under Subpart 1, 3, 4 or 5 of Part VII of
the Regulations;


operated by an air carrier under Subpart 1, 3, 4 or 5 of Part VII of
the Regulations,
■ {ii) after having been a crew member on board an aircraft

the Regulations, or
■ {iii) to participate in mandatory training required by an air carrier

in relation to the operation of an aircraft operated under Subpart
1, 3, 4 or 5 of Part VII of the Regulations, if the person will be
o (d) a screening authority at an aerodrome where persons other than

passengers are screened or can be screened;
o (e) the operator of an aerodrome listed in Schedule 1.
• Non-application
o (b) a person who arrives at an aerodrome on board an aircraft

as adverse weather or an equipment malfunction, and who enters a
restricted area to board an aircraft for a flight not more than 24 hours
after the arrival time of the diverted flight;
o (c) a member of emergency response provider personnel who is

o (d) a peace officer who is responding to an emergency;
o (e) the holder of an employee identification document issued by a

department or departmental corporation listed in Schedule 2 or a
member identification document issued by the Canadian Forces; or
o (f) a person who is delivering equipment or providing services within

a restricted area that are urgently needed and critical to aerodrome
operations and who has obtained an authorization from the operator
AR02027 86
of the aerodrome before doing so.
Prohibition
• 17.31 (1) A person must not enter a restricted area unless they are a fully
vaccinated person.
• Exception
(2) Subsection (1) does not apply to a person who has been issued a
document under the procedure referred to in paragraph 17.22(2)(d) or
17.24(2)(d).
17.32 A person must provide to a screening authority or the operator of an

aerodrome, on their request,
• (a) in the case of a fully vaccinated person, the evidence of COVID-19

vaccination referred to in section 17.10; and
• (b) in the case of a person who has been issued a document under the
procedure referred to in paragraph 17.22(2)(d) or 17.24(2)(d), the
document issued to the person.
Request for evidence

present themselves for screening at a non-passenger screening checkpoint
or a passenger screening checkpoint, provide the evidence referred to in
paragraph 17.32(a) or (b).
Declaration
• 17.34 (1) If a person who is a fully vaccinated person or who has been
issued a document under the procedure referred to in paragraph
17.22(2)(d) is unable, following a request to provide evidence under
section 17.33, to provide the evidence, the person may
o (a) sign a declaration confirming that they are a fully vaccinated

procedure referred to in paragraph 17.22(2)(d); or
o (b) if the person has signed a declaration under paragraph (a) no

more than seven days before the day on which the request to provide
evidence is made, provide that declaration.
• Exception
AR02028 87
(2) Subsection (1) does not apply to the holder of a document of
entitlement that expires within seven days after the day on which the
request to provide evidence under section 17.33 is made.
• Notification to aerodrome operator
(3) If a person signs a declaration referred to in paragraph (1)(a}, the

screening authority must notify the operator of the aerodrome as soon
as feasible of the person's name, the date on which the declaration was
signed and, if applicable, the number or identifier of the person's
document of entitlement.
• Provision of evidence
(4) A person who signed a declaration under paragraph (1 )(a) must

provide the evidence referred to in paragraph 17.32(a) or (b) to the
operator of the aerodrome within seven days after the day on which the
declaration is signed.
• Suspension of restricted area access
(5) An operator of an aerodrome must ensure that the restricted area

access of a person who does not provide the evidence within seven days
as required under subsection (4) is suspended until the person provides
the evidence.
Record keeping - suspension
• 17.35 (1) The operator of the aerodrome must keep a record of the
following information in respect of a person each time the restricted area
access of the person is suspended under subsection 17.34(5):
o (b) the number or identifier of the person's document of entitlement,

if applicable;
o (c) the date of the suspension; and
o (d) the reason for the suspension.
• Retention
(2) The operator must retain the record for a period of at least 12 months
(3) The operator of the aerodrome must make the record available to the
Minister on request.
Prohibition
AR02029 88
• 17.36 (1) A screening authority must deny a person entry to a restricted
area if, following a request to provide evidence under section 17.33, the
person does not provide the evidence or, if applicable, does not sign or
provide a declaration under subsection 17.34(1).
(2) If a screening authority denies a person entry to a restricted area, it

must notify the operator of the aerodrome as soon as feasible of the
person's name, the date on which the person was denied entry and, if
applicable, the number or identifier of the person's document of
entitlement.

access of a person who was denied entry under subsection (1) is
suspended until the person provides the requested evidence or the
signed declaration.
17.37 A person must not provide evidence that they know to be false or
misleading.
Notice to Minister
17.38 A screening authority or the operator of an aerodrome that has

reason to believe that a person has provided evidence that is likely to be
false or misleading must notify the Minister of the following not more than
72 hours after the provision of the evidence:
• (a) the person's name;
• (b) the number or identifier of the person's document of entitlement, if

applicable; and
• (c) the reason the screening authority or the operator of an aerodrome

believes that the evidence is likely to be false or misleading.
Record keeping - denial of entry

information in respect of a person each time the person is denied entry
to a restricted area under subsection 17.36(1):

if applicable;
AR02030 89
o (c) the date on which the person was denied entry and the location;
and
o (d) the reason why the person was denied entry to the restricted area.
• Retention
(2) The screening authority must retain the record for a period of at least
12 months after the day on which the record was created.
(3) The screening authority must make the record available to the
Requirement to establish and implement
17.40 The operator of an aerodrome must ensure that a document of

entitlement is only issued to a fully vaccinated person or a person who has
been issued a document under the procedure referred to in paragraph
17.22(2)(d).
Masks
Non-application
age who is unable to tolerate wearing a mask;
unable to wear a mask for a medical reason;
o (e) a person who is unable to remove their mask without assistance;
o (g) a gate agent.
• Mask readily available
less than six years of age must ensure that a mask is readily available to
the child before boarding an aircraft for a flight.
• Wearing of mask
mask when wearing one is required under section 21 and complies with
any instructions given by a gate agent under section 22 if the child
AR02031 90
0 (a) is at least two years of age but less than six years of age and is
able to tolerate wearing a mask; or
Notification
• (a) be in possession of a mask before boarding;
• (b) wear the mask at all times during the boarding process, during the
flight and from the moment the doors of the aircraft are opened until the
person enters the air terminal building; and
with respect to wearing a mask.
Obligation to possess mask

mask before boarding an aircraft for a flight.
Wearing of mask - persons
must require a person to wear a mask at all times during the boarding
process and during a flight that the private operator or air carrier
operates.
0 (a) when the safety of the person could be endangered by wearing a

mask;

instructs the person to wear a mask;

the mask to address unforeseen circumstances or the person's
special needs; or

personnel or a crew member authorizes the removal of the mask to
verify the person's identity.

AR02032 91

o (e) a person who has expertise related to the aircraft, its equipment or
Compliance

respect to wearing a mask.

• (a) the person is not in possession of a mask; or

agent or a crew member with respect to wearing a mask.
Refusal to comply
with respect to wearing a mask, the private operator or air carrier must
■ (ii) the person's name, date of birth and contact information,

email address,
■ (iii) the person's seat number, and

AR02033 92
(2) The private operator or air carrier must retain the record for a period
of at least 12 months after the date of the flight.
(3) The private operator or air carrier must make the record available to
the Minister on request.
Wearing of mask - crew member
must require a crew member to wear a mask at all times during the
carrier operates.

wearing a mask;
o (b) when the wearing of a mask by the crew member could interfere
with operational requirements or the safety of the flight; or

medications.
Wearing of mask - gate agent
must require a gate agent to wear a mask during the boarding process
for a flight that the private operator or air carrier operates.
• Exceptions

wearing a mask; or
o (b) when the gate agent is drinking, eating or taking oral medications.
AR02034 93
Deplaning
Non-application
• 27 ( 1) Section 28 does not apply to any of the following persons:
0 (a) a child who is less than two years of age;
0 (e) a person who is unable to remove their mask without assistance;

• Wearing of mask
mask when wearing one is required under section 28 if the child
Wearing of mask - person
28 A person who is on board an aircraft must wear a mask at all times from
the moment the doors of the aircraft are opened until the person enters the
air terminal building, including by a passenger loading bridge.
Screening Authority
Non-application
0 (d) a person who is unconscious;

AR02035 94

• Wearing of mask
mask when wearing one is required under subsection 30(2) and removes
it when required by a screening officer to do so under subsection 30(3) if
the child

mask at all times during screening.
• Wearing of mask - person

referred to in subsection (1) must wear a mask at all times during
screening.
• Requirement to remove mask
(3) A person who is required by a screening officer to remove their mask

during screening must do so.
• Wearing of mask - screening officer
(4) A screening officer must wear a mask at a passenger screening

being screened.
• 31 ( 1) A person who presents themselves at a non-passenger screening

checkpoint to enter into a restricted area must wear a mask at all times.
(2) Subject to subsection (3), a screening officer must wear a mask at all
times at a non-passenger screening checkpoint.
• Exceptions
AR02036 95

wearing a mask; or

medications.

notified to wear a mask and refuses to do so to pass beyond a passenger
screening checkpoint into a restricted area.
mask to pass beyond a non-passenger screening checkpoint into a
restricted area.
Designation

• Maximum amounts
• Notice

and must specify
AR02037 96

o (d) that the person on whom the notice is served or to whom it is sent
period.
Repeal
Due to COVID-19, No. 55, made on February 23, 2022, is repealed.
SCHEDULE 1{Subsections 1(1) and 17.1(1)

and paragraphs 17.1{2){c), 17.20{a) and {b),
17.21{2){d) and 17.30{1){a) to {c) and {e))
Aerodromes
ICAO Location
Name Indicator
Alma CYTF
Bagotville CYBG
Baie-Comeau CYBC
Bathurst CZBF
Campbell River CYBL

AR02038 97
ICAO Location
Name Indicator
Charle CYCL
Charlottetown CYYG
Comox CYQQ
Dawson Creek CYDQ
Deer Lake CYDF
Fort McMurray CYMM
Fort St. John CYXJ
Gaspe CYGP
Goose Bay CYYR
Grande Prairie CYQU
Iles-de-la-Madeleine CYGR
Iqaluit CYFB
Kamloops CYKA
Kelowna CYLW
Kingston CYGK
Leth bridge CYQL

AR02039 98
ICAO Location
Name Indicator
Lloyd minster CYLL
London CYXU
Medicine Hat CYXH
Mont-Joli CYYY
Montreal International (Mirabel) CYMX

International)
Montreal (St. Hubert) CYHU
Nanaimo CYCD
North Bay CYYB
Penticton CYYF
Prince George CYXS
Prince Rupert CYPR
Quesnel CYQZ
Rouyn-Noranda CYUY
Saint John CYSJ
Samia (Chris Hadfield) CYZR
Sept-lies CYZV
Smithers CYYD
St. Anthony CYAY

AR02040 99
ICAO Location
Name Indicator
Stephenvi Ile CYJT
Sudbury CYSB
Terrace CYXT
Thompson CYTH
Thunder Bay CYQT
Val-d'Or CYVO
Vancouver (Coal Harbour) CYHC
Wabush CYWK
Williams Lake CYWL
Windsor CYQG

International)
Yellowknife CYZF
SCHEDULE 2{Subparagraph 17.22{2){a){iii)

and paragraphs 17.24{2){a) and 17.30{2){e))
Departments and Departmental Corporations
Name
Canada Border Services Agency
Canadian Security Intelligence Service

AR02041 100
Name
Correctional Service of Canada
Department of Agriculture and Agri-Food
Department of Employment and Social Development
Department of Fisheries and Oceans
Department of Health
Department of National Defence
Department of the Environment
Department of Public Safety and Emergency Preparedness
Department of Transport
Public Health Agency of Canada
Royal Canadian Mounted Police

Column 1 Column 2
Maximum Amount of Penalty{$)
Designated Provision Individual Corporation
Subsection 2(1) 5,000 25,000
Subsection 2(2) 5,000 25,000
Subsection 2(3) 5,000 25,000
Subsection 2(4) 5,000 25,000
Section 4 5,000 25,000
Section 5 5,000 25,000
Subsection 8(1) 5,000 25,000
Subsection 8(2) 5,000 25,000

AR02042 101
Column 1 Column 2
Subsection 8(4) 5,000 25,000
Subsection 8(7) 5,000 25,000
Section 9 5,000 25,000
Section 10 5,000
Section 12 5,000 25,000
Section 13.1 5,000
Section 15 5,000
Section 16 5,000 25,000
Section 17 5,000 25,000
Section 17.2 25,000
Section 17.7 25,000
Section 17.9 5,000
Subsection 17.14(1) 25,000
Subsection 17.14(2) 25,000
Section 17.15 25,000
Subsection 17.17(1) 25,000

AR02043 102
Column 1 Column 2
Subsection 17.17(2) 25,000
Subsection 17.17(3) 25,000
Subsection 17.22(1) 25,000
Subsection 17.24(1) 25,000
Subsection 17.25(1) 25,000
Subsection 17.25(2) 25,000
Section 17.32 5,000
Section 17.33 25,000
Subsection 17.34(3) 25,000
Subsection 17.34(5) 25,000
Subsection 17.35(1) 25,000
Subsection 17.35(2) 25,000
Subsection 17.35(3) 25,000
Subsection 17.36(1) 25,000
Subsection 17.36(2) 25,000
Subsection 17.36(3) 25,000
Section 17.37 5,000
Section 17.38 25,000
Subsection 17.39(1) 25,000
Subsection 17.39(2) 25,000
Subsection 17.39(3) 25,000
Section 17.40 25,000
Section 19 5,000 25,000

AR02044 103
Column 1 Column 2
Section 20 5,000
Subsection 21 (1) 5,000 25,000
Section 22 5,000
Section 23 5,000 25,000
Subsection 24(1) 5,000 25,000
Subsection 24(2) 5,000 25,000
Subsection 24(3) 5,000 25,000
Subsection 25(1) 5,000 25,000
Subsection 26(1) 5,000 25,000
Section 28 5,000
0 Transport Canada is closely monitoring the COVID-19 situation. In response, we have issued
some transP-ortation-related measures and guidance. Please check if any of these
cannot get through, please contact us by~-

AR02045 104
Date modified:
2022-02-28
AR02046 105

________________________________
arr r an l r n
r n n n ar
AR02047 106
Memorandum
Date: January 24, 2022
Re: History of Interim Orders re: Travel Restrictions in Canada
Date Interim Order Title Comments
March 17, 2020 Interim Order to Prevent Certain Persons from

Boarding Flights to Canada due to COVID-19

Boarding Flights to Canada due to COVID-19, No. 2


Boarding Flights in Canada Due to COVID-19
April 6, 2020 Interim Order to Prevent Certain Persons from


Boarding Flights in Canada Due to COVID-19, No. 2



April 30. 2020 Interim Order to Prevent Certain Persons from


May 13, 2020 Interim Order to Prevent Certain Persons from


May 26, 2020 Interim Order to Prevent Certain Persons from Item not found

Page 1 of 5
AR02048 107
Memorandum
June 4, 2020 Interim Order to Prevent Certain Persons from
Interim Order to Prevent Certain Persons from Item not found

Interim Order to Prevent Certain Persons from Item not found


Boarding Flights in Canada Due to COVID-19, No.
10

June 17, 2020 Interim Order Respecting Certain Requirements for

Civil Aviation Due to Covid-19

Civil Aviation Due to Covid-19, No. 2
July 13, 2020 Interim Order Respecting Certain Requirements for


August 7, 2020 Interim Order Respecting Certain Requirements for


September 2, 2020 Interim Order Respecting Certain Requirements for



October 8, 2020 Interim Order Respecting Certain Requirements for


November 4, 2020 Interim Order Respecting Certain Requirements for

Page 2 of 5
AR02049 108
Memorandum

December 4, 2020 Interim Order Respecting Certain Requirements for



January 6, 2021 Interim Order Respecting Certain Requirements for


February 1, 2021 Interim Order Respecting Certain Requirements for



March 4, 2021 Interim Order Respecting Certain Requirements for



April 12, 2021 Interim Order Respecting Certain Requirements for

April 22, 2021 Interim Order Respecting Certain Requirements for

May 5, 2021 Interim Order Respecting Certain Requirements for



Page 3 of 5
AR02050 109
Memorandum
















Civil Aviation Due to Covid-19, No. 47 and

Page 4 of 5
AR02051 110
Memorandum




Page 5 of 5
AR02052 111

________________________________
arr r an l r n
r n n n ar
--
AR02053
--1■1 I 7 I I 11 tl I ·••■ t •· 1 • u • . WI DIii

112
vaccine Development, T•tlng,

and Regulatlon
•1111,. . ._ . . . .. . ,. .
......... I I 7 •••
I IIF1PS. . IIIE71 ■---•M
n ■1d'llilil■l• ■11Z 111111 IIIMU'-
- a:211a1 ■ •sztua:.a..•
$ 7 5 ■"■ &Ml tl . . . . . .
II IA lb IF. • ••■ 1111 ·••z■• .....
-••
a.: e cfDI
1 •• a r, ·
aur:n I a
• nu
._!_______
··---·····
... ...
HAIi 11111 • · - - • - • •
11111---1111111 :• II 1111•
..............
11 I I II 11111111 aur• ■----■tll . . . . . .
. . . . . . . . .l!i •• 11,HI M IIIAtl
,
- - - - • ,,,.,.._..,.., ,,, a•• t11•fllrl••--
••1■ 11-•r11 ■ st ■•l■ llll■l-111 111
··--
---•nlO II
. . . . ..,. . . . . .....,. . . . . . . . . . . . . . . . . ,..,aau
-
I . . . . . . . . . . . . . . . . . .Zll.■lf d11 I IIIL fll 11 I It ■ 7$ Ell ........ •f•III I
-~1.llll ■LMCJaer;
■•·••••·•••. .- •. .,,■ I J■ ----~•:u

71111_.1$1111. . Zilillf. . . . . .ll■ZLZII
$ •-■-
•••..•·--•--■--tJl f •-•--•--11111
.,,.. -- ....•·•··
iJ
•1 ■ 1,1 ■11t--■■ 11111111•: I I 111 . . . . . . . .ZIICll ■ lllllt Ill
IIIIM--Ulllt:.1 ■ 11 ■ 1 I ttf■LU----■--711 hi fl
,, .. ,, •.••,.,1,11,u11n•--■ -ll■l&Zll'llllal. . . .. .
.••11•-·· 1£11\11$1111> II I•.., unsr II II i II ■ 121. . .. .
- - - - - - - - - - I 117 1r11■z.,.,1111r I IRI

I JI.
ITII ,., 1111 I JII ■ 11;M1r:1111nu111 dlllC lifl! n,.........
, ....... .
- Ill! ·---~■JI 111 ■1 It l t - - • - - - -

■111 t..lllllt ■&_-■1_1••8111•11"'? 1 ,-,Zlllll_l _lf_"■IZII
-111-■ 11 F •■r■-MatCll•fll■l!ltlf 1,t • . . ,, $
AR02054 113
- It J
1■•111 I IPll!llalll ■ 111 IPI I . Ill • II. . 31 11 I CM f/1 I I If 11 • - -
_m, I •n••..~···••1 - Ill

. . .i\ IJ
Ell • . . , . , _ . _. . . . . . . . • •
s.Jllltt••··••1111•1■
a
■ 1111.r1t1111ru1111w1 1 11r:wrt•T1 ,r •
. . . . . . . . . . . . . . . , II BillErlt-■• ..... II I ltal..lllJ& 1171111....
..........
•I,,, m• , ..... ,.,I ...... w:1101111••= II I Rmldl
............,_......
A ·-
-----•a
111111 U&lfl ....
IM!U •1211:Jll-..._.,wa.ful& Ai,._&U•tJJ
II IIP t I~ U• · Si llllrflsi. .l · - - • - •
-■-.11.a_&UUa--••••••••-a•■-•b&L••■ al
II ■I 111111111t••'I M11111 lalllPI. . JII) Ill a
PM•t::r ....
.. ,. ,........,:,:::■: - - - ,.............._ • ...,..
• I 11111--·• L IS b •-■--■AlliM-ZZQlilt--■I
........ . ,. . . . ._ _ ••• , , , . . .. . . . . . , 111,11 . . . . . . . . .
IIIJI lllll&,---11--1'111,---■ --■•----■■-

IIEIZ••.. •·•--•..
- t l l l l t I It,. . . .- .
1-, 1 l7'111, I 1111 ---1111111 P 11 FIIRLW,■-■-

t. I El
:JSll ■:a
_
1'111,-- ■ II i 1&--11■ -. r 111•-...a
. ._ . , _ _ _ _111. . . . tlER
11••
lilllJ(l & • 2. 111 I$ :t J ,0 I& . . . . . . . ......,. I i ■-Mllll>I I I • .......
.........
---■ Jill
_1,_,.,,.
llzJOI lhl. . . . l ■ 11 . . . . . . . . . . . . . . . .t<l !IIWll
t U I O - • • ? I llflltllllll al---■
l'r.J :.--,•JI I
. . . . . . . . . . . . . . 21111 _.....,,1 ,..., 1111 , . . .. . . .
u....-.-•,a•u-•
..
.................... .
I di • ....
-••&JIJllll·••w••rn 11:IIUlll.......
..,.,,,,,
I I I ,. . . I I
b II M At&fllll........
I
....--------
---•···•---- L
,,.......
-••111••--u110Fi
tll• ■1•••---•--■f.......
-■IIIEBZZ-•-_,■rllML ■--
ltli!U . . . . . . . . . . . . . ,1&1J1Hll'JIJ1 L 21211 ■ 11•1111•■-.-
..............
■•1 ..I ----■-■---
lat-1 ■
· • ----~-■-•--,
lil---L-t\lJIIIIIIPllt..s I IIULJIIII _ _ _ _ _ _ _ _
AR02055 114
•-..-•...•••••••..,.. 21 ,1■ 1-•••m ••
. . . . I FI , . . . . .111[1 _ _ 11[1111• I 'N-11t; · · - • -
11111lx1111.1l1■ . .-•s1P141--. ■ JI ■ •1er1111
- • I -. . . . . . . . P S"llll11TTJ
••ar••·..
•■1----M;;IMll;a
·•1
11 ■111•11·•111(•1111,1111 . . . . . . . . . , 1111•11•1•*--
• • • • • • • • • - • • • I 11
.........,..
At1Piil,._, . . ..,.............
................. , TIIMJt.1 I p■ llll I lllfl■llt . . . . . . . . . . ,.,,• •
-,1 ■1 ■tll-111-4' 1111. . .ISLnn..-■-■-- I II 11 f- ■-1111111

•-a• I -
........,..
'119111•141. . . . . . . . .. . . ,. . Ill 1111 Ill fllllll[J.111 t?II • ■-r 111 11
-.:JilJ:111 a bit :.•---
·•-•Riilflla12.l•·•n■
n112,. . . . . . . . . . . ._■Ill.I 111 . . . -·-·
•• n11•t1111111n11111■1u11 • •
1111 I & LI I I . . . .-
1 11 t:••-- ••
. . . . . . . . . . . . , •. I ...... I i I I• . . . . . .
la- ■• iihlll---1111£ ::I
.... ....
--·-·------······
11111111■1-
...,.•. - -..•11•• .....

... -...... ---1111811
4'.....■■IIIIH_ _,,_
111,111, ...................
JI, JJ I I IM
........................................,, ......-
-•••••L_.1a••••••
II& I 1• .. -■- ..- - - - ...- - II 11 llf•
1 • 111
............... ,t:a,u.r•11111.tr • en r,e.
•0!211•--- ""' ___ :,, ·-•-•:

------•-1111,............ . :r.: , .. : ··'" •
...........................
nn:_.•11•---
..,...1111••-..• ......
---.-. ____. •nr.11 •■--1.11.1,11 -•111111111tt
--•11 1n.•Jlll1'•11.1 •• t I - • IP Ill 4'1t.t . . . . l lS:PIH JIPU

IU
. . . . . . . II I :P::7: i\ll■lt--■1411_ _ _,........,_ _..._
-••••••••--••01'11■ 1•• 1:1:2&11sa
...,.u ■ 1■ 111 as,en,_,._
...............I••..._.••_..,.II
,,,.,...,__r,llllll,
....,,..
• - - -. . . . .- 11•1 - - - ~ A 2
I IL
-·----■-- ■nJ IIRIIIIII-Wlllnae-•• ■ 1 l?ri

• ••••••. -•-■-1a1.•1a.,-■-•••12r:w-...
AR02056 115
•-•• rs111••--...•·•n1 •-
,...,._..,111, •••••ua•1u1·111--
•••• 1111•11n·1111. . .
.,..•..__ :rr• r•••-••-•rsH
--•••1111,. ■~rsi1srn,._
11••--
. . , ,.............
-■ llitil -------JSHl2 _ _ _1ll,aa~
r 1 •"' ·•• m1-.11 lillt/tt..-
-••• 1 .tlJIZ21 ■------••-•---•n FI ,6'1W•

.__...._ 1•••21111111& 1&1122 s,21n1111 ••••1.112.111 1117111111
- • • : m,w................ :, ... :•••••••••
11i11111t• ■r12rz1••• ....• - - - 121■•1:
•111Gtl ...,.,,..._._._.
• 11111111 .a a••--••11■ 1.111

•IIJJtrtW111111•1■■-11■ --■
..,.,.......
............,_,__
•ili!l(IJ ■ l•-••1•··•-11,
• . . . ,_ _ _ 1,.11111: 1,, . . . . . . . . . . .1111111
11111. . .1L. I .,,1111•--w■lla II Utt,• u II _ _,e1&1111■.-■

-,1■-■5111~1 I 11'1:r'IILl&I 111111:1_,11. . . . .--■ tll ■ i ~ I I 11
. . . . . . . . . . . . . . . 1 ...._ ,. . . . ._ _ _ , . . . . .. . . .
..... 11- ■••-----.11 •.......,..,,•.,,OW9..,....
. . . . . . . . . . . . . 1111 ,,._..,_ _... II,_._,..,..
11■ 111111-■--------·
-••m••.... ••• ..••111•------.. ••• ....-
•
• A,,l 1barJ~. . .- - UJ . . . . . . -.-le&lmJ•-
••1•1 1 I11•11111-•--------
• 111■ JI
•r• fJt I I « ........... , Jl't,IP..,_
P ■SJU. . . .fL_rtt
,....... ,. ,,, ....., ,,n::er•1111•-.•-- •z

2mra1, . . . . .111 ■ ur121&12
C C I~
a
••11•11111S1JD!1 I I
,..--•---..••11■1111 ?1111•111111 . , ,
tn IJTl•t I _....,..1■ 11112: 1 : ~ - -..•-..---■
-••••1: ,.....,.._.... n111 •1 :a:zrn111•-
1li111111""aaa..1111•••biibl- ,... ,.,
•••• •--■-lit a ■ e: Pr 1•1 . . . . . . . . . . u,11a11 • • • •

•• a■ •M-•• 1 t • • - - 111 □ t _.__ _,.., uarr l
AR02057 116
Z.:lilil _ _ _ _ - - . . - . - 1 ..1u:..-,11.-u111., . .
I I I ,_II
- - - · lllll••&I ..FI F-IIW'IIIII.I 11111:11. . . l ■ IPRIHfa_ . . .

• ..,...__,. . . . ._ _ 1 lllr ......---■-11111177
. . . - . • - • - - - , • - - 111tu1 ._... . . . rmr 11111111
II II llll--111111••-- • IIIIIFIII $ I
llillPllllg.~.,,,. ..... 1b i Pi. . a,
PS.I 1-11•
1 hi I I PIC•-----..
....... ft:: l l 1111111 UII Ill il.1111 ,111•• I II Ill -■--■---..
MClnrloll•
1bd iilllv Ii :"!Cl l W • lliLhf I I • - , - U t • if I . . . . .- .
1• ■----■■ 1•11t• ?f ■RI-Jll•t--11 . . . . . .. . . .
■--II Jill I . . . . .. . . . , _ , . _ . : . , lllltl Ii II ■ •zl Q:I 1111 11•
-2□ 22111•----------.
-
-.:■ fl II •1111ft 2■fll-il■ I IIZIIWf,. hi I :IFIJIFJ .,_.,_
-·-·
•11 ■ 1111111:■ lt h -
........
._,U.G.t I
um, U U - - ' -..•••. . . . . . •1■ 1111
£1,,.._._,._.,ft:a 22--Flfdtl .£ .......a
. ..._._-.,CIIIF ZS.,,._.IFIILJ$.IDl,_W
I II - - 111111•1st ef JI III IUI - IIJ ill • • fll? 11•fl11? I ,._
1"111 :CtUI-
Nii$ t l I 111'.iJINDl-lli ii£ t ......... Q gal.,.._..

, . f:MJ . . . . . a,111111 Mill I :•1111111 1111111 _,, 13519111.IIWI 1111111111
1ann1111 llit&&IIIIIIU I . . . ..,,.,. I tin II .... ·-·••111 I Ill
•11••
U I J n1 ■'IIIW•1111111111■1 ■ 11 • . . ., P-□ --fJO ••
l■I r,r •11 ■ 11 ■1 1011 ....... PPllllll'*I • • 1
..........211•
ltlj I "11111 • • •JfdHOIMI I API 111& _ _ _
llit•·••n•-·· ... I
--•N-lllrf1l ■ :1124L:1 □ •1 :a,

. ..-. .......,,. ■ 11•2•11...,..,, •••,a_,..,
- - _ _ , . . ,• •
..
111 IIB
•:1111■ 11&
AR02058
............
••-u-.~•••••
...... ......
.............
,
.
117
.......................__
.....................
...,. mu,...._...
,,,,,
........
,
., ..,.. ,,,
-. ......_.... ...
. . .11. . . . . . . . . . . . . . . . .
,, ,
_ . , . 121; J ■■111••·••
..........••••1A1 I
--••m ,,..,......
• - - • • d iid~. .111-111
-·····••11:-■1.-.
T 1D19lllfl-
.,J.IGGl-·IIIIJ •n11 • • •11■11
ll■ •S11 ••••••·--•; Ii I JlltDCllll lllla.1111111'1•111- ■ I
••••=
11119111J1,._,IIM ■-ll ■ II
hi n , ..
r-
11 ■111111111111~1 II , . . . PI I • · •
P1111R1-..,,••11 1
an 1111••• 11111 11111111111111••-. . .• • • . . , . • -
rm 1 11111
---··· . -..
111-■1111 . . . . . . . . . . . ._ . . ._ , ..-
.............................:a.. . . . . . . .-
,
. . . . . ., . . .. . . .
...
.................
"'·-•--•2
11115 Ism IPIISA - - -
....,...
AM...
·----
c.. .,..
..L,4211••·--•li!n•flt :adull_W___,
A-■- 1111 tll lL •••
&---ll■ lillPlla
0. -All ... L IP
. . . IIUl!I 111
...,. ••2111 1, .....,...,._......,_....., -····

A.._
.,_
.............. ,,11111
AR02059 118
This is Exhibit “. ” referred to in the

Affidavit of Natalie Grcic sworn before
me virtually this 10 day of March, 2022
________________________________
arr r an l r n
r n n n ar
AR02060 119
FEATURE
11) Check for updates
Madrid, Spain
BMJ INVESTIGATION
BMJ: first published as 10.1136/bmj.n2635 on 2 November 2021. Downloaded from http://www.bmj.com/ on 7 March 2022 by guest. Protected by copyright.
Cite this as: BMJ 2021;375:n2635
http://dx.doi.org/10.1136/bmj.n2635
Published: 2 November 2021 Covid-19: Researcher blows the whistle on data integrity issues in
Pfizer’s vaccine trial
Revelations of poor practices at a contract research company helping to carry out Pfizer’s pivotal
covid-19 vaccine trial raise questions about data integrity and regulatory oversight. Paul D Thacker
reports
Paul D Thacker investigative journalist
In autumn 2020 Pfizer’s chairman and chief executive, executives later questioned Jackson for taking the
Albert Bourla, released an open letter to the billions photos.
of people around the world who were investing their
Early and inadvertent unblinding may have occurred
hopes in a safe and effective covid-19 vaccine to end
on a far wider scale. According to the trial’s design,
the pandemic. “As I’ve said before, we are operating
unblinded staff were responsible for preparing and
at the speed of science,” Bourla wrote, explaining to
administering the study drug (Pfizer’s vaccine or a
the public when they could expect a Pfizer vaccine
placebo). This was to be done to preserve the blinding
to be authorised in the United States.1
of trial participants and all other site staff, including
But, for researchers who were testing Pfizer’s vaccine the principal investigator. However, at Ventavia,
at several sites in Texas during that autumn, speed Jackson told The BMJ that drug assignment
may have come at the cost of data integrity and confirmation printouts were being left in participants’
patient safety. A regional director who was employed charts, accessible to blinded personnel. As a
at the research organisation Ventavia Research Group corrective action taken in September, two months
has told The BMJ that the company falsified data, into trial recruitment and with around 1000
unblinded patients, employed inadequately trained participants already enrolled, quality assurance
vaccinators, and was slow to follow up on adverse checklists were updated with instructions for staff to
events reported in Pfizer’s pivotal phase III trial. Staff remove drug assignments from charts.
who conducted quality control checks were
In a recording of a meeting in late September2020
overwhelmed by the volume of problems they were
between Jackson and two directors a Ventavia
finding. After repeatedly notifying Ventavia of these
executive can be heard explaining that the company
problems, the regional director, Brook Jackson,
wasn’t able to quantify the types and number of errors
emailed a complaint to the US Food and Drug
they were finding when examining the trial
Administration (FDA). Ventavia fired her later the
paperwork for quality control. “In my mind, it’s
same day. Jackson has provided The BMJ with dozens
something new every day,” a Ventavia executive says.
of internal company documents, photos, audio
“We know that it’s significant.”
recordings, and emails.
Ventavia was not keeping up with data entry queries,
Poor laboratory management shows an email sent by ICON, the contract research
On its website Ventavia calls itself the largest organisation with which Pfizer partnered on the trial.
privately owned clinical research company in Texas ICON reminded Ventavia in a September 2020 email:
and lists many awards it has won for its contract “The expectation for this study is that all queries are
work.2 But Jackson has told The BMJ that, during the addressed within 24hrs.” ICON then highlighted over
two weeks she was employed at Ventavia in 100 outstanding queries older than three days in
September 2020, she repeatedly informed her yellow. Examples included two individuals for which
superiors of poor laboratory management, patient “Subject has reported with Severe
safety concerns, and data integrity issues. Jackson symptoms/reactions … Per protocol, subjects
was a trained clinical trial auditor who previously experiencing Grade 3 local reactions should be
held a director of operations position and came to contacted. Please confirm if an UNPLANNED
Ventavia with more than 15 years’ experience in CONTACT was made and update the corresponding
clinical research coordination and management. form as appropriate.” According to the trial protocol
Exasperated that Ventavia was not dealing with the a telephone contact should have occurred “to
problems, Jackson documented several matters late ascertain further details and determine whether a
one night, taking photos on her mobile phone. One site visit is clinically indicated.”
photo, provided to The BMJ, showed needles
Worries over FDA inspection
discarded in a plastic biohazard bag instead of a
sharps container box. Another showed vaccine Documents show that problems had been going on
packaging materials with trial participants’ for weeks. In a list of “action items” circulated among
identification numbers written on them left out in the Ventavia leaders in early August 2020, shortly after
open, potentially unblinding participants. Ventavia the trial began and before Jackson’s hiring, a Ventavia
executive identified three site staff members with
the bmj | BMJ 2021;375:n2635 | doi: 10.1136/bmj.n2635 1

AR02061
FEATURE 120
whom to “Go over e-diary issue/falsifying data, etc.” One of them • Participants placed in a hallway after injection and not being
was “verbally counseled for changing data and not noting late monitored by clinical staff
entry,” a note indicates.
• Lack of timely follow-up of patients who experienced adverse
At several points during the late September meeting Jackson and events
the Ventavia executives discussed the possibility of the FDA showing
up for an inspection (box 1). “We’re going to get some kind of letter • Protocol deviations not being reported
of information at least, when the FDA gets here . . . know it,” an • Vaccines not being stored at proper temperatures
executive stated.
• Mislabelled laboratory specimens, and
Box 1: A history of lax oversight • Targeting of Ventavia staff for reporting these types of problems.
When it comes to the FDA and clinical trials, Elizabeth Woeckner,
Within hours Jackson received an email from the FDA thanking her
president of Citizens for Responsible Care and Research Incorporated
for her concerns and notifying her that the FDA could not comment
(CIRCARE),3 says the agency’s oversight capacity is severely
on any investigation that might result. A few days later Jackson
under-resourced. If the FDA receives a complaint about a clinical trial,
she says the agency rarely has the staff available to show up and inspect.
received a call from an FDA inspector to discuss her report but was
And sometimes oversight occurs too late. told that no further information could be provided. She heard
In one example CIRCARE and the US consumer advocacy organisation nothing further in relation to her report.
Public Citizen, along with dozens of public health experts, filed a detailed In Pfizer’s briefing document submitted to an FDA advisory
complaint in July 2018 with the FDA about a clinical trial that failed to committee meeting held on 10 December 2020 to discuss Pfizer’s
comply with regulations for the protection of human participants.4 Nine application for emergency use authorisation of its covid-19 vaccine,
months later, in April 2019, an FDA investigator inspected the clinical
the company made no mention of problems at the Ventavia site.
site. In May this year the FDA sent the triallist a warning letter that
substantiated many of the claims in the complaints. It said, “[I]t appears
The next day the FDA issued the authorisation of the vaccine.8
that you did not adhere to the applicable statutory requirements and FDA In August this year, after the full approval of Pfizer’s vaccine, the
regulations governing the conduct of clinical investigations and the FDA published a summary of its inspections of the company’s
protection of human subjects.”5 pivotal trial. Nine of the trial’s 153 sites were inspected. Ventavia’s
“There’s just a complete lack of oversight of contract research sites were not listed among the nine, and no inspections of sites
organisations and independent clinical research facilities,” says Jill where adults were recruited took place in the eight months after
Fisher, professor of social medicine at the University of North Carolina the December 2020 emergency authorisation. The FDA’s inspection
School of Medicine and author of Medical Research for Hire: The Political
officer noted: “The data integrity and verification portion of the
Economy of Pharmaceutical Clinical Trials.
Ventavia and the FDA BIMO [bioresearch monitoring] inspections were limited because
A former Ventavia employee told The BMJ that the company was nervous
the study was ongoing, and the data required for verification and
and expecting a federal audit of its Pfizer vaccine trial. comparison were not yet available to the IND [investigational new
“People working in clinical research are terrified of FDA audits,” Jill Fisher drug].”
told The BMJ, but added that the agency rarely does anything other than
Other employees accounts
inspect paperwork, usually months after a trial has ended. “I don’t know
why they’re so afraid of them,” she said. But she said she was surprised In recent months Jackson has reconnected with several former
that the agency failed to inspect Ventavia after an employee had filed a Ventavia employees who all left or were fired from the company.
complaint. “You would think if there’s a specific and credible complaint One of them was one of the officials who had taken part in the late
that they would have to investigate that,” Fisher said. September meeting. In a text message sent in June the former official
In 2007 the Department of Health and Human Services’Office of the apologised, saying that “everything that you complained about was
Inspector General released a report on FDA’s oversight of clinical trials
spot on.”
conducted between 2000 and 2005. The report found that the FDA
inspected only 1% of clinical trial sites.6 Inspections carried out by the Two former Ventavia employees spoke to The BMJ anonymously
FDA’s vaccines and biologics branch have been decreasing in recent for fear of reprisal and loss of job prospects in the tightly knit
years, with just 50 conducted in the 2020 fiscal year.7 research community. Both confirmed broad aspects of Jackson’s
complaint. One said that she had worked on over four dozen clinical
The next morning, 25 September 2020, Jackson called the FDA to trials in her career, including many large trials, but had never
warn about unsound practices in Pfizer’s clinical trial at Ventavia. experienced such a “helter skelter” work environment as with
She then reported her concerns in an email to the agency. In the Ventavia on Pfizer’s trial.
afternoon Ventavia fired Jackson—deemed “not a good fit,”
“I’ve never had to do what they were asking me to do, ever,” she
according to her separation letter.
told The BMJ. “It just seemed like something a little different from
Jackson told The BMJ it was the first time she had been fired in her normal—the things that were allowed and expected.”
20 year career in research.
She added that during her time at Ventavia the company expected
Concerns raised a federal audit but that this never came.
In her 25 September email to the FDA Jackson wrote that Ventavia After Jackson left the company problems persisted at Ventavia, this
had enrolled more than 1000 participants at three sites. The full employee said. In several cases Ventavia lacked enough employees
trial (registered under NCT04368728) enrolled around 44 000 to swab all trial participants who reported covid-like symptoms, to
participants across 153 sites that included numerous commercial test for infection. Laboratory confirmed symptomatic covid-19 was
companies and academic centres. She then listed a dozen concerns the trial’s primary endpoint, the employee noted. (An FDA review
she had witnessed, including: memorandum released in August this year states that across the
full trial swabs were not taken from 477 people with suspected cases
of symptomatic covid-19.)
2 the bmj | BMJ 2021;375:n2635 | doi: 10.1136/bmj.n2635

AR02062 121
FEATURE
“I don’t think it was good clean data,” the employee said of the data
Ventavia generated for the Pfizer trial. “It’s a crazy mess.”
A second employee also described an environment at Ventavia
unlike any she had experienced in her 20 years doing research. She
told The BMJ that, shortly after Ventavia fired Jackson, Pfizer was
notified of problems at Ventavia with the vaccine trial and that an
audit took place.
Since Jackson reported problems with Ventavia to the FDA in
September 2020, Pfizer has hired Ventavia as a research
subcontractor on four other vaccine clinical trials (covid-19 vaccine
in children and young adults, pregnant women, and a booster dose,
as well an RSV vaccine trial; NCT04816643, NCT04754594,
NCT04955626, NCT05035212). The advisory committee for the Centers
for Disease Control and Prevention is set to discuss the covid-19
paediatric vaccine trial on 2 November.
Provenance and peer review: commissioned; externally peer reviewed.
Competing interests: PDT has been doubly vaccinated with Pfizer’s vaccine.
1 Bourla A. An open letter from Pfizer chairman and CEO Albert Bourla. Pfizer. https://www.pfiz-
er.com/news/hot-topics/an_open_letter_from_pfizer_chairman_and_ceo_albert_bourla.
2 Ventavia. A leading force in clinical research trials. https://www.ventaviaresearch.com/company.
3 Citizens for Responsible Care and Research Incorporated (CIRCARE). http://www.cir-
care.org/corp.htm.
4 Public Citizen. Letter to Scott Gottlieb and Jerry Menikoff. Jul 2018. https://www.citizen.org/wp-
content/uploads/2442.pdf.
5 Food and Drug Administration. Letter to John B Cole MD. MARCS-CMS 611902. May 2021.
https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-
letters/jon-b-cole-md-611902-05052021.
6 Department of Health and Human Services Office of Inspector General. The Food and Drug
Administration’s oversight of clinical trials. Sep 2007. https://www.oig.hhs.gov/oei/reports/oei-
01-06-00160.pdf.
7 Food and Drug Administration. Bioresearch monitoring. https://www.fda.gov/media/145858/down-
load.
8 FDA takes key action in fight against covid-19 by issuing emergency use authorization for first
covid-19 vaccine. Dec 2020. https://www.fda.gov/news-events/press-announcements/fda-takes-
key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19.
This article is made freely available for use in accordance with BMJ's website terms and conditions for
the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download
and print the article for any lawful, non-commercial purpose (including text and data mining) provided
that all copyright notices and trade marks are retained.
the bmj | BMJ 2021;375:n2635 | doi: 10.1136/bmj.n2635 3

AR02063 122

________________________________
arr r an l r n
r n n n ar
AR02064 123
Memorandum
RE: Countries with Travel Mandates
AUSTRALIA 2021
Northern Territory - Unvaccinated returning Territorians and people approved to enter the NT
need to complete 14 days mandatory supervised quarantine at their own cost.
Unvaccinated visitors are not allowed to enter the NT. 1
South Australia - If you’re unvaccinated and don’t have an approved medical exemption, you
can’t enter SA. This includes returning South Australian residents. 2
Australian Capital Territory - Domestic and international testing - You don’t need to isolate or
quarantine if you’re getting a COVID-19 test before domestic or international travel and you have
no COVID-19 symptoms. International travellers who are not fully vaccinated - 18 years and over
- International travellers who are aged 18 years and over and not fully vaccinated must complete
a mandatory 14-day quarantine period at their port of entry. If travel to the ACT is required for
exceptional or compassionate reasons, they will need to obtain an exemption from ACT Health. 3
Tasmanian - Unvaccinated travellers - People who are not fully vaccinated — excluding people
aged under 12 years and 2 months or who have a medical exemption, see above — cannot enter
Tasmania unless approved. This includes Tasmanian residents. 4
Victoria - If you are not fully vaccinated - International arrivals aged 18 years and over who are
not fully vaccinated — excluding those with a medical exemption — and who don’t meet the
eligibility criteria will need to undertake 14 days hotel quarantine. They will need to contribute to
the cost. 5 *Note that there is no quarantine requirement for interstate travel.
Western Australia - International arrivals - Anyone entering WA from overseas must complete
a G2G Pass declaration — see below for details. This must be completed and submitted prior to
travel. Passengers travelling to Australia must provide proof of a negative COVID-19 PCR test
result at the time of check-in. The PCR test must have been taken 72 hours or less prior to
departure. Direct international arrivals must complete 14 days of hotel quarantine when they arrive
in WA at a government approved facility at your own expense.
You must be tested for COVID-19 on:
• the day following your arrival

• day 5 of quarantine
• day 13 of quarantine
• day 17 (after you have left quarantine)
• day 21 (after you have left quarantine)
1
https://www.healthdirect.gov.au/covid19-restriction-checker/domestic-travel/nt
2
https://www.healthdirect.gov.au/covid19-restriction-checker/domestic-travel/sa
3
https://www.healthdirect.gov.au/covid19-restriction-checker/domestic-travel/act
4
https://www.healthdirect.gov.au/covid19-restriction-checker/domestic-travel/tas
5
https://www.healthdirect.gov.au/covid19-restriction-checker/domestic-travel/vic
AR02065 124
Direct international arrivals will not be permitted to travel domestically or continue on any
domestic connections until they have completed the 14-day quarantine period. 6
AUSTRALIA 2022 UPDATE
Passengers must have a Covid-19 vaccination certificate showing that they were fully vaccinated
at least 7 days before departure. This does not apply to:
• Nationals and residents to Australia

• Passengers with an approved travel exemption
• Passengers travelling with passenger caps
• Passengers between 12 and 17 years traveling with a fully vaccinated parents
Passengers entering or transiting through Australia must have a negative Covid-19 test taken at
most 3 days before departure from the first embarkation point, a negative Covid-19 rapid antigen
test taken at most 24 hours before departure. This does not apply to:
• Passengers younger than 4 years

• Passengers arriving from Kiribati, Myanmar, Niue, Samoa, Solomon Isl., Tokelau, Tonga,
Tuvalu or Vanuatu
• Passengers arriving from Belize, Cook Isl., Fiji, French Polynesia, Marshall Isl.,
Micronesia, Nauru, New Caledonia, Palau, Papua New Guinea, Timor-Leste or Wallis and
Futuna Isl. with a negative Covid-19 test taken at most 96 hours before departure from the
last embarkation point
• Passengers with a recovery certificate issued at most 30 days before departure from the
first embarkation point
Passengers must complete a “Digital Passport Declaration” form and present it at the time of
check-in. Passengers could be subject to quarantine for 14 days at the first point of entry.
Quarantine arrangements for airline crew are subject to respective state or territory requirements.
ISRAEL 2021
By Air: Before boarding the flight, present airline with:
1. A confirmation of completion of the exit statement form.

2. If you stayed in Israel for more than 72 hours – one of the following documents:
o A Negative result on a PCR test taken within 72 hours before boarding

o A valid green pass issued by the Israeli Ministry of Health on the basis of
vaccination or recovery 7
Israeli citizens and residents are banned from leaving Israel to a country on the red list. 8
By Land and Sea: No testing or quarantine requirements, with the exception of Jordan 9
6
https://www.healthdirect.gov.au/covid19-restriction-checker/domestic-travel/wa
7
https://corona.health.gov.il/en/abroad/
8
https://corona.health.gov.il/en/country-status?countryStatusId=4&page=2
9
https://corona.health.gov.il/en/abroad/leaving-israel-by-sea-and-land/
AR02066 125
ISREAL UPDATE 2022
Passengers must complete an “Entry Statement” at most 48 hours before departure of the last direct
flight to Israel. They will receive electronic approval from the Ministry of Health. They will
receive electronic approval from the Ministry and a Green Pass which must be presented before
boarding. Passengers and airline crew who have been outside Israel for more than 72 hours
entering or transiting through Israel must have a negative Covid-19 test taken at most 72 hours
before departure from the first embarkation point. The test certificate must be in English and
indicate the passenger’s passport number. This does not apply to:
• Nationals and residents of Israel

• Passengers and airline crew with a positive Covid-19 test taken at least 8 days and at most
90 days before departure from the first embarkment
• Airline crew who stay in Israel for less than 72 hours
Passengers are subject to a Covid-19 PCR test upon arrival at their own expense and self-isolation
until the test result is ready. Passengers with a Covid-19 vaccination certificate showing that they
were fully vaccinated with Sputnik V or Sputnik Light are subject to a Covid-19 serological test
upon arrival. Airline crews are subject to a Covid-19 PCR or rapid antigen test upon arrival. This
does not apply to airline crew with any type of negative Covid-19 PCR test taken at most 7 days
before arrival. Passengers and airline crew could be subject to self-isolation for up to 14 days.
ANGUILLA 2021
Travel Requirements for Visitors - All visitors to Anguilla who are eligible to be vaccinated
against COVID-19, are required to be fully vaccinated at least three weeks before arrival (i.e.
persons 18 and older). Exemptions include: Pregnant woman and children under the age of 17
years old. No medical exemptions will be granted.
Anguilla’s Executive Council has lifted all quarantine requirements for international leisure
visitors staying at hotels or villas, regardless of their length of stay. Full requirements for travel
are listed below. 10
For Residents of Anguilla Leaving The Island – 1. You are permitted to leave Anguilla for no
more than 1 night stay in a neighboring island. 2. Residents are issued a Day Pass Certificate. 3.
Residents will not be tested prior to leaving the island (unless required by island you are visiting)
or upon return, nor be required to quarantine upon return. 4. Residents must submit to a COVID-
19 test on 4th day after return to Anguilla. 5. To obtain Day Pass Certificate bring vaccine card,
passport, evidence of Anguilla residency, proof of permission to enter neighboring island to
Ministry of Health between 10am-2pm daily prior to date of travel. 11
ANGUILLA UPDATE 2022
Passengers must complete an “Application for Entry” before departure. They must present an
“Electronic Travel Authorization Certificate” upon arrival. Passengers must have a negative
Covid-19 antigen test taken at most 48 hours before arrival. The test must be based on a
nasopharyngeal swab, or a negative Covid-19 PCR test taken 2 to 5 days before arrival. Passengers
must have a Covid-19 vaccination certificate showing that they were fully vaccinated at least 21
10
https://www.anguilla-beaches.com/covid-19.html
11
https://www.anguilla-beaches.com/covid-19.html
AR02067 126
days before arrival. This does not apply to residents of Anguilla or passengers younger than 18
years. Passengers must have health insurance to cover Covid-19 expenses. Passengers are subject
to the Covid-19 PCR test upon arrival. Passengers are subject to quarantine for up to 14 days.
This does not apply to passengers with a Covid-19 vaccination certificate showing they were fully
vaccinated at least 21 days before arrival.
ST. KITTS AND NEVIS 2021
At this time, only fully vaccinated international travellers will be permitted in Nevis. All travellers
are required to take an RT-PCR test 72 hours prior to arrival. The specimen taken must be
nasopharyngeal from an accredited approved lab 12
ST. KITTS AND NEVIS UPDATE 2022
Passengers entering or transiting through St. Kitts and Nevis must have a printed Covid-19
vaccination certivicate showing that they were fully vaccinated at least 14 days before arrival. This
does not apply to nationals and residents of St. Kitts and Nevis and passengers younger than 18
years traveling with their fully vaccinated parents. Passengers entering or transiting through St.
Kitts and Nevis must have a printed Covid-19 PCR test taken at most 3 days before departure from
embarkation point. This does not apply to passengers younger than 12 years. Passengers must
complete a “Customs, Border and Health Entry Form” before departure. Passengers and airline
crew are subject to medical screening and must have a confirmation of an approved
accommodation.
FIJI 2021
All visitors to Fiji must be fully vaccinated, this includes Fijian Citizens. Only in exceptional
circumstances will an exemption be provided at the discretion of the Permanent Secretary for
Health and Medical Services. 13
FIJI UPDATE 2022
Passengers entering or transiting Fiji must have a Covid-19 vaccination certificate showing that
they were fully vaccinated at least 14 days before departure. This does not apply to passengers
younger than 18 years traveling with a fully vaccinated parent. Passengers entering Fiji from a
country other than Australia, Austria, Bahrain, Belgium, Cambodia, Canada, Chile, China, Chinese
Taipei, Cook Isl., Cyprus, Czechia, Denmark, Finland, France, French Polynesia, Germany,
Greece, Guam, Hong Kong, Ireland, Israel, Italy, Japan, Kiribati, Korea, Kuwait, Luxembourg,
Macao, Malaysia, Malta, Marshall Isl., Micronesia, Mongolia, Nauru, Netherlands, New
Caledonia, New Zealand, Norfolk Isl., Northern Mariana Isl., Norway, Oman, Palau, Portugal,
Qatar, Samoa, Saudi Arabia, Singapore, Spain, Sri Lanka, Sweden, Switzerland, Thailand, Tonga,
Turkey, Tuvalu, United Arab Emirates, United Kingdom, USA, Vanuatu or Wallis and Futuna Isl.
must have a pre-approval from the Covid-19 Risk Mitigation Taskforce or the Fijian Immigration
Department. This does not apply to nationals of Fiji. Passengers or transiting through Fiji from
the above-noted countries must have a negative Covid-19 PCR test taken at most 2 days before
departure from the first embarkation point or a negative Covid-19 rapid test taken at most 24 hours
before departure of the last direct flight to Fiji. This does not apply to passengers younger than 12
12
https://nevisisland.com/travel-
requirements/?gclid=Cj0KCQiAq7COBhC2ARIsANsPATGWBJY3FPr_hoWDLgAwbYZ0tPogQoaSUpTRscntN
oXHzg9kkSTrVVUaAsKBEALw_wcB
13
https://www.fiji.travel/articles/frequently-asked-questions-travelling-to-fiji
AR02068 127
years or passengers with a positive Covid-19 test taken at most 30 days before departure. They
must have a medical certificate issued by a medical practitioner showing they are fit to fly and
have completed an isolation period. Passengers arriving from the above-noted countries must have
proof of at least 3 nights of pre-paid accommodation at a Care Fiji Commitment hotel and certified
transport from the airport. They must have stayed in one of the above-noted countries in the last
14 days. Passengers arriving from a country other than the ones noted above must have proof of
pre-paid accommodation of at least 14 nights at a Fiji Managed Quarantine facility. Passengers
must have health insurance to cover Covid-19 expenses. This does not apply to nationals and
residents of Fiji. Passengers transiting through Fiji for up to 72 hours are subject to quarantine
until their connection flight at a Care Fiji Commitment hotel.
AUSTRIA 2021
New stricter entry measures came in effect on 20 December. To enter Austria, the “2-G+” rule is
currently in place. In addition to proof of vaccination/recovery, you need a negative PCR
test OR proof of a booster jab. 14
AUSTRIA UPDATE 2022
Passengers without a negative Covid-19 antigen test taken at most 24 hours before arrival, or a
negative Covid-19 PCR test taken at most 72 hours before arrival, or a Covid-19 recovery
certificate issued at most 180 days before arrival, or a Covid-19 vaccination certificate showing
that at most 270 days before arrival they were fully vaccinated or received a booster dose. A
Covid-19 vaccination certificate showing that they were fully vaccinated with Janssen at least 21
days and at most 270 days before arrival. A Covid-19 vaccination certificate showing that they
received a booster dose of Janssen at most 270 days before arrival. Proof of previous infection
and a Covid-19 vaccination certificate showing that at least 21 days and at most 270 days before
arrival they received the first dose of AstraZeneca, Covaxin, Covishield, Covovax, Moderna,
Nuvaxovid, Pfizer-BioNTech, Sinopharm or Sinovac, are subject to quarantine or self-isolation
for up to 10 days. This does not apply to passengers younger than 12 years. Passengers could be
subject to presenting a completed “Pre-Travel Clearance” upon arrival.
SAUDI ARABIA 2021
You need a tourist VISA, PCR test, Medical Insurance that will cover the cost of Covid-19
treatment if you get sick and Everyone who enters Saudi must be vaccinated with an approved
vaccine. 15
SAUDI ARABIA UPDATE 2022
Passengers are not allowed to enter. This does not apply to:
• Nationals of Saudi Arabia

• First degree family members of nationals of Saudi Arabia
• Residents of Saudi Arabia arriving from Afghanistan, Ethopia, Lebanon or Turkey
with a Covid-19 vaccination certificate showing that they were fully vaccinated in
Saudi Arabia
14
https://www.austria.info/en/service-and-facts/coronavirus-information/entry-regulations
15
https://www.visitsaudi.com/en/health-regulations
AR02069 128
• Residents of Saudi Arabia who have not been in or transited through the above noted
countries in the past 14 days
• Nationals of Bahrain, Kuwait, Oman, Qatar and United Arab Emirates. They must not
have been in or transited through the above noted countries in the past 14 days
• Passengers with an exit/entry, work, residence or visit visa issued by Saudi Arabia.
They must not have been in or transited through the aforementioned countries in the
past 14 days
• Passengers with a tourist visa issued by Saudi Arabia who have not been in or transited
through the aforementioned countries in the past 14 days
• Domestic workers of nationals Saudi Arabia. They must be accompanied by the
sponsor.
Passengers arriving from Afghanistan, Ethopia, Lebanon or Turkey are not allowed to transit.
Passengers must have a negative Covid-19 antigen or PCR test taken at most 48 hours before
departure of the last direct flight to Saudi Arabia. This does not apply to the following:
• Nationals of Saudi Arabia and their travelling companions, arriving from Ukraine.
They are subject to a Covid-19 test after arrival
• Nationals of Saudi Arabia who have tested positive at least 10 days before departure
• Nationals of Saudi Arabia who have tested positive at least 7 days before departure
with a Covid-19 vaccination certificate showing that they were:
o Fully vaccinated at most 8 months before departure; or
o Fully vaccinated and received a booster dose at least 14 days before departure
Passengers must have a Covid-19 vaccination certificate showing that they were fully vaccinated
with Janssen at least 14 days and at most 8 months before departure or fully vaccinated with the
others at most 8 months before departure or fully vaccinated and received a booster dose. They
must register and download the Tawakkalna App and submit their personal details within 8 hours
after the arrival.
SINGAPORE 2021
Persons who are medically unfit to be vaccinated are not allowed to travel under the VTL (Air).
Unvaccinated short-term visitors will not be allowed to travel to Singapore. However,
unvaccinated: Singapore Citizens, Permanent Residents, and Long-Term Pass holders who have
received entry approval via the SC/PR Familial Ties Lane may still travel to Singapore on a non-
designated flight. They will be subject to the prevailing Stay-Home Notice (SHN) and COVID-19
test requirements upon entry into Singapore. 16
SINGAPORE UPDATE 2022
Passengers are not allowed to enter Singapore. This does not apply to:
• Nationals or permanent residents of Singapore.

• Passengers with a Long-Term Visit Pass (LTVP), Immigration Exemption Order (IEO),
Work Pass (including Employment Pass, Training Employment Pass, EntrePass,
16
https://safetravel.ica.gov.sg/vtl/faq
AR02070 129
Personalised Employment Pass, TechPass, Work Holiday Pass, S Pass), Dependant's Pass,
Student's Pass (STP), or the respective In-Principle Approval (IPA).
• Passengers with a Work Permit, or the corresponding IPA, with an Approval Letter for
Entry (ALE) from the Ministry of Manpower (MOM) or Safe Travel Office (STO).
• Passengers with an approval letter from the Safe Travel Office (STO), Ministry of Foreign
Affairs (MFA), Ministry of Education (MOE), Ministry of Health (MOH), or Ministry of
Trade and Industry (MTI)
• Passengers with a Business Travel Pass (BTP) or a Pre-Approved Business Pass (PBP)
• Passengers with an Air Travel Pass approval letter issued by Singapore if they have only
been in China (People's Rep.), Chinese Taipei, Macao (SAR China) or Singapore in the
past 7 days.
• Passengers arriving in Singapore on a designated VTL flight.
• This does not apply to residents of Brunei Darussalam if they:
o have a valid SafeTravel Pass approval letter issued by Singapore under the
Singapore-Brunei Reciprocal Green Lane; and
o have a medical certificate with a negative Coronavirus (COVID-19) PCR test taken
at most 3 days before departure from the first embarkation point; and
o stayed in Brunei Darussalam in the last 14 days before departure; and
o have a return ticket or proof of other transportation arrangements to depart from
Singapore.
Passengers must have a negative COVID-19 PCR or rapid antigen test taken at most 2 days before
the day of departure from the first embarkation point. For passengers with a positive COVID-19
test taken in the past 7 days (for fully vaccinated passengers) or 14 days (for not fully vaccinated
passengers), the negative COVID-19 test must be taken at least 72 hours after the positive test. If
passengers have transited for more than 24 hours before arriving in Singapore, the negative test
must be taken at most 2 days before the day of departure of the last direct flight to Singapore. This
does not apply to passengers younger than 3 years or passengers with proof of recovery or
passengers with a letter of exemption issued by a Singapore Government Agency. Passengers
arriving on a Vaccinated Travel Lane (VTL) flight must: have a Vaccinated Travel Pass (Air)
approval letter issued by Singapore; and have a COVID-19 vaccination certificate
CHINA 2021
After reviewing the embassy site and multiple sites online it is possible that you may not be able
to enter China right now even if you are vaccinated. Due to the lack of information, I am not able
to find out if domestic travel is allowed for unvaccinated citizens. 17
CHINA UPDATE 2022
Entry by foreign nationals holding a visa is suspended. This does not apply to:
• foreign nationals with a visa issued after 28 March 2020 with the place of issue outside the
Mainland of China. They must not arrive from Bangladesh, Belgium, France, India, Italy,
Philippines, Russian Fed. and United Kingdom
• foreign nationals with a diplomatic, service, courtesy or C visa
• foreign nationals with a visa issued after 3 November 2020
• passengers with an invitation letter issued by the Beijing Organising Committee for the
2022 Olympic and Paralympic Winter Games
17
https://www.chinahighlights.com/travelguide/china-travel-reopen-restrictions.htm#entry
AR02071 130
Entry by foreign nationals with a residence permit is suspended. This does not apply to:
• foreign nationals with a permanent residence permit

• foreign nationals with a residence permit with the purpose 'work', 'personal matters' or
'reunion'. They must not arrive from Bangladesh, Belgium, France, India, Italy, Philippines,
Russian Fed. and United Kingdom.
Entry by foreign nationals with an APEC Business Travel Card is suspended.

4. Port visas, 24/72/144-hour visa-free transit policy, Hainan 30-day visa-free policy, 15-day visa-
free policy specified for foreign cruise-group-tour through Shanghai Port, Guangdong 144-hour
visa-free policy specified for foreign tour groups from Hong Kong or Macao SAR, and Guangxi
15-day visa-free policy specified for foreign tour groups of ASEAN countries are suspended.
Foreign nationals coming to the mainland of China for necessary economic, trade, scientific or
technological activities or out of emergency humanitarian needs may apply for visas at Chinese
embassies or consulates. Passengers are subject to medical screening and quarantine for 14 days
at the first point of entry. Passengers must complete an "Exit/Entry Health Declaration Form" and
present a QR code before departure. Nationals of China (People's Rep.) must have a green QR
code with an 'HS' mark. The code can be obtained from the WeChat App 'Fang Yi Jian Kang Ma
Guo Ji Ban' by uploading a negative Coronavirus (COVID-19) nucleic acid test result issued at
most 2 days before departure and a negative IgM antibody test result issued at most 2 days before
departure. A positive IgM antibody test result could be accepted with a COVID-19 vaccination
certificate. More details can be found at the website of the respective Chinese embassy. Passengers
not arriving directly in China (People's Rep.) must repeat both tests in the transit countries and
obtain a new green QR code with an 'HS' mark in each transit country.
BRAZIL 2021
Presentation to the airline responsible for the flight, before boarding, of proof, printed or
electronically, of vaccination with immunization agents approved by the National Health
Surveillance Agency or by the World Health Organization or by the authorities of the country
where the traveler was immunized, whose application of the last dose or single dose has occurred
at least fourteen days before the date of shipment. 18
BRAZIL UPDATE 2022
Passengers must have a COVID-19 vaccination certificate showing that they were fully vaccinated
at least 14 days before departure from the first embarkation point. This does not apply to nationals
and residents of Brazil or passengers younger than 12 years. Passengers entering or transiting
through Brazil must have a negative COVID-19 RT-PCR test taken at most 72 hours before
departure from the first embarkation point or a negative COVID-19 antigen test taken at most 24
hours before departure from the first embarkation point. This does not apply to:
• passengers younger than 2 years

• passengers younger than 12 years and travelling accompanied by a companion. The
companion must have a negative antigen or RT-PCR test result.
• passengers with two positive COVID-19 RT-PCR tests. The tests must be taken at least 14
days apart and the second test at most 72 hours before departure; and
18
https://www.in.gov.br/en/web/dou/-/portaria-interministerial-n-661-de-8-de-dezembro-de-2021-366015007
AR02072 131
• a COVID-19 recovery certificate in English, Portuguese or Spanish showing that they are
asymptomatic and fit to fly. The certificate must show the travel date.
Nationals and residents of Brazil without a COVID-19 vaccination certificate who departed Brazil
after 14 December 2021, are subject to quarantine for 14 days. Passengers and airline crew must
complete a "Traveler's Health Declaration" form at most 24 hours before departure from the first
embarkation point and present it upon arrival. Airline crew are subject to quarantine in a hotel
room until their next flight. This does not apply to airline crew with a COVID-19 vaccination
certificate.
IRAN 2021
Foreign travelers who cannot provide the results of a PCR test will be turned away. Additionally,
travelers must provide a double-vaccination certificate issued no sooner than two weeks prior to
entry. Iranian nationals entering without vaccination certificates must undergo a PCR test, and
quarantine at a designated location until the result is clear. 19
IRAN UPDATE 2022
Passengers arriving from or who have transited through Botswana, Eswatini, France, Lesotho,
Malawi, Mozambique, Namibia, South Africa, United Kingdom or Zimbabwe in the past 14 days
are not allowed to enter. This does not apply to nationals and residents of Iran.
Passengers entering or transiting through Iran must have a negative COVID-19 PCR or RT-PCR
test taken at most 72 hours before departure from the first embarkation point. This does not apply
to passengers younger than 12 years. Passengers must have a COVID-19 vaccination certificate in
English showing that they were fully vaccinated at least 14 days and at most 9 months before
arrival or fully vaccinated and received a booster dose. This does not apply to nationals of Iran or
passengers younger than 12 years.
Passengers could be subject to a COVID-19 test upon arrival when arriving from Albania,
Armenia, Belarus, Bosnia and Herzegovina, Brunei Darussalam, Burundi, Costa Rica, Cuba,
Dominican Rep., Egypt, El Salvador, Estonia, Ethiopia, Gabon, Georgia, Grenada, Guatemala,
Guyana, Haiti, Honduras, Iraq, Jamaica, Kenya, Korea (Dem. People's Rep.), Kosovo, Latvia,
Liberia, Malaysia, Mexico, Moldovia, Mongolia, Montenegro, Myanmar, North Macedonia
(Rep.), Nicaragua, Papua New Guinea, Philippines, Romania, Russian Fed., Serbia, Seychelles,
Slovenia, Sudan, Suriname, Syria, Tajikistan, Tanzania, Thailand, Turkey, Trinidad and Tobago,
Turkmenistan, USA, Ukraine, United Kingdom, Uzbekistan, Venezuela, Vietnam or Yemen.
This does not apply to passengers 12 years and younger. Passengers could be subject to COVID-
19 test upon arrival and quarantine at their own expense. Nationals and residents of Iran arriving
from or who have transited through Botswana, Eswatini, France, Lesotho, Malawi, Mozambique,
Namibia, South Africa, United Kingdom or Zimbabwe in the past 14 days are subject to a COVID-
19 test upon arrival and quarantine for 14 days at a hotel in the airport. Passengers must complete
a "Self-declaration Form" before arrival.
19
https://ir.usembassy.gov/covid-19-information/
AR02073 132
RUSSIA 2021
Entry to the Russian Federation of foreign citizens of other countries, as well as stateless persons,
is restricted until further notice. The issuance of tourist visas, including visas in the form of an
electronic document, has also been temporarily suspended. 20
RUSSIA UPDATE 2022
Nationals and residents of Botswana, Eswatini, Hong Kong (SAR China), Kenya, Lesotho,
Madagascar, Mozambique, Namibia, South Africa, Tanzania and Zimbabwe are not allowed to
enter. Passengers and airline crew who in the past 10 days have been in Botswana, Eswatini, Hong
Kong (SAR China), Kenya, Lesotho, Madagascar, Mozambique, Namibia, South Africa, Tanzania
or Zimbabwe are not allowed to enter. This does not apply to nationals of the Russian Fed.
Passengers are not allowed to enter. This does not apply to nationals of the Russian Fed. and their
family members or permanent residents of the Russian Fed. Passengers entering or transiting the
Russian Fed. must have a negative COVID-19 PCR test taken at most 2 days before arrival. The
test result must be in English or Russian. A notarized translation to Russian is accepted. This does
not apply to nationals of the Russian Fed. or passengers arriving from Armenia, Azerbaijan,
Belarus, Kazakhstan, Moldova (Rep.), Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan.
Passengers arriving from Armenia, Azerbaijan, Belarus, Kazakhstan, Moldova (Rep.),

Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan must have a negative COVID-19 PCR test
taken at most 2 days before arrival. The test result must have a green QR code obtained in the app
'Traveling without COVID-19'. This does not apply to nationals of the Russian Fed. Nationals of
the Russian Fed. arriving from Botswana, China (People's Rep.), Eswatini, Hong Kong (SAR
China), Kenya, Israel, Lesotho, Madagascar, Mozambique, Namibia, South Africa, Tanzania,
United Kingdom or Zimbabwe are subject to a COVID-19 antigen test upon arrival.
Passengers arriving from China (People's Rep.), Israel or United Kingdom are subject to a COVID-
19 antigen test upon arrival. This does not apply to nationals of the Russian Fed.
Flights from Morocco and Tanzania to the Russian Fed. are suspended.
Passengers must complete an "Application Form" and present it upon arrival.
KAZAKHSTAN 2021
Currently, passengers are not allowed to enter and transit Kazakhstan except for:
• Nationals of Kazakhstan
• Residents of Kazakhstan (may enter once every 30 days)
• Spouse, parents, children of nationals/residents of Kazakhstan (may enter once every 30
days)
• Nationals of Armenia, Belarus, Egypt, Georgia, Germany, South Korea, Kyrgyzstan,
Montenegro, Netherlands, Qatar, Russia, Tajikistan, Turkey, Ukraine, United Arab
Emirates and Uzbekistan
• Diplomatic passport holders and their families
• People with Kazakhstan visa and approved by Deputy Prime Minister of Kazakhstan
• Passengers traveling as students with an invitation letter from an educational institution of
Kazakhstan
• Passengers traveling on business and approved by the Deputy Prime Minister of
Kazakhstan
20
https://tourism.gov.ru/en/contents/turistam/restriction-of-entry-to-the-territory-of-the-russian-federation-until-
may-01-2020
AR02074 133
Most flights to Kazakhstan remain suspended. Visa exemptions for nationals of 57 countries have
been suspended. 21
KHAZAKSTAN UPDATE 2022
Passengers are not allowed to enter and transit. This does not apply to:
• nationals of Kazakhstan or residents of Kazakhstan. They are only allowed to enter once
in 15 days.
• nationals of Argentina, Armenia, Australia, Austria, Azerbaijan, Bahrain, Belarus,
Belgium, Brazil, Bulgaria, Canada, Chile, China (People's Rep.), Colombia, Croatia,
Cyprus, Czech, Denmark, Ecuador, Egypt, Estonia, Finland, France, Georgia, Germany,
Greece, Hungary, Iceland, India, Indonesia, Iran, Ireland (Rep.), Israel, Italy, Japan, Korea
(Rep.), Kuwait, Kyrgyzstan, Latvia, Luxembourg, Malaysia, Maldives, Malta, Mexico,
Moldova (Rep.), Monaco, Mongolia, Montenegro, Netherlands, New Zealand, Norway,
Oman, Philippines, Poland, Portugal, Qatar, Romania, Russian Fed., Saudi Arabia, Serbia,
Singapore, Slovakia, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, Tajikistan,
Thailand, Turkey, USA, Ukraine, United Arab Emirates, Uzbekistan, Vatican City (Holy
See) and Viet Nam
• passengers with a British passport
• passengers with a Hong Kong (SAR China) passport
• spouses, parents and children of nationals or residents of Kazakhstan. They are only
allowed to enter once in 15 days
• passengers with a diplomatic passport and their family members
• passengers with a visa issued by Kazakhstan and approved by the Deputy Prime Minister
of Kazakhstan
• passengers travelling as students with an invitation letter from an educational institution
of Kazakhstan
• passengers travelling on business and approved by the Deputy Prime Minister of
Kazakhstan
Passengers must have a negative COVID-19 PCR test taken at most 72 hours before arrival. The
test certificate must be issued in English, Kazakh or Russian. This does not apply to passengers
with a COVID-19 vaccination certificate showing that they were fully vaccinated at least 14 days
and at most 6 months before arrival. Passengers with a COVID-19 vaccination certificate showing
that they were fully vaccinated and received a booster dose at least 14 days before arrival.
Passengers younger than 5 years. Passengers are subject to medical screening.
USA 2021
Noncitizens who are nonimmigrants and seeking to enter the United States by air are required to
show proof of being fully vaccinated against COVID-19 before boarding a flight to the United
States from a foreign country. If you are not fully vaccinated against COVID-19, you
will NOT be allowed to board a flight to the United States, unless you meet the criteria for an
exception under the Proclamation and CDC’s Order. Yes, at this time all noncitizen nonimmigrant
air passengers traveling to the United States, regardless of antibody status, are required to provide
proof of COVID-19 vaccination. 22
21
https://www.visakazakhstan.com/travel-restrictions/
22
https://www.cdc.gov/coronavirus/2019-ncov/travelers/proof-of-vaccination.html
AR02075 134
USA UPDATE 2022
Passengers entering or transiting through the USA must have a COVID-19 vaccination certificate
showing that they were fully vaccinated at least 15 days (day of vaccination + 14 days) before
arrival. Passenger details in the certificate must match those stated in the passport/travel
document. A combination of these vaccines is accepted if administered at least 17 days apart.
This does not apply to:
• Nationals and residents of the USA

• Passengers younger than 18
• Passengers with a letter issued by a doctor proving that the passenger is medically unable
to receive the vaccine
• Passengers with the following visas: A-1, A-2, C-2, C-3 (as a foreign government official
or immediate family member of an official), E-1 (as an employee of TECRO or TECO or
the employee's immediate family members), G-1, G-2, G-3, G-4, NATO-1 through NATO-
4, or NATO-6 (or seeking to enter as a non-immigrant in one of those NATO
classifications)
• Passengers with a letter of invitation or another official document, issued by the USA, by
other governments or by the United Nations, travelling on duty
• Nationals of Afghanistan, Algeria, Angola, Armenia, Benin, Burkina Faso, Burundi,
Cameroon, Central African Rep., Chad, Congo, Congo (Dem. Rep.), Cote d'Ivoire,
Djibouti, Egypt, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Haiti, Iraq,
Kenya, Kiribati, Liberia, Libya, Madagascar, Malawi, Mali, Mozambique, Myanmar,
Namibia, Nicaragua, Niger, Nigeria, Papua New Guinea, Senegal, Sierra Leone, Solomon
Isl., Somalia, South Sudan, Syria, Tanzania, Togo, Uganda, Vanuatu, Yemen and Zambia,
with a visa issued by the USA, excluding B -1 and B -2 visas
• Members of the U.S. Armed Forces, their spouses, and children younger than 18 years
• Merchant seamen with one of the following visas: C, D, C1/D, B1, H or L.
Passengers entering or transiting through the USA must have a negative COVID-19 test taken at
most 1 day before departure from the first embarkation point. Tests accepted are antigen, NAAT,
RT-LAMP, RT-PCR or TMA. This does not apply to:

• US military personnel
• Passengers with a positive COVID-19 test taken at most 90 days before departure from the
first embarkation point
• A letter issued by a health authority stating that the passenger has been cleared for travel
• Until 1 March 2022, nationals of USA and their family members arriving from Ukraine.
DV visas issued in September 2020 that expired are accepted for entry. Nationals of the U.S.A.
are allowed to enter with an expired passport. This does not apply to emergency passports which
must be valid on arrival. Passengers could be subject to self-isolation or self-quarantine. This
does not apply to:
• Passengers with a COVID-19 recovery certificate proving recovery in the past 90 days
• Passengers with a COVID-19 vaccination certificate showing that they were fully
vaccinated at least 15 days (day of vaccination + 14 days) before arrival. A combination
of these vaccines is accepted if administered at least 17 days apart.
AR02076
TAB 13
AR02077 F
I FEDERAL1COURT
D
É
L COUR FÉDÉRALE P
E O
D S
March 11, 2022 É
11 mars 2022

Kevin Lemieux
BETWEEN:
CAL
I 17

AND AEDAN MACDONALD
Applicants
-and-

Respondents
AFFIDAVIT OF THE
HONOURABLE A. BRIAN PECKFORD
(Sworn March 11, 2022)
I, The Honourable A. Brian Peckford, of the City of Parksville, in the Province of British
Columbia, SWEAR AND SAY THAT:
1. I am one of the Applicants herein, and as such have a personal knowledge of matters
2. I am 79 years old. I was born in the Town of Whitbourne Newfoundland. I am a Canadian

citizen and I currently live in the small City of Parksville on Vancouver Island, British
Columbia.
1
AR02078 2
-
3. Most of my family, including my daughter and two grandchildren, live in Newfoundland,

where I served as the third Premier of Newfoundland for ten years, from March 26, 1979,
to March 22, 1989. The distance between where I live in Parksville and where my daughter
and grandchildren live is 7,195 kilometers. I also have one brother in Nova Scotia and two
brothers in Ontario.
4. It is my normal practice to travel across Canada by commercial airlines both for personal
and business reasons.
5. During my tenure as Premier of Newfoundland, I was personally involved in the extensive

federal and provincial negotiations where I reviewed the various drafts of what is now the
Constitution Act, 1982, including the Charter of Rights and Freedoms (the "Charter").
This was one of the most rewarding and challenging moments of my personal life and
political career. Negotiating and drafting the Constitution Act was an undertaking that all
First Ministers took incredibly seriously as we recognized the gravity and long-lasting
implications of such a momentous legal document that defines the limits of government
infringement of our fundamental rights and freedoms.
6. I am the only living signatory and First Minister who helped draft the Constitution Act. I
was appointed to the Queen’s Privy Council of Canada in 1982.
7. I am gravely concerned about how the Federal Government is restricting my rights and
freedoms protected under the Constitution Act and infringing the Charter rights of all
Canadians in response to Covid-19.
8. The negotiation process between the First Ministers took approximately 18 months prior
to November 5, 1981, when the deal was finally struck. The days, weeks and months
leading up to this day were intense. They involved numerous proposals and revisions of
the Charter, particularly those relating to section 1 exceptions that would allow
governments to infringe Charter rights.
2
AR02079 3
9. My discussions and negotiations relating to section 1 of the Charter occurred directly with
the then Prime Minister Pierre Trudeau and other provincial Premiers, including Angus
MacLean (Prince Edward Island), Richard Hatfield (New Brunswick), John Buchanan
(Nova Scotia), Rene Levesque (Quebec), Bill Davis (Ontario), Sterling Lyon (Manitoba),
Allan Blakeney (Saskatchewan), Peter Lougheed (Alberta), and Bill Bennett (British
Columbia),
10. Through those negotiations, the proposal from Newfoundland's delegation was one of the
reasons that section 1 of the Charter was introduced. The concern that I and other Premiers
had was that the Charter needed to allow the governments to take extraordinary measures
in extraordinary situations when the Country's very existence is at stake. Circumstances
such as an imminent war or insurrection or the Country being in some other equally dire
state.
11. As a First Minister, I understood the historic moment involved in drafting the Charter.
The Constitution Act was meant to instill permanence, continuance, sustainability, unlike
any other regular law made by one government. The narrow scope of circumstances under
section 1 of the Constitution Act that would allow the government to override rights was
deliberately designed to reflect a situation involving the permanence of our nation's
fundamental rights and freedoms.
12. When the First Ministers and I negotiated and signed the Charter, I took my roles and
responsibilities in protecting Canadians very seriously. I continue to do so to this day.
Federal Travel Ban
13. In and around August of 2021, I became aware that the Federal Government was preparing
to make a law that restricted unvaccinated Canadians from travelling by air and rail in and
outside Canada.
14. I understand that on or around October 29, 2021, the Federal Government announced that
they had enacted Interim Order Respecting Certain Requirements for Civil Aviation Due
3
AR02080 4
to COVID-19, No. 43 (the "Travel Ban"). I understand the Travel Ban has been amended
several times, and currently, Order No. 56 of the Travel Ban is in force. Attached hereto
and marked as Exhibit "A" to this my Affidavit is a copy of that Order.
15. In or about September 2021, Prime Minister Justin Trudeau made concerning and alarming
comments regarding unvaccinated people. Specifically, the Prime Minister said:
We are going to end this pandemic with vaccination.
We know people who are a little hesitant, who can be convinced.
But also people who are fiercely opposed to vaccination…who do not

believe in science.
Who are often misogynistic, often are racist. There are not very many of
them, but they take a lot of space.
And there, we have a choice to make, as a leader, as a country. Do we

tolerate these people?
Or do we say: come on… most people 80% of Quebecers have done the
right thing, gotten vaccinated, we want to get back to the things we like.
It's those people who are going to block us now…
Attached hereto and marked as Exhibit "B" to this my Affidavit is a copy of the certified
translation and transcript of the Prime Minister's comments that were made on public
television in or around September 2021. Here is the link to that video Prime Minister
Calling Unvaccinated Misogynistic Racist TV Interview 2021.
16. On December 21, 2021, Prime Minister Justin Trudeau issued a mandate letter to the
Minister of Transportation. The Prime Minister expressly directed the Minister of
Transportation to "enforce vaccination requirements across the federally-regulated
4
AR02081 5
-
transport sector" and to "require that travellers on interprovincial trains, commercial

flights, cruise ships and other federally-regulated vessels be vaccinated." Attached hereto
and marked as Exhibit "C" to this my Affidavit is a copy of the mandate letter.
17. Knowing my objectives and those of the other First Ministers when we signed the Charter,
I am concerned about my, and my fellow Canadians, rights to travel anywhere in Canada
or leave Canada, to pursue a livelihood anywhere in Canada, freedom to assemble, to
associate, and the right to life, liberty and the security of the person and the right to equality
before the law. These are all fundamental individual rights and freedoms protected by the
Charter held by me and all Canadians.
18. As the last living First Minister who helped draft the Charter, the circumstances we have
been facing from December 2021 and through to March 2022 with Covid-19 are not the
type of peril that I had intended would fall within the overriding provisions of section 1 of
the Charter.
19. When we negotiated and drafted the Charter, I understood that I was creating a law of
permanence and significant effect, hence the Constitution Act - not just a federal or
provincial statute that could be easily changed in the political winds of changing parties
or social views. I only intended section 1 to be applied in extraordinary circumstances
where the survival of Canada as a country was in peril from war, or insurrection or other
existential threat. I had drafted and agreed to a similar threshold in section 4(2) regarding
the special circumstances for continuation of a House of Commons or Legalstive
Assembly.
20. The official Government of Canada's advisories as of February 16, 2022, regarding Covid-
19 highlight the nature of circumstances posed by Covid-19:
Most people with mild symptoms will recover on their own.

Adults and children with mild COVID-19 symptoms can stay at home
while recovering. You don't need to go to the hospital.
and
5
AR02082 6
-
It's important that you continue to follow the recommendations and

restrictions of your local public health authority on quarantine or isolation
if you:
• may have COVID-19 (for example, you feel sick or have been
exposed)
• have tested positive for COVID-19
If you have to quarantine or isolate, follow appropriate precautions to

reduce the risk of illness spreading within your home.
Adults and children with mild COVID-19 symptoms can stay at home
while recovering. You don't need to go to the hospital if symptoms are
mild.
Attached hereto and marked as Exhibit "D" and Exhibit "E" to this my Affidavit is the
official Government of Canada's advisory regarding Covid-19. "Most people with mild
symptoms will recover on their own", "quarantine or isolate" and "you don't need to go to
the hospital". The advisory does not say the Country is in peril, war, or insurrection
21. As a 79-year-old man, I do not consider myself to be a health threat to others, and if
anything, others may expose me to various risks, including Covid-19. I am aware that my
age puts me in a high-risk category for Covid-19. However, I believe I should be allowed
to assess the risk and benefit of taking the Covid-19 vaccination. Living in a free country
involves making choices and assessing risks. I can understand the risks of exposure to
Covid-19 and am perfectly capable of determining whether this is a risk I am willing to
take. If others are afraid, they should limit who they see, but I disagree that others' fears
can be used to override protections guaranteed under the Charter and shut down various
parts of our society and trample on my rights and the rights of everyone else.
22. The Travel Ban has hindered me from being able to attend speaking engagements across
Canada because I am unable to travel by plane. I am also unable to visit my family in
Ontario, Newfoundland and Nova Scotia, which I regularly do once or twice a year. At the
age of 79, I am not prepared to drive over 7000 kilometres one way to see my family. That
drive could take me a week, and I would have to do it again just to get home. As both a
driver and a passenger, I have experienced icy and snow-covered roads on interprovincial
6
AR02083 7
-
highways during the winter months. I believe that making that return trip, especially in the
winter, would put my life at risk.
23. My conscience is very strong, and I am fiercely against coercion. I believe that I should
not be pressured or coerced into taking a medical treatment which is new, just to get on an
airplane. My conscience is deeply affected by the knowledge that the federal government
is preventing people from seeing their families who live far away, simply because they
have not taken a novel medical treatment. My conscience is also strongly impacted by the
pressure imposed upon me by the federal government to take this new medical treatment
without fully explaining the various risks of doing so. I do not see the Minister of Transport
or the Prime Minister doing press conferences explaining the known side effects or
possible known adverse events of these new Covid-19 vaccines. I know that Health
Canada has warning labels on these vaccines for blood clots, Bell's Palsy, myocarditis, and
other serious conditions, but the risks of these conditions and others have never been
explained to me by the very people who are telling me I cannot board an airplane without
taking the medical treatment. I feel under duress and that I cannot give my fully informed
voluntary consent to this medical treatment.
24. I am angry that the federal government has imposed a requirement that forces me to reveal
my personal medical status in order to board an airplane to see my family. It is not the
federal government's business to learn what vaccines I have or have not taken. Medical
information ought to be private and confidential. Forcing an intrusion on my privacy in
order to travel across Canada is egregious.
25. What I find perhaps the most disturbing is that the federal government has mandated a
two-tiered society where one group of people has benefits while another group is
disadvantaged. As a person who has chosen not to receive the new medical treatment, I
am all of a sudden treated as an outcast, labelled a racist and misogynist, and as an
undesirable person not fit to be seated with vaccinated people on an airplane. The Covid-
19 vaccinated are allowed to travel by airplane and to see their families and the
unvaccinated are not. This is not the Canada I know and love, and this type of segregation
causes me utmost sadness.
7
AR02084 8
26. I believe that what is happening in our nation is a flagrant disregard for sacred individual
written rights and freedoms in our most supreme legal document that is only 40 years old.
The Government of Canada has been enforcing arbitrary and coercive Covid-19 measures
while discriminating against unvaccinated Canadians like me.
27. I swear this affidavit bona fide in support of the within application to strike down the
Travel Ban and for no improper purpose.
SWORN BEFORE ME by A. Brian Peckford, )

of the City of Parksville, in the Province of )
Alberta, before me at the City of Brampton, in )
the Province of Ontario, this 11 th day of )
March 2022 in accordance with 0. Reg. )
431/20 Administering Oath or Declaration )
Remotely ) A. BRIAN PECKFORD P.C.
)
A Notary Public in and

for the Province of Ontario
Barrister, Solicitor, Notary Public
103 • 60 Queen St. E
Brampton, ON
L6V 1A9
8
AR02085 9

of A ian c od sworn before me
virtually this 11 day of ar , 2022.
________________________________
7
\
arr r an l r n
r n n n ar
AR02086 10
Interim Order Respecting Certain
Requirements for Civil Aviation Due to
COVID-19, No. 56

regulation made pursuant to sections 4.71d and 4.9.b., paragraphs 7.6(1 )(a)i;;
and (b).!:! and section 7.7-e. of the Aeronautics Actf;
• as.C.2004,c. 15,s. 5
• 12s.c. 2014, c. 39, s. 144
• i;;S.C.2015, c. 20,s. 12
• .!:!s.c . 2004,c. 15,s. 18
• fS.C. 2001,c.29,s. 39
• fR.S., c. A-2
annexed Order;
• 9S.C. 2004, c. 15, s. 11 (1)
Therefore, the Minister of Transport, pursuant to subsection 6.41 (1 }9 of the

Ottawa, February 28, 2022
Omar Alghabra
Interpretation
Definitions

accredited person
AR02087 11
accredited person means a foreign national who holds a passport that
contains a valid diplomatic, consular, official or special representative
acceptance issued by the Chief of Protocol for the Department of Foreign
Affairs, Trade and Development. (personne accreditee)
aerodrome property
aerodrome property means, in respect of an aerodrome listed in
Schedule 1, any air terminal buildings or restricted areas or any facilities
used for activities related to aircraft operations or aerodrome operations
that are located at the aerodrome. (terrains de /'aerodrome)

aerodrome security personnel has the same meaning as in section 3 of
the Canadian Aviation Security Regulations, 2012. (personnel de surete de
/'aerodrome)
air carrier
aerien)
Canadian Forces
Canadian Forces means the armed forces of Her Majesty raised by
Canada. (Forces canadiennes)

Chief Public Health Officer means the Chief Public Health Officer
appointed under subsection 6( 1) of the Public Health Agency of Canada
Act. (administrateur en chef)
COVID-19
COVID-19 antigen test

COVID-19 antigen test means a COVID-19 screening or diagnostic
immunoassay that
o (a) detects the presence of a viral antigen indicating the presence of
COVID-19;
o (b) is authorized for sale or distribution in Canada or in the
jurisdiction in which it was obtained;
o (c) if the test is self-administered, is observed and whose result is
verified

laboratory or testing provider that provided the test; and
o (d) if the test is not self-administered, is performed by an accredited
laboratory or testing provider. (essai antigenique relatif ala COVID-19)

AR02088 12
COVID-19 molecular test means a COVID-19 screening or diagnostic test,
including a test performed using the method of polymerase chain
reaction (PCR) or reverse transcription loop-mediated isothermal
amplification (RT-LAMP), that
o (a) if the test is self-administered, is observed and whose result is
verified
laboratory or testing provider that provided the test; or
o (b) if the test is not self-administered, is performed by an accredited
laboratory or testing provider. (essai moleculaire relatif ala COVID-19)
document of entitlement
document of entitlement has the same meaning as in section 3 of the
Canadian Aviation Security Regulations, 2012. (document d'autorisation)
foreign national
foreign national has the same meaning as in subsection 2(1) of the
Immigration and Refugee Protection Act. (etranger)

non-passenger screening checkpoint has the same meaning as in section
3 of the Canadian Aviation Security Regulations, 2012. (point de controle des
non-passagers)
operator of an aerodrome
operator of an aerodrome means the person in charge of an aerodrome
where activities related to civil aviation are conducted and includes an
employee, agent or mandatary or other authorized representative of that
person. (exploitant)

passagers)
peace officer
Regulations
restricted area
screening authority
AR02089 13
screening officer
testing provider
testing provider means
o (a) a person who may provide COVID-19 screening or diagnostic
testing services under the laws of the jurisdiction where the service is
provided; or
o (b) an organization, such as a telehealth service provider or
pharmacy, that may provide COVID-19 screening or diagnostic testing
services under the laws of the jurisdiction where the service is
provided and that employs or contracts with a person referred to in
paragraph (a). (fournisseur de services d'essais)
variant of concern
variant of concern means a variant of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) that is designated as a variant of concern by
the World Health Organization. (variant preoccupant)
• Interpretation
Regulations.
• Conflict
• Definition of mask
(4) For the purposes of this Interim Order, a mask means any mask,
including a non-medical mask, that meets all of the following
requirements:
o (a) it is made of multiple layers of tightly woven materials such as

cotton or linen;

gaping;

AR02090 14
• Masks - lip reading
(5) Despite paragraph (4)(a), the portion of a mask in front of a wearer's

lips may be made of transparent material that permits lip reading if
o (a) the rest of the mask is made of multiple layers of tightly woven
materials such as cotton or linen; and
of the mask.
(6) For the purposes of this Interim Order, a fully vaccinated person
if



the Chief Public Health Officer, that the regimen is suitable, having
regard to the scientific evidence related to the efficacy of that
regimen in preventing the introduction or spread of COVID-19 or
any other factor relevant to preventing the introduction or spread
of COVID-19; or

the Chief Public Health Officer, that the vaccines and the regimen
are suitable, having regard to the scientific evidence related to the
efficacy of that regimen and the vaccines in preventing the
introduction or spread of COVID-19 or any other factor relevant to
preventing the introduction or spread of COVID-19.
AR02091 15
Notification

government.

comply with it.
• Vaccination

AR02092 16
• Definitions

agent de quarantaine
agent de controle
Confirmation


• Exception

Prohibition

to provide under subsection 3( 1).
Foreign Nationals
Prohibition

Exception
AR02093 17
Health Check
Non-application

Health check

o (a) a fever;
o (b) a cough;
• Notification

o (b) they have, or have reasonable grounds to suspect they have,

COVID-19;

previous 10 days for a medical reason related to COVID-19; or
o (d) in the case of a flight departing in Canada, they are the subject of a
• Confirmation
AR02094 18
0 (a) the person has, or has reasonable grounds to suspect that they
have, COVID-19;

misleading.

or misleading.
• Exception

whether any person boarding the aircraft is exhibiting any of the
symptoms referred to in subsection (1 ).
Prohibition

exhibit

AR02095 19
the situations described in paragraphs 8(3)(a}, (b) or (c) applies to that
person; or
Period of 1O days

permitted to board another aircraft for a period of 1O days after the denial,
COVID-19.
COVID-19 Tests - Flights to Canada

Application

• Non-application
that they received a result for a COVID-19 molecular test or a COVID-19
antigen test.
Notification
molecular test or a COVID-19 antigen test.
AR02096 20
0 (a) a negative result for a COVID-19 molecular test that was
flight's initial scheduled departure time;
o (b) a negative result for a COVID-19 antigen test that was performed
on a specimen collected no more than one day before the flight's
initial scheduled departure time; or
o (c) a positive result for a COVID-19 molecular test that was performed
on a specimen collected at least 1O days and no more than 180 days
before the flight's initial scheduled departure time.
• Location of test - outside Canada
(1.1) The COVID-19 tests referred to in paragraphs (1 )(a) and (b) must be
performed outside Canada.
(2) For the purposes of paragraphs (1 )(a) and (b) and subsection (1.1 },
the COVID-19 molecular test or COVID-19 antigen test must not have
been performed in a country where, as determined by the Minister of
Health, there is an outbreak of a variant of concern or there are
reasonable grounds to believe that there is an outbreak of such a variant.
Evidence - alternative testing protocol
13.1 Despite subsections 13(1) and (1.1), a person referred to in section 2.22
of the Order entitled Minimizing the Risk of Exposure to COVID-19 in Canada
Order (Quarantine, Isolation and Other Obligations) must, before boarding an
aircraft for a flight, provide to the private operator or air carrier operating
the flight evidence of a COVID-19 molecular test or a COVID-19 antigen test
that was carried out in accordance with an alternative testing protocol
referred to in that section.
Evidence - molecular test
• 14 (1) Evidence of a result for a COVID-19 molecular test must include
0 (b) the name and civic address of the accredited laboratory or the
result;
and

AR02097 21
(2) Evidence of a result for a COVID-19 antigen test must include
result;
and

test or a COVID-19 antigen test that they know to be false or misleading.
Notice to Minister
has provided evidence of a resu It for a COVID-19 molecular test or a COVID-
19 antigen test that is likely to be false or misleading must notify the
Minister as soon as feasible of the person's name and contact information
and the date and number of the person's flight.
Prohibition

molecular test or a COVID-19 antigen test in accordance with the
requirements set out in section 13 or 13.1.
Vaccination - Flights Departing from an

Aerodrome in Canada
Application


o (c) an air carrier operating a flight departing from an aerodrome

listed in Schedule 1.
AR02098 22
• Non-application

operated by an air carrier

operated by an air carrier,
■ (ii) after having been a crew member on board an aircraft

operated by an air carrier, or

in relation to the operation of an aircraft, if the person will be
o (d) a person who arrives at an aerodrome from any other country on

Canada;
o (e) a person who arrives at an aerodrome on board an aircraft

diverted flight.
Notification
for a flight that the air carrier operates that
• (a) they must be a fully vaccinated person or a person referred to in any

of paragraphs 17.3(2)(a) to (c) or any of subparagraphs 17.3(2)(d)(i) to
(iv) or (e)(i) to (vii);
• (b) they must provide to the air carrier evidence of COVID-19 vaccination
demonstrating that they are a fully vaccinated person or evidence that
they are a person referred to in any of paragraphs 17.3(2)(a) to (c) or any
of subparagraphs 17.3(2)(d)(i) to (iv) or (e)(i) to (vii); and
• (c) if they submit a request referred to in section 17.4, they must do so

within the period set out in subsection 17.4(3).
AR02099 23
entering a restricted area unless they are a fully vaccinated person.
• Exception
(2) Subsection (1) does not apply to
o (a) a foreign national, other than a person registered as an Indian

under the Indian Act, who is boarding the aircraft for a flight to an
taken by the person to Canada from any other country;
o (b) a permanent resident who is boarding the aircraft for a flight to an

taken by the person to Canada from any other country for the
purpose of entering Canada to become a permanent resident;
o (c) a foreign national who is boarding an aircraft for a flight to a

country other than Canada or to an aerodrome in Canada for the
purpose of boarding an aircraft for a flight to a country other than
Canada and who has received either
■ (i) a negative result for a COVID-19 molecular test that was

performed on a specimen collected no more than 72 hours before
the flight's initial scheduled departure time,
■ (ii) a negative result for a COVID-19 antigen test that was

performed on a specimen collected no more than one day before
the flight's initial scheduled departure time, or
■ (iii) a positive result for a COVID-19 molecular test that was

performed on a specimen collected at least 1O days and no more
than 180 days before the flight's initial scheduled departure time;
o (d) a person who has received a result for a COVID-19 molecular test
or a COVID-19 antigen test described in subparagraph (c)(i}, (ii) or (iii)
and who is
■ (i) a person who has not completed a COVID-19 vaccine dosage

regimen due to a medical contraindication and who is entitled to
be accommodated on that basis under applicable legislation by
■ (ii) a person who has not completed a COVID-19 vaccine dosage

regimen due to a sincerely held religious belief and who is entitled
to be accommodated on that basis under applicable legislation by
AR02100 24
■ (iii) a person who is boarding an aircraft for a flight for the purpose
of attending an appointment for an essential medical service or
treatment, or
■ (iv) a competent person who is at least 18 years old and who is

boarding an aircraft for a flight for the purpose of accompanying a
person referred to in subparagraph {iii) if the person needs to be
accompanied because they
■ (A) are under the age of 18 years,
■ (B) have a disability, or
■ (C) need assistance to communicate; or
o (e) a person who has received a result for a COVID-19 molecular test
or a COVID-19 antigen test described in subparagraph (c)(i), (ii) or {iii)
and who is boarding an aircraft for a flight for a purpose other than
an optional or discretionary purpose, such as tourism, recreation or
leisure, and who is
■ (i) a person who entered Canada at the invitation of the Minister of

Health for the purpose of assisting in the COVID-19 response,
■ {ii) a person who is permitted to work in Canada as a provider of

emergency services under paragraph 186(t) of the Immigration and
Refugee Protection Regulations and who entered Canada for the
purpose of providing those services,
■ (iii) a person who entered Canada not more than 90 days before
the day on which this Interim Order came into effect and who, at
the time they sought to enter Canada,
■ (A) held a permanent resident visa issued under subsection

139( 1) of the Immigration and Refugee Protection Regulations,
and
■ (B) was recognized as a Convention refugee or a person in

similar circumstances to those of a Convention refugee within
the meaning of subsection 146(1) of the Immigration and
Refugee Protection Regulations,
■ (iv) a person who has been issued a temporary resident permit
within the meaning of subsection 24( 1) of the Immigration and
Refugee Protection Act and who entered Canada not more than 90
AR02101 25
days before the day on which this Interim Order came into effect
as a protected temporary resident under subsection 151.1 (2) of the
Immigration and Refugee Protection Regulations,
■ (v) an accredited person,
■ (vi) a person holding a D-1, 0-1 or C-1 visa who entered Canada to
take up a post and become an accredited person, or
■ (vii) a diplomatic or consular courier.
Persons - subparagraphs 17.3(2)(d)(i) to (iv)
• 17.4 (1) An air carrier must issue a document to a person referred to in

any of subparagraphs 17.3(2)(d)(i) to (iv) who intends to board an aircraft
for a flight that the air carrier operates or that is operated on the air
carrier's behalf under a commercial agreement if
o (a) in the case of a person referred to in any of subparagraphs 17.3(2)

(d)(i) to (iii), the person submits a request to the air carrier in respect
of that flight in accordance with subsections (2) and (3) or such a
request is submitted on their behalf;
o (b) in the case of a person referred to in subparagraph 17.3(2)(d)(i) or

(ii), the air carrier is obligated to accommodate the person on the
basis of a medical contraindication or a sincerely held religious belief
under applicable legislation by issuing the document; and
0 (c) in the case of a person referred to in subparagraph 17.3(2)(d)(iv),

the person who needs accompaniment submits a request to the air
carrier in respect of that flight in accordance with subsections (2) and
(3) or such a request is submitted on their behalf.
• Request - contents
(2) The request must be signed by the requester and include the
following:
o (a) the person's name and home address and, if the request is made
by someone else on the person's behalf, that person's name and
home address;
0 (b) the date and number of the flight as well as the aerodrome of
departure and the aerodrome of arrival;
o (c) in the case of a person described in subparagraph 17.3(2)(d)(i),
■ (i) a document issued by the government of a province confirming

that the person cannot complete a COVID-19 vaccination regimen
due to a medical condition, or
AR02102 26
■ (ii) a medical certificate signed by a medical doctor or nurse
practitioner who is licensed to practise in Canada certifying that
the person cannot complete a COVID-19 vaccination regimen due
to a medical condition and the licence number issued by a
professional medical licensing body to the medical doctor or nurse
practitioner;
o (d) in the case of a person described in subparagraph 17.3(2)(d)(ii), a

statement sworn or affirmed by the person before a person
appointed as a commissioner of oaths in Canada attesting that the
person has not completed a COVID-19 vaccination regimen due to a
sincerely held religious belief, including a description of how the belief
renders them unable to complete such a regimen; and
o (e) in the case of a person described in subparagraph 17.3(2)(d)(iii), a

document that includes
■ (i) the signature of a medical doctor or nurse practitioner who is

licensed to practise in Canada,
■ (ii) the licence number issued by a professional medical licensing

body to the medical doctor or nurse practitioner,
■ (iii) the date of the appointment for the essential medical service
or treatment and the location of the appointment,
■ (iv) the date on which the document was signed, and
■ (v) if the person needs to be accompanied by a person referred to

in subparagraph 17.3(2)(d)(iv), the name and contact information
of that person and the reason that the accompaniment is needed.
• Timing of request
(3) The request must be submitted to the air carrier
o (a) in the case of a person referred to in subparagraph 17.3(2)(d)(i) or

(ii), 21 days before the day on which the flight is initially scheduled to
depart; and
o (b) in the case of a person referred to in subparagraph 17.3(2)(d)(iii)

or (iv), 14 days before the day on which the flight is initially scheduled
to depart.
• Special circumstances
(4) In special circumstances, an air carrier may issue the document

referred to in subsection (1) in response to a request submitted after the
period referred to in subsection (3).
• Content of document
AR02103 27
(5) The document referred to in subsection (1) must include
o (a) a confirmation that the air carrier has verified that the person is a
person referred to in any of subparagraphs 17.3(2)(d)(i) to (iv); and
departure and the aerodrome of arrival.
Record keeping
• 17.5 (1) An air carrier must keep a record of the following information:
o (a) the number of requests that the air carrier has received in respect
of each exception referred to in subparagraphs 17.3(2)(d)(i) to (iv);
o (b) the number of documents issued under subsection 17.4(1 ); and
o (c) the number of requests that the air carrier denied.
• Retention
(2) An air carrier must retain the record for a period of at least 12 months
request.
Copies of requests
• 17.6 (1) An air carrier must keep a copy of a request for a period of at
least 90 days after the day on which the air carrier issued a document
under subsection 17.4(1) or refused to issue the document.
(2) The air carrier must make the copy available to the Minister on
request.
17.7 Before permitting a person to board an aircraft for a flight that the air
carrier operates, the air carrier must request that the person provide
• (a) evidence of COVID-19 vaccination demonstrating that they are a fully

vaccinated person;
• (b) evidence that they are a person referred to in paragraph 17.3(2)(a) or

(b); or
• (c) evidence that they are a person referred to in paragraph 17.3(2)(c) or

any of subparagraphs 17.3(2)(d)(i) to (iv) or (e)(i) to (vii) and that they
have received a result for a COVID-19 molecular test or a COVID-19
antigen test.
AR02104 28
[17.8 reserved]
17.9 A person must, at the request of an air carrier, provide to the air carrier
the evidence referred to in paragraph 17.7(a), (b) or (c).
• 17.10 (1) Evidence of COVID-19 vaccination must be evidence issued by a

non-governmental entity that is authorized to issue the evidence of
COVID-19 vaccination in the jurisdiction in which the vaccine was
administered, by a government or by an entity authorized by a
government, and must contain the following information:
o (b) the name of the government or of the entity;
0 (c) the brand name or any other information that identifies the
o (d) the dates on which the vaccine was administered or, if the

Resu It of COVID-19 test
• 17.11 (1) A result for a COVID-19 molecular test or a COVID-19 antigen

test is a result described in subparagraph 17.3(2)(c){i), {ii) or (iii).
• Evidence - molecular test
elements set out in paragraphs 14(1 )(a) to (d).
(3) Evidence of a result for a COVID-19 antigen test must include the
elements set out in paragraphs 14(2)(a) to (d).
Person - paragraph 17.3(2)(a)
• 17.12 (1) Evidence that the person is a person referred to in paragraph

17.3(2)(a) must be
AR02105 29
0 (a) a travel itinerary or boarding pass that shows that the initial
not more than 24 hours after the departure time of a flight taken by

• Person - paragraph 17.3(2}{b)

(b) must be
o (a) a travel itinerary or boarding pass that shows that the initial
not more than 24 hours after the departure time of the flight taken by
0 (b) a document entitled "Confirmation of Permanent Residence"

issued by the Department of Citizenship and Immigration that
confirms that the person became a permanent resident on entry to
Canada after the flight taken by the person to Canada from any other
country.
• Person - paragraph 17.3(2)(c)

(c) must be
o (a) a travel itinerary or boarding pass that shows that the person is
boarding an aircraft for a flight to a country other than Canada or to
an aerodrome in Canada for the purpose of boarding an aircraft for a
flight to a country other than Canada; and

• Person - subparagraphs 17.3(2)(d)(i) to (iv)
(4) Evidence that the person is a person referred to in any of

subparagraphs 17.3(2)(d)(i) to (iv) must be a document issued by an air
carrier under subsection 17.4(1) in respect of the flight for which the
person is boarding the aircraft or entering the restricted area.
• Person - subparagraph 17.3(2)(e}{i)

17.3(2)(e}{i) must be a document issued by the Minister of Health that
indicates that the person was asked to enter Canada for the purpose of
assisting in the COVID-19 response.
AR02106 30
• Person - subparagraph 17.3(2)(e)(ii}

17.3(2)(e)(ii) must be a document from a government or non-
governmental entity that indicates that the person was asked to enter
Canada for the purpose of providing emergency services under
paragraph 186(t) of the Immigration and Refugee Protection Regulations.
• Person - subparagraph 17.3(2)(e)(iii)

17.3(2)(e)(iii) must be a document issued by the Department of
Citizenship and Immigration that confirms that the person has been
recognized as a Convention refugee or a person in similar circumstances
to those of a Convention refugee within the meaning of subsection
146(1) of the Immigration and Refugee Protection Regulations.
• Person - subparagraph 17.3(2)(e)(iv)

17.3(2)(e)(iv) must be a document issued by the Department of
Citizenship and Immigration that confirms that the person entered
Canada as a protected temporary resident under subsection 151.1 (2) of
the Immigration and Refugee Protection Regulations.
• Person - subparagraph 17.3(2)(e)(v)

17.3(2)(e)(v) must be their passport containing a valid diplomatic,
consular, official or special representative acceptance issued by the Chief
of Protocol for the Department of Foreign Affairs, Trade and
Development.
• Person - subparagraph 17.3(2)(e)(vi)

17.3(2)(e)(vi) must be the person's D-1, 0-1 or C-1 visa.
• Person - subparagraph 17.3(2)(e)(vii)

17.3(2)(e)(vii) must be
o (a) in the case of a diplomatic courier, the official document

confirming their status referred to in Article 27 of the Vienna
Convention on Diplomatic Relations, as set out in Schedule I to the
Foreign Missions and International Organizations Act; and
AR02107 31
o (b) in the case of a consular courier, the official document confirming
their status referred to in Article 35 of the Vienna Convention on
Consular Relations, as set out in Schedule II to that Act.
False or misleading information
• 17.13 (1) A person must not submit a request referred to in section 17.4
that contains information that they know to be false or misleading.
• False or misleading evidence
(2) A person must not provide evidence that they know to be false or
misleading.
Notice to Minister - information
• 17.14 (1) An air carrier that has reason to believe that a person has
submitted a request referred to in section 17.4 that contains information
that is likely to be false or misleading must notify the Minister of the
following not more than 72 hours after receiving the request:
o (c) the reason the air carrier believes that the information is likely to
be false or misleading.
• Notice to Minister - evidence
(2) An air carrier that has reason to believe that a person has provided
evidence that is likely to be false or misleading must notify the Minister
of the following not more than 72 hours after the provision of the
evidence:
o (c) the reason the air carrier believes that the evidence is likely to be
false or misleading.
17.15 An air carrier must not permit a person to board an aircraft for a flight
that the air carrier operates if the person does not provide the evidence they
are required to provide under section 17.9.
[17.16 reserved]

AR02108 32
respect of a person each time the person is denied permission to board
an aircraft for a flight under section 17.15:
o (a) the person's name and contact information, including the person's
home address, telephone number and email address;
o (b) the date and flight number;
0 (c) the reason why the person was denied permission to board the
aircraft; and
o (d) whether the person had been issued a document under

subsection 17.4(1) in respect of the flight.
• Retention
(2) The air carrier must retain the record for a period of at least 12
months after the date of the flight.
request.
[17.18 and 17.19 reserved]

Application
17.20 Sections 17.21 to 17.25 apply to

Schedule 1, other than an air carrier who operates a commercial air
• (c) NAV CANADA.
• 17.21 (1) For the purposes of sections 17.22 to 17.25, relevant person, in
respect of an entity referred to in section 17.20, means a person whose
duties involve an activity described in subsection (2) and who is
0 (b) an employee of the entity's contractor or agent or mandatary;
o (d) the entity's lessee or an employee of the entity's lessee, if the

AR02109 33
• Activities
(2) For the purposes of subsection (1 ), the activities are

aerodrome operations or commercial flight operations - such as
aircraft refuelling services, aircraft maintenance and repair services,
baggage handling services, supply services for the operator of an
aerodrome, an air carrier or NAV CANADA, fire prevention services,
runway and taxiway maintenance services or de-icing services - and
that take place on aerodrome property or at a location where NAV
CANADA provides civil air navigation services;


and

(2) The policy must
o (a) require that a person who is 12 years and four months of age or
older be a fully vaccinated person before accessing aerodrome
property, unless they are a person
■ (i) who intends to board an aircraft for a flight that an air carrier
operates,
■ {ii) who does not intend to board an aircraft for a flight and who is
accessing aerodrome property for leisure purposes or to
accompany a person who intends to board an aircraft for a flight,
■ {iii) who is the holder of an employee identification document

issued by a department or departmental corporation listed in
Schedule 2 or a member identification document issued by the
AR02110 34
Canadian Forces, or
■ (iv) who is delivering equipment or providing services within a

restricted area that are urgently needed and critical to aerodrome
operations and who has obtained an authorization from the
operator of the aerodrome before doing so;
o (b) despite paragraph (a), allow a person who is subject to the policy
and who is not a fully vaccinated person to access aerodrome
property if the person has not corn pleted a COVID-19 vaccine dosage
religious belief;

person referred to in paragraph (b) that demonstrates that the
o (d) provide for a procedure for issuing to a person whose evidence

has been verified under the procedure referred to in paragraph (c) a
document confirming that they are a person referred to in paragraph
(b);
o (e) provide for a procedure that ensures that a person subject to the
policy provides, on request, the following evidence before accessing
aerodrome property:

■ (ii) in the case of a person referred to in paragraph (d), the

document issued to the person under the procedure referred to in
that paragraph;
o (f) provide for a procedure that allows a person to whom sections

17.31 to 17.40 apply- other than a person referred to in subsection
17.34(2)-who is a fully vaccinated person or a person referred to in
paragraph (b) and who is unable to provide the evidence referred to
in paragraph (e) to temporarily access aerodrome property if they
provide a declaration confirming that they are a fully vaccinated
procedure referred to in paragraph (d);

paragraph (d) is tested for COVID-19 at least twice every week;
AR02111 35
0 (h) provide for a procedure that ensures that a person who receives a
positive result for a COVID-19 test taken under the procedure referred
to in paragraph (g) is prohibited from accessing aerodrome property
until the end of the period for which the public health authority of the
province or territory in which the aerodrome is located requires them
to isolate after receiving a positive result; and
o (i) provide for a procedure that ensures that a person referred to in

paragraph (h) who undergoes a COVID-19 molecular test is exempt
from the procedure referred to in paragraph (g) for a period of 180
days after the person received a positive result from that test.
complete a COVID-19 vaccine dosage regimen on the basis of a medical
contraindication only if they provide a medical certificate from a medical
doctor or nurse practitioner who is licensed to practise in Canada
certifying that the person cannot complete a COVID-19 vaccination
regimen due to a medical condition and specifying whether the condition
is permanent or temporary.
complete a COVID-19 vaccine dosage regimen on the basis of their
sincerely held religious belief only if they submit a statement sworn or
affirmed by them attesting that they have not completed a COVID-19
employee of the operator of an aerodrome or a person hired by the
operator of an aerodrome to provide a service, the policy must provide
that a document is to be issued to the employee or person confirming
that they did not complete a COVID-19 vaccine dosage regimen on the
basis of their sincerely held religious belief only if the operator of the
aerodrome is obligated to accommodate them on that basis under the
Canadian Human Rights Act by issuing such a document.
AR02112 36

contractor or agent or mandatary; and
o (b) in the case of an employee of the operator of an aerodrome's

property.
entity

(a) to (h) and subsections 17.24(3) to (6); and

procedure referred to in paragraph 17.24(2)(d) and who is
0 (ii) an employee of the entity's contractor or agent or mandatary,

(2) The policy must
o (a) require that a relevant person, other than the holder of an

employee identification document issued by a department or
departmental corporation listed in Schedule 2 or a member
identification document issued by the Canadian Forces, be a fully
vaccinated person before accessing aerodrome property or, in the
case of NAV CANADA, a location where NAV CANADA provides civil air
navigation services;
AR02113 37
o (b) despite paragraph (a), allow a relevant person who is subject to
the policy and who is not a fully vaccinated person to access
NAV CANADA provides civil air navigation services, if the relevant

relevant person referred to in paragraph (b) that demonstrates that
the relevant person has not completed a COVID-19 vaccine dosage
religious belief;
o (d) provide for a procedure for issuing to a relevant person whose

evidence has been verified under the procedure referred to in
paragraph (c) a document confirming that they are a relevant person
referred to in paragraph (b);
o (e) provide for a procedure that ensures that a relevant person

subject to the policy provides, on request, the following evidence
before accessing aerodrome property:

■ {ii) in the case of a relevant person referred to in paragraph (d),

the document issued to the relevant person under the procedure
referred to in that paragraph;
o (f) provide for a procedure that ensures that a relevant person

referred to in paragraph (d) is tested for COVID-19 at least twice every
week;
o (g) provide for a procedure that ensures that a relevant person who
receives a positive result for a COVID-19 test under the procedure
referred to in paragraph (f) is prohibited from accessing aerodrome
property until the end of the period for which the public health
authority of the province or territory in which the aerodrome is
located requires them to isolate after receiving a positive test result;
o (h) provide for a procedure that ensures that a relevant person

referred to in paragraph (g) who undergoes a COVID-19 molecular
test is exempt from the procedure referred to in paragraph (f) for a
period of 180 days after the relevant person received a positive result
from that test;
AR02114 38
o (i) set out procedures for reducing the risk that a relevant person will
interaction, occurring on aerodrome property or at a location where
NAV CANADA provides civil air navigation services, with an
procedure referred to in paragraph (d) and who is a person referred
to in any of subparagraphs 17.23(b)(i) to (iv), which procedures may
include protocols related to

■ {ii) physical distancing and the wearing of masks, and
o 0) establish a procedure for collecting the following information with

operations between a relevant person and a person referred to in any
of subparagraphs 17.23(b)(i) to (iv) who is unvaccinated and has not
been issued a document under the procedure referred to in
paragraph (d) or whose vaccination status is unknown:
■ {ii) contact information for the relevant person and the other
person;
o (k) establish a procedure for recording the following information and

policy,
■ {ii) the number of relevant persons who require access to a

restricted area,
■ {iii) the number of relevant persons who are fully vaccinated

persons and those who are not,

due to COVID-19,
■ (v) the number of relevant persons who have been issued a

document under the procedure referred to in paragraph (d), the
reason for issuing the document and a confirmation that the
relevant persons have submitted evidence of COVID-19 tests taken
in accordance with the procedure referred to in paragraph (f),
AR02115 39
requirement referred to in paragraph (a), (f) or (g),

referred to in paragraph (a), (f) or (g),

(i) to (iv) who are unvaccinated and who have not been issued a
document under the procedure referred to in paragraph (d), or
whose vaccination status is unknown, who have an in-person
interaction related to commercial flight operations with a relevant
person and a description of any procedures implemented to
reduce the risk that a relevant person will be exposed to the virus
that causes COVID-19 due to such an interaction, and
■ (ix) the number of instances in which the air carrier or NAV

CANADA, as applicable, is made aware that a person with respect
to whom information was collected under paragraph U) received a
positive result for a COVID-19 test, the number of relevant persons
tested for COVID-19 as a result of this information, the results of
those tests and a description of any impacts on commercial flight
operations; and
o (I) require the air carrier or NAV CANADA, as applicable, to keep the
information referred to in paragraph (k) for a period of at least 12
did not complete a COVID-19 vaccine dosage regimen on the basis of a
medical contraindication only if they provide a medical certificate from a
medical doctor or nurse practitioner who is licensed to practise in
Canada certifying that the relevant person cannot complete a COVID-19
vaccination regimen due to a medical condition and specifying whether
the condition is permanent or temporary.
did not complete a COVID-19 vaccine dosage regimen on the basis of
their sincerely held religious belief only if they submit a statement sworn
or affirmed by them attesting that they have not completed a COVID-19
AR02116 40
employee of an entity or a relevant person hired by an entity to provide a
service, the policy must provide that a document is to be issued to the
employee or the relevant person confirming that they did not complete a
COVID-19 vaccine dosage regimen on the basis of their sincerely held
religious belief only if the entity is obligated to accommodate the
relevant person on that basis under the Canadian Human Rights Ad by
issuing such a document.
o (a) in the case of an employee of an entity's contractor or agent or

mandatary; and



request.
Vaccination - Aerodromes in Canada

Application
o (a) subject to paragraph (c), a person entering a restricted area at an

aerodrome listed in Schedule 1 from a non-restricted area for a
reason other than to board an aircraft for a flight operated by an air
AR02117 41
carrier;
o (b) a crew member entering a restricted area at an aerodrome listed

in Schedule 1 from a non-restricted area to board an aircraft for a
flight operated by an air carrier under Subpart 1, 3, 4 or 5 of Part VII of
the Regulations;


the Regulations,
■ {ii) after having been a crew member on board an aircraft

the Regulations, or
■ {iii) to participate in mandatory training required by an air carrier

in relation to the operation of an aircraft operated under Subpart
1, 3, 4 or 5 of Part VII of the Regulations, if the person will be
o (d) a screening authority at an aerodrome where persons other than

passengers are screened or can be screened;
o (e) the operator of an aerodrome listed in Schedule 1.
• Non-application
o (b) a person who arrives at an aerodrome on board an aircraft

as adverse weather or an equipment malfunction, and who enters a
restricted area to board an aircraft for a flight not more than 24 hours
after the arrival time of the diverted flight;
o (c) a member of emergency response provider personnel who is

o (d) a peace officer who is responding to an emergency;
o (e) the holder of an employee identification document issued by a

department or departmental corporation listed in Schedule 2 or a
member identification document issued by the Canadian Forces; or
o (f) a person who is delivering equipment or providing services within

a restricted area that are urgently needed and critical to aerodrome
operations and who has obtained an authorization from the operator
AR02118 42
of the aerodrome before doing so.
Prohibition
• 17.31 (1) A person must not enter a restricted area unless they are a fully
vaccinated person.
• Exception
(2) Subsection (1) does not apply to a person who has been issued a
document under the procedure referred to in paragraph 17.22(2)(d) or
17.24(2)(d).
17.32 A person must provide to a screening authority or the operator of an

aerodrome, on their request,
• (a) in the case of a fully vaccinated person, the evidence of COVID-19

vaccination referred to in section 17.10; and
• (b) in the case of a person who has been issued a document under the
procedure referred to in paragraph 17.22(2)(d) or 17.24(2)(d), the
document issued to the person.
Request for evidence

present themselves for screening at a non-passenger screening checkpoint
or a passenger screening checkpoint, provide the evidence referred to in
paragraph 17.32(a) or (b).
Declaration
• 17.34 (1) If a person who is a fully vaccinated person or who has been
issued a document under the procedure referred to in paragraph
17.22(2)(d) is unable, following a request to provide evidence under
section 17.33, to provide the evidence, the person may
o (a) sign a declaration confirming that they are a fully vaccinated

procedure referred to in paragraph 17.22(2)(d); or
o (b) if the person has signed a declaration under paragraph (a) no

more than seven days before the day on which the request to provide
evidence is made, provide that declaration.
• Exception
AR02119 43
(2) Subsection (1) does not apply to the holder of a document of
entitlement that expires within seven days after the day on which the
request to provide evidence under section 17.33 is made.
(3) If a person signs a declaration referred to in paragraph (1)(a}, the

screening authority must notify the operator of the aerodrome as soon
as feasible of the person's name, the date on which the declaration was
signed and, if applicable, the number or identifier of the person's
document of entitlement.
• Provision of evidence
(4) A person who signed a declaration under paragraph (1 )(a) must

provide the evidence referred to in paragraph 17.32(a) or (b) to the
operator of the aerodrome within seven days after the day on which the
declaration is signed.

access of a person who does not provide the evidence within seven days
as required under subsection (4) is suspended until the person provides
the evidence.
Record keeping - suspension
• 17.35 (1) The operator of the aerodrome must keep a record of the
following information in respect of a person each time the restricted area
access of the person is suspended under subsection 17.34(5):

if applicable;
o (c) the date of the suspension; and
o (d) the reason for the suspension.
• Retention
(2) The operator must retain the record for a period of at least 12 months
(3) The operator of the aerodrome must make the record available to the
Prohibition
AR02120 44
• 17.36 (1) A screening authority must deny a person entry to a restricted
area if, following a request to provide evidence under section 17.33, the
person does not provide the evidence or, if applicable, does not sign or
provide a declaration under subsection 17.34(1).
(2) If a screening authority denies a person entry to a restricted area, it

must notify the operator of the aerodrome as soon as feasible of the
person's name, the date on which the person was denied entry and, if
applicable, the number or identifier of the person's document of
entitlement.

access of a person who was denied entry under subsection (1) is
suspended until the person provides the requested evidence or the
signed declaration.
17.37 A person must not provide evidence that they know to be false or
misleading.
Notice to Minister
17.38 A screening authority or the operator of an aerodrome that has

reason to believe that a person has provided evidence that is likely to be
false or misleading must notify the Minister of the following not more than
72 hours after the provision of the evidence:
• (a) the person's name;
• (b) the number or identifier of the person's document of entitlement, if

applicable; and
• (c) the reason the screening authority or the operator of an aerodrome

believes that the evidence is likely to be false or misleading.
Record keeping - denial of entry

information in respect of a person each time the person is denied entry
to a restricted area under subsection 17.36(1):

if applicable;
AR02121 45
o (c) the date on which the person was denied entry and the location;
and
o (d) the reason why the person was denied entry to the restricted area.
• Retention
(2) The screening authority must retain the record for a period of at least
12 months after the day on which the record was created.
(3) The screening authority must make the record available to the
Requirement to establish and implement
17.40 The operator of an aerodrome must ensure that a document of

entitlement is only issued to a fully vaccinated person or a person who has
been issued a document under the procedure referred to in paragraph
17.22(2)(d).
Masks
Non-application
o (g) a gate agent.
• Mask readily available
less than six years of age must ensure that a mask is readily available to
the child before boarding an aircraft for a flight.
• Wearing of mask
mask when wearing one is required under section 21 and complies with
any instructions given by a gate agent under section 22 if the child
AR02122 46
Notification
• (a) be in possession of a mask before boarding;
• (b) wear the mask at all times during the boarding process, during the
flight and from the moment the doors of the aircraft are opened until the
person enters the air terminal building; and
with respect to wearing a mask.
Obligation to possess mask

mask before boarding an aircraft for a flight.
Wearing of mask - persons
must require a person to wear a mask at all times during the boarding
process and during a flight that the private operator or air carrier
operates.
0 (a) when the safety of the person could be endangered by wearing a

mask;

instructs the person to wear a mask;

the mask to address unforeseen circumstances or the person's
special needs; or

personnel or a crew member authorizes the removal of the mask to
verify the person's identity.

AR02123 47

o (e) a person who has expertise related to the aircraft, its equipment or
Compliance

respect to wearing a mask.

• (a) the person is not in possession of a mask; or

agent or a crew member with respect to wearing a mask.
Refusal to comply
with respect to wearing a mask, the private operator or air carrier must
■ (ii) the person's name, date of birth and contact information,

email address,
■ (iii) the person's seat number, and

AR02124 48
(2) The private operator or air carrier must retain the record for a period
of at least 12 months after the date of the flight.
(3) The private operator or air carrier must make the record available to
the Minister on request.
Wearing of mask - crew member
must require a crew member to wear a mask at all times during the
carrier operates.

wearing a mask;
o (b) when the wearing of a mask by the crew member could interfere
with operational requirements or the safety of the flight; or

medications.
Wearing of mask - gate agent
must require a gate agent to wear a mask during the boarding process
for a flight that the private operator or air carrier operates.
• Exceptions

wearing a mask; or
o (b) when the gate agent is drinking, eating or taking oral medications.
AR02125 49
Deplaning
Non-application
• 27 ( 1) Section 28 does not apply to any of the following persons:
0 (a) a child who is less than two years of age;
0 (e) a person who is unable to remove their mask without assistance;

• Wearing of mask
mask when wearing one is required under section 28 if the child
Wearing of mask - person
28 A person who is on board an aircraft must wear a mask at all times from
the moment the doors of the aircraft are opened until the person enters the
air terminal building, including by a passenger loading bridge.
Screening Authority
Non-application

AR02126 50

• Wearing of mask
mask when wearing one is required under subsection 30(2) and removes
it when required by a screening officer to do so under subsection 30(3) if
the child

mask at all times during screening.
• Wearing of mask - person

referred to in subsection (1) must wear a mask at all times during
screening.
• Requirement to remove mask
(3) A person who is required by a screening officer to remove their mask

during screening must do so.
(4) A screening officer must wear a mask at a passenger screening

being screened.
• 31 ( 1) A person who presents themselves at a non-passenger screening

checkpoint to enter into a restricted area must wear a mask at all times.
(2) Subject to subsection (3), a screening officer must wear a mask at all
times at a non-passenger screening checkpoint.
• Exceptions
AR02127 51

wearing a mask; or

medications.

notified to wear a mask and refuses to do so to pass beyond a passenger
screening checkpoint into a restricted area.
mask to pass beyond a non-passenger screening checkpoint into a
restricted area.
Designation

• Maximum amounts
• Notice

and must specify
AR02128 52

o (d) that the person on whom the notice is served or to whom it is sent
period.
Repeal
Due to COVID-19, No. 55, made on February 23, 2022, is repealed.
SCHEDULE 1{Subsections 1(1) and 17.1(1)

and paragraphs 17.1{2){c), 17.20{a) and {b),
17.21{2){d) and 17.30{1){a) to {c) and {e))
Aerodromes
ICAO Location
Name Indicator
Alma CYTF
Bagotville CYBG
Baie-Comeau CYBC
Bathurst CZBF
Campbell River CYBL

AR02129 53
ICAO Location
Name Indicator
Charle CYCL
Charlottetown CYYG
Comox CYQQ
Dawson Creek CYDQ
Deer Lake CYDF
Fort McMurray CYMM
Fort St. John CYXJ
Gaspe CYGP
Goose Bay CYYR
Grande Prairie CYQU
iles-de-la-Madeleine CYGR
Iqaluit CYFB
Kamloops CYKA
Kelowna CYLW
Kingston CYGK
Leth bridge CYQL

AR02130 54
ICAO Location
Name Indicator
Lloyd minster CYLL
London CYXU
Medicine Hat CYXH
Mont-Joli CYYY
Montreal International (Mirabel) CYMX

International)
Montreal (St. Hubert) CYHU
Nanaimo CYCD
North Bay CYYB
Penticton CYYF
Prince George CYXS
Prince Rupert CYPR
Quesnel CYQZ
Rouyn-Noranda CYUY
Saint John CYSJ
Sarnia (Chris Hadfield) CYZR
Sept-iles CYZV
Smithers CYYD
St. Anthony CYAY

AR02131 55
ICAO Location
Name Indicator
Stephenvi Ile CYJT
Sudbury CYSB
Terrace CYXT
Thompson CYTH
Thunder Bay CYQT
Val-d'Or CYVO
Vancouver (Coal Harbour) CYHC
Wabush CYWK
Williams Lake CYWL
Windsor CYQG

International)
Yellowknife CYZF
SCHEDULE 2{Subparagraph 17.22{2){a){iii)

and paragraphs 17.24{2){a) and 17.30{2){e))
Departments and Departmental Corporations
Name
Canada Border Services Agency
Canadian Security Intelligence Service

AR02132 56
Name
Correctional Service of Canada
Department of Agriculture and Agri-Food
Department of Employment and Social Development
Department of Fisheries and Oceans
Department of Health
Department of National Defence
Department of the Environment
Department of Public Safety and Emergency Preparedness
Department of Transport
Royal Canadian Mounted Police

Column 1 Column 2
Subsection 2(1) 5,000 25,000
Subsection 2(2) 5,000 25,000
Subsection 2(3) 5,000 25,000
Subsection 2(4) 5,000 25,000
Section 4 5,000 25,000
Section 5 5,000 25,000
Subsection 8(1) 5,000 25,000
Subsection 8(2) 5,000 25,000

AR02133 57
Column 1 Column 2
Maximum Amount of Penalty($)
Subsection 8(4) 5,000 25,000
Subsection 8(7) 5,000 25,000
Section 9 5,000 25,000
Section 10 5,000
Section 12 5,000 25,000
Section 13.1 5,000
Section 15 5,000
Section 16 5,000 25,000
Section 17 5,000 25,000
Section 17.2 25,000
Section 17.7 25,000
Section 17.9 5,000
Subsection 17.14(1) 25,000
Subsection 17.14(2) 25,000
Section 17.15 25,000
Subsection 17.17(1) 25,000

AR02134 58
Column 1 Column 2
Subsection 17.17(2) 25,000
Subsection 17.17(3) 25,000
Subsection 17.22(1) 25,000
Subsection 17.24(1) 25,000
Subsection 17.25(1) 25,000
Subsection 17.25(2) 25,000
Section 17.32 5,000
Section 17.33 25,000
Subsection 17.34(3) 25,000
Subsection 17.34(5) 25,000
Subsection 17.35(1) 25,000
Subsection 17.35(2) 25,000
Subsection 17.35(3) 25,000
Subsection 17.36(1) 25,000
Subsection 17.36(2) 25,000
Subsection 17.36(3) 25,000
Section 17.37 5,000
Section 17.38 25,000
Subsection 17.39(1) 25,000
Subsection 17.39(2) 25,000
Subsection 17.39(3) 25,000
Section 17.40 25,000
Section 19 5,000 25,000

AR02135 59
Column 1 Column 2
Section 20 5,000
Subsection 21 (1) 5,000 25,000
Section 22 5,000
Section 23 5,000 25,000
Subsection 24(1) 5,000 25,000
Subsection 24(2) 5,000 25,000
Subsection 24(3) 5,000 25,000
Subsection 25(1) 5,000 25,000
Subsection 26(1) 5,000 25,000
Section 28 5,000
C, Transport Canada is closely monitoring the COVID-19 situation. In response, we have issued
some trmsportation-related measures and guidance. Please check if any of these
cannot get through, please contact us bY. email.

AR02136 60
Date modified:
2022-02-28
AR02137 61

________________________________
arr r an l r n
r n n n ar
AR02138 62

1 0:00-0 :03 Justin Trudeau Yes, we are go ing to get out of this pandemic through vaccination.
2 0:03-0:09 Justin Trudeau We know people w ho are a little
3 hesitant, who can be convinced,
4 0:09-0:13 Justin Trudeau but also people who are fiercely opposed to vaccination ...
5 0:13-0:14 Journa liste w ho are extrem ists .
6 0:14-0:16 Justin Trudeau ... who do not believe in science,
7 0:16-0:24 Justin Trudeau who often are misogynistic, often are racist...
8 There are not very many of them, but they take up a lot of space.
9 0:24-0:28 Justin Trudeau And there, we have a choice to make,
10 as a leader, as a country -
11 0:28-0:31 Ju stin Trudeau do we tolerate those people, or do we say:
12 0:31 -0:36 Ju stin Trudeau come on ... most people,
13 80% of Quebeckers have done the right thing,
14 0:37-0:40 Justin Trudeau gotten vaccinated, we want to get back to the things we like,
15 0:40-0:43 Justin Trudea u it's those people w ho are going to block us now ...
/, f/,e 1111rfersig11t:rf, Leo M. l smd, Certified T m11slntor, l,olrfer <if Prc~fessio11nl Cord # 79'[ iss11erf hy
OTTIA Q (O rdre des tmrf11cfe11rs, ter111i11olog11es et i11terpretes ng rees r/11 Q 11ebe1/0 rrfer <if Tm11slntors,
Ter111i11ologists mu! l,1terpreters <if Q uebec) l,erehy certify f/,nf the obow is n true n11d f11it-ftf11l fm11slntio11
<if a11 orig inal dorn 111e11 f wri ffe11 i11 Fr('llc/1.
/11 ,l'il11ess tlwr('()f I sig 11 this J111111n ry 2J , 2022
(5 14) 2 12.84I1
(l) 40 3-648-301 0 Toll Free: 1-888- 556-554 1 W l[i)la nguagcsirn Q 11300, 404 6t h Ave SW Calga ry, Al3, T2P0R9 \ w w w .languagcsim.com J
AR02139 63
misogyn.html*

AR02140 64

~T->.
________________________________
arr r an l r n
r n n n ar
1/18/22, 7:28 PM Minister of Transport Mandate Letter
AR02141 65
December 16, 2021
Office of the Cabinet du

Prime Minister Premier ministre
Oltawa, Canada K1A OA2
Dear Minister Alghabra:
Thank you for continuing to serve Canadians as Minister of Transport.
From the beginning of this pandemic, Canadians have faced a once-in-a-century

challenge. And through it all, from coast to coast to coast, people have met the
moment. When it mattered most, Canadians adapted, helped one another, and stayed
true to our values of compassion, courage and determination. That is what has
defined our path through this pandemic so far. And that is what will pave our way
forward.
During a difficult time, Canadians made a democratic choice. They entrusted us to

finish the fight against COVID-19 and support the recovery of a strong middle class. At
the same time, they also gave us clear direction: to take bold, concrete action to build
a healthier, more resilient future. That is what Canadians have asked us to do and it is
exactly what our Government is ready to deliver. We will work to build that brighter
future through continued collaboration, engagement, and the use of science and
evidence-based decision-making. With an unwavering focus on delivering results, we
will work constructively with Parliamentarians and maintain our strong partnerships
with provincial, territorial and municipal governments and Indigenous partners. This
decade has had an incredibly difficult start, but this is the moment to rebuild a more
resilient, inclusive and stronger country for everyone.
The science is clear. Canadians have been clear. We must not only continue taking real
climate action, we must also move faster and go further. As Canadians are increasingly
experiencing across the country, climate change is an existential threat. Building a
cleaner, greener future will require a sustained and collaborative effort from all of us.
As Minister, I expect you to seek opportunities within your portfolio to support our
whole-of-government effort to reduce emissions, create clean jobs and address the
climate-related challenges communities are already facing.
This year, Canadians were horrified by the discovery of unmarked graves and burial
sites near former residential schools. These discoveries underscore that we must
move faster on the path of reconciliation with First Nations, Inuit and Métis Peoples.
We know that reconciliation cannot come without truth and our Government will
continue to invest in that truth. As Ministers, each of us has a duty to further this work,
https://pm.gc.ca/en/mandate-letters/2021/12/16/minister-transport-mandate-letter 1/6
AR02142 -66
both collectively and as individuals. Consequently, I am directing every Minister to
implement the United Nations Declaration on the Rights of Indigenous Peoples and to
work in partnership with Indigenous Peoples to advance their rights.
We must continue to address the profound systemic inequities and disparities that
remain present in the core fabric of our society, including our core institutions. To this
effect, it is essential that Canadians in every region of the country see themselves
reflected in our Government’s priorities and our work. As Minister, I expect you to
include and collaborate with various communities, and actively seek out and
incorporate in your work, the diverse views of Canadians. This includes women,
Indigenous Peoples, Black and racialized Canadians, newcomers, faith-based
communities, persons with disabilities, LGBTQ2 Canadians, and, in both official
languages.
Across our work, we remain committed to ensuring that public policies are informed
and developed through an intersectional lens, including applying frameworks such as
Gender-based Analysis Plus (GBA Plus) and the quality of life indicators in decision-
making.
Canadians continue to rely on journalists and journalism for accurate and timely news.
I expect you to maintain professional and respectful relationships with journalists to
ensure that Canadians are well informed and have the information they need to keep
themselves and their families safe.
Throughout the course of the pandemic, Canadians and their governments have
adapted to new realities. Governments must draw on lessons learned from the
pandemic to further adapt and develop more agile and effective ways to serve
Canadians. To this end, I expect all Ministers to evaluate ways we can update our
practices to ensure our Government continues to meet the challenges of today and
tomorrow.
The success of this Parliament will require Parliamentarians, both in the House of
Commons and the Senate, to work together across all parties to get big things done
for Canadians. I expect you to maintain constructive relationships with your
Opposition Critics and coordinate any legislation with the Leader of the Government in
the House of Commons. As Minister, you are accountable to Parliament both
individually, for your style of leadership and the performance of your responsibilities,
and collectively, in support of our Ministry and decisions taken by Cabinet. Open and
Accountable Government sets out these core principles and the standards of conduct
expected of you and your office. I expect you to familiarize yourself with this
document, which outlines my expectations for each member of the Ministry.
AR02143 67
Our platform lays out an ambitious agenda. While finishing the fight against the
pandemic must remain our central focus, we must continue building a strong middle
class and work toward a better future where everyone has a real and fair chance at
success and no one is left behind.
As Minister of Transport, your immediate priority is to enforce vaccination

requirements across the federally-regulated transport sector that are in place and to
continue to advance the restart and rebuilding of the commercial air sector. You will
also prioritize work to make High Frequency Rail a reality, and to advance measures
that support Canada’s transition to net-zero, including accelerating the transition to
zero emission vehicles.
To realize these objectives, I ask that you achieve results for Canadians by delivering
the following commitments.
• Require that travellers on interprovincial trains, commercial flights, cruise ships and
other federally-regulated vessels be vaccinated, and continue to work with the
federally regulated transportation sector to ensure that COVID-19 vaccination is
prioritized for those workers.
• Continue working with the Minister of Public Safety and the Minister of Health to
protect the health and safety of Canadians through safe, responsible and
compassionate management of the border with the United States and other ports
of entry into Canada.
• Launch a procurement process and move forward with the High Frequency Rail
project in the Toronto to Quebec City corridor using electrified technology, working
towards the ultimate goal of extending the high frequency rail project to
Southwestern Ontario.
• Continue to advance the restart of a competitive and viable air sector, strengthen
air passenger rights and take steps to accelerate the adoption of advanced
technologies, including right touch travel, in order to rebuild public confidence and
future prospects of the air sector, including efficient and affordable travel options
that connect regions and communities to each other and international markets.
• Continue to support Canada’s transition to net zero by advancing measures to:

0 Improve the affordability and accelerate the adoption of zero-emission vehicles,
including used vehicles, by Canadian households and businesses;
0 Develop a strategy to decarbonize emission-intensive on-road freight; and
0 Support global efforts to reduce emissions in the air and marine sectors.
• Work with the Minister of Foreign Affairs to continue to advance Canada’s ongoing
response to the tragic downing of flight PS752, notably to advance the Safer Skies
AR02144 68
Initiative and pursue reforms to the International Civil Aviation Organization’s
accident investigation regime to improve the credibility and transparency of future
safety investigations.
• In partnership with Indigenous Peoples, continue to implement commitments

made under the Oceans Protection Plan, and with the support of the Minister of
Fisheries, Oceans and the Canadian Coast Guard, work to launch the next phase of
the Oceans Protection Plan to continue efforts to deliver world-leading marine
safety systems, increase protection for marine species and ecosystems and create
stronger partnerships with Indigenous and other coastal communities, while
strengthening marine research and science.
• Advance measures that further improve the safety and security of Canada’s rail
system, particularly in light of the impacts of climate change and severe weather on
railway operations.
• Work with provinces, territories and willing municipalities on solutions to allow

them a greater role in managing and regulating boating on their lakes and rivers so
that they promote free access, while ensuring the safety of boaters and the
protection of the environment.
• Complete the Ports Modernization Review with an aim to update governance

structures that promote investment in Canadian ports.
• Continue to work with all stakeholders involved, including the Government of

Quebec, the municipalities, and the Canadian Pacific Railway, toward the rapid
completion of the Lac-Mégantic bypass.
• Complete negotiations to repatriate and rehabilitate the Quebec Bridge.
• With the support of the Minister of Intergovernmental Affairs, Infrastructure and

Communities and the Minister of Innovation, Science and Industry, work to reduce
and prevent supply chain bottlenecks in Canada’s transportation networks through
the National Trade Corridors Fund and legislative and regulatory authorities. Your
efforts will complement the work led by the Minister of International Trade, Export
Promotion, Small Business and Economic Development and the Minister of
Innovation, Science and Industry to strengthen and secure supply chains.
• Work with the Minister of Public Safety, President of the Queen’s Privy Council for
Canada and Minister of Emergency Preparedness, Minister of Fisheries, Oceans
and the Canadian Coast Guard and Minister of Health, among other colleagues, to
ensure the Government of Canada continues to be prepared to proactively mitigate
and respond to emerging incidents and hazards.
AR02145 69
As Minister, you are also responsible for actively engaging with your Cabinet and
Caucus colleagues. As we deliver on our platform commitments, it will be important
that members of the Ministry continue to collaborate and work constructively to
support rigorous and productive Cabinet decision-making. I expect you to support
your colleagues in delivering their commitments, leveraging the expertise of your
department and your own lived experiences.
To best achieve results for Canadians, Ministers must be rigorous and coordinated in
our approach to implementation. I would therefore ask that you return to me with a
proposed approach for the delivery of your mandate commitments, including
priorities for early implementation. Furthermore, to ensure we are accountable for our
work, I will be asking you to publicly report to me, and all Canadians, on your progress
toward these commitments on a regular basis.
As we have been reminded throughout the pandemic, adapting to change is not only
something government should do, it is something government must do. As you work
to fulfil our commitments, I expect you to actively consider new ideas and issues as
they emerge, whether through public engagement, your work with Parliamentarians
or advice from the public service. I also expect you to work with your Deputy Minister
to assess priorities on a continual basis as we build a better future for all Canadians. In
addition to achieving results, you are responsible for overseeing the work of your
department and ensuring the effective operation of your portfolio.
As you staff your office and implement outreach and recruitment strategies for
federally appointed leadership positions and boards, I ask that you uphold the
principles of equity, diversity and inclusion. This helps ensure that federal workplaces
are dynamic and reflective of the Canadians we serve. You will also ensure your
Minister’s office and portfolio are reflective of our commitment to healthy and safe
workplaces.
Canadians expect us to work hard, speak truthfully and be committed to advancing

their interests and aspirations. When we make mistakes – as we all will – Canadians
expect us to acknowledge them, and most importantly, to learn from them.
I know I can count on you to fulfill the important responsibilities entrusted in you, and
to turn to me, and the Deputy Prime Minister, early and often to support you in your
role as Minister.
Sincerely,
Rt. Hon. Justin Trudeau, P.C., M.P.

Prime Minister of Canada
AR02146 70
-
AR02147 71

________________________________
arr r an l r n
r n n n ar
AR02148 72
l♦I
of Canada du Canada
Canada.ca > Coronavirus disease (COVID-19)
Coronavirus disease (COVID-19):

Symptoms and treatment
Outbreak update
Prevention and risks
Canada's response
Guidance documents
Want to join the effort to limit the spread of COVID-19?
Download COVID Alert
× COVID-19 Virtual
On this page Assistant

AR02149 73
• COVID-19 symptoms
• If you have severe symptoms
• If you’re sick or caring for someone who’s sick
• Getting tested
• Treating COVID-19
• Long-term symptoms
COVID-19 symptoms
Symptoms of COVID-19 can vary:
• from person to person

• in different age groups
• depending on the COVID-19 variant
Symptoms may take up to 14 days to appear after exposure to COVID-19.
COVID-19 vaccines remain effective at preventing severe COVID-19 illness

and death. However, vaccines are not 100% effective and you may still
become infected with or without symptoms.
Some of the more commonly reported symptoms include:
• new or worsening cough

• shortness of breath or difficulty breathing
• temperature equal to or more than 38°C
• feeling feverish
• chills
• fatigue or weakness
• muscle or body aches
• new loss of smell or taste
× COVID-19 Virtual
• headache Assistant
• abdominal pain, diarrhea and vomiting

AR02150 74
• feeling very unwell
You can infect others even if you don't have symptoms

You may be infected but not have symptoms. However, you can still spread
the virus to others. You may:
• develop symptoms later (be pre-symptomatic)

• never develop symptoms (be asymptomatic)
Follow the advice of your local public health authority on quarantine or

isolation if you:
• don’t have symptoms but have been exposed to someone who has or
who may have COVID-19
• have tested positive
Vaccination efforts continue to increase vaccine coverage and lower

community transmission. Even with increased coverage, continue to follow
the advice of your local public health authority on the use of individual
public health measures.
Learn more about:
• COVID-19: Effectiveness and benefits of vaccination

• COVID-19: Provincial and territorial resources
• COVID-19: How to quarantine or isolate at home
• Vaccines for COVID-19
• COVID-19: Individual public health measures
If you have severe symptoms

Call 911 or your local emergency number if you×develop
COVID-19severe
Virtual symptoms,
Assistant
such as:
AR02151 75
• significant difficulty breathing
• chest pain or pressure
• new onset of confusion
• difficulty waking up
Follow instructions for safe transport if taking an ambulance or a private

vehicle to a hospital or clinic.
If you’re sick or caring for someone who’s

sick
If you’re infected with COVID-19, even if not ill, follow the advice of your
local public health authority for isolating at home. Most people with mild
symptoms will recover on their own.
Adults and children with mild COVID-19 symptoms can stay at home while
recovering. You don’t need to go to the hospital.
If you’re caring for someone at home who has or may have COVID-19, you
should follow the appropriate precautions to prevent the spread of illness.
Learn more about:

• COVID-19: How to care at home for someone who has or may have
been exposed
Getting tested
The only way to confirm you have COVID-19 is through a laboratory test.
Follow the testing directions provided by your local

× public health authority
COVID-19 Virtual
if you have: Assistant
AR02152 76
• symptoms
• been exposed to a person with COVID-19
People who are partially or fully vaccinated may still be asked to get a
COVID-19 test.
If you’ve been tested and are waiting for the results, follow instructions:
• on how to quarantine or isolate and

• from your local public health authority
Learn more about:
• Testing for COVID-19

If you've tested positive

If you've tested positive for COVID-19, you must isolate at home and away
from others, even if you don’t have any symptoms.
If you develop symptoms during your isolation period:
• continue isolating and

• follow directions provided by your local public health authority or
health care provider
Learn more about:

COVID Alert
× COVID-19 Virtual
Consider downloading and using the COVID Alert Assistant
app. It can let people
know of possible exposures before any symptoms appear.
AR02153 77
If the app notifies you about potential exposure, you should follow the
guidance from your local public health authority.
You can help slow the spread of infection and prevent future outbreaks.
Treating COVID-19
If you’re concerned about your symptoms, consult your health care
provider. They may recommend steps or medications you can take to
relieve some of your symptoms, like fever and cough.
Follow the advice of your health care provider, who may prescribe
treatments.
Learn more about:
• COVID-19 treatments
Long-term symptoms
Some people who become infected with COVID-19 may experience long-
term symptoms, even after they recover from their initial infection. This is
sometimes called post COVID-19 condition or long COVID.
Studies are underway to further understand what causes post COVID-19

condition and how to diagnose and treat it.
If you think you have this condition, talk to your health care provider about
how to manage your symptoms.
Learn more about post COVID-19 condition.
Related links × COVID-19 Virtual

Assistant
AR02154 78
• Digital factsheets, printable posters and shareable videos on COVID-19
(multilingual products available)
• COVID-19: Social media and promotional resources for Health Canada
and Public Health Agency of Canada
I
What COVID-19 information do you need?
• Travel
0 Find out if you can travel to Canada
0 Testing and quarantine requirements
0 Vaccinated travellers entering Canada
0 Travelling within Canada
0 Compassionate exemptions
0 Foreign workers coming to Canada
■ Arriving in Canada and mandatory quarantine
■ Health requirements and general guidance
■ Compliance and inspections
0 Passport services
■ Apply for a Canadian passport
--- ----
■ Renew your passport
---------
eServiceCanada and appointment support
■
-----------
• Testing
0 Testing for COVID-19 in Canada
0 How to get rapid tests
0 Provincial and territorial resources
0 Testing and screening in the workplace
0 Rapid Antigen testing devices
0 Nucleic acid-based testing (including PCR)
• Vaccines × COVID-19 Virtual
Assistant
0 About the COVID-19 proof of vaccination
AR02155 79
0 How to get your Canadian COVID-19 proof of vaccination
0 Using your Canadian COVID-19 proof of vaccination
■ When travelling within Canada
■ When travelling internationally
■ How to use your proof when you return to Canada
0 COVID-19 vaccines overview
0 Getting a vaccine or a booster
0 Authorized vaccines
0 Vaccine safety and possible side effects
• Income support
0 Get a list of benefits and support tailored to you
• Health and safety
0 Prevention
■ Prevention for individuals
■ Prevention for communities
■ Wearing masks
■ Physical distancing and how it helps minimize COVID-19
■ Hygiene
-·
■ Reduce the spread of COVID-19 in the workspace
0 Risks and spread
0 Symptoms and treatment
■ Provincial and territorial self-assessment tools
■ What are the symptoms?
■ How long do symptoms take to appear?
■ Treatment?
■ Should I call my doctor?
• Additional economic and financial support
0 Individuals and families × COVID-19 Virtual
Assistant
0 Support for businesses
--
AR02156 80
0 Support for sectors
0 Organizations helping Canadians
Did you find what you were looking for?
□□
Yes No
What was wrong?
0 I can't find the information

0 The information is hard to understand
0 There was an error or something didn't work
0 Other reason
Please provide more details
You will not receive a reply. Telephone numbers and email addresses will be removed.
Maximum 300 characters
Submit
Share this page
Date modified:
2022-01-14
× COVID-19 Virtual
Assistant
AR02157 81

________________________________
arr r an l r n
r n n n ar
3/11/22, 12:01 AM COVID-19: Symptoms, treatment, what to do if you feel sick- Canada.ea
AR02158 82
l♦I
of Canada du Canada
Canada.ea > Coronavirus disease (COVID-19).
COVID-19: Symptoms, treatment, what

to do if you feel sick
Outbreak UP-date
Prevention and risks
Canada's resP-onse
Guidance documents
Join the effort to limit the spread of COVID-19
Get a COVI D-19 test near you
x COVID-19 Virtual
Assistant
On this page
https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/symptoms.html 1/9
AR02159 83
• COVID-19 SY.mP-toms
• !f..Y.ou have severe SY.mP-toms
• What to do if Y.OU're sick or were exP-osed
• Caring for others
• Treating COVID-19
• Long-term SY.mP-toms
COVID-19 symptoms
Symptoms of COVID-19 can vary:
• from person to person

• in different age groups
• depending on the COVID-19 variant
Some of the more commonly reported symptoms include:
• sore throat
• runny nose
• sneezing
• new or worsening cough
• shortness of breath or difficulty breathing
• temperature equal to or more than 38°C
• feeling feverish
• chills
• fatigue or weakness
• muscle or body aches
• new loss of smell or taste
• headache
• abdominal pain, diarrhea and vomiting x COVID-19Virtual
• feeling very unwell Assistant
AR02160 84
If you don't feel well or if you have any symptoms, even if mild,
assume you may have COVID-19. Immediately isolate at home and away
from others. Check with your local public health authority for more advice,
including where and how to get tested if recommended.
You may be infected but not have symptoms. However, you can still spread
the virus to others. You may:
• develop symptoms later (be pre-symptomatic)

• never develop symptoms (be asymptomatic)
If you've been in contact with someone who has COVID-19, contact your
local public health authority for advice on what to do next.
Learn more about:
• COVID-19: How to guarantine or isolate at home

• Testing for COVID-19: When to get tested and testing results
• COVID-19: Contact your local P-Ublic health authority
Start of symptoms
You may start experiencing symptoms anywhere from 1 to 14 days after
exposure. Typically, symptoms appear between 3 and 7 days after
exposure.
Vaccination prevents severe illness

Vaccination is one of the most effective ways to protect our families,
communities and ourselves against COVID-19. Evidence indicates that the
vaccines used in Canada are very effective at preventing severe illness,
hospitalization and death from COVID-19.
However, vaccines are not 100% effective and y~u59{!Q;'IJ}tYtrt~1!come

/"\ss1~~nl 1
infected with or without symptoms.

AR02161 85
Learn more about:
• Vaccines for COVID-19: How to get vaccinated
Public health measures

When layered together, public health measures are effective in reducing
the spread of COVID-19, including variants of concern.
Regardless of your vaccination status, you should continue to:
• follow the advice of your local public health authority

• layer multiple individual public health measures to protect yourself and
others
Learn more about:

• COVID-19: Prevention for individuals
If you have severe symptoms

Call 911 or your local emergency number if you develop severe symptoms,
such as:
• trouble breathing or severe shortness of breath

• persistent pressure or pain in the chest
• new onset of confusion
• difficulty waking up or staying awake
• pale, grey or blue-coloured skin, lips or nail beds
Follow instructions for safe transP-ort if taking an ambulance or a private

vehicle to a hospital or clinic.
x COVID-19Virtual
Assistant
What to do if you're sick or were exposed

AR02162 86
It's important that you continue to follow the recommendations and
restrictions of your local public health authority on quarantine or isolation
if you:
• may have COVID-19 (for example, you feel sick or have been exposed)
• have tested positive for COVID-19
If you have to quarantine or isolate, follow appropriate precautions to

reduce the risk of illness spreading within your home.
Adults and children with mild COVID-19 symptoms can stay at home while
recovering. You don't need to go to the hospital if symptoms are mild.
Check with your local public health authority about quarantine or isolation
periods, and reporting.
Choose your local public health authority:

------------
AIbe rt a V
Submit ]
Learn more about:
• Testing for COVID-19: When to get tested and testing results

• COVID-19: How to guarantine or isolate at home
Caring for others

You may be caring for someone at home who has or may have COVID-19. If
so, you should follow the appropriate precautions to reduce the risk of
illness spreading within your home.
x COVID-19 Virtual
Adults and children with mild COVID-19 symptomS\oonir11tay at home while
recovering. You don't need to go to the hospital if symptoms are mild.
AR02163 87
Learn more about:
• COVID-19: How to care at home for someone who has or may have
been exP-osed
Treating COVID-19
If you're concerned about your symptoms, consult your health care
provider. They may recommend steps or medications you can take to
relieve some of your symptoms, like fever and cough.
Follow the advice of your health care provider, who may prescribe
treatments.
Learn more about:
• COVID-19 treatments
Long-term symptoms
Some people who become infected with COVID-19 may experience long-
term symptoms, even after they recover from their initial infection. This is
sometimes called post COVID-19 condition or long COVID.
Studies are underway to further understand what causes post COVID-19

condition and how to diagnose and treat it.
If you think you have this condition, talk to your health care provider about
how to manage your symptoms.
Learn more about:
• Post COVID-19 condition

x COVID-19Virtual
Assistant
Related links
AR02164 88
• Digital factsheets,_P-rintable P-OSters and shareable videos on COVTD-19
.(multilingual P-roducts available).
• COVID-19: Social media and P-romotional resources for Health Canada
and Public Health AgencY. of Canada
e What COVID-19 information do you need?

• Travel
° Find out if Y.OU can travel to Canada
0 Testing and guarantine reguirements
o Vaccinated travellers entering Canada
o Travelling within Canada
o ComP-assionate exemP-tions
° Foreign workers coming to Canada
■ Arriving in Canada and mandatory guarantine
■ Health reguirements and general guidance
■ ComP-liance and insP-ections
o Passport services
■ AP-.P-1.Y. for a Canadian P-aSSP-Ort
■ Renew your P-aSSP-Ort

■ eServiceCanada and aP-,P-Ointment SUP-.P-Ort
• Testing
0 Testing for COVID-19 in Canada
o How to get raP-id tests
0 Provincial and territorial resources
o Testing and screening in the workP-lace
o RaP-id Antigen testing devices
o Nucleic acid-based testing_(including PCR).
• Vaccines x C0VID-19Virtual
0 About the COVID-19 P-roof of vaccinatfBttant
AR02165 89
o How to gfil.Y.our Canadian COVID-19 P-roof of vaccination
o Using your Canadian COVID-19 proof of vaccination
■ When travelling within Canada
■ When travelling internationally
■ How to use Y.Our P-roof when you return to Canada
o COVID-19 vaccines overview
o Getting a vaccine or a booster
o Authorized vaccines
o Vaccine safety and P-Ossible side effects
• Income support
o Get a list of benefits and SUP-.P-Ort tailored to you
• Health and safety
o Prevention
■ Prevention for individuals
■ Prevention for communities
■ Wearing masks
■ Physical distancing and how it helP-S minimize COVID-19
■ !:iY.g iene
■ Reduce the SP-read of COVID-19 in the worksP-ace
o Risks and SP-read
o Symptoms and treatment
■ Provincial and territorial self-assessment tools
■ What are the symP-toms?
■ How long do symP-toms take to aP-,P-ear?
■ Treatment?
■ Should I call my doctor?
• Additional economic and financial support
o Individuals and families x covm-19Virtual
Assistant
o SUP-,P-Ort for businesses
AR02166 90
o SUP-P-Ort for sectors
o Organizations helP-ing Canadians
What was wrong?

0 I can't find the information
0 The information is hard to understand
0 There was an error or something didn't work
0 Other reason
Please provide more details
Submit
(Z Share this page
Date modified:
2022-02-16
x COVID-19 Virtual
Assistant
AR02167
TAB 14
AR02168 F
I FEDERAL1COURT
D
É
L COUR FÉDÉRALE P
E O
D S
March 11, 2022 É
11 mars 2022

Kevin Lemieux
BETWEEN:
CAL
I 11

AND AEDAN MACDONALD
Applicants
-and-

Respondents
AFFIDAVIT OF LEESHA NIKKANEN

(Sworn March ____,
11th 2022)
I, Leesha Nikkanen, of the City of Surrey, in the Province of British Columbia, SWEAR AND
SAY THAT:
1. I am one of the Applicants herein, and as such have a personal knowledge matters
2. I am a Canadian citizen born in Ontario. I am a certified high school teacher with over ten
years of teaching experience in Canada and overseas in Beijing, China.
1
AR02169 2
-
3. I currently live and work in Surrey, British Columbia. I have a degree in English and
History from Queen's University in Kingston, Ontario. I also have my Bachelor of
Education from Queen's University.
4. I got married in February of 2019 in Saskatchewan, had a wedding celebration in Ontario

(in June of 2019 and then moved to Surrey with my husband, Bradley, in August 2019
because this is where we can make a livable wage. We both acquired well-paying jobs, but
many of our family members live elsewhere. Most of my family lives in Ontario, and
others live in Calgary and the United States. My mother died in 2016, and my father is
getting elderly. I am very worried about him and miss him terribly.
5. My husband's mother, a sixties indigenous scoop survivor, and his grandmother, an

indigenous residential school survivor, live in Edmonton, Alberta. We are very close to
his family.
6. I recently suffered from a miscarriage. This was my first pregnancy, and we were
incredibly excited about having a baby. I hope to be pregnant very soon again, but the
stress and uncertainty about what we can and cannot do and the government changing the
rules all the time and treating us like criminals is not helping my mental and physical
wellbeing.
The Federal Travel Ban
7. In October 2021, I heard that the Federal Government was preparing to make a law
restricting unvaccinated Canadians from air and rail in and outside Canada.
8. I understand that currently, Interim Order Respecting Certain Requirements for Civil
Aviation Due to COVID-19, No. 56 (the "Travel Ban ") is in effect. I have had a hard time
understanding the constantly changing laws and requirements. I also found that the
government did not provide much information about the Travel Ban, and I had to rely on
my airline companies and the news to inform myself about the Travel Ban.
2
AR02170 3
-
9. I was very angry and frustrated at the government for even considering creating these laws,
and I felt pretty unsure about how to proceed. I was shocked, and I honestly did not believe
that the government would go through with this law. I lived in communist China for three
and a half years, and this action by the government is precisely what they do in China to
limit freedoms. The Chinese Communist Party creates propaganda to scare citizens, and
then they pass laws to limit travel or limit the assembly of people, etc.
10. Given my frustration in learning about the impending Travel Ban, I reached out to Swoop
airline in October and November of 2021. I unsuccessfully attempted to speak with a
Swoop agent many times, and I left numerous messages for them to contact me to
understand if and how my travel rights would be affected.
11. I kept reassuring my husband that we would be able to fly home for Christmas because I
could not fathom that the federal government would ever restrict our right to travel within
Canada and deny our right to see our families. I could never see that happening in the
Country I grew up in and love. I love Canada because we feel safe having the Charter and
laws protecting us from government and institutional abuse. I have seen firsthand how
government abuse affects its citizens, and it is terrifying. I still cannot comprehend that
the government would tell my indigenous husband and me that we could not fly in the land
that belonged to his ancestors.
12. In or around February of 2021, my husband and I contracted Covid-19. We were sick for
a few days and recovered like the regular flu during a flu season. We stayed home for the
entire two-week quarantine period. I had a cough that lingered a bit longer.
13. The Travel Ban has had a massive impact on our lives. We can no longer see our family
without flying because my husband only gets paid when he is working. We cannot afford
to take the two or three weeks off that would be needed to drive to Edmonton or Ontario.
We also do not have the financial means to pay to fly by private chartered aircraft to visit
family or travel for work.
3
AR02171 4
-
14. I have not seen my mother-in-law, his grandma, or any of my family from Ontario since
our wedding celebration in June 2019, with the exception of my dad, brother, and sister-
in-law in February 2020 just before the pandemic when they flew out for a conference.
Finances and other circumstances prevented us from going before this Christmas. I was
very excited that I was finally going to be able to make it home for Christmas in 2021.
15. My mom has passed away, my father is on his own, and he is getting elderly. I want to see
him at least a few times before he also passes. I had not seen him since right before Covid
hit when he travelled to British Columbia with my brother and sister-in-law, but he has
since stopped travelling beyond a short drive from his home. With the Travel Bans now in
place. I worry that I will not be able to attend his funeral, and I am devastated at this
prospect if the Covid mandates and laws do not change soon.
16. I am saddened that the government is stealing family memories from me. They have no
right, and I am angry and worse, I feel helpless in this situation.
17. My husband and I both sought a religious exemption. After numerous attempts to call and
email Swoop, I finally got through to a Swoop Airlines representative, and the woman
suggested that I apply with their parent company WestJet. The forms were available on
the website, and I filled them out that night. We got them signed the very next day with a
notary public and emailed them out the day after they were available, as our trip back to
Ontario for Christmas (2021) was three weeks away. We had booked our flights on July
21st, 2021, before the Travel Ban was passed. We were supposed to fly with Swoop
Airlines from Abbotsford to Toronto on December 21st, 2021, returning a week later.
Attached hereto and marked Exhibit "A" to this my Affidavit is a copy of the flight's
book for December 21st, 2021.
18. The WestJet exemption forms were complicated to fill out technically and substantially.
WestJet only provided one line in the fillable pdf to answer challenging and complex
questions about my deep-held religious beliefs. It felt like they were trying to trick us.
Attached hereto and marked Exhibit "B" to this my Affidavit is a copy of my religious
exemption request to WestJet.
4
AR02172 5
-
19. On December 16th, 2021, I received an email from WestJet airlines that my husband and
my exemptions had been denied. We were not given any reasons why we were denied.
The email also stated we could not ask for feedback, nor could we apply again. Attached
hereto and marked as Exhibit "C" to this my Affidavit is a copy of the denial. This made
me feel like the whole process was fixed. It felt like the WestJet form was made, so it was
impossible to get an exemption, and they had no intention of offering an exemption in any
event. WestJet's email states that we do "not meet Transport Canada's requirements for
this exemption," which made me angrier as I, as a Canadian citizen, was not privy to these
"guidelines" that they seemed to be experts on. And I questioned why Transport Canada
was counselling WestJet on the exemption requirements.
20. I have an English/History degree, yet I was starting to feel like you needed a law degree
and know someone in power to uphold my rights. I went on the Canadian government
website before I filled out the forms. They did not give guidelines for the general public,
and it made me question why private companies are given more direction on these
mandates than the average layperson.
21. Also, isn't the government supposed to provide clear guidance on how to fill out these
forms to help citizens be successful at making their requests? On the day when I checked,
all the government websites provided as "guidance" was a list of Christian sects that had
leaders who made public statements in support of the vaccines; my religious sect was not
listed. I have always gone to Pentecostal/non-denominational, Vineyard churches or
charismatic churches. No leader from any of these sects was quoted on the website as
accepting the vaccine. The Covid-19 vaccine violates my religious beliefs on several
levels. Firstly, it is known that vaccines use fetal cells from aborted fetuses in formulating
vaccines. Our faith sees abortion as murder, and I cannot, in all conscience, support a
product that supports this industry. Despite this, my religious exemption was denied.
22. Further, WestJet did not tell me why I was denied, they said I couldn't talk to anyone for
feedback about why I was denied, and the email stated that I could not apply again. I am
angered beyond words that a private company has been given this much power over my
5
AR02173 6
-
freedom to move freely within Canada. This is nothing short of fascism. The whole process
felt and feels like a big sham.
23. I also have many allergies and insensitivities to foods and chemicals, which I am greatly
concerned about. I have reacted recently to antibiotics, to a vitamin which caused such
extreme pain that I went into the emergency room, and to a cleaner that my work deemed
"safe," but to which I had an anaphylactic reaction and had to be put on oxygen. I continue
to avoid all medication and many foods. Due to my health issues, I feel that taking the
vaccine will pose more risk than benefit; for me, taking the vaccine is like playing Russian
Roulette. Further, it is next to impossible to get a complete list of ingredients in the
vaccines due to proprietary reasons. This is very concerning to me, given my medical
issues. I have also heard that the medical exemptions were extremely difficult to obtain,
and I did not want to feel betrayed by the system again after my request for a religious
exemption. Everything about this process has been incredibly stressful, unpleasant and
disappointing. I feel like I am being stripped of my rights and liberties. I have not done
anything criminal, and I feel like I am being treated like a criminal.
24. My main reasons for opting out of this vaccination experiment are my allergies and severe
sensitivities. Last year, I was put on oxygen after reacting to a cleaning product at work
which I was told was 'safe.' I have a doctor's note that I am allergic to the contents of that
product. Attached hereto and marked as Exhibit "D" to this my Affidavit is a copy of my
doctor's note.
25. I am also insensitive to wheat/gluten, soy, sulphites and some medications. Last year, my
dentist put me on an antibiotic, and I broke out in boils after one day; I discontinued use
after one day. Sulphites give me such extreme pain that I can hardly walk. I have also
reacted to some vitamins. Costco's vitamin D makes me so sick that I thought I had a
bladder infection last year and was off work for a week. Several months later, in
September, when I started retaking their vitamin D, I had to go to the emergency room
because of shooting pain in my stomach. That's when I figured out that I was reacting to
their vitamin D, as that is all I had changed in my regular diet. If some of these everyday
products and foods cause severe reactions, I cannot put my life and health at risk for a
6
AR02174 7
-
vaccine I don't even know what is in it. It is unconscionable that anyone could try to force
me to risk my life and health like that.
26. One of the reasons that I cannot take the Covid-19 inoculation is because I have allergies
and chemical sensitivities.
27. I also do not want to support an unethical product that uses aborted fetal tissue. This violates
my religious beliefs and my conscience. I was pregnant, and I didn't want to risk having a
miscarriage. The Covid-19 vaccines are still in the testing phase, and I do not want to
participate in this medical experiment. And I don't want to risk not being able to get
pregnant again.
28. I do not support companies that make these vaccines and their forcing countries worldwide
to waive their liability. This does not instill confidence in the product and the manufacturer.
It also makes me question how our government agrees to this type of waiver of liability
and still mandating these products on us.
29. It is unbelievable and unjustified to me that the government can impose a medical
experiment that seems to have more risk than benefit. I do not wish to partake in this
worldwide human experiment.
30. Based on my own understanding and conscience, I will not be taking the inoculation after
an extensive review of the scientific research and medical data.
31. The Travel Ban is infringing on my Charter rights, human rights and the Nuremberg Code
to take an experimental mRNA gene therapy. Further, I find these travel bans and other
mandates incredibly discriminatory. I have had friends, colleagues, superiors refer to
unvaccinated people negatively. I heard my Prime Minister Justin Trudeau call
unvaccinated people racist and misogynistic. I cannot believe that the leader of Canada is
using language that can cause so much hate and division in Canada.
7
AR02175 8
32. I am disgusted and distraught that I cannot fly with my indigenous husband to see his sixties
scoop victim mom and his residential school surviving grandma. This is outrageous. When
I lived in China, I asked my Chinese mentor how the Chinese government could arrest
Christians, Muslims, etc., when they say that religion is not illegal. This is how there is a
literal genocide in China of Muslim Uyghurs. The government restricts citizens' right to
travel freely and assemble and then arrest whomever they choose - which tends to be
anyone who believes in God or is spiritual. It has been eerie to watch these communist
tactics play out on Facebook, on the news media, and between friends since Covid.
33. This is why I am challenging the Federal Government's Travel Ban. I need to fight while
we still have an ounce of democracy left. I do not believe that the government has the right
to coerce me, threaten me and bully me into putting something into my body that I do not
want. By maintaining that the Constitution is supreme and maintaining that even this
Federal government cannot get away with taking away our right to travel freely and practice
our faith, then we are standing up for democracy. I will fight for my freedom, even when
it is difficult or uncomfortable.
34. I swear this Affidavit bona fide in support of the within application and for no improper
purpose.
SWORN BEFORE ME by Leesha Nikkanen, )

of the City of Surrey, in the Province of )
British Columbia, before me at the City of )
Brampton, in the Regional Municipality of )
Peel, this � day of March 2022 in
accordance with 0. Reg. 431/20
)
)
__ (!
ll'"'
LEESHA NIKKANEN
UAf8CBCFE6134fC ...
Administering Oath or Declaration Remotely )
)
)
)
)

103- 60 Queen St. E
Brampton, ON
L6V 1A9
8
AR02176 9

of L ha i an n sworn before me
virtually this ____.day
11t of
h
________________________________
AR02177 10
Your Swoop Itinerary

This is not a boarding pass.
Thanks for booking with Swoop! Please review your

itinerary details and important travel information below.
Your reservation code is: X4PQWF
Flight WO407
Tuesday December 21, 2021
m
Abbotsford, BC (YXX) to Toronto, ON (YYZ)
Departs YXX
04:55 PM
Arrives YYZ
12:10 AM
Terminal 3
Bradley James Wulff

Ii]
No Seat Assigned
No Carry on Bag, Checked bags x 1

AR02178 11
Leesha Nikkanen
Iii
No Seat Assigned
No Carry on Bag, No Checked Bag
Flight WO406
Tuesday December 28, 2021
Toronto, ON (YYZ) to Abbotsford, BC (YXX)
Departs YYZ
01:50 PM
Terminal 3
Arrives YXX
04:10 PM
Bradley James Wulff

Iii]
No Seat Assigned
No Carry on Bag, Checked bags x 1
Leesha Nikkanen
l!i
AR02179 12
No Seat Assigned
No Carry on Bag, No Checked Bag
MISSING SOMETHING?
You can still add bags, upgrade your seat, and purchase
travel insurance.
Manage my booking
Your Receipt
Air Transportation Charges $646.40
2 x Adult Base Fare $606.60
4 x Air Passenger Protection Regulation Surcharge$11.80
4 x Nav Canada Surcharge $28.00
Extras $104.00
Checked bags x 2 $104.00
Taxes, Fees, & Charges $135.24
Air Travellers Security Charge (ATSC) $28.50

AR02180 13
Goods and Services Tax (GST) $38.94
Airport Improvement Fee (AIF) $60.00
Harmonized Sales Tax (HST) $7.80
Total $885.64 CAD
Payments
BRADLEY JAMES WULFD
GST/HST #795444918RT0001
Baggage
Buy your bags early and save! Swoop allows one free personal item
such as a purse, laptop bag or briefcase. The max dimensions are
41cm x 15cm x 33cm (16" x 6" x 13"). For all other baggage fees
and information, please refer to our Baggage page. Browse all other
travel information here.
You have received this notification because you have booked a flight with Swoop. This
email was sent to n order to provide information related to your
flight. Replies to this email will not be received. Check out our privacy policy for
more details.
If you are denied boarding or your baggage is lost or damaged, you may be entitled to
certain standards of treatment and compensation under the Air Passenger Protection
Regulations. For more information about your passenger rights please contact your air
carrier or visit the Canadian Transportation Agency's website.
Si l'embarquement vous est refusé ou si vos bagages sont perdus ou endommagés,

vous pourriez avoir droit au titre du Règlement sur la protection des passagers aériens,
à certains avantages au titre des normes de traitement applicables et à une indemnité.
Pour de plus amples renseignements sur vos droits, veuillez communiquer avec votre
transporteur aérien ou visiter le site Web de l'Office des transports du Canada.
AR02181 14
For further information on the treatment of passengers and minimum compensation

owed by Swoop and the recourse against Swoop available to passengers, including
their recourse to the Agency, please refer to our tariff page.
Ill
330, 4311 12 St NE, Calgary, AB T2E 4P9, Canada
FlySwoop.com
AR02182 15

11th of
________________________________
AR02183 16
WEST)ETr;f>
GUEST REQUEST FOR TEMPORARY E X EMPTION :

COVID-19 NON - VACCINATION BASED ON RELIGIOUS GROUNDS
This form must be completed In its entirety by WestJet/Swoop guests seeking a temporary exemp tion on religious grounds
with respect to Transpor1 Canada's Covid- 19 vaccination requirement. All pages must be reviewed and completed by the
person to be exempted and/ or the requester, as well as by the required Commissioner o f Oaths. Incomplete exemption
requests will not be considered. This form must be complet ed In full and submitted t o the West jet Group for approval
no less than 21 days prior to d eparture.
Approved temporary exempuons are valid for a three month period with WestJet or Swoop. Guests are required to submit
a new request for a temporary exemption on religious grounds for any new trips beyond this period. Approved t emporary
exem puons are applicable on Westjet and Swoop flights only, a nd do not extend to t ravel w ith any other airline. Westj et and
Swoop guests are responsible for keeping t heir own record of any approved exemptions, and must carry a copy of Westjet's
approval, together with this completed form, for the duration of their trip.
This f orm Is interactiv e. You can type your inform at ion Into the form and then print before you sign. If you fill it in by hand,
be sure to prim legibly; this will help avoid processing delays. Submit completed forms to WestJet by e-mail to
rel1g1ous exemption@westiet corn.
WestJet approves exemptions at its sole discretion. WestJet's decision to approve or decline an exemption request 1s final
and not subject to appeal. Please note that Westjet o r Swoop does not provide refunds fo r trips cancelled because of an
accommodation request that 1s not approved.
Fees for vaccination exe mptions, including any costs associat ed with the services of a Commission o f Oach s or for
obtaining a Cov id-19 molecular test, are the responsibility of the applicant.
Last name cprO\ilde name r Yact(y a.s ~houm ori rravcl ldent1ficar10Tt) First name Middle name
Wulff Bradley James
Blrthdate MM/DD/YYYY Gender
/1989 0 Female @ Male
E-mail Contact number
Address Town/City
Surrey
Province/Srate Postal code/ZIP Country
BC Canada
Existing WestJet OP Number (1/)Oil h,,d a pr-r...1011~ nc. c>m,1M1fntion aprn.wa/J Wes tJet Rewards 10 top1111n.td bur t..1/, a•W' 1J1 t'H,r pn~t ,1.,,, ,.,,rro,"' wnluiJ
Intended date of t ravel ~1Mt0D/VYYY Flight origin Flight destination

12/21/2021 Abbotsford - YXX Toronto - YYZ
Page 1 of4 vl.0

AR02184 17
Guest name
WESTJET~
Bradley James Wulff
PREVIOUS EX EMPTION REQUE S T S
Has a previous temporary exemption re q uest .,been made for this

person on We stJet or any other carrier/airline. @ No O Yes
If yes. please provide details.
Da te
MM/DD/Y\'YY Nam e of carrier/airline
Was the temporary exemption approved?

Q No O Yes
REQUE S TER INFORMA T ION
Complete if requester is different tha n person seeking temporary exemption.
l ast name (provide narnt." Cl..accO, as slimu1 on travel 1deni1ficat1cin)

First name
Middle name
E-m ail
Contact number
Address
Town/ City
Province/Sta ce
Postal code/ZI P
Country
P R I VACY AGREEM E NT
,. '"""• w,m _ """ m ,, '"' coU '"'' " aao """"'" , , '"' ,e " '"" •a,ocm • "'" oa '";, <ocm • "'
""'""" •a '"' ' "" m,ma<ma , , .,, em,"" •" ,a, '"'oose, o< "'"""Mg m, ,.,me,,,,. "'"' s, aa, """""ag
.,_,_ "''" >ae ""''"""""' '"" ,a,, '",mm,""" w; Ube Ueo, """' " "" ,a "'"'aa,e w;<a We,,"' '"""' '"'<y.
Page 2 of 4 Vl.O
AR02185 18
Guesc na me
WESTJET~
Bradley James Wulff
CONDITIONS OF AC C OMMOD A TIO N
Bradley Wulff
I, - -- -- - - -- - - ~ understand that if approved, WestJet w ill p rovide appropriate accommodations to me. I
agree t o abide by t he terms o f any religious accommodation, In cluding a requirement that I present WestJet with Covid-1 9
molecular test results taken:
Within 72 hours of m y sch eduled deparrure time, w here the result Is neganve, or
At least 14 d ays before but not more than 180 days pnor to my scheduled departure tim e, w here the result 1s positive
Bradley Wulff
I, - - - -- - - - - - - - ~ u nderstand that any accommo dation provided by WestJet is for the purpose o f travel
w ithin or out of Canad a, and I will still be subject t o all border entry requ irement s Including quarantine requirements
im posed u nder the Quoronctne Aa .
QUESTIONNAIRE
Please note that leaders and members of a nu mb er of religions and religious denominations (Islam, Roman Cat holic,
Judaism , Greek Orthodox, Mennonit es, Jehov ah's Witnesses, Ch ristian Science) have released public statements Indicating
their support o f COVID-1 9 vaccines In the interest of public health.
With w hat religion/ religiou s denomination do you Identify?
Christian - Pentecostal/ various denominations (not mentioned above)
Describe how you are a practiclng m em ber of this religion/ religious denomination
I have been been a believer 1n my faith for many years. Before Covid, I allended church regularly.
Explain th e connection between your re ligious beliefs and your inability to recelve a Covid•19 vaccine
Pfizer whlstlerblower admits vaccines have aborted tissue; Further, our faith - and the Charter - guaruntees our right to movement.
What speci fic rellg1ous beliefs or au thorities do you re ly upon to demonstrate that your rcllgion/rehglous denom mat ,on precludes you
from receiving a Covld-19 vaccine?
The bible. The bible says "thou shall not murder" - feta I tissue; The Holy Spint. We reel personally convicted (faith) not to take 1t
Page3of4 vl.O
AR02186 19
Guest name
WESTJET~
Bradley James W ulff
Do your religious beltefs preclude you from receiving other vaccines or medications? If yes, please provide examples. If no, please explain
why not.
Yes. Any medication that takes away our free will to travel - protected by God's laws and sectlon 6 and 7 (Charter).
Can you provide documentation from religious leaders or other practitioners of your faith that explain the connection between your
religious beliefs and you r objection to the vaccine, and the accommodation you are seeking? If yes, please attach documentation. If no.
We Oy in 21 days. It takes 14 mln lo process. Will provide if requested. (Lack or word count for answers infringes DUE PROCESS).
DECLARATION
I hereby make oath or solemnly affir m and say:

I am unable to be vaccinated against Covid-19 because of my sincere religious belief:
t am requesting a temporary exemption from Transport Canada's requirement t o be fully vaccinated for air travel, on the basis of
religion,
The Information provided 1n support of this application is accurate and truthful;
1 acknowledge that 1t Is an offence under section 131 o r the Criminal Code to make a false statement under oath or solemn affirmation,
knowing that the statement 1s false; and
I acknowledge that it ls an offence under section 366 of the Criminal Code to make a false document, knowing 1t to be false
Signatu re Full name
G1-11}}f ~
Bradley James Wulff
/o
Date MMIDD/YYYY Location
11 13012821-
12 l /2.D2 ( fly/0-4:: Surrey, BC
S IGNA T U RE OF COMMISSIONER OF OATHS
SWORN or SOLEMNLY AFFIRMED before me at (Mw1ic1pall/)'I In (Prov1t1Ct! or ~lll(f! (tJWltf'\) On (rl,ICe)
letn3 ~ Dec I, 2.02.}

Full namtAlexandra M. Kravetz
A Notary Public in and for
the Province of Bntlsh Columbia
5501 Salt Lane
Langley, B.C. V3A 5E9
Permanent Comm1ss1on
Page 4 o/4 vl O
" .
AR02187 20
WESTJET ;;>
GUE S T REQUEST FOR TEMPORARY EXEMPTION :

COVID-19 NON-VACCINATION BASED ON RELIGIOUS GROUND S
This Form must be com pleted In Its entire ty by WestJeUSw oop guests seeking a tem porary exemption on religious grounds
with res pect to Tra nsport Canada's Covid-19 vacci nation req uirement. All pages m ust b e reviewed and completed by the
person to be exempted and/ or th e requester, as w ell as by the required Commissioner or Oaths. I ncomplete exe mption
requests w ill not be considered. This form must be completed in full and submitted to the WestJet Group for approva l
no less than 21 days prior to departure.
Approved temporary exemptions are valid for a th ree month period with WestJet or Sw oo p. Guests are required to submit
a new request for a temporary exemption on religious grounds fo r any new trips beyond this peri od. Approved t emporary
exemptions are applicable on WestJet and Sw oop flights only, and do not extend to t rave l w ith any other airline. WestJet and
Swoop g uests are responsible for keeping t heir ow n record of any approved exemptions, and must carry a copy of WestJet's
approval, tog ether w ith t his completed form, for the duration of their trip.
This form is Interactive. You ca n type your information Into t he form and t hen print before yo u sign. Jf you fill It In by hand,
be su re to pnnt legibly; t his w ill help avoid processing delays. Submit com pleted form s to WestJet by e-mail to
religious exemption@westjet.com.
WestJ et approves exem ptions at its sole d iscretion. WestJet's decision to approve or decline an exem ption request 1s final
and not sub1ecc to appeal. Please note that WestJet or Swoop does not provide refunds for tn ps cancelled because of an
accommodation request that 1s not approved .
Fees for vaccination exemptions, Including any costs associated with the services of a Commissi on of Oaths or for
obtaining a Covid-19 molecular test , are t h e responsibility of the applicant.
Last name (provide name exacrty as shown on travel 1dencijicacwn) First name Middle name
Nikkanen l eesha Rebecca
Bl rthdate MM/ DD/YYYY Gender
977 @ Female 0 Ma le
Contact number
Address Tow n/City
Surrey
Provi nce/State Postal code/ z:I P Country
BC Canada
Existing WestJet OP Number (l['t•ou had a prrvtous occommodnnon ,1pproval) W estJet Rewa rd s l D (optional bu( n 1/l atd.e '" our pmi 1~1011 o{somt' st"n·1c,·sJ
Int ended dat e of travel MM/DD/YYYY Flight origin Flig ht d estina t ion
12/21/2021 Abbolsford • YXX Toronto - YYZ
Page 1 of4 v 1.0

AR02188 21
Guest nam e
W ESTJET 'il'>
Leesha Rebecca N1kkanen
PREVIOUS E X E M PTION REQU ES TS
Has a previous temporary exempti on re quest been m ad e fo r this

,!. No ) Yes
person on Westj et or any other carrier/ airline?
If yes, please provide det ails.
Date MMIDD/YYYY Name of ca rr ie r/ai rline
Was the tem porary exemption approve d? Q No Q Yes
REQUESTER IN F ORMATION
Complete 1f requester Is different than person seeking temporary exemption.
Last name (provide name e,\arcly as shown 011 travel 1denuji.cation) First nam e Midd le name
E-mail Con tact number
Address Town/ City
Province/State Post al code/ZIP Co unt ry
PRIVACY AGR EE MEN T
Leesha Nikkanen
I, - - - - - - - - - - - ~ consent to the collectlon and retention of the personal Information on this form and
contained in any documentation I have provided for the purposes of adjudicating my exemption request and fac1htat1ng
travel, with the understanding chat t his informatton will be kept conndentlal In accordance w ith WestJet's Privacy Polley.
Page2of4 v J.0
AR02189 22
Guest name
WESTJET~
Leesha Rebecca N1kkanen
CONDITIONS OF ACCOMMODATION
Leesha N1kkanen
I, - - - - -- -- - -- ~ understand that 1f approved, WestJet will provide appropriate accommodations to me. I
agree to abide by the terms of any religious accommodation. including a requirement that I present WestJet with Covid-19
molecular test results taken.
W11hln 72 hours of my scheduled departure l ime. where the result is negative, or
Al least 14 days before but not more than 180 days prior to my scheduled departure time, where the result ,s positive
Leesha N1kkanen
I, - - - - - -- - - - -~ understand that any accommodation provided by WestJet Is for the purpose o f travel
within or out of Ca nada, and I will still be subject to all border entry requirements including quarantine requirements
imposed under the Quaranrlne Acr.
QUESTIONNAIRE
Please note that leaders and members of a number of religions and religious denominations (Islam, Roman Catholic,
Judaism, Greek Orthodox, Mennonites, Jehovah's Witnesses, Christian Science) have released public statements indicating
their support of COVID-19 vaccines 1n the Interest of public health.
With wha t religion/religious denomination do you identify?
Chnstlan - Pentecostal/ vanous denominations (not mentioned above)
Describe how you are a practlclng member o f this religion/religious denomination
I have been a member of a church since I was a baby. Before Covid, I attended church regularly - twice a week or more.
Explain th e connection between your rellglous beliefs and your inability to receive a Covid-19 vaccine
Pfizer wh,stlerblower admits vaccines have aborted tissue; Further, our faith - and the Charter - guaruntees our nght to movement.
What specific rel1g1ous beliefs or au thorities do you rely upon to demonstra te that your religion/ religious denomination precludes you
from receiving a Covid- 19 vaccine?
The bible. The bible says "thou shall not murder" - fatal tissue, The Holy Spirit. We feel personally convicted (faith) not to take 1t
Page3of4 vl 0
AR02190 23
WESTJET f/',
Do your r'f llolou1 bc llct, rirrclud you from rr,~h,lng other v,..1ccln01 or mrdlc•tlon,7 It y1-1, plr&i1.* pr0".11dt11 ,./1111m,,I~ U ,.,, pf••~ •✓~"''
why not,
Yos Any modIcotlon thnt tokos owoy our rroo will to trovot . protoclud by God'• t;i,n; and £1JGUon 6 ani:I 7 (C:MrtlJI)
Con you provide documontnllon from retlolous lcoelcrs o r other practitioners of your 131th that -,ptaln th~ c.onn~cuon b~ 11••n J Wf
religious bellcr, 011d your objection t o t he vaccine, and the accommodation you ore seel-lng7 II yes, pteaj~ anach docum•nt..1100. If no,
We Oy In 21 onys. 11 takes 14 mln Lo procoss. WIii provIdo If roqueated (Laci< of word count tor an1were 111frlngot1 OUE PP.OCES;;J
D ECLARATION
I hereby make oath or solemnly atnrm and say:

I am unable to be vaccinated against Covld· 19 because o f my sincere religious belie'I;
I am reques1lng a temporary exempuon from Transport Canada's requirement to be fully vawn.ned for a,, tra,el, on the t,a:.,s of
rellgIon,
The informa1lon provided ,n support or this application Is accurate and trul.hful;
I acknowledge that It ,s an offence under section 131 of I.he Crlmlnal Code to make a false statement under oath or solemn aH'11ma•JOn
knowing that the statement Is false, and
I acknowledge that It Is an o ffence under section 366 of the Criminal Code to make a false dowment. <n<T'11n9 ,t to be fa~
Si gnature~
~ ~
,r (_- - -- - - -- - -- -Full name
Leesha Rebecca Nikkanen
Date / / / ~ Coa,,o
""""" I2. 0 I 2-0 '2. / ~ '"""·ac
SIGNATURE O F COMMISSIONER OF OATHS
SWORN or SOLEMNLY AFFIRMED before me at (Mwucipalory} In (Prov111ce or State. Co:JJ1rryJ On (,...it~
g .c De.c. . l 1'2..0?.. I
Full name
Alexandra M. Kravetz
A Notary Pubhc rn and for
lhe Province of Bnbsh Columbia
5501 Satt Lane
Langley B C V3A 5E9
Permanent Cornmis=
Page 4 of-: ll.O

AR02191 24

11th of
________________________________
AR02192 25
From: Religious Exemption <religious.exemption@westjet.com>

Date: December 16, 2021 at 9:31:40 AM PST
To:
Subject: Not approved for a COVID-19 Vaccine Exemption On Religious Grounds

Hello Leesha Nikkanen,
Not approved for a COVID-19 Vaccine Exemption on Religious Grounds

We have reviewed your request for a temporary exemption to the
COVID-19 vaccination requirement on religious grounds. The
information you have provided does not meet Transport Canada’s
requirements for this exemption. Your request for an exemption to the
COVID-19 vaccination requirement for air travel with WestJet is not
approved.
This determination is based on our review of your request form and any
additional materials you provided. The result cannot be appealed and
Westjet will not respond to further inquiries with respect to this
application.
As per the Government of Canada regulations, as of October 30th 2021,

all passengers the age of 12 years plus 4 months, or older, must be fully
vaccinated in order to board domestic or international flights departing
AR02193 26
from most airports in Canada. Therefore, you are currently restricted

from travel with WestJet, WestJet Encore and Swoop.
If you have current travel booked with WestJet, you may cancel your
booking at no charge and receive a full refund to original form of
payment, if a flexible fare was purchased that includes this. For all other
fares, you will receive a full refund to travel bank in the event of
cancellation.
Kind regards,
Regulatory Guest Relations Team
Privileged and confidential
This electronic message and any attached documents are intended only for the named addressee(s). This communication from WestJet
may contain information that is privileged, confidential or otherwise protected from disclosure and it must not be disclosed, copied,
forwarded or distributed without authorization. If you have received this message in error, please notify the sender immediately and delete
the original message. Thank you.
AR02194 27
From: Bradley Wulff

Date: December 16, 2021 at 10:19:58 AM PST
To: Leesha Nikkanen <l
Subject: Fwd: Not approved for a COVID-19 Vaccine Exemption On Religious Grounds
Brad Wulff | Landscape Construction Foreman
New Rhodes Construction
Toll
IMPORTANT: The contents of this email and any attachments are confidential. They are
intended for the named recipient(s) only. If you receive this email by mistake, please notify
the sender and do not disclose the contents to anyone or make copies thereof. Please
confirm that the email address of the sender is from New Rhodes Construction. Emails
should always end with "@newrhodesconstruction.com". If you receive an email from NRC
under another sender, please notify us immediately at +1 (778) 657-5944 .
From: Religious Exemption <religious.exemption@westjet.com>

Sent: Thursday, December 16, 2021 9:31:45 AM
To: 'bradwulff@ >
Cc: 'leesha.nikkanen <l
AR02195 28
Subject: Not approved for a COVID-19 Vaccine Exemption On Religious Grounds

Hello Bradley Wulff,
Not approved for a COVID-19 Vaccine Exemption on Religious Grounds

We have reviewed your request for a temporary exemption to the
COVID-19 vaccination requirement on religious grounds. The
information you have provided does not meet Transport Canada’s
requirements for this exemption. Your request for an exemption to the
COVID-19 vaccination requirement for air travel with WestJet is not
approved.
This determination is based on our review of your request form and any
additional materials you provided. The result cannot be appealed and
Westjet will not respond to further inquiries with respect to this
application.
As per the Government of Canada regulations, as of October 30th 2021,

all passengers the age of 12 years plus 4 months, or older, must be fully
vaccinated in order to board domestic or international flights departing
from most airports in Canada. Therefore, you are currently restricted
from travel with WestJet, WestJet Encore and Swoop.
If you have current travel booked with WestJet, you may cancel your
booking at no charge and receive a full refund to original form of
payment, if a flexible fare was purchased that includes this. For all other
fares, you will receive a full refund to travel bank in the event of
cancellation.
Kind regards,
Regulatory Guest Relations Team
Privileged and confidential
This electronic message and any attached documents are intended only for the named addressee(s). This communication from WestJet
may contain information that is privileged, confidential or otherwise protected from disclosure and it must not be disclosed, copied,
forwarded or distributed without authorization. If you have received this message in error, please notify the sender immediately and delete
the original message. Thank you.
AR02196 29

11th of
________________________________
AR02197 30
JAN O7 2J21
,,-~ Surrey Schools

CONFIDENTIAL
District Medical Certificate - Accommodation
£MPLOYff NO:
Please indicate the type of medical accommodation you are requesting:
• modified/reduced work hours ~
• assignment/location change
• specialised equipment/furniture
• Other
I, (J>kascp,1n1name/ LE: C>l1A t-J \k:.l<At--lE:. , hereby authorize my physician to complete

this Physician Statement and release this Medical Certificate to my Employer. The guidelines of the College of
Physicians and Surgeons are applicable.
~ -;:::::i
Employee's Signature
7
2 .,- '----- Date: o<:kc
Please describe the details of the accommodation you are requesting as identi
s e · r
Does this person have a diagnosed medical condition resulting In disability? Yes
Please describe the nature of the disability, ie. physical impairment, psychological condition
~Ve.,--e 91.\\e_,.-°.tl'-. h~0C.~On . . .. .

The BC Human Rights Tribunal Yden tifies a dIsabIllty for the purposes of occammadat1on as a d1sabI/1ty of a phys,cot 01
m ental condition that is permanent, ongoing, and episodic or of some persistence and; o substantial or significant limit
on that pe,wn's ability to cor,y out some of Ii e's important functions or activities such os employment.
2. In what way does your patient's medical condition require them to be accommodated in the workplace?
Avo·,JC\t\ce_ ;- ~\~~ ~cJ- -\tb~er.i ~t.r~

'f'~°' <:_~O >"
Page 1 of 2
AR02198 31
r
3. Please indicate relevant functional limitations directly related to their employment. fie lifting, ,,anding,
sitting, walking, etc.)
4. Has this person been referred to a specialist?/ie.• ~ psyr:hologlst/ Yes CJ No

If no, please explain
V\O ~ .
5. What medical follow-ups, if any, are occurring related to this disability?
Ji.~-\\·,~~~. fu .-u.ll&_J \o\low ~ .
6. Is this person following a prescribed treatment plan? Yes No CJ

7. Is this medical condition and/or functional limitations expected to change over time? Yes
If yes, expected time frame 7 )\A O'vYf (t) ~ / /\Jcrr::
k,, own
Has their medical condition reached a plateau? Yes CJ No c::J
PHYSICIAN INFORMATION :
Address_ _ _ _ _ _ _ _ _ _ _ _ _ _ __
Off~~?'6'~/D 36340
Phone: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __ 310-138 13th St. E, N Van, V7L OES
Tt I: 604.770.0164 / Fax: 604.770.0165
info@bewe llm ed ical.ca
The Information In this ~pon Is con,Tdered c:onfidttntia/ Completed fo rrm may be ~ l e ~ by on external
medlrol cansultont who /J' govemed by their own professional protoro/J con~mlng confttlentla/tty
LEADERSHIP IN LEARNING
Surrey School Dlslricl 36 Human Resources Deparlrne11t 14033 92nd Avenue, Surrey, 8 .C. V3V 087
AR02199
TAB 15
AR02200 F
I 1COURT
FEDERAL
D
É
L COUR FÉDÉRALE P
E O
D S
March 11, 2022 É
11 mars 2022

Kevin Lemieux
BETWEEN
CAL
I 16

KEN BAIGENT, DREW BELOBABA, NATALIE CRCIC,
AND AEDAN MACDONALD
Applicants
-and-
Respondents
AFFIDAVIT OF ROBERT DREW BELOBABA

(Sworn March ____,
11th 2022)
I, Robert Drew Belobaba, of the Village of Horton in the County of Somerset, England, SWEAR
AND SAY THAT:
1. I am one of the Applicants herein, and I have a personal knowledge of the facts and matters
herein referred to me except where indicated to be on information and belief, and where
so stated, I verily believe them to be true.
2. I am a 48-year-old Canadian Citizen. I moved to the United Kingdom in November 2005

from Canada. I am a non-practicing member of the Law Society of Saskatchewan and the
Law Society of England and Wales. I have practiced law in Canada and the United
Kingdom, including personal injury law.
3. Currently, I am working as a self-employed courier. In addition to this, I am also a partner

in an antiques and vintage furniture online retail business.
1
AR02201 -2
4. Having practiced personal injury law, I am confident in my ability to comprehend

specialist medical writing. My wife is a practicing pharmacist who holds a highly educated
understanding of naturopathic nutrition.
5. I have visited Canada in 2016, 2017, 2018, and three times in 2019. In 2019, I inherited
property in Outlook, Saskatchewan.
6. In the spring of 2019, I was diagnosed with Type II diabetes. From the time I had
discovered that I have Type II diabetes, I have taken a proactive role in monitoring and
maintaining my health.
7. In late December 2019 or early January 2020, I read about reports of mysterious cases of
pneumonia in Wuhan, China. I continued to follow the news about the disease, which
became steadily more alarming. As more continued to develop with Covid-19, I became
especially concerned about my Diabetes, as people with Diabetes who contract Covid-19
were more likely to have a potentially fatal outcome from this co-morbidity. I began
reading the scientific literature on Covid to understand the disease. As a result of my
research, I started taking daily supplements of Vitamins C, D, and Zinc.
8. During the first lockdown (March to June 2020), the sales of my antique business
collapsed. I needed to find alternative employment, and I deliberately chose to get a job at
a large warehouse because I knew the work would be physical and help me lose weight. I
knew that being overweight was a very significant co-morbidity that could lead to a bad
outcome if I contracted Covid-19. From the beginning of my employment there in late
June 2020 until my resignation in August 2021, I lost approximately 15 kg in weight and
improved my overall health.
9. I was receptive to getting vaccinated when the Covid-19 vaccines were first announced in
autumn 2020. However, by the time I was eligible to receive a vaccine in the spring of
2021, I was less confident and resolved to wait and see whether they had any serious side
effects before making a decision. Several occurrences had taken place that made me no
longer want a vaccination. My elderly father was vaccinated last spring. After his first
2
AR02202 -3
dose of the vaccine, he became very weak and ill. He subsequently contracted pneumonia
and was hospitalized. My business partner received two doses of the Astra Zeneca vaccine.
About a month after her second dose, she suffered from blood clotting. Weeks after this,
while receiving treatment for her blood clotting, she began hemorrhaging from her mouth
and eventually was hospitalized for a month. A friend’s mother was vaccinated and then
caught Covid anyways, as did my stepbrother. In his case, he was very ill and took several
weeks to recover.
10. The language used by Canadian politicians, and in particular our Prime Minister Justin
Trudeau towards the unvaccinated Canadians, is disturbing. The divisional words Justin
Trudeau spoke in his interview during his last Federal election in the summer of 2021 were
alarming. In this interview, Justin Trudeau communicated in French that unvaccinated
people are “racists” and “misogynists.” Attached hereto and marked as Exhibit “A” to
this my Affidavit is a certified translated transcription of Justin Trudeau’s public
comments on public television.
11. In another public interview, Justin Trudeau also said:
When people see that we’re in lockdowns or serious public health

restrictions right now because of the risk posed to all of us by unvaccinated
people, people get angry. And we have put forward many, many different
measures to encourage, to reassure, to incentivize, to educate, to cajole, to
remind people that it is never too late to do the right thing.
We need to continue to do the right thing, the way all Canadians -- or the
vast majority of Canadians are, keep each other safe, make sure our
country gets back to the things we love as quickly as possible.
It is disturbing to me to see Justin Trudeau make such discriminatory remarks about good,
hardworking and law-abiding Canadians. Attached hereto and marked as Exhibit “B” to
this my Affidavit is a certified transcription of Justin Trudeau’s public comments on
January 5, 2021.
3
AR02203 -4
12. To me, the divisive words used by Justin Trudeau are frighteningly reminiscent of the
demonization suffered by my Serbian relatives at the hands of the Ustashe government in
Croatia during the Second World War as part of its genocidal policies towards its minority
citizens.
13. I believe that the steps I have taken to improve my health and my immune system during
Covid-19 have paid off. On or about August 1, 2021, I developed a cough. The following
day I had chills and felt a little unwell. I did a Lateral Flow Test at home, and the test
results came back positive for Covid-19. I subsequently took a PCR test which confirmed
a Positive Covid-19 diagnosis. Attached hereto and marked as Exhibit “C” to this my
Affidavit is an extract from my medical records showing that I had a positive PCR test on
August 4, 2021.
14. My symptoms from Covid-19 were very mild. The most serious symptom I experienced
was losing my sense of smell. Beyond this, I just felt lethargic and a little “off.” My wife
also contracted Covid-19 during the time I did. My wife was not as diligent as me in taking
preventative measures and, as a result, suffered considerably worse than me. When my
wife and I contracted Covid-19, all three of our children were homebound with us. One of
my children just had a runny nose for a couple of days. My other two children never
displayed any symptoms of Covid-19.
15. On or about the 29th day of November 2021, I attended a private medical clinic to obtain
a Covid-19 Antibodies test. The test results of this Antibody Test indicated that I did have
a recent or prior Covid-19 infection. Attached hereto and marked as Exhibit “D” to this
my Affidavit is a copy of the correspondence I received from Bupa on November 29, 2021,
confirming that I had tested positive for Covid-19 antibodies.
16. During the federal election campaign, our Prime Minister of Canada and leader of the
Liberal Party of Canada, Justin Trudeau, promised that he would ban all unvaccinated
Canadians from travelling by air; if reelected. Around October 2021, I learned that the
Federal Government was preparing this law that restricted unvaccinated Canadians from
air and rail, both in and outside Canada.
4
AR02204 -5
17. I understand that at the end of October 2021, the Federal Government announced that they
had enacted Interim Order Respecting Certain Requirements for Civil Aviation Due to
COVID-19, No. 43(the “Travel Ban”). They have subsequently changed the Order many
times and in force currently is Interim Order Respecting Certain Requirements for Civil
Aviation Due to COVID-19, No. 52.
18. It is my understanding the Travel Ban has changed numerous times since it was first
enacted. I have had a hard time understanding the constantly changing laws and
requirements.
19. The Travel Ban causes significant, negative impacts on my life by preventing me from
returning to Canada. Although I can still fly into Canada as an unvaccinated individual, I
cannot fly directly from the United Kingdom into the Saskatoon airport, the closest airport
to my Canadian residence. There are no direct flights from the United Kingdom to airports
in Saskatchewan. I would have to fly into Calgary or Winnipeg and then hire a car to drive
to my Canadian residence.
20. In addition, there are no direct flights to Kelowna airport either, the nearest airport to where
my elderly father resides. Furthermore, I would be unable to board a flight to return home
to the United Kingdom as an unvaccinated traveller and do not have the financial means
to pay to fly by private chartered aircraft to visit family or travel for work.
21. Based on my conscience, belief, personal understanding and extensive review of the
scientific research and medical data, I cannot take the Covid-19 vaccinations for a variety
of the following reasons:
a I have acquired natural immunity to Covid-19 through contracting and recovering

from the disease;
b I have taken responsibility for improving my general health and believe that my body
can sufficiently fight off any future Covid-19 infections;
5
AR02205 6
c Having to disclose my private medical information to airlines and to the federal

government is an invasion of my privacy;
d I feel very strongly that I have a right to my own bodily autonomy and ought not to
be coerced into taking a medical treatment just to travel back to my home in Canada,
especially when the party coercing me to get the vaccine has not disclosed all of the
risks of the vaccine to me;
e The Covid-19 vaccines do not prevent infection or transmission of the Covid-19 virus.
I see no personal or public health benefits to be taking one;
f The vaccines have not undergone sufficient safety testing; and,
g There is considerable evidence of adverse side-effects from the Covid-19 vaccines,

and substantially evident from the short time frame that they have been available.
22. I swear this Affidavit bona fide in support of the within application and for no improper
purpose.
SWORN BEFORE ME by Robert Drew )

Belobaba, of the Village of Norton, in the )
County of Somerset, England, before me at )
the City of Brampton, in the Province of )
Ontario, this ~ day of March 2022 in )
accordance with 0. Reg. 431/20 )
Administering Oath or Declaration Remotely ) ROBERTDifflW°fiiftOBABA
)
)
)
)
)

103 - 60 Queen St. E
Brampton, ON
L6V 1A9
6
AR02206 7

of ob t D lobaba sworn before me
11th
virtually this ____day of .....
________________________________
AR02207 8

1 0:00-0 :03 Justin Trudeau Yes, we are going to get out of this pandemic through vaccination.
2 0:03-0:09 Justin Trudeau We know people who are a little
3 hesitant, who can be convinced,
4 0:09-0 :13 Justin Trudeau but also people who are fiercely opposed to vaccination ...
5 0:13-0:14 Journaliste who are extremists.
6 0:14-0:16 Justin Trudeau ... who do not believe in science,
7 0:16-0:24 Justin Trudeau who often are misogynistic, often are racist...
8 There are not very many of them, but they take up a lot of space .
9 0:24-0 :28 Justin Trudeau And there, we have a choice to make,
10 as a leader, as a country -
11 0:28-0:31 Justin Trudeau do we tolerate those people, or do we say:
12 0:31 -0:36 Justin Trudeau come on ... most people,
13 80% of Quebeckers have done the right thing,
14 0:37-0:40 Justin Trudeau gotten vaccinated, we want to get back to the things we like,
15 0:40-0:43 Justin Trudeau it's those people who are going to block us now ...
I, the 1111dersigl/f:.' d, Leo M. lsmi''f, Certified 1 m11 sl11tor, holder of Pnfessio1111l Cord #791 iss11ed hy
OTTIAQ (Ordre des tmd11cteurs, ter111i11olog11es et i11terpretcs 11grees r/11 Q111!fwc/Order of Trn11sl11lors,
Ten11i11ologists 1111d /11terpreters of Quebec) herehy cert~N t/111t the 11/?m1e is 11 tme 1111d fnitl,f11I tm11 s/11tio11
of 1111 origi1111/ dorn111e11t writte11 i11 Fre11c/1.
/11 ll'if11ess thereof I sig11 tl,is j11111111ry 27, 2022
(514) 212.8411
40 3-648-3010 Toll Free: 1-888-556-554 1 '# @language im Q 11300, 404 6th Ave SW alga ,y, A[3, T P0R9 ( www.langu;;igesim.com ._)
AR02208 9
misogyn.html*

AR02209 10

11th
________________________________
AR02210 11
1
·
·
·
·
· · · · · · · · · · · ·AUDIO TRANSCRIPTION
·
·
·
·
·
·
·
·
·
· · ·_______________________________________________________
· · · · ·PRIME MINISTER JUSTIN TRUDEAU PLEADS WITH THE
· · · · · · · · · UNVACCINATED TO GET THE SHOT
· · · · · · · · · · · · ·JANUARY 5, 2022
· · ·_______________________________________________________
·
·
·
·
·
·
·
·

403-531-0590 YVer1f
AR02211 12
2
·1· ·(AUDIO BEGINS)

·2· ·JUSTIN TRUDEAU:· · · · · Well, I think, first of all,
·3· ·we do have to recognize that the vast majority of
·4· ·Canadians have stepped up, have been there to get
·5· ·themselves vaccinated, to protect their loved ones,
·6· ·(UNREPORTABLE SOUND), to protect frontline health
·7· ·workers, and that is significant.· We're amongst the --
·8· ·the -- the top countries in the world in terms of
·9· ·citizens stepping forward to do the right thing
10· ·(UNREPORTABLE SOUND).
11· · · · So it's not just about governments and health
12· ·workers frustrated that there are Canadians who still
13· ·continue to choose to not get vaccinated.· It's fellow
14· ·Canadians as well.· When people are seeing cancer
15· ·treatments and elective surgeries put off because beds
16· ·are filled with people who chose not to get vaccinated,
17· ·they're frustrated.· When people see that we're in
18· ·lockdowns or serious public health restrictions right
19· ·now because of the risk posed to all of us by
20· ·unvaccinated people, people get angry.
21· · · · And we have put forward many, many different
22· ·measures to encourage, to reassure, to incentivize, to
23· ·educate, to cajole, to remind people that it's never
24· ·too late to do the right thing.· It's never too late to
25· ·go and get your first dose of vaccine.· I can tell you
26· ·that that frontline health worker who's giving you your
27· ·first dose of the vaccine, even now in January 2022,

403-531-0590 YVer1f
AR02212 13
3
·1· ·will be immensely pleased to be able to give you that

·2· ·first dose of vaccine, even today, because they'd much
·3· ·rather be giving you an injection, a vaccine, than
·4· ·intubating you in an ICU.
·5· · · · We need to continue to do the right thing, the way
·6· ·all Canadians -- or the vast majority of Canadians are,
·7· ·keep each other safe, make sure our country gets back
·8· ·to the things we love as quickly as possible.
·9· ·(AUDIO CONCLUDES)
10· ·_______________________________________________________
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27

403-531-0590 YVer1f
AR02213 14
4
·1· ·CERTIFICATE OF TRANSCRIPT:

·2
·3· · · · I, Jolina Hale, certify that the foregoing pages
·4· ·are a complete and accurate transcript of the audio
·5· ·recording, taken down by me in shorthand and
·6· ·transcribed from my shorthand notes to the best of my
·7· ·skill and ability.
·8· · · · Dated at the City of Medicine Hat, Province of
·9· ·Alberta, this 8th day of March 2022.
10
11
12
13· ·________________________________
14· ·Jolina Hale
15· ·Official Court Reporter
16
17
18
19
20
21
22
23
24
25
26
27

403-531-0590 YVer1f
AR02214 15
1
Court 4:15 incentivize 2:22 public 2:18

2 injection 3:3 put 2:15,21 U
D intubating 3:4
2022 2:27 4:9 UNREPORTAB
Q
Dated 4:8 LE 2:6,10
J
8 day 4:9 quickly 3:8 unvaccinated
dose 2:25,27 3:2 January 2:27 2:20
8th 4:9 Jolina 4:3,14 R
E JUSTIN 2:2 V
A reassure 2:22
educate 2:23 recognize 2:3 vaccinated 2:5,
ability 4:7 L 13,16
elective 2:15 recording 4:5
accurate 4:4 vaccine 2:25,27
encourage 2:22 late 2:24 remind 2:23
Alberta 4:9 3:2,3
lockdowns 2:18 Reporter 4:15
angry 2:20 vast 2:3 3:6
F love 3:8 restrictions 2:18
audio 2:1 3:9 4:4 loved 2:5 risk 2:19
fellow 2:13 W
B filled 2:16
M S worker 2:26
foregoing 4:3
back 3:7 workers 2:7,12
forward 2:9,21 majority 2:3 3:6 safe 3:7
beds 2:15 world 2:8
frontline 2:6,26 make 3:7 shorthand 4:5,6
BEGINS 2:1 frustrated 2:12, March 4:9 significant 2:7
17 measures 2:22 skill 4:7
C Medicine 4:8 SOUND 2:6,10
G stepped 2:4
cajole 2:23
Canadians 2:4, N stepping 2:9
give 3:1
12,14 3:6 surgeries 2:15
giving 2:26 3:3 notes 4:6
cancer 2:14 governments
CERTIFICATE 2:11 T
4:1 O
certify 4:3 terms 2:8
H Official 4:15 thing 2:9,24 3:5
choose 2:13
chose 2:16 Hale 4:3,14 things 3:8
P today 3:2
citizens 2:9 Hat 4:8
City 4:8 health 2:6,11,18, pages 4:3 top 2:8
complete 4:4 26 people 2:14,16, transcribed 4:6
CONCLUDES 17,20,23 transcript 4:1,4
3:9 I pleased 3:1 treatments 2:15
continue 2:13 3:5 posed 2:19 TRUDEAU 2:2
countries 2:8 ICU 3:4 protect 2:5,6
country 3:7 immensely 3:1 Province 4:8

403-531-0590
AR02215 16

11th
________________________________
BAR02216
LOS BA, Robert ( r) The 17
eadow SU+gery
B OBA , Robert (M r) D l or Shll1 :
R port Path: Loca l R cord
Devonway, nnin Ro d, Horton, llm nst r, Som s t, A Q
HS umb r: U u I GP: AUSTI , AD L (Dr)
V lues nd Inv st tlons (L t est v lue)

0 -Au • 02 R -CoV- ( ev r p ry yndrom
coronavlru 2) R ucl ic acld) d ctlon
LA) . p
p . 0 0 0 c o n d
AR02217 18

virtually this ____day
11th of .....
________________________________
AR02218 19
--
Bu~

Covid-19 IgG antibody result
Name: Robert Drew Belobaba
Date of birth: 1 974
Date of appointment: 29 November 2021
Test: Anti-SARS-CoV-2 IgG Method: SureScreen Lateral Flow Test Cassette
Your rapid antibody test today was POSITIVE for Covid-19 IgG antibodies.
A positive result means that Covid-19 antibodies were detected in your blood. This means that you have
previously been infected with Covid-19. The presence of antibodies in your blood does not mean that you cannot
catch Covid-19 again or pass it onto others. As such you should continue to follow the current government
guidelines around social distancing, infection control and self-isolation.
Whilst the Bupa COVID-19 antibody test can show if you have detectable antibodies as a result of having had
COVID-19 infection, it will not show antibodies produced in response to vaccinations currently given in
the UK, and should not be used for this purpose.
A negative result means that Covid-19 antibodies were not detected in your blood. This most likely means you
have not been infected with Covid-19. However, some individuals previously infected with Covid-19 will
not have detectable antibodies on testing. This could be for various reasons including being tested too early after
infection, a short-lived antibody response which is no longer detectable by the time the test is taken
or producing an antibody response that is too small to detect.
You should continue to follow the current government guidelines around social distancing, infection control and
self-isolation regardless of your result.
(Please note this test is designed to look for evidence of previous infection, at least 20 days after a Covid-19
infection. If you have been infected more recently than this, then the test may still produce a negative result as
your body has not yet had time to produce antibodies).
This test does not look for evidence of current infection and cannot provide information on whether someone is
currently infected with Covid-19.
If you have further concerns or questions, you are entitled to a follow up call with a Bupa Nurse on our Anytime
HealthLine service within 3 months of your appointment, please call them on 0345 604 0537. Lines are open 24/7.
Connor Robbins
Date 29 November 2021
AR02219
TAB 16
AR02220 F
I FEDERAL1COURT
D
É
L COUR FÉDÉRALE P
E O
D S
March 11, 2022 É
11 mars 2022

Kevin Lemieux
BETWEEN
CAL
I 8

AND AEDAN MACDONALD
Applicants
-and-

Respondents
AFFIDAVIT OF AEDAN MACDONALD

(Sworn March____,
11th 2022
I, Aedan MacDonald, of the City of Langley, in the Province of British Columbia, SWEAR
AND SAY THAT:
1. I am one of the Applicants herein, and as such have a personal knowledge matters
2. I am an 18 first-year student attending Trinity Western University on partial academic and

athletic scholarships. I was born in London, Ontario, where I spent eight years before
1
AR02221 2
-
moving to Nairobi, Kenya, in August 2011. In 2016, my family and I moved to Toronto,
where I finished high school, before moving to British Columbia to further my studies.
3. I have spent my high school career training to play rugby in university. Prior to restrictions
with BC Rugby, I trained 4 days a week for a total of 8.5 hours a week including extensive
weight training. I invested significant time and energy training to be ready to play at the
highest level of competition of university rugby in Canada. Doing so was no easy task, but
it was something I needed both for my physical and mental health. In early November of
2021, I was told by my coach that I was no longer permitted to play in competition, and
worse, I was not able to train at all. The mental strain this caused me was extremely
detrimental. I was isolated, depressed, losing critical training for the future of my rugby
career in university, and felt entirely separated from my teammates.
4. I have continued to train on my own because doing so is important for my physical and
mental well-being and I hope to be able to return to play with my team very soon.
5. In late September 2021, I heard that the Federal Government was preparing to make a law
restricting unvaccinated Canadians from travelling by air and rail domestically and
internationally.
6. On October 29, 2021, the Federal Government announced that they had enacted the
Interim Order Respecting Certain Requirements for Civil Aviation Due to COVID-19, No.
43 (“Travel Ban”) which I understand restricts my right to travel by air or rail in Canada
or out of Canada. I understand that the Travel Ban was amended several times after that
day.
7. I have had a hard time understanding the constantly changing laws and requirements and
how they apply to me. The seemingly uncertain decisions made by our Federal
Government concerning the Travel Ban leave me with an overwhelming feeling of distrust.
2
AR02222 3
-
8. The Travel Ban is negatively impacting me in several ways. I am unable to travel freely
home to Ontario or Quebec. I was unable to go home for the Christmas holidays in 2021,
while vaccinated individuals were permitted to travel abroad without providing proof of a
negative molecular Covid-19 test.
9. I find it hard to understand the public health rules and what changed in the one-month span
between when I had travelled in November to when the Travel Ban was enacted on
December 20, 2021.
10. On January 6th, 2022, I contracted Covid-19, and within a matter of days, I recovered
completely. I experienced mild headaches, sore throat and a cough. Despite now having
natural immunity to the virus, I am still not able to travel either by air or rail. I do not have
the financial means to pay to fly by private chartered aircraft to visit family.
11. I cannot take the Covid-19 vaccination in good conscience because the vaccine was
developed using the abortion-derived HEK-293 cell line. As a devout Christian of the
Reformed Presbyterian Church, on the advice of religious leaders, and through my own
conscience, I understand the absolute inadmissibility of medicines prepared using aborted
fetal cells. In the past I have received vaccines which had been developed using the
HEK-293 cell line. However now in my adulthood and being able to consciously make
decisions based on my own personal health and bodily autonomy, I have decided to
abstain from, to the absolute best of my ability, all medical procedures and products
which have used this cell line in their production.
12. I am also alarmed about the potentially dangerous side effects of the Covid-19 vaccine in
young males, particularly athletes, and specifically the rapid rise in cases of
myocarditis. I have observed that the Federal Government and public health officials have
stated that it is “rare” and “most cases have been mild and resolved quickly.” Attached
hereto and marked as Exhibit “A” to this my Affidavit is a copy of the Government of
Canada advisory regarding myocarditis following Covid-19 vaccination.
3
AR02223 4
-
13. I find it concerning that public health officials suggest that inflammation of a vital organ,
like the heart, can be regarded as a minor incident. As a young athlete in my first year of
university, I take my health and future health with an extreme level of care and
consideration.
14. For me, the possibility of developing myocarditis is far too significant a risk to outweigh
the yet unknown and changing benefits of the Covid-19 vaccine.
15. The federal government has not properly explained these risks to me, or the other risks of
this new medical treatment. Nowhere on Transport Canada’s website lists the risks and
known adverse events associated with the Covid-19 vaccine. Without doing my own
research, I never would have known that these vaccines have safety warnings for blood
clots, Bell’s Palsy, myocarditis, or other serious conditions that could affect me and my
future.
16. Based on my sincerely held religious beliefs and my conscience, and after an extensive
review of the scientific research and medical data, I see no positive factors in which I
would be persuaded to override my religious convictions and my personal concerns for
my health and wellbeing.
17. I also feel segregated from other Canadians. It is astounding how I am being treated
differently and like a second-class citizen merely for exercising my freedom to choose what
medical treatment I receive and for looking out for my health and safety.
4
AR02224 5
purpose.
SWORN BEFORE ME by Aedan )

MacDonald, of the City of Langley, in the )
Province of British Columbia, before me at )
the City of Brampton, in the Province of )
Ontario, t h i s ~ day of March 2022 in )
accordance with 0. Reg. 431/20 )
Administering Oath or Declaration Remotely ) AEDAN MACDONALD
)
)
)
)

103 - 60 Queen St. E
Brampton, ON
L6C 1A9
5
AR02225 6

of A dan MacDonald sworn before me
virtually this ____day
11th of .....
7
________________________________
\
3/10/22, 5:47 PM Archive 28: Summary of NACI advice on vaccination with COVID-19 vaccines following myocarditis (with or without pericarditis) [2 ...
AR02226 7
We have archived this page and will not be

updating it.
You can use it for research or reference.
l♦I
of Canada du Canada
Canada.ea > Health > HealthY. living > Vaccines and immunization
> National Advisory Committee on Immunization (NACI): Statements and P-Ublications
Archive 28: Summary of NACI advice on

vaccination with COVID-19 vaccines
following myocarditis (with or without
pericarditis) [2022-01-14]
Publication date: January 14, 2022
I
O Notice to reader
This is an archived version. Please refer to current COVID-19 vaccine
pages:
• NACI statements and P-Ublications
• COVID-19 vaccine: Canadian Immunization Guide
On this page
• Overview
Overview
https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-advice-vaccination-covid- ... 1/4
AR02227 8
• On January 14, 2022, the Public Health Agency of Canada (PHAC) -
released updated guidance from the National Advisory Committee on
Immunization (NACI) in the COVID-19 vaccine chapter of the Canadian
Immunization Guide, on the topic vaccination following myocarditis
and pericarditis. This chapter includes NACI's recommendations on the
use of COVID-19 vaccines up to and including January 14, 2022.
• Rare cases of myocarditis (inflammation of the heart muscle) and
pericarditis (inflammation of the heart lining) following vaccination
with COVID-19 mRNA vaccines have been reported in Canada and
internationally. Most cases have occurred in males 12 to 29 years of
age after a second dose of an mRNA vaccine. Most cases have been
mild and resolved quickly.
• Following review of the latest evidence and consultation with Canadian
cardiologists, NACI has issued updated guidance on re-vaccination with
COVID-19 vaccines for those who experienced myocarditis and/or
pericarditis after a previous dose of an mRNA COVID-19 vaccine.
• Since June 2021, NACI has recommended that people who experienced
myocarditis and/or pericarditis after a first dose of an mRNA COVID-19
vaccine should wait to get their second dose until more information
was available.
NACI continues to recommend that:
In most circumstances, and as a precautionary measure until more

information is available, further doses of mRNA COVID-19 vaccines
should be deferred among people who experienced myocarditis (with
or without pericarditis) within 6 weeks of receiving a previous dose of
an mRNA COVID-19 vaccine. This includes any person who had an
abnormal cardiac investigation including electrocardiogram (ECG),
elevated troponins, echocardiogram or cardiac MRI after a dose of an
mRNA vaccine.
https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-advice-vaccination-covid-... 2/4
AR02228 9
NACI now recommends that:
Those with a history compatible with pericarditis and who either had
no cardiac workup or had normal cardiac investigations, can receive
the next dose once they are symptom free and at least 90 days has
passed since vaccination.
Some people with confirmed myocarditis (with or without pericarditis)

after a dose of an mRNA COVID-19 vaccine may choose to receive
another dose of vaccine after discussing the risks and benefits with
their healthcare provider. If another dose of vaccine is offered, they
should be offered the Pfizer-BioNTech 30 mcg vaccine due to the lower
reported rate of myocarditis and/or pericarditis following the Pfizer-
BioNTech 30 mcg vaccine compared to the Moderna 100 mcg vaccine.
Informed consent should include discussion about the unknown risk of
recurrence of myocarditis and/or pericarditis following receipt of
additional doses of Pfizer-BioNTech COVID-19 vaccine in individuals with
a history of confirmed myocarditis and/or pericarditis after a previous dose
of mRNA COVID-19 vaccine, as well as the need to seek immediate
medical assessment and care should symptoms develop.
• NACI will continue to review and monitor the evidence on vaccination

following myocarditis and/or pericarditis after a dose of an mRNA
COVID-19 vaccine as it emerges and will update their
recommendations as needed.
• To read the full guidance, please refer to the new COVID-19 vaccine
chaP-ter in the Canadian Immunization Guide.
• If you would like to be notified about the release of new NACI guidance
or updates to the CIG, please subscribe to the NACI & CIG P-Ublications
mailing list.
AR02229 10
Date modified:
2022-03-07
AR02230
TAB 17
AR02231
Court File No .: T-168-22
FEDERAL COURT
BETWEEN :
THE HONOURABLE A. BRIAN PECKFORD, LEESHA NIKKANEN, KEN BAIGENT,

DREW BELOBABA, NATALIE GRCIC, AND AEDAN MACDONALD
Applicants
- and -
ATTORNEY GENERAL OF CANADA

Respondent
AFFIDAVIT OF RYAN JEAN-LOUIS
I, Ryan Jean-Louis, of Calgary, Alberta, SWEAR THAT:
1. I am a paralegal in the office of the Justice Centre for Constitutional Freedoms and as such
have personal knowledge of the facts herein deposed except where based on information
and belief, in which case I verily believe the same to be true.
2. On August 5, 2022 , I reviewed the Government of Canada webpage which described the
suspension of the mandatory vaccination requirement for domestic travellers and federally
regulated transportation workers and federal employees, attached hereto as Exhibit "A"
and available at the following link:
https://www.canada.ca/en/transpo11-canada/news/2022/06/suspension-of-the-mandatory-
vaccination-reguirement-for-domestic-travellers-and-federally-regulated-transportation-
workers.html
3. On August 5, 2022, I reviewed the Government of Canada webpage which described the
requirements, as of July 22, 2022, for vaccinated individuals travelling to Canada, attached
hereto as Exhibit "B" and available at the following link:
https://travel .gc.ca/travel-covid/travel-restrictions/covid-vaccinated-travellers-entering-
canada
AR02232
4. On August 5, 2022, I reviewed the Government of Canada website which described the
requirements, as of July 22, 2022, for individuals who do not qualify as fully vaccinated
and are travelling to Canada, attached hereto as Exhibit "C" and available at the following
link:
https://travel.gc .ca/travel-covid/travel-restrictions/flying-canada-checklist/covid-19-
testing-trave 11 ers-coming ~ into-canada
5. On August 5, 2022, I reviewed the Government of Canada website, which displayed a news
release from the Public Health Agency of Canada, which described border measures in
Canada in relation to Covid-19, attached hereto as Exhibit "D" and available at the
following link:
https://www.canada.ca/en/public-health/news/2022/06/government-of-canada-maintains-
current-border-measures-for-trave llers-entering-canada. html
6. On August 5, 2022, I reviewed the CPAC website, which displayed a video of a news
conference from June 14, 2022, in which Federal Ministers Announced the Easing of
COVID-19 Vaccine mandates, available at the following link:
https://www .cpac.ca/episode?id=3 ba7 6b4a-f9ab-42d9-9d97-7cd0fab2fa98
7. I swear this affidavit bonafide, for no improper purpose.
SWORN BEFORE ME at Calgary, Alberta, )

this •Sf\- day of August, 2022 )
)
)
)
)
)
)
2
AR02233
This is Exhibit "A" referred to in the Affidavit of Ryan

Jean-Louis sworn before me this 5th day of August 2022.
0~ Grt°:J
r for Oaths in and for the Province of
AR02234
8/3/22 , 12:48 PM Suspension of the mandatory vaccination requirement for domestic travellers and federally regulated transportation workers - Can ...
l♦I
of Canada du Canada
Canada.ea > TransP-ort Canada
Suspension of the mandatory vaccination

requirement for domestic travellers and
federally regulated transportation
workers
From: TransP-ort Canada
Backgrounder
Today, the Government of Canada announced that, as of June 20, it will
suspend vaccination requirements for domestic and outbound travel, federally
regulated transportation sectors and federal government employees.
While the suspension of vaccine mandates reflects an improved public health

situation in Canada, the COVID-19 virus continues to evolve and circulate in
Canada and globally. Given this context, and because vaccination rates and
virus control in other countries varies significantly, current vaccination
requirements at the border will remain in effect. This will reduce the potential
impact of international travel on our health care system and serve as added
protection against any future variant. Other public health measures, such as
wearing a mask, continue to apply and will be enforced throughout a
traveller's journey on a plane or train.
Requirement for vaccinations suspended for domestic and outbound

travel
https://www.canada.ca/en/transport-canada/news/2022/06/suspension-of-the-mandatory-vaccination-requirement-for-domestic-travellers-and-federally... 1/4
AR02235
8/3/22, 12:48 PM Suspension of the mandatory vaccination requirement for domestic travellers and federally regulated transportation workers - Can ...
• As of June 20, 2022, at 00:01 EDT, vaccination will no longer be a

requirement to board a plane or train in Canada.
• This change does not affect border measures that require all travellers
entering Canada to continue following entry requirements, including
vaccination.
• Other public health measures, such as wearing a mask, continue to apply
and will be enforced throughout a traveller's journey on a plane or train.
• Given the unique nature of cruise ships, including the fact that passengers
are in close contact with each other for extended periods of time,
vaccination against COVID-19 is still required for passengers and crew on
cruise ships.
• Adherence to strict P-Ublic health re~uirements on cruise ships will still be
required.
Federally regulated transportation sector workers

• As of June 20, 2022, at 00:01 EDT, employers in the federally regulated air,
rail, and marine sectors will no longer be required to have mandatory
vaccination policies in place for employees.
• Employers will be responsible for establishing return-to-work practices.
• Furthermore, the Government of Canada is no longer moving forward
with the proposed regulations to make vaccination mandatory in all
federally regulated workplaces.
Masking Requirements
• Travellers on federally regulated planes and trains continue to be required
to wear a mask throughout their journey except for brief periods (e.g.,
eating or drinking).
• Passengers on cruise ships will be expected to follow the masking
requirements and other hygiene measures as directed by the ship's crew,
https://www.canada.ca/en/transport-canada/news/2022/06/suspension-of-the-mandatory-vaccination-requirement-for-domestic-travellers-and-federally... 2/4
AR02236
regardless of whether they are foreign or domestic.
Face masks are the most basic, visible, and low-cost measure for reducing
transmission of COVID-19. Studies show that masks reduce spread of the
disease, especially in enclosed areas or in areas with reduced ventilation.
Public health experts continue to recommend the use of masks in crowded
spaces and indoor settings.
Science-based decision making

Following a successful vaccination campaign, 32 million eligible Canadians
have been vaccinated against COVID-19. The Government of Canada's decision
to suspend the mandatory vaccination requirement for the domestic
transportation sector was informed by key indicators, including
• the evolution of the virus;

• the epidemiologic situation and modelling (stabilization of infection and
hospitalizations across the country);
• vaccine science; and
• high levels of vaccination in Canada against COVID-19.
The Government of Canada will continue to evaluate measures and will not
hesitate to make adjustments based on the latest public health advice and
science to keep Canadians and the transportation system safe and secure.
Entry requirements remain for travel to Canada from abroad

Canadian citizens and Canadian permanent residents returning from
international destinations who do not qualify for the fully vaccinated traveller
exemption continue to be required to provide a valid pre-entry test result,
remain subject to Day 1 and Day 8 molecular testing, and quarantine for 14
days.
https:l/www.canada.ca/en/transport-canada/news/2022/06/suspension-of-the-mandatory-vaccination-requirement-for-domestic-travellers-and-federally... 3/4
AR02237
In addition, all travellers entering Canada are required to input their

mandatory information in ArriveCAN within 72 hours before their arrival in
Canada. Travellers who arrive without completing their ArriveCAN submission
may be subject to Day 1, Day 8 molecular testing, quarantine for 14 days, and
to fines or other enforcement actions, regardless of their vaccination status.
Remote communities
With the suspension of the vaccination mandate for domestic and outbound
travel, the testing accommodation for remote communities is no longer
required. The Government of Canada will continue to work with communities,
Indigenous groups, provinces and territories, and operators to support
remote communities as the pandemic evolves.
Foreign nationals
Vaccine requirements for entry into Canada by foreign nationals remain
unchanged at this time. Foreign nationals who are not fully vaccinated
continue to be prohibited entry into Canada. With the suspension of the
domestic mandate, unvaccinated foreign nationals will continue to be able to
depart Canada by plane or train.
Search for related information by keyword: TR TransP-ort I Coronavirus

diseases I TransP-ort Canada I Canada I TransP-ort and infrastructure I
Coronavirus (COVID-19). I general P-Ublic I backgrounders I Hon. Omar
Alghabra
Date modified:
2022-06-14
https://www.canada.ca/en/transport-canada/news/2022/06/suspension-of-the-mandatory-vaccination-requirement-for-domestic-travellers-and-federally. .. 4/4
AR02238
This is Exhibit "B" referred to in the Affidavit of Ryan

Jean-Louis sworn before me this 5th day of August
2022.
Commiss1
Alberta
AR02239
8/3/22 , 12:50 PM Travel to Canada: Requirements for COVID-19 vaccinated travellers
l♦I
of Canada du Canada
Canada.ea > Travel > Travel, testing and borders
Travel to Canada: Requirements for

COVID-19 vaccinated travellers
On this page
• Check if you gualify as a fully vaccinated traveller
• Checklist of what to have readY. at the border
• Pre-entry testing is not reguired
• MandatorY. use of ArriveCAN (account,_P-roof, helP-}
• Arrival testing if selected
• Children or deP-endents
Check if you qualify as a fully vaccinated

traveller
To qualify as a fully vaccinated traveller to Canada, you must:
• have received at least 2 doses of a COVID-19 vaccine accepted for
travel, a mix of 2 accepted vaccines
0 or at least 1 dose of the Janssen/Johnson & Johnson vaccine
• have received your second dose at least 14 calendar days before you
enter Canada
0 Example: if your second dose was anytime on Thursday, July 1,
then Thursday, July 15 would be the first day that you meet the 14
day condition
https ://Ira vel .gc.ea/Ira vel-covi d/trave I-restri ctio ns/ covi d-va cci nated-trave Ile rs-enteri ng-ca nad a 1/12
AR02240
8/3/22, 12:50 PM Travel to Canada: Requirements for COVID-19 vaccinated travellers
0 this timing is only required for your second dose, not for third or
fourth doses
• have no signs or symptoms of COVID-19
• have ArriveCAN receipt with letter A, I, or V beside your name by
ugloading_groof of vaccination in ArriveCAN
► Accepted vaccines
► If your proof of vaccination is not in English or French
► What is not accepted as a fully vaccinated traveller
Checklist of what you need to have ready at

the border
To enter or return to Canada as a fully vaccinated traveller, you must
follow all of these requirements.
Whether you're driving or flying, have the following items with you for
assessment by a government official at the border (land border crossings
do not provide WiFi for travellers):
D ArriveCAN receigt with letter A,J, or V beside the vaccinated

traveller's name
D Proof of vaccination that was ugloaded into ArriveCAN (original or

gager COP-,Y.),
D Pregare for arrival testing if selected
D Travel document entered in ArriveCAN (e.g. passport)
https://travel.gc.ca/travel-covid/travel-restrictions/covid-vaccinated-travellers-entering-canada 2/12
AR02241
For travellers boarding a cruise ship, visit the Cruise shiP- travel page for
requirements specific to cruise ships.
Pre-entry testing is not required

Pre-entry tests are not required for fully vaccinated travellers entering
Canada by land, air or water. You must still use ArriveCAN within 72 hours
before your arrival to Canada.
Unvaccinated and partially vaccinated children under the age of 12 are not
required to provide a valid pre-entry test result, if they are accompanying a
fully vaccinated adult.
Children who are less than 5 years old are not required to test, regardless
of their vaccination status.
Mandatory use of ArriveCAN (account,

proof, help)
ArriveCAN continues to be mandatory for all travellers to Canada. It is also
required to qualify for the fully vaccinated traveller exemption from
quarantine and testing. If you don't submit your travel information and
proof of vaccination using ArriveCAN you could be fined $5,000.
You must use the ArriveCAN mobile aP-P- or sign in on a comP-uter to

enter your proof of vaccination and travel information.
• To be ready for your trip, create your free ArriveCAN account

• Proof of vaccination and travel documents can be saved in your
ArriveCAN traveller profile before any planned travel
• To get an ArriveCAN receipt, submit your travel and vaccination
information within 72 hours before your arrival to Canada
AR02242
0 If you arrive by boat (including ferry), submit when you enter

Canada
° For travellers boarding a cruise ship, visit the Cruise shiP- travel
page for requirements specific to cruise ships
No smartphone or short trip? You still need to enter your information and
submit in ArriveCAN up to 72 hours before your arrival in Canada or before
a short trip outside Canada. Sign in to ArriveCAN from a comP-uter to get
your ArriveCAN receipt. Print your receipt and take it with you when you
travel. You can also have someone submit y,our travel information on your
behalf.
► Upload proof of vaccination in ArriveCAN before you travel
Troubleshooting vaccination issues in ArriveCAN
► You couldn't upload proof
► No receipt from ArriveCAN
► Getting emails or calls about quarantine or testing
► Your ArriveCAN receipt doesn't include the letters A, I, or V
• ArriveCAN general troubleshooting and helP-

• Contact ArriveCAN
People entering by land who haven't completed ArriveCAN and obtained

their receipt will be informed by a Border Services Officer of the
requirements to submit their information through ArriveCAN. You may be
allowed to:
• provide information on entry if there's no history of previous ArriveCAN

non-compliance, (if it's operationally feasible)
AR02243
• choose to return to the U.S. to complete your submission and re-enter

(note, if you're a foreign national, you must return to the U.S. to
complete your submission)
If you don't provide your information through ArriveCAN, you may be

subject to:
• quarantine
• Arrival and Day-8 testing
• possible enforcement for non-compliance including potential fines of
$5,000 per infraction (plus applicable provincial surcharges)
Arrival tests if selected

Upon your entry to Canada by air or at a land border crossing, you may be
randomly selected for a mandatory arrival test. You must complete your
arrival test with an approved test provider. Your test provider is based on
where you entered the country.
The test is free.
► Who must take an arrival test if selected to do so upon arrival
► Already recovered from COVID-19
Arriving by air
On your entry to Canada, check your email to find out if you've been
selected for mandatory random arrival testing.
If you're selected for testing, you'll receive an email within 15 minutes of

completing your customs declaration and receiving your kiosk receipt. This
email will have important information about where and when to get tested.
AR02244
It will be sent to the same email address you used for ArriveCAN. The email
will be from noreply.pasdereponses@notification.canada.ca or
quarantine.covid19.quarantaine@phac-aspc.gc.ca.
Follow the instructions in the email. It will have important information

about where and when to get tested.
• You can take public transportation, including connecting flights

without waiting for your arrival test results.
• You aren't required to quarantine while awaiting your test result if
you're randomly selected for a mandatory arrival test.
If you're landing in one of the airports listed below, you may be selected for
mandatory random testing. If selected, you must contact your test provider
for instructions on where and when to complete your test.
When you register, use the same email address you used for your
ArriveCAN account.
You can complete your test in-person or pick up a self-swab kit at select test
provider locations, select pharmacies, or via a virtual appointment for a
self-swab test.
Take advantage of near-airport locations, where available, for the quickest

and easiest way to complete your arrival test.
• Calgfil,Y_(YYC) - Switch Health

o If you're arriving at Calgary airport (YYC), pick up your test kit at the
Switch Health clinic, located pre-security in the departures level of
the domestic terminal (8:00 a.m. to 6:00 p.m. MDT).
• Montreal (YUL) - Biron
0 If you're arriving at Montreal Airport (YU L), you can complete your
test at the Biron clinic located in the departures area (Gate 11)
(5:00 a.m. to 2:00 a.m. EDT).
AR02245
• Toronto (YYZ) - Lifelabs

0 If you're arriving at Toronto Pearson airport (YYZ), you can
complete your arrival test at the Lifelabs nearby walk-in airport
location: 6900 Airport Rd, Hall 3, Mississauga, Ontario (7:00 a.m. -
11 :00 p.m. EDT).
• Vancouver (YVR) - Lifelabs
0 If you're arriving at the Vancouver airport (YVR), you can complete
your arrival test at the Lifelabs nearby walk-in airport location:
6084 Russ Baker Way, Richmond, British Columbia (7:00 a.m. - 5:00
p.m. PDT)
Arrival testing at land borders
If you're selected for testing, you'll be given a self-swab kit when you arrive
at a land border crossing. You'll complete your test kit via a virtual
telehealth appointment with Y.OUr test P-rovider. You'll need to follow the
instructions in your self-swab kit to complete the test at your destination. If
you're unable to complete a video appointment, contact your test provider
for more testing options.
Use only the test kit that you received at the land border, or from the
approved test provider. Tests done using any other test kit won't be valid for
the testing requirement.
Completing your arrival test
Use only the test kits that you received at the border, not any other test kits
you may have. The instructions, web links and telephone numbers are all
provided in the kit.
To complete your arrival test you must:
AR02246
1. Register with the approved test provider for the province of your point
of entry. Use the same email address you used for ArriveCAN.
2. Schedule your test with the test provider
3. Complete the test by end of day the next calendar day after arriving
into Canada
• For example, if you arrived to Canada at 9:00 a.m. on July 1, you should
complete your arrival test by 11 :59 p.m. on July 2.
You must keep your ArriveCAN e-receipt number until your test is
complete. If you arrived by air, you should also keep the email
notification.
If you haven't completed your test on time, you'll be contacted by phone

from 1-888-336-7735. It's important that you answer this call.
► Fines and consequences of failing to complete the testing

requirements
Find your test provider

Your test provider is based on where you entered the country.
► British Columbia, Ontario, Saskatchewan, Yukon
► Alberta, New Brunswick, Nova Scotia, Prince Edward Island,

► Manitoba
► Quebec
Your arrival test results
AR02247
Most travellers will be notified of their test result within 4 days. If you
haven't received your test result in this time frame, you should contact your
test provider.
You may not receive your test result if:
• you provided incorrect contact information

• information is missing
• the test is still being processed
• there's an inconclusive result
If a fully vaccinated traveller or unvaccinated child under 12 years of

age tests positive on their arrival test:
• theY. must isolate for 10 days

• report your test results to PHAC by calling 1-833-641-0343
If a fully vaccinated parent, step-parent, guardian, or tutor has

travelled with a child and they experience symptoms or test positive:
• unvaccinated children under 12 years of age must ~uarantine for 14

days and monitor for SY.mP-toms
• report your unvaccinated child's test results and/or symptoms to PHAC
by ea 11 in g 1-833-641-0343
• the fully vaccinated adult should verify which local public health
requirements they must follow
If selected for arrival testing, you must provide proof of your test results, if
asked, to any federal, provincial, territorial or municipal government official
or peace officer.
► Invalid or indeterminate results from your arrival test
After your arrival

AR02248
• There are some federal requirements that you or any fully vaccinated
children who travelled with you must follow for 14 days after entry
into Canada. You're required to:
0 report any positive results from a government-required test if you
were selected to complete one
0 wear a mask during your entire travel journey (onboard a flight,
train or federally-regulated vessel, as well as in airports and other
points of entry). Passengers on cruise ships must follow the
masking requirements of the cruise ship operator.
0 Note: Some federal rules may be different from the provincial or
territorial rules. For example, you may be required to wear a mask
on public transportation in some provinces. In this case, you must
follow the stricter rules.
0 While masks are not required after your arrival, you may still wish
to wear one as they are an effective individual public health
measure that you can easily implement to protect yourself and
others.
• Unvaccinated children aged 5 through 11 need to wear a mask in
public settings (including schools and day camps) for 14 days after
arrival to Canada
Children or dependents
Any unvaccinated children must properly wear a well-constructed and
well-fitting mask when in public spaces for the first 14 days after entry.
This includes schools and daycares.
► Children who are under 5 years of age
► Children aged 5 through 11
AR02249
► Youth aged 12 to 17
► Unvaccinated adult dependents
ArriveCAN: If your submission includes travellers who are not exempt from
the requirement to quarantine (for example, unvaccinated 12 to 17 year-
aids or unvaccinated dependent adults), you will receive ArriveCAN
notifications and will be asked to complete daily reporting for the
unvaccinated travellers.
You must use ArriveCAN to enter Canada
You must use ArriveCAN within 72 hours of your entry into Canada
• Find answers to common ArriveCAN issues

• Need urgent help? Contact ArriveCAN by_P-hone or email
~~
► Need urgent help with a problem? Contact us
What was wrong? Please provide more details
https://travel .gc.ca/travel-covid/travel-restrictions/covid-vaccinated-travellers-entering-canada 11 /12

AR02250
Submit
e Share this page
Date modified:
2022-07-22
https://travel .gc.ca/travel-covid/travel-restrictions/covid-vaccinated-travellers-entering-canada 12/12

AR02251
This is Exhibit "C" referred to in the Affidavit of

Ryan Jean-Louis sworn before me this 5th day of
Augu 022.
~~Gv-f'd--
0 er for Oaths in and for the Province of
AR02252
8/3/22 , 12:51 PM Travel to Canada: Testing and quarantine if not qualified as fully vaccinated - Travel restrictions in Canada - Travel.gc.ca
l♦I
of Canada du Canada
Canada.ea > Travel > Travel, testing and borders

> Checklists for re~uirements and exemP-tions
Travel to Canada: Testing and quarantine

if not qualified as fully vaccinated
COVID-19 testing and quarantine requirements to enter Canada if you don't
qualify as a fully vaccinated traveller.
On this page
• Who should use these instructions
• Checklist to be ready for the border
• Pre-entry testing_(acceP-ted tY.P-es, timing)
• You must use ArriveCAN
• Arrival testing
• Quarantine in a suitable P-lace
• ComP-lete Y.OUr DaY.-8 test
• Fines and P-enalties
Who should use these instructions to enter

Canada
If you don't qualify as fully vaccinated and are allowed to enter
Canada, use these instructions for yourself and accompanying
unvaccinated children to meet testing, ArriveCAN and quarantine
requirements.
https ://Ira vel .g c.ea/Ira ve I-covid/travel-restri ctio ns/flyi ng-canada-checkl isU covid-19-tes Ii ng-tra ve Ile rs-co mi ng-i nto-ca na da 1/12
AR02253
8/3/22, 12:51 PM Travel to Canada: Testing and quarantine if not qualified as fully vaccinated - Travel restrictions in Canada - Travel.gc.ca
If you expect to qualify or have qualified at the border as fully vaccinated,

these instructions are not for you. Find out if you qualify and follow the
steP-s for fully vaccinated travellers for yourself and your accompanying
children.
Under certain circumstances, you may be exempt from some requirements

if the purpose of your travel is related to .S.P-ecial situations.
Who can enter Canada

Canadian citizens (including dual citizens), people registered under the
Indian Act, permanent residents of Canada, and protected persons
(refugee status) are allowed to enter Canada. You may face penalties and
fines of up to $5,000 (plus applicable surcharges) if you fail to meet all of
the requirements, including using ArriveCAN.
Foreign nationals (including United States citizens): if you don't qualify

as fully vaccinated, you'll only be allowed to enter Canada in specific
circumstances. Check first to avoid being turned back at the border: Find
out if you can enter Canada
Checklist for entering by air or land if you

don't qualify as fully vaccinated
Entering by water? Follow the ArrivingJlY. water or ferrY. checklist
You must meet these requirements if you don't qualify as a fully vaccinated
traveller, or you may face delays and possible fines of up to $5,000 (plus
applicable surcharges):
D Foreign nationals: Find out if you can enter Canada
D Get your P-re-entrY. test result

https ://travel. g c. ca/travel-covid/travel-restri ctions/flyi ng-canada-checkl ist/ covi d-19-testi ng-tra vel lers-co mi ng-i nto-ca nada 2/12
AR02254
D Assess Y.OUr Quarantine P-lan before Y.OU travel
D Use ArriveCAN to submit Y.OUr travel, testing and Quarantine P-lans
before Y.OU enter
D ElY.ing: register in advance for your arrival test
Requirements after you arrive

• Taking.Y.our arrival test
• Getting.1Q.Y.our P-lace of Quarantine
• Quarantine for 14 days (how, starting, ending and leaving),
• Next daY.: reP-ort Y.Ou've arrived
• Getting.Y.our arrival test results while in Quarantine
• ComP-lete Y.OUr DaY.-8 test (results),
Pre-entry testing (accepted types, timing)

for travellers not qualified as fully
vaccinated
Travellers who don't qualify as fully vaccinated must provide proof of a valid
pre-entry test result when entering Canada by air, land or water. You must
input information about your pre-entry test result in ArriveCAN.
• Children who are less than 5 years old aren't required to test,
regardless of their vaccination status
• Children under the age of 12 accompanied by an adult who qualifies as
fully vaccinated don't require a pre-entry test. You should follow the
steP-s for fully vaccinated travellers
What to do if you test P-OSitive on Y.Our P-re-entry test
https ://travel. gc. ca/travel-covid/travel-restrictions/flyi ng-canad a-checklisU covid-19-tes Ii ng-trave Ilers-com ing-i nto-ca nad a 3/12
AR02255
► How to provide proof of a valid pre-entry test
Get your ArriveCAN receipt to enter

You must submit information about your pre-entry test results, contact and
travel details, and your test, travel and quarantine plan through ArriveCAN
within 72 hours before you arrive in Canada. If you fail to do so, you could
be subject to a $5,000 fine (plus applicable surcharges).
► How to get your ArriveCAN receipt
Arrival testing
When you enter Canada at an airport or at a land border, you must
complete two COVID-19 molecular tests. You'll complete your tests with an
approved test provider.
Complete your first test by the end of the next calendar day after arriving
into Canada.
You can take public transportation, including connecting flights to your

place of quarantine without waiting for your arrival test results.
Your second test must be completed on day 8 of your mandatory 14-day

quarantine (except for travellers who are only passing through on their way
to or from Alaska).
If you complete your test via an in-person appointment, you must

immediately return to your place of quarantine.
There's no fee for the arrival test.

hllps ://Ira vel .g c. ca/travel-covid/travel-restrictions/flyi ng-ca nada-checklist/covid-19-testi ng-travellers-comi ng-i nto-ca nada 4/12
AR02256
Arriving by air
On entry to Canada, check your email for information on your testing
obligations. An email will be sent to the same email address you used for
ArriveCAN.
You'll receive an email within 15 minutes of completing your customs

declaration and receiving your kiosk receipt. It will be sent to the same
email address you used for ArriveCAN. The email will be from
noreply.pasdereponses@notification.canada.ca or
quarantine.covid19.quarantaine@phac-aspc.gc.ca.
Follow the instructions in the email. It will have important information

about where and when to get tested.
You can complete your test in-person or pick up a self-swab kit at select test
provider locations, select pharmacies, or via a virtual appointment for a
self-swab test.
Take advantage of near-airport locations, where available, for the quickest

and easiest way to complete your arrival test.
Arriving by land
You'll be given 2 self-swab kits to complete when you arrive at a land
border crossing. You'll need to follow the instructions in your self-swab kits
to complete the tests at your destination. You'll complete your test via a
virtual telehealth appointment with your test provider. If you're unable to
complete a video appointment, contact your test provider for more testing
options.
Use only the test kits that you received at the land border, or from the
approved test provider. Tests done using any other test kit won't be valid for
the testing requirement.
https ://travel. g c. ca/travel-covid/travel-restrictions/flying-cana d a-checklist/covi d-19-testi ng-tra ve lle rs-co ming-i nto-canada 5/12
AR02257
Complete your mandatory testing

To complete your arrival and day-8 tests you must:
1. Register with the approved test provider for the province of your point
of entry. Use the same email address you used for ArriveCAN
2. Schedule your test with the test provider
3. Complete your arrival test by end of day the next calendar day after
arriving into Canada, as well as a test on day 8 of your mandatory 14-
day quarantine
You must keep your ArriveCAN e-receipt number until your test is
complete. If you arrived by air, you should also keep the email
notification.
If you haven't completed your test on time, you'll be contacted by phone

from 1-888-336-7735. It's important that you answer this call.
Find your test provider

Your test provider is based on where you entered the country.
► British Columbia, Ontario, Saskatchewan, Yukon
► Alberta, New Brunswick, Nova Scotia, Prince Edward Island,

► Manitoba
► Quebec
► Travellers driving between Alaska and the continental United States
https ://travel. gc. ca/travel-covid/travel-restri cli ons/flyi ng-ca nada-checklist/covi d-19-testi ng-travellers-comi ng-into-ca nada 6/12
AR02258
Getting your arrival test results at your place of quarantine

Completing your test in-person or picking up a self-swab kit at a select test
provider location or a select pharmacy is the quickest and easiest way meet
this requirement.
Most travellers will be notified of their test result within 4 days. If you
haven't received your test result in this time frame, you should contact y:our
test P-rovider.
If you requested that a self-swab test kit be sent to you, you should contact
your test provider if you:
• didn't receive your kit

• lost or damaged your kit
• didn't receive your results
• received invalid or indeterminate test results
• don't have internet access
• need drop-off or pick-up information
► Negative results for your arrival test
► Positive results on your arrival test
► Invalid or indeterminate results from your arrival test
Quarantine in a suitable place for 14 days

Travellers who don't qualify as fully vaccinated must quarantine for 14 days
to limit the spread of COVID-19 and variants in Canada.
Planning your 14 day quarantine
https ://travel .g c. ca/travel-covid/travel-restrictions/flying-ca nad a-checklist/ covi d-19-testi ng-travel le rs-comi ng-into-canada 7/12
AR02259
You must demonstrate that you have a suitable plan for quarantine for 14
days. You're expected to make these plans, within your own means, before
travelling to Canada. Your quarantine plan must be entered into ArriveCAN.
► Assess your quarantine plan
Starting your quarantine period

Your quarantine period begins on the day that you arrive in Canada.
For example, if you arrive at 8:15 am on Thursday, October 1, then

Thursday is considered day 1 of your quarantine period. Your quarantine
period would end 14 full days later, at 11 :59 pm on Wednesday, October 14.
► Getting to your place of quarantine
Report that you've arrived at your place of quarantine

The day after you arrive in Canada, whether you travel by air, land or
marine, you must use ArriveCAN to:
• confirm that you've arrived at the address you provided for your
quarantine or isolation location
• complete daily COVID-19 symptom self-assessments until the
completion of your quarantine period or until you report symptoms
ReP-ort via ArriveCAN or P-hone
How to quarantine
While in quarantine:
• Do not leave your place of quarantine unless it is for a medical

emergency, an essential medical service or treatment, to obtain a
COVID-19 test, or it is pre-authorized by a Quarantine Officer
https ://travel. gc. ca/travel-covid/travel-restricti ons/flying-ea nad a-checklisU covid-19-testi ng-travellers-comi ng-into-ca nada 8/12
AR02260
• Use only private outdoor spaces (i.e. balcony)

• Do not have any visits from friends, family or other guests
• Do not use shared spaces such as lobbies, courtyards, restaurants,
gyms or pools
► Quarantining with others in the same household
► Symptoms or testing positive while in quarantine
► Leaving Canada during your quarantine period
► COVID-19 testing or medical emergencies while in quarantine
Expect calls, emails and visits from the Government of Canada

The Government of Canada uses the information you provided in
ArriveCAN to verify that you:
• arrived at your place of quarantine

• are providing daily symptom reports
You will receive live or automated calls. You must answer calls from 1-888-
336-7735 and answer all questions truthfully to demonstrate your
compliance with the law.
You will receive email reminders of your quarantine requirements.
► Getting a visit from a screening officer
Complete your Day-8 test while in

quarantine
https ://travel. gc. ea/Ira vel-covid/travel-restrictions/flying-ca nad a-checklisU covid-19-testi ng-travel lers-co mi ng-i nto-ca nad a 9/12
AR02261
When you enter Canada, you'll receive a self-swab kit to use on day 8 of
your mandatory quarantine (except for travellers who are only passing
through on their way to or from Alaska). Only use the test kit that you
received at the border. Don't use any other test kits that you may have.
The instructions, web links and telephone numbers are all provided in the
kit.
How to comP-lete Y.Our self-swab kit
► Fines and consequences of failing to complete your Day-8 test
Day-8 test results and leaving quarantine
► Negative results for your test
► Positive results for your test
► Test result not yet available
Penalties and fines

Consequences for failure to comply with the Quarantine Act or the
Emergency Order
Failure to comply with the requirements of the Quarantine Act or the
Minimizing the Risk of Exposure to COVID-19 in Canada Order is an offence
under the Quarantine Act and could lead to fines, imprisonment or both.
► Visits from law enforcement officers
► Penalties, fines and imprisonment
► Examples of behaviour that could result in a fine
https :1/tra vel. gc. ca/tra ve I-covid/travel-restri ctions/flying-ca na da-checklist/ covid-19-testi ng-tra ve Ilers-comi ng-into-ca nad a 10/12
AR02262
8/3/22 , 12:51 PM Travel to Canada: Testing and quarantine if not qualified as fully vaccinated - Travel restrictions in Canada - Travel.gc.ca
If you receive a fine, you must still comply fully with the mandatory testing
and quarantine requirements outlined in the Minimizing the Risk of Exposure
to COVID-19 in Canada Order.
You must use ArriveCAN to enter Canada
You must use ArriveCAN within 72 hours of your entry into Canada
• Find answers to common ArriveCAN issues

• Need urgent help? Contact ArriveCAN by_P-hone or email
~~
► Need urgent help with a problem? Contact us
What was wrong? Please provide more details
Submit
https ://Ira vel .g c.ea/Ira vel-covid/tra ve I-restri cti ons/flyi ng-ca nad a-checkl ist/covi d-1 9-testi ng-tra vel lers-com ing-i nto-ca nad a 11 /12
AR02263
e Share this page
Date modified:
2022-07-22
https ://travel. g c. ca/trave I-covid/travel-restri ctio ns/flying-ca nada-checklist/ covid-19-testi ng-travel lers-comi ng-i nto-canada 12/12
AR02264
This is Exhibit "D" referred to in the Affidavit of

Ryan Jean-Louis sworn before me this 5th day of
Aug 2022.
J~Cv-~
ner for Oaths in and for the Province of
AR02265
8/3/22, 12:52 PM Government of Canada maintains current border measures for travellers entering Canada - Canada.ea
l♦I
of Canada du Canada
Canada.ea > Public Health Agenq~ of Canada
Government of Canada maintains current

border measures for travellers entering
Canada
From: Public Health AgencY. of Canada
News release
June 29, 2022 I Ottawa, ON I Public Health Agency of Canada
To help keep people in Canada safe, the Government of Canada put in place
border measures to reduce the risk of the importation and transmission of
COVID-19 and new variants in Canada related to international travel.
Today, the Government of Canada announced it is extending current border

measures for travellers entering Canada. Requirements for travellers arriving
to Canada are expected to remain in effect until at least September 30, 2022.
In addition, the pause of mandatory random testing will continue at all

airports until mid-July, for travellers who qualify as fully vaccinated. The pause
was put in place on June 11, 2022, and is allowing airports to focus on
streamlining their operations, while the Government of Canada moves
forward with its planned move of COVID-19 testing for air travellers outside of
airports to select test provider stores, pharmacies, or by virtual appointment.
Mandatory random testing continues at land border points of entry, with no
changes. Travellers who do not qualify as fully vaccinated, unless exempt, will
continue to test on Day 1 and Day 8 of their 14-day quarantine.
https ://www.canada.ca/en/public-health/news/2022/06/government-of-canada-maintains-current-border-measures-for-travellers-entering-canada .html 1/6

AR02266
Moving testing outside of airports will allow Canada to adjust to increased

traveller volumes while still being able to monitor and quickly respond to new
variants of concern, or changes to the epidemiological situation. Border
testing is an important tool in Canada's detection and surveillance of COVID-
19 and has been essential in helping us slow the spread of the virus. Data from
the testing program are used to understand the current level and trends of
importation of COVID-19 into Canada. Border testing also allows for the
detection and identification of new COVID-19 variants of concern that could
pose a significant risk to the health and safety of Canadians. In addition, this
data has and continues to inform the Government of Canada's safe easing of
border measures.
All travellers must continue to use ArriveCAN (free mobile app or website) to
provide mandatory travel information within 72 hours before their arrival in
Canada, and/or before boarding a cruise ship destined for Canada, with few
exceptions. Additional efforts are being undertaken to enhance compliance
with ArriveCAN, which is already over 95% for travellers arriving by land and
air combined.
Quotes
https://www.canada.ca/en/public-health/news/2022/06/government-of-canada-maintains-current-border-measures-for-travellers-entering-canada.html 2/6
AR02267
"As we move into the next phase of our COVID-19 response, it is

important to remember that the pandemic is not over. We must
continue to do all that we can to keep ourselves and others safe from
the virus. It is also important for individuals to remain up to date with
the recommended vaccinations to ensure they are adequately
protected against infection, transmission, and severe complications.
As we have said all along, Canada's border measures will remain
flexible and adaptable, guided by science and prudence."
The Honourable Jean-Yves Duclos

Minister of Health
"Today's announcement would not be possible without Canadians'

continued efforts to vaccinate themselves, wear their masks, and
follow public health advice while travelling. Our Government's
commitment will always be to protect passengers, employees, and
their communities from the impacts of COVID-19, while keeping our
transportation system strong, efficient, and resilient for the long-
term."
The Honourable Omar Alghabra

AR02268
"Our Government is deeply invested in growing our visitor economy,

and the Canadian economy as a whole. From our reputation as a safe
travel destination to our world-class attractions and wide-open
spaces, Canada has it all and we are ready to welcome back domestic
and international tourists, while prioritizing their safety and well-
being. We will continue to work with all orders of governments and
partners to reduce the friction in the travel system and ensure a
memorable travel experience for all."
The Honourable Randy Boissonnault

Minister of Tourism and Associate Minister of Finance
"The health and safety of Canadians is our government's top priority.

At the same time, we will continue to add resources to ensure that
travel and trade can keep moving - and I especially want to thank
Canada Border Services Agency employees for their tireless work. We
always take action to secure our borders and protect our
communities, because that's what Canadians expect."
The Honourable Marco E L. Mendicino

Minister of Public Safety
Associated links
• COVID-19: Travel, testing and borders
• COVID-19: Vaccinated travellers entering Canada
• ArriveCAN
• COVID-19: Boardingllights and trains in Canada
https://www.canada.ca/en/public-health/news/2022/06/government-of-canada-maintains-currenl-border-measures-for-travellers-entering-canada.hlml 4/6
AR02269
• Summa(Y. data about travellers, testing and comP-liance
Contacts
Marie-France Proulx
Press Secretary
Office of the Honourable Jean-Yves Duclos
Minister of Health
613-957-0200
Laurel Lennox
Press Secretary
Office of the Honourable Omar Alghabra
Minister of Transport, Ottawa
Lau re I.I en n ox@tc. g c. ea
Media Relations
613-957-2983
media@hc-sc.gc.ca
Media Relations
Transport Canada, Ottawa
media@tc.gc.ca
613-993-0055
Search for related information by keyword: HE Health and SafetY. I Public

Health AgencY. of Canada I Health Canada I Canada I Coronavirus (COVID-
1.2). I Return to Canada I travellers I news releases
Date modified:
AR02270
2022-06-29
AR02271
TAB 18
AR02272
Dossier N° T-247-22 (CF)
COUR FÉDÉRALE
ENTRE :
L’HONORABLE MAXIME BERNIER
Demandeur
et
LE PROCUREUR GÉNÉRAL DU CANADA
Défendeurs
AFFIDAVIT DU DEMANDEUR MAXIME BERNIER

(Assermenté le 13 mars 2022)
Je soussigné, MAXIME BERNIER, ayant mon domicile professionnel au

1, rue Nicholas, suite 700, en la ville d’Ottawa, province de l’Ontario, Canada,
K1N 7B7, DÉCLARE SOUS SERMENT QUE :
1. Je suis demandeur en l’instance.
2. Je suis né le 18 janvier 1963 à Saint-Georges, en Beauce, au Québec.
3. Après des études en administration et en droit, j’ai occupé, dans les années
1990 et au début des années 2000, des emplois dans les domaines de la
finance et de l’économie.
4. Entre 2006 et 2019, j’ai eu le privilège de siéger à la Chambre des

Communes du Canada en qualité de député de Beauce.
5. Je suis le chef fondateur du Parti populaire du Canada (« PPC ») l’automne

2018; je me consacre à cette fonction à temps plein. Je défends une
philosophie politique qui tient du libéralisme classique, prônant la liberté et
responsabilité individuelles. Je préconise un gouvernement fédéral de taille
relativement réduite, qui respecte notre Constitution, notre Charte des
droits et libertés ainsi que la division des pouvoirs entre le palier fédéral et
les provinces.
6. Le PPC est un parti fédéral de premier plan. Ayant obtenu plus de 840 000
AR02273
voix et 4,9% des votes, il est arrivé au cinquième rang à l’issue de l’élection
générale de 2021.
7. Je suis le seul chef d’un parti politique fédéral majeur qui défende vraiment
la liberté et la responsabilité individuelles, le libre marché, la levée des
barrières commerciales interprovinciales, la réforme de la formule de
péréquation, l’abolition de l’aide étrangère (sauf lors de catastrophes
majeures), l’abolition des subventions aux entreprises, l’abolition de la
gestion de l’offre en matière agricole et le retrait du Canada de l’Accord de
Paris sur le climat et du Pacte mondial sur les migrations des Nations Unies,
pour ne nommer que quelques-unes de nos politiques.
8. J’ai participé à la rédaction de l’Avis de demande de contrôle judiciaire daté

du 10 février 2022 et produit au dossier T-247-22. Les faits qui y sont
allégués sont vrais à ma connaissance personnelle.
9. J’ai pris connaissance de l'Arrêté d’urgence no 53 visant certaines

exigences relatives à l’aviation civile en raison de la COVID-19, ainsi que
des arrêtés qui l’ont précédé et suivi (ci-après, collectivement, « Arrêtés »).
10. Je retiens des Arrêtés qu’il est interdit aux personnes non « entièrement
vaccinée[s] » de voyager par avion, sauf exemption médicale.
11. Je retiens, en outre, que les personnes qui seraient en mesure de

démontrer qu’elles ont déjà contracté la Covid-19 ou qui ont des anticorps
contre la Covid-19 ne sont pas considérées comme « entièrement
vaccinée[s] »
12. En ce qui concerne la Covid-19, je suis le seul chef d’un parti politique
fédéral majeur qui soit franchement et ouvertement opposé, par principe et
depuis le début de la pandémie, aux mesures de confinement, aux
restrictions au droit de circuler, aux couvre-feux, à la fermeture obligée des
commerces et lieux de rassemblement, à l’obligation de porter le masque
dans les lieux fréquentés par le public, à l’instauration d’un passeport
vaccinal comme préalable au droit de travailler ou d’obtenir des biens et
services généralement offerts au public, à la répression des manifestations
pacifiques d’opposition aux mesures dites sanitaires (Freedom Convoy
2022, notamment).
13. Or, les grands médias écrits, radiophoniques et télévisuels canadiens

n’accordent au PPC que très peu d’attention relativement aux autres partis
fédéraux. Les revues de presse que me procure mon directeur des
communications quotidiennement et ce, depuis quelques années, me
permettent de l’affirmer ici avec certitude.
14. Ce refus des grands médias d’accorder au PPC une attention à peu près
représentative de son poids politique m’oblige, pour arriver à diffuser le
message politique du PPC, à investir plus d’énergie dans des façons
2
AR02274
alternatives de rejoindre les électeurs : conférences, rallyes et autres

activités « en présentiel ».
15. En qualité de chef d’un parti national, je dois aller la rencontre de milliers
de personnes à chaque année et participer à diverses activités politiques
et intellectuelles dans toutes les régions du pays : rencontrer les membres
des associations de comté du PPC, prononcer des discours dans des
universités et des chambres de commerces à travers le pays, rencontrer
des candidats potentiels pour notre parti, aider à bâtir l’infrastructure du
PPC dans chaque circonscription, et
16. Je ne nie pas l’utilité des médias sociaux comme Twitter, YouTube et
Rumble, mais j’ai pu constater, depuis mes débuts en politique élective, que
les activités de terrain (en personne) sont celles qui offrent à un chef de
parti les meilleures conditions de communication avec les citoyens. En
effet, il n’existe aucun substitut valable à la présence humaine.
17. De plus, la réalité des régions est difficile à saisir à travers le seul prisme
des grands médias, car ceux-ci sont essentiellement métropolitains. Selon
mon expérience, rien ne remplace un séjour sur place pour bien percevoir
les enjeux régionaux et le pouls de la population, des entreprises et
organismes locaux.
18. La possibilité de rencontrer les gens en personne prend aussi une

importance particulière chez les électeurs aînés qui sont moins (ou pas du
tout) familiers avec Internet et les technologies de l’information.
19. Contrairement à certains politiciens au pouvoir, je pratique la politique « en

présentiel ». Je ne m’isole pas chez moi ou au chalet pour de vagues
raisons sanitaires, je n’esquive pas mes adversaires politiques, je ne suis
pas partisan de la fermeture arbitraire du Parlement, je ne méprise pas mes
concitoyens et n’évite pas d’aller à leur rencontre quand ils sont en
désaccord avec moi.
20. En 2021, j’ai parcouru plus de 79 000 km en avion au Canada pour les
besoins de mon travail.
21. Le PPC et moi n’avons pas les moyens de noliser un avion pour mes
activités politiques. Cela représenterait une dépense de plusieurs milliers
de dollars par voyage.
22. J’habite à Montréal avec mon épouse. À l’échelle d’un trimestre ou d’une
année, voyager autrement que par avion n’est raisonnablement faisable
que dans un rayon relativement limité autour de mon lieu de résidence.
23. Parcourir des dizaines de milliers de kilomètres en voiture ou en autobus

prendrait beaucoup plus de temps que ne le permet un emploi du temps
efficace.
3
AR02275
24. Le 16 décembre 2021, le premier ministre a enjoint au ministre des

Transports d'exiger que les voyageurs sur les vols commerciaux à l'intérieur
et au départ du Canada soient vaccinés, tel qu’il appert de la lettre de
mandat du 16 décembre 2021, annexe A. Le ministre des Transports a
pris les Arrêtés en conséquence.
25. Les Arrêtés font de moi le seul chef d’un parti fédéral majeur qui soit
empêché de voyager par avion pour accomplir sa mission politique, laquelle
inclut, ironiquement, la contestation des mesures Covid du gouvernement
libéral.
26. En restreignant ma mobilité en fonction de mon statut vaccinal, les Arrêtés

violent mes droits de participation aux discussions démocratiques et au
processus électoral.
27. Depuis janvier 2022, en raison des Arrêtés, j’ai dû renoncer à plusieurs
activités démocratiques qui s’inscrivaient dans le cadre normal de mes
fonctions politiques. Je n’ai pas pu participer en tant qu’orateur dans des
rallyes à Calgary en janvier dernier, à St-John’s Terre-Neuve-et-Labrador
en février dernier et à Victoria en Colombie-Britanique ce mois-ci.
28. Je suis en bonne condition physique. J’ai toujours été plutôt sportif. J’ai joué
au football aux niveaux secondaire et collégial. Depuis mes 30 ans, je fais
régulièrement de la course à pied – entre 40 et 70 kilomètres par semaine.
29. En fait de Covid-10, les chances de guérison des personnes de moins de

60 ans sans comorbidités (groupe dont je fais partie) excèdent 99,9%.
30. J’ai choisi de ne pas me faire inoculer contre la Covid-19 en raison des
risques associés à ce médicament biologique expérimental, aux effets à
court et à long terme encore méconnus.
31. À ma connaissance, six vaccins sont actuellement autorisés au Canada

pour traiter les symptômes de la Covid-19 : AstraZeneca, Moderna, Pfizer,
Johnson & Johnson, Novavax et Medicago, tel qu’il appert des avis de
Santé Canada ci-joints comme annexe B.
32. Ces vaccins sont toujours en cours d'essais cliniques, dont l'achèvement
est prévu en 2023 ou plus tard.
33. Il est notoire et de connaissance judiciaire qu’aucun desdits vaccins

n'empêche l'infection ou la transmission de la Covid-19.
34. Au fil des mois depuis les débuts de la campagne de vaccination à la fin
2020, je me suis renseigné sur les effets secondaires potentiels répertoriés
par Santé Canada, tel qu’il appert des données et avis ci-joints en liasse
comme annexe C.
4
AR02276
35. Les effets secondaires du vaccin peuvent être sévères, voire mortels :
myocardite, péricardite, paralysie de Bell, thrombose, thrombocytopénie
immunitaire et thromboembolie veineuse, par exemple. Je crains
légitimement ces possibles conséquences indésirables.
36. Je ne suis pas moralement opposé à la vaccination. J’ai déjà eu le vaccin

contre la choléra, le tétanos, la diphtérie, l’hépatite A et B, la méningite à
méningocoques et la fièvre typhoïde. J’ai d’ailleurs conseillé à mon père,
âgé de 87 ans et diabétique, de se faire vacciner.
37. Vaccinés comme non-vaccinés peuvent être infectés par la Covid-19 et la

transmettre.
38. Je préfère développer une immunité naturelle et j’accepte les risques

découlant de cette décision.
39. J’ai d’ailleurs contracté la Covid-19 à l’automne 2021, tel qu’il appert des
documents médicaux ci-joints comme annexe D, dont j’ai caviardé les
informations confidentielles (numéro RAMQ, numéro de dossier du
médecin, adresse résidentielle).
40. Je me suis remis sans mal de cette infection. Environ une semaine après
l’apparition des premiers symptômes, j’ai retrouvé un état général normal :
aucun manque d’énergie, aucune douleur, etc. Je ne garde aucune
séquelle de la Covid-19.
41. L’environnement des aérodromes et des aéronefs ne présente aucun

risque particulier ou accru de propagation de la Covid-19. Les Arrêtés ne
parent donc à aucun risque appréciable pour la sûreté aérienne ou la
sécurité du public en contexte aéronautique.
42. Le premier ministre du Canada a tenu des propos intolérants et

diffamatoires au sujet des personnes qui refusaient le vaccin contre la
Covid-19, tel qu’il appert des extraits audio et vidéo ci-joints comme
annexe E.
43. J’ai pu constater, depuis le début 2021, le colportage de stéréotypes, de

propos dégradants et diffamatoires, de mensonges et d’allégations quasi
haineuses au sujet des non-vaccinés par de grands médias d’information,
des personnalités publiques influentes et nombre de politiciens fédéraux et
provinciaux, tel qu’il appert des extraits écrits, audio et vidéo ci-joints en
liasse comme annexe F.
44. À l’instar de ces discours discriminatoires et répréhensibles, les Arrêtés

traitent les personnes non vaccinées, dont je suis, comme des citoyens de
seconde zone, des indésirables, des pestiférés.
45. Les Arrêtés, lus dans le contexte des autres mesures gouvernementales
5
AR02277
relatives à la Covid-19, me semblent punitifs et d’autant plus vexatoires

qu’ils sont futiles sur le plan de la santé et de la science.
46. Les faits que j’allègue au présent affidavit sont vrais à ma connaissance
personnelle.
Déclaré sous serment devant moi par )
l’Honorable Maxime Bernier, à distance, le )
13 mars 2022, conformément aux normes )
d’assermentation applicables dans la )
province du Québec. )
Alexandra Pasca, avocate

Commissaire a l'assermentation
445, boulevard Saint-Laurent
Montreal QC H2Y 3TB
6
AR02278
Annexe A [sur clé USB ci-jointe]

à l’affidavit du demandeur
Maxime Bernier, assermenté à
distance devant moi le 13 mars
2022

Montreal QC H2Y 3T8
7
AR02279
December 16, 2021
Office of the Cabinet du

Prime Minister Premier ministre
Ottawa. Canada K1AOA2
Dear Minister Alghabra:
Thank you for continuing to serve Canadians as Minister of Transport.
From the beginning of this pandemic, Canadians have faced a once-in-a-century

challenge. And through it all, from coast to coast to coast, people have met the
moment. When it mattered most, Canadians adapted, helped one another, and
stayed true to our values of compassion, courage and determination. That is
what has defined our path through this pandemic so far. And that is what will
pave our way forward.
During a difficult time, Canadians made a democratic choice. They entrusted us

to finish the fight against COVID-19 and support the recovery of a strong middle
class. At the same time, they also gave us clear direction: to take bold, concrete
action to build a healthier, more resilient future. That is what Canadians have
asked us to do and it is exactly what our Government is ready to deliver. We will
work to build that brighter future through continued collaboration, engagement,
and the use of science and evidence-based decision-making. With an
unwavering focus on delivering results, we will work constructively with
Parliamentarians and maintain our strong partnerships with provincial, territorial
and municipal governments and Indigenous partners. This decade has had an
incredibly difficult start, but this is the moment to rebuild a more resilient,
inclusive and stronger country for everyone.
The science is clear. Canadians have been clear. We must not only continue
taking real climate action, we must also move faster and go further. As
Canadians are increasingly experiencing across the country, climate change is
AR02280
an existential threat. Building a cleaner, greener future will require a sustained
and collaborative effort from all of us. As Minister, I expect you to seek
opportunities within your portfolio to support our whole-of-government effort to
reduce emissions, create clean jobs and address the climate-related challenges
communities are already facing.
This year, Canadians were horrified by the discovery of unmarked graves and
burial sites near former residential schools. These discoveries underscore that
we must move faster on the path of reconciliation with First Nations, Inuit and
Metis Peoples. We know that reconciliation cannot come without truth and our
Government will continue to invest in that truth. As Ministers, each of us has a
duty to further this work, both collectively and as individuals. Consequently, I am
directing every Minister to implement the United Nations Declaration on the
Rights of Indigenous Peoples and to work in partnership with Indigenous
Peoples to advance their rights.
We must continue to address the profound systemic inequities and disparities

that remain present in the core fabric of our society, including our core
institutions. To this effect, it is essential that Canadians in every region of the
country see themselves reflected in our Government's priorities and our work.
As Minister, I expect you to include and collaborate with various communities,
and actively seek out and incorporate in your work, the diverse views of
Canadians. This includes women, Indigenous Peoples, Black and racialized
Canadians, newcomers, faith-based communities, persons with disabilities,
LGBTQ2 Canadians, and, in both official languages.
Across our work, we remain committed to ensuring that public policies are
informed and developed through an intersectional lens, including applying
frameworks such as Gender-based Analysis Plus (GBA Plus) and the quality of
life indicators in decision-making.
Canadians continue to rely on journalists and journalism for accurate and timely
news. I expect you to maintain professional and respectful relationships with
journalists to ensure that Canadians are well informed and have the information
AR02281
they need to keep themselves and their families safe.
Throughout the course of the pandemic, Canadians and their governments have
adapted to new realities. Governments must draw on lessons learned from the
pandemic to further adapt and develop more agile and effective ways to serve
Canadians. To this end, I expect all Ministers to evaluate ways we can update
our practices to ensure our Government continues to meet the challenges of
today and tomorrow.
The success of this Parliament will require Parliamentarians, both in the House
of Commons and the Senate, to work together across all parties to get big things
done for Canadians. I expect you to maintain constructive relationships with
your Opposition Critics and coordinate any legislation with the Leader of the
Government in the House of Commons. As Minister, you are accountable to
Parliament both individually, for your style of leadership and the performance of
your responsibilities, and collectively, in support of our Ministry and decisions
taken by Cabinet. Open and Accountable Government sets out these core
principles and the standards of conduct expected of you and your office. I
expect you to familiarize yourself with this document, which outlines my
expectations for each member of the Ministry.
Our platform lays out an ambitious agenda. While finishing the fight against the
pandemic must remain our central focus, we must continue building a strong
middle class and work toward a better future where everyone has a real and fair
chance at success and no one is left behind.
As Minister of Transport, your immediate priority is to enforce vaccination

requirements across the federally-regulated transport sector that are in place
and to continue to advance the restart and rebuilding of the commercial air
sector. You will also prioritize work to make High Frequency Rail a reality, and to
advance measures that support Canada's transition to net-zero, including
accelerating the transition to zero emission vehicles.
To realize these objectives, I ask that you achieve results for Canadians by
delivering the following commitments.
AR02282
• Require that travellers on interprovincial trains, commercial flights,
cruise ships and other federally-regulated vessels be vaccinated, and
continue to work with the federally regulated transportation sector to
ensure that COVID-19 vaccination is prioritized for those workers.
• Continue working with the Minister of Public Safety and the Minister of
Health to protect the health and safety of Canadians through safe,
responsible and compassionate management of the border with the
United States and other ports of entry into Canada.
• Launch a procurement process and move forward with the High

Frequency Rail project in the Toronto to Quebec City corridor using
electrified technology, working towards the ultimate goal of extending
the high frequency rail project to Southwestern Ontario.
• Continue to advance the restart of a competitive and viable air sector,

strengthen air passenger rights and take steps to accelerate the
adoption of advanced technologies, including right touch travel, in
order to rebuild public confidence and future prospects of the air
sector, including efficient and affordable travel options that connect
regions and communities to each other and international markets.
• Continue to support Canada's transition to net zero by advancing

measures to:
o Improve the affordability and accelerate the adoption of zero-
emission vehicles, including used vehicles, by Canadian
households and businesses;
o Develop a strategy to decarbonize emission-intensive on-road

freight; and
o Support global efforts to reduce emissions in the air and marine

sectors.
AR02283
• Work with the Minister of Foreign Affairs to continue to advance
Canada's ongoing response to the tragic downing of flight PS752,
notably to advance the Safer Skies Initiative and pursue reforms to
the International Civil Aviation Organization's accident investigation
regime to improve the credibility and transparency of future safety
investigations.
• In partnership with Indigenous Peoples, continue to implement

commitments made under the Oceans Protection Plan, and with the
support of the Minister of Fisheries, Oceans and the Canadian Coast
Guard, work to launch the next phase of the Oceans Protection Plan
to continue efforts to deliver world-leading marine safety systems,
increase protection for marine species and ecosystems and create
stronger partnerships with Indigenous and other coastal communities,
while strengthening marine research and science.
• Advance measures that further improve the safety and security of

Canada's rail system, particularly in light of the impacts of climate
change and severe weather on railway operations.
• Work with provinces, territories and willing municipalities on solutions

to allow them a greater role in managing and regulating boating on
their lakes and rivers so that they promote free access, while ensuring
the safety of boaters and the protection of the environment.
• Complete the Ports Modernization Review with an aim to update

governance structures that promote investment in Canadian ports.
• Continue to work with all stakeholders involved, including the

Government of Quebec, the municipalities, and the Canadian Pacific
Railway, toward the rapid completion of the Lac-Megantic bypass.
• Complete negotiations to repatriate and rehabilitate the Quebec

Bridge.
AR02284
• With the support of the Minister of Intergovernmental Affairs,
Infrastructure and Communities and the Minister of Innovation,
Science and Industry, work to reduce and prevent supply chain
bottlenecks in Canada's transportation networks through the National
Trade Corridors Fund and legislative and regulatory authorities. Your
efforts will complement the work led by the Minister of International
Trade, Export Promotion, Small Business and Economic
Development and the Minister of Innovation, Science and Industry to
strengthen and secure supply chains.
• Work with the Minister of Public Safety, President of the Queen's

Privy Council for Canada and Minister of Emergency Preparedness,
Minister of Fisheries, Oceans and the Canadian Coast Guard and
Minister of Health, among other colleagues, to ensure the
Government of Canada continues to be prepared to proactively
mitigate and respond to emerging incidents and hazards.
As Minister, you are also responsible for actively engaging with your Cabinet
and Caucus colleagues. As we deliver on our platform commitments, it will be
important that members of the Ministry continue to collaborate and work
constructively to support rigorous and productive Cabinet decision-making. I
expect you to support your colleagues in delivering their commitments,
leveraging the expertise of your department and your own lived experiences.
To best achieve results for Canadians, Ministers must be rigorous and

coordinated in our approach to implementation. I would therefore ask that you
return to me with a proposed approach for the delivery of your mandate
commitments, including priorities for early implementation. Furthermore, to
ensure we are accountable for our work, I will be asking you to publicly report to
me, and all Canadians, on your progress toward these commitments on a
regular basis.
As we have been reminded throughout the pandemic, adapting to change is not

AR02285
only something government should do, it is something government must do. As
you work to fulfil our commitments, I expect you to actively consider new ideas
and issues as they emerge, whether through public engagement, your work with
Parliamentarians or advice from the public service. I also expect you to work
with your Deputy Minister to assess priorities on a continual basis as we build a
better future for all Canadians. In addition to achieving results, you are
responsible for overseeing the work of your department and ensuring the
effective operation of your portfolio.
As you staff your office and implement outreach and recruitment strategies for
federally appointed leadership positions and boards, I ask that you uphold the
principles of equity, diversity and inclusion. This helps ensure that federal
workplaces are dynamic and reflective of the Canadians we serve. You will also
ensure your Minister's office and portfolio are reflective of our commitment to
healthy and safe workplaces.
Canadians expect us to work hard, speak truthfully and be committed to

advancing their interests and aspirations. When we make mistakes - as we all
will - Canadians expect us to acknowledge them, and most importantly, to learn
from them.
I know I can count on you to fulfill the important responsibilities entrusted in you,
and to turn to me, and the Deputy Prime Minister, early and often to support you
in your role as Minister.
Sincerely,
Rt. Hon. Justin Trudeau, P.C., M.P.

Prime Minister of Canada
AR02286
Annexe B [sur clé USB ci-jointe]

2022

Montreal QC H2Y 3TB
8
AR02287
l♦I
Gouvernement Government
du Canada of Canada
Canada.ea > Maladie a coronavirus (COVID-191 > Vaccins contre la COVID-19
Vaccins approuves contre la COVID-19

Informations sur les vaccins contre la COVID-19, y compris les vaccins
approuves, les types de vaccins et la surveillance continue de la securite
Endemande
• Comment se faire vacciner
• Ap_provisionnement en vaccins du Canada
• Preuve de vaccination
• Effets secondaires signales suite a la vaccination COVID-19
• Methodes d'approbation des vaccins et traitements
• Liste des drogues et vaccins ap_prouves et des drogues a
indications supplementaires
• Nombre de personnes vaccinees
Vaccins approuves
Vaccin Sgikevax de Moderna contre la COVID-19
Apropos du vaccin, fonctionnement, mode d'administration, ingredients, allergies,
effets secondaires possibles, surveillance de la securite
Vaccin ComirnatY- de Pfizer-BioNTech contre la COVID-19

AR02288
Vaccin Vaxzevria d'AstraZeneca contre la COVID-19

Vaccin de Janssen (Johnson & Johnson) contre la COVID-19

Vaccin Nuvaxovid de Novavax contre la COVID-19

Vaccin Covifenz de Medicago contre la COVID-19

AR02289
Types de vaccins
Les vaccins abase d'ARNm
Apropos des vaccins a base d'ARNm, de leur fonctionnement, securite, efficacite et
surveillance
Vaccins abase de vecteurs viraux

Apropos des vaccins a base de vecteurs viraux, de leur fonctionnement, securite,
efficacite et surveillance
Vaccins asous-unites Rroteigues

Apropos des vaccins a sous-unites proteiques, de leur fonctionnement, securite,
Vaccins Rroduits sur Rlantes

Apropos des vaccins a sous-unites proteiques, de leur fonctionnement, securite,
Avez-vous trouve ce que vous cherchiez?
Qu'est-ce qui n'allait pas?

AR02290
Je ne peux pas trouver !'information
0 L'information est difficile a comprendre
0 II y avait une erreur / quelque chose ne fonctionnait pas
0 Autre raison
Veuillez fournir plus de details
Vous ne recevrez aucune reponse. Les numeros de telephone et les adresses electroniques
seront supprimes.
Maximum de 300 caracteres
Soumettre ]
~ Partagez cette page
Date de modification :
2022-02-24
AR02291
Annexe C [sur clé USB ci-jointe]

2022

a
Commissaire l'assermentation
Montreal QC H2Y 3TB
9
AR02292
I
♦ Gouvernernent Government
I du Canada of Canada
Canada.ea > Maladie a coronavirus (COVID-19)_ > Vaccins contre la COVID-19
Effets secondaires signales apres la

vaccination contre la COVID-19 au
Canada
Sommaire Rapport hebdomadaire Rapports archives
Nous mettons cette page ajour tous les vend red is a 12 h, heure de l'Est.
Une mise en contexte et sommaire du rap_port sont disponibles.
Ce rapport a ete mis ajour le 4 mars 2022 et ii comprend les

donnees jusqu'au 25 fevrier 2022.
Sur cette page

• Ce gue vous devez savoir
• Signaux relatifs a la securite
• Autres mises ajour sur la securite
• Definitions
• Comment signaler un effet secondaire
• Sommaire des rap_ports de declaration d'effets secondaires suivant
!'immunisation
• Rap_ports de declaration d'effets secondaires suivant !'immunisation
par nom de vaccin
• Rap_ports de declaration d'effets secondaires suivant !'immunisation
par sexe et groupe d'age
AR02293
• Effets secondaires signales
• Evenements indesirables presentant un interet particulier
• Information detaillee sur les signaux relatifs a la securite, aux autres
mises ajour sur la securite et aux deces
• Remarques sur les donnees
• Remerciements, citation sug_geree, liens connexes
Ce que vous devez savoir en date du 25 fevrier 2022
Aucun 40011
nouveau signal 80794153 Nombre total de
relatif ala Total des doses
rapports de declaration
administrees
securite n'a d'effets secondaires
ete identifie au suivant !'immunisation
Canada (0,050% de toutes les
(3 signaux continuent
doses administrees)
d'etre surveilles)
l J
0
31596 127
Nombre total de
8415 Nouveaux effets
Nombre total de
rapports de declaration secondaires suivant
rapports de declaration
d'effets secondaires !'immunisation
d'effets secondaires
suivant !'immunisation signales et traites
graves suivant
sans gravite suivant entre le 19 fevrier et
!'immunisation
!'immunisation le 25 fevrier 2022
AR02294
(0,039% de toutes les (0,010% de toutes les (71 nouveaux sans

doses administrees) doses administrees) gravite et 56
nouveaux graves)
• Les avantages des vaccins autorises au Canada continuent de

l'emporter sur les risques.
• Sante Canada, l'Agence de la sante publique du Canada (ASPC), les
provinces et territoires et les fabricants continuent de surveiller de
pres la securite des vaccins contre la COVID-19. Nous repondrons
immediatement a tout probleme de securite et informerons les
Canadiens de tout risque qui se presente au Canada.
• Des 40 011 rapports de declaration individuels {0,050% de toutes les
doses administrees), 8 415 ont ete juges graves {0,010% de toutes
les doses administrees).
Signaux relatif ala securite

• Aucun nouveau signal relatif a la securite n'a ete releve cette
semaine.
• L'ASPC et Sante Canada continuent de surveiller 3 signaux:
o Thromboses avec thrombocytopenie suivant !'immunisation
contre la COVID-19 avec le vaccin Vaxzevria
d' AstraZeneca/COVISHIELD continuent de faire l'objet d'une
surveillance etroite. Sante Canada a mis ajour la monographie
de produit du vaccin Vaxzevria d' AstraZeneca (PDF)_ et celle du
vaccin COVISHIELD contre la COVID-19 (PDF)_ afin d'y inclure les
renseignements sur ces evenements, tres rares, de caillots
sanguins associes a de faibles taux de plaquettes suite a la
vaccination. Pour plus d'information, veuillez consulter I' avis
_public sur le vaccin Vaxzevria d'AstraZenecaLCOVISHIELD
AR02295
o Syndrome de Guillain-Barre (5GB) au Canada presente un taux
plus eleve apres !'administration du vaccin Vaxzevria
d' AstraZeneca/COVISHIELD contre la COVID-19 que ce qui est
attendu dans la population en general. Sante Canada a mis a
jour la monographie de produit du vaccin Vaxzevria
d' AstraZeneca (PDF)_ et celle du vaccin COVISHIELD contre la
COVID-19 (PDF)_ pour y inclure de !'information sur le 5GB.
Veuillez consulter la description de produit du vaccin Vaxzevria
d' AstraZenecaLCOVISHIELD contre la COVID-19
o Myocardite (inflammation du muscle cardiaque) et pericardite
(inflammation de l'enveloppe du cceur) suivant la vaccination
avec les vaccins a ARN messager. Les donnees au Canada
indiquent maintenant un nombre de cas plus eleve chez les
jeunes (de moins de 40 ans) que ce a quoi on pourrait
normalement s' attend re dans ce groupe d' age dans la
population genera le. Sante Canada a recemment mis a jour la
monographie du vaccin Spikevax de Moderna (PDF)_ et celle du
vaccin ComirnatY- de Pfizer-BioNTech contre la COVID-19 (PDF)_
afin d'y inclure les informations sur ces risques. Veuillez
consulter I' avis public sur les vaccins Spikevax de Moderna et
ComirnatY- de Pfizer-BioNTech pour plus d'information.
• Veuillez vous referer aux renseignements detaillees sur les signaux
relatifs a la securite et aux deces.
Autres mises ajour sur la securite
• L'ASPC et Sante Canada continuent de surveiller de pres les rapports
canadiens et internationaux, notamment sur les effets secondaires
suivants:
AR02296
o Syndrome de fuite capillaire apres vaccination avec le vaccin
Vaxzevria d' AstraZeneca/COVISHIELD. Sante Canada a mis a jour
la monographie de produit du vaccin Vaxzevria d' AstraZeneca
_(PDF)_ et celle du vaccin COVISHIELD contre la COVID-19 (PDF)_
afin d'y inclure des informations sur le syndrome de fuite
capillaire, y compris une contre-indication pour les patients qui
ont deja souffert de ce syndrome. Pour plus d'information,
veuillez consulter l'avis public sur le vaccin Vaxzevria
d' AstraZenecaLCOVISHIELD.
o Paralysie faciale/paralysie de Bell suivant la vaccination avec un
vaccin a ARNm contre la COVID-19. Sante Canada a mis a jour la
monographie du vaccin Spikevax de Moderna (PDF)_ et celle du
vaccin ComirnatY- de Pfizer-BioNTech contre la COVID-19 (PDF)_
pour y inclure information sur Paralysie faciale/paralysie de Bell.
o Thrombocytopenie immune et thromboembolie veineuse (TEV) a
la suite de la vaccination avec le vaccin Janssen contre la
COVID-19. Sante Canada a mis a jour la monographie de produit
du vaccin de Janssen contre la COVID 19 afin d'y inclure de
!'information sur la thrombocytopenie immune et sur la TEV.
Pour plus d'information, veuillez consulter les avis publics sur les
vaccins Janssen et Vaxzevria d' AstraZeneca contre la COVID 19.
o Thrombocytopenie, y compris sa forme immune, apres la
vaccination avec le vaccin Vaxzevria d'AstraZeneca contre la
COVID-19. Sante Canada a mis a jour la monographie de produit
du vaccin Vaxzevria d' AstraZeneca pour y inclure de
!'information sur la thrombocytopenie, y compris sur la TEV.
Pour plus d'information, consultez l'avis public sur le vaccin
Vaxzevria d' AstraZeneca contre la COVID-19.
AR02297
Definitions
T Effets secondaires suivant !'immunisation (ESSI)
Un ESSI est un evenement imprevu sur le plan medical qui suit

!'immunisation.
• un signe defavorable ou imprevu (p. ex., un eruption cutanee)

• un resultat de laboratoire anormal
• un sympt6me
• une maladie
Pour de plus amples renseignements, veuillez consulter le document intitule. Report of
CIOMS/WHO Working group on Vaccine Pharmacovigilance. Geneva : CIOMS and WHO;
2012 du Council for International Organizations of Medical Sciences (CIOMS) et de
!'Organisation mondiale de la sante (OMS) (en Anglais seulement).!.
T Rapport de declaration d'effets secondaires
Un rapport d'ESSI represente 1 personne, mais qu'il peut contenir

plus d'un sympt6me (c'est-a-dire un ou plusieurs effets secondaires,
graves ou non, suivant !'immunisation (.E..S.Sl...Ce.ff.ets. . .s.e. c.on.d. .a. .i..r.e..s.
suivant l'immunisation)J).
T Effet secondaire grave
Un effet secondaire est considere comme grave s'il :
• entraTne la mort
• met la vie en danger (un evenement/une reaction ou le patient
courait un risque reel et non hypothetique de deces au moment
de l'evenement/de la reaction)
• necessite une hospitalisation ou une prolongation de
AR02298
!'hospitalisation
• entraTne une incapacite ou un handicap persistant ou important
• entraTne une anomalie congenitale ou une malformation
T Evenements importants sur le plan medical
Tout evenement medical qui ne met pas la vie en danger

immediatement, mais qui necessite une intervention pour prevenir
l'un des resultats enumeres ci-dessus peut aussi etre considere
comme grave. Cette definition est basee sur la Conference
internationale sur !'harmonisation des exigences techniques
relatives a l'homologation des produits pharmaceutiques a usage
humain. Voir:
Conference internationale sur !'harmonisation.
T Evenements indesirables presentant un interet particulier (EIIP)
II s'agit d'un evenement important sur le plan medical predetermine

qui peut avoir un lien de causalite avec un vaccin. L'evenement doit
etre soigneusement surveille et confirme par des etudes plus
poussees.
Pour plus de details, consultez : Organisation mondiale de la sante : Vaccins contre la
COVID-19 : Manuel de surveillance de la securite (en anglais)
T Definition du signal relatif a la securite
Element d'information indiquant !'existence d'un nouveau lien de

causalite possible entre le vaccin et un evenement qui pourrait avoir
une incidence sur la sante. L'evenement est soit inconnu, soit
AR02299
documente de maniere incomplete. II pourrait aussi indiquer un
nouvel aspect d'une association connue. L'objectif principal de la
surveillance des vaccins apres la commercialisation est de detecter
les problemes d'innocuite, comme:
• une augmentation possible de la gravite ou de la frequence

prevue des effets secondaires suivant !'immunisation
• OU un OU plusieurs evenements imprevus (c.-a-d. un evenement
qui ne correspond pas a !'information ou a l'etiquetage des
produits canadiens).
Pour plus de details, consultez : Organisation mondiale de la sante : Vaccins contre la
COVID-19 : Manuel de surveillance de la securite (en anglais)
Comment signaler un effet secondaire

Si vous eprouvez un effet secondaire suivant !'immunisation avec un
vaccin contre la COVID-19 au Canada, veuillez communiquer avec votre
fournisseur de soins de sante. Renseignez-vous sur le signalement des
effets secondaires.
Sommaire des rapports de declaration des

effets secondaires suivant l'immunisation
Cette page contient des donnees detaillees relatives aux cas signales
dans le Systeme canadien de surveillance des effets secondaires suivant
!'immunisation (SCSESSI) de l'Agence de la sante publique du Canada et
dans le Programme Canada Vigilance de Sante Canada. Les doses
administrees utilisees pour le calcul des taux de declarations ont ete
ajustees pour tenir compte du delai entre la vaccination et la declaration.
AR02300
Les donnees sur cette page peuvent changer au fur et a mesure que de
nouveaux renseignements sur les cas deviennent disponibles.
II y a eu au total 40 011 rapports (50,1 rapports par 100 000 doses

administrees) en date du 25 fevrier 2022, dont 8 415 etaient consideres
comme graves (10,5 rapports par 100 000 doses administrees). Le taux
de declaration d'effets secondaires graves est demeure peu eleve. Le
nombre cumulatif et hebdomadaire de rapports, de meme que le taux de
rapports hebdomadaires, est indique a la Figure 1.
Figure 1. INombre hebdomadaire v de rapports relatifs

aux effets secondaires des vaccins contre la COVID-19 au sein
Ide toute la population v , et total des doses administrees par
semaine en date du 25 fevrier 2022 (n=40 011)
Vl 1 200
t:'.
0
CL
~ 1000
....
(].J
"O
-~C1l
4-- 800
::J
E soo
::J
u
(].J
j ~ ~ m~ rumM..,_,. . . ,. . . ,. . . ,. . . ,. . . ,. . . ,. . . ,. . . ,. . . ,. .
r'..,_,......,......,......,......,......,......,......,......,......,,__,L,r'L,r''-,JL,r'L,r''-,JL,r'L,r''-,JL,JL,r''-,JL,r' ..... ....., ~ ...... ....,L,r''-,JL,r'L,r''-,J .......
Rapports hebdomadaires re~us

■ Grave ■ Sans gravite
Remarque sur les donnees : Les zones ombrees representent une periode (retard) ou ii pourrait
y avoir eu des delais dans la reception et le traitement des formulaires de declaration. II pourrait
egalement y avoir eu des retards dans la reception des donnees sur les doses administrees.
Puisque !'information sur les doses administrees par groupe d'age n'etait disponible qu'a
compter du 23 avril 2021, pour les personnes de 12 ans et plus, et du 27 novembre 2021 pour les
enfants de moins de 12 ans, les taux de declaration des effets secondaires et les nombres de
doses administrees par groupe d'age ne sont pas consignes avant cette date.
AR02301
Les rapports de declaration du groupe d'age des 11 ans qui ont re<;u la dose du vaccin Comirnaty
de Pfizer-BioNtech contre la COVID-19 recommandee pour les 12 ans et plus avant que la dose
a
pediatrique soit approuvee sont inclus dans les rapports du groupe d'age des 5 11 ans. Le
a
groupe d'age des 5 11 ans comprend aussi des rapports d'enfants nes en 2017 qui n'avaient
pas encore 5 ans au moment de la vaccination .
► Figure 1 - Texte descriptif
Rapports de declaration d'effets

secondaires suivant l'immunisation par
nom du vaccin
La figure 2 presente la repartition des rapports par nom de vaccin. Pour
les doses administrees par type de vaccin, visitez la _page Web sur la
couverture vaccinale. Sante Canada a autorise !'administration de doses
de rappel du vaccin Comirnaty de Pfizer-BioNTech le 9 novembre 2021 et
du vaccin Spikevax de Moderna le 12 novembre 2021.
Les doses de rappel sont administrees aux adultes dans le muscle (voie
intramusculaire) au mains six mois apres que ceux-ci aient re~u une serie
primaire complete de vaccins. Le 19 novembre 2021, !'utilisation du
vaccin Comirnaty de Pfizer-BioNTech a ete autorisee chez les enfants de 5
a 11 ans (dose de 1O µg). Sante Canada a autorise le vaccin Vaxzevria
d' AstraZeneca contre la COVID 19 le 21 novembre 2021 et le vaccin
Janssen contre la COVID-19 le 23 novembre 2021 au titre du Reglement sur
Jes aliments et drogues.
Bien que !'utilisation des vaccins Nuvavoxid de Novavax et Covifenz de
Medicago ait ete approuvee au Canada le 17 et le 24 fevrier 2022
respectivement, les vaccins n'ont pas ete distribues durant la periode
couverte par le present rapport.
Pour obtenir plus d'information sur les vaccins autorises:

AR02302
• Vaccin ComirnatY- de Pfizer-BioNTech contre la COVID-19
o information sur les doses de rappel du vaccin ComirnatY- de
Pfizer-BioNTech
o information sur le vaccin ComirnatY- de Pfizer-BioNTech chez les
enfants de 5 a 11 ans
• Vaccin Spikevax de Moderna contre la COVID-19
o information sur les doses de rappel du vaccin Spikevax de
Moderna
• Vaccin Vaxzevria d' AstraZeneca contre la COVID-19
o information sur l'autorisation du vaccin Vaxzevria d'AstraZeneca
• Vaccin de Janssen Uohnson &Johnson) contre la COVID-19
o information sur l'autorisation du vaccin Janssen
• Vaccin Novaxovid de Novavax contre la COVID-19
o information sur l'autorisation du vaccin Nuvaxovid de Novavax
• Vaccin Covifenz de Medicago contre la COVID-19
o information sur l'autorisation du vaccin Covifenz de Medicago
Le taux de rapports d'effets secondaires sans gravite est plus eleves pour
chaque vaccin, et le taux de declaration d'effets graves demeurent
faibles. Actuellement, le taux de declaration d'effets secondaires suivant
la deuxieme dose est moins eleves que celui qui suit la premiere dose.
Les donnees concernant les deuxiemes et troisiemes doses ne tiennent
pas compte du vaccin re<;u pour les doses precedentes. En general, les
rapports d'effets secondaires sans gravite refletent !'information fournie
dans les _pages sur les vaccins.
Remarque: Parmi les 40 011 declarations d'effets secondaires, 64 {O, 16

%) concernaient des personnes qui avaient re<;u un vaccin contre
!'influenza et un vaccin contre la COVID-19 le meme jour.
AR02303
Figure 2: Nombre v de rapports d'effets secondaires au sein
de toute la population v par nom de vaccin et nombre de doses
date du 25 fevrier 2022 (n=40 406)
30000
Vl
.µ
,.._ 25000
0
Cl.
Cl. 20000
ro
,.._
(lJ
"O 15000
(lJ
,.._
.0
E 10000
0
z
5000
Total Dose 1 Dose 2Dose 3

r::::;::i
I ,- I
--.-- ---.-- - 1 I
~ ---.-- ---.-- ---.--
Comirnaty Pfizer-BioNTech Spikevax Moderna Vaxzevria AstraZeneca/COVISHIELD Janssen lnconnu

Norn du vaccin
■ Grave ■ Sans gravite
Le total inclut des rapports dans lesquels on ne precise pas de quelle dose ii s'agit.
Remarque sur les donnees : Les rapports de declaration du groupe d'age des 11 ans qui ont rec;u
une dose d'un vaccin contre la COVID 19 destinee aux personnes de 12 ans et plus avant
!'approbation de la dose pediatrique sont inclus dans les rapports du groupe d'age des 5 11 a
a
ans. Le groupe d'age des 5 11 ans comprend aussi des rapports d'enfants nes en 2017 qui
n'avaient pas encore 5 ans au moment de la vaccination .
► Figure 2 - Texte descriptif
Rapports de declaration d'effets

secondaires suivant l'immunisation par
sexe et groupe d'age
• Le taux de declaration d'effets secondaires etait le plus eleve chez les
40 a 49 ans (66,5 rapports par 100 000 doses administrees), suivi des
50 a 59 ans (57,2 rapports par 100 000 doses administrees)
• Le taux de declaration d'effets secondaires etaient le mains eleve
chez les 5 a 11 ans.
AR02304
• II y a 24 declarations d'effets secondaires chez des enfants de 11 ans
qui ont possiblement re(u la dose du vaccin Comirnaty de Pfizer-
BioNtech contre la COVID-19 recommandee pour les personnes de
12 ans et plus. Ces declarations sont incluses dans le groupe d'age
des s a 11 ans.
• Dans !'ensemble, la plupart des rapports provenaient de femmes
(73,0 %) et le taux de declaration chez les femmes etait de 67,8
rapports par 100 000 doses administrees, compare a 26,5 rapports
par 100 000 doses administrees chez les hommes. Cependant, dans
le groupe d'age des 5 a 11 et des 12 a 17 ans, la proportion et le taux
de declaration etaient similaires chez les hommes et chez les
femmes.
o On ne sait pas avec exactitude si cela est partiellement d0 au
comportement favorisant la sante (p. ex. declarer les effets
secondaires) ou aux differences biologiques entre les femmes et
les hommes.
• Les femmes declarent des effets secondaires dans une proportion et
un taux plus eleves. Cette tendance a egalement ete observee aux
Etats Unis (en anglais seulement), au RoY-aume Uni (en anglais
seulement) et dans d' autres paY-S,
o Sante Canada, l'ASPC et les autorites de sante publique
provinciales et territoriales poursuivront leurs activites de
surveillance, mais ils ne considerent pas qu'il s'agit d'un
probleme de securite.
Figure 3: Nombre v de rapports d'effets secondaires par groupe

d'age v en date du 25 fevrier 2022 (n=40 011)
AR02305
0a4 5.0 .
5a11 •
12 a 11
Vl
Q)
, a.i 18 a 29
C
C
ru 30 a 39
Q)
01 40a 49
<ru
"O
Q) 50 a 59
Cl.
::J
60 a 69
....0
~
10 a 19
80+
lnconnu -
0 1 000 2 000 3 000 4 000 5 000 6 000 7 000 8 000
Nombre de rapports
Remarque sur les donnees : Les rapports de declaration du groupe d'age des 11 ans qui ont
re~u la dose du vaccin Comirnaty de Pfizer-BioNtech contre la COVID-19 recommandee pour les
12 ans et plus avant que la dose pediatrique soit approuvee etaient auparavant inclus dans les
rapports du groupe d'age des 12 a 17 ans. Depuis le 17 decembre 2021, ils sont inclus dans les
rapports du groupe d'age des 5 a 11 ans, peu importe la dose re~ue. Le groupe d'age des 5 a 11
ans comprend aussi des rapports d'enfants nes en 2017 qui n'avaient pas encore 5 ans au
moment de la vaccination .
T Figure 3 - Texte descriptif
Nombre et taux (par 100 000 doses administrees) de rapports

d'effets secondaires par groupe d'age et par sexe en date du 25
fevrier 2022 (n=40 011)
Filtrer les articles I Affiche 1 a 1ode 11 entrees

Afficher 1O I v entrees
Groupe
d'age ltl~I Total lt l~I Homme lt l~I Femme lt l~I Autres lt l~
Inconnu 770 159 317 0
AR02306
Groupe
d'age t ~ Total lt l~ I Homme lt l~ I Femme lt l~ I Autres lt l.,
80+ 1 781 448 1 280 2
10 a79 3 220 870 2 207 4
60 a 69 5 622 1 442 3 939 10
50 a 59 7 371 1 577 5 501 14
40 a49 7 682 1 561 5 829 23
30 a39 6 691 1 583 4 838 13
18 a 29 5 175 1 763 3 190 16
12 a 11 1 365 692 625 7
5 a 11 3 334 149 155 0
Suivant _.
~ 2
1
Les rapports sans indication du sexe ont ete retires en raison du
nombre peu eleve.
2 Par 100 000 doses administrees.
3
Le groupe d'age des 5 a 11 ans comprend aussi des rapports
d'enfants nes en 2017 qui n'avaient pas encore 5 ans au moment de
la vaccination.
AR02307
Effets secondaires signales

• Tousles rapports de declaration d'effets secondaires suivant
!'immunisation re~us par Sante Canada et l'ASPC sont inclus dans le
present rapport qu'un lien avec les vaccins ait ete etabli ou non.
Nous procedons ainsi parce que nous devons examiner toutes les
donnees auxquelles nous avons acces pour detecter tout signal
precoce relatif a la securite.
• Sante Canada, I' ASPC, les provinces et les territoires, et les fabricants
continuent de surveiller etroitement la securite des vaccins contre la
COVID-19. Les effets secondaires graves seront evalues pour
determiner s'ils constituent un nouveau signal relatif a la securite.
• Si un nouveau lien entre un probleme de securite et !'immunisation
est etabli, Sante Canada prendra les mesures qui s'imposent. Par
exemple, nous pourrions mettre a jour !'information sur le produit,
transmettre aux professionnels de la sante ou au public en general
de !'information sur les nouveaux risques ou changer l'usage
recommande du produit.
• Les 40 011 rapports d'effets secondaires representent 40 011
personnes qui ont indique un ou plusieurs effets secondaires. Parmi
les 40 011 rapports, les effets secondaires les plus souvent signales
sont presentes a la figure 4.
• La plupart des effets secondaires ne sont pas graves.
Figure 4: INombre v des effets secondaires les plus souvent

signales par type de vaccin (ITotal v) en date du 25
fevrier 2022 (n= 102 679)
Afftcher moins d'effets secondaires

AR02308
ParesthEls ie (chatouillement ou picotement)
Douleur au point d' injection
Wei de tete
Prurit (d8mangeaisons)
Dyspnee (essoufflement)
Fatigue
Urticaire (eruptions cutanees)
Vl Douleur lhoracique
- (l) Fi8\lfe::: 38°C
Hypo-esth8sie (engourdissement)
ro l::tourdissements
C Nausea
01 l:.ryth8me au pointd 'injection (rougeur)
.vi Enflure au point d' injection
..., a
lnconfort la poitrine
C !:.!')'theme (rougeur)
(l) Douleur
>
::::,
lv'lhralgie (douleur auxarticulations)
Enflure des ganglions l~pthiques
0 Eruption cutanee
Vl \.bmissements
Vl Myocardite/p8ricardite
::::, Frissons
a.. Diarrhee
Palpitations
Chaleur au point d' injection
Vl
(l) Douleurs auxextrElmites
l::ruption cutanee g8n8ralis8e (non allergique)
Vl Myalgie (douleur musculaires)
(l) AsthBnie
I...
Serrement a la gorge
ro Prurit au point d' injection
"O Tachycardia (pouls rapide)
C Dysphagie (difficulte a avatar)
0 Toux
u ~ laise (inconfort)
(l) Visage gonfle
Vl Douleurs abdominales
...,Vl l::ruption cutanee au point d' injection
Sentiment de chaleur
(l)
Gonflement peripherique
tt
UJ
Paralys ie de Bell/Paralysie faciale
Cellul ite au point d' injection
Hyperhidrose (transpiration excess ive)
Hypersensibilit0
Reaction au point d' injection
Maphyiaxie
Langue enflee
Gonflem ent des 18\ofes
Dermatite allergique
- ,_ ,_ 2- 2- 3- 3- ·- ·- 5- 5- 6- 6-
Nombre d'effets secondaires
Veuillez noter qu'un rapport d'effets secondaires represente 1 personne et qu'il peut contenir plus d'un
effet secondaire.
► Figure 4: Texte descriptif
Evenements indesirables presentant un

interet particulier
Les evenements indesirables presentant un interet particulier (EIIP) sont
des evenements medicaux significatifs pre-determines qui ont le
potentiel d'etre causalement associe avec un vaccin. Ceux-ci doivent etre
soigneusement suivis et contr61es par de nouvelles etudes plus
a pp ro fond i e s. Les EII P Ce.v..e. ne. m. ent.s. . .i.nd. e...s.i..r.a...b..l. .e..s.. .P..r..e...s..e..ota..ot.. .un i nt.e...r.e.t.
particulier). peuvent etre consideres comme graves ou sans gravite et
peuvent inclure:
• Des evenements presentant un interet particulier a cause de leur

AR02309
association avec des infections de COVID-19
• Des evenements presentant un interet particulier lies aux vaccins en
general (p. ex., au type specifique du vaccin ou aux adjuvants).
La liste des EIIP (evenements indesirables presentant un interet

particulier). ci-dessous tient compte des listes dressees par les groupes
d'experts, les fabricants et les organismes de reglementation suivants:
• la Brighton Collaboration (en anglais seulement)

• le Vaccine COVID-19 Monitoring Readiness protocol (en anglais
seulement)
La liste des EIIP (evenements indesirables presentant un interet

_p_a_.rt..i. c.u..l. .i. e...r.). change au gre de !'evolution du profil d'innocuite d'un vaccin.
Bien que les evenements indesirables puissent survenir apres
!'administration d'un vaccin contre la COVID-19, ils ne sont pas
necessairement associes au vaccin. Sante Canada et l'ASPC evaluent les
rapports pour determiner si le vaccin pourrait avoir joue un role dans ces
evenements.
En date du 25 fevrier 2022, les EIIP (.evene_ments _ ...i.nd.es_i..ra.bJes_ _pres_entant

un interet particulier) les plus frequemment signales etaient la
myocardite/pericardite et la paralysie de Bell (Tableau 1).
AR02310
I
Tableau 1. Nombre v et taux de rapports (par 100,000 doses
administrees) d'evenements indesirables presentant un
interet particulier signales par nom de vaccin (
lrotal v) en date du 25 fevrier
2022 (n=6 178).
Categorie de .E.l.lP..
( evenements EIIP (evenements
indesirables presentant indesirables P-resentant un Nombre
un interet P-articulier) interet P-articulier). total
Maladies auto-immunes Syndrome de Guillain-Barre 1 122
Thrombocytopenie (faible taux 250

de plaquettes) 1 *
Sous-total 372
Systeme cardiovasculaire Arret cardiaque 41
Insuffisance cardiaque 46
Infarctus du myocarde (crise 104

cardiaque)
Myocardite 1 / pericardite 1 857

(inflammation du muscle
cardiaque et de la muqueuse
autour du cceur)
Sous-total 2 048
Systeme circulatoire Thrombose veineuse cerebra le 20

sanguin (sinus)
Thrombose cerebrale 10
AR02311
.(.eve.n.e.m.en.ts. EIIP (.eve_n_e_me.n.ts
_i_ndesira.bles. pre.senta..n.t in.des.i.ra.bl.es. . .prese.nta..n.t... .u..n. Nombre
_un int.eret.. pa_rti.c.uJie.r) in.te.ret... pa_rtic.uli er) total
Vascularite cutanee 35
Thrombose veineuse profonde 297
Embolie 16
Hemorragie (saignement) 67
Embolie pulmonaire 432
Thrombose (caillot) 296
Syndrome de thrombose avec 108

thrombocytopenie (caillot avec
faible taux de plaquettes)
Sous-total 1 281
Systeme hepato-gastro- Insuffisance renale aigue 57

intestinal et renal
Glomerulonephrite 17
(inflammation des reins) et
syndrome nephrotique
(troubles renaux)
Lesion du foie 38
Sous-total 112
Nerfs et systeme nerveux Paralysie de Bell 1/Paralysie 834

central faciale
AR02312
Accident vasculaire cerebral 212

(AVC)
Myelite transverse 13
(Inflammation de la moelle
epiniere) 2
Sous-total 1 059
Autres systemes Anaphylaxie 2 788
COVID-19 3 357
Syndrome inflammatoire 13
multisystemique 2
Sous-total 1 158
Issues de grossesse 4 Restriction de la croissance 5

fcetale
Avortement spontane 71
Sous-total 76
Systeme respiratoire Syndrome de detresse 5

respiratoire aigue
Sous-total 5
Peau et muqueuses, Engelures 25

AR02313
systeme osseux et
Erytheme multiforme (reaction 42
articulations
cutanee immunitaire)
Sous-total 67
Toutes les categories Total 6178

AESI
1Inclut les effets secondaires qui repondent aux criteres de niveau 1 a4

du niveau de certitude diagnostique de la Brighton Collaboration (en
anglais seulement).
2
Inclut les effets secondaires qui repondent aux criteres de niveau 1 a3
du niveau de certitude diagnostique de la Brighton Collaboration (en
anglais seulement).
3
Les vaccins contre la COVID-19 qui sont actuellement autorises ne
peuvent pas causer d'infections parce qu'ils ne contiennent pas de
virus vivant. Bien qu'ils soient tres efficaces pour prevenir les formes
graves de COVID-19 et les deces, aucun vaccin n'est efficace a 100% et
des cas de COVID-19 surviendront encore. Pour les vaccins suivant un
protocole comportant deux doses, la protection debute 14 jours apres la
premiere dose et de 7 a 14 jours apres la deuxieme dose.
4
Lignes directrices de l'OMS sur les ESSI lies a la grossesse (en anglais
seulement).
*Les nombres et les taux ont ete ajustes en consequence, a la suite d'une
AR02314
revue medicale des donnees.
Veuillez noter qu'un rapport represente une personne, mais qu'il

peut contenir plus d'un evenement indesirable.
Information detaillee sur les signaux

relatifs ala securite, aux autres mises a
jour sur la securite et aux deces
Ces rapports n'impliquent pas de relation causale entre le vaccin et
l'evenement indesirable. Certains evenements medicaux non lies au
vaccin se produisent par hasard apres la vaccination, et ce,
particulierement lorsque des millions de personnes sont vaccinees.
T Syndrome de thrombose avec thrombocytopenie
• Le SY-ndrome de thrombose avec thrombocytopenie (STT)_ (en

anglais seulement) est caracterise par des caillots sanguins
associes a de faible taux de plaquettes. La thrombocY-topenie
thrombotiQue immunitaire induite par le vaccin (TTIV) (en
anglais seulement), aussi connue sous le nom de
thrombocytopenie immunitaire prothrombotique induite par le
vaccin (TIPIV), est caracterisee par une thrombose avec
thrombocytopenie qui est induite par un vaccin et pour laquelle
ii y a une presence confirmee en laboratoire d'anticorps diriges
contre le facteur plaquettaire 4 (PF4).
• Les nombres et les taux ont ete ajustes en consequence, a la
suite d'une revue medicale des donnees.
• En date du 25 fevrier 2022, ii y avait 108 cas de syndrome de
thrombose avec thrombocytopenie qui repondaient aux
AR02315
criteres de niveau 1 a 4 du niveau de certitude diagnostique
de la Brighton Collaboration (en anglais seulement). De tous
les cas de thromboses avec thrombocytopenie :
o 69 cas ont ete signales apres !'administration du vaccin
Vaxzevria d' AstraZeneca/COVISHIELD, 27 apres
!'administration du vaccin Comirnaty de Pfizer-BioNTech, et
12 apres !'administration du vaccin Spikevax de Moderna
• Parmi les 69 cas de STT apres !'administration du vaccin
Vaxzevria d'AstraZeneca/COVISHIELD
o les sympt6mes se sont manifestes entre 1 et 48 jours apres
la vaccination
o l'age median est de 57 ans (variant de 34 et 88 ans)
o 38 cas ont ete deceles chez des hommes [age median 58
a 78 ans)], 30 cas ont ete deceles chez
ans (variant de 34
des femmes [age median 55 ans (agees de 40 a 88 ans)] et
l'age et le sexe d'un cas n'a pas ete precise
o 62 cas ont ete declares apres la premiere dose de vaccin, et
dans 7 cas, ii n'a pas ete precise de quelle dose ii s'agissait
o 38 rapports de cas etaient accompagnes de resultats
demontrant la presence d'anticorps diriges contre le
facteur plaquettaire 4 (PF4), ce qui indique une TTIV (aussi
connue sous le nom TIPIV} (en anglais seulement)
o 6 personnes sont decedees (ces deces font encore l'objet
d'une enquete)
T Syndrome de Guillain-Barre
• En date du 25 fevrier 2022, un total de 122 rapports de SGB qui

repondaient aux criteres de niveau 1 a 4 du niveau de certitude
AR02316
diagnostique de la Brighton Collaboration (en anglais
seulement) a ete denombre. Parmi les cas de SGB :
o 39 cas ont ete signales apres !'administration du vaccin
Vaxzevria d' AstraZeneca/COVISHIELD, 55 cas apres
!'administration du vaccin Comirnaty de Pfizer-BioNTech, 27
cas apres I' administration du vaccin Spikevax de Moderna
et le nom du vaccin de 1 immunisation n'etait pas precise
o les analyses actuelles montrent que le taux de declaration
de SGB suite a !'administration du vaccin Vaxzevria
d' AstraZeneca/COVISHIELD est plus eleve que celui observe
apres !'administration du vaccin Comirnaty de Pfizer-
BioNTech et du vaccin Spikevax de Moderna.
o le nombre de cas de SGB apres !'administration d'un vaccin
Vaxzevria d' AstraZeneca/COVISHIELD est plus eleve que ce
a quoi on s'attend normalement dans la population en
general
• Parmi les 39 cas de SGB apres !'administration du vaccin
Vaxzevria d' AstraZeneca/COVISHIELD :
o Les sympt6mes sont apparus entre 6 heures et 25 jours
apres la vaccination
o L' age median est de 56 ans (variant de 40 a 77 ans)
o 28 cas ont ete signales chez des hommes [ages median de
56 ans (ages de 40a 66 ans)], 9 chez des femmes [age
median de 53 ans (ages de 40 a 77 ans)], et le sexe et l'age
de 2 cas n' a pas ete precise
o 30 cas ont ete signales apres la premiere dose, et dans 9
cas, ii n'etait pas precise de quelle dose ii s'agissait
AR02317
T Myocardites/pericardites
• La mY-ocardite (en anglais seulement) est une inflammation du

muscle du coeur tandis que la pericardite est une inflammation
de l'enveloppe du cceur.
• En date du 25 fevrier 2022, 1 857 cas de
myocardite/pericardite repondaient aux criteres de niveau 1 a
4 du niveau de certitude diagnostique de la Brighton
Collaboration (en anglais seulement).
• Parmi les cas de myocardite/pericardite:
o 1 178 cas avaient ete signales apres !'administration du
vaccin Comirnaty de Pfizer-BioNTech, 641 apres
!'administration du vaccin Spikevax de Moderna, 32 apres
!'administration du vaccin Vaxzevria
d'AstraZeneca/COVISHIELD, 1 apres le vaccine du Janssen et
le nom du vaccin de 5 immunisations n'etait pas precise
• Le taux de declaration de myocardite/pericardite apres la
vaccination avec le vaccin Spikevax de Moderna contre la
COVID-19 est plus eleve que le taux apres la vaccination avec le
vaccin Comirnaty de Pfizer-BioNTech, tous ages et tous sexes
confondus.
• Parmi les 1 178 cas de myocardite/pericardite qui avaient rec;u le
vaccin Comirnaty de Pfizer-BioNTech (administre aux personnes
de 5 ans et plus) :
o Les sympt6mes sont apparus entre 1 minute et 212 jours
apres le vaccin
o L'age median est de 30 ans (variant de 6 a 93 ans)
o 692 cas ont ete deceles chez des hommes [age median 24
ans (variant de 8 a 84 ans)], 438 chez des femmes [age
AR02318
median 40 ans (variant de 6 a 93 ans)], le sexe de 2
personnes etait « autre », et le sexe de 46 personnes n'a pas
ete precise
o 526 cas ont ete signales apres la premiere dose de vaccin,
573 cas apres la deuxieme dose de vaccin, 27 apres la
troisieme dose, et pour 52 cas la dose n'etait pas precisee
o Les analyses actuelles montrent que le nombre de cas de
myocardite/pericardite suivant !'administration du vaccin
Comirnaty de Pfizer-BioNTech est plus eleve que ce a quoi
on pourrait normalement s'attendre chez les hommes et
femmes ages de moins de 30 ans dans la population
generale, et ce, particulierement apres la deuxieme dose
• Parmi les 641 cas de myocardite/pericardite qui avaient re~u le
vaccin Spikevax de Moderna (administre aux personnes de 12
ans et plus) :
o Les sympt6mes sont apparus entre 5 minutes et 82 jours
apres le vaccin
o L' age median etait de 30 ans (variant de 13 a 95 ans)
o 442 cas de myocardite/pericardite ont ete deceles chez des
hommes [age median 27 ans (variant de 13a 95 ans)], 178
chez des femmes [age median 35 ans (agees de 18 a 88
ans)], le sexe de 2 personnes etait « autre » et le sexe de 19
personnes n'etait pas precise
o 168 cas etaient apres la premiere dose de vaccin, 423 cas
apres la deuxieme dose de vaccin, 28 cas apres la troisieme
dose de vaccin, et dans 22 cas la dose n'etait pas precisee
o Les analyses actuelles montrent que le nombre de cas de
myocardite/pericardite apres la vaccination avec le vaccin
Spikevax de Moderna est plus eleve que ce a quoi on
AR02319
pourrait normalement s'attendre dans la population en
general, particulierement chez les hommes et femmes ages
de moins de 40 ans et apres la deuxieme dose
• Les preuves evoluent et les recherches relatives a une
eventuelle association entre la myocardite/pericardite et les
vaccins a ARN messager se poursuivent.
T Syndrome de fuite capillaire
• En date du 25 fevrier 2022, 2 cas de syndrome de fuite

capillaire ont fait l'objet d'un examen medical afin d'en verifier
le diagnostic. L'affection s'est declaree apres !'administration de
la premiere dose du vaccin Vaxzevria
d' AstraZeneca/COVISHIELD.
T Deces
• En date du 25 fevrier 2022, un total de 304 cas indiquaient un

deces survenu apres !'administration d'un vaccin. Bien que ces
deces puissent survenir suite a la vaccination avec un vaccin
contre la COVID-19, ils ne sont pas necessairement causalement
lies au vaccin. Apres une revue medicale des cas a l'aide des
categories d'evaluation de la causalite du centre collaborateur
de l'OMS pour la pharmacovigilance internationale a Up_psala
(en anglais seulement), ii a ete determine que:
o 160 deces ne pouvaient pas etre classifies a cause du
manque d'information disponible
o 98 deces n'etaient pas lies a la vaccination contre la
COVID-19
AR02320
o 46 des deces signales font encore l'objet d'une sous
enquete
Remarques sur les donnees

Les donnees presentees dans le present rapport sont des estimations. II
se peut qu'elles ne representent pas fidelement les effets secondaires
lies aux vaccins contre la COVID-19 a l'echelle nationale pour les raisons
suivantes:
1. II peut y avoir des retards dans la reception et le traitement des

formula ires de declaration, ce qui peut contribuer aux variations
dans le nombre de cas presentes chaque semaine. Ces retards
peuvent etre attribuables au fait que les administrations enquetent
et examinent chaque effet secondaire avant de soumettre
!'information a l'ASPC. Les pratiques de declaration ont egalement
leurs limites, notamment le nombre insuffisant de declarations,
!'information manquante et les differences dans les methodes de
declaration d'effets secondaires suite a !'administrations des vaccins
au Canada.
2. Chaque semaine, les donnees historiques (nombre hebdomadaire et
cumulatif de declarations) sont mises ajour au besoin pour tenir
compte des retards dans la reception et le traitement des
formulaires de declaration.
3. L'information recueillie prend en consideration uniquement les
effets secondaires des personnes qui ont soumis un rapport, et non
pas toutes les personnes qui ont subi un effet secondaire puisque
toutes les personnes n'ont pas signale des effets secondaires.
4. II se peut que les nouveaux renseignements dans le present rapport
AR02321
ne soient pas exhaustifs, mais representent plut6t les resultats
preliminaires des donnees re<;ues chaque semaine.
5. Certaines administrations qui produisent des rapports utilisent le
terme « genre » au lieu de « sexe ».
6. L'information sur les doses de vaccin contre la COVID-19
administrees proviennent de nos partenaires des provinces et
territoires, ou de leurs sites Web. Plus de details sur les doses de
vaccin contre la COVID-19 administrees,_ consultez la page sur la
couverture vaccinale.
7. Les donnees du present rapport refletent les rapports combines du
SCSESSI et du Programme Canada Vigilance. Le Programme Canada
Vigilance re<;oit les rapports de declaration d'effets secondaires
directement de fabricants de vaccins, de professionnels de la sante
et de consommateurs. Le SCSESSI re<;coit des rapports de
declaration d'effets secondaires des autorites de sante publique
regionales. Bien que les donnees de ces 2 programmes de
surveillance soient soigneusement amalgamees, ces programmes
sont assujettis a des exigences de production de rapports et a des
definitions differentes. II se peut egalement que les rapports
hebdomadaires contiennent des rapports en double.
8. Les effets secondaires d'interet special sont evalues selon les criteres
de la Brighton Collaboration (en anglais seulement).
9. Veuillez noter que les chiffres des ESSI et EIIP indiques a la figure 4 et
au tableau 1 pourraient etre rajustes a la suite d'une revision
medicale des cas.
1O. Pour les effets secondaires dont le nombre est peu eleve (moins de
1O) ou lorsque les donnees sur les doses administrees sont
incompletes, les taux ne seront pas fournis.
AR02322
Remerciements
La realisation du rapport hebdomadaire ne serait pas possible sans la
collaboration de nos partenaires des autorites de sante publique
federale, provinciales et territoriales, de meme que de toutes les
personnes qui prennent part a la vaccination au Canada.
Nous tenons aussia remercier toutes les personnes qui ont pris le temps
d'envoyer un rapport d'effet secondaire d'avoir contribue a la securite
des vaccins au Canada.
Citation suggeree
Agence de la sante publique du Canada. Rapport sur la securite de la
vaccination contre la COVID-19 au Canada. Ottawa: Agence de la sante
publique du Canada; 4 mars 2022. https:LLsante-infobase.canada.ca
Lcovid-19Lsecurite-vaccinsL
Liens connexes
• SY-steme canadien de surveillance des effets secondaires suivant
!'immunisation (SCSESSI)_
• Programme canadien de surveillance active de !'immunisation
_{IMPACT)_
• Reseau national canadien d'evaluation de la securite des vaccins
_{CANVAS)_
• Programme Canada Vigilance
• Recherche de produits pharmaceutiques en ligne
• Liste de vaccins autorises contre la COVID-19
• Portail des vaccins et traitements pour la COVID-19
AR02323
• Vaccination contre la COVID-19 au Canada
Avez-vous trouve ce que vous cherchiez?
Qu'est-ce qui n'allait pas?
0 La reponse dontj'ai besoin n'est pas la

0 L'information n'est pas claire
0 Je ne suis pas au bon endroit
0 Quelque chose est brise ou incorrect
0 Autre raison
Veuillez fournir plus de details
(N'incluez pas d'information personnelle. Notez que vous ne recevrez aucune reponse.)
Maximum de 300 caracteres
Soumettre ]
G Partagez cette page
Date de modification:
2022-03-04
AR02324
Annexe D [sur clé USB ci-jointe]

2022

a
Montreal QC H2Y 3TB
10
AR02325
.wr II l{ UNlV,Mll' 'J'A111 , OJri
Nm: :I I.I MJ\Xll1Jll
-
I
DIN: O
C'OV 11> - 1 I 11 TJ\l\N
An l se: Coronavi u [~J\H. - CoV-2 , COVID - 1 It ompl1

TAAN
~S-CoV-2 (TAAN Rl\C)
Commentaire (PRJ\C)
ln:o technique (PRAC)
An a lyse au C
h
5N'1
In f ormations de l ' or onn nee
Vo yage Hors Queb c Non
Co n nu positif < 3 moi · Non
Pr e sence de symp Orn ? Oui
AV EC sympt6mes M7 Popul ion / Commun u
Pr i orite M7
No TRU
Verifie le: 2021 - 09-29 10 : 27 Par: Cybele Bergeron , MD
2021 - 10 - 14 1249 Imprime par Page 1 de 1

AR02326
H N 'VFll ~ r n rU-0 A A ,I ,.
N 111:
: U N/\M:
N 'l!U
'ff
!) t /hr 111 11
An Ut llC, Hj V Jl I ,till • Al .i - V-
l\VEC symp I Commun, u

Connu po i , • 3 mois
Mo e d ' avis nvoi

No TRU
Pre·ence d ym 6mes? Oui
M7
0?]-0 -2.7 14?.
imen m
cination Aucun
Analyso : Criblage/Sequen~age n .
SARS-CoV-2
Mu ion P681R D
Comm n ire interpretation : r -s n
n -CoV-2 pr occu an
e e C • L S V r i an S po !-l
ion P681R inclu n .1.
e ses ou -lj n (don
D 1 ·a- ous-lignees) . M l
a declara ion obligatoire , un
declaration doi etre faiLe
direc ion de sante publique d
region socio sanitaire du ciLoyen .
I n fo technique RT - PCR effec uee avec une epr uv
non commerciale developpee et
validee localement s u r l ' appareil
Roche Cobas 6800 .
An aly s e au Centre hospitalier universitaire de Sherbrooke
3001 12e Avenue Nord
Sherbrooke , QC JlH 5N4
2 0 21-1 0 - 14 125 0 Irnpri rne par Page 1 de 1

AR02327
c,,,u,, ln rtf?~r~
1111/ Vl'f: ,r. fn d Sil nfO
e t d ,m'tlfc f soc/:1ux
d o /u M ,wri d11·C I ·
du • llfr, d J•Qu db c H 1,'.J
Quebec ~IIH
PAR COURRI
29 seplembr 1
Objet : Demando d'isolement d'un cas posltif a la COVID-19
MAXIM E BERNI R
Par la presenle, I Direction de la sanle publique et respons bilile populationn elle d

Mauricie-et-du-Cenlr -du-Quebec vou s demande d'ellr a
n isolement la maison pour I
periode du 2021 -09-22 u 2021 -10-02 inclusivement, puisqu e vou s avez ete tesle positif
la COVID-19.
a
Vous trouverez sur le site du MSSS , les consignes suivre pour la personne en
a
isolement la maison afin d'eviter de transmellre la Covid-19 aux autres personnes. Voici
le lien web.
Merci pour votre collaboration.
Tremblay, Marie-Genevieve
Direction de sante publique et responsabilite populationnelle

CIUSSS MCQ
p.j.
Centre administratif Bonaventure

550, rue Bonaventure.
Trois-Rivieres (Quebec) G9A 285
www.ciusssmcq.ca
AR02328
Annexe E [sur clé USB ci-jointe]

2022

a
Montreal QC H2Y 3TB
11
AR02329
Direct link to Annexe_E_l_JTrudeau_JSnyder video:
https://jccf.sha repo int.com/:v:/s/Lega ITeam/EWlvjs53 lzJ Pt cl 6JXJssB31L Wq9n n n rlsGORkygd lqA ?e=Ed
Tncy
Direct link to Annexe - E- 2- JTrudeau - Usine video:
https ://jccf.sharepoint .com/:v:/s/LegalTeam/EaAzLWm lKUVGqgxqnz6tO-

0BwJ jC9q WMYCJGtcgCTDcUw?e=J lDzlA
Direct link to Annexe - E- 3- JTrudeau - Chalet video:
https://jccf.sharepoint.com/:v:/s/LegalTeam/EZozx4SimhZNmmfJJHK9DQ0BCv cjCO Z0cyfS9kBqNG4w?

e=XfUn98
Direct link to Annexe - E- 4- JTrudeau - Presse video:
https://jccf.sharepoint.com/:v:/s/LegalTeam/ERhVTrJdlDFEtllja6UKU8UBXua5Ymv8BopqrZbUiREFIA?e=
SuSZMJ
AR02330
Annexe F [sur clé USB ci-jointe]

2022

a
Montreal QC H2Y 3TB
12
AR02331
THE CO NVERSATION
ft.cad em ic rigour, journalistic flair
JAMES ROSS/AAP
'It's almost like grooming': how anti-vaxxers, conspiracy

theorists, and the far-right came together over COVID
Published: September 21, 2021 2.48am EDT
Josh Roose
Senior Research Fellow, Deakin University
Scenes of protesters clad in hi-vis jackets and shouting anti-vaccination slogans have dominated the
news this week. As the ABC reported:
Some of those gathered held a banner reading 'freedom', while others sang the national
anthem and chanted '.F** the jab'.
Some attacked union offices, drawing criticism from officials such as ACTU chief Sally McManus, who
described the protests as being orchestrated "by violent right-wing extremists and anti-vaccination
activists."
These images may shock some but for researchers like me - who research far-right nationalist and
conspiracy movements, and explore the online spaces where these people organise - these scenes
came as no real surprise.
AR02332
Far right nationalists, anti-vaxxers, libertarians and conspiracy theorists have come together over
COVID, and capitalised on the anger and uncertainty simmering in some sections of the community.
They appear to have found fertile ground particularly among men who feel alienated, fearful about
their employment and who spend a lot of time at home scrolling social media and encrypted
messaging apps.
The latest in a continuum
It's important to see what's occurring with these protests as part of a continuum rather than a series
of unrelated incidents. This week's protests are related to anti-lockdown protests held in 2020, and
earlier this year.
It was at first limited to the conspiracy theorist and anti-vaxxer crowd. Some were just upset by
lockdowns but most of the planning conversation online was being led by anti-vaxxers and QAnon
activists.
These movements thrive on anxiety, anger, a sense of alienation, a distrust in government and
institutions. It's really no coincidence this is occurring most vigorously in Melbourne given what this
city has been through with lockdowns.
It has really built momentum over the last year and, more recently, been infiltrated by far right
groups.
Read more: Far-right groups have used COVID to expand their footprint in Australia.
Here are the ones you need to know about
The far right are capable recruiters
If you go back two years ago, anti-vaxxers were a tiny minority. They have grown significantly in size
and influence online.
I have observed in my research the far right consciously appropriating the language of anti-vaxxers, of
the conspiracy movements, seeking to exploit their anger and distrust.
I spend a lot of time on the encrypted messaging groups used by these groups and in the online spaces
where they organise. I have seen the same names popping up, and growing use of hard right or far
right national socialist iconography.
It is almost like grooming. The far right are a lot more capable of recruitment than we give them credit
for. They have found an audience who are angry, frustrated and looking for someone to blame.
AR02333
This is particularly the case among young men who are increasingly attracted to right wing
nationalism and make up the majority of protesters. Victoria Police Commissioner Shane Patton has
said the majority of protesters at the Saturday protest were men aged 25-40, who came with violent
intent.
Many of these groups share similar ideas: that there is a cabal of politicians and elites who are
oppressing you. That freedom is at risk, that one must stand up for liberty, that there is a wealthy and
unelected ruling class controlling you.
COVID - with all the fear, uncertainty, lockdowns, policing and employment impacts it brings - has
helped bring these groups together.
Victoria police earlier this year warned a parliamentary inquiry into extremism that:
online commentary on COVID-19 has provided a recruiting tool for right-wing extremist
groups, linking those interested in alternative wellness, anti-vaccination and anti-authority
conspiracy theories with white supremacist ideologies.
The far right has really sought to mobilise frustrated people and push them more toward right-wing
narratives, particularly white nationalist narratives.
There is a strong historical animosity toward trade unions (as the vanguard of the political left) by the
far right. It would be disingenuous to view the far right as unintelligent thugs. They are learned in the
history of national socialism and fascism and the preconditions for its rise.
So you see the far right working very hard to undermine trade unions and the way they represent the
organised working class. There is an attempt to undermine trust in trade unions and paint them as
traitors and sell-outs who are in bed with the government.
Among the protesters there was a really self conscious effort to represent themselves as themselves as
tradies and workers. Some observed protest organisers encouraging people to wear hi-vis clothing to
these rallies.
It's important to note the construction industry and trade union movement in general are incredibly
diverse, and there will be different and competing views around vaccines, masks and lockdowns.
Some of these protesters actually are tradies, some may not be. Some are union members, others are
not. But the broader point is there is a group of people who are incredibly angry about the situation
they find themselves in, and resentment is proving fertile terrain for organised groups.
Where to from here?
This is not an easy knot to unpick, but there are three main approaches I think would really help.
AR02334
The first is we really need to get people back to work. That is critical. People's self esteem and
livelihood is tied up in work and the ability to put food on the table, in staying busy and socially
connected (which is often via work).
By ensuring safe, secure employment for people, you really take away one of the main drivers of
anger, resentment (and too much time to scroll around social media) that is helping push people
toward extremism.
The second is politicians need to think hard and fast about what they can do to help rebuild trust in
them, in government and in our institutions. Politicians can't hide behind press conferences and press
releases to get their message out. They need to get out and build trust, face-to-face with the
community. Of course, that has been constrained by lockdown but this work is urgent and important.
Politicians need to lead and create relationships with the community again.
The third thing is we as a society need to think carefully about social media, and perhaps about
regulation. We need a long-term approach to media literacy training, to teach media literacy in
schools and to educate people about social media echo chambers.
Read more: To shut downfar-right extremism in Australia, we must confront the

ecosystem of hate
AR02335
TORONTO STAR
r ill Newsletters
1
Today's I
1111
Signln
Sports
paper ~ Betting
This copy is for your personal n on-commercial use only. To order presentation-ready copies of Toronto Star content for distr ibution to colleagues, clients or customers, or inquire about
permissions/licensing, please go to: www.TorontoStarReprints.com
] ~
CANADA
Anti-vaccine campaign 'very concerning,' says Ontario's

health minister
Christine Elliott expressed fundamental disagreement with the billboard ads paid for by
Vaccination Choice Canada, an advocacy group that describes its mandate as ensuring people are
fully informed and educated about immunizations for themselves and their children.
By Michelle McQuigge The Canadian Press

A Wed., Feb. 27, 2019 0 4 min. read
0 Article was updated Feb. 28, 2019
JOIN THE CONVERSATION
An ad campaign from a group of open vaccine skeptics that briefly dotted some streets in the Toronto area represents a "very
concerning" development in the ongoing fight against misinformation, Ontario's health minister said Wednesday.
Christine Elliott expressed fundamental disagreement with the billboard ads paid for by Vaccination Choice Canada, an
advocacy group that describes its mandate as ensuring people are fully informed and educated about immunizations for
themselves and their children.
The campaign, which rolled out across more than 50 digital billboards around the city last week but appeared to have been taken
down ahead of schedule on Wednesday, featured a rotation of four slogans and direct questions that a group spokesman said
aimed to ensure that Canadians are "truly informed" when they consent to getting vaccinated.
The group's vice-president, Ted Kuntz, said the company responsible for disseminating the campaign faced pressure from an
"unknown" source to remove the ads, saying the move suggests Ontario's public policy does not support public education.
Elliott disagreed, lamenting the amount of public misinformation on medical subjects, redoubling calls for Ontario residents to
get their vaccines and suggesting failure to do so has already had consequences.
Read More:
What you need to know about measles in the wake of the latest outbreak in B.C.
Vaccination registry for B.C. schoolchildren coming 'as soon as possible,' says ministry
Measles unlikely to spread, but Vancouver doctor recommends vaccinations for all
"A certain number of people need to be vaccinated in order for it to be effective," Elliott said after directly criticizing the
Toronto-targeted campaign. "It's not necessarily happening now, and we're seeing things come forward like tuberculosis
AR02336
outbreaks in certain parts of Ontario, measles outbreaks and so on. So we are going to continue, through the Ministry of Health,
to encourage people to have their children vaccinated and to receive regular inoculations themselves."
Elliott did not offer details on which parts of the province she was referring to.
The billboards at the heart of the campaign are meant to encourage parents to do research before proceeding with
immunizations, Kuntz said, adding the group commonly described as "anti-vaxxers" are in fact former vaccine supporters who
have grown "risk-aware" through their own research and experience.
The messages in circulation as part of the campaign were meant to raise questions and spur discussion and deeper research, said
Kuntz, who describes himself as the parent of a now-deceased child injured by a vaccine in infancy.
Half the campaign's messages posed the questions "What are the risks?" and "How many is too many?" The other two came in
the form of statements - "Educate before you vaccinate" and "No shots, no school? Not true."
Dr. Vinita Dubey, associate medical officer of health at Toronto Public Health, described the messages at the core of the
campaign as "half-truths."
Dubey agreed that over-vaccinating children is dangerous, for instance, but said current immunization protocols are safe,
evidence-tested and effective in protecting both individuals and broader populations.
She said the same held true for the message challenging vaccination policies in schools. Ontario parents are required to provide
vaccination certificates for their children, she said, but noted they also have the option to obtain an exemption for their kids
based on medical, religious or philosophical grounds.
"They misrepresent information on vaccines," Dubey said of the billboards. "This is a common tactic that the anti-vaccine
movement uses to try and change people's opinion on vaccines, and that is our biggest concern."
Kuntz dismissed Dubey's characterization, calling common critiques of the group's messaging "dishonest."
"A parent can't decide what is best for oneself and one's children without adequate information about the benefits and risks.
Good products, backed by solid evidence of safety and effectiveness, are not afraid of educated and informed parents," he said.
The Public Health Agency of Canada said in a statement that Canadian parents "rightly have questions about vaccines," but that
the science on the topic is unequivocal.
"Vaccines can prevent infectious diseases that once killed or harmed many infants, children and adults," spokeswoman Anna
Maddison said.
"However, there is a small but vocal antivaccination community that spreads false information. They use powerful emotional
images and misinformation with their message. This creates confusion and fear for parents who are trying to make the best
decisions for the health and well-being of their children."
Timothy Caulfield, a Canada Research Chair in health law and policy at the University of Alberta, said the number of people who
are staunchly opposed to vaccines form a very small minority. Their messaging, however, finds an increasingly receptive ear
among the 20 to 30 per cent of Canadians who express "vaccine hesitancy," he said.
Caulfield said science has unequivocally settled the debate, describing a "mountain of evidence" on the provaccination side
compared to a "small mound" fuelling the skeptics' arguments.
But he said antivaccination messaging is reaching a wider audience, thanks to both social media and broader political forces that
have roiled countries around the world.
"The profile of the 'antivax' movement, I think, is connected to this rise in populism and this growing distrust of experts ... and
our institutions," Caulfield said. "That gives space to these kinds of views and allows them to flourish."
More from The Star & Partners

AR02337
Copyright owned or licensed by Toronto Star Newspapers Limited. All rights reserved. Republication or distribution of this content is expressly prohibited without the prior written consent of
Toronto Star Newspapers Limited and/ or its licensors. To order copies of Toronto Star articles, please go to: www.TorontoStarReprints.com
AR02338
AR02339
•
Canada, Trudeau says of campaign protests
HOLLY MCKENZIE-SUTTER
WELLAND, ONT .
THE CANADIAN PRESS
PUBLISHED SEPTEMBER 6, 2021
This article was published more than 6 months ago. Some information may no longer be current.
Liberal Leader Justin Trudeau and Chrystia Freeland tour the factory at Valbruna ASW Inc. during
Trudeau's election campaign tour in Welland, Ont., on Sept. 6.
CARLOS OSORIO/REUTERS
Justin Trudeau said his pandemic recovery policies won't be shaped by the demands of
what he called "anti-vaxxer mobs" that have dogged his campaign events in recent
weeks, including some who threw debris at the Liberal leader on Monday.
AR02340
• HC JJlCU);CU LU CXLCllU JJdllUCllllL SUJJJJUllS lUl wurn.C1' dHU UUSlllC"CS 11 lllS
government is re-elected on Sept. 20.
A noisy crowd of a few dozen people gathered outside the gate to the facility as Trudeau
spoke inside, expressing anger over COVID-19 vaccines and pandemic measures. A
similar group attended a whistle stop event in Newmarket, Ont., the night before,
shouting slurs at Liberal volunteers, supporters and the leader himself as he shook hands
and greeted people.
Trudeau said Monday that he "can't back down" when faced with the aggressive group as
he campaigns for a shot to keep leading the country through the worsening fourth wave
of the COVID-19 pandemic.
"Yes, there is a small fringe element in this country that is angry, that doesn't believe in
science, that is lashing out with racist, misogynistic attacks," Trudeau said.
"But Canadians, the vast majority of Canadians, are not represented by them, and I know
will not allow those voices, those special interest groups, those protesters - I don't even
want to call them protesters, those anti-vaxxer mobs - to dictate how this country gets
through this pandemic."
Federal election 2021: What are the challenges facing the major political
parties before Canada votes on Sept. 20?
Canadian federal election 2021: Latest updates and essential reading ahead of
Sept. 20 vote
Federal election poll tracker: Follow the latest Nanos-Globe-CTV numbers

ahead of the Sept. 20 vote
He said the country needs leadership to recover from the pandemic, and painted his main
rival in the election as ill-suited to do so because of his less stringent stance on
mandatory vaccination for workers. He linked Tory Leader Erin O'Toole's positions to the
"fringe" anti-vaccine crowd.
"They don't get to dictate policy of this government, so it is puzzling to people to see that
on vaccines and on so many other things, Erin O'Toole is at least taking some of his cues
AR02341
. ole has said he supports CUVJU-l!cl vaccmation as sate anct ettective anct p!ectgect to
try and get the national immunization rate above 90 per cent, but aims to offer rapid
testing as an alternative to people who don't get vaccinated.
On Monday, he declined again to say how many of his party's candidates are vaccinated
against COVID-19 and accused Trudeau of dividing the country over vaccination choices
when many are still hesitant about them.
"I really think this isn't a time to create an us-versus-them approach," O'Toole said. "Mr.
Trudeau tried to do that right out of the gate."
People angry at Trudeau congregated in progressively larger numbers at all of the

leader's campaign stops in southern Ontario on Monday.
After late afternoon event in London, Ont., some people in the noisy throng threw dime-
sized rocks at Trudeau as he walked out of the microbrewery to his campaign bus.
Trudeau later downplayed the incident, though he acknowledged to reporters that some
of the projectiles might have struck him on the shoulder.
A large number of people in the crowd in London were dressed in People's Party of
Canada gear. One woman was handing out merchandise for the party and Chelsea Hillier,
a local candidate, was on site with her supporters.
She said the crowd has been building "networks" over the last 18 months that have
enabled like-minded people to mobilize at Trudeau's events.
"There is literally nowhere that he can go that we won't know about it," Hillier said.
One policy pledge Trudeau's campaign highlighted on Monday was a promise to legally
protect businesses and organizations asking for proof of COVID-19 vaccination from staff
and customers.
Trudeau said the federal Justice Department is looking at a "number of ways" to support
legislation to ensure legal protections for businesses that "do the right thing" with
mandatory vaccination policies. The Liberals have also promised $1 billion for provinces
AR02342
Physician groups and other stakeholders have called for a more unified national policy
on the vaccine certificates, however, as some provinces resist introducing them.
Trudeau said the federal government cannot unilaterally impose such a system, but said
re-elected Liberals would "work together" with the provinces using the funding offer to
help them get one running.
The Liberal leader has faced criticism for plunging the country into an election with the
pandemic still ongoing and a fourth wave of infections ramping up.
Trudeau addressed that on Monday, saying the "stark choices" over approaches to
pandemic recovery highlight the necessity of the vote.
"For people who still wonder whether or not we really needed an election right now, just
take a look at the issues and the intensity of debate over so many big issues that really
matter to Canadians," he said.
Follow the party leaders and where they stand on the issues this election campaign by
signing up for our Morning or Evening Update newsletters.
For subscribers only: Get exclusive political news and analysis by signing up for the
Politics Briefing.
AR02343
TORONTO STAR
r ill Newsletters
1
Today's I
Signln
1111
Sports
paper ~ Betting
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about
] ~
TORSTAR INVESTIGATION
COVID-19 conspiracy theories are spreading online like

a virus. An inside look at a dangerous misinformation
movement that's spilling into the real world
Like the virus, the hashtag #nomorelockdowns has spread across borders, taking root in India, the
U.S., the U.K. and Canada, where its use has intensified.
By Grant Lafleche Standard Reporter

Edward Tian Special to the Star
Thu., July 22, 2021 0 18 min . read
@ Article was updated Sep. 17, 2021
Don Garfat was frustrated by the impact the pandemic was having on his community.
The forced closing of businesses and tight restrictions on church services seemed particularly unfair.
It was the spring of 2020, and the storm of pandemic news and information was bewildering. Garfat didn't know how to express
his frustration.
In Renfrew County, an hour west of Ottawa, he cuts trees in summer and shovels snow in winter, he said. He homeschools his
son and daughter. He leans on his faith in Jesus. He was not politically active, not a protester.
Then he found No More Lockdowns on Facebook.

AR02344
Ahead of a looming federal election Monday, the once-fringe People's Party of

Canada is riding a wave of anti-vaccine mandate and anti-lockdown sentiment
exacerbated by increased distrust in sitting politicians and growing interest in
conspiracy theories.
Garfat became one of tens of thousands of Canadians who have visited flourishing anti-lockdown, anti-vaccine online
communities inhabited by people from all walks oflife.
These digital spaces, using hash tags like #nomorelockdowns as a signal flare to attract new followers, have grown rapidly by
providing common ground for believers in a kaleidoscope of conspiracy theories and pushing claims that the pandemic is an
elaborate hoax to undermine liberty and that vaccines threaten human health.
AR02345
AR02346
Under this big tent, anti-vaccine, anti-lockdown and anti-mask groups have become all but indistinguishable. Some, like No
More Lockdowns, now claim to be in a "cultural battle for the future of our country."
A Torstar investigation of this digital universe has tracked its spread from social media to real-world protests in defiance of
public health orders. Some social media groups have memberships in the tens of thousands. Some participants organize protests
at vaccine clinics. One anti-lockdown Facebook group urged members to sneak inside hospitals to make videos they hoped
would prove the health-care system was not overwhelmed by COVID-19.
Public health officials worry the movement threatens efforts to end the pandemic. If the anti-vaccine movement can convince
even a small percentage of Canadians to forgo immunization, COVID-19 will continue to spread. That cluster of unsure
Canadians - sometimes called the vaccine-hesitant - are caught in a tug of war between public health authorities and anti-
vaxxers.
It was in this sprawling community that Garfat discovered answers and fellowship .
"It's nice to know you're not alone, that you' re not the only one that is against lockdowns," he said.
Inspired, Garfat found a large weathered wooden billboard along a quiet stretch of the Trans-Canada Highway between the
Noah's Ark-themed Logos Land motel and Haley Station. On it he displayed a silhouette of a man in jail above white block letters
that say "No More Lockdowns." Under it, in black, is the phrase once made famous by Nancy Reagan: "Just Say No."
It was just one of the more than 55,000 signs the No More Lockdowns organization claims to have sold to date.
"I did what I felt my conscience said was right, what it was telling me to do. I'm not an orator. But I could do this. I could put it
up," said Garfat.
His devotion to the cause was praised on the official No More Lockdowns Twitter account, which called Garfat a "freedom
lover," and signified the comment with the hash tag #nomorelockdowns.
Garfat had gone looking for answers. What he found was a movement.
AR02347
Like the novel coronavirus itself, the hash tag #nomorelockdowns has spread across borders and oceans, taking root in India,
Nepal, the United States, the United Kingdom and Canada.
Hash tags, a frequent feature of social media posts to signify what a message is about, are used by politicians, musicians, activists
and others to build audiences.
#Nomorelockdowns has been among the most pervasive social media flags that helped stitch together, among others,
movements from disparate communities: QAnon conspiracy theorists; denizens of the Christian and conservative right; and
adherents of the often pseudo-scientific wellness industry.
Torstar tracked the dissemination and evolution of #nomorelockdowns and other anti-lockdown and anti-vaccine hash tags.
Torstar collected every original tweet that used the hash tag from January 2020 to early June 2021, and analyzed its content to
identify what country the Twitter user was writing about. There was no discernable country in about 30 per cent of the 27,000
tweets examined.
The analysis found the use of #nomorelockdowns intensified once it became a fixture of anti-lockdown social media rhetoric in
Ontario, often accompanied by more generic hash tags about Canadian politics including #cdnpoli and #ontpoli.
While the hashtag was sporadically used in the early months of the pandemic, its first use by a prominent Canadian figure came
in October 2020. Lanark-Frontenac-Kingston independent Ontario MPP Randy Hillier included #nomorelockdowns when
sharing a video of anti-lockdown protests in Toronto.
In the months that followed, Hillier, the de facto leader of No More Lockdowns with folk-hero-like status among believers,
routinely tacked the hashtag on to his messages to his more than 38,000 Twitter followers.
It did not take long for #nomorelockdowns to catch on. By the end of 2020, there were more than 3,100 original tweets related
to Canada that used the hash tag.
Since the beginning of 2021, there have been another 6,400 tweets - more than any other country.
The hashtag's use in tweets related to Canada surged in April and May, coinciding with large anti-lockdown rallies across the
country.
Torstar's analysis only captures a glimpse of the online, anti-lockdown conversations in Canada. The analysis does not include
the number of times a tweet has been shared, placing the message before thousands of more eyes.
There are other hashtags used alongside #nomorelockdowns, variants of sorts that are often more openly conspiratorial in tone.
The hashtag #wearelivingalie first appeared in tweets about another country, emerging in the United States during the fractious
partisan aftermath of the 2020 presidential election.
When it crossed the 49th parallel, Hillier was again a key vector for its spread. On Dec. 18, he tweeted in defence of a handful of
doctors who were "speaking out against the lie."
On April 1, 2021, Hillier tweeted out a photo of Adolf Hitler at a Nuremberg rally and claimed pandemic restrictions are
tyrannical. It was shared more than 1,400 times. Of those, 657 were harsh criticisms of Hillier's reference to the Nazis. But it was
also shared another 825 times without comment. The tweet was liked 2,180 times.
"The Third ....wave. Everyone who has ever been to the sea, knows there is no end to waves. It's only 28 days this time. Truth
does not mind being questioned. Lies do not like to be challenged. #onpoli #WeAreLivingaLie #nomorelockdowns," wrote
Hillier.
Two days later, Hillier fired back at his critics on Twitter, implying those who did not like his message were in favour of tyranny.
It was liked more than 1,000 times.
Hillier told Torstar he did not know about the origins of the hashtags. Rather, he was looking for "a message that was easy for
people to understand, that was easy to communicate, so that's the term that I ended up at."
That the Canadian movements borrow ideas from other countries comes as no surprise to those watching their evolution
around the world.
Most of the core anti-lockdown and anti-vaccine messages globally originate from only 12 social media influencers, according to
the U.K.-based Centre for Countering Digital Hate (CCDH).
AR02348
The CCDH calls them "The Disinformation Dozen," largely American social media influencers, among them anti-vaccine
conspiracy theorist Robert F. Kennedy Jr, dietary supplement salesman Joseph Mercola, and popular osteopath Sherri
Tenpenny.
They are the "Kim Kardashians of the anti-vaccine market," said CCDH CEO Imran Ahmed. "This is an American disease and
the influence, the super spreaders globally are primarily American."
The key messages by Canadian anti-vaxxers on social media - ranging from the debunked claim that vitamins will protect
against COVID-19 to ideas that vaccines are unnatural and dangerous - are mirror images of messages created by the
Disinformation Dozen.
Anita Sutcliffe is a personal support worker who worries that death may arrive at the tip of a vaccine needle.
The retirement home she works for saw four of its residents die in the spring from COVID-19 before they could be fully
vaccinated.
In the friendly confines of the End the Lockdowns Niagara chat room on Telegram - a social media site that allows for the
creation of encrypted, invitation-only channels - she claimed the retirement home had been able to resist the ravages of the
novel coronavirus until the vaccines arrived.
''We lost vaccine-hesitant residents after the 1st injection. They received their 2nd injection on May 1st. Could be devastating,"
wrote Sutcliffe ofShorthills Villa Retirement Community in the small town ofFonthill, north of Welland.
Sheltered from authorities and the risk of being banned from Twitter, Facebook or Instagram, private groups or encrypted
channels like Telegram also grow the anti-vaccination movement by sharing ideas and facilitating the planning of events -
including those that eventually carry the #nomorelockdowns hash tag - before they become public knowledge.
Torstar monitored some of these groups and channels for several months. False information about vaccines and pandemic
restrictions are shared daily, including claims that vaccinated people shed toxic particles that turn the non-vaccinated into
living magnets, that doctors and journalists will be tried and executed for war crimes, and that vaccines are lethal.
While adverse reactions to vaccines are real, if rare, they are grossly exaggerated on these channels, with unverified testimonials
taken as gospel.
The AstraZeneca vaccine carries with it a l-in-50,000 chance ofrare blood clots after the first dose. Of the more than 2.1 million
doses of AstraZeneca administered in Canada, the Public Health Agency of Canada said 55 cases of serious blood clots have been
detected and six people have died.
Sutcliffe appears to have turned to Telegram after Shorthills general manager Zaid Hassani, concerned anti-vaccination
propaganda will impede efforts to protect residents, told her to stop pushing her rhetoric at work, Hassani said.
"Of course no one is speaking up. Mostly sheep le there," wrote Sutcliffe, who spent half of May off-duty because she refused to
be tested for COVID-19.
Hassani said the deadly outbreak happened in April after the home had brought in part-time PSWs who also worked at other
homes. One of them likely carried the virus into Shorthills, infecting 37 of the 50 people who live there.
The vaccination ofresidents had started, but first doses only provide partial protection against COVID-19, and not enough time
had passed for that dose to reach its maximum efficacy.
"I pretty much grew up with some of these residents since I was little, I've known them," Hassani said. "I was kind of worried
that this whole anti-vax movement would have more of an impact. And that really worried me because a lot of the people that are
consuming that sort of information are people who have family inside retirement homes."
Hassani said Sutcliffe has been barred from the residence and they are still determining what disciplinary action she will face.
He said Sutcliffe was not fired because "we could not come to an agreement with the union." Sutcliffe has also been given
educational materials about vaccines.
Sutcliffe is not the only health-care worker in Ontario to come under scrutiny for views on vaccines.
The College of Physicians and Surgeons of Ontario has reviewed complaints about doctors who have allegedly pushed
disinformation about the pandemic and vaccines on social media. Dr. Patrick Phillips is under investigation for social media
posts claiming vaccines are killing people and pushing vitamin Das a COVID-19 treatment.
AR02349
As of the publication of this story, Dr. Phillips, who works in an emergency room in Kirkland Lake, Ont., has not been disciplined
by the CPSO. But on June 25, Phillips - who did not respond to a request for an interview from Torstar - tweeted that he will
likely lose his job and will ask the public for financial support.
Sutcliffe declined to discuss the claims she made in the Telegram chat room about vaccines at Shorthills, saying in an email she
cannot "come forward publicly with information which was discussed amongst us in a members-only group," and that "I cannot
provide sensitive details and breach confidentiality nor jeopardize my livelihood, as I am a single mother and sole provider for
my family."
On a brisk November afternoon, hundreds of anti-vaccine protesters gathered outside Toronto City Hall to push back against
mandatory public health measures.
"Stop the slaughter of the innocents," blared one sign, echoing the protesters' claims that vaccines were unsafe experiments that
would mutilate children and were taking away the right of people to make their own health-care decisions.
It was 1919.
That year the Anti-Vaccination League - an early 20th-century counterpart to No More Lockdowns - had organized the event
to oppose a mandatory smallpox vaccination order issued by the city after an outbreak.
"There have always been these people, ever since the idea of vaccination was introduced, who were hesitant or skeptical about it
or had negative things to say about it," said Jonathan Berman, physiologist, historian and author of "Anti-vaxxers: How to
Challenge a Misinformed Movement."
The early anti-vaccination movement originated in England, Berman said. The first Toronto Anti-Vaccination League was
formed in 1900, according to Toronto historian Jamie Bradburn.
Fear of vaccines and a loss of personal liberty, no matter the century, has always driven the spread of these movements, Berman
said.
While current anti-vaccine rhetoric is often a reformulation of older claims - vaccines "mutilating children" in 1919 now
appears as mRNA vaccines being experimental "gene therapy'' - modern misinformation campaigns have a potent weapon in
the internet.
"There are situations that attract people to conspiracy theories. We are in one of them right now," said Timothy Caulfield, a
Canada Research Chair in health law and policy at the University of Alberta, who has studied the rise and spread of conspiracy
theories. ''Where there is uncertainty, where there's fear, where people are looking for answers, conspiracy theories can also
become more attractive. And the other thing the conspiracy theories offer is a complete narrative for reality."
It is a resilient narrative unconstrained by evidence, something Caulfield saw in his study on the social media debate around the
malaria drug hydroxychloroquine as a COVID-19 treatment - an idea that gained steam when promoted by then-president
Donald Trump.
While clinical trials show the drug does not prevent or treat COVID-19, hydroxychloroquine remains a potent symbol of
freedom of choice.
''We were surprised with the degree to which it was almost entirely an ideological discussion," Caulfield said. "It was about
Trump. It was about freedom.You know, it wasn't about what the evidence says about hydroxychloroquine."
The ideologies at the heart of the anti-vaccine community are a big tent, allowing for distinct conspiracy theory communities
with common values - that include fears of government overreach, a high value placed on unrestricted liberty and a distrust of
experts and media - to come together in what Caulfield calls "clusters of belief."
Trump flags, banners of the right-wing 1776 movement- named after the year of the American Revolution - and the yellow
"don't tread on me" flag, all ubiquitous during the Jan. 6 riots at the U.S. Capitol, are sometimes flown at Canadian rallies
alongside No More Lockdown flags or signs claiming vaccines are linked to 5G networks or that the pandemic is a plot by Bill
Gates.
Believers in QAnon - a sprawling American conspiracy theory about, among other things, an international cabal of satanic,
pedophile sex traffickers trying to undermine democracy- are regulars at anti-lockdown rallies in Canada. Even alternative
AR02350
medicine and new age believers, part of what Caulfield and Berman call "the wellness" or "conspirituality" community, are part
of the movement, often pushing vitamins and other non-medical cures for COVID-19.
In this ideological stew, participants can be exposed to more radical, even more dangerous ideas, said Ahmed from the CCDH.
"What (US legislators) have realized is what they saw as being a bit of online fun actually has an offline cost," said Ahmed.
Those vulnerable to extremist rhetoric online might spread the virus, which could kill someone, or "they might go and buy an
outfit and storm the Capitol," he said.
When an organizer of a large April 10 anti-lockdown protest in St. Catharines, Ont., said lockdowns and vaccines are part of a
"satanic agenda," it may have spoken to both QAnon believers and those on the Christian right.
The online calls to action are influential enough to motivate people like Garfat to step toward the big tent, participate in the flow
of ideas and attend large rallies. In May, Garfat went to Toronto to attend one of the nation's largest anti-lockdown protests.
The adherents of these overlapping ideologies don't always get along, however.
In July, Hillier began feuding with Christopher Saccoccia, AKA "Chris Sky'' - the anti-vaxxer folk hero who has recently been
charged for allegedly making a death threat against Premier Doug Ford.
Saccoccia is not the only member of the community under police investigation. The Niagara Regional Police are currently
investigating at least two death threats made against St. Catharines Liberal MP Chris Bittle. He said threats were made after he
tweeted encouragement to residents to get vaccinated. Medical officers of health across the country have reported consistent
incidents of harassment and death threats.
During the crests of the COVID-19 waves, emergency rooms filled with those whose lungs were failing.
ICUs in some communities were so full, patients were hopscotched to hospitals that still had room. Regular services were shut
down, delaying surgeries.
At the height of the third wave, more than 2,200 Ontarians were hospitalized with the virus, with more than 825 of them in
ICUs.
But according to Randy Hillier, there was no crisis.
Hillier claims hospitals were never overwhelmed. He often tweets about what he claims is a government and media-fueled lie
about how COVID-19 impacted hospitals.
His tweets are liked a thousand times or more. An April 15 tweet, which featured a video of an empty hospital hallway in Barrie -
similar to the videos made by the members of the 6,000 member strong Film Your Hospital Facebook group - was presented by
Hillier as evidence the pandemic was a fraud.
In the world according to Hiller, the pandemic is not about a virus. It is tyranny and the end of freedom.
"That's not being hyperbolic. I say that with complete sincerity," said Hillier. "When the government can tell you how many
people that can be in your house, and that it would be unlawful to have more than five people in your house ... your mobility is
determined by the state. What part of that is not consistent with an authoritarian government or with communism?"
A former Progressive Conservative Party leadership hopeful described in his hometown newspaper as "Don Cherry in plaid and
rubber boots," Hillier said the provincial government's lack of a pandemic "exit plan" and the deleterious impacts oflockdowns
on the economy and peoples' lives spurred him to launch his protest movement in October.
His anti-lockdown rhetoric has transmuted to include broader COVID conspiracies. He uses his Twitter page to broadcast
unverified claims of people harmed by the vaccine. A June 21 tweet cited a post by Dr. Phillips and said, "the risk from the
vaccine is far greater than the virus for many people. #onpoli #wearelivingalie." The message was retweeted 407 times and liked
by 983 users.
Hillier has not been acting alone. He had the support of a cadre of Christian pastors who were not just participants in the anti-
lockdown big tent. They were key players helping it expand its spread online and in the real world.
In September, claiming Christians are being persecuted by the press, the government and the courts, the group of pastors signed
"The Niagara Declaration 2020." Citing pandemic lockdowns, moves to ban conversion therapy and other grievances, the
declaration says there is to be "no interference from civil authorities in the spiritual matters of the Church of Jesus Christ."
AR02351
The declaration springboarded the formation of The Liberty Coalition, a religious anti-lockdown group akin to politically active
evangelical organizations in the United States.
Michael Thiessen, pastor at Grace Baptist Church in Alliston, Ont., a leader of the group and author of the declaration, said that
while No More Lockdowns and the coalition share goals, they are separate organizations.
However, they have acted in concert for months. No More Lockdowns joined Twitter on Jan. 12, followed by the Liberty
Coalition three days later. Less than a month after the first tweets by the organizations, both using #nomorelockdowns, the
coalition sponsored the End the Lockdowns Caucus.
That caucus, led by Hillier, brought together politicians opposed to lockdowns, including People's Party of Canada leader
Maxime Bernier, Hastings-Lennox and Addington MP Derek Sloan, who voted against banning conversion therapy, and
Christian Heritage Party national leader Rod Taylor.
Collectively they have become the political leadership of the movement and are treated like rock stars at rallies.
The politicians have stood alongside Thiessen at rallies, with Bernier declaring on July 6 they have "come together under the
Liberty Coalition of Canada."
Crosses and "Trust the Lord, not Doug Ford" signs appear alongside flags and signs of other communities in the movement.
This alliance is no longer limiting itself to attacking lockdowns. Aside from engaging in cultural wars, the coalition is actively
campaigning for donations to fund its expansion.
Ending the threat of COVID-19 means getting needles into enough arms so the virus cannot effectively spread anymore.
Reaching this herd immunity for highly contagious diseases like measles requires vaccinating more than 95 per cent of the
population.
For COVID-19, the target is as high as 89 per cent- or higher to combat more infectious variants - according to Public Health
Ontario. And that is where the math becomes problematic.
"Right now, we aren't immunizing around 11 per cent of the population because we are not vaccinating children under 12 yet,"
said Dr. Mustafa Hirji, Niagara's acting medical officer of health. "So right away, the maximum number of people we can get is 89
percent."
A mid-June poll by the Angus Reid Institute showed that a full nine per cent of adult Canadians say they won't get vaccinated,
and another seven per cent is either unsure or is going to wait.
As of July 16, less than 44 per cent of Canadians were fully vaccinated against COVID-19, according to the Public Health Agency
of Canada.
Canada is unlikely to reach herd immunity, Hirji predicts.
Alberta, Manitoba and Quebec have tried to incentivize vaccination with lotteries. But those looking hard at the issue say the
reasons behind hesitancy are complex, as are the anti-vaccination messages.
Movement adherents like Don Garfat- who would not say ifhe will get vaccinated- believe vitamins and staying healthy will
ward off COVID-19. Medical experts say this will not prevent infection or serious illness, but that does not impact the belief,
which is often shared in the movement's social media posts.
"The hesitant are trying to find a lot of information. And by doing so, they can encounter some pretty well designed anti-vaccine
stuff online," said Eve Dube, a medical anthropologist at the National Institute of Public Health in Quebec. "They are quite good
in packaging their information and taking a bit of science and then a bit of nonscience to send a message that could be quite
convincing if you're already not too sure about vaccination."
Distrust is the nemesis of herd immunity, one health officials are not doing enough to combat, said Angus Thomson, senior
social scientist for the demand for immunization program at UNICEF.
"We are investing billions and billions of dollars to purchase and distribute COVID-19 vaccines to over 100 countries around the
world. And we are investing a fraction of a fraction of a per cent in building public trust for those incoming vaccination programs
ahead of time," said Thomson. "There's no public immunity without public trust and we've taken it for granted because people
AR02352
just lined up. And for the last 30 years we've been running on goodwill and luck. And now we're seeing very clearly the impact of
that failure to invest in communication."
In the wake of that failure, tensions around vaccinations are growing. U.S. President Joe Eiden criticized Facebook for allowing
vaccine disinformation on its platforms. Arsonists have attacked a vaccine clinic in France. A new round oflarge anti-vaccine
protests in Canada are being planned for this weekend. Ontario's chief medical officer Dr. Kieran Moore said 83 per cent of
recent COVID-19 cases are among those who have not got their shots.
And anti-vaccine disinformation is pumped out consistently on social media even as efforts to expand vaccinations continue.
In response to news about the virus spreading among unvaccinated people, No More Lockdowns tweeted on July 6 that it was
"equally plausible" that vaccinated people are also vectors for the virus to mutate.
The tweet used #wearelivingalie.
Grant Lafleche is a St. Catharines-based investigative reporter with the Standard. Reach him via email:
grant.lafleche@niagaradailies.com
Edward Tian is an open-source investigator and computer science student at Princeton University. Follow him on Twitter:
@edward_the6
Read more about: Twitter
Toronto Star Newspapers Limited and/or its licensors. To order copies of Toronto Star articles, please go to: www.TorontoStarReprints.com
AR02353
LA
PRESSE
COVID-19
La desinformation, ecueil possible

sur la route du vaccin
(Paris) La desinformation, a l'ampleur inedite en 2020, pourrait-
elle entraver de futures campagnes de vaccination contre la
COVI D-19 ? Alors que la confiance dans les institutions est deja
largement entamee, cette eventualite inquiete medecins et
auto rites.
Mis a jour le 26 nov. 2020
JULIE CHARPENTRAT
AGENCE FRANCE-PRESSE
AR02354
Vehiculee ala vitesse de Facebook, Twitter, YouTube ou WhatsApp, « la
desinformation a pris une ampleur inegalee », observe Sylvain Delouvee, chercheur
en psychologie sociale al'Universite de Rennes-2.
Le phenomene, d'une ampleur enorme, a en outre un « impact negatif sur la

confiance clans les vaccins, les institutions et les decouvertes scientifiques en
general», abonde Rory Smith, de l'ONG de lutte contre la desinformation First
Draft.
Des le mois de fevrier, l'OMS s'alarmait face acette « infodemie » dangereuse:

parce que les populations peuvent s'intoxiquer avec des produits presentes comme
des remedes (alcool, eau de javel, medicaments ... ) mais aussi parce que les infox
peuvent dissuader de suivre les recommandations sanitaires, comme porter un
masque ou se faire vacciner.
Remedes bidon, fausses affirmations sur les masques ou theses complotistes autour
d'une vaste machination mondiale pour asservir les populations, « la pandemie de
COVID-19 a aussi mis en lumiere le caractere mondial » de la desinformation, qui
« transcende naturellement langues et frontieres », explique Rory Smith.
L'AFP a publie depuis janvier plus de 2000 articles de verification autour de fausses
allegations sur le Covid, qui entretiennent doute et confusion sur la pandemie, avec
en point d'orgue frequent le futur vaccin.
Depuis des mois, des milliers d'internautes clament leur refus d'etre vaccines. Mi-
novembre, la responsable de la vaccination al'OMS Rachel O'Brien se disait « tres
preoccupee » par la desinformation et ses consequences sur l'acceptation du vaccin.
Porosite
Meme s'il est difficile de mesurer precisement l'impact des infox sur le sentiment
anti-vaccinal et sur la decision in fine de se faire vacciner ou non, plusieurs etudes
relevent neanmoins une grande parasite entre les deux, meme si d'autres facteurs
AR02355
entrent aussi en jeu.
Les vagues de desinformation sont « associees a une baisse moyenne des taux de
vaccination», avance meme le chercheur Steven Wilson, qui a examine en detail
l'impact des reseaux sociaux sur « !'hesitation vaccinale » clans une etude publiee
en octobre clans le « British Medical Journal-Global Health».
Les inquietudes sont d'autant plus grandes que !'adhesion a un futur vaccin sera
particulierement cruciale clans un contexte de pandemie qui paralyse une bonne
partie du monde et face a laquelle un vaccin largement diffuse ressemble a un billet
de sortie indispensable, notent experts et scientifiques.
Une adhesion deja largement entamee depuis des annees.
Deja surrepresentes sur !'internet, les groupes anti-vaccins, tres organises, se sont
encore renforces avec la pandemie, profitant d'une « chambre d'echo » d'une
ampleur inedite, parfois relayee par des celebrites via des reseaux sociaux « qui
permettent a des groupes marginaux de diffuser leur message » a une audience tres
large, comme le note Steven Wilson.
On retrouve d'ailleurs plusieurs fausses affirmations sur les vaccins clans les deux
documentaires complotistes a succes « Plandemic » (Etats-Unis) puis « Hold-Up»
(France). Quant a l'idee selon laquelle le vaccin contre le Covid servira a implanter
des puces electroniques ... elle a represente l'un des« cartons» de 2020.
Cette deferlante intervient sur un terrain propice clans de nombreux pays, ou les
opinions publiques sont deja reticentes, comme en Suede ou en France.
Selan un sondage lpsos, seuls 54 % des Frarn;ais declaraient en octobre qu'ils se

feraient vacciner contre la COVID-19: ro points de mains que les Americains, 22 de
mains que les Canadiens, et en retard de 33 points sur les lndiens.
AR02356
Sur 15 pays, 73 % des personnes interrogees affirmaient qu'elles se feraient vacciner
contre le Covid si un vaccin existait, 4 points de mains qu'en aout.
Question de confiance
Au-dela de la question des vaccins se pose celle de la« confiance » dans les
institutions, expliquent les experts du sujet. « Le meme point commun » des theses
complotistes, « c'est que nos "elites" nous mentent », explique Sylvain Delouvee.
L'idee que la COVID-19 est« une machination» ou « fait partie d'un plan des
"elites" pour controler la population mondiale » est l'une des plus virales sur les
reseaux sociaux, note aussi Rory Smith.
Resultat, toute prise de parole pen;ue comme officielle est decredibilisee d'avance.
La desinformation « s'appuie sur une montee des defiances vis-a-vis de toute forme
d'autorite instituee, gouvernementale ou scientifique », observe encore
M. Delouvee, une tendance qui s'est notamment illustree en France dans le
mouvement heteroclite des« Gilets Jaunes ».
« Quand on regarde la correlation entre le refus de la vaccination et[ ... ] le manque

de confiance dans le gouvernement et dans le systeme en general, on voit que les
deux chases sont paralleles », notait aussi recemment la virologue Marie-Paule
Kieny, presidente du comite scientifique sur le vaccin en France.
Autre difficulte, le discours anti-vaccin profite aussi du fait que des questions
fondees peuvent encore etre posees sur leur efficacite - pour l'instant seulement
avancee par les fabricants - de ces vaccins mis au point en un temps record, leur
disponibilite (notamment dans les pays pauvres) ou encore autour de !'utilisation
de certaines technologies nouvelles.
« Quand les gens ne peuvent pas acceder a des informations fiables sur les vaccins
et que la defiance envers les acteurs et institutions liees aux vaccins est forte, la
AR02357
desinformation s'empresse de remplir ce vide », note First Draft.
D'ou les multiples appels ala plus grande transparence, « element indispensable
pour obtenir !'adhesion» au futur vaccin, selon Daniel Floret, de la Haute Autorite
de Sante.
© La Presse Inc. Taus droits reserves.

AR02358
LA
PRESSE
Danger public
AR02359
Bill Gates avait prevenu le monde.

Publie le 21 avr. 2020
ISABELLE HACHEY
LA PRESSE
C'etait en des temps tres anciens, aux temps de !'innocence ... en 2015. Le fondateur
de Microsoft avait alors declare, clans un TED Talk, que la menace la plus perilleuse
alaquelle l'humanite etait confrontee n'etait pas une guerre nucleaire, mais un
virus microscopique qui tuerait des millions de gens.
La planete n'etait pas prete a faire face aune pandemie, s'inquietait Bill Gates clans
sa conference. Les systemes de sante risquaient de crouler sous le poids des
malades.
A l'epoque, on a hausse les epaules.
Ouais, bof...
Cinq ans plus tard, des millions d'internautes visionnent le TED Talk de Bill Gates
sur YouTube. Mais pour bon nombre d'entre eux, ce n'est pas pour se dire qu'ils
auraient bien du l'ecouter. Plutot pour se convaincre que le philanthrope ... a lui-
meme cause la pandemie !
AR02360
PHOTO OLIVIER JEAN, ARCHIVES LA PRESSE
« En temps normal, les vedettes qui croient que les nuages sont des produits chimiques repandus en secret par
les gouvernements ne meritent pas qu'on s'y attarde. Mais nous ne sommes pas en temps normal. Nous sommes
en pleine crise. Chaque jour, on fait le decompte des marts de la COVID-19 », souligne notre chroniqueuse.
Bill Gates est devenu « la star d'une explosion de theories du complot sur la
pandemie », rapporte le New York Times. Les internautes s'en donnent a cceur
joie : il a cree le virus pour tirer profit d'un vaccin dont il a deja le secret, pour
proceder a l'abattage selectif de la population mondiale ou encore - tant qu'a y
etre - pour inj ecter des puces electroniques sous la peau des gens, cette bande de
moutons endormis.
Bill Gates peut bien avoir contribue au developpement et a la distribution de

vaccins (notamment contre la rougeole et la polio) clans le monde, ce n'est pas c;a
qui arretera les conspirationnistes.
Parmi eux, il y a la comedienne Lucie Laurier, qui a photographie des nuages clans
AR02361
le ciel de Montreal, en octobre, pour les diffuser sur Twitter. Pardon, ai-je ecrit
nuages? Je voulais dire« epandages », des epandages quotidiens, elle n'est pas la
seule al'avoir remarque, « on ne veut pas notre bien ... »
Depuis le debut de la crise, la popularite de Lucie Laurier a bondi sur les reseaux
sociaux - et pas pour les bonnes raisons. C'est que, voyez-vous, elle se mefie du
« milliardaire blafard ». Encore plus d'un eventuel vaccin contre la COVID-19.
Lucie Laurier a decline ma demande d'entrevue. Sur Twitter, elle ecrit: « L'ennemi
invisible? Le chaos est cree pour imposer l'ordre. Si vous ne vous rendez pas
compte de l'effort mondial concerte de nous controler par la peur, d'aneantir les
petites entreprises, de se debarrasser de ceux qu'ils ne jugent plus utiles, vous vous
reveillerez trap tard. »
,......,f......
............. ,...
.....f ..
Vous me direz qu'on ne devrait pas preter attention aux elucubrations des
conspirationnistes.
Sans doute. En temps normal, les vedettes qui croient que les nuages sont des
« chemtrails », des produits chimiques repandus en secret par les gouvernements,
ne meritent pas qu'on s'y attarde.
Mais nous ne sommes pas en temps normal. Nous sommes en pleine crise. Chaque
jour, on fait le decompte des marts de la COVID-19. Lundi seulement, il yen a eu
62, au Quebec.
Soixante-deux.
Le gouvernement a demande l'aide de nombreux artistes pour convaincre la

population de rester ala maison et respecter les consignes de la Sante publique.
Alors, si une comedienne soutient en public que tout c;a n'est qu'une mascarade, on
peut imaginer qu'il y aura quelques zigotos pour la croire. Et pour ne plus croire
AR02362
aux regles destinees, je le rappelle, a sauver des vies.
Bref, en ces temps de pandemie, Lucie Laurier et les autres complotistes ne sont
pas juste pitoyables. lls sont un danger public .
...,.,r,.....,....., .
.. ,.,r.. ,.,1...
PHOTO HUGO-SEBASTIEN AUBERT, ARCHIVES LA PRESSE
La comedienne Lucie Laurier
Le danger est decuple quand des medias traditionnels leur offrent une tribune - et
la credibilite qui vient avec. Le 16 avril, Lucie Laurier a accorde une entrevue a Eric
Duhaime, animateur au FM93 de Quebec.
Apropos d'un eventuel vaccin obligatoire contre la COVID-19, Lucie Laurier s'est
emportee: « C'est carrement notre integrite physique qui est mise en danger! 11
n'en est pas question! Mon corps m'appartient ! »
AR02363
Puis, elle a lance un appel a!'insurrection des« gars de Quebec», parce qu'on a
« besoin de testosterone » et que « la revolution ne va pas se faire sur le Plateau » :
« Un moment donne, la, vous etes en train de vous faire emasculer. Pis moi, je
trouve qu'on a besoin de gens qui se levent debout pis qui demandent des
comptes. »
Je les imagine s'entasser sur la Grande Allee, ces gars bourres de testosterone,
pancarte ala main, casquette rouge vissee sur la tete. Libarte !
Bien sur, on n'est pas aux Etats-Unis. N'empeche, alors que les autorites sanitaires
font tout pour contenir la propagation de la pandemie, ce genre d'appel ala revolte
est carrement irresponsable .
. ,.....,.....,...
... f .....f .....f ..
C'est a cause de l'anxiete ambiante, disent les psys.
Partout clans le monde, les gens cherchent des reponses a leurs angoisses. C'est
humain. Comme la science a encore tres peu a leur offrir, les complotistes
remplissent le trou noir avec leurs inebranlables certitudes.
Partout clans le monde, les theories proliferent. Au Quebec, le vlogueur Alexis

Cossette-Trudel a vu sa popularite exploser: l'auditoire de son canal, Radio-
Quebec, est cinq fois plus eleve qu'auparavant, a revele La Presse clans un recent
reportage.
Avant la pandemie, Alexis Cossette-Trudel crachait sa hargne du Fardoche a la peau

noire de la nouvelle serie Passe-Partout et accusait Justin Trudeau de pedophilie.
Pas chic, j'en conviens. Mais c;a ne tuait personne.
Aujourd'hui, ses theories du complot sur le coronavirus risquent d'avoir un

impact dans le vrai monde.
Paree que Cossette-Trudel doit bien avoir une influence sur ses dizaines de milliers
AR02364
d'auditeurs. Ne serait-ce que leur donner !'impression de faire partie d'une minorite
d'allumes, ceux qui savent, pendant que le reste de la populace continue de se
laisser berner.
Quand le gouvernement adopte un plan d'urgence, les allumes sont incapables d'y
voir des mesures destinees a sauver des vies. lls ne voient que les griffes d'un Etat
policier se refermer sur eux.
Je leur concede une chose : ce virus est liberticide. A cause de lui, on a ferme des
commerces, on a enferme la population. A cause de lui, on donne des amendes a
des gens ordinaires pour les punir de faire des chases ... ordinaires.
Les temps exceptionnels justifient ces mesures exceptionnelles, nous explique-

t-on.
Peut-etre. Mais l'ironie, en ces temps fous, c'est qu'on juge crucial d'imposer des
amendes de 1546 $ a des sans-abri parce qu'ils ne respectent pas les regles du
confinement ... tout en laissant deblaterer les conspirationnistes qui risquent de
faire beaucoup plus de dommages.
© La Presse Inc. Tous droits reserves.

AR02365
TORONTO STAR
r ill Newsletters
1
Today's I
Signln
1111
Sports
paper ~ Betting
] ~
STAR COLUMNISTS loP1N10N I
Disturbing rise of the cult of hard-line anti-vaxxers

The serious long-term threat from this anti-vax cult is its ability to spread disinformation to their
followers via social media and other outlets.
By Bob Hepburn Star Columnist

Wed., Feb. 2, 2022 0 3 min. read
Make no mistake about it, there's a cult of hard-line anti-vaxxers spreading across Canada that is becoming bolder, more daring
- and more dangerous.
Fuelled by paranoia and conspiracy theories, these anti-vax cultists are taking more and more public action that threatens to
become violent as they try to shove their far-right activism and vision of"freedom" into the national spotlight.
Most Canadians got their first real look at this anti-vax, anti-lockdown cult as they watched the trucker protests in recent days
in downtown Ottawa and at the Alberta-Montana border.
Intoxicated by their power to gain widespread media coverage, not just here but around the world, these hard-line anti-vaxxers
were on full display, spreading mayhem and fear, defying all public health guidelines around COVID-19, demanding the
overthrow of the duly elected government, waving a Confederate flag (a symbol of white supremacy), threatening workers in
fast-food outlets and more.
The more serious long-term threat from this new anti-vax cult is its ability to spread disinformation (along with warnings of
pending violence) to their followers via social media and other online outlets.
Importantly, it's up to those of us who are vaccinated, as well as the more rational among vaccine-hesitant Canadians, to call out
this cult-like behaviour and show we don't in anyway support it.
A cult is generally considered to be a group or movement held together by a shared belief or cause that is generally unacceptable
to mainstream society and creates obedience and dependency by requiring a high level of commitment by its followers.
Steven Hassan, a leading U.S. cult expert and former Moonie cult member, says anti-vaxxers are using the same tactics as
religious cults to gain followers . Writing for CNN Business Perspectives last fall, he says cult leaders use emotional-control
techniques that expose people to a series of "persistent, irrational fears that initiate a closed cycle of fearful images, thoughts
and feelings."
"Anti-vax influencers" are using the same techniques today, Hassan argues, noting they use social media "to bombard their
targets with message that sow doubt, fear and confusion about the COVID-19 vaccine."
Specifically, they highlight examples of adverse vaccine reactions without saying how rare they are, withhold positive
information about the vaccines, distort information by misinterpreting data, casting doubt about public-health experts, and
spreading outright lies on social media about vaccinations.
AR02366
Here in Canada, cult-like anti-vaxxers are stepping up their tactics of harassment and intimidation, especially against health-
care professionals and politicians - all with the aim of getting them to reverse their stand on the need for vaccinations and some
lockdown restrictions.
One Canadian medical officer of health, writing anonymously last week in the Healthy Debate online website, argues that anti-
vaxxers, who have protested outside their home, "demonstrate a cult-like phenomenon and are conflating broad antagonism
with the system and government with anti-vaccination (and anti-lockdown, anti-mask) rhetoric."
Journalists are also targeted by anti-vax cultists. Like the health-care workers and politicians, they receive warnings that their
homes are being watched, their addresses and vehicle licence plate numbers are being posted online.
How can we fight back against this cult's misinformation and intimidation tactics that threaten the health of all of us?
First, share good information about vaccines from trusted medical experts.
Second, don't try to engage with anti-vaxxers on social media to point out the errors and lies in their misinformation campaigns
because it can backfire by just spreading their lies to a wider audience.
Three, insist that police act to ensure the safety of health-care workers and others by laying criminal charges against anti-
vaxxers who harass or intimidate them.
We should not remain silent.
That's because, as the medical officer of health stated so forcefully in Healthy Debates, "we need to act urgently before more
individuals are recruited, their support base grows and confidence in vaccines and public health more broadly erodes further."
Bob Hepburn is a Star politics columnist based in Toronto. Twitter: @BobHepburn
Toronto Star Newspapers Limited and/or its licensors. To order copies of Toronto Star articles, please go to: www.TorontoStarReprints.com
AR02367
LA
PRESSE
L:empire antivax de Robert F.

Kennedy fils
AR02368
PHOTO FLAVIO LO SCALZO, ARCHIVES REUTERS
Robert F. Kennedy Jr., le neveu de l'ancien president americain John F. Kennedy, lors d'une manifestation contre
la vaccination contre la COVID-19, le 13 novembre 2021 .
(Providence) Robert F. Kennedy fils monte sur la scene d'une

eglise du sud de la Californie, rayonnant de confiance et balayant
la foule en delire avec les memes yeux bleus per~ants que de son
pere, Bobby Kennedy. Puis, ii se lance dans une diatribe contre
les vaccins. Les democrates « ont bu le Kool-Aid ! », a-t-il lance
aux personnes rassemblees pour une conference d'extreme droite
pour la « defense de la sante et de la liberte ».
Publie le 16 dee. 2021
MICHELLE R. SMITH
ASSOCIATED PRESS
AR02369
« C'est une faute professionnelle medicale criminelle de donner aun enfant un de

ces vaccins », a affirme M. Kennedy clans une video de l'evenement, une de ses
nombreuses affirmations contraires au consensus juridique, scientifique et de la
sante publique.
II fait la promotion de son livre
Ensuite, M. Kennedy enchaine en faisant la promotion de son livre. Si seulement

300 participants le precommandaient sur Amazon le soir meme, dit-il ala foule, le
bouquin atterrira sur la liste des best-sellers et les acheteurs feraient « un pied de
nez aAmazon et Jeff Bezos ».
Taus les benefices, a-t-il promis, iront a son association, Children's Health Defence
(CHD).
Alors que de nombreuses organisations et entreprises abut non lucratif ont peine a
survivre pendant la pandemie, le groupe antivaccin de M. Kennedy a prospere. Une
enquete de l'Associated Press revele que Children's Health Defence a accumule
fonds et adeptes quand M. Kennedy a utilise la visibilite que lui confere son
prestigieux nom de famille pour ouvrir des portes, amasser des fonds et donner de
la credibilite a son groupe. Des documents montrent que les revenus du groupe ont
plus que double en 2020, a 6,8 millions de dollars americains.
Depuis le debut de la pandemie, Children's Health Defence a augmente le lectorat

de son bulletin, qui propage des informations biaisees, des faits fragmentaires et
des theories du complot pour repandre la mefiance face aux vaccins anti-
COVID-19. Le groupe a meme lance une chaine de television sur !'internet et un
studio de tournage.
Actif au Canada, publie en fran~ais

AR02370
CHD a des ambitions mondiales: en plus d'ouvrir de nouvelles succursales aux
Etats-Unis, le groupe compte desormais des avant-pastes au Canada, en Europe et,
plus recemment, en Australie. 11 traduit des articles en frarn;ais, allemand, italien et
espagnol, et multiplie les embauches.
Selan les donnees de Similarweb, une societe de recherche numerique qui analyse
le trafic Web, Children's Health Defense est devenu un des« sites de medecine
alternative et naturelle » les plus populaires au monde, atteignant un pie de pres de
4,7 millions de visites par mois. Le site recevait mains de 150000 visites mensuelles
avant la pandemie.
Pour augmenter son influence, Children's Health Defence a cible avec ses fausses
affirmations des groupes qui pourraient etre plus enclins a se mefier du vaccin, y
compris les meres et les noirs americains, affirment des experts. Selan eux, cette
strategie peut avoir des consequences mortelles : alors que la pandemie a fait plus
de 5 millions de victimes, la desinformation est consideree comme une menace a la
sante publique.
Robert Kennedy fils est le neveu du president democrate assassine en 1963 John
Kennedy et fils du procureur general Bobby Kennedy, assassine durant en 1968
durant sa campagne presidentielle.
Sensibles atous les complots
Aux Etats-Unis en particulier, les vaccins sont devenus un probleme politique

epineux. Or, !'opposition de M. Kennedy aux vaccins l'a parfois rapproche des forces
antidemocratiques de droite qui font cause commune avec le mouvement
antivaccin. Cet heritier de la famille democrate la plus connue au pays a participe a
des manifestations relayant le mensonge de Donald Trump selon lequel les
elections de 2020 ant ete volees. 11 s'est aussi associe a des personnes qui ant
celebre OU minimise l'assaut du 6 janvier contre le Capitole.
M. Kennedy est un element cle du mouvement antivaccin depuis des annees, mais
AR02371
des medecins et des defenseurs de la sante publique ont declare al'AP que la
COVID-19 l'a propulse a un autre niveau.
« Avec la pandemie, il a ete turbocompresse », a declare le docteur David Gorski,

qui est chirurgien cancerologue ala faculte de medecine de l'universite Wayne
State et un adversaire du mouvement antivaccin.
« Mouvement de propagande »
Le cardiologue Richard Allen Williams, qui est professeur de medecine a

l'Universite de la Californie a Los Angeles et le fondateur du Minority Health
Institute, a declare que M. Kennedy dirigeait « un mouvement de propagande » et
« une operation absolument raciste » particulierement dangereuse pour la
communaute noire.
« 11 est vraiment le chef de file de la campagne de desinformation, a declare le

docteur Williams, qui a ecrit plusieurs livres sur la race et la medecine. Tant de
gens, meme clans les cercles scientifiques, ne realisent pas ce que fait Kennedy. »
Meme des membres de la famille Kennedy qualifient son travail de « dangereux ».
M. Kennedy, 67 ans, s'est taille une carriere en tant qu'auteur a succes et grand
avocat specialise clans l'environnement, luttant pour d'importantes causes de sante
publique telles que l'eau potable. Son travail en tant que porte-parole de ce
mouvement aurait probablement defini sa participation ala vie publique
americaine.
Pique par le complot antivax
Mais il y a plus de 15 ans, il est devenu obsede par la conviction que les vaccins ne
sont pas securitaires. Bien qu'il existe de rares cas de reactions graves aux vaccins,
les milliards de doses administrees clans le monde sont la preuve tangible de leur
securite. Selan !'Organisation mondiale de la sante (OMS), les vaccins previennent
AR02372
jusqu'a cinq millions de deces par an.
Pendant la pandemie, M. Kennedy est devenu une source omnipresente de fausses

informations sur la COVID-19 et les vaccins. Plus tot cette annee, il a ete inclus
clans la Disinformation Dozen par le Centre de lutte a la haine numerique. Cette
ONG affirme que Robert Kennedy fils et le site internet de Children's Health
Defence sont parmi les principaux diffuseurs de fausses informations sur les
vaccins en ligne.
Laporte-parole de M. Kennedy, Rita Shreffler, a indique a l'AP le 6 decembre qu'il

n'etait pas disponible pour une entrevue pour ce reportage.
Le 2 decembre, cependant, elle avait ecrit a AP pour se plaindre d'un « black-out

total des medias grand public » a propos du livre de M. Kennedy et proposer des
entrevues.
Un journaliste d'AP a repondu clans les 20 minutes et a envoye plusieurs courriels

de suivi. Lorsque Mme Shreffler a finalement repondu, elle a demande que la« liste
de questions soit approuvee avant de planifier un entretien ». AP a decline cette
restriction, et M. Shreffler a alors indique que M. Kennedy ne parlerait pas avec
l'Associated Press.
Desinformation antivax
Plus de 200 millions d'Americains ont rec;u un vaccin contre la COVID-19, et les
effets secondaires graves sont extremement rares, selon le suivi de la securite du
gouvernement. Ce suivi et ces tests sur des dizaines de milliers de personnes ont
montre que les vaccins sont SLLrs et efficaces pour reduire le risque de maladie grave
et de deces, et que les risques pour la sante poses par le vaccin sont bien inferieurs
aux risques poses par le virus.
Children's Health Defence et ses partisans, cherchant a saper ce message, utilisent

des techniques astucieuses pour fournir de la desinformation antivax meme a ceux
AR02373
qui n'en cherchent pas.
L'AP a trouve des liens vers Children's Health Defence sur Facebook. Alors que
plusieurs ont ete partages sous forme de publications sur les pages d'autres
militants antivaccins, plusieurs autres references ont ete placees dans les
commentaires de pages Facebook generalement consultees pour obtenir des
informations fiables, y compris les pages Facebook officielles du gouvernement
dans les 50 Etats et dans les services de sante de presque tous les Etats.
« Le vaccin n'a pas ete cree pour nous sauver tous d'une pandemie. La pandemie a
ete creee pour nous amener aprendre le vaccin et plus encore», a ecrit une
personne en fevrier sous une publication Facebook du departement de la Sante et
des Services sociaux de Caroline du Nord. Le commentaire comprend un lien vers
un article du Children's Health Defence qui, en janvier, affirmait que 329 deces a la
suite du vaccin contre la COVID-19 avaient ete signales au systeme federal de
surveillance de la securite des vaccins (qui a ete utilise a mauvais escient par les
militants antivaccins).
Pages Facebook canadiennes
Les gens ont egalement partage des liens CHD sous des messages publies par des
gouverneurs, des ecoles, des hopitaux, des avant-pastes militaires, des universites,
des organes de presse et meme une equipe de soccer professionnelle. Une senatrice
de l'Alaska a partage des liens CHD sur sa page Facebook au mains quatre fois
depuis mars. lls ont egalement ete partages en dehors des Etats-Unis, sur des pages
Facebook dans des endroits comme le Canada, la Norvege et la Grece.
M. Kennedy a des centaines de milliers d'abonnes sur Facebook et Twitter, bien

qu'il ait ete expulse de la plate-forme lnstagram de Facebook plus tot cette annee.
Children's Health Defence reste presente sur les trois plateformes.
Depuis janvier, les publications liees au vaccin contre la COVID-19 de Children's

Health Defence ont ete partagees plus frequemment sur Twitter que les liens vers
AR02374
le contenu concernant les vaccins sur des sites grand public tels que CNN, Fox
News, NPR et les Centres de controle et de prevention de la maladie des Etats-Unis
(CDC), selon l'Observatoire sur les medias sociaux de l'Universite de l'lndiana, qui
suit le contenu lie au vaccin contre la COVID-19 sur Twitter.
En quelques semaines, a constate l'Observatoire, le contenu du CHD au sujet du

vaccin contre la COVID-19 a ete partage plus souvent que celui du New York Times
et du Washington Post.
Une autre equipe de recherche a decouvert que le groupe de M. Kennedy, ainsi

qu'un groupe desormais supprime appele Stop Mandatory Vaccination (Halte ala
vaccination obligatoire), avaient achete plus de la moitie de la publicite antivaccins
sur Facebook avant la pandemie. Un membre de cette equipe, David Broniatowski
de l'universite George Washington, a declare que les groupes avaient cible avec ces
publicites Facebook les femmes en age de procreer en utilisant des donnees
demographiques.
« lls sont beaucoup plus efficaces que notre infrastructure de sante
publique. C'est en partie parce qu'ils ont juste une base centralisee avec une
idee tres claire de ce qu'ils veulent faire. »
- David Broniatowski de l'universite George Washington
L'efficacite du CHD s'explique en partie de sa presence au cceur d'un reseau de sites

antivax qui se relient et s'amplifient. Cela cree une chambre d'echo de
desinformation qui renforce les faux recits minimisant les dangers de la COVID-19
et qui exagere les risques du vaccin. Par exemple, le lendemain de !'approbation
complete par la Food and Drug Administration (FDA) du vaccin Pfizer, M. Kennedy
et le CHD ont envoye un article affirmant a tort que le vaccin autorise n'etait pas
celui qui etait disponible, a illustre Dorit Reiss, qui est professeur ala Faculte de
droit de l'Universite de la Californie a Hastings et un expert en droit des vaccins.
AR02375
« Cela a commence avec CHD le lendemain de !'approbation, puis a ete repris par
les voix de la droite », a dit M. Reiss.
L'idee a circule clans les medias marginaux d'extreme droite. Puis, plus d'un mois
apres la publication de l'article, le senateur republicain Ron Johnson du Wisconsin
a participe a!'emission de Tucker Carlson sur Fox News et repete la faussete que le
vaccin approuve n'etait pas disponible aux Etats-Unis.
Cela est devenu l'un des plus gros articles de CHD de l'annee derniere, avec environ
40000 interactions sur Facebook, selon CrowdTangle, un outil appartenant a
Facebook qui permet de suivre le contenu sur les plateformes.
Dans les commentaires sur le site de CHD, les gens ont exprime leur colere, leur
peur et leurs appels al'action. « Vous savez, plus je lisles nouvelles, plus mon
estomac se contracte en une petite boule », a ecrit l'un d'eux. « Et ils se demandent
pourquoi nous ne leur faisons pas confiance et pourquoi les gens ne seront pas
vaccines», a declare un autre. L'un d'eux a suggere aux gens de marcher sur
Washington a!'occasion du 2oe anniversaire des attentats dun septembre, en
ecrivant: « Faites que le 6 janvier ressemble a un pique-nique ».
En plus de sa montee en puissance sur les reseaux sociaux, le site internet de CHD
a egalement connu une explosion de trafic. Selan Similarweb, en novembre 2019,
quelques mois avant le debut de la pandemie, Children's Health Defence a rec;u n9
ooo visites. Cela etait passe a environ trois millions de visites le mois dernier, apres
avoir culmine en aout apres de 4,7 millions.
Et son bulletin quotidien atteint plus de huit millions de personnes par mois par
courriel, selon un appel de collecte de fonds de CHD qui visait a recolter un million
de dollars d'ici le 30 novembre. L'AP n'a pas ete en mesure de verifier cette
affirmation de maniere independante.
En novembre, M. Kennedy a publie son livre The Real Anthony Fauci, clans lequel il
accuse le principal specialiste des maladies infectieuses du pays d'avoir aide a
AR02376
orchestrer « un coup d'Etat historique contre la democratie occidentale ». Un
porte-parole du Dr Fauci n'a pas souhaite faire de commentaire.
lvermectine et hydroxychloroquine
M. Kennedy utilise egalement le livre pour promouvoir des traitements contre la

COVID-19 non prouves tels que l'ivermectine, qui est destine atraiter les parasites,
et le medicament antipaludique hydroxychloroquine. 11 soutient aussi que la
securite des vaccins pour enfants n'est pas correctement testee, meme si la FDA
exige trois phases de tests impliquant des centaines de milliers de personnes avant
d'approuver un vaccin infantile.
Sa sceur, Kerry Kennedy, qui dirige l'organisme Robert F. Kennedy Human Rights,
le groupe de defense des droits internationaux fonde par leur mere, Ethel, a declare
al'AP qu'il etait irresponsable d'attaquer des medecins et des scientifiques.
Plusieurs, dont le docteur Fauci, ont rec;u des menaces de mart, ce qui peut
dissuader les gens d'entrer clans la profession.
« Notre famille sait qu'une menace de mort doit etre prise au serieux », a-t-
elle declare, une allusion aux assassinats de John F. Kennedy et de Robert

Kennedy.
Le groupe de Mme Kennedy, qui soutient les vaccinations obligatoires decretees

par le gouvernement et le passeport sanitaire, a decerne au docteur Fauci son prix
« Ripple of Hope » (vague d'espoir) l'annee derniere.
M. Kennedy fils, en revanche, a passe des mois a faire la promotion de son livre,
notamment lors de la conference d'extreme droite Reawaken America clans le sud
de la Californie en juillet. Le mois dernier, CHD a exhorte ses partisans a acheter le
livre immediatement afin qu'il figure sur la liste des best-sellers du New York
Times. Certains commentateurs sur le site de CHD ont declare avoir achete
plusieurs exemplaires pour stimuler les ventes. L'un d'eux a declare qu'il en avait
achete neuf et qu'il prevoyait d'en acheter davantage pour les mettre clans des
AR02377
boites d'echange de livres de quartier « pour aider a propulser le livre au premier
rang de la liste des best-sellers du New York Times».
Le vceu de M. Kennedy a ete exauce. Son livre a atteint le n° 5 sur la liste du Times
le mois dernier et le n° 1 sur Amazon. 11 s'etait vendu a pres de 166000 exemplaires
jusqu'au debut du mois de decembre, selon NPD BookScan, qui suit environ 85 %
des ventes d'imprimes.
Avec Roger Stone
Le message antivaccin de M. Kennedy l'a rapproche de nombreuses personnalites

qui ont attaque les normes et les institutions democratiques du pays. Une photo
publiee sur lnstagram le 18 juillet, et apparemment prise dans les coulisses de
l'evenement Reawaken America, le montre aux cotes de l'allie de l'ancien president
Donald Trump, Roger Stone ; de la profiteuse antivaccins Charlene Bollinger ; et de
l'ancien conseiller ala securite nationale Michael Flynn, qui ont tous repete le
mensonge selon lequel les elections de 2020 ont ete volees.
M. Kennedy a participe a plusieurs evenements avec Mme Bollinger et son mari,

meme apres que leur groupe d'action politique ait parraine un rassemblement
d'antivaccins pro-Trump pres du Capitole le 6 janvier, lorsque, comme l'AP l'a
signale precedemment, Mme Bollinger a celebre l'attaque et son maria essaye
d'entrer dans le Capitole. M. Kennedy a filme une conversation video pour leur
groupe au printemps.
11 a egalement courtise les principaux donateurs du Parti republicain, notamment

Leila et David Centner, qui figuraient sur la liste des membres du conseil
d'administration du CHD pour 2021. Le couple est surtout connu pour l'ecole
privee qu'il a creee a Miami, la Centner Academy, qui a mis en place des politiques
antivaccins pour les enfants et les enseignants.
Theorie discreditee sur le mercure

AR02378
M. Kennedy dit souvent qu'il a commence a s'interesser aux vaccins apres qu'une
mere lui ait dit qu'elle croyait que son fils avait developpe l'autisme ala suite d'une
exposition au mercure contenu dans un vaccin.
Cette theorie a ete completement deboulonnee. Cette forme de mercure, le

thimerosal, a ete supprimee des vaccins infantiles il y a des annees sans aucun effet
sur les niveaux d'autisme. Pourtant, M. Kennedy et d'autres continuent d'affirmer,
contre le consensus scientifique, que les vaccins sont lies a l'autisme, aux allergies
alimentaires et a une foule d'autres problemes medicaux. Parmi les ingredients
contre lesquels il met en garde, il y a des substances courantes telles que
!'aluminium, l'acetaminophene, le fluorure et les additifs alimentaires.
En 2015, M. Kennedy a rejoint Eric Gladen, qui avait fonde en 2007 un groupe
appele World Mercury Project dans le sud de la Californie. M. Gladen pense qu'il a
ete empoisonne au mercure ala suite d'une injection contre le tetanos et il a realise
un film intitule Trace Amounts.
M. Gladen a declare al'AP que des membres de la famille Kennedy l'avaient exhorte
aprendre ses distances avec le groupe apres qu'il ait projete son film dans la maison
de la s~ur de M. Kennedy a Malibu. Le lendemain matin, se souvient M. Gladen,
M. Kennedy l'a appele a 6 heures pour lui dire qu'il pourrait compter sur lui.
Le World Mercury Project avait du mal a rester a flat, mais tout a change lorsque
M. Kennedy s'est implique. 11 etait « une machine », faisant des recherches, ecrivant
des lettres ouvertes, pronon~ant des discours et se connectant avec des personnes
bien placees, a declare M. Gladen. 11 n'y avait « presque aucune limite » a qui ils
pouvaient rejoindre.
Le World Mercury Project, qui n'avait inscrit que 13n4 $ de revenus sur sa
declaration d'impot de 2014, a declare des revenus 467443 $ l'annee suivante, apres
!'implication de M. Kennedy.
M. Gladen a demissionne du World Mercury Project pour des raisons de sante en

AR02379
aout 2016, mais continue de soutenir son travail.
M. Kennedy est devenu president du conseil d'administration et chef du

contentieux. Le groupe s'est rebaptise Children's Health Defense en 2018,
supprimant le mot « mercure » de son nom et annorn;ant une mission elargie. Un
communique de presse a mis l'accent sur l'autisme, le TDAH et d'autres
« epidemies de sante » affectant les enfants. 11 n'a mentionne les vaccins qu'une
seule fois, presque de maniere incidente.
M. Kennedy a declare aTucker Carlson lors d'une entrevue a Fox en juillet 2017 que
son travail sur les vaccins etait « probablement le pire choix de carriere que j'aie
jamais fait ». Lorsque l'animateur de Fox News lui a demande s'il « etait paye pour
cela », Kennedy a repondu: « Non, je ne le suis pas. En fait, je perds meme de
l'argent ».
Selan ses declarations de revenus, M. Kennedy a rec;u 131250 $ de Children's Health

Defence en 2017. En 2018, il a rec;u 184375 $. En 2019, l'annee la plus recente
disponible, sa remuneration etait passee a 255000 $. M. Kennedy a declare ce mois-
ci au site conspirationniste lnfoWars qu'il avait « le contraire d'un motif de profit».
« J'ai probablement perdu 80 % de mes revenus acause de ce que je fais, ainsi que
de nombreuses amities, en plus de relations endommagees, meme avec des
membres de ma famille », a declare M. Kennedy.
Pourtant, le succes de la collecte de fonds de CHD n'a fait qu'augmenter avec

!'implication de M. Kennedy, et aucune annee n'a ete plus fructueuse que 2020.
Des documents deposes par le groupe en Californie montrent qu'en 2018, CHD a
declare un chiffre d'affaires brut de l,l million de dollars. Cela est passe a pres de
3 millions US en 2019. En 2020, l'annee la plus recente disponible, les revenus
avaient plus que double pour atteindre 6,8 millions US.
Le groupe a indique qu'il avait depense plus de 3,5 millions US en depenses de

programmes l'annee derniere, la premiere annee de la pandemie. Cela comprend la
AR02380
production de 49 « videos educatives » et de six livres electroniques, a rapporte
CHD a Guidestar.
Le groupe de M. Kennedy a egalement fait pression concernant la legislation sur les

vaccins clans les Etats ; collecte d'importantes sommes d'argent aupres d'interets
particuliers, tels que les chiropraticiens ; et depose plusieurs poursuites, dont une
poursuite de 5 millions l'annee derniere contre Facebook. 11 pretend notamment
que Facebook a desactive le« bouton de don» sur sa page, nuisant aux efforts de
financement de CHD. Rien qu'en mai 2019, selon sa poursuite, Children's Health
Defence dit avoir rec;u 24872 $ US de dons d'utilisateurs de sa page Facebook. Un
juge federal a rejete la poursuite en juin, mais CHD fait appel.
Profiter du nom Kennedy
M. Kennedy utilise egalement son nom de famille et son heritage pour collecter des
fonds.
A plusieurs reprises, il a offert un voyage au complexe Kennedy a Cape Cod comme

leurre pour recueillir des dons pour Children's Health Defence. Alors que des
photos de famille et des images de personnes, dont le president John F. Kennedy,
defilaient sur l'ecran d'un appel Facebook, Robert F. Kennedy fils a declare que le
gagnant rencontrerait des membres de la famille Kennedy lors de la visite.
« 11 y a toujours beaucoup de monde et une bonne conversation, a-t-il declare clans

une video publiee en 2020. Si ma mere decide de venir, l'aventure est garantie. »
Kerry Kennedy a declare que son frere avait supprime du contenu familial a sa
demande. Pourtant, a-t-elle note, il continue de faire reference au nom du
president Kennedy pour faire avancer sa position antivaccins.
AR02381
« Quiconque croit cela ne connait pas son histoire. Les vaccins ont ete un effort
majeur de John F. Kennedy, ala fois en tant que senateur et plus tard en tant que
president», a-t-elle declare.
« j'aime Bobby, (mais) je pense qu'il se trompe completement sur cette question et
qu'il est tres dangereux, a-t-elle declare. Le fait de ne pas se faire vacciner met la vie
des gens en danger. Cela a non seulement un impact sur la personne qui refuse le
vaccin, mais met en peril la communaute clans son ensemble.»
Mais cela ne l'a pas decourage. 11 nomme souvent les principaux responsables
gouvernementaux et scientifiques auxquels il a acces, y compris Francis Collins, le
directeur des National Institutes of Health.
« Une partie de l'avantage de faire partie de ma famille est que je peux avoir ces
personnes au telephone presque instantanement », a declare M. Kennedy ala
Centner Academy.
M. Collins a declare a l'AP qu'il etait « tres dec;u » de M. Kennedy.
« Avec la puissance de son nom - avec son heritage remarquable et une famille qui
a tant fait pour l'Amerique - qu'il l'utilise pour repandre des mensonges sans se
rendre compte, en se regardant clans le miroir, qu'il fait du mal », a declare
M. Collins, ajoutant, « Honte alui ».

AR02382
LA
PRESSE
Enseignante antivaccin dans une ecole primaire
Pas un cas isole

AR02383
PHOTO DAVID BOILY, ARCHIVES LA PRESSE
« Taus les jours, je dais cotoyer des membres du personnel qui ne respectent pas les mesures », affirme une
enseignante.
L'enseignante d'arts plastiques de l'ecole primaire Saint-Emile, a

Montreal, qui s'expose a« des consequences» pour ne pas avoir
respecte les consignes sanitaires, n'est pas un cas isole,
contrairement ace qu'affirme le gouvernement.
Publie le 25 sept. 2021
SUZANNE COLPRON
LA PRESSE
Des parents et des professeurs inquiets nous ont fait part de situations troublantes,
vendredi, ala suite de la publication de la chronique d'lsabelle Hachey sur
AR02384
!'adoption par le gouvernement d'une loi interdisant les manifestations contre les
mesures sanitaires a mains de 50 metres des ecoles, des services de garde et des
etablissements de sante, intitulee « Proteger les eleves hors des ecoles ... et dedans
auss1 ».
Lisez la chronique d'lsabelle HacheY..
A Chelsea, pres de Gatineau, la directrice de l'ecole primaire Montessori, Nancy

Courchesne, relaie sur Facebook des publications antivaccins et antimasques, dans
un franc;ais truffe de fautes.
« Evidemment le monde ne mais pas les priorites au bonne place ! Une vrai
tristesse », peut-on lire.
Le 2 septembre, elle a fait partager un montage video ou le premier ministre

Fran~ois Legault et le directeur national de sante publique du Quebec, Dr Horacio
Arruda, demandent de ne pas utiliser de masques a des fins preventives, lors de la
premiere vague de la pandemie de COVID-19. « j'ai jamais vu autant de
contradiction! lls le disent eux meme et on force des enfants a porter ea
8 hrs [sic] », ecrit-elle.
Mme Courchesne, une femme d'affaires nommee directrice de l'ecole Montessori de

Chelsea au debut de la pandemie, n'a pas rappele La Presse.
Le 5 septembre, elle a aussi relaye une publication de Denis Rancourt, ancien

professeur de physique congedie en 2009 par l'Universite d'Ottawa apres avoir
accorde une note de A a tous ses etudiants. « Nous continuons a nous demander:
"Pourquoi les donnees ne sont-elles pas autorisees a etre examinees et pourquoi les
experts independants sont-ils censures s'ils tentent de le faire ?", ecrit ce dernier. 11
est incomprehensible, et decidement anti-canadien, de voir reduire au silence des
medecins et des scientifiques de la sante hautement estimes dans notre pays et
dans le monde entier. »
AR02385
Une mere, qui a requis l'anonymat pour preserver l'anonymat de son enfant ayant
frequente cette ecole privee, s'interroge : « Comment est-ce possible qu'une telle
personne assure la gestion d'un etablissement scolaire? Je veux bien croire ala
liberte d'expression, mais est-ce vraiment le cas ici? »
Ailleurs au Quebec, des profs et des parents nous ont fait part d'un relachement par
rapport aux mesures sanitaires.
« Taus les jours, je dais cotoyer des membres du personnel qui ne respectent pas
les mesures », affirme une enseignante.
« Jouer ala police du masque avec les eleves, c'est une chose ; le faire avec ses
collegues parce que la direction est tannee de gerer tout ce qui vient avec la
pandemie, e'en est une autre. On nous impose des reunions ou la distanciation est
impossible, faute de place, et ou le port du masque n'est pas exige », poursuit-elle.
« Je suis antivaccination »
La Presse a aussi parle aun professeur de cegep qui ne cache pas etre antivaccin.
« Moi, je suis antivaccination. Par contre, je suis [pour le] libre choix », nous a-t-il
dit, nous demandant de taire son nom et celui de l'etablissement qui l'emploie, de
peur de represailles. « Si quelqu'un pense qu'il devrait recevoir le vaccin parce qu'il
pense que c'est bon pour lui, qui suis-je pour juger mon prochain? Mais, moi, j'ai
decide que mon corps n'a pas besoin d'un vaccin et que je ne suis pas un danger
public pour les autres. Jene vois pas pourquoi je recevrais un vaccin ni pourquoi je
me ferais mettre en quarantaine. »
Cet enseignant dit vivre sa vie « exactement comme avant la COVID ».
« La COVI D, pour moi, n'existe pas. C'est une maladie, un virus, mais je vis
comme s'il n'etait pas la. Je porte le masque dans les endroits publics ou je
AR02386
dois le porter comme un bon citoyen. Je me lave les mains comme un bon
citoyen. Mais je ne m'empeche pas de faire des calins, donner des tapes
dans les mains et ainsi de suite. »
- Un professeur de cegep dans un entretien avec La Presse
Des parents, mis au courant de la situation, ont avise la direction du cegep ou il

enseigne. « Mais aux dernieres nouvelles, il est toujours en paste», indique-t-on.
Le directeur de l'etablissement n'a pas rappele La Presse.
Au Quebec, les cas de COVID-19 se multiplient clans les ecoles: plus d'un
etablissement sur trois a deja rapporte au mains un cas d'infection depuis le debut
de l'annee scolaire. Deja, le mois dernier, des experts reclamaient la vaccination
obligatoire clans le reseau de !'education, particulierement au primaire, ou les
enfants ne sont pas vaccines, mais egalement au secondaire, au cegep et a
l'universite.
On ne peut pas evidemment etablir de lien de cause a effet entre ces eclosions
scolaires et un faible pourcentage de professeurs non vaccines. Mais !'inquietude
exprimee par des parents et des enseignants met en relief le malaise quant a
l'absence de direction sur !'obligation vaccinale clans le systeme scolaire.
Selan un sondage commande par le gouvernement a la fin du mois d'aout, 97,9 %

des enseignants du primaire et du secondaire seraient pleinement vaccines contre
la COVID-19 ou en voie de l'etre. Seuls 2,r % ne seraient pas vaccines (environ
2000 enseignants) et r,7 % n'auraient pas de rendez-vous et n'auraient pas
!'intention de se faire vacciner.

AR02387
LA
PRESSE
La vaccination, une certaine

immunite contre le complotisme,
croient des experts
AR02388
PHOTO HUGO-SEBASTIEN AUBERT, ARCHIVES LA PRESSE
Manifestation contre les mesures sanitaires, a Montreal , le 20 decembre dernier
Alors que la campagne de vaccination de masse contre la

COVI D-19 s'entame au Quebec, les complotistes et les
antimasques, eux, sont encore bel et bien presents dans la
province. Leur nombre, qui a explose pendant la deuxieme vague
l'automne dernier, pourrait toutefois diminuer avec le temps, au
fur et a mesure que la protection contre le virus « se normalise ».
Malgre tout, un defi demeure: l'hesitation d'une bonne frange de
la population ase faire vacciner.
Publie le 1er mars 2021
AR02389
HENRI OUELLETTE-VEZINA
LA PRESSE
« Je pense que beaucoup de gens vont changer leur vision, en quelque sorte, avec la
vaccination. La vie vase normaliser. c;a va tranquillement devenir mains obsedant,
cette question de la theorie du complot », explique a La Presse la Dre Cecile
Rousseau, responsable de l'equipe clinique Polarisation du CIUSSS du Centre-
Ouest-de-l'lle-de-Montreal.
A ses yeux, la perspective d'une societe deconfinee et vaccinee donnera une bouffee
d'oxygene a bien des Quebecois qui ont souffert d'isolement dans la derniere
annee. « On peut s'imaginer qu'a terme, c;a va faire en sorte que les gens sortent un
peu de leur isolement, soient mains sur !'internet, consomment mains de contenus
de maniere compulsive. Tout c;a nourrit le complotisme », raisonne la
Dre Rousseau.
Plus sollicitee depuis le debut de la pandemie, son equipe clinique fournit

notamment une evaluation et du soutien aux « prises en etau de la radicalisation »,
ce qui comprend les theories du complot, mais aussi l'extremisme ideologique ou
encore le supremacisme blanc.
D'apres les analyses de la clinique, les theories du complot liees a la COVID-19 ont
surtout pris de la vigueur au tournant de la deuxieme vague. « Le printemps
dernier, la premiere reponse de la majorite, c;'a ete la peur et la sideration. Tout le
monde restait done chez soi, de fac;on exceptionnelle. Sauf qu'on ne peut pas rester
paniques des annees. La vie doit continuer. Comme beaucoup se sentaient
impuissants, le complotisme est venu donner du sens a leur vie. lls avaient
!'impression qu'au mains, maintenant, ils comprenaient », rajoute la docteure.
« C'est un deni du danger, comme pendant une guerre. Quand ii y a des

bombardements, les gens sont paniques. Puis, ~a se "chronicise", et la
AR02390
menace est banalisee. Les enfants se mettent meme ajouer sur les bombes
et les obus. »
- La ore Cecile Rousseau, psychiatre
Encore beaucoup d'hesitation vaccinale
11 reste que « !'hesitation vaccinale », elle, augmente al'echelle du pays, convient la

Dre Rousseau. Recemment, une etude de l'Universite de Sherbrooke concluait que
seulement 59 % des Canadiens souhaitent recevoir le vaccin contre la COVID-19.
Les memes donnees avaient ete publiees en juin et evaluaient plutot cette
proportion apresque 69 %. « Ces resultats sont inquietants alors que les
scientifiques fixent a environ 70 % le taux de personnes vaccinees a atteindre pour
parvenir a l'immunite collective », lisait-on clans le rapport d'etude, codirige par
l'enseignante Marie-Eve Carignan, specialisee en communication de crise.
« Ces resultats devraient serieusement inquieter nos dirigeants. Un plan
d'action doit etre mis de l'avant pour renverser cette tendance et combattre
la peur et la desinformation associees au vaccin. »
- Marie-Eve Carignan, professeure de communication a l'Universite de Sherbrooke
Selan elle, vu la « correlation positive significative entre la propension a adherer

aux idees conspirationnistes et la propension a refuser la vaccination », il y a lieu
« de se questionner sur l'impact potentiel des idees conspirationnistes en termes de
sante publique » au Quebec et au Canada.
Un constat que partage la professeure a l'Ecole de sante publique de l'Universite de

Montreal Roxane Borges Da Silva. « Tant qu'on n'a pas une immunite assez grande,
entre 60 % et 80 % selon les differentes etudes, la crise risque de perdurer. C'est
seulement quand la vaccination atteindra ces cibles qu'on reviendra ala vie
normale et que, done, ces craintes collectives vont tranquillement disparaitre »,
AR02391
explique-t-elle.
« Dans toutes les crises sanitaires et epidemies que l'humanite a vecues, depuis le
xv111e siecle, on a vu des conspirationnistes emerger, etant donne la peur et
!'incertitude. Maintenant, la question, c'est toujours de savoir s'ils vont s'arreter. Je
ne le sais pas, mais si c'etait le cas, il y aura certainement d'autres occasions pour
qu'ils se redonnent une voix », conclut Mme Borges Da Silva.

AR02392
LA
PRESSE
Le passeport et les
• •
ant1vacc1ns
AR02393
PHOTO MARCO CAMPANOZZI, ARCHIVES LA PRESSE
Christian Dube, ministre de la Sante et des Services sociaux, en conference de presse jeudi
FRANCIS VAILLES
LA PRESSE
Les chiffres sont clairs : les nouveaux malades de la

COVID-19 sont ceux qui n'ont pas ete vaccines,
essentiellement. Et ces malades, ils sont soignes par notre
systeme de sante, qui est finance par nos impots collectifs.
Publie le 10 juill. 2021
a
Des lors, pourquoi ne pas contraindre les recalcitrants se faire vacciner? Pourquoi
AR02394
ne pas exiger le passeport vaccinal pour avoir acces aux services publics et prives,
a
ce qui les obligerait se faire piquer?
L'analyse statistique publiee cette semaine par le ministre de la Sante et des

a
Services sociaux, Christian Dube, nous amene nous poser ce genre de questions.
Selon cette breve analyse, les deuxtiers des nouveaux cas quotidiens de COVID-19
sont enregistres chez ceux qui n'ont rec;u aucune des deux doses de vaccin. Encore
plus marquant: parmi les personnes hospitalisees, 4 sur 5 n'avaient rec;u aucune
dose.
Lisez « 95 % ay:ant contracte le virus n'etaient ~as ~leinement vaccines »
Le ministre prend tousles moyens non contraignants pour inciter les refractaires -
notamment les 18-39 ans - apasser al'acte. En publiant son tweet statistique,
mercredi, le ministre a presente la vaccination comme une arme contre un
repoussant reconfinement lors d'une possible quatrieme vague.
Et jeudi, ii a avise la population que ceux qui auront re~u deux doses auront
des privileges advenant une eclosion, grace a leur passeport vaccinal, comme
l'acces aux bars.
Le ministre evite toute mesure coercitive, par exemple !'obligation d'etre

pleinement vaccine pour obtenir des services essentiels (alimentation, sante, etc.).
Ou encore la facturation des frais d'hospitalisation aux patients atteints de
COVID-19 qui auraient refuse de se faire vacciner pour des raisons autres que
medicales.
Une telle facture d'hospitalisation est fort salee. En moyenne, un patient hospitalise
a
pour la COVID-19 coute 15 000 $, facture qui grimpe 50 000 $ lorsque des soins
intensifs sont requis, selon un rapport de l'Institut canadien d'information sur la
a
sante (ICIS). La facture d'hospitalisation liee la COVID-19 est quatre fois plus
a
elevee que celle d'un sejour moyen l'hopital autre que pour la COVID-19.
AR02395
Les antivaccins, qu'on trouve souvent parmi les groupes anticonfinement ou parmi
ceux qui nient !'existence meme de la COVID-19, crieraient au loup, probablement.
Ces groupes souvent de droite populiste reclament pourtant la liberte et la fin du
« gouvernemaman ».
Or, ce « gouvernemaman » leur offre justement des so ins gratuits, contrairement

aux Etats-Unis, ou ces apotres de la liberte totale doivent payer les frais
d'hospitalisation lorsqu'ils sont malades ou encore acquitter une prime d'assurance
privee parfois plus elevee selon leurs antecedents medicaux.
Cela dit, la facturation poserait des problemes ethiques importants. Laissera-t-on

mourir un patient sans moyens, qu'il soit complotiste ou non?
Et ace compte, si l'Etat decide de faire payer les frais d'hospitalisation pour la
COVID-19, pourquoi ne le ferait-il pas pour les autres patients qui mettent
sciemment leur sante a risque, comme les fumeurs, les chauffeurs automobiles
imprudents, les personnes qui ont un comportement sexuel a risque, les personnes
qui s'alimentent mal, etc. ?
Et encore, pourquoi n'y aurait-il pas une gradation selon le niveau de risque? Un
fumeur occasionnel paierait-il moins qu'un fumeur regulier?
Surtout, une sante publique coherente veut tenir compte des motifs qui en incitent
certains a fumer, a boire OU a trop manger, par exemple. Leurs comportements
peuvent venir de leur education, de leur milieu de vie, de leur environnement, de
stress particuliers, etc.
Un fumeur qui aurait appris a vider deux paquets par jour en imitant ses parents
pauvres serait penalise doublement s'il devait en plus payer ses soins.
Est-ce different pour la COVID-19? Un peu, quand meme. Car le patient qui est
atteint risque d'en contaminer plusieurs autres, davantage qu'un fumeur avec la
fumee secondaire ou un automobiliste qui roule a 140 km/h.
AR02396
Ne l'oublions pas, meme ceux qui sont vaccines peuvent attraper la
COVID-19, souvent avec moins de consequences, mais parfois avec autant
de virulence, puisque la double vaccination est efficace pour 90 a95 % des
cas, pas pour 100 %.
Et qu'arriverait-il s'il y avait une quatrieme vague? Et que les malades,
a
essentiellement ceux non vaccines, occupaient des places l'hopital, avec le
personnel, dont ne pourraient beneficier les patients atteints d'autres problemes de
sante?
Souhaitons que les mesures incitatives de Christian Dube portent leurs fruits. Et
que la proportion des Quebecois avec deux doses atteigne rapidement la cible pour
a
avoir une immunite collective, soit 75 % 80 % pour les 12 ans et plus.
En attendant, le Quebec peut etre fier de sa solidarite collective. La province est l'un
des endroits ou le taux de vaccination est le plus eleve au monde (71,8 % de toute la
population avec au moins une dose et 82,1 % des 12 ans et plus).
a
Aux Etats-Unis, une large part de la population, celle moins instruite, plus droite
et plus rurale, refuse de se faire vacciner, ce qui fait stagner la progression vers
l'immunite collective. Ainsi, 55 % de !'ensemble des Americains a rec;u au moins une
dose, soit pres de 17 points de pourcentage de moins qu'au Quebec (71,8 %). Bien
content d'etre quebecois !
© La Presse Inc. Tous droits reserves .

AR02397
LA
PRESSE
Le probleme avec le nrRaoult

AR02398
Les fl.eurs, d'abord. J'aime !'emission Bien entendu, ala

radio de Radio-Canada. J'aime ecouter Stephan Bureau
confesser toutes sortes de personnalites, sa fa<;on de nous
les faire decouvrir, sans prejuges, sous un nouveaujour.
Publie le 27 mai 2021
ISABELLE HACHEY
LA PRESSE
Le pot, maintenant. Mercredi matin, Stephan Bureau n'a pas reussi a faire c;a.
Remarquez, personne ne s'attendait ace qu'il nous revele la face cachee de
Didier Raoult.
AR02399
PHOTO CHRISTOPHE SIMON, AGENCE FRANCE-PRESSE
Didier Raoult, directeur de l'lnstitut hospitalo-universitaire de Marseille
En fait, beaucoup auraient prefere que l'animateur n'accorde pas de tribune

au controverse - le mot est faible - directeur de l'lnstitut hospitalo-
universitaire de Marseille. Et, dans ce cas precis, je partage cette opinion.
Pas parce que Didier Raoult est controverse. J 'interviewerais volontiers les pires
dictateurs de la planete si on m'en donnait !'occasion. On ne fait pas dujournalisme
pour ne donner la parole qu'a des etres respectables.
Non, le probleme avec le Dr Raoult, c'est que cet infectiologue est devenu lui-
meme ... viral. Une reference incontournable chez les negationnistes de la pandemie.
Un gourou suivi passionnement, aveuglement, par les complotistes antimasques,
antivaccins, anti-toutte -vous savez, ceux qui sont tellement fiers de nous dire qu'ils
ont fait leurs recherches.
Ceux-la adorent Didier Raoult. Ils le venerent, meme s'il est desormais clair que le
AR02400
doc de Marseille avait tout faux apropos de son traitement a l'hydroxychloroquine.
Et meme si les faits ne cessent de le contredire.
Enjanvier 2020, par exemple, ce grand specialiste des infections epidemiques

raillait : « Il y a trois Chinois qui meurent et c;a fait une alerte mondiale ... »
En fevrier 2020: « La chose la plus intelligente qui a ete dite, c'est par Trump qui a
dit que cela allait disparaitre au printemps ... »
En mai 2020 : « La chance qu'un vaccin pour une maladie emergente devienne un
outil de sante publique est proche de zero. [...] Trouver un vaccin est un defi idiot ! »
J e pourrais continuer longtemps. Au fil de la pandemie, Didier Raoult s'est fait une
specialite de dire une chose et son contraire. Avec une ligne directrice: la pandemie
n'est pas si grave; elle ne menace pas la sante publique.
Pas etonnant que le Dr Raoult soit venere par les complotistes de la planete : il leur
dit ce qu'ils veulent entendre. Il alimente leur delire. Il retarde le groupe.
***
Stephan Bureau comprend ceux qui se sont opposes ace qu'une tribune soit offerte
a Didier Raoult a la radio publique, mais ne partage pas leur avis. « Pour juger, il faut
quand meme encore entendre », s'est-il defendu en ondes.
Mais l'autre probleme avec le or Raoult, bien franchement, c'est qu'on l'a deja
assez entendu. Plus qu'assez, meme.
Et que pour vraimentjuger, il aurait fallu entendre des reponses a des questions pas
mal plus serrees.
En 42 minutes d'interview, l'animateur n'a pas trouve le moyen d'interroger

Didier Raoult sur la poursuite que ce dernier vient de deposer contre Elisabeth Bik,
microbiologiste neerlandaise specialisee en integrite scientifique.
AR02401
Pourtant, cette histoire est un pur scandale.
***
Elisabeth Bik est un chien de garde des publications scientifiques. Elle a force la
retractation de plus de 400 faux articles de recherche. Elle se specialise dans le
plagiat, les manquements ethiques, les manipulations d'images et les fraudes
scientifiques.
En mars 2020, la microbiologiste s'est penchee sur une etude du Dr Raoult qui
vantait les vertus de l'hydroxychloroquine pour traiter la COVID-19. Elle a note que
trois patients traites avaient ete transferes aux soins intensifs. Un autre etait mort.
Or, ces patients avaient ete exclus de l'etude.
Forcement, une fois ces patients disparus, les donnees paraissaient tres
prometteuses ...
Elisabeth Bik a ensuite releve des problemes de methodologie ou de manipulation

de donnees dans des dizaines d'autres publications du Dr Raoult et de ses equipes.
Pendant des mois, le Dr Raoult a repondu en insultant la chercheuse. « U ne

a
cinglee », a-t-il lache la tele nationale. « Une chasseuse de sorcieres », « une fille
qui me traque », « une chercheuse ratee », a-t-il encore peste.
Puis, le Dr Raoult et Eric Chabriere, un professeur d'Aix-Marseille, ont lache les

chiens : ils ont publie les coordonnees personnelles de la microbiologiste sur les
I •
reseaux soc1aux ...
Le 29 avril, les deux hommes ont depose une poursuite contre Elisabeth Bik aupres
du procureur de Marseille, l'accusant de « harcelement, tentative de chantage et
extorsion ».
***
Tentative de chantage? Selon Le Monde, un simple tweet d'Elisabeth Bik serait a

AR02402
a
l'origine de cette accusation. En reponse une attaque sur son integrite, elle avait
a
suggere l'Institut du Dr Raoult de la soutenir par l'entremise d'un site de
financement participatif.
L'ironie du message - soulignee par une emoticone - semble avoir echappe au

Dr Raoult et ason confrere.
Harcelement? Cette fois, ce sont les critiques - serieuses et documentees - des

articles publies par le Dr Raoult qui seraient en cause.
Disons-le sans detour, cette poursuite est une basse manoouvre, de la part du
Dr Raoult, pour tenter de reduire Elisabeth Bik au silence. Non seulement
elle, mais tous les experts qui auraient l'audace de critiquer ses travaux, a
l'avenir.
AR02403
PHOTO COMMONS WIKIMEDIA
Elisabeth Bik, microbiologiste neerlandaise specialisee en integrite scientifique
Admettons que ce n'est pas tres scientifique, comme procede. Qa releve de

l'obscurantisme.
D'ailleurs, des centaines de scientifiques ont signe une lettre de soutien leur a
consCBur. Jamais des scientifiques ne devraient etre harceles de la sorte, estiment-
ils, pour avoir mis en lumiere des manquements dans les travaux de recherche de
AR02404
leurs pairs.
Avec cette poursuite honteuse, c'est la science elle-meme que le Dr Raoult tente de
baillonner.
***
a
Mais vous n'aurez pas entendu parler de cette affaire, mercredi, !'emission Bien
entendu. « D'aucuns m'ont predit que j'allais organiser le suicide de ma carriere
simplement en vous invitant », a glisse Stephan Bureau au Dr Raoult en de but
d'interview.
Franchement, je ne pense pas.
Jene pense pas qu'il faille du courage pour interviewer Didier Raoult. J e pense qu'il
en faut pour le critiquer. Pour soulever des questions difficiles sur l'integrite de ses
travaux. Sur le populisme scientifique qu'il exploite sans gene. Sur son influence
inquietante dans la sphere complotiste.
Qa prend du courage parce que Didier Raoult dispose d'une armee de partisans en
ligne. De petits soldats teigneux, qui attaquent en meute, qui abreuvent d'insultes,
a
qui menacent de mort. Demandez ceux qui ont ose le critiquer. Demandez aux
journalistes scientifiques. Aux chroniqueurs. Aux medecins.
a
Demandez Elisabeth Bik.

AR02405
LA
PRESSE
Les anti-masques et les

imb8ciles
AR02406
C'est tentant de traiter les anti-masques d'abrutis. C'est

meme parfois tout a fait justifie. J e pense aces deux
manifestants anti-masques tout fiers d'agresser une
journaliste de TVA lors d'une intervention en direct,
dimanche.
Publie le 28 juill. 2020
RIMA ELKOURI
LA PRESSE
a
Ce n'est pas parce qu'ils sourient la camera que c'est drole. Laliberte d'expression
ou d'opinion n'inclut pas le droit d'agresser des journalistes qui font leur travail. Elle
n'inclut pas non plus le droit au sexisme. Qa vaut en temps « normal». Qa vaut
AR02407
encore plus en temps de pandemie, ou les regles de distanciation physique
s'imposent.
Lorsqu'on voit les derapages des manifestations anti-masques qui ont eu lieu a
a
Montreal et Quebec durant le week-end au nom de la « liberte », on peut se
demander de quelle liberte il est question ici. Laliberte d'intimider? Laliberte
d'agresser? Laliberte de mettre en peril la sante des autres et de s'en prendre leur a
integrite physique ?
PHOTO ERICK LABBE, LE SOLEIL
Des manifestants contre le port du masque devant le parlement a Quebec , dimanche
On ne peut que denoncer haut et fort ces inquietants derapages, comme l'a fait lundi
la vice-premiere ministre Genevieve Guilbault. Mais une fois qu'on a dit c;a, une
question demeure : que faire de ce discours inquietant selon lequel la pandemie est
finie ou n'ajamais existe?
Dans certains cas, on ne peut rien faire. Il n'y a aucun dialogue possible. Aucune
AR02408
possibilite d'avoir une discussion rationnelle.
En fait, je me demande meme si c'est bien necessaire de donner une tribune dans
les medias aces manifestants souvent adeptes de theories du complot. Ils ont bien
sur le droit de manifester. Mais on a aussi le droit de les ignorer.
L'objectivite enjournalisme ne consiste pas a accorder autant de temps d'antenne

aux pro-masques et aux anti-masques, aux anti-racistes et aux racistes, aux
environnementalistes et aux climatosceptiques, aux pro-vaccins et aux anti-
vacc1ns.
Toutes les opinions ne se valent pas. Chacun a bien sur le droit ases propres
opinions. Mais pas ases propres faits.
« Laliberte d'opinion est une farce si !'information sur les faits n'est pas garantie et
si ce ne sont pas les faits eux-memes qui font l'objet du debat », disait lajournaliste
et philosophe Hannah Arendt en 1961. C'est toujours aussi vrai aujourd'hui.
On peut les ignorer, done. Ne pas leur servir de porte-voix au nom de la liberte
d'opinion. Mais c;a n'efface pas le fait qu'un tel discours n'est pas uniquement le
propre de gens imbeciles, irrationnels ou irresponsables.
Un sondage CROP rendu public la semaine derniere revelait que si la majorite des
Quebecois sont favorables au port du masque dans les commerces, certains
segments de la population sont plus recalcitrants: lesjeunes de 18 a 34 ans (20 %)
et les citoyens de la region de Quebec (24 %). Oui, c'est une minorite. Mais elle n'est
quand meme pas negligeable. Si une personne sur cinq ne respecte pas les
consignes, cela ne peut qu'augmenter les risques de voir monter en fleche les
nouveaux cas de COVID-19. C'est d'ailleurs deja le cas. La vice-premiere ministre
Genevieve Guilbault disait lundi observer une tendance inquietante chez lesjeunes
de 15 a 34 ans.
> Lisez notre article sur le sondage CROP

AR02409
Alors que faire? Pour convaincre les recalcitrants, les autorites de sante
publique ont davantage interet a comprendre ce qui motive leur
comportement plutot qu'a leur faire la morale. Reconnaitre en premier lieu la
confusion et la mefiance que leur propre discours changeant a suscitees ...
Si vous avez entendu pendant des mois le Dr Arruda dire que le port du masque est
presque inutile, il faut etre en mesure d'expliquer de maniere encore plus
convaincante pourquoi, tout a coup, ce qui etait presque inutile hier encore est
devenu obligatoire. Par ailleurs, si les autorites mettent l'accent dans leurs bilans
quotidiens sur les morts et insistent sans cesse sur le fait que la COVID-19 est
surtout dangereuse pour les personnes agees, on peut difficilement se surprendre de
voir des jeunes se sentir invincibles devant la maladie et ne pas trop se formaliser
des regles sanitaires.
Il serait bon de leur rappeler, comme l'a fait la vice-premiere ministre, qu'en plus
d'etre des vecteurs de transmission pour des personnes plus vulnerables, ils
peuvent eux-memes etre tres malades, se retrouver aux soins intensifs et en garder
des sequelles.
Partout au pays, c'est chez lesjeunes de moins de 39 ans qu'on a constate les taux les
plus eleves de cas de COVID-19 depuis deux semaines (61 %). Et ils comptaient
pour 21 % des hospitalisations liees ala COVID-19, a souligne l'administratrice en
chef de la Sante publique au Canada, la Dre Theresa Tam.
Dans un article fort interessant sur les anti-masques publie dans The Atlantic,
l'epidemiologiste et professeure a la Harvard Medical School, Julia Marcus
soulignait que si la colere a l'egard des gens qui s'opposent au port du couvre-visage
est comprehensible et que l'on peut eprouver uncertain soulagement ales traiter de
tousles noms, cela demeure contre-productif. On convainc rarement quelqu'un de
changer de comportement en l'humiliant. En fait, le plus souvent, cela produit l'effet
contraire.
AR02410
> Lisez l'article de The Atlantic (en anglais)
a
Les autorites de sante publique auraient en ce sens inten~t s'inspirer des legons
a
que l'on a pu tirer de la crise du sida, observe l'epidemiologiste. Aux Etats-Unis, la
fin des annees 80, les campagnes de prevention du sida qui misaient sur la morale,
a
la honte et la peur sont souvent tombees plat. Le fait que le Congres ait banni en
1987 l'usage de fonds federaux destines ades campagnes qui pourraient
« promouvoir ou encourager» les activites homosexuelles n'a pas aide. Sur une
affiche montrant une pierre tombale, on pouvait lire des choses comme: « Une
a
mauvaise reputation n'est pas la seule chose qu'on obtient en couchant droite et a
gauche». Le genre de messages qui ratait la cible ... A!'inverse, ce qui fonctionnait
beaucoup mieux, ce sont les campagnes qui misaient sur la reduction des mefaits en
s'interessant aux besoins humains fondamentaux des gens. Des campagnes qui
tenaient compte des raisons pour lesquelles les gens pouvaient etre recalcitrants a
adopter le condom et y repondaient.
a
La crise de la COVID-19 est bien des egards differente de la crise du sida. Mais elle
nous a appris une chose: de la meme fagon qu'on n'a convaincu personne de porter
un condom par la honte, on ne convaincra personne de porter un masque en le
traitant d'imbecile.

AR02411
LA
PRESSE
Les differents visages

des antimasques
AR02412
PHOTO GRAHAM HUGHES, ARCHIVES LA PRESSE CANADIENNE
Manifestation antimasque, le 12 septembre a Montreal
Les manifestations antimasques qui se multiplient au Quebec

n'ont rien d'un mouvement spontane de citoyens exasperes.
Derriere cette vague de contestation, un groupe aux relents
conspirationnistes de plus en plus structure recolte les dons par
centaines de milliers de dollars. De petits commandos
d'internautes inquiets traquent leurs moindres publications pour
exposer leurs derives.
Publie le 26 sept. 2020
TRISTAN PELOQUIN
LA PRESSE
AR02413
« Liberte, liberte, liberte ! » Le samedi 12 septembre, la foule est dense devant les
bureaux de Radio-Canada. Apres avoir marche bruyamment clans les rues de
Montreal, ils sont des milliers aapplaudir a tout rompre l'homme qui prend la
parole sur scene.
PHOTO GRAHAM HUGUES, ARCHIVES LA PRESSE CANADIENNE
QAnon designe une nebuleuse pro-Trump, qui repand des theories du complot en ligne.
« Je suis tellement fier de vous, lance Stephane Blais ala foule galvanisee, ou
flottent des drapeaux pro-Donald Trump, des pancartes faisant l'apologie du
mouvement complotiste QAnon et des slogans denonc;ant la « tyrannie » et la
« pandemie planifiee par l'elite ».
« On a un devoir de proteger nos enfants. Y'a personne qui va toucher ama

fille ! Et y'a personne qui va toucher avos enfants non plus. On va tous
AR02414
s'entraider, on va se tenir, et on dit a Legault que c'est pas vrai qu'on est des
dociles : on est des leaders. »
- Stephane Blais
Peu connu du grand public, mais venere par certains internautes, l'homme est ala
tete d'une organisation qui a vu le jour le 7 mai dernier: la Fondation pour la
defense des droits et libertes du peuple. 11 est aussi le chef de Citoyens au pouvoir,
un parti politique officiellement inscrit aupres du Directeur general des elections
du Quebec, qui a rec;u 33 959 $ d'allocations publiques en 2019 apres avoir obtenu
0,35 % du vote populaire lors des elections generales de novembre 2018.
C'est cette nouvelle fondation, qui partage la meme adresse de bureau que Citoyens
au pouvoir, qui est al'origine d'une action judiciaire intentee le 8 juin par l'avocat
Guy Bertrand contre le gouvernement du Quebec pour invalider plusieurs mesures
imposees clans le cadre de la lutte contre la pandemie. La demarche juridique a
coute quelque 125 ooo $ a!'organisation, avant que le celebre constitutionnaliste se
retracte en denonc;ant les « declarations souvent intempestives » et les « propos
mensongers » de Stephane Blais, qui « ne peuvent qu'induire en erreur [ses] fans et
la population ».
AR02415
NON au
MASQUE
,.~ Bl\G1'101RE
De nombreux antimasques ant defile a visage decouvert, le 12 septembre a Montreal.
Juste avant de deposer la poursuite, M. Blais a affirme sur Facebook que l'action
demontrerait, « preuves al'appui, que cet episode du COVID-19 n'est rien d'autre
qu'un coup d'Etat international d'une clique de puissants malfrats contre les
peuples du monde ».
La Fondation a aussi verse des les premiers jours de son existence 50 ooo $ a
Vaccine Choice Canada, organisme represente par l'avocat constitutionnaliste
ontarien Rocco Galati pour financer un autre recours judiciaire visant notamment
Justin Trudeau. La procedure soutient que la« pandemie de COVID a ete pre-
planifiee » et est un « complot dirige par Bill Gates et d'autres milliardaires, des
corporations et des oligarques du vaccin, de l'industrie pharmaceutique et des
technologies, atravers l'OMS ».
AR02416
M. Blais a promis au debut septembre sur Facebook que les « criminels, politiciens
corrompus, pedophiles [et les] traitres » seraient « juges tres severement pour [leur]
collaboration, [leur] lachete et [leurs] crimes contre l'humanite ».«Le processus de
divulgation commencera cet automne pour le Quebec et le Canada. Lanceurs
d'alertes et arrestations de personnes d'influence au menu», affirmait-il. M. Blais
n'a pas repondu anos demandes d'entrevue.
D'ou vient l'argent?
Mais d'ou vient l'argent? A la mi-mai, le parti politique Citoyens au pouvoir a

organise sur Facebook et YouTube une grande campagne de financement, clans le
cadre d'un « webothon » diffuse en direct. La comedienne Lucie Laurier et Alexis
Cossette-Trudel, une figure de proue du mouvement complotiste qui affirme sur
son canal YouTube Radio-Quebec que « tout le monde autour de Justin Trudeau
baigne clans la pedophilie », faisaient partie des invites d'honneur. Daniel Pilon, un
candidat defait de Citoyens au pouvoir, dont la page Facebook compte plus de
50 ooo abonnes, y figurait aussi, aux cotes d'Andre Pitre, allias « Stu-Pitt », un
ancien conferencier du groupe identitaire La Meute qui exploite maintenant le Stu-
Dio, un media alternatif campe tres a droite.
M. Blais a declare sur Facebook que La Fondation a recolte 300 000 $ dans
les 72 heures qui ont suivi le « webothon ». Et l'argent a continue d'entrer. En
date du 17 juillet, !'organisation disait avoir recolte 468 000 $, en partie
place dans une fiducie supervisee par un bureau d'avocats.
L'organisation versait aussi un salaire de 1000 $ par semaine a M. Blais et a un autre

administrateur, selon des etats financiers intermediaires consultes par La Presse.
Des dissensions internes sont vite apparues. Caroline Mailloux, une administratrice
qui recevait un salaire de 1500 $ par semaine, a claque la porte en evoquant un abus
de confiance avec M. Blais. Dans un message publie sur Facebook mais supprime
par la suite, elle a souleve differentes irregularites. Elle a notamment affirme avoir
AR02417
eu !'instruction d'informer les donateurs que des rec;us aux fins d'impot seraient
envoyes clans les six prochaines semaines. La Fondation n'est ace jour toujours pas
inscrite au registre federal des organismes de bienfaisance autorise a emettre de
tels rec;us.
D'autres irregularites soulevees par Mme Mailloux, qui impliquaient le parti

politique Citoyens au pouvoir, ont attire le regard du Directeur general des
elections du Quebec. Ce dernier confirme a La Presse avoir « procede a des
verifications quanta la conformite des contributions politiques du parti », mais
refuse de commenter davantage. 11 ne s'agit pas d'une enquete, mais bien de
verifications, precise le DGEQ, qui confirme par ailleurs qu'aucun constat
d'infraction n'a ete remis clans ce dossier.
Mme Mailloux a refuse d'accorder une entrevue a La Presse.
Citoyens au pouvoir et la Fondation dementent les affirmations de Mme Mailloux.

M. Blais les a qualifiees de« tentative de salissage » clans une entrevue accordee au
site chretien Theovox. La Fondation a fait faire une revue diligente par un avocat et
un comptable, a la suite de quoi des etats financiers non definitifs ont ete publies
sur Facebook, ou ils ont pu etre consultes par La Presse. M. Blais a aussi justifie son
salaire de rooo $ par semaine en disant travailler plus de 40 heures par semaine
pour la fondation et avoir refuse des mandats comme comptable pour s'acquitter
de ses taches.
M. Blais, dont le bureau de comptable se trouve aussi a la meme adresse que la

Fondation et le parti politique qu'il dirige, s'est egalement trouve clans la ligne de
mire du syndic de l'Ordre des CPA, dont il est membre. Dans une lettre que
M. Blais a lui-meme rendue publique sur Facebook, le syndic adjoint, Claude
Maurer, lui a demande des eclaircissements au sujet de la fiducie ou l'argent de la
Fondation a ete depose.
Le syndic a egalement exige des explications sur des declarations publiques de

M. Blais, selon qui cet episode du COVID-19 est un « pretexte pour nous
AR02418
conditionner ala docilite et ala repression policiere », que le Dr Horacio Arruda
reve en secret que ses petits-enfants « soient vaccines de force et vivent clans un
Etat policier » et que la« deuxieme vague [de la pandemie] est planifiee ».
« Je suis d'opinion que ces assertions gratuites et sans fondement vont al'encontre
de l'honneur et la <lignite de la profession de CPA», ecrit le syndic adjoint de cet
ordre, qui compte 45 ooo membres professionnels. L'Ordre des CPA a refuse de
nous accorder une entrevue sur cette enquete.
M. Blais a replique clans une video sur Facebook que cette incursion du syndic est
« une commande politique pour [l]'ecceurer » et a exige la demission du syndic
adjoint « sur-le-champ ».«Ne vous approchez plus, je suis en cour contre le
gouvernement du Quebec. Je suis en train de defendre vos propres enfants. Si je
m'exprime comme chef de parti politique ou comme president d'une fondation a
l'effet que le COVID, c'est une grippe qui n'est pas plus virulente qu'une grippe
standard, c'est parce que j'ai raison, et on va aller le plaider en cour. Est-ce que c'est
clair? a-t-il martele. Restez sur votre terrain, et ne venez pas faire de politique. »
Serie de manifestations
Depuis le 25 juillet, la Fondation concentre ses efforts sur !'organisation partout au

Quebec de marches pacifiques pour« la liberation du peuple ». Des figures de
proue du mouvement identitaire radical, comme Steeve « L'artiss » Charland, ex-
dirigeant de La Meute, un groupe anti-immigration et oppose al'lslam, y
participent en mobilisant leurs propres bases clans ces evenements.
AR02419
PHOTO YAN DOUBLET, ARCHIVES LE SOLEIL
Manifestation antimasque a Quebec, le 15 septembre
On y apen;oit regulierement sur scene les memes porte-parole - Alexis Cossette-

Trudel, Daniel Pilon, Steeve Charland et Stephane Blais. Plus en marge, Mario Roy,
« membre en regle » du groupe ultranationaliste « Storm Alliance», selon qui une
bonne partie des employes de la Direction de la protection de la jeunesse (DPJ)
participent a un « reseau d'enlevement d'enfants » motive par le financement
gouvernemental lie ala prise en charge d'enfants, fait aussi quelques apparitions
lors de ces evenements. M. Roy a profite la semaine derniere d'une manifestation
devant l'Assemblee nationale a Quebec, organisee par le groupe Appel ala liberte et
relayee par la Fondation pour la defense des droits et libertes du peuple, pour
deposer une requete en desaveu contre le gouvernement, suivi d'une plainte
criminelle privee contre Horacio Arruda et Frarn;ois Legault.
AR02420
Le mouvement semble prendre de l'ampleur et attire dans certains cas plusieurs
milliers de participants.
Noyaute par la droite identitaire radicale
« Le groupe est noyaute par des individus de la droite identitaire radicale, qui a vu
dans le contexte actuel une occasion de se structurer comme jamais », affirme
David Morin, cotitulaire de la Chaire UNESCO en prevention de la radicalisation et
de l'extremisme violent de l'Universite de Sherbrooke.
De nombreux antimasques ant defile a visage decouvert, le 12 septembre a Montreal.
Le chercheur estime que les tetes d'affiche du mouvement ont decide d'unir leurs
forces pour mieux propager leur message. « C'est une structure d'opportunite, un
peu comme un consortium, al'interieur duquel chacun est independant et a son
AR02421
propre modele d'affaires », note M. Morin.
« Ces gens faisaient front commun ii y a quelques mois en affirmant que
!'immigration et l'lslam sont des menaces. Leur discours a glisse dans le

complotisme. L:ennemi, c'est maintenant le gouvernement et l'elite, qui
cherchent a eliminer la race blanche. »
- David Morin, cotitulaire de la Chaire UNESCO en prevention de la radicalisation et

de l'extremisme violent de l'Universite de Sherbrooke
« Leurs strategies ont toutes un point commun: jouer sur l'anxiete et le sentiment
d'urgence, en disant que si nous impose d'abord le masque, c'est pour que l'Etat
puisse ensuite rentrer chez nous», poursuit le chercheur.
La prochaine grande manifestation, prevue le rr octobre prochain a Montreal,

promet une serie de conferenciers, dont Stephane Blais, Lucie Laurier, Alexis
Cossette-Trudel, Steeve Charland et Daniel Pilon. lls seront aux cotes de pasteurs
evangeliques que M. Morin n'hesite pas a qualifier d'« integristes religieux ».«Plus
c;a va, plus on constate que les groupes progressistes sont exclus de ce mouvement-
la », note-t-il.
Mission : epingler les conspirationnistes
lls appellent c;a « organiser un BBQ». Pendant toute une soiree, ils sont une
dizaine d'internautes reunis virtuellement sur Messenger, et epluchent minute par
minute chacune des videos produites par les tetes d'affiche de la« complosphere »
quebecoise.
AR02422
PHOTO OLIVIER JEAN, LA PRESSE
Martin Gaudet, qui anime la page Facebook « Menage du dimanche » et la baladoemission Le crachoir, et Nick
Denomme, l'un des responsables des Illumines du Quebec
lls cataloguent chaque affirmation douteuse clans un tableur Excel, isolent les
extraits les plus croustillants et balancent le tout au« Deep Steak», un ecosysteme
de contenus satiriques sur les reseaux sociaux, voue exclusivement aux derives
complotistes quebecoises.
Martin Gaudet, qui anime la page Facebook « Menage du dimanche » et la

baladoemission Le crachoir avec les trouvailles de ces collaborateurs, les appelle ses
« cyberconcierges ». « lls font un job sanitaire, vraiment. Notre but est d'exposer les
canneries que disent les complotistes. Le jour ou ils finiront par depasser la ligne,
on sera la pour les exposer. »
Le Deep Steak (le nom est une boutade qui fait reference au « Deep State » des
theses conspirationnistes, ce soi-disant reseau de hauts fonctionnaires qui
AR02423
controlerait les gouvernements mondiaux) est le premier a avoir revele le
desistement de l'avocat Guy Bertrand de la cause financee par la Fondation pour la
defense des droits et libertes du peuple. Ses membres ont aussi mis au jour les
dissensions au sein de la Fondation pour la defense des droits et libertes du peuple
au cours de l'ete.
« On a dans le groupe des juristes, des fiscalistes, des gens qui travaillent
dans le domaine de la securite, meme des specialistes de la theologie, qui

analysent tout ce qui sort des reseaux conspis. »
- Martin Gaudet
Son groupe n'est pas le seul amener un combat du genre. Le groupe Facebook Les
illumines du Quebec et l'Observatoire des delires conspirationnistes sont clans la
meme mouvance. « Nous, on se concentre sur les videos live. On cherche a illustrer
la connerie humaine, lance Nick Denomme, un des responsables des Illumines du
Quebec. Je peux me taper des videos de trois heures juste pour garder un resume
de cinq minutes qu'on balance clans les reseaux. C'est un hobby, une fac;on de
surveiller l'extreme droite. »
Groupe secret
Un autre groupe prive et secret, dont trois membres ont accepte de parler a
La Presse sous le couvert de l'anonymat par crainte que leurs comptes ne soient
cibles par des denonciations, prefere agir clans l'ombre. Une de ses membres, une
secretaire juridique de formation qui dit avoir des disques durs remplis de captures
d'ecran de comptes complotistes, a depose des dizaines de plaintes au Barreau
contre des conspirationnistes qui donnent ouvertement des conseils juridiques aux
autres. Ses denonciations ont contribue a lancer au mains trois enquetes du syndic.
« 11 y a beaucoup de gens qui ont des devoirs professionnels, comme des infirmieres
AR02424
et des medecins, qui partagent de la desinformation a outrance. On cherche des
manieres legales de les tenir responsables. On fait des signalements a leurs ordres
professionnels et on s'echange entre nous des formulaires types pour le faire le plus
efficacement possible», explique un professeur de psychologie qui s'est recemment
attaque a une collegue qui diffusait des theories fumeuses sur les liens entre la
COVID-19 et la telephonie 5G ainsi que sur le« nouvel ordre mondial ».«<;a
marche ! Absolument. Elle a rec;u une lettre de son ordre professionnel et elle a
perdu toutes ses tribunes. Elle se plaint de s'etre fait museler, mais elle a manque a
son devoir en partageant de la fausse information. »
Le professeur de politique appliquee David Morin, cotitulaire de la chaire UNESCO

en prevention de la radicalisation et de l'extremisme violent, previent que
l'approche est un couteau a double tranchant. « <;a perturbe !'organisation. <;a peut
destabiliser le noyau dur, mais c;a fait aussi des martyrs. C'est une technique qui
peut meme rendre le noyau dur sympathique » aux yeux des sympathisants plus
moderes.
Martin Gaudet le reconnait: leur approche a aussi un cote« un peu obsessif ».

« Mais le <liable est clans les details. Si tu veux debunker ces gens-la, il faut que tu
sois clans l'exces », croit-il.
Petit florilege de citations conspirationnistes
« Pourquoi toutes ces mesures ultracontraignantes? Ma reponse : parce
que cette crise etait premeditee. Le virus est un pretexte pour nous
conditionner ala docilite et ala repression policiere. »
- Stephane Blais, president de la Fondation pour la defense des droits et libertes du
peuple
« Cet episode du COVID-19 n'est rien d'autre qu'un coup d'Etat
international d'une clique de puissants malfrats contre les peuples du

AR02425
monde. »
- Stephane Blais, president de la Fondation pour la defense des droits et libertes du

peuple
« Tout le monde autour de Justin Trudeau baigne dans la pedophilie. [ ...]
Les personnes autour de lui sont systematiquement arretees. »
- Alexis Cossette-Trudel, dans un de ses webjournaux de Radio-Quebec
« Si votre enfant a des symptomes, ne l'envoyez pas al'ecole, parce qu'ils

vont le tester et le prendre, meme s'il n'est pas malade. [ ...] Gardez-le a la
maison, ~a va empecher les salopards de rentrer chez vous et prendre le
controle. »
- Alexis Cossette-Trudel, lors d'une manifestation antimasque a Montreal
« lls disent toujours qu'ils ont des preuves [de !'existence du virus]. Sauf que
nous autres, les preuves qu'on voit parce qu'on jase avec les gens, parce
qu'on serre des mains de vrai monde, quand on parle ades gens qui
travaillent en sante, [on se fait dire que] les ailes COVID sont vides, les
ailes psychiatriques sont pleines. Fais le calcul. »
- Steeve l:Artiss Charland, dans une video publiee sur sa page Facebook

AR02426
LA
PRESSE
Oui au passeport vaccinal

AR02427
Parlons vaccination. Qa avance. Et <;a avance bien.

Publie le 24 avr. 2021
PATRICK LAGACE
LA PRESSE
Les 80 ans et plus sont vaccines a 88 %. Les 70-79, a 87 %. Et les 60-69? A. 66 %.

Avec les prises de rendez-vous pour une premiere dose a venir: 86 %.
Chez les 50 a 59 ans, le taux de vaccination est de 29 %, mais cette statistique est
trompeuse : les 55 ans et moins viennent tout juste de devenir admissibles a la
vaccination. On aura bientot un meilleur portrait du succes de la vaccination chez
les 50-59 ans ...
Ou des degats de !'hesitation vaccinale.
Carles experts sont formels : la societe sera efficacement protegee quand une masse
critique - oscillant entre 70 % et 80 % - de nos concitoyens sera vaccinee. La Sante
publique federale a fixe vendredi la barre a 75 % (premiere dose) pour retrouver un
semblant de liberte enjuillet.
La reticence vaccinale est un probleme : en CHSLD, seulement 62 % des

employes sont vaccines. Cela favorise les infections de personnes vaccinees -
meme vaccinee, une personne agee a un systeme immunitaire plus
vulnerable - en CHSLD.
(Il faut les encourager, leur expliquer, bien sur. Mais la-dessus,je trouve les
syndicats de la sante bien discrets ... )
L'exemple des travailleurs de la sante en CHSLD est important: si on n'atteint pas la

cible des 70 % a 80 % de la population du Quebec vaccinee rapidement, c'est
l'immunite de toute la societe qui sera deficiente. C'est la sante des plus vulnerables
AR02428
qui sera en danger. Les prochaines semaines seront un test pour l'idee vaccinale.
Si la sensibilisation vaccinale ne fonctionne pas, il faudra se resoudre a implanter

une mesure qui encouragera tres, tres, tres, tres, tres, tres, tres fortement les
Quebecois reticents a se faire vacciner.
Oui, je parle du passeport vaccinal.
***
La Loi sur la sante publique du Quebec donne le pouvoir au gouvernement de rendre

la vaccination obligatoire, si une maladie contagieuse menace gravement la sante
de la population.
Alerte! Ace point-ci de cette chronique, les negationnistes sanitaires sont deja
grimpes dans les rideaux pour m'accuser de favoriser la dictature ...
Je tiens ales rassurer immediatement, meme si les faits leur sont bien
souvent etrangers : je ne suis pas favorable a la vaccination obligatoire.
Non, la coercition serait contre-productive pour l'idee meme de la vaccination. Et

elle donnerait aux negationnistes la chance de se transformer en Jeanne d'A rc de
You Tube dont la « resistance» deviendrait inevitablement virale (!). Posez-vous la
question: c;a prendrait combien de policiers pour maitriser un conspirationniste
afin qu'il se fasse vacciner ?
Voila, juste poser cette question, c;a torpille l'idee meme de la vaccination
obligatoire.
Mais il y a une solution de rechange : le passeport vaccinal.
***
J e resume le concept de passeport vaccinal: c'est un laissez-passer, un sesame, qui

vous permet de participer a des activites precises dans la societe.
AR02429
PHOTO ODED BALILTY, ARCHIVES ASSOCIATED PRESS
Des lsraeliens montrent leur « passeport vert », preuve de leur vaccination contre la COVID-19 ou de leur
guerison complete, a l'entree d'un stade de soccer de Tel-Aviv, en mars dernier.
Vous etes vaccine ?
Vous pouvez aller au gym, dans les salles de spectacle, dans les restaurants, dans les
salles de classe ...
Si - et seulement si - les taux de vaccination ne nous permettent pas d'atteindre

l'immunite collective qui protegera la societe contre les ravages du virus, ce
passeport deviendra sans doute inevitable. Le ministre de la Sante Christian Dube
en parle ouvertement.
Je sais, je sais: l'idee d'un passeport vaccinal fait l'objet de debats incluant
toute une palette de considerations ethiques. Et ces debats sont absolument
passionnants ... en theorie.
AR02430
Dans le reel, si - et seulement si - les taux de vaccination sont trop bas pour
atteindre l'immunite collective parce que le discours conspi-negationniste ne bien
avant la pandemie aura suffisamment endommage le principe meme de la
vaccination anti-COVID-19, il faudra se demander quelle reponse opposer a cette
menace a l'immunite collective.
Les gens ont le droit de ne pas vouloir etre vaccines.
Ils ont le droit d'etre obscurantistes et egdistes, aussi.
La societe n'a pas ales accommoder, ceux-la, a l'infini.
***
Mardi dans Le Devoir, le professeur Pierre Trudel a evoque ces passeports

vaccinaux, deja implantes en Israel et en chantier ailleurs. Ila souligne que cette
idee a generalement passe avec succes le test des tribunaux. Est-ce que les
tribunaux, ici, torpilleraient l'idee du passeport vaccinal?
Disons que nos tribunaux n'ont pas demontre un gout prononce pour le
torpillage des mesures sanitaires depuis 13 mois, malgre les contestations :
sur 43 contestations, le Procureur general en a perdu .. . 3.
Exemple marquant : dans une decision pourtant favorable a la communaute

hassidique de Montreal au debut 2021, lajuge Chantal Masse a quand meme
rappele que l'Etat imposait des mesures sanitaires qui visent a proteger
« !'important objectif de preserver la vie et la sante de tous » en rappelant que « tous
ont droit a la vie».
Alors on ne peut pas forcer les gens a se faire vacciner, meme qu'on ne devrait pas.
Mais la societe n'a pas non plus a recompenser l'ego:isme individuel si la reticence
vaccinale en vient a menacer l'immunite collective, si la barre des 75 % n'est pas
atteinte.
AR02431
On pourrait alors tres certainement essayer d'interdire aux plus reticents d'entre
nous l'acces aux cinemas, aux salles de spectacle, aux bars, aux gyms, aux ligues
sportives, aux cegeps, aux universites, de meme qu'aux festivals et aux restaurants ...
a
Les reticents pourraient ainsi tres bien revendiquer leur droit l'ego:isme ... isoles
dans leur divan de salon.

AR02432
LA
PRESSE
Passeport pour les problemes

AR02433
Rivee amon ecran,jeudi matin,j'ai un peu retrouve cette
febrilite oubliee d'avoir areserver de precieux billets pour
le show qu'il ne faut surtout pas manquer au Centre Bell.
Au bout de quelques minutes,j'ai reussi. J'avais rendez-
vous avec le vaccin.
Mis a jour le 27 fevr. 2021
ISABELLE HACHEY
LA PRESSE
Enfin, pas moi. Ma mere. Son rendez-vous est fixe au 14 mars, a Place du Royaume,
centre d'achats de Chicoutimi ouj'ai englouti tous lesjeudis soir demon
adolescence.
Nous y voila done enfin. La delivrance semble a portee de main. Le Saint Graal. Le
sesame du retour a la vie normale. La vaccination de masse.
Un an que c;a dure. Le 14 mars 2020, je signais dans ces pages un « Plaidoyer pour le
bidet » apres avoir risque ma vie en reportage au rayon du papier de toilette, chez
Costco.
> (RE)LISEZ Plaidoyer pour le bidet
Deuxjours plus tot, le gouvernement avait decrete l'etat d'urgence. Nous ignorions
encore tout de la courbe a aplatir, de la distanciation sociale, des cinq a sept sur
Zoom, du confinement, du deconfinement, du reconfinement et - bienheureux
etions-nous - des complotistes antimasques.
AR02434
Ala dure, nous avons appris avivre avec la pandemie. Traverse de petits et grands
deuils. Cesse de nous serrer la main, de nous faire la bise, de nous reunir. Bientot,
tout c;a sera derriere nous.
Bientot, mais pas tout de suite. Pas encore.
***
On n'en peut plus, des restrictions. On a besoin de sortir, de voir du monde, de

prendre nos petits-enfants dans nos bras. De reprendre notre vie ou on l'avait
laissee en mars 2020.
Christian Dube est conscient de notre lassitude collective. J eudi, en conference de

presse, le ministre de la Sante a laisse entendre qu'il avait en main une solution pour
a
accelerer le retour la normale : le passeport vaccinal.
PHOTO RONEN ZVULUN, REUTERS
Depuis une semaine, les lsraeliens doivent avoir une preuve de vaccination contre le coronavirus pour acceder a
AR02435
certains endroits publics.
Qa prendrait la forme d'un code QR, sur un telephone intelligent, qui prouverait que
son proprietaire est vaccine - et qui lui ouvrirait les portes des lieux publics.
Au premier abord, on est tente de se dire : voila un moyen efficace de redonner leur
souffle aux industries du tourisme, du spectacle et de la restauration, toutes trois
etranglees par une annee noire de restrictions sanitaires.
Radio-Canada rapportait vendredi que le passeport vaccinal ne servirait pour

l'instant qu'a voyager. La veille, Christian Dube semblait neanmoins tres ouvert a
une utilisation dans les commerces.« Un passeport de vaccination digital, pour moi,
c'est tout a fait normal», a-t-il dit.
Sauf qu'a bien y penser, ii n'y a pas grand-chose de « normal » a exiger des
gens qu'ils montrent patte blanche immunitaire pour avoir le privilege de
frequenter des lieux publics. c;a ne s'est jamais vu.
Inevitablement, c;a creerait deux classes de citoyens : les vaccines, qui auraient
acces a tout. Et les autres.
***
On dirait un scenario de science-fiction. En Israel, c'est deja une realite. Depuis

dimanche, la societe est coupee en deux. Les Israeliens inocules portent un badge
vert et peuvent frequenter piscines, salles de gym, hotels et salles de concert. Ceux
qui n'ont pas rec;u le vaccin portent un badge pourpre et n'ont acces a rien de tout
cela.
L'objectif avoue? Persuader. Le systeme de badges est une « maniere d'encourager

de plus en plus de gens a se faire vacciner », a explique le ministre de la Sante, Yuli
Edelstein. Personne n'a envie d'etre laisse en plan.
Le probleme, c'est que les non-vaccines ne sont pas tous des citoyens negligents OU
AR02436
des antivax bornes. Beaucoup ne peuvent pas etre vaccines : les enfants de moins de
16 ans, les personnes aux prises avec certaines conditions medicales ...
Et puis, il y a tous ceux qui attendent leur tour.
***
En Israel, la campagne de vaccination en est deja a mi-parcours. Au Quebec, elle ne

fait que commencer. Elle durera des mois. Avec la vaccination de masse s'ouvre un
nouveau chapitre de cette pandemie.
Un chapitre un peu paradoxal, au cours duquel de plus en plus de Quebecois seront

vaccines sans que l'immunite collective soit atteinte pour autant.
Le danger, c'est que les vaccines se mettent acroire qu'ils peuvent balancer
leurs masques et faire tout ce qu'ils veulent. Le passeport vaccinal risque de
renforcer ce faux sentiment d'immunite.
Rappelons-le, le vaccin n'empeche pas la personne qui le regoit de contracter le

SARS-CoV-2, seulement de ne pas souffrir des symptomes. On ignore si les
vaccines infectes peuvent transmettre le virus aux non-vaccines, qui risqueraient
alors de tomber malades.
Autrement dit, une fois que vous aurez regu le vaccin, vous serez bientot tires
d'affaire. Mais pas necessairement vos proches, vos voisins, votre epicier ou votre
serveur. Ceux-la, vous pourriez encore les mettre en danger.
Meme vaccines, vous devrez continuer de faire attention. Pas pour vous ; pour les
autres.
***
Le passeport vaccinal ne nous permettrait done pas de reprendre une vie normale.
Pas sans mettre plein de gens vulnerables a risque.
AR02437
Et puis, jusqu'ou pousserait-on la discrimination? Voyager a l'etranger, c'est une
chose. Aller au resto, e'en est une autre. Mais faire son marche? Louer un appart?
Decrocher un emploi? Au Royaume-U ni, deja, une entreprise a fait savoir qu'elle
appliquerait la politique No jab, no job.
Pas de vaccin, pas de boulot.
La pandemie a exacerbe les iniquites sociales. Le passeport vaccinal risquerait

de les faire exploser.
Pour finir, imaginez les frustrations si, apres une annee de privations, on donnait
plein de privileges a une classe de citoyens. Imaginez le sentiment d'injustice.
J eudi, l'ancien maire de Montreal Denis Coderre a enflamme la twittosphere en

remerciant l'equipe du ministre Dube d'avoir regle un probleme informatique, ce qui
lui apermis de prendre rendez-vous pour la vaccination de ses parents.
Traitement de faveur? L'ex-maire soutient qu'il n'a fait que signaler le bogue.
N'empeche. Monsieur Gagnon de Pointe-aux-Trembles, lui, aurait du se debrouiller
avec ses problemes. Qa n'a echappe a personne. On n'en etait qu'aujour 1 de la
vaccination de masse, et la foule etait furieuse.
Imaginez sa colere si les privilegies du vaccin se mettaient a festoyer dans les bars
et les restaurants pendant que la plebe restait cloitree chez elle ...
Rectificatif
Cette chronique a ete rectifiee. Contrairement ace qui etait mentionne dans la version
originale, les personnes immunosupprimees, les femmes enceintes et celles qui
allaitent peuvent recevoir le vaccin, avec l'approbation de leur medecin traitant. Nos
excuses.

AR02438
LA
PRESSE
Portrait-robot du non-vaccine
AR02439
PHOTO DOMINICK GRAVEL, ARCHIVES LA PRESSE, PHOTOMONTAGE LA PRESSE
Manifestation contre les mesures sanitaires, en decembre dernier, a Montreal
ISABELLE HACHEY
LA PRESSE
Les deux tiers des adultes quebecois non vaccines

adherent aune vision complotiste, selon des donnees
inedites obtenues par La Presse. Les efforts doivent se
concentrer sur le tiers restant, plus susceptibles de relever
la manche, estime la medecin en sante publique Melissa
Genereux.
Publie le 27 janvier
AR02440
C'est un homme, plutotjeune. Un pere de famille, qui vit en

milieu rural. 11 n'est pas tres riche. Pas tres scolarise, non
plus. 11 s'informe sur les reseaux sociaux. 11 est adroite de
l'echiquier politique. 11 est anxieux et depressif.
Voila un portrait type - brosse a tres gros traits - du Quebecois non vaccine. Mais
attention: c;a ne leve qu'une partie du voile.
« Il y a toutes sortes de raisons qui font en sorte que les gens ne veulent pas etre
vaccines», constate la nre Melissa Genereux, professeure a la faculte de medecine
et des sciences de la sante de l'Universite de Sherbrooke.
Un certain flou enveloppe les 540 000 adultes non vaccines au Quebec. Tantot on
les presente comme des « antivax » forcenes, des coucous irrecuperables, tantot on
les decrit plutot comme des sans-abri, des immigrants ou des vieillards isoles. Le
portrait d'ensemble est embrouille.
AR02441
PHOTO MAXI ME PICARD, ARCHIVES LA TRIBUNE
La ore Melissa Genereux, professeure a la faculte de medecine et des sciences de la sante de l'Universite de
Sherbrooke
Grace aux travaux de la n re Genereux, on peut enfin y voir plus clair. Les chiffres
presentes ici sont tires d'une enquete realisee en octobre aupres de 10 368 adultes
quebecois. Cette enquete fait elle-meme partie d'une vaste etude en cours sur les
impacts psychosociaux de la pandemie.
« En faisant des croisements, on peut dresser le profil des non-vaccines, meme si ce

n'etait pas !'intention de depart», explique la nre Genereux.
AR02442
Portrait des adultes non vaccines au Quebec

(socio-economique)
Non- Non-
. ,,.
vaccines
. ,,.
vaccines
..
avec v1s1on
. .
sans v1s1on
complotiste complotiste Vaccines
(n= 659) (n= 350) (n= 9359)
Milieu rural ■ 20% ■ 20% 113 %
Hemmes 48 %
18a34ans 36 % 42 % 1 24%
Vit avec au
moIns un 34% 30% l 2s%
enfant
Oiplome
32 % 33 % 46 %
universitaire
Revenu du
menage de
33 % 30% 1 20%
30 000$ OU
moIns
Revenu du
menage de
30% 34% 45 %
80 000$ OU
AR02443
plus
Source: Donnees tirees d'une enquete en ligne menee par la ore Melissa Genereux -
et l'Universite de Sherbrooke aupres de 10 368 adultes quebecois -
Un constat se degage: parmi les quelque 10 % de Quebecois non vaccines, les deux
tiers adherent a une vision complotiste. Ceux-la, on s'en doute bien, sont les plus
difficiles a persuader de !'importance de relever la manche pour lutter contre la
pandemie.
Reste un tiers, parmi les non-vaccines, qui ne souscrivent pas le moins du monde a
ces theories du complot.
AR02444
Portrait des adultes non vaccines au

Quebec (orientation politique et profil
informationnel)
Non- Non-
.
vaccines
; .
vaccines
;
. . ..
avec v1s1on sans v1s1on
complotiste complotiste Vaccines
(n= 659) (n= 350) (n= 9359)
ldeologie de
gauche
17% I s% 112%
ldeologie de
24% I s% I s%
droite
Source
d'information
reguliere: 38 % 23 % 121 %
reseaux
soc1aux
Confiance
envers le
gouvernement
26 %
-
Confiance
envers les
experts
.. 72 % 94%
AR02445
Source: Donnees tirees d'une enquete en ligne menee par la ore Melissa Genereux ■:
et l'Universite de Sherbrooke aupres de 10 368 adultes quebecois
Les donnees montrent que ceux-ci perc;oivent davantage la menace liee a la

COVID-19 que les complotistes. D'ailleurs, ils se conforment aussi davantage aux
mesures sanitaires. Ils font moins « leurs propres recherches » sur le web. Ils font
davantage confiance aux autorites et aux experts.
C'est ce tiers de non-vaccines que les campagnes de vaccination doivent viser.
« Pour moi, ii y a de l'espoir pour ces gens-la. On a pas mal plus de chances
de les convaincre [que de convaincre les complotistes]. »
- La ore
Melissa Genereux, professeure a la faculte de medecine et des sciences de la
sante de l'Universite de Sherbrooke
Rien ne sert de s'obstiner a faire entendre raison a une personne ... qui ne veut rien
entendre. Qa risque meme d'empirer les choses. « Notre but, c'est de toujours faire
avancer un peu plus dans la bonne direction, sans pour autant insister de maniere a
alimenter leur vision complotiste. »
* **
Il faut arreter de mettre tousles non-vaccines dans le meme panier, previent

Melissa Genereux.
« Quand le premier ministre a commence aparler des 10 % de non-vaccines qui

nuisent aux 90 % de vaccines, c'est venu me chercher. Un discours qui divise les
gens ne nous mettra pas sur la voie du retablissement du bien-etre collectif »
La Dre Genereux sait de quoi elle parle.

AR02446
Elle etait directrice de sante publique de l'Estrie lors de la tragedie ferroviaire de
Lac-Megantic, en 2013. Au cours des annees qui ont suivi !'explosion, elle a cree une
« boite aoutils » pour aider la communaute durement eprouvee aretrouver une vie
normale.
a
Cette boite outils, Melissa Genereux l'a ensuite trimballee dans d'autres
collectivites touchees par des catastrophes: la ville de Fort McMurray, en Alberta,
ravagee par un incendie en 2016; les regions inondees du Quebec en 2019. On a
sollicite son expertisejusqu'en Guadeloupe et au Royaume-Uni.
Bref, la ore Genereux en connait un rayon sur les impacts along terme d'une
catastrophe. Elle sait que l'onde de choc de la pandemie se fera sentir bien
apres que le virus aura disparu - OU aura ete, atout le moins, dompte.
« La fac;on dont une communaute est affectee par une catastrophe est toujours
sensiblement la meme », dit-elle. Meme anxiete, memes depressions, memes idees
a
suicidaires. Meme tendance, au sein de la communaute touchee, se dechirer. Et a
se mefier des autorites.
« Ce sont des classiques qui surviennent ala suite de crises. On n'est pas surpris de
ce qui arrive, mais il faut en etre conscient pour adopter des strategies efficaces. »
Lorsqu'elle dirigeait la Sante publique en Estrie, la nre Genereux avait deploye des
brigades d'etudiants charges de cogner aux portes des citoyens - une strategie qui a
a
d'ailleurs ete proposee nouveau mercredi par Quebec solidaire.
Le but de ces tournees, explique la medecin, etait d'entamer un dialogue avec les
hesitants vaccinaux. Surtout pas de mettre un pied dans la porte pour tenter de leur
a a
vendre le vaccin tout prix - une approche qui aurait ete vouee l'echec.
***
a
Quand elle a entendu le ministre delegue la Sante et aux Services sociaux, Lionel
Carmant, tendre la main aux non-vaccines, lundi, Melissa Genereux a pense:
AR02447
« Mieux vaut tard que jamais. »
Cette approche positive, le gouvernement aurait du l'adopter des le premier jour.
« Les emotions influencent davantage les comportements que le simple
acces a !'information. »
- La ore Melissa Genereux, professeure a la faculte de medecine et des sciences de la

sante de l'Universite de Sherbrooke
« Si on n'avait qu'a dire aux gens: "Voici les connaissances. Appliquez-les et c;a va
bien aller", tout le monde mangerait moins et bougerait plus et il y aurait moins
d'obesite sur la planete. C'est beaucoup plus complexe que c;a. »
La science le demontre: ce qui fonctionne, c'est l'ecoute. L'ouverture. Et, oui, ce mot
tellement galvaude par les temps qui courent: la bienveillance.
La Dre Genereux cite cette phrase, en anglais, qui resume bien le tout : People only
care about what you know when they know that you care.
Les gens s'interessent ace que vous savez dans la mesure ou ils savent que vous
vous interessez a eux.
NON-VACCINES ET COMPLOTISTES
Non-vaccine: personne n'ayant pas rec;u deux doses.
Complotiste : personne ayant repondu avec une moyenne superieure a 3/5 aux
enonces suivants (1 correspondant a « totalement en desaccord », 5 a
« totalement en accord ») :
1. La verite sur la « soi-disant pandemie de COVID-19 » est cachee au public.

AR02448
a
2. Les gens doivent se reveiller et commencer poser des questions.
3. Les questions legitimes sur « la soi-disant pandemie de COVID-19 » sont

supprimees par le gouvernement, les medias et les universites.
4. Desjournalistes, des scientifiques et des responsables gouvernementaux

a
sont impliques dans un complot visant dissimuler des informations
importantes sur « la soi-disant pandemie de COVID-19 ».
5. Une enquete impartiale et independante sur « la soi-disant pandemie de

COVID-19 » montrerait une fois pour toutes qu'on nous a grandement menti.
Source : enquete en ligne menee par l'Universite de Sherbrooke du 1er au

17 octobre 2021 aupres de 10 368 adultes de toutes les regions du Quebec

AR02449
Shocking anti-vaccine protests that

plagued Canada's election
spawned resurgent far-right
movement
By Caroline Orr I Analysis I September 19th 2021
#76 of 78 articles from the Special Report:

Democracy and Integrity Reporting Project
~ Maxlme BemlM O
, . . @MaximeBernier
When tyranny becomes law, revolution becomes our

duty.
#VotePPC
~r::anhi,- h\/ r::arnlinc r1rr fnr r:::an:=iirl::a 'c:: l\l;:iitinn::al ()hc::0in":::i.r
GET TOP STORIES IN YOUR INBOX.

Your email address Sign up
AR02450
(0 Listen to article)
While vaccines and mask policies are viewed favorably by

most Canadians, the vocal minority who oppose them are a
growing threat - not only to public health, but to public safety
and even democracy itself.
Leading up to the election, anti-vaccine protests drew angry,

unruly crowds outside hospitals and other health care facilities
across Canada, blocking patients and employees trying to
access the buildings, and in at least one instance, forcing
cancer patients to get out of cars and walk through the
unmasked mob. Protesters have reportedly verbally and
physically assaulted health care workers, while others have
used social media to issue threats of violence against doctors
and nurses.
Last month, anti-vaccine protesters showed up at the home of

an Ontario education minister and, upon learning that he
wasn't there, decided to harass his neighbors instead. On the
campaign trail, Trudeau has been tracked by angry crowds of
anti-vaxxers shouting profanities and making Nazi references.
Less than two weeks after security concerns forced him to
cancel a rally in Ontario, Trudeau was hit with gravel thrown
by an anti-vaccine protester at one of his campaign events.

Sign up
AR02451
With election day near, Canada's anti-vaccine movement is

more active - and more angry - than ever, and some
extremism experts are worried about what will happen when
the protesters no longer have an election to direct their
outrage towards.
"They're going to be trouble for some time," Kurt Phillips,

board member of the Canadian Anti-Hate Network and
founder of Anti-Racist Canada, told Canada's National
Observer. "The rage that exists in the movement - I don't
know where that goes [after the election]. It could explode."
Nonetheless, possibly the first time ever in Canada, and

certainly the first time in recent history, vaccination has taken
the center stage as a major campaign issue in the federal
election.
Prime Minister Justin Trudeau invoked the pandemic when he

announced the election in August, saying voters deserve to
have a say in who leads the country during its recovery from
COVID-19. While mask requirements, vaccine mandates, and
other restrictions are already in place, Trudeau promised to
pursue an aggressive strategy to combat COVID if the Liberal
government remains in power, and criticized his opponent,
Conservative leader Erin O'Toole, for opposing vaccine
mandates. In August, Trudeau pledged a billion dollars to help
provinces create their own vaccine passport systems - a move
G&<Ji:i°Qp'5i'romg ¥ lmlJNIJOX.
Sign up
AR02452
From Yellow Vesters to anti-vaxxers

Similar to in the U.S., the anti-vaccine movement in Canada is
driven by a multitude of factors, including distrust of the
government and other institutions, animosity towards experts
and authorities, cultural grievances, rejection of mainstream
science, and the creeping influence of extremism in
mainstream discourse on the right. Much of the anger and
opposition to vaccination is propelled by misinformation and
conspiracy theories alleging that vaccines are unsafe, harmful,
or part of some sort of plot aimed at establishing a biometric
surveillance system or other form of government control.
The anti-vaccine movement has close ties to extremist groups,

Christian nationalists, QAnon conspiracy theorists, run of the
mill grifters and scam artists, and other right-wing causes like
the Yellow Vest movement, which now airs its grievances
under the banner of anti-vaccine activism.
"Every single prominent Yellow Vester that I'm aware of is now

an anti-vaxxer," Phillips said.
Like the Yellow Vest movement - which saw oil and gas
pipeline protest being used as cover for right-wing extremist
activity - the anti-vaccine movement has become entangled
with far-right extremism as white nationalists and other
extremists use the guise of vaccine skepticism to push
G!tr"ttffllSU~ ~lfNlj(!OOories targeting Jews,
immigrants, health care workers, and others. Sign up
AR02453
Populism and far-right politics

In modern history, the rise of the anti-vaccine movement and
associated nativist, anti-immigrant attitudes has often
coincided with waves of far-right populism.
European populist parties like Italy's Five Star Movement have

grown their coalition by raising baseless concerns about
vaccine safety and campaigning against vaccine mandates,
resulting in decreased childhood vaccination rates and
resurgences of diseases like measles. From the start of the
pandemic, far-right extremists in Italy have flooded social
media with articles blaming migrants for the deadly pandemic,
while in Austria and Germany, far-right politicians have used
the pandemic to spread conspiracy theories about vaccines
and call for crackdowns on immigration. Anti-Semitic vaccine
conspiracy theories have also been linked to a rise in hate
crimes targeting synagogues and Jewish schools in
Switzerland.

Sign up
AR02454
The link between populism and anti-vaccine sentiment is

apparent in Canada, too. Throughout 2020 and 2021, the
People's Party of Canada (PPC) has capitalized on the
grievance-based energy of the anti-vaccine movement to
mobilize supporters and draw in new voters. PPC leader
Maxime Bernier is a founding member of the "End the
Lockdown Caucus" and has made opposition to public health
measures such as mask mandates, vaccine passports, and
lockdowns - which he calls "tyrannical" and "Orwellian" - a
centerpiece of his campaign.
Local PPC candidates have been riding the wave of anti-

vaccine anger and, at times, contributing to it.
Mark Friesen, a PPC candidate in Saskatoon-Grasswood who

was involved in the Yellow Vest protests, has pivoted to
organizing "freedom" rallies in opposition to vaccines and
other public health restrictions, and has appeared alongside
the Canadian Frontline Nurses, one of the main organizers of
the protests. Ron Vaillant, PPC candidate for Calgary Shepard,
has repeatedly compared vaccination to Naziism, while fellow
PPC candidate Marc Emery suggested in a tweet last week that
Trudeau deserves to be executed like Italian fascist dictator
Benito Mussolini. He ultimately deleted the tweet at the
request of Bernier.

Sign up
AR02455
Another PPC candidate, Peter Taras, recently tweeted a picture

of a dozen bodies hanging in Nuremberg, Germany, following
the Nuremberg trials. Taras implied that the bodies belonged
to "members of the media who lied and misled" people "right
along with medical doctors and nurses who participated in
medical experiments." He later deleted the tweet and denied
that he was suggesting anything violent or threatening in his
tweet.
Earlier this month, Anti-Hate Canada identified several people

associated with the PPC, along with known white nationalists,
at the violent rally where gravel was thrown at Trudeau. Shane
Marshall, the riding director for PPC candidate Chelsea Hillier
- daughter of No More Lockdowns co-founder Randy Hillier -
was reportedly in attendance, as was far-right YouTuber and
self-described nationalist Tyler Russell, who leads a fledgling
far-right nationalist movement called Canada First.
On social media, anti-vaccine groups are littered with

messages encouraging people to vote PPC in the upcoming
election, and white nationalist groups like the Canadian
Nationalist Front have thrown their support behind Bernier
and the PPC. In recent polls, the PPC has reached record-high
levels of support, putting the party in a position to potentially
have a significant impact on the election.
Anti-vaccine violence
Sign up
AR02456
Even if the PPC doesn't succeed at the ballot box, there are
likely to be lasting consequences from the party's 2021
campaign. The coalition of far-right groups that coalesced
during the pandemic now has a political party to legitimize it
and give it a voice, which has energized them and may help
them form a larger, more organized movement in the future.
Regardless of the election outcome, the pandemic will still be
here and whoever is leading the country will have to contend
with a mobilized, motivated minority of the population that
views government and science as threats that need to be
eliminated.
Furthermore, although Bernier has avoided explicitly calling

for or condoning violence, his incendiary rhetoric -
particularly his frequent use of the word "tyranny" to describe
the Liberal government - echoes the rhetoric of far-right
militias like the Three Percenters and serves as a "dog whistle"
to extremists, said Phillips.
To those who truly buy into the far-right narrative, the election
isn't just about who will be the next prime minister. It's also
about fighting back against what they believe to be a malicious,
tyrannical government trying to use vaccines and lockdowns
to strip away their freedom. With stakes that high, Phillips
fears that someone may interpret the PPC's messaging as a call
to do whatever it takes to stop the government from enforcing
vaccine mandates, even if it takes violence.
Sign up
AR02457
"Most people will hear that [message] and won't act on it, won't
do anything," Phillips said. "But at some point, somebody will."
SOD
lHOIC
Graphic by Caroline Orr
That's exactly what some far-right extremists are hoping for.

Messages posted on far-right discussion boards show
anonymous users proposing violence as the only solution and
talking about leveraging anti-vaccine conspiracy theories to
encourage people to commit attacks against vaccine
producers.
As recent events have made clear, the threat of violence

associated with the anti-vaccine movement isn't just
hypothetical. It's a problem spreading around the world.

Sign up
AR02458
Earlier this month, several U.K. police officers were injured

after anti-vaccine protesters tried to storm the building of the
health ministry in charge of the country's vaccination efforts.
This came just after the U.K.'s Daily Mail infiltrated a group of
200 anti-vaccine military veterans called Veterans 4 Freedom
and found that members were discussing weaponry and
plotting attacks on vaccination centers. A week later, police in
Italy raided the homes of anti-vaccine activists after
discovering that they had been using Telegram to plot violent
attacks against members of government and the general public
in opposition to vaccine passports. Earlier this year, when the
mayor of a town in southwest Poland tried to mandate the
COVID-19 vaccine, a mob of anti-vaxxers - some wearing
military fatigues - descended on his house, issuing death
threats and comparing him to a Nazi. In Belgium, a prominent
virologist had to go into hiding in a safe house after receiving
threats from a soldier armed with a rocket launcher, a machine
gun, body armor, and a pistol.

Sign up
AR02459
In the U.S., anti-vaccine protests have led to stabbings and

violent attacks against journalists and others. Over the
summer, a breast cancer patient in California was sprayed with
bear mace and physically assaulted after confronting
protesters outside of a health care clinic. And last year, FBI
agents shot and killed a Missouri man during a confrontation
that took place when agents tried to arrest him in connection
with a domestic terror plot. The man, who reportedly
expressed racist and anti-government sentiments online, was
allegedly planning to detonate a car bomb outside of a
hospital, with the goal of causing mass casualties.
The anti-vaccine movement in Canada has direct ties to the far-

right groups in the U.S. that are behind these violent protests,
as well as other acts of violence and terror like the January 6
insurrection. There are also apparent links between the
organizers and leaders of Canada's anti-vaccine movement and
Trump insiders like Steve Bannon and Gen. Michael Flynn,
who spent months spreading the very same election
conspiracy theories that incited the Capitol riot.
Some far-right figures have already started spreading

disinformation in Canada about the election being stolen or
rigged and there's a real possibility that some of these people
won't accept the election outcome as legitimate, just as they
don't accept the science of vaccination as valid.

Sign up
AR02460
That's the new reality we're dealing with in this post-truth,

choose-your-adventure world where sizable swaths of the
population have abandoned science, expertise, and
knowledge-producing institutions in favor of Google searches
and snake oil salesmen. The next leader of Canada, whoever
that may be, will not only have to lead the country's pandemic
recovery while navigating a resurgent, potentially violent
movement fighting them every step of the way - they'll also
have to figure out how to do it while dealing with segments of
society who have given up on the very values that hold society
together.
Comments
Subscribe to join the conversation . Already a subscriber? Log in.
Patricia Spencer I 6 months ago
Thank you for this analysis. It's unnerving ... ! wish that Bernier could be held
accountable for the lies that he is spreading.

Sign up
AR02461
Monika Marcovici I 6 months ago
So disappointed by the lack of objective analytsis. in rhis article that simply spouts
propaganda. Exoected more from the NO.
John Tobias I 6 months ago
I'd take your comment a wee bit more seriously if it wasn't filled with several
spelling errors. That being said, the gist of your comment is ludicrously wrong.
mary NOKLEBY I 6 months ago
It would be informative for all of us if you pointed out which parts of this article
are propaganda, ie: not true. As it stands, you are sounding like a follower of
some of the idiocy the NO is describing, by calling what sounds pretty
evidence based to me (these events did happen) biased. While we've all heard
the line 'reality has a left wing bias'....that isn't a statement of fact, but an
observation of how right wing fringe movements be lieve they can 'disbelieve'
whatever they don't want to be true.
Truth operates under more stringent parameters.
Ian Graham I 6 months ago
Agreed Monika, thank you for speaking up.
Tris Pargeter I 6 months ago

Sign up
AR02462
It's ENTIRELY objective analysis.

Obviously you don't even know what that phrase means.
You're clearly one of the right-wing people described in the article. You give
yourself away with not only your profound inability to reason, but also your
inability to even spell.
Bob Stuart I 6 months ago
The vaccines would fall under much less suspicion if they were produced in non-
profit facilities associated with Universities. Any casual observer can tell that drug
companies maximize profit by managing disease. Left to the beancounters, they will
keep raising the price on Insulin until so many diabetics are dying that demand
goes down.
While it is likely true that public production of vaccines would be more cost
effective, we would have had to go down a different road 40 years ago, to have
even our own Connaught Labs still in place. The neoliberal right wing privatized
whatever it could ...... including long term care homes, with the results we've all
witnessed.
But lamenting the privatization and free market growth of Big Pharma is
something many of us do, proceeding with the fallacy of sweeping
generalization and arguing that Big Pharma created, or is 'managing' this
pandemic for its personal profit is a half truth at best. We live in the world our
choices created .... and Big Pharma was all we had in the west to mount the
attack on covid. Cuba is different and has its own vaccine products ...... as does
Russia.
The crazv oart of these crazies is the simole think. one bia ldeoloav of their

Sign up
AR02463
Let's all of us speak up against those single small ideas .......that get force fed
into Conspiracy Theories from Hell. The Covid is our enemy....... not the many
organizations struggling to stop its continued growth, mutation and danger to
us all.
Rufus Polson I 6 months ago
Kind of ironic that the anti-vaxxers are in fact the very same people who
consistently vote for relentless privatization and greater power for profit-
maximizers. If you have a problem with rapacious corporations,
(sorry, interface kicked me out and posted part of my comment. As I was

saying,)
If you have a problem with rapacious corporations, VOTE FOR SOCIALISTS
AND SOCIAL DEMOCRATS, DAMMIT! How do these people expect
doctrinaire hypercapitalists to help them against greedy companies?
Andrew Stewart I 6 months ago

Sign up
AR02464
Thank you for this welcome analysis. I was shocked, yesterday, to witness a
reckless crowd of many thousands of unmasked people asking for "liberty" and
"freedom" (what do these words even mean any more?) marching south down
Bathurst St and east along College St in Toronto yesterday (Saturday afternoon). No
coincidence, I'm sure, that the march occurred on the same day as the Capitol riot
supporters marched in Washington. I have never seen a bigger crowd on Toronto's
streets for anything -- there were at least 5000 people, probably closer to 10,000. A
steady stream of people unaccountably blocking these streets for their selfish
cause. The police were evidently taken by surprise, or worse, as they only in the
later stages of the march showed up on bicycles, and there was pretty much
nothing they could (or would) do, vastly outnumbered as they were. There is no
mention of this march in today's media (on CBC or Toronto Star). Why is that?
Perhaps to avoid further incitement of irresponsible people. I am glad the National
Observer is calling attention to this issue, an American disease of the mind that has
spread around the world.
Well said. Thank you for this information. One can't help but wonder if the
police would be so late to the party, or so timid in reaction, were this a Black
Lives Matter rally....... or even something being led by Antifa. The leeway we
give white nationalists says something about us all. .... but about our police
force???
What happened to the tear gas and rubber bullets?? I assumed they were
standard fare.

Sign up
AR02465
There have been bigger demonstrations in Toronto; anti-WTO demonstrations

were far bigger, probably anti-Iraq-war ones were too. And the police weren't
helpless--again, they're prepared to deal violently with big demonstrations, and
showed it with the anti-WTO marches. There was surely plenty of advance
warning on social media, which the police monitor; if those ten thousand
people could find out about it, so could the cops. If they were "surprised" it was
because they chose to be. I can only conclude they decided not to do anything
because they don't see fascists as a threat. This is normal. The general rule is,
violent right wing demonstrations are expressions of free speech to be
protected, while peaceful left wing demonstrations are dangerous threats
which must be stopped.
I agree with your analysis ............ and it strengthens my growing respect for
the Defund the Police advocates. I was shocked recently to learn that
some Vancouver police make a larger salary than social workers with four
years of university........... 60,000 as opposed to 100,000 seems no small
chunk of change for defenders of law and order that likely didn't have to
take university courses. But then, the right wing ..... law and order, crew are
more part of the power elite than most of us likely realize.
Robert Broughton I 6 months ago
I have no doubt that the anti-vaxx/PPC protests are being orchestrated. I would like
to know more about who is funding it.

Sign up
AR02466
Very much agreed.
Reading this article I'm reminded of Greta's phrase: "Change is coming, whether
you like it or not". The radical right wing fringe obviously don't like it.. ...
Charles H Jefferson I 6 months ago
From what I have gleaned from the debates about climate change and the
Covid-19 pandemic, Greta's issue is that we as a species are overburdening this
Earth's Biosphere by the way advanced societies consume the finite resource
base available. Past time to ease up and leave some some for our young and
theirs. Nature deals with such excess consumption by all species by throwing
up barriers such as diseases, and sustenance availability. If the species fails to
adjust to the available environment it dies out. We as a species operate as
though we are exempt! History shows we are not! We brought on this
pandemic by the way modern societies operate, travelling the globe taking it
with us. Europeans did it with their diseases in 1492 or there about, to the
Americas and devastated our kind that occupied this space. To the extent we
are successful in blunting this pandemic, Nature will add further constraints,
until we adjust our cultures to ones that the Biosphere can sustain. Too many
taking too much brings on disaster. Any successful cattle rancher knows that., I
believe. The anti-vaxers are perhaps a crude push-back from something in our
DNA, not realizing they are helping to reduce our population, one of the ways
we hope to prolong our and other species existence on this planet.! According
to the Global Footprint Network we are fast exhausting our Biosphere
inheritance, relying on using an increasing percentage of the finite capital with
no wav to reolace it. Greta is oerhaos savina 'Pav attention to that fundamental

Sign up
AR02467
Yes,
Ian Graham I 6 months ago
Dear Caroline Orr,

I am appalled at your and your editors' wholesale buyin and amplification of the
mainstream official story about the threat of covid and the efficacy and safety of
vaccines. No mention of preventative precautions widely shown to be effective,
such as Frontline Covid Caregives Coalition has researched. No mention of the lack
of safety data due to the EUA rushing these vaccines into service. No mention of
the death rates from the vaccines being reported by NHS in England and
elsewhere, no mention of alternatives for preventive care like vit D and more.
Liberal, progressive and leftwing news and opinion outlets like NO are abdicating
their self-proclaimed mandate to investigate all sides and being co-opted in this
case by the establishment agenda which evidently includes passivity among the
populace.
See Prof Mark C Miller, Media Relations, New York University on why the virus
threat is the extreme example of use of fear and hatred to fuel a propaganda
campaign. https://rumble.com/embed/vjmc91/?pub=4
Also Prof Julie Ponesse Prof of Ethics at my alma mater Huron College UWO
London ON makes a public statement just before she was fired from her post of 20
yrs for refusing to be vaccinated. https://rumble.com/embed/vjmc91/?pub=4
thank you for listening, Ms Orr
Yours truly,
Diane Devenyi I 6 months ago

Sign up
AR02468
Thanks for your comment Ian. My sister is a naturopathic doctor and she has
been shocked and saddened by the failure of the Canadian governments (at
every level) to call for every possible prophylactic and early treatment currently
being used by doctors who are following the Hippocratic oath to do no harm.
Doctors around the world are begging their governments to support research
and use less invasive treatments instead of unilaterally promoting untested (in
the long term) gene therapies. Not once has Trudeau talked about healthy
lifestyle changes for improving our immune systems. What might've happened
if in March 2020 Trudeau declared that it's time for a massive health promotion
initiative by the Canadian government? In all this time nothing like that has
occurred. We've watched Only fearful hand wringing and hoping for a single
billionaire-producing remedy.
Moreover, health care providers have been informed that they stand to lose
their licences if they question the government's narrative. Such censorship has
never been previously imposed in Canada.
It's not true that every person who feels uncomfortable with these experimental
jabs is a right wing extremist. I know many people who normally vote Liberal,
NDP and Green who feel abandoned by their parties with respect to vaccine
passports and don't know how to vote. The PPC is the only party who promises
to express their concerns, which is sad.
The media are directly responsible for inflaming an "us vs them" situation. I'm
disappointed, Ms. Orr, that you have contributed to this very dangerous
situation -and have one question for you: has your article increased or
reduced hatred in the world?
Many of us are disappointed that it took so long for the Alberta

government to act on restricting anti vaccers from crowded indoor spaces.

Sign up
AR02469
There is much that could be improved about our health care system ..... but
Canada has far fewer deaths per size of our population than the empire to
the south of us. Part of that is due to our willingness to obey social
distancing rules, part of that is due to our robust public health care system.
And while the deaths of others doesn't seem to compute for some
opponents of current vaccine policy, over 27,000 Canadians have now lost
their lives to this virus.
The time for a diversity of methods is not during a pandemic; and

arguments that vaccines are the threat and not the short term solution are
just not borne out by evidence on the ground.
Your concerns about an 'us vs them' situation are trivial, compared to the
safety of all Canadians. This morning I went swimming and used the sauna
for the first time without worry.... a few anti vaccers hollared at the girls
monitoring who came into the facility......... but my husband and I had the
most relaxing recreation we've enjoyed in nearly 2 years. Because
Alberta's 'restriction exemption'( conservative talk for vaccine passports)
came into effect today.
We hate no one ...... but we're sick to death of the know it alls who think they
have a better solution to Covid. I suspect we're not alone.

Sign up
AR02470
Geoffrey Pounder I 6 months ago
The article focusses exclusively on right-wing resistance to vaccines, masks, and

common-sense public health measures. Some commentary on the left-wing variety
would be welcome. E.g., Robert F. Kennedy, Jr.
https://www.politico.com/magazine/story/2019/05/08/robert-kennedy-jr-mea ...
Otherwise rational (former) Facebook friends who accept climate science

unreservedly and call for urgent climate action embrace COVID "scepticism" and
conspiracy theories.
We underestimate the influence of the anti-vaxxer narrative at our peril. This
movement is not exclusively right-wing.
essicalexicus.medium.com/im-a-teacher-i-m-about-to-quit-f7afd11109dd
And here's a depressing article from a teacher in the United States, about how it
could get worse. We should be cognizant of the 'intersectionality' of the anti vaccer
movement and the Trumpster folk. It's neither a democratic nor a free speech
group ..... pretending we 'all need to come together' and accept 'alternative
treatment for covid' or 'alternative views of science' is specious, once we
understand how intolerant these people can actually be. And how violent.
f nordvie I 6 months ago
"That's the new reality we're dealing with in this post-truth, choose-your-adventure
world where sizable swaths of the population have abandoned science, expertise,
and knowledge-producing institutions in favor of Google searches and snake oil
salesmen."

Sign up
AR02471
How else did anyone think it would turn out, when kids are encouraged to use
"inventive spelling," when there's nothing everyone must learn, and no one has to
learn anything they don't find entertaining to do, when kids who don't like the
assignment hand in something else instead, and are given full marks because they
handed *something* in ...
The thing is, a whole lot of people have been on the downside of some of the
amazing improvements that science and industry have handed us: improvements
shareholders love, and workers find themselves laid off over.
I might put it that sizeable swaths of the population were fed a bogus economic
theory, a system that gave a free ride and a lot of cashola to highly damaging
industries, so that people without a basic, rounded education could be paid
inordinate amounts of money, at the same time as our economic and media
systems kept repeating the idea that an individual's worth is not in how much better
they made the world or someone's experience of it, but that it's measured in how
much someone'll pay for their participation.
Both government policies and processes, and media have together fashioned a
very clear picture of "the undeserving" ... and since once unemployed and
unemployable they recognize how they're being treated, but angry that they're not
being seen in the full glory of their true worth: that measured by their period of
greatest income.
They were always told that certain people were undeserving, and they happily
scapegoated them. Now that they're in a similar position, it should probably be
fairly easy to understand the self-righteous anger.
And given the extent of our education system's basic digital literacy training ...
nope. Doesn't exist. We were told it was happening ... but nothing did. So these
people can't read distinctions beyond approximate general meanings of headlines.
It's not their fault. No one taught them. They think they're reading science, but it's
just headline spin.

Sign up
AR02472
I've helped quite a few people understand the difference, over the past year and a
half or so particularly.
There's no point in assuming that everyone doing something that ultimately is

neither smart, nor rationable, nor reasonable, is informed by evil intent. It's pretty
easy for people with university educations to decide that they put in the time, so
should be paid more. It's pretty easy for people with university educations to
assume that everyone else has access to the particular skills that to them seem like
second nature.
People don't usually get left behind by choice.
Well argued. Unfortunately, the majority of us, educated or not, drank the
neoliberal koolaid peddled over 30 years ago .......... and now a majority of us are
discovering in one way or another, that we were to be among the losers. You're
right about how 'blaming the poor' and 'equating worth with income' have
contributed to the mess ......... perhaps a new era of compassion, sharing and
returning to our so called 'Christian values' might save us???
For sure the anger, the blame game, and the paranoia are going nowhere
good.
© Observer Media Group 2022

Sign up
Quick Links •
AR02473
(https://www.mcg~ Office for Science and Society Search
(loss/)
Separating Sense from Nonsense
Subscribe to the OSS Weekly Newsletter!
Sign-Up Here (https://www.mcgill.ca/oss/newsletter)
Home (loss/)
The Anti-Vaccine Movement in 2020

The popular depiction of antivaxxers as "earthy-crunchy" doesn't tell the whole story.
Anti-vaccine sentiment is strongly associated with conspiracy thinking and protection of
individual freedoms, traits that are finding a home among far-right groups.
Jonathan Jarry M.Sc. (loss/articles-by-author f (http://www.facebook.com

/ Jonathan Jarry M.Sc.) 122 May 2020 /sharer.php?u=https%3A
//www.mcgill.ca/oss/article/covid-19-
COVID-19 (/oss/categm:y/article-categories
pseudoscience/anti-vaccine-
/covid-19)
movement-2020&!= The%20Anti-
Pseudoscience (loss/category/article-categories
Vaccine%20Movement%20in%202020)
/pseudoscience)
in (http://www.linkedin.com/shareArticle?mini =true&u rl =https %3N /www.mcgill.ca/oss/ article/covid-19-pseudoscience
/anti-vaccine-movement-2020&title= The%20Anti-Vaccine%20Movement%20in%202020&
summary=What%20does%20an%20antivaxxer%20and%20a%20far-right%20activist%20have%20in%20common
%3F%20If%20the%20thought%20of%20someone%20who%20opposes%20vaccines%20brings%20to%20mind%20tie-
dye%20shirts%20and%20tree%20hugging%2C%20your%20answer%20may%20be%20%E2%80%9Cnothing.
%E2%80%9D%20But%20clearly%2C%20some%20do%20have%20a%20commonality
%3A%20protesting%20the%20COVID-19%20lockdowns.&source=Office%20for%20Science%20and%20Society%20)
(http://twitter.com/share?url =https%3A
//www.mcgill.ca/oss/article/covid-19-
pseudoscience/anti-vaccine-movement-
2020&count=horizontal&
via= McGillOSS&text= The%20Anti-
Vaccine%20Movement%20in%202020&
counturl=www.mcgill.ca/oss/article
/ covid-19-pseudoscience/anti-vaccine-
movement-2020)
W hat does an antivaxxer and a far-right activist have in

common? If the thought of someone who opposes vaccines
brings to mind tie-dye shirts and tree hugging, your
answer may be "nothing." But clearly, some do have a commonality:
protesting the COVID-19 lockdowns. Coverage from these protests
_(hru;>s:/LpressprQgress.ca/canadas-anti-lockdown-protests-are-
a:ragtag-coalition-of-anti-vaccine-activists-conspirru:y-theorists-and-
the-far-right/?fbclid = IwAR32gN QLilxsexFvdH u-lnG40mW-
3FXtTgwHDVRSzkCC9XlWa 9 lN oL--oAw). often show people
holding signs slapped with antivaccine rhetoric next to pro-militia
activists and white supremacists. This phenomenon can also be seen
AR02474
among homeschoolers according to Anne Borden, a pro-vaccine
homeschooler who fights against phony autism cures. "The first
antivaxxers I ever met were left-leaning unschoolers when I was an
unschooled teenager. They were very much a part of the early efforts
to 'stop the Food and Drug Administration' from regulating
alternative medicine. What has happened in recent years is that this
demographic of homeschooling is being now recruited by the radical
right on social media, and some are turning right. And this is very
concerning."
This may leave you wondering just what is happening to the anti-
vaccine movement in 2020.
The central dogma of the anti-vaccine ideology is that vaccines cause

autism and other bad health effects, and that governments and the
pharmaceutical industry knowingly suppress this information. This
tenet, we easily imagine, is tightly wedded to the political left. It's a
hippy-dippy attitude, we often think, borne out of an irrational fear of
chemicals, and there are indeed prominent spokespeople for the
movement who fit this sketch. Joe Mercola made his fortune selling
natural health products and has contributed more than $2.9 million
to the National Vaccine Information Center
_(https://www.washingtonpost.comLinvestigations/2019/lQ
L15/fdc01078-c29c-lle9-b5e4-54aa56d5b7ce story.html) in the U.S.,
an anti-vaccine advocacy group. There is Robert F. Kennedy, Jr., a
Democrat and environmentalist, who is a major public figure on the
anti-vaccination scene as the chairman of the Children's Health
Defense. This branch of the movement shows a distrust of
pharmaceutical companies and a_pursuit of purity _(http:,:/ /horizon-
magazine.eu/article/rise-vaccine-hesitancy-related-pursuit-purity-
prof-heidi-larson.html). Their wrongful idea that nature is inherently
good ends up framing their thinking, which is why in the age of
COVID we read about their "natural immunity theory": that barriers
to germs, like physical distancing and masks, weaken our immune
system. Vaccines are just one more synthetic loaded gun aimed at our
immune system, they say. The embedding of antivaxx sentiment
within this nature worship is familiar to many of us. But there is a
segment of the anti-vaccination movement on the far right, drawn to
its libertarian streak of distrusting the government, and there exists
at least one prominent bridge between leftist antivaxxers and the
political right in the United States: Donald Trump.
Before associating with the Republicans and as far back as 2007

_(https:LLwww.insider.com/how-donald-trump-became-an-anti-
vaccinationist-20l9-9?amp)_, Trump had publicly expressed the
erroneous belief that vaccines cause autism. He has helped raise
money over the years for his friend Bob Wright, who founded the
charity Autism Speaks whose stance on vaccines has been deemed
"controversial." And Trump himself invited Robert F. Kennedy, Jr., to
chair a commission on vaccine safety (which ended up dying on the
vine). Trump, it should be pointed out, is the first American
president to be on the record as having anti-vaccine views, an
influence that cannot be ignored. A survex
_(https://linkinghub.elsevier.com/retrieve/pii/S0022103119302628)
involving Americans who voted in the 2016 presidential election
revealed that Trump voters expressed more vaccine concern
(specifically about the MMR vaccine, wrongly linked to autism) than
non-Trump voters, a result which the authors conclude was
explained by their conspiracist ideation. This association between
the current right-wing of American politics and questioning the value
and safety of vaccines can also be seen in Gallup polls
_(https:/ /news.gallup.com/poll/276929/fewer-continue-vaccines-
important.aspxt For the years 2001, 2015 and 2019, the percentage
of Democrats who say it is either extremely or very important for
parents to vaccinate their children has moved from 97% to 88% to
92%. For the same time points, Republicans went from 93% to 82% to
AR02475
79%.
Beyond political affiliation, researchers can shed some additional

light on who an antivaxxer tends to be and how they think.
Interviews with Australian parents who reject vaccines revealed they
see themselves as virtuous but oppressed, and vaccinators are
perceived as an "Unhealthy Other" (https://www.sciencedirect.com
/science/article/pii/S0264410Xl830149X). Those who reject
vaccines may have a skewed perception of the risks posed by them
and the diseases they prevent, with some evidence
_Qmpi/publichealth.jmir.orgL2018Ll~Ll showing that Internet
searches may increase the perception that childhood vaccines are
risky. And alfilge investigation (https://psycnet.apa.org
/doiLanding?doi =10.1037%2Fhea0000586l into the anti-
vaccination phenomenon, conducted in 24 countries by a team at the
University of Queensland, revealed a strong pattern: people who
reported more conspiratorial beliefs tended to be more anti-vaccine.
This association was particularly strong in Western nations, like
Canada and the U.S. Next in line was the link between anti-
vaccination attitudes and the resistance to having their freedom
taken away from them. The authors report that "more conservative
participants also had stronger antivaccination attitudes." What was
not linked to antivaxx beliefs was education.
The prototypical antivaxxer described above, though, does not exist

in a vacuum. The people who espouse these views can find each other
quite easily because of the existence of an important conduit that
allows their claims, anxieties and incitements to spread: social media.
Even though social media giants have said they would crack down on
vaccine misinformation, anti-vaccine communities quickly adapt to
the new rules, like a guided virus mutating with a purpose. For
example, the word "vaccine" disappears in the name of their group,
replaced by "medical freedom." And according to a recent massive
Rnalysis of 100 million Facebook users worldwide
_(http;//www.nature.com/articles/s41586-020-228l-l), online
supporters of anti-vaccine views have been more successful by some
measures than those of us publicly supporting vaccines. They are
smaller numerically but occupy a more central position in the
network; they are heavily involved with clusters of Facebook users
who haven't made up their mind about vaccines; and they offer a
wide variety of "potentially attractive" stories (about safety concerns,
about government conspiracies, about natural immunity) that can
attract a greater diversity of people compared to pro-vaccine
messaging which tends to be one-note. This diversity is also
encouraged by social media companies. Platforms like Face book and
YouTube want to hold onto your eyeballs so they recommend other
content. Renee DiResta, a security researcher, told BuzzFeed News
that as she joined more anti-vaccine parenting groups on Facebook
for the purpose of investigating them,-1:he_platform recommended
more and more conspiracist groups (https://www.buzzfeednews.com
/article/craigsilverman/how-facebook-groups-are-being-exploited-
to-spread): about chemtrails, about the flat Earth, about the
Pizzagate conspiracy theory. She called this phenomenon
"radicalization via the recommendation engine." And as Anne
Borden was telling me, there is active cross-pollination happening on
social media with the far right. "Right-wing movements have deeply
infiltrated the social media spaces of the antivaxx and vaccine-
hesitant homeschoolers and alt-schoolers. They recruit in antivaxx
and Facebook groups related to complementary and alternative
medicine."
What these concerns and conspiracy theories may mean

for the future
When we pull at this big ball of conspiracy theories and pro-freedom
sentiment, we can find some genuine concerns buried inside. Jon
AR02476
Perry, the founder of the Stated Clearly science communication
project, pointed me in the direction of a Face book meme declaring
that its poster would not be "vaccinated (chipped) for the
coronavirus." "The meme," he told me, "is a mixed bag of legitimate
concerns about tracking devices, a justifiable mistrust of billionaires
and large organizations, common knowledge that most large nations
dabble (or have dabbled) in bio-weapons research, a far less
warranted (but not totally baseless) fear of new vaccines, and many
more, all combined with a horrible confusion about medical patents
and virus naming structures." A project like ID2020
~(h!:ms://id2020.org/}, aimed at providing everyone with a secure
digital identification, can be twisted by a distrustful, pattern-seeking
mind into a cover for Bill Gates' nefarious plan to monitor every
human being. The fact that multiple coronavirus vaccines use the
virus' RNA can be misinterpreted into the fear that vaccines will
mutate our own DNA. Justified worries are fed by misunderstandings
and further amplified by a conspiracist mindset in online
communities cross-pollinated by radical political actors, leading to
progressive vaccine-hesitant parents holding hands with the anti-
lockdown movement. Like a big ball of colourful rubber bands, these
disparate-looking actors share an underlying property and end up
sticking together.
While this big wobbly ball looks overwhelming, there are discreet
actions pro-vaccine people and organizations can take to minimize
the damage caused by anti-vaccine attitudes, and because these
attitudes tend to be tied to the belief in a grand conspiracy, the recent
publication of the Conspiracx Theoiy Handbook
~(h!:ms://www.climatechangecommunication.org&p-content
/uploads/2020/QJ/ConspiracyTheoryHandbook.pdfl can be of help.
When addressing members of the public unlikely to endorse
conspiracy theories, the Handbook recommends empowering people
with facts, uncovering the bad logic in the initial argument, linking to
fact-checking websites, and exposing the lack of credibility of the
sources of these theories. Trying to reach extremists, on the other
hand, is usually a fool's errand; personally, I'd rather address the
people on the fence and we have preliminary evidence
~(h!:ms://mcgill.ca/oss/article/health/motivating-parents-vaccinate-
quebec-initiativel that empathy and really listening to the concerns
of vaccine-hesitant parents can improve their attitudes toward
vaccines.
If safe and effective vaccines against the new coronavirus end up

being approved (which is not a guarantee, though over 90
experimental vaccines are at various testing stages), I wonder how
much public confidence will have been eroded by this reenergized
anti-vaccine movement and their radical allies. In the past decade,
the United States has seen a 10% overall decline
jhttps;/Lnews.gallup.cmn/PQIIL276229/fewer-continue-vaccines-
important.aspx} in the number of parents who feel it's extremely or
very important to vaccinate their children (from 94% in 2001 to 84%
in 2019), with 11% saying they think vaccines are more dangerous
than the disease they are meant to prevent. Meanwhile, in 2015,
almost two in five respondents to a Canadian survey
~(http://www.cbc.ca/news/health/vaccines-widely-accepted-byc:
canadians-as-effective-poll-suggests-1.29550471 agreed that the
science on vaccinations isn't quite clear. What these numbers
capture is not just antivaxxers, however. Their movement is a small
and vocal minority, but its fear-based messaging reaches a larger
segment of the population: the vaccine hesitant. And people on the
fence about vaccines are now being served an incredible buffet of
prickly anxieties: from genuine concerns that a corona virus vaccine
may be rushed to the loud cries of "my body, my temple", all the way
to stories of Bill Gates' evil plan to depopulate the world, with the
occasional viral video like Plandemic fuelling this unease with a
veneer of respectability. How much damage this ever-growing ball
AR02477
will cause on its way down the slope is anyone's guess, but we have
genuine reason to be worried.
If you have concerns about vaccines based on specific allegations that

you have heard, check out the website "AntiAntiVax"
_(htms:LLantiantivax.flurf.netL)_ which addresses many of these
claims.
Take-home message:
- Even though well-known parts of the anti-vaccine movement are
on the political left, anti-vaccine sentiment is more pronounced on
the right
-There is a strong association between anti-vaccination and belief
in conspiracy theories and a significant link between anti-
vaccination and the resistance to having your freedom taken away
from you
- Anti-vaccine Facebook users, although relatively small in
numbers, have been very successful at spreading their message on
the platform, which has facilitated their fraternization with other
conspiracy theorists.
@CrackedScience (http;/ /twitter.com/crackedsciencel
Leave a comment! (https_://www.facebook.com/McGillOSS/posts

/3006205786085523? xts [OJ =68.ARCahA!jlolVWV-
VezaYeaK5LbxcSy2Q~7VjDVddmwoa2RXVJavWkSYN56u d8 r
h65WgXCgyZnCpEgyj6thf-BVFPgl6x9Fy0sp5b7j2mNSz-
ReKlocWVxhrWrxeieSUrTHAJa0QcVlzF z!Ja60P87Zefk-Mt-
DaaF3WOtljVGzekC5jSY05Q6XTltReRekwX73Zac71Mdgz3JhqlMi
CN5hE5m3aJlM7tmfmf7UmUukwVz2arMfr4VGQ68vSimqcXCGJG
ZJMhsKzN6ZAiVL1SK mv8Q2YkXs4QEiOM9KzPiROfsG zCtGeK
2ByaDVbljblL PVgeRiyIERETJO& tn =-R)
Keywords:
antivaxxer (/oss/category/tags/antivaxxer) vaccines (/ass/category/tags/vaccines)
vaccination (/ass/category/tags/vaccination)
vaccine hesitancy (/ass/category/tags/vaccine-hesitancy)
activism (/ass/category/tags/activism)
distrust in government (/ass/category/tags/distrust-government)
Donald Trump (/oss/category/tags/donald-trump)
Republican (/ass/category/tags/republican) lockdown (/oss/category/tags/lockdown)
covid19 (/oss/category/tags/covid19)
homeschooling (/oss/category/tags/homeschooling)
anti-vaccine (/ass/category/tags/anti-vaccine)
Robert Kennedy Jr. (/oss/category/tags/robert-kennedy-jr)
autism (/ass/category/tags/autism) Bill Gates (/ass/category/tags/bill-gates)
conspiracy theories (/ass/category/ tags/conspiracy-theories)
What to read next

AR02478
Accessibility (https://www.mcgill.ca
/accessibility)
_{b!!P-S://www.mgiill.ca)
Copyright© 2022 McGill University
Log in Iii
(/oss/saml_login?destination=node
/8254)
AR02479
LA
PRESSE
Theories complotistes et mefiance

envers le vaccin sont liees, selon
une etude
AR02480
PHOTO NEXU SCIENCE COMMUNICATION ET TRINITY COLLEGE VIA REUTERS
La fausse theorie a laquelle les participants adherent le plus est celle selon laquelle le coronavirus a ete
deliberement fabrique dans un laboratoire de la ville chinoise de Wuhan, d'ou est partie l'epidemie.
(Paris) Jusqu'a un tiers de la population de certains pays est

susceptible de croire a de fausses informations et a des theories
complotistes sur la COVI D-19, qui ont pour effet d'augmenter la
mefiance envers la vaccination, ont averti des chercheurs
mercredi.
Publie le 13 act. 2020
AGENCE FRANCE-PRESSE
« Nous avons trouve un lien clair entre le fait de croire ades theories
AR02481
conspirationnistes et la reticence envers un futur vaccin », a commente l'un des
auteurs de cette etude, Sander van der Linden, chercheur en psychologie sociale a
l'universite de Cambridge (Angleterre).
Publiee clans la revue britannique Royal Society Open Science, cette etude se base
sur des enquetes d'opinion realisees au Royaume-Uni (deux vagues successives
d'environ rooo participants), aux Etats-Unis, en lrlande, au Mexique et en Espagne
(700 participants a chaque fois) .
Selan ces travaux, la fausse theorie a laquelle les participants adherent le plus est
celle selon laquelle le coronavirus a ete deliberement fabrique clans un laboratoire
de la ville chinoise de Wuhan, d'ou est partie l'epidemie.
Quelque 33 % des participants mexicains et 37 % des participants espagnols jugent

cette theorie « fiable » (entre 22 et 23 % au Royaume-Uni et aux Etats-Unis).
La fausse affirmation selon laquelle la pandemie de COVID-19 « fait partie d'un

plan pour imposer la vaccination mondiale » est jugee fiable par 22 % des
participants mexicains, r8 % des participants irlandais, espagnols et americains, et
13 % des participants britanniques.
Autre fausse theorie, celle selon laquelle les symptomes de la COVID-19 sont
aggraves par les nouveaux reseaux de telephonie mobile 5G: r6 % des participants
mexicains et espagnols y adherent (n % en lrlande, 8 % au Royaume-Uni et aux
Etats-Unis).
Les participants a l'enquete ont ete interroges a la fois sur leurs intentions quanta
un futur vaccin et sur la fiabilite qu'ils accordent a ces differentes theories (sur une
echelle de r a 7).
Selan les chercheurs, meme une petite augmentation de la croyance en ces theories
entraine une baisse importante de la confiance clans les vaccins chez la personne
interrogee.
AR02482
Ces theories sont propagees sur les reseaux sociaux. La semaine derniere, Facebook
a annonce le retrait de tous les comptes lies ala mouvance conspirationniste
« QAnon », alors que le nombre d'adeptes de ce mouvement d'extreme droite pro-
Trump a explose al'approche de la presidentielle americaine.
« En plus de signaler les fausses affirmations, les gouvernements et les societes de

technologie devraient chercher le moyen d'ameliorer !'education aux medias
numeriques clans la population. Sinon, developper un vaccin pourrait ne pas etre
suffisant », estime Sander van der Linden.

AR02483
TORONTO STAR
r ill Newsletters
1
Today's I
Signln
1111
Sports
paper ~ Betting
] ~
CANADA
This uniquely Canadian conspiracy theory group was on

the edges of obscurity. Then vaccine mandates came
down
Some anti-vaxxers, feeling pushed to the margins due to government mandates, have found solace
in conspiracy movements, bolstering their numbers.
By Alex McKeen Vancouver Bureau

Sun., Nov. 14, 2021 ('.) 15 min. read
JOIN THE CONVERSATION
VANCOUVER-It's a rainy Sunday and inside a small church on the east side of Vancouver, talk has turned to mutiny.
About 20 unmasked people have trickled into the church's wooden pews for a meeting, eating potluck soup, holding long hugs by
way of greeting and chatting about their own version of current affairs.
The cloudy weather has left the space dark inside, with only intermittent bursts of sunshine coming in through colourful
stained-glass windows. Artwork of Jesus, dreamcatchers, and circles of hands cover every spare patch of wall.
Topics among those gathered range from the certain - that COVID-19 was planned by the global elite; to the speculative - the
fate of micro chipped individuals lucky enough to survive their COVID-19 vaccine.
One woman breaks away from her private conversation, looking down to make a comment to no one in particular.
"We must sound just crazy," she says. "To someone who doesn't know about this stuff yet."
The conversations between those in attendance eventually fall silent, as a large, older man sitting at the front of the church
begins to talk. He speaks in a slow, commanding drawl, a man in a cowboy hat standing sentry behind him.
"You might step off the ship of commerce, but did your mind follow you?" the man introduced as maathlaatlaa booms, gesturing
to his own head.
"Are you still caught in the world of corporatocracy up here?
"This is our de jure government we're building," he says. "We have invited you to walk beside us."
Some in the pews nod their heads, or let out a murmur of agreement.
Among those gathered here, "stepping off the ship of commerce," refers to leaving society as we know it and being freed from the
constraints of Canada's institutions and laws.
AR02484
Members of this group will also talk about commandeering the "vessel." That vessel is the Canadian government - and they
want to take it over.
Welcome to the latest meeting of the Peoples of the Salmon.
While there are only 20 people at the church, this group's online footprint is bigger. A recent petition boasts more than 19,000
signatures.
It's a manifestation of what experts describe as a uniquely Canadian brand of conspiracy-theory-laden, anti-government belief
- one that's picked up steam during the pandemic. If you've wondered where Canadians go when their beliefs diverge so
strongly from reality that everything- from vaccines, to Canada's own elections - seem like a conspiracy, it's to places such as
this.
The general trend worries experts, for both the social harm they say it can do, and the fear that it might, in some rare cases, lead
to violence.
Let it be said upfront: this particular group, eating soup in the pews of a darkened church, does not have any obvious or viable
path to overthrowing the government. They say they have no plans at all to incite violence - that they fight with the pen, not the
sword.
At the Sunday meeting, a woman named Dayna Furst, an erstwhile anti-vaccination organizer who has taken over recruiting for
the Peoples of the Salmon group since mid-September, is wrapped in a ceremonial blanket.
It is meant to symbolize the protection of her spirit outside of the corporate world, with a $10 Canadian bill pinned above her
heart.
The symbolism is keenly felt in the room. Furst, and many others, cry.
"We need everybody to spread our petition to collect signatures," Furst had told an earlier meeting. "So that we can take over the
government."
The origin story of the Peoples of the Salmon could be said to start with one man's grievances with the legal system.
These days, he goes by "popois." In the past, he has been known as David Quinn. The B.C. Supreme Court says he's not allowed to
file any more lawsuits by either name.
The founder of the Peoples of the Salmon was declared a "vexatious litigant" by the B.C. court in 2018 for undertaking a series of
"pseudolegal" battles over the course of nine years - claiming repeatedly and with no success that the court's jurisdiction did
not apply to him and certain neighbours because he, as an Indigenous person, had not consented to participate in the court's
rules.
After that, as he explains it, he started thinking of ways to move even further outside the government system.
"We started (the group) two years ago, when we were looking for a name other than a country," he told the Star in an interview.
"So I came up with Peoples of the Salmon, and it's the de jure government west of the Rockies, north of the 49th parallel, and
south of the Yukon."
He's describing the geographic area ofB.C., but says he is willing to "adopt" any Canadian regardless of where they are located
into his imagined regime. In doing so, he says, he can make them "sovereign" - as he claims to be, and untouchable by the legal
system. He and the older man present at the church meeting, maathlaatlaa, both refer to themselves as "headsmen" of the group,
but it's popois who is the main spokesperson and organizer.
maathlaatlaa is a more enigmatic figure, serving as something of a spiritual adviser inaccessible to members of the group except
at the Sunday meetings. On the phone with the Star, he said it wasn't right to think of his role in the group as a "title" or
"position" - that's language used in the corporatocracy, he said.
"popois and me, we are flesh, blood and bone. We're not corpses like the corporation," he said.
popois' claims to sovereignty are not true in the eyes of the law, and that's been established by his dozens of failed court petitions
and cases.
AR02485
Yet popois knows that speaking in the language of Indigenous land claims adds an air oflegitimacy to his pitch. That, he says, it
what differentiates his group from other "sovereigntists."
The name of his group, the Peoples of the Salmon, is based on a theme important to the Coast Salishpeople in western B.C. and
the U.S. Pacific Northwest, referring to the importance of salmon in their cultures.
popois is himself a member of the shish:ilh nation in B.C., but the nation has said in previous court filings he does not represent
or speak for them. The Star reached out to the current chief of the shish:ilh nation but did not hear back.
While the shish:ilh, which has been a self-governing nation since 1986, and other First Nations across Canada have a legitimate
right to self-determination and governance - rights that in some cases are being negotiated through treaty talks and the court
system at present - popois appears to be using the familiar term for a purpose that is detached from those realities. And it's
resonating beyond Indigenous circles.
White Canadian anti-government leaders, such as Odessa Orlewicz, who runs a far-right social network with her husband in
Vancouver, have previously given little focus to reconciliation efforts in Canada, but have taken up popois' statements with
reverence.
"The Indigenous have asked us ... to bring together the non-Indigenous Canadians with the Indigenous Canadians," she said in
one of her most-viewed videos last month. "The tyranny above, they want the Indigenous and the white man to be fighting each
other right now. Well, those Indigenous and non-Indigenous that are awake know they're trying to do that.
"The Indigenous can't do it without us, and we can't do it without them."
The ideology popois espouses is sometimes called the "sovereigntist" movement, sometimes the "freemen" approach.
AR02486
It purports that people can prevent laws from applying to them by "withdrawing their consent," and its appeal has motivated
groups in Canada and the U.S. to try to get their taxes refunded and gain immunity from criminal law, with no success, since the
1960s. It's also a conspiracy theory at its roots, because it claims the legal system itself is an elaborate ruse, and that people who
are "awake" can just opt out.
A prominent Canadian espousing this type of thinking is David Lindsay, a "sovereign citizen" activist who has served jail time for
refusing to pay taxes, and more recently has organized anti-vaccine rallies in Kelowna, B.C. He also has given interviews with
Paul Fromm, a white nationalist - ties the Star has not made to the Peoples of the Salmon group.
popois is careful to distinguish his group from the "freemen" types. He says others may talk a big game about freemen, but they
don't have the same legal mechanisms for achieving it as he does.
popois started to get into this thinking sometime around 2009, the year he filed his first court challenge, which was a lawsuit
against police officers who charged him for driving without licence plates.
He's a former fisherman from the shish:ilh Nation on B.C.'s sunshine coast- a remote coastal community that, despite being on
the mainland ofB.C., is only accessible by ferry.
This is worth pausing on, because it points to one of the group leader's early gripes with Canada. popois, who these days lives
mostly in Vancouver, was one of many making his livelihood off fishing Pacific salmon, but the population of salmon has been
declining since the 1990s, due to a combination of climate change, overfishing and habitat destruction. Like many others, popois
places the blame for the decline squarely on the government of Canada, what he calls the "corporation of Canada," for allowing
fish farms along the coast, a practice that may interfere with wild fish.
"The corporation has done with the fish farms the same as what they did with the buffalo," he told the Star.
The group only began taking off last summer, when popois posted a flagship petition on its website, claiming that anyone who
signed was "withdrawing consent" from the laws of Canada, and submitting instead to a new order run by him.
That caught the notice of some right-wing conspiracy theory influencers, who were already interested in looking for ways to
defy government authority on policies such as vaccine mandates.
The petition had little traffic when it was first posted on Sept.16. But it started gaining steam on Oct. 8, after a B.C. anti-
government protester named Pat King posted it with one of his livestreamed videos. The same thing happened about a week
later, when another right-wing influencer from Vancouver, Orlewicz, also posted the petition. The petition is still well short of
its stated five-million-signature goal, but it claims to have more than 19,000 signatures.
If all those signatures genuinely come from Canadians, it's an alarming indication of how many people are eager to actively
oppose Canadian institutions.
The Star reached out to the creator of the petition platform, which is run through a plug-in on the website builder WordPress.
Steve Davis, the contact for the Australian-based plug-in provider 123host, said the number of signatories listed on the Peoples
of the Salmon website should be accurate, unless a person with coding skills has been fudging it on the back end of the website or
stuffing the petition with names. Due to the fact the signatures increased at the same time the petition was publicized on right-
wing networks, though, that person would have to be fairly sophisticated, fudging the number in concert with the dates the
petition was publicized, and not at other times.
The group also has an active Telegram channel with about 150 volunteers, and daily meetings where they plan how to fundraise
for "legal fees" associated with their aims. In one recorded meeting viewed by the Star, participants were asked to cough up a
$1,000 donation to attend a webinar with "experts" promising to start legal actions to help them retrieve tens of thousands of
dollars in taxes.
To those unfamiliar with legal concepts, and who want to believe popois' message, one can see how there's an air of feasibility to
his pitch. He relies on two real legal principles, it's just that neither can be used in the way he describes. One is the right of
Indigenous peoples to self-determination, and the other is an obscure American contract law called the Uniform Commercial
Code (which he says, wrongly, is legal mechanism for declaring independence from the state of Canada).
The Peoples of the Salmon offers one window into a world in which conspiracy theory groups are increasingly vying for the
attention, time and money of Canadians. And in Canada, during the COVID-19 pandemic, that potential audience is larger than
you might expect.
A poll done by the firm Leger for Elections Canada in April showed that conspiracy-theory thinking is common among a large
minority of the country.
AR02487
The study, which surveyed 2,500 Canadians, reported 17 per cent said they believed the government was trying to cover up the
link between vaccines and autism, and that 30 per cent said they thought new drugs or technologies were being tested on people
without their knowledge.
A further 40 per cent of respondents indicated they subscribed to thinking that certain big events have been the product of a
"small group who secretly manipulate world events."
What popois knows is that the appeal of his pitch is broadening, as Canadians who strongly oppose vaccination find themselves
increasingly on the fringes of society.
"If you don't get your vax and your passport, you're going to be on unemployment," popois told the Star, referring to those
individuals who have lost their jobs as a result of vaccine mandates at workplaces. "So all these people: where are they going to
go? What are they going to do?"
He said he hopes they will join him and his plan to declare as sovereign citizens any Canadians willing to follow him.
Helmut-Harry Loewen, a researcher of the far-right and retired University of Winnipeg instructor, said that, even if they're not
explicit about it, the increasingly inflammatory language employed by sovereigntist groups can be a concern.
The Peoples of the Salmon are explicit about their non-violent intentions. Asked whether he is worried anything he says will be
used to justify anyone else's violent intentions, popois says he is not.
"No. The sword that we use is the pen. And this is the first time in history that documents have been so used properly that there
is no defence against them," he said. "Our people aren't of that nature. And there aren't enough of us to carry out that kind of
threat."
Still, Loewen said anti-government theories can be interpreted by individual actors in the most concerning of ways.
A ready example: the QAnon conspiracy theory, which says the world is run by a pedophile ring, seems to have inspired Corey
Hurren to attempt to attack Prime Minister Justin Trudeau in 2020.
Experts say it's not that people who go down these rabbit holes are just gullible - there's something conspiracy theories and the
groups that form around them do for people on a personal level.
In a QAnon chat room or church meeting of the Peoples of the Salmon, there's a lot of validation, a lot of hugging, and therefore a
lot of social encouragement to keep following the conspiracy theory, while eschewing other sources of information.
It's easy to see how Canadian anti-vaxxers, pushed further and further to the margins by vaccine mandates but steadfast in their
ill-formed beliefs, could find some solace in a group like that.
But wherever groups coalesce around an alternative reality, there is potential for danger, Loewen said.
Think about the January insurrection in the U.S., in which participants expressed seemingly genuine belief that their actions
threatening the capitol amounted to patriotism.
"If governments are constructed as an enemy, what does that do? It forms the rhetorical platform for further action," Loewen
said. ''We saw what happened in the U.S. with the months and months oflies told about the election and how that resulted in the
insurrection of Jan. 6."
Alberta legal scholar Donald J. Netolitzky tried to summarize the consequences of groups such as the Peoples of the Salmon
broadening their appeal. It's not that they would threaten a country's institution in any of the ways they claim to, he said. But
there was a huge social cost to both the legal system, the people who fall prey to these schemes and anyone unfortunate enough
to be on the receiving end of a person whose actions are inspired by them.
One such person was the landlady of a Calgary man named Mario Antonacci. Around 2012, he claimed he was a "freeman-on-
the-land" and that his rental property was an "embassy." He threatened her with action by "Territorial Marshals" if she would
not pay money to him. Eventually, he was arrested and evicted.
Richard Warman, another legal scholar who has worked with N etolitzky and with the Canadian Anti-Hate Network, said the fact
the anti-vaccine movement is currently mobilized as a result of the pandemic is a potential boon to groups like this.
"The anti-government sovereign citizen movement is an opportunistic infection. If it can find a new host population, like the
anti-vaxxers, it will infect them as much as possible," he said. "It will try to use that population that is already susceptible to
AR02488
conspiracy theory messages and introduce them to this overarching conspiracy theory."
Both Loewen and Warman pointed out that where these movements become the most concerning is where they begin to overlap
with racist, anti-Semitic and openly hateful neo-Nazi group members. There is no indication that the Peoples of the Salmon
group have done this, or made any moves toward violence.
Loewen and Warman warn that a strong anti-government message can be just the thing that brings apparently disparate groups
together under one banner, and potentially inspire "lone wolf' types to take violent actions.
That's how, for example, at the London, Ont., campaign event where Canada's prime minister was pelted with gravel, anti-
vaccine conspiracy theorists found themselves shouting alongside members of the white nationalist group Canada First.
Bringing these groups together does not mean they will all adopt the thinking of the most extreme among them, but it does open
up this possibility, something Loewen calls "far-right mobilization."
popois chooses his words carefully while making what he admits are extraordinary claims. He has a low, calm, slightly raspy
voice that could fit a radio announcer.
He spoke once on the phone with the Star, explaining about the group and its background, but saying he didn't think his ideas
would be permitted to be printed in the newspaper, because he believes the Canadian state controls such sources of information.
Subsequently, other members of the group contacted by the Star and who initially expressed interest in discussing the Peoples
of the Salmon stopped responding. But popois invited the Star to a group meeting, saying that even if his group was portrayed in
a negative light, it would just be further evidence of the deep state at work.
popois said he is not trying to dismantle Canada and install himself as the prime minister of a new country. But only because he
says he is already the leader of the land. And the word "country'' does not apply.
"I am the leader of this government presently," he said in an interview with the Star. "When you consent to myself you're
consenting to being under our jurisdiction."
If that sounds far-fetched, he said, it's nothing compared to the way we've all been duped into believing in our legal system, he
said. The ideology he is actively recruiting other susceptible Canadians into is one he really seems to believe. And it's based on
legal-sounding terminology that dangles the promise of defecting from an unwanted authority- like a country, for instance.
Alex McKeen is a Vancouver-based reporter for the Star. Follow her on Twitter: @alex_mcl<een
Read more about: Vancouver, British Columbia

AR02489
Copyright owned or licensed by Toronto Star Newspapers Limited.All rights reserved. Republication or distribution of this content is expressly prohibited without the prior written consent of
Toronto Star Newspapers Limited and/or its licensors. To order copies of Toronto Star articles, please go to: www.TorontoStarReprin ts.com
AR02490
LA
PRESSE
Vie et mort d'un complotiste

AR02491
PATRICK LAGACE
LA PRESSE
Je cite Bernard Lachance, figure de proue du

conspirationnisme quebecois: « Les pandemies n'existent
pas. Ni SRASCOV2 Ni VIH. Et il n'y a pas eu de grippe
espagnole causee par un virus il y a cent ans. La franc-
ma<;onnerie existe depuis plus de 300 ans et les mensonges
mondiaux ne date pas d'hier. La virologie est une religion
moderne. »
Publie le 12 mai 2021
AR02492
Ce genre de folie qui,jadis, vous confinait aux marges du discours socialement
a
acceptable. En 2021, c;a vous donne des clics repetition, de l'attention ... de l'amour.
Bernard Lachance est mort, hier.
C'est sa samr Lise qui en a fait l'annonce sur sa page Face book: « J e vous informe du
deces, ce matin, demon frere Bernard qui allait avoir 47 ans enjuin. Son deni du
a
VIH l'aura mene sa mort. Ne voulant pas enrichir Big Pharma, il a investi des
milliers de dollars dans des produits naturels plein la maison ... »
A Tristan Peloquin de La Presse, l'autre sIBur de M. Lachance, Marie-Claude, a

confie hier que son frere se « purgeait » ces derniers temps des medicaments pris
a
dans sa vie, l'aide de produits naturels. S'en est suivie une diarrhee qui a dure des
semaines: « Quandje l'ai vu pour la derniere fois il y a quelquesjours, il etait
squelettique. »
a
Lachance etait complotiste avant que ce soit la mode, sije peux dire: il harcelait
depuis des annees le DrRejean Thomas, son ancien medecin, Rejean Thomas qui
soigne les porteurs du VIH avec le traitement miraculeux qui a sauve des millions
de personnes : la tritherapie.
a
Bernard Lachance ne croyait pas la tritherapie. Il avait cesse depuis des annees de
prendre ses medicaments, qui reduisent - pour la plupart des malades - le VIH a
a
une maladie chronique avec laquelle on vit, par opposition une maladie qui vous
tue, comme c'etaitjadis le cas.
J'ai echange hier avec Vincent Audet-Nadeau, qui connaissait Bernard Lachance
a
depuis leur enfance Montmagny, pres de Quebec. Il admirait le front de bIBuf de
Bernard Lachance, cette audace qui lui faisait defoncer des portes, qui l'avait fait
a
atterrir sur le plateau d'Oprah Winfrey aux Etats-Unis, qui l'avait pousse louer le
Centre Bell pour s'y produire.
Mais rien de cela n'avait debouche sur une carriere solide, qui aurait pule faire
vivre, rayonner. Comme des milliers d'autres, cote showbiz, Bernard Lachance fut
AR02493
un feu de paille.
Vincent Audet-Nadeau aurait voulu faire un documentaire sur son ami d'enfance,
au tour de son refus de la tritherapie. Mais Lachance voulait que ce docu soit une
inculpation de Big Pharma. Le documentariste refusait. Il tentait de le raisonner, a
coups de faits, d'arguments ... Peine perdue.
Il croit, aujourd'hui, s'y etre mal pris avec son ami d'enfance: « La raison n'a pas
raison de tout. Tout le monde a sa part d'irrationnel, Bernard manifestement pas
mal plus qu'un autre ... Mais il y avait dans sa maniere d'etre quelque chose de
profondement humain. »
Puis, au gre de notre conversation, Vincent Audet-Nadeau a touche a quelque chose

dontj'essaie de deviner les contours depuis un an. Ce desir de briller, chez les
fleurons du conspirationnisme : « Bernard cherchait la reconnaissance, en quelque
part. Il y a quelque chose de lie au fait d'etre reconnu. »
Beaucoup, beaucoup de gens qui avaient, pendant un temps, brille, eux aussi, dans
leurs domaines respectifs ... Puis qui ont perdu cette lumiere. Et dans les theories
fumeuses du negationnisme sanitaire, ils ont (re)trouve cette lumiere.
Des exemples?
Ken Pereira, les jumeaux Tadros, Lucie Laurier : ils ont tous flirte avec une certaine
gloire, qui leur a echappe. Dans le complotisme, ces gens-la ont retrouve une
certaine lumiere. Ce matin, chez Paul Arcand, Lise Lachance a explique que son
frere avait sombre dans le complotisme pour un ensemble de raisons complexes.
Parmi celles-ci: « Ila toujours voulu avoir !'attention.» Chez les croises du complot,
il l'avait.
On peut ajouter Alexis Cossette-Trudel et Maxime Bernier, deux idoles du

mouvement complotiste. Avec ses deux doctorats, le premier devrait enseigner
dans une universite ; avec son parcours politique, le deuxieme devrait etre un po ids
lourd du Parti conservateur. Les deux sont des blagues sur deux pattes qui rallient
AR02494
les plus illumines d'entre nous. Ils ne sont pas ce que leurs parcours les destinait a
devenir.
Bernard Lachance avait done frole la gloire, la celebrite et le succes dans le monde
qui le passionnait: la chanson. Ila trouve des clics, de la gloriole et une micro-
celebrite dans les marecages numeriques du complotisme.
J e trouve que les mots de Vincent Audet-Nadeau apropos de Bernard Lachance

decrivent bien cet areopage de personnages qui creent et propagent de la
desinformation made in Quebec depuis un an: « Il y a quelque chose de lie au fait
d'etre reconnu ... »
Ce qui m'amene a deux evidences.
Un, le negationnisme sanitaire a fait briller des gens comme ils avaient rarement
brille. La desinformation est un business lucratif, pour le portefeuille ou pour l'ego.
Oules deux.
Deux, en constatant la triste fin de Bernard Lachance : la desinformation tue.
Mais sa mort ne changera rien a la radicalisation des croyants de tout-est-arrange-

avec-le-gars-des-vues: pour eux, deja, la mort de Lachance a ete recyclee en coup
fourre de Big Pharma, qui aurait voulu le faire taire.
Ceux-la vandalisent depuis hier la page Facebook de Lise Lachance, la traitant de

tous les noms pour avoir ose dire que le deni avait tue son frere.

AR02495
Direct link to Annexe - F- 22- VAX NATION 1 SHOW ME YOUR PAPERS:
https ://jccf.sharepoint .com/:v:/s/LegalTeam/EQST8KvQwEhDoQ6FHaVFSQ4By4jtfi0yt5FwiTRzjL-

YFA ?e=jJ RSVh
AR02496
TAB 19
AR02497
DECLARATION ASSERMENTEE
Je, soussigne, NABIL BELKACEM BEN NAOUM, avocat, domicilie au 285, place
d'Youville, app.18, Montreal, province de Quebec, H2Y 2A4, affirme solennellement ce
qui suit:
1. Je suis le requerant de la presente demande en controle judiciaire;
2. Je suis un citoyen canadien de 27 ans exen;ant la profession d'avocat a temps

plein dans la region de Montreal;
3. Jene suis pas vaccine contre la COVID-19;
4. Je suis un homme actif et en sante n'ayant aucune comorbidite ; De plus, je fais

du sport quotidiennement;
5. Je possede egalement la citoyennete algerienne et je suis ne en Algerie;
6. La grande majorite de ma famille y reside toujours;
7. J'ai egalement des membres de ma famille residant notamment en France, en

Belgique, en ltalie, en Espagne et aux Etats-Unis, que je visite sur une base
annuelle;
8. Je suis issu d'une famille tres nombreuse dont les traditions et celebrations sont
frequentes et impliquent des reunions familiales; mariages, succes au
baccalaureat, ceremonies, anniversaires, etc. Pour ces raisons, j'ai pris l'avion
pour revoir ma famille notamment en 2016, 2018 et 2019;
9. Je souhaitais m'y rendre cette annee pour les 90 ans de mon grand-pere, mais le
gouvernement canadien m'en a prive;
10. L'Arrete m'empeche de rentrer dans mon second chez moi, un pays dont je suis
un ressortissant, me causant un prejudice moral inqualifiable;
11. En plus de mes activites professionnelles quotidiennes d'avocat, je possede une

entreprise offrant des services de suspension de easier judiciaire a travers le
Canada; j'etudie la possibilite de developper egalement une section en droit de
!'immigration;
12. Je souhaite developper ces activites ailleurs qu'au Quebec et j'ai entrepris un
voyage de prospection a Vancouver en septembre 2021; Je m'y suis alors rendu
en avian;
1
AR02498
13. L'Arrete me paralyse dans ces demarches puisque mon horaire charge ne me
permet pas de traverser le pays en voiture; Je suis, de facto, confine au Quebec;
14. J'ai attrape la COVID-19 en mars 2020 ainsi qu'en decembre 2021 ; les effets pour
moi etaient mineurs;
15. Je me suis remis de la COVID-19 les deux fois sans probleme et sans sequelle;
16. J'ai deja developpe a deux reprises des anticorps contre la maladie et celle-ci n'a
eu aucun effet prejudiciable sur ma personne, je ne vois done pas de benefices au
vaccin ; les « formes graves » de la maladie etant infinitesimales pour les
personnes de man age et de ma condition physique ; de meme, le vaccin ne
protege ni contre la contamination ni contre la transmission ;
17. A !'inverse, Sante Canada et l'Agence de sante publique du Canada indiquent des
risques pour tous les vaccins de developper des conditions medicales serieuses,
incluant des thromboses, syndrome de Guillain-Barre, myocardite, pericardite,
paralysie facials et syndrome de fuite capillaire ; le risque de myocardite etant plus
prevalant chez les jeunes hommes ;
18. La decision pour moi de ne pas me vacciner contre la COVID-19 se base done sur
une analyse objective des benefices et des risques comme tout majeur capable
devrait pouvoir le faire ;
19. Dans les dernieres semaines, les discours des gouvernements canadien et
quebecois se sont radicalises ; les citoyens non vaccines sont diffames, honnis et
menaces sur une base quotidienne, je m'inquiete pour ma securite personnelle en
demeurant au Canada et souhaite avoir la possibilite de prendre l'avion pour fuir
ce regime en cas de situation d'urgence ;
20. En l'espace d'une seule annee, les gouvernements du Canada et du Quebec ant
etabli des mesures de segregation supprimant les citoyens non-vaccines de la
sphere publique;
21. Durant la derniere annee, les seuls endroits qui m'etaient encore accessibles
etaient l'epicerie et mon travail; je m'en suis trouve profondement malheureux et
je souhaite done quitter le pays dans un avenir rapproche car de demeurer au
Canada dans ces conditions m'est devenu invivable;
22. Je redoute fortement qu'a la vitesse au vont les choses, je n'aurai plus acces a
ces derniers endroits puisque le gouvernement du Quebec laisse planer la menace
d'etendre le passeport vaccinal a d'autres lieux; ma demarche est aussi dans le
but d'etre en mesure de quitter le pays advenant la situation au je me retrouverais
dans une precarite importante, ne pouvant travailler et etant confine a mon
domicile;
2
AR02499
23. La decision de Transports Canada constitue une pression indue sur ma personne
et menace mon consentement libre et eclaire a subir un traitement medical;
24. Cette pression indue me fait considerer me soumettre a une procedure medicale
contre mon consentement pour pouvoir revoir ma famille et m'emanciper dans mes
activites professionnelles; Face a un tel vice, je n'ai d'autres choix que de
demander !'intervention de la Gour federale;
25. J'ai etudie le droit pendant 5 ans, je pratique comme avocat et devant la
destruction quotidienne de mes droits et libertes, m'amenant a !'humiliation de
demander a un juge la permission de prendre l'avion, j'ai pris la decision de quitter
le Canada dans le futur afin de m'etablir definitivement dans un pays democratique
respectant sa Constitution;
26. Je souhaite faire des voyages de prospection des maintenant aux Etats-Unis, en
Europe ou en Amerique latine afin de preparer cette demarche d'emancipation;
27. Par son Arrete, le gouvernement canadien m'empeche de quitter le territoire

national afin d'organiser cette demarche ;
28. Je me retrouve ainsi dans une situation assimilable aux citoyens des regimes les
plus dictatoriaux au monde, a savoir prisonnier de man pays ;
29. La presente demande en controle judiciaire constitue le seul recours efficace et

approprie susceptible d'etre exerce pour remedier a la violation de mes droits
constitutionnels ;
30. Les questions soulevees par la demande en controle judiciaire sont serieuses, et
ii est dans man interet immediat qu'elles soient tranchees par cette cour;
31. J'ai pris connaissance des faits allegues dans la presente demande en controle
judiciaire et ceux-ci sont vrais ;
32. Tous les faits allegues dans la presente declaration assermentee sont vrais et
sinceres.
Affirme solennellement a Laval, le 11 mars 2022 ET J'AI SIGNE :

Montreal, le 11 mars 2022
~
NABIL BELKACEM BEN NAOUM
Me Jimmy Oppedisano Requerant
Barreau du Quebec #338469-1
3
AR02500
TAB 20
AR02501
No de Cour : T-145-22
COUR FÉDÉRALE
ENTRE :
NABIL BEN NAOUM
Demandeur
et
Défendeur
ET ENTRE :
Demandeur
et
Défendeur
ET ENTRE :
AND AEDAN MACDONALD
Applicants
and
Respondent
AR02502
No du Cour : T-1991-21
ET ENTRE :
Applicants
and
Respondent
AFFIDAVIT DE MARIE-MYCHELLE PAQUETTE
PROCUREUR GÉNÉRAL DU CANADA

Ministère de la Justice Canada
Bureau régional des Prairie (Winnipeg)
601 – 400 St. Mary Avenue
Winnipeg, MB R3C 4K5
Télécopieur : (204) 983-3636
Par : Sharlene Telles-Langdon, Mariève Sirois-Vaillancourt, Robert Drummond,

Pascale-Catherine Guay, Raymond Lee, James Elford, Mahan Keramati,
Virginie Harvey, Sarah Chênevert-Beaudoin, Michaël Fortier
Tél :
Courriels :
Procureur du défendeur
AR02503
COUR FÉDÉRALE
ENTRE :
NABIL BEN NAOUM
Demandeur
et
Défendeur
ET ENTRE :
Demandeur
et
Défendeur
ET ENTRE :
AND AEDAN MACDONALD
Applicants
and
Respondent
AR02504
ET ENTRE:
Applicants
and
Respondent
AFFIDAVIT DE MARIE-MYCHELLE PAQUETTE
Je, soussigné, MARIE-MYCHELLE PAQUETTE, parajuriste à l’emploi de Justice

Canada, dont les bureaux sont situés au 200, boulevard René-Lévesque Ouest, Complexe Guy-
Favreau, Tour Est, 9e étage, à Montréal, province de Québec, AFFIRME SOLENNELLEMENT
QUE :
1. Je suis parajuriste pour Justice Canada et, à ce titre, je suis impliquée dans différents
recours judiciaires introduits à l’encontre du Procureur général du Canada ou Sa Majesté la Reine
en chef du Canada relativement aux exigences vaccinales, dont les dossiers mentionnés dans le
présent intitulé.
2. Dans le cadre de mes fonctions, j’ai acquis une connaissance des faits suivants.
3. Le 23 juin 2021, le gouvernement du Québec a pris le décret 885-2021. Je joins à cet

affidavit comme pièce « A » une copie du décret en question.
4. Ce décret a été modifié à plusieurs reprises par des arrêtés ministériels (ci-après les
« arrêtés »), jusqu’à son abrogation le 31 mars 2022. Je joins à cet affidavit les arrêtés en question :
 Arrêté 2021‑049 du 1er juillet 2021, pièce « B »;
 Arrêté 2021-050 du 2 juillet 2021, pièce « C »;
 Arrêté 2021-053 du 10 juillet 2021, pièce « D »;
 Arrêté 2021-055 du 30 juillet 2021, pièce « E »;
 Arrêté 2021-057 du 4 août 2021, pièce « F »;

AR02505
 Arrêté 2021‑058 du 13 août 2021, pièce « G »;
 Arrêté 2021‑059 du 18 août 2021, pièce « H »;
 Arrêté 2021‑060 du 24 août 2021, pièce « I »;
 Arrêté 2021‑061 du 31 août 2021, pièce « J »;
 Arrêté 2021‑062 du 3 septembre 2021, pièce « K »;
 Arrêté 2021-063 du 9 septembre 2021, pièce « L »
 Arrêté 2021-065 du 24 septembre 2021, pièce « M »;
 Arrêté 2021-066 du 1er octobre 2021, pièce « N »;
 Arrêté 2021-067 du 8 octobre 2021, pièce « O »;
 Arrêté 2021‑068 du 9 octobre 2021, pièce « P »;
 Arrêté 2021-069 du 12 octobre 2021, pièce « Q »;
 Arrêté 2021-073 du 22 octobre 2021, pièce « R »;
 Arrêté 2021-074 du 25 octobre 2021, pièce « S »;
 Arrêté 2021‑077 du 29 octobre 2021, pièce « T »;
 Arrêté 2021-078 du 2 novembre 2021, pièce « U »;
 Arrêté 2021‑079 du 14 novembre 2021, pièce « V »;
 Arrêté 2021-083 du 10 décembre 2021, pièce « W »;
 Arrêté 2021‑086 du 13 décembre 2021, pièce « X »;
 Arrêté 2021‑087 du 14 décembre 2021, pièce « Y »;
 Arrêté 2021‑089 du 19 décembre 2021, pièce « Z »;
 Arrêté 2021‑090 du 20 décembre 2021, pièce « AA »;
 Arrêté 2021-092 du 22 décembre 2021, pièce « BB »;
 Arrêté 2021‑096 du 31 décembre 2021, pièce « CC »;

AR02506
 Arrêté 2022-001 du 2 janvier 2022, pièce « DD »;
 Arrêté 2022‑004 du 15 janvier 2022, pièce « EE »;
 Arrêté 2022‑011 du 29 janvier 2022, pièce « FF »;
 Arrêté 2022‑012 du 4 février 2022, pièce « GG »;
 Arrêté 2022‑013 du 5 février 2022, pièce « HH »;
 Arrêté 2022‑015 du 11 février 2022, pièce « II »;
 Arrêté 2022-018 du 19 février 2022, pièce « JJ »;
 Arrêté 2022-019 du 25 février 2022, pièce « KK »;
 Arrêté 2022-020 du 4 mars 2022, pièce « LL »;
 Arrêté 2022-021 du 11 mars 2022, pièce « MM »;
 Arrêté 2022-026 du 31 mars 2022, pièce « NN »;
 Arrêté 2022-027 du 31 mars 2022, pièce « OO ».
5. Le 1er septembre 2021, le gouvernement du Québec a pris le décret 1173-2021. Je joins à

cet affidavit comme pièce « PP » une copie du décret en question.
6. Ce décret a été modifié à plusieurs reprises, par le décret 1276-021 et des arrêtés, jusqu’à
son abrogation le 12 mars 2022. Je joins à cet affidavit le décret et les arrêtés en question :
 Décret 1276-021 du 24 septembre 2021, pièce « QQ »;
 Arrêté 2021-067 du 8 octobre 2021, pièce « O »;
 Arrêté 2021-079 du 14 novembre 2021, pièce « V »;
 Arrêté 2021-081 du 14 novembre 2021, pièce « RR »;
 Arrêté 2021-082 du 17 novembre 2021, pièce « SS »;
 Arrêté 2021-089 du 19 décembre 2021, pièce « Z »;
 Arrêté 2022-004 du 15 janvier 2022, pièce « EE »;

AR02507
 Arrêté 2022-007 du 23 janvier 2022, pièce « TT »;
 Arrêté 2022-013 du 5 février 2022, pièce « HH »;
 Arrêté 2022-015 du 11 février 2022, pièce « II »;
 Arrêté 2022-017 du 15 février 2022, pièce « UU »;
 Arrêté 2022-018 du 19 février 2022, pièce « JJ »;
 Arrêté 2022-019 du 25 février 2022, pièce « KK »;
 Arrêté 2022-021 du 11 mars 2022, pièce « MM ».
7. Le 24 septembre 2021, le gouvernement du Québec a pris le décret 1276-2021, joint

précédemment à cet affidavit comme pièce « QQ ».
8. Ce décret a été modifié à plusieurs reprises par des arrêtés, jusqu’à son abrogation le
31 mars 2022. Je joins à cet affidavit les arrêtés en question :
 Arrêté 2021-070 du 15 octobre 2021, pièce « VV »;
 Arrêté 2021‑072 du 16 octobre 2021, pièce « WW »;
 Arrêté 2021‑080 du 14 novembre 2021, pièce « XX »;
 Arrêté 2022-030 du 31 mars 2022, pièce « YY »;
 Erratum de l’arrêté 2022-030 du 31 mars 2022, pièce « ZZ ».
9. Le 20 avril 2022, j’ai consulté le site de l’Institut national de santé publique du Québec,
qui recense sous forme de tableau l’« Ensemble des événements et mesures liés à la COVID-19 en
ordre chronologique », entre 2020 et 2022. Je joins à cet affidavit comme pièce « AAA » une
capture d’écran de ce site, dont a dernière mise à jour date du 15 février 2022.
10. Je souscris à cet affidavit dans le cadre des recours déposés en Cour fédérale par les
demandeurs dans les présents dossiers et à aucune autre fin.
AR02508
11. Tous les faits allégués dans cet affidavit sont vrais.
ET J’AI SIGNÉ, par voie technologique, dans la

ville de Saint-Colomban, province de Québec, ce
21e jour d’avril 2022.
u r•
MARIE-MYCHELLE PAQUETTE
Affirmé solennellement devant moi, par

voie technologique, dans la ville de Saint-
Rémi, province de Québec, ce 21e jour
d’avril 2022.
Anna Mrowczynski #237706

Commissaire à l’assermentation pour
le Québec et pour l’extérieur du Québec
AR02509
Ceci est la pièce « A » au soutien de

l’affidavit de MARIE-MYCHELLE PAQUETTE
affirmé solennellement devant moi,
par moyen technologique
dans la ville de Saint-Rémi, province de Québec,
ce 21e jour d’avril 2022.

Commissaire à l’assermentation pour le Québec et l’extérieur du Québec
© Éditeur officiel du Québec, 2021
AR02510
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 25 juin 2021, 153e année, no 25A 2851A
du 21 janvier 2021, 2021-004 du 27 janvier 2021, 2021-005 5 octobre 2020, 2020-084 du 27 octobre 2020, 2020-087
du 28 janvier 2021, 2021-008 du 20 février 2020, 2021-009 du 4 novembre 2020, 2020-091 du 13 novembre 2020,
du 25 février 2021, 2021-010 du 5 mars 2021, 2021-013 2020-096 du 25 novembre 2020, 2020-097 du 1er décembre
du 13 mars 2021, 2021-015 du 16 mars 2021, 2021-016 du 2020, 2020-099 et 2020-100 du 3 décembre 2020,
19 mars 2021, 2021-017 du 26 mars 2021, 2021-019 du 2020-102 du 9 décembre 2020, 2020-107 du 23 décembre
28 mars 2021, 2021-020 du 1er avril 2021, 2021-021 du 2020, 2021-003 du 21 janvier 2021, 2021-005 du 28 janvier
5 avril 2021, 2021-022 et 2021-023 du 7 avril 2021, 2021, 2021-010 du 5 mars 2021, 2021-013 du 13 mars 2021,
2021-024 du 9 avril 2021, 2021-025 du 11 avril 2021, 2021-017 du 26 mars 2021, 2021-022 du 7 avril 2021,
2021-026 du 14 avril 2021, 2021-027 du 16 avril 2021, 2021-024 du 9 avril 2021, 2021-027 du 16 avril 2021,
2021-028 du 17 avril 2021, 2021-029 du 18 avril 2021, 2021-028 du 17 avril 2021, 2021-032 du 30 avril 2021,
2021-031 du 28 avril 2021, 2021-032 du 30 avril 2021, 2021-036 du 15 mai 2021, 2021-039 du 28 mai 2021,
2021-033 du 5 mai 2021, 2021-034 du 8 mai 2021, 2021-040 du 5 juin 2021, 2021-043 du 11 juin 2021,
2021-038 du 20 mai 2021, 2021-039 du 28 mai 2021, 2020-047 du 18 juin 2021 et 2021-048 du 23 juin 2021,
2021-040 du 5 juin 2021, 2021-041 du 7 juin 2021, sauf dans la mesure où elles ont été modifiées par ces
2021-043 du 11 juin 2021, 2021-044 du 14 juin 2021, décrets ou ces arrêtés, continuent de s’appliquer jusqu’au
2021-045 et 2021-046 du 16 juin 2021, 2020-047 du 18 juin 2 juillet 2021 ou jusqu’à ce que le gouvernement ou le
2021 et 2021-048 du 23 juin 2021, le ministre a également ministre de la Santé et des Services sociaux les modifie
pris certaines mesures afin de protéger la population; ou y mette fin;
At t en du qu’il y a lieu de renouveler l’état d’urgence Qu e le ministre de la Santé et des Services sociaux
sanitaire pour une période de dix jours; soit habilité à prendre toute mesure prévue aux paragra-
phes 1° à 8° du premier alinéa de l’article 123 de la Loi
Il est or don n é, en conséquence, sur la recomman- sur la santé publique (chapitre S-2.2).
dation du ministre de la Santé et des Services sociaux :
Le greffier du Conseil exécutif,
Que l’état d’urgence sanitaire soit renouvelé jusqu’au Yves Ouel l et
2 juillet 2021;
75126
Que les mesures prévues par les décrets numéros 177-
2020 du 13 mars 2020, 222-2020 du 20 mars 2020,
460-2020 du 15 avril 2020, 505-2020 du 6 mai 2020, Gouvernement du Québec
566-2020 du 27 mai 2020, 615-2020 du 10 juin 2020,
651-2020 du 17 juin 2020, 689-2020 du 25 juin 2020, Décret 885-2021, 23 juin 2021
810-2020 du 15 juillet 2020, 813-2020 du 22 juillet 2020,
885-2020 du 19 août 2020, 913-2020 du 26 août 2020, Con c er n a n t l’ordonnance de mesures visant à
943-2020 du 9 septembre 2020, 947-2020 du 11 septembre protéger la santé de la population dans la situation de
2020, 964-2020 du 21 septembre 2020, 1020-2020 du pandémie de la COVID-19
30 septembre 2020, 135-2021 du 17 février 2021 et 799-
2021 du 9 juin 2021 et par les arrêtés numéros 2020-004 At t en du que l’Organisation mondiale de la Santé a
du 15 mars 2020, 2020-007 du 21 mars 2020, 2020-008 déclaré une pandémie de la COVID-19 le 11 mars 2020;
du 22 mars 2020, 2020-014 du 2 avril 2020, 2020-015 du
4 avril 2020, 2020-016 du 7 avril 2020, 2020-017 du 8 avril At t en du qu’en vertu de l’article 118 de la Loi sur
2020, 2020-019 et 2020-020 du 10 avril 2020, 2020-022 la santé publique (chapitre S-2.2) le gouvernement peut
du 15 avril 2020, 2020-023 du 17 avril 2020, 2020-026 déclarer un état d’urgence sanitaire dans tout ou partie
du 20 avril 2020, 2020-027 du 22 avril 2020, 2020-028 du territoire québécois lorsqu’une menace grave à la santé
du 25 avril 2020, 2020-029 du 26 avril 2020, 2020-030 de la population, réelle ou imminente, exige l’application
du 29 avril 2020, 2020-032 du 5 mai 2020, 2020-033 immédiate de certaines mesures prévues à l’article 123 de
du 7 mai 2020, 2020-034 du 9 mai 2020, 2020-035 du cette loi pour protéger la santé de la population;
10 mai 2020, 2020-037 du 14 mai 2020, 2020-039 du
22 mai 2020, 2020-042 du 4 juin 2020, 2020-044 du At t en du qu e cette pandémie constitue une menace
12 juin 2020, 2020-049 du 4 juillet 2020, 2020-059 du réelle grave à la santé de la population qui exige l’appli-
26 août 2020, 2020-060 du 28 août 2020, 2020-061 du cation immédiate de certaines mesures prévues à l’arti
1er septembre 2020, 2020-062 du 4 septembre 2020, cle 123 de cette loi;
2020-064 du 17 septembre 2020, 2020-067 du 19 septembre
2020, 2020-069 du 22 septembre 2020, 2020-076 du
2852A AR02511GAZETTE OFFICIELLE DU QUÉBEC, 25 juin 2021, 153e année, no 25A Partie 2
At t en du qu’au cours de l’état d’urgence sanitaire, jusqu’au 11 novembre 2020 par le décret numéro 1150-
malgré toute disposition contraire, le gouvernement ou 2020 du 4 novembre 2020, jusqu’au 18 novembre 2020
le ministre de la Santé et des Services sociaux, s’il a été par le décret numéro 1168-2020 du 11 novembre 2020,
habilité, peut, sans délai et sans formalité, prendre l’une jusqu’au 25 novembre 2020 par le décret numéro 1210-
des mesures prévues aux paragraphes 1° à 8° du premier 2020 du 18 novembre 2020, jusqu’au 2 décembre 2020
alinéa de l’article 123 de cette loi pour protéger la santé par le décret numéro 1242-2020 du 25 novembre 2020,
de la population; jusqu’au 9 décembre 2020 par le décret numéro 1272-
2020 du 2 décembre 2020, jusqu’au 18 décembre 2020
At t en d u qu e, par le décret numéro 177-2020 du par le décret numéro 1308-2020 du 9 décembre 2020,
13 mars 2020, le gouvernement a déclaré l’état d’urgence jusqu’au 25 décembre 2020 par le décret numéro 1351-
sanitaire et a pris certaines mesures afin de protéger 2020 du 16 décembre 2020, jusqu’au 1er janvier 2021
la population; par le décret numéro 1418-2020 du 23 décembre 2020,
jusqu’au 8 janvier 2021 par le décret numéro 1420-2020 du
At t en du qu e l’état d’urgence sanitaire a été renou- 30 décembre 2020, jusqu’au 15 janvier 2021 par le décret
velé jusqu’au 29 mars 2020 par le décret numéro 222- numéro 1‑2021 du 6 janvier 2021, jusqu’au 22 janvier 2021
2020 du 20 mars 2020, jusqu’au 7 avril 2020 par le décret par le décret numéro 3‑2021 du 13 janvier 2021, jusqu’au
numéro 388-2020 du 29 mars 2020, jusqu’au 16 avril 2020 29 janvier 2021 par le décret numéro 31‑2021 du 20 janvier
par le décret numéro 418-2020 du 7 avril 2020, jusqu’au 2021, jusqu’au 5 février 2021 par le décret numéro 59‑2021
24 avril 2020 par le décret numéro 460-2020 du 15 avril du 27 janvier 2021, jusqu’au 12 février 2021 par le décret
2020, jusqu’au 29 avril 2020 par le décret numéro 478- numéro 89-2021 du 3 février 2021, jusqu’au 19 février
2020 du 22 avril 2020, jusqu’au 6 mai 2020 par le décret 2021 par le décret numéro 103-2021 du 10 février 2021,
numéro 483-2020 du 29 avril 2020, jusqu’au 13 mai 2020 jusqu’au 26 février 2021 par le décret numéro 124-2021
par le décret numéro 501-2020 du 6 mai 2020, jusqu’au du 17 février 2021, jusqu’au 5 mars 2021 par le décret
20 mai 2020 par le décret numéro 509-2020 du 13 mai numéro 141-2021 du 24 février 2021, jusqu’au 12 mars
2020, jusqu’au 27 mai 2020 par le décret numéro 531- 2021 par le décret numéro 176-2021 du 3 mars 2021,
2020 du 20 mai 2020, jusqu’au 3 juin 2020 par le décret jusqu’au 19 mars 2021 par le décret numéro 204-2021
numéro 544-2020 du 27 mai 2020, jusqu’au 10 juin 2020 du 10 mars 2021, jusqu’au 26 mars 2021 par le décret
par le décret numéro 572-2020 du 3 juin 2020, jusqu’au numéro 243-2021 du 17 mars 2021, jusqu’au 2 avril 2021
17 juin 2020 par le décret numéro 593-2020 du 10 juin par le décret numéro 291-2021 du 24 mars 2021 jusqu’au
2020, jusqu’au 23 juin 2020 par le décret numéro 630- 9 avril 2021 par le décret numéro 489-2021 du 31 mars
2020 du 17 juin 2020, jusqu’au 30 juin 2020 par le décret 2021, jusqu’au 16 avril 2021 par le décret numéro 525-
numéro 667-2020 du 23 juin 2020, jusqu’au 8 juillet 2020 2021 du 7 avril 2021, jusqu’au 23 avril 2021 par le décret
par le décret numéro 690-2020 du 30 juin 2020, jusqu’au numéro 555-2021 du 14 avril 2021, jusqu’au 30 avril 2021
15 juillet 2020 par le décret numéro 717-2020 du 8 juillet par le décret numéro 570-2021 du 21 avril 2021, jusqu’au
2020, jusqu’au 22 juillet 2020 par le décret numéro 807- 7 mai 2021 par le décret numéro 596-2021 du 28 avril
2020 du 15 juillet 2020, jusqu’au 29 juillet 2020 par le décret 2021, jusqu’au 14 mai 2021 par le décret numéro 623-
numéro 811-2020 du 22 juillet 2020, jusqu’au 5 août 2020 2021 du 5 mai 2021, jusqu’au 21 mai 2021 par le décret
par le décret numéro 814-2020 du 29 juillet 2020, jusqu’au numéro 660-2021 du 12 mai 2021, jusqu’au 28 mai 2021
12 août 2020 par le décret numéro 815-2020 du 5 août par le décret numéro 679-2021 du 19 mai 2021, jusqu’au
2020, jusqu’au 19 août 2020 par le décret numéro 818- 4 juin 2021 par le décret numéro 699-2021 du 26 mai
2020 du 12 août 2020, jusqu’au 26 août 2020 par le décret 2021, jusqu’au 11 juin 2021 par le décret numéro 740-
numéro 845-2020 du 19 août 2020, jusqu’au 2 septembre 2021 du 2 juin 2021, jusqu’au 18 juin 2021 par le décret
2020 par le décret numéro 895-2020 du 26 août 2020, numéro 782-2021 du 9 juin 2021, jusqu’au 25 juin 2021
jusqu’au 9 septembre 2020 par le décret numéro 917-2020 par le décret numéro 807-2021 du 16 juin 2021 et jusqu’au
du 2 septembre 2020, jusqu’au 16 septembre 2020 par le 2 juillet 2021 par le décret numéro 849-2021 du 23 juin
décret numéro 925-2020 du 9 septembre 2020, jusqu’au 2021;
23 septembre 2020 par le décret numéro 948-2020 du
16 septembre 2020, jusqu’au 30 septembre 2020 par le At t en du que ce dernier décret prévoit que les mesures
décret numéro 965-2020 du 23 septembre 2020, jusqu’au prévues par les décrets numéros 177-2020 du 13 mars
7 octobre 2020 par le décret numéro 1000-2020 du 30 sep- 2020, 222-2020 du 20 mars 2020, 460-2020 du 15 avril
tembre 2020, jusqu’au 14 octobre 2020 par le décret 2020, 505-2020 du 6 mai 2020, 566-2020 du 27 mai
numéro 1023-2020 du 7 octobre 2020, jusqu’au 21 octobre 2020, 615-2020 du 10 juin 2020, 651-2020 du 17 juin
2020 par le décret numéro 1051-2020 du 14 octobre 2020, 2020, 689-2020 du 25 juin 2020, 810-2020 du 15 juillet
jusqu’au 28 octobre 2020 par le décret numéro 1094- 2020, 813-2020 du 22 juillet 2020, 885-2020 du 19 août
2020 du 21 octobre 2020, jusqu’au 4 novembre 2020 2020, 913-2020 du 26 août 2020, 943-2020 du 9 septem
par le décret numéro 1113-2020 du 28 octobre 2020, bre 2020, 947-2020 du 11 septembre 2020, 964-2020 du
AR02512
21 septembre 2020, 1020-2020 du 30 septembre 2020, du 30 septembre 2020 et 947-2020 du 11 septembre 2020,
135-2021 du 17 février 2021 et 799-2021 du 9 juin 2021 modifié par le décret numéro 1020-2020 du 30 septembre
et par les arrêtés numéros 2020-004 du 15 mars 2020, 2020, prévoient notamment des obligations relatives
2020-007 du 21 mars 2020, 2020-008 du 22 mars 2020, au port du couvre-visage dans les lieux intérieurs qui
2020-014 du 2 avril 2020, 2020-015 du 4 avril 2020, accueillent le public et les services de transports collectifs;
2020-016 du 7 avril 2020, 2020-017 du 8 avril 2020,
2020-019 et 2020-020 du 10 avril 2020, 2020-022 du At t en du qu e le décret numéro 799-2021 du 9 juin
15 avril 2020, 2020-023 du 17 avril 2020, 2020-026 du 2021, modifié par les arrêtés numéros 2021-043 du 11 juin
20 avril 2020, 2020-027 du 22 avril 2020, 2020-028 du 2021, 2021-044 du 14 juin 2021, 2021-046 du 16 juin
25 avril 2020, 2020-029 du 26 avril 2020, 2020-030 du 2021, 2021-047 du 18 juin 2021 et 2021-048 du 23 juin
29 avril 2020, 2020-032 du 5 mai 2020, 2020-033 du 7 mai 2021, prévoit notamment certaines mesures particulières
2020, 2020-034 du 9 mai 2020, 2020-035 du 10 mai 2020, applicables sur certains territoires;
2020-037 du 14 mai 2020, 2020-039 du 22 mai 2020,
2020-042 du 4 juin 2020, 2020-044 du 12 juin 2020, At t en du que la situation actuelle de la pandémie de
2020-049 du 4 juillet 2020, 2020-059 du 26 août 2020, la COVID-19 permet d’assouplir certaines mesures mises
2020-060 du 28 août 2020, 2020-061 du 1er septembre en place pour protéger la santé de la population, tout en
2020, 2020-062 du 4 septembre 2020, 2020-064 du maintenant certaines d’entre elles nécessaires pour conti-
17 septembre 2020, 2020-067 du 19 septembre 2020, nuer de la protéger;
2020-069 du 22 septembre 2020, 2020-076 du 5 octobre
2020, 2020-084 du 27 octobre 2020, 2020-087 du Il est or don n é, en conséquence, sur la recomman-
4 novembre 2020, 2020-091 du 13 novembre 2020, dation du ministre de la Santé et des Services sociaux :
2020-096 du 25 novembre 2020, 2020-097 du 1er décembre
2020, 2020-099 et 2020-100 du 3 décembre 2020, Qu e constitue un service ou un soutien aux fins du
2020-102 du 9 décembre 2020, 2020-107 du 23 décembre présent décret :
2020, 2021-003 du 21 janvier 2021, 2021-005 du 28 janvier
2021, 2021-010 du 5 mars 2021, 2021-013 du 13 mars 1° un service ou un soutien requis par une personne
2021, 2021-017 du 26 mars 2021, 2021-022 du 7 avril 2021, en raison de son état de santé ou à des fins de sécurité,
2021-024 du 9 avril 2021, 2021-027 du 16 avril 2021, à des fins de soins personnels ou esthétiques, à des fins
2021-028 du 17 avril 2021, 2021-032 du 30 avril 2021, commerciales ou professionnelles, de garde d’enfant ou
2021-036 du 15 mai 2021, 2021-039 du 28 mai 2021, de personnes vulnérables, de répit, d’aide domestique,
2021-040 du 5 juin 2021, 2021-043 du 11 juin 2021, d’aide aux activités de la vie quotidienne, de tutorat ou
2021-044 du 14 juin 2021, 2021-046 du 16 juin 2021, de dispensation de cours;
2021-047 du 18 juin 2021 et 2021-048 du 23 juin 2021, sauf
dans la mesure où elles ont été modifiées par ces décrets 2° un service d’entretien, de réparation ou de rénova-
ou ces arrêtés, continuent de s’appliquer jusqu’au 2 juillet tion résidentiel;
2021 ou jusqu’à ce que le gouvernement ou le ministre de
la Santé et des Services sociaux les modifie ou y mette fin; 3° une visite à des fins de vente ou de location de
la résidence;
At t en du que le décret numéro 689-2020 du 25 juin
2020, modifié par les décrets numéros 817-2020 du 5 août 4° une visite nécessaire à l’exercice d’un travail ou
2020, 885-2020 du 19 août 2020, 943-2020 du 9 septem d’une profession;
bre 2020, 1020-2020 du 30 septembre 2020, 433-2021
du 24 mars 2021, 735-2021 du 26 mai 2021 et 799-2021 5° tout autre service ou soutien de même nature;
du 9 juin 2021 et par les arrêtés numéros 2020-051 du
10 juillet 2020, 2020-053 du 1er août 2020, 2020-059 du Que, lorsque la tenue d’un registre de participants ou
26 août 2020, 2021-013 du 13 mars 2021 et 2021-047 du de clients est prévue dans le présent décret :
18 juin 2021, prévoit notamment certaines mesures en
matière de distanciation; 1° la personne à qui incombe cette obligation doive
consigner au registre les noms, les numéros de téléphone
At t en d u qu e les décrets numéros 810-2020 du et, le cas échéant, les adresses électroniques de tout
15 juillet 2020, modifié par les décrets numéros 813- participant ou tout client;
2020 du 22 juillet 2020, 885-2020 du 19 août 2020 et
1020-2020 du 30 septembre 2020 et par les arrêtés 2° tout participant ou tout client soit tenu de divulguer
numéros 2020-059 du 26 août 2020 et 2020-064 du à cette personne les renseignements nécessaires aux fins
17 septembre 2020, 813-2020 du 23 juillet 2020, modifié de la tenue de ce registre;
par le décret numéro 885-2020 du 19 août 2020 et 1020-2020
3° les renseignements consignés à ce registre ne x. une gare de train ou d’autobus, une gare fluviale,
puissent être communiqués qu’à une autorité de santé une station de métro ou un aéroport;
publique ou à une personne autorisée à agir en son nom
aux fins de la tenue d’une enquête épidémiologique et ne xi. un cabinet privé de professionnels;
puissent être utilisés par quiconque à une autre fin;
xii. une aire commune, incluant un ascenseur, d’une
4° ces renseignements doivent être détruits 30 jours résidence privée pour aînés;
suivant leur consignation;
Que, sous réserve des mesures particulières prévues
Qu’aux fins du présent décret : par le présent décret ou par tout décret ou arrêté pris sub-
séquemment, dans tout lieu, une personne maintienne,
1° un comptoir servant à la consommation de nourri- dans la mesure du possible, une distance de deux mètres
ture ou d’alcool soit assimilé à une table; avec toute autre personne, sauf :
2° on entende par : 1° si les personnes rassemblées sont les occupants
d’une même résidence privée ou de ce qui en tient lieu;
a) « couvre-visage » un masque ou un tissu bien ajusté
qui couvre le nez et la bouche; 2° si une personne reçoit d’une autre personne un
service ou son soutien;
b) « lieu extérieur public » tout lieu extérieur autre que
le terrain d’une résidence privée ou de ce qui en tient lieu; 3° dans une résidence privée ou ce qui en tient lieu,
dans une résidence de tourisme ou dans un établissement
c) « lieu qui accueille le public » la partie accessible au de résidence principale;
public des lieux suivants, dans la mesure où elle est fermée
ou partiellement couverte et qu’il ne s’agit pas d’une unité 4° si les personnes sont réunies autour d’une même
d’hébergement : table d’un restaurant, d’un bar ou de toute salle utilisée
à des fins de restauration ou de consommation d’alcool;
i. un commerce de vente au détail, un centre com-
mercial ou un bâtiment ou un local où est exploitée une 5° pour les enfants, lorsqu’ils fréquentent un centre
entreprise de services, incluant une entreprise de soins de la petite enfance, une garderie, un service de garde en
personnels ou d’esthétique; milieu familial, un camp de vacances ou un camp de jour;
ii. un restaurant ou un bar; 6° pour les membres du personnel de garde d’un centre
de la petite enfance ou d’une garderie ainsi que pour la
iii. un lieu de culte; personne offrant des services de garde en milieu familial
et, le cas échéant, pour son assistante, mais uniquement
iv. un lieu où sont offerts des activités ou des services lorsqu’ils interagissent avec les enfants qui sont sous
de nature culturelle ou de divertissement; leur garde;
v. un lieu où sont pratiquées des activités sportives 7° pour les élèves de l’éducation préscolaire ou de
ou récréatives; l’enseignement primaire ou secondaire de la formation
générale des jeunes, lorsqu’ils bénéficient de tout service
vi. une salle de location ou un autre lieu utilisé pour offert par un centre de services scolaire, une commission
accueillir des évènements, incluant des congrès et des scolaire ou un établissement d’enseignement privé;
conférences, ou pour tenir des réceptions;
8° pour les membres du personnel d’un centre de ser-
vii. un lieu où sont offerts des services municipaux vices scolaire, d’une commission scolaire ou d’un établis-
ou gouvernementaux; sement d’enseignement privé, mais uniquement lorsqu’ils
interagissent avec les élèves de l’éducation préscolaire qui
viii. une aire commune, incluant un ascenseur, d’un sont sous leur responsabilité;
établissement d’hébergement touristique;
Que, dans toute aire commune d’un centre commercial,
ix. un bâtiment ou un local utilisé par un établissement d’un parc aquatique, d’un parc d’attractions ou d’un site
d’enseignement; thématique, une distance de deux mètres soit maintenue
entre toute personne qui y circule, sauf :
AR02514
1° si elles sont des occupants d’une même résidence 3° qu’il s’agisse d’un élève du troisième cycle de
privée ou de ce qui en tient lieu; l’enseignement primaire ou de l’enseignement secondaire
de la formation générale des jeunes qui se trouve dans un
2° si l’une reçoit de l’autre un service ou son soutien; bâtiment ou un local utilisé par un établissement d’ensei-
gnement et qui n’est en présence d’aucune autre personne
Qu e, dans les salles de classe des établissements que des élèves de son groupe ou de membres du personnel
universitaires, des collèges, des établissements d’ensei- de l’établissement;
gnement collégial privés et des autres établissements
qui dispensent des services d’enseignement de niveau 4° qu’elle déclare que sa condition médicale l’en
collégial ou universitaire ou des services de formation empêche;
continue, dans les salles où sont dispensés les services
éducatifs et d’enseignement de la formation profession- 5° qu’elle y reçoive un soin, y bénéficie d’un service
nelle et de la formation générale des adultes et dans les ou y pratique une activité physique ou une autre activité
salles d’audience, une distance minimale de 1,5 mètre qui nécessite de l’enlever, auquel cas elle peut retirer son
soit maintenue latéralement entre les étudiants, les élèves couvre-visage pour la durée de ce soin, de ce service ou
ou les personnes du public lorsqu’ils sont assis, à moins : de cette activité;
1° qu’il s’agisse d’occupants d’une même résidence 6° qu’elle retire momentanément son couvre-visage
privée ou de ce qui en tient lieu; pour boire ou manger, ou à des fins d’identification;
2° que l’une des personnes reçoive d’une autre per- 7° qu’elle y travaille ou y exerce sa profession;
sonne un service ou son soutien;
8° qu’il s’agisse d’une personne du public, d’un élève
3° qu’il s’agisse d’élèves de l’éducation préscolaire ou ou d’un étudiant qui se trouve dans un lieu visé au sixième
de l’enseignement primaire ou secondaire de la formation alinéa, dans la mesure où les conditions qui y sont prévues
générale des jeunes d’un même groupe, lorsqu’ils béné- sont respectées;
ficient de tout service offert par un centre de services
scolaire, une commission scolaire ou un établissement 9° qu’elle se trouve dans une salle d’audience sans être
d’enseignement privé; visée au paragraphe précédent, ou dans une salle de déli-
bération des jurés;
Que les personnes rassemblées qui exercent leur droit
de manifester pacifiquement : 10° qu’elle consomme de la nourriture ou une boisson
dans un restaurant, dans une aire de restauration d’un
1° portent un couvre-visage; centre commercial ou d’un commerce d’alimentation,
dans un bar ou dans toute autre salle utilisée à des fins de
2° maintiennent entre elles une distance de deux mètres restauration ou de consommation de boissons;
avec toute personne, sauf si une personne reçoit d’une
autre personne un service ou son soutien; 11° qu’elle soit assise dans un endroit autre qu’un lieu
de culte et qu’elle respecte l’une des conditions suivantes :
Que l’organisateur de tout rassemblement aux fins de
l’exercice du droit de manifester pacifiquement soit tenu a) une distance de deux mètres est maintenue avec
de prendre des mesures pour informer les participants toute autre personne qui n’est ni un occupant d’une même
qu’ils doivent porter un couvre-visage; résidence privée ou de ce qui en tient lieu, ni une personne
qui lui fournit un service ou un soutien;
Qu’il soit interdit à l’exploitant d’un lieu qui accueille
le public d’y admettre une personne qui ne porte pas un b) elle est séparée par une barrière physique permettant
couvre-visage ou de tolérer qu’une personne qui ne porte de limiter la contagion de toute personne qui n’est ni un
pas un couvre-visage s’y trouve, à moins : occupant d’une même résidence privée ou de ce qui en
tient lieu, ni une personne qui lui fournit un service ou
1° qu’elle soit âgée de moins de 10 ans; un soutien;
2° qu’il s’agisse d’un élève de l’éducation préscolaire Que, malgré le paragraphe 7° de l’alinéa précédent :
ou du premier ou deuxième cycle de l’enseignement
primaire de la formation générale des jeunes qui se trouve 1° dans un immeuble autre qu’un immeuble d’habita-
dans un bâtiment ou un local utilisé par un établissement tion, qu’il constitue un lieu qui accueille le public ou non,
d’enseignement; il soit interdit à l’exploitant d’admettre toute personne,
y compris une personne qui y travaille ou y exerce sa 1° d’accéder à un lieu qui accueille le public ou de s’y
profession, lorsqu’elle ne porte pas un couvre-visage, ou trouver, à moins qu’elle soit visée par l’une des exceptions
de tolérer qu’elle se trouve dans un hall d’entrée, une aire prévues au neuvième alinéa;
d’accueil ou un ascenseur de l’immeuble sans porter un
couvre-visage; 2° d’accéder à un immeuble autre qu’un immeuble
d’habitation, qu’il constitue un lieu qui accueille le public
2° une personne qui travaille ou exerce sa profession ou non, ou de se trouver dans un hall d’entrée, une aire
dans un lieu qui accueille le public demeure soumise d’accueil ou un ascenseur de l’immeuble, à moins qu’elle
aux règles applicables en matière de santé et de sécurité soit visée par l’une des exceptions prévues aux para-
du travail; graphes 1° à 6° ou 8° à 11° du neuvième alinéa;
Qu’il soit interdit à l’exploitant d’un service de trans- 3° d’accéder à un autobus, un minibus, un métro,
port collectif par autobus, minibus, métro, bateau, train un bateau, un train ou un avion utilisé dans le cadre de
ou avion d’y admettre une personne qui ne porte pas un l’exploitation d’un service de transport collectif ou à un
couvre-visage ou de tolérer qu’elle se trouve dans un tel véhicule automobile utilisé à des fins de transport rému-
moyen de transport sans porter un couvre-visage, à moins : néré de personnes, sauf s’il s’agit de covoiturage, ou
de se trouver dans un tel moyen de transport, à moins
1° qu’elle soit âgée de moins de 10 ans; qu’elle soit visée par l’une des exceptions prévues au
onzième alinéa;
2° qu’il s’agisse d’un élève de l’éducation préscolaire
ou du premier ou deuxième cycle de l’enseignement Que, lorsqu’une prestation de travail peut être rendue à
primaire de la formation générale des jeunes qui se trouve distance, le télétravail à partir d’une résidence principale
dans un moyen de transport scolaire; ou de ce qui en tient lieu soit privilégié;
3° qu’elle déclare que sa condition médicale Qu e, malgré toute autre disposition contraire d’un
l’en empêche; décret ou d’un arrêté ministériel pris en application de
l’article 123 de la Loi sur la santé publique (chapitre S-2.2),
4° que le moyen de transport soit son lieu de les mesures suivantes s’appliquent :
travail habituel;
1° dans une résidence privée ou ce qui en tient lieu
5° qu’elle consomme de la nourriture ou une boisson ou dans une unité d’hébergement ou un dortoir d’un éta-
alors qu’elle se trouve dans une aire réservée pour la res- blissement d’hébergement touristique, un maximum de
tauration ou la consommation de boissons; 10 personnes peuvent s’y trouver, sauf s’il s’agit des occu-
pants d’un maximum de trois résidences privées ou de ce
6° qu’elle retire momentanément son couvre-visage qui en tient lieu;
pour boire ou manger, ou à des fins d’identification;
2° sur le terrain, le balcon ou la terrasse d’une rési-
7° sur un traversier, qu’elle demeure à l’intérieur de dence privée ou de ce qui en tient lieu ou sur le terrain
son véhicule; d’une unité d’hébergement touristique, un maximum de
20 personnes peuvent s’y trouver, sauf s’il s’agit des occu-
Qu e les interdictions prévues à l’alinéa précédent pants d’un maximum de trois résidences privées ou de ce
s’appliquent également, sous réserve des mêmes excep- qui en tient lieu; 
tions, au chauffeur d’un véhicule automobile utilisé à des
fins de transport rémunéré de personnes autrement que 3° malgré les paragraphes 1° et 2°, peut se trouver dans
dans le cadre de l’exploitation d’un service de transport une résidence privée ou ce qui en tient lieu ou dans une
collectif, sauf s’il s’agit de covoiturage; unité d’hébergement ou un dortoir d’un établissement
d’hébergement touristique, incluant le terrain, le balcon
Que la personne dont le lieu de travail habituel est un ou la terrasse d’une telle résidence ou d’une telle unité
moyen de transport visé au onzième alinéa ou un véhi- d’hébergement, toute personne présente pour y recevoir
cule automobile visé au douzième alinéa demeure soumise ou y offrir un service ou un soutien, selon le cas, et qui
aux règles applicables en matière de santé et de sécurité n’en est pas un occupant;
du travail;
4° lors d’une cérémonie funéraire ou de mariage :
Qu’il soit interdit à toute personne qui ne porte pas un
couvre-visage : a) un maximum de 250 personnes peuvent faire partie
de l’assistance;
AR02516
b) les personnes qui assistent à la cérémonie doivent c) un maximum de 20 personnes peuvent être réunies
demeurer assises; autour d’une même table située à l’extérieur, sauf s’il s’agit
des occupants d’un maximum de trois résidences privées
c) un roulement de personnes est permis lors de ou de ce qui en tient lieu;
l’exposition du corps ou des cendres et de la réception des
condoléances, à condition que le nombre de personnes d) malgré les sous-paragraphes b et c, peut se trouver
présentes simultanément ne dépasse jamais un maximum autour d’une table avec les personnes qui y sont visées :
de 50 personnes;
i. toute personne présente pour y offrir un service ou
d) l’organisateur doit tenir un registre des participants; un soutien requis par une personne en raison de son état
de santé ou à des fins de sécurité, le cas échéant;
5° dans un bâtiment abritant un lieu de culte :
ii. toute autre personne qui nécessite ou à qui elles
a) un maximum de 250 personnes peuvent faire partie procurent assistance, le cas échéant;
de l’assistance pour l’ensemble de ce bâtiment;
e) seules les personnes assises à une table peuvent
b) une distance minimale de deux mètres est mainte- recevoir un service ou consommer des boissons;
nue entre les personnes qui s’y trouvent, même lorsqu’elles
demeurent à leur place et ne circulent pas, à moins : f) les clients ne peuvent se servir directement dans
un buffet ou un comptoir libre-service de couverts ou
i. qu’il s’agisse d’occupants d’une même résidence d’aliments;
privée ou de ce qui en tient lieu;
8° en plus de ce que prévoit le paragraphe précédent,
ii. que l’une des personnes reçoive d’une autre per- l’exploitant d’un restaurant doit tenir un registre de tout
sonne un service ou son soutien; client admis dans son établissement, sur une terrasse
de son établissement ou tout autre lieu extérieur qu’il
c) les personnes respectant les conditions prévues exploite, sauf ceux qui sont admis pour la réception d’une
au sous-paragraphe b peuvent retirer leur couvre-visage commande à emporter ou d’une commande à l’auto;
lorsqu’elles restent silencieuses ou ne s’expriment qu’à
voix basse; 9° en plus de ce que prévoit le paragraphe 7°, dans un
casino, une maison de jeux, un bar, une discothèque, une
d) un ministre du culte ou une personne qui agit comme microbrasserie ou une distillerie, l’exploitant doit tenir
bénévole dans un tel lieu peut retirer son couvre-visage un registre de tout client admis dans son établissement,
lorsqu’il maintient une distance minimale de deux mètres sur une terrasse de son établissement ou tout autre lieu
avec toute autre personne; extérieur qu’il exploite;
6° un maximum de 250 personnes peuvent faire partie 10° dans les pièces et terrasses visées par un permis
de l’assistance dans une salle d’audience; autorisant la vente ou le service de boissons alcooliques
pour consommation sur place :
7° dans un casino, une maison de jeux, un bar, une dis-
cothèque, une microbrasserie, une distillerie, un restaurant, a) le permis ne peut être exploité que de huit heures
une aire de restauration d’un centre commercial ou d’un à minuit;
commerce d’alimentation ou dans toute autre salle utilisée
à des fins de restauration ou de consommation d’alcool : b) il est interdit de consommer des boissons alcoo-
liques entre deux et huit heures;
a) les lieux, incluant les terrasses, sont aménagés pour
qu’une distance de deux mètres soit maintenue entre les c) la pratique de la danse est interdite;
tables, à moins qu’une barrière physique permettant de
limiter la contagion ne les sépare; d) une distance de deux mètres est maintenue avec le
public lors de la présentation de spectacles;
b) un maximum de 10 personnes peuvent être réunies
autour d’une même table située à l’intérieur, sauf s’il s’agit 11° le titulaire d’un permis de bar :
des occupants d’un maximum de trois résidences privées
ou de ce qui en tient lieu;
a) ne peut admettre simultanément, dans chaque pièce II) possède des accès extérieurs distincts pour les
et sur chaque terrasse de l’établissement où est exploité le entrées et les sorties;
permis, qu’un maximum de 50 % du nombre de personnes
pouvant y être admises en vertu de ce permis, ou y tolérer III) donne accès à des installations sanitaires et des
un nombre de personnes supérieur à ce maximum; comptoirs alimentaires distincts;
b) ne peut admettre une personne dans les pièces ou ii. les places doivent avoir été réservées à l’avance;
sur les terrasses indiquées sur le permis en dehors des
heures où il peut être exploité ni tolérer qu’une personne iii. l’organisateur de l’évènement :
y demeure plus deux heures après l’heure à laquelle ce
permis doit cesser d’être exploité, à moins qu’il ne s’agisse I) assure une surveillance des accès extérieurs
d’un employé de l’établissement ou que le deuxième alinéa à chacune des entrées et des sorties et des accès à
de l’article 62 de la Loi sur les permis d’alcool (chapitre chaque section;
P-9.1) trouve application;
II) fixe un horaire pour les entrées et les sorties afin
12° les mesures prévues au paragraphe 10° et au sous- d’éviter les attroupements;
paragraphe a du paragraphe 11° s’appliquent, compte tenu
des adaptations nécessaires, aux titulaires de permis de b) une distance minimale de 1,5 mètre est maintenue
production artisanale, de producteur artisanal de bière ou latéralement entre les personnes qui s’y trouvent, à moins :
de brasseur, lorsqu’ils permettent la consommation sur
place de boissons alcooliques conformément à leur permis i. qu’il s’agisse d’occupants d’une même résidence
de fabrication de boissons alcooliques; privée ou de ce qui en tient lieu;
13° le paragraphe 7° ne s’applique pas dans une café- ii. que l’une des personnes reçoive d’une autre per-
téria, ou ce qui en tient lieu : sonne un service ou son soutien;
a) d’un centre de services scolaire, d’une commis- iii. qu’il s’agisse d’élèves de l’éducation préscolaire
sion scolaire ou d’un établissement d’enseignement privé ou de l’enseignement primaire ou secondaire de la for-
lorsqu’il offre des services aux élèves de l’éducation mation générale des jeunes d’un même groupe, lorsqu’ils
préscolaire ou de l’enseignement primaire ou secondaire bénéficient de tout service offert par un centre de ser-
de la formation générale des jeunes, et ce, pourvu qu’une vices scolaire, une commission scolaire ou un établisse-
distance minimale de deux mètres soit maintenue entre ment d’enseignement privé ou des enfants d’un camp de
les élèves de groupes différents; vacances ou d’un camp de jour;
b) utilisée dans le cadre des activités d’un camp de c) toute personne du public demeure assise à sa place;
vacances ou d’un camp de jour, et ce, pourvu qu’une dis-
tance minimale de deux mètres soit maintenue entre les 15° malgré le paragraphe 14°, peuvent assister à un évè-
enfants de groupes différents; nement ou un entraînement sportif amateur, sans places
assignées, un maximum de 25 personnes à l’intérieur;
14° dans les cinémas et les salles où sont présentés les
arts de la scène, y compris les lieux de diffusion, pour 16° lors d’un évènement extérieur ouvert au public
une production, un tournage audiovisuel, un spectacle auquel assistent ou participent plus de 50 personnes,
intérieur, ainsi que pour un entraînement ou un évènement incluant un festival, autre qu’un évènement se déroulant
sportif intérieur : dans un ciné-parc ou un autre lieu utilisé à des fins simi-
laires, les conditions suivantes s’appliquent :
a) peuvent faire partie de l’assistance de chaque salle
un maximum de 250 personnes ou de 3 500 personnes, a) chaque site ou, pour un circuit ou un parcours
mais, dans ce dernier cas, uniquement lorsque les condi- déambulatoire, chaque lieu de départ, d’arrivée ou
tions suivantes sont réunies : d’attroupement :
i. la salle est divisée en sections distinctes regroupant i. accueille un maximum de 3 500 participants ou
chacune un maximum de 250 personnes et chacune de spectateurs;
ces sections :
ii. est délimité par une barrière physique;
I) est délimitée;
AR02518
iii. est non contigu avec tout autre site, lieu de départ, III) qu’il s’agisse d’élèves de l’éducation préscolaire
d’arrivée ou d’attroupement du même évènement ou de ou de l’enseignement primaire ou secondaire de la for-
tout autre évènement, et des voies d’accès ou d’attente mation générale des jeunes d’un même groupe, lorsqu’ils
séparées sont utilisées pour y accéder, sauf si un maxi- bénéficient de tout service offert par un centre de ser-
mum de 3 500 participants ou spectateurs se trouvent dans vices scolaire, une commission scolaire ou un établisse-
l’ensemble des sites et lieux; ment d’enseignement privé ou des enfants d’un camp de
vacances ou d’un camp de jour;
iv. sauf dans les cas prévus au sous-paragraphe c, est
d’une superficie minimale de 10 mètres carrés par per- d) l’organisateur de l’évènement est tenu :
sonne du public qui participe ou assiste à l’évènement;
i. de s’assurer que les mesures prévues au présent para-
v. dispose de voies d’accès ne permettant pas simulta- graphe sont respectées;
nément les entrées et les sorties;
ii. de n’admettre que les participants ou les spectateurs
b) dans le cas d’un circuit ou d’un parcours déambu- ayant réservé leur place;
latoire, les départs doivent être organisés afin de limiter
les attroupements tout au long du circuit ou du parcours; iii. de prendre des mesures pour informer les parti-
cipants et les spectateurs des mesures de distanciation
c) pour chaque site ou partie de site où les personnes physique qu’ils doivent respecter;
s’attroupent, assises ou relativement immobiles, autour
d’une attraction, pour manger, pour attendre ou pour assis- iv. de mettre fin à l’évènement s’il devient impossible
ter à une projection cinématographique, à une présentation que les règles prévues au présent paragraphe ou les règles
d’arts de la scène, y compris une diffusion, à une produc- de distanciation physique soient respectées;
tion, à un tournage audiovisuel, à un spectacle ou à la pré-
sentation d’un entraînement ou d’un évènement sportif : v. d’assurer la surveillance des lieux et de contrôler
les entrées et les sorties des personnes qui assistent ou
i. toute personne du public demeure assise à la place participent à l’évènement, pour chacun des sites et des
qui lui a été assignée, sauf lorsque le site est divisé en sections, selon le cas;
sections distinctes regroupant chacune un maximum de
250 personnes et que chacune de ces sections : 17° dans les ciné-parcs ou tout autre lieu utilisé à des
fins similaires :
I) est délimitée par une barrière physique;
a) il est possible d’assister à la présentation de films ou
II) est d’une superficie minimale de quatre mètres de toute forme de spectacle depuis une voiture;
carrés par personne du public qui s’y trouve;
b) un maximum de 3 500 personnes peuvent faire
III) est séparée des autres sections par une distance partie de l’assistance;
minimale de deux mètres;
c) les voitures demeurent distancées de façon à assurer
IV) dispose de voies d’accès ne permettant pas simul- qu’une distance de 1,5 mètre peut être respectée entre les
tanément les entrées et les sorties; personnes latéralement;
ii. pour une projection cinématographique, une pré- 18° pour la pratique des jeux de quilles, de fléchettes,
sentation d’arts de la scène, y compris une diffusion, une de billard ou d’autres jeux de même nature, ainsi que dans
production, un tournage audiovisuel, un spectacle ou une les arcades et, pour leurs activités intérieures, les sites
présentation d’un entraînement ou d’un évènement spor- thématiques, les centres et parcs d’attractions, les centres
tif, une distance minimale de 1,5 mètre est maintenue d’amusement, les centres récréatifs et les parcs aquatiques,
latéralement entre les personnes qui y assistent, à moins : l’exploitant du lieu doit :
I) qu’il s’agisse d’occupants d’une même résidence a) admettre uniquement les clients ayant une
privée ou de ce qui en tient lieu; réservation;
II) que l’une des personnes reçoive d’une autre per- b) tenir un registre de tout client admis dans son
sonne un service ou un soutien; établissement;
19° sauf dans une résidence privée ou ce qui en tient ou de la formation générale aux adultes par un centre
lieu, incluant le terrain, le balcon ou la terrasse d’une de services scolaire, une commission scolaire ou un éta-
telle résidence, il est interdit à quiconque d’organiser ou blissement d’enseignement privé, pourvu que les élèves
de participer à une activité de karaoké; de groupes différents maintiennent une distance de deux
mètres, dans la mesure du possible;
20° dans une salle d’entraînement physique, l’exploi-
tant doit tenir un registre de tout client admis dans son d) qu’elle fasse partie de l’offre d’un camp de vacances
établissement; ou d’un camp de jour;
21° toute activité de loisir ou de sport est suspendue, e) qu’elle fasse partie de l’offre de formation en matière
à moins : de loisir et de sport dans les programmes d’enseignement
de niveau collégial ou universitaire;
a) qu’elle soit pratiquée dans un lieu intérieur dont les
activités ne sont pas autrement suspendues dans l’une des f) que, pour le sport professionnel ou de haut niveau,
situations suivantes : lors de l’entraînement et lors de la pratique de ce sport,
les conditions suivantes soient respectées par les athlètes
i. avec ou sans encadrement, par un groupe d’au plus et le personnel d’encadrement :
25 personnes;
i. un environnement protégé est mis en place, lequel
ii. dans le cadre d’une activité extrascolaire ou d’une permet de limiter les contacts entre les athlètes et le per-
sortie scolaire : sonnel d’encadrement et le reste de la population, confor-
mément à un protocole sanitaire approuvé par le ministre
I) par les élèves de la formation générale des jeunes de la Santé et des Services sociaux, et les athlètes et le
d’un même groupe; personnel d’encadrement ne peuvent quitter cet environ-
nement et le réintégrer sans respecter les mesures prévues
II) par un groupe d’au plus 25 élèves de la formation au protocole;
générale des jeunes sous la supervision constante d’une
autre personne pour guider ou encadrer l’activité, pourvu ii. le protocole sanitaire approuvé par le ministre de la
que les élèves de groupes différents maintiennent une Santé et des Services sociaux est respecté en tout temps,
distance de deux mètres, dans la mesure du possible; autant avant, pendant et après l’intégration dans l’envi-
ronnement protégé;
b) qu’elle soit pratiquée dans un lieu extérieur dont les
activités ne sont pas autrement suspendues, dans l’une des 22° un salon regroupant plusieurs exposants ou com-
situations suivantes : merces de vente au détail peut se tenir dans une salle
louée ou une salle communautaire, auquel cas l’arrêté
i. par un groupe d’au plus 50 personnes, auxquels numéro 2020-100 du 3 décembre 2020 s’applique, avec
peut s’ajouter une autre personne pour guider ou enca- les adaptations nécessaires, l’organisateur du salon étant
drer l’activité; assimilé à l’exploitant d’un centre commercial et les expo-
sants et commerces aux exploitants d’un établissement
ii. dans le cadre d’une activité extrascolaire ou d’une commercial de vente au détail;
sortie scolaire :
23° un maximum de 250 personnes peuvent se trouver
I) par les élèves de la formation générale des jeunes dans une salle louée ou une salle communautaire mise
d’un même groupe; à la disposition de quiconque, dans l’une des situations
suivantes :
II) par un groupe d’au plus 50 élèves de la formation
générale des jeunes auquel peut s’ajouter une autre per- a) à l’occasion d’une assemblée, d’un congrès, d’une
sonne pour guider ou encadrer l’activité, pourvu que les réunion, d’une cérémonie funéraire, de mariage, de recon-
élèves de groupes différents maintiennent une distance de naissance ou de graduation ou d’un autre évènement de
deux mètres, dans la mesure du possible; même nature, auquel les participants assistent en demeu-
rant assis;
c) qu’elle fasse partie de l’offre des programmes d’édu-
cation physique et à la santé, de sport-études, d’art-études b) aux fins d’une activité organisée :
et de concentration sportive et autres projets pédagogiques
particuliers de même nature dispensés dans le cadre des
services éducatifs de la formation générale des jeunes
AR02520
i. dans le cadre de la mission d’un organisme commu- f) à l’occasion d’une cérémonie religieuse, lorsque
nautaire dont les activités sont liées au secteur de la santé les conditions prévues au sous-paragraphe b du para-
ou des services sociaux; graphe 5° sont respectées;
ii. nécessaire à la poursuite des activités, autres que g) pour les activités d’un camp de vacances ou d’un
de nature évènementielle ou sociale, s’inscrivant dans le camp de jour;
cadre de l’exploitation d’une entreprise ou de celles d’un
établissement d’enseignement, d’un tribunal, d’un arbitre, Qu’il soit interdit à quiconque :
d’une association de salariés, de professionnels, de cadres,
de hors-cadre ou d’employeurs, d’un poste consulaire, 1° d’admettre dans tout lieu dont il a le contrôle un
d’une mission diplomatique, d’un ministère ou d’un orga- nombre de personnes supérieur au nombre maximal de
nisme public; personnes pouvant s’y trouver en vertu du présent décret;
24° un maximum de 25 personnes peuvent se trouver 2° de se trouver dans un lieu lorsque le nombre maxi-
dans tout lieu intérieur, autre qu’une résidence privée ou mal de personnes pouvant s’y trouver en vertu du présent
ce qui en tient lieu, lorsqu’il est utilisé aux fins d’y tenir décret est dépassé;
une activité de nature évènementielle ou sociale qui n’est
pas autrement visée par le présent alinéa; Que le présent décret remplace le décret numéro 799-
2021 du 9 juin 2021, modif ié par les ar rêtés
25° un maximum de 50 personnes peuvent se trouver numéros 2021-043 du 11 juin 2021, 2021-044 du 14 juin
dans une salle louée ou une salle communautaire dans 2021, 2021-046 du 16 juin 2021, 2021-047 du 18 juin 2021
les autres cas que ceux prévus aux paragraphes 22° à 24°, et 2021-048 du 23 juin 2021;
sauf lorsque la salle est utilisée aux fins des activités d’un
camp de vacances ou d’un camp de jour; Que soient abrogés :
26° il est interdit d’organiser un rassemblement de plus 1° le onzième alinéa du décret numéro 566-2020 du
de 50 personnes dans un lieu extérieur public, y compris 27 mai 2020, modifié par les décrets numéros 615-2020
dans le cadre d’un évènement de nature sociale, com- du 10 juin 2020, 651-2020 du 17 juin 2020 et 885-2020
merciale, religieuse, culturelle, sportive, de loisir ou de du 19 août 2020 et par les arrêtés numéros 2020-044 du
divertissement, ou d’y participer, sauf dans les situations 12 juin 2020 et 2020-047 du 19 juin 2020;
suivantes :
2° les troisième et sixième alinéas du décret
a) lorsque les personnes rassemblées exercent leur numéro 615-2020 du 10 juin 2020, modifié par le décret
droit de manifester pacifiquement; 689-2020 du 25 juin 2020 et par l’arrêté numéro 2020-047
du 19 juin 2020;
b) dans le cadre des services aux élèves de l’éducation
préscolaire ou de l’enseignement primaire ou secondaire 3° le décret numéro 689-2020 du 25 juin 2020, modifié
de la formation générale des jeunes offerts par un centre par les décrets numéros 817-2020 du 5 août 2020, 885-
de services scolaire, une commission scolaire ou un 2020 du 19 août 2020, 943-2020 du 9 septembre 2020,
établissement d’enseignement privé; 1020-2020 du 30 septembre 2020, 433-2021 du 24 mars
2021, 735-2021 du 26 mai 2021 et 799-2021 du 9 juin 2021
c) dans le cadre d’un évènement se déroulant confor- et par les arrêtés numéros 2020-051 du 10 juillet 2020,
mément au paragraphe 16°; 2020-053 du 1er août 2020, 2020-059 du 26 août 2020,
2021-013 du 13 mars 2021 et 2021-047 du 18 juin 2021;
d) dans un ciné-parc ou un autre lieu utilisé à des fins
similaires, conformément aux conditions prévues au 4° le décret numéro 810-2020 du 15 juillet 2020, modi-
paragraphe 17°; fié par les décrets numéros 813-2020 du 22 juillet 2020,
885-2020 du 19 août 2020 et 1020-2020 du 30 septembre
e) à l’occasion d’une assemblée, d’un congrès, d’une 2020 et par les arrêtés numéros 2020-059 du 26 août 2020
réunion, d’une cérémonie funéraire, de mariage, de recon- et 2020-064 du 17 septembre 2020;
naissance ou de graduation ou d’un autre évènement de
même nature, auquel les participants assistent en demeu- 5° le décret numéro 813-2020 du 22 juillet 2020, modi-
rant assis, à condition qu’un maximum de 250 personnes fié par les décrets numéros 885-2020 du 19 août 2020 et
y soient rassemblées et que chacune demeure assise à 1020-2020 du 30 septembre 2020;
sa place;
6° le décret numéro 913-2020 du 26 août 2020;
7° l’arrêté numéro 2020-059 du 26 août 2020, modifié

par le décret numéro 433-2021 du 24 mars 2021;
8° le deuxième alinéa de l’arrêté 2020-061 du

1er septembre 2020;
9° le premier alinéa du décret numéro 943-2020 du

9 septembre 2020;
10° le décret numéro 947-2020 du 11 septembre 2020,

modifié par le décret 1020-2020 du 30 septembre 2020;
11° le décret 1020-2020 du 30 septembre 2020, modifié

par les décrets numéros 1039-2020 du 7 octobre 2020,
2-2021 du 8 janvier 2021, 102-2021 du 5 février 2021 et 799-
2020 du 9 juin 2021 et par les arrêtés numéros 2020-074
du 2 octobre 2020, 2020-077 du 8 octobre 2020, 2020-079
du 15 octobre 2020, 2020-080 du 21 octobre 2020,
2020-081 du 22 octobre 2020, 2020-084 du 27 octobre
2020, 2020-085 du 28 octobre 2020, 2020-086 du
1er novembre 2020, 2020-087 du 4 novembre 2020,
2020-090 du 11 novembre 2020, 2020-091 du 13 novembre
2020, 2020-093 du 17 novembre 2020, 2020-104 du
15 décembre 2020, 2020-105 du 17 décembre 2020,
2020-106 du 20 décembre 2020, 2021-001 du 15 janvier
2021 et 2021-005 du 28 janvier 2021;
Que le ministre de la Santé et des Services sociaux soit

habilité à ordonner toute modification ou toute précision
relative aux mesures prévues par le présent décret;
Que le présent décret prenne effet le 28 juin 2021.
Le greffier du Conseil exécutif,

Yves Ouel l et
75125
AR02522
Ceci est la pièce « B » au soutien de


AR02523
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 8 juillet 2021, 153e année, no 27A 3833A
Arrêtés ministériels
-
A.M., 2021
Arrêté numéro 2021-049 du ministre de la Santé
et des Services sociaux en date du 1er juillet 2021
Loi sur la santé publique

2020, jusqu’au 19 août 2020 par le décret numéro 818-
2020 du 12 août 2020, jusqu’au 26 août 2020 par le décret
numéro 845-2020 du 19 août 2020, jusqu’au 2 septembre
2020 par le décret numéro 895-2020 du 26 août 2020,
jusqu’au 9 septembre 2020 par le décret numéro 917-
2020 du 2 septembre 2020, jusqu’au 16 septembre 2020
(chapitre S-2.2) par le décret numéro 925-2020 du 9 septembre 2020,
jusqu’au 23 septembre 2020 par le décret numéro 948-
Con c er n a n t l’ordonnance de mesures visant à 2020 du 16 septembre 2020, jusqu’au 30 septembre 2020
protéger la santé de la population dans la situation de par le décret numéro 965-2020 du 23 septembre 2020,
pandémie de la COVID-19 jusqu’au 7 octobre 2020 par le décret numéro 1000-2020
du 30 septembre 2020, jusqu’au 14 octobre 2020
Le min ist r e de l a Sa n t é et d es Ser vices soc iau x, par le décret numéro 1023-2020 du 7 octobre 2020
jusqu’au 21 octobre 2020 par le décret numéro 1051-
Vu l’article 118 de la Loi sur la santé publique (chapitre 2020 du 14 octobre 2020, jusqu’au 28 octobre 2020
S-2.2) qui prévoit que le gouvernement peut déclarer un par le décret numéro 1094-2020 du 21 octobre 2020,
état d’urgence sanitaire dans tout ou partie du territoire jusqu’au 4 novembre 2020 par le décret numéro 1113-
québécois lorsqu’une menace grave à la santé de la popu- 2020 du 28 octobre 2020, jusqu’au 11 novembre 2020
lation, réelle ou imminente, exige l’application immédiate par le décret numéro 1150-2020 du 4 novembre 2020,
de certaines mesures prévues à l’article 123 de cette loi jusqu’au 18 novembre 2020 par le décret numéro 1168-
pour protéger la santé de la population; 2020 du 11 novembre 2020, jusqu’au 25 novembre 2020
par le décret numéro 1210-2020 du 18 novembre 2020,
Vu le décret numéro 177-2020 du 13 mars 2020 qui jusqu’au 2 décembre 2020 par le décret numéro 1242-
déclare l’état d’urgence sanitaire dans tout le territoire 2020 du 25 novembre 2020, jusqu’au 9 décembre 2020
québécois pour une période de 10 jours; par le décret numéro 1272-2020 du 2 décembre 2020,
jusqu’au 18 décembre 2020 par le décret numéro 1308-
Vu que l’état d’urgence sanitaire a été renouvelé jusqu’au 2020 du 9 décembre 2020, jusqu’au 25 décembre 2020
29 mars 2020 par le décret numéro 222-2020 du 20 mars par le décret numéro 1351-2020 du 16 décembre 2020,
2020, jusqu’au 7 avril 2020 par le décret numéro 388-2020 jusqu’au 1er janvier 2021 par le décret numéro 1418-2020
du 29 mars 2020, jusqu’au 16 avril 2020 par le décret du 23 décembre 2020, jusqu’au 8 janvier 2021 par le
numéro 418-2020 du 7 avril 2020, jusqu’au 24 avril 2020 décret numéro 1420-2020 du 30 décembre 2020, jusqu’au
par le décret numéro 460-2020 du 15 avril 2020, jusqu’au 15 janvier 2021 par le décret numéro 1-2021 du 6 janvier
29 avril 2020 par le décret numéro 478-2020 du 22 avril
2021, jusqu’au 22 janvier 2021 par le décret numéro 3-2021
2020, jusqu’au 6 mai 2020 par le décret numéro 483-
du 13 janvier 2021, jusqu’au 29 janvier 2021 par le décret
2020 du 29 avril 2020, jusqu’au 13 mai 2020 par le décret
numéro 31-2021 du 20 janvier 2021, jusqu’au 5 février 2021
numéro 501-2020 du 6 mai 2020, jusqu’au 20 mai 2020
par le décret numéro 59-2021 du 27 janvier 2021, jusqu’au
par le décret numéro 509-2020 du 13 mai 2020, jusqu’au
27 mai 2020 par le décret numéro 531-2020 du 20 mai 12 février 2021 par le décret numéro 89-2021 du 3 février
2020, jusqu’au 3 juin 2020 par le décret numéro 544- 2021, jusqu’au 19 février 2021 par le décret numéro 103-
2020 du 27 mai 2020, jusqu’au 10 juin 2020 par le décret 2021 du 10 février 2021, jusqu’au 26 février 2021 par le
numéro 572-2020 du 3 juin 2020, jusqu’au 17 juin 2020 décret numéro 124-2021 du 17 février 2021, jusqu’au
par le décret numéro 593-2020 du 10 juin 2020, jusqu’au 5 mars 2021 par le décret numéro 141-2021 du 24 février
23 juin 2020 par le décret numéro 630-2020 du 17 juin 2021, jusqu’au 12 mars 2021 par le décret numéro 176-
2020, jusqu’au 30 juin 2020 par le décret numéro 667- 2021 du 3 mars 2021, jusqu’au 19 mars 2021 par le décret
2020 du 23 juin 2020, jusqu’au 8 juillet 2020 par le décret numéro 204-2021 du 10 mars 2021, jusqu’au 26 mars 2021
numéro 690-2020 du 30 juin 2020, jusqu’au 15 juillet par le décret numéro 243-2021 du 17 mars 2021, jusqu’au
2020 par le décret numéro 717-2020 du 8 juillet 2020, 2 avril 2021 par le décret numéro 291-2021 du 24 mars
jusqu’au 22 juillet 2020 par le décret numéro 807-2020 2021, jusqu’au 9 avril 2021 par le décret numéro 489-2021
du 15 juillet 2020, jusqu’au 29 juillet 2020 par le décret du 31 mars 2021, jusqu’au 16 avril 2021, par le décret
numéro 811-2020 du 22 juillet 2020, jusqu’au 5 août 2020 numéro 525-2021 du 7 avril 2021, jusqu’au 23 avril 2021
par le décret numéro 814-2020 du 29 juillet 2020, jusqu’au par le décret numéro 555-2021 du 14 avril 2021, jusqu’au
12 août 2020 par le décret numéro 815-2020 du 5 août 30 avril 2021 par le décret numéro 570-2021 du 21 avril
3834A AR02524GAZETTE OFFICIELLE DU QUÉBEC, 8 juillet 2021, 153e année, no 27A Partie 2
2021, jusqu’au 7 mai 2021 par le décret numéro 596- A.M., 2021
numéro 623-2021 du 5 mai 2021, jusqu’au 21 mai 2021 Arrêté numéro 2021-051 du ministre de la Santé
par le décret numéro 660-2021 du 12 mai 2021, jusqu’au et des Services sociaux en date du 6 juillet 2021
28 mai 2021 par le décret numéro 679-2021 du 19 mai
2021, jusqu’au 4 juin 2021 par le décret numéro 699- Loi sur la santé publique
2021 du 26 mai 2021, jusqu’au 11 juin 2021 par le décret (chapitre S-2.2)
numéro 740-2021 du 2 juin 2021, jusqu’au 18 juin 2021
par le décret numéro 782-2021 du 9 juin 2021, jusqu’au Con c er n a n t l’ordonnance de mesures visant à
25 juin 2021 par le décret numéro 807-2021 du 16 juin protéger la santé de la population dans la situation de
2021, jusqu’au 2 juillet 2021 par le décret numéro 849- pandémie de la COVID-19
2021 du 23 juin 2021 et jusqu’au 9 juillet 2021 par le décret
numéro 893-2021 du 30 juin 2021; Le min ist r e de l a Sa n t é et d es Ser vices soc iau x,
Vu que le décret numéro 885-2021 du 23 juin 2021 Vu l’article 118 de la Loi sur la santé publique (chapitre
prévoit notamment certaines mesures particulières appli- S-2.2) qui prévoit que le gouvernement peut déclarer un
cables sur certains territoires; état d’urgence sanitaire dans tout ou partie du territoire
québécois lorsqu’une menace grave à la santé de la popu-
Vu que ce décret habilite également le ministre de la lation, réelle ou imminente, exige l’application immédiate
Santé et des Services sociaux à ordonner toute modifica- de certaines mesures prévues à l’article 123 de cette loi
tion ou toute précision relative aux mesures qu’il prévoit; pour protéger la santé de la population;
Vu que le décret numéro 893-2021 du 30 juin 2021 Vu le décret numéro 177-2020 du 13 mars 2020 qui
habilite le ministre de la Santé et des Services sociaux déclare l’état d’urgence sanitaire dans tout le territoire
à prendre toute mesure prévue aux paragraphes 1° québécois pour une période de 10 jours;
à 8° du premier alinéa de l’article 123 de la Loi sur la
santé publique; Vu que l’état d’urgence sanitaire a été renouvelé jusqu’au
29 mars 2020 par le décret numéro 222-2020 du 20 mars
Con sidér a n t que la situation actuelle de la pandémie 2020, jusqu’au 7 avril 2020 par le décret numéro 388-2020
de la COVID-19 permet d’assouplir certaines mesures du 29 mars 2020, jusqu’au 16 avril 2020 par le décret
mises en place pour protéger la santé de la population, numéro 418-2020 du 7 avril 2020, jusqu’au 24 avril 2020
tout en maintenant certaines d’entre elles nécessaires pour par le décret numéro 460-2020 du 15 avril 2020, jusqu’au
continuer de la protéger; 29 avril 2020 par le décret numéro 478-2020 du 22 avril
2020, jusqu’au 6 mai 2020 par le décret numéro 483-
Ar r êt e c e qui suit : 2020 du 29 avril 2020, jusqu’au 13 mai 2020 par le décret
numéro 501-2020 du 6 mai 2020, jusqu’au 20 mai 2020
Que le dispositif du décret numéro 885-2021 du 23 juin par le décret numéro 509-2020 du 13 mai 2020, jusqu’au
2021 soit modifié : 27 mai 2020 par le décret numéro 531-2020 du 20 mai
2020, jusqu’au 3 juin 2020 par le décret numéro 544-
1° par l’insertion, dans le paragraphe 8° du neuvième 2020 du 27 mai 2020, jusqu’au 10 juin 2020 par le décret
alinéa et après « au sixième alinéa », de « ou au para- numéro 572-2020 du 3 juin 2020, jusqu’au 17 juin 2020
graphe 14° du seizième alinéa » ; par le décret numéro 593-2020 du 10 juin 2020, jusqu’au
23 juin 2020 par le décret numéro 630-2020 du 17 juin
2° par le remplacement, dans les paragraphes 16° 2020, jusqu’au 30 juin 2020 par le décret numéro 667-
et 17° du seizième alinéa, de « 3 500 » par « 5 000 », 2020 du 23 juin 2020, jusqu’au 8 juillet 2020 par le décret
partout où cela se trouve; numéro 690-2020 du 30 juin 2020, jusqu’au 15 juillet
2020 par le décret numéro 717-2020 du 8 juillet 2020,
Qu e les mesures prévues au présent arrêté prennent jusqu’au 22 juillet 2020 par le décret numéro 807-2020
effet le 2 juillet 2021. du 15 juillet 2020, jusqu’au 29 juillet 2020 par le décret
numéro 811-2020 du 22 juillet 2020, jusqu’au 5 août 2020
Québec, le 1er juillet 2021 par le décret numéro 814-2020 du 29 juillet 2020, jusqu’au
12 août 2020 par le décret numéro 815-2020 du 5 août
Le ministre de la Santé et des Services sociaux, 2020, jusqu’au 19 août 2020 par le décret numéro 818-
Ch r ist ia n Du bé 2020 du 12 août 2020, jusqu’au 26 août 2020 par le décret
numéro 845-2020 du 19 août 2020, jusqu’au 2 septembre
75224 2020 par le décret numéro 895-2020 du 26 août 2020,
AR02525
Ceci est la pièce « C » au soutien de


AR02526
Arrêté numéro 2021-050 du ministre de la Santé et des Services

sociaux en date du 2 juillet 2021

(chapitre S-2.2)
CONCERNANT l’ordonnance de mesures

visant à protéger la santé de la population dans
la situation de pandémie de la COVID-19
---ooo0ooo---
LE MINISTRE DE LA SANTÉ ET DES SERVICES SOCIAUX,
VU l’article 118 de la Loi sur la santé publique

(chapitre S-2.2) qui prévoit que le gouvernement peut déclarer un état
d’urgence sanitaire dans tout ou partie du territoire québécois lorsqu’une
menace grave à la santé de la population, réelle ou imminente, exige
l’application immédiate de certaines mesures prévues à l’article 123 de
cette loi pour protéger la santé de la population;
VU le décret numéro 177-2020 du 13 mars 2020 qui déclare

l’état d’urgence sanitaire dans tout le territoire québécois pour une période
de 10 jours;
AR02527
VU que l’état d’urgence sanitaire a été renouvelé jusqu’au

29 mars 2020 par le décret numéro 222-2020 du 20 mars 2020, jusqu’au
7 avril 2020 par le décret numéro 388-2020 du 29 mars 2020, jusqu’au
16 avril 2020 par le décret numéro 418-2020 du 7 avril 2020, jusqu’au
24 avril 2020 par le décret numéro 460‑2020 du 15 avril 2020, jusqu’au
29 avril 2020 par le décret numéro 478‑2020 du 22 avril 2020, jusqu’au
6 mai 2020 par le décret numéro 483-2020 du 29 avril 2020, jusqu’au
13 mai 2020 par le décret numéro 501‑2020 du 6 mai 2020, jusqu’au
20 mai 2020 par le décret numéro 509-2020 du 13 mai 2020, jusqu’au
27 mai 2020 par le décret numéro 531-2020 du 20 mai 2020, jusqu’au
3 juin 2020 par le décret numéro 544‑2020 du 27 mai 2020, jusqu’au
10 juin 2020 par le décret numéro 572-2020 du 3 juin 2020, jusqu’au
17 juin 2020 par le décret numéro 593‑2020 du 10 juin 2020, jusqu’au
8 juillet 2020 par le décret numéro 690‑2020 du 30 juin 2020, jusqu’au
15 juillet 2020 par le décret numéro 717‑2020 du 8 juillet 2020, jusqu’au
22 juillet 2020 par le décret numéro 807-2020 du 15 juillet 2020, jusqu’au
29 juillet 2020 par le décret numéro 811‑2020 du 22 juillet 2020, jusqu’au
5 août 2020 par le décret numéro 814‑2020 du 29 juillet 2020, jusqu’au
12 août 2020 par le décret numéro 815‑2020 du 5 août 2020, jusqu’au
19 août 2020 par le décret numéro 818-2020 du 12 août 2020, jusqu’au
26 août 2020 par le décret numéro 845‑2020 du 19 août 2020, jusqu’au
2 septembre 2020 par le décret numéro 895-2020 du 26 août 2020,
jusqu’au 9 septembre 2020 par le décret numéro 917‑2020 du
2 septembre 2020, jusqu’au 16 septembre 2020 par le décret numéro
925‑2020 du 9 septembre 2020, jusqu’au 23 septembre 2020 par le décret
numéro 948‑2020 du 16 septembre 2020, jusqu’au 30 septembre 2020 par
le décret numéro 965‑2020 du 23 septembre 2020, jusqu’au 7 octobre 2020
par le décret numéro 1000‑2020 du 30 septembre 2020, jusqu’au
14 octobre 2020 par le décret numéro 1023‑2020 du 7 octobre 2020
jusqu’au 21 octobre 2020 par le décret numéro 1051-2020 du
14 octobre 2020, jusqu’au 28 octobre 2020 par le décret numéro 1094‑2020
du 21 octobre 2020, jusqu’au 4 novembre 2020 par le décret numéro
1113‑2020 du 28 octobre 2020, jusqu’au 11 novembre 2020 par le décret
numéro 1150‑2020 du 4 novembre 2020, jusqu’au 18 novembre 2020 par le
décret numéro 1168-2020 du 11 novembre 2020, jusqu’au
25 novembre 2020 par le décret numéro 1210‑2020 du 18 novembre 2020,
jusqu’au 2 décembre 2020 par le décret numéro 1242‑2020 du
25 novembre 2020, jusqu’au 9 décembre 2020 par le décret numéro
AR02528
1272‑2020 du 2 décembre 2020, jusqu’au 18 décembre 2020 par le décret

numéro 1308-2020 du 9 décembre 2020, jusqu’au 25 décembre 2020 par le
décret numéro 1351‑2020 du 16 décembre 2020, jusqu’au 1er janvier 2021
par le décret numéro 1418‑2020 du 23 décembre 2020, jusqu’au
8 janvier 2021 par le décret numéro 1420-2020 du 30 décembre 2020,
jusqu’au 15 janvier 2021 par le décret numéro 1‑2021 du 6 janvier 2021,
jusqu’au 5 février 2021 par le décret numéro 59‑2021 du 27 janvier 2021,
jusqu’au 12 février 2021 par le décret numéro 89‑2021 du 3 février 2021,
jusqu’au 5 mars 2021 par le décret numéro 141-2021 du 24 février 2021,
jusqu’au 12 mars 2021 par le décret numéro 176‑2021 du 3 mars 2021,
jusqu’au 19 mars 2021 par le décret numéro 204-2021 du 10 mars 2021,
jusqu’au 26 mars 2021 par le décret numéro 243-2021 du 17 mars 2021,
jusqu’au 2 avril 2021 par le décret numéro 291‑2021 du 24 mars 2021,
jusqu’au 9 avril 2021 par le décret numéro 489‑2021 du 31 mars 2021,
jusqu’au 16 avril 2021, par le décret numéro 525-2021 du 7 avril 2021,
jusqu’au 23 avril 2021 par le décret numéro 555-2021 du 14 avril 2021,
jusqu’au 30 avril 2021 par le décret numéro 570-2021 du 21 avril 2021,
jusqu’au 7 mai 2021 par le décret numéro 596-2021 du 28 avril 2021,
jusqu’au 14 mai 2021 par le décret numéro 623-2021 du 5 mai 2021,
jusqu’au 4 juin 2021 par le décret numéro 699-2021 du 26 mai 2021,
jusqu’au 11 juin 2021 par le décret numéro 740-2021 du 2 juin 2021,
jusqu’au 18 juin 2021 par le décret numéro 782‑2021 du 9 juin 2021,
jusqu’au 25 juin 2021 par le décret numéro 807-2021 du 16 juin 2021,
jusqu’au 2 juillet 2021 par le décret numéro 849‑2021 du 23 juin 2021 et
jusqu’au 9 juillet 2021 par le décret numéro 893-2021 du 30 juin 2021;
VU que le décret numéro 885-2021 du 23 juin 2021, modifié

par l’arrêté numéro 2021-049 du 1er juillet 2021, prévoit notamment
certaines mesures particulières applicables sur certains territoires;
AR02529
VU que ce décret habilite également le ministre de la Santé

et des Services sociaux à ordonner toute modification ou toute précision
relative aux mesures qu’il prévoit;
VU que le décret numéro 893-2021 du 30 juin 2021 habilite

le ministre de la Santé et des Services sociaux à prendre toute mesure
prévue aux paragraphes 1° à 8° du premier alinéa de l’article 123 de la Loi
sur la santé publique;
CONSIDÉRANT QUE la situation actuelle de la pandémie

de la COVID-19 permet d’assouplir certaines mesures mises en place pour
protéger la santé de la population, tout en maintenant certaines d’entre
elles nécessaires pour continuer de la protéger;
ARRÊTE CE QUI SUIT :
QUE le seizième alinéa du dispositif du décret numéro

885‑2021 du 23 juin 2021, modifié par l’arrêté numéro 2021-049 du
1er juillet 2021, soit de nouveau modifié :
1° dans le sous-paragraphe c du paragraphe 16°, par le

remplacement :
a) dans le sous-sous-paragraphe i :
i. de « 250 personnes » par « 500 personnes »;
ii. dans le sous-sous-sous-paragraphe II, de « quatre mètres

carrés » par « deux mètres carrés »;
AR02530
b) dans le sous-sous-paragraphe ii, de « 1,5 mètre » par

« 1 mètre »;
2° dans le sous-paragraphe c du paragraphe 17° par le

remplacement de « 1,5 mètre » par « 1 mètre ».
Québec, le 2 juillet 2021 j

u
Le ministre de la Santé et des Services i
sociaux, l
l
e
t
CHRISTIAN DUBÉ
AR02531
Ceci est la pièce « D » au soutien de


AR02532
numéro 489-2021 du 31 mars 2021, jusqu’au 16 avril 2021,

par le décret numéro 525-2021 du 7 avril 2021, jusqu’au
2021, jusqu’au 30 avril 2021 par le décret numéro 570-
numéro 596-2021 du 28 avril 2021, jusqu’au 14 mai 2021
-A.M., 2021
et des Services sociaux en date du 10 juillet 2021

par le décret numéro 623-2021 du 5 mai 2021, jusqu’au (chapitre S-2.2)
21 mai 2021 par le décret numéro 660-2021 du 12 mai
2021, jusqu’au 28 mai 2021 par le décret numéro 679- Con c er n a n t l’ordonnance de mesures visant à
2021 du 19 mai 2021, jusqu’au 4 juin 2021 par le décret protéger la santé de la population dans la situation de
numéro 699-2021 du 26 mai 2021, jusqu’au 11 juin 2021 pandémie de la COVID-19
par le décret numéro 740-2021 du 2 juin 2021, jusqu’au
18 juin 2021 par le décret numéro 782-2021 du 9 juin 2021, Le min ist r e de l a Sa n t é et d es Ser vices soc iau x,
jusqu’au 25 juin 2021 par le décret numéro 807-2021 du
16 juin 2021, jusqu’au 2 juillet 2021 par le décret Vu l’article 118 de la Loi sur la santé publique
numéro 849-2021 du 23 juin 2021, jusqu’au 9 juillet (chapitre S-2.2) qui prévoit que le gouvernement peut
2021 par le décret numéro 893-2021 du 30 juin 2021 et déclarer un état d’urgence sanitaire dans tout ou partie
jusqu’au 16 juillet 2021 par le décret numéro 937-2021 du du territoire québécois lorsqu’une menace grave à la santé
7 juillet 2021; de la population, réelle ou imminente, exige l’application
immédiate de certaines mesures prévues à l’article 123 de
Vu que le décret numéro 937-2021 du 7 juillet 2021 cette loi pour protéger la santé de la population;
habilite le ministre de la Santé et des Services sociaux
à prendre toute mesure prévue aux paragraphes 1° Vu le décret numéro 177-2020 du 13 mars 2020 qui
à 8° du premier alinéa de l’article 123 de la Loi sur la déclare l’état d’urgence sanitaire dans tout le territoire
santé publique; québécois pour une période de 10 jours;
Considér a n t que la situation actuelle de la pandémie Vu que l’état d’urgence sanitaire a été renouvelé
de la COVID-19 permet d’assouplir certaines mesures jusqu’au 29 mars 2020 par le décret numéro 222-2020
mises en place pour protéger la santé de la population, du 20 mars 2020, jusqu’au 7 avril 2020 par le décret
tout en maintenant certaines d’entre elles nécessaires pour numéro 388-2020 du 29 mars 2020, jusqu’au 16 avril 2020
continuer de la protéger; par le décret numéro 418-2020 du 7 avril 2020, jusqu’au
Ar r êt e c e qui suit : 2020, jusqu’au 29 avril 2020 par le décret numéro 478-
Que, malgré toute disposition contraire d’un décret ou numéro 483-2020 du 29 avril 2020, jusqu’au 13 mai 2020
d’un arrêté ministériel pris en application de l’article 123 par le décret numéro 501-2020 du 6 mai 2020, jusqu’au
de la Loi sur la santé publique, un rassemblement extérieur 20 mai 2020 par le décret numéro 509-2020 du 13 mai
puisse être organisé par un centre de services scolaire, 2020, jusqu’au 27 mai 2020 par le décret numéro 531-
une commission scolaire ou un établissement d’enseigne- 2020 du 20 mai 2020, jusqu’au 3 juin 2020 par le décret
ment privé aux fins de la tenue d’un bal de graduation numéro 544-2020 du 27 mai 2020, jusqu’au 10 juin 2020
rassemblant un maximum de 250 élèves de l’enseignement par le décret numéro 572-2020 du 3 juin 2020, jusqu’au
secondaire de la formation générale des jeunes en plus des 17 juin 2020 par le décret numéro 593-2020 du 10 juin
personnes requises pour la tenue de ce bal; 2020, jusqu’au 23 juin 2020 par le décret numéro 630-
2020 du 17 juin 2020, jusqu’au 30 juin 2020 par le décret
Que le présent arrêté prenne effet le 8 juillet 2021. numéro 667-2020 du 23 juin 2020, jusqu’au 8 juillet 2020
Québec, le 7 juillet 2021 15 juillet 2020 par le décret numéro 717-2020 du 8 juillet
2020, jusqu’au 22 juillet 2020 par le décret numéro 807-
Le ministre de la Santé et des Services sociaux, 2020 du 15 juillet 2020, jusqu’au 29 juillet 2020 par le
Ch r ist ia n Du bé décret numéro 811-2020 du 22 juillet 2020, jusqu’au 5 août
75377 jusqu’au 12 août 2020 par le décret numéro 815-2020 du
5 août 2020, jusqu’au 19 août 2020 par le décret
numéro 818-2020 du 12 août 2020, jusqu’au 26 août 2020
par le décret numéro 845-2020 du 19 août 2020, jusqu’au
4138A AR02533
GAZETTE OFFICIELLE DU QUÉBEC, 15 juillet 2021, 153e année, no 28A Partie 2
2 septembre 2020 par le décret numéro 895-2020 du 18 juin 2021 par le décret numéro 782-2021 du 9 juin 2021,
26 août 2020, jusqu’au 9 septembre 2020 par le décret jusqu’au 25 juin 2021 par le décret numéro 807-2021 du
numéro 917-2020 du 2 septembre 2020, jusqu’au 16 juin 2021, jusqu’au 2 juillet 2021 par le décret
16 septembre 2020 par le décret numéro 925-2020 du numéro 849-2021 du 23 juin 2021, jusqu’au 9 juillet
9 septembre 2020, jusqu’au 23 septembre 2020 par le 2021 par le décret numéro 893-2021 du 30 juin 2021 et
décret numéro 948-2020 du 16 septembre 2020, jusqu’au jusqu’au 16 juillet 2021 par le décret numéro 937-2021 du
30 septembre 2020 par le décret numéro 965-2020 du 7 juillet 2021;
23 septembre 2020, jusqu’au 7 octobre 2020 par le décret
numéro 1000-2020 du 30 septembre 2020, jusqu’au Vu que l’arrêté numéro 2020-100 du 3 décembre 2021
14 octobre 2020 par le décret numéro 1023-2020 du prévoit notamment certaines mesures concernant l’acha-
7 octobre 2020 jusqu’au 21 octobre 2020 par le décret landage des centres commerciaux et des établissements
numéro 1051-2020 du 14 octobre 2020, jusqu’au 28 octobre commerciaux de vente au détail;
2020 par le décret numéro 1094-2020 du 21 octobre 2020,
jusqu’au 4 novembre 2020 par le décret numéro 1113- Vu que le décret numéro 885-2021 du 23 juin 2021,
2020 du 28 octobre 2020, jusqu’au 11 novembre 2020 modifié par les arrêtés numéros 2021-049 du 1er juillet
par le décret numéro 1150-2020 du 4 novembre 2020, 2021 et 2021-050 du 2 juillet 2021, prévoient notam-
jusqu’au 18 novembre 2020 par le décret numéro 1168- ment certaines mesures particulières applicables sur
2020 du 11 novembre 2020, jusqu’au 25 novembre 2020 certains territoires;
par le décret numéro 1210-2020 du 18 novembre 2020,
jusqu’au 2 décembre 2020 par le décret numéro 1242-2020 Vu que ce décret habilite également le ministre de la
du 25 novembre 2020, jusqu’au 9 décembre 2020 par le Santé et des Services sociaux à ordonner toute modifica-
décret numéro 1272-2020 du 2 décembre 2020, jusqu’au tion ou toute précision relative aux mesures qu’il prévoit;
18 décembre 2020 par le décret numéro 1308-2020 du
9 décembre 2020, jusqu’au 25 décembre 2020 par le Vu que le décret numéro 937-2021 du 7 juillet 2021
décret numéro 1351-2020 du 16 décembre 2020, jusqu’au habilite le ministre de la Santé et des Services sociaux
1er janvier 2021 par le décret numéro 1418-2020 du à prendre toute mesure prévue aux paragraphes 1°
23 décembre 2020, jusqu’au 8 janvier 2021 par le décret à 8° du premier alinéa de l’article 123 de la Loi sur la
numéro 1420-2020 du 30 décembre 2020, jusqu’au santé publique;
15 janvier 2021 par le décret numéro 1-2021 du 6 janvier
2021, jusqu’au 22 janvier 2021 par le décret numéro 3-2021 Considér a n t que la situation actuelle de la pandémie
du 13 janvier 2021, jusqu’au 29 janvier 2021 par le décret de la COVID-19 permet d’assouplir certaines mesures
numéro 31-2021 du 20 janvier 2021, jusqu’au 5 février mises en place pour protéger la santé de la population,
2021 par le décret numéro 59-2021 du 27 janvier 2021, tout en maintenant certaines d’entre elles nécessaires pour
jusqu’au 12 février 2021 par le décret numéro 89-2021 continuer de la protéger;
du 3 février 2021, jusqu’au 19 février 2021 par le décret
numéro 103-2021 du 10 février 2021, jusqu’au 26 février Ar r êt e c e qui suit :
2021 par le décret numéro 124-2021 du 17 février 2021,
jusqu’au 5 mars 2021 par le décret numéro 141-2021 du Que le décret numéro 885-2021 du 23 juin 2021, modi-
24 février 2021, jusqu’au 12 mars 2021 par le décret fié par les arrêtés numéros 2021-049 du 1er juillet 2021 et
numéro 176-2021 du 3 mars 2021, jusqu’au 19 mars 2021 2021-050 du 2 juillet 2021, soit de nouveau modifié :
par le décret numéro 204-2021 du 10 mars 2021, jusqu’au
26 mars 2021 par le décret numéro 243-2021 du 17 mars 1° par le remplacement, dans les quatrième et
2021, jusqu’au 2 avril 2021 par le décret numéro 291- cinquième alinéas, de « de deux mètres » par
2021 du 24 mars 2021, jusqu’au 9 avril 2021 par le décret « d’un mètre »;
numéro 489-2021 du 31 mars 2021, jusqu’au 16 avril 2021,
par le décret numéro 525-2021 du 7 avril 2021, jusqu’au 2° par la suppression du sixième alinéa;
2021, jusqu’au 30 avril 2021 par le décret numéro 570- 3° par le remplacement du septième alinéa par
2021 du 21 avril 2021, jusqu’au 7 mai 2021 par le décret le suivant :
numéro 596-2021 du 28 avril 2021, jusqu’au 14 mai 2021
par le décret numéro 623-2021 du 5 mai 2021, jusqu’au « Que les personnes rassemblées qui exercent leur
21 mai 2021 par le décret numéro 660-2021 du 12 mai droit de manifester pacifiquement maintiennent entre
2021, jusqu’au 28 mai 2021 par le décret numéro 679- elles une distance d’un mètre avec toute personne, sauf si
2021 du 19 mai 2021, jusqu’au 4 juin 2021 par le décret une personne reçoit d’une autre personne un service ou
numéro 699-2021 du 26 mai 2021, jusqu’au 11 juin 2021 son soutien; »;
AR02534
4° par la suppression du huitième alinéa; « a) à l’intérieur :
5° dans le neuvième alinéa : i. les lieux sont aménagés pour qu’une distance mini-
male de deux mètres soit maintenue entre les tables, à
a) par le remplacement du paragraphe 8° par moins qu’une barrière physique permettant de limiter la
les suivants : contagion ne les sépare;
« 8° qu’il s’agisse d’un élève ou d’un étudiant qui se ii. un maximum de 10 personnes peuvent être réunies
trouve assis dans une salle de classe d’un établissement autour d’une même table située à l’intérieur, sauf s’il s’agit
universitaire, d’un collège, d’un établissement des occupants d’un maximum de trois résidences privées
d’enseignement collégial privé ou d’un autre établissement ou de ce qui en tient lieu;
qui dispense des services d’enseignement de niveau
collégial ou universitaire ou des services de formation b) à l’extérieur :
continue ou dans une salle où sont dispensés les
services éducatifs et d’enseignement de la formation i. les lieux sont aménagés pour qu’une distance mini-
professionnelle et de la formation générale des adultes et male d’un mètre soit maintenue entre les tables, à moins
qui maintient latéralement une distance minimale d’un qu’une barrière physique permettant de limiter la conta-
mètre avec toute autre personne qui n’est ni un occupant gion ne les sépare;
d’une même résidence privée ou de ce qui en tient lieu,
ni une personne qui lui fournit un service ou un soutien; ii. un maximum de 20 personnes peuvent être réunies
autour d’une même table située à l’extérieur, sauf s’il s’agit
« 8.1° qu’il s’agisse d’une personne du public qui se des occupants d’un maximum de trois résidences privées
trouve assise dans une salle d’audience et qui maintient ou de ce qui en tient lieu; »;
latéralement une distance minimale d’un mètre avec
toute autre personne qui n’est ni un occupant d’une même ii. par le remplacement, dans ce qui précède le sous-
résidence privée ou de ce qui en tient lieu, ni une personne sous-paragraphe i du sous-paragraphe d, de « malgré
qui lui fournit un service ou un soutien; »; les sous-paragraphes b et c » par « malgré le sous-sous-
paragraphe ii des sous-paragraphes a et b »;
b) par l’insertion, dans le sous-paragraphe a du para-
graphe 11° et après « deux mètres », de « , ou d’un mètre c) par le remplacement, dans le paragraphe 13°, de « de
si les personnes demeurent silencieuses ou ne parlent qu’à deux mètres » par « d’un mètre », partout où cela se trouve;
voix basse, »;
d) dans le paragraphe 14° :
6° dans le seizième alinéa :
i. par le remplacement de ce qui précède le sous-sous-
a) dans le paragraphe 5° : paragraphe i du sous-paragraphe b par ce qui suit :
i. par le remplacement de ce qui précède le sous-sous- « b) la distance d’une place doit être laissée libre entre
paragraphe i du sous-paragraphe b par ce qui suit : chaque personne, à moins : »;
« b) les personnes qui s’y trouvent maintiennent une ii. par l’insertion, après le sous-paragraphe c,
distance minimale de deux mètres ou d’un mètre si les du suivant :
personnes demeurent silencieuses ou ne parlent qu’à voix
basse, même lorsqu’elles demeurent à leur place et ne « d) les personnes du public peuvent retirer leur couvre-
circulent pas, à moins : »; visage lorsqu’elles sont assises et qu’elles demeurent silen-
cieuses ou ne parlent qu’à voix basse; »;
ii. par le remplacement, dans le paragraphe c, de « res-
pectant les conditions prévues au sous-paragraphe b » par e) par le remplacement du paragraphe 15° par
« qui demeurent à leur place et ne circulent pas »; le suivant :
b) dans le paragraphe 7° : « 15° malgré le paragraphe 14°, peuvent assister à un
évènement ou un entraînement amateur intérieur :
i. par le remplacement des sous-paragraphes a, b et c
par les suivants :
4140A AR02535
GAZETTE OFFICIELLE DU QUÉBEC, 15 juillet 2021, 153e année, no 28A Partie 2
a) un maximum de 50 personnes lorsqu’elles sont k) par l’insertion, à la fin du sous-paragraphe c du para-
assises dans les gradins ou dans tout autre type d’amé- graphe 26°, de « ou 16.1° »;
nagement permettant aux personnes de s’asseoir à des
places déterminées; 7° par l’insertion, après le dix-septième alinéa,
du suivant :
b) un maximum de 25 personnes dans les autres cas; »;
« Qu e l’exploitant d’un centre commercial ou d’un
f) dans le paragraphe 16° : commerce de vente au détail, ainsi que l’organisateur
d’un salon regroupant plusieurs exposants ou commerces
i. par le remplacement, dans le sous-sous- de vente au détail soient tenus de prendre les mesures
paragraphe iv du sous-paragraphe a, de « 10 mètres nécessaires pour assurer, en tout temps, le contrôle
carrés » par « cinq mètres carrés »; de l’achalandage de manière à ce que les règles de
distanciation prévues au présent décret puissent
ii. par le remplacement, dans le sous-sous- être respectées; »;
paragraphe ii du sous-paragraphe c, de « une distance
minimale de 1 mètre est maintenue latéralement entre Qu e l’arrêté numéro 2020-100 du 3 décembre 2020
les personnes qui y assistent » par « la distance d’une place soit abrogé;
doit être laissée libre entre chaque personne »;
Que le présent arrêté prenne effet le 12 juillet 2021.
g) par l’insertion, après le paragraphe 16°, du suivant :
Québec, le 10 juillet 2021
« 16.1° malgré le paragraphe 16°, peuvent assister à un
évènement ou un entraînement amateur extérieur : Le ministre de la Santé et des Services sociaux,
Ch r ist ia n Du bé
a) un maximum de 100 personnes assises dans les gra-
dins ou dans tout autre type d’aménagement permettant 75381
aux personnes de s’asseoir à des places déterminées;
b) un maximum de 50 personnes, dans les autres cas; »;
h) par le remplacement du paragraphe 20° par

le suivant :
« 20° dans une salle d’entraînement physique :
a) l’exploitant doit tenir un registre de tout client admis

dans son établissement;
b) une distance minimale de deux mètres doit être

maintenue en tout temps entre toute personne qui n’est
ni un occupant d’une même résidence privée ou de ce qui
en tient lieu, ni une personne qui lui fournit un service
ou un soutien; »;
i) par le remplacement, dans le paragraphe 21°, de

« de deux mètres » par « d’un mètre », partout où cela
se trouve;
j) par le remplacement du paragraphe 22° par

le suivant :
« 22° un salon regroupant plusieurs exposants ou

commerces de vente au détail peut se tenir dans une salle
louée ou une salle communautaire, auquel cas les mesures
prévues au dix-huitième alinéa doivent être respectées; »;
AR02536
Ceci est la pièce « E » au soutien de


AR02537
© ~diteur officiel du Quebec, 2021
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 5 août 2021, 153 e année, n o 31A 4593A
-
A.M., 2021
Arrêté numéro 2021-055 du ministre de la Santé et
des Services sociaux en date du 30 juillet 2021

26 août 2020, jusqu’au 9 septembre 2020 par le décret
numéro 917-2020 du 2 septembre 2020, jusqu’au
9 septembre 2020, jusqu’au 23 septembre 2020 par le
décret numéro 948-2020 du 16 septembre 2020, jusqu’au
(chapitre S-2.2) 23 septembre 2020, jusqu’au 7 octobre 2020 par le décret
numéro 1000-2020 du 30 septembre 2020, jusqu’au
CONCERNANT l’ordonnance de mesures visant à 14 octobre 2020 par le décret numéro 1023-2020 du
protéger la santé de la population dans la situation de 7 octobre 2020 jusqu’au 21 octobre 2020 par le décret
pandémie de la COVID-19 numéro 1051-2020 du 14 octobre 2020, jusqu’au 28 octobre
2020 par le décret numéro 1094-2020 du 21 octobre 2020,
LE M I N ISTRE DE LA SANTE ET DES SERVI CES SOCI AUX, jusqu’au 4 novembre 2020 par le décret numéro 1113-
2020 du 28 octobre 2020, jusqu’au 11 novembre 2020
Vu l’article 118 de la Loi sur la santé publique (chapitre par le décret numéro 1150-2020 du 4 novembre 2020,
S-2.2) qui prévoit que le gouvernement peut déclarer un jusqu’au 18 novembre 2020 par le décret numéro 1168-
état d’urgence sanitaire dans tout ou partie du territoire 2020 du 11 novembre 2020, jusqu’au 25 novembre 2020
québécois lorsqu’une menace grave à la santé de la popu- par le décret numéro 1210-2020 du 18 novembre 2020,
lation, réelle ou imminente, exige l’application immédiate jusqu’au 2 décembre 2020 par le décret numéro 1242-
de certaines mesures prévues à l’article 123 de cette loi 2020 du 25 novembre 2020, jusqu’au 9 décembre 2020
pour protéger la santé de la population; par le décret numéro 1272-2020 du 2 décembre 2020,
jusqu’au 18 décembre 2020 par le décret numéro 1308-
Vu le décret numéro 177-2020 du 13 mars 2020 qui 2020 du 9 décembre 2020, jusqu’au 25 décembre 2020
déclare l’état d’urgence sanitaire dans tout le territoire par le décret numéro 1351-2020 du 16 décembre 2020,
québécois pour une période de 10 jours; jusqu’au 1er janvier 2021 par le décret numéro 1418-2020
du 23 décembre 2020, jusqu’au 8 janvier 2021 par le décret
Vu que l’état d’urgence sanitaire a été renouvelé numéro 1420-2020 du 30 décembre 2020, jusqu’au
jusqu’au 29 mars 2020 par le décret numéro 222-2020 15 janvier 2021 par le décret numéro 1-2021 du 6 janvier
du 20 mars 2020, jusqu’au 7 avril 2020 par le décret 2021, jusqu’au 22 janvier 2021 par le décret numéro 3-2021
numéro 388-2020 du 29 mars 2020, jusqu’au 16 avril 2020 du 13 janvier 2021, jusqu’au 29 janvier 2021 par le décret
par le décret numéro 418-2020 du 7 avril 2020, jusqu’au numéro 31-2021 du 20 janvier 2021, jusqu’au 5 février
24 avril 2020 par le décret numéro 460-2020 du 15 avril 2021 par le décret numéro 59-2021 du 27 janvier 2021,
2020, jusqu’au 29 avril 2020 par le décret numéro 478- jusqu’au 12 février 2021 par le décret numéro 89-2021 du
2020 du 22 avril 2020, jusqu’au 6 mai 2020 par le décret 3 février 2021, jusqu’au 19 février 2021 par le décret
numéro 483-2020 du 29 avril 2020, jusqu’au 13 mai 2020 numéro 103-2021 du 10 février 2021, jusqu’au 26 février
par le décret numéro 501-2020 du 6 mai 2020, jusqu’au 2021 par le décret numéro 124-2021 du 17 février 2021,
20 mai 2020 par le décret numéro 509-2020 du 13 mai jusqu’au 5 mars 2021 par le décret numéro 141-2021 du
2020, jusqu’au 27 mai 2020 par le décret numéro 531- 24 février 2021, jusqu’au 12 mars 2021 par le décret
2020 du 20 mai 2020, jusqu’au 3 juin 2020 par le décret numéro 176-2021 du 3 mars 2021, jusqu’au 19 mars 2021
numéro 544-2020 du 27 mai 2020, jusqu’au 10 juin 2020 par le décret numéro 204-2021 du 10 mars 2021, jusqu’au
par le décret numéro 572-2020 du 3 juin 2020, jusqu’au 26 mars 2021 par le décret numéro 243-2021 du 17 mars
17 juin 2020 par le décret numéro 593-2020 du 10 juin 2021, jusqu’au 2 avril 2021 par le décret numéro 291-
2020, jusqu’au 23 juin 2020 par le décret numéro 630- 2021 du 24 mars 2021, jusqu’au 9 avril 2021 par le décret
2020 du 17 juin 2020, jusqu’au 30 juin 2020 par le décret numéro 489-2021 du 31 mars 2021, jusqu’au 16 avril 2021,
numéro 667-2020 du 23 juin 2020, jusqu’au 8 juillet 2020 par le décret numéro 525-2021 du 7 avril 2021, jusqu’au
par le décret numéro 690-2020 du 30 juin 2020, jusqu’au 23 avril 2021 par le décret numéro 555-2021 du 14 avril
15 juillet 2020 par le décret numéro 717-2020 du 8 juillet 2021, jusqu’au 30 avril 2021 par le décret numéro 570-
2020, jusqu’au 22 juillet 2020 par le décret numéro 807- 2021 du 21 avril 2021, jusqu’au 7 mai 2021 par le décret
2020 du 15 juillet 2020, jusqu’au 29 juillet 2020 par le numéro 596-2021 du 28 avril 2021, jusqu’au 14 mai 2021
décret numéro 811-2020 du 22 juillet 2020, jusqu’au 5 août par le décret numéro 623-2021 du 5 mai 2021, jusqu’au
2020 par le décret numéro 814-2020 du 29 juillet 2020, 21 mai 2021 par le décret numéro 660-2021 du 12 mai
jusqu’au 12 août 2020 par le décret numéro 815-2020 2021, jusqu’au 28 mai 2021 par le décret numéro 679-
du 5 août 2020, jusqu’au 19 août 2020 par le décret 2021 du 19 mai 2021, jusqu’au 4 juin 2021 par le décret
numéro 818-2020 du 12 août 2020, jusqu’au 26 août 2020 numéro 699-2021 du 26 mai 2021, jusqu’au 11 juin 2021
par le décret numéro 845-2020 du 19 août 2020, jusqu’au par le décret numéro 740-2021 du 2 juin 2021, jusqu’au
2 septembre 2020 par le décret numéro 895-2020 du 18 juin 2021 par le décret numéro 782-2021 du 9 juin 2021,
AR02538
4594A GAZETTE OFFICIELLE DU QUÉBEC, 5 août 2021, 153 e année, n o 31A Partie 2
jusqu’au 25 juin 2021 par le décret numéro 807-2021 2° dans le quatorzième alinéa :
du 16 juin 2021, jusqu’au 2 juillet 2021 par le décret
numéro 849-2021 du 23 juin 2021, jusqu’au 9 juillet 2021 a) par le remplacement du sous-paragraphe a du
par le décret numéro 893-2021 du 30 juin 2021, jusqu’au paragraphe 4° par le sous-paragraphe suivant :
16 juillet 2021 par le décret numéro 937-2021 du 7 juillet
2021, jusqu’au 23 juillet 2021 par le décret numéro 1062- « a) peuvent faire partie de l’assistance :
2021 du 14 juillet 2021 et jusqu’au 30 juillet 2021 par
le décret numéro 1069-2021 du 21 juillet 2021 et i. un maximum de 250 personnes à l’intérieur;
jusqu’au 6 août 2021 par le décret numéro 1072-2021 du
28 juillet 2021; ii. un maximum de 500 personnes à l’extérieur; »;
Vu que le décret numéro 885-2021 du 23 juin 2021, b) par le remplacement, dans le sous-paragraphe a du
er
modifie par les arretes numeros 2021-049 du juillet paragraphe 10°, de « minuit » par « une heure »;
2021, 2021-050 du 2 juillet 2021 et 2021-053 du 10 juillet
2021, prévoit notamment certaines mesures particulières c) par la suppression du sous-paragraphe b du
applicables sur certains territoires; paragraphe 11°;
Vu que ce décret habilite également le ministre de la ~ dans le sous-paragraphe a du paragraphe 14° :

Sante et des Services sociaux aordonner toute modifica-
tion ou toute précision relative aux mesures qu’il prévoit; i. par le remplacement, dans ce qui précède le sous-
sous-paragraphe i, de « 250 personnes ou de 3 500 per-
Vu que l’arrêté numéro 2020-035 du 10 mai 2020, sonnes » par « 500 personnes ou de 7 500 personnes »;
modifie par les arretes numeros 2020-044 du 12 juin
2020, 2020-064 du 17 septembre 2020, 2020-067 du ii. par le remplacement, dans ce qui précède le sous-
19 septembre 2020 et 2021-036 du 15 mai 2021 pré- sous-sous-paragraphe I du sous-sous-paragraphe i, de
voit notamment le versement d’un montant forfaitaire à « 250 personnes » par « 500 personnes »;
certaines personnes salariées du réseau de la santé et des
services sociaux; e) par le remplacement, dans le sous-paragraphe a du
paragraphe 15°, de « 50 personnes » par « 250 personnes »;
Vu que le décret numéro 1072-2021 du 28 juillet 2021
habilite le ministre de la Santé et des Services sociaux f) dans le paragraphe 16° :
à prendre toute mesure prévue aux paragraphes 1° à 8°
du premier alinéa de l’article 123 de la Loi sur la santé i. par le remplacement de « 5 000 » par « 15 000 »,
publique; partout où cela se trouve;
CONSIDERANT QUE la situation actuelle de la pandémie 11. par !'insertion, a la fin du sous-sous-paragraphe ii du
de la COVID-19 permet d’assouplir certaines mesures sous-paragraphe d, de « , à l’exception des événements de
mises en place pour protéger la santé de la population, moins de 500 participants ou spectateurs qui demeurent
tout en maintenant certaines d’entre elles nécessaires pour assis à des places déterminées »;
continuer de la protéger;
g) par le remplacement, dans le sous-paragraphe a
ARRETE CE QUI SUIT: du paragraphe 16.1°, de « 100 person nes » par
« 500 personnes »;
QUE le dispositif du décret numéro 885-2021 du
23 juin 2021, modi fie par les arretes numeros 2021-049 h) dans le sous-paragraphe f du paragraphe 21° :
du 1er juillet 2021, 2021-050 du 2 juillet 2021 et 2021-053
du 10 juillet 2021, soit de nouveau modifie: i. par le remplacement, dans ce qui précède le sous-
sous-paragraphe i, de « lors de l’entraînement et lors de la
1° par le remplacement du paragraphe 7° du neuvième pratique de ce sport » par « si l’entraînement ou la pratique
alinéa par les paragraphes suivants : de ce sport exige un nombre de personnes supérieur à celui
prévu par le sous-sous-paragraphe i du sous-paragraphe a
« 7° sur un traversier, qu’elle demeure à l’intérieur de ou par le sous-sous-paragraphe i du sous-paragraphe b »;
son véhicule ou sur un pont extérieur;
ii. par le remplacement du sous-sous-paragraphe i par
8° qu’elle se trouve sur l’étage extérieur d’un le suivant :
véhicule; »;
AR02539
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 5 août 2021, 153 e année, n o 31A 4595A
« i. un environnement protégé est mis en place, lequel I) technicien ou technicienne en éducation spécialisée
permet de limiter les risques de transmission entre les (2686);
athlètes et le personnel d’encadrement et le reste de la
population, conformément à un protocole sanitaire m) éducateur ou éducatrice (2691); »;
approuvé par le ministre de la Santé et des Services
sociaux; »; QUE les mesures prévues au premier alinéa du présent
arrete prennent eflet le Ier août 2021.
dans le paragraphe 26° :
Québec, le 30 juillet 2021
i. par le remplacement, dans le sous-paragraphe e,
de « 250 personnes y soient rassemblées et que chacune Le ministre de fa Sante e1 des Services sociaux,
demeure assise à sa place » par « 500 personnes y soient CHRISTIAN D UBE
rassemblées et que chacune demeure assise à une place
déterminée »; 75431
ii. par le remplacement, dans le sous-paragraphe f ,

de « lorsque » par « à condition qu’un maximum de 500
personnes y soient rassemblées et que »;
QUE le premier alinéa du dispositif de l’arrêté

numero 2020-035 du 10 mai 2020, modifie par les arretes
numéros 2020-044 du 12 juin 2020, 2020-064 du
17 septembre 2020, 2020-067 du 19 septembre 2020 et
2021-036 du 15 mai 2021, soit de nouveau modifie par
l’insertion, après le paragraphe 3°, du suivant :
« 3.1° en centre de protection de l’enfance et de la

jeunesse, pour les installations et les lieux désignés
par le ministre de la Santé et des Services sociaux, une
personne salariée reçoit un montant forfaitaire de 100,00 $
par semaine de travail, de même que les montants prévus
au paragraphe 2°, selon les mêmes conditions et modalités,
lorsqu’elle détient un des titres d’emploi suivants :
a) spécialiste en activités cliniques (1407);
b) criminologue (1544);
c) psychologue (1546);
d) travailleur social ou travailleuse sociale (1550);
e) agent ou agente de relations humaines (1553);
.f) agent ou agente de planification, de programmation

et de recherche (1565);
g) réviseur ou réviseure (1570);
h) psychoéducateur ou psychoéducatrice (1652);
travailleur ou travailleuse communautaire (2375);
j) technicien ou technicienne en travail social (2586);
k) aide social ou aide sociale (2588);

AR02540
Ceci est la pièce « F » au soutien de


AR02541
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 12 août 2021, 153e année, no 32A 5047A
-
A.M., 2021
et des Services sociaux en date du 4 août 2021

jusqu’au 12 août 2020 par le décret numéro 815-2020 du
5 août 2020, jusqu’au 19 août 2020 par le décret
numéro 818-2020 du 12 août 2020, jusqu’au 26 août 2020
par le décret numéro 845-2020 du 19 août 2020, jusqu’au
26 août 2020, jusqu’au 9 septembre 2020 par le décret
(chapitre S-2.2) numéro 917-2020 du 2 septembre 2020, jusqu’au
CONCERNANT l’ordonnance de mesures visant à 9 septembre 2020, jusqu’au 23 septembre 2020 par le
protéger la santé de la population dans la situation de décret numéro 948-2020 du 16 septembre 2020, jusqu’au
pandémie de la COVID-19 30 septembre 2020 par le décret numéro 965-2020 du
23 septembre 2020, jusqu’au 7 octobre 2020 par le décret
LE MI N ISTRE DE LA SANTE ET DES SERV ICES SOCIAUX, numéro 1000-2020 du 30 septembre 2020, jusqu’au
14 octobre 2020 par le décret numéro 1023-2020 du
Vu l’article 118 de la Loi sur la santé publique (chapitre 7 octobre 2020 jusqu’au 21 octobre 2020 par le décret
S-2.2) qui prévoit que le gouvernement peut déclarer un numéro 1051-2020 du 14 octobre 2020, jusqu’au 28 octobre
état d’urgence sanitaire dans tout ou partie du territoire 2020 par le décret numéro 1094-2020 du 21 octobre 2020,
québécois lorsqu’une menace grave à la santé de la popu- jusqu’au 4 novembre 2020 par le décret numéro 1113-
lation, réelle ou imminente, exige l’application immédiate 2020 du 28 octobre 2020, jusqu’au 11 novembre 2020
de certaines mesures prévues à l’article 123 de cette loi par le décret numéro 1150-2020 du 4 novembre 2020,
pour protéger la santé de la population; jusqu’au 18 novembre 2020 par le décret numéro 1168-
2020 du 11 novembre 2020, jusqu’au 25 novembre 2020
Vu le décret numéro 177-2020 du 13 mars 2020 qui par le décret numéro 1210-2020 du 18 novembre 2020,
déclare l’état d’urgence sanitaire dans tout le territoire jusqu’au 2 décembre 2020 par le décret numéro 1242-2020
québécois pour une période de 10 jours; du 25 novembre 2020, jusqu’au 9 décembre 2020 par le
décret numéro 1272-2020 du 2 décembre 2020, jusqu’au
Vu que l’état d’urgence sanitaire a été renouvelé 18 décembre 2020 par le décret numéro 1308-2020 du
jusqu’au 29 mars 2020 par le décret numéro 222-2020 9 décembre 2020, jusqu’au 25 décembre 2020 par le
du 20 mars 2020, jusqu’au 7 avril 2020 par le décret décret numéro 1351-2020 du 16 décembre 2020, jusqu’au
numéro 388-2020 du 29 mars 2020, jusqu’au 16 avril 2020 1er janvier 2021 par le décret numéro 1418-2020 du
par le décret numéro 418-2020 du 7 avril 2020, jusqu’au 23 décembre 2020, jusqu’au 8 janvier 2021 par le décret
24 avril 2020 par le décret numéro 460-2020 du 15 avril numéro 1420-2020 du 30 décembre 2020, jusqu’au
2020, jusqu’au 29 avril 2020 par le décret numéro 478- 15 janvier 2021 par le décret numéro 1-2021 du 6 janvier
2020 du 22 avril 2020, jusqu’au 6 mai 2020 par le décret 2021, jusqu’au 22 janvier 2021 par le décret numéro 3-2021
numéro 483-2020 du 29 avril 2020, jusqu’au 13 mai 2020 du 13 janvier 2021, jusqu’au 29 janvier 2021 par le décret
par le décret numéro 501-2020 du 6 mai 2020, jusqu’au numéro 31-2021 du 20 janvier 2021, jusqu’au 5 février
20 mai 2020 par le décret numéro 509-2020 du 13 mai 2021 par le décret numéro 59-2021 du 27 janvier 2021,
2020, jusqu’au 27 mai 2020 par le décret numéro 531- jusqu’au 12 février 2021 par le décret numéro 89-2021
2020 du 20 mai 2020, jusqu’au 3 juin 2020 par le décret du 3 février 2021, jusqu’au 19 février 2021 par le décret
numéro 544-2020 du 27 mai 2020, jusqu’au 10 juin 2020 numéro 103-2021 du 10 février 2021, jusqu’au 26 février
par le décret numéro 572-2020 du 3 juin 2020, jusqu’au 2021 par le décret numéro 124-2021 du 17 février 2021,
17 juin 2020 par le décret numéro 593-2020 du 10 juin jusqu’au 5 mars 2021 par le décret numéro 141-2021 du
2020, jusqu’au 23 juin 2020 par le décret numéro 630- 24 février 2021, jusqu’au 12 mars 2021 par le décret
2020 du 17 juin 2020, jusqu’au 30 juin 2020 par le décret numéro 176-2021 du 3 mars 2021, jusqu’au 19 mars 2021
numéro 667-2020 du 23 juin 2020, jusqu’au 8 juillet 2020 par le décret numéro 204-2021 du 10 mars 2021, jusqu’au
par le décret numéro 690-2020 du 30 juin 2020, jusqu’au 26 mars 2021 par le décret numéro 243-2021 du 17 mars
15 juillet 2020 par le décret numéro 717-2020 du 8 juillet 2021, jusqu’au 2 avril 2021 par le décret numéro 291-
2020, jusqu’au 22 juillet 2020 par le décret numéro 807- 2021 du 24 mars 2021, jusqu’au 9 avril 2021 par le décret
2020 du 15 juillet 2020, jusqu’au 29 juillet 2020 par le numéro 489-2021 du 31 mars 2021, jusqu’au 16 avril 2021,
décret numéro 811-2020 du 22 juillet 2020, jusqu’au 5 août par le décret numéro 525-2021 du 7 avril 2021, jusqu’au
AR02542
5048A GAZETTE OFFICIELLE DU QUÉBEC, 12 août 2021, 153e année, no 32A Partie 2
23 avril 2021 par le décret numéro 555-2021 du 14 avril 2021, 2021-053 du 10 juillet 2021 et 2021-055 du 30 juillet
2021, jusqu’au 30 avril 2021 par le décret numéro 570- 2021, soit de nouveau modi fie par l'insertion, a la fin du
2021 du 21 avril 2021, jusqu’au 7 mai 2021 par le décret paragraphe 2°, de « ou des enfants d’un camp de vacances
numéro 596-2021 du 28 avril 2021, jusqu’au 14 mai 2021 ou d’un camp de jour »;
par le décret numéro 623-2021 du 5 mai 2021, jusqu’au
21 mai 2021 par le décret numéro 660-2021 du 12 mai QUE soit abrogé l’arrêté numéro 2020-096 du
2021, jusqu’au 28 mai 2021 par le décret numéro 679- 25 novembre 2020.
2021 du 19 mai 2021, jusqu’au 4 juin 2021 par le décret
numéro 699-2021 du 26 mai 2021, jusqu’au 11 juin 2021 Québec, le 4 août 2021
18 juin 2021 par le décret numéro 782-2021 du 9 juin Le ministre de la Sante e/ des Services sociaux,
2021, jusqu’au 25 juin 2021 par le décret numéro 807- CHRISTIAN DUBE
2021 du 16 juin 2021, jusqu’au 2 juillet 2021 par le décret
numéro 849-2021 du 23 juin 2021, jusqu’au 9 juillet 2021 75437
16 juillet 2021 par le décret numéro 937-2021 du 7 juillet
2021, jusqu’au 23 juillet 2021 par le décret numéro 1062-
2021 du 14 juillet 2021 et jusqu’au 30 juillet 2021 par le
décret numéro 1069-2021 du 21 juillet 2021 et jusqu’au
6 août 2021 par le décret numéro 1072-2021 du 28 juillet
2021 et jusqu’au 13 août 2021 par le décret numéro 1074-
2021 du 4 août 2021;
Vu que le décret numéro 885-2021 du 23 juin

2021, modifié par les arrêtés numéros 2021-049 du
1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053 du
10 juillet 2021 et 2021-055 du 30 juillet 2021, prévoit
notamment certaines mesures particulières applicables
sur certains territoires;
Vu que ce décret habilite également le ministre de la

tion ou toute précision relative aux mesures qu’il prévoit;
Vu que l’arrêté numéro 2020-096 du 25 novembre 2020

prévoit notamment la suspension de toute procédure élec-
torale d’une élection scolaire au sens de la Loi sur les
élections scolaires (chapitre E-2.3);
Vu que le décret numéro 1074-2021 du 4 août 2021

à prendre toute mesure prévue aux paragraphes 1°
santé publique;
CONSIOERANT QUE la situation actuelle de la pandémie

de la COVID-19 permet d’assouplir certaines mesures
mises en place pour protéger la santé de la population,
tout en maintenant certaines d’entre elles nécessaires pour
ARRETE CE QUI SUIT:
QUE le septième alinéa du dispositif du décret

numero 885-2021 du 23 juin 2021, modi fie par Jes arretes
numéros 2021-049 du 1er juillet 2021, 2021-050 du 2 juillet
AR02543
Ceci est la pièce « G » au soutien de


AR02544
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
-
A.M., 2021
et des Services sociaux en date du 13 août 2021

A RRETE CE QUI SUIT:

23 juin 2021, modifie par Jes arretes numeros 2021-049
du 1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053
du 10 juillet 2021, 2021-055 du 30 juillet 2021 et 2021-057
(chapitre S-2.2) du 4 aout 2021, soit de nouveau mod ifie:
CONCERNANT l’ordonnance de mesures visant à 1° par l’ajout, à la fin du quatrième alinéa, du
protéger la santé de la population dans la situation de paragraphe suivant :
pandémie de la COVID-19
« 9° pour les élèves et les étudiants dans les salles de
LE MINISTRE OE LA SANTE ET DES SERVICES SOCIAUX, classe des établissements universitaires, des collèges,
des établissements d’enseignement collégial privés et
Vu l’article 118 de la Loi sur la santé publique des autres établissements qui dispensent des services
(chapitre S-2.2) qui prévoit que le gouvernement peut d’enseignement de niveau collégial ou universitaire et
déclarer un état d’urgence sanitaire dans tout ou partie dans les salles où sont dispensés les services éducatifs
du territoire québécois lorsqu’une menace grave à la santé et d’enseignement de la formation professionnelle et de
de la population, réelle ou imminente, exige l’application la formation générale des adultes lorsqu’ils sont assis; »;
cette loi pour protéger la santé de la population; 2° dans le septième alinéa :
Vu le décret numéro 177-2020 du 13 mars 2020 qui a) par le remplacement des paragraphes 1° à 3° par
déclare l’état d’urgence sanitaire dans tout le territoire les suivants :
québécois pour une période de 10 jours;
« 1° qu’elle soit âgée de moins de 10 ans et qu’il ne
Vu que l’état d’urgence sanitaire a toujours été renou- s’agisse pas d’un élève qui se trouve dans un bâtiment
velé depuis cette date par divers décrets, notamment par ou un local utilisé par un établissement d’enseignement;
le décret numéro 1080-2021 du 11 août 2021;
Vu que le décret numéro 885-2021 du 23 juin 2021, qui se trouve dans un bâtiment ou un local utilisé par un
modifie par Jes arretes numeros 2021-049 du er
juillet établissement d’enseignement ou des enfants d’un camp
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet de vacances ou d’un camp de jour;
2021, 2021-055 du 30 juillet 2021 et 2021-057 du 4 août
2021, prévoit notamment certaines mesures particulières 3° qu’il s’agisse d’un élève de l’enseignement primaire
applicables dans tout le territoire québécois;
ou de l’enseignement secondaire de la formation générale
Vu que ce décret habilite également le ministre de la des jeunes qui se trouve dans une salle où sont dispensés
les services éducatifs et d’enseignement; »;
Sante et des Services sociaux a ordonner toute modifica-
b) par le remplacement du paragraphe 8° par le suivant:
habilite le ministre de la Santé et des Services sociaux « 8° qu’il s’agisse d’un élève ou d’un étudiant qui se
à prendre toute mesure prévue aux paragraphes 1° trouve assis dans une salle de classe d’un établissement
à 8° du premier alinéa de l’article 123 de la Loi sur la universitaire, d’un collège, d’un ét ablissement
santé publique; d’enseignement collégial privé ou d’un autre établissement
qui dispense des services d’enseignement de niveau
CONSIDERANT QUE la situation actuelle de la pandémie
collégial ou universitaire ou des services de formation
de la COVID-19 permet d’assouplir certaines mesures continue ou dans une salle où sont dispensés les services
mises en place pour protéger la santé de la population, éducatifs et d’enseignement de la formation professionnelle
tout en maintenant certaines d’entre elles nécessaires pour et de la formation générale des adultes; »;
AR02545
3° par le remplacement des paragraphes 1° et 2° du 5° par l'ajout, a la fin, de )'annexe suivante:

neuvième alinéa par les suivants :
« Annexe I – Établissements d’enseignement où des
« 1° qu’elle soit âgée de moins de 10 ans et qu’il ne mesures particulières s’appliquent
s’agisse pas d’un élève qui se trouve dans un moyen de
transport scolaire; — Cégep d’Ahuntsic
— Cégep de Rosemont
qui se trouve dans un moyen de transport scolaire; »; — Cégep André-Laurendeau
— Cégep Marie-Victorin
4° dans le quatorzième alinéa :
— Cégep de Sept-Îles
a) par la suppression, dans le sous-paragraphe a du
— Institut Teccart
paragraphe 13°, de « , et ce, pourvu qu’une distance
minimale d’un mètre soit maintenue entre les élèves de — Collège TAV
groupes ditferents»;
— Institut d’enregistrement du Canada
b) par le remplacement, dans le sous-sous- — Collège d’enseignement en immobilier inc.
paragraphe iii du sous-paragraphe b du paragraphe 14°
— Collège de l’immobilier du Québec
et dans le sous-sous-sous-paragraphe III du sous-sous-
paragraphe ii du sous-paragraphe C du paragraphe 16°, de — Collège l’Avenir de Rosemont inc.
« d’un même groupe » par « d’une même école »;
— Institut de technologie agroalimentaire du Québec
c) dans le paragraphe 21° :
(campus de La Pocatière) »;
QuE le present arrete prenne etfet le 16 aoOt 2021.

i. par le remplacement du sous-sous-paragraphe ii des
sous-paragraphes a et b par le suivant :
Québec, le 13 août 2021
« ii. dans le cadre d’une activité extrascolaire ou d’une Le minis/re de la Sanle et des Services sociaux,
sortie scolaire par les élèves de la formation générale des
CHRISTIAN DUBE
jeunes d’une même école; »;
75493
ii. par la suppression, dans le sous-paragraphe C ,
de « , pourvu que les élèves de groupes différents
maintiennent une distance d’un mètre, dans la mesure
du possible »;
d) par l'ajout, a la fin, des paragraphes suivants:
« 27° les activités de nature évènementielle ou sociale

ayant lieu dans un bâtiment ou un local utilisé par un
établissement d’enseignement visé à l’annexe I ou sur le
terrain d’un tel établissement ou organisées par ce dernier
sont suspendues;
28° les étudiants qui se trouvent dans tout bâtiment

ou local utilisé par un établissement d’enseignement
visé à l’annexe I doivent porter en tout temps un masque
de procédure, sous réserve des exceptions prévues aux
paragraphes 4° à 7° du septième alinéa; »;
AR02546
Ceci est la pièce « H » au soutien de


AR02547
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï

Arretes ministeriels
A.M., 2021 CONSIDERANT QUE la situation actuelle de la pandem ie

de la COVID-19 permet d'assouplir certaines mesures
Arrete numero 2021-059 du ministre de la Sante et mises en place pour proteger la sante de la population,
des Services sociaux en date du 18 aoiH 2021 tout en maintenant certaines d'entre elles necessaires pour
continuer de la proteger;
Loi sur la sante publique
(chapitre S-2.2) A RRETE CE QUI SUIT:
C ONCER NANT l'ordonnance de mesures visant it QuE le dispositif du decret numero 885-2021 du
proteger la sante de la population clans la situation de 23 juin 202 1, modifie par Jes arretes numeros 2021-049
pandemie de la COVID-1 9 du l" juillet 2021, 2021-050 du 2 juillet 2021, 2021 -053
du 10 juillet 2021, 2021- 055 du 30 juillet 2021, 2021-057
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, du 4 aout 2021 et 2021-058 du 13 ao0t 2021 , soit de
nouveau modifie:
Vu l'article 118 de la Loi sur la sante publique (chapitre
S-2.2) qui prevoit que le gouvernement peut declarer un I O par le rem placement du paragraphe 8° du
etat d' urgence sanitaire dans tout ou partie du territoire septieme alinea par le suivant:
quebecois lorsqu'une menace grave a la sante de la popu-
lation, reelte ou imminente, exige !'application immediate «8° qu'il s'agisse d' un eleve qui se trouve assis dans
de certaines mesures prevues a l'article 123 de cette loi une salle 0(1 sont dispenses les services educatifs et
pour proteger la sante de la population; d'enseignement de la formation professionnelle et de la
formation generale des adultes; »;
Vu le decret numero 177-2020 du 13 mars 2020 qui
declare l'etat d' urgence sanitaire dans tout le territoire 2° par le remplacement du paragraphe 28° du
quebecois pour une periode de 10 jours; quatorzieme alinea par le suivant:
Vu que l'etat d' urgence sanitaire a toujours ete renou- « 28° pour les etudiants des etablissements d'ensei-
vele depuis cette date par divers decrets, notamment par gnement universitaire, des colleges, des etablissements
le decret numero 1127-2021 du 18 ao0t 2021 ; d'enseignement collegial prives et des autres etablis -
sements qui dispensent des services d'enseignement
Vu que le decret numero 885-2021 du 23 juin 2021, de niveau collegial ou universitaire ou des services de
modifie par les arretes numeros 2021- 049 du 1" juillet formation continue, un masque de procedure doit etre
2021 , 2021-050 du 2 juillet 2021, 2021-053 du JO juillet porte en tout temps lorsqu'ils se tro uvent dans tout
202 1, 2021- 055 du 30 juillet 2021, 2021- 057 du 4 ao0t batiment ou local utilise par l'etablissement, sous reserve
2021 et 2021- 058 du 13 aoOt 2021 , prevoit notamment des exceptions prevues aux paragraphes 4° a7° et J0° du
certaines mesures particulieres applicables dans tout le septieme alinea; »;
territoire quebecois;
Q u E le present arrete prenne effet le 19 ao0t 202 1.
Vu que ce decret habilite egalement le ministre de la
Sante et des Services sociaux a ordonner toute modifica- Quebec, le 18 taout 2021
tion ou toute precision relative aux mesures qu'il prevoit;
Le ministre de la Santé et des Services sociaux,
Vu que le decret numero 1127-2021 du 18 ao0t 2021 CHRISTIAN DUBE
habilite le ministre de la Sante et des Services sociaux
a prendre toute mesure prevue aux paragraphes 1° a 8° 75522
du premier alinea de !'article 123 de la Loi sur la
sante publique;
AR02548
Ceci est la pièce « I » au soutien de


AR02549
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
A.M., 2021 1° par la suppression du paragraphe 8 ° du

septieme alinea;
Arrete oumero 2021-060 du mioistre de la Saote et
des Services sociaux en date du 24 aoilt 202 1 2° par le rernplacement du paragraphe 28° du
quatorzieme alinea par Jes paragraphes suivants:
Loi sur la sante publique
(chapitre S-2.2) «28° pour Jes eleves et Jes etudiants des etablissements
d 'enseignement universitaire, des colleges, des
CONCERNANT l'ordonnance de mesures visant ii
etablissements d'enseignement collegial prives et
proteger la sante de la population clans la situation de
pandemie de la COYID-19 des autres etablissements qui dispensent des services
d'enseignement de niveau collegial ou universitaire et des
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, etablissements oit sont dispenses des services educatifs
et d'enseignement de la formation professionnelle ou
Vu l'article 118 de la Loi sur la sante publ ique (chapitre de la formation generate des adultes ou des services
S-2.2) qui prevoit que le gouvernernent peut declarer un de formation continue, un masque de procedure do it
etat d'urgence sanitaire clans tout ou partie du territoire etre porte en tout temps lorsqu'ils se trouvent dans tout
quebecois lorsqu'une menace grave a la sante de la popu- batiment ou local utilise par l'etablissement, sous reserve
lation, reelle ou imminente, exige !'application immediate des exceptions prevues aux paragraphes 4° a 7° et 10°
de certaines mesures prevues a )'article 123 de cette Joi du septieme alinea;
pour proteger la sante de la population;
29° les eleves de l'enseignement primaire ou secon-
Vu le decret numero 177-2020 du 13 mars 2020 qui daire de la formation generale des jeunes qui se trouvent
declare l'etat d'urgence sanitaire dans tout le territoire dans tout batiment ou local utilise par un centre de ser-
quebecois pour une periode de 10 jours; vices scolaire, une commission scolaire ou un etablisse-
ment d'enseignement prive situe sur le territoire de l' une
Vu que l'etat d'urgence sanitaire a toujours ete renou- des regions sociosanitaires prevues a )'annexe II doivent
vele depuis cette date par divers decrets, notamment par porter en tout temps un masque de procedure, sous reserve
le decret numero 1127-2021 du 18 aoC,t 2021; des exceptions suivantes:
Vu que le decret numero 885-2021 du 23 juin 2021, a) l'eleve presente l'une des conditions medicates
modifie par Jes arretes numeros 2021-049 du 1" juillet suivantes:
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
2021, 202 1-055 du 30 juillet 2021, 2021- 057 du 4 aout i. ii est incapable de mettre ou de retirer un masque
2021, 2021-058 du 13 aout 2021 et 2021- 059 du 18 aout de procedure par lui-meme en raison d'une incapacite
2021, prevoit notamment certaines mesures particulieres
physique;
appl icables dans tout le territoire quebecois;
Vu que ce decret habilite egalement le ministre de la ii. une deformation faciale;

tion ou toute precision relative aux mesures qu'il prevoit; iii. en raison d'un trouble cognitif, d' une deficience
intellectuelle, d' un trouble du spectre de l'autisme ou
Vu que le decret numero I 127-2021 du 18 aout 2021 d'une autre condition de sante mentale, ii n'est pas en
habilite le ministre de la Sante et des Services sociaux mesure de comprendre !'obligation de porter un masque
a prendre toute mesure prevue aux paragraphes 1° de procedure ou le port de celui- ci entra'ine une desorga-
a 8° du premier alinea de !'article 123 de la Loi sur la nisation ou une detresse significative;
sante publique;
iv. toute autre condition medicale en raison de laquelle
CONSIDERANT Qu'i l y a lieu d'ordonner certaines le port du masque de procedure estjuge prejudiciable ou
mesures pour proteger la sante de la population; dangereux, pour laquelle une attestation par un profes-
sionnel habilite a poser un diagnostic peut etre exigee;
ARRETE CE QUI SUIT:
b) l'eleve rer;oit un soin, y beneficie d'un service ou y
Q u E le dispositif du decret numero 885-2021 du pratique une activite physique ou une autre activite qui
23 juin 2021 , modi fie par les arretes numeros 2021-049 necessite de l'enlever, auquel cas ii peut retirer son masque
du l" juillet 2021 , 2021- 050 du 2juillet 2021, 2021-053 de procedure pour la duree de ce soin, de ce service ou
du 10 juillet 2021, 2021-055 du 30 juillet 2021 , 2021-057 de cette activite;
du 4 aout 2021, 2021-058 du 13 aout 2021 et 2021-059 du
18 aout 2021, soit de nouveau modi fie:
AR02550
c) l'eleve retire momentanement son masque de proce- A.M., 2021

dure pour boire ou manger, ou ii des fins d'identification;
A rrete numero 2021-4556 du ministre de la Justice
d) l'eleve a des besoins particuliers lies ii la parole, en date du 20 aout 202 1
au langage et a la communication ou re9oit des services
d'accueil et de soutien ii l'apprentissage de la langue Loi sur le ministere de la Justice
fran1yaise dans le cadre des services educatifs et (chapitre M- 19)
d'enseignement;
CoNCERNANT la prolongation de mesures visant a
e) l'eleve interagit avec une personne visee au assurer la bonne administration de la justice dans la
paragraphe precedent; situation de la pandemie de la COVID-19
f) en classe, lorsque la temperature exterieure deter-
minee par Environnement Canada est de 25°C ou plus, ii LE MINISTRE DE LA JUSTICE,
mains que le local soit climatise; »;
Vu !'article 5.1 de la Loi sur le m inistere de la Justice
3° par le rem placement de !'annexe I par la suivante: (chapitre M- 19), qui prevoit que, lorsqu'un etat d'urgence
est declare par le gouvernement ou qu'une situation rend
« A nnexe I - Etablissements d'enseignement ou des impossible, en fait, le respect des regles du Code de pro-
mesures particulieres s'appliquent cedure civile (chapitre C-25.01) ou du Code de procedure
penale (chapitre C-25.1), le ministre de la Justice peut, si
- Cegep d'Ahuntsic; la bonne administration de la justice le necessite, modi-
-Cegep de Rosemont; fier toute regle de procedure, en adopter une nouvelle ou
prevoir toute autre mesure;
- Cegep Marie-Victorin;
- Cegep de Sept-Iles; Vu que cet article prevoit que ces mesures sont publiees
ii la Gazette offi cielle du Québec, peuvent prendre effet ii
- lnstitut Teccart; la date de cette declaration d'etat d'urgence ou de la surve-
- College TAY; nance de cette situation ou atoute date ulterieure qui y est
indiquee et qu'elles sont applicables pour la periode fi xee
- Institut d'enregistrement du Canada; par le ministre de la Justice, laquelle ne peut exceder un
- College l'Avenir de Rosemont inc. »; an suivant la fin de cet etat d'urgence ou de cette situation.
4° par l'ajout, ii la fin, de !'annexe suivante: Vu que cet article prevoit que le ministre de la Justice
peut prolonger cette periode, avant son expiration, chaque
« Annexe II - Regions sociosanitaires oi1 le port du annee pendant 5 ans si la bonne administration de la
masque de procedure est obligatoire en tout temps pour justice le necessite;
les eleves de l'enseignement primaire ou secondaire de la
formation generale des jeunes Vu que cet article prevoit qu'avant de prolonger ces
- Region sociosanitaire de la Mauricie et du mesures, le ministre doit prendre en consideration leurs
Centre-du-Quebec; effets sur les droits des personnes, obtenir !'accord dujuge
en chef du Quebec et du juge en chef de la Cour supe-
- Region sociosanitaire de l' Estrie; rieure ou de la Cour du Quebec, selon leur competence, et
- Region sociosanitaire de Montreal; prendre en consideration l'avis du Barreau du Quebec et,
le cas echeant, de la Chambre des notaires du Quebec ou
- Region sociosanitaire de l'Outaouais; de la Chambre des huissiers de justice du Quebec;
- Region sociosanitaire de Laval;
Vu qu'en vertu de !'article 12 de la Loi sur les regle-
- Region sociosanitaire de Lanaudiere; ments (chapitre R-18.1), un projet de reglement peut etre
- Region sociosanitaire des Laurentides; edicte sans avoir fait l'objet de la publication prealable
prevue a!'article 8 de cette loi lorsque l'autorite qui l'edicte
- Region sociosanitaire de la Monteregie. ». est d'avis qu'un motifprevu par la loi en vertu de laquelle
le projet peut etre edicte le justifie ou que l'urgence de la
Quebec, le 24 ao0t 2021
situation !'impose;
CHRISTIAN D UBE Vu qu'en vertu de l'article 13 de cette loi, le motifjus-
tifiant !'absence de publication prealable doit etre publie
75527 avec le reglement;
AR02551
Ceci est la pièce « J » au soutien de


AR02552
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 2 septembre 2021, 153e année, no 35A 5195A
-
A.M., 2021
des Services sociaux en date du 31 août 2021

CONSIDERANT QU ’il y a lieu d’ordonner certaines
mesures pour protéger la santé de la population;
ARRETE CE QUI SUIT:
QuE le dispositif du décret numéro 885-2021 du

(chapitre S-2.2) 23 juin 2021, modifie par les arretes numeros 2021-049
CONCERNANT l’ordonnance de mesures visant à du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
protéger la santé de la population dans la situation de du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
pandémie de la COVID-19 18 août 2021 et 2021-060 du 24 août 2021, soit de nouveau
modi fie par le rem placement de l'annexe I par la suivante:
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX,
« Annexe I – Établissements d’enseignement où des
Vu l’article 118 de la Loi sur la santé publique mesures particulières s’appliquent
(chapitre S-2.2) qui prévoit que le gouvernement peut
déclarer un état d’urgence sanitaire dans tout ou partie — Cégep de Rosemont;
du territoire québécois lorsqu’une menace grave à la santé
de la population, réelle ou imminente, exige l’application — Cégep Marie-Victorin;
cette loi pour protéger la santé de la population; — Institut Teccart;
Vu le décret numéro 177-2020 du 13 mars 2020 qui — Collège TAV;
déclare l’état d’urgence sanitaire dans tout le territoire
québécois pour une période de 10 jours; — Institut d’enregistrement du Canada;
Vu que l’état d’urgence sanitaire a toujours été renou- — Collège l’Avenir de Rosemont inc. ».
velé depuis cette date par divers décrets, notamment par
le décret numéro 1150-2021 du 25 août 2021; Québec, le 31 août 2021
Vu que le décret numéro 885-2021 du 23 juin 2021, le ministre de fa Sante et des Services sociaux,
modifie par les arretes numeros 2021-049 du 1er juillet CHRISTIAN DUBE
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août 75556
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
2021 et 2021-060 du 24 août 2021, prévoit notamment
certaines mesures particulières applicables dans tout le
territoire québécois;


santé publique;
AR02553
Ceci est la pièce « K » au soutien de

-~ ,r,
AR02554
Arrêté numéro 2021-062 du ministre de la Santé et des Services

sociaux en date du 3 septembre 2021

(chapitre S-2.2)
CONCERNANT l’ordonnance de mesures

visant à protéger la santé de la population dans
la situation de pandémie de la COVID-19
---ooo0ooo---
LE MINISTRE DE LA SANTÉ ET DES SERVICES SOCIAUX,
VU l’article 118 de la Loi sur la santé publique

(chapitre S-2.2) qui prévoit que le gouvernement peut déclarer un état
d’urgence sanitaire dans tout ou partie du territoire québécois lorsqu’une
menace grave à la santé de la population, réelle ou imminente, exige
l’application immédiate de certaines mesures prévues à l’article 123 de
cette loi pour protéger la santé de la population;
VU le décret numéro 177-2020 du 13 mars 2020 qui déclare

l’état d’urgence sanitaire dans tout le territoire québécois pour une période
de 10 jours;
AR02555
VU que l’état d’urgence sanitaire a toujours été renouvelé

depuis cette date par divers décrets, notamment par le décret numéro
1172-2021 du 1er septembre 2021;
VU que le décret numéro 885-2021 du 23 juin 2021, modifié

par les arrêtés numéros 2021‑049 du 1er juillet 2021, 2021‑050 du
2 juillet 2021, 2021‑053 du 10 juillet 2021, 2021-055 du 30 juillet 2021,
2021-057 du 4 août 2021, 2021‑058 du 13 août 2021, 2021‑059 du
18 août 2021, 2021‑060 du 24 août 2021 et 2021‑061 du 31 août 2021,
prévoit notamment certaines mesures particulières applicables dans tout le
VU que ce décret habilite également le ministre de la Santé

et des Services sociaux à ordonner toute modification ou toute précision
relative aux mesures qu’il prévoit;
VU que le décret numéro 1172-2021 du 1er septembre 2021

habilite le ministre de la Santé et des Services sociaux à prendre toute
mesure prévue aux paragraphes 1° à 8° du premier alinéa de l’article 123
de la Loi sur la santé publique;
CONSIDÉRANT QU’il y a lieu d’ordonner certaines mesures

pour protéger la santé de la population;
ARRÊTE CE QUI SUIT :

23 juin 2021, modifié par les arrêtés numéros 2021-049 du 1er juillet 2021,
2021-050 du 2 juillet 2021, 2021-053 du 10 juillet 2021, 2021-055 du
30 juillet 2021, 2021-057 du 4 août 2021, 2021‑058 du 13 août 2021,
2021‑059 du 18 août 2021, 2021‑060 du 24 août 2021 et 2021‑061 du
31 août 2021, soit de nouveau modifié par l’insertion, après le
paragraphe 21° du quatorzième alinéa, du paragraphe suivant :
AR02556
« 21.1° dans la détermination du nombre maximal de

personnes qui pratiquent un sport d’équipe en application des
sous‑paragraphes a et b du paragraphe 21°, seuls les joueurs présents
dans l’aire dédiée au jeu sont pris en compte; ».
Québec, le 3 septembre 2021 s

e
Le ministre de la Santé et des Services p
sociaux, t
e
m
b
r
CHRISTIAN DUBÉ
e
AR02557
Ceci est la pièce « L » au soutien de


AR02558
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
QUE toute procédure, autre que référendaire, qui fait

partie du processus décisionnel d’un organisme munici-
pal et qui implique le déplacement ou le rassemblement
de citoyens soit accompagnée d’une consultation écrite,
annoncee au prealable par un avis public, qui prend fin au
même moment que la procédure qu’elle accompagne; cette
-
A.M., 2021
des Services sociaux en date du 9 septembre 2021

consultation écrite peut également remplacer la procédure (chapitre S-2.2)
en question, auquel cas elle est d’une durée de 15 jours;
CONCERNANT l’ordonnance de mesures visant à
QUE le dispositif de l’arrêté 2020-084 du 27 octobre protéger la santé de la population dans la situation de
2020 soit modifie par !'insertion, dans ce qui precede le pandémie de la COVID-19
paragraphe 1° du premier alinéa et après « élections »,
de « partielles »; LE MJNISTRE DE LA SANTE ET DES SERVICES SOCIAUX,
QuE soient abrogés : Vu l’article 118 de la Loi sur la santé publique (chapitre
S-2.2) qui prévoit que le gouvernement peut déclarer un
1° le sixième alinéa du dispositif de l’arrêté état d’urgence sanitaire dans tout ou partie du territoire
numero 2020-008 du 22 mars 2020, modi fie par le decret québécois lorsqu’une menace grave à la santé de la popu-
numéro 566-2020 du 27 mai 2020 et par les arrêtés numé- lation, réelle ou imminente, exige l’application immédiate
ros 2020-033 du 7 mai 2020 et 2020-044 du 12 juin 2020; de certaines mesures prévues à l’article 123 de cette loi
2° le sixième alinéa du dispositif de l’arrêté
numéro 2020-049 du 4 juillet 2020; Vu le décret numéro 177-2020 du 13 mars 2020 qui
3° les premier, troisième, quatrième et cinquième québécois pour une période de 10 jours;
alinéas du dispositif de l’arrêté numéro 2020-033 du
7 mai 2020, modifie par l'arrete numero 2020-049 du Vu que l’état d’urgence sanitaire a toujours été renou-
4 juillet 2020; velé depuis cette date par divers décrets, notamment par
le décret numéro 1200-2021 du 8 septembre 2021;
QUE, malgré le paragraphe 3° de l’alinéa précédent, le
premier alinéa du dispositif de l’arrêté numéro 2020-033 Yu que le décret numéro 885-2021 du 23 juin 2021,
du 7 mai 2020, tel que modifie, demeure applicable atoute
er
modifie par Jes arretes numeros 2021-049 du juillet
procédure d’enregistrement des personnes habiles à voter 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
en cours et atout scrutin referendaire dont la date est fi xee 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
au plus tard le 31 août 2021; 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août 2021,
2021-060 du 24 août 2021, 2021-061 du 31 août 2021 et
QuE le present arrete pre nne effet le 22 juille t 2021. 2021-062 du 3 septembre 2021, prévoit notamment cer-
taines mesures particulières applicables dans tout le
Québec, le 16 juillet 2021 territoire québécois;
Le ministre de la Sante et des Services sociaux, Vu que ce décret habilite également le ministre de la
CHRISTIAN D UBE Sante et des Services sociaux a ordonner toute modifica-
75647
Vu que le décret numéro 1200-2021 du 8 septembre
2021 habilite le ministre de la Santé et des Services
sociaux à prendre toute mesure prévue aux para-
graphes 1° à 8° du premier alinéa de l’article 123 de la
Loi sur la santé publique;
CoNSJDERANT QU ’il y a lieu d’ordonner certaines

AR02559
5326A GAZETTE OFFICIELLE DU QUÉBEC, 16 septembre 2021, 153e année, no 37A Partie 2
ARRETE CE QUI SUIT:
QUE l’annexe II du décret numéro 885-2021 du 23 juin

10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
31 août 2021 et 2021-062 du 3 septembre 2021, soit rem-
placée par la suivante :
« Annexe II – Régions sociosanitaires où le port du

masque de procédure est obligatoire en tout temps pour
les élèves de l’enseignement primaire ou secondaire de la
formation générale des jeunes
—Région sociosanitaire de la Mauricie et du

Centre-du-Québec;
—Région sociosanitaire de l’Estrie;
—Région sociosanitaire de Montréal;
—Région sociosanitaire de l’Outaouais;
—Région sociosanitaire de Chaudières-Appalaches,

mais uniquement pour les territoires des municipalités
régionales de comté des Appalaches, de Beauce-Sartigan
et des Etchemins;
—Région sociosanitaire de Laval;
—Région sociosanitaire de Lanaudière;
—Région sociosanitaire des Laurentides;
—Région sociosanitaire de la Montérégie. ».
Québec, le 9 septembre 2021
Le minis/re de la Sante et des Services sociaux,

CHRISTIAN DUBE
75636
AR02560
Ceci est la pièce « M » au soutien de


AR02561
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
5708A GAZETTE OFFICIELLE DU QUÉBEC, 30 septembre 2021, 153e année, no 39A Partie 2
Vu que la situation sur le territoire demeure preoccu- Vu que l'etat d'urgence sanitaire a toujours ete renou-
pante, !'agglomeration de Montreal a renouvele pour une vele depuis cette date par divers decrets, notarnment par
cent neuvieme fois, par la resolution numero CE21 1518 le decret numero 1251-2021 du 22 septembre 2021;
du lundi 23 aoOt 2021, la declaration d'etat d'urgence pour
une autre periode de cinq jours, se terminant le samedi Vu que le decret numero 885-2021 du 23 juin 2021 ,
28 aoOt 2021; modifie par les arretes numeros 2021-049 du ,., juillet
2021 , 202 1-050 du 2 juillet 2021, 2021-053 du 10 juillet
Vu que !'agglomeration de Montreal demande a la 2021, 2021- 055 du 30 juillet 2021, 2021 -057 du 4 aoGt
ministre de la Securite publique d'autoriser de nouveau 2021, 2021-058 du 13 aoOt 2021, 2021-059 du 18 aoGt
le renouvellement de l'etat d'urgence pour une periode 2021, 2021-060 du 24 aout 2021 , 202 1-061 du 31 aoOt
de cinq jours; 2021 , 2021-062 du 3 septembre 2021 et 2021- 063 du
9 septembre 2021, prevoit notamment certaines mesures
En consequence,j'autorise !' agglomeration de Montreal particulieres applicables dans tout le territoire quebecois;
a renouveler l' etat d'urgence local declare le vendredi
27 rnars 2020 pour une periode additionnelle de cinqjours, Vu que ce decret habilite egalement le ministre de la
se terminant le samedi 28 aoOt 2021. Sante et des Services sociaux a ordonner toute modifica-
tion ou toute precision relative aux mesures qu'i I prevoit;
Quebec, le 1cr septembre 2021
Vu que le decret numero 1251-2021 du 22 septembre
La ministre de la Sécurité publique, 2021 habilite le ministre de la Sante et des Services
GENEVIEVE GUILBAULT sociaux a prendre toute mesure prevue aux paragra-
phes 1° a 8° du premier alinea de !'article 123 de la
75720 Loi sur la sante publique;
CoNSIDERANT ou' il y a lieu d'o rdonner certaines

A.M., 2021 rnesures pour proteger la sante de la population;
Arrete numero 2021-065 du ministre de la Sante et ARRETE CE QUI SUIT:

des Services sociaux en date du 24 septembre 2021
QuE ('annexe 11 du decret numero 885-2021 du 23 juin
Loi sur la sante publique 2021, modifie par les arretes numeros 2021 - 049 du
(chapitre S-2.2) 1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053 du
10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057 du
CONCERNANT l'ordonnance de mesures visant ii 4 aoOt 202 1, 2021 - 058 du 13 aout 2021 , 2021- 059 du
proteger la sante de la population dans la situation de 18 aoftt 2021 , 2021- 060 du 24 aout 2021 , 2021-061 du
pandemie de la COVID-1 9 31 aoftt 2021 , 2021-062 du 3 septembre 2021 et 2021-063
du 9 septembre 2021 , soit remplacee par la suivante:
«Annexe II - Regions sociosanitaires ou le port du
Vu !'article 118 de la Loi sur la sante publique (chapitre masque de procedure est obligatoire en tout temps pour
S-2.2) qui prevoit que le gouvernement peut declarer un les eleves de l'enseignement primaire ou secondaire de la
etat d' urgence sanitaire dans tout ou partie du territoire formation genera le des jeunes
quebecois lorsqu' une menace grave a la sante de la popu-
lation, reelle ou irnm inente, exige !'application immediate - Region sociosanitai re de la Mauricie et du
de certaines mesures prevues a !'article 123 de cette loi Centre- du-Quebec;
-Region sociosanitaire de l'Estrie;
Vu le decret numero 177-2020 du 13 mars 2020 qui
declare l'etat d'urgence sanitaire dans tout le territoire - Region sociosanitaire de Montreal;
quebecois pour une periode de LO jours;
- Region sociosanitaire de l' Outaouais;
AR02562
- Region sociosanitaire de Chaudieres-Appalaches,

mais uniquement pour Jes territoires des municipa-
lites regionales de comte des Appalaches, de Beauce-
Sartignan, des Etchemins et de Robert-Cliche;
-Region sociosanitaire de Laval;
- Region sociosanitaire de Lanaudiere;
- Region sociosanitaire des Laurentides;
-Region sociosanitaire de la Monteregie.».
QUE Jes mesures prevues au present arrete prennent

effet le 28 septembre 2021.
Quebec, le 24 septembre 2021

CHRISTIAN D UBE
75722
AR02563
Ceci est la pièce « N » au soutien de


AR02564
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 7 octobre 2021, 153e année, no 40A 6095A
-
A.M., 2021
des Services sociaux en date du 1er octobre 2021

ARRETE CE QUI SUIT:
Qu’un technicien ambulancier visé à l’article 8 du

(chapitre S-2.2) Règlement sur les activités professionnelles pouvant être
exercées dans le cadre des services et soins préhospitaliers
CONCE R NANT l’ordonnance de mesures visant à d’urgence (chapitre M-9, r. 2.1) puisse exercer les activités
protéger la santé de la population dans la situation de prévues aux articles 7 et 9 de ce règlement au sein d’un
pandémie de la COVID-19 établissement public de santé et de services sociaux, sous
l'autorite du directeur des soins infirmiers;
LE MINISTRE DE LA SANTE ET DES SERVICES SOCJAUX,
Qu ’un technicien ambulancier en soins avancés visé
Vu l’article 118 de la Loi sur la santé publique (chapitre aux articles 10 ou 11 de ce règlement puisse exercer les
S-2.2) qui prévoit que le gouvernement peut déclarer un activités prévues aux articles 7, 9, 12 et 13 de ce règlement
état d’urgence sanitaire dans tout ou partie du territoire au sein d’un établissement public de santé et de services
québécois lorsqu’une menace grave à la santé de la popu- sociaux, sous l'autorite du directeur des soins infirmiers;
lation, réelle ou imminente, exige l’application immédiate
de certaines mesures prévues à l’article 123 de cette loi QUE le dispositif du décret numéro 885-2021 du
pour protéger la santé de la population; 23 juin 2021, modifie par les arretes numeros 2021-049
Vu le décret numéro 177-2020 du 13 mars 2020 qui du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
déclare l’état d’urgence sanitaire dans tout le territoire du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
québécois pour une période de 10 jours; 18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
Vu que l’état d’urgence sanitaire a toujours été renou- du 9 septembre 2021 et 2021-065 du 24 septembre 2021,
velé depuis cette date par divers décrets, notamment par soit de nouveau modi fie:
le décret numéro 1277-2021 du 29 septembre 2021;
1° par la suppression du sous-sous-paragraphe xii du
Vu que le décret numéro 885-2021 du 23 juin 2021, sous-paragraphe c du paragraphe 2° du troisième alinéa;
modif ié par les ar rêtés numéros 2021-049 du
1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053 du 2° par le remplacement du paragraphe 2° du neuvième
10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057 alinéa par le paragraphe suivant :
du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du « 2° qu’il s’agisse d’un élève de l’éducation préscolaire
31 août 2021, 2021-062 du 3 septembre 2021, 2021-063 dans un moyen de transport scolaire où il n’y a que des
du 9 septembre 2021 et 2021-065 du 24 septembre 2021, élèves de l’éducation préscolaire; »;
prévoit notamment certaines mesures particulières
applicables dans tout le territoire québécois; 3° dans le quatorzième alinéa :
Vu que ce décret habilite également le ministre de la a) par le remplacement du sous-paragraphe b du para-
Sante et des Services sociaux aordonner toute modifica- graphe 29° par les suivants :
« b) l’élève de l’enseignement primaire peut retirer son
Vu que le décret numéro 1277-2021 du 29 septem- masque de procédure pendant qu’il reçoit un soin, béné-
bre 2021 habilite le ministre de la Santé et des Services ficie d'un service ou pratique une activite qui necessite
sociaux à prendre toute mesure prévue aux paragraphes 1° de l’enlever, qu’il participe à une activité parascolaire,
à 8° du premier alinéa de l’article 123 de la Loi sur la à un programme de sport-études, d’art-études ou de
santé publique; concentration sportive ou à d’autres projets pédagogiques
AR02565
6096A GAZETTE OFFICIELLE DU QUÉBEC, 7 octobre 2021, 153e année, no 40A Partie 2
particuliers de même nature ou qu’il participe à un

cours d’éducation physique et, dans ce dernier cas,
qu’il maintient une distance de deux mètres avec les
autres élèves;
b.1) l’élève de l’enseignement secondaire peut retirer

son masque de procédure pendant qu’il reçoit un soin,
bénéficie d’un service ou pratique une activité qui
nécessite de l’enlever, qu’il participe à une activité para-
scolaire, à un programme de sport-études, d’art-études
ou de concentration sportive ou à d’autres projets
pédagogiques particuliers de même nature ou qu’il
participe à un cours d’éducation physique; »;
b) par l’ajout, après le paragraphe 29°, du suivant :
« 30° les septième, huitième et douzième alinéas

s’appliquent aux aires communes, incluant un ascenseur,
d’une résidence privée pour aînés située sur le territoire
de l’une des régions sociosanitaires prévues à l’Annexe II;
toutefois, le couvre-visage porté doit être un masque
de procédure; »;
4° par la suppression, dans le titre de l’Annexe II, de

« en tout temps pour les élèves de l’enseignement primaire
ou secondaire de la formation générale des jeunes »;
QUE les mesures prévues au paragraphe 2° et au

sous-paragraphe a du paragraphe 3° du troisième alinéa
prennent effet le 4 octobre 2021.
Québec, le 1er octobre 2021
le minis/re de la Sanle et des Services sociaux.

CHRISTIAN D U BE
75750
AR02566
Ceci est la pièce « O » au soutien de


AR02567
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
-
A.M., 2021
Arrêté 2021-067 du ministre de la Santé
et des Services sociaux en date du 8 octobre 2021

CONSIDERANT QU'il y a lieu d’ordonner certaines
ARRETE CE QUI SUIT:

(chapitre S-2.2) 23 juin 2021, modifie par les arretes numeros 2021-049
CONCERNANT l’ordonnance de mesures visant à du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
protéger la santé de la population dans la situation de du 4 août 2021, 2021-058 du 13 août 2021, 2021-059
pandémie de la COVID-19 du 18 août 2021, 2021-060 du 24 août 2021, 2021-061
du 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
LE MINISTRE DE LA SANTE ET DES SERVICES SOC IAUX, du 9 septembre 2021, 2021-065 du 24 septembre 2021 et
2021-066 du 1er octobre 2021, soit de nouveau mod ifie :
Vu l’article 118 de la Loi sur la santé publique (chapitre
S-2.2) qui prévoit que le gouvernement peut déclarer un 1° par l’ajout, à la fin du quatrième alinéa, des
état d’urgence sanitaire dans tout ou partie du territoire paragraphes suivants :
lation, réelle ou imminente, exige l’application immédiate « 10° pour les participants à un congrès ou à
de certaines mesures prévues à l’article 123 de cette loi une conférence;
11° pour les participants ou les personnes du public,
Vu le décret numéro 177-2020 du 13 mars 2020 qui lorsqu’ils sont assis à l’intérieur dans une assemblée,
déclare l’état d’urgence sanitaire dans tout le territoire une réunion, une cérémonie de reconnaissance ou de
québécois pour une période de 10 jours; graduation ou un autre événement de même nature, un
cinéma, une salle où sont présentés des arts de la scène,
Vu que l’état d’urgence sanitaire a toujours été renou- y compris un lieu de diffusion, pour une production, un
velé depuis cette date par divers décrets, notamment par tournage audiovisuel, un spectacle intérieur, ainsi que
le décret numéro 1293-2021 du 6 octobre 2021; lors d’un entraînement ou un évènement sportif inté-
rieur, mais uniquement lorsque l'organisateur verifie que
Vu que le décret numéro 885-2021 du 23 juin 2021, ces participants ou ces personnes du public, lorsqu’ils
modifie par les arretes numeros 2021-049 du 1er juillet sont âgés de 13 ans et plus, sont adéquatement protégés
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet contre la COVID-19, au sens du décret numéro 1173-2021
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août du 1er septembre 2021 et ses modifications subsequentes,
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août 2021, de la manière prévue à ce décret et sous réserves des
2021-060 du 24 août 2021, 2021-061 du 31 août 2021, exceptions qui y sont prévues;
2021-062 du 3 septembre 2021, 2021-063 du 9 septembre
2021, 2021-065 du 24 septembre 2021 et 2021-066 du 12° pour les participants ou les personnes du public,
1er octobre 2021, prévoit notamment certaines mesures lorsqu’ils sont assis à l’extérieur dans une assemblée,
particulières applicables dans tout le territoire québécois; une réunion, une cérémonie de reconnaissance ou de
graduation ou un autre événement de même nature, un
Vu que ce décret habilite également le ministre de la stade, un amphithéâtre extérieur, une agora ou dans une
Sante et des Services sociaux a ordonner toute modifica- autre infrastructure permanente du même type, mais
tion ou toute précision relative aux mesures qu’il prévoit; uniquement lorsque l'organisateur verifie que ces parti-
cipants ou ces personnes du public, lorsqu’ils sont âgés
Vu que le décret numéro 1293-2021 du 6 octobre 2021 de 13 ans et plus, sont adéquatement protégés contre la
habilite le ministre de la Santé et des Services sociaux COVID-19, au sens du décret numéro 1173-2021
à prendre toute mesure prévue aux paragraphes 1° du 1er septembre 2021 et ses modifications subsequentes,
à 8° du premier alinéa de l’article 123 de la Loi sur la de la manière prévue à ce décret et sous réserves des
santé publique; exceptions qui y sont prévues; »;
AR02568
2° dans le quatorzième alinéa : QUE le dispositif du décret numéro 1173-2021

du 1er septembre 2021, modi fie par le decret numero 1276-
a) par le remplacement du paragraphe 14° par 202 1 du 24 septembre 2021, soil de nouveau modi fie par
les suivants : l'ajout, a la fin du troisieme alinea, du paragraphe suivant:
« 14° dans les cinémas et les salles où sont présentés « 11° à une assemblée, une réunion, une cérémonie de
les arts de la scene, y compris les lieux de diffusion, pour reconnaissance ou de graduation ou d’un autre évènement
une production, un tournage audiovisuel, un spectacle de même nature auquel assistent plus de 250 personnes à
intérieur, ainsi que pour un entraînement ou un évènement l’intérieur ou plus de 500 personnes à l’extérieur; ».
sportif intérieur, toute personne du public demeure assise
à sa place; Québec, le 8 octobre 2021
14.1° lors d’une assemblée, d’une réunion, d’une céré- Le ministre de la Sante et des Services sociaux.
monie de reconnaissance ou de graduation ou d’un autre CHRISTIAN D UBE
évènement de même nature qui se déroule à l’intérieur,
tout participant demeure assis à sa place; »; 75775
b) par l’ajout, après le paragraphe 16.1°, du suivant :

A.M., 2021
« 16.2° le paragraphe 16° ne s’applique pas à un
événement extérieur qui se déroule dans un stade, un Arrêté 2021-068 du ministre de la Santé
amphithéâtre, une agora ou une autre infrastructure et des Services sociaux en date du 9 octobre 2021
permanente du même type lorsque les personnes du public
demeurent assises à leur place; »; Loi sur la santé publique
(chapitre S-2.2)
c) par l'ajout, a la fin du paragraphe 21°, du sous-
paragraphe suivant : CONCERNANT l’ordonnance de mesures visant à
protéger la santé de la population dans la situation de
« g) que, pour les chorales et les orchestres amateurs : pandémie de la COVID-19
i. elle soit pratiquée par un groupe d’au plus LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX,
100 personnes;
ii. qu’une distance de deux mètres soit maintenue : S-2.2) qui prévoit que le gouvernement peut déclarer un
état d’urgence sanitaire dans tout ou partie du territoire
I) entre les chanteurs entre eux et avec toute québécois lorsqu’une menace grave à la santé de la popu-
autre personne; lation, réelle ou imminente, exige l’application immédiate
de certaines mesures prévues à l’article 123 de cette loi
II) entre les instrumentistes à vent entre eux et avec pour protéger la santé de la population;
toute autre personne;
Vu le décret numéro 177-2020 du 13 mars 2020 qui
iii. que les musiciens, autres que les instrumentistes à déclare l’état d’urgence sanitaire dans tout le territoire
vent, portent un masque de procédure; »; québécois pour une période de 10 jours;
d) par la suppression du sous-paragraphe a du Vu que l’état d’urgence sanitaire a toujours été renou-
paragraphe 23°; velé depuis cette date par divers décrets, notamment par
le décret numéro 1293-2021 du 6 octobre 2021;
e) par le remplacement, dans le sous-paragraphe e
du paragraphe 26°, de « , à condition qu’un maximum Vu que le décret numéro 885-2021 du 23 juin 2021,
er
de 500 personnes y soient rassemblées et que cha- modifie par les arretes numeros 2021 -049 du juillet
cune demeure assise à une place déterminée » par 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
« à leur place »; 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
AR02569
Ceci est la pièce « P » au soutien de


AR02570
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
2° dans le quatorzième alinéa : QUE le dispositif du décret numéro 1173-2021

du 1er septembre 2021, modi fie par le decret numero 1276-
a) par le remplacement du paragraphe 14° par 202 1 du 24 septembre 2021, soil de nouveau modi fie par
les suivants : l'ajout, a la fin du troisieme alinea, du paragraphe suivant:
« 14° dans les cinémas et les salles où sont présentés « 11° à une assemblée, une réunion, une cérémonie de
les arts de la scene, y compris les lieux de diffusion, pour reconnaissance ou de graduation ou d’un autre évènement
une production, un tournage audiovisuel, un spectacle de même nature auquel assistent plus de 250 personnes à
intérieur, ainsi que pour un entraînement ou un évènement l’intérieur ou plus de 500 personnes à l’extérieur; ».
sportif intérieur, toute personne du public demeure assise
à sa place; Québec, le 8 octobre 2021
14.1° lors d’une assemblée, d’une réunion, d’une céré- Le ministre de la Sante et des Services sociaux.
monie de reconnaissance ou de graduation ou d’un autre CHRISTIAN DUBE
évènement de même nature qui se déroule à l’intérieur,
tout participant demeure assis à sa place; »; 75775
b) par l’ajout, après le paragraphe 16.1°, du suivant :
« 16.2° le paragraphe 16° ne s’applique pas à un

événement extérieur qui se déroule dans un stade, un
amphithéâtre, une agora ou une autre infrastructure
permanente du même type lorsque les personnes du public
demeurent assises à leur place; »;
-A.M., 2021

(chapitre S-2.2)
c) par l'ajout, a la fin du paragraphe 21°, du sous-
paragraphe suivant : CONCERNANT l’ordonnance de mesures visant à
« g) que, pour les chorales et les orchestres amateurs : pandémie de la COVID-19
i. elle soit pratiquée par un groupe d’au plus LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX,
100 personnes;
ii. qu’une distance de deux mètres soit maintenue : S-2.2) qui prévoit que le gouvernement peut déclarer un
I) entre les chanteurs entre eux et avec toute québécois lorsqu’une menace grave à la santé de la popu-
autre personne; lation, réelle ou imminente, exige l’application immédiate
II) entre les instrumentistes à vent entre eux et avec pour protéger la santé de la population;
iii. que les musiciens, autres que les instrumentistes à déclare l’état d’urgence sanitaire dans tout le territoire
vent, portent un masque de procédure; »; québécois pour une période de 10 jours;
d) par la suppression du sous-paragraphe a du Vu que l’état d’urgence sanitaire a toujours été renou-
paragraphe 23°; velé depuis cette date par divers décrets, notamment par
e) par le remplacement, dans le sous-paragraphe e
du paragraphe 26°, de « , à condition qu’un maximum Vu que le décret numéro 885-2021 du 23 juin 2021,
de 500 personnes y soient rassemblées et que cha- modifie par les arretes numeros 2021 -049 du er juillet
cune demeure assise à une place déterminée » par 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
« à leur place »; 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
AR02571
2021, 2021-062 du 3 septembre 2021, 2021-063 du 9 sep- QUE les mesures prévues au présent arrêté prennent
tembre 2021, 2021-065 du 24 septembre 2021, 2021-066 effet le 11 octobre 2021.
du 1er octobre 2021 et 2021-067 du 8 octobre 2021, prévoit
notamment certaines mesures particulières applicables Québec, le 9 octobre 2021
dans tout le territoire québécois;
Le ministre de la Sante et des Services sociaux,
Vu que ce décret habilite également le ministre de la CHRISTIAN DUBE
tion ou toute précision relative aux mesures qu’il prévoit; 75776
Vu que le décret numéro 1293-2021 du 6 octobre 2021

habilite le ministre de la Santé et des Services sociaux A.M., 2021
à 8° du premier alinéa de l’article 123 de la Loi sur la Arrêté 2021-069 du ministre de la Santé
santé publique; et des Services sociaux en date du 12 octobre 2021
CONSIDERANT Qu' il y a lieu d’ordonner certaines Loi sur la santé publique

mesures pour protéger la santé de la population; (chapitre S-2.2)
ARRETE CE QUI SUIT: (ONCERNANT l’ordonnance de mesures visant à

Q UE l’annexe II du décret numéro 885-2021 du pandémie de la COVID-19
23 juin 2021, modifie par les arretes numeros 2021-049
du 1er juillet 2021, 2021- 050 du 2 juillet 2021, LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX,
2021-057 du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 Vu l’article 118 de la Loi sur la santé publique (chapitre
du 18 août 2021, 2021-060 du 24 août 2021, 2021-061 S-2.2) qui prévoit que le gouvernement peut déclarer un
du 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063 état d’urgence sanitaire dans tout ou partie du territoire
du 9 septembre 2021, de 2021-065 du 24 septembre 2021, québécois lorsqu’une menace grave à la santé de la popu-
du 2021-066 du 1er octobre 2021 et 2021-067 du 8 octobre lation, réelle ou imminente, exige l’application immédiate
2021, soit remplacée par la suivante : de certaines mesures prévues à l’article 123 de cette loi
« Annexe II — Régions sociosanitaires où le port du
masque de procédure est obligatoire Vu le décret numéro 177-2020 du 13 mars 2020 qui
— Région sociosanitaire de la Mauricie et du québécois pour une période de 10 jours;
Centre-du-Québec;
Vu que l’état d’urgence sanitaire a toujours été renou-
— Région sociosanitaire de l’Estrie; velé depuis cette date par divers décrets, notamment par
— Région sociosanitaire de Montréal;
Vu que le décret numéro 885-2021 du 23 juin 2021,
— Région sociosanitaire de l’Outaouais; modifie par les arretes numeros 2021-049 du I er juillet
— Région sociosanitaire de Chaudières-Appalaches, 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
mais uniquement pour les territoires des municipalités 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
régionales de comté des Appalaches, de Beauce-Sartignan, 2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
de Bellechasse, des Etchemins, de la Nouvelle-Beauce et 2021, 2021-062 du 3 septembre 2021, 2021-063 du
de Robert-Cliche; 9 septembre 2021, 2021-065 du 24 septembre 2021,
2021-066 du 1er octobre 2021, 2021-067 du 8 octobre
— Région sociosanitaire de Laval; 2021 et 2021-068 du 9 octobre 2021, prévoit notamment
— Région sociosanitaire de Lanaudière; territoire québécois;
— Région sociosanitaire de la Montérégie. »;

AR02572
Ceci est la pièce « Q » au soutien de


AR02573
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
2021, 2021-062 du 3 septembre 2021, 2021-063 du 9 sep- QUE les mesures prévues au présent arrêté prennent
tembre 2021, 2021-065 du 24 septembre 2021, 2021-066 effet le 11 octobre 2021.
du 1er octobre 2021 et 2021-067 du 8 octobre 2021, prévoit
notamment certaines mesures particulières applicables Québec, le 9 octobre 2021

santé publique;
CONSIDERANT Qu' il y a lieu d’ordonner certaines

-A.M., 2021

mesures pour protéger la santé de la population; (chapitre S-2.2)
ARRETE CE QUI SUIT: (ONCERNANT l’ordonnance de mesures visant à

Q UE l’annexe II du décret numéro 885-2021 du pandémie de la COVID-19
du 1er juillet 2021, 2021- 050 du 2 juillet 2021, LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX,
2021-057 du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 Vu l’article 118 de la Loi sur la santé publique (chapitre
du 18 août 2021, 2021-060 du 24 août 2021, 2021-061 S-2.2) qui prévoit que le gouvernement peut déclarer un
du 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063 état d’urgence sanitaire dans tout ou partie du territoire
du 9 septembre 2021, de 2021-065 du 24 septembre 2021, québécois lorsqu’une menace grave à la santé de la popu-
du 2021-066 du 1er octobre 2021 et 2021-067 du 8 octobre lation, réelle ou imminente, exige l’application immédiate
2021, soit remplacée par la suivante : de certaines mesures prévues à l’article 123 de cette loi
« Annexe II — Régions sociosanitaires où le port du
masque de procédure est obligatoire Vu le décret numéro 177-2020 du 13 mars 2020 qui
— Région sociosanitaire de la Mauricie et du québécois pour une période de 10 jours;
Centre-du-Québec;
— Région sociosanitaire de l’Estrie; velé depuis cette date par divers décrets, notamment par
— Région sociosanitaire de l’Outaouais; modifie par les arretes numeros 2021-049 du I er juillet
— Région sociosanitaire de Chaudières-Appalaches, 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
régionales de comté des Appalaches, de Beauce-Sartignan, 2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
de Bellechasse, des Etchemins, de la Nouvelle-Beauce et 2021, 2021-062 du 3 septembre 2021, 2021-063 du
de Robert-Cliche; 9 septembre 2021, 2021-065 du 24 septembre 2021,
2021-066 du 1er octobre 2021, 2021-067 du 8 octobre
— Région sociosanitaire de Laval; 2021 et 2021-068 du 9 octobre 2021, prévoit notamment
— Région sociosanitaire de Lanaudière; territoire québécois;

AR02574
Vu que ce décret habilite également le ministre de la QuE le présent arrêté remplace l’arrêté numéro 2021-068
Sante et des Services sociaux a ordonner toute modifica- du 9 octobre 2021.
Québec, le 12 octobre 2021
habilite le ministre de la Santé et des Services sociaux Le ministre de la Sante et des Services sociaux,
à prendre toute mesure prévue aux paragraphes 1° CHRISTIAN DUBE
santé publique; 75781

ARRETE CE QUI SUIT:
QUE l’annexe II du décret numéro 885-2021 du 23 juin

du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
du 9 septembre 2021, de 2021-065 du 24 septembre 2021,
du 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre
2021 et 2021-068 du 9 octobre 2021, soit remplacée par
la suivante :

masque de procédure est obligatoire
— Région sociosanitaire de la Mauricie et du

Centre-du-Québec;
— Région sociosanitaire de l’Estrie;
— Région sociosanitaire de l’Outaouais;
— Région sociosanitaire de Chaudières-Appalaches,

régionales de comté des Appalaches, de Beauce-Sartignan,
de Bellechasse, des Etchemins, de la Nouvelle-Beauce et
de Robert-Cliche;
— Région sociosanitaire de Laval;
— Région sociosanitaire de Lanaudière;
— Région sociosanitaire des Laurentides;

AR02575
Ceci est la pièce « R » au soutien de


AR02576
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
-
A.M., 2021
des Services sociaux en date du 22 octobre 2021

ARRETE C E QUI SUIT:
Q UE l’Annexe I du décret numéro 885-2021 du 23 juin

(chapitre S-2.2) du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
CONCE RNAN T l’ordonnance de mesures visant à 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
protéger la santé de la population dans la situation du 9 septembre 2021, 2021-065 du 24 septembre 2021,
de pandémie de la COVID-19 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
2021-068 du 9 octobre 2021 et 2021-069 du 12 octobre
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, 2021, soit remplacée par :
Vu l’article 118 de la Loi sur la santé publique (chapitre « Annexe I – Établissement d’enseignement où
S-2.2) qui prévoit que le gouvernement peut déclarer un des mesures particulières s’appliquent
québécois lorsqu’une menace grave à la santé de la popu- — Collège l’Avenir de Rosemont inc. »;
de certaines mesures prévues à l’article 123 de cette loi Q UE les mesures prévues au présent arrêté prennent
pour protéger la santé de la population; effet le 25 octobre 2021.
Vu le décret numéro 177-2020 du 13 mars 2020 qui Québec, le 22 octobre 2021
québécois pour une période de 10 jours; Le minis/re de la Sante el des Services sociaux,
CHRISTIAN DUBE
velé depuis cette date par divers décrets, notamment par 75832

modifie par les arretes numeros 2021-049 du 1er juillet
A.M., 2021
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet Arrêté numéro 2021-074 du ministre de la Santé et
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août des Services sociaux en date du 25 octobre 2021
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
2021, 2021-060 du 24 août 2021, 2021-061 du 31 août 2021, Loi sur la santé publique
2021-062 du 3 septembre 2021, 2021-063 du 9 septem- (chapitre S-2.2)
bre 2021, 2021-065 du 24 septembre 2021, 2021-066 du
1er octobre 2021, 2021-067 du 8 octobre 2021, 2021-068 CONCERNANT l’ordonnance de mesures visant à
du 9 octobre 2021 et 2021-069 du 12 octobre 2021, prévoit protéger la santé de la population dans la situation
notamment certaines mesures particulières applicables de pandémie de la COVID-19
Sante et des Services sociaux aordonner toute modifica- Vu l’article 118 de la Loi sur la santé publique (chapitre
tion ou toute précision relative aux mesures qu’il prévoit; S-2.2) qui prévoit que le gouvernement peut déclarer un
CoNSIDERANT ou ’il y a lieu d’ordonner certaines québécois lorsqu’une menace grave à la santé de la popu-
mesures pour protéger la santé de la population; lation, réelle ou imminente, exige l’application immédiate
AR02577
Ceci est la pièce « S » au soutien de


AR02578
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
A.M., 2021 ARRETE C E QUI SUIT:
Arrêté numéro 2021-073 du ministre de la Santé et Q UE l’Annexe I du décret numéro 885-2021 du 23 juin
des Services sociaux en date du 22 octobre 2021 2021, modifié par les arrêtés numéros 2021-049 du
Loi sur la santé publique 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
(chapitre S-2.2) du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
CONCE RNAN T l’ordonnance de mesures visant à 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
protéger la santé de la population dans la situation du 9 septembre 2021, 2021-065 du 24 septembre 2021,
de pandémie de la COVID-19 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
2021-068 du 9 octobre 2021 et 2021-069 du 12 octobre
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, 2021, soit remplacée par :
Vu l’article 118 de la Loi sur la santé publique (chapitre « Annexe I – Établissement d’enseignement où
S-2.2) qui prévoit que le gouvernement peut déclarer un des mesures particulières s’appliquent
québécois lorsqu’une menace grave à la santé de la popu- — Collège l’Avenir de Rosemont inc. »;
de certaines mesures prévues à l’article 123 de cette loi Q UE les mesures prévues au présent arrêté prennent
pour protéger la santé de la population; effet le 25 octobre 2021.
Vu le décret numéro 177-2020 du 13 mars 2020 qui Québec, le 22 octobre 2021
québécois pour une période de 10 jours; Le minis/re de la Sante el des Services sociaux,
CHRISTIAN DUBE
velé depuis cette date par divers décrets, notamment par 75832
-

modifie par les arretes numeros 2021-049 du 1er juillet
A.M., 2021
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet Arrêté numéro 2021-074 du ministre de la Santé et
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août des Services sociaux en date du 25 octobre 2021
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
2021, 2021-060 du 24 août 2021, 2021-061 du 31 août 2021, Loi sur la santé publique
2021-062 du 3 septembre 2021, 2021-063 du 9 septem- (chapitre S-2.2)
bre 2021, 2021-065 du 24 septembre 2021, 2021-066 du
1er octobre 2021, 2021-067 du 8 octobre 2021, 2021-068 CONCERNANT l’ordonnance de mesures visant à
du 9 octobre 2021 et 2021-069 du 12 octobre 2021, prévoit protéger la santé de la population dans la situation
notamment certaines mesures particulières applicables de pandémie de la COVID-19
Sante et des Services sociaux aordonner toute modifica- Vu l’article 118 de la Loi sur la santé publique (chapitre
CoNSIDERANT ou ’il y a lieu d’ordonner certaines québécois lorsqu’une menace grave à la santé de la popu-
AR02579
Vu le décret numéro 177-2020 du 13 mars 2020 qui — Région sociosanitaire de l’Outaouais;

québécois pour une période de 10 jours; — Région sociosanitaire de Chaudières-Appalaches,
Vu que l’état d’urgence sanitaire a toujours été renou- régionales de comté des Appalaches, de Beauce-Sartignan,
velé depuis cette date par divers décrets, notamment par de Bellechasse, des Etchemins, de la Nouvelle-Beauce et
le décret numéro 1330-2021 du 20 octobre 2021; de Robert-Cliche;
Vu que le décret numéro 885-2021 du 23 juin 2021, — Région sociosanitaire de Laval;

modifie par Jes arretes numeros 2021 -049 du I er juillet
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet — Région sociosanitaire de Lanaudière;
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août — Région sociosanitaire des Laurentides;
2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
2021, 2021-062 du 3 septembre 2021, 2021-063 du — Région sociosanitaire de la Montérégie. »;
9 septembre 2021, 2021-065 du 24 septembre 2021,
2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021, QUE les mesures prévues au présent arrêté prennent
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre effet le 26 octobre 2021.
2021 et 2021-073 du 22 octobre 2021, prévoit notamment
certaines mesures particulières applicables dans tout le Québec, le 25 octobre 2021
Le ministre de la Sante e1 des Services sociaux.
CoNSJDERANT ou ’il y a lieu d’ordonner certaines

mesures pour protéger la santé de la population; A.M., 2021
A RRETE CE QUI SUIT : Arrêté numéro 2021-075 du ministre de la Santé
QUE l’Annexe II du décret numéro 885-2021 du
23 juin 2021 , modi fie par les arretes numeros 2021-049 Loi sur la santé publique
du 1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053 (chapitre S-2.2)
du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du CONCERNANT l’ordonnance de mesures visant à
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du protéger la santé de la population dans la situation de
31 août 2021, 2021-062 du 3 septembre 2021, 2021-063 pandémie de la COVID-19
du 9 septembre 2021, 2021-065 du 24 septembre 2021,
2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021, LE M INISTRE DE LA SANTE ET DES SERVICES SOCIAUX ,
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021
et 2021-073 du 22 octobre 2021, soit remplacée par : Vu l’article 118 de la Loi sur la santé publique (chapitre
« Annexe II – Régions sociosanitaires où le port état d’urgence sanitaire dans tout ou partie du territoire
du masque de procédure est obligatoire québécois lorsqu’une menace grave à la santé de la popu-
— Région sociosanitaire du Bas-Saint-Laurent, mais de certaines mesures prévues à l’article 123 de cette loi
uniquement pour le territoire de la municipalité régionale pour protéger la santé de la population;
de comté de La Matapédia;
— Région sociosanitaire de la Mauricie et du Centre- déclare l’état d’urgence sanitaire dans tout le territoire
du-Québec; québécois pour une période de 10 jours;
— Région sociosanitaire de l’Estrie; Vu que l’état d’urgence sanitaire a toujours été renou-
— Région sociosanitaire de Montréal; le décret numéro 1330-2021 du 20 octobre 2021;
AR02580
Ceci est la pièce « T » au soutien de


AR02581
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 4 novembre 2021, 153e année, no 44A 6697A
-
A.M., 2021

22 octobre 2021 et 2021-074 du 25 octobre 2021, prévoit

(chapitre S-2.2) tion ou toute précision relative aux mesures qu’il prévoit;
CONCERNANT l’ordonnance de mesures visant à Vu que l’arrêté numéro 2021-071 du 16 octobre 2021
protéger la santé de la population dans la situation de prévoit notamment le versement de certains montants for-
pandémie de la COVID-19 faitaires à certaines personnes salariées du réseau de la
santé et des services sociaux;
LE MINISTRE DE LA SANTE ET DES SERVICES SOC IAUX,
Vu que le décret numéro 1349-2021 du 27 octobre
Vu l’article 118 de la Loi sur la santé publique (chapitre 2021 habilite le ministre de la Santé et des Services
S-2.2) qui prévoit que le gouvernement peut déclarer un sociaux à prendre toute mesure prévue aux paragra-
état d’urgence sanitaire dans tout ou partie du territoire phes 1° à 8° du premier alinéa de l’article 123 de la
québécois lorsqu’une menace grave à la santé de la popu- Loi sur la santé publique;
de certaines mesures prévues à l’article 123 de cette loi CONSIDERANT QUE la situation actuelle de la pandémie
pour protéger la santé de la population; de la COVID-19 permet d’assouplir certaines mesures
Vu le décret numéro 177-2020 du 13 mars 2020 qui tout en maintenant certaines d’entre elles nécessaires pour
déclare l’état d’urgence sanitaire dans tout le territoire continuer de la protéger;
ARRETE CE QUI SUIT:
velé depuis cette date par divers décrets, notamment par QuE le dispositif du décret numéro 885-2021 du
le décret numéro 1349-2021 du 27 octobre 2021; 23 juin 2021 , modifie par Jes arretes numeros 2021-049
du 1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053 du
Vu que l’arrêté numéro 2020-099 du 3 décembre 2020, 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057 du
modifie par Jes arretes numeros 2021-005 du 28 janvier 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
2021, 2021-022 du 7 avril 2021, 2021-024 du 9 avril 18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
2021, 2021-027 du 16 avril 2021 et 2021-028 du 17 avril 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
2021, prévoit notamment l’autorisation, pour certaines du 9 septembre 2021, 2021-065 du 24 septembre 2021,
personnes, d'administrer un vaccin contre l'influenza 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
ou contre la COVID-19 ou de mélanger des substances 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021,
en vue de compléter la préparation d’un vaccin contre la 2021-073 du 22 octobre 2021 et 2021-074 du 25 octobre
COVID-19, à certaines conditions; 2021, soit de nouveau modi fie par:
Vu que le décret numéro 885-2021 du 23 juin 2021, 1° dans le quatorzième alinéa :
er
modifie par les arretes numeros 2021-049 du juillet
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet a) par le remplacement, dans le sous-sous-paragraphe
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août du sous paragraphe a du paragraphe 7°, de « de
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août 2021, deux mètres » par « d’un mètre »;
2021-060 du 24 août 2021, 2021-061 du 31 août 2021,
2021-062 du 3 septembre 2021, 2021-063 du 9 septembre b) par la suppression des sous-paragraphes a et b du
2021, 2021-065 du 24 septembre 2021, 2021-066 du paragraphe 10°;
1er octobre 2021, 2021-067 du 8 octobre 2021, 2021-068 du
9 octobre 2021, 2021-069 du 12 octobre 2021, 2021-073 du c) par la suppression du paragraphe 11°;
AR02582
6698A GAZETTE OFFICIELLE DU QUÉBEC, 4 novembre 2021, 153e année, no 44A Partie 2
d) par l’insertion, après le paragraphe 14.1°, du suivant : A.M. 2021

« 14.2° l’exception prévue au paragraphe 11° du Arrêté numéro 2021-078 du ministre de la Santé et
septième alinéa ne s’applique pas aux participants ou aux des Services sociaux en date du 2 novembre 2021
personnes du public visés aux paragraphes 14° et 14.1°
du présent alinéa; »; Loi sur la santé publique
(chapitre S-2.2)
e) par le remplacement du paragraphe 25° par
le suivant : CONCERNANT l’ordonnance de mesures visant à
« 25° un maximum de 50 personnes peuvent se trouver pandémie de la COVID-19
dans une salle louée ou une salle communautaire dans les
autres cas que ceux prévus aux paragraphes 22° à 24°, LE MINISTRE DE LA SANTE ET D ES SERV IC ES SOCIAUX ,
sauf :
a) lorsque la salle est utilisee aux fins des activites d' un S-2.2) qui prévoit que le gouvernement peut déclarer un
camp de vacances ou d’un camp de jour; état d’urgence sanitaire dans tout ou partie du territoire
b) à l’occasion d’une assemblée, d’un congrès, d’une lation, réelle ou imminente, exige l’application immédiate
réunion, d’une cérémonie de reconnaissance ou de de certaines mesures prévues à l’article 123 de cette loi
graduation ou d’un autre évènement de même nature; »; pour protéger la santé de la population;
QUE le dispositif de l’arrêté numéro 2020-099 du Vu le décret numéro 177-2020 du 13 mars 2020 qui
3 decembre 2020, modifie par les arretes numeros 202 1-005 déclare l’état d’urgence sanitaire dans tout le territoire
du 28 janvier 2021, 2021-022 du 7 avril 2021, 2021-024 du québécois pour une période de 10 jours;
9 avril 2021, 2021-027 du 16 avril 2021 et 2021-028 du
17 avril 2021, soit de nouveau modifiepar le remplace- Vu que l’état d’urgence sanitaire a toujours été renou-
ment, dans les cinquième et sixième alinéas, de « 6 ans » velé depuis cette date par divers décrets, notamment par
par « cinq ans »; le décret numéro 1349-2021 du 27 octobre 2021;
QUE le dispositif de l’arrêté numéro 2021-071 du Vu que le décret numéro 885-2021 du 23 juin 2021,
er
16 octobre 202 1 soit modifie: modifie par les a rretes numeros 2021-049 du juillet
1° par l’insertion, dans le vingt-cinquième alinéa, et 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
après « établissement privé non conventionné », de « ou 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
une maison de soins palliatifs au sens du paragraphe 2° 2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
de !'article 3 de la Loi concernant les soins de fin de vie 2021, 2021-062 du 3 septembre 2021, 2021-063 du
(chapitre S-32.0001) »; 9 septembre 2021, 2021-065 du 24 septembre 2021,
2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
2° par l’insertion, dans le vingt-sixième alinéa et après 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021,
« résidence privée pour aînés », de « ou une institution reli- 2021-073 du 22 octobre 2021, 2021-074 du 25 octobre
gieuse qui maintient une installation d’hébergement et de 2021 et 2021-077 du 29 octobre 2021, prévoit notamment
soins de longue durée pour y recevoir ses membres ou certaines mesures particulières applicables dans tout le
ses adhérents »; territoire québécois;
QUE les mesures prévues par le présent arrêté prennent Vu que ce décret habilite également le ministre de la
effet le Ier novembre 2021. Sante et des Services sociaux a ordonner toute modifica-
CON SIDERANT QU ’il y a lieu d’ordonner certaines
le ministre de la Sante et des Services sociaux, mesures pour protéger la santé de la population;
C HRIST IAN DUBE
75886
AR02583
Ceci est la pièce « U » au soutien de


AR02584
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
d) par l’insertion, après le paragraphe 14.1°, du suivant :
« 14.2° l’exception prévue au paragraphe 11° du

septième alinéa ne s’applique pas aux participants ou aux
personnes du public visés aux paragraphes 14° et 14.1°
du présent alinéa; »;
-A.M. 2021
des Services sociaux en date du 2 novembre 2021

(chapitre S-2.2)
e) par le remplacement du paragraphe 25° par
le suivant : CONCERNANT l’ordonnance de mesures visant à
« 25° un maximum de 50 personnes peuvent se trouver pandémie de la COVID-19
dans une salle louée ou une salle communautaire dans les
autres cas que ceux prévus aux paragraphes 22° à 24°, LE M I NISTRE DE LA SANTE ET D ES SERVIC ES SOCIAUX ,
sauf :
a) lorsque la salle est utilisee aux fins des activites d' un S-2.2) qui prévoit que le gouvernement peut déclarer un
camp de vacances ou d’un camp de jour; état d’urgence sanitaire dans tout ou partie du territoire
b) à l’occasion d’une assemblée, d’un congrès, d’une lation, réelle ou imminente, exige l’application immédiate
réunion, d’une cérémonie de reconnaissance ou de de certaines mesures prévues à l’article 123 de cette loi
graduation ou d’un autre évènement de même nature; »; pour protéger la santé de la population;
QUE le dispositif de l’arrêté numéro 2020-099 du Vu le décret numéro 177-2020 du 13 mars 2020 qui
3 decembre 2020, modifie par les arretes numeros 202 1-005 déclare l’état d’urgence sanitaire dans tout le territoire
du 28 janvier 2021, 2021-022 du 7 avril 2021, 2021-024 du québécois pour une période de 10 jours;
9 avril 2021, 2021-027 du 16 avril 2021 et 2021-028 du
17 avril 2021, soit de nouveau modifiepar le remplace- Vu que l’état d’urgence sanitaire a toujours été renou-
ment, dans les cinquième et sixième alinéas, de « 6 ans » velé depuis cette date par divers décrets, notamment par
par « cinq ans »; le décret numéro 1349-2021 du 27 octobre 2021;
QUE le dispositif de l’arrêté numéro 2021-071 du Vu que le décret numéro 885-2021 du 23 juin 2021,
er
16 octobre 202 1 soit modifie: modifie par les a rretes numeros 2021-049 du juillet
1° par l’insertion, dans le vingt-cinquième alinéa, et 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
après « établissement privé non conventionné », de « ou 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
une maison de soins palliatifs au sens du paragraphe 2° 2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
de !'article 3 de la Loi concernant les soins de fin de vie 2021, 2021-062 du 3 septembre 2021, 2021-063 du
(chapitre S-32.0001) »; 9 septembre 2021, 2021-065 du 24 septembre 2021,
2° par l’insertion, dans le vingt-sixième alinéa et après 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021,
« résidence privée pour aînés », de « ou une institution reli- 2021-073 du 22 octobre 2021, 2021-074 du 25 octobre
gieuse qui maintient une installation d’hébergement et de 2021 et 2021-077 du 29 octobre 2021, prévoit notamment
soins de longue durée pour y recevoir ses membres ou certaines mesures particulières applicables dans tout le
ses adhérents »; territoire québécois;
QUE les mesures prévues par le présent arrêté prennent Vu que ce décret habilite également le ministre de la
effet le Ier novembre 2021. Sante et des Services sociaux a ordonner toute modifica-
le ministre de la Sante et des Services sociaux, mesures pour protéger la santé de la population;
C H R IST IAN DUBE
75886
AR02585
ARRETE CE QUJ SUIT: — Région sociosanitaire des Laurentides;
QUE le dispositif du décret numéro 885-2021 du 23 juin — Région sociosanitaire de la Montérégie. »;

1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053 du Q U E les mesures prévues par le présent arrêté prennent
10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057 effet le 3 novembre 2021.
du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du Québec, le 2 novembre 2021
du 9 septembre 2021, 2021-065 du 24 septembre 2021, Le minis/re de la Sante et des Services sociaux,
2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021, CHRISTIAN DUBE
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021,
2021-073 du 22 octobre 2021, 2021-074 du 25 octobre 2021 75894
et 2021-077 du 29 octobre 2021, soit de nouveau modi fie:
1° par le remplacement du paragraphe 30° du quator-

zième alinéa par le suivant :
« 30° les septième, huitième et douzième alinéas

d’une résidence privée pour aînés située sur le territoire
de l’une des régions sociosanitaires prévues à l’Annexe
II, à l’exception de la région sociosanitaire de la Côte-
Nord; toutefois, le couvre-visage porté doit être un masque
de procédure; »;
2° par le remplacement de l’Annexe II par la suivante :

masque de procédure est obligatoire
— Région sociosanitaire du Bas-Saint-Laurent, mais

uniquement pour le territoire de la municipalité régionale
— Région sociosanitaire de la Mauricie et du

Centre-du-Québec;
— Région sociosanitaire de la Côte-Nord, mais uni-

quement pour le territoire de la Ville de Baie-Comeau;
— Région sociosanitaire de Chaudières-Appalaches,

régionales de comté des Appalaches, de Beauce-Sartigan,
de Bellechasse, des Etchemins, de la Nouvelle-Beauce et
de Robert-Cliche;
— Région sociosanitaire de Laval;

AR02586
Ceci est la pièce « V » au soutien de


AR02587
w W¼·¬»«® ±ºº·½·»´ ¼« Ï«7¾»½ô îðîï
-
A.M., 2021

Vu que ces décrets habilitent également le ministre
de la Santé et des Services sociaux à ordonner toute
modification ou toute précision relative aux mesures
qu’ils prévoient;
CONSIDERANT QUE la situation actuelle de la pandémie

(chapitre S-2.2) de la COVID-19 permet d’assouplir certaines mesures
CONCERNANT l’ordonnance de mesures visant à tout en maintenant certaines d’entre elles nécessaires pour
protéger la santé de la population dans la situation de continuer de la protéger;
ARRETE CE QUJ SUIT:
LE MI N ISTRE DE LA SANTE ET DES SERV ICES SOC IAUX,
Vu l’article 118 de la Loi sur la santé publique (chapitre 23 juin 202 1, modifie par les arretes numeros 202 1-049
S-2.2) qui prévoit que le gouvernement peut déclarer un du 1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053
état d’urgence sanitaire dans tout ou partie du territoire du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
québécois lorsqu’une menace grave à la santé de la popu- du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
lation, réelle ou imminente, exige l’application immédiate 18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
de certaines mesures prévues à l’article 123 de cette loi 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
pour protéger la santé de la population; du 9 septembre 2021, 2021-065 du 24 septembre 2021,
Vu le décret numéro 177-2020 du 13 mars 2020 qui 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021
déclare l’état d’urgence sanitaire dans tout le territoire 2021-069 du 12 octobre 2021, 2021-073 du 22 octobre 2021,
québécois pour une période de 10 jours; 2021-074 du 25 octobre 2021 2021-077 du 29 octobre 2021
et 202 1-078 du 2 novembre 202 1 soit de nouveau modifie:
velé depuis cette date par divers décrets, notamment par 1° par la suppression du deuxième alinéa;
le décret numéro 1415-2021 du 10 novembre 2021;
2° par le remplacement des paragraphes 10° à 12° du
Vu que le décret numéro 885-2021 du 23 juin 2021, quatrième alinéa par le paragraphe suivant :
er
modifie par les arretes numeros 202 1-049 du juillet
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet « 10° pour les participants à une activité ou les
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août personnes du public ayant accès à ce lieu, mais uniquement
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août lorsque l'organisateur ou l'exploitant du lieu verifie que
2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
ces participants ou personnes, lorsqu’ils sont âgés de
2021, 2021-062 du 3 septembre 2021, 2021-063 du
13 ans et plus, sont adéquatement protégés contre la
COVID-19, au sens du décret numéro 1173-2021 du
1er septembre 2021 et ses modifications subsequentes, de la
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021
manière prévue à ce décret et sous réserve des exceptions
2021-074 du 25 octobre 2021 2021-077 du 29 octobre 2021 et qui y sont prévues; »;
2021-078 du 2 novembre 2021, prévoit notamment
certaines mesures particulières applicables dans tout le 3° par la suppression du cinquième alinéa;
4° par le remplacement du paragraphe 11° du
Vu que le décret numéro 1173-2021 du 1er septembre septième alinéa par le suivant :
2021, modifié par le décret numéro 1276-2021 du
24 septembre 2021 et par l’arrêté 2021-067 du 8 octobre « 11° qu’elle pratique une activité de karaoké et qu’elle
2021, prévoit l’obligation d’être adéquatement protégé respecte l’une des conditions suivantes :
pour accéder à certains lieux ou pour participer à
certaines activités;
AR02588
a) une distance de deux mètres est maintenue avec les e) par la suppression, dans le paragraphe 12°, de
musiciens, les autres chanteurs et les spectateurs; « et au sous-paragraphe a du paragraphe 11° »;
b) elle est séparée par une barrière physique permettant j) par la suppression des paragraphes 14° à 16.2°, 18°
de limiter la contagion de toute personne qui n’est ni un et 19°;
occupant d’une même résidence privée ou de ce qui en
tient lieu, ni une personne qui lui fournit un service ou g) par le remplacement des paragraphes 20°, 21°
un soutien; »; et 21.1° par les suivants :
5° par la suppression du treizième alinéa; « 20° dans une salle d’entraînement physique, une
distance minimale de deux mètres doit être maintenue
6° dans le quatorzième alinéa : entre les personnes qui pratiquent une activité physique
nécessitant que le couvre-visage soit retiré;
a) par le remplacement des paragraphes 4° et 5° par
les suivants : 21° pour les chorales et les orchestres amateurs, les
conditions suivantes doivent être respectées :
« 4° lors d’une cérémonie funéraire, un roulement de
personnes est permis lors de l’exposition du corps ou des a) dans le cadre d’une activité extrascolaire, elle est
cendres et de la réception des condoléances, à condition pratiquée par un groupe d’au plus 100 personnes;
que le nombre de personnes présentes simultanément ne
dépasse jamais un maximum de 50 personnes; b) une distance de deux mètres est maintenue :
5° dans un bâtiment abritant un lieu de culte, un i. entre les chanteurs entre eux et avec toute autre
ministre du culte ou une personne qui agit comme personne, si les chanteurs ne portent pas de masque
bénévole dans un tel lieu peut retirer son couvre-visage de procédure;
lorsqu’il maintient une distance minimale d’un mètre avec
toute autre personne; »; ii. entre les instrumentistes à vent entre eux et avec
b) dans le paragraphe 7° :
c) les musiciens, autres que les instrumentistes à vent,
i. par la suppression du sous-paragraphe e; portent un masque de procédure; »;
ii. par le remplacement du sous-paragraphe f par h) par la suppression du paragraphe 23°;

le suivant :
i) par la suppression dans le paragraphe 24° de
«j) les clients peuvent se servir directement dans « évènementielle ou »;
un buffet ou un comptoir libre-service de couverts ou
d’aliments, mais uniquement lorsque l’exploitant du lieu j) par la suppression du paragraphe 25°;
verifie que ces clients, lorsqu'ils sont ages de 13 ans et
plus, sont adéquatement protégés contre la COVID-19, au k) par le remplacement du paragraphe 26° par
sens du décret numéro 1173-2021 du 1er septembre 2021 et le suivant :
ses modifications subsequentes, de la maniere prevue ace
décret et sous réserve des exceptions qui y sont prévues; »; « 26° il est interdit d’organiser un rassemblement de
plus de 50 personnes dans un lieu extérieur public dans le
c) par la suppression des paragraphes 8° et 9°; cadre d’un évènement de nature sociale, ou d’y participer,
sauf à l’occasion d’une cérémonie funéraire, de mariage,
d) par le remplacement du paragraphe 10° par de reconnaissance ou de graduation ou d’un autre évène-
le suivant : ment de même nature; »;
« 10° dans les pièces et terrasses visées par un permis 0 par la suppression du paragraphe 27°;
autorisant la vente ou le service de boissons alcooliques
pour consommation sur place, une distance de deux mètres m) dans le paragraphe 29° :
est maintenue avec le public lors de la présentation
de spectacles; »; i. par la suppression, dans ce qui précède le sous-
paragraphe a, de « ou secondaire »;
AR02589
ii. par la suppression dans le sous-paragraphe b de j) par l'ajout, a la fin, des paragraphes suivants:
« de l’enseignement primaire »;
« 12° à une activité de nature évènementielle;
iii. par la suppression du sous-paragraphe b.1;
13° à une activité, se déroulant dans une salle louée ou
n) par la suppression de l’annexe I; dans une salle communautaire, organisée dans le cadre
de la mission d’un organisme communautaire dont les
QuE le dispositif du décret numéro 1173-2021 du activités sont liées au secteur de la santé ou des services
1er septembre 2021, modifie par le decret numero 1276-2021 sociaux à laquelle participent plus de 250 personnes à
du 24 septembre 2021 et par l’arrêté numéro 2021-067 du l’intérieur ou plus de 500 personnes à l’extérieur;
8 octobre 2021 , soit de nouveau modi fie:
14° à une activité, se déroulant dans une salle louée
1° dans le troisième alinéa : ou dans une salle communautaire, nécessaire à la pour-
suite des activités, autres que de nature évènementielle
a) par le remplacement du paragraphe 1° par le suivant : ou sociale, s’inscrivant dans le cadre de l’exploitation
d’une entreprise ou de celles d’un établissement d’ensei-
« 1° à un évènement extérieur ouvert au public, à gnement, d’un tribunal, d’un arbitre, d’une association
l’exception d’un évènement se déroulant dans un ciné- de salariés, de professionnels, de cadres, de hors-cadre
pare ou un autre lieu utilise a des fins similaires; »; ou d’employeurs, d’un poste consulaire, d’une mission
diplomatique, d’un ministère ou d’un organisme public à
b) par la suppression, dans le paragraphe 2°, de « , à laquelle participent plus de 250 personnes à l’intérieur ou
l’exception d’un évènement ou d’un entraînement ama- plus de 500 personnes à l’extérieur;
teur auquel assistent un maximum de 25 personnes ou
un maximum de 250 personnes lorsqu’elles sont assises 15° à une cérémonie funéraire ou de mariage à laquelle
dans les gradins ou dans tout autre type d’aména- assistent plus de 250 personnes à l’intérieur ou plus de
gement permettant aux personnes de s’asseoir à des 500 personnes à l’extérieur;
places déterminées »;
16° à un lieu de culte dont l’assistance pour l’ensemble
c) par le remplacement, dans le paragraphe 5°, de « ou du bâtiment où il est situé est de plus de 250 personnes;
d’un commerce d’alimentation, incluant » par « , d’un
commerce d’alimentation, d’un chalet d’un centre d’activi- 17° à une cérémonie religieuse à l’extérieur à laquelle
tés sportives, d’un lieu intérieur ou d’un bâtiment adjacent assistent plus de 500 personnes; »;
d’un relais de motoneige ou de quad dans lesquels sont
offerts des repas pour consommation sur place, incluant 2° par l’insertion, après le troisième alinéa, du suivant :
leur cafétéria et leur salle multiusage et »;
« QUE , malgré l’alinéa précédent, ne soit pas tenue
d) dans le paragraphe 9° : d'etre adequatement protegee toute personne qui offre un
soutien ou un service à une personne pour la pratique
i. par le remplacement, dans ce qui précède le sous- d’une activité sportive, mais uniquement pendant qu’elle
paragraphe a, de « ou une activité physique » par « , une offre ce soutien ou ce service;»;
activité physique ou de loisir »;
QUE les mesures prévues au présent arrêté prennent
ii. par le remplacement du sous-paragraphe c par effet le 15 novem bre 2021.
les suivants :
Québec, le 14 novembre 2021
« C) pour participer à une activité de loisir extrascolaire;
Le ministre de fa Sante et des Services sociaux,
d) pour participer à un camp de vacances ou à un camp CHRISTIAN DUBE
de jour;
75956
e) pour accéder à une bibliothèque ou à un musée; »;
e) par l’insertion, après le paragraphe 10°, du suivant :
« 10.1° pour utiliser un remonte-pente ou une télécabine

d’une station de ski ou d’un centre de glisse; »;
AR02590
Ceci est la pièce « W » au soutien de


AR02591
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 16 décembre 2021, 153e année, no 50A 7333A
-
A.M., 2021
et des Services sociaux en date du 10 décembre 2021

Vu que le décret numéro 1510-2021 du 8 décembre
sociaux à prendre toute mesure prévue aux paragraphes 1°
santé publique;
(chapitre S-2.2) CONSID ERANT QU ’il y a lieu d’ordonner certaines
protéger la santé de la population dans la situation de ARRETE CE QUI SU IT:
pandemie de la COVID-1 9
QuE le dispositif du décret numéro 885-2021
LE MINISTRE DE LA SANTE ET DES SERV ICES SOC IAUX, du 23 juin 202 1, modifle par les arretes numeros 2021-049
Vu l’article 118 de la Loi sur la santé publique du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
(chapitre S-2.2) qui prévoit que le gouvernement peut du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
déclarer un état d’urgence sanitaire dans tout ou partie 18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
du territoire québécois lorsqu’une menace grave à la santé 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
de la population, réelle ou imminente, exige l’application du 9 septembre 2021, 2021-065 du 24 septembre 2021,
immédiate de certaines mesures prévues à l’article 123 de 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
cette loi pour protéger la santé de la population; 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021,
Vu le décret numéro 177-2020 du 13 mars 2020 qui 2021, 2021-077 du 29 octobre 2021, 2021-078 du
déclare l’état d’urgence sanitaire dans tout le territoire 2 novembre 2021 et 2021-079 du 14 novembre 2021, soit de
québécois pour une période de 10 jours; nouveau modifie:
Vu que l’état d’urgence sanitaire a toujours été renou- 1° par le remplacement, dans le paragraphe 30° du
velé depuis cette date par divers décrets, notamment par onzième alinéa, de « de la région sociosanitaire de la Côte-
le décret numéro 1510-2021 du 8 décembre 2021; Nord » par « des régions sociosanitaires de la Capitale-
Nationale et de la Côte-Nord »;
modifie par les arretes numeros 2021- 049 du 1er juillet 2° par le remplacement de l’Annexe II par la suivante :
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août « Annexe II – Régions sociosanitaires où le port du
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août masque de procédure est obligatoire
2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
2021, 2021-062 du 3 septembre 2021, 2021-063 du — Région sociosanitaire du Bas-Saint-Laurent, mais
9 septembre 2021, 2021-065 du 24 septembre 2021, uniquement pour le territoire de la municipalité régionale
2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021, de comté de La Matapédia;
2021-073 du 22 octobre 2021, 2021-074 du 25 octobre 2021, — Région sociosanitaire de la Capitale-Nationale,
2021-077 du 29 octobre 2021, 2021-078 du 2 novembre à l’exception des municipalités régionales de comté de
2021 et 2021-079 du 14 novembre 2021, prévoit notam- Charlevoix et de Charlevoix-Est;
ment certaines mesures particulières applicables dans tout
le territoire québécois; — Région sociosanitaire de la Mauricie et du
Centre-du-Québec;
Sante et des Services sociaux aordonner to ute modifica- — Région sociosanitaire de l’Estrie;
© Editeur officiel du Quebec 2021

AR02592
7334A GAZETTE OFFICIELLE DU QUÉBEC, 16 décembre 2021, 153e année, no 50A Partie 2
— Région sociosanitaire de l’Outaouais; Yu que ce décret prévoit que le ministre de la

Santé et des Services sociaux peut prendre toute autre
— Région sociosanitaire de la Côte-Nord, mais uni- mesure requise pour s’assurer que le réseau de la
quement pour le territoire de la Ville de Baie-Comeau; santé et des services sociaux dispose des ressources
humaines nécessaires;
— Région sociosanitaire de Chaudière-Appalaches,
mais uniquement pour les territoires des municipalités Yu que l’état d’urgence sanitaire a toujours été renou-
régionales de comté des Appalaches, de Beauce-Sartigan, velé depuis cette date par divers décrets, notamment par
de Bellechasse, des Etchemins, de la Nouvelle-Beauce et le décret numéro 1510-2021 du 8 décembre 2021;
de Robert-Cliche;
Vu que l’arrêté numéro 2021-071 du 16 octobre 2021
— Région sociosanitaire de Laval; prévoit notamment l’octroi de montants forfaitaires pour
certaines personnes salariées dont le titre d’emploi fait
— Région sociosanitaire de Lanaudière; partie de la categorie du personnel en soins infirmiers
et cardio-respiratoires, tel que prévu à la Nomenclature
— Région sociosanitaire des Laurentides; des titres d’emploi, des libellés, des taux et des échelles
de salaire du réseau de la santé et des services sociaux et
— Région sociosanitaire de la Montérégie. ». certains cadres;
Québec, le 10 décembre 2021 Yu que le décret numéro 1510-2021 du 8 décembre

Le ministre de la Sante et des Services sociaux, sociaux à prendre toute mesure prévue aux paragraphes 1°
CHRISTIAN D U BE à 8° du premier alinéa de l’article 123 de la Loi sur la
santé publique;
76113
CoNSIDERANT ou' il y a lieu d’ordonner certaines
A.M., 2021
ARRETE CE QUI SUIT:
et des Services sociaux en date du 13 décembre 2021 Qu'aux fins du present arrete, on entende par:
Loi sur la santé publique 1° « établissement » un établissement public ou privé
(chapitre S-2.2) conventionné au sens de la Loi sur les services de santé
et les services sociaux (chapitre S-4.2) ou de la Loi sur les
CONCERNANT l’ordonnance de mesures visant à services de santé et les services sociaux pour les autoch-
protéger la santé de la population dans la situation de tones cris (chapitre S-5);
pandemie de la COVID-19
2° « personne salariée » une personne salariée d’un éta-
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, blissement dont le titre d’emploi fait partie de la catégorie
du personnel en soins infirmiers et cardio-respiratoires,
Yu l’article 118 de la Loi sur la santé publique tel que prévu à la Nomenclature des titres d’emploi, des
(chapitre S-2.2) qui prévoit que le gouvernement peut libellés, des taux et des échelles de salaire du réseau de la
déclarer un état d’urgence sanitaire dans tout ou partie santé et des services sociaux, à l’exception des externes en
du territoire québécois lorsqu’une menace grave à la santé soins infirmiers et des externes en inhalotherapie;
de la population, réelle ou imminente, exige l’application
immédiate de certaines mesures prévues à l’article 123 de 3° « cadre » un cadre au sens de l’article 3 du
cette loi pour protéger la santé de la population; Règlement sur certaines conditions de travail applicables
aux cadres des agences et des établissements de santé et
Yu le décret numéro 177-2020 du 13 mars 2020 qui de services sociaux (chapitre S-4.2, r. 5.1) qui assume des
déclare l’état d’urgence sanitaire dans tout le territoire responsabilités hiérarchiques, fonctionnelles ou conseil
québécois pour une période de 10 jours; auprès des personnes salariées et qui appartient à l’un des
titres de familles d’emploi suivants :
© Editeur officiel du Quebec. 2021

AR02593
Ceci est la pièce « X » au soutien de


AR02594
– celles situées sur le territoire de la Côte-Nord, 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
s’étendant à l’est de Havre-St-Pierre, jusqu’à la limite du 2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
Labrador, y compris l’Île d’Anticosti; 2021, 2021-062 du 3 septembre 2021, 2021-063 du
— le secteur II, composé des localités suivantes : 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
– la municipalité de Fermont; 2021-073 du 22 octobre 2021, 2021-074 du 25 octobre
2021, 2021-077 du 29 octobre 2021, 2021-078 du
– celles situées sur le territoire de la Côte-Nord situé 2 novembre 2021, 2021-079 du 14 novembre 2021 et
à l’est de la Rivière Moisie et s’étendant jusqu’à Havre- 2021-083 du 10 décembre 2021, prévoit notamment
St-Pierre inclusivement; certaines mesures particulières applicables dans tout le
– celles des Îles-de-la-Madeleine.
Yu que ce décret habilite également le ministre de la
Québec, le 13 décembre 2021 Sante et des Services sociaux a ordonner toute modifica-
CHRISTIA N DUBE Yu que le décret numéro 1510-2021 du 8 décembre
76162 sociaux à prendre toute mesure prévue aux paragraphes 1°
-
santé publique;
A.M., 2021
CoNSIDERANT ou’il y a lieu d’ordonner certaines
Arrêté numéro 2021-086 du ministre de la Santé mesures pour protéger la santé de la population;
AR RETE C E QUI SUIT:
(chapitre S-2.2) Q UE le dispositif du décret numéro 885-2021 du
23 juin 2021, modifie par Jes arretes numeros 2021-049
CONCERNANT l’ordonnance de mesures visant à du 1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053
protéger la santé de la population dans la situation de du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
pandemie de la COVID-19 du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
Yu l’article 118 de la Loi sur la santé publique 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre
(chapitre S-2.2) qui prévoit que le gouvernement peut 2021, 2021-068 du 9 octobre 2021, 2021-069 du
déclarer un état d’urgence sanitaire dans tout ou partie 12 octobre 2021, 2021-073 du 22 octobre 2021,
du territoire québécois lorsqu’une menace grave à la santé 2021-074 du 25 octobre 2021, 2021-077 du 29 octobre
de la population, réelle ou imminente, exige l’application 2021, 2021-078 du 2 novembre 2021, 2021-079 du
immédiate de certaines mesures prévues à l’article 123 de 14 novembre 2021 et 2021-083 du 10 décembre 2021, soit
cette loi pour protéger la santé de la population; de nouveau modifie :
Vu le décret numéro 177-2020 du 13 mars 2020 qui 1° par l’insertion, dans le paragraphe 30° du onzième
déclare l’état d’urgence sanitaire dans tout le territoire alinéa et après « Côte-Nord » de « et des municipalités
québécois pour une période de 10 jours; régionales de comté de Lévis et Lotbinière pour la région
sociosanitaire de Chaudière-Appalaches »;
Yu que l’état d’urgence sanitaire a toujours été renou-
velé depuis cette date par divers décrets, notamment par 2° par le remplacement de l’Annexe II par la suivante :
le décret numéro 1510-2021 du 8 décembre 2021;
Yu que le décret numéro 885-2021 du 23 juin 2021, masque de procédure est obligatoire
modifie par les arrêtés numéros 2021-049 du 1er juillet
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet — Région sociosanitaire du Bas-Saint-Laurent, mais
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août uniquement pour le territoire de la municipalité régionale

AR02595
— Région sociosanitaire de la Capitale-Nationale, de la population, réelle ou imminente, exige l’application

à l’exception des municipalités régionales de comté de immédiate de certaines mesures prévues à l’article 123 de
Charlevoix et de Charlevoix-Est; cette loi pour protéger la santé de la population;
— Région sociosanitaire de la Mauricie et du Centre- Vu le décret numéro 177-2020 du 13 mars 2020 qui
du-Québec; déclare l’état d’urgence sanitaire dans tout le territoire
— Région sociosanitaire de Montréal; velé depuis cette date par divers décrets, notamment par
— Région sociosanitaire de la Côte-Nord, mais uni- modifie par les arretes numeros 202 1-049 du I er juillet
quement pour le territoire de la Ville de Baie-Comeau; 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
— Région sociosanitaire de Chaudière-Appalaches, 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
régionales de comté des Appalaches, de Beauce-Sartigan, 2021, 2021-062 du 3 septembre 2021, 2021-063 du
de Bellechasse, des Etchemins, de Lévis, de Lotbinière, 9 septembre 2021, 2021-065 du 24 septembre 2021,
de la Nouvelle-Beauce et de Robert-Cliche; 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
— Région sociosanitaire de Laval; 2021, 2021-073 du 22 octobre 2021, 2021-074 du
25 octobre 2021, 2021-077 du 29 octobre 2021, 2021-078
— Région sociosanitaire de Lanaudière; du 2 novembre 2021, 2021-079 du 14 novembre 2021,
2021-083 du 10 décembre 2021 et 2021-086 du
— Région sociosanitaire des Laurentides; 13 décembre 2021, prévoit notamment certaines mesures
particulières applicables dans tout le territoire québécois;
— Région sociosanitaire de la Montérégie. ».
Québec, le 13 décembre 2021 Sante et des Services sociaux a ordo nner toute modifica-
C HRISTI AN D U BE Vu que le décret numéro 1510-2021 du 8 décembre
santé publique;
A.M., 2021
CONSIDERANT QU’il y a lieu d’ordonner certaines
ARRETE CE QUI SUIT:
(chapitre S-2.2) QUE le dispositif du décret numéro 885-2021 du
23 juin 202 1, modifie par les arretes numeros 2021-049
pandemie de la COY ID-19 du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
LE MI N ISTRE DE LA SANTE ET DES SE RVICES SOCIAUX, 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
Yu l’article 118 de la Loi sur la santé publique 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
(chapitre S-2.2) qui prévoit que le gouvernement peut 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre
déclarer un état d’urgence sanitaire dans tout ou partie 2021, 2021-073 du 22 octobre 2021, 2021-074 du
du territoire québécois lorsqu’une menace grave à la santé 25 octobre 2021, 2021-077 du 29 octobre 2021, 2021-078
© Ed iteur officiel du Quebec. 2021

AR02596
Ceci est la pièce « Y » au soutien de


AR02597
— Région sociosanitaire de la Capitale-Nationale, de la population, réelle ou imminente, exige l’application

à l’exception des municipalités régionales de comté de immédiate de certaines mesures prévues à l’article 123 de
Charlevoix et de Charlevoix-Est; cette loi pour protéger la santé de la population;
— Région sociosanitaire de la Mauricie et du Centre- Vu le décret numéro 177-2020 du 13 mars 2020 qui
du-Québec; déclare l’état d’urgence sanitaire dans tout le territoire
— Région sociosanitaire de Montréal; velé depuis cette date par divers décrets, notamment par
— Région sociosanitaire de la Côte-Nord, mais uni- modifie par les arretes numeros 2021-049 du I er juillet
quement pour le territoire de la Ville de Baie-Comeau; 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
— Région sociosanitaire de Chaudière-Appalaches, 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
régionales de comté des Appalaches, de Beauce-Sartigan, 2021, 2021-062 du 3 septembre 2021, 2021-063 du
de Bellechasse, des Etchemins, de Lévis, de Lotbinière, 9 septembre 2021, 2021-065 du 24 septembre 2021,
de la Nouvelle-Beauce et de Robert-Cliche; 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
— Région sociosanitaire de Laval; 2021, 2021-073 du 22 octobre 2021, 2021-074 du
— Région sociosanitaire de Lanaudière; du 2 novembre 2021, 2021-079 du 14 novembre 2021,
2021-083 du 10 décembre 2021 et 2021-086 du
— Région sociosanitaire des Laurentides; 13 décembre 2021, prévoit notamment certaines mesures
— Région sociosanitaire de la Montérégie. ».
Québec, le 13 décembre 2021 Sante et des Services sociaux a ordonner toute modifica-
CHRISTIAN DUBE Vu que le décret numéro 1510-2021 du 8 décembre
-
santé publique;
A.M., 2021
ARRETE CE QUI SUIT:
(chapitre S-2.2) QUE le dispositif du décret numéro 885-2021 du
pandemie de la COYID-19 du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
Yu l’article 118 de la Loi sur la santé publique 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
(chapitre S-2.2) qui prévoit que le gouvernement peut 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre
déclarer un état d’urgence sanitaire dans tout ou partie 2021, 2021-073 du 22 octobre 2021, 2021-074 du
du territoire québécois lorsqu’une menace grave à la santé 25 octobre 2021, 2021-077 du 29 octobre 2021, 2021-078
© Ed iteur officiel du Quebec. 2021

AR02598
du 2 novembre 2021, 2021-079 du 14 novembre 2021,

2021-083 du 10 décembre 2021 et 2021-086 du
13 decembre 202 1, soit de nouveau modifie par le rem -
placement du paragraphe 30° du onzième alinéa par
le suivant :
« 30° les cinquième, sixième et dixième alinéas

d’une résidence privée pour aînés, sauf sur les territoires
des régions sociosanitaires du Nunavik et des Terres-Cries-
de-la-Baie-James; toutefois, le couvre-visage porté doit
être un masque de procédure; ».
Québec, le 14 décembre 2021
le ministre de la San/e et des Services sociaux,

C HRISTI AN DUBE
76172

AR02599
Ceci est la pièce « Z » au soutien de


AR02600
-
A.M., 2021
des Services sociaux en date du 19 décembre 2021

Yu que ces décrets habilitent également le ministre
de la Santé et des Services sociaux à ordonner toute
qu’ils prévoient;
Yu que le décret numéro 1540-2021 du 15 décembre

(chapitre S-2.2) 2021 habilite le ministre de la Santé et des Services
sociaux à prendre toute mesure prévue aux paragra-
CONCERNANT l’ordonnance de mesures visant à phes 1° à 8° du premier alinéa de l’article 123 de la
protéger la santé de la population dans la situation de Loi sur la santé publique;
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, mesures pour protéger la santé de la population;
Yu l’article 118 de la Loi sur la santé publique (chapitre ARRETE CE QUI SUIT:
état d’urgence sanitaire dans tout ou partie du territoire QU E le dispositif du décret numéro 885-2021 du
québécois lorsqu’une menace grave à la santé de la popu- 23 juin 2021, modifie par les arretes numeros 2021-049
lation, réelle ou imminente, exige l’application immédiate du 1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053 du
de certaines mesures prévues à l’article 123 de cette loi 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057 du
pour protéger la santé de la population; 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
Yu le décret numéro 177-2020 du 13 mars 2020 qui 31 août 2021, 2021-062 du 3 septembre 2021, 2021-063
déclare l’état d’urgence sanitaire dans tout le territoire du 9 septembre 2021, 2021-065 du 24 septembre 2021,
québécois pour une période de 10 jours; 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
Yu que l’état d’urgence sanitaire a toujours été renou- 2021-073 du 22 octobre 2021, 2021-074 du 25 octobre
velé depuis cette date par divers décrets, notamment par 2021, 2021-077 du 29 octobre 2021, 2021-078 du
le décret numéro 1540-2021 du 15 décembre 2021; 2 novembre 2021, 2021-079 du 14 novembre 2021,
2021-083 du 10 décembre 2021, 2021-086 du 13 décembre
Vu que le décret numéro 885-2021 du 23 juin 2021, 2021 et 2021-087 du 14 décembre 2021, soit de nouveau
er
modifie par les arretes numeros 2021-049 du juillet modifie:
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août 1° par l’ajout, à la fin du paragraphe 2° du
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août 2021, deuxième alinéa, du sous-paragraphe suivant :
2021-060 du 24 août 2021, 2021-061 du 31 août 2021,
2021-062 du 3 septembre 2021, 2021-063 du 9 septembre « d) « surface de vente » la superficie totale reservee a
2021, 2021-065 du 24 septembre 2021, 2021-066 du la vente, à des services connexes à la vente et au public
1er octobre 2021, 2021-067 du 8 octobre 2021, 2021-068 du pour avoir accès aux produits et aux services, incluant
9 octobre 2021, 2021-069 du 12 octobre 2021, 2021-073 les zones de circulation, les zones de paiement et, le cas
du 22 octobre 2021, 2021-074 du 25 octobre 2021, échéant, les aires de préparation des aliments lorsque la
2021-077 du 29 octobre 2021, 2021-078 du 2 novembre personne qui y est affectee est aussi chargee de servir
2021, 2021-079 du 14 novembre 2021, 2021-083 du les clients; »;
10 décembre 2021, 2021-086 du 13 décembre 2021 et
2021-087 du 14 décembre 2021, prévoit notamment 2° par le remplacement, dans le paragraphe 3° du
certaines mesures particulières applicables dans tout le troisième alinéa, de « dans une résidence de tourisme ou
territoire québécois; dans un établissement de résidence principale » par « dans
une unité d’hébergement ou dans un dortoir d’un établis-
Vu que le décret numéro 1173-2021 du 1er septembre sement d’hébergement touristique »;
24 septembre 2021 et par les arrêtés 2021-067 du 8 octobre 3° par la suppression des paragraphes 3° et 11° du
2021, 2021-079 et 2021-081 du 14 novembre 2021 et cinquième alinéa;
2021-082 du 17 novembre 2021, prévoit l’obligation d’être
adéquatement protégé pour accéder à certains lieux ou
pour participer à certaines activités;

AR02601
4° dans le onzième alinéa : « 10° dans les pièces et terrasses visées par un permis
autorisant la vente ou le service de boissons alcooliques
a) par le remplacement du paragraphe 5° par le suivant : pour consommation sur place :
« 5° dans un bâtiment abritant un lieu de culte : a) la pratique de la danse est interdite;
a) l’assistance maximale pour l’ensemble de ce b) une distance de deux mètres est maintenue avec le
a 50 % de sa capacite habituelle, sans
batiment est fixe public lors de la présentation de spectacles;
dépasser un maximum de 250 personnes;
c) le titulaire de permis ne peut admettre simultané-
b) un ministre du culte ou une personne qui agit ment, dans chaque pièce et sur chaque terrasse de l’éta-
comme bénévole dans un tel lieu peut retirer son couvre- blissement où est exploité le permis, qu’un maximum de
visage lorsqu’il maintient une distance minimale de 50% du nombre de personnes pouvant y etre admises en
deux mètres avec toute autre personne; vertu de ce permis, ou y tolérer un nombre de personnes
supérieur à ce maximum;
c) les personnes qui s’y trouvent demeurent à leur place
et ne circulent pas; »; 11° sauf dans une résidence privée ou ce qui en tient
lieu, incluant le terrain, le balcon ou la terrasse d’une
b) dans le paragraphe 7° : telle résidence, il est interdit à quiconque d’organiser ou
de participer à une activité de karaoké; »;
i. par l’insertion, dans ce qui précède le sous-
paragraphe a et après « restaurant, », de « un chalet d’un d) par l’insertion, après le paragraphe 13°, du suivant :
centre d’activités sportives, un lieu intérieur ou un bâti-
ment adjacent d’un relais de motoneige ou de quad, »; « 14° dans les cinémas et les salles où sont présentés
les arts de la scene, y compris les lieux de diffusion, pour
ii. dans le sous-paragraphe a : une production, un tournage audiovisuel, un spectacle
intérieur, ainsi que pour un entraînement ou un événement
I) par le remplacement du sous-sous-paragraphe i par sportif intérieur :
le suivant :
a) l’assistance maximale de chaque salle est fixée
« i. les lieux sont aménagés en espaçant les tables au a 50% de sa capacite habituelle, a moins qu'il s'agisse
maximum, en autant qu’une distance minimale d’un mètre d’élèves de l’éducation préscolaire ou de l’enseignement
soit maintenue entre elles, à moins qu’une barrière phy- primaire ou secondaire de la formation générale des jeunes
sique permettant de limiter la contagion ne les sépare; »; d' une meme ecole, lorsqu' ils beneficient de tout service
offert par un centre de services scolaire, une corn mission
II) par l’ajout, à la fin, du sous-sous-paragraphe scolaire ou un établissement d’enseignement privé ou des
suivant : enfants d’un camp de vacances ou d’un camp de jour et des
personnes qui accompagnent ces élèves ou ces enfants;
« iii. la capacite du lieu est fi xee a 50% de sa capa-
cité habituelle; »; b) la distance d’une place doit être laissée libre entre
chaque personne, à moins :
iii. par le remplacement du sous-paragraphe f par
les suivants : i. qu’il s’agisse d’occupants d’une même résidence
privée ou de ce qui en tient lieu;
« e) seules les personnes assises à une table peuvent
recevoir un service ou consommer des boissons; ii. que l’une des personnes reçoive d’une autre per-
sonne un service ou son soutien;
J) les clients ne peuvent se servir directement dans
un buffet ou un comptoir libre-service de couverts iii. qu’il s’agisse d’élèves de l’éducation préscolaire
ou d’aliments; »; ou de l’enseignement primaire ou secondaire de la for-
mation générale des jeunes d’une même école, lorsqu’ils
c) par le remplacement du paragraphe 10° par beneficient de tout service offert par un centre de ser-
les suivants : vices scolaire, une commission scolaire ou un établisse-
ment d’enseignement privé ou des enfants d’un camp de
vacances ou d’un camp de jour;

AR02602
c) toute personne du public demeure assise à sa place; iii. les personnes, à l’exception des spectateurs, qui
se trouvent à l’extérieur de l’aire dédiée au jeu doivent
d) le couvre-visage porté par le public doit être un maintenir entre eux une distance minimale de deux mètres
masque de procédure; »; en tout temps;
e) par le remplacement des paragraphes 20° et 21° par 1v. la capacite de tout vestiaire est fixee a 50% de sa
les suivants : capacité habituelle;
« 18° la capacite d' un spa ou d'un sauna, est fixee a b) elle s’inscrit dans le cadre des services éducatifs
50 % de sa capacite habituelle; offerts aux eleves de la formation genera le des jeunes;
19° dans une salle d’entraînement physique : c) elle fait partie de l'offre des programmes de sport-
études, d’art-études et de concentration sportive et autres
a) la capacité maximale de la salle est fixée à un projets pédagogiques particuliers de même nature dispen-
maximum de 50% de sa capacite habituelle; sés dans le cadre des services éducatifs de la formation
générale des jeunes par un centre de services scolaire,
b) une distance minimale de deux mètres doit une commission scolaire ou un établissement d’enseigne-
être maintenue entre les personnes qui pratiquent une ment privé;
activité physique;
d) elle fait partie de l'offre d' un camp de vacances ou
20° toute compétition, tout tournoi ou tout autre événe- d’un camp de jour;
ment de même nature organisé pour la pratique d’activités
de loisir ou de sport est suspendu à moins qu’il soit orga- e) elle fait partie de l'offre de formation en matiere de
nise a l'exterieur ou qu'il constitue un processus qualifiant loisir et de sport dans les programmes d’enseignement de
pour les Jeux olympiques ou paralympiques et les cham- niveau collégial ou universitaire;
pionnats du monde et que les conditions suivantes soient
respectées par les athlètes et le personnel d’encadrement : j) il s’agit d’un sport professionnel ou de haut niveau
dont l’entraînement ou la pratique exige un nombre de
a) un environnement protégé est mis en place, lequel personnes supérieur à celui prévu par le sous-paragraphe a
permet de limiter les risques de transmission entre les et les conditions suivantes sont respectées par les athlètes
athlètes et le personnel d’encadrement et le reste de la popu- et le personnel d’encadrement :
lation, conformément à un protocole sanitaire approuvé
par le ministre de la Santé et des Services sociaux; i. un environnement protégé est mis en place, lequel
permet de limiter les risques de transmission entre les
b) le protocole sanitaire approuvé par le ministre de la athlètes et le personnel d’encadrement et le reste de la popu-
Santé et des Services sociaux est respecté en tout temps, lation, conformément à un protocole sanitaire approuvé
autant avant, pendant et après l’intégration dans l’envi- par le ministre de la Santé et des Services sociaux;
ii. le protocole sanitaire approuvé par le ministre de la
c) capacite de tout vestiai re est fi xee a 50 % de sa capa- Santé et des Services sociaux est respecté en tout temps,
cité habituelle; autant avant, pendant et après l’intégration dans l’envi-
21° toute activité intérieure de loisir ou de sport est
suspendue, sauf dans les cas suivants : 111. la capacite de tout vestiaire est fixee a 50 % de sa
capacité habituelle;
a) elle est pratiquée, avec ou sans encadrement, seul
ou en groupes d’au plus 25 personnes, sous réserve que g) pour les chorales et les orchestres amateurs, les
les conditions suivantes soient respectées : conditions suivantes sont respectées :
i. les groupes demeurent séparés, le cas échéant; i. dans le cadre d’une activité extrascolaire, elle est
pratiquée par un groupe d’au plus 100 personnes;
ii. dans les sports d’équipe, seules les personnes pré-
sentes dans l’aire dédiée au jeu sont prises en compte dans ii. une distance de deux mètres est maintenue :
la détermination du nombre maximal de personnes;

AR02603
I) entre les chanteurs entre eux et avec toute autre 23.1° la capacité d’une salle utilisée pour un congrès
personne, si les chanteurs ne portent pas de masque est fixee a 50% de sa capacite habituelle;
de procédure;
24° un maximum de 25 personnes peuvent se trouver
II) entre les instrumentistes à vent entre eux et avec dans tout lieu intérieur, autre qu’une résidence privée ou
toute autre personne; ce qui en tient lieu, lorsqu'il est utilise aux fins d'une
réception de mariage ou de funérailles;
iii. les musiciens, autres que les instrumentistes à vent,
portent un masque de procédure; 25° un maximum de 10 personnes ou les occupants
d’un maximum de trois résidences privées ou de ce qui en
21.1° l’achalandage maximal de tout établissement tient lieu peuvent se trouver dans tout lieu intérieur, autre
commercial de vente au détail visé par la Loi sur les qu’une résidence privée ou ce qui en tient lieu, lorsqu’il est
heures et les jours d’admission dans les établissements utilise aux fins d' y tenir une activite de nature sociale qui
commerciaux (chapitre H-2.1) est fixe a un client par n’est pas autrement visée par le présent alinéa; »;
20 mètres carrés de surface de vente ou à un client si
un tel établissement a une surface de vente moindre que h) dans le paragraphe 29° :
20 mètres carrés;
i. par le remplacement de ce qui précède le sous-
21.2° l’achalandage maximal de tout centre commer- paragraphe a, par ce qui suit :
cial est fixe aun client par 20 metres carres de sa superficie
accessible à la clientèle; « les élèves de l’enseignement primaire et secondaire de
la formation générale des jeunes qui se trouvent dans tout
21.3° malgré les paragraphes 21.1° et 21.2°, le présent bâtiment ou local utilisé par un centre de services scolaire,
decret n'a pas pour effet d'empecher un client d'entrer une commission scolaire ou un établissement d’enseigne-
accompagné d’enfants mineurs ou de toute autre personne ment privé doivent porter en tout temps un masque de
qui nécessite ou à qui il procure assistance dans un éta- procédure, sous réserve des exceptions suivantes : »;
blissement dont l’achalandage maximal ne permettrait pas
à ces personnes d’entrer en l’absence d’autres clients; »; ii. par le remplacement dans le sous-paragraphe e de
« paragraphe » par « sous-paragraphe »;
j) par le remplacement, dans le paragraphe 22° de « au
dix-huitième alinéa » par « aux paragraphes 21.1° à 21.3° »; 5° par l'ajout, a la fin du douzieme alinea, du para-
graphe suivant :
g) par le remplacement du paragraphe 24° par
les suivants : « 3° de tolérer dans tout lieu dont il a le contrôle ou
dans toute file d'attente formee pour y acceder toute per-
« 23° la capacité d’une salle louée ou d’une salle sonne ne respectant pas les règles de distanciation prévues
communautaire mise à la disposition de quiconque est au présent décret; »;
fixee a 50 % de la capacite habituelle de la salle, sans
dépasser un maximum de 250 personnes, dans l’une des 6° par le remplacement du treizième alinéa par
situations suivantes : les suivants :
a) à l’occasion d’une assemblée, d’une réunion, d’une « QUE l’exploitant d’un centre commercial ou d’un com-
cérémonie funéraire, de mariage, de reconnaissance ou merce de vente au détail, ainsi que l’organisateur d’un
de graduation ou d’un autre événement de même nature, salon regroupant plusieurs exposants ou commerces de
auquel les participants assistent en demeurant assis; vente au détail soient tenus :
b) aux fins d'une activite organisee necessaire a la 1° de prendre les mesures nécessaires pour assurer,
poursuite des activités, autres que de nature événemen- en tout temps, dans son établissement, son centre ou son
tielle ou sociale, s’inscrivant dans le cadre de l’exploitation salon et dans toute file d'attente formee pour y acceder,
d’une entreprise ou de celles d’un établissement d’ensei- le contrôle de l’achalandage de manière à ce que les
gnement, d’un tribunal, d’un arbitre, d’une association règles de distanciation prévues au présent décret puissent
de salariés, de professionnels, de cadres, de hors-cadre être respectées;
ou d’employeurs, d’un poste consulaire, d’une mission
diplomatique, d’un ministère ou d’un organisme public;

AR02604
2° d'afficher, a chaque entree de son etablissement, 2° par le remplacement, dans le dix-huitième alinéa
de son centre ou de son salon, l’achalandage maximal de « ou à une aire de restauration d’un centre commercial
déterminé conformément au paragraphe 21.1° ou 21.2° ou d’un commerce d’alimentation » par « , à une aire de
du onzième alinéa; restauration d’un centre commercial ou d’un commerce
d’alimentation ou à un lieu de culte »;
Q UE, malgré le paragraphe 1° du douzième alinéa,
l’exploitant d’un centre commercial puisse admettre une QUE les mesures prévues au présent arrêté prennent
personne qui doit circuler dans les aires communes de etfet le 20 decembre 2021.
ce centre pour accéder à des lieux où sont dispensés des
services de santé et de services sociaux ou des services Québec, le 19 décembre 2021
gouvernementaux, ou aux tribunaux judiciaires ou admi-
nistratifs qui s’y trouvent, le cas échéant; »; Le ministre de la Sante el des Services sociaux,
CHRISTIAN DUBE
7° par la suppression de l’annexe II;
76227
QUE le dispositif le décret numéro 1173-2021 du
1er septembre 2021, modifie par le decret numero 1276-
2021 du 24 septembre 2021 et par les arrêtés 2021-067 A.M., 2021
du 8 octobre 2021, 2021-079 et 2021-081 du 14 novembre
2021 et 2021-082 du 17 novembre 2021, soit de Arrêté numéro 2021-090 du ministre de la Santé et
nouveau modi fie: des Services sociaux en date du 20 décembre 2021
1° dans le troisième alinéa : Loi sur la santé publique

(chapitre S-2.2)
a) par le remplacement du paragraphe 11° par
le suivant : CoNCERNANT l’ordonnance de mesures visant à
« 11° à une assemblée, une réunion, une cérémonie de pandémie de la COVID-19
reconnaissance ou de graduation ou d’un autre événement
de même nature qui se déroule à l’intérieur ou auquel LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX ,
assiste plus de 500 personnes à l’extérieur; »;
b) par la suppression dans le paragraphe 14° de « plus S-2.2) qui prévoit que le gouvernement peut déclarer un
de 250 personnes à l’intérieur ou »; état d’urgence sanitaire dans tout ou partie du territoire
c) par le remplacement des paragraphes 15° et 16° par lation, réelle ou imminente, exige l’application immédiate
les suivants : de certaines mesures prévues à l’article 123 de cette loi
« 15° à une cérémonie funéraire ou de mariage à
laquelle assistent plus de 25 personnes à l’intérieur ou Vu le décret numéro 177-2020 du 13 mars 2020 qui
plus de 500 personnes à l’extérieur; déclare l’état d’urgence sanitaire dans tout le territoire
16° à un lieu de culte, sauf pour une cérémonie de
mariage ou de funérailles à laquelle assiste 25 personnes Vu que ce décret prévoit que le ministre de la Santé
ou moins; »; et des Services sociaux peut prendre toute autre mesure
requise pour s’assurer que le réseau de la santé et des
d) par l'ajout, a la fin, du paragraphe suivant: services sociaux dispose des ressources humaines
nécessaires;
« 18° à un spa ou un sauna, sauf pour recevoir des soins
personnels qui y sont dispensés; »; Vu que l’état d’urgence sanitaire a toujours été renou-

AR02605
Ceci est la pièce « AA » au soutien de

-~ '1
AR02606
2° d'afficher, a chaque entree de son etablissement, 2° par le remplacement, dans le dix-huitième alinéa
de son centre ou de son salon, l’achalandage maximal de « ou à une aire de restauration d’un centre commercial
déterminé conformément au paragraphe 21.1° ou 21.2° ou d’un commerce d’alimentation » par « , à une aire de
du onzième alinéa; restauration d’un centre commercial ou d’un commerce
d’alimentation ou à un lieu de culte »;
Q UE, malgré le paragraphe 1° du douzième alinéa,
l’exploitant d’un centre commercial puisse admettre une QUE les mesures prévues au présent arrêté prennent
personne qui doit circuler dans les aires communes de etfet le 20 decembre 2021.
ce centre pour accéder à des lieux où sont dispensés des
services de santé et de services sociaux ou des services Québec, le 19 décembre 2021
gouvernementaux, ou aux tribunaux judiciaires ou admi-
nistratifs qui s’y trouvent, le cas échéant; »; Le ministre de la Sante el des Services sociaux,
CHRISTIAN DUBE
7° par la suppression de l’annexe II;
76227
-
QUE le dispositif le décret numéro 1173-2021 du
2021 du 24 septembre 2021 et par les arrêtés 2021-067 A.M., 2021
2021 et 2021-082 du 17 novembre 2021, soit de Arrêté numéro 2021-090 du ministre de la Santé et
nouveau modi fie: des Services sociaux en date du 20 décembre 2021
1° dans le troisième alinéa : Loi sur la santé publique

(chapitre S-2.2)
a) par le remplacement du paragraphe 11° par
le suivant : CoNCERNANT l’ordonnance de mesures visant à
« 11° à une assemblée, une réunion, une cérémonie de pandémie de la COVID-19
reconnaissance ou de graduation ou d’un autre événement
de même nature qui se déroule à l’intérieur ou auquel LE MINISTRE DE LA SAN TE ET DES SERVICES SOCIAUX ,
assiste plus de 500 personnes à l’extérieur; »;
b) par la suppression dans le paragraphe 14° de « plus S-2.2) qui prévoit que le gouvernement peut déclarer un
de 250 personnes à l’intérieur ou »; état d’urgence sanitaire dans tout ou partie du territoire
c) par le remplacement des paragraphes 15° et 16° par lation, réelle ou imminente, exige l’application immédiate
les suivants : de certaines mesures prévues à l’article 123 de cette loi
« 15° à une cérémonie funéraire ou de mariage à
laquelle assistent plus de 25 personnes à l’intérieur ou Vu le décret numéro 177-2020 du 13 mars 2020 qui
plus de 500 personnes à l’extérieur; déclare l’état d’urgence sanitaire dans tout le territoire
16° à un lieu de culte, sauf pour une cérémonie de
mariage ou de funérailles à laquelle assiste 25 personnes Vu que ce décret prévoit que le ministre de la Santé
ou moins; »; et des Services sociaux peut prendre toute autre mesure
d) par l'ajout, a la fin, du paragraphe suivant: services sociaux dispose des ressources humaines
nécessaires;
« 18° à un spa ou un sauna, sauf pour recevoir des soins
personnels qui y sont dispensés; »; Vu que l’état d’urgence sanitaire a toujours été renou-

AR02607
Vu que le décret numéro 885-2021 du 23 juin 2021, du 3 septembre 2021, 2021-063 du 9 septembre 2021,
modifie par les arretes numeros 2021-049 du I er juillet 2021-065 du 24 septembre 2021, 2021-066 du 1er octobre
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet 2021, 2021-067 du 8 octobre 2021, 2021-068 du 9 octobre
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août 2021, 2021-069 du 12 octobre 2021, 2021-073 du
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août 2021, 22 octobre 2021, 2021-074 du 25 octobre 2021, 2021-077
2021-060 du 24 août 2021, 2021-061 du 31 août 2021, du 29 octobre 2021, 2021-078 du 2 novembre 2021,
2021-062 du 3 septembre 2021, 2021-063 du 9 septembre 2021-079 du 14 novembre 2021, 2021-083 du 10 décembre
2021, 2021-065 du 24 septembre 2021, 2021-066 du 2021, 2021-086 du 13 décembre 2021, 2021-087 du
1er octobre 2021, 2021-067 du 8 octobre 2021, 2021-068 du 14 décembre 2021 et 2021-089 du 19 décembre 2021, soit
9 octobre 2021, 2021-069 du 12 octobre 2021, 2021-073 de nouveau modifie:
du 22 octobre 2021, 2021-074 du 25 octobre 2021,
2021-077 du 29 octobre 2021, 2021-078 du 2 novembre 1° par l’insertion, après le paragraphe 6°, du suivant :
2021, 2021-079 du 14 novembre 2021, 2021-083 du
10 décembre 2021, 2021-086 du 13 décembre 2021, « 6.1° les activités exercées dans les lieux suivants
2021-087 du 14 décembre 2021 et 2021-089 du sont suspendues :
19 décembre 2021, prévoit notamment certaines mesures
particulières applicables dans tout le territoire québécois; a) les arcades et, pour leurs activités intérieures, les
biodômes, les planétariums, les insectariums, les jardins
Vu que ce décret habilite également le ministre de la botaniques, les aquariums, les jardins zoologiques,
Sante et des Services sociaux a ordonner toute modifica - les sites thématiques, les centres et parcs d’attraction,
tion ou toute précision relative aux mesures qu’il prévoit; les centres d’amusement, les centres récréatifs et les
parcs aquatiques;
2021 habilite le ministre de la Santé et des Services b) les bars et les discothèques;
sociaux à prendre toute mesure prévue aux paragra-
phes 1° à 8° du premier alinéa de l’article 123 de la c) les casinos et les maisons de jeux;
Loi sur la santé publique;
d) les cinémas et les salles où sont présentés des arts
CONSIDERANT QU ’il y a lieu d’ordonner certaines de la scene, y cornpris les lieux de diffusion;
e) les microbrasseries et les distilleries, uniquement
ARRETE CE QUI SUIT: pour leurs services de consommation sur place de boisson;
Qu’un intervenant autorisé au sens de la Loi concer- j) les salles à manger des restaurants, mais uniquement
nant le partage de certains renseignements de santé de 22 h à 5 h le lendemain;
(chapitre P-9.0001) puisse, s'il est mandate a cet effet par
le cadre responsable du bureau de santé d’un établisse- g) les comptoirs alimentaires et les aires de restaura-
ment, se servir de ses autorisations d’accès lui permettant tion situés dans tout lieu où se pratique une activité de
de recevoir communication des renseignements contenus loisir ou de sport;
dans les banques de renseignements de santé du domaine
laboratoire du Dossier sante Quebec afin de verifier les h) les salles d’entraînement physique;
résultats de tests de dépistage de la COVID-19 de toute
personne qui travaille ou exerce sa profession pour cet i) les saunas et les spas, à l’exception des soins person-
établissement et qu’il puisse les communiquer au bureau nels qui y sont dispensés;
de santé;
j) tout lieu intérieur, autre qu’une résidence privée ou
QUE le onzième alinéa du dispositif du décret ce qui en tient lieu, lorsqu’il est utilisé pour la pratique de
numero 885-2021 du 23 juin 2021, modi fie par les arretes jeux de qui Iles, de flechettes, de billard ou d'autres jeux
numéros 2021-049 du 1er juillet 2021, 2021-050 du de même nature; »;
30 juillet 2021, 2021-057 du 4 août 2021, 2021-058 du 2° par la suppression, dans le paragraphe 7°, de « un
13 août 2021, 2021-059 du 18 août 2021, 2021-060 du casino, une maison de jeux, un bar, une discothèque, une
24 août 2021, 2021-061 du 31 août 2021, 2021-062 microbrasserie, une distillerie, »;
© Editeur officiel du Quebec 202 I

AR02608
3° par la suppression du sous-paragraphe b du g) aux fins d'y tenir une activite de nature sociale qui
paragraphe 10°; n’est pas autrement visée par le présent alinéa, auquel
cas un maximum de 10 personnes ou les occupants d’un
4° par la suppression du paragraphe 12°; maximum de trois résidences privées ou de ce qui en tient
lieu peuvent s’y trouver;
5° par le remplacement du paragraphe 14° par
le suivant : 23° malgré le paragraphe précédent, la tenue d’acti-
vités à distance doit être privilégiée; »;
« 14° le public ne peut assister à une production ou
à un tournage audiovisuel intérieur, à une captation de 8° par l’insertion, après le paragraphe 26°, du suivant :
spectacle intérieur ou à un entraînement ou un évènement
sportif intérieur, à l’exception, dans ces deux derniers cas, « 27° tous les employés des entreprises, des organismes
d’un parent qui accompagne son enfant mineur; »; ou de !'administration publique qui effectuent des tiiches
administratives ou du travail de bureau continuent ces
6° par la suppression des paragraphes 18° et 19°; tâches en télétravail, dans leur résidence privée ou ce qui
en tient lieu, à l’exception des employés dont la présence
7° par le remplacement des paragraphes 22° à 25° par est essentielle à la poursuite des activités de l’entreprise,
les suivants : de l’organisme ou de l’administration publique; »;
« 22° aucune personne ne peut se trouver dans une salle 9° par l’insertion, après le paragraphe 30°, des
louée ou une salle communautaire mise à la disposition suivants :
de quiconque, sauf dans les cas suivants :
« 31° pour les journées du calendrier scolaire 2021-
a) dans le cadre d’un salon regroupant plusieurs expo- 2022, les services éducatifs de l’éducation préscolaire,
sants ou commerces de vente au détail, auquel cas les de l’enseignement primaire et de l’enseignement secon-
mesures prévues aux paragraphes 21.1° à 21.3° doivent daire de la formation générale des jeunes de même que
être respectées; ceux de la formation générale des adultes et de la forma-
tion professionnelle dispensés par les centres de services
b) aux fins d'une activite organisee necessaire a la scolaires, les commissions scolaires et les établissements
poursuite des activités, autres que de nature évènemen- d’enseignement privés sont suspendus, à l’exception :
tielle ou sociale, s’inscrivant dans le cadre de l’exploitation
d’une entreprise ou de celles d’un établissement d’ensei- a) des services éducatifs de la formation profession-
gnement, d’un tribunal, d’un arbitre, d’une association de nelle, lorsque l’évaluation des compétences prévue aux
salariés, de professionnels, de cadres, de hors-cadre ou programmes d’études nécessite la présence de l’élève en
d’employeurs, d’un poste consulaire, d’une mission diplo- classe ou lorsque l’acquisition des compétences nécessite
matique, d’un ministère ou d’un organisme public, auquel la présence de l’élève en milieu de travail dans le cadre
cas la capacite de la salle est fixee a 50 % de sa capacite d’un stage;
habituelle, sans dépasser un maximum de 250 personnes;
b) des services educati fs offerts aux eleves handicapes
c) aux fins d'une activite qui s'inscrit dans le cadre ou en difficulte d'adaptation ou d'apprentissage qui fre -
de la mission d’un organisme communautaire dont quentent une école spécialisée ou une classe spécialisée
les activités sont liées au secteur de la santé ou des appartenant aux services régionaux ou suprarégionaux
services sociaux; de scolarisation;
d) pour une production, un tournage audiovisuel ou 32° les activités relatives à la vaccination contre la
pour la captation de spectacle; COVID-19 et à la distribution des autotests de dépistage
de la COVID-19 prévues dans les écoles et les établisse-
e) pour une activité de loisir ou de sport pratiquée ments d’enseignement privés sont maintenues;
conformément au paragraphe 21°;
33° les activités des services de garde en milieu
j) aux fins d'une reception de mariage ou de fune - scolaire sont suspendues;
railles, auquel cas un maximum de 25 personnes peuvent
s’y trouver;

AR02609
34° des services de garde exceptionnels en milieu Yu le décret numéro 177-2020 du 13 mars 2020 qui
scolaire sont organisés par les centres de services scolaires déclare l’état d’urgence sanitaire dans tout le territoire
et les commissions scolaires et ils sont prioritairement québécois pour une période de 10 jours;
fournis aux enfants de l’éducation préscolaire et de l’ensei-
gnement primaire dont l’un des parents ne peut fournir sa Yu que ce décret prévoit que le ministre de la Santé
prestation de travail en télétravail; et des Services sociaux peut prendre toute autre mesure
35° activités extrascolaires de l’éducation préscolaire, services sociaux dispose des ressources humaines
de l’enseignement primaire et de l’enseignement secon- nécessaires;
daire sont suspendues;
Yu que l’état d’urgence sanitaire a toujours été renou-
36° les établissements universitaires, les collèges velé depuis cette date par divers décrets, notamment par
institués en vertu de la Loi sur les collèges d’enseignement le décret numéro 1540-2021 du 15 décembre 2021;
général et professionnel (chapitre C-29), les établisse-
ments d’enseignement privés qui dispensent des services Vu que ce décret habilite le ministre de la Santé et
d’enseignement collégial et tout autre établissement qui des Services sociaux à prendre toute mesure prévue aux
dispense des services d’enseignement de niveau collégial paragraphes 1° à 8° du premier alinéa de l’article 123 de
ou universitaire ou des services de formation continue la Loi sur la santé publique;
doivent organiser la formation à distance pour dispenser
leurs services d’enseignement, à moins que l’acquisition CoNSIDERANT ou ’il y a lieu d’ordonner certaines
ou l’évaluation des connaissances prévues au programme mesures pour protéger la santé de la population;
d’études de l’étudiant nécessite sa présence en classe ou
en milieu de travail dans le cadre d’un stage; »; A RRETE C E QUI SUIT:
QUE les mesures prévues au présent arrêté prennent QUE le septième alinéa du dispositif de l’arrêté
etfet le 20 decembre 2021. numero 2020-022 du 15 avril 2020, modifie par les arretes
numéros 2020-034 du 9 mai 2020, 2020-039 du 22 mai
Québec, le 20 décembre 2021 2020, 2021-010 du 5 mars 2021, 2021-022 du 7 avril 2021
et 2021-024 du 9 avril 2021 , soit de nouveau modifie par
le ministre de la Sante et des Services sociaux, la suppression de « âgée de moins de 70 ans »;
CHRISTIAN D UBE
QUE le paragraphe 2° du cinquième alinéa du dispo-
76229 sitif de l’arrêté numéro 2020-087 du 4 novembre 2020,
modifie par l'arrete numero 2021-022 du 7 avril 2021 ,
soit de nouveau modi fie par la suppression de « agees de
A.M., 2021 moins de 70 ans »;
Arrêté numéro 2021-091 du ministre de la Santé et QUE le paragraphe 2° du sixième alinéa du dispo-
des Services sociaux en date du 21 décembre 2021 sitif de l’arrêté numéro 2020-099 du 3 décembre 2020,
modifie par les arretes numeros 2021-005 du 28 janvier
Loi sur la santé publique 2021, 2021-022 du 7 avril 2021, 2021-024 du 9 avril 2021,
(chapitre S-2.2) 2021-027 du 16 avril 2021 et 2021-028 du 17 avril 2021,
soit de nouveau modi fie par la suppression de« agees de
CONCERNANT l’ordonnance de mesures visant à moins de 70 ans ».
pandémie de la COVID-19 Québec, le 21 décembre 2021
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, Le minis/re de la Sante et des Services sociaux,
CHRISTIAN DUBE
S-2.2) qui prévoit que le gouvernement peut déclarer un 76230

AR02610
Ceci est la pièce « BB » au soutien de

.i,linjnf
AR02611
A.M., 2021 Vu que le décret numéro 1173-2021 du 1er septembre

Arrêté numéro 2021-092 du ministre de la Santé 24 septembre 2021 et par les arrêtés 2021-067 du 8 octobre
et des Services sociaux en date du 22 décembre 2021 2021, 2021-079 et 2021-081 du 14 novembre 2021,
2021-082 du 17 novembre 2021 et 2021-089 du
Loi sur la santé publique 19 décembre 2021, prévoit l’obligation d’être adéquate-
(chapitre S-2.2) ment protégé pour accéder à certains lieux ou pour parti-
ciper à certaines activités;
protéger la santé de la population dans la situation de Vu que ces décrets habilitent également le ministre
pandémie de la COVID-19 de la Santé et des Services sociaux à ordonner toute
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, qu’ils prévoient;
Vu l’article 118 de la Loi sur la santé publique (chapitre Vu que le décret numéro 1624-2021 du 22 décembre
S-2.2) qui prévoit que le gouvernement peut déclarer un 2021 habilite le ministre de la Santé et des Services
état d’urgence sanitaire dans tout ou partie du territoire sociaux à prendre toute mesure prévue aux paragraphes 1°
québécois lorsqu’une menace grave à la santé de la popu- à 8° du premier alinéa de l’article 123 de la Loi sur la
lation, réelle ou imminente, exige l’application immédiate santé publique;
pour protéger la santé de la population; CONSIDERANT QU’il y a lieu d’ordonner certaines
déclare l’état d’urgence sanitaire dans tout le territoire ARRETE CE QUI SUIT:
QUE le onzième alinéa du dispositif du décret
Vu que l’état d’urgence sanitaire a toujours été renou- numéro 885-2021 du 23 juin 2021, modifié par les
velé depuis cette date par divers décrets, notamment par arrêtés numéros 2021-049 du 1er juillet 2021, 2021-050
le décret numéro 1624-2021 du 22 décembre 2021; du 2 juillet 2021, 2021-053 du 10 juillet 2021, 2021-055 du
30 juillet 2021, 2021-057 du 4 août 2021, 2021-058 du
Vu que le décret numéro 885-2021 du 23 juin 2021, 13 août 2021, 2021-059 du 18 août 2021, 2021-060 du
modifie par les arretes numeros 2021-049 du 1er juillet 24 août 2021, 2021-061 du 31 août 2021, 2021-062 du
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet 3 septembre 2021, 2021-063 du 9 septembre 2021,
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août 2021-065 du 24 septembre 2021, 2021-066 du 1er octobre
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août 2021, 2021, 2021-067 du 8 octobre 2021, 2021-068 du 9 octobre
2021-060 du 24 août 2021, 2021-061 du 31 août 2021, 2021, 2021-069 du 12 octobre 2021, 2021-073 du
2021-062 du 3 septembre 2021, 2021-063 du 9 septembre 22 octobre 2021, 2021-074 du 25 octobre 2021, 2021-077
2021, 2021-065 du 24 septembre 2021, 2021-066 du du 29 octobre 2021, 2021-078 du 2 novembre 2021,
1er octobre 2021, 2021-067 du 8 octobre 2021, 2021-068 du 2021-079 du 14 novembre 2021, 2021-083 du 10 décembre
9 octobre 2021, 2021-069 du 12 octobre 2021, 2021-073 du 2021, 2021-086 du 13 décembre 2021, 2021-087 du
22 octobre 2021, 2021-074 du 25 octobre 2021, 2021-077 14 décembre 2021, 2021-089 du 19 décembre 2021 et
du 29 octobre 2021, 2021-078 du 2 novembre 2021, 2021-090 du 20 decembre 2021, soit de nouveau modifie:
2021-079 du 14 novembre 2021, 2021-083 du 10 décembre
2021, 2021-086 du 13 décembre 2021, 2021-087 du 1° dans le paragraphe 1° :
14 décembre 2021, 2021-089 du 19 décembre 2021 et
2021-090 du 20 décembre 2021, prévoit notamment a) par le remplacement de « 10 personnes » par
certaines mesures particulières applicables dans tout le « six personnes »;

AR02612
b) par le remplacement de « trois résidences » par A.M., 2021

« deux résidences »;
2° dans le sous-sous-paragraphe ii du sous- et des Services sociaux en date du 23 décembre 2021
paragraphe a du paragraphe 7° :
a) par le remplacement de « 10 personnes » par (chapitre S-2.2)
« 6 personnes »;
b) par le remplacement de « trois résidences » par protéger la santé de la population dans la situation de
« deux résidences »; pandémie de la COVID-19
3° dans le sous-paragraphe g du paragraphe 22° : LE MINISTRE DE LA SANTE ET D ES SERV IC ES SOCIAUX ,
a) par le remplacement de « 10 personnes » par Vu l’article 118 de la Loi sur la santé publique (chapitre
« 6 personnes »; S-2.2) qui prévoit que le gouvernement peut déclarer un
b) par le remplacement de « trois résidences » par québécois lorsqu’une menace grave à la santé de la popu-
« deux résidences »; lation, réelle ou imminente, exige l’application immédiate
QUE le dispositif du décret numéro 1173-2021 du pour protéger la santé de la population;
2021 du 24 septembre 2021 et par les arrêtés Vu le décret numéro 177-2020 du 13 mars 2020 qui
numéros 2021-067 du 8 octobre 2021, 2021-079 et déclare l’état d’urgence sanitaire dans tout le territoire
2021-081 du 14 novembre 2021, 2021-082 du 17 novembre québécois pour une période de 10 jours;
2021 et 2021-089 du 19 décembre 2021, soit de nouveau
modi fie par la suppression du neuvieme alinea; Vu que l’état d’urgence sanitaire a toujours été renou-
QUE, le 26 décembre 2021, un établissement commer- le décret numéro 1624-2021 du 22 décembre 2021;
cial visé à la Loi sur les heures et les jours d’admission
dans les établissements commerciaux (chapitre H-2.1) Vu que ce décret prévoit que le ministre de la
puisse, en plus des périodes légales d’admission prévues Santé et des Services sociaux peut prendre toute autre
à cette loi, admettre le public de 10h00 à 13h00. mesure requise pour s’assurer que le réseau de la
santé et des services sociaux dispose des ressources
QUE les mesures prévues au premier alinéa du dispositif humaines nécessaires;
du present arrete prennent effet le 26 decembre 202 1.
Vu que ce décret habilite le ministre de la Santé et
Québec, le 22 décembre 2021 des Services sociaux à prendre toute mesure prévue aux
paragraphes 1° à 8° du premier alinéa de l’article 123 de
Le ministre de la Sante et des Services sociaux, la Loi sur la santé publique;
C HRIST IAN DUBE
76235 mesures pour protéger la santé de la population;
ARRETE CE QUI SUIT:
QuE l'arrete numero 2021-032 du 30 avril 2021, modifie

par les arrêtés numéros 2021-034 du 8 mai 2021 et
202 1-082 du 17 novembre 2021, soit de nouveau modifie:
1° par l’insertion, dans ce qui précède le sous-

paragraphe a du paragraphe 1° du premier alinéa et après
« vaccination », de « ou de dépistage »;

AR02613
Ceci est la pièce « CC » au soutien de


AR02614
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 6 janvier 2022, 154e année, no 1A 11A
Vu que ce décret habilite le ministre de la Santé et québécois lorsqu’une menace grave à la santé de la popu-
des Services sociaux a prendre toute mesure prevue aux lation, reelle ou imminente, exige !'application immediate
paragraphes 1° ii 8° du premier alinea de !'article 123 de de certaines mesures prévues à l’article 123 de cette loi
la Loi sur la santé publique; pour protéger la santé de la population;
CONSIDE.RANT QU’il y a lieu d’ordonner certaines Vu le decret numero 177-2020 du 13 mars 2020 qui
mesures pour protéger la santé de la population; déclare l’état d’urgence sanitaire dans tout le territoire
ARRETE CE QUI SUIT:
QUE les dispositions nationales et locales des conven- vele depuis cette date par divers decrets, notamment par
tions collectives en vigueur dans le réseau de la santé le décret numéro 1628-2021 du 29 décembre 2021;
et des services sociaux, de meme que les conditions de
travail applicables aux employes syndicables non syn - Vu que le decret numero 885-2021 du 23 juin 2021,
diques et aux employes non syndicables du reseau de la modifie par les arretes numeros 2021-049 du I er juillet
sante et des services sociaux soient modifiees afin que 2021, 202 1-050 du 2 juillet 2021, 2021-053 du 10 juillet
toute personne salariée qui est en isolement en raison de 2021 , 2021-055 du 30 juillet 2021 , 2021-057 du 4 aofit
la COY I D-19, qui est asymptomatique et qui est rappelee 2021, 2021-058 du 13 aoOt 2021 , 2021-059 du 18 aoOt
au travail puisse, pour la dun~e pendant laquelle elle aurait 2021, 2021-060 du 24 aoOt 2021, 2021 -061 du 31 aoOt
dO etre en isolement, beneficier des avant.ages suivants: 2021, 2021-062 du 3 septembre 2021, 2021-063 du
9 septembre 2021 , 2021-065 du 24 septembre 2021,
1° remboursement des frais de stationnement, dans la 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021 ,
mesure oi1 el le n'est pas deja titulaire d'un abonnement 2021-068 du 9 octobre 2021, 202 1-069 du 12 octobre
mensuel, trimestriel, annuel ou autre; 2021 , 2021-073 du 22 octobre 2021, 2021 -074 du
25 octobre 2021, 2021-077 du 29 octobre 2021, 2021 -078
2° remboursement des frais de transport autorise ou du 2 novembre 2021, 2021-079 du 14 novembre 2021,
organisé par l’employeur; 2021-083 du 10 decembre 2021, 2021-086 du 13 decembre
2021 , 2021-087 du 14 decembre 2021, 2021-089 du
3° fourniture d'un repas, lorsque possible, afin de 19 decembre 2021, 2021 -090 du 20 decembre 2021 et
limiter les déplacements au sein d’une installation. 2021 -092 du 22 decembre 2021, prevoit notamment
Quebec, le 31 decembre 2021 territoire québécois;
le ministre de la Sante et des Services sociaux, Vu que ce décret habilite également le ministre de la
CHRISTIAN DUBE Sante et des Services sociaux a ordonner toute modifica-
76241
-
A.M., 2021 sociaux aprendre toute mesure prevue aux paragraphes 1°
a 8° du premier alinea de !'article 123 de la Loi sur Ja
Arrêté numéro 2021-096 du ministre de la Santé santé publique;
CoNSIDERANT ou ’il y a lieu d’ordonner certaines
Loi sur la santé publique mesures pour protéger la santé de la population;
(chapitre S-2.2)
ARRETE C E QUI SUIT:
protéger la santé de la population dans la situation de QUE le dispositif du décret numéro 885-2021 du
pandémie de la COVID-19 23 juin 2021, modifie par les arretes numeros 2021-049
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
du 4 aoflt 2021, 2021-058 du 13 aofit 2021, 2021-059 du
Vu l’article 118 de la Loi sur la santé publique (chapitre 18 aot'.it 2021, 2021-060 du 24 aofit 2021 , 2021-061 du
S-2.2) qui prévoit que le gouvernement peut déclarer un 31 aofit 2021, 202 1-062 du 3 septembre 2021, 2021-063
état d’urgence sanitaire dans tout ou partie du territoire du 9 septembre 2021, 2021-065 du 24 septembre 2021,
© Editeur officiel du Quebec 202 2

AR02615
12A GAZETTE OFFICIELLE DU QUÉBEC, 6 janvier 2022, 154e année, no 1A Partie 2
2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021, b) pour obtenir, dans une pharmacie, des produits
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre pharmaceutiques, hygieniques ou sanitaires, ou un
2021, 2021-073 du 22 octobre 2021 , 2021-074 du service professionnel;
25 octobre 2021, 2021 -077 du 29 octobre 2021 , 2021 -078
du 2 novembre 2021 , 2021-079 du 14 novembre 2021 , c) pour recevoir des services éducatifs d’un établis-
2021-083 du 10 decembre 2021, 2021-086 du 13 decembre sement de la formation générale des adultes et de la for-
2021 , 2021-087 du 14 decembre 2021, 2021-089 du mation professionnelle ou des services d’enseignement
19 decembre 2021, 2021 -090 du 20 decembre 2021 et d'un etablissement universitaire, d'un college institue
2021- 092 du 22 decembre 2021, soit de nouveau modi fie: en vertu de la Loi sur les collèges d’enseignement géné-
ral et professionnel (chapitre C-29), d' un etablissement
1° dans le onzieme alinea: d’enseignement privé qui dispense des services d’ensei-
gnement collégial ou de tout autre établissement qui
a) par le remplacement du paragraphe 1° par dispense des services d’enseignement de niveau collégial
Jes su ivants : ou universitaire;
« 1° dans une residence privee ou ce qui en tient Iieu, d) pour obtenir un permis de pratique requis pour
seuls les occupants peuvent s’y trouver; l'exercice d'une profession ou toute autre certification
nécessaire pour la pratique d’un métier;
1.1° dans une unite d' hebergement d' un etablissement
d' hebergement touristique, seuls les occupants d' une e) pour obtenir des soins ou des services requis par
meme residence privee ou de ce qui en tient lieu peuvent son etat de sante, y compris pour se faire vacciner contre
s’y trouver; »; la COVID-19;
b) par le remplacement des paragraphes 3° et 4° par f) pour la réalisation d’un don de sang ou d’autres pro-
les suivants: du its biologiques d'origine humaine a Hema-Quebec;
<< 3° malgre Jes paragraphes IO a2° : g) pour porter assistance aune personne dans le besoin,
pour fournir un service ou un soutien à une personne pour
a) peut se trouver dans une residence privee, ce qui en des fins de securite, pour assurer la garde d' un enfant ou
tient lieu, ou une unite d'hebergement d' un etablissement d' une personne vulnerable, pour visiter une personne en
d'hebergement touristique, incluant le terrain d'une telle fin de vie ou encore pour un motif d' urgence;
residence ou d'une telle unite, toute personne presente
pour y recevoir ou y offrir un service ou un soutien, selon h) pour se conformer à un jugement rendu par un tri-
le cas, et qui n'en est pas un occupant; bunal, pour repondre a une assignation pour comparaitre
devant un tribunal ou pour permettre l'exercice des droits
bJ une personne résidant seule peut recevoir une autre de garde ou d'acces parentaux;
personne dans sa résidence privée ou ce qui en tient lieu;
i) pour prendre un autobus assurant un service inter-
c) lorsqu’une personne réside seule ou uniquement regional ou interprovincial, un train, un avian ou un
avec ses enfants a charge, ils peuvent former un groupe navire assurant le service de traverse de Matane Baie-
stable avec les occupants d’une seule autre résidence Comeau- Godbout, ':farrington Harbour-Chevery, Riviere
privée et ces personnes peuvent alors se trouver dans l’une Saint-Augustin ou lie d'Entree- Cap-aux-Meules ou le
ou l’autre des résidences privées de ces personnes ou de service de desserte maritime des Îles-de-la-Madeleine ou
ce qui en tient lieu; de l’Île d’Anticosti et de la Basse-Côte-Nord du réseau de
la Societe des traversiers du Quebec, ou pour se rendre, a
3.1° i I est interd it a toute person ne, entre 22 heu res et la suite de son trajet, a sa destination;
5 heures, de se trouver hors de sa residence ou de ce qui
en tient lieu ou du terrain d' une telle residence, a moins }) pour obtenir, dans une station-service, un bien ou un
qu'elle demontre etre hors de ce lieu: service requis pour le bon fonctionnement d’un véhicule
a
ou des denrees alimentaires, )'exception des boissons
a) pour fournir une prestation de travail ou de services alcooliques, mais uniquement dans le cadre de l'une des
professionnels nécessaire à la continuité des activités exceptions prevues aux sous-paragraphes a à i;
ou des services qui ne sont pas visés par une suspen-
sion en vertu d'un decret ou d'un arrete pris en vertu de k) pour accompagner une personne ayant besoin
!'article 123 de la Loi sur la sante publique, incluant le d’assistance dans l’une des situations autorisées en vertu
transport des biens nécessaires à la poursuite de ces acti- des sous-paragraphes a à j;
vités ou services;

AR02616
3.2° les restaurants, les commerces de vente au detail, c) des épiceries pour les commandes en ligne ou par
les entreprises de soins personnels ou d'esthetique, les telephone, la collecte et la livraison;
lieux ou sont exercees des activites culturelles, sportives,
de plein air ou de loisirs qui ne sont pas suspendues par d) des pharmacies situées dans les surfaces hors centre
un decret ou un arrete pris en vertu de !'article 123 de la commercial pour les commandes en ligne ou par téléphone
Loi sur la santé publique ne peuvent accueillir le public et pour la livraison de médicaments et de produits phar-
entre 21h30 et 5 heures, saufs'il s'agit d' une pharmacie maceutiques, hygieniques et sanitaires; »;
ou d’une station service;
j) par !'insertion, apres le paragraphe 11°, du suivant:
3.3° entre 22 heures et 5 heures, ii est interdit a une
pharmacie ou à une station-service de vendre des produits « 12° dans un chalet d' un centre d'activites sportives
ou d'offrir des services autres que ceux prevus aux sous- ainsi que dans tout lieu intérieur ou dans tout bâtiment
paragraphes b et j du paragraphe 3.1 °; adjacent d' un relais de motoneige ou de quad, ii est
interdit à la clientèle d’y consommer de la nourriture ou
3.4° le paragraphe 3.1 ° ne s'applique pas aux personnes une boisson; »;
sans-abris;
g) par la suppression du paragraphe 17°;
4° un maximum de 25 personnes peuvent assister a
toute cérémonie funéraire; »; h) dans le paragraphe 21° :
c) par la suppression du sous-paragraphe a du i. par le remplacement du sous-paragraphe a par

paragraphe 5°; le suivant:
d) dans le paragraphe 6.1 ° : « a) elle est pratiquee dans un lieu ou les activites ne
sont pas autrement suspendues, avec ou sans encadrement,
i. par l'ajout, a la fin du sous-paragraphe e de « ou seul, avec une autre personne ou par les occupants d' une
de nourriture »; a
meme residence privee ou de ce qui en tient lieu, condi-
tion que la capacite du vestiaire, le cas echeant, soit fixee
ii. par le remplacement du sous-paragraphe f par à 50 % de sa capacité habituelle; »;
le suivant:
ii. par la suppression du sous-paragraphe C ;
«j) Jes restaurants et les aires de restauration, notam -
ment celles des centres commerciaux, des commerces iii. par la suppression, dans le sous-paragraphe f,
d'alimentation et des haltes- routieres, sauf pour les de « dont l'entrafnement ou la pratique exige un
livraisons, les commandes a em porter ou les commandes nombre de personnes supérieur à celui prévu par le
à l’auto; »; sous-paragraphe a »;
iii. par l'ajout, a la fin, du sous-paragraphe suivant: iv. par la suppression du sous-paragraphe g;
« k) les lieux de culte, sauf pour une ceremonie i) par le remplacement des sous-paragraphes f et g du
funéraire; »; paragraphe 22° par le suivant:
e) par le remplacement des paragraphes 7° a 10° par «j) aux fins d' une ceremonie de funeraire; »;
le suivant:
j) par !' insertion, apres le paragraphe 26°, du suivant:
«7° Jes etablissements commerciaux de vente au detail
et les entreprises de soins personnels ou d’esthétique sont « 26.1° ii est interdit d'organiser un rassemblement
fermes au public le dimanche, a !'exception: de plus de 250 personnes clans un lieu exterieur public,
y compris dans le cadre d’un événement de nature
a) des pharmacies, des depanneurs et des commerciale, religieuse, culturelle, sportive, de loisir
stations service; ou de divertissement, ou d'y participer, sauf lorsque
les personnes rassemblees exercent leur droit de
b) des restaurants pour les commandes a l'auto, les manifester pacifiquement; »;
commandes pour emporter et la livraison;

AR02617
h) par le remplacement des paragraphes 31 ° a 36° par 32° les paragraphes 31° et 31.1° ne s'appliquent pas
les su ivants : aux eleves handicapes OU en difficulte d'adaptation OU
d’apprentissage qui fréquentent une école spécialisée ou
« 31° pour les deux premieres journees de janvier du une classe specialisee appartenant aux services regionaux
calendrier scolaire 2021-2022 au cours desquelles les ou supraregionaux de scolarisation;
enseignants travaillent, les centres de services scolaires,
les commissions scolaires et les établissements d’ensei- 33° pour les eleves handicapes OU en difficulte d'adap -
gnement prives : tation ou d’apprentissage qui fréquentent des classes ou
des groupes spécialisés qui ne sont pas dans une école
a) organisent des services éducatifs à distance pour ou une classe visee au paragraphe precedent, les etablis-
les eleves de !'education prescolaire, de l'enseignement sements d’enseignement peuvent dispenser des services
primaire et de l’enseignement secondaire de la formation educatifs en presentiel, mais ils favorisent les services
générale des jeunes pour poursuivre l’atteinte des objectifs educatifs a distance prevus aux paragraphes 31 ° et 31.1°;
des programmes d’activités et des programmes d’études
et les dispensent, le cas echeant, aux eleves qui auraient 34° tout eleve de !'education prescolaire et de l'ensei -
d0 les recevoir en presentiel; gnement primaire et secondaire de la formation générale
des jeunes qui n’a pas le matériel nécessaire pour rece-
b) organisent des services éducatifs à distance pour les voir les services d’enseignement à distance ou qui n’a pas
élèves de la formation générale des adultes et de la forma- accès au réseau Internet ou dont l’accès est inadéquat peut
tion professionnelle et les dispensent, le cas echeant, aux exceptionnellement se rendre dans l'etablissement d'ensei-
eleves qui auraient d0 les recevoir en presentiel, a moins gnement qu'il frequente pour beneficier des ressources
que l’acquisition ou l’évaluation des compétences prévues matérielles et de l’accès à un réseau Internet permettant
au programme d’études de l’élève ne nécessite sa présence de recevoir des services d’enseignement à distance;
en classe ou en milieu de travail dans le cadre d’un stage;
35° pour lesjournees du calendrier scolaire 2021-2022,
31.1 ° a partir de la troisieme journee du mois de les services de garde en milieu scolaire suspendent
janvier du calendrier scolaire 2021-2022 au cours de leurs activités;
laquelle les enseignants travaillent ou au plus tard le
premier jour consacre aux services educatifs, les centres 36° malgre le paragraphe precedent, pour lesjournees
de services scolaires, les commissions scolaires et les eta- du calendrier scolaire 2021-2022, des services de garde
blissements d'enseignement prives: exceptionnels en milieu scolaire sont organises par les
centres de services scolaires et Jes commissions scolaires,
a) organisent des services éducatifs à distance et les ainsi que par les établissements d’enseignement privés qui
dispensent aux eleves de !'education prescolaire et de offrent habituellement de tels services, et ils sont priori -
l’enseignement primaire de la formation générale tairement fournis aux eleves de !'education prescolaire et
des jeunes selon l’offre minimale de services prévue de l’enseignement primaire dont l’un des parents ne peut
en annexe; fournir sa prestation de travail en télétravail;
b) organisent les services éducatifs à distance et les 37° les activites extrascolaires de !'education presco-
dispensent aux eleves de l'enseignement secondaire de la laire, de l'enseignement primaire, de l'enseignement
formation generale des jeunes selon l'horaire habituel, ii secondaire, de la formation generale des adultes et de la
moins que l’acquisition ou l’évaluation des compétences formation professionnelle sont suspendues;
prévues au programme d’études de l’élève ne nécessite
sa présence en milieu de travail pour la formation à un 38° les etablissements universitaires, les colleges ins -
métier semi-spécialisé ou pour la formation préparatoire titués en vertu de la Loi sur les collèges d’enseignement
au travail; general et professionnel (chapitre C-29), les etablisse-
ments d’enseignement privés qui dispensent des services
c) organisent les services éducatifs à distance et les dis- d’enseignement collégial et tout autre établissement qui
pensent aux eleves de la formation generale des adultes et dispense des services d’enseignement de niveau collégial
de la formation professionnelle, a moins que !'acquisition ou universitaire ou des services de formation continue
ou l’évaluation des compétences prévues au programme doivent organiser la formation à distance pour dispenser
d’études de l’élève ne nécessite sa présence en classe ou leurs services d'enseignement, a moins que !'acquis ition
en milieu de travail dans le cadre d’un stage; ou l’évaluation des connaissances prévues au programme
d’études de l’étudiant nécessite sa présence en classe ou
en milieu de travail dans le cadre d’un stage; »;

AR02618
2° par l'ajout, a la fin du douzieme alinea, du

paragraphe suivant:
« 4° de se trouver d ans un lieu dont les activités sont

suspendues en vertu du présent décret; »;
3° par l'ajout, a la fin, de ('annexe suivante:
« ANNEXE
OFFRE MINIMALE DE SERVICES
Heures d’enseignement Heures de travail Heures de disponibilité

ou d’activités de autonome fourni par de l’enseignant par jour
formation et d’éveil l’enseignant par ou par semaine pour
par semaine semaine par eleve repondre aux besoins
des élèves
Prescolaire 11,5 heures d'activites 2 heures 2,3 heures par jour
de formation et d’éveil
en groupe ou personnalisées
1er cycle primaire 10,5 heures d'enseignement 3 heures 2,5 heures par jour
(1re et 2e année)
2e cycle primaire 13 heures d’enseignement 5 heures 2 heures par jour
(3e et 4e année)
3e cycle primaire 13 heures d'enseignement 7,5 heures 2 heures par jour
(5e et 6e année)
»;
QuE les mesures prevues au present arrete prennent québécois lorsqu’une menace grave à la santé de la popu-
effet le 31 decembre 2021 a 17 heures. lation, reelle ou imminente, exige !'application immediate
Quebec, le 31 decembre 2021 pour protéger la santé de la population;
l e ministre de la Same et des Services sociaux, Vu le decret nurnero 177-2020 du 13 mars 2020 qui
CHRISTIAN DUBE déclare l’état d’urgence sanitaire dans tout le territoire
76242
vele depuis cette date par divers decrets, notarnrnent par
A.M., 2022 le décret numéro 1628-2021 du 29 décembre 2021;
et des Services sociaux en date du 2 janvier 2022 Yu que le decret numero 885-2021 du 23 juin 2021 ,
rnodifie par les arretes nurneros 2021-049 du I er juillet
Loi sur la santé publique 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
(chapitre S-2.2) 2021, 2021-055 du 30 juillet 2021 , 2021- 057 du 4 aofit
2021, 2021-058 du J3 aofit 2021, 2021-059 du 18 aofit 2021,
CONC ER NANT l’ordonnance de mesures visant à 2021 -060 du 24 aoGt 2021 , 2021-061 du 31 aofit 2021 ,
protéger la santé de la population dans la situation de 2021-062 du 3 septembre 2021, 2021-063 du 9 septembre
pandémie de la COVID-19 2021, 2021-065 du 24 septembre 2021, 2021-066 du
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAU X, 9 octobre 2021 , 2021-069 du 12 octobre 2021 , 2021-073 du
22 octobre 2021 , 202 1-074 du 25 octobre 202 1, 2021-077
Vu l’article 118 de la Loi sur la santé publique (chapitre du 29 octobre 2021, 2021-078 du 2 novembre 2021 ,
S-2.2) qui prévoit que le gouvernement peut déclarer un 2021-079 du 14 novembre 2021, 2021-083 du 10 decembre

AR02619
Ceci est la pièce « DD » au soutien de


AR02620
2° par l'ajout, a la fin du douzieme alinea, du

paragraphe suivant :
« 4° de se trouver d ans un lieu dont les activités sont

suspendues en vertu du présent décret; »;
3° par l'ajout, a la fin, de ('annexe suivante:

« ANNEXE
OFFRE MINIMALE DE SERVICES
Heures d’enseignement Heures de travail Heures de disponibilité

ou d’activités de autonome fourni par de l’enseignant par jour
formation et d’éveil l’enseignant par ou par semaine pour
par semaine semaine par eleve repondre aux besoins
des élèves
Prescolaire 11,5 heures d'activites 2 heures 2,3 heures par jour
en groupe ou personnalisées
1er cycle primaire 10,5 heures d'enseignement 3 heures 2,5 heures par jour
(1re et 2e année)
(3e et 4e année)
3e cycle primaire 13 he ures d'enseignement 7,5 he ures 2 heures par jour
(5e et 6e année)
»;
QuE les mesures prevues au present arrete prennent québécois lorsqu’une menace grave à la santé de la popu-
effet le 31 decembre 2021 a 17 heures. lation, reelle ou imminente, exige !'application immediate
Quebec, le 31 decembre 2021 pour protéger la santé de la population;
le ministre de la Same et des Services sociaux, Vu le decret numero 177-2020 du 13 mars 2020 qui
CHRISTIAN DUBE déclare l’état d’urgence sanitaire dans tout le territoire
76242
vele depuis cette date par divers decrets, notamment par
A.M., 2022 le décret numéro 1628-2021 du 29 décembre 2021;
et des Services sociaux en date du 2 janvier 2022 Vu que le decret numero 885-2021 du 23 juin 202 1,
modifie par les arretes numeros 2021-049 du I er juillet
Loi sur la santé publique 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
(chapitre S-2.2) 2021, 2021-055 du 30 juillet 2021 , 2021- 057 du 4 aofit
2021, 2021-058 du J3 aofit 2021, 2021-059 du 18 aofit 2021,
CONCERNANT l’ordonnance de mesures visant à 2021 -060 du 24 aoGt 2021 , 2021-061 du 31 aofit 2021 ,
protéger la santé de la population dans la situation de 2021-062 du 3 septembre 2021, 2021-063 du 9 septembre
pandémie de la COVID-19 2021, 2021-065 du 24 septembre 2021, 2021-066 du
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, 9 octobre 2021, 2021-069 du 12 octobre 2021 , 2021-073 du
Vu l’article 118 de la Loi sur la santé publique (chapitre du 29 octobre 2021, 2021-078 du 2 novembre 2021 ,
S-2.2) qui prévoit que le gouvernement peut déclarer un 2021-079 du 14 novembre 2021, 2021-083 du 10 decembre

AR02621
2021, 2021-086 du 13 decernbre 2021, 2021-087 du

14 decernbre 2021, 2021- 089 du 19 decernbre 2021,
2021-090 du 20 decernbre 2021, 2021-092 du 22 decernbre
2021 et 2021-096 du 31 decembre 2021, prevoit notarn -
ment certaines mesures particulières applicables dans tout
le territoire québécois;


sociaux aprendre toute rnesure prevue aux paragraphes I0
a 8° du premier alinea de )'article 123 de la Loi sur la
santé publique;

ARRETE CE QUI SUIT:
QuE le onzieme alinea du dispositif du decret

numero 885-2021 du 23 juin 2021, rnodifie par Jes
arretes numeros 2021 -049 du l er juillet 2021, 2021-050
du 2 juillet 2021, 2021-053 du 10 juillet 2021, 2021-055
du 30 juillet 2021, 2021-057 du 4 aolit 2021, 2021-058 du
13 aolit 2021, 2021-059 du 18 aolit 2021 , 2021-060 du
24 aout 2021, 2021 -061 du 31 aoGt 2021, 2021 -062 du
3 septembre 2021, 2021 -063 du 9 septernbre 2021,
2021-065 du 24 septembre 2021 , 2021-066 du 1er octobre
2021, 2021-067 du 8 octobre 2021, 2021-068 du 9 octobre
2021, 2021- 069 du 12 octobre 2021, 2021-073 du
du 29 octobre 2021, 2021-078 du 2 novernbre 2021 ,
2021-079 du 14 novembre 2021, 2021-083 du 10 decernbre
2021, 2021-086 du 13 decembre 2021, 2021 -087 du
14 decembre 2021, 2021-089 du 19 decembre 2021,
2021-090 du 20 decembre 2021, 2021-092 du 22 decernbre
2021 et du 2021-096 du 31 decembre 2021, soit de nou-
veau modifiepar l'ajout, a la fin du paragraphe 3.1°, du
sous-paragraphe suivant:
« I) pour les besoins de son chien, dans un rayon

maximal d'un kilometre autour de sa residence ou de ce
qui en tient lieu; ».
Quebec, le 2 janvier 2022

CHRISTIAN DUBE
76243

AR02622
Ceci est la pièce « EE » au soutien de


AR02623
Agent administratif, classe 2 - secteur administration québécois lorsqu’une menace grave à la santé de la popu-
ou agente administrative, classe 2 - secteur administration lation, reelle ou imminente, exige l'application immediate
Agent administratif, classe 2 - secteur secretariat ou pour protéger la santé de la population;
agente administrative, classe 2 - secteur secretariat
Agent administratif, classe 3 - secteur administration déclare l’état d’urgence sanitaire dans tout le territoire
ou agente administrative, classe 3 - secteur administration québécois pour une période de 10 jours;
Agent administratif, classe 3 - secteur secretariat ou Vu que l’état d’urgence sanitaire a toujours été renou-
agente administrative, classe 3 - secteur secretariat vele depuis cette date par divers decrets, notarnrnent par
le décret numéro 4-2022 du 12 janvier 2022;
Agent administratif, classe 4 - secteur administration
ou agente administrative, classe 4 - secteur administration Yu que l'arrete numero 2020-008 du 22 mars 2020,
modifie par le decree numero 566-2020 du 27 mai 2020
Agent administratif, classe 4 - secteur secretariat ou et par Jes arretes numeros 2020-033 du 7 mai 2020,
agente adm inistrative, classe 4 - secteur secretariat»; 2020-044 du 12 juin 2020 et 2021-054 du 16 juillet
2021, prevoit notamment certaines mesures applicables
QuE le dispositi f de l'arrete numero 2021 -081 aux conventions collectives ou ententes dans le reseau
du 14 novembre 2021, modifie par les arretes nume - de l’éducation;
ros 2021-085 du 13 décembre 2021 et 2021-088 du
16 decembre 2021, soit de nouveau modifie par l'ajout, a Vu que le decret nurnero 885-2021 du 23 juin 2021 ,
la fin du quinzieme alinea, du paragraphe suivant : rnodifie par Jes arretes nurneros 202 1-049 du Ier juillet
2021, 2021 -050 du 2 juillet 2021, 2021-053 du 10 juillet
(( 12° ceux prevus a l'arrete numero 2022 -003 du 2021, 2021-055 du 30 juillet 2021, 202 1-057 du 4 aout
15 janv ier 2022; »; 2021, 202 1-058 du 13 aout 2021, 2021-059 du 18 aout
2021, 2021-060 du 24 aotit 2021, 2021-061 du 31 aout
QuE Jes rnesures prevues au present arrete prennent 2021 , 2021-062 du 3 septembre 2021, 202 1-063 du
effet le 16 janvier 2022. 9 septembre 2021, 2021 -065 du 24 septembre 2021 ,
2021-066 du Ier octobre 2021, 2021-067 du 8 octobre 2021,
Quebec, le 15 janvier 2022 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021,
2021-073 du 22 octobre 2021 , 2021-074 du 25 octobre 2021,
Le ministre de la Sante et des Services sociaux, 2021-077 du 29 octobre 2021, 2021-078 du 2 novembre
CHRISTIAN DUBE 2021, 2021-079 du 14 novembre 2021 , 2021-083 du
10 decembre 2021, 2021-086 du l3 decembre 2021,
763 16 2021-087 du 14 decembre 2021, 2021-089 du 19 decembre
2021 , 2021- 090 du 20 decembre 2021, 2021 -092 du
22 decembre 2021, 2021-096 du 31 decembre 2021 et
A.M., 2022 2022-001 du 2 janvier 2022, prevoit notamment cer-
taines mesures particulieres applicables dans tout le
Arrêté numéro 2022-004 du ministre de la Santé et territoire québécois;
des Services sociaux en date du 15 janvier 2022
Yu que le décret numéro 1173-2021 du 1er septembre
Loi sur la santé publique 202 1, modi fie par le decret numero 1276 -2021 du 24 sep-
(chapitre S-2.2) tembre 2021 et par les arretes numeros 2021-067 du
8 octobre 2021 , 202 1-079 et 202 1-081 du 14 novembre
CONCERNANT l’ordonnance de mesures visant à 2021 , 2021-082 du 17 novembre 2021 et 2021-089 du
protéger la santé de la population dans la situation de 19 decembre 2021, prevoit !'obligation d'etre adequate-
pandémie de la COVID-19 ment protege pour acceder acertains lieux ou pour parti-
ciper à certaines activités;
LE MINI STRE DE LA SANTE ET DES SERVICES SOCIAUX,
Vu l’article 118 de la Loi sur la santé publique (chapitre de la Sante et des Services sociaux a ordonner toute
S-2.2) qui prévoit que le gouvernement peut déclarer un modification ou toute precision relative aux mesures
état d’urgence sanitaire dans tout ou partie du territoire qu’ils prévoient;

AR02624
Vu que le décret numéro 4-2022 du 12 janvier 2022 1° dans le onzieme alinea:

a prendre toute mesure prevue aux paragraphes 1° a) par la suppression des paragraphes 3.1° a 3.4°;
a 8° du premier alinea de !'article 123 de la Loi sur la
santé publique; b) par le remplacement, dans le paragraphe 4°, de
«toute ceremonie funeraire» par «une ceremonie fune -
CoNSIDERANT ou ’il y a lieu d’ordonner certaines raire se deroulant a l'interieur»;
c) par la suppression du paragraphe 7°;
ARRET E CE QUI SUIT:
d) par l'ajout apres le paragraphe 12° du suivant:
QuE le dispositif de l'arrete numero 2020-008 du
22 mars 2020, modifie par le decret numero 566-2020 du « 13° le paragraphe 6.1° ne s'applique pas dans une
27 mai 2020 et par Jes arretes numeros 2020-033 du 7 mai cafeteria ou ce qui en tient lieu :
2020, 2020-044 du 12 juin 2020 et 2021-054 du 16 juillet
2021 , soit de nouveau modifie par l'ajout, a la fin du a) d'un centre de services scolaire, d'une commis-
quatrieme alinea, des paragraphes suivants: sion scolaire ou d’un établissement d’enseignement privé
lorsqu' il offre des services aux eleves de !'education
« 5° les articles relatifs aux regles de formation prescolaire, de l'enseignement primaire, de l'enseigne-
des groupes d'eleves, exception faite des regles de ment secondaire de la formation generale des jeunes, de
compensation pour depassement des maxima d'eleves la formation professionnelle ou de la formation générale
par groupe, sont modifies pour permettre a l'employeur des adultes;
de repondre aux besoins;
b) d'un etablissement universitaire, d' un college ins-
6° les articles relatifs a la tache annuelle de l'ensei - titue en vertu de la Loi sur les colleges d'enseignement
gnant sont modifies pour permettre a l'employeur de general et professionnel (chapitre C-29), d ' un etablis-
repondre aux besoins; »; sement d’enseignement privé qui dispense des services
d’enseignement collégial et de tout autre établissement qui
Q u E le deuxieme alinea du dispositif du decret dispense des services d’enseignement de niveau collégial
numero 885-2020 du 19 ao0t 2020, modifie par le decret ou universitaire ou des services de formation continue,
numero 943-2020 du 9 septembre 2020, soit de nouveau uniquement lorsque les conditions suivantes sont reunies:
modi fie par l'ajout, a la fin, du paragraphe suivant:
i. une distance d'un metre est maintenue entre les
« 3° ceux dont la classe comprend au moins 60 % tables, a moins qu' une barriere physique permettant de
d 'eleves tenus de suivre les consignes d'isolement limiter la contagion ne les sépare;
établies par une autorité de santé publique en raison de la
COVID-19, et ce, a compter de la deuxieme journee du ii. un maximum de six personnes sont reunies autour
calendrier scolaire suivant l'atteinte de ce pourcentage; »; d' une meme table;
QUE le dispositif du décret numéro 885-2021 du c) utilisée dans le cadre des activités d’un camp de
23 juin 2021 , modi fie par les arretes numeros 2021-049 vacances ou d'un camp de jour, et ce, pourvu qu'une
du 1er juillet 202 1, 2021-050 du 2 juillet 2021, 202 1-053 distance minimale d' un metre soit maintenue entre les
du 10 juillet 2021, 2021- 055 du 30 juillet 2021, 2021-057 enfants de groupes difl:erents; »;
du 4 aoGt 2021, 2021-058 du 13 aoGt 2021, 2021-059 du
18 aoGt 2021 , 2021-060 du 24 ao0t 2021, 2021-061 du e) par !'insertion, apres le sous-paragraphe b du para-
31 aoGt 2021, 2021-062 du 3 septembre 2021, 2021- 063 graphe 21 °, du sous-paragraphe su ivant:
du 9 septembre 2021 , 2021-065 du 24 septembre 2021 ,
2021- 066 du Ier octobre 2021, 2021-067 du 8 octobre 2021, «c) elle fait partie de l'offre des programmes de sport-
2021- 068 du 9 octobre 2021, 2021- 069 du 12 octobre 2021, etudes, d'art-etudes et de concentration sportive et autres
202 1-073 du 22 octobre 2021 , 202 1-074 du 25 octobre 2021, projets pedagogiques particuliers de meme nature offerts
2021- 077 du 29 octobre 2021, 2021- 078 du 2 novembre aux eleves de l'enseignement primaire et secondaire de la
202 1, 2021-079 du 14 novembre 2021, 2021-083 du formation generale des jeunes; »;
10 decembre 2021 , 2021 - 086 du 13 decembre 2021 ,
2021- 087 du 14 decembre 2021, 2021-089 du 19 decembre .fJ par le remplacement, dans le paragraphe 29°, du
202 1, 2021-090 du 20 decembre 2021 , 202 1-092 du
sous-paragraphe b par le suivant0 :
22 decembre 2021, du 2021- 096 du 31 decembre 2021
et 2022- 001 du 2 janvier 2022, soit de nouveau modi fie:

AR02625
« b) l'eleve peut retirer son masque de procedure pen - 2° par la suppression, dans le paragraphe 14°, de
dant qu' il re9oit un soin ou beneficie d' un service qui « , se déroulant dans une salle louée ou dans une salle
necessite de l'en lever ou joue d'un instrument a vent;»; communautaire, »;
g) par le rem placement des paragraphes 31 ° a 38° par Qu E les mesures prevues au present arrete prennent
les su ivants: effet le 17 janvier 2022 a 5h, a !'exception de celle prevue
au paragraphe 1° du quatrieme alinea qui prend effet
«31° lorsqu' un enseignant de ('education prescolaire, le 18 janvier 2022;
de l’enseignement primaire ou de l’enseignement
secondaire de la formation générale des jeunes d’un centre Quebec, le 15 janvier 2022
de services scolaire, d' une commission scolaire ou d'un
établissement d’enseignement privé ne peut se présenter Le minis/re de fa Sante et des Services sociaux,
à l’école parce qu’il est isolé en raison de la COVID-19 CHRISTIAN 0UBJi
mais qu'il est apte au travail, ii doit, a la demande de
l'employeur, dispenser les services d'enseignement a 76317
distance depuis son lieu d'isolement aux eleves presents
en classe qui sont surveilles par un adulte, lequel assure
en outre un soutien technique aux eleves;
32° le paragraphe 31 ° ne s'applique pas aux ensei -

gnants d’une école spécialisée ou d’une classe spécialisée
pour des eleves handicapes ou en difficulte d'adaptation
ou d'apprentissage qui relevent de services regionaux ou
supraregionaux de scolarisation;
33° les activites extrascolaires de !'education pres -

colaire, de l'enseignement primaire, de l'enseignement
secondaire de la formation generale des jeunes, de la
formation générale des adultes et de la formation pro-
fessionnelle sont suspendues, sauf si elles sont offertes a
distance aux eleves qui ne sont pas dans un etablissement
d’enseignement;
2° par !'insertion, apres le douzieme al inea, du suivant:
« Qu E, malgre le paragraphe 4° de l'alinea precedent,

une personne puisse se trouver dans un tel lieu pour y
exercer une activite n'ayant pas ete autrement suspendue
par tout decret OU en beneficier; »;
3° par la suppression de l'annexe;
QuE le troisieme alinea du dispositif du decret

numéro 1173-2021 du 1er septembre 2021, modifie par le
decret numero 1276-2021 du 24 septembre 2021 et par les
arretes numeros 202 1-067 du 8 octobre 2021 , 2021-079 et
2021-081 du 14novembre2021 , 2021-082du 17novembre
2021 et 2021-089 du 19 decembre 2021 , soit de
nouveau modi fie:
1° par )' insertion , apres le paragraphe 4°, du

paragraphe suivant:
«4.1° a une succursale de la Societe des alcools du

Quebec ou de la Societe quebecoise du cannabis; »;

AR02626
Ceci est la pièce « FF » au soutien de


AR02627
394A GAZETTE OFFICIELLE DU QUÉBEC, 3 février 2022, 154e année, no 5A Partie 2
A.M., 2022 ARRETE CE QUJ SUIT:
Arrêté numéro 2022-010 du ministre de la Santé et QUE le cinquierne alinea du dispositif de l'arrete
des Services sociaux en date du 27 janvier 2022 nurnero 2020-087 du 4 novembre 2020, modifie par les
arretes numeros 2021-022 du 7 avril 202 1 et 2021-091 du
Loi sur la santé publique 21 decernbre 202 1, soit de nouveau modifie par l'ajout,
(chapitre S-2.2) a la fin, du paragraphe suivant:
CONCERNANT l’ordonnance de mesures visant à (( 40 les premiers répondants non visés au paragra-
protéger la santé de la population dans la situation de phe 3°, a la condition d'avoir suivi une formation a cet effet
pandémie de la COVID-19 dispensee sous l'autorite du directeur des soins infirmiers
d'un etablissement de sante et de services sociaux et d'etre
LE MINISTRE DE LA SANTE ET DES SE RVICES SOCIAUX, sous la supervision d'un infirmier ou d'une infirmiere,
d'un medecin, d ' un inhalotherapeute, d'un infirmier ou
Vu l’article 118 de la Loi sur la santé publique (chapitre d'une infirmiere auxiliaire ou d ' un technologiste medi -
S-2.2) qui prévoit que le gouvernement peut déclarer un cal, lequel doit etre present sur Jes lieux ou est effectue
état d’urgence sanitaire dans tout ou partie du territoire le prélèvement; ».
lation, reelle ou imminente, exige I'application immediate Quebec, le 27 janvier 2022
pour protéger la santé de la population; Le ministre de la Sante et des Services sociaux,
CHRISTIAN DUBE
déclare l’état d’urgence sanitaire dans tout le territoire 76406
quebecois pour une periode de I 0 jours;
Vu que ce décret prévoit également que le ministre

de la Sante et des Services sociaux peut prendre toute
A.M., 2022
mesure requise pour s’assurer que le réseau de la Arrêté numéro 2022-011 du ministre de la Santé et
sante et des services sociaux dispose des ressources des Services sociaux en date du 29 janvier 2022
humaines nécessaires;
Vu que l'etat d' urgence sanitaire a toujours ete renou - (chapitre S-2.2)
le decret numero 94-2022 du 26 janvier 2022; CONCERNANT l’ordonnance de mesures visant à
Vu que l'arrete numero 2020-087 du 4 novembre 2020, pandémie de la COVID-19
modifie par les arretes numeros 202 1-022 du 7 avril 202 1
et 202 1-091 du 21 decembre 2021, prevoit notamment la LE M IN ISTRE DE LA SA NTE ET DES SERVIC ES SOC IAU X,
possibilité pour le directeur médical national des services
prehospitaliers d'urgence de delivrer, sans frais et sans Vu l’article 118 de la Loi sur la santé publique (chapitre
obligation de suivre un programme d’intégration ou de S-2.2) qui prévoit que le gouvernement peut déclarer un
formation, une autorisation speciale d'etat d' urgence sani- état d’urgence sanitaire dans tout ou partie du territoire
taire permettant d'effectuer les prelevements necessaires au québécois lorsqu’une menace grave à la santé de la popu-
test de dépistage de la COVID-19 à certaines conditions; lation, reelle ou imminente, exige !'application immediate
Vu que le decret numero 94-2022 du 26 janvier 2022 pour protéger la santé de la population;
a prendre toute mesure prevue aux paragraphes I O a 8° Vu le décret numéro 177-2020 du 13 mars 2020 qui
du premier alinéa de l’article 123 de la Loi sur la déclare l’état d’urgence sanitaire dans tout le territoire
santé publique; quebecois pour une periode de 10 jours;
CONSIDERANT QU ’il y a lieu d’ordonner certaines Vu que l'etat d'urgence sanitaire a toujours ete renou -
mesures pour protéger la santé de la population; vele depuis cette date par divers decrets, notamment par
le decret numero 94-2022 du 26 janvier 2022;

AR02628
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 3 février 2022, 154e année, no 5A 395A
Vu le decret numero 964-2020 du 21 septembre 2020 22 octobre 2021, 2021-074 du 25 octobre 2021, 2021-077
prévoit la rémunération des enseignants retraités depuis du 29 octobre 2021, 2021-078 du 2 novembre 2021,
le 1er jui llet 2015, titulaires d' une autorisation d'enseigner, 2021-079 du 14 novembre 2021, 2021-083 du 10 decembre
qui reviennent au travail pour dispenser l’éducation prés- 2021 , 2021 -086 du 13 decernbre 2021, 2021 -087 du
colaire ou l’enseignement primaire ou secondaire; 14 decembre 2021, 2021-089 du 19 decembre 2021 ,
2021-090 du 20 decembre 202 1, 2021-092 du 22 decembre
Vu que le decret numero 885-2021 du 23 juin 2021, 2021, 2021-096 du 31 decembre 2021, 2022-001 du
modifie par les arretes numeros 2021-049 du 1er juillet 2 janvier 2022 et 2022-004 du 15 janvier 2022, soit de
2021, 2021-050 du 2juillet 2021, 2021-053 du 10 juillet nouveau modifie:
2021, 2021-055 du 30 juil let 2021, 2021 -057 du 4 aoilt
2021 , 2021-058 du 13 ao0t 2021, 2021-059 du 18 ao0t 2021, 1° par le remplacement des paragraphes 1° et 1.1° par
2021-060 du 24 ao0t 2021, 2021-061 du 31 ao0t 2021, le suivant:
2021-062 du 3 septembre 2021, 2021 -063 du 9 septembre
2021, 2021-065 du 24 septembre 2021, 2021-066 du « 10 dans une résidence privée ou ce qui en tient lieu
1er octobre 2021, 2021-067 du 8 octobre 2021, 2021-068 du ou dans une unité d’hébergement ou un dortoir d’un éta-
9 octobre 2021, 2021 -069 du 12 octobre 202 1, 2021 -073 blissement d'hebergernent touristique, un maximum de
du 22 octobre 2021, 2021-074 du 25 octobre 202 1, quatre personnes peuvent s'y trouver, sauf s'il s'agit des
2021-077 du 29 octobre 2021, 2021-078 du 2 novembre occupants d'un maximum de deux residences privees ou
2021 , 2021 -079 du 14 novembre 2021, 2021 -083 du de ce qui en tient lieu; »;
10 decembre 2021, 2021- 086 du 13 decembre 2021,
2021-087 du 14 decembre 2021, 2021 -089 du 19 decembre 2° par le rem placement du paragraphe 3° par le suivant:
2021, 2021-090 du 20 decembre 2021, 2021-092 du
22 decembre 202 1, 2021 -096 du 31 decembre 202 1, «3° malgre les paragraphes 1° et 2°, peut se trouver
2022-00 I du 2 janvier 2022 et 2022-004 du 15 janvier dans une résidence privée ou ce qui en tient lieu ou dans
2022, prevoit notamment certaines mesures particulieres une unité d’hébergement ou un dortoir d’un établissement
applicables dans tout le territoire québécois; d'hebergement touristique, incluant le terrain, le balcon
ou la terrasse d’une telle résidence ou d’une telle unité
Vu que le decret numero 94-2022 du 26 janvier d'hebergement, toute personne presente pour y recevoir
2022 habilite le ministre de la Santé et des Services ou y otfrir un service ou un soutien, selon le cas, et qui
sociaux a prendre toute mesure prevue aux paragra- n’en est pas un occupant; »;
phes 1° a 8° du premier alinea de !'article 123 de la
Loi sur la santé publique; 3° dans le paragraphe 6.1° :
CONS IDERANT QUE la situation actuelle de la pandémie a) par le remplacement du sous-paragraphe a par
de la COVID-19 permet d’assouplir certaines mesures les suivants:
mises en place pour proteger la sante de la population,
tout en maintenant certaines d’entre elles nécessaires pour « a) les arcades et, pour leurs activites interieures,
continuer de la protéger; les sites thematiques, les centres et pares d'attraction,
les centres d’amusement et les parcs aquatiques;
ARRETE CE QUI SUIT:
a.1) les centres récréatifs pour leurs activités inté-
QUE le premier alinéa du dispositif du décret rieures, a mains que les activites qui s'y deroulent fassent
numero 964-2020 du 21 septembre 2020 soit modifie par parties de l'offre des programmes de sport-etudes, d'art-
la suppression de « depuis le 1er juillet 2015 »; etudes et de concentration sportive et autres projets peda-
gogiques particuliers de meme nature offerts aux eleves
QUE le onzième alinéa du dispositif du décret de l’enseignement primaire et secondaire de la formation
numero 885-2021 du 23 juin 2021, modifie par les generale des jeunes; »;
arretes numeros 2021-049 du 1er juillet 2021, 2021-050 du
2 juillet 202 1, 2021 -053 du 10 juillet 2021, 2021-055 du b) par la suppression, dans le sous-paragraphe e, de
30 juillet 2021, 2021-057 du 4 aoilt 2021, 2021-058 du « ou de nourriture »;
13 aoilt 2021, 2021-059 du 18 aout 2021 , 2021-060 du
24 aoilt 202 1, 2021-061 du 3 1 aoilt 2021, 2021-062 c) par le remplacement des sous-paragraphes f et g par
du 3 septembre 2021 , 2021-063 du 9 septembre 2021, le suivant:
2021-065 du 24 septembre 2021, 2021-066 du Ier octobre
2021, 2021-067 du 8 octobre 2021, 2021 -068 du 9 octobre « f) les salles a manger des restaurants, mais unique-
2021, 2021-069 du 12 octobre 2021, 2021-073 du ment de minuit à 5 h le lendemain; »;

AR02629
d) par l'ajout, a la fin, du sous-paragraphe suivant: d) seules les personnes assises à une table peuvent
recevoir un service ou consommer des boissons;
« I) tout lieu interieur, autre qu' une residence privee ou
ce qui en tient lieu, lorsqu'il est utilise aux fins d'y tenir e) les clients ne peuvent se servir directement dans
une activité de nature évènementielle ou sociale qui n’est un buffet ou un comptoir libre-service de couverts
pas autrement visée par le présent décret; »; ou d’aliments;
4° par !'i nsertion, apres le paragraphe 6.1 °, f) le service se termine à 23 heures;

des suivants:
g) toute boisson alcoolique ne peut etre servie qu'en
« 7° dans un restaurant, un chalet d'un centre d'acti - accompagnement d’aliments;
vites sportives, un lieu interieur ou un biitiment adjacent
d ' un relais de motoneige ou de quad, une aire de h) la pratique de la danse est interdite;
restauration d’un centre commercial ou d’un commerce
d’alimentation ou dans toute autre salle utilisée à des fins go le titulaire d' un permis autorisant la vente ou le
de restau ration : service de boissons alcooliques pour consommation sur
place ne peut admettre simultanement, dans chaque piece
a) à l’intérieur de l'etablissement ou est exploite le perm is, qu' un maxi -
mum de 50 % du nombre de personnes pouvant y etre
i. les lieux sont amenages en espa9ant les tables au admises en vertu de ce perm is, ou y tolerer un nombre de
maximum, en autant qu'une distance mini male d' un metre personnes superieur ii ce maximum;»;
soit maintenue entre elles, a moins qu'une barriere phy-
sique permettant de limiter la contagion ne les sépare; 5° par la suppression du paragraphe 12°;
ii. un maximum de quatre personnes peuvent etre 6° par le remplacement, dans le paragraphe 13°,
reunies auteur d'une meme table situee a l' interieur, sauf de «6.1° » par «7° »;
s'il s'agit des occupants d' un maximum de deux residences
privées ou de ce qui en tient lieu; 7° par la suppression de ce qui suit:
iii. la capacite du lieu est fixee ii 50 % de sa « 13° le paragraphe 7° ne s'applique pas dans une
capacité habituelle; cafeteria, ou ce qui en tient lieu:
bJ a l'exterieur: a) d'un centre de services scolaire, d'une commis-

sion scolaire ou d’un établissement d’enseignement privé
i. les lieux sont amenages pour qu' une distance mini - lorsqu' i I offre des services aux eleves de !'education
male d'un metre soit maintenue entre les tables, ii moins préscolaire ou de l’enseignement primaire ou secondaire
qu’une barrière physique permettant de limiter la conta- de la formation generale des jeunes;
gion ne les sépare;
b) utilisée dans le cadre des activités d’un camp de
ii. un maximum de quatre personnes peuvent etre vacances ou d'un camp de jour, et ce, pourvu qu'une
reunies autour d' une meme table, saufs'il s'agit des occu- distance minimale d’un mètre soit maintenue entre les
pants d' un maximum de deux residences privees ou de ce enfants de groupes differents; »;
qui en tient lieu;
go par !'insertion, apres le paragraphe 14°, du suivant:
c) malgré le sous-sous-paragraphe ii des sous-
paragraphes a et b, peut se trouver autour d' une table avec « 15° la capacite interieure d ' un biodome, d' un
les personnes qui y sont visees: planetarium, d'un insectarium, d'un jardin botanique,
d' un aquarium et d'un jardin zoologique est fixee a 50 %
i. toute personne presente pour y offrir un service ou de sa capacité habituelle; »;
un soutien requis par une personne en raison de son état
de sante OU a des fins de securite, le cas echeant; 9° dans le paragraphe 21°:
ii. toute autre personne qui nécessite ou à qui elles a) par !' insertion , apres le sous-paragraphe a
procurent assistance, le cas echeant; du suivant:

AR02630
« a .I) elle est organisee dans un lieu ou les activites 12° par la suppression du paragraphe 33°;
ne sont pas autrement suspendues pour un groupe de
personnes iigees de moins de 18 ans, selon les condi- QUE les mesures prevues au present arrete prennent
tions su ivantes: effet le 31 janvier 2022.
i. au plus 25 personnes sont présentes sur l’aire dédiée Quebec, le 29 janvier 2022
au loisir ou au jeu;
ii. si un sport d'equipe est pratique, les parties contre CHRISTIAN DUBE
un autre groupe sont interdites;
76412
iii. la capacite du vestiaire, le cas echeant, est fixee
a 50% de sa capacite habituelle;»;
b) par !'insertion , apres le sous-paragraphe c,
du suivant:
« c.l) elle s'inscrit dans le cadre des activites extra-

scolaires offertes aux eleves d' un meme etablissement de
la formation generale des jeunes; »;
c) par !'insertion, apres le sous-paragraphe e ,

du suivant:
« e.I) s'il s'agit de l'entrainement de joueurs de toute

équipe sportive d’un établissement d’enseignement de
niveau universitaire, d' un college institue en vertu de la
Loi sur les collèges d’enseignement général et profession-
nel (chapitre C-29), d'un etablissement d'enseignement
privé qui dispense des services d’enseignement collégial
qui, d'une part, n'est pas constituee dans le cadre des ser-
vices d'enseignement et qui, d'autre part, pratique son
sport de manière inter-collégiale ou inter-universitaire; »;
10° par le rem placement, dans le paragraphe 26. 1°, de

« dans un lieu exterieur public» par « sur un meme site
d' un lieu exterieur public>>;
11° par !'insertion, apres le paragraphe 28°, du suivant:
«28.1° malgre le paragraphe precedent, les eleves et les

etudiants des etablissements d'enseignement universitaire,
des colleges, des etablissements d'enseignement collegial
privés et des autres établissements qui dispensent des ser-
vices d’enseignement de niveau collégial ou universitaire
et des etablissements ou sont dispenses des services edu -
catifs et d’enseignement de la formation professionnelle
ou de la formation générale des adultes ou des services de
formation continue, doivent porter un masque de proce -
dure lors de la pratique de toute activité sportive dans tout
biitiment ou local utilise par l'etablissement; »;

AR02631
Ceci est la pièce « GG » au soutien de


AR02632
A.M., 2022 Vu que le décret numéro 114-2022 du 2 février 2022

Arrêté numéro 2022-012 du ministre de la Santé et a prendre toute mesure prevue aux paragraphes 1°
des Services sociaux en date du 4 février 2022 a 8° du premier alinea de !'article 123 de la Loi sur la
santé publique;
(chapitre S-2.2) CON SIDERANT QUE la situation actuelle de la pandémie
C ONC ER N ANT l’ordonnance de mesures visant à mises en place pour proteger la sante de la population,
protéger la santé de la population dans la situation de tout en maintenant certaines d’entre elles nécessaires pour
pandémie de la COVID-19 continuer de la protéger;
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, ARRETE CE o u 1 s u n:
Vu l’article 118 de la Loi sur la santé publique (chapitre Q U E le onzième alinéa du dispositif du décret
S-2.2) qui prévoit que le gouvernement peut déclarer un numero 885-2021 du 23 juin 2021 , modifie par Jes arretes
état d’urgence sanitaire dans tout ou partie du territoire numéros 2021-049 du 1er juillet 2021 , 2021 -050 du
québécois lorsqu’une menace grave à la santé de la popu- 2 juillet 2021, 2021-053 du 10 juillet 2021, 2021-055 du
lation, reel le ou imminente, exige !'application immediate 30 juillet 2021 , 2021- 057 du 4 aout 2021, 2021-058 du
de certaines mesures prévues à l’article 123 de cette loi 13 aout 2021 , 2021-059 du 18 aout 2021, 2021-060
pour protéger la santé de la population; du 24 aoGt 2021, 2021-061 du 31 aoGt 2021, 2021 -062
du 3 septembre 2021 , 2021-063 du 9 septembre 2021,
Vu le décret numéro 177-2020 du 13 mars 2020 qui 2021-065 du 24 septembre 2021, 2021-066 du 1er octobre
déclare l’état d’urgence sanitaire dans tout le territoire 2021, 2021-067 du 8 octobre 2021, 2021-068 du 9 octobre
quebecois pour une periode de lO jours; 202 1, 2021 - 069 du 12 octobre 2021 , 2021 - 073 du
22 octobre 2021, 2021-074 du 25 octobre 2021 , 2021-077
Vu que l'etat d'urgence sanitaire a toujours ete renou- du 29 octobre 2021 , 2021-078 du 2 novembre 2021,
vele depuis cette date par divers decrets, notamment par 2021-079 du 14 novembre 2021, 2021-083 du lO decembre
le décret numéro 114-2022 du 2 février 2022; 2021 , 2021-086 du 13 decembre 2021, 2021-087 du
14 decembre 2021, 2021-089 du 19 decembre 2021,
Vu que le decret numero 885-2021 du 23 juin 2021, 2021-090 du 20 decembre202I, 2021-092 du 22 decembre
modifie par Jes arretes numeros 2021-049 du 1er juillet 2021, 2021-096 du 31 decembre 2021, 2022-001 du
202 1, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet 2 janvier 2022, 2022-004 du 15 janvier 2022 et 2022-011
2021 , 2021-055 du 30 juillet 2021, 2021-057 du 4 aoGt du 29 janvier 2022, soit de nouveau modifie:
2021, 2021-058 du 13 aoGt 2021, 2021 -059 du 18 aout
2021 , 2021-060 du 24 aoGt 2021, 2021-061 du 31 aout 1° par !'insertion, apres le paragraphe 15°, du suivant :
2021, 2021-062 du 3 septembre 2021, 2021-063 du
9 septembre 2021, 2021-065 du 24 septembre 2021, « 16° )ors d'un evenement exterieur ouvert au public,
2021-066 du Ier octobre 2021 , 2021-067 du 8 octobre 2021 , incluant un festival, )'assistance maximale est d'au plus
2021-068 du 9 octobre 2021 , 2021-069 du 12 octobre 2021, 1 000 personnes par site; »;
2021-077 du 29 octobre 2021, 2021-078 du 2 novembre 2° par le remplacement de ce qui precede le sous-sous-
2021, 2021-079 du 14 novembre 2021 , 2021-083 du paragraphe i du sous-paragraphe a. I du paragraphe 21°
10 decembre 2021, 2021-086 du 13 decembre 2021, par ce qui suit:
2021-087 du 14 decembre 2021, 2021-089 du 19 decembre
2021 , 2021-090 du 20 decembre 2021 , 2021-092 du « a.1) elle est organisée dans un lieu où les activités
22 decembre 2021, 2021-096 du 31 decembre 202L ne sont pas autrement suspendues pour un groupe de per-
2022-001 du 2 janvier 2022, 2022-004 du 15 janvier sonnes agees de moins de 18 ans ou, dans le cas ou elle
2022 et 2022-011 du 29 janvier 2022, prevoit notamment est organisée par une fédération d’organismes sportifs ou
certaines mesures particulières applicables dans tout le un organisme reconnus par le ministre de !'Education, du

AR02633
Loisir et du Sport, pour un groupe compose de personnes Vu que le decret numero 885-2021 du 23 juin 2021 ,
âgées de moins de 18 ans et de personnes nées après le modifie par les arretes numeros 2021-049 du l er juillet
1er janvier 2001, selon les conditions suivantes: »; 2021 , 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
2021, 2021 -055 du 30 juillet 2021 , 2021 -057 du 4 aoGt
3° par le rem placement du paragraphe 26.1 ° par 2021, 2021-058 du 13 aout 2021 , 2021-059 du 18 aoGt
le suivant: 2021, 2021 -060 du 24 aoGt 2021 , 2021-061 du 31 aoGt
2021, 2021-062 du 3 septembre 2021, 2021-063 du
((26.1° ii est interdit d'organiser un rassemblement de 9 septembre 2021, 2021-065 du 24 septem bre 2021 ,
plus de 250 personnes sur un meme site d'un lieu exterieur 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
public, y compris dans le cadre d'un evenement de nature 2021-068 du 9 octobre 2021 , 2021-069 du 12 octobre 2021 ,
commerciale, religieuse, culturelle, sportive, de loisir ou 2021-073 du 22 octobre 2021 , 2021-074 du 25 octobre 2021 ,
de divertissement, ou d'y participer, sauf: 2021-077 du 29 octobre 2021, 2021-078 du 2 novembre
2021 , 2021-079 du 14 novembre 2021, 2021-083 du
a) lorsque les personnes rassemblees exercent leur 10 decembre 2021, 2021-086 du 13 decembre 2021 ,
droit de manifester pacifiquement; 2021-087 du 14 decembre 2021, 2021-089 du 19 decembre
2021, 2021-090 du 20 decembre 2021 , 2021 -092 du
b) dans le cadre d’un évènement se déroulant confor- 22 decembre 2021 , 2021-096 du 31 decembre 2021 ,
mement au paragraphe 16°; ». 2022-001 du 2janvier 2022, 2022-004 du IS janvier 2022,
2022-011 du 29 janv ier 2022 et 2022-0 I 2 du 4 fevrier
Quebec, le 4 fevrier 2022 2022, prevoit notamment certaines mesures particulieres
CHRISTIAN D U BE Vu que le décret numéro 1173-2021 du 1er septembre
2021, modifie par le decret numero 1276 -2021 du
76435 24 septembre 2021 et par les arretes numeros 2021-067
2021, 2021-082 du 17 novembre 2021, 2021-089 du
A.M., 2022 19 decembre 2021 , 2022-004 du IS janvier 2022 et
2022-007 du 23 janvier 2022, prevoit !'obligation d'etre
Arrêté numéro 2022-013 du ministre de la Santé et adequatement protege pour acceder a certains lieux ou
des Services sociaux en date du 5 février 2022 pour participer à certaines activités;
Loi sur la santé publique Vu que ces décrets habilitent également le ministre
(chapitre S-2.2) de la Sante et des Services sociaux a ordonner toute
modification ou toute precision relative aux mesures
CONCER N A N T l’ordonnance de mesures visant à qu’ils prévoient;
pandémie de la COVID-19 Vu que le décret numéro 114-2022 du 2 février 2022
LE MINISTRE DE LA SANTE ET DES S E RVIC ES SOC IAUX, a prend re toute mesu re prevue aux paragraphes 1°
Vu l’article 118 de la Loi sur la santé publique (chapitre santé publique;
état d’urgence sanitaire dans tout ou partie du territoire CoNSIDERANT QUE la situation actuelle de la pandémie
québécois lorsqu’une menace grave à la santé de la popu- de la COVID-19 permet d’assouplir certaines mesures
lation, reelle ou imminente, exige !'application immediate mises en place pour proteger la sante de la population,
de certaines mesures prévues à l’article 123 de cette loi tout en maintenant certaines d’entre elles nécessaires pour
pour protéger la santé de la population; continuer de la protéger;
Vu le décret numéro 177-2020 du 13 mars 2020 qui ARRETE CE QUI SUIT:
quebecois pour une periode de 10 jours; QUE le onzième alinéa du dispositif du décret
numero 885-2021 du 23 juin 2021 , modifie par les arretes
Vu que l'etat d'urgence sanitaire a toujours ete renou - numéros 2021-049 du 1er juillet 2021, 2021 -050 du
vele depuis cette date par divers decrets, notamment par 2 juillet 2021, 2021 -053 du 10 juillet 2021, 2021-055
le décret numéro 114-2022 du 2 février 2022; du 30 juillet 2021, 2021-057 du 4 aout 2021, 2021-058

AR02634
Ceci est la pièce « HH » au soutien de


AR02635
Loisir et du Sport, pour un groupe compose de personnes Vu que le decret numero 885-2021 du 23 juin 2021 ,
âgées de moins de 18 ans et de personnes nées après le modifie par les arretes numeros 2021-049 du l er juillet
1er janvier 2001, selon les conditions suivantes: »; 2021 , 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
2021, 2021 -055 du 30 juillet 2021 , 2021 -057 du 4 aofit
3° par le rem placement du paragraphe 26.1 ° par 2021, 2021-058 du 13 aofit 2021 , 2021-059 du 18 aofit
le suivant: 2021, 2021 -060 du 24 aofit 2021, 2021-061 du 31 aofit
2021, 2021-062 du 3 septembre 2021. 2021-063 du
((26.1° ii est interdit d'organiser un rassemblement de 9 septembre 2021, 2021-065 du 24 septem bre 2021 ,
plus de 250 personnes sur un meme site d'un lieu exterieur 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
public, y compris dans le cadre d'un evenement de nature 2021-068 du 9 octobre 2021 , 2021-069 du 12 octobre 2021 ,
commerciale, religieuse, culturelle, sportive, de loisir ou 2021-073 du 22 octobre 2021 , 2021-074 du 25 octobre 2021 ,
de divertissement, ou d'y participer, sauf: 2021-077 du 29 octobre 2021, 2021-078 du 2 novembre
2021, 2021-079 du 14 novembre 2021, 2021-083 du
a) lorsque les personnes rassemblees exercent leur 10 decembre 2021, 2021-086 du 13 decembre 2021,
droit de manifester pacifiquement; 2021-087 du 14 decembre 2021, 2021-089 du 19 decembre
2021, 2021-090 du 20 decembre 2021, 2021 -092 du
b) dans le cadre d’un évènement se déroulant confor- 22 decembre 2021 , 2021-096 du 31 decembre 2021 ,
mement au paragraphe 16°; ». 2022-001 du 2janvier 2022, 2022-004 du IS janvier 2022,
2022-011 du 29 janv ier 2022 et 2022-012 du 4 fevrier
Quebec, le 4 fevrier 2022 2022, prevoit notamment certaines mesures particulieres
CHRISTIAN DUBE Vu que le décret numéro 1173-2021 du 1er septembre
76435 24 septembre 2021 et par les arretes numeros 2021-067
2021, 2021-082 du 17 novembre 2021, 2021-089 du
A.M., 2022 19 decembre 2021 , 2022-004 du 15 janvier 2022 et
2022-007 du 23 janvier 2022, prevoit !'obligation d'etre
Arrêté numéro 2022-013 du ministre de la Santé et adequatement protege pour acceder a certains lieux ou
des Services sociaux en date du 5 février 2022 pour participer à certaines activités;
Loi sur la santé publique Vu que ces décrets habilitent également le ministre
(chapitre S-2.2) de la Sante et des Services sociaux a ordonner toute
CONCER N ANT l’ordonnance de mesures visant à qu’ils prévoient;
pandémie de la COVID-19 Vu que le décret numéro 114-2022 du 2 février 2022
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, a prendre toute mesure prevue aux paragraphes 1°
lation, reelle ou imminente, exige !'application immediate mises en place pour proteger la sante de la population,
quebecois pour une periode de 10 jours; QUE le onzième alinéa du dispositif du décret
numero 885-2021 du 23 juin 2021 , modifie par les arretes
Vu que l'etat d'urgence sanitaire a toujours ete renou - numéros 2021-049 du 1er juillet 2021, 2021 -050 du
vele depuis cette date par divers decrets, notamment par 2 juillet 2021, 2021 -053 du IO juillet 2021, 2021- 055
le décret numéro 114-2022 du 2 février 2022; du 30 juillet 2021, 2021-057 du 4 aofit 2021, 2021-058

AR02636
du 13 aout 2021, 2021 -059 du 18 aout 2021, 2021-060 adultes d'un meme etablissement, lorsqu'ils beneficient de
du 24 aout 2021, 2021-061 du 31 aout 2021, 2021-062 tout service offert par un centre de services scolaire, une
du 3 septembre 2021, 2021-063 du 9 septembre 2021, commission scolaire ou un établissement d’enseignement
2021-065 du 24 septembre 2021, 2021-066 du l er octobre privé ou des enfants d’un camp de vacances ou d’un camp
2021, 2021-067 du 8 octobre 2021, 2021-068 du 9 octobre de jour et des personnes qui accompagnent ces eleves ou
2021, 2021-069 du 12 octobre 2021, 2021-073 du ces enfants;
22 octobre 2021, 202 1-074 du 25 octobre 2021, 2021-077
du 29 octobre 2021, 2021-078 du 2 novembre 2021, b) toute personne du public demeure assise à sa place;
2021-079 du 14 novembre 2021, 2021-083 du lO decembre
2021, 2021 -086 du 13 decembre 2021, 2021-087 du c) le couvre-visage porte par le public doit etre un
14 decembre 2021, 2021- 089 du 19 decembre 2021, masque de procédure; »;
2021-090 du 20 decembre 2021, 2021-092 du 22 decembre
2021, 2021-096 du 31 decembre 2021, 2022-001 du 5° par !' insertion, dans le sous-paragraphe f du
2 janvier 2022, 2022-004 du 15 janvier 2022, 2022-01 I paragraphe 22° et apres << ceremonie funeraire », de
du 29 janvier 2022 et 2022-012 du 4 fevrier 2022, soit de « ou de mariage »;
nouveau modi fie:
6° par la suppression du paragraphe 28.1 °;
1° par le remplacement du paragraphe4° par le suivant:
7° par le rem placement du sous- paragraphe b du para-
«4° lors d' une ceremonie funeraire ou de mariage: graphe 29° par le suivant:
a) un maximum de 250 personnes peuvent faire partie « b) l’élève peut retirer son masque de procédure pen-
de )'assistance, sans depasser 50 % de la capacite habi - dant qu'il rec;:oit un soin, beneficie d'un service ou pratique
tuelle du lieu où elle se déroule; une activité physique ou une autre activité qui nécessite
de l’enlever; »;
b) aucun roulement de personnes n’est permis lors de
!'exposition du corps ou des cendres et de la reception QUE le quatrième alinéa du dispositif du décret
des condoleances et le nombre maximal de personnes numéro 1173-2021 du 1er septembre 2021, modifie par le
présentes est de 50 personnes; »; decret numero 1276 -2021 du 24 septembre 2021 et par les
arretes numeros 2021-067 du 8 octobre 2021, 2021-079 et
2° par !'insertion, avant le sous-paragraphe b du para- 2021-081 du l4novembre2021 ,202l-082du l7novembre
graphe 5°, du sous-paragraphe suivant: 2021, 202 1-089 du 19 decembre 2021, 2022-004 du
15 janvier 2022 et 2022-007 du 23 janvier 2022, soit de
« a) )'assistance maximale pour !'ensemble de ce nouveau modifiepar le rem placement des paragraphes 15°
batiment est fixee a 50% de sa capacite habituelle, sans et 16° par Jes suivants:
depasser un maximum de 250 personnes; »;
« 15° ii une ceremonie funeraire a laquelle assistent
3° par la suppression, dans le paragraphe 6.1°, des plus de 50 personnes à l’intérieur;
sous-paragraphes d et k;
15.1 à une cérémonie de mariage à l’intérieur;
4° par le remplacement du paragraphe 14° par
le suivant: 16° a un lieu de culte, sauf pour une ceremonie fune-
raire à laquelle assistent 50 personnes ou moins; »;
« 14° dans les cinemas et les salles ou sont presentes
les arts de la scene, y compris les lieux de diffusion, pour QuE les mesures prevues au present arrete prennent
une production, un tournage audiovisuel, un spectacle effet le 7 fevrier 2022, a !'exception de celles prevues aux
interieur, ainsi que pour un entra7nement ou un evenement sous-paragraphes 6° et 7° du premier alinea qui prennent
sport if interieur: effet le 5 fevrier 2022.
a) !'assistance maximale de chaque salle est fixee a Quebec, le 5 fevrier 2022

50 % de sa capacite habituelle sans depasser un maximum
de 500 personnes, a moins qu'elle soit composee d'eleves le ministre de fa Sante el des Services sociaux,
de l’éducation préscolaire ou de l’enseignement primaire CHRISTIAN DUBE
ou secondaire de la formation genera le des jeunes, de la
formation professionnelle et de la formation générale des 76434

AR02637
Ceci est la pièce « II » au soutien de


AR02638
A.M., 2022 Vu que le décret numéro 1173-2021 du 1er septembre

2021, modifie par le decret numero 1276-2021 du
Arrêté numéro 2022-015 du ministre de la Santé 24 septembre 2021 et par les arretes numeros 2021-067
et des Services sociaux en date du 11 février 2022 du 8 octobre 2021, 2021 -079 et 2021-081 du 14 novembre
2021 , 2021 -082 du 17 novembre 2021, 2021 -089 du
Loi sur la santé publique 19 decembre 2021, 2022-004 du 15 janvier 2022,
(chapitre S-2.2) 2022-007 du 23 janvier 2022 et 2022-013 du 5 fevrier
2021 , prevoit !'obligation d'etre adequatement pro-
CONCERNANT l’ordonnance de mesures visant à tege pour acceder a certains lieux ou pour participer a
protéger la santé de la population dans la situation de certaines activites;
pandemie de la COVID-1 9
LE MINISTRE DE LA SANTE ET DES SERVICES SOC IAUX, de la Sante et des Services sociaux a ordon ner toute
Vu l’article 118 de la Loi sur la santé publique (chapitre qu'ils prevoient;
S-2.2) qui prevoit que le gouvernement peut declarer un
état d’urgence sanitaire dans tout ou partie du territoire Vu que le décret numéro 131-2022 du 9 février 2022
québécois lorsqu’une menace grave à la santé de la popu- habilite le ministre de la Sante et des Services sociaux
lation, reelle ou imminente, exige l'application immediate a prendre toute mesure prevue aux paragraphes 1°
de certaines mesures prévues à l’article 123 de cette loi a 8° du premier alinea de !'article 123 de la Loi sur la
pour proteger la sante de la population; sante publique;
Vu le décret numéro 177-2020 du 13 mars 2020 qui CONSIDERANT QUE la situation actuelle de la pandémie
déclare l’état d’urgence sanitaire dans tout le territoire de la COVID- 19 permet d'assouplir certaines mesures
quebecois pour une periode de 10 jours; m ises en place pour proteger la sante de la population,
Vu que l'etat d\1rgence sanitaire a toujours ete renou- continuer de la proteger;
le decret numero 131-2022 du 9 fevrier 2022; ARRETE CE QUI SUIT:
Vu que le decret numero 885-2021 du 23 juin 2021, QuE le onzieme alinea du dispositif du decret
modifie par les arretes numeros 2021-049 du 1er juillet numero 885-2021 du 23 juin 2021, modifie par les
2021 , 2021-050 du 2 juillet 2021, 2021-053 du JO juillet arretes numeros 2021-049 du Ier juillet 2021, 2021 -050
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 aoGt du 2 juillet 2021, 2021-053 du JO juillet 2021, 2021-055
2021 , 2021-058 du 13 aoOt 2021, 2021-059 du 18 ao11t 2021, du 30 juillet 2021, 2021-057 du 4 aout 2021, 2021- 058 du
2021-060 du 24 ao0t 2021, 2021-061 du 31 aout 2021, 13 ao0t 2021, 2021-059 du 18 ao0t 2021, 2021-060 du
2021-062 du 3 septembre 2021, 2021-063 du 9 septembre 24 aout 2021, 2021-061 du 31 ao0t 2021 , 202 1-062 du
2021 , 2021-065 du 24 septembre 2021, 2021-066 du 3 septembre 2021 , 2021-063 du 9 septembre 2021,
1er octobre 2021, 2021-067 du 8 octobre 2021, 2021-068 du 2021-065 du 24 septembre 2021, 2021-066 du Ier octobre
9 octobre 2021, 2021-069 du 12 octobre 2021, 2021-073 du 2021, 2021 - 067 du 8 octobre 2021, 2021- 068 du
22 octobre 2021, 2021-074 du 25 octobre 2021, 2021-077 9 octobre 2021, 2021-069 du 12 octobre 2021 , 2021-073 du
du 29 octobre 2021, 2021-078 du 2 novembre 2021, 22 octobre 2021, 2021-074 du 25 octobre 2021, 2021-077
2021-079 du 14 novembre 2021, 2021-083 du JO decembre du 29 octobre 2021 , 2021-078 du 2 novembre 2021 ,
2021 , 2021 -086 du 13 decembre 2021, 2021-087 du 2021-079 du 14 novembre 2021, 2021-083 du 10 decembre
14 decembre 2021, 2021-089 du 19 decembre 2021 , 2021, 2021-086 du 13 decembre 2021, 2021 -087 du
2021-090 du 20 decembre 2021, 2021-092 du 22 decembre 14 decembre 2021, 2021-089 du 19 decembre 2021,
2021, 2021 -096 du 31 decembre 2021, 2022-001 du 2021-090 du 20 decembre 2021, 2021-092 du 22 decembre
2janvier 2022, 2022-004 du 15 janvier 2022, 2022-01 I du 2021, 2021-096 du 31 decembre 2021, 2022-001 du
29 janvier 2022, 2022-012 du 4 fevrier 2022 et 2022-013 2 janvier 2022, 2022-004 du 15 janvier 2022, 2022-011 du
du 5 fevrier 2022, prevoit notamment certaines mesures 29 janvier 2022, 2022-012 du 4 fevrier 2022 et 2022-013
particulieres applicables dans tout le territoire quebecois; du 5 fevrier 2022, soit de nouveau modifie:

AR02639
1° par la suppression des paragraphes 1° ii 3°; 8 ° par ]'insertion, dans le sous- paragraphe a
du paragraphe 14° et apres « ii moins qu'elle soil»,
2° par la suppression, dans ce qui precede le sous- de « un iquement »;
paragraphe a du paragraphe 4°, de «ou de mariage»;
9° par !'insertion, ii la fin du paragraphe 15°, de
3° par le remplacement du paragraphe 6° par le suivant: «, ii moins qu'elle soit uniquement composee. d'eleves
de l’éducation préscolaire ou de l’enseignement primaire
((6° dans une salle d'audience: ou secondaire de la formation generate des jeunes, de la
formation professionnelle et de la formation générale des
a) un maximum de 250 personnes peuvent faire partie adultes d' un meme etablissement, lorsqu'ils beneficient de
de !'assistance; tout service offert par un centre de services scolaire, une
commission scolaire ou un établissement d’enseignement
b) !ors d'un mariage, le couvre-visage porte par privé ou des enfants d’un camp de vacances ou d’un camp
le public doit etre un masque de procedure et doit etre de jour et des personnes qui accompagnent ces eleves ou
conserve en tout temps, sous reserve des exceptions pre- ces enfants »;
vues aux paragraphes 1°, 4° ou 6° du cinquieme alinea;»;
10° par le remplacement, dans le paragraphe 16°, de
4 ° dans le paragraphe 6.1 ° : « I 000 » par « 5 000 »;
a) par le remplacement du paragraphe a.1 par 11° par le rem placement du paragraphe 20° par
le suivant les suivants
(( a.1) les centres récréatifs pour leurs activités « 19° dans les centres recreatifs vises au sous-sous-
interieures, sauf: paragraphe ii du sous-paragraphe a.I du paragraphe 6.1 °,
la capacite d'accueil est fixee a 50% de sa capacite habi -
i. pour les activites qui font parties de l'offre des pro- tuelle, de meme que la capacite de tout vestiaire, ii moins
grammes de sport-eludes, d'art-etudes et de concentra- que la clientele soit composee uniquement d'eleves de
tion sportive et autres projets pedagogiques particu Iiers l’éducation préscolaire ou de l’enseignement primaire
de meme nature offerts aux eleves de l'enseignement pri - ou secondaire de la formation generale des jeunes, de la
maire et secondaire de la formation generale des jeunes; formation professionnelle et de la formation générale des
adultes d'un meme etablissement, lorsqu'ils beneficient de
ii. pour Jes activites de golf et d'escalade; »; tout service offert par un centre de services scolaire, une
commission scolaire ou un établissement d’enseignement
b) par la suppression des sous-paragraphes h et i privé ou des enfants d’un camp de vacances ou d’un camp
de jour et des personnes qui accompagnent ces eleves ou
5° par le remplacement, dans le sous-sous-paragraphe ces enfants;
ii des sous-paragraphes a et b du paragraphe 7°, de
((quatre» par «dix» et de «deux» par «trois»; 19.1° dans Jes salles d'entrainement physique:
6° par ]'insertion, apres le paragraphe 11°, du suivant: a) la capacite d'accueil est fixee ii 50 % de sa
capacite habituelle;
« 12° le sous-sous-paragraphe iii du sous-paragraphe a
du paragraphe 7° ne s 'applique pas dans une cafeteria ou b) la capacite de tout vestiaire est fixee a 50 % de sa
ce qui en tient l' un d' un etablissement universitaire, d' un capacite habituelle;
college institue en vertu de la Loi sur les colleges d'ensei -
gnement general et professionnel (chapitre C 29), d'un eta- c) une distance minimale d'un metre doit etre
blissement d’enseignement privé qui dispense des services maintenue entre les personnes qui pratiquent une
d’enseignement collégial et de tout autre établissement qui activite physique;
dispense des services d’enseignement de niveau collégial
ou universitaire ou des services de formation continue;»; d) le couvre-visage porte par le public doit etre un
masque de procedure;
7° par la suppression du sous-paragraphe b du
paragraphe 13°;

AR02640
19.2° dans les saunas et les spas, la capacite d'accueil «c.1) elle s'inscrit dans le cadre des activites extra-
est fixee a 50 % de sa capacite habituelle, de meme que la scolaires offertes aux eleves de la formation generale des
capacite de tout vestiaire, saufpour les soins personnels jeunes, de la formation professionnelle et de la formation
qui y sont dispenses; generale des adu ltes; »;
20° toute competition, tout tournoi ou tout autre evene - 13° par !'insertion, a la fin du sous- paragraphe f du
ment de meme nature organise pour la pratique d'activites paragraphe 22°, de« a laquelle assistent un maximum de
de loisir ou de sport est suspendu, a moins: 250 personnes, sans depasser 50 % de la capacite habi -
tuelle de la salle ));
a) qu' il soit organise a l'exterieur et que la capacite de
tout vestiaire soit t'ixee a 50% de sa capacite habituelle; Q uE le quatrieme alinea du dispositif du decret
numéro 1173-2021 du 1er septembre 2021, modifie par le
b) qu’il constitue un processus qualifiant pour les décret numéro 1276-2021 du 24 septembre 2021 et par les
Jeux olympiques ou paralympiques et Jes championnats arretes numeros 2021-067 du 8 octobre 2021, 2021-079 et
du monde et que les conditions suivantes soient respectées 2021-081 du 14 novembre 2021, 2021-082 du 17 novembre
par les athletes et le personnel d'encadrement: 2021, 202 1-089 du 19 decembre 2021, 2022-004 du
15 janvier 2022, 2022-007 du 23 janvier 2022 et 2022-013
i. un environnement protege est mis en place, lequel du 5 fevrier 2021, soit de nouveau modifie par !'insertion,
permet de limiter les risques de transmission entre a la fin du paragraphe 15.1° de« , sauf si elle se deroule
les athletes et le personnel d'encadrement et le reste dans une salle d’audience >>;
de la population, conformement a un protocole sani -
taire approuve par le ministre de la Sante et des QuE Jes mesures prevues au present arrete prennent
Services sociaux; etfet le 14 fevrier 2022, a !'exception de celles prevues aux
paragraphes 1° et 5° a 7° du premier alinea qui prennent
ii. le protocole sanitaire approuvé par le ministre effet le 12 fevrier 2022.
de la Sante et des Services sociaux est respecte en tout
temps, autant avant, pendant et apres !'integration dans Quebec, le 11 fevrier 2022
l'environnement protege;
le minis/re de fa Sante el des Services sociaux,
iii. la capacite de tout vestiaire est fixee a 50 % de sa CHRISTIAN DUBE
capacite habituel le;»;
76466
12° dans le paragraphe 21°:
a) dans le sous-paragraphe a.1 A.M., 2022

i. par la suppression, dans ce qui precede le sous-sous- Arrêté numéro 2022-017 du ministre de la Santé
paragraphe i, de « pour un groupe de personnes agees de et des Services sociaux en date du 15 février 2022
moins de 18 ans ou, dans le cas ou elle est organisee par
une fédération d’organismes sportifs ou un organisme Loi sur la santé publique
reconnus par le ministre de !'Education, du Loisir et du ( chapitre S-2.2)
Sport, pour un groupe compose de personnes agees de
moins de 18 ans et de personnes nees apres le Ier janvier CONCERNANT l’ordonnance de mesures visant à
2001 »; protéger la santé de la population dans la situation de
pandemie de la COVJD- 19
ii. par la suppression du sous-sous-paragraphe ii;
b) par l' insertion, a la fin du sous-paragraphe b, de
((, de la formation professionnelle et de la formation géné- Yu l’article 118 de la Loi sur la santé publique (chapitre
rale des adultes »; S-2.2) qui prevoit que le gouvernement peut declarer un
c) par le remplacement du sous-paragraphe c. l, par québécois lorsqu’une menace grave à la santé de la popu-
le suivant lation, reelle ou imminente, exige !' application immediate

AR02641
Ceci est la pièce « JJ » au soutien de


AR02642
Vu que !'agglomeration de Montreal a renouvele pour A.M., 2022

une sixième fois, le vendredi 14 janvier 2022, par la réso-
lution numéro CE22 0089, la déclaration d’état d’urgence Arrêté numéro 2022-018 du ministre de la Santé et
pour une période additionnelle de cinq jours, se terminant des Services sociaux en date du 19 février 2022
au plus tard le mercredi 19 janvier 2022;
Vu que !'agglomeration de Montreal a renouvele pour (chapitre S-2.2)
une septième fois, le mercredi 19 janvier 2022, par la réso-
lution numéro CE22 0119, la déclaration d’état d’urgence CONCERNANT l’ordonnance de mesures visant à
pour une période additionnelle de cinq jours, se terminant protéger la santé de la population dans la situation de
au plus tard le lundi 24 janvier 2022; pandémie de la COVID-19

Vu que !'agglomeration de Montreal a renouvele pour
une huitieme fois, le lundi 24 janvier 2022, par la reso -
lution numéro CE22 0130, la déclaration d’état d’urgence Vu !'article 118 de la Loi sur la sante publique (chapitre
pour une période additionnelle de cinq jours, se terminant S-2.2) qui prevoit que le gouvernement peut declarer un
au plus tard le samedi 29 janvier 2022; état d’urgence sanitaire dans tout ou partie du territoire
Vu que !'agglomeration de Montreal a renouvele pour lation, réelle ou imminente, exige l’application immédiate
une neuvième fois, le vendredi 28 janvier 2022, par la
résolution numéro CE22 0132, la déclaration d’état
d’urgence pour une période additionnelle de cinq jours, se V u le décret numéro 177-2020 du 13 mars 2020 qui
terminant au plus tard le mercredi 2 février 2022; déclare l’état d’urgence sanitaire dans tout le territoire
Vu que !'agglomeration de Montreal a renouvele pour
une dixième fois, le mercredi 2 février 2022, par la réso- Vu que l’état d’urgence sanitaire a toujours été renou-
lution numéro CE22 0142, la déclaration d’état d’urgence velé depuis cette date par divers décrets, notamment par le
pour une période additionnelle de cinq jours, se terminant décret numéro 149-2022 du 16 février 2022;
au plus tard le lundi 7 février 2022;
Vu que la situation sur le territoire demeure préoccu- modifie par les arretes numeros 2021-049 du I er juillet
pante, !'agglomeration de Montreal a renouvele pour une 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
onzième fois, par la résolution numéro CE22 0149 du lundi 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
7 février 2022, la déclaration d’état d’urgence pour une 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
autre période de cinq jours, se terminant au plus tard le 2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
samedi 12 février 2022; 2021, 2021-062 du 3 septembre 2021, 2021-063 du
Vu que !'agglomeration de Montreal demande a la 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre
ministre de la Sécurité publique d’autoriser de nouveau 2021, 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre
le renouvellement de l’état d’urgence pour une période 2021, 2021-073 du 22 octobre 2021, 2021-074 du
maximale de cinq jours; 25 octobre 2021, 2021-077 du 29 octobre 2021, 2021-078
En consequence,j'autorise !'agglomeration de Montreal 2021-083 du 10 décembre 2021, 2021-086 du 13 décembre
à renouveler l’état d’urgence local déclaré le mardi 2021, 2021-087 du 14 décembre 2021, 2021-089 du
21 décembre 2021 pour une période additionnelle maxi- 19 décembre 2021, 2021-090 du 20 décembre 2021,
male de cinq jours, se terminant au plus tard le samedi 2021-092 du 22 décembre 2021, 2021-096 du 31 décembre
12 fevrier 2022. 2021, 2022-001 du 2 janvier 2022, 2022-004 du 15 janvier
2022, 2022-011 du 29 janvier 2022, 2022-012 du 4 février
Quebec, le 17 fevrier 2022 2022, 2022-013 du 5 février 2022 et 2022-015 du 11 février
2022, prévoit notamment certaines mesures particulières
La ministre de la Securite publique, applicables dans tout le territoire québécois;
GENEVIEVE GUILBAULT
Vu que le décret numéro 1173-2021 du 1er septembre
76516 2021, modifié par le décret numéro 1276-2021 du
24 septembre 2021 et par les arrêtés numéros 2021-067

AR02643
2021, 2021-082 du 17 novembre 2021, 2021-089 du « b) un roulement de personnes est permis lors de
19 décembre 2021, 2022-004 du 15 janvier 2022, 2022-007 l’exposition du corps ou des cendres et de la réception
du 23 janvier 2022, 2022-013 du 5 février 2021, 2022-015 des condoléances, à condition que le nombre de personnes
du 11 février 2022 et 2022-017 du 15 février 2022, prévoit présentes simultanément ne dépasse jamais un maximum
l’obligation d’être adéquatement protégé pour accéder à de 50 personnes; »;
certains lieux ou pour participer à certaines activités;
b) par le remplacement, dans le sous-paragraphe a du
Vu que ces decrets habilitent egalement le ministre de la paragraphe 5°, de « 250 » par « 500 »;
a
Sante et des Services sociaux ordonner toute modification
c) dans le paragraphe 6. JO
ou toute précision relative aux mesures qu’ils prévoient; :
Vu que le décret numéro 149-2022 du 16 février 2022 i. par la suppression des sous-paragraphes a et a . I;
habilite le ministre de la Sante et des Services sociaux 11. par la suppression, dans le sous- paragraphe j, de
a prendre toute mesure prevue aux paragraphes I O a 8° « de quilles, »;
du premier alinéa de l’article 123 de la Loi sur la
santé publique; iii. par la suppression du sous-paragraphe /;
CONSIDERANT QUE la situation actuelle de la pandémie d) par la suppression, dans le sous-paragraphe a
de la COVID-19 permet d’assouplir certaines mesures du paragraphe 14°, de « sans depasser un maximum de
mises en place pour protéger la santé de la population, 500 personnes »;
continuer de la protéger; e) par le rem placement, dans le paragraphe 19°,
de « dans les centres récréatifs visés au sous-sous-
ARRETE CE QUI SUIT: paragraphe ii du sous-paragraphe a.1 du paragraphe 6.1 °,
la capacité d’accueil » par « pour la pratique des jeux de
QUE le dispositif du décret numéro 885-2021 du quilles ou d’autres jeux de même nature, ainsi que dans
23 juin 2021, modifie par les arretes numeros 2021-049 du les arcades et, pour leurs activités intérieures, les sites
1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053 du thematiques, les centres et pares d'attractions, Jes centres
10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057 du d’amusement, les centres récréatifs et les parcs aquatiques,
4 août 2021, 2021-058 du 13 août 2021, 2021-059 du la capacité d’accueil du lieu »;
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
31 août 2021, 2021-062 du 3 septembre 2021, 2021-063 f) par le rem placement des paragraphes 21.1 ° a22° par
du 9 septembre 2021, 2021-065 du 24 septembre 2021, le suivant :
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre «22° dans une salle louée ou une salle communautaire
2021, 2021-073 du 22 octobre 2021, 2021-074 du mise à la disposition de quiconque :
25 octobre 2021, 2021-077 du 29 octobre 2021, 2021-078 a) aucune limite de capacité n’est fixée dans les
du 2 novembre 2021, 2021-079 du 14 novembre 2021, cas suivants :
2021, 2021-087 du 14 décembre 2021, 2021-089 du i. dans le cadre un salon regroupant plusieurs exposants
19 décembre 2021, 2021-090 du 20 décembre 2021, ou commerces de vente au détail, auquel cas les mesures
2021-092 du 22 décembre 2021, 2021-096 du 31 décembre prévues au quatorzième alinéa doivent être respectées;
2022, 2022-011 du 29 janvier 2022, 2022-012 du 4 février ii. aux fins d' une activite qui s'inscrit dans le cadre de la
2022, 2022-013 du 5 février 2022 et 2022-015 du 11 février mission d’un organisme communautaire dont les activités
2022, soit de nouveau modifie : sont liées au secteur de la santé ou des services sociaux;
I O dans le onzième alinéa : iii. aux fins d' une activite de loisir ou de sport pratiquee
conformement au paragraphe 21 °;
a) dans le paragraphe 4°:
b) la capacite de la salle est fixee a50 % de sa capacite
i. par le remplacement, dans le sous-paragraphe a, de habituelle, sans depasser un maximum de 500 personnes a
« 250 » par « 500 »; l’occasion d’une assemblée, d’un congrès, d’une réunion,
d’une cérémonie funéraire, de mariage, de reconnaissance
11. par le remplacement du sous-paragraphe b par ou de graduation ou d’un autre évènement de même nature,
le suivant : auquel les participants assistent en demeurant assis;

AR02644
c) la capacite de la salle est fixee a50 % de sa capacite QUE les mesures prevues au present arrete prennent effet
habituelle, sans depasser un maximum de 250 personnes le 21 fevrier 2022.
aux fins d'une activite organisee necessaire a la poursuite
des activités, autres que de nature évènementielle ou Quebec, le 19 fevrier 2022
sociale, s’inscrivant dans le cadre de l’exploitation d’une
entreprise ou de celles d’un établissement d’enseignement, Le ministre de la Sante et des S ervices sociaux,
d’un tribunal, d’un arbitre, d’une association de salariés, de CHRISTIAN DUBE
professionnels, de cadres, de hors-cadre ou d'employeurs,
d’un poste consulaire, d’une mission diplomatique, d’un 76511
ministère ou d’un organisme public;
d) la capacite de la salle est fixee a 50 % de sa capacite

habituelle aux fins d'une production, un tournage audio-
visuel ou pour la captation de spectacle;
e) la capacite de la salle est fixee a 50 personnes dans

les autres cas; »;
g) par le remplacement, dans le paragraphe 26.1 °, de

« 250 » par « 500 »;
2 ° par la suppression du paragraphe 2 ° du

quatorzième alinéa;
3° par la suppression du quinzieme alinea;

2021 du 24 septembre 2021 et par les arrêtés
numéros 2021-067 du 8 octobre 2021, 2021-079 et
2021, 2021-089 du 19 décembre 2021, 2022-004 du
15 janvier 2022, 2022-007 du 23 janvier 2022, 2022-013
du 5 février 2021, 2022-015 du 11 février 2022 et 2022-017
du 15 fevrier 2022, soit de nouveau modifie:
1° dans le troisieme alinea:
a) par !'insertion, apres le paragraphe 13°, du suivant:
« I 3.1 ° à une activité se déroulant dans une salle louée

ou dans une salle communautaire, dans un cas visé au
sous-paragraphe c du paragraphe 22° du onzieme alinea
du décret numéro 885-2021 du 23 juin 2021 et ses modi-
fications subsequentes; »;
b) par la suppression du paragraphe 15°;
c) par !' insertion, a la fin du paragraphe 15.1 °, de

« ou dans un lieu de culte »;
d) par la suppression du paragraphe 16°;
2° par la suppression, dans le dix-septieme alinea, de

« ou à un lieu de culte »;

AR02645
Ceci est la pièce « KK » au soutien de


AR02646
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 3 mars 2022, 154e année, no 9A 903A
-
A.M. 2022
des Services sociaux en date du 25 février 2022

et 2022-018 du 19 fevrier 2022, prevoit notamment

(chapitre S-2.2) 24 septembre 2021 et par les arretes numeros 2021-067
CONCERNANT l’ordonnance de mesures visant à 2021, 2021-082 du 17 novembre 2021, 2021-089 du
protéger la santé de la population dans la situation de 19 decembre 2021, 2022-004 du 15 janvier 2022,
pandémie de la COVID-19 2022-007 du 23 janvier 2022, 2022-013 du 5 fevrier 2021,
2022-015 du 11 fevrier 2022, 2022-017 du 15 fevrier 2022
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, et 2022-018 du 19 fevrier 2022, prevoit !'obligation d'etre
adequatement protege pour acceder a certains lie ux ou
Vu l’article 118 de la Loi sur la santé publique (chapitre pour participer à certaines activités;
état d’urgence sanitaire dans tout ou partie du territoire Vu que ces décrets habilitent également le ministre
québécois lorsqu’une menace grave à la santé de la popu- de Ja Sante et des Services sociaux a ordonner toute
lation, reelle ou imminente, exige l'application immediate modification ou toute precision relative aux mesures
de certaines mesures prévues à l’article 123 de cette loi qu’ils prévoient;
Vu que le décret numéro 181-2022 du 23 février 2022
Vu le décret numéro 177-2020 du 13 mars 2020 qui habilite le ministre de la Sante et des Services sociaux
déclare l’état d’urgence sanitaire dans tout le territoire a prendre toute mesure prevue aux paragraphes 1°
quebecois pour une periode de 10 jours; a 8° du premier alinea de )'article 123 de la Loi sur la
santé publique;
Vu que l'etat d\1rgence sanitaire a toujours ete renou -
vele depuis cette date par divers decrets, notamment par CONSIDERANT QUE la situation actuelle de la pandémie
le décret numéro 181-2022 du 23 février 2022; de la COVID-19 permet d’assouplir certaines mesures
mises en place pour proteger la sante de la population,
Vu que le decret numero 885-202 1 du 23 juin 2021, tout en maintenant certaines d’entre elles nécessaires pour
modifie par les arretes numeros 2021-049 du 1er juillet continuer de la protéger;
2021 , 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 aoGt ARRETE CE QUI SUIT:
2021, 2021-058 du 13 aoGt 2021, 2021-059 du 18 aoGt
2021, 2021-060 du 24 aout 2021, 2021 -061 du 31 aout QuE le dispositif du decret numero 885-2021 du
2021, 2021-062 du 3 septembre 2021 , 2021-063 du 23 juin 2021, modifie par les arretes numeros 2021-049
9 septembre 2021 , 2021-065 du 24 septembre 2021, du 1er juillet 2021, 2021-050 du 2 juillet 2021, 2021 -053
2021-066 du Ier octobre 2021 , 2021-067 du 8 octobre 2021 , du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021, du 4 aoilt 2021, 2021-058 du 13 aoilt 2021, 2021-059 du
2021-073 du 22 octobre 2021, 2021-074 du 25 octobre 2021, 18 aoilt 2021, 2021-060 du 24 aoGt 2021, 2021-061 du
2021-077 du 29 octobre 202 1, 2021-078 du 2 novembre 31 aout 2021, 2021-062 du 3 septembre 2021, 2021-063
2021, 2021 -079 du 14 novembre 2021, 2021-083 du du 9 septembre 202 1, 202 1-065 du 24 septembre 202 1,
10 decembre 2021 , 2021-086 du 13 decembre 2021, 2021-066 du Ier octobre 2021, 2021-067 du 8 octobre 2021,
2021-087 du 14 decembre 2021, 2021-089 du 19 decembre 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021,
2021, 2021-090 du 20 decembre 2021, 2021-092 du 2021-073 du 22 octobre 2021 , 2021-074 du 25 octobre 2021,
22 decembre 2021, 2021-096 du 31 decembre 2021, 2021-077 du 29 octobre 2021, 2021-078 du 2 novembre
2022-001 du 2 janvier 2022, 2022-004 du 15 janvier 2022, 2021, 202 1-079 du 14 novembre 202 1, 202 1-083 du
2022-011 du 29 janvier 2022, 2022-012 du 4 fevrier 2022, 10 decembre 2021 , 2021-086 du 13 decembre 2021 ,
2022-013 du 5 fevrier 2022, 2022-015 du 11 fevrier 2022 2021-087 du 14 decembre 2021, 2021-089 du 19 decembre

AR02647
904A GAZETTE OFFICIELLE DU QUÉBEC, 3 mars 2022, 154e année, no 9A Partie 2
2021, 2021 -090 du 20 decembre 2021 , 2021-092 du e) par !'insertion, dans le paragraphe 19° et apres
22 decembre 2021 , 2021- 096 du 31 decembre 2021, « quilles », de «, de billard ou de flechettes »;
2022-001 du 2janvier2022, 2022-004 du 15 janvier 2022,
2022-011 du 29 janvier 2022, 2022- 012 du 4 fevrier 2022, j) par le rem placement des paragraphes 20° et 21 ° par
2022-013 du 5 fevrier 2022, 2022-0 15 du 11 fevrier 2022 le suivant:
et 2022-018 du 19 fevrier 2022, soit de nouveau modifie:
«21° pour toute activite interieure de loisir ou de sport,
IO par la suppression du sous- paragraphe d du la capacite du vestiaire, le cas echeant, est fixee a 50% de
paragraphe 2° du deuxieme alinea; sa capacité habituelle; »;
2° dans le onzieme alinea: g) dans le paragraphe 22° :
a) par la suppression du paragraphe 4°, des sous- i. par le remplacement du sous-sous-paragraphe iii du
paragraphe a des paragraphes 5° et 6° et du paragraphe 6.1°; sous-paragraphe a par les suivants:
b) dans le paragraphe 7° : « iii. aux fins d'une activite de loisir ou de sport;
1. par ['insertion, dans ce qui precede le sous- iv. a !'occasion d'une assemblee, d'un congres, d' une
paragraphe a et avant « un restaurant», de « dans un reunion, d' une ceremonie funeraire, de mariage, de
casino, une maison de jeux, unbar, une discotheque, une reconnaissance ou de graduation ou d’un autre évène-
m icrobrasserie, une d isti llerie, »; ment de meme nature, auquel les participants assistent en
demeurant assis;
ii. par le remplacement, dans le sous-paragraphef,
de « 23 heures » par « minuit »; v. aux fins d'une activite organisee necessaire a la
poursuite des activites, autres que de nature evenemen-
iii. par la suppression du sous-paragraphe g; tielle ou sociale, s'inscrivant dans le cadre de !'exploitation
d’une entreprise ou de celles d’un établissement d’ensei-
c) par le remplacement du paragraphe 8° par Jes gnement, d'un tribunal, d' un arbitre, d'une association
suivants: de salaries, de professionnels, de cadres, de hors-cadre
ou d'employeurs, d' un poste consulaire, d'une mission
«8° le titulaire d' un permis autorisant la vente ou diplomatique, d' un ministere ou d' un organisme public;
le service de boissons alcooliques pour consommation
sur place: vi. aux fins d' une production, d' un tournage audio -
visuel ou pour la captation de spectacle, lorsque que la
a) ne peut admettre simultanement, dans chaque capacité habituelle de la salle est de 10 000 personnes
piece de l'etablissement ou est exploite le permis, qu'un ou moins; »;
maximum de 50% du nombre de personnes pouvant y etre
admises en vertu de ce permis, ou y tolerer un nombre de ii. par le remplacement des paragraphes b à d par
personnes superieur ace maximum; le suivant:
b) ne peut exploiter s on perm is que de huit heures « d) aux fins d' une production, d'un tournage audio -
à minuit; visuel ou pour la captation de spectacle, lorsque la
capacité habituelle de la salle est de plus de 10 000 per-
9° les mesures prevues au paragraphe 8° s'appliquent, sonnes, !'assistance maximale est fixee a 50% de cette
compte tenu des adaptations necessaires, aux titulaires de capacité habituelle; »;
perm is de production artisanale, de producteur artisanal
de biere ou de brasseur, lorsqu'ils permettent la consom - h) par la suppression des paragraphes 23° a 27°;
mation sur place de boissons alcooliques conformément
à leur permis de fabrication de boissons alcooliques; »; 3° par la suppression du paragraphe 4° du
douzieme alinea;
d) par le remplacement du sous-paragraphe a du para-
graphe 14° par le suivant: 4° par la suppression du treizieme alinea;
« a) !"assistance maximale de chaque salle dont la QUE le troisième alinéa du dispositif du décret
capacité habituelle est de plus de 10 000 personnes est numéro 1173-2021 du 1er se ptembre 2021 , modifie par le
fixee a 50% de cette capacite habituelle; »; decret numero 1276 -2021 du 24 septembre 2021 et par les

AR02648
arretes numeros 2021-067 du 8 octobre 2021, 2021-079 et

2021-081 du 14 novembre 2021, 2021-082 du l 7 novembre
2021 , 2021-089 du 19 decembre 2021 , 2022-004 du
15 janvier 2022, 2022-007 du 23 janvier 2022, 2022-013
du 5 fevrier 2021 , 2022-015 du 11 fevrier 2022, 2022-017
du 15 fevrier 2022 et 2022-018 du 19 fevrier 2022, soit de
nouveau modi fie:
1° par !' insertion, a la fin du paragraphe 8° de« qui se

déroule à l’intérieur »;
2° par la suppression, a la fin du paragraphe 11°, de

«ou auquel assiste plus de 500 personnes a l'exterieurn;
3° par la suppression, a la fin du paragraphe 13° de

«ou plus de 500 personnes a l'exterieur»;
4° par le remplacement, dans le paragraphe 13.1°, de

« sous-paragraphe C » par « sous-paragraphe e »;
5° par la suppression des paragraphes 14° et 17°;
Que les mesures prevues au present arrete prennent

effet le 28 fevrier 2022, a !'exception de celle prevue
au paragraphe 4° du deuxieme alinea qui prend effet le
25 fevrier 2022.
Quebec, le 25 fovrier 2022
le ministre de la Sante et des Services sociaux,

CHRISTIAN D UBE
76558

AR02649
Ceci est la pièce « LL » au soutien de


AR02650
-
A.M. 2022
et des Services sociaux en date du 4 mars 2022

15 janvier 2022, 2022-011 du 29 janvier 2022, 2022-0 12 du
4 fevrier 2022, 2022-013 du 5 fevrier 2022, 2022-015 du
11 fevrier 2022, 2022-018 du 19 fevrier 2022 et 2022-019
du 25 fevrier 2022, prevoit notamment certaines mesures
(chapitre S-2.2) Vu que ce décret habilite également le ministre de la
CONCERNANT l’ordonnance de mesures visant à tion ou toute precision relative aux mesures qu'il prevoit;
pandémie de la COVID-19 Vu que le décret numéro 211-2022 du 2 mars 2022
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, a prendre toute mesure prevue aux paragraphes 1°
a 8° du premier alinea de )'article 123 de la Loi sur la
lation, reelle ou imminente, exige !'application immediate m ises en place pour proteger la sante de la population,
quebecois pour une periode de 10 jours; QUE le dispositif du décret numéro 885-2021 du
Vu que l'etat d\1rgence sanitaire a toujours ete renou - du 1er juillet 2021, 2021-050 du 2juillet 2021, 2021-053 du
vele depuis cette date par divers decrets, notamment par 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057 du
le décret numéro 211-2022 du 2 mars 2022; 4 aout 2021 , 2021-058 du 13 aout 2021, 2021-059 du
18 aout 2021, 2021-060 du 24 aout 2021, 2021-061 du
Vu que le decret numero 885-2021 du 23 juin 2021, 31 aout 2021, 2021-062 du 3 septembre 2021, 2021-063
modifie par les arretes numeros 2021-049 du 1er juillet du 9 septembre 2021 , 2021-065 du 24 septembre 2021,
2021 , 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 aout 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 2021,
2021 , 2021-058 du 13 aout 2021, 2021-059 du 18 aof1t 2021, 2021 -073 du 22 octobre 2021 , 2021-074 du 25 octobre
2021-060 du 24 aout 2021, 2021-061 du 31 aout 2021, 2021 , 2021-077 du 29 octobre 2021 , 2021-078 du
2021-062 du 3 septembre 2021, 2021-063 du 9 septembre 2 novembre 2021, 2021-079 du 14 novembre 2021 ,
2021 , 2021-065 du 24 septembre 2021, 2021-066 du 2021-083 du 10 decembre 2021 , 2021-086 du 13 decembre
1er octobre 2021, 2021-067 du 8 octobre 2021 , 2021-068 2021, 2021-087 du 14 decembre 2021, 2021 -089 du
du 9 octobre 2021, 2021-069 du 12 octobre 2021, 19 decembre 2021, 2021-090 du 20 decembre 2021,
2021-073 du 22 octobre 2021, 2021-074 du 25 octobre 2021-092 du 22 decembre 2021, 2021-096 du 31 decembre
2021, 2021 -077 du 29 octobre 2021, 2021-078 du 2021 , 2022-001 du 2 janvier 2022, 2022-004 du
2 novembre 2021, 2021-079 du 14 novembre 2021, 15 janvier 2022, 2022-011 du 29 janvier 2022, 2022-012 du
2021-083 du 10 decembre 2021, 2021-086 du 13 decembre 4 fevrier 2022, 2022-013 du 5 fevrier 2022, 2022-015 du
2021 , 2021-087 du 14 decembre 2021 , 2021-089 du 11 fevrier 2022, 2022-018 du 19 fevrier 2022 et 2022-019
19 decembre 2021, 2021-090 du 20 decembre 2021, du 25 fevrier 20222, soit de nouveau modi fie par l' inser-
2021 -092 du 22 decembre 2021, 2021 -096 du 31 decembre tion, dans le paragraphe 29° du onzieme alinea et avant
2021, 2022- 001 du 2 janvier 2022, 2022-004 du le sous-paragraphe a, du suivant:

AR02651
« 0.a) l’élève est assis en classe ou dans un local utilisé

par un service de garde en milieu scolaire; »;
QuE la mesure prevue au present arrete prenne effet

le 7 mars 2022.
Quebec, le 4 mars 2022

CHRISTIAN DUBE
76571

AR02652
Ceci est la pièce « MM » au soutien de


AR02653
A.M., 2022 du 25 fevrier 2022 et 2022-020 du 4 rnars 2022, prevoit

Arrêté numéro 2022-021 du ministre de la Santé dans tout le territoire québécois;
et des Services sociaux en date du 11 mars 2022
Loi sur la santé publique 2021, modifie par le decret numero 1276-2021 du
(chapitre S-2.2) 24 septembre 2021 et par les arrêtés numéros 2021-067
CONCERNANT l’ordonnance de mesures visant à protéger 2021, 202 1-082 du I 7 novem bre 2021, 2021-089 du
la santé de la population dans la situation de pandémie 19 decembre 2021, 2022-004 du 15 janvier 2022, 2022-007
de la COVID-19 du 23 janvier 2022, 2022-013 du 5 fevrier 2021, 2022-015
du 11 fevrier 2022, 2022-0 l 7 du 15 fevrier 2022, 2022-018
LE MINISTRE DE LA SANTE ET DES SERVICES SOCIAUX, du 19 fevrier 2022 et 2022-019 du 25 fevrier 2022, prevoit
l’obligation d’être adéquatement protégé pour accéder à
Vu l’article 118 de la Loi sur la santé publique (chapitre certains lieux ou pour participer à certaines activités;
état d’urgence sanitaire dans tout ou partie du territoire Vu que ces décrets habilitent également le ministre de la
québécois lorsqu’une menace grave à la santé de la popu- Sante et des Services sociaux aordonner toute modification
lation, reelle ou imminente, exige !'application immediate ou toute précision relative aux mesures qu’ils prévoient;
pour protéger la santé de la population; Vu que le décret numéro 214-2022 du 9 mars 2022
Vu le décret numéro 177-2020 du 13 mars 2020 qui à prendre toute mesure prévue aux paragraphes 1° à 8°
déclare l’état d’urgence sanitaire dans tout le territoire du premier alinéa de l’article 123 de la Loi sur la
québécois pour une période de 10 jours; santé publique;
Vu que l’état d’urgence sanitaire a toujours été renou- CONSlDERANT QUE la situation actuelle de la pandémie
vele depuis cette date par divers decrets, notamment par de la COVID-19 permet d’assouplir certaines mesures
le décret numéro 214-2022 du 9 mars 2022; mises en place pour proteger la sante de la population,
Vu que le decret numero 885-2021 du 23 juin 2021, continuer de la protéger;
modifie par les arretes numeros 2021 -049 du I er juillet
2021, 2021-050 du 2juillet 2021, 2021-053 du 10 juillet ARRETE CE QUI SUIT:
2021, 2021 -055 du 30 juillet 2021, 2021-057 du 4 aoflt
2021, 2021 -058 du 13 aoflt 2021, 2021-059 du 18 aoflt QuE le dispositif du décret numéro 885-2021 du
2021, 2021-060 du 24 aoflt 2021, 2021 -06 I du 31 aoflt 23 juin 2021, modifie par les arretes numeros 2021-049 du
2021, 2021 -062 du 3 septembre 2021, 2021-063 du 1er juillet 2021, 2021-050 du 2 juillet 2021, 2021-053 du
9 septembre 2021 , 2021-065 du 24 septembre 2021, 10juillet2021, 2021-055 du 30juillet 2021, 2021-057 du
2021-066 du 1er octobre 202 I, 2021-067 du 8 octobre 2021 , 4 aoflt 2021, 2021-058 du 13 ao0t 2021, 2021 -059 du
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre 18 ao0t 2021, 2021 -060 du 24 aout 2021, 2021 -061 du
2021, 2021-073 du 22 octobre 2021, 2021-074 du 3 I ao0t 2021, 2021-062 du 3 septem bre 2021, 2021 -063
25 octobre 2021, 2021-077 du 29 octobre 2021, 2021-078 du 9 septembre 2021, 2021-065 du 24 septembre 2021 ,
du 2 novembre 2021, 2021-079 du 14 novembre 2021, 2021-066 du 1er octobre 202 1, 2021-067 du 8 octobre 202 1,
2021-083 du 10 decembre 2021, 2021-086 du 13 decembre 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre
2021, 2021-087 du 14 decernbre 2021, 2021-089 du 2021, 2021 -073 du 22 octobre 2021, 2021 -074 du
19 decembre 2021, 2021-090 du 20 decembre 2021, 25 octobre 2021, 2021 -077 du 29 octobre 2021, 2021 -078
2021-092 du 22 decembre 2021, 2021 -096 du 31 decembre du 2 novembre 2021, 2021-079 du 14 novembre 2021,
2021, 2022-00 I du 2 janvier 2022, 2022-004 du 2021-083 du l 0 decem bre 2021, 202 1-086 du 13 decembre
15 janvier 2022, 2022-011 du 29 janvier 2022, 2022-012 2021, 2021-087 du 14 decembre 2021 , 2021-089 du
du 4 fevrier 2022, 2022-013 du 5 fevrier 2022, 2022-015 19 decembre 2021, 2021-090 du 20 decembre 2021,
du I I fevrier 2022, 2022-0 18 du 19 fevrier 2022, 2022-0 19 2021 -092 du 22 decembre 2021, 2021-096 du 31 decembre

AR02654
2021, 2022-00 I du 2 janvier 2022, 2022-004 du QUE l’organisateur d’une activité ou l’exploitant d’un
15 janvier 2022, 2022-0 I I du 29 janvier 2022, 2022-0 12 lieu qui a consigné les informations concernant une
du 4 fevrier 2022, 2022-013 du 5 fevrier 2022, 2022-0 15 personne obtenues a la suite de la verification de son
du 11 fevrier 2022, 2022-0 18 du 19 fevrier 20222022-019 code QR en application du decret numero 1173 202 I du
du 25 fevrier 2022 et 2022-020 du 4 mars 2022, soil de 1er septembre 2021 , tel que modifie, soit tenu de detruire
nouveau modifie: les renseignements ainsi consignés;
1° par la suppression du sous-paragraphe b du QUE le dispositif de l’arrêté numéro 2022-005 du
paragraphe 2° du deuxième alinéa et des troisième et 21 janvier 2022 soit modifie par le remplacement, dans
quatrième alinéas; le premier alinea, de « permettant à une personne de
présenter la preuve qu’elle est adéquatement protégée
2° dans le onzième alinéa : contre la COVID-19 au sens du décret numéro 1173-2021
du 1er septembre 2021 et ses modifications subsequentes »
a) par le remplacement du paragraphe 5° par le suivant : par « qu' une personne a re9u du gouvernement du Quebec
lui permettant de présenter la preuve qu’elle est adéquate-
« 5° un ministre du culte ou une personne qui agit ment protégée contre la COVID-19 »;
comme bénévole dans un lieu de culte peut y retirer son
couvre-visage lorsqu’il maintient une distance minimale QuE les mesures prevues au present arrete prennent effet
de un mètre avec toute autre personne; »; le 12 mars 2022.
b) par le remplacement du paragraphe 6° par le suivant : Quebec, le 11 mars 2022
« 6° !ors d'un mariage dans une salle d'audience, le Le ministre de la Sante et des Services sociaux,
couvre-visage doit etre po11e par le public en tout temps, CHRISTIAN DUBE
sous reserve des exceptions prevues aux paragraphes I 0 ,
4° ou 6° du troisième alinéa; »; 76645
c) par la suppression des sous-paragraphes a à C et e à h
du paragraphe 7° et des paragraphes 8° et 9°;
d) par le remplacement du paragraphe 11° par

le suivant :
« 11° sauf dans une résidence privée ou ce qui en tient

lieu, incluant le terrain, le balcon ou la terrasse d' une telle
residence, toute personne qui participe a une activite de
karaoke doit, selon le cas, porter un masque de procedure
ou être distancée de deux mètres de toute autre personne
ou en être séparée par une cloison; »;
e) par la suppression des paragraphes 12° et 13°,

des sous-paragraphes a et b du paragraphe 14°, des
paragraphes 15° a 19°, des sous-paragraphes a à c du
paragraphe 19.1° et des paragraphes 19.2° à 22°;
3° par la suppression des douzième et treizième alinéas;
QuE le décret numéro 1173-2021 du 1er septembre 2021,

modifie par le decret numero 1276-2021 du 24 septembre
2021 et par les arrêtés numéros 2021-067 du 8 octobre
2021, 2021-079 et 2021 -081 du 14 novembre 2021,
2021-082 du 17 novembre 2021, 2021 -089 du 19 decembre
2021, 2022-004 du 15 janvier 2022, 2022-007 du
23 janvier 2022, 2022-013 du 5 fevrier 2021 , 2022-015
du 11 fevrier 2022, 2022-017 du 15 fovrier 2022,
2022-018 du 19 février 2022 et 2022-019 du 25 février
2022, soit abrog é.

AR02655
Ceci est la pièce « NN » au soutien de


AR02656
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 7 avril 2022, 154e année, no 14A 1581A
A.M., 2022 2° les articles relatifs aux horaires de travail sont modi-
fiés pour permettre à l’employeur de répondre aux besoins;
des Services sociaux en date du 31 mars 2022 3° les articles relatifs à l’octroi d’une rémunéra-
Loi sur la santé publique tion ou d’une compensation additionnelle à celle versée
(chapitre S-2.2) pour la rémunération des heures normales et du temps
supplémentaire lorsque des services doivent être main-
Conc er na nt l’ordonnance de mesures visant à tenus, notamment en raison d’un cas de force majeure,
protéger la santé de la population dans la situation de sont inapplicables;
4° pour les fins du programme Soutien aux soins
Le ministre de la Santé et des Services sociaux, d’assistance en établissement de santé, les articles relatifs à
la semaine régulière de travail sont modifiés pour permettre
Vu l’article 118 de la Loi sur la santé publique (chapitre à l’employeur de répondre aux besoins;
état d’urgence sanitaire dans tout ou partie du territoire 5° les articles relatifs aux règles de formation des
québécois lorsqu’une menace grave à la santé de la popu- groupes d’élèves, exception faite des règles de compensa-
lation, réelle ou imminente, exige l’application immédiate tion pour dépassement des maxima d’élèves par groupe,
de certaines mesures prévues à l’article 123 de cette loi sont modifiés pour permettre à l’employeur de répondre
pour protéger la santé de la population; aux besoins;
Vu le décret numéro 177-2020 du 13 mars 2020 qui 6° les articles relatifs à la tâche annuelle de l’enseignant
déclare l’état d’urgence sanitaire dans tout le territoire sont modifiés pour permettre à l’employeur de répondre
québécois pour une période de 10 jours; aux besoins;
velé depuis cette date par divers décrets, notamment par 7° toute personne retraitée du réseau de l’éducation,
le décret numéro 595-2022 du 30 mars 2022; titulaire d’une autorisation d’enseigner, qui revient au
travail pour dispenser l’éducation préscolaire ou l’ensei-
Vu que ce décret habilite également le ministre de gnement primaire ou secondaire est rémunérée conformé-
la Santé et des Services sociaux à prendre toute mesure ment à, selon le cas, l’échelle ou l’échelle de traitement
prévue aux paragraphes 1° à 8° du premier alinéa de applicable au personnel enseignant dans les conventions
l’article 123 de la Loi sur la santé publique; collectives ou ententes de niveau national en vigueur;
Considér ant qu’il est souhaité de consolider en un Qu’en plus de ce que prévoit l’alinéa précédent, les
seul arrêté ministériel l’ensemble des mesures concernant conventions collectives ou ententes, de niveau national,
l’éducation; local ou régional en vigueur entre les centres de services
scolaires ou les commissions scolaires d’une part, et
Arrête ce qui suit : l’ensemble des syndicats concernés d’autre part, soient
modifiées suivant ce qui suit, pour les fins du programme
Que les conventions collectives ou ententes, de niveau Soutien aux soins d’assistance en établissement de santé :
national, local ou régional en vigueur entre les centres de
services scolaires ou les commissions scolaires d’une part, 1° les règles relatives à la formation des groupes
et l’ensemble des syndicats d’autre part, soient modifiées d’élèves ne s’appliquent pas aux cours offerts à distance;
suivant ce qui suit :
2° les cours offerts à distance ne sont pas comptabilisés
1° les articles relatifs au mouvement de personnel
aux fins de la moyenne d’élèves par groupe;
ayant trait, notamment, au comblement des absences ou
au remplacement, à l’affectation, la réaffectation ou au
déplacement du personnel sont modifiés pour permettre à 3° l’enseignant qui dispense un cours du programme
l’employeur d’affecter le personnel à l’endroit et au Soutien aux soins d’assistance en établissement de santé
moment où les besoins le justifient. Le personnel peut ainsi bénéficie d’une prime temporaire de 10 %, non cotisable
être affecté à des tâches d’un autre titre d’emploi, dans une aux fins du régime de retraite, applicable sur le salaire
autre unité d’accréditation ou chez un autre employeur; prévu à l’échelle de son titre d’emploi ou au taux horaire

1582A AR02657GAZETTE OFFICIELLE DU QUÉBEC, 7 avril 2022, 154e année, no 14A Partie 2
qui lui est applicable, selon le cas, pour les heures effecti- Que les services éducatifs à distance prévus à l’alinéa
vement travaillées pour lesquelles il est rémunéré dans le précédent soient dispensés selon l’offre minimale de ser-
cadre de cette formation; vices prévue en annexe;
Qu’un centre de services scolaire et qu’une com- Que, lorsqu’un enseignant de l’éducation préscolaire, de
mission scolaire doive, avant d’appliquer une mesure l’enseignement primaire ou de l’enseignement secondaire
prévue aux paragraphes 1° à 6° du premier alinéa et au de la formation générale des jeunes d’un centre de services
deuxième alinéa, consulter les syndicats concernés, à scolaire, d’une commission scolaire ou d’un établissement
moins que l’urgence de la situation ne permette pas de le d’enseignement privé ne peut se présenter à l’école parce
faire; dans ce cas, les syndicats devront être avisés dans qu’il est isolé en raison de la COVID-19 mais qu’il est
les meilleurs délais; apte au travail, il doit, à la demande de l’employeur, dis-
penser les services d’enseignement à distance depuis son
Que soit exclu de la somme des traitements visés à lieu d’isolement aux élèves présents en classe qui sont
l’article 10.5 du Règlement d’application de la Loi sur le surveillés par un adulte, lequel assure en outre un soutien
régime de retraite du personnel d’encadrement (chapitre technique aux élèves;
R-12.1, r. 1), le traitement relatif aux fonctions du pen-
sionné du régime de retraite du personnel d’encadrement Que l’alinéa précédent ne s’applique pas aux ensei-
qui a été embauché dans une fonction de cadre ou de hors- gnants d’une école spécialisée ou d’une classe spécialisée
cadre par un centre de services scolaire, une commission pour des élèves handicapés ou en difficulté d’adaptation
scolaire ou un établissement d’enseignement privé agréé ou d’apprentissage qui relèvent de services régionaux ou
aux fins de subventions en vertu de la Loi sur l’enseigne- suprarégionaux de scolarisation;
ment privé (chapitre E-9.1) qui dispense des services édu-
catifs visés aux paragraphes 1° à 5° de l’article 1 de cette Que, pour les élèves et les étudiants des établissements
loi, pour les fins de la pandémie de la COVID-19; d’enseignement universitaire, des collèges, des établisse-
ments d’enseignement collégial privés et des autres éta-
Que les établissements d’enseignement privés qui blissements qui dispensent des services d’enseignement
dispensent des services éducatifs visés aux paragra- de niveau collégial ou universitaire et des établissements
phes 4° à 9° de l’article 1 de la Loi sur l’enseignement où sont dispensés des services éducatifs et d’enseignement
privé puissent dispenser leurs services éducatifs par de la formation professionnelle ou de la formation géné-
formation à distance; rale des adultes ou des services de formation continue,
un masque de procédure doive être porté en tout temps
Que des services éducatifs soient dispensés à distance lorsqu’ils se trouvent dans tout bâtiment ou local utilisé
par les centres de services scolaires, les commissions par l’établissement, sous réserve des exceptions suivantes :
scolaires et les établissements d’enseignement privés aux
élèves suivants de l’éducation préscolaire et de l’ensei- 1° l’élève ou l’étudiant déclare que sa condition médi-
gnement primaire et secondaire de la formation générale cale l’en empêche;
des jeunes :
2° l’élève ou l’étudiant y reçoit un soin, y bénéficie
1° ceux dont l’état de santé ou celui d’une personne d’un service ou y pratique une activité physique ou une
avec qui ils résident les met à risque de complications autre activité qui nécessite de l’enlever, auquel cas il peut
graves s’ils contractent la COVID-19, lorsqu’un médecin retirer son masque pour la durée de ce soin, de ce service
recommande que ces élèves ne fréquentent pas un ou de cette activité;
établissement scolaire;
3° l’élève ou l’étudiant retire momentanément son
2° ceux dont la classe est visée par une recommandation masque pour boire ou manger, ou à des fins d’identification;
ou un ordre d’isolement de la part d’une autorité de santé
publique en raison d’un cas de COVID-19 déclaré chez un 4° l’élève ou l’étudiant y travaille ou y exerce
employé ou un élève de l’établissement d’enseignement sa profession;
concerné, et ce, au plus tard deux jours à compter de la
recommandation ou de l’ordonnance; 5° l’élève ou l’étudiant consomme de la nourriture ou
une boisson dans un restaurant, dans une aire de restaura-
3° ceux dont la classe comprend au moins 60 % d’élèves tion d’un commerce d’alimentation, dans un bar ou dans
tenus de suivre les consignes d’isolement établies par une toute autre salle utilisée à des fins de restauration ou de
autorité de santé publique en raison de la COVID-19, et consommation de boisson;
ce, à compter de la deuxième journée du calendrier scolaire
suivant l’atteinte de ce pourcentage;

AR02658
Que les élèves de l’enseignement primaire et secondaire 3° le décret numéro 964-2020 du 21 septembre 2020,
de la formation générale des jeunes qui se trouvent dans modifié par l’arrêté numéro 2022-011 du 29 janvier 2022;
tout bâtiment ou local utilisé par un centre de services sco-
laire, une commission scolaire ou un établissement d’ensei- 4° les paragraphes 28°, 29°, 31° et 32° du
gnement privé doivent porter en tout temps un masque de neuvième alinéa du décret 885-2021 du 23 juin 2021,
procédure, sous réserve des exceptions suivantes : modifié par les arrêtés numéros 2021-049 du 1er juillet
1° l’élève est assis en classe ou dans un local utilisé par 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
un service de garde en milieu scolaire; 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
2° l’élève présente l’une des conditions médicales 2021, 2021-060 du 24 août 2021, 2021-061 du 31 août
suivantes : 2021, 2021-062 du 3 septembre 2021, 2021-063 du
a) il est incapable de mettre ou de retirer un masque 2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021,
de procédure par lui-même en raison d’une incapacité 2021-068 du 9 octobre 2021, 2021-069 du 12 octobre
physique; 2021, 2021-073 du 22 octobre 2021, 2021-074 du
b) une déformation faciale; du 2 novembre 2021, 2021-079 du 14 novembre 2021,
c) en raison d’un trouble cognitif, d’une déficience 2021, 2021-087 du 14 décembre 2021, 2021-089 du
intellectuelle, d’un trouble du spectre de l’autisme ou d’une 19 décembre 2021, 2021-090 du 20 décembre 2021,
autre condition de santé mentale, il n’est pas en mesure de 2021-092 du 22 décembre 2021, 2021-096 du 31 décembre
comprendre l’obligation de porter un masque de procédure 2021, 2022-001 du 2 janvier 2022, 2022-004 du
ou le port de celui-ci entraîne une désorganisation ou une 15 janvier 2022, 2022-011 du 29 janvier 2022, 2022-012
détresse significative; du 4 février 2022, 2022-013 du 5 février 2022, 2022-015
d) toute autre condition médicale en raison de laquelle du 11 février 2022, 2022-018 du 19 février 2022, 2022-019
le port du masque de procédure est jugé préjudiciable ou du 25 février 2022, 2022-020 du 4 mars 2022 et 2022-021
dangereux, pour laquelle une attestation par un profes- du 11 mars 2022;
sionnel habilité à poser un diagnostic peut être exigée;
5° l’arrêté numéro 2020-008 du 22 mars 2020, modifié
 3° l’élève peut retirer son masque de procédure pen- par le décret numéro 566-2020 du 27 mai 2020 et par les
dant qu’il reçoit un soin, bénéficie d’un service ou pratique arrêtés numéros 2020-033 du 7 mai 2020, 2020-044 du
une activité physique ou une autre activité qui nécessite 12 juin 2020, 2021-054 du 16 juillet 2021, 2022-004 du
de l’enlever; 15 janvier 2022 et 2022-024 du 25 mars 2022;
4° l’élève retire momentanément son masque de procé- 6° le septième alinéa de l’arrêté numéro 2020-035 du
dure pour boire ou manger, ou à des fins d’identification; 10 mai 2020;
5° l’élève a des besoins particuliers liés à la parole, 7° les cinquième et sixième alinéas de l’arrêté
au langage et à la communication ou reçoit des services numéro 2020-044 du 12 juin 2020, modifié par l’arrêté
d’accueil et de soutien à l’apprentissage de la langue fran- numéro 2021-036 du 15 mai 2021;
çaise dans le cadre des services éducatifs et d’enseignement;
6° l’élève interagit avec une personne visée au 8° le troisième alinéa de l’arrêté numéro 2020-049 du
paragraphe précédent; 4 juillet 2020, modifié par les arrêtés numéros 2021-054
du 16 juillet 2021 et 2022-024 du 25 mars 2022;
7° en classe, lorsque la température extérieure déter-
minée par Environnement Canada est de 25°C ou plus, à 9° l’arrêté numéro 2020-102 du 9 décembre 2020;
moins que le local soit climatisé;
10° les cinquante-sixième et cinquante-septième
Que soient abrogés : alinéas de l’arrêté numéro 2021-085 du 13 décembre 2021,
modifié par les arrêtés numéros 2021-093 du 23 décembre
1° le décret numéro 651-2020 du 17 juin 2020, modifié 2021 et 2022-008 du 23 janvier 2022;
par le décret numéro 885-2020 du 19 août 2020;
2° le décret numéro 885-2020 du 19 août 2020, modifié 11° les dix-neuvième et vingtième alinéas de l’arrêté
par les décrets numéros 943-2020 du 9 septembre 2020 et numéro 2022-003 du 15 janvier 2022, modifié par l’arrêté
433-2021 du 24 mars 2021 et par l’arrêté numéro 2022-004 numéro 2022-008 du 23 janvier 2022.
du 15 janvier 2022;

ANNEXE
SEUILS MINIMAUX DE SERVICES ÉDUCATIFS À DISTANCE
Heures d’enseignement Heures de travail autonome Heures de disponibilité

ou d’activités de formation fourni par l’enseignant de l’enseignant par jour
et d’éveil par semaine par semaine par élève ou par semaine pour
répondre aux besoins
des élèves
Préscolaire 11,5 heures d’activités de 2 heures S.O.
formation et d’éveil en groupe
11,5 heures d’activités

personnalisées
1er cycle primaire 10,5 heures d’enseignement 3 heures 2,5 heures par jour
(1re et 2e année)
(3e et 4e année)
3e cycle primaire 13 heures d’enseignement 7,5 heures 2 heures par jour
(5e et 6e année)
1er cycle secondaire 15 heures d’enseignement 7,5 heures 5 heures par semaine
(1re, 2e et 3e secondaire)
2e cycle secondaire 15 heures d’enseignement 7,5 heures 5 heures par semaine
(4e et 5e secondaire)
Québec, le 31 mars 2022

Christian Dubé
77080
A.M., 2022 Vu le décret numéro 177-2020 du 13 mars 2020 qui

Arrêté numéro 2022-027 du ministre de la Santé et québécois pour une période de 10 jours;
des Services sociaux en date du 31 mars 2022
Loi sur la santé publique velé depuis cette date par divers décrets, notamment par
(chapitre S-2.2) le décret numéro 595-2022 du 30 mars 2022;
Co nc er na nt l’ordonnance de mesures visant à Vu que ce décret habilite également le ministre de
protéger la santé de la population dans la situation de la Santé et des Services sociaux à prendre toute mesure
pandémie de la COVID-19 prévue aux paragraphes 1° à 8° du premier alinéa de
l’article 123 de la Loi sur la santé publique;
Vu l’article 118 de la Loi sur la santé publique (chapitre modifié par les arrêtés numéros 2021-049 du 1er juillet
S-2.2) qui prévoit que le gouvernement peut déclarer un 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
état d’urgence sanitaire dans tout ou partie du territoire 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
québécois lorsqu’une menace grave à la santé de la popu- 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
lation, réelle ou imminente, exige l’application immédiate 2021, 2021 060 du 24 août 2021, 2021-061 du 31 août
2021, 2021-062 du 3 septembre 2021, 2021-063 du

AR02660
Ceci est la pièce « OO » au soutien de


ANNEXE
SEUILS MINIMAUX DE SERVICES ÉDUCATIFS À DISTANCE
Heures d’enseignement Heures de travail autonome Heures de disponibilité

ou d’activités de formation fourni par l’enseignant de l’enseignant par jour
et d’éveil par semaine par semaine par élève ou par semaine pour
répondre aux besoins
des élèves
Préscolaire 11,5 heures d’activités de 2 heures S.O.
formation et d’éveil en groupe
11,5 heures d’activités

personnalisées
1er cycle primaire 10,5 heures d’enseignement 3 heures 2,5 heures par jour
(1re et 2e année)
(3e et 4e année)
3e cycle primaire 13 heures d’enseignement 7,5 heures 2 heures par jour
(5e et 6e année)
1er cycle secondaire 15 heures d’enseignement 7,5 heures 5 heures par semaine
(1re, 2e et 3e secondaire)
2e cycle secondaire 15 heures d’enseignement 7,5 heures 5 heures par semaine
(4e et 5e secondaire)

Christian Dubé
77080
A.M., 2022 Vu le décret numéro 177-2020 du 13 mars 2020 qui

Arrêté numéro 2022-027 du ministre de la Santé et québécois pour une période de 10 jours;
des Services sociaux en date du 31 mars 2022
Loi sur la santé publique velé depuis cette date par divers décrets, notamment par
(chapitre S-2.2) le décret numéro 595-2022 du 30 mars 2022;
Co nc er na nt l’ordonnance de mesures visant à Vu que ce décret habilite également le ministre de
protéger la santé de la population dans la situation de la Santé et des Services sociaux à prendre toute mesure
pandémie de la COVID-19 prévue aux paragraphes 1° à 8° du premier alinéa de
l’article 123 de la Loi sur la santé publique;
Vu l’article 118 de la Loi sur la santé publique (chapitre modifié par les arrêtés numéros 2021-049 du 1er juillet
S-2.2) qui prévoit que le gouvernement peut déclarer un 2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet
état d’urgence sanitaire dans tout ou partie du territoire 2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août
québécois lorsqu’une menace grave à la santé de la popu- 2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
lation, réelle ou imminente, exige l’application immédiate 2021, 2021 060 du 24 août 2021, 2021-061 du 31 août
2021, 2021-062 du 3 septembre 2021, 2021-063 du

AR02662
9 septembre 2021, 2021-065 du 24 septembre 2021, a) un commerce de vente au détail, un centre com-
2021-066 du 1er octobre 2021, 2021-067 du 8 octobre 2021, mercial ou un bâtiment ou un local où est exploitée une
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre entreprise de services, incluant une entreprise de soins
2021, 2021-073 du 22 octobre 2021, 2021-074 du personnels ou d’esthétique;
du 2 novembre 2021, 2021-079 du 14 novembre 2021, b) un restaurant ou un bar;
2021, 2021-087 du 14 décembre 2021, 2021-089 du c) un lieu de culte;
19 décembre 2021, 2021-090 du 20 décembre 2021,
2021-092 du 22 décembre 2021, 2021-096 du 31 décembre d) un lieu où sont offerts des activités ou des services
2021, 2022-001 du 2 janvier 2022, 2022-004 du 15 janvier de nature culturelle ou de divertissement;
2022, 2022-011 du 29 janvier 2022, 2022-012 du 4 février
2022, 2022-013 du 5 février 2022, 2022-015 du 11 février e) un lieu où sont pratiquées des activités sportives
2022, 2022-018 du 19 février 2022, 2022-019 du 25 février ou récréatives;
2022, 2022-020 du 4 mars 2022, 2022-021 du 11 mars
2022 et 2022-026 du 31 mars 2022, prévoit notamment f) une salle de location ou un autre lieu utilisé pour
certaines mesures particulières applicables dans tout le accueillir des évènements, incluant des congrès et des
territoire québécois; conférences, ou pour tenir des réceptions;
Considér ant qu’il est souhaité de consolider en un seul g) un lieu où sont offerts des services municipaux
arrêté ministériel l’ensemble des mesures sanitaires; ou gouvernementaux;
Arrête ce qui suit : h) une aire commune, incluant un ascenseur, d’un
établissement d’hébergement touristique;
Que constitue un service ou un soutien aux fins du
présent arrêté : i) un bâtiment ou un local utilisé par un établissement
d’enseignement;
1° un service ou un soutien requis par une personne
en raison de son état de santé ou à des fins de sécurité, j) une gare de train ou d’autobus, une gare fluviale, une
à des fins de soins personnels ou esthétiques, à des fins station de métro ou un aéroport;
commerciales ou professionnelles, de garde d’enfant ou
de personnes vulnérables, de répit, d’aide domestique, k) un cabinet privé de professionnels;
d’aide aux activités de la vie quotidienne, de tutorat ou de
dispensation de cours; Qu’il soit interdit à l’exploitant d’un lieu qui accueille
le public d’y admettre une personne qui ne porte pas un
2° un service d’entretien, de réparation ou de rénova- couvre-visage ou de tolérer qu’une personne qui ne porte
tion résidentiel; pas un couvre-visage s’y trouve, à moins :
3° une visite à des fins de vente ou de location de 1° qu’elle soit âgée de moins de 10 ans et qu’il ne
la résidence; s’agisse pas d’un élève qui se trouve dans un bâtiment
ou un local utilisé par un établissement d’enseignement;
4° une visite nécessaire à l’exercice d’un travail ou
d’une profession; 2° qu’il s’agisse d’un élève de l’éducation préscolaire
qui se trouve dans un bâtiment ou un local utilisé par un
5° tout autre service ou soutien de même nature; établissement d’enseignement ou des enfants d’un camp
de vacances ou d’un camp de jour;
Qu’aux fins du présent arrêté, on entende par :
3° qu’elle déclare que sa condition médicale
1° « couvre-visage » un masque ou un tissu bien ajusté l’en empêche;
qui couvre le nez et la bouche;
4° qu’elle y reçoive un soin, y bénéficie d’un service
2° « lieu qui accueille le public » la partie accessible au ou y pratique une activité physique ou une autre activité
public des lieux suivants, dans la mesure où elle est fermée qui nécessite de l’enlever, auquel cas elle peut retirer son
ou partiellement couverte et qu’il ne s’agit pas d’une unité couvre-visage pour la durée de ce soin, de ce service ou
d’hébergement : de cette activité;

5° qu’elle retire momentanément son couvre-visage 4° que le moyen de transport soit son lieu de travail
pour boire ou manger, ou à des fins d’identification; habituel;
6° qu’elle y travaille ou y exerce sa profession; 5° qu’elle consomme de la nourriture ou une boisson
alors qu’elle se trouve dans une aire réservée pour la res-
7° qu’il s’agisse d’une personne du public qui se trouve tauration ou la consommation de boissons;
assise dans une salle d’audience et qui maintient latérale-
ment une distance minimale d’un mètre avec toute autre 6° qu’elle retire momentanément son couvre-visage
personne qui n’est ni un occupant d’une même résidence pour boire ou manger, ou à des fins d’identification;
privée ou de ce qui en tient lieu, ni une personne qui lui
fournit un service ou un soutien; 7° sur un traversier, qu’elle demeure à l’intérieur de son
véhicule ou sur un pont extérieur;
8° qu’elle se trouve dans une salle d’audience sans être
visée au paragraphe précédent, ou dans une salle de déli- 8° qu’elle se trouve sur l’étage extérieur d’un véhicule;
bération des jurés;
Que les interdictions prévues à l’alinéa précédent
9° qu’elle consomme de la nourriture ou une boisson s’appliquent également, sous réserve des mêmes excep-
dans un restaurant, dans une aire de restauration d’un tions, au chauffeur d’un véhicule automobile utilisé à des
centre commercial ou d’un commerce d’alimentation, fins de transport rémunéré de personnes autrement que
dans un bar ou dans toute autre salle utilisée à des fins de dans le cadre de l’exploitation d’un service de transport
restauration ou de consommation de boissons; collectif, sauf s’il s’agit de covoiturage;
Que, malgré le paragraphe 6° de l’alinéa précédent : Que la personne dont le lieu de travail habituel est un
moyen de transport visé au cinquième alinéa ou un véhi-
1° dans un immeuble autre qu’un immeuble d’habita- cule automobile visé au sixième alinéa demeure soumise
tion, qu’il constitue un lieu qui accueille le public ou non, aux règles applicables en matière de santé et de sécurité
il soit interdit à l’exploitant d’admettre toute personne, y du travail;
compris une personne qui y travaille ou y exerce sa pro-
fession, lorsqu’elle ne porte pas un couvre-visage, ou de Qu’il soit interdit à toute personne qui ne porte pas un
tolérer qu’elle se trouve dans un hall d’entrée, une aire couvre-visage :
d’accueil ou un ascenseur de l’immeuble sans porter un
couvre-visage; 1° d’accéder à un lieu qui accueille le public ou de s’y
trouver, à moins qu’elle soit visée par l’une des exceptions
2° une personne qui travaille ou exerce sa profession prévues au troisième alinéa;
dans un lieu qui accueille le public demeure soumise
aux règles applicables en matière de santé et de sécurité 2° d’accéder à un immeuble autre qu’un immeuble
du travail; d’habitation, qu’il constitue un lieu qui accueille le public
ou non, ou de se trouver dans un hall d’entrée, une aire
Qu’il soit interdit à l’exploitant d’un service de trans- d’accueil ou un ascenseur de l’immeuble, à moins qu’elle
port collectif par autobus, minibus, métro, bateau, train soit visée par l’une des exceptions prévues aux paragra-
ou avion d’y admettre une personne qui ne porte pas un phes 1° à 5° ou 7° à 9° du troisième alinéa;
couvre-visage ou de tolérer qu’elle se trouve dans un tel
moyen de transport sans porter un couvre-visage, à moins : 3° d’accéder à un autobus, un minibus, un métro,
un bateau, un train ou un avion utilisé dans le cadre de
1° qu’elle soit âgée de moins de 10 ans et qu’il ne l’exploitation d’un service de transport collectif ou à un
s’agisse pas d’un élève qui se trouve dans un moyen de véhicule automobile utilisé à des fins de transport rému-
transport scolaire; néré de personnes, sauf s’il s’agit de covoiturage, ou de se
trouver dans un tel moyen de transport, à moins qu’elle soit
2° qu’il s’agisse d’un élève de l’éducation préscolaire visée par l’une des exceptions prévues au cinquième alinéa;
dans un moyen de transport scolaire où il n’y a que des
élèves de l’éducation préscolaire; Que les troisième, quatrième et huitième alinéas
3° qu’elle déclare que sa condition médicale d’une résidence privée pour aînés, sauf sur les territoires
l’en empêche; des régions sociosanitaires du Nunavik et des Terres-Cries-
de-la-Baie-James; toutefois, le couvre-visage porté doit
être un masque de procédure;

AR02664
Qu’un ministre du culte ou une personne qui agit A.M., 2022

comme bénévole dans un lieu de culte peut y retirer son
couvre-visage lorsqu’il maintient une distance minimale Arrêté numéro 2022-028 du ministre de la Santé et
d’un mètre avec toute autre personne; des Services sociaux en date du 31 mars 2022
Que lors d’un mariage dans une salle d’audience, le Loi sur la santé publique
couvre-visage soit porté par le public en tout temps, sous (chapitre S-2.2)
réserve des exceptions prévues aux paragraphes 1°, 3°
ou 5° du troisième alinéa; Co nc er na nt l’ordonnance de mesures visant à
Que dans les cinémas et les salles où sont présentés les pandémie de la COVID-19
arts de la scène, y compris les lieux de diffusion, pour une
production, un tournage audiovisuel, un spectacle intérieur, Le ministre de la Santé et des Services sociaux,
dans les salles d’entraînement physique, ainsi que pour un
entraînement ou un événement sportif intérieur, le couvre- Vu l’article 118 de la Loi sur la santé publique (chapitre
visage porté par le public soit un masque de procédure; S-2.2) qui prévoit que le gouvernement peut déclarer un
Que le décret numéro 885-2021 du 23 juin 2021, québécois lorsqu’une menace grave à la santé de la popu-
modifié par les arrêtés numéros 2021-049 du 1er juillet lation, réelle ou imminente, exige l’application immédiate
2021, 2021-050 du 2 juillet 2021, 2021-053 du 10 juillet de certaines mesures prévues à l’article 123 de cette loi
2021, 2021-055 du 30 juillet 2021, 2021-057 du 4 août pour protéger la santé de la population;
2021, 2021-058 du 13 août 2021, 2021-059 du 18 août
2021, 2021-060 du 24 août 2021, 2021-061 du 31 août Vu le décret numéro 177-2020 du 13 mars 2020 qui
2021, 2021-062 du 3 septembre 2021, 2021-063 du déclare l’état d’urgence sanitaire dans tout le territoire
9 septembre 2021, 2021-065 du 24 septembre 2021, québécois pour une période de 10 jours;
2021-068 du 9 octobre 2021, 2021-069 du 12 octobre Vu que l’état d’urgence sanitaire a toujours été renou-
2021, 2021-073 du 22 octobre 2021, 2021-074 du velé depuis cette date par divers décrets, notamment par
25 octobre 2021, 2021-077 du 29 octobre 2021, 2021-078 le décret numéro 595-2022 du 30 mars 2022;
2021-083 du 10 décembre 2021, 2021-086 du 13 décembre Vu que ce décret habilite également le ministre de
2021, 2021-087 du 14 décembre 2021, 2021-089 du la Santé et des Services sociaux à prendre toute mesure
19 décembre 2021, 2021-090 du 20 décembre 2021, prévue aux paragraphes 1° à 8° du premier alinéa de
2021-092 du 22 décembre 2021, 2021-096 du 31 décembre l’article 123 de la Loi sur la santé publique;
2022, 2022-011 du 29 janvier 2022, 2022-012 du 4 février Considér ant qu’il est souhaité de consolider en un seul
2022, 2022-013 du 5 février 2022, 2022-015 du 11 février arrêté ministériel l’ensemble des mesures opérationnelles;
2022, 2022-018 du 19 février 2022, 2022-019 du 25 février
2022, 2022-020 du 4 mars 2022, 2022-021 du 11 mars Arrête ce qui suit :
2022 et 2022-026 du 31 mars 2022, soit abrogé.
Que les services liés à la COVID-19 fournis par cor-
Québec, le 31 mars 2022 respondance ou par voie de télécommunication par des
professionnels de la santé soient considérés comme des
Le ministre de la Santé et des Services sociaux, services assurés;
Christian Dubé
Que malgré le premier alinéa du dispositif de l’arrêté
77081 numéro 2020-037 du 14 mai 2020, la durée des privilèges
octroyés à un médecin ou à un dentiste qui a été aug-
mentée en vertu de cet arrêté ne puisse l’être au-delà du
31 mai 2022;

AR02665
Ceci est la pièce « PP » au soutien de


AR02666
2020, 2020-101 du 5 décembre 2020, 2020-102 du 29 avril 2020, 2020-032 du 5 mai 2020, 2020-033 du 7 mai
9 décembre 2020, 2020-103 du 13 décembre 2020, 2020-104 2020, 2020-034 du 9 mai 2020, 2020-035 du 10 mai 2020,
du 15 décembre 2020, 2020-105 du 17 décembre 2020, 2020-037 du 14 mai 2020, 2020-039 du 22 mai 2020,
2020-106 du 20 décembre 2020, 2020-107 du 23 décembre 2020-042 du 4 juin 2020, 2020-044 du 12 juin 2020,
2020, 2020-108 du 30 décembre 2020, 2021-001 du 2020-049 du 4 juillet 2020, 2020-060 du 28 août 2020,
15 janvier 2021, 2021-003 du 21 janvier 2021, 2021-004 du 2020-061 du 1er septembre 2020, 2020-062 du 4 septembre
27 janvier 2021, 2021-005 du 28 janvier 2021, 2021-008 2020, 2020-064 du 17 septembre 2020, 2020-067 du
du 20 février 2020, 2021-009 du 25 février 2021, 19 septembre 2020, 2020-069 du 22 septembre 2020,
2021-010 du 5 mars 2021, 2021-013 du 13 mars 2021, 2020-076 du 5 octobre 2020, 2020-084 du 27 octobre
2021-015 du 16 mars 2021, 2021-016 du 19 mars 2021, 2020, 2020-087 du 4 novembre 2020, 2020-091 du
2021-017 du 26 mars 2021, 2021-019 du 28 mars 2021, 13 novembre 2020, 2020-097 du 1er décembre 2020,
2021-020 du 1er avril 2021, 2021-021 du 5 avril 2021, 2020-099 du 3 décembre 2020, 2020-102 du 9 décembre
2021-022 et 2021-023 du 7 avril 2021, 2021-024 du 9 avril 2020, 2020-107 du 23 décembre 2020, 2021-003 du
2021, 2021-025 du 11 avril 2021, 2021-026 du 14 avril 21 janvier 2021, 2021-005 du 28 janvier 2021, 2021-010 du
2021, 2021-027 du 16 avril 2021, 2021-028 du 17 avril 5 mars 2021, 2021-017 du 26 mars 2021, 2021-022 du 7 avril
2021, 2021-029 du 18 avril 2021, 2021-031 du 28 avril 2021, 2021-024 du 9 avril 2021, 2021-027 du 16 avril 2021,
2021, 2021-032 du 30 avril 2021, 2021-033 du 5 mai 2021, 2021-028 du 17 avril 2021, 2021-032 du 30 avril 2021,
2021-034 du 8 mai 2021, 2021-036 du 15 mai 2021, 2021-036 du 15 mai 2021, 2021-039 du 28 mai 2021,
2021-039 du 28 mai 2021, 2021-040 du 5 juin 2021, 2021-049 du 1er juillet 2021, 2021-050 du 2 juillet 2021,
2021-041 du 7 juin 2021, 2021-043 du 11 juin 2021, 2021-051 du 6 juillet 2021, 2021-052 du 7 juillet 2021,
2021-044 du 14 juin 2021, 2021-045 et 2021-046 du 2021-053 du 10 juillet 2021, 2021-054 du 16 juillet 2021,
16 juin 2021, 2021-047 du 18 juin 2021, 2021-048 du 2021-055 du 30 juillet 2021, 2021-057 du 4 août 2021,
23 juin 2021, 2021-049 du 1er juillet 2021, 2021-050 du 2021-058 du 13 août 2021, 2021-059 du 18 août 2021,
2 juillet 2021, 2021-051 du 6 juillet 2021, 2021-052 du 2021-060 du 24 août 2021 et 2021-061 du 31 août 2021,
7 juillet 2021, 2021-053 du 10 juillet 2021, 2021-054 du sauf dans la mesure où elles ont été modifiées par ces
16 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057 décrets ou ces arrêtés, continuent de s’appliquer jusqu’au
du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 10 septembre 2021 ou jusqu’à ce que le gouvernement ou
du 18 août 2021, 2021-060 du 24 août 2021 et 2021-061 le ministre de la Santé et des Services sociaux les modifie
du 31 août 2021, le ministre a également pris certaines ou y mette fin;
mesures afin de protéger la population;
At t en du qu’il y a lieu de renouveler l’état d’urgence habilité à prendre toute mesure prévue aux paragraphes 1°
sanitaire pour une période de dix jours; à 8° du premier alinéa de l’article 123 de la Loi sur la santé
publique (chapitre S-2.2).
Il est or don n é, en conséquence, sur la recomman-
dation du ministre de la Santé et des Services sociaux : Le greffier du Conseil exécutif,
Yves Ouel l et
Que l’état d’urgence sanitaire soit renouvelé jusqu’au
10 septembre 2021; 75558
Qu e les mesures prévues par les décrets numéros

177-2020 du 13 mars 2020, 222-2020 du 20 mars 2020, Gouvernement du Québec
460-2020 du 15 avril 2020, 505-2020 du 6 mai 2020,
566-2020 du 27 mai 2020, 615-2020 du 10 juin 2020, Décret 1173-2021, 1er septembre 2021
651-2020 du 17 juin 2020, 885-2020 du 19 août 2020,
943-2020 du 9 septembre 2020, 964-2020 du 21 septembre Con c er n a n t l’ordonnance de mesures visant à
2020, 135-2021 du 17 février 2021 et 885-2021 du 23 juin protéger la santé de la population dans la situation de
2021 et par les arrêtés numéros 2020-004 du 15 mars pandémie de la COVID-19
2020, 2020-007 du 21 mars 2020, 2020-008 du 22 mars
2020, 2020-014 du 2 avril 2020, 2020-015 du 4 avril 2020, At t en du que l’Organisation mondiale de la Santé a
2020-016 du 7 avril 2020, 2020-017 du 8 avril 2020, déclaré une pandémie de la COVID-19 le 11 mars 2020;
2020-019 et 2020-020 du 10 avril 2020, 2020-022 du
15 avril 2020, 2020-023 du 17 avril 2020, 2020-026 du At t en du qu’en vertu de l’article 118 de la Loi sur
20 avril 2020, 2020-027 du 22 avril 2020, 2020-028 du la santé publique (chapitre S-2.2) le gouvernement peut
25 avril 2020, 2020-029 du 26 avril 2020, 2020-030 du déclarer un état d’urgence sanitaire dans tout ou partie
5192A AR02667
GAZETTE OFFICIELLE DU QUÉBEC, 2 septembre 2021, 153e année, no 35A Partie 2
du territoire québécois lorsqu’une menace grave à la santé 21 janvier 2021, 2021-005 du 28 janvier 2021, 2021-010
de la population, réelle ou imminente, exige l’application du 5 mars 2021, 2021-017 du 26 mars 2021, 2021-022 du
immédiate de certaines mesures prévues à l’article 123 de 7 avril 2021, 2021-024 du 9 avril 2021, 2021-027 du
cette loi pour protéger la santé de la population; 16 avril 2021, 2021-028 du 17 avril 2021, 2021-032 du
30 avril 2021, 2021-036 du 15 mai 2021, 2021-039 du
At t en du qu e cette pandémie constitue une menace 28 mai 2021, 2021-040 du 5 juin 2021, 2021-046 du
réelle grave à la santé de la population qui exige 16 juin 2021, 2021-049 du 1er juillet 2021, 2021-050 du
l’application immédiate de certaines mesures prévues à 2 juillet 2021, 2021-051 du 6 juillet 2021, 2021-052 du
l’article 123 de cette loi; 7 juillet 2021, 2021-053 du 10 juillet 2021, 2021-054 du
At t en du qu’au cours de l’état d’urgence sanitaire, 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
malgré toute disposition contraire, le gouvernement ou 18 août 2021, 2021-060 du 25 août 2021 et 2021-061 du
le ministre de la Santé et des Services sociaux, s’il a été 31 août 2021, sauf dans la mesure où elles ont été
habilité, peut, sans délai et sans formalité, prendre l’une modifiées par ces décrets ou ces arrêtés, continuent de
des mesures prévues aux paragraphes 1° à 8° du premier s’appliquer jusqu’au 10 septembre 2021 ou jusqu’à ce que
alinéa de l’article 123 de cette loi pour protéger la santé le gouvernement ou le ministre de la Santé et des Services
de la population; sociaux les modifie ou y mette fin;
At t en d u qu e, par le décret numéro 177-2020 du At t en du qu’il y a lieu d’ordonner certaines mesures

13 mars 2020, le gouvernement a déclaré l’état d’urgence pour protéger la santé de la population;
sanitaire et a pris certaines mesures afin de protéger
la population; Il est or don n é, en conséquence, sur la recomman-
dation du ministre de la Santé et des Services sociaux :
At t en du que l’état d’urgence sanitaire a toujours été
renouvelé depuis cette date par divers décrets, notamment Qu’aux fins du présent décret, on considère « adéqua-
par le décret numéro 1172-2021 du 1er septembre 2021; tement protégée contre la COVID-19 », une personne qui,
selon le cas :
At t en du que ce dernier décret prévoit que les mesures
prévues par les décrets numéros 177-2020 du 13 mars 1° a reçu deux doses de l’un ou l’autre des vaccins à
2020, 222-2020 du 20 mars 2020, 460-2020 du 15 avril ARNm de Moderna ou de Pfizer-BioNTech ou du vaccin
2020, 505-2020 du 6 mai 2020, 566-2020 du 27 mai 2020, AstraZeneca/COVIDSHIELD, avec un intervalle minimal
615-2020 du 10 juin 2020, 651-2020 du 17 juin 2020, de 28 jours entre les doses et dont la dernière dose a été
885-2020 du 19 août 2020, 943-2020 du 9 septembre reçue depuis 7 jours ou plus;
2020, 964-2020 du 21 septembre 2020, 135-2021 du
17 février 2021 et 885-2021 du 23 juin 2021 et par les 2° a contracté la COVID-19 et a reçu, depuis 7 jours
arrêtés numéros 2020-004 du 15 mars 2020, 2020-007 du ou plus, une dose de l’un ou l’autre des vaccins visés au
21 mars 2020, 2020-008 du 22 mars 2020, 2020-014 du paragraphe 1° avec un intervalle minimal de 21 jours après
2 avril 2020, 2020-015 du 4 avril 2020, 2020-016 du la maladie;
7 avril 2020, 2020-017 du 8 avril 2020, 2020-019 et
2020-020 du 10 avril 2020, 2020-022 du 15 avril 2020, 3° a reçu une dose du vaccin Janssen depuis 14 jours
2020-023 du 17 avril 2020, 2020-026 du 20 avril 2020, ou plus;
2020-027 du 22 avril 2020, 2020-028 du 25 avril 2020,
2020-029 du 26 avril 2020, 2020-030 du 29 avril 2020, Que soit également assimilée à une personne adéqua-
2020-032 du 5 mai 2020, 2020-033 du 7 mai 2020, tement protégée contre la COVID-19 une personne qui,
2020-034 du 9 mai 2020, 2020-035 du 10 mai 2020, selon le cas :
2020-037 du 14 mai 2020, 2020-039 du 22 mai 2020,
2020-042 du 4 juin 2020, 2020-044 du 12 juin 2020, 1° présente une contre-indication à la vaccination
2020-049 du 4 juillet 2020, 2020-060 du 28 août 2020, contre cette maladie attestée par un professionnel de la
2020-061 du 1er septembre 2020, 2020-062 du 4 septembre santé habilité à poser un diagnostic et qui est inscrite au
2020, 2020-064 du 17 septembre 2020, 2020-067 du registre de vaccination maintenu par le ministre de la
19 septembre 2020, 2020-069 du 22 septembre 2020, Santé et des Services sociaux;
2020, 2020-087 du 4 novembre 2020, 2020-091 du 2° a participé à l’étude clinique menée par Medicago
13 novembre 2020, 2020-097 du 1er décembre 2020, inc.visant à valider la sécurité ou l’efficacité d’un candi-
2020-099 du 3 décembre 2020, 2020-102 du 9 décembre dat-vaccin contre la COVID-19;
2020, 2020-107 du 23 décembre 2020, 2021-003 du
AR02668
Que toute personne du public âgée de 13 ans ou plus a) pour la pratique d’un tel sport ou d’une activité qui
soit tenue, afin de participer aux activités ou d’accéder fait partie de l’offre des programmes de sport-études ou
aux lieux suivants, d’être adéquatement protégée contre d’art-études et des programmes d’éducation physique et à
la COVID-19, d’en présenter la preuve au moyen d’une la santé, de concentration sportive et autres projets péda-
pièce d’identité et du code QR qu’elle a reçu à cette fin du gogiques particuliers de même nature dispensés dans le
gouvernement du Québec et d’en permettre la vérification cadre des services éducatifs de la formation générale des
au moyen de l’application VaxiCode Verif : jeunes ou de la formation générale aux adultes par un
centre de services scolaire, une commission scolaire ou
1° à un évènement extérieur ouvert au public, auquel un établissement d’enseignement privé, à l’exception des
assistent ou participent plus de 50 personnes, à l’exception : compétitions sportives, des ligues et des tournois;
a) d’un évènement se déroulant dans un ciné-parc ou b) pour la pratique d’un tel sport ou d’une telle activité
un autre lieu utilisé à des fins similaires; qui fait partie de l’offre de formation en matière de sport et
de loisir dans les programmes d’enseignement de niveau
b) d’un évènement ou d’un entraînement amateur collégial ou universitaire, à l’exception des compétitions
auquel assistent un maximum de 500 personnes assises sportives, des ligues et des tournois;
dans les gradins ou dans tout autre type d’aménage-
ment permettant aux personnes de s’asseoir à des places c) pour la pratique d’un sport professionnel ou de
déterminées; haut niveau qui évolue dans un environnement protégé
conformément au sous-paragraphe f du paragraphe 21°
2° à un cinéma, à une salle où sont présentés les arts de du quatorzième alinéa du décret numéro 885-2021 du
la scène, y compris un lieu de diffusion, à une production, 23 juin 2021, modifié par les arrêtés numéros 2021‑049
à un tournage audiovisuel, à un spectacle intérieur et à du 1er juillet 2021, 2021‑050 du 2 juillet 2021, 2021‑053
un entraînement ou à un évènement sportif intérieur, à du 10 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
l’exception d’un évènement ou d’un entraînement ama- du 4 août 2021, 2021‑058 du 13 août 2021, 2021-059 du
teur auquel assistent un maximum de 25 personnes ou 18 août 2021, 2021-060 du 24 août 2021 et 2021-061 du
un maximum de 250 personnes lorsqu’elles sont assises 31 août 2021;
dans les gradins ou dans tout autre type d’aménage-
ment permettant aux personnes de s’asseoir à des places 10° à une activité physique impliquant des contacts
déterminées; fréquents ou prolongés ou à un sport d’équipe pratiqués à
l’extérieur, sauf dans les cas suivants :
3° à un biodôme, un planétarium, un insectarium, un
jardin botanique, un aquarium et un jardin zoologique; a) pour la pratique d’un tel sport ou d’une telle activité
qui fait partie de l’offre des programmes de sport-études
4° à un casino, à une maison de jeux ou pour participer ou d’art-études et des programmes d’éducation physique
à un bingo; et à la santé, de concentration sportive et autres projets
pédagogiques particuliers de même nature dispensés dans
5° à un bar, à une discothèque, à une microbrasserie, à le cadre des services éducatifs de la formation générale
une distillerie, à un restaurant, à une aire de restauration des jeunes ou de la formation générale aux adultes par un
d’un centre commercial ou d’un commerce d’alimentation, centre de services scolaire, une commission scolaire ou
incluant les terrasses de tels lieux, sauf pour une un établissement d’enseignement privé, à l’exception des
commande à emporter ou une commande à l’auto; compétitions sportives, des ligues et des tournois;
6° à une arcade, à un site thématique, à un centre ou à b) pour la pratique d’un tel sport ou d’une telle activité
un parc d’attraction, à un centre d’amusement, à un centre qui fait partie de l’offre de formation en matière de sport et
récréatif et à un parc aquatique ainsi que pour la pratique de loisir dans les programmes d’enseignement de niveau
des jeux de quilles, de fléchettes, de billard ou d’autres collégial ou universitaire, à l’exception des compétitions
jeux de même nature; sportives, des ligues et des tournois;
7° à une croisière touristique ou récréative; c) pour la pratique libre d’une telle activité ou d’un
tel sport;
8° à un congrès ou à une conférence;
d) pour la pratique d’un sport professionnel ou de
9° à tout lieu public intérieur afin d’y pratiquer un sport haut niveau qui évolue dans un environnement protégé
ou une activité physique, sauf dans les cas suivants : conformément au sous-paragraphe f du paragraphe 21°
du quatorzième alinéa du décret numéro 885-2021 du
23 juin 2021, tel que modifié;
5194A AR02669
GAZETTE OFFICIELLE DU QUÉBEC, 2 septembre 2021, 153e année, no 35A Partie 2
Que les élèves et les étudiants de l’enseignement pri- Qu e, malgré les troisième, cinquième et septième
maire ou secondaire de la formation générale des jeunes, alinéas, une personne du public âgée de 13 ans ou plus
des collèges, des établissements d’enseignement collé- qui réside à l’extérieur du Québec puisse participer aux
gial privés et des autres établissements qui dispensent activités ou accéder aux lieux visés au troisième alinéa
des services d’enseignement de niveau collégial ne soient en présentant une pièce d’identité et une preuve officielle
pas tenus d’être adéquatement protégés, d’en présenter la rédigée en français ou en anglais qu’elle a reçu une dose du
preuve, ni de présenter une pièce d’identité pour accéder à vaccin Janssen ou deux doses de tout autre vaccin contre
tout lieu dans lequel ils bénéficient de services éducatifs, la COVID-19 émise par les autorités de sa province, de
offerts par un centre de services scolaire, une commis- son territoire ou de son pays de résidence;
sion scolaire, un établissement d’enseignement privé, un
collège, un établissement d’enseignement collégial privé Que la pièce d’identité présentée en vertu de l’alinéa
ou un autre établissement qui dispense des services précédent soit émise par un ministère, un organisme
d’enseignement de niveau collégial; public ou un établissement d’enseignement, démontre
que la personne concernée réside à l’extérieur du Québec
Que l’organisateur de toute activité et l’exploitant de et, dans le cas d’une personne âgée de 16 ans ou plus et
tout lieu visés au troisième alinéa soient tenus de vérifier, de moins de 75 ans, comporte une photographie de la
à l’aide de l’application VaxiCode Verif, que toute personne personne concernée;
du public âgée de 13 ans ou plus qui souhaite participer
à une telle activité ou être admise dans un tel lieu est Que le présent décret n’ait pas pour effet d’empêcher
adéquatement protégée contre la COVID-19 et de vérifier les personnes sans-abri d’accéder à un restaurant ou à
l’identité de cette personne, sous réserve des exceptions une aire de restauration d’un centre commercial ou d’un
prévues aux troisième et quatrième alinéas; commerce d’alimentation;
Qu e la vérification de l’identité prévue au troisième Qu’à l’égard du présent décret, les sanctions pénales
alinéa et à l’alinéa précédent s’effectue au moyen d’une prévues à l’article 139 de la Loi sur la santé publique
pièce d’identité émise par un ministère, un organisme (chapitre S-2.2) ne soient applicables qu’aux infractions
public ou un établissement d’enseignement qui, dans le commises à compter du 15 septembre 2021;
cas d’une personne âgée de 16 ans ou plus et de moins
de 75 ans, comporte une photographie de la personne Que le ministre de la Santé et des Services sociaux soit
concernée; habilité à ordonner toute modification ou toute précision
relative aux mesures prévues par le présent décret.
Que l’organisateur de toute activité et l’exploitant de
tout lieu visés au troisième alinéa ne puissent permettre la Le greffier du Conseil exécutif,
participation à une telle activité d’une personne du public Yves Ouel l et
âgée de 13 ans ou plus ou l’accès à un tel lieu que si la véri-
fication de son code QR, faite au moyen de l’application 75559
VaxiCode Verif, révèle qu’elle est adéquatement protégée
contre la COVID-19, sous réserve des exceptions prévues
aux troisième et quatrième alinéas;
Que l’organisateur de toute activité ou l’exploitant de

tout lieu visés aux paragraphes 9° ou 10° du troisième
alinéa puisse, dans le cadre d’une activité récurrente qui
nécessite que la personne concernée s’inscrive et si cette
personne y consent, procéder aux vérifications prévues
aux alinéas précédents uniquement au moment de la
première présence de la personne concernée et consigner
les informations ainsi obtenues;
Que l’organisateur ou l’exploitant visé à l’alinéa précé-

dent détruise les renseignements qu’il a consignés lorsque
la personne visée cesse de participer à l’activité;
Qu e, sous réserve du huitième alinéa, il soit interdit

à quiconque de conserver, en tout ou en partie, les ren-
seignements obtenus pour les fins de toute vérification
effectuée en vertu du présent décret;
AR02670
Ceci est la pièce « QQ » au soutien de


AR02671
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 25 septembre 2021, 153e année, no 38B 5571B
Décrets administratifs
Gouvernement du Québec du 15 mars 2020, 2020-007 du 21 mars 2020, 2020-008

du 22 mars 2020, 2020-014 du 2 avril 2020, 2020-015 du
Décret 1276-2021, 24 septembre 2021 4 avril 2020, 2020-016 du 7 avril 2020, 2020-017 du 8 avril
2020, 2020-019 et 2020-020 du 10 avril 2020, 2020-022
Con c er n a n t l’ordonnance de mesures visant à du 15 avril 2020, 2020-023 du 17 avril 2020, 2020-026
protéger la santé de la population dans la situation de du 20 avril 2020, 2020-027 du 22 avril 2020, 2020-028
pandémie de la COVID-19 du 25 avril 2020, 2020-029 du 26 avril 2020, 2020-030
du 29 avril 2020, 2020-032 du 5 mai 2020, 2020-033 du
At t en du qu e l’Organisation mondiale de la Santé a 7 mai 2020, 2020-034 du 9 mai 2020, 2020-035 du 10 mai
déclaré une pandémie de la COVID-19 le 11 mars 2020; 2020, 2020-037 du 14 mai 2020, 2020-039 du 22 mai 2020,
2020-042 du 4 juin 2020, 2020-044 du 12 juin 2020,
At t en du qu’en vertu de l’article 118 de la Loi sur 2020-049 du 4 juillet 2020, 2020-060 du 28 août 2020,
la santé publique (chapitre S-2.2) le gouvernement peut 2020-061 du 1er septembre 2020, 2020-062 du 4 septembre
déclarer un état d’urgence sanitaire dans tout ou partie 2020, 2020-064 du 17 septembre 2020, 2020-067 du
du territoire québécois lorsqu’une menace grave à la santé 19 septembre 2020, 2020-069 du 22 septembre 2020,
de la population, réelle ou imminente, exige l’application 2020-076 du 5 octobre 2020, 2020-084 du 27 octobre
immédiate de certaines mesures prévues à l’article 123 de 2020, 2020-087 du 4 novembre 2020, 2020-091 du
cette loi pour protéger la santé de la population; 13 novembre 2020, 2020-097 du 1er décembre 2020,
At t en du qu e cette pandémie constitue une menace 2020, 2020-107 du 23 décembre 2020, 2021-003 du
réelle grave à la santé de la population qui exige 21 janvier 2021, 2021-005 du 28 janvier 2021, 2021-010
l’application immédiate de certaines mesures prévues à du 5 mars 2021, 2021-017 du 26 mars 2021, 2021-022
l’article 123 de cette loi; du 7 avril 2021, 2021-024 du 9 avril 2021, 2021-027
du 16 avril 2021, 2021-028 du 17 avril 2021, 2021-032
At t en du qu’au cours de l’état d’urgence sanitaire, du 30 avril 2021, 2021-036 du 15 mai 2021, 2021-039
malgré toute disposition contraire, le gouvernement ou du 28 mai 2021, 2021-040 du 5 juin 2021, 2021-046 du
le ministre de la Santé et des Services sociaux, s’il a été 16 juin 2021, 2021-049 du 1er juillet 2021, 2021-050 du
habilité, peut, sans délai et sans formalité, prendre l’une 2 juillet 2021, 2021-051 du 6 juillet 2021, 2021-052 du
des mesures prévues aux paragraphes 1° à 8° du premier 7 juillet 2021, 2021-053 du 10 juillet 2021, 2021-054 du
alinéa de l’article 123 de cette loi pour protéger la santé 16 juillet 2021, 2021-055 du 30 juillet 2021, 2021-057
de la population; du 4 août 2021, 2021-058 du 13 août 2021, 2021-059 du
18 août 2021, 2021-060 du 24 août 2021, 2021-061 du
At t en d u qu e, par le décret numéro 177-2020 du 31 août 2021, 2021-062 du 3 septembre 2021 et 2021-063
13 mars 2020, le gouvernement a déclaré l’état d’urgence du 9 septembre 2021, sauf dans la mesure où elles ont été
sanitaire et a pris certaines mesures afin de protéger modifiées par ces décrets ou ces arrêtés, continuent de
la population; s’appliquer jusqu’au 1er octobre 2021 ou jusqu’à ce que le
gouvernement ou le ministre de la Santé et des Services
At t en du que l’état d’urgence sanitaire a toujours été sociaux les modifie ou y mette fin;
renouvelé depuis cette date par divers décrets, notamment
par le décret numéro 1251-2021 du 22 septembre 2021; At t en du qu’il y a lieu d’ordonner certaines mesures
At t en du que ce dernier décret prévoit que les mesures
prévues par les décrets numéros 177-2020 du 13 mars Il est or don n é, en conséquence, sur la recomman-
2020, 222-2020 du 20 mars 2020, 460-2020 du 15 avril dation du ministre de la Santé et des Services sociaux :
2020, 505-2020 du 6 mai 2020, 566-2020 du 27 mai 2020,
615-2020 du 10 juin 2020, 651-2020 du 17 juin 2020, Qu ’aux f ins du présent décret, on considère
885-2020 du 19 août 2020, 943-2020 du 9 septembre « adéquatement protégée contre la COVID-19 », une
2020, 964-2020 du 21 septembre 2020, 135-2021 du personne qui, selon le cas :
17 février 2021, 885-2021 du 23 juin 2021 et 1173-2021
du 1er septembre 2021 et par les arrêtés numéros 2020-004
5572B AR02672
GAZETTE OFFICIELLE DU QUÉBEC, 25 septembre 2021, 153e année, no 38B Partie 2
1° a reçu deux doses de l’un ou l’autre des vaccins à 5° un cabinet privé :
ARNm de Moderna ou de Pfizer-BioNTech ou du vaccin
AstraZeneca/COVIDSHIELD, avec un intervalle minimal a) d’infirmier ou d’infirmière;
de 21 jours entre les doses et dont la dernière dose a été
reçue depuis sept jours ou plus; b) d’infirmier ou d’infirmière auxiliaire;
2° a contracté la COVID-19 et a reçu, depuis sept jours c) d’inhalothérapeute;

ou plus, une dose de l’un ou l’autre des vaccins visés au
paragraphe 1° avec un intervalle minimal de 21 jours après d) de médecin;
la maladie;
e) de pharmacien;
3° a reçu une dose du vaccin Janssen depuis 14 jours
ou plus; f) de sage-femme;
4° a contracté la COVID-19 dans les six derniers mois; 6° un laboratoire d’imagerie médicale;
Que soit également assimilée à une personne adéqua- 7° un local exploité par un organisme ayant conclu
tement protégée contre la COVID-19 une personne qui, une entente en vertu de l’article 108 de la Loi sur les
selon le cas : services de santé et les services sociaux (chapitre S-4.2)
pour la prestation de certains services de santé et de
1° présente une contre-indication à la vaccination services sociaux;
contre cette maladie attestée par un professionnel de la
santé habilité à poser un diagnostic et qui est inscrite au Qu e, pour l’application des paragraphes 1° et 5° de
registre de vaccination maintenu par le ministre de la l’alinéa précédent, tout lieu autre qu’une installation
Santé et des Services sociaux; maintenue par un établissement de santé et de services
sociaux ou qu’un cabinet de professionnel où sont offerts
2° a par ticipé à l’étude clinique menée par des services par un tel établissement ou un tel cabinet
Medicago inc. visant à valider la sécurité ou l’efficacité soit assimilé, selon le cas, à une telle installation ou à
d’un candidat-vaccin contre la COVID-19; un tel cabinet, mais uniquement en ce qui concerne les
intervenants qui fournissent les services de santé ou les
Qu’aux fins du présent décret, on entende par « inter- services sociaux;
venant du secteur de la santé et des services sociaux »
une personne, rémunérée ou non, dont les activités, selon Qu e, malgré ce qui précède, ne soit pas tenu d’être
le cas : adéquatement protégé :
1° impliquent des contacts directs avec des per- 1° l’exploitant d’une ressource intermédiaire ou d’une
sonnes à qui sont offerts des services de santé et des ressource de type familial dont le lieu principal de rési-
services sociaux; dence est situé dans une telle ressource, de même que les
membres de sa famille qui y résident;
2° impliquent des contacts directs avec des interve-
nants visés au paragraphe 1°, notamment en raison du 2° un agent de la paix ou un pompier qui, dans l’exer-
partage d’espaces communs; cice de ses fonctions, doit se rendre dans un milieu visé
au quatrième alinéa;
Que les intervenants du secteur de la santé et des ser-
vices sociaux qui agissent dans les milieux suivants soient Que soit également tenu d’être adéquatement protégée
tenus d’être adéquatement protégés contre la COVID-19 : contre la COVID-19 toute personne qui fournit des ser-
vices dans le cadre de la modalité de soutien à domicile
1° une installation maintenue par un établissement de allocation directe – chèque emploi-service;
santé et de services sociaux;
Qu e tout intervenant du secteur de la santé et des
2° une ressource intermédiaire; services sociaux, membre d’un ordre professionnel et
agissant dans un des milieux visés au quatrième alinéa
3° une ressource de type familial; qui n’est pas adéquatement protégé contre la COVID-19
commette un acte dérogatoire à la dignité de sa profession;
4° une résidence privée pour aînés;
AR02673
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 25 septembre 2021, 153e année, no 38B 5573B
Qu’un intervenant du secteur de la santé et des services publique du Québec et le ministère des Transports, mais
sociaux qui agit dans un milieu visé au quatrième alinéa dans ce cas uniquement pour le Service aérien gouverne-
soit tenu de transmettre une preuve qu’il est adéquatement mental, même s’ils se trouvent dans un autre milieu que
protégé contre la COVID-19 à l’exploitant du milieu où ceux visés au quatrième alinéa, et à ces entités;
il exerce;
Que l’exploitant d’une ressource intermédiaire ou d’une
Que, sur demande de son ordre professionnel, un pro- ressource de type familial transmette à l’établissement de
fessionnel visé au quatrième alinéa soit tenu de lui trans- santé et de services sociaux avec lequel il a conclu une
mettre une preuve qu’il est adéquatement protégé contre entente, une attestation indiquant que les intervenants du
la COVID-19; secteur de la santé et des services sociaux qui sont tenus
d’être adéquatement protégés contre la COVID-19 le sont;
Que toute personne visée au septième alinéa soit tenue,
sur demande de la personne à qui elle fournit les services, Que lorsque l’exploitant d’une ressource intermédiaire
de lui transmettre une preuve qu’elle est adéquatement ou d’une ressource de type familial ne transmet pas l’attes-
protégée contre la COVID-19; tation prévue à l’alinéa précédent, l’établissement de santé
et de services sociaux avec lequel cette ressource a conclu
Qu e la transmission de la preuve exigée en vertu du une entente cesse de la rétribuer et puisse déplacer les
neuvième alinéa s’effectue au plus tard le 1er octobre 2021 usagers qui y sont pris en charge vers un autre milieu
ou, à défaut, le plus rapidement possible à compter du de vie;
moment où cette preuve est disponible;
Qu’un établissement de santé et de services sociaux
Que l’exploitant d’un milieu visé au quatrième alinéa puisse transmettre au ministre une liste d’intervenants
soit tenu de vérifier que tout intervenant du secteur de la du secteur de la santé et des services sociaux qui agissent
santé et des services sociaux qui doit être adéquatement dans les installations qu’il maintient pour lesquels il
protégé contre la COVID-19 l’est; souhaite vérifier s’ils sont adéquatement protégés;
Qu’un intervenant du secteur de la santé et des ser- Qu’un ordre professionnel d’un professionnel visé
vices sociaux devant être adéquatement protégé contre la au quatrième alinéa puisse transmettre au ministre une
COVID-19 qui n’en a pas fourni la preuve à l’exploitant liste d’intervenants du secteur de la santé et des services
d’un milieu visé au quatrième alinéa ne puisse réintégrer sociaux membres de l’ordre pour lesquels il souhaite véri-
ce milieu; fier s’ils sont adéquatement protégés;
Qu’un intervenant du secteur de la santé et des services Qu e le président ou, en son absence, le directeur
sociaux qui ne peut réintégrer un milieu en application de général ou le secrétaire de l’ordre professionnel de tout
l’alinéa précédent ne reçoive, selon le cas, aucune rémuné- professionnel visé au quatrième alinéa :
ration, bénéfice, honoraire ou autre forme de compensa-
tion, à moins que, à la discrétion de son employeur, il n’ait 1° suspende le droit d’exercer des activités profession-
été réaffecté à d’autres tâches, visées à son titre d’emploi, nelles de tout professionnel qui n’est pas adéquatement
le cas échéant, qui ne nécessitent pas d’être adéquatement protégé contre la COVID-19 ou limite ce droit à l’exer-
protégé contre la COVID-19; cice de ces activités d’une façon à ce qu’il ne puisse les
exercer ni dans un milieu visé au quatrième alinéa, ni par
Qu’une personne visée au septième alinéa qui ne correspondance ou par voie télécommunication, y compris
fournit pas à une personne la preuve qu’elle est adéqua- la télésanté;
tement protégée contre la COVID-19 conformément au
onzième alinéa ne puisse lui offrir des services; 2° avise le ministre de la Santé et des Services sociaux
de toute suspension ou limitation d’un droit d’exercice
Qu e les mesures prévues aux neuvième, douzième, effectuée en vertu du paragraphe précédent;
treizième, quatorzième et quinzième alinéas s’appliquent,
avec les adaptations nécessaires, aux intervenants du sec- Que le Collège des médecins du Québec et l’Ordre des
teur de la santé et des services sociaux qui agissent dans le pharmaciens du Québec avisent la Régie de l’assurance
cadre des activités exercées par les entreprises d’économie maladie du Québec de toute suspension ou limitation d’un
sociale en aide à domicile, la Corporation d’Urgences- droit d’exercice effectuée en vertu du paragraphe 1° du
santé, les titulaires de permis d’exploitation de services vingt-deuxième alinéa;
ambulanciers, Héma-Québec, l’Institut national de santé
5574B AR02674
GAZETTE OFFICIELLE DU QUÉBEC, 25 septembre 2021, 153e année, no 38B Partie 2
Qu e toute personne, société ou organisme ne puisse 3° une personne qui visite un proche en fin de vie;
imposer aucune pénalité ou exiger aucune indemnité ou
autre réparation pour le motif qu’une personne, en raison 4° un parent ou un tuteur d’un enfant hébergé dans un
de l’application du présent décret, a refusé à une personne centre de réadaptation pour les jeunes en difficulté d’adap-
l’accès à un endroit, a mis fin à un contrat ou a eu recours tation de même que toute personne ayant un droit de visite
à une autre personne, une autre société ou un autre orga- ordonné par une décision rendue par la Cour du Québec; »;
nisme pour la remplacer;
3° dans le cinquième alinéa :
Que le décret numéro 1173-2021 du 1er septembre 2021
soit modifié : a) par l’insertion, après « visés au troisième », de
« ou au cinquième »;
1° par le remplacement, dans le paragraphe 1° du
premier alinéa, de « 28 jours » par « 21 jours »; b) par le remplacement de « prévues aux troisième et
quatrième alinéas » par « prévues aux troisième, quatrième
2° par l’insertion, après le quatrième alinéa, et sixième alinéas »;
des suivants :
4° par le remplacement, dans le sixième alinéa, de
« Qu e toute personne du public âgée de 13 ans ou « au troisième et à l’alinéa précédent » de « aux troisième,
plus soit tenue, afin d’accéder aux lieux suivants, d’être cinquième et septième alinéas »;
adéquatement protégée contre la COVID-19, d’en pré-
senter la preuve au moyen d’une pièce d’identité et du 5° dans le septième alinéa :
code QR qu’elle a reçu à cette fin du gouvernement du
Québec et d’en permettre la vérification au moyen de a) par l’insertion, après « visés au troisième », de
l’application VaxiCode Verif : « ou au cinquième »;
1° une installation maintenue par un établissement de b) par le remplacement de « prévues aux troisième et
santé et de services sociaux; quatrième alinéas » par « prévues au troisième, quatrième
et sixième alinéas »;
2° une ressource intermédiaire;
6° par le remplacement, dans le dixième alinéa, de
3° une ressource de type familial; « huitième » par « dixième »;
4° une résidence privée pour aînés; 7° par le remplacement, dans le onzième alinéa, de « et
septième » par « , septième et neuvième »;
Que, malgré l’alinéa précédent, les personnes suivantes
ne soient pas tenues d’être adéquatement protégées, d’en Qu e les premier, deuxième, troisième, quatrième,
présenter la preuve, ni de présenter une pièce d’identité cinquième, sixième et septième alinéas de l’arrêté
pour accéder aux lieux qui y sont visés : numéro 2021-024 du 9 avril 2021, modifié par les arrêtés
numéros 2021-028 du 17 avril 2021 et 2021-032 du 30 avril
1° une personne qui accède à un de ces lieux pour y 2021, soient abrogés;
recevoir des services de santé ou des services sociaux;
2° une personne qui accompagne : habilité à ordonner toute modification ou toute précision
relative aux mesures prévues par le présent décret;
a) un enfant de moins de 14 ans;
Qu e les mesures prévues aux quatrième, cinquième,
b) une personne qui accouche; sixième, septième, huitième, treizième, quatorzième,
quinzième, seizième, dix-neuvième, vingt-deuxième,
c) une personne inapte à consentir aux soins requis vingt-troisième, vingt-quatrième, vingt-cinquième et
par son état de santé; vingt-sixième alinéas prennent effet le 15 octobre 2021.
d) une personne qui, en raison de son état de santé ou Le greffier du Conseil exécutif,
à des fins de sécurité, requiert une assistance qui ne peut Yves Ouel l et
lui être fournie par l’exploitant du lieu;
75712
AR02675
Ceci est la pièce « RR » au soutien de


AR02676
2° les intervenants du secteur de la santé et des ser- Que soit abrogé l’arrêté numéro 2021-070 du 15 octobre
vices sociaux visés au paragraphe 2° de l’alinéa précédent 2021.
qui agissent dans les milieux suivants :
a) une installation maintenue par un établissement de
santé et de services sociaux; Le ministre de la Santé et des Services sociaux,
b) une ressource intermédiaire non visée par la
Loi sur la représentation des ressources de type familial 75957
-
et de certaines ressources intermédiaires et sur le régime
de négociation d’une entente collective les concernant
(chapitre R-24.0.2); A.M., 2021
c) une résidence privée pour aînés, à l’exception de Arrêté numéro 2021-081 du ministre de la Santé et
celles de neuf places et moins; des Services sociaux en date du 14 novembre 2021
Que, pour l’application du sous-paragraphe a du para- Loi sur la santé publique

graphe 2° de l’alinéa précédent, tout lieu autre qu’une (chapitre S-2.2)
installation maintenue par un établissement de santé et
de services sociaux où sont offerts des services par un tel Con c er n a n t l’ordonnance de mesures visant à
établissement soit assimilé à une telle installation, mais protéger la santé de la population dans la situation de
uniquement en ce qui concerne les intervenants qui four- pandémie de la COVID-19
nissent les services de santé ou les services sociaux;
Le min ist r e de l a Sa n t é et des Ser vices soc iau x,
Qu’un intervenant du secteur de la santé et des ser-
vices sociaux visé au quatrième alinéa soit tenu de trans- Vu l’article 118 de la Loi sur la santé publique (chapitre
mettre une preuve qu’il est adéquatement protégé contre S-2.2) qui prévoit que le gouvernement peut déclarer un
la COVID-19, selon le cas, à l’établissement de santé et état d’urgence sanitaire dans tout ou partie du territoire
de services sociaux où il souhaite être embauché ou com- québécois lorsqu’une menace grave à la santé de la popu-
mencer à exercer sa profession, à l’exploitant du milieu où lation, réelle ou imminente, exige l’application immédiate
il exerce ou, dans le cas d’un élève, d’un étudiant ou d’un de certaines mesures prévues à l’article 123 de cette loi
stagiaire, à son établissement d’enseignement; pour protéger la santé de la population;
Qu e la transmission de la preuve exigée en vertu de Vu le décret numéro 177-2020 du 13 mars 2020 qui
l’alinéa précédent s’effectue le plus rapidement possible déclare l’état d’urgence sanitaire dans tout le territoire
à compter du moment où cette preuve est disponible; »; québécois pour une période de 10 jours;
3° par le remplacement, dans le treizième alinéa, de Vu que l’état d’urgence sanitaire a toujours été renou-
« Que l’exploitant d’un milieu visé au quatrième alinéa » velé depuis cette date par divers décrets, notamment par
par « Qu’un établissement de santé et de services sociaux le décret numéro 1415-2021 du 10 novembre 2021;
ou l’exploitant d’un milieu visé par le paragraphe 2° du
quatrième alinéa »; Vu que le décret numéro 1173-2021 du 1er septembre
4° par l’insertion dans le quatorzième alinéa et après 24 septembre 2021 et par les arrêtés 2021-067 du 8 octobre
« ne puisse » de « intégrer ou »; 2021 et 2021-079 du 14 octobre 2021, prévoit l’obligation
d’être adéquatement protégé pour accéder à certains lieux
5° par la suppression des seizième et dix-septième ou pour participer à certaines activités;
alinéas;
6° par le remplacement, dans les dix-huitième et Santé et des Services sociaux à ordonner toute modifica-
dix-neuvième alinéas, de « ou d’une ressource de type tion ou toute précision relative aux mesures qu’il prévoit;
familial » par « visée au présent arrêté »;
Cons id ér a n t qu’il y a lieu d’ordonner certaines
7° par la suppression des vingt-et-unième, vingt- mesures pour protéger la santé de la population;
deuxième, vingt-troisième et vingt-cinquième alinéas;
6840A AR02677
GAZETTE OFFICIELLE DU QUÉBEC, 18 novembre 2021, 153e année, no 46A Partie 2
Ar r êt e ce qui suit : Que les enseignants exerçant dans un centre de réadap-

tation pour les jeunes en difficulté d’adaptation exploité
Qu’aux fins du présent arrêté, on entende par « inter- par un établissement de santé et de services sociaux ne
venant de la santé et des services sociaux » une personne soient pas visés par le présent arrêté;
travaillant ou exerçant sa profession pour :
Qu’un intervenant de la santé et des services sociaux
1° un établissement de santé et de services sociaux; soit tenu de passer des tests de dépistage de la COVID-19,
conformément aux modalités du présent arrêté, sauf :
2° une ressource intermédiaire non visée par la
Loi sur la représentation des ressources de type familial 1° s’il a reçu deux doses de l’un ou l’autre d’un vaccin
et de certaines ressources intermédiaires et sur le régime à ARNm de Moderna ou de Pfizer-BioNTech ou du vaccin
de négociation d’une entente collective les concernant AstraZeneca/COVIDSHIELD, avec un intervalle minimal
(chapitre R-24.0.2); de 21 jours entre les doses et dont la dernière dose a été
reçue depuis au moins sept jours;
3° une résidence privée pour aînés à l’exception de
celle de neuf places et moins; 2° s’il a contracté la COVID-19 et a reçu, depuis
sept jours ou plus, une dose de l’un ou l’autre des vaccins
4° une maison de soins palliatifs au sens du para- visés au paragraphe 1° avec un intervalle minimal de
graphe 2° de l’article 3 de la Loi concernant les soins de 21 jours après la maladie;
fin de vie (chapitre S-32.0001);
3° s’il a reçu une dose du vaccin Janssen depuis au
5° une institution religieuse qui maintient une instal- moins 14 jours;
lation d’hébergement et de soins de longue durée pour y
recevoir ses membres ou ses adhérents; 4° s’il a reçu une dose d’un vaccin mentionné au para-
graphe 1° depuis au moins 7 jours et depuis moins de
6° un centre médical spécialisé au sens de l’article 333.1 60 jours;
de la Loi sur les services de santé et les services sociaux
(chapitre S-4.2); 5° s’il présente une contre-indication à la vaccination
contre cette maladie attestée par un professionnel de la
7° un laboratoire d’imagerie médicale au sens 30.1 de santé habilité à poser un diagnostic et qui est inscrite au
la Loi sur les laboratoires médicaux et sur la conservation registre de vaccination maintenu par le ministre de la
des organes et des tissus (chapitre L-0.2); Santé et des Services sociaux;
8° la Corporation d’Urgences-santé; 6° s’il a par ticipé à l’étude clinique menée
par Medicago inc. visant à valider la sécurité ou l’efficacité
9° les titulaires de permis d’exploitation de services d’un candidat-vaccin contre la COVID-19;
ambulanciers;
7° s’il a contracté la COVID-19 depuis moins
10° Héma-Québec; de 60 jours;
11° l’Institut national de santé publique du Québec; 8° s’il a reçu deux doses d’un vaccin contre la COVID-19,
dont l’un est un vaccin reçu à l’extérieur du Canada,
12° le ministère des Transports, mais dans ce cas uni- autre que ceux visés aux paragraphes 1° et 3°, et l’autre
quement pour le Service aérien gouvernemental; un vaccin à ARNm de Moderna ou de Pfizer BioNTech,
avec un intervalle minimal de 21 jours entre les doses et
Qu’un sous-contractant fournissant des soins aux dont la dernière dose a été reçue depuis 7 jours ou plus;
usagers ou aux résidents des milieux visés par le pré-
sent arrêté soit assimilé à un intervenant de santé et de Qu’un intervenant de la santé et des services sociaux
services sociaux; soit tenu de fournir à l’exploitant du milieu ou au respon-
sable de son organisation la preuve qu’il a reçu le ou les
Que pour les paragraphes 8° à 12° du premier alinéa vaccins mentionnés à l’alinéa précédent, le cas échéant,
soient uniquement visés par le présent arrêté les inter- ou qu’il répond aux conditions mentionnées aux para-
venants ayant des contacts physiques directs avec des graphes 5°, 6° ou 7° de cet alinéa;
personnes à qui sont offerts des services de santé et des
services sociaux;
AR02678
Qu’un établissement de santé et de services sociaux transmet pas les preuves qui lui sont demandées en appli-
puisse transmettre au ministre une liste d’intervenants cation de l’alinéa précédent ne puisse offrir des services à
de la santé et des services sociaux travaillant ou exer- la personne lui en ayant fait la demande;
çant dans les installations qu’il maintient pour lesquels il
souhaite vérifier s’ils sont adéquatement protégés; Qu’un intervenant de la santé et des services sociaux qui
est tenu de passer des tests de dépistage de la COVID-19
Qu’un intervenant de la santé et des services sociaux en vertu du cinquième alinéa ne puisse bénéficier des
tenu de passer un test de dépistage de la COVID-19 en primes ou montants forfaitaires suivants :
application du cinquième alinéa doive passer un minimum
de trois tests par semaine, effectués par un professionnel 1° ceux prévus à l’arrêté numéro 2020-015 du 4 avril
autorisé, et en fournir les résultats à l’exploitant du milieu 2020, modifié par les arrêtés numéros 2020-017 du 8 avril
ou au responsable de son organisation; 2020, 2020-023 du 17 avril 2020, 2020-031 du 3 mai
2020, 2020-034 du 9 mai 2020, 2020-038 du 15 mai 2020
Qu e malgré l’alinéa précédent, un intervenant de et 2020-061 du 1er septembre 2020;
la santé et des services sociaux qui travaille moins de
trois jours par semaine soit tenu de passer un nombre 2° ceux prévus à l’arrêté numéro 2020-017 du 8 avril
minimum de test de dépistage de la COVID 19 équiva- 2020;
lent au nombre de jours où il est présent dans le milieu ou
travaille pour son organisation; 3° ceux prévus à l’arrêté numéro 2020-019 du 10 avril
2020;
visé au huitième ou neuvième alinéa doive passer les tests 4° ceux prévus à l’arrêté numéro 2020-020 du 10 avril
de dépistage en dehors de ses heures de travail et qu’il ne 2020, modifié par l’arrêté numéro 2020-044 du 12 juin
reçoive aucune rémunération ni remboursement de frais 2020;
en lien avec de tels tests;
5° ceux prévus à l’arrêté numéro 2020-028 du 25 avril
Qu’un intervenant de la santé et des services 2020;
sociaux qui refuse ou omet de fournir la preuve visée
au sixième alinéa, de passer un test de dépistage de la 6° ceux prévus à l’arrêté numéro 2020-035 du 10 mai
COVID-19 obligatoire en application du présent arrêté 2020, modifié par les arrêtés numéros 2020-044 du
ou de fournir les résultats d’un test conformément au 12 juin 2020, 2020-064 du 17 septembre 2020, 2020-067
huitième alinéa ne puisse être réaffecté ni être en télétra- du 19 septembre 2020, 2021-036 du 15 mai 2021 et 2021-055
vail et que son absence constitue une absence non auto du 30 juillet 2021;
risée sans perte d’ancienneté;
7° ceux prévus à l’arrêté numéro 2020-044 du 12 juin
Que les privilèges d’un médecin, d’un pharmacien ou 2020;
d’un dentiste refusant ou omettant de passer un test de
dépistage de la COVID-19 obligatoire en application du 8° ceux prévus à l’arrêté numéro 2020-049 du 4 juillet
présent arrêté soient suspendus; 2020, modifié par l’arrêté numéro 2021-054 du 16 juillet
2021;
Qu e toute personne qui fournit des services dans le
cadre de la modalité de soutien à domicile allocation 9° ceux prévus à l’arrêté numéro 2020-107 du
directe – chèque emploi-service ou dans le cadre d’une 23 décembre 2020 modifié par les décrets numéros 2-2021
entreprise d’économie sociale en aide à domicile soit tenue du 8 janvier 2021 et 799-2021 du 9 juin 2021 et par les
de transmettre, sur demande de la personne à qui elle arrêtés numéros 2021-001 du 15 janvier 2021 et 2021-051
fournit les services, la preuve qu’elle a reçu le ou les vac- du 6 juillet 2021;
cins mentionnés au cinquième alinéa ou qu’elle répond
aux conditions mentionnées aux paragraphes 5°, 6° ou 7° 10° ceux prévus à l’arrêté numéro 2021-032 du 30 avril
de cet alinéa ou le résultat d’un test de dépistage de la 2021, modifié par l’arrêté numéro 2021-034 du 8 mai 2021;
COVID-19 effectué depuis moins de 72 heures;
11° ceux prévus à l’arrêté numéro 2021-071 du
Qu e toute personne qui fournit des services dans le 16 octobre 2021;
cadre de la modalité de soutien à domicile allocation
directe – chèque emploi-service ou dans le cadre d’une
entreprise d’économie sociale en aide à domicile et qui ne
6842A AR02679
Qu’un intervenant de la santé et des services sociaux b) par l’ajout, à la fin, du paragraphe suivant :
ne soit pas admissible aux montants forfaitaires prévus
à l’arrêté numéro 2021-071 du 16 octobre 2021 dans les « 5° une institution religieuse qui maintient une
cas suivants : installation d’hébergement et de soins de longue durée
pour y recevoir ses membres ou ses adhérents »;
1° s’il n’a pas reçu une première dose d’un vaccin
contre la COVID-19 le 15 décembre 2021, à moins 3° par l’insertion, après le sixième alinéa, du suivant :
qu’il soit visé à l’un des paragraphes 5° à 7° du
cinquième alinéa; « Que soit également tenue d’être adéquatement proté-
gée contre la COVID-19 pour accéder aux milieux visés
2° s’il ne reçoit pas une deuxième dose d’un vaccin au cinquième alinéa du présent décret, la personne four-
dans un délai de 60 jours suivant la première dose et nissant des services de santé et de services sociaux à une
qu’il n’est pas visé par les paragraphes 2°, 3°, 5° à 7° du personne, y étant hébergé ou y résidant, dans le cadre d’un
cinquième alinéa, auquel cas il est alors tenu de rembour- contrat de services conclu avec celle-ci; »;
ser les montants forfaitaires reçus en vertu de cet arrêté;
4° dans le septième alinéa :
3° si, en date du 15 décembre 2021, il était visé par
le paragraphe 7° du cinquième alinéa et qu’il ne reçoit a) par le remplacement, dans le sous-paragraphe a du
pas une première dose d’un vaccin visé au paragraphe 1° paragraphe 2°, de « 14 ans » par « 18 ans »;
de cet alinéa dans un intervalle de 60 jours suivant la
réception d’un résultat positif à un test de dépistage de la b) par l’ajout, à la fin, du paragraphe suivant :
COVID-19, auquel cas il est alors tenu de rembourser les
montants forfaitaires reçus en vertu de cet arrêté; « 5° une personne qui, dans l’exercice de ses fonctions,
doit se rendre dans un milieu visé au cinquième alinéa; »;
Qu e le décret numéro 1173-2021 du 1er septembre
2021, modifié par le décret numéro 1276-2021 du 5° par l’insertion, après le septième alinéa, du suivant :
24 septembre 2021 et par les arrêtés numéros 2021-067 du
8 octobre 2021 et 2021-079 du 14 novembre 2021, soit de « Qu e malgré le sixième alinéa, un proche aidant ne
nouveau modifié : pouvant démontrer être adéquatement protégé puisse
accéder aux milieux visés s’il peut présenter la preuve
1° dans le premier alinéa : d’un résultat négatif d’un test de dépistage contre la
COVID-19 effectué depuis moins de 72 heures; »;
a) par le remplacement du paragraphe 1° par le suivant :
Que soient abrogés :
« 1° a reçu deux doses de l’un ou l’autre d’un vaccin à
ARNm de Moderna ou de Pfizer-BioNTech ou du vaccin 1° les premier, deuxième, troisième, quatrième,
AstraZeneca/COVIDSHIELD, avec un intervalle minimal cinquième, sixième et septième alinéas de l’arrêté
de 21 jours entre les doses et dont la dernière dose a été numéro 2021-024 du 9 avril 2021, modifié par les arrêtés
reçue depuis sept jours ou plus; »; numéros 2021-028 du 17 avril 2021, 2021-032 du 30 avril
2021, 2021-046 du 16 juin 2021 et 2021-072 du 16 octobre
b) par l’ajout, à la fin, du paragraphe suivant : 2021 et par le décret numéro 1276-2021 du 24 septembre
2021;
« 4° a reçu deux doses d’un vaccin contre la COVID-19,
dont l’un est un vaccin reçu à l’extérieur du Canada, autre 2° les premier, deuxième, troisième, quatrième et
que ceux visés aux paragraphes 1° et 3°, et l’autre un sixième alinéas de l’arrêté numéro 2021-072 du 16 octobre
vaccin à ARNm de Moderna ou de Pfizer BioNTech, avec 2021.
un intervalle minimal de 21 jours entre les doses et dont
la dernière dose a été reçue depuis sept jours ou plus; »; Québec, le 14 novembre 2021
2° dans le sixième alinéa : Le ministre de la Santé et des Services sociaux,

a) par la suppression, dans ce qui précède le para-
graphe 1°, de « du public »; 75958
AR02680
Ceci est la pièce « SS » au soutien de


AR02681
-
A.M., 2021
et des Services sociaux en date du 17 novembre 2021

Vu que le décret numéro 1433-2021 du 17 novembre
sociaux à prendre toute mesure prévue aux paragraphes 1°
santé publique;
(chapitre S-2.2) Considér a n t que la situation actuelle de la pandémie
Con c er n a n t l’ordonnance de mesures visant à mises en place pour protéger la santé de la population,
protéger la santé de la population dans la situation de tout en maintenant certaines d’entre elles nécessaires pour
pandémie de la COVID-19 continuer de la protéger;
Le min ist r e de l a Sa n t é et d es Ser vices soc iau x, Ar r êt e c e qui suit :
Vu l’article 118 de la Loi sur la santé publique Qu e les modalités suivantes s’appliquent à toute
(chapitre S-2.2) qui prévoit que le gouvernement peut élection partielle municipale :
déclarer un état d’urgence sanitaire dans tout ou partie
du territoire québécois lorsqu’une menace grave à la santé 1° elle est assujettie aux dispositions de la Loi sur
de la population, réelle ou imminente, exige l’application les élections et les référendums dans les municipalités
immédiate de certaines mesures prévues à l’article 123 de (chapitre E-2.2), telle que modifiée par le Règlement modi-
cette loi pour protéger la santé de la population; fiant certaines dispositions en matière municipale afin de
faciliter le déroulement de l’élection générale municipale
Vu le décret numéro 177-2020 du 13 mars 2020 qui du 7 novembre 2021 dans le contexte de la pandémie de
déclare l’état d’urgence sanitaire dans tout le territoire la COVID-19, édicté par le directeur général des élections
québécois pour une période de 10 jours; (2021 G.O.2, 2111B);
Vu que l’état d’urgence sanitaire a toujours été renou- 2° la période électorale au sens de l’article 364 de
velé depuis cette date par divers décrets, notamment par cette loi commence le cinquante-et-unième jour précé-
le décret numéro 1433-2021 du 17 novembre 2021; dant celui fixé pour le scrutin et se termine le jour fixé
pour le scrutin;
Vu que l’arrêté numéro 2021-032 du 30 avril 2021,
modifié par l’arrêté numéro 2021-034 du 8 mai 2021, Que la Nomenclature des titres d’emploi, des libellés,
prévoit des montants forfaitaires pour certaines personnes des taux et des échelles de salaire du réseau de la santé
salariées affectées aux activités de vaccination contre et des services sociaux, prévue par les dispositions natio-
la COVID-19; nales et locales des conventions collectives applicables
dans le réseau de la santé et des services sociaux, soit
Vu que le décret numéro 1173-2021 du 1er septembre modifiée de la manière suivante :
24 septembre 2021 et par les arrêtés 2021-067 du 8 octobre 1° par l’ajout du titre d’emploi « technicien ambu-
2021 ainsi que 2021-079 et 2021-081 du 14 novembre lancier », de la description de libellé et des exigences
2021, prévoit l’obligation d’être adéquatement pro- suivantes :
tégé pour accéder à certains lieux ou pour participer à
certaines activités; « a) le technicien ambulancier dispense les activités de
soins aux usagers de façon sécuritaire, selon les directives
Vu que ce décret habilite également le ministre de la spécifiques du personnel de la Direction des soins infir-
Santé et des Services sociaux à ordonner toute modifica- miers ou d’un médecin, le cas échéant;
6914A AR02682
b) le technicien ambulancier dispense des acti-

vités de soins aux usagers, conformément à l’arrêté
numéro 2021-066 du 1er octobre 2021 et aux protocoles
d’intervention clinique élaborés par le ministre de la
Santé et des Services sociaux, tel que prévu à l’article 65
de la Loi sur les services préhospitaliers d’urgence
(chapitre S-6.2);
c) le technicien ambulancier utilise les méthodes

de soins en vigueur dans l’établissement de santé et de
services sociaux;
d) le technicien ambulancier doit être titulaire d’une

carte de statut actif de technicien ambulancier para-
médic en vertu du Registre national de la main-d’œuvre
des techniciens ambulanciers. »;
2° par l’ajout, pour le titre d’emploi de technicien

ambulancier, des mêmes conditions de travail que celles
relatives au titre d’emploi 2466 - Chargé ou chargée de
l’assurance qualité et de la formation aux services pré-
hospitaliers d’urgence prévu à cette nomenclature;
Qu e le premier alinéa du dispositif de l’arrêté

numéro 2021-032 du 30 avril 2021, modifié par l’arrêté
numéro 2021-034 du 8 mai 2021, soit de nouveau modifié :
1° par le remplacement du sous-paragraphe f du para-

graphe 1° par le suivant :
« f) 90,00 $ par jour effectivement travaillé, pour un

maximum de 450,00 $ par semaine, pour toute période de
travail de quatre semaines consécutives supplémentaire à
celle prévue au sous-paragraphe e; »;
2° par la suppression du paragraphe 5°;
Qu e le dispositif du décret numéro 1173-2021 du

1er septembre 2021, modifié par le décret numéro 1276-
2021 du 24 septembre 2021 et par les ar rêtés
2021-081 du 14 novembre 2021, soit de nouveau modifié
par la suppression du sous-paragraphe d du paragraphe 10°
du troisième alinéa;
Qu e l’arrêté numéro 2020-084 du 27 octobre 2020,

modifié par l’arrêté numéro 2021-054 du 16 juillet 2021,
soit abrogé.

75982
AR02683
Ceci est la pièce « TT » au soutien de


276B AR02684
GAZETTE OFFICIELLE DU QUÉBEC, 27 janvier 2022, 154e année, no 4B Partie 2
En conséquence, j’autorise l’agglomération de Montréal 1er septembre 2021 et ses modifications subséquentes, soit
à renouveler l’état d’urgence local déclaré le mardi révoqué sans délai lorsque le ministre de la Santé et des
21 décembre 2021 pour une période additionnelle maxi- Services sociaux ou un directeur de santé publique a des
male de cinq jours, se terminant au plus tard le lundi motifs sérieux de croire que cette preuve a été obtenue
10 janvier 2022. sans droit, notamment au moyen de déclarations fausses
ou trompeuses;
Québec, le 6 janvier 2022
Que le ministre ou, le cas échéant, le directeur de santé
La ministre de la Sécurité publique, publique concerné, soit tenu, aussitôt que possible de com-
Geneviève Guilbault muniquer par écrit à la personne dont le code QR a été
révoqué conformément à l’alinéa précédent les motifs au
76370 soutien de cette révocation, de lui donner l’occasion de
présenter ses observations et, s’il y a lieu, de produire
des documents;
A.M., 2022
Que le ministre puisse faire les corrections nécessaires
Arrêté numéro 2022-005 du ministre de la Santé au registre de vaccination dès la révocation du code QR.
et des Services sociaux en date du 21 janvier 2022
Québec, le 21 janvier 2022
(chapitre S-2.2) Le ministre de la Santé et des Services sociaux,
Con c er n a n t l’ordonnance de mesures visant à
protéger la santé de la population dans la situation de 76379
Le min ist r e de l a Sa n t é et d es Ser vices soc iau x, A.M., 2022

Vu l’article 118 de la Loi sur la santé publique (chapitre Arrêté numéro 2022-007 du ministre de la Santé
S-2.2) qui prévoit que le gouvernement peut déclarer un et des Services sociaux en date du 23 janvier 2022
québécois lorsqu’une menace grave à la santé de la popu- Loi sur la santé publique
lation, réelle ou imminente, exige l’application immédiate (chapitre S-2.2)
pour protéger la santé de la population; Con c er n a n t l’ordonnance de mesures visant à
Vu le décret numéro 177-2020 du 13 mars 2020 qui pandémie de la COVID-19
québécois pour une période de 10 jours; Le min ist r e de l a Sa n t é et d es Ser vices soc iau x,
Vu que l’état d’urgence sanitaire a toujours été renou- Vu l’article 118 de la Loi sur la santé publique (chapitre
velé depuis cette date par divers décrets, notamment par S-2.2) qui prévoit que le gouvernement peut déclarer un
le décret numéro 51-2022 du 19 janvier 2022; état d’urgence sanitaire dans tout ou partie du territoire
Vu que ce décret habilite le ministre de la Santé et lation, réelle ou imminente, exige l’application immédiate
des Services sociaux à prendre toute mesure prévue aux de certaines mesures prévues à l’article 123 de cette loi
paragraphes 1° à 8° du premier alinéa de l’article 123 de pour protéger la santé de la population;
la Loi sur la santé publique;
Cons id ér a n t qu’il y a lieu d’ordonner certaines déclare l’état d’urgence sanitaire dans tout le territoire
mesures pour protéger la santé de la population; québécois pour une période de 10 jours;
Ar r êt e c e qui suit : Vu que l’état d’urgence sanitaire a toujours été renou-

Qu e le code QR permettant à une personne de pré- le décret numéro 51-2022 du 19 janvier 2022;
senter la preuve qu’elle est adéquatement protégée contre
la COVID-19 au sens du décret numéro 1173-2021 du

AR02685
Partie 2 GAZETTE OFFICIELLE DU QUÉBEC, 27 janvier 2022, 154e année, no 4B 277B
Vu que le décret numéro 1173-2021 du 1er septembre b) de l’accès aux aires communes d’un centre
2021, modifié par le décret numéro 1276-2021 du commercial;
24 septembre 2021 et par les arrêtés numéros 2021-067
du 8 octobre 2021, 2021-079 et 2021-081 du 14 novembre c) d’une pharmacie;
2021, 2021-082 du 17 novembre 2021, 2021-089 du
19 décembre 2021 et 2022-004 du 15 janvier 2022, prévoit d) d’une station–service; »;
l’obligation d’être adéquatement protégé pour accéder à
certains lieux ou pour participer à certaines activités; 3° par l’insertion, après le quatrième alinéa, du suivant :
Vu que ce décret habilite également le ministre de la « Que, malgré le paragraphe 4.2° du troisième alinéa,
Santé et des Services sociaux à ordonner toute modifica- une personne qui n’est pas adéquatement protégée contre
tion ou toute précision relative aux mesures qu’il prévoit; la COVID-19 qui accède à une pharmacie située dans un
commerce de vente en gros ou de vente au détail dont la
Vu que le décret numéro 51-2022 du 19 janvier 2022 surface de vente est de 1500 mètres carrés ou plus pour y
habilite le ministre de la Santé et des Services sociaux recevoir un service pharmaceutique soit accompagnée en
à prendre toute mesure prévue aux paragraphes 1° tout temps lors de ses déplacements par un employé de ce
à 8° du premier alinéa de l’article 123 de la Loi sur la commerce, de cette pharmacie ou de toute autre personne
santé publique; mandatée par eux à cet effet et qu’elle ne puisse y acheter
d’autres produits que ceux liés au service pharmaceutique
Cons id ér a n t qu’il y a lieu d’ordonner certaines qu’elle reçoit; »;
Qu e les mesures prévues au présent arrêté prennent
Ar r êt e c e qui suit : effet le 24 janvier 2022.
Qu e le dispositif du décret numéro 1173-2021 du Québec, le 23 janvier 2022

2021 du 24 septembre 2021 et par les ar rêtés Le ministre de la Santé et des Services sociaux,
numéros 2021-067 du 8 octobre 2021, 2021-079 et Ch r ist ia n Du bé
2021, 2021-089 du 19 décembre 2021 et 2022-004 du 76380
15 janvier 2022, soit de nouveau modifié :
1° par l’insertion, avant le premier alinéa du suivant : A.M., 2022

« Qu’aux fins du présent décret, on entende par « surface Arrêté numéro 2022-008 du ministre de la Santé
de vente et de prestation de services » la superficie totale et des Services sociaux en date du 23 janvier 2022
réservée à la vente, à des services connexes à la vente, à
la réparation et à l’entretien de véhicules, et au public pour Loi sur la santé publique
avoir accès aux produits et aux services, incluant les zones (chapitre S-2.2)
de circulation, les zones de paiement et, le cas échéant,
les aires de préparation des aliments lorsque la personne Con c er n a n t l’ordonnance de mesures visant à
qui y est affectée est aussi chargée de servir les clients; »; protéger la santé de la population dans la situation de
2° par l’insertion, dans le troisième alinéa et après le
paragraphe 4.1°, du suivant : Le min ist r e de l a Sa n t é et d es Ser vices soc iau x,
« 4.2° à tout centre de réparation et d’entretien de Vu l’article 118 de la Loi sur la santé publique (chapitre
véhicules et à tout commerce de vente en gros ou de S-2.2) qui prévoit que le gouvernement peut déclarer un
vente au détail, dont la surface de vente et de prestation de état d’urgence sanitaire dans tout ou partie du territoire
services est de 1500 mètres carrés ou plus, à l’exception : québécois lorsqu’une menace grave à la santé de la popu-
a) d’un établissement d’alimentation dont l’activité de certaines mesures prévues à l’article 123 de cette loi
principale consiste à vendre au détail une gamme générale pour protéger la santé de la population;
de produits alimentaires;

AR02686
Ceci est la pièce « UU » au soutien de


AR02687
19.2° dans les saunas et les spas, la capacité d’accueil « c.1) elle s’inscrit dans le cadre des activités extra-
est fixée à 50 % de sa capacité habituelle, de même que la scolaires offertes aux élèves de la formation générale des
capacité de tout vestiaire, sauf pour les soins personnels jeunes, de la formation professionnelle et de la formation
qui y sont dispensés; générale des adultes; »;
20° toute compétition, tout tournoi ou tout autre évène- 13° par l’insertion, à la fin du sous-paragraphe f du
ment de même nature organisé pour la pratique d’activités paragraphe 22°, de « à laquelle assistent un maximum de
de loisir ou de sport est suspendu, à moins : 250 personnes, sans dépasser 50 % de la capacité habi-
tuelle de la salle »;
a) qu’il soit organisé à l’extérieur et que la capacité de
tout vestiaire soit fixée à 50 % de sa capacité habituelle; Qu e le quatrième alinéa du dispositif du décret
numéro 1173-2021 du 1er septembre 2021, modifié par le
b) qu’il constitue un processus qualifiant pour les décret numéro 1276-2021 du 24 septembre 2021 et par les
Jeux olympiques ou paralympiques et les championnats arrêtés numéros 2021-067 du 8 octobre 2021, 2021-079 et
du monde et que les conditions suivantes soient respectées 2021-081 du 14 novembre 2021, 2021-082 du 17 novembre
par les athlètes et le personnel d’encadrement : 2021, 2021-089 du 19 décembre 2021, 2022-004 du
15 janvier 2022, 2022-007 du 23 janvier 2022 et 2022-013
i. un environnement protégé est mis en place, lequel du 5 février 2021, soit de nouveau modifié par l’insertion,
permet de limiter les risques de transmission entre à la fin du paragraphe 15.1° de « , sauf si elle se déroule
les athlètes et le personnel d’encadrement et le reste dans une salle d’audience »;
de la population, conformément à un protocole sani-
taire approuvé par le ministre de la Santé et des Qu e les mesures prévues au présent arrêté prennent
Services sociaux; effet le 14 février 2022, à l’exception de celles prévues aux
paragraphes 1° et 5° à 7° du premier alinéa qui prennent
ii. le protocole sanitaire approuvé par le ministre effet le 12 février 2022.
de la Santé et des Services sociaux est respecté en tout
temps, autant avant, pendant et après l’intégration dans Québec, le 11 février 2022
l’environnement protégé;
iii. la capacité de tout vestiaire est fixée à 50 % de sa Ch r ist ia n Du bé
capacité habituelle; »;
76466
12° dans le paragraphe 21° :
a) dans le sous-paragraphe a.1 : A.M., 2022

i. par la suppression, dans ce qui précède le sous-sous- Arrêté numéro 2022-017 du ministre de la Santé
paragraphe i, de « pour un groupe de personnes âgées de et des Services sociaux en date du 15 février 2022
moins de 18 ans ou, dans le cas où elle est organisée par
une fédération d’organismes sportifs ou un organisme Loi sur la santé publique
reconnus par le ministre de l’Éducation, du Loisir et du (chapitre S-2.2)
Sport, pour un groupe composé de personnes âgées de
moins de 18 ans et de personnes nées après le 1er janvier Co nc er na nt l’ordonnance de mesures visant à
2001 »; protéger la santé de la population dans la situation de
ii. par la suppression du sous-sous-paragraphe ii;
b) par l’insertion, à la fin du sous-paragraphe b, de
« , de la formation professionnelle et de la formation géné- Vu l’article 118 de la Loi sur la santé publique (chapitre
rale des adultes »; S-2.2) qui prévoit que le gouvernement peut déclarer un
c) par le remplacement du sous-paragraphe c.1, par québécois lorsqu’une menace grave à la santé de la popu-
le suivant : lation, réelle ou imminente, exige l’application immédiate

656A AR02688
GAZETTE OFFICIELLE DU QUÉBEC, 17 février 2022, 154e année, no 7A Partie 2
Vu le décret numéro 177-2020 du 13 mars 2020 qui 1° par la suppression du premier alinéa;
québécois pour une période de 10 jours; 2° par la suppression des paragraphes 4.1° et 4.2°
du quatrième alinéa;
velé depuis cette date par divers décrets, notamment par 3° par la suppression du sixième alinéa;
le décret numéro 131-2022 du 9 février 2022;
Que les mesures prévues au présent arrêté prennent effet
Vu que le décret numéro 1173-2021 du 1er septembre le 16 février 2022.
24 septembre 2021 et par les arrêtés numéros 2021-067 Québec, le 15 février 2022
2021, 2021-082 du 17 novembre 2021, 2021-089 du Le ministre de la Santé et des Services sociaux,
19 décembre 2021, 2022-004 du 15 janvier 2022, Ch r ist ia n Du bé
2022-007 du 23 janvier 2022, 2022-013 du 5 février 2021
et 2022-015 du 11 février 2022, prévoit l’obligation d’être 76475
adéquatement protégé pour accéder à certains lieux ou
pour participer à certaines activités;

Santé et des Services sociaux à ordonner toute modifica-
Vu que le décret numéro 131-2022 du 9 février 2022

à prendre toute mesure prévue aux paragraphes 1° à 8°
du premier alinéa de l’article 123 de la Loi sur la
santé publique;
Considérant que la situation actuelle de la pandémie

Arrête ce qui suit :
Qu e le dispositif du décret numéro 1173-2021 du

2021 du 24 septembre 2021 et par les arrêtés
2021-081 du 14 novembre 2021, 2021-082 du
17 novembre 2021, 2021-089 du 19 décembre 2021,
2022-004 du 15 janvier 2022, 2022-007 du 23 janvier
2022, 2022-013 du 5 février 2021 et 2022-015 du 11 février
2022, soit de nouveau modifié :

AR02689
Ceci est la pièce « VV » au soutien de


AR02690
-
A.M., 2021

A
Q
:
soit reportée au 15 novembre 2021 la prise

d’effet des quatrième, cinquième, sixième, septième,
huitième, treizième, quatorzième, quinzième, seizième,
dix-neuvième, vingt-deuxième, vingt-troisième,
(chapitre S-2.2) vingt-quatrième et vingt-sixième alinéas du décret
numéro 1276-2021 du 24 septembre 2021, sauf à l’égard :
C. l’ordonnance de mesures visant à
protéger la santé de la population dans la situation de 1° des étudiants et des stagiaires;
2° des bénévoles;
L S S ,
3° des personnes qui sont embauchées ou qui com-
V l’article 118 de la Loi sur la santé publique (chapitre mencent à exercer leur profession dans les milieux visés
S-2.2) qui prévoit que le gouvernement peut déclarer un après le 15 octobre 2021;
québécois lorsqu’une menace grave à la santé de la popu- 4° des sous-contractants ne fournissant pas de soins
lation, réelle ou imminente, exige l’application immédiate aux usagers ou aux résidents des milieux visés.
pour protéger la santé de la population; Québec, le 15 octobre 2021
V le décret numéro 177-2020 du 13 mars 2020 qui Le ministre de la Santé et des Services sociaux,
déclare l’état d’urgence sanitaire dans tout le territoire C D
75807
V que ce décret prévoit que le ministre de la
Santé et des Services sociaux peut prendre toute autre
mesure requise pour s’assurer que le réseau de la A.M., 2021
santé et des services sociaux dispose des ressources
humaines nécessaires; Arrêté numéro 2021-071 du ministre de la Santé
V que l’état d’urgence sanitaire a toujours été renou-
velé depuis cette date par divers décrets, notamment par Loi sur la santé publique
le décret numéro 1313-2021 du 13 octobre 2021; (chapitre S-2.2)
V que le décret numéro 1276-2021 du 24 septembre C l’ordonnance de mesures visant à

2021 prévoit notamment l’obligation pour certains inter- protéger la santé de la population dans la situation de
venants du secteur de la santé et des services sociaux pandémie de la COVID-19
d’être adéquatement protégés;
L S S ,
V que ce décret habilite également le ministre de la
Santé et des Services sociaux à ordonner toute modifica- V l’article 118 de la Loi sur la santé publique (chapitre
C ’il y a lieu d’ordonner certaines québécois lorsqu’une menace grave à la santé de la popu-
AR02691
Ceci est la pièce « WW » au soutien de


AR02692
Q. le deuxième alinéa de l’arrêté numéro 2020-035 — Région sociosanitaire des Laurentides;

du 10 mai 2020, modifié par les arrêtés numéro 2020-044
du 12 juin 2020, 2020-064 du 17 septembre 2020, — Région sociosanitaire de la Montérégie.
2020-067 du 19 septembre 2020, 2021-036 du 15 mai 2021
et 2021-055 du 30 juillet 2021, soit de nouveau modifié par ANNEXE II – Régions sociosanitaires visées
l’insertion dans le sous-paragraphe a du paragraphe 1°
et après « les congés mobiles » de « , les congés pour une — Région sociosanitaire de l’Abitibi-Témiscamingue;
visite médicale liée à la grossesse »;
— Région sociosanitaire de la Côte-Nord;
Q l’arrêté numéro 2021-017 du 26 mars 2021, modi-
fié par les arrêtés numéros 2021-028 du 17 avril 2021, — Région sociosanitaire de la Gaspésie — Îles-de-
2021-036 du 15 mai 2021, 2021-039 du 28 mai 2021 et la-Madeleine;
2021-040 du 5 juin 2021, soit modifié :
— Région sociosanitaire du Nord-du-Québec;
1° par l’ajout, à la fin du dixième alinéa, du paragraphe
suivant : — Région sociosanitaire du Nunavik;
« 4° leurs frais de repas, incluant le pourboire, à — Région sociosanitaire de l’Outaouais;

raison de 10,40 $ par déjeuner, 14,30 $ par dîner et 21,55 $
par souper; »; — Région sociosanitaire des Terres-Cries-de-la-
Baie-James.
2° par l’insertion, après le dixième alinéa, du suivant :
« Q , nonobstant le sixième alinéa, soit considéré
comme des heures régulières de travail le temps de Le ministre de la Santé et des Services sociaux,
déplacement des prestataires de services dont le lieu C D
de travail est situé dans l’une des régions visées au
septième alinéa; »; 75808
3° par l’insertion, après le seizième alinéa, du suivant :
« Q les paragraphes 2° et 3° de l’alinéa précédent

ne s’appliquent pas aux prestataires de services dont le
lieu de travail est situé dans l’une des régions visées au
septième alinéa; ».
-A.M., 2021

ANNEXE I – Régions sociosanitaires visées (chapitre S-2.2)
— Région sociosanitaire du Bas-Saint-Laurent; C l’ordonnance de mesures visant à

— Région sociosanitaire du Saguenay—Lac-Saint-Jean; pandémie de la COVID-19
— Région sociosanitaire de la Capitale-Nationale; L S S ,
— Région sociosanitaire de la Mauricie et Centre- V l’article 118 de la Loi sur la santé publique (chapitre
du-Québec; S-2.2) qui prévoit que le gouvernement peut déclarer un
— Région sociosanitaire de l’Estrie; québécois lorsqu’une menace grave à la santé de la popu-
— Région sociosanitaire de Montréal; de certaines mesures prévues à l’article 123 de cette loi
— Région sociosanitaire de Chaudière-Appalaches;
V le décret numéro 177-2020 du 13 mars 2020 qui
— Région sociosanitaire de Laval; déclare l’état d’urgence sanitaire dans tout le territoire
6606A AR02693
GAZETTE OFFICIELLE DU QUÉBEC, 21 octobre 2021, 153e année, no 42A Partie 2
V. que ce décret prévoit que le ministre de la Santé 2° une ressource intermédiaire non visée par la
et des Services sociaux peut prendre toute autre mesure Loi sur la représentation des ressources de type familial
requise pour s’assurer que le réseau de la santé et des servi- et de certaines ressources intermédiaires et sur le régime
ces sociaux dispose des ressources humaines nécessaires; de négociation d’une entente collective les concernant
(chapitre R-24.0.2);
V que l’état d’urgence sanitaire a toujours été renou-
velé depuis cette date par divers décrets, notamment par 3° une résidence privée pour aînés, à l’exception de
le décret numéro 1313-2021 du 13 octobre 2021; celles de neuf places et moins;
V l’arrêté numéro 2021-024 du 9 avril 2021, modifié Q l’alinéa précédent ne s’applique pas aux personnes
par les arrêtés numéros 2021-028 du 17 avril 2021, visées aux paragraphes 1° à 4° du premier alinéa du dis-
2021-032 du 30 avril 2021 et 2021-046 du 16 juin 2021 et positif de l’arrêté numéro 2021-070 du 15 octobre 2021;
par le décret numéro 1276-2021 du 24 septembre 2021, qui
prévoit notamment l’obligation pour certaines personnes Q ’un intervenant du secteur de la santé et des ser-
de fournir à leur employeur la preuve qu’elles ont reçu vices sociaux au sens du décret numéro 1276-2021 du
une dose d’un vaccin contre la COVID-19 ou de passer 24 septembre 2021 qui n’a reçu aucune dose d’un vaccin
un minimum de trois tests de dépistage de la COVID-19 contre la COVID-19, n’a pas contracté la COVID-19 dans
par semaine et d’en fournir la preuve à leur employeur; les six derniers mois et n’est pas assimilé à une personne
adéquatement protégée contre la COVID-19 au sens du
V que le décret numéro 1276-2021 du 24 septembre deuxième alinéa de ce décret, ne puisse bénéficier des
2021 prévoit notamment l’obligation pour certains interve- primes ou montants forfaitaires suivants :
nants du secteur de la santé et des services sociaux d’être
adéquatement protégés; 1° ceux prévus à l’arrêté numéro 2020-015 du
4 avril 2020, modifié par les arrêtés numéros 2020-017
V que ce décret habilite également le ministre de la du 8 avril 2020, 2020-023 du 17 avril 2020, 2020-031
Santé et des Services sociaux à ordonner toute modifica- du 3 mai 2020, 2020-034 du 9 mai 2020, 2020-038
tion ou toute précision relative aux mesures qu’il prévoit; du 15 mai 2020 et 2020-061 du 1er septembre 2020, à
l’exception des primes de 4 % et 8 % versées à une per-
V que le décret numéro 1313-2021 du 13 octobre 2021 sonne qui détient le titre d’emploi de préposé ou de
habilite le ministre de la Santé et des Services sociaux préposée aux bénéficiaires;
à 8° du premier alinéa de l’article 123 de la Loi sur la 2° ceux prévus à l’arrêté numéro 2020-017 du
santé publique; 8 avril 2020;
C ’il y a lieu d’ordonner certaines 3° ceux prévus à l’arrêté numéro 2020-019 du

mesures pour protéger la santé de la population; 10 avril 2020;
A : 4° ceux prévus à l’arrêté numéro 2020-020 du

10 avril 2020, modifié par l’arrêté numéro 2020-044 du
Q l’arrêté numéro 2021-024 du 9 avril 2021, modi- 12 juin 2020;
fié par les arrêtés numéros 2021-028 du 17 avril 2021,
2021-032 du 30 avril 2021 et 2021-046 du 16 juin 2021 5° ceux prévus à l’arrêté numéro 2020-028 du
et par le décret numéro 1276-2021 du 24 septembre 2021, 25 avril 2020;
s’applique, avec les adaptations nécessaires, à la personne
n’ayant reçu aucune dose de vaccin contre la COVID-19, 6° ceux prévus à l’arrêté numéro 2020-035 du 10 mai
n’ayant pas contracté la COVID-19 dans les six derniers 2020, modifié par les arrêtés numéros 2020-044 du
mois et qui n’est pas assimilée à une personne adéquate- 12 juin 2020, 2020-064 du 17 septembre 2020, 2020-067
ment protégée contre la COVID-19 au sens du deuxième du 19 septembre 2020, 2021-036 du 15 mai 2021 et
alinéa du décret numéro 1276-2021 du 24 septembre 2021 2021-055 du 30 juillet 2021, à l’exception du montant
dans la mesure où elle a des contacts directs avec des forfaitaire prévu au paragraphe 1° du premier alinéa versé
personnes à qui sont offerts des services de santé et des à une personne qui détient le titre d’emploi de préposé ou
services sociaux et qu’elle exerce ses fonctions dans l’un de préposée aux bénéficiaires;
de ces milieux :
1° une installation maintenue par un établissement de 12 juin 2020;
AR02694
8° ceux prévus à l’arrêté numéro 2020-049 du c) par le remplacement, dans le paragraphe 4°, de
4 juillet 2020, modifié par l’arrêté numéro 2021-054 du « et ne reçoit aucune rémunération » par « , ne reçoit
16 juillet 2021; aucune rémunération et son absence est réputée être une
absence non autorisée, sans perte d’ancienneté »;
23 décembre 2020 modifié par les décrets numéros 2-2021 2° par la suppression des paragraphes 4° et 5° du
du 8 janvier 2021 et 799-2021 du 9 juin 2021 et par les cinquième alinéa;
arrêtés numéros 2021-001 du 15 janvier 2021 et 2021-051
du 6 juillet 2021; Q les mesures prévues au présent arrêté prennent
effet le 16 octobre 2021, à l’exception :
30 avril 2021, modifié par l’arrêté numéro 2021-034 du 1° de celles prévues au troisième alinéa qui prennent
8 mai 2021; effet le 17 octobre 2021;
11° ceux prévus à l’arrêté numéro 2021-071 du 2° de celles prévues aux premier et deuxième alinéas
16 octobre 2021; qui prennent effet le 18 octobre 2021;
Q. ’à compter du 15 novembre 2021, le troisième alinéa 3° de celles prév ues au parag raphe 1° du
s’applique à tout intervenant du secteur de la santé et des cinquième alinéa qui prennent effet le 25 octobre 2021.
services sociaux qui n’est pas adéquatement protégé ou
assimilé comme tel; Québec, le 16 octobre 2021
Q le décret numéro 1276-2021 du 24 septembre 2021 Le ministre de la Santé et des Services sociaux,
soit modifié : C D
1° par l’ajout, à la fin du neuvième alinéa, de « ou, dans 75809

le cas d’un élève, d’un étudiant ou d’un stagiaire, à son
établissement d’enseignement »;
2° par l’insertion, après le vingt-quatrième alinéa,

du suivant :
« Q , pour un intervenant du secteur de la santé et des

services sociaux à l’emploi d’un établissement de santé
et de services sociaux public ou privé conventionné, une
absence visée au quinzième alinéa soit réputée être une
absence non autorisée, sans perte d’ancienneté; »;
Q l’arrêté numéro 2021-024 du 9 avril 2021, tel que

modifié, soit de nouveau modifié :
1° dans le deuxième alinéa :
a) par l’insertion, après le paragraphe 2.1°, du suivant :
« 2.2° les tests de dépistage de la COVID-19 prévus

aux paragraphes 2° et 2.1° doivent être passés en-dehors
des heures de travail et la personne salariée ne reçoit
aucune rémunération ni remboursement de frais en lien
avec un tel test; »;
b) par le remplacement, dans le paragraphe 3°, de

« doit, lorsque possible » par « peut »;
AR02695
Ceci est la pièce « XX » au soutien de


6838A AR02696
-
A.M., 2021

« Qu’aux fins du présent décret, on considère « adé-
quatement protégée contre la COVID-19 », une personne
qui, selon le cas :
1° a reçu deux doses de l’un ou l’autre d’un vaccin à

ARNm de Moderna ou de Pfizer BioNTech ou du vaccin
(chapitre S-2.2) AstraZeneca/COVIDSHIELD, avec un intervalle minimal
de 21 jours entre les doses et dont la dernière dose a été
Con c er n a n t l’ordonnance de mesures visant à reçue depuis sept jours ou plus;
pandémie de la COVID-19 2° a contracté la COVID-19 et a reçu, depuis sept jours
ou plus, une dose de l’un ou l’autre des vaccins visés au
Le min ist r e de l a Sa n t é et des Ser vices soc iau x, paragraphe 1° avec un intervalle minimal de 21 jours après
la maladie;
S-2.2) qui prévoit que le gouvernement peut déclarer un 3° a reçu une dose du vaccin Janssen depuis au moins
état d’urgence sanitaire dans tout ou partie du territoire 14 jours;
lation, réelle ou imminente, exige l’application immédiate 4° a reçu deux doses d’un vaccin contre la COVID-19,
de certaines mesures prévues à l’article 123 de cette loi dont l’un est un vaccin reçu à l’extérieur du Canada, autre
pour protéger la santé de la population; que ceux visés aux paragraphes 1° et 3°, et l’autre un
vaccin à ARNm de Moderna ou de Pfizer BioNTech, avec
Vu le décret numéro 177-2020 du 13 mars 2020 qui un intervalle minimal de 21 jours entre les doses et dont
déclare l’état d’urgence sanitaire dans tout le territoire la dernière dose a été reçue depuis sept jours ou plus; »;
2° par le remplacement des troisième, quatrième,
Vu que l’état d’urgence sanitaire a toujours été renou- cinquième, sixième, septième, huitième, neuvième,
velé depuis cette date par divers décrets, notamment par dixième, onzième et douzième alinéas par les suivants :
le décret numéro 1415-2021 du 10 novembre 2021;
« Qu’aux fins du présent décret, on entende par « inter-
Vu que le décret numéro 1276-2021 du 24 septembre venant du secteur de la santé et des services sociaux » :
2021, modifié par l’arrêté numéro 2021-072 du 16 octobre
2021, prévoit notamment l’obligation pour certains inter- 1° les personnes qui sont embauchées ou qui com-
venants du secteur de la santé et des services sociaux mencent à exercer leur profession pour un établissement
d’être adéquatement protégés; de santé et de services sociaux;
Vu que ce décret habilite également le ministre de la 2° les personnes suivantes qui ont des contacts phy-
Santé et des Services sociaux à ordonner toute modifica- siques directs avec des personnes à qui sont offerts des
tion ou toute précision relative aux mesures qu’il prévoit; services de santé et des services sociaux ou qui ont
des contacts physiques directs avec des personnes qui
Considér a n t que la situation actuelle de la pandémie offrent de tels services notamment en raison du partage
de la COVID-19 permet d’assouplir certaines mesures d’espaces communs :
tout en maintenant certaines d’entre elles nécessaires pour a) des élèves, des étudiants et des stagiaires;
b) des bénévoles;
Ar r êt e ce qui suit :
c) des sous-contractants ne fournissant pas de soins
Que le décret numéro 1276-2021 du 24 septembre 2021, aux usagers ou aux résidents des milieux visés, à l’excep-
modifié par l’arrêté numéro 2021-072 du 16 octobre 2021, tion de ceux agissant dans un contexte d’urgence;
soit de nouveau modifié :
Que soient tenus d’être adéquatement protégés :
1° par le remplacement du premier alinéa par
le suivant : 1° les intervenants du secteur de la santé et des services
sociaux visés au paragraphe 1° de l’alinéa précédent;
AR02697
2° les intervenants du secteur de la santé et des ser- Que soit abrogé l’arrêté numéro 2021-070 du 15 octobre
vices sociaux visés au paragraphe 2° de l’alinéa précédent 2021.
qui agissent dans les milieux suivants :
a) une installation maintenue par un établissement de
santé et de services sociaux; Le ministre de la Santé et des Services sociaux,
b) une ressource intermédiaire non visée par la
Loi sur la représentation des ressources de type familial 75957
et de certaines ressources intermédiaires et sur le régime
de négociation d’une entente collective les concernant
(chapitre R-24.0.2); A.M., 2021
c) une résidence privée pour aînés, à l’exception de Arrêté numéro 2021-081 du ministre de la Santé et
celles de neuf places et moins; des Services sociaux en date du 14 novembre 2021
Que, pour l’application du sous-paragraphe a du para- Loi sur la santé publique

graphe 2° de l’alinéa précédent, tout lieu autre qu’une (chapitre S-2.2)
installation maintenue par un établissement de santé et
de services sociaux où sont offerts des services par un tel Con c er n a n t l’ordonnance de mesures visant à
établissement soit assimilé à une telle installation, mais protéger la santé de la population dans la situation de
uniquement en ce qui concerne les intervenants qui four- pandémie de la COVID-19
Le min ist r e de l a Sa n t é et des Ser vices soc iau x,
vices sociaux visé au quatrième alinéa soit tenu de trans- Vu l’article 118 de la Loi sur la santé publique (chapitre
mettre une preuve qu’il est adéquatement protégé contre S-2.2) qui prévoit que le gouvernement peut déclarer un
la COVID-19, selon le cas, à l’établissement de santé et état d’urgence sanitaire dans tout ou partie du territoire
de services sociaux où il souhaite être embauché ou com- québécois lorsqu’une menace grave à la santé de la popu-
mencer à exercer sa profession, à l’exploitant du milieu où lation, réelle ou imminente, exige l’application immédiate
il exerce ou, dans le cas d’un élève, d’un étudiant ou d’un de certaines mesures prévues à l’article 123 de cette loi
stagiaire, à son établissement d’enseignement; pour protéger la santé de la population;
Qu e la transmission de la preuve exigée en vertu de Vu le décret numéro 177-2020 du 13 mars 2020 qui
l’alinéa précédent s’effectue le plus rapidement possible déclare l’état d’urgence sanitaire dans tout le territoire
à compter du moment où cette preuve est disponible; »; québécois pour une période de 10 jours;
3° par le remplacement, dans le treizième alinéa, de Vu que l’état d’urgence sanitaire a toujours été renou-
« Que l’exploitant d’un milieu visé au quatrième alinéa » velé depuis cette date par divers décrets, notamment par
par « Qu’un établissement de santé et de services sociaux le décret numéro 1415-2021 du 10 novembre 2021;
ou l’exploitant d’un milieu visé par le paragraphe 2° du
quatrième alinéa »; Vu que le décret numéro 1173-2021 du 1er septembre
4° par l’insertion dans le quatorzième alinéa et après 24 septembre 2021 et par les arrêtés 2021-067 du 8 octobre
« ne puisse » de « intégrer ou »; 2021 et 2021-079 du 14 octobre 2021, prévoit l’obligation
d’être adéquatement protégé pour accéder à certains lieux
5° par la suppression des seizième et dix-septième ou pour participer à certaines activités;
alinéas;
6° par le remplacement, dans les dix-huitième et Santé et des Services sociaux à ordonner toute modifica-
dix-neuvième alinéas, de « ou d’une ressource de type tion ou toute précision relative aux mesures qu’il prévoit;
familial » par « visée au présent arrêté »;
Cons id ér a n t qu’il y a lieu d’ordonner certaines
7° par la suppression des vingt-et-unième, vingt- mesures pour protéger la santé de la population;
deuxième, vingt-troisième et vingt-cinquième alinéas;
AR02698
Ceci est la pièce « YY » au soutien de


AR02699
8° l’arrêté numéro 2020-087 du 4 novembre 2020, Vu que ce décret habilite également le ministre de
modifié par les arrêtés numéros 2021-022 du 7 avril 2021, la Santé et des Services sociaux à prendre toute mesure
2021-091 du 21 décembre 2021, 2022-010 du 27 janvier prévue aux paragraphes 1° à 8° du premier alinéa de
2022 et 2022-024 du 25 mars 2022; l’article 123 de la Loi sur la santé publique;
9° l’arrêté numéro 2020-099 du 3 décembre 2020, Considér ant qu’il est souhaité de consolider en un
modifié par les arrêtés numéros 2021-005 du 28 janvier seul arrêté ministériel l’ensemble des mesures concer-
2021, 2021-022 du 7 avril 2021, 2021-024 du 9 avril 2021, nant les ressources humaines du réseau de la santé et des
l’arrêté numéro 2021-027 du 16 avril 2021, 2021-028 du services sociaux;
17 avril 2021, 2021-077 du 29 octobre 2021 et 2021-091
du 21 décembre 2021. Arrête ce qui suit :
Québec, le 31 mars 2022 Qu’aux fins du présent arrêté, on entende par :
Le ministre de la Santé et des Services sociaux, 1° « agence de placement de personnel » une personne,
Christian Dubé société ou autre entité dont au moins l’une des activités
consiste à offrir des services de location de personnel;
77083
2° « organisme du secteur de la santé et des services
sociaux » un établissement de santé et de services sociaux,
A.M., 2022 une ressource intermédiaire, une ressource de type familial
ou une résidence privée pour aînés;
des Services sociaux en date du 31 mars 2022 3° « prestataire de services » une personne physique
qui, dans le cadre d’un contrat de services, incluant un
Loi sur la santé publique contrat de services de location de personnel, fournit à un
(chapitre S-2.2) organisme du secteur de la santé et des services sociaux
une prestation de services;
Concernant l’ordonnance de mesures visant à protéger
la santé de la population dans la situation de pandémie Que les dispositions nationales et locales des conven-
de la COVID-19 tions collectives en vigueur dans le réseau de la santé et
des services sociaux de même que les conditions de tra-
Le ministre de la Santé et des Services sociaux, vail applicables au personnel salarié non syndiqué soient
modifiées, afin de permettre à l’employeur de répondre aux
Vu l’article 118 de la Loi sur la santé publique (chapitre besoins de la population, selon les conditions suivantes :
état d’urgence sanitaire dans tout ou partie du territoire 1° les articles relatifs aux congés annuels sont
québécois lorsqu’une menace grave à la santé de la popu- modifiés pour permettre à toute personne de monnayer,
lation, réelle ou imminente, exige l’application immédiate à sa demande, ses journées de vacances à taux simple
de certaines mesures prévues à l’article 123 de cette loi en lieu et place de la prise de journées de vacances qui
pour protéger la santé de la population; excèdent celles prévues à la Loi sur les normes du travail
(chapitre N-1.1);
déclare l’état d’urgence sanitaire dans tout le territoire 2° les articles relatifs aux mouvements de personnel
québécois pour une période de 10 jours; ayant trait, notamment, à la promotion, au transfert, à la
rétrogradation, aux mutations volontaires, à la procédure
Vu que ce décret prévoit que le ministre de la Santé de supplantation, au poste temporairement dépourvu de
et des Services sociaux peut prendre toute autre mesure son titulaire, au remplacement, à l’affectation, à la réaf-
requise pour s’assurer que le réseau de la santé et des ser- fectation ou au déplacement du personnel sont modifiés
vices sociaux dispose des ressources humaines nécessaires; pour permettre à une personne d’accepter volontairement
un déplacement temporaire ou une affectation temporaire
Vu que l’état d’urgence sanitaire a toujours été renou- (intra ou inter établissement);
le décret numéro 595-2022 du 30 mars 2022;

3° aux fins du paragraphe précédent : c) le personnel additionnel ainsi embauché ne béné-
ficie pas de droits acquis quant à une embauche future et
a) la personne qui accepte un tel déplacement ou une devra se soumettre au processus de sélection habituel
telle affectation bénéficie du salaire le plus avantageux, en conformément aux dispositions en vigueur au sein de
plus de continuer de bénéficier des primes et suppléments l’établissement visé;
rattachés à son poste ou à son affectation avant le déplace-
ment, à l’exception des primes d’inconvénient; 7° la personne salariée immunodéprimée ou âgée de
70 ans et plus dont l’état de santé nécessite une réaffecta-
b) malgré le sous-paragraphe précédent, la personne qui tion est retirée du travail si l’employeur n’a pu mettre en
bénéficie d’une prime rattachée au milieu dans lequel elle place du télétravail ou offrir une réaffectation. La personne
travaille habituellement, et qui doit être déplacée dans un salariée à temps complet continue de recevoir sa rému-
milieu où une prime différente y est rattachée, bénéficie de nération comme si elle était au travail, à l’exception des
la prime la plus avantageuse des deux milieux; primes d’inconvénient, et la salariée à temps partiel est
rémunérée de la même façon selon les quarts prévus à son
c) pour la personne qui convertit normalement la horaire de travail;
prime de nuit en temps chômé, aucune récupération ne
peut être effectuée en lien avec le montant de la prime 8° la personne salariée à temps complet qui doit s’isoler
ainsi convertie; à la demande de son employeur ou parce qu’elle a reçu un
ordre d’isolement d’une autorité de santé publique continue
d) la personne qui bénéficie de congés mobiles continue de recevoir sa rémunération comme si elle était au travail, à
de les accumuler; l’exception des primes d’inconvénient, et la personne sala-
riée à temps partiel est rémunérée de la même façon selon
e) la personne conserve le même port d’attache les quarts prévus à son horaire de travail, à l’exception de
en cas de déplacement aux fins du calcul des allocations la personne salariée qui voyage après le 16 mars 2020 à
de déplacement; 23 h 59 et qui a reçu un ordre d’isolement d’une autorité
de santé publique, laquelle peut anticiper des journées de
4° les articles relatifs aux contrats à forfait ou aux vacances ou des congés de maladie lors de son isolement,
contrats d’entreprise sont inopérants; si applicable;
5° l’employeur peut procéder à l’embauche de person- 9° la personne salariée à temps complet en attente d’un
nel additionnel en octroyant le statut de personne salariée résultat du test de dépistage de la COVID-19 qui doit
temporaire à toute personne ainsi embauchée. Le contrat s’isoler à la demande de son employeur ou parce qu’elle a
d’embauche en vertu de ce statut est valide jusqu’au reçu un ordre d’isolement d’une autorité de santé publique
31 décembre 2022. Toutefois, l’employeur peut rési- continue de recevoir sa rémunération comme si elle était
lier le contrat de travail en tout temps avec un préavis au travail, à l’exception des primes d’inconvénient, et la
d’une semaine; personne salariée à temps partiel est rémunérée de la même
façon selon les quarts prévus à son horaire de travail;
6° pour l’application du paragraphe 5° :
10° pour l’application du paragraphe 9° :
a) la personne embauchée sous le statut de personne
salariée temporaire bénéficie uniquement des disposi- a) si le résultat du test est positif, la personne salariée
tions des conventions collectives du réseau de la santé et qui ne bénéficie pas du régime prévu à la Loi sur les acci-
des services sociaux relatives à la rémunération, incluant dents du travail et les maladies professionnelles (chapitre
les primes, les suppléments et le temps supplémentaire. A-3.001) peut être admissible au régime d’assurance
Cependant, cette personne salariée reçoit les bénéfices mar- salaire en conformité avec les dispositions prévues aux
ginaux applicables à la personne salariée à temps partiel conventions collectives.La personne salariée est présumée
non couverte par les régimes d’assurance vie, d’assurance avoir débuté son délai de carence, le cas échéant, pendant
médicaments et d’assurance salaire; la période d’attente du résultat et d’isolement;
b) l’employeur n’est pas tenu de respecter les exigences b) aucune somme ne peut être récupérée par
de la « Nomenclature des titres d’emploi, des libellés, des l’employeur auprès de la personne salariée, à la suite du
taux et des échelles de salaire du réseau de la santé et résultat d’un test;
des services sociaux » pour toute embauche de personnel
additionnel, à l’exception des exigences liées aux ordres 11° la personne salariée qui effectue un quart de travail
professionnels, en autant qu’elle réponde aux exigences complet en temps supplémentaire se voit offrir durant ce
normales de la tâche; quart de travail, le choix entre un repas, lorsque disponible,

AR02701
et une compensation financière de 15,00 $, à l’exception 14° aux fins de la rémunération de la personne sala-
de la personne salariée en télétravail et de celle qui se riée, la prime temporaire est assimilée à une prime
qualifie pour l’allocation de repas lors de déplacements en d’inconvénient;
conformité avec les dispositions applicables des conven-
tions collectives; 15° un montant forfaitaire de 5,00 $ par quart de travail,
lequel peut être divisé en demi-quart de travail, est versé
12° la personne salariée qui effectue un quart complet à la personne salariée qui est désignée par son supérieur
de travail en temps supplémentaire de soir, de nuit ou de immédiat pour être accompagnée par les candidats ins-
fin de semaine peut bénéficier d’une allocation équivalant crits à la formation menant à l’obtention d’une attestation
à un montant fixe de 30,00 $ en compensation des frais de d’études professionnelles en soutien aux soins d’assis-
garde d’enfants âgés de 13 ans et moins, sur présentation tance en établissement de santé et qui détient un des titres
de pièces justificatives; d’emploi suivants, prévus à la Nomenclature des titres
d’emploi, des libellés, des taux et des échelles de salaire
13° une personne salariée et un cadre intermédiaire, tel du réseau de la santé et des services sociaux :
que défini à l’article 3 du Règlement sur certaines condi-
tions de travail applicables aux cadres des agences et des a) infirmier ou infirmière (2471);
établissements de santé et de services sociaux (chapitre
S-4.2, r. 5.1) bénéficient d’une prime temporaire établie b) infirmier ou infirmière auxiliaire (3455);
comme suit :
c) préposé ou préposée aux bénéficiaires (3480);
a) la personne salariée qui travaille dans l’un ou l’autre
des milieux énumérés ci-dessous reçoit une prime de 8 % d) préposé ou préposée (certifié A) aux bénéfi-
applicable sur le salaire prévu à l’échelle de son titre ciaires (3459);
d’emploi pour les heures travaillées dans ce milieu :
16° le montant forfaitaire prévu au paragraphe 15° est
i. les urgences (à l’exception des urgences versé à la personne salariée pour le quart ou le demi-quart
psychiatriques); de travail où elle est effectivement accompagnée par les
candidats inscrits à cette formation, et ce, uniquement
ii. les unités de soins intensifs, lorsqu’au moins un cas pour la durée de leur formation pratique et peu importe le
de diagnostic à la COVID-19 a été confirmé (à l’exception nombre de candidats qui l’accompagnent;
des soins intensifs psychiatriques);
17° aux fins de la rémunération de la personne salariée,
iii. les cliniques dédiées (dépistage et évaluation) à le montant forfaitaire prévu au paragraphe 15° est assimilé
la COVID 19; à une prime d’inconvénient;
iv. les unités identifiées par un établissement afin de 18° le montant forfaitaire prévu au paragraphe 15° ne
regrouper la clientèle présentant un diagnostic positif à peut être cumulé avec toute autre prime assimilable à une
la COVID-19; prime de responsabilité ou de formation;
v. les unités d’hébergement des centres d’hébergement 19° toute personne salariée temporaire visée au para-
et de soins de longue durée; graphe 5°, affectée aux activités de vaccination ou de
dépistage contre la COVID-19 qui fournit une prestation
vi. les autres unités d’hébergement, lorsqu’au moins un de travail minimale, effectivement travaillée, d’une jour-
cas de diagnostic à la COVID-19 a été confirmé; née ou de deux demi-journées par semaine bénéficie du
versement des montants forfaitaires quotidiens suivants,
viii. les services de soutien à domicile; divisibles en demi-journée :
b) la personne salariée qui ne travaille pas dans l’un ou a) 15,00 $ par jour effectivement travaillé, pour un
l’autre de ces milieux reçoit une prime de 4 % applicable maximum de 75,00 $ par semaine, pour une première
sur le salaire prévu à l’échelle de son titre d’emploi pour période de travail de deux semaines consécutives;
les heures travaillées;
b) 20,00 $ par jour effectivement travaillé, pour un
c) le cadre intermédiaire reçoit une prime de 4 % de son maximum de 100,00 $ par semaine, pour une deuxième
salaire pour les heures travaillées; période de travail de quatre semaines consécutives;

c) 30,00 $ par jour effectivement travaillé, pour un 23° la mise en œuvre d’un horaire atypique pour la
maximum de 150,00 $ par semaine, pour une troisième personne salariée visée au quatre-vingt-seizième alinéa;
période de travail de quatre semaines consécutives;
24° l’affectation par l’employeur d’une personne
d) 45,00 $ par jour effectivement travaillé, pour un salariée qui s’est engagée en application du soixante-
maximum de 225,00 $ par semaine, pour une quatrième douzième alinéa au cent-vingt-septième alinéa à un centre
période de travail de quatre semaines consécutives; d’activités ou service qui permettra à celle-ci de respecter
son engagement, et ce, dans la mesure où elle répond aux
e) 65,00 $ par jour effectivement travaillé, par un exigences normales de la tâche;
maximum de 325,00 $ par semaine, pour une cinquième
période de travail de quatre semaines consécutives; Que les paragraphes 1° à 6° du deuxième alinéa
s’appliquent, avec les adaptations nécessaires, aux condi-
f) 90,00 $ par jour effectivement travaillé, pour un tions de travail du personnel d’encadrement et du person-
maximum de 450,00 $ par semaine, pour toute période de nel non visé par la Loi concernant les unités de négocia-
travail de quatre semaines consécutives supplémentaire à tion dans le secteur des affaires sociales (chapitre U-0.1)
celle prévue au sous-paragraphe e; des établissements publics et privés conventionnés et
aux ententes conclues avec le Regroupement Les sages-
20° lorsqu’une personne salariée a un horaire de travail femmes du Québec;
atypique, elle bénéficie du versement des montants for-
faitaires prévus au paragraphe 19° au prorata des heures Que les paragraphes 7° à 14° du deuxième alinéa
effectivement travaillées par rapport au nombre d’heures s’appliquent, avec les adaptations nécessaires, aux condi-
prévues à son titre d’emploi, selon la Nomenclature des tions de travail du personnel non visé par la Loi concer-
titres d’emploi, des libellés, des taux et des échelles de nant les unités de négociation dans le secteur des affaires
salaire du réseau de la santé et des services sociaux, à sociales des établissements publics et privés conventionnés
la condition d’avoir effectivement travaillé un minimum et aux ententes conclues avec le Regroupement Les sages-
d’une journée ou de deux demi-journées par semaine; femmes du Québec;
21° pour l’application des paragraphes 19° et 20° : Qu’un établissement de santé et de services sociaux
doive, avant d’appliquer une mesure prévue par les
a) une journée ou une demi-journée correspond, selon paragraphes 4° à 6° du deuxième alinéa , consulter les
le cas, au nombre d’heures ou à la moitié du nombre syndicats locaux ou les associations concernés, à moins
d’heures par jour prévu au titre d’emploi de la personne que l’urgence de la situation ne permette pas de le faire.
salariée selon la Nomenclature des titres d’emploi, des Dans ce cas, les syndicats devront être avisés dans les
libellés, des taux et des échelles de salaire du réseau de la meilleurs délais;
Que soit exclu de la somme des traitements visés à
b) les heures effectivement travaillées incluent les l’article 10.5 du Règlement d’application de la Loi sur le
heures régulières seulement, à l’exclusion des vacances, régime de retraite du personnel d’encadrement (chapitre
des congés fériés, du temps supplémentaire et de tout autre R-12.1, r. 1), le traitement relatif aux fonctions du
type d’absence, rémunéré ou non; pensionné du régime de retraite du personnel d’encadre-
ment qui a été embauché sous le statut de personne salariée
c) une semaine débute le dimanche; temporaire en vertu du paragraphe 6° du deuxième alinéa
dans une fonction de cadre ou de hors-cadre ou qui, sans
22° lorsqu’une personne n’effectue pas la prestation être nommé dans un poste de cadre chez l’employeur, y
de travail minimale prévue au paragraphe 19° au cours exerce temporairement une fonction de cadre pour les fins
d’une semaine, le calcul du montant forfaitaire à verser de la pandémie de la COVID-19, conformément à l’article 2
reprend à partir du montant prévu au sous-paragraphe a du du Règlement sur certaines conditions de travail appli-
paragraphe 19°, sauf lorsque la personne s’absente aux fins cables aux cadres des agences et des établissements de
de subir un test de dépistage de la COVID-19, lorsqu’elle santé et de services sociaux;
doit s’isoler à la demande de son employeur ou parce
qu’elle a reçu un ordre d’isolement d’une autorité de santé Que soit accordées au personnel à l’emploi des titu-
publique ou lorsqu’elle a été atteinte de la COVID-19 et laires de permis d’exploitation de services ambulanciers,
qu’en raison de cette maladie elle est en absence invalidité, des centres de communication santé ou de la Corporation
auquel cas le calcul du montant forfaitaire à verser reprend d’urgences-santé :
à partir du montant auquel elle aurait eu droit n’eut été de
cette absence;

AR02703
1° une prime temporaire de 8 % du salaire prévu à c) au terme de la période de quatre semaines consécu-
l’échelle du titre d’emploi pour chaque heure travaillée tives de travail prévues, la personne salariée qui maintient
par un technicien ambulancier visé par l’article 63 de la Loi les conditions d’admissibilité peut recevoir de nouveau ces
sur les services préhospitaliers d’urgence (chapitre S-6.2); montants forfaitaires selon la même séquence;
2° une prime temporaire de 4 % du salaire prévu à 3° en centre hospitalier, en centre de protection de
l’échelle du titre d’emploi pour chaque heure travaillée l’enfance et de la jeunesse, en centre de réadaptation et
par le personnel salarié, syndiqué ou non, du secteur en centre local de services communautaires, pour les ins-
préhospitalier d’urgence qui n’est pas visé par le para- tallations, les centres d’activités ou les lieux désignés par
graphe 1°, incluant les cadres intermédiaires; le ministre de la Santé et des Services sociaux, une per-
sonne salariée reçoit un montant forfaitaire de 100,00 $
Que la prime temporaire prévue à l’alinéa précédent par semaine de travail, de même que les montants prévus
soit assimilée à une prime d’inconvénient aux fins de la au paragraphe 2°, selon les mêmes conditions et modali-
rémunération de la personne qui la reçoit; tés, lorsqu’elle détient un des titres d’emploi énumérés à
l’annexe I ou lorsqu’elle est affectée au soutien adminis-
Que les dispositions nationales et locales des conven- tratif au sein d’un secteur clinique et détient un des titres
tions collectives en vigueur dans le réseau de la santé d’emploi énumérés à l’annexe II;
et des services sociaux, de même que les conditions de
travail applicables au personnel salarié non syndiqué de 4° dans l’un des milieux visés par les paragraphes 2°
ce réseau, soient modifiées afin que la personne salariée et 3°, un montant forfaitaire de 500,00 $ par semaine est
qui travaille effectivement le nombre d’heures prévu à son versé lorsque la personne salariée est déplacée par son
titre d’emploi selon la Nomenclature des titres d’emploi, employeur dans une autre région sociosanitaire identifiée
des libellés, des taux et des échelles de salaire du réseau par le ministre de la Santé et des Services sociaux et à plus
de la santé et des services sociaux bénéficie des mesures de 70 km de son domicile; dans un tel cas, les modalités
suivantes, selon les conditions et les modalités suivantes : suivantes s’appliquent :
1° en centre d’hébergement et de soins de longue durée, a) les montants forfaitaires prévus aux paragraphes
dans son lieu de rattachement habituel ou lors d’une affec- précédents sont cumulables au montant forfaitaire prévu
tation dans un tel centre, ou lors d’une affectation dans au présent paragraphe;
une résidence privée pour aînés, dans une ressource inter-
médiaire ou dans une ressource de type familial du pro- b) l’établissement où est déplacée la personne salariée
gramme de soutien à l’autonomie des personnes âgées, et la personne salariée peuvent convenir d’une répartition
un montant forfaitaire de 100,00 $ ou, dans le cas d’une de travail sur une base autre qu’hebdomadaire et sur une
personne salariée qui détient le titre d’emploi de préposé période de plus de cinq jours;
ou préposée aux bénéficiaires, un montant de 139,75 $, par
semaine de travail est versé; Que, malgré l’alinéa précédent, une personne sala-
riée ne puisse bénéficier des montants forfaitaires qui y
2° en centre d’hébergement et de soins de longue durée, sont prévus si elle bénéficie de ceux prévus aux paragra-
pour les installations ou les lieux désignés par le ministre phes 20° à 22° du deuxième alinéa;
de la Santé et des Services sociaux, dans son lieu de rat-
tachement habituel ou lors d’une affectation dans un tel Que les conditions et modalités suivantes s’appli-
centre, ou lors d’une affectation dans une résidence privée quent à l’égard des montants forfaitaires prévus au
pour aînés ou dans une ressource intermédiaire ou une res- neuvième alinéa :
source de type familial du programme de soutien à l’auto-
nomie des personnes âgées, un montant supplémentaire à 1° aux fins du calcul d’admissibilité aux montants
celui prévu au paragraphe précédent et correspondant au forfaitaires, les heures effectivement travaillées incluent
montant suivant est versé : les heures régulières et excluent le temps supplémen-
taire et tout type d’absence, rémunéré ou non, autre que
a) un montant forfaitaire de 200,00 $ pour la première les suivantes :
période de travail de deux semaines consécutives effecti-
vement travaillées; a) les vacances, les congés fériés, les congés mobiles,
les congés pour une visite médicale liée à la grossesse,
b) un montant forfaitaire de 400,00 $ pour la période les libérations syndicales internes ainsi que le temps
de travail de deux semaines effectivement travaillées pendant lequel une personne salariée, détentrice d’un poste
consécutives et subséquentes à la période prévue au sous- à temps complet, convertit normalement la prime de nuit
paragraphe a; en temps chômé;

b) la période durant laquelle la personne salariée est cadre intermédiaire dont l’emploi a été identifié par son
en isolement dans l’attente du résultat d’un test de dépis- employeur et le ministre de la Santé et des Services sociaux
tage de la COVID-19 demandé par les autorités de santé comme comportant des tâches directement liées à la pan-
publique ou par son employeur ou est en isolement à la démie de la COVID-19 bénéficie d’une prime temporaire
suite du résultat positif d’un tel test de dépistage; établie comme suit :
2° les montants forfaitaires sont calculés et versés au 1° la personne salariée reçoit une prime de 4 % appli-
prorata des heures régulières effectivement travaillées dans cable sur le salaire prévu à l’échelle de son titre d’emploi
les milieux visés, à l’exclusion des motifs d’absence men- pour les heures travaillées;
tionnés au paragraphe 1°;
2° le cadre intermédiaire reçoit une prime de 4 % de son
3° lorsque l’horaire de travail d’une personne salariée salaire pour les heures travaillées;
est réparti sur une base autre qu’hebdomadaire et sur une
période de plus de cinq jours, la personne salariée béné- 3° aux fins de la rémunération de la personne salariée
ficie du versement des montants forfaitaires prévus, à la ou du cadre intermédiaire, la prime temporaire est assi-
condition que la moyenne des heures de travail effectuée milée à une prime d’inconvénient;
au cours de la période de référence ainsi modifiée soit
équivalente ou supérieure au nombre d’heures hebdoma- Que la personne salariée ou le cadre intermédiaire
daires de travail prévu au titre d’emploi applicable selon visé à l’alinéa précédent qui doit être déplacé en vue
la Nomenclature des titres d’emploi, des libellés, des taux d’assurer la continuité des soins et des services dans le
et des échelles de salaire du réseau de la santé et des ser- contexte de la pandémie de la COVID-19 bénéficie des
vices sociaux; avantages suivants :
Qu’aux fins de l’application des montants forfaitaires 1° il continue de bénéficier des primes et suppléments
prévus au neuvième alinéa, la période d’admissibilité rattachés à son poste avant le déplacement, à l’exception
débute le dimanche; des primes d’inconvénient dans le cas où le déplacement
s’effectue dans un milieu où aucune prime n’y est rattachée;
Que les mesures prévues au neuvième, dixième,
onzième et douzième alinéas ne s’appliquent pas à la per- 2° lorsqu’il convertit normalement la prime de nuit en
sonne salariée qui effectue des tâches dans les services temps chômé, aucune récupération ne peut être effectuée
administratifs de l’établissement; en lien avec le montant de la prime ainsi convertie;
Que les mesures applicables aux paragraphes 1° et 2° du 3° lorsqu’une personne salariée bénéficie de congés
neuvième alinéa s’appliquent avec les adaptations néces- mobiles, elle continue de les accumuler;
saires, aux personnes suivantes :
Qu’il soit interdit à tout prestataire de services qui a été
1° un pharmacien; en contact avec une personne atteinte ou suspectée d’être
atteinte de la COVID-19 ou qui est en attente du résultat
2° un pharmacien chef I; d’un test de dépistage de la COVID-19 de travailler, au
cours des 14 jours suivants son dernier contact avec une
3° un pharmacien chef II; telle personne, dans un service ou une unité d’un orga-
nisme du secteur de la santé et des services sociaux où
4° un pharmacien chef III; aucun usager ou résident n’est dans une de ces situations;
5° un pharmacien chef IV; Que tout prestataire de services soit tenu de compléter la
formation « Prévention et contrôle des infections : forma-
6° un pharmacien chef-adjoint I; tion de base en contexte de la COVID-19 », ainsi que toute
autre formation supplémentaire en matière de prévention
7° un pharmacien chef-adjoint II; et de contrôle des infections exigée par un organisme du
secteur de la santé et des services sociaux avant d’y effec-
Que les dispositions des conventions collectives appli- tuer sa prestation de services;
cables au personnel salarié syndiqué d’Héma-Québec et
de l’Institut national de santé publique du Québec, de Qu’il soit interdit à toute agence de placement de per-
même que les conditions de travail applicables au personnel de fournir à un organisme du secteur de la santé
sonnel salarié non syndiqué de ces organismes soient et des services sociaux les services d’un prestataire de
modifiées de façon à ce qu’une personne salariée ou un services qui, selon le cas :

AR02705
1° a été en contact, au cours des 14 derniers jours, avec c) infirmier clinicien assistant infirmier-chef, infirmière
une personne atteinte ou suspectée d’être atteinte de la clinicienne assistante infirmière-chef, infirmier clinicien
COVID-19 ou qui est en attente du résultat d’un test de assistant du supérieur immédiat, infirmière clinicienne
dépistage de la COVID-19, pour une affectation dans un assistante du supérieur immédiat (1912);
service ou une unité où aucun usager ou résident n’est dans
une telle situation; d) conseiller ou conseillère en soins infirmiers (1913);
2° n’a pas complété la formation « Prévention et e) infirmier praticien spécialisé, infirmière praticienne
contrôle des infections : formation de base en contexte de la spécialisée (1915);
COVID-19 » ainsi que toute autre formation en matière de
prévention et de contrôle des infections exigée par l’orga- f) infirmier premier assistant en chirurgie, infirmière
nisme du secteur de la santé et des services sociaux à qui première assistante en chirurgie (1916);
il offre des services;
g) infirmier clinicien spécialisé, infirmière clinicienne
Que tout prestataire de services et toute agence de place- spécialisée (1917);
ment de personnel soit tenue de transmettre à l’organisme
du secteur de la santé et des services sociaux à qui il offre 2° 71,87 $, pour les titres d’emploi suivants du regrou-
des services et qui en fait la demande les renseignements pement des titres d’emploi d’infirmier ou d’infirmière :
et documents suivants :
a) infirmier ou infirmière chef d’équipe (2459);
1° la liste des endroits où a travaillé le prestataire de
services concerné au cours des 14 jours précédant son b) infirmier moniteur ou infirmière monitrice (2462);
affectation, de même que, le cas échéant, le fait qu’il a été
en contact, durant cette période, avec une personne atteinte c) infirmier ou infirmière (2471);
ou suspectée d’être atteinte de la COVID-19 ou qui est en
attente du résultat d’un test de dépistage de la COVID-19; d) infirmier ou infirmière (Institut Pinel) (2473);
2° la preuve que le prestataire de services concerné e) assistant-infirmier-chef, assistante-infirmière-chef,

a complété les formations visées au paragraphe 2° de assistant du supérieur immédiat, assistante du supérieur
l’alinéa précédent; immédiat (2489);
Qu’il soit interdit à un prestataire de services et à une f) infirmier ou infirmière en dispensaire (2491);
agence de placement de personnel, dont le contrat a été
conclu, modifié ou renouvelé depuis le 13 mars 2020, de 3° 47,65 $, pour les titres d’emploi du regroupe-
fournir à un organisme du secteur de la santé et des services ment suivants des titres d’emploi d’infirmier ou
sociaux, en échange d’un paiement ou d’une autre rétribu- d’infirmière auxiliaire :
tion, sous quelque forme que ce soit, dont la valeur excède
la tarification horaire suivante, toute journée de travail d’un a) infirmier ou infirmière auxiliaire chef d’équipe
prestataire de services dont les services correspondent aux (3445);
tâches du personnel visé par un des titres d’emploi sui-
vants, prévus à la Nomenclature des titres d’emploi, des b) infirmier ou infirmière auxiliaire (3455);
libellés, des taux et des échelles de salaire du réseau de la
santé et des services sociaux : 4° 41,96 $, pour les titres d’emploi suivants du regrou-
pement des titres d’emploi de préposé ou préposée
1° 74,36 $, pour les titres d’emploi suivants du regrou- aux bénéficiaires :
pement des titres d’emploi d’infirmier clinicien ou d’infir-
mière clinicienne : a) préposé ou préposée (certifié A) aux bénéficiaires
(3459);
a) infirmier clinicien ou infirmière clinicienne
(Institut Pinel) (1907); b) préposé ou préposée aux bénéficiaires (3480);
b) infirmier clinicien ou infirmière clinicienne (1911); c) préposé ou préposée en établissement nordique
(3505);

5° 32,08 $, pour le titre d’emploi auxiliaire aux services 2° leurs frais de déplacement par un autre moyen de
de santé et sociaux (3588); transport qu’une automobile;
6° 80,00 $, pour les titres d’emploi suivants du regrou- 3° leurs frais d’hébergement;
pement des titres d’emploi d’inhalothérapeute :
4° leurs frais de repas, incluant le pourboire, à raison
a) inhalothérapeute (2244); de 10,40 $ par déjeuner, 14,30 $ par dîner et 21,55 $
par souper;
b) coordonnateur ou coordonnatrice technique
(inhalothérapie) (2246); Que, nonobstant le vingt-deuxième alinéa, soit consi-
déré comme des heures régulières de travail le temps
c) chargé ou chargée de l’enseignement clinique de déplacement des prestataires de services dont le
(inhalothérapie) (2247); lieu de travail est situé dans l’une des régions visées au
vingt-troisième alinéa;
d) assistant-chef inhalothérapeute ou assistante-chef
inhalothérapeute (2248); Qu’il soit interdit à tout prestataire de services et à
toute agence de placement de personnel de réclamer ou de
Que les taux horaires prévus à l’alinéa précédent soient recevoir par journée de travail d’un prestataire de services
majorés de 20 % si le lieu de travail du prestataire de visé au vingt-deuxième alinéa un paiement ou une autre
services est situé dans l’une des régions sociosanitaires rétribution, sous quelque forme que ce soit, d’une valeur
suivantes : excédant la tarification horaire fixée aux vingt-deuxième
et vingt-troisième alinéas;
1° l’Abitibi-Témiscamingue;
Que tout contrat de services en vigueur le 15 mai 2020
2° le Bas-Saint-Laurent; conclu par un organisme du secteur de la santé et des
services sociaux pour obtenir les services d’un presta-
3° la Côte-Nord; taire de services ne puisse être modifié pour augmenter
la tarification qui est prévue à ce contrat lorsque celle-ci
4° le Nord-du-Québec; est inférieure à la tarification maximale permise par le
présent arrêté;
5° la Gaspésie—Îles-de-la-Madeleine;
Qu’il soit interdit à quiconque d’embaucher une per-
6° le Nunavik; sonne ayant un lien d’emploi avec un organisme du secteur
de la santé et des services sociaux, un ministère ou un
7° les Terres-Cries-de-la-Baie-James; organisme du gouvernement du Québec visé à l’annexe C
de la Loi sur le régime de négociation des conventions
Que toute stipulation d’un contrat prévoyant un paie- collectives dans les secteurs public et parapublic (chapitre
ment ou une autre rétribution, sous quelque forme que ce R-8.2), un centre de services scolaire, une commission sco-
soit, d’une valeur excédant la tarification fixée au vingt- laire, un collège institué en vertu de la Loi sur les collèges
deuxième ou au vingt-troisième alinéa soit sans effet; d’enseignement général et professionnel (chapitre C-29)
ou une université afin que cette personne agisse par la suite
Que, nonobstant le vingt-deuxième alinéa, les presta- comme prestataire de services dans le cadre d’un contrat de
taires de services affectés au service du soutien à domicile services conclu avec un organisme du secteur de la santé
puissent recevoir une compensation maximale de 0,48 $ par et des services sociaux;
kilomètre parcouru dans le cadre de leurs déplacements
visant à dispenser des services à des usagers; Qu’il soit également interdit à quiconque d’embaucher
une personne qui reçoit une subvention d’un établissement
Que, nonobstant le vingt-deuxième alinéa, les presta- de santé et de services sociaux, du ministre de la Santé
taires de services affectés dans un lieu de travail situé dans et des Services sociaux ou d’un organisme sous sa res-
l’une des régions visées au vingt-troisième alinéa puissent ponsabilité, ou une personne ayant un lien d’emploi avec
recevoir un remboursement, sur présentation des pièces une telle personne afin qu’elle agisse par la suite comme
justificatives, des frais encourus suivants, selon le cas : prestataire de services dans le cadre d’un contrat de ser-
vices conclu avec un organisme du secteur de la santé et
1° leurs frais de déplacement en automobile, au taux des services sociaux;
maximum de 0,48 $ par kilomètre parcouru entre la rési-
dence du prestataire de services et son lieu de travail;

AR02707
Qu’un organisme du secteur de la santé et des services Qu’il soit interdit à tout établissement public ou éta-
sociaux puisse mettre fin à tout contrat de services conclu blissement privé conventionné au sens de la Loi sur les
pour obtenir les services d’un prestataire de services pen- services de santé et les services sociaux (chapitre S-4.2)
dant l’état d’urgence sanitaire pour pouvoir procéder à ou de la Loi sur les services de santé et les services sociaux
l’embauche de la personne concernée, notamment à titre pour les autochtones cris (chapitre S-5) de déplacer une
de personne salariée temporaire, et ce, sans pénalité ou personne salariée afin de libérer un quart de travail pour
autre réparation ou indemnité pour l’organisme et le pres- répondre aux disponibilités d’un prestataire de services;
tataire de services;
Qu’il soit interdit aux agences de placement de person-
Qu’il soit interdit à tout prestataire de services et à toute nel de faire valoir tout engagement de non-concurrence ou
agence de placement de personnel : toute convention ayant des effets similaires, notamment en
réclamant des pénalités, des réparations ou des indemnités,
1° de fournir à un organisme du secteur de la santé et ou d’exercer toute mesure de représailles à l’encontre de
des services sociaux les services d’un prestataire de ser- toute personne qui souhaite être embauchée par un orga-
vices qui a ou a eu un lien d’emploi avec un tel organisme nisme du secteur de la santé et des services sociaux;
dans les 90 jours précédant le début de son affectation;
Qu’il soit interdit à quiconque, à l’exception d’un
2° de fournir à un organisme du secteur de la santé et organisme du secteur de la santé et des services sociaux,
des services sociaux les services d’un prestataire de ser- d’embaucher une infirmière, un infirmier, un inhalothéra-
vices pour une affectation d’une durée inférieure à 14 jours; peute, une infirmière auxiliaire ou un infirmier auxiliaire
qui a ou a eu un lien d’emploi avec un tel organisme dans
3° de fournir à un organisme du secteur de la santé et les 90 jours précédents, aux fins de l’administration par une
des services sociaux les services d’un prestataire de ser- telle personne du vaccin contre la COVID-19;
vices qui est déjà affecté au sein d’un autre organisme du
secteur de la santé et des services sociaux; Qu’il soit interdit à toute agence de placement de
personnel de fournir à quiconque les services d’un pro-
Que les paragraphes 2° et 3° de l’alinéa précédent fessionnel visé à l’alinéa précédent qui a ou a eu un lien
ne s’appliquent pas aux prestataires de services dont le d’emploi avec un tel organisme dans les 90 jours précé-
lieu de travail est situé dans l’une des régions visées au dents aux fins de l’administration par une telle personne
vingt-troisième alinéa; du vaccin contre la COVID-19;
Que tout prestataire de services dont les services ne Qu e les vingt-deuxième, vingt-troisième, vingt-
sont pas offerts par l’entremise d’une agence de place- quatrième, vingt-cinquième, vingt-sixième, vingt-huitième,
ment et toute agence de placement de personnel soit tenu vingt-neuvième, trentième, trente-et-unième, trente-
de fournir à tout organisme du secteur de la santé et des troisième, trente-cinquième et trente-sixième alinéas ne
services sociaux, une déclaration assermentée signée par s’appliquent pas à l’égard d’un prestataire de services
lui, ou selon le cas, par l’un de ses dirigeants, attestant affecté avant le 17 avril 2021 au sein d’un organisme du
que le prestataire de services dont il offre les services n’a secteur de la santé et des services sociaux situé dans l’une
pas ou n’a pas eu de lien d’emploi avec un organisme du des régions sociosanitaires visées au vingt-troisième alinéa;
secteur de la santé et des services sociaux dans les 90 jours
précédant le début de son affectation et que le prestataire Qu e les vingt-deuxième, vingt-troisième, vingt-
de services n’est pas affecté, au même moment, au sein quatrième, vingt-cinquième, vingt-sixième et vingt-
d’un autre organisme du secteur de la santé et de services huitième alinéas ne s’appliquent pas :
sociaux. Une telle déclaration assermentée peut viser plu-
sieurs personnes affectées au sein du même organisme; 1° aux contrats conclus avant le 13 mars 2020 entre une
agence de placement de personnel et le Centre d’acquisi-
Que les trente-troisième et trente-cinquième alinéas tions gouvernementales qui a acquis les droits et obliga-
du présent arrêté ne s’appliquent pas à la fourniture de tions des groupes d’approvisionnement en commun recon-
services correspondant aux tâches du personnel visé par nus par le ministre de la Santé et des Services, même s’ils
le titre d’emploi de surveillant d’établissement (6422) ou ont été modifiés ou renouvelés depuis cette date;
de gardien ou gardienne (6438), prévu à la Nomenclature
des titres d’emploi, des libellés, des taux et des échelles 2° aux contrats de gré à gré du Centre d’acquisitions
de salaire du réseau de la santé et des services sociaux; gouvernementales conclus pour le compte du ministre de
la Santé et des services sociaux ou d’un établissement de

santé et de services sociaux qui prévoit la poursuite de la b) a participé à l’étude clinique menée par Medicago
prestation de services des contrats visés au paragraphe 1°, inc. visant à valider la sécurité ou l’efficacité d’un candi-
et ce, dans le respect des conditions prévues au dat-vaccin contre la COVID-19;
troisième tiret du troisième alinéa du dispositif du décret
numéro 177-2020 du 13 mars 2020, tel qu’il se lisait lors 3° on entende par « intervenant du secteur de la santé
de son abrogation par l’arrêté numéro 2022-023 du 23 mars et des services sociaux » :
2022, et à la condition que ces contrats de gré à gré :
a) les personnes qui sont embauchées ou qui com-
a) soient d’une durée maximale d’un an; mencent à exercer leur profession pour un établissement
de santé et de services sociaux;
b) soient conclus avec une agence de placement de per-
sonnel qui, à la date de la conclusion de ce contrat, détient b) les personnes suivantes qui ont des contacts phy-
une autorisation de contracter délivrée par l’Autorité des siques directs avec des personnes à qui sont offerts des
marchés publics; services de santé et des services sociaux ou qui ont
c) prévoient que les autres termes et conditions, dont offrent de tels services notamment en raison du partage
la tarification, seront identiques à ceux prévus au contrat d’espaces communs :
visé au paragraphe 1°;
i. des élèves, des étudiants et des stagiaires;
Qu’aux fins du quarante-quatrième au cinquante-
quatrième alinéa : ii. des bénévoles;
1° on considère « adéquatement protégée contre la iii. des sous-contractants ne fournissant pas de soins aux
COVID-19 », une personne qui, selon le cas : usagers ou aux résidents des milieux visés, à l’exception
de ceux agissant dans un contexte d’urgence;
a) a reçu deux doses de l’un ou l’autre d’un vaccin à
ARNm de Moderna ou de Pfizer BioNTech ou du vaccin Que soient tenus d’être adéquatement protégés :
AstraZeneca/ COVIDSHIELD, avec un intervalle minimal
de 21 jours entre les doses et dont la dernière dose a été 1° les intervenants du secteur de la santé et des services
reçue depuis sept jours ou plus; sociaux visés au sous-paragraphe a du paragraphe 3° du
quarante-troisième alinéa;
b) a contracté la COVID-19 et a reçu, depuis sept jours
ou plus, une dose de l’un ou l’autre des vaccins visés au 2° les intervenants du secteur de la santé et des services
paragraphe 1° avec un intervalle minimal de 21 jours après sociaux visés au sous-paragraphe b du paragraphe 3°
la maladie; du quarante-troisième alinéa qui agissent dans les
milieux suivants :
c) a reçu une dose du vaccin Janssen depuis au moins
14 jours; a) une installation maintenue par un établissement de
d) a reçu deux doses d’un vaccin contre la COVID-19,
dont l’un est un vaccin reçu à l’extérieur du Canada, autre b) une ressource intermédiaire non visée par la Loi sur
que ceux visés aux sous-paragraphes a et c et l’autre un la représentation des ressources de type familial et de cer-
vaccin à ARNm de Moderna ou de Pfizer BioNTech, avec taines ressources intermédiaires et sur le régime de négo-
un intervalle minimal de 21 jours entre les doses et dont la ciation d’une entente collective les concernant (chapitre
dernière dose a été reçue depuis sept jours ou plus; R-24.0.2);
2° soit également assimilée à une personne adéqua- c) une résidence privée pour aînés, à l’exception de
tement protégée contre la COVID-19 une personne qui, celles de neuf places et moins;
selon le cas :
Que, pour l’application du sous-paragraphe a du para-
a) présente une contre-indication à la vaccination contre graphe 2° de l’alinéa précédent, tout lieu autre qu’une
cette maladie attestée par un professionnel de la santé habi- installation maintenue par un établissement de santé et de
lité à poser un diagnostic et qui est inscrite au registre de services sociaux où sont offerts des services par un tel
vaccination maintenu par le ministre de la Santé et des établissement soit assimilé à une telle installation, mais
Services sociaux; uniquement en ce qui concerne les intervenants qui four-

AR02709
Qu’un intervenant du secteur de la santé et des ser- Qu’un établissement de santé et de services sociaux
vices sociaux visé au quarante-quatrième alinéa soit tenu puisse transmettre au ministre une liste d’intervenants du
de transmettre une preuve qu’il est adéquatement protégé secteur de la santé et des services sociaux qui agissent dans
contre la COVID-19, selon le cas, à l’établissement de les installations qu’il maintient pour lesquels il souhaite
santé et de services sociaux où il souhaite être embauché vérifier s’ils sont adéquatement protégés;
ou commencer à exercer sa profession, à l’exploitant du
milieu où il exerce ou, dans le cas d’un élève, d’un étudiant Que toute personne, société ou organisme ne puisse
ou d’un stagiaire, à son établissement d’enseignement; imposer aucune pénalité ou exiger aucune indemnité ou
autre réparation pour le motif qu’une personne, en raison
Que la transmission de la preuve exigée en vertu de de l’application du présent arrêté, a refusé à une personne
l’alinéa précédent s’effectue le plus rapidement possible à l’accès à un endroit, a mis fin à un contrat ou a eu recours à
compter du moment où cette preuve est disponible; une autre personne, une autre société ou un autre organisme
pour la remplacer;
ou l’exploitant d’un milieu visé par le paragraphe 2° du Qu’aux fins du cinquante-sixième au soixante-dixième
quarante-quatrième alinéa soit tenu de vérifier que alinéa, on entende par « intervenant de la santé et des
tout intervenant du secteur de la santé et des services services sociaux » une personne travaillant ou exerçant sa
sociaux qui doit être adéquatement protégé contre la profession pour :
COVID-19 l’est;
1° un établissement de santé et de services sociaux;
vices sociaux devant être adéquatement protégé contre la 2° une ressource intermédiaire non visée par la
COVID-19 qui n’en a pas fourni la preuve à l’exploitant Loi sur la représentation des ressources de type familial
d’un milieu visé au quarante-quatrième alinéa ne puisse et de certaines ressources intermédiaires et sur le régime
intégrer ou réintégrer ce milieu; de négociation d’une entente collective les concernant;
Qu’un intervenant du secteur de la santé et des services 3° une résidence privée pour aînés à l’exception de celle
sociaux qui ne peut réintégrer un milieu en application de de neuf places et moins;
l’alinéa précédent ne reçoive, selon le cas, aucune rému-
nération, bénéfice, honoraire ou autre forme de compensa- 4° une maison de soins palliatifs au sens du paragra-
tion, à moins que, à la discrétion de son employeur, il n’ait phe 2° de l’article 3 de la Loi concernant les soins de fin
été réaffecté à d’autres tâches, visées à son titre d’emploi, de vie (chapitre S-32.0001);
le cas échéant, qui ne nécessitent pas d’être adéquatement
protégé contre la COVID-19; 5° une institution religieuse qui maintient une instal-
Que l’exploitant d’une ressource intermédiaire non recevoir ses membres ou ses adhérents;
visée par la Loi sur la représentation des ressources de type
familial et de certaines ressources intermédiaires et sur le 6° un centre médical spécialisé au sens de l’arti-
régime de négociation d’une entente collective les concer- cle 333.1 de la Loi sur les services de santé et les
nant transmette à l’établissement de santé et de services services sociaux;
sociaux avec lequel il a conclu une entente, une attestation
indiquant que les intervenants du secteur de la santé et 7° un laboratoire d’imagerie médicale au sens 30.1 de
des services sociaux qui sont tenus d’être adéquatement la Loi sur les laboratoires médicaux et sur la conservation
protégés contre la COVID-19 le sont; des organes et des tissus (chapitre L-0.2);
Que lorsque l’exploitant d’une ressource intermédiaire 8° la Corporation d’Urgences-santé;

non visée par la Loi sur la représentation des ressources
de type familial et de certaines ressources intermédiaires 9° les titulaires de permis d’exploitation de services
et sur le régime de négociation d’une entente collective les ambulanciers;
concernant ne transmet pas l’attestation prévue à l’alinéa
précédent, l’établissement de santé et de services sociaux 10° Héma-Québec;
avec lequel cette ressource a conclu une entente cesse de
la rétribuer et puisse déplacer les usagers qui y sont pris 11° l’Institut national de santé publique du Québec;
en charge vers un autre milieu de vie;
12° le ministère des Transports, mais dans ce cas uni-
quement pour le Service aérien gouvernemental;

Qu’un sous-contractant fournissant des soins aux 7° s’il a contracté la COVID-19 depuis moins de
usagers ou aux résidents des milieux visés au cinquante- 60 jours;
cinquième alinéa soit assimilé à un intervenant de santé et
de services sociaux; 8° s’il a reçu deux doses d’un vaccin contre la
COVID-19, dont l’un est un vaccin reçu à l’extérieur du
Que pour les paragraphes 8° à 12° du cinquante- Canada, autre que ceux visés aux paragraphes 1° et 3°,
cinquième alinéa soient uniquement visés par les et l’autre un vaccin à ARNm de Moderna ou de Pfizer
cinquante-neuvième, soixantième, soixante-et-unième, BioNTech, avec un intervalle minimal de 21 jours entre
soixante-deuxième, soixante-troisième, soixante- les doses et dont la dernière dose a été reçue depuis
quatrième, soixante-cinquième, soixante-sixième, soixante- 7 jours ou plus;
septième, soixante-huitième et soixante-neuvième alinéas
les intervenants ayant des contacts physiques directs avec 9° s’il travaille exclusivement en télétravail à partir de
des personnes à qui sont offerts des services de santé et son domicile;
des services sociaux;
Que les enseignants exerçant dans un centre de réadap- soit tenu de fournir à l’exploitant du milieu ou au respon-
tation pour les jeunes en difficulté d’adaptation exploité sable de son organisation la preuve qu’il a reçu le ou les
par un établissement de santé et de services sociaux ne vaccins mentionnés à l’alinéa précédent, le cas échéant,
soient pas visés par les cinquante-neuvième, soixantième, ou qu’il répond aux conditions mentionnées aux paragra-
soixante-et-unième, soixante-deuxième, soixante- phes 5°, 6° ou 7° de cet alinéa;
troisième, soixante-quatrième, soixante-cinquième,
soixante-sixième, soixante-septième, soixante-huitième Qu’un établissement de santé et de services sociaux
et soixante-neuvième alinéas; puisse transmettre au ministre une liste d’intervenants de
la santé et des services sociaux travaillant ou exerçant dans
Qu ’un intervenant de la santé et des services les installations qu’il maintient pour lesquels il souhaite
sociaux soit tenu de passer des tests de dépistage de la vérifier s’ils sont adéquatement protégés;
COVID-19, conformément aux modalités des soixante-
deuxième, soixante-troisième, soixante-quatrième et
soixante-cinquième alinéas, sauf :
tenu de passer un test de dépistage de la COVID-19 en
application du cinquante-neuvième alinéa doive passer un
1° s’il a reçu deux doses de l’un ou l’autre d’un vaccin
à ARNm de Moderna ou de Pfizer-BioNTech ou du vaccin minimum de trois tests par semaine, effectués par un pro-
AstraZeneca/ COVIDSHIELD, avec un intervalle minimal fessionnel autorisé, et en fournir les résultats à l’exploitant
de 21 jours entre les doses et dont la dernière dose a été du milieu ou au responsable de son organisation;
reçue depuis au moins sept jours;
Que malgré l’alinéa précédent, un intervenant de
2° s’il a contracté la COVID-19 et a reçu, depuis la santé et des services sociaux qui travaille moins de
sept jours ou plus, une dose de l’un ou l’autre des vaccins trois jours par semaine soit tenu de passer un nombre mini-
visés au paragraphe 1° avec un intervalle minimal de 21 mum de test de dépistage de la COVID-19 équivalent au
jours après la maladie; nombre de jours où il est présent dans le milieu ou travaille
pour son organisation;
3° s’il a reçu une dose du vaccin Janssen depuis au
moins 14 jours; Qu’un intervenant de la santé et des services sociaux
visé au soixante-deuxième ou soixante-troisième alinéa
4° s’il a reçu une dose d’un vaccin mentionné au doive passer les tests de dépistage en dehors de ses heures
paragraphe 1° depuis au moins 7 jours et depuis moins de travail et qu’il ne reçoive aucune rémunération ni
de 60 jours; remboursement de frais en lien avec de tels tests;
5° s’il présente une contre-indication à la vaccination Qu’un intervenant de la santé et des services sociaux qui
contre cette maladie attestée par un professionnel de la refuse ou omet de fournir la preuve visée au soixantième
santé habilité à poser un diagnostic et qui est inscrite au alinéa, de passer un test de dépistage de la COVID-19
registre de vaccination maintenu par le ministre de la Santé obligatoire en application du cinquante-neuvième alinéa
et des Services sociaux; ou de fournir les résultats d’un test conformément au
soixante-deuxième alinéa ne puisse être réaffecté ni être
6° s’il a participé à l’étude clinique menée en télétravail et que son absence constitue une absence non
par Medicago inc. visant à valider la sécurité ou l’efficacité autorisée sans perte d’ancienneté;
d’un candidat-vaccin contre la COVID-19;

AR02711
Que les privilèges d’un médecin, d’un pharmacien ou 3° « cadre » un cadre au sens de l’article 3 du Règlement
d’un dentiste refusant ou omettant de passer un test de sur certaines conditions de travail applicables aux
dépistage de la COVID-19 obligatoire en application du cadres des agences et des établissements de santé et
cinquante-neuvième alinéa soient suspendus; de services sociaux qui assume des responsabilités
hiérarchiques, fonctionnelles ou conseil auprès des
Que toute personne qui fournit des services dans le cadre personnes salariées et qui appartient à l’un des titres de
de la modalité de soutien à domicile allocation directe familles d’emploi suivants :
– chèque emploi-service ou dans le cadre d’une entreprise
d’économie sociale en aide à domicile soit tenue de trans- a) chef d’unité dans un groupe de médecine de famille
mettre, sur demande de la personne à qui elle fournit les ou dans un groupe de médecine de famille universitaire;
services, la preuve qu’elle a reçu le ou les vaccins mention-
nés au cinquante-neuvième alinéa ou qu’elle répond aux b) coordonnateur ou chef d’activités à la direction des
conditions mentionnées aux paragraphes 5°, 6° ou 7° de cet services professionnels (gestion des lits, continuum de
alinéa ou le résultat d’un test de dépistage de la COVID-19 soins, gestion des séjours);
effectué depuis moins de 72 heures;
c) coordonnateur à la direction des soins infirmiers;
Que toute personne qui fournit des services dans le cadre
de la modalité de soutien à domicile allocation directe d) chef de service, de programme, d’unité, d’activités
– chèque emploi-service ou dans le cadre d’une entreprise à la direction des soins infirmiers;
d’économie sociale en aide à domicile et qui ne transmet
pas les preuves qui lui sont demandées en application de e) chef de secteur à la direction des soins infirmiers;
l’alinéa précédent ne puisse offrir des services à la per-
sonne lui en ayant fait la demande; f) conseiller cadre à la direction des soins infirmiers;
Qu’un intervenant de la santé et des services sociaux qui g) coordonnateur ou chef d’activités à la direction des
est tenu de passer des tests de dépistage de la COVID-19 soins infirmiers (soir, nuit, fds et fériés/hébergement);
en vertu du cinquante-neuvième alinéa ne puisse bénéficier
des primes, montants forfaitaires, allocations ou compen- h) adjoint hiérarchique à la direction des soins
sations financières prévus au présent arrêté; infirmiers;
Qu’un intervenant de la santé et des services sociaux qui i) coordonnateur des services d’inhalothérapie;
est exempté de passer un test de dépistage de la COVID-19
uniquement en application du paragraphe 9° du cinquante- j) chef de service en inhalothérapie;
neuvième alinéa ne puisse bénéficier des primes, montants
forfaitaires, allocations ou compensations financières visés k) gestionnaire responsable d’un centre d’hébergement
à l’alinéa précédent; de soins de longue durée;
Qu’aux fins du soixante-douzième alinéa au cent-vingt- l) chef d’unité en hébergement dans un centre d’héber-
septième alinéa, on entende par : gement de soins de longue durée;
1° « établissement » un établissement public ou privé m) chef dans une unité en périnatalité, en néonatologie
conventionné au sens de la Loi sur les services de santé et ou en pédiatrie, dans un centre hospitalier de soins géné-
les services sociaux ou de la Loi sur les services de santé raux et spécialisés;
et les services sociaux pour les autochtones cris;
n) chef de programme Info-Santé;
2° « personne salariée » une personne salariée d’un
établissement dont le titre d’emploi fait partie de la o) chef d’unité dans un centre hospitalier psychiatrique;
catégorie du personnel en soins infirmiers et cardio-
respiratoires, tel que prévu à la Nomenclature des titres p) coordonnateur d’activités d’établissements;
du réseau de la santé et des services sociaux, à l’excep- Qu’une personne salariée reçoive, pour chaque quart de
tion des externes en soins infirmiers et des externes travail effectivement travaillé durant une fin de semaine
en inhalothérapie; en sus des quarts de travail prévus à son horaire, un
montant de :

1° 200 $ si elle travaille dans une installation maintenue Que toute personne salariée qui travaillait pour un éta-
par un établissement située dans une région sociosanitaire blissement en date du 23 septembre 2021 et qui s’engage
visée à l’annexe III; auprès de cet établissement à y travailler à temps complet
pour une durée minimale d’une année reçoive, lors de la
2° 400 $ si elle travaille dans une installation maintenue signature de son engagement, un montant forfaitaire de :
par un établissement située dans une région sociosanitaire
visée à l’annexe IV; 1° 5 000 $ si elle travaille dans une installation main-
tenue par un établissement située dans une région socio-
Que pour recevoir le montant forfaitaire prévu à l’alinéa sanitaire visée à l’annexe III;
précédent, la personne salariée soit tenue d’être présente au
travail, selon son horaire, au cours des sept jours précédant 2° 8 000 $ si elle travaille dans une installation main-
et suivant le quart de travail effectivement travaillé durant tenue par un établissement située dans une région socio-
la fin de semaine; sanitaire visée à l’annexe IV;
Qu’aux fins de l’admissibilité aux montants forfaitaires Que la personne salariée qui travaillait pour un établis-
prévus au soixante-douzième alinéa, soit réputée présente sement en date du 23 septembre 2021 et qui déménage
au travail la personne salariée qui bénéficie d’un congé avant le 31 mars 2022, puisse s’engager auprès d’un autre
férié, d’une libération syndicale ou, le cas échéant, de la établissement à y travailler à temps complet pour une durée
conversion de la prime de soir ou de nuit en temps chômé; minimale d’une année et qu’elle puisse recevoir le montant
forfaitaire visé à l’alinéa précédent;
Que toute personne salariée qui a un horaire de jour et
qui s’engage, pour une durée de quatre semaines consécu- Que la personne visée au soixante-dix-neuvième, au
tives, à plutôt travailler à temps complet de soir ou de nuit quatre-vingtième ou au quatre-vingt-unième alinéa reçoive
reçoive, à la fin de cette période, un montant forfaitaire un montant forfaitaire de 10 000 $ à la fin de la période
de 2 000 $; prévue à son engagement, en autant que ce dernier ait
été respecté;
Que l’alinéa précédent s’applique également à toute per-
sonne salariée qui a un poste ou une affectation avec des Que toute personne salariée qui a un statut de personne
quarts de rotation et qui accepte de travailler uniquement salariée à temps complet sans travailler le nombre d’heures
de soir ou de nuit; prévu à la Nomenclature des titres d’emploi, des libellés,
des taux et des échelles de salaire du réseau de la santé
Que, pour recevoir la somme prévue au soixante- et des services sociaux parce qu’elle bénéficie d’un amé-
quinzième alinéa, la personne salariée soit tenue d’être nagement d’horaire avec réduction du temps de travail
présente au travail, selon son horaire, pour toute la qui s’engage auprès d’un établissement à travailler selon
période visée; l’horaire convenu pour une durée minimale d’une année
reçoive au maximum 60 % des montants forfaitaires visés
Que, pour les fins de l’alinéa précédent, soit réputée aux quatre-vingtième, quatre-vingt-unième ou quatre-
être présente au travail la personne salariée qui bénéficie vingt-deuxième alinéas;
d’un congé férié;
Que toute personne salariée qui s’engage auprès d’un
Que toute personne qui ne travaillait pas pour un éta- établissement à y travailler à temps partiel au moins 9 jours
blissement en date du 23 septembre 2021 et qui s’engage par période de 14 jours pour une durée minimale d’une
à travailler à titre de personne salariée pour un établis- année reçoive au maximum 50 % des montants forfai-
sement à temps complet pour une durée minimale d’une taires visés aux soixante-dix-neuvième, quatre-vingtième,
année reçoive, lors de son entrée en fonction, un montant quatre-vingt-unième ou quatre-vingt-deuxième alinéas;
forfaitaire de :
Que toute personne salariée demeure admissible aux
1° 2 000 $ si elle travaille dans une installation main- montants forfaitaires prévus aux soixante-dix-neuvième,
tenue par un établissement située dans une région socio- quatre-vingtième, quatre-vingt-unième et quatre-vingt-
sanitaire visée à l’annexe III; deuxième alinéas lorsqu’elle bénéficie d’un congé sans
solde pour enseigner à condition qu’elle travaille pour
2° 5 000 $ si elle travaille dans une installation main- l’établissement un minimum de 7 jours par période de
tenue par un établissement située dans une région socio- 14 jours et qu’auquel cas elle reçoive, au maximum les
sanitaire visée à l’annexe IV; pourcentages suivants de ces montants forfaitaires :

AR02713
1° 70 % lorsqu’elle travaille 7 jours par période de Qu e, malgré ce que prévoient les soixante-dix-
14 jours; neuvième, quatre-vingtième, quatre-vingt-unième, quatre-
vingt-deuxième, quatre-vingt-troisième et quatre-vingt-
2° 80 % lorsqu’elle travaille 8 jours par période de quatrième alinéas, la personne retraitée embauchée soit
14 jours; tout de même admissible aux montants forfaitaires visés
à ces alinéas et que ceux-ci soient payés au prorata des
3° 90 % lorsqu’elle travaille 9 jours par période de heures régulières effectivement travaillées au cours de
14 jours; l’année, si elle travaille à temps partiel ou s’il y a rupture
du lien d’emploi avant la fin de son engagement;
Que l’alinéa précédent s’applique uniquement à une
personne salariée qui respecte les conditions suivantes : Que, pour l’application des quatre-vingt-dixième et
quatre-vingt-onzième alinéas, soit assimilées à des heures
1° l’enseignement est en lien direct avec les domaines régulières effectivement travaillées les congés annuels, les
d’exercice des personnes salariées appartenant à la catégo- congés mobiles, les congés fériés ainsi que, sauf pour les
rie du personnel en soins infirmiers et cardio-respiratoires, personnes retraitées embauchées, un maximum de 10 jours
tel que prévu à la Nomenclature des titres d’emploi, des de toute autre absence autorisée;
libellés, des taux et des échelles de salaire du réseau de la
santé et des services sociaux; Que la personne retraitée qui s’engage à travailler pour
un établissement en application du soixante-dix-neuvième,
2° elle travaille l’équivalent d’un temps complet quatre-vingtième, quatre-vingt-unième, ou quatre-vingt-
lorsque sa prestation de travail dans l’établissement est deuxième alinéa puisse recevoir, à la fin de la période
additionnée à ses charges de cours; prévue à son engagement, en autant que ce dernier ait été
respecté, un remboursement des frais, jusqu’à concurrence
Que, pour être admissible à recevoir les montants forfai- de la somme habituellement exigée pour une année d’exer-
taires visés aux soixante-dix-neuvième, quatre-vingtième, cice, qu’elle a déboursés pour obtenir le droit d’exercer les
quatre-vingt-unième, quatre-vingt-deuxième, quatre-vingt- activités professionnelles nécessaires, selon les exigences
troisième et quatre-vingt-quatrième alinéas, la personne de la Nomenclature des titres d’emploi, des libellés, des
salariée doive avoir signé son engagement au plus tard le taux et des échelles de salaire du réseau de la santé et des
31 mars 2022 et être disponible à travailler selon le nombre services sociaux;
de jours de travail par semaine prévus à son engagement
à cette date; Que toute personne travaillant pour un établissement,
à l’exception d’un médecin, qui lui réfère une personne
Qu’une personne salariée en congé de maternité, de salariée qui n’est pas à l’emploi d’un établissement pour
paternité, d’adoption ou parental puisse signer son enga- qu’elle y soit embauchée à titre de personne salariée
gement après le 31 mars 2022 pour une durée ne pouvant reçoive une prime de référencement de 500 $ si cette per-
excéder le 31 mars 2023, en autant qu’elle soit disponible sonne réussit sa période de probation et complète au moins
à travailler à temps complet ou 9 jours par période de six mois de service au sein de cet établissement;
14 jours, dans le cas d’une personne salariée à temps
partiel, à la date de son retour au travail et qu’alors elle Qu’aux fins de l’application de l’alinéa précédent, un
reçoive, selon le cas, les montants forfaitaires visés au stagiaire soit réputé être à l’emploi d’un établissement;
soixante-dix-neuvième, quatre-vingtième ou quatre-
vingt-deuxième, quatre-vingt-troisième et quatre-vingt- Que toute personne salariée travaillant dans une ins-
quatrième alinéas en un seul versement, à la fin de son tallation maintenue par un établissement située dans une
engagement, en autant que ce dernier ait été respecté; région sociosanitaire visée à l’annexe III qui s’engage à
travailler à temps complet pour une installation mainte-
Que les personnes salariées visées aux soixante-dix- nue par un établissement située dans une région sociosa-
neuvième, quatre-vingtième ou quatre-vingt-unième nitaire visée à l’annexe IV pour une période d’au moins
alinéas puissent se prévaloir de la conversion de la prime quatre mois consécutifs reçoive, lors de la signature de son
de soir ou de nuit en temps chômé; engagement, un montant forfaitaire de 1 000 $;
Que les montants forfaitaires mentionnés aux soixante- Que la personne salariée visée à l’alinéa précédent
dix-neuvième, quatre-vingtième, quatre-vingt-unième, reçoive un montant forfaitaire de 3 000 $ à la fin de la
quatre-vingt-deuxième, quatre-vingt-troisième et quatre- période prévue à son engagement, en autant que ce dernier
vingt-quatrième alinéas soient payés au prorata des heures ait été respecté;
régulières effectivement travaillées;

Que toute personne salariée qui a un statut à temps b) elle prend plus de 10 jours de congés sans solde auto-
complet sans travailler le nombre d’heures prévu à la risés ou, pour les montants forfaitaires visés aux quatre-
Nomenclature des titres d’emploi, des libellés, des taux vingt-seizième, quatre-vingt-dix-septième, quatre-vingt-
et des échelles de salaire du réseau de la santé et des ser- dix-huitième et quatre-vingt-dix-neuvième alinéas, plus
vices sociaux parce qu’elle bénéficie d’un aménagement de 4 jours de congés sans solde autorisés;
d’horaire avec réduction du temps de travail et qui tra-
vaille dans une installation maintenue par un établissement c) elle ne respecte pas l’engagement convenu;
située dans une région sociosanitaire visée à l’annexe III,
qui s’engage, pour une période d’au moins quatre mois Que, pour les fins du calcul du nombre de jours prévu
consécutifs, à travailler selon l’horaire convenu dans une au sous-paragraphe b du paragraphe 2° de l’alinéa pré-
installation maintenue par un établissement située dans cédent, ne soient pas considérés, les absences autorisées
une région sociosanitaire visée à l’annexe IV, reçoive au dans le cas d’une sortie prévue à la convention collective
maximum 60 % des montants forfaitaires visés aux quatre- de la personne salariée qui travaille dans une installation
vingt-seizième et quatre-vingt-dix-septième alinéas; maintenue par un établissement située dans un secteur visé
à l’annexe V;
Que toute personne salariée travaillant dans une installa-
tion maintenue par un établissement située dans une région Que l’engagement de la personne salariée qui a signé un
sociosanitaire visée à l’annexe III qui s’engage, pour une engagement à travailler à temps complet pour une durée
période d’au moins quatre mois consécutifs, à travailler à minimale d’une année dans une installation maintenue
temps partiel au moins 9 jours par période de 14 jours pour par un établissement située dans une région sociosanitaire
une installation maintenue par un établissement située dans visée à l’annexe III et qui cesse volontairement de tra-
une région sociosanitaire visée à l’annexe IV reçoive au vailler pour cet établissement afin de travailler dans une
maximum 50 % des montants forfaitaires visés aux quatre- installation maintenue par un établissement située dans une
vingt-seizième et quatre-vingt-dix-septième alinéas; région sociosanitaire visée à l’annexe IV soit réputé conclu
avec ce dernier établissement et que la personne salariée
Que les montants forfaitaires mentionnés aux quatre- reçoive les montants forfaitaires applicables à chacune de
vingt-seizième, quatre-vingt-dix-septième, quatre-vingt- ces régions au prorata du temps travaillé dans chacune
dix-huitième et quatre-vingt-dix-neuvième alinéas soient d’elles;
payés au prorata des heures régulières effectivement
travaillées; Que la personne qui n’est pas domiciliée dans une
région visée à l’annexe IV, qui s’y installe pour travail-
Que, pour l’application de l’alinéa précédent, soit assi- ler à titre de personne salariée dans une installation d’un
milées à des heures régulières effectivement travaillées les établissement qui y est située et s’engage à travailler dans
congés annuels, les congés mobiles, les congés fériés ainsi cette installation à temps complet pour une durée minimale
que, sauf pour les personnes retraitées embauchées, un de deux ans reçoive un montant forfaitaire de 24 000 $ dont
maximum de quatre jours de toute autre absence autorisée; les versements sont répartis ainsi :
Que les conditions et modalités suivantes s’appliquent 1° 12 000 $ lors de l’entrée en fonction;
à l’égard des montants forfaitaires prévus aux soixante-
dix-neuvième, quatre-vingtième, quatre-vingt-unième, 2° 12 000 $ un an après l’entrée en fonction;
quatre-vingt-deuxième, quatre-vingt-troisième, quatre-
vingt-quatrième, quatre-vingt-seizième, quatre-vingt-dix- Que la personne visée à l’alinéa précédent soit tenue
septième, quatre-vingt-dix-huitième et quatre-vingt-dix- de rembourser tout montant reçu si elle ne respecte pas
neuvième alinéas : son engagement;
1° tout montant reçu en trop par la personne salariée Que toute personne salariée qui a un statut de personne
doit être remboursé à l’établissement ou peut être com- salariée à temps complet sans travailler le nombre d’heures
pensé par celui-ci; prévu à la Nomenclature des titres d’emploi, des libellés,
des taux et des échelles de salaire du réseau de la santé
2° une personne salariée devient inadmissible aux mon- et des services sociaux parce qu’elle bénéficie d’un
tants forfaitaires et doit rembourser tout versement reçu aménagement d’horaire avec réduction du temps de travail
sans qu’aucun prorata n’y soit appliqué dans l’une des qui s’engage auprès d’un établissement à y travailler selon
situations suivantes : l’horaire convenu pour une durée minimale de deux ans
reçoive 60 % des montants forfaitaires visés au cent-
a) elle s’est absentée sans que cette absence soit cinquième alinéa;
autorisée;

AR02715
Que toute personne salariée qui s’engage auprès d’un Que toute personne qui exerce des fonctions équiva-
établissement à y travailler à temps partiel au moins 9 lentes à une personne salariée, qui a un statut à temps
jours par période de 14 jours pour une durée minimale de complet, qui bénéficie d’un aménagement d’horaire avec
deux ans reçoive 50 % des montants forfaitaires visés au réduction du temps de travail et qui s’engage auprès d’un
cent-cinquième alinéa; établissement ou d’une maison de soins palliatifs visé
à l’alinéa précédent à travailler selon l’horaire convenu
Que la personne salariée visée au quatre-vingt-seizième pour une durée minimale d’une année reçoive au maximum
alinéa puisse recevoir, pour chaque aller-retour entre sa 60 % des montants forfaitaires visés aux quatre-vingtième
résidence et son lieu de travail, le remboursement des ou quatre-vingt-deuxième alinéas;
frais suivants :
Que toute personne qui exerce des fonctions équiva-
1° les frais de déplacement en automobile, au taux lentes à une personne salariée et qui s’engage auprès d’un
maximum de 0,48 $ par kilomètre parcouru entre sa rési- établissement ou d’une maison de soins palliatifs visé au
dence et son lieu de travail; cent-douzième alinéa à y travailler à temps partiel au moins
9 jours par période de 14 jours pour une durée minimale
2° les frais réels de déplacement par un autre moyen de d’une année reçoive au maximum 50 % des montants
transport qu’une automobile; forfaitaires visés aux soixante-dix-neuvième, quatre-
vingtième ou quatre-vingt-deuxième alinéas;
3° les frais d’hébergement encourus;
Qu’une personne qui exerce des fonctions équivalentes à
4° le temps de déplacement; une personne salariée pour un établissement ou une maison
de soins palliatifs visé au cent-douzième alinéa, qui est en
5° les frais de repas, incluant le pourboire, à raison congé de maternité, de paternité, d’adoption ou parental
de 10,40 $ par déjeuner, 14,30 $ par dîner et 21,55 $ puisse signer son engagement après le 31 mars 2022 pour
par souper; une durée ne pouvant excéder le 31 mars 2023, en autant
qu’elle soit disponible à travailler à temps complet ou
Que les montants prévus au paragraphe 5° de l’alinéa 9 jours par période de 14 jours, dans le cas d’une personne
précédent soient majorés : à temps partiel, à la date de son retour au travail et qu’alors
elle reçoive, selon le cas, les montants forfaitaires visés
1° de 30 % si les repas sont pris dans un établissement au soixante-dix-neuvième, quatre-vingtième ou quatre-
commercial d’une municipalité située entre le 49ième et le vingt-deuxième alinéas en un seul versement, à la fin de
50ième parallèle, à l’exception de la municipalité de Baie- son engagement, en autant que ce dernier ait été respecté;
Comeau et des municipalités de la péninsule gaspésienne;
Que les mêmes modalités que celles prévues aux
2° de 50 % si les repas sont pris dans un établisse- soixante-dix-septième, quatre-vingt-neuvième, quatre-
ment commercial d’une municipalité située au-delà du vingt-dixième, quatre-vingt-onzième, quatre-vingt-
50ième parallèle, à l’exception des municipalités de Port- douzième et cent-deuxième alinéas s’appliquent à la per-
Cartier et de Sept-Îles; sonne visée aux cent-douzième, cent-treizième, cent-dix-
quatorzième ou cent-quinzième alinéas;
Qu’en raison de circonstances exceptionnelles, des frais
de repas supérieurs aux montants maximums prévus aux Que toute personne qui travaille pour une résidence
alinéas précédents puissent être remboursés par le dirigeant privée pour aînés ou une institution religieuse qui main-
de l’organisme public ou la personne qu’il désigne si des tient une installation d’hébergement et de soins de longue
explications jugées valables le justifie; durée pour y recevoir ses membres ou ses adhérents, qui y
exerce des fonctions équivalentes à une personne salariée
Que les montants forfaitaires prévus aux soixante-dix- et qui s’engage auprès de cette résidence à y travailler à
neuvième, quatre-vingtième et quatre-vingt-deuxième ce titre à temps complet pour une durée minimale d’une
alinéas s’appliquent, avec les adaptations nécessaires, à année reçoive, un montant forfaitaire de :
la personne qui travaille pour un établissement privé non
conventionné ou une maison de soins palliatifs au sens du 1° 2 500 $ lors de la signature de son engagement;
paragraphe 2° de l’article 3 de la Loi concernant les soins
de fin de vie et qui y exerce des fonctions équivalentes à 2° 5 000 $ à la fin de la période prévue à son engage-
une personne salariée; ment, en autant que ce dernier ait été respecté;

Que toute personne qui exerce des fonctions équiva- Qu’un cadre bénéficie d’une allocation temporaire de
lentes à une personne salariée, qui a un statut à temps 14 % applicable sur son salaire au sens de l’article 3 du
complet, qui bénéficie d’un aménagement d’horaire avec Règlement sur certaines conditions de travail applicables
réduction du temps de travail et qui s’engage auprès d’une aux cadres des agences et des établissements de santé et
résidence privée pour aînés ou d’une institution religieuse de services sociaux;
visé à l’alinéa précédent à travailler selon l’horaire convenu
pour une durée minimale d’une année reçoive au maximum Que l’allocation visée à l’alinéa précédent soit versée
60 % des montants forfaitaires visés à cet alinéa; sous la forme d’un montant forfaitaire, au prorata du temps
travaillé, y compris les congés fériés, les congés mobiles,
Que toute personne qui exerce des fonctions équiva- les congés annuels et les congés sociaux;
lentes à une personne salariée et qui s’engage auprès d’une
résidence privée pour aînés ou d’une institution religieuse Que ne soit plus admissible à l’allocation temporaire,
visé au cent-dix-septième alinéa à y travailler à temps le cadre :
partiel au moins 9 jours par période de 14 jours pour une
durée minimale d’une année reçoive au maximum 50 % 1° ayant cumulé plus de 10 jours d’absence sans solde,
des montants forfaitaires visés à cet alinéa; en excluant les absences découlant de l’application d’une
entente de préretraite progressive ou d’un congé pour acti-
Qu’une personne qui exerce des fonctions équivalentes
vité en milieu nordique;
à une personne salariée pour une résidence privée pour
aînés ou d’une institution religieuse visé au cent-dix-
septième alinéa, qui est en congé de maternité, de paternité, 2° s’étant absenté sans que cette absence soit autorisée;
d’adoption ou parental puisse signer son engagement après
le 31 mars 2022 pour une durée ne pouvant excéder le Que les cadres dont les postes ont été abolis au cours
31 mars 2023, en autant qu’elle soit disponible à travailler des deux années précédant le 13 décembre 2021 et qui ont
à temps complet ou 9 jours par période de 14 jours, dans obtenu une indemnité de fin d’emploi conformément aux
le cas d’une personne à temps partiel, à la date de son articles 119 et 122 du Règlement sur certaines conditions
retour au travail et qu’alors elle reçoive, selon le cas, les de travail applicables aux cadres des agences et des éta-
montants forfaitaires visés au cent-dix-septième alinéa en blissements de santé et de services sociaux puissent être
un seul versement, à la fin de son engagement, en autant réengagés pour occuper un poste de cadre;
que ce dernier ait été respecté;
Que les cent-vingt-troisième, cent-vingt-quatrième,
Que les mêmes modalités que celles prévues aux quatre- cent-vingt-cinquième et cent-vingt-sixième alinéas
vingt-septième, quatre-vingt-neuvième, quatre-vingt- s’appliquent aux cadres qui travaillent pour une maison de
dixième, quatre-vingt-onzième, quatre-vingt-douzième et soins palliatifs, avec les adaptations nécessaires;
cent-deuxième alinéas s’appliquent à la personne visée aux
cent-dix-septième, cent-dix-huitième, cent-dix-neuvième Qu’aux fins du cent-vingt-neuvième au cent-quarante-
ou cent-vingtième alinéas; huitième alinéa, on entende par :
Qu’une personne ne devienne pas inadmissible à 1° « établissement » un établissement public ou privé
recevoir les montants forfaitaires prévus aux soixante- conventionné au sens de la Loi sur les services de santé et
douzième, soixante-quinzième, soixante-dix-neuvième, les services sociaux ou de la Loi sur les services de santé
quatre-vingtième, quatre-vingt-unième, quatre-vingt- et les services sociaux pour les autochtones cris;
deuxième, quatre-vingt-troisième, quatre-vingt-quatrième,
quatre-vingt-cinquième, quatre-vingt-onzième, quatre- 2° « personne salariée » une personne salariée d’un éta-
vingt-treizième, quatre-vingt-quatorzième, quatre-vingt- blissement dont le titre d’emploi fait partie de l’une des
seizième, quatre-vingt-dix-septième, quatre-vingt-dix- catégories suivantes, tel que prévu à la Nomenclature des
huitième, quatre-vingt-dix-neuvième, cent-cinquième, titres d’emploi, des libellés, des taux et des échelles de
cent-septième, cent-huitième, cent-neuvième, cent- salaire du réseau de la santé et des services sociaux :
douzième, cent-treizième, cent-quatorzième, cent-
quinzième, cent-dix-septième, cent-dix-huitième, cent- a) catégorie du personnel en soins infirmiers et
dix-neuvième et cent-vingtième alinéas et que le prorata cardio-respiratoires;
applicable à ces montants, le cas échéant, ne soit pas affecté
lorsqu’elle s’absente aux fins de subir un test de dépistage b) catégorie du personnel paratechnique, des services
de la COVID-19, lorsqu’elle doit s’isoler à la demande de auxiliaires et de métiers;
son employeur ou parce qu’elle a reçu un ordre d’isolement
d’une autorité de santé publique ou lorsqu’elle a été atteinte c) catégorie du personnel de bureau, des techniciens et
de la COVID-19 et qu’en raison de cette maladie elle est des professionnels de l’administration;
en absence invalidité;

AR02717
d) catégorie des techniciens et des professionnels de la journées de vacances, les congés fériés, les congés mobiles,
santé et des services sociaux; les journées de libérations syndicales internes, les congés
pour une visite médicale liée à la grossesse, la conver-
3° « cadre » un cadre au sens de l’article 3 du Règlement sion de prime de soir ou de nuit en temps chômé ainsi
sur certaines conditions de travail applicables aux que les journées où la personne salariée s’absente parce
cadres des agences et des établissements de santé et de qu’elle doit s’isoler à la demande de son employeur ou
services sociaux; parce qu’elle a reçu un ordre d’isolement d’une autorité
de santé publique;
Qu’une personne salariée d’un établissement qui effec-
tue un quart de travail complet en sus de la totalité des Qu’une personne salariée visée au cent-trentième ou
heures prévues à sa semaine normale de travail, tel que cent-trente-et-unième alinéa puisse, à compter du 1er mai
mentionné à son titre d’emploi prévu à la Nomenclature 2022, demander que chaque demi-journée de vacances
des titres d’emploi, des libellés, des taux et des échelles de accumulée en application de ces alinéas lui soit payée, à
salaire du réseau de la santé et des services sociaux, soit taux simple;
rémunérée à taux double pour ce quart supplémentaire;
Qu’une personne salariée à temps partiel d’un établisse-
Que, pour tout quart de travail complet effectué en sus ment reçoive un montant forfaitaire de 100 $ par semaine
de la totalité des heures prévues à sa semaine normale de si elle travaille effectivement au moins 30 heures sans
travail, tel que mentionné à son titre d’emploi, une per- atteindre le nombre d’heures prévues à son titre d’emploi;
sonne salariée d’un établissement, autre qu’une personne
retraitée embauchée ou qu’une personne salariée tempo- Qu’aux fins de l’admissibilité d’une personne au
raire visée au paragraphe 5° du deuxième alinéa, accumule montant forfaitaire prévu à l’alinéa précédent, les heures
une demi-journée de vacances, représentant 50 % d’un effectivement travaillées incluent les heures régulières,
quart de travail complet, qui peut être utilisée à compter les journées de vacances, les congés fériés, les congés
du 1er mai 2022, et ce, sans échéance; mobiles, les congés pour une visite médicale liée à la gros-
sesse, les journées de libérations syndicales internes ainsi
Que la personne salariée à temps complet ayant un que les journées où la personne salariée s’absente parce
qu’elle doit s’isoler à la demande de son employeur ou
horaire atypique qui travaille, en sus de la totalité des
parce qu’elle a reçu un ordre d’isolement d’une autorité de
heures prévues à sa semaine normale de travail, deux quarts
santé publique;
de travail d’une durée de 4 heures de façon consécutive à
deux quarts de travail de 12 heures : Qu’une personne salariée ne soit pas admissible au
montant forfaitaire prévu au cent-trente-sixième alinéa
1° soit rémunérée à taux double pour ces deux quarts si elle s’absente pour un motif autre que ceux prévus au
supplémentaires de 4 heures; cent-trente-septième alinéa;
2° accumule 4 heures de vacances qui peuvent être Qu’une personne salariée à temps partiel d’un établis-
utilisées à compter du 1er mai 2022, et ce, sans échéance; sement qui effectue un quart de travail consécutif à son
quart de travail soit rémunérée à taux double pour le quart
Que malgré le paragraphe 2° de l’alinéa précédent, supplémentaire si, dans la même semaine, elle a effective-
la personne retraitée embauchée ou la personne salariée ment travaillé, dans un centre d’activités où des services
temporaire visée au paragraphe 5° du deuxième alinéa sont dispensés 24 heures par jour et 7 jours par semaine,
reçoive plutôt un montant forfaitaire équivalent à 4 heures un autre quart de travail complet de soir, de nuit ou de fin
de vacances; de semaine, à taux régulier, en sus des heures normalement
prévues à son poste ou à son affectation temporaire, selon
Que, pour tout quart de travail complet effectué en sus le cas;
de la totalité des heures prévues à sa semaine normale de
travail, tel que mentionné à son titre d’emploi, la personne Que, pour l’application de l’alinéa précédent, soient
retraitée embauchée ou la personne salariée temporaire considérés aux fins du calcul des heures normalement
visée au paragraphe 5° du deuxième alinéa reçoive un mon- prévues à son poste ou à son affectation temporaire, selon
tant forfaitaire équivalent à une demi-journée de vacances, le cas, les heures régulières, les journées de vacances, les
représentant 50 % d’un quart de travail complet; congés fériés, les congés mobiles, les heures de libérations
syndicales internes, les congés pour une visite médicale
Que, pour l’application des cent-vingt-neuvième, cent- liée à la grossesse ainsi que les journées où la personne
trentième, cent-trente-et-unième et cent-trente-deuxième salariée s’absente parce qu’elle doit s’isoler à la demande
alinéas, soient considérés aux fins du calcul des heures de son employeur ou parce qu’elle a reçu un ordre d’iso-
de la semaine normale de travail, les quarts réguliers, les lement d’une autorité de santé publique;

Qu ’une personne salariée d’un établissement ne Qu’un cadre qui travaille pour un établissement privé
puisse bénéficier de la mesure prévue au cent-trente- non conventionné, une maison de soins palliatifs au sens
neuvième alinéa plus d’une fois par semaine; du paragraphe 2° de l’article 3 de la Loi concernant les
soins de fin de vie et qui accepte de remplacer un cadre ou
Qu’une personne salariée d’un établissement puisse un employé non cadre à l’extérieur de son horaire habituel
recevoir, là où le service existe, pour chaque quart de trade travail est rémunéré selon son salaire habituel et que
vail effectué en temps supplémentaire, le paiement ou le ce salaire soit majoré à 150 % pour toute heure effectuée
remboursement de ses frais réels et raisonnables de dépla- au-delà de 40 heures par semaine;
cement en taxi entre son domicile et son lieu de travail, soit
pour l’aller, soit pour le retour, soit pour les deux, selon le Qu’un cadre d’un établissement qui accepte de rempla-
besoin de la personne salariée; cer un cadre ou un employé non cadre à l’extérieur de son
horaire habituel de travail est rémunéré selon son salaire
Qu’une personne salariée d’un établissement n’ait pas habituel et que ce salaire soit majoré à 150 % pour toute
à payer les frais d’un espace de stationnement lorsqu’il est heure effectuée au-delà de 40 heures par semaine;
disponible et géré par l’établissement pour la période du
16 janvier 2022 au 14 mai 2022; Que toutes les primes, toutes les allocations et tous les
montants forfaitaires versés en vertu du présent arrêté ne
Que les dispositions nationales et locales des conven- soient pas cotisables aux fins du régime de retraite;
tions collectives en vigueur dans le réseau de la santé et
des services sociaux, de même que les conditions de travail Que soient abrogés :
applicables aux employés syndicables non syndiqués et
aux employés non syndicables du réseau de la santé et des 1° le décret numéro 1276-2021 du 24 septembre 2021,
services sociaux soient modifiées afin de permettre la mise modifié par les arrêtés numéros 2021-072 du 16 octobre
en œuvre des mesures prévues du cent-vingt-huitième au 2021 et 2021-080 du 14 novembre 2021;
cent-quarante-troisième alinéa;
2° l’arrêté numéro 2020-007 du 21 mars 2020;
Que les mesures prévues du cent-vingt-huitième au
cent-quarante-troisième alinéa s’appliquent, avec les adap- 3° l’arrêté numéro 2020-015 du 4 avril 2020, modifié
tations nécessaires, aux conditions de travail du personnel par les arrêtés numéros 2020-016 du 7 avril 2020,
non visé par la Loi concernant les unités de négociation 2020-017 du 8 avril 2020, 2020-023 du 17 avril 2020,
dans le secteur des affaires sociales des établissements 2020-031 du 3 mai 2020, 2020-034 du 9 mai 2020,
publics et privés conventionnés et les ententes conclues 2020-038 du 15 mai 2020, 2022-003 du 15 janvier 2022
avec le Regroupement Les sages-femmes du Québec soient et 2022-023 du 23 mars 2022;
modifiées de la même manière;
4° l’arrêté numéro 2020-017 du 8 avril 2020;
Que les mesures prévues aux cent-vingt-neuvième, cent-
trentième, cent-trente-et-unième, cent-trente-deuxième, 5° l’arrêté numéro 2020-020 du 10 avril 2020, modifié
cent-trente-quatrième, cent-trente-cinquième, cent-trente- par les arrêtés numéros 2020-044 du 12 juin 2020 et
sixième, cent-trente-septième, cent-trente-huitième, cent- 2022-024 du 25 mars 2022;
trente-neuvième et cent-quarantième alinéas s’appliquent,
avec les adaptations nécessaires, à la personne qui travaille 6° l’arrêté numéro 2020-023 du 17 avril 2020;
pour un établissement privé non conventionné, une maison
de soins palliatifs au sens du paragraphe 2° de l’arti- 7° l’arrêté numéro 2020-035 du 10 mai 2020, modi-
cle 3 de la Loi concernant les soins de fin de vie, une rési- fié par les arrêtés numéros 2020-044 du 12 juin 2020,
dence privée pour aînés, une ressource intermédiaire du 2020-064 du 17 septembre 2020, 2020-067 du
programme de soutien à l’autonomie des personnes âgées 19 septembre 2020, 2021-036 du 15 mai 2021, 2021-055
non visée par la Loi sur la représentation des ressources du 30 juillet 2021, 2021-071 du 16 octobre 2021,
de type familial et de certaines ressources intermédiaires 2021-094 du 30 décembre 2021, 2022-003 du 15 janvier
et sur le régime de négociation d’une entente collective les 2022 et 2022-008 du 23 janvier 2022;
concernant ou une institution religieuse qui maintient une
installation d’hébergement et de soins de longue durée pour 8° l’arrêté numéro 2020-049 du 4 juillet 2020, modifié
y recevoir ses membres ou ses adhérents et qui y exerce des par les arrêtés numéros 2021-054 du 16 juillet 2021,
fonctions équivalentes à une personne salariée; 2022-024 du 25 mars 2022 et 2022-026 du 31 mars 2022;

AR02719
9° l’arrêté numéro 2020-107 du 23 décembre 2020, Aide-cuisinier ou aide-cuisinière

modifié par les décrets numéros 2-2021 du 8 janvier 2021
et 799-2021 du 9 juin 2021 et par les arrêtés numéros Assistant ou assistante en pathologie
2021-001 du 15 janvier 2021, 2021-051 du 6 juillet 2021,
2022-023 du 23 mars 2022 et 2022-024 du 25 mars 2022; Assistant ou assistante en réadaptation
10° l’arrêté numéro 2021-017 du 26 mars 2021, modifié Assistant ou assistante technique au laboratoire ou
par les arrêtés numéros 2021-028 du 17 avril 2021, en radiologie
2021-036 du 15 mai 2021, 2021-039 du 28 mai 2021,
2021-040 du 5 juin 2021, 2021-071 du 16 octobre 2021 et Assistant ou assistante technique aux soins de la santé
2022-008 du 23 janvier 2022;
Assistant ou assistante technique en pharmacie
11° l’arrêté numéro 2021-032 du 30 avril 2021, modifié
par les arrêtés numéros 2021-034 du 8 mai 2021, 2021-082 Assistant ou assistante technique senior en pharmacie
du 17 novembre 2021 et 2021-093 du 23 décembre 2021;
Assistant-chef (laboratoire) ou assistante-chef
12° l’arrêté numéro 2021-081 du 14 novembre 2021, (laboratoire)
modifié par les arrêtés numéros 2021-085 du 13 décembre
2021, 2021-088 du 16 décembre  2021 et 2022-003 du Assistant-chef inhalothérapeute ou assistante-chef
15 janvier 2022; inhalothérapeute;
13° l’arrêté numéro 2021-085 du 13 décembre 2021, Assistant-chef physiothérapeute ou assistante-chef

modifié par les arrêtés numéros 2021-093 du 23 décembre physiothérapeute
2021, 2022-008 du 23 janvier 2022 et 2022-026 du
31 mars 2022; Assistant-chef technicien en diététique ou assistante-
chef technicienne en diététique
14° l’arrêté numéro 2021-095 du 31 décembre 2021;
Assistant-chef technologue en électrophysiologie médi-
15° l’arrêté numéro 2022-003 du 15 janvier 2022, cale ou assistante-chef technologue en électrophysiologie
modifié par l’arrêté numéro 2022-008 du 23 janvier 2022. médicale
Annexe I Assistant-chef technologue en radiologie ou assistante-

chef technologue en radiologie
Agent ou agente de planification, de programmation et
de recherche Assistant-infirmier-chef ou assistante-infirmière-chef
ou assistant du supérieur immédiat ou assistante du
Agent ou agente de relations humaines supérieur immédiat
Agent ou agente d’intervention Audiologiste
Agent ou agente d’intervention en milieu chef d’équipe Audiologiste-orthophoniste
Agent ou agente d’intervention en milieu médico-légal Auxiliaire aux services de santé et sociaux
Agent ou agente d’intervention en milieu médico-légal Bactériologiste

chef d’équipe
Biochimiste
Agent ou agente d’intervention en milieu psychiatrique
Biochimiste clinique
chef d’équipe Biochimiste clinique chef de laboratoire niveau I
Aide de service Biochimiste clinique chef de laboratoire niveau II
Aide social ou aide sociale Boucher ou bouchère

Brancardier ou brancardière Ergothérapeute
Buandier ou buandière Externe en inhalothérapie
Caissier ou caissière à la cafétéria Externe en soins infirmiers
Candidat à l’exercice de la profession d’infirmier ou Externe en technologie médicale

candidate à l’exercice de la profession d’infirmière
Gardien ou gardienne de résidence
Candidat à l’exercice de la profession d’infirmière
auxiliaire ou candidate à l’exercice de la profession d’infir- Hygiéniste dentaire
mière auxiliaire
Infirmier auxiliaire chef d’équipe ou infirmière auxi-
Candidat infirmier praticien spécialisé ou candidate liaire chef d’équipe
infirmière praticienne spécialisée
Infirmier auxiliaire en stage d’actualisation ou infirmière
Chargé ou chargée clinique de sécurité transfusionnelle auxiliaire en stage d’actualisation
Chargé ou chargée de l’enseignement clinique Infirmier auxiliaire ou infirmière auxiliaire

(inhalothérapie)
Infirmier chef d’équipe ou infirmière chef d’équipe
Chargé ou chargée de l’enseignement clinique
(physiothérapie) Infirmier clinicien assistant infirmier-chef ou infirmière
clinicienne assistante infirmière-chef ou infirmier clinicien
Chargé ou chargée technique de sécurité transfu- assistant du supérieur immédiat ou infirmière clinicienne
sionnelle assistante du supérieur immédiat
Chef de module Infirmier clinicien ou infirmière clinicienne
Commis surveillant d’unité (Institut Pinel) Infirmier clinicien ou infirmière clinicienne (Institut
Pinel)
Conseiller d’orientation ou conseillère d’orientation
Infirmier clinicien spécialisé ou infirmière clinicienne
Conseiller ou conseillère en soins infirmiers spécialisée
Coordonnateur ou coordonnatrice technique (inhalo- Infirmier en dispensaire ou infirmière en dispensaire

thérapie)
Infirmier en stage d’actualisation ou infirmière en stage
Coordonnateur ou coordonnatrice technique (labo- d’actualisation
ratoire)
Infirmier moniteur ou infirmière monitrice
Coordonnateur ou coordonnatrice technique (radiologie)
Infirmier ou infirmière
Coordonnateur ou coordonnatrice technique en électro-
physiologie médicale Infirmier ou infirmière (Institut Pinel)
Criminologue Infirmier praticien spécialisé ou infirmière praticienne

spécialisée
Cuisinier ou cuisinière
Infirmier premier assistant en chirurgie ou infirmière
Cytologiste première assistante en chirurgie
Diététiste-nutritionniste Ingénieur biomédical ou ingénieure biomédicale
Éducateur ou éducatrice Inhalothérapeute

AR02721
Instituteur ou institutrice clinique (laboratoire) Préposé ou préposée aux bénéficiaires
Instituteur ou institutrice clinique (radiologie) Préposé ou préposée aux bénéficiaires chef d’équipe
Intervenant spécialisé ou intervenante spécialisée en Préposé ou préposée aux magasins

pacification et en sécurité (Institut Pinel)
Préposé ou préposée en établissement nordique
Magasinier ou magasinière
Préposé ou préposée en physiothérapie ou ergothérapie
Moniteur ou monitrice en loisirs
Préposé ou préposée en retraitement des dispositifs
Orthophoniste médicaux
Nettoyeur ou nettoyeuse Préposé ou préposée en salle d’opération
Pâtissier-boulanger ou pâtissière-boulangère Presseur ou presseuse
Perfusionniste clinique Psychoéducateur ou psychoéducatrice
Pharmacien Psychologue
Pharmacien chef I Puéricultrice / garde-bébé
Pharmacien chef II Responsable de milieu de vie
Pharmacien chef III Responsable des services de sage-femme
Pharmacien chef IV Réviseur ou réviseure
Pharmacien chef-adjoint I Sage-femme
Pharmacien chef-adjoint II Secrétaire médicale
Physicien médical Sexologue
Physiothérapeute Sexologue clinicien
Préposé ou préposée à l’unité ou au pavillon Sociothérapeute (Institut Pinel)
Préposé ou préposée à la buanderie Spécialiste clinique en biologie médicale
Préposé ou préposée à l’accueil Spécialiste en activités cliniques
Préposé ou préposée à l’entretien ménager (travaux Spécialiste en sciences biologiques et physiques

légers) sanitaires
Préposé ou préposée à l’entretien ménager (travaux Surveillant ou surveillante en établissement

lourds)
Technicien de laboratoire médical diplômé ou techni-
Préposé ou préposée au service alimentaire cienne de laboratoire médical diplômée
Préposé ou préposée au transport Technicien ou technicienne classe B
Préposé ou préposée au transport des bénéficiaires Technicien ou technicienne d’intervention en loisir

handicapés physiques
Technicien ou technicienne en alimentation

Technicien ou technicienne en cytogénétique clinique Agent administratif, classe 3 - secteur administration

ou agente administrative, classe 3 - secteur administration
Technicien ou technicienne en diététique
Agent administratif, classe 3 - secteur secrétariat ou
Technicien ou technicienne en éducation spécialisée agente administrative, classe 3 - secteur secrétariat
Technicien ou technicienne en physiologie Agent administratif, classe 4 - secteur administration

cardiorespiratoire ou agente administrative, classe 4 - secteur administration
Technicien ou technicienne en travail social Agent administratif, classe 4 - secteur secrétariat ou

agente administrative, classe 4 - secteur secrétariat.
Technologiste médical ou technologiste médicale
Annexe III
Technologue en électrophysiologie médicale
Région sociosanitaire du Bas-Saint-Laurent;
Technologue en imagerie médicale du domaine de la
médecine nucléaire Région sociosanitaire du Saguenay—Lac-Saint-Jean;
Technologue en imagerie médicale du domaine du Région sociosanitaire de la Capitale-Nationale;

radiodiagnostic
Région sociosanitaire de la Mauricie et Centre-
Technologue en physiothérapie du-Québec;
Technologue en radiologie (Système d’information et Région sociosanitaire de l’Estrie;

d’imagerie numérique)
Région sociosanitaire de Montréal;
Technologue en radio-oncologie
Région sociosanitaire de Chaudière-Appalaches;
Technologue spécialisé ou technologue spécialisée en
échographie - pratique autonome Région sociosanitaire de Laval;
Technologue spécialisé ou technologue spécialisée en Région sociosanitaire de Lanaudière;

imagerie médicale
Région sociosanitaire des Laurentides;
radio-oncologie Région sociosanitaire de la Montérégie.
Travailleur ou travailleuse communautaire Annexe IV
Travailleur social ou travailleuse sociale.  Région sociosanitaire de l’Outaouais;
Annexe II Région sociosanitaire de l’Abitibi-Témiscamingue;
Agent administratif, classe 1 - secteur administration Région sociosanitaire de la Côte-Nord;

Région sociosanitaire du Nord-du-Québec;
agente administrative, classe 1 - secteur secrétariat Région sociosanitaire de la Gaspésie — Îles-de-la-
Madeleine;
ou agente administrative, classe 2 - secteur administration Région sociosanitaire du Nunavik;
Agent administratif, classe 2 - secteur secrétariat ou Région sociosanitaire des Terres-Cries-de-la-Baie-James.

agente administrative, classe 2 - secteur secrétariat

AR02723
Annexe V
Le secteur V, composé des localités de Tasiujak,

Ivujivik, Kangiqsualujjuaq, Aupaluk, Quaqtaq, Akulivik,
Kangiqsujuaq, Kangirsuk, Salluit, Tarpangajuk et Umiujaq;
Le secteur IV, composé des localités de Wemindji,

Eastmain, Fort Rupert (Waskaganish), Nemaska
(Nemiscau), Inukjuak, Puvirnituq, Kuujjuak, Kuujjuarapik,
Poste-de-la-Baleine (Whapmagoostui), Schefferville et
Kawawachikamach;
Le secteur III, composé des localités suivantes :
— celles situées sur le territoire situé au nord du

51e degré de latitude incluant Mistissini, Chisasibi, Oujé-
Bougoumou, Radisson, et Waswanipi, à l’exception de
Fermont et des localités spécifiées aux secteurs IV et V;
— Parent, Sanmaur et Clova;
— celles situées sur le territoire de la Côte-Nord,

s’étendant à l’est de Havre-St-Pierre, jusqu’à la limite du
Labrador, y compris l’Île d’Anticosti;
Le secteur II, composé des localités suivantes :
— la municipalité de Fermont;
— celles situées sur le territoire de la Côte-Nord situé

à l’est de la Rivière Moisie et s’étendant jusqu’à Havre-
St-Pierre inclusivement;
— celles des Îles-de-la-Madeleine.

77084

AR02724
Ceci est la pièce « ZZ » au soutien de


AR02725
Erratum
A.M., 2022 Vu que ce décret habilite également le ministre de la

Santé et des Services sociaux à prendre toute mesure
Arrêté numéro 2022-030 du ministre de la Santé et prévue aux paragraphes 1° à 8° du premier alinéa de
des Services sociaux en date du 31 mars 2022 l’article 123 de la Loi sur la santé publique;
Loi sur la santé publique Con sidér a n t qu’il est souhaité de consolider en un
(chapitre S-2.2) seul arrêté ministériel l’ensemble des mesures concer-
nant les ressources humaines du réseau de la santé et des
Concernant l’ordonnance de mesures visant à protéger services sociaux;
la santé de la population dans la situation de pandémie
de la COVID-19 Ar r êt e c e qui suit :
Gazette officielle du Québec, Partie 2, 7 avril 2022, Qu’aux fins du présent arrêté, on entende par :
154e année, numéro 14A, page 1595A.
1° « agence de placement de personnel » une personne,
À la page 1595A, on aurait dû lire : société ou autre entité dont au moins l’une des activités
consiste à offrir des services de location de personnel;
« A.M., 2022
2° « organisme du secteur de la santé et des services
Arrêté numéro 2022-030 du ministre de la Santé et sociaux » un établissement de santé et de services sociaux,
des Services sociaux en date du 31 mars 2022 une ressource intermédiaire, une ressource de type fami-
lial ou une résidence privée pour aînés;
(chapitre S-2.2) 3° « prestataire de services » une personne physique
qui, dans le cadre d’un contrat de services, incluant un
Con c er n a n t l’ordonnance de mesures visant à contrat de services de location de personnel, fournit à un
protéger la santé de la population dans la situation de organisme du secteur de la santé et des services sociaux
pandémie de la COVID-19 une prestation de services;
Le min ist r e de l a Sa n t é et d es Ser vices soc iau x, Que les dispositions nationales et locales des conven-
tions collectives en vigueur dans le réseau de la santé et
Vu l’article 118 de la Loi sur la santé publique (chapitre des services sociaux de même que les conditions de travail
S-2.2) qui prévoit que le gouvernement peut déclarer un applicables au personnel salarié non syndiqué soient modi-
état d’urgence sanitaire dans tout ou partie du territoire fiées, afin de permettre à l’employeur de répondre aux
québécois lorsqu’une menace grave à la santé de la popu- besoins de la population, selon les conditions suivantes :
de certaines mesures prévues à l’article 123 de cette loi 1° les articles relatifs aux congés annuels sont modi-
pour protéger la santé de la population; fiés pour permettre à toute personne de monnayer, à sa
demande, ses journées de vacances à taux simple en
Vu le décret numéro 177-2020 du 13 mars 2020 qui lieu et place de la prise de journées de vacances qui
déclare l’état d’urgence sanitaire dans tout le territoire excèdent celles prévues à la Loi sur les normes du travail
québécois pour une période de 10 jours; (chapitre N-1.1);
Vu que ce décret prévoit que le ministre de la Santé 2° les articles relatifs aux mouvements de personnel
et des Services sociaux peut prendre toute autre mesure ayant trait, notamment, à la promotion, au transfert, à la
requise pour s’assurer que le réseau de la santé et des ser- rétrogradation, aux mutations volontaires, à la procédure
vices sociaux dispose des ressources humaines nécessaires; de supplantation, au poste temporairement dépourvu de
son titulaire, au remplacement, à l’affectation, à la réaf-
Vu que l’état d’urgence sanitaire a toujours été renou- fectation ou au déplacement du personnel sont modifiés
velé depuis cette date par divers décrets, notamment par pour permettre à une personne d’accepter volontairement
le décret numéro 595-2022 du 30 mars 2022; un déplacement temporaire ou une affectation temporaire
(intra ou inter établissement);

3° aux fins du paragraphe précédent : c) le personnel additionnel ainsi embauché ne béné-
ficie pas de droits acquis quant à une embauche future
a) la personne qui accepte un tel déplacement ou une et devra se soumettre au processus de sélection habituel
telle affectation bénéficie du salaire le plus avantageux, en conformément aux dispositions en vigueur au sein de
plus de continuer de bénéficier des primes et suppléments l’établissement visé;
rattachés à son poste ou à son affectation avant le déplace-
ment, à l’exception des primes d’inconvénient; 7° la personne salariée immunodéprimée ou âgée de
70 ans et plus dont l’état de santé nécessite une réaffec-
b) malgré le sous-paragraphe précédent, la personne tation est retirée du travail si l’employeur n’a pu mettre
qui bénéficie d’une prime rattachée au milieu dans lequel en place du télétravail ou offrir une réaffectation. La per-
elle travaille habituellement, et qui doit être déplacée dans sonne salariée à temps complet continue de recevoir sa
un milieu où une prime différente y est rattachée, bénéficie rémunération comme si elle était au travail, à l’exception
de la prime la plus avantageuse des deux milieux; des primes d’inconvénient, et la salariée à temps partiel
est rémunérée de la même façon selon les quarts prévus
c) pour la personne qui convertit normalement la à son horaire de travail;
prime de nuit en temps chômé, aucune récupération ne
peut être effectuée en lien avec le montant de la prime 8° la personne salariée à temps complet qui doit s’isoler
ainsi convertie; à la demande de son employeur ou parce qu’elle a reçu un
ordre d’isolement d’une autorité de santé publique conti-
d) la personne qui bénéficie de congés mobiles continue de recevoir sa rémunération comme si elle était au
nue de les accumuler; travail, à l’exception des primes d’inconvénient, et la per-
sonne salariée à temps partiel est rémunérée de la même
e) la personne conserve le même port d’attache en façon selon les quarts prévus à son horaire de travail, à
cas de déplacement aux fins du calcul des allocations l’exception de la personne salariée qui voyage après le
de déplacement; 16 mars 2020 à 23 h 59 et qui a reçu un ordre d’isolement
d’une autorité de santé publique, laquelle peut anticiper
4° les articles relatifs aux contrats à forfait ou aux des journées de vacances ou des congés de maladie lors
contrats d’entreprise sont inopérants; de son isolement, si applicable;
5° l’employeur peut procéder à l’embauche de per- 9° la personne salariée à temps complet en attente
sonnel additionnel en octroyant le statut de personne d’un résultat du test de dépistage de la COVID-19 qui
salariée temporaire à toute personne ainsi embauchée. doit s’isoler à la demande de son employeur ou parce
Le contrat d’embauche en vertu de ce statut est valide qu’elle a reçu un ordre d’isolement d’une autorité de santé
jusqu’au 31 décembre 2022. Toutefois, l’employeur peut publique continue de recevoir sa rémunération comme si
résilier le contrat de travail en tout temps avec un préavis elle était au travail, à l’exception des primes d’inconvé-
d’une semaine; nient, et la personne salariée à temps partiel est rémunérée
de la même façon selon les quarts prévus à son horaire
6° pour l’application du paragraphe 5° : de travail;
a) la personne embauchée sous le statut de personne 10° pour l’application du paragraphe 9° :
salariée temporaire bénéficie uniquement des dispositions
des conventions collectives du réseau de la santé et des a) si le résultat du test est positif, la personne sala-
services sociaux relatives à la rémunération, incluant riée qui ne bénéficie pas du régime prévu à la Loi sur
les primes, les suppléments et le temps supplémentaire. les accidents du travail et les maladies professionnelles
Cependant, cette personne salariée reçoit les bénéfices (chapitre A-3.001) peut être admissible au régime d’assu-
marginaux applicables à la personne salariée à temps rance salaire en conformité avec les dispositions prévues
partiel non couverte par les régimes d’assurance vie, aux conventions collectives. La personne salariée est pré-
d’assurance médicaments et d’assurance salaire; sumée avoir débuté son délai de carence, le cas échéant,
pendant la période d’attente du résultat et d’isolement;
b) l’employeur n’est pas tenu de respecter les exigences
de la « Nomenclature des titres d’emploi, des libellés, des b) aucune somme ne peut être récupérée par
taux et des échelles de salaire du réseau de la santé et l’employeur auprès de la personne salariée, à la suite du
des services sociaux » pour toute embauche de personnel résultat d’un test;
additionnel, à l’exception des exigences liées aux ordres
professionnels, en autant qu’elle réponde aux exigences 11° la personne salariée qui effectue un quart de
travail complet en temps supplémentaire se voit offrir
normales de la tâche;
durant ce quart de travail, le choix entre un repas, lorsque

AR02727
disponible, et une compensation financière de 15,00 $, 14° aux fins de la rémunération de la personne
à l’exception de la personne salariée en télétravail et de salariée, la prime temporaire est assimilée à une
celle qui se qualifie pour l’allocation de repas lors de prime d’inconvénient;
déplacements en conformité avec les dispositions appli-
cables des conventions collectives; 15° un montant forfaitaire de 5,00 $ par quart de
t ravail, lequel peut être divisé en demi-quart de travail,
12° la personne salariée qui effectue un quart complet est versé à la personne salariée qui est désignée par son
de travail en temps supplémentaire de soir, de nuit ou de supérieur immédiat pour être accompagnée par les can-
fin de semaine peut bénéficier d’une allocation équivalant didats inscrits à la formation menant à l’obtention d’une
à un montant fixe de 30,00 $ en compensation des frais de attestation d’études professionnelles en soutien aux soins
garde d’enfants âgés de 13 ans et moins, sur présentation d’assistance en établissement de santé et qui détient un
de pièces justificatives; des titres d’emploi suivants, prévus à la Nomenclature
des titres d’emploi, des libellés, des taux et des échelles
13° une personne salariée et un cadre intermédiaire, tel de salaire du réseau de la santé et des services sociaux :
que défini à l’article 3 du Règlement sur certaines condi-
tions de travail applicables aux cadres des agences et des a) infirmier ou infirmière (2471);
établissements de santé et de services sociaux (chapitre
S-4.2, r. 5.1) bénéficient d’une prime temporaire établie b) infirmier ou infirmière auxiliaire (3455);
comme suit :
c) préposé ou préposée aux bénéficiaires (3480);
a) la personne salariée qui travaille dans l’un ou l’autre
des milieux énumérés ci-dessous reçoit une prime de d) préposé ou préposée (certifié A) aux bénéfi-
8 % applicable sur le salaire prévu à l’échelle de son titre ciaires (3459);
d’emploi pour les heures travaillées dans ce milieu :
16° le montant forfaitaire prévu au paragraphe 15° est
i. les urgences (à l’exception des urgences versé à la personne salariée pour le quart ou le demi-quart
psychiatriques); de travail où elle est effectivement accompagnée par les
candidats inscrits à cette formation, et ce, uniquement
ii. les unités de soins intensifs, lorsqu’au moins un cas pour la durée de leur formation pratique et peu importe
de diagnostic à la COVID-19 a été confirmé (à l’exception le nombre de candidats qui l’accompagnent;
des soins intensifs psychiatriques);
17° aux fins de la rémunération de la personne salariée,
iii. les cliniques dédiées (dépistage et évaluation) à le montant forfaitaire prévu au paragraphe 15° est assimilé
la COVID-19; à une prime d’inconvénient;
iv. les unités identifiées par un établissement afin de 18° le montant forfaitaire prévu au paragraphe 15° ne
regrouper la clientèle présentant un diagnostic positif à peut être cumulé avec toute autre prime assimilable à une
la COVID-19; prime de responsabilité ou de formation;
v. les unités d’hébergement des centres d’hébergement 19° toute personne salariée temporaire visée au para-
et de soins de longue durée; graphe 5°, affectée aux activités de vaccination ou de
dépistage contre la COVID-19 qui fournit une prestation
vi. les autres unités d’hébergement, lorsqu’au moins un de travail minimale, effectivement travaillée, d’une jour-
cas de diagnostic à la COVID-19 a été confirmé; née ou de deux demi-journées par semaine bénéficie du
versement des montants forfaitaires quotidiens suivants,
viii. les services de soutien à domicile; divisibles en demi-journée :
b) la personne salariée qui ne travaille pas dans l’un ou a) 15,00 $ par jour effectivement travaillé, pour
l’autre de ces milieux reçoit une prime de 4 % applicable un maximum de 75,00 $ par semaine, pour une
sur le salaire prévu à l’échelle de son titre d’emploi pour première période de travail de deux semaines consécutives;
les heures travaillées;
b) 20,00 $ par jour effectivement travaillé, pour un maxi-
c) le cadre intermédiaire reçoit une prime de 4 % de mum de 100,00 $ par semaine, pour une deuxième période
son salaire pour les heures travaillées; de travail de quatre semaines consécutives;

c) 30,00 $ par jour effectivement travaillé, pour un maxi- 23° la mise en œuvre d’un horaire atypique pour la
mum de 150,00 $ par semaine, pour une troisième période personne salariée visée au quatre-vingt-quinzième alinéa;
de travail de quatre semaines consécutives;
24° l’affectation par l’employeur d’une personne
d) 45,00 $ par jour effectivement travaillé, pour un maxi- salariée qui s’est engagée en application du soixante-et-
mum de 225,00 $ par semaine, pour une quatrième période onzième alinéa au cent-vingt-sixième alinéa à un centre
de travail de quatre semaines consécutives; d’activités ou service qui permettra à celle-ci de respecter
son engagement, et ce, dans la mesure où elle répond aux
e) 65,00 $ par jour effectivement travaillé, par un maxi- exigences normales de la tâche;
mum de 325,00 $ par semaine, pour une cinquième période
de travail de quatre semaines consécutives; Qu e les paragraphes 1° à 6° du deuxième alinéa
s’appliquent, avec les adaptations nécessaires, aux
f) 90,00 $ par jour effectivement travaillé, pour un conditions de travail du personnel d’encadrement et du
maximum de 450,00 $ par semaine, pour toute période personnel non visé par la Loi concernant les unités de
de travail de quatre semaines consécutives supplémentaire négociation dans le secteur des affaires sociales (chapitre
à celle prévue au sous-paragraphe e; U-0.1) des établissements publics et privés conventionnés
et aux ententes conclues avec le Regroupement Les sages-
20° lorsqu’une personne salariée a un horaire de travail femmes du Québec;
atypique, elle bénéficie du versement des montants for-
faitaires prévus au paragraphe 19° au prorata des heures Qu e les paragraphes 7° à 14° du deuxième alinéa
effectivement travaillées par rapport au nombre d’heures s’appliquent, avec les adaptations nécessaires, aux condi-
prévues à son titre d’emploi, selon la Nomenclature des tions de travail du personnel non visé par la Loi concer-
titres d’emploi, des libellés, des taux et des échelles de nant les unités de négociation dans le secteur des affaires
salaire du réseau de la santé et des services sociaux, à sociales des établissements publics et privés conven-
la condition d’avoir effectivement travaillé un minimum tionnés et aux ententes conclues avec le Regroupement
d’une journée ou de deux demi-journées par semaine; Les sages-femmes du Québec;
21° pour l’application des paragraphes 19° et 20° : Qu’un établissement de santé et de services sociaux
doive, avant d’appliquer une mesure prévue par les para-
a) une journée ou une demi-journée correspond, selon graphes 4° à 6° du deuxième alinéa, consulter les syn-
le cas, au nombre d’heures ou à la moitié du nombre dicats locaux ou les associations concernés, à moins
d’heures par jour prévu au titre d’emploi de la personne que l’urgence de la situation ne permette pas de le faire.
salariée selon la Nomenclature des titres d’emploi, des Dans ce cas, les syndicats devront être avisés dans les
libellés, des taux et des échelles de salaire du réseau de la meilleurs délais;
Qu e soit exclu de la somme des traitements visés à
b) les heures effectivement travaillées incluent les l’article 10.5 du Règlement d’application de la Loi sur le
heures régulières seulement, à l’exclusion des vacances, régime de retraite du personnel d’encadrement (chapitre
des congés fériés, du temps supplémentaire et de tout autre R-12.1, r. 1), le traitement relatif aux fonctions du pen-
type d’absence, rémunéré ou non; sionné du régime de retraite du personnel d’encadrement
qui a été embauché sous le statut de personne salariée
c) une semaine débute le dimanche; temporaire en vertu du paragraphe 5° du deuxième alinéa
dans une fonction de cadre ou de hors-cadre ou qui, sans
22° lorsqu’une personne n’effectue pas la prestation de être nommé dans un poste de cadre chez l’employeur, y
travail minimale prévue au paragraphe 19° au cours d’une exerce temporairement une fonction de cadre pour les
semaine, le calcul du montant forfaitaire à verser reprend fins de la pandémie de la COVID-19, conformément à
à partir du montant prévu au sous-paragraphe a du para- l’article 2 du Règlement sur certaines conditions de travail
graphe 19°, sauf lorsque la personne s’absente aux fins de applicables aux cadres des agences et des établissements
subir un test de dépistage de la COVID-19, lorsqu’elle doit de santé et de services sociaux;
s’isoler à la demande de son employeur ou parce qu’elle a
reçu un ordre d’isolement d’une autorité de santé publique Qu e soit accordées au personnel à l’emploi des titu-
ou lorsqu’elle a été atteinte de la COVID-19 et qu’en raison laires de permis d’exploitation de services ambulanciers,
de cette maladie elle est en absence invalidité, auquel des centres de communication santé ou de la Corporation
cas le calcul du montant forfaitaire à verser reprend à d’urgences-santé :
partir du montant auquel elle aurait eu droit n’eut été de
cette absence;

AR02729
1° une prime temporaire de 8 % du salaire prévu à c) au terme de la période de quatre semaines consécu-
l’échelle du titre d’emploi pour chaque heure travaillée tives de travail prévues, la personne salariée qui maintient
par un technicien ambulancier visé par l’article 63 les conditions d’admissibilité peut recevoir de nouveau ces
de la Loi sur les services préhospitaliers d’urgence montants forfaitaires selon la même séquence;
(chapitre S-6.2);
3° en centre hospitalier, en centre de protection de
2° une prime temporaire de 4 % du salaire prévu à l’enfance et de la jeunesse, en centre de réadaptation et
l’échelle du titre d’emploi pour chaque heure travaillée par en centre local de services communautaires, pour les
le personnel salarié, syndiqué ou non, du secteur préhos- installations, les centres d’activités ou les lieux désignés
pitalier d’urgence qui n’est pas visé par le paragraphe 1°, par le ministre de la Santé et des Services sociaux, une
incluant les cadres intermédiaires; personne salariée reçoit un montant forfaitaire de 100,00 $
par semaine de travail, de même que les montants prévus
Que la prime temporaire prévue à l’alinéa précédent au paragraphe 2°, selon les mêmes conditions et modali-
soit assimilée à une prime d’inconvénient aux fins de la tés, lorsqu’elle détient un des titres d’emploi énumérés à
rémunération de la personne qui la reçoit; l’annexe I ou lorsqu’elle est affectée au soutien adminis-
tratif au sein d’un secteur clinique et détient un des titres
Que les dispositions nationales et locales des conven- d’emploi énumérés à l’annexe II;
tions collectives en vigueur dans le réseau de la santé
et des services sociaux, de même que les conditions de 4° dans l’un des milieux visés par les paragraphes 2°
travail applicables au personnel salarié non syndiqué de et 3°, un montant forfaitaire de 500,00 $ par semaine est
ce réseau, soient modifiées afin que la personne salariée versé lorsque la personne salariée est déplacée par son
qui travaille effectivement le nombre d’heures prévu à son employeur dans une autre région sociosanitaire identifiée
titre d’emploi selon la Nomenclature des titres d’emploi, par le ministre de la Santé et des Services sociaux et à plus
des libellés, des taux et des échelles de salaire du réseau de 70 km de son domicile; dans un tel cas, les modalités
de la santé et des services sociaux bénéficie des mesures suivantes s’appliquent :
suivantes, selon les conditions et les modalités suivantes :
a) les montants forfaitaires prévus aux paragraphes
1° en centre d’hébergement et de soins de longue précédents sont cumulables au montant forfaitaire prévu
durée, dans son lieu de rattachement habituel ou lors d’une au présent paragraphe;
affectation dans un tel centre, ou lors d’une affectation
dans une résidence privée pour aînés, dans une ressource b) l’établissement où est déplacée la personne salariée
intermédiaire ou dans une ressource de type familial du et la personne salariée peuvent convenir d’une répartition
programme de soutien à l’autonomie des personnes âgées, de travail sur une base autre qu’hebdomadaire et sur une
un montant forfaitaire de 100,00 $ ou, dans le cas d’une période de plus de cinq jours;
personne salariée qui détient le titre d’emploi de préposé
ou préposée aux bénéficiaires, un montant de 139,75 $, par Qu e, malgré l’alinéa précédent, une personne sala-
semaine de travail est versé; riée ne puisse bénéficier des montants forfaitaires qui y
sont prévus si elle bénéficie de ceux prévus aux para-
2° en centre d’hébergement et de soins de longue graphes 19° à 22° du deuxième alinéa;
durée, pour les installations ou les lieux désignés par le
ministre de la Santé et des Services sociaux, dans son lieu Qu e les conditions et modalités suivantes s’appli
de rattachement habituel ou lors d’une affectation dans un quent à l’égard des montants forfaitaires prévus au
tel centre, ou lors d’une affectation dans une résidence neuvième alinéa :
privée pour aînés ou dans une ressource intermédiaire ou
une ressource de type familial du programme de soutien à 1° aux fins du calcul d’admissibilité aux montants
l’autonomie des personnes âgées, un montant supplémen- forfaitaires, les heures effectivement travaillées incluent
taire à celui prévu au paragraphe précédent et correspon- les heures régulières et excluent le temps supplémen-
dant au montant suivant est versé : taire et tout type d’absence, rémunéré ou non, autre que
les suivantes :
a) un montant forfaitaire de 200,00 $ pour la pre-
mière période de travail de deux semaines consécutives a) les vacances, les congés fériés, les congés mobiles,
effectivement travaillées; les congés pour une visite médicale liée à la grossesse,
les libérations syndicales internes ainsi que le temps pen-
b) un montant forfaitaire de 400,00 $ pour la période dant lequel une personne salariée, détentrice d’un poste
de travail de deux semaines effectivement travaillées à temps complet, convertit normalement la prime de nuit
consécutives et subséquentes à la période prévue au
en temps chômé;
sous-paragraphe a;

b) la période durant laquelle la personne salariée est un cadre intermédiaire dont l’emploi a été identifié par
en isolement dans l’attente du résultat d’un test de dépis- son employeur et le ministre de la Santé et des Services
tage de la COVID-19 demandé par les autorités de santé sociaux comme comportant des tâches directement liées
publique ou par son employeur ou est en isolement à la à la pandémie de la COVID-19 bénéficie d’une prime tem-
suite du résultat positif d’un tel test de dépistage; poraire établie comme suit :
2° les montants forfaitaires sont calculés et versés au 1° la personne salariée reçoit une prime de 4 % appli-
prorata des heures régulières effectivement travaillées cable sur le salaire prévu à l’échelle de son titre d’emploi
dans les milieux visés, à l’exclusion des motifs d’absence pour les heures travaillées;
mentionnés au paragraphe 1°;
2° le cadre intermédiaire reçoit une prime de 4 % de
3° lorsque l’horaire de travail d’une personne salariée son salaire pour les heures travaillées;
est réparti sur une base autre qu’hebdomadaire et sur une
période de plus de cinq jours, la personne salariée béné- 3° aux fins de la rémunération de la personne salariée
ficie du versement des montants forfaitaires prévus, à la ou du cadre intermédiaire, la prime temporaire est assi-
condition que la moyenne des heures de travail effectuée milée à une prime d’inconvénient;
au cours de la période de référence ainsi modifiée soit
équivalente ou supérieure au nombre d’heures hebdoma- Qu e la personne salariée ou le cadre intermédiaire
daires de travail prévu au titre d’emploi applicable selon visé à l’alinéa précédent qui doit être déplacé en vue
la Nomenclature des titres d’emploi, des libellés, des d’assurer la continuité des soins et des services dans le
taux et des échelles de salaire du réseau de la santé et des contexte de la pandémie de la COVID-19 bénéficie des
services sociaux; avantages suivants :
Qu’aux fins de l’application des montants forfaitaires 1° il continue de bénéficier des primes et suppléments
prévus au neuvième alinéa, la période d’admissibilité rattachés à son poste avant le déplacement, à l’excep-
débute le dimanche; tion des primes d’inconvénient dans le cas où le dépla-
cement s’effectue dans un milieu où aucune prime n’y
Qu e les mesures prévues au neuvième, dixième, est rattachée;
onzième et douzième alinéas ne s’appliquent pas à la per-
sonne salariée qui effectue des tâches dans les services 2° lorsqu’il convertit normalement la prime de nuit en
administratifs de l’établissement; temps chômé, aucune récupération ne peut être effectuée
en lien avec le montant de la prime ainsi convertie;
Qu e les mesures applicables aux paragraphes 1°
et 2° du neuvième alinéa s’appliquent avec les adaptations 3° lorsqu’une personne salariée bénéficie de congés
nécessaires, aux personnes suivantes : mobiles, elle continue de les accumuler;
1° un pharmacien; Qu’il soit interdit à tout prestataire de services qui a été
en contact avec une personne atteinte ou suspectée d’être
2° un pharmacien chef I; atteinte de la COVID-19 ou qui est en attente du résultat
d’un test de dépistage de la COVID-19 de travailler, au
3° un pharmacien chef II; cours des 14 jours suivants son dernier contact avec une
telle personne, dans un service ou une unité d’un orga-
4° un pharmacien chef III; nisme du secteur de la santé et des services sociaux où
aucun usager ou résident n’est dans une de ces situations;
5° un pharmacien chef IV;
Que tout prestataire de services soit tenu de complé-
6° un pharmacien chef-adjoint I; ter la formation « Prévention et contrôle des infections :
formation de base en contexte de la COVID-19 », ainsi
7° un pharmacien chef-adjoint II; que toute autre formation supplémentaire en matière de
prévention et de contrôle des infections exigée par un
Que les dispositions des conventions collectives appli- organisme du secteur de la santé et des services sociaux
cables au personnel salarié syndiqué d’Héma-Québec et avant d’y effectuer sa prestation de services;
de l’Institut national de santé publique du Québec, de
même que les conditions de travail applicables au per- Qu’il soit interdit à toute agence de placement de per-
sonnel salarié non syndiqué de ces organismes soient sonnel de fournir à un organisme du secteur de la santé
modifiées de façon à ce qu’une personne salariée ou et des services sociaux les services d’un prestataire de
services qui, selon le cas :

AR02731
1° a été en contact, au cours des 14 derniers jours, avec c) infirmier clinicien assistant infirmier-chef, infir-
une personne atteinte ou suspectée d’être atteinte de la mière clinicienne assistante infirmière-chef, infirmier
COVID-19 ou qui est en attente du résultat d’un test de clinicien assistant du supérieur immédiat, infirmière
dépistage de la COVID-19, pour une affectation dans un clinicienne assistante du supérieur immédiat (1912);
service ou une unité où aucun usager ou résident n’est
dans une telle situation; d) conseiller ou conseillère en soins infirmiers (1913);
2° n’a pas complété la formation « Prévention et e) infirmier praticien spécialisé, infirmière praticienne
contrôle des infections : formation de base en contexte de spécialisée (1915);
la COVID-19 » ainsi que toute autre formation en matière
de prévention et de contrôle des infections exigée par f) infirmier premier assistant en chirurgie, infirmière
l’organisme du secteur de la santé et des services sociaux première assistante en chirurgie (1916);
à qui il offre des services;
g) infirmier clinicien spécialisé, infirmière clinicienne
Qu e tout prestataire de services et toute agence de spécialisée (1917);
placement de personnel soit tenue de transmettre à l’orga-
nisme du secteur de la santé et des services sociaux à qui 2° 71,87 $, pour les titres d’emploi suivants du regrou-
il offre des services et qui en fait la demande les rensei- pement des titres d’emploi d’infirmier ou d’infirmière :
gnements et documents suivants :
a) infirmier ou infirmière chef d’équipe (2459);
1° la liste des endroits où a travaillé le prestataire de
services concerné au cours des 14 jours précédant son b) infirmier moniteur ou infirmière monitrice (2462);
affectation, de même que, le cas échéant, le fait qu’il a
été en contact, durant cette période, avec une personne c) infirmier ou infirmière (2471);
atteinte ou suspectée d’être atteinte de la COVID-19 ou
qui est en attente du résultat d’un test de dépistage de d) infirmier ou infirmière (Institut Pinel) (2473);
la COVID-19;
e) assistant-infirmier-chef, assistante-infirmière-chef,
2° la preuve que le prestataire de services concerné assistant du supérieur immédiat, assistante du supérieur
a complété les formations visées au paragraphe 2° de immédiat (2489);
l’alinéa précédent;
f) infirmier ou infirmière en dispensaire (2491);
Qu’il soit interdit à un prestataire de services et à une
agence de placement de personnel, dont le contrat a été 3° 47,65 $, pour les titres d’emploi du regrou-
conclu, modifié ou renouvelé depuis le 13 mars 2020, de pement suivants des titres d’emploi d’infirmier ou
fournir à un organisme du secteur de la santé et des ser- d’infirmière auxiliaire :
vices sociaux, en échange d’un paiement ou d’une autre
rétribution, sous quelque forme que ce soit, dont la valeur a) i n f i r m ier ou i n f i r m ière au x iliai re chef
excède la tarification horaire suivante, toute journée de d’équipe (3445);
travail d’un prestataire de services dont les services cor-
respondent aux tâches du personnel visé par un des titres b) infirmier ou infirmière auxiliaire (3455);
d’emploi suivants, prévus à la Nomenclature des titres
d’emploi, des libellés, des taux et des échelles de salaire 4° 41,96 $, pour les titres d’emploi suivants du regrou-
du réseau de la santé et des services sociaux : pement des titres d’emploi de préposé ou préposée
aux bénéficiaires :
1° 74,36 $, pour les titres d’emploi suivants du regrou-
pement des titres d’emploi d’infirmier clinicien ou a) préposé ou préposée (certifié A) aux bénéfi-
d’infirmière clinicienne : ciaires (3459);
a) infirmier clinicien ou infirmière clinicienne b) préposé ou préposée aux bénéficiaires (3480);
(Institut Pinel) (1907);
c) pré p osé ou pré p osé e e n ét abl is se me nt
b) infirmier clinicien ou infirmière clinicienne (1911); nordique (3505);

5° 32,08 $, pour le titre d’emploi auxiliaire aux services 2° leurs frais de déplacement par un autre moyen de
de santé et sociaux (3588); transport qu’une automobile;
6° 80,00 $, pour les titres d’emploi suivants du regrou- 3° leurs frais d’hébergement;
pement des titres d’emploi d’inhalothérapeute :
4° leurs frais de repas, incluant le pourboire, à raison
a) inhalothérapeute (2244); de 10,40 $ par déjeuner, 14,30 $ par dîner et 21,55 $
par souper;
b) coordonnateur ou coordonnatrice technique
(inhalothérapie) (2246); Que, nonobstant le vingt-et-unième alinéa, soit consi-
déré comme des heures régulières de travail le temps
c) chargé ou chargée de l’enseignement clinique de déplacement des prestataires de services dont le
(inhalothérapie) (2247); lieu de travail est situé dans l’une des régions visées au
vingt-deuxième alinéa;
d) assistant-chef inhalothérapeute ou assistante-chef
inhalothérapeute (2248); Qu’il soit interdit à tout prestataire de services et à
toute agence de placement de personnel de réclamer ou de
Qu e les taux horaires prévus à l’alinéa précédent recevoir par journée de travail d’un prestataire de services
soient majorés de 20 % si le lieu de travail du pres- visé au vingt-et-unième alinéa un paiement ou une autre
tataire de services est situé dans l’une des régions rétribution, sous quelque forme que ce soit, d’une valeur
sociosanitaires suivantes : excédant la tarification horaire fixée aux vingt-et-unième
et vingt-deuxième alinéas;
1° l’Abitibi-Témiscamingue;
Que tout contrat de services en vigueur le 15 mai 2020
2° le Bas-Saint-Laurent; conclu par un organisme du secteur de la santé et des
services sociaux pour obtenir les services d’un presta-
3° la Côte-Nord; taire de services ne puisse être modifié pour augmenter
la tarification qui est prévue à ce contrat lorsque celle-ci
4° le Nord-du-Québec; est inférieure à la tarification maximale permise par le
présent arrêté;
5° la Gaspésie—Îles-de-la-Madeleine;
Qu’il soit interdit à quiconque d’embaucher une per-
6° le Nunavik; sonne ayant un lien d’emploi avec un organisme du secteur
de la santé et des services sociaux, un ministère ou un
7° les Terres-Cries-de-la-Baie-James; organisme du gouvernement du Québec visé à l’annexe C
de la Loi sur le régime de négociation des conventions
Que toute stipulation d’un contrat prévoyant un paie- collectives dans les secteurs public et parapublic (chapitre
ment ou une autre rétribution, sous quelque forme que R-8.2), un centre de services scolaire, une commission
ce soit, d’une valeur excédant la tarification fixée au scolaire, un collège institué en vertu de la Loi sur les
vingt-et-unième ou au vingt-deuxième alinéa soit collèges d’enseignement général et professionnel (chapitre
sans effet; C-29) ou une université afin que cette personne agisse par
la suite comme prestataire de services dans le cadre d’un
Que, nonobstant le vingt-et-unième alinéa, les presta- contrat de services conclu avec un organisme du secteur
taires de services affectés au service du soutien à domicile de la santé et des services sociaux;
puissent recevoir une compensation maximale de 0,48 $
par kilomètre parcouru dans le cadre de leurs déplace- Qu’il soit également interdit à quiconque d’embaucher
ments visant à dispenser des services à des usagers; une personne qui reçoit une subvention d’un établissement
de santé et de services sociaux, du ministre de la Santé
Que, nonobstant le vingt-et-unième alinéa, les presta- et des Services sociaux ou d’un organisme sous sa res-
taires de services affectés dans un lieu de travail situé dans ponsabilité, ou une personne ayant un lien d’emploi avec
l’une des régions visées au vingt-deuxième alinéa puissent une telle personne afin qu’elle agisse par la suite comme
recevoir un remboursement, sur présentation des pièces prestataire de services dans le cadre d’un contrat de ser-
justificatives, des frais encourus suivants, selon le cas : vices conclu avec un organisme du secteur de la santé et
des services sociaux;
1° leurs frais de déplacement en automobile, au taux
maximum de 0,48 $ par kilomètre parcouru entre la rési-
dence du prestataire de services et son lieu de travail;

AR02733
Qu’un organisme du secteur de la santé et des services Qu’il soit interdit à tout établissement public ou éta-
sociaux puisse mettre fin à tout contrat de services conclu blissement privé conventionné au sens de la Loi sur les
pour obtenir les services d’un prestataire de services pen- services de santé et les services sociaux (chapitre S-4.2) ou
dant l’état d’urgence sanitaire pour pouvoir procéder à de la Loi sur les services de santé et les services sociaux
l’embauche de la personne concernée, notamment à titre pour les autochtones cris (chapitre S-5) de déplacer une
de personne salariée temporaire, et ce, sans pénalité ou personne salariée afin de libérer un quart de travail pour
autre réparation ou indemnité pour l’organisme et le pres- répondre aux disponibilités d’un prestataire de services;
tataire de services;
Qu’il soit interdit aux agences de placement de person-
Qu’il soit interdit à tout prestataire de services et à toute nel de faire valoir tout engagement de non-concurrence ou
agence de placement de personnel : toute convention ayant des effets similaires, notamment en
réclamant des pénalités, des réparations ou des indemni-
1° de fournir à un organisme du secteur de la santé et tés, ou d’exercer toute mesure de représailles à l’encontre
des services sociaux les services d’un prestataire de ser- de toute personne qui souhaite être embauchée par un
vices qui a ou a eu un lien d’emploi avec un tel organisme organisme du secteur de la santé et des services sociaux;
dans les 90 jours précédant le début de son affectation;
Qu’il soit interdit à quiconque, à l’exception d’un
2° de fournir à un organisme du secteur de la santé organisme du secteur de la santé et des services sociaux,
et des services sociaux les services d’un prestataire de d’embaucher une infirmière, un infirmier, un inhalothéra-
services pour une affectation d’une durée inférieure peute, une infirmière auxiliaire ou un infirmier auxiliaire
à 14 jours; qui a ou a eu un lien d’emploi avec un tel organisme dans
les 90 jours précédents, aux fins de l’administration par
3° de fournir à un organisme du secteur de la santé une telle personne du vaccin contre la COVID-19;
et des services sociaux les services d’un prestataire de
services qui est déjà affecté au sein d’un autre organisme Qu’il soit interdit à toute agence de placement de per-
du secteur de la santé et des services sociaux; sonnel de fournir à quiconque les services d’un profes-
sionnel visé à l’alinéa précédent qui a ou a eu un lien
Qu e les paragraphes 2° et 3° de l’alinéa précédent d’emploi avec un tel organisme dans les 90 jours précé-
ne s’appliquent pas aux prestataires de services dont le dents aux fins de l’administration par une telle personne
lieu de travail est situé dans l’une des régions visées au du vaccin contre la COVID-19;
vingt-deuxième alinéa;
Qu e les vingt-et-unième, vingt-deuxième, vingt-
Qu e tout prestataire de services dont les services ne t roisième, v i ng t- qu at r ième, v i ng t- ci nqu ième,
sont pas offerts par l’entremise d’une agence de place- vingt-septième, vingt-huitième, vingt-neuvième,
ment et toute agence de placement de personnel soit tenu trentième, trente-deuxième, trente-quatrième et trente-
de fournir à tout organisme du secteur de la santé et des cinquième alinéas ne s’appliquent pas à l’égard d’un pres-
services sociaux, une déclaration assermentée signée par tataire de services affecté avant le 17 avril 2021 au sein
lui, ou selon le cas, par l’un de ses dirigeants, attestant que d’un organisme du secteur de la santé et des services
le prestataire de services dont il offre les services n’a pas sociaux situé dans l’une des régions sociosanitaires visées
ou n’a pas eu de lien d’emploi avec un organisme du sec- au vingt-deuxième alinéa;
teur de la santé et des services sociaux dans les 90 jours
précédant le début de son affectation et que le prestataire Qu e les vingt-et-unième, vingt-deuxième, vingt-
de services n’est pas affecté, au même moment, au sein troisième, vingt-quatrième, vingt-cinquième et vingt-
d’un autre organisme du secteur de la santé et de services septième alinéas ne s’appliquent pas :
sociaux. Une telle déclaration assermentée peut viser plu-
sieurs personnes affectées au sein du même organisme; 1° aux contrats conclus avant le 13 mars 2020 entre
une agence de placement de personnel et le Centre
Qu e les trente-deuxième et trente-quatrième alinéas d’acquisitions gouvernementales qui a acquis les droits et
du présent arrêté ne s’appliquent pas à la fourniture de obligations des groupes d’approvisionnement en commun
services correspondant aux tâches du personnel visé par reconnus par le ministre de la Santé et des Services, même
le titre d’emploi de surveillant d’établissement (6422) ou s’ils ont été modifiés ou renouvelés depuis cette date;
de gardien ou gardienne (6438), prévu à la Nomenclature
des titres d’emploi, des libellés, des taux et des échelles 2° aux contrats de gré à gré du Centre d’acquisitions
de salaire du réseau de la santé et des services sociaux; gouvernementales conclus pour le compte du ministre
de la Santé et des services sociaux ou d’un établissement

de santé et de services sociaux qui prévoit la poursuite b) a participé à l’étude clinique menée par Medicago
de la prestation de services des contrats visés au para- inc. visant à valider la sécurité ou l’efficacité d’un
graphe 1°, et ce, dans le respect des conditions prévues au candidat-vaccin contre la COVID-19;
troisième tiret du troisième alinéa du dispositif du décret
numéro 177-2020 du 13 mars 2020, tel qu’il se lisait lors de 3° on entende par « intervenant du secteur de la santé
son abrogation par l’arrêté numéro 2022-023 du 23 mars et des services sociaux » :
2022, et à la condition que ces contrats de gré à gré :
a) les personnes qui sont embauchées ou qui com-
a) soient d’une durée maximale d’un an; mencent à exercer leur profession pour un établissement
de santé et de services sociaux;
b) soient conclus avec une agence de placement de per-
sonnel qui, à la date de la conclusion de ce contrat, détient b) les personnes suivantes qui ont des contacts phy-
une autorisation de contracter délivrée par l’Autorité des siques directs avec des personnes à qui sont offerts des
marchés publics; services de santé et des services sociaux ou qui ont
c) prévoient que les autres termes et conditions, dont offrent de tels services notamment en raison du partage
la tarification, seront identiques à ceux prévus au contrat d’espaces communs :
visé au paragraphe 1°;
i. des élèves, des étudiants et des stagiaires;
Qu’aux fins du quarante-troisième au cinquante-
troisième alinéa : ii. des bénévoles;
1° on considère « adéquatement protégée contre la iii. des sous-contractants ne fournissant pas de soins
COVID-19 », une personne qui, selon le cas : aux usagers ou aux résidents des milieux visés, à l’excep-
tion de ceux agissant dans un contexte d’urgence;
a) a reçu deux doses de l’un ou l’autre d’un vaccin à
ARNm de Moderna ou de Pfizer BioNTech ou du vaccin Que soient tenus d’être adéquatement protégés :
AstraZeneca/ COVIDSHIELD, avec un intervalle mini-
mal de 21 jours entre les doses et dont la dernière dose a 1° les intervenants du secteur de la santé et des services
été reçue depuis sept jours ou plus; sociaux visés au sous-paragraphe a du paragraphe 3° du
quarante-deuxième alinéa;
b) a contracté la COVID-19 et a reçu, depuis sept jours
ou plus, une dose de l’un ou l’autre des vaccins visés au 2° les intervenants du secteur de la santé et des ser-
sous-paragraphe a avec un intervalle minimal de 21 jours vices sociaux visés au sous-paragraphe b du paragraphe 3°
après la maladie; du quarante-deuxième alinéa qui agissent dans les
milieux suivants :
c) a reçu une dose du vaccin Janssen depuis au moins
14 jours; a) une installation maintenue par un établissement de
d) a reçu deux doses d’un vaccin contre la COVID-19,
dont l’un est un vaccin reçu à l’extérieur du Canada, autre b) une ressource intermédiaire non visée par la
que ceux visés aux sous-paragraphes a et c et l’autre un Loi sur la représentation des ressources de type familial
vaccin à ARNm de Moderna ou de Pfizer BioNTech, avec et de certaines ressources intermédiaires et sur le régime
un intervalle minimal de 21 jours entre les doses et dont la de négociation d’une entente collective les concernant
dernière dose a été reçue depuis sept jours ou plus; (chapitre R-24.0.2);
2° soit également assimilée à une personne adéqua- c) une résidence privée pour aînés, à l’exception de
tement protégée contre la COVID-19 une personne qui, celles de neuf places et moins;
selon le cas :
Que, pour l’application du sous-paragraphe a du para-
a) présente une contre-indication à la vaccination graphe 2° de l’alinéa précédent, tout lieu autre qu’une
contre cette maladie attestée par un professionnel de la installation maintenue par un établissement de santé et
santé habilité à poser un diagnostic et qui est inscrite au de services sociaux où sont offerts des services par un tel
registre de vaccination maintenu par le ministre de la établissement soit assimilé à une telle installation, mais
Santé et des Services sociaux; uniquement en ce qui concerne les intervenants qui four-

AR02735
Qu’un intervenant du secteur de la santé et des ser- Qu’un établissement de santé et de services sociaux
vices sociaux visé au quarante-troisième alinéa soit tenu puisse transmettre au ministre une liste d’intervenants
de transmettre une preuve qu’il est adéquatement protégé du secteur de la santé et des services sociaux qui agissent
contre la COVID-19, selon le cas, à l’établissement de dans les installations qu’il maintient pour lesquels il sou-
santé et de services sociaux où il souhaite être embauché haite vérifier s’ils sont adéquatement protégés;
ou commencer à exercer sa profession, à l’exploitant du
milieu où il exerce ou, dans le cas d’un élève, d’un étudiant Qu e toute personne, société ou organisme ne puisse
ou d’un stagiaire, à son établissement d’enseignement; imposer aucune pénalité ou exiger aucune indemnité ou
autre réparation pour le motif qu’une personne, en raison
Qu e la transmission de la preuve exigée en vertu de de l’application du présent arrêté, a refusé à une personne
l’alinéa précédent s’effectue le plus rapidement possible à l’accès à un endroit, a mis fin à un contrat ou a eu recours
compter du moment où cette preuve est disponible; à une autre personne, une autre société ou un autre orga-
nisme pour la remplacer;
ou l’exploitant d’un milieu visé par le paragraphe 2° du Qu’aux fins du cinquante-cinquième au soixante-
quarante-troisième alinéa soit tenu de vérifier que neuvième alinéa, on entende par « intervenant de la santé
tout intervenant du secteur de la santé et des services et des services sociaux » une personne travaillant ou exer-
sociaux qui doit être adéquatement protégé contre la çant sa profession pour :
COVID-19 l’est;
1° un établissement de santé et de services sociaux;
vices sociaux devant être adéquatement protégé contre la 2° une ressource intermédiaire non visée par la
COVID-19 qui n’en a pas fourni la preuve à l’exploitant Loi sur la représentation des ressources de type familial
d’un milieu visé au quarante-troisième alinéa ne puisse et de certaines ressources intermédiaires et sur le régime
intégrer ou réintégrer ce milieu; de négociation d’une entente collective les concernant;
Qu’un intervenant du secteur de la santé et des services 3° une résidence privée pour aînés à l’exception de
sociaux qui ne peut réintégrer un milieu en application de celle de neuf places et moins;
l’alinéa précédent ne reçoive, selon le cas, aucune rémuné-
ration, bénéfice, honoraire ou autre forme de compensa- 4° une maison de soins palliatifs au sens du para-
tion, à moins que, à la discrétion de son employeur, il n’ait graphe 2° de l’article 3 de la Loi concernant les soins de
été réaffecté à d’autres tâches, visées à son titre d’emploi, fin de vie (chapitre S-32.0001);
le cas échéant, qui ne nécessitent pas d’être adéquatement
protégé contre la COVID-19; 5° une institution religieuse qui maintient une instal-
Qu e l’exploitant d’une ressource intermédiaire non recevoir ses membres ou ses adhérents;
visée par la Loi sur la représentation des ressources de
type familial et de certaines ressources intermédiaires 6° un centre médical spécialisé au sens de l’article 333.1
et sur le régime de négociation d’une entente collective de la Loi sur les services de santé et les services sociaux;
les concernant transmette à l’établissement de santé et de
services sociaux avec lequel il a conclu une entente, une 7° un laboratoire d’imagerie médicale au sens 30.1 de
attestation indiquant que les intervenants du secteur de la la Loi sur les laboratoires médicaux et sur la conservation
santé et des services sociaux qui sont tenus d’être adéqua- des organes et des tissus (chapitre L-0.2);
tement protégés contre la COVID-19 le sont;
8° la Corporation d’Urgences-santé;
Que lorsque l’exploitant d’une ressource intermédiaire
non visée par la Loi sur la représentation des ressources 9° les titulaires de per mis d’exploitation de
de type familial et de certaines ressources intermédiaires services ambulanciers;
et sur le régime de négociation d’une entente collective les
concernant ne transmet pas l’attestation prévue à l’alinéa 10° Héma-Québec;
précédent, l’établissement de santé et de services sociaux
avec lequel cette ressource a conclu une entente cesse de 11° l’Institut national de santé publique du Québec;
la rétribuer et puisse déplacer les usagers qui y sont pris
en charge vers un autre milieu de vie; 12° le ministère des Transports, mais dans ce cas uni-
quement pour le Service aérien gouvernemental;

Qu’un sous-contractant fournissant des soins aux 7° s’il a contracté la COVID-19 depuis moins
usagers ou aux résidents des milieux visés au cinquante- de 60 jours;
quatrième alinéa soit assimilé à un intervenant de santé
et de services sociaux; 8° s’il a reçu deux doses d’un vaccin contre la
COVID-19, dont l’un est un vaccin reçu à l’extérieur du
Qu e pour les paragraphes 8° à 12° du cinquante- Canada, autre que ceux visés aux paragraphes 1° et 3°,
quatrième alinéa soient uniquement visés par les et l’autre un vaccin à ARNm de Moderna ou de Pfizer-
cinquante-huitième, cinquante-neuvième, soixantième, BioNTech, avec un intervalle minimal de 21 jours entre
soixante-et-unième, soixante-deuxième, soixante- les doses et dont la dernière dose a été reçue depuis
troisième, soixante-quatrième, soixante-cinquième, 7 jours ou plus;
soixante-sixième, soixante-septième et soixante-huitième
alinéas les intervenants ayant des contacts physiques 9° s’il travaille exclusivement en télétravail à partir
directs avec des personnes à qui sont offerts des services de son domicile;
de santé et des services sociaux;
Que les enseignants exerçant dans un centre de réadap- soit tenu de fournir à l’exploitant du milieu ou au respon-
tation pour les jeunes en difficulté d’adaptation exploité sable de son organisation la preuve qu’il a reçu le ou les
par un établissement de santé et de services sociaux ne vaccins mentionnés à l’alinéa précédent, le cas échéant,
soient pas visés par les cinquante-huitième, cinquante- ou qu’il répond aux conditions mentionnées aux para-
neuvième, soixantième, soixante-et-unième, soixante- graphes 5°, 6° ou 7° de cet alinéa;
deuxième, soixante-troisième, soixante-quatrième,
soixante-cinquième, soixante-sixième, soixante-septième Qu’un établissement de santé et de services sociaux
et soixante-huitième alinéas; puisse transmettre au ministre une liste d’intervenants
de la santé et des services sociaux travaillant ou exerçant
Qu’un intervenant de la santé et des services sociaux dans les installations qu’il maintient pour lesquels il sou-
soit tenu de passer des tests de dépistage de la COVID-19, haite vérifier s’ils sont adéquatement protégés;
conformément aux modalités des soixante-et-unième,
soixante-deuxième, soixante-troisième et soixante- Qu’un intervenant de la santé et des services sociaux
quatrième alinéas, sauf : tenu de passer un test de dépistage de la COVID-19 en
application du cinquante-huitième alinéa doive passer un
1° s’il a reçu deux doses de l’un ou l’autre d’un vaccin minimum de trois tests par semaine, effectués par un pro-
à ARNm de Moderna ou de Pfizer-BioNTech ou du vaccin fessionnel autorisé, et en fournir les résultats à l’exploitant
AstraZeneca/ COVIDSHIELD, avec un intervalle mini- du milieu ou au responsable de son organisation;
mal de 21 jours entre les doses et dont la dernière dose a
été reçue depuis au moins sept jours; Qu e malgré l’alinéa précédent, un intervenant de
la santé et des services sociaux qui travaille moins de
2° s’il a contracté la COVID-19 et a reçu, depuis trois jours par semaine soit tenu de passer un nombre
sept jours ou plus, une dose de l’un ou l’autre des vaccins minimum de test de dépistage de la COVID-19 équiva-
visés au paragraphe 1° avec un intervalle minimal de lent au nombre de jours où il est présent dans le milieu ou
21 jours après la maladie; travaille pour son organisation;
3° s’il a reçu une dose du vaccin Janssen depuis au Qu’un intervenant de la santé et des services sociaux
moins 14 jours; visé au soixante-et-unième ou soixante-deuxième alinéa
doive passer les tests de dépistage en dehors de ses heures
4° s’il a reçu une dose d’un vaccin mentionné au de travail et qu’il ne reçoive aucune rémunération ni rem-
paragraphe 1° depuis au moins 7 jours et depuis moins boursement de frais en lien avec de tels tests;
de 60 jours;
5° s’il présente une contre-indication à la vaccination qui refuse ou omet de fournir la preuve visée au cinquante-
contre cette maladie attestée par un professionnel de la neuvième alinéa, de passer un test de dépistage de la
santé habilité à poser un diagnostic et qui est inscrite au COVID-19 obligatoire en application du cinquante-
registre de vaccination maintenu par le ministre de la huitième alinéa ou de fournir les résultats d’un test confor-
Santé et des Services sociaux; mément au soixante-et-unième alinéa ne puisse être réaf-
fecté ni être en télétravail et que son absence constitue une
6° s’il a par ticipé à l’étude clinique menée absence non autorisée sans perte d’ancienneté;
par Medicago inc. visant à valider la sécurité ou l’efficacité
d’un candidat-vaccin contre la COVID-19;

AR02737
Que les privilèges d’un médecin, d’un pharmacien ou de services sociaux qui assume des responsabilités hiérar-
d’un dentiste refusant ou omettant de passer un test de chiques, fonctionnelles ou conseil auprès des personnes
dépistage de la COVID-19 obligatoire en application du salariées et qui appartient à l’un des titres de familles
cinquante-huitième alinéa soient suspendus; d’emploi suivants :
Qu e toute personne qui fournit des services dans le a) chef d’unité dans un groupe de médecine de famille
cadre de la modalité de soutien à domicile allocation ou dans un groupe de médecine de famille universitaire;
entreprise d’économie sociale en aide à domicile soit tenue b) coordonnateur ou chef d’activités à la direction des
de transmettre, sur demande de la personne à qui elle services professionnels (gestion des lits, continuum de
fournit les services, la preuve qu’elle a reçu le ou les vac- soins, gestion des séjours);
cins mentionnés au cinquante-huitième alinéa ou qu’elle
répond aux conditions mentionnées aux paragraphes 5°, c) coordonnateur à la direction des soins infirmiers;
6° ou 7° de cet alinéa ou le résultat d’un test de dépistage
de la COVID-19 effectué depuis moins de 72 heures; d) chef de service, de programme, d’unité, d’activités
à la direction des soins infirmiers;
Qu e toute personne qui fournit des services dans le
cadre de la modalité de soutien à domicile allocation e) chef de secteur à la direction des soins infirmiers;
entreprise d’économie sociale en aide à domicile et qui ne f) conseiller cadre à la direction des soins infirmiers;
transmet pas les preuves qui lui sont demandées en appli-
cation de l’alinéa précédent ne puisse offrir des services à g) coordonnateur ou chef d’activités à la direction des
la personne lui en ayant fait la demande; soins infirmiers (soir, nuit, fds et fériés/hébergement);
Qu’un intervenant de la santé et des services sociaux h) adjoi nt h iéra rch ique à la di rect ion des
qui est tenu de passer des tests de dépistage de la soins infirmiers;
COVID-19 en vertu du cinquante-huitième alinéa ne
puisse bénéficier des primes, montants forfaitaires, i) coordonnateur des services d’inhalothérapie;
allocations ou compensations financières prévus au
présent arrêté; j) chef de service en inhalothérapie;
Qu’un intervenant de la santé et des services sociaux k) gestionnaire responsable d’un centre d’hébergement
qui est exempté de passer un test de dépistage de la de soins de longue durée;
COVID-19 uniquement en application du paragraphe 9°
du cinquante-huitième alinéa ne puisse bénéficier des l) chef d’unité en hébergement dans un centre d’héber-
primes, montants forfaitaires, allocations ou compensa- gement de soins de longue durée;
tions financières visés à l’alinéa précédent;
m) chef dans une unité en périnatalité, en néonatologie
Qu’aux fins du soixante-et-onzième alinéa au ou en pédiatrie, dans un centre hospitalier de soins géné-
cent-vingt-sixième alinéa, on entende par : raux et spécialisés;
1° « établissement » un établissement public ou privé n) chef de programme Info-Santé;
conventionné au sens de la Loi sur les services de santé et
les services sociaux ou de la Loi sur les services de santé o) chef d’unité dans un centre hospitalier psychiatrique;
et les services sociaux pour les autochtones cris;
p) coordonnateur d’activités d’établissements;
2° « personne salariée » une personne salariée d’un éta-
blissement dont le titre d’emploi fait partie de la catégorie Qu’une personne salariée reçoive, pour chaque quart de
du personnel en soins infirmiers et cardio-respiratoires, travail effectivement travaillé durant une fin de semaine
tel que prévu à la Nomenclature des titres d’emploi, des en sus des quarts de travail prévus à son horaire, un
libellés, des taux et des échelles de salaire du réseau de la montant de :
santé et des services sociaux, à l’exception des externes en
soins infirmiers et des externes en inhalothérapie; 1° 200 $ si elle travaille dans une installation mainte-
nue par un établissement située dans une région sociosa-
3° « cadre » un cadre au sens de l’article 3 du nitaire visée à l’annexe III;
Règlement sur certaines conditions de travail applicables

2° 400 $ si elle travaille dans une installation mainte- 1° 5 000 $ si elle travaille dans une installation main-
nue par un établissement située dans une région sociosa- tenue par un établissement située dans une région socio-
nitaire visée à l’annexe IV; sanitaire visée à l’annexe III;
Qu e pour recevoir le montant forfaitaire prévu à 2° 8 000 $ si elle travaille dans une installation main-
l’alinéa précédent, la personne salariée soit tenue d’être tenue par un établissement située dans une région socio-
présente au travail, selon son horaire, au cours des sanitaire visée à l’annexe IV;
sept jours précédant et suivant le quart de travail effecti-
vement travaillé durant la fin de semaine; Qu e la personne salariée qui travaillait pour un éta-
blissement en date du 23 septembre 2021 et qui déménage
Qu’aux fins de l’admissibilité aux montants forfai- avant le 31 mars 2022, puisse s’engager auprès d’un autre
taires prévus au soixante-et-onzième alinéa, soit répu- établissement à y travailler à temps complet pour une
tée présente au travail la personne salariée qui bénéficie durée minimale d’une année et qu’elle puisse recevoir le
d’un congé férié, d’une libération syndicale ou, le cas montant forfaitaire visé à l’alinéa précédent;
échéant, de la conversion de la prime de soir ou de nuit en
temps chômé; Qu e la personne visée au soixante-dix-huitième, au
soixante-dix-neuvième ou au quatre-vingtième alinéa
Que toute personne salariée qui a un horaire de jour et reçoive un montant forfaitaire de 10 000 $ à la fin de la
qui s’engage, pour une durée de quatre semaines consécu- période prévue à son engagement, en autant que ce dernier
tives, à plutôt travailler à temps complet de soir ou de nuit ait été respecté;
reçoive, à la fin de cette période, un montant forfaitaire
de 2 000 $; Qu e toute personne salariée qui a un statut de per-
sonne salariée à temps complet sans travailler le nombre
Qu e l’alinéa précédent s’applique également à toute d’heures prévu à la Nomenclature des titres d’emploi, des
personne salariée qui a un poste ou une affectation avec libellés, des taux et des échelles de salaire du réseau de
des quarts de rotation et qui accepte de travailler unique- la santé et des services sociaux parce qu’elle bénéficie
ment de soir ou de nuit; d’un aménagement d’horaire avec réduction du temps de
travail qui s’engage auprès d’un établissement à travailler
Qu e, pour recevoir la somme prévue au soixante- selon l’horaire convenu pour une durée minimale d’une
quatorzième alinéa, la personne salariée soit tenue d’être année reçoive au maximum 60 % des montants forfaitaires
présente au travail, selon son horaire, pour toute la visés aux soixante-dix-neuvième, quatre-vingtième ou
période visée; quatre-vingt-unième alinéas;
Qu e, pour les fins de l’alinéa précédent, soit réputée Que toute personne salariée qui s’engage auprès d’un
être présente au travail la personne salariée qui bénéficie établissement à y travailler à temps partiel au moins
d’un congé férié; 9 jours par période de 14 jours pour une durée minimale
d’une année reçoive au maximum 50 % des montants
Que toute personne qui ne travaillait pas pour un éta- forfaitaires visés aux soixante-dix-huitième, soixante-
blissement en date du 23 septembre 2021 et qui s’engage dix-neuvième, quatre-vingtième ou quatre-vingt-
à travailler à titre de personne salariée pour un établis- unième alinéas;
sement à temps complet pour une durée minimale d’une
année reçoive, lors de son entrée en fonction, un montant Que toute personne salariée demeure admissible aux
forfaitaire de : montants forfaitaires prévus aux soixante-dix-huitième,
soixante-dix-neuvième, quatre-vingtième et quatre-vingt-
1° 2 000 $ si elle travaille dans une installation main- unième alinéas lorsqu’elle bénéficie d’un congé sans solde
tenue par un établissement située dans une région socio- pour enseigner à condition qu’elle travaille pour l’établis-
sanitaire visée à l’annexe III; sement un minimum de 7 jours par période de 14 jours et
qu’auquel cas elle reçoive, au maximum les pourcentages
2° 5 000 $ si elle travaille dans une installation main- suivants de ces montants forfaitaires :
tenue par un établissement située dans une région socio-
sanitaire visée à l’annexe IV; 1° 70 % lorsqu’elle travaille 7 jours par période de
14 jours;
Que toute personne salariée qui travaillait pour un éta-
blissement en date du 23 septembre 2021 et qui s’engage 2° 80 % lorsqu’elle travaille 8 jours par période de
auprès de cet établissement à y travailler à temps complet 14 jours;
pour une durée minimale d’une année reçoive, lors de la
signature de son engagement, un montant forfaitaire de :

AR02739
3° 90 % lorsqu’elle travaille 9 jours par période de des heures régulières effectivement travaillées au cours de
14 jours; l’année, si elle travaille à temps partiel ou s’il y a rupture
du lien d’emploi avant la fin de son engagement;
Que l’alinéa précédent s’applique uniquement à une
personne salariée qui respecte les conditions suivantes : Que, pour l’application des quatre-vingt-neuvième et
quatre-vingt-dixième alinéas, soit assimilées à des heures
1° l’enseignement est en lien direct avec les domaines régulières effectivement travaillées les congés annuels,
d’exercice des personnes salariées appartenant à la les congés mobiles, les congés fériés ainsi que, sauf pour
catégorie du personnel en soins infirmiers et cardio- les personnes retraitées embauchées, un maximum de
respiratoires, tel que prévu à la Nomenclature des titres 10 jours de toute autre absence autorisée;
du réseau de la santé et des services sociaux; Qu e la personne retraitée qui s’engage à travailler
pour un établissement en application du soixante-dix-
2° elle travaille l’équivalent d’un temps complet huitième, soixante-dix-neuvième, quatre-vingtième ou
lorsque sa prestation de travail dans l’établissement est quatre-vingt-unième alinéa puisse recevoir, à la fin de la
additionnée à ses charges de cours; période prévue à son engagement, en autant que ce der-
nier ait été respecté, un remboursement des frais, jusqu’à
Que, pour être admissible à recevoir les montants concurrence de la somme habituellement exigée pour une
forfaitaires visés aux soixante-dix-huitième, soixante- année d’exercice, qu’elle a déboursés pour obtenir le droit
dix-neuvième, quatre-vingtième, quatre-vingt-unième, d’exercer les activités professionnelles nécessaires, selon
quatre-vingt-deuxième et quatre-vingt-troisième alinéas, les exigences de la Nomenclature des titres d’emploi, des
la personne salariée doive avoir signé son engagement au libellés, des taux et des échelles de salaire du réseau de la
plus tard le 31 mars 2022 et être disponible à travailler santé et des services sociaux;
selon le nombre de jours de travail par semaine prévus à
son engagement à cette date; Que toute personne travaillant pour un établissement,
à l’exception d’un médecin, qui lui réfère une personne
Qu’une personne salariée en congé de maternité, de salariée qui n’est pas à l’emploi d’un établissement pour
paternité, d’adoption ou parental puisse signer son enga- qu’elle y soit embauchée à titre de personne salariée
gement après le 31 mars 2022 pour une durée ne pouvant reçoive une prime de référencement de 500 $ si cette per-
excéder le 31 mars 2023, en autant qu’elle soit disponible sonne réussit sa période de probation et complète au moins
à travailler à temps complet ou 9 jours par période de six mois de service au sein de cet établissement;
14 jours, dans le cas d’une personne salariée à temps
partiel, à la date de son retour au travail et qu’alors elle Qu’aux fins de l’application de l’alinéa précédent, un
reçoive, selon le cas, les montants forfaitaires visés au stagiaire soit réputé être à l’emploi d’un établissement;
soixante-dix-huitième, soixante-dix-neuvième ou au
quatre-vingt-unième, quatre-vingt-deuxième et quatre- Que toute personne salariée travaillant dans une ins-
vingt-troisième alinéas en un seul versement, à la fin de tallation maintenue par un établissement située dans une
son engagement, en autant que ce dernier ait été respecté; région sociosanitaire visée à l’annexe III qui s’engage à
travailler à temps complet pour une installation maintenue
Qu e les personnes salariées visées aux soixante- par un établissement située dans une région sociosanitaire
dix-huitième, soixante-dix-neuvième ou quatre- visée à l’annexe IV pour une période d’au moins quatre
vingtième alinéas puissent se prévaloir de la conversion mois consécutifs reçoive, lors de la signature de son enga-
de la prime de soir ou de nuit en temps chômé; gement, un montant forfaitaire de 1 000 $;
Que les montants forfaitaires mentionnés aux soixante- Qu e la personne salariée visée à l’alinéa précédent
dix-huitième, soixante-dix-neuvième, quatre-vingtième, reçoive un montant forfaitaire de 3 000 $ à la fin de la
quatre-vingt-unième, quatre-vingt-deuxième et quatre- période prévue à son engagement, en autant que ce dernier
vingt-troisième alinéas soient payés au prorata des heures ait été respecté;
régulières effectivement travaillées;
Qu e toute personne salariée qui a un statut à temps
Qu e, malgré ce que prévoient les soixante-dix- complet sans travailler le nombre d’heures prévu à la
huitième, soixante-dix-neuvième, quatre-vingtième, Nomenclature des titres d’emploi, des libellés, des taux
quatre-vingt-unième, quatre-vingt-deuxième et quatre- et des échelles de salaire du réseau de la santé et des ser-
vingt-troisième alinéas, la personne retraitée embauchée vices sociaux parce qu’elle bénéficie d’un aménagement
soit tout de même admissible aux montants forfaitaires d’horaire avec réduction du temps de travail et qui
visés à ces alinéas et que ceux-ci soient payés au prorata travaille dans une installation maintenue par un

établissement située dans une région sociosanitaire visée à c) elle ne respecte pas l’engagement convenu;
l’annexe III, qui s’engage, pour une période d’au moins
quatre mois consécutifs, à travailler selon l’horaire Que, pour les fins du calcul du nombre de jours prévu
convenu dans une installation maintenue par un éta- au sous-paragraphe b du paragraphe 2° de l’alinéa pré-
blissement située dans une région sociosanitaire visée cédent, ne soient pas considérés, les absences autorisées
à l’annexe IV, reçoive au maximum 60 % des mon- dans le cas d’une sortie prévue à la convention collective
tants forfaitaires visés aux quatre-vingt-quinzième et de la personne salariée qui travaille dans une installation
quatre-vingt-seizième alinéas; maintenue par un établissement située dans un secteur
visé à l’annexe V;
Que toute personne salariée travaillant dans une ins-
tallation maintenue par un établissement située dans une Que l’engagement de la personne salariée qui a signé un
région sociosanitaire visée à l’annexe III qui s’engage, engagement à travailler à temps complet pour une durée
pour une période d’au moins quatre mois consécutifs, à minimale d’une année dans une installation maintenue
travailler à temps partiel au moins 9 jours par période par un établissement située dans une région sociosani-
de 14 jours pour une installation maintenue par un éta- taire visée à l’annexe III et qui cesse volontairement de
blissement située dans une région sociosanitaire visée travailler pour cet établissement afin de travailler dans une
à l’annexe IV reçoive au maximum 50 % des mon- installation maintenue par un établissement située dans
tants forfaitaires visés aux quatre-vingt-quinzième et une région sociosanitaire visée à l’annexe IV soit réputé
quatre-vingt-seizième alinéas; conclu avec ce dernier établissement et que la personne
salariée reçoive les montants forfaitaires applicables à
Que les montants forfaitaires mentionnés aux quatre- chacune de ces régions au prorata du temps travaillé dans
vingt-quinzième, quatre-vingt-seizième, quatre-vingt-dix- chacune d’elles;
septième et quatre-vingt-dix-huitième alinéas soient payés
au prorata des heures régulières effectivement travaillées; Qu e la personne qui n’est pas domiciliée dans une
région visée à l’annexe IV, qui s’y installe pour travail-
Que, pour l’application de l’alinéa précédent, soit assi- ler à titre de personne salariée dans une installation d’un
milées à des heures régulières effectivement travaillées les établissement qui y est située et s’engage à travailler
congés annuels, les congés mobiles, les congés fériés ainsi dans cette installation à temps complet pour une durée
que, sauf pour les personnes retraitées embauchées, un minimale de deux ans reçoive un montant forfaitaire de
maximum de quatre jours de toute autre absence autorisée; 24 000 $ dont les versements sont répartis ainsi :
Que les conditions et modalités suivantes s’appliquent 1° 12 000 $ lors de l’entrée en fonction;
à l’égard des montants forfaitaires prévus aux soixante-
dix-huitième, soixante-dix-neuvième, quatre-vingtième, 2° 12 000 $ un an après l’entrée en fonction;
quatre-vingt-unième, quatre-vingt-deuxième, quatre-
vingt-troisième, quatre-vingt-quinzième, quatre-vingt- Que la personne visée à l’alinéa précédent soit tenue
seizième, quatre-vingt-dix-septième et quatre-vingt-dix- de rembourser tout montant reçu si elle ne respecte pas
huitième alinéas : son engagement;
1° tout montant reçu en trop par la personne salariée Qu e toute personne salariée qui a un statut de per-
doit être remboursé à l’établissement ou peut être com- sonne salariée à temps complet sans travailler le nombre
pensé par celui-ci; d’heures prévu à la Nomenclature des titres d’emploi, des
libellés, des taux et des échelles de salaire du réseau de
2° une personne salariée devient inadmissible aux la santé et des services sociaux parce qu’elle bénéficie
montants forfaitaires et doit rembourser tout versement d’un aménagement d’horaire avec réduction du temps de
reçu sans qu’aucun prorata n’y soit appliqué dans l’une travail qui s’engage auprès d’un établissement à y travail-
des situations suivantes : ler selon l’horaire convenu pour une durée minimale de
deux ans reçoive 60 % des montants forfaitaires visés au
a) elle s’est absentée sans que cette absence cent-quatrième alinéa;
soit autorisée;
Que toute personne salariée qui s’engage auprès d’un
b) elle prend plus de 10 jours de congés sans solde établissement à y travailler à temps partiel au moins
autorisés ou, pour les montants forfaitaires visés aux 9 jours par période de 14 jours pour une durée minimale
quatre-vingt-quinzième, quatre-vingt-seizième, quatre- de deux ans reçoive 50 % des montants forfaitaires visés
vingt-dix-septième et quatre-vingt-dix-huitième alinéas, au cent-quatrième alinéa;
plus de 4 jours de congés sans solde autorisés;

AR02741
Qu e la personne salariée visée au quatre-vingt- une durée minimale d’une année reçoive au maximum
quinzième alinéa puisse recevoir, pour chaque aller-retour 60 % des montants forfaitaires visés aux soixante-dix-
entre sa résidence et son lieu de travail, le remboursement neuvième ou quatre-vingt-unième alinéas;
des frais suivants :
Que toute personne qui exerce des fonctions équiva-
1° les frais de déplacement en automobile, au taux lentes à une personne salariée et qui s’engage auprès d’un
maximum de 0,48 $ par kilomètre parcouru entre sa rési- établissement ou d’une maison de soins palliatifs visé au
dence et son lieu de travail; cent-onzième alinéa à y travailler à temps partiel au moins
9 jours par période de 14 jours pour une durée minimale
2° les frais réels de déplacement par un autre moyen d’une année reçoive au maximum 50 % des montants for-
de transport qu’une automobile; faitaires visés aux soixante-dix-huitième, soixante-dix-
neuvième ou quatre-vingt-unième alinéas;
3° les frais d’hébergement encourus;
Qu’une personne qui exerce des fonctions équivalentes
4° le temps de déplacement; à une personne salariée pour un établissement ou une
maison de soins palliatifs visé au cent-onzième alinéa,
5° les frais de repas, incluant le pourboire, à raison qui est en congé de maternité, de paternité, d’adoption ou
de 10,40 $ par déjeuner, 14,30 $ par dîner et 21,55 $ parental puisse signer son engagement après le 31 mars
par souper; 2022 pour une durée ne pouvant excéder le 31 mars 2023,
en autant qu’elle soit disponible à travailler à temps com-
Que les montants prévus au paragraphe 5° de l’alinéa plet ou 9 jours par période de 14 jours, dans le cas d’une
précédent soient majorés : personne à temps partiel, à la date de son retour au tra-
vail et qu’alors elle reçoive, selon le cas, les montants
1° de 30 % si les repas sont pris dans un établisse- forfaitaires visés au soixante-dix-huitième, soixante-
ment commercial d’une municipalité située entre dix-neuvième ou quatre-vingt-unième alinéas en un seul
le 49ième et le 50ième parallèle, à l’exception de la muni- versement, à la fin de son engagement, en autant que ce
cipalité de Baie-Comeau et des municipalités de la dernier ait été respecté;
péninsule gaspésienne;
Qu e les mêmes modalités que celles prévues aux
2° de 50 % si les repas sont pris dans un établisse- quatre-vingt-sixième, quatre-vingt-huitième, quatre-
ment commercial d’une municipalité située au-delà du vingt-neuvième, quatre-vingt-dixième, quatre-vingt-
50 ième parallèle, à l’exception des municipalités de onzième et cent-unième alinéas s’appliquent à la personne
Port-Cartier et de Sept-Îles; visée aux cent-onzième, cent-douzième, cent-treizième ou
cent-quatorzième alinéas;
Qu’en raison de circonstances exceptionnelles, des frais
de repas supérieurs aux montants maximums prévus aux Qu e toute personne qui travaille pour une résidence
alinéas précédents puissent être remboursés par le diri- privée pour aînés ou une institution religieuse qui main-
geant de l’organisme public ou la personne qu’il désigne tient une installation d’hébergement et de soins de longue
si des explications jugées valables le justifie; durée pour y recevoir ses membres ou ses adhérents, qui y
exerce des fonctions équivalentes à une personne salariée
Que les montants forfaitaires prévus aux soixante-dix- et qui s’engage auprès de cette résidence à y travailler à
huitième, soixante-dix-neuvième et quatre-vingt-unième ce titre à temps complet pour une durée minimale d’une
alinéas s’appliquent, avec les adaptations nécessaires, à année reçoive, un montant forfaitaire de :
la personne qui travaille pour un établissement privé non
conventionné ou une maison de soins palliatifs au sens du 1° 2 500 $ lors de la signature de son engagement;
paragraphe 2° de l’article 3 de la Loi concernant les soins
de fin de vie et qui y exerce des fonctions équivalentes à 2° 5 000 $ à la fin de la période prévue à son engage-
une personne salariée; ment, en autant que ce dernier ait été respecté;
Que toute personne qui exerce des fonctions équiva- Que toute personne qui exerce des fonctions équiva-
lentes à une personne salariée, qui a un statut à temps lentes à une personne salariée, qui a un statut à temps
complet, qui bénéficie d’un aménagement d’horaire avec complet, qui bénéficie d’un aménagement d’horaire avec
réduction du temps de travail et qui s’engage auprès d’un réduction du temps de travail et qui s’engage auprès d’une
établissement ou d’une maison de soins palliatifs visé à résidence privée pour aînés ou d’une institution reli-
l’alinéa précédent à travailler selon l’horaire convenu pour gieuse visé à l’alinéa précédent à travailler selon l’horaire

convenu pour une durée minimale d’une année reçoive Qu’un cadre bénéficie d’une allocation temporaire de
au maximum 60 % des montants forfaitaires visés à 14 % applicable sur son salaire au sens de l’article 3 du
cet alinéa; Règlement sur certaines conditions de travail applicables
Que toute personne qui exerce des fonctions équiva- de services sociaux;
lentes à une personne salariée et qui s’engage auprès d’une
résidence privée pour aînés ou d’une institution religieuse Que l’allocation visée à l’alinéa précédent soit versée
visé au cent-seizième alinéa à y travailler à temps partiel sous la forme d’un montant forfaitaire, au prorata du
au moins 9 jours par période de 14 jours pour une durée temps travaillé, y compris les congés fériés, les congés
minimale d’une année reçoive au maximum 50 % des mobiles, les congés annuels et les congés sociaux;
montants forfaitaires visés à cet alinéa;
Que ne soit plus admissible à l’allocation temporaire,
Qu’une personne qui exerce des fonctions équiva- le cadre :
lentes à une personne salariée pour une résidence privée
pour aînés ou d’une institution religieuse visée au cent- 1° ayant cumulé plus de 10 jours d’absence sans solde,
seizième alinéa, qui est en congé de maternité, de pater- en excluant les absences découlant de l’application d’une
nité, d’adoption ou parental puisse signer son engagement entente de préretraite progressive ou d’un congé pour acti-
après le 31 mars 2022 pour une durée ne pouvant excéder vité en milieu nordique;
le 31 mars 2023, en autant qu’elle soit disponible à travail-
ler à temps complet ou 9 jours par période de 14 jours, 2° s’étant absenté sans que cette absence soit autorisée;
dans le cas d’une personne à temps partiel, à la date de
son retour au travail et qu’alors elle reçoive, selon le cas, Que les cadres dont les postes ont été abolis au cours
les montants forfaitaires visés au cent-seizième alinéa en des deux années précédant le 13 décembre 2021 et qui ont
un seul versement, à la fin de son engagement, en autant obtenu une indemnité de fin d’emploi conformément aux
que ce dernier ait été respecté; articles 119 et 122 du Règlement sur certaines conditions
de travail applicables aux cadres des agences et des éta-
Qu e les mêmes modalités que celles prévues aux blissements de santé et de services sociaux puissent être
quatre-vingt-sixième, quatre-vingt-huitième, quatre- réengagés pour occuper un poste de cadre;
vingt-neuvième, quatre-vingt-dixième, quatre-vingt-
onzième et cent-unième alinéas s’appliquent à la personne Qu e les cent-vingt-deuxième, cent-vingt-troisième,
visée aux cent-seizième, cent-dix-septième, cent-dix- cent-vingt-quatrième et cent-vingt-cinquième alinéas
huitième ou cent-dix-neuvième alinéas; s’appliquent aux cadres qui travaillent pour une maison
de soins palliatifs, avec les adaptations nécessaires;
Qu’une personne ne devienne pas inadmissible à
recevoir les montants forfaitaires prévus aux soixante- Qu’aux fins du cent-vingt-huitième au cent-quarante-
et-onzième, soixante-quatorzième, soixante-dix-huitième, septième alinéa, on entende par :
soixante-dix-neuvième, quatre-vingtième, quatre-vingt-
unième, quatre-vingt-deuxième, quatre-vingt-troisième, 1° « établissement » un établissement public ou privé
quatre-vingt-quatrième, quatre-vingt-septième, quatre- conventionné au sens de la Loi sur les services de santé et
vingt-dixième, quatre-vingt-douzième, quatre-vingt- les services sociaux ou de la Loi sur les services de santé
treizième, quatre-vingt-quinzième, quatre-vingt- et les services sociaux pour les autochtones cris;
seizième, quatre-vingt-dix-septième, quatre-vingt-dix-
huitième, cent-quatrième, cent-sixième, cent-septième, 2° « personne salariée » une personne salariée d’un
cent-huitième, cent-onzième, cent-douzième, cent- établissement dont le titre d’emploi fait partie de l’une
treizième, cent-quatorzième, cent-seizième, cent-dix- des catégories suivantes, tel que prévu à la Nomenclature
septième, cent-dix-huitième et cent-dix-neuvième alinéas des titres d’emploi, des libellés, des taux et des échelles
et que le prorata applicable à ces montants, le cas échéant, de salaire du réseau de la santé et des services sociaux :
ne soit pas affecté lorsqu’elle s’absente aux fins de subir un
test de dépistage de la COVID-19, lorsqu’elle doit s’isoler a) catégorie du personnel en soins infirmiers et
à la demande de son employeur ou parce qu’elle a reçu cardio-respiratoires;
un ordre d’isolement d’une autorité de santé publique ou
lorsqu’elle a été atteinte de la COVID-19 et qu’en raison b) catégorie du personnel paratechnique, des services
de cette maladie elle est en absence invalidité; auxiliaires et de métiers;

AR02743
c) catégorie du personnel de bureau, des techniciens Que, pour l’application des cent-vingt-huitième, cent
et des professionnels de l’administration; vingt-neuvième, cent-trentième et cent-trente-deuxième
alinéas, soient considérés aux fins du calcul des heures
d) catégorie des techniciens et des professionnels de la de la semaine normale de travail, les quarts réguliers,
santé et des services sociaux; les journées de vacances, les congés fériés, les congés
mobiles, les journées de libérations syndicales internes,
3° « cadre » un cadre au sens de l’article 3 du les congés pour une visite médicale liée à la grossesse, la
Règlement sur certaines conditions de travail applicables conversion de prime de soir ou de nuit en temps chômé
aux cadres des agences et des établissements de santé et de ainsi que les journées où la personne salariée s’absente
services sociaux; parce qu’elle doit s’isoler à la demande de son employeur
ou parce qu’elle a reçu un ordre d’isolement d’une autorité
Qu’une personne salariée d’un établissement qui effec- de santé publique;
tue un quart de travail complet en sus de la totalité des
heures prévues à sa semaine normale de travail, tel que Qu’une personne salariée visée au cent-vingt-neuvième
mentionné à son titre d’emploi prévu à la Nomenclature ou au cent-trentième alinéa puisse, à compter du 1er mai
des titres d’emploi, des libellés, des taux et des échelles de 2022, demander que chaque demi-journée de vacances
salaire du réseau de la santé et des services sociaux, soit accumulée en application de ces alinéas lui soit payée, à
rémunérée à taux double pour ce quart supplémentaire; taux simple;
Que, pour tout quart de travail complet effectué en sus Qu’une personne salariée à temps partiel d’un établisse-
de la totalité des heures prévues à sa semaine normale ment reçoive un montant forfaitaire de 100 $ par semaine
de travail, tel que mentionné à son titre d’emploi, une si elle travaille effectivement au moins 30 heures sans
personne salariée d’un établissement, autre qu’une per- atteindre le nombre d’heures prévues à son titre d’emploi;
sonne retraitée embauchée ou qu’une personne salariée
temporaire visée au paragraphe 5° du deuxième alinéa, Qu’aux fins de l’admissibilité d’une personne au mon-
accumule une demi-journée de vacances, représentant tant forfaitaire prévu à l’alinéa précédent, les heures
50 % d’un quart de travail complet, qui peut être utilisée effectivement travaillées incluent les heures régulières,
à compter du 1er mai 2022, et ce, sans échéance; les journées de vacances, les congés fériés, les congés
mobiles, les congés pour une visite médicale liée à la gros-
Qu e la personne salariée à temps complet ayant sesse, les journées de libérations syndicales internes ainsi
un horaire atypique qui travaille, en sus de la totalité que les journées où la personne salariée s’absente parce
des heures prévues à sa semaine normale de travail, qu’elle doit s’isoler à la demande de son employeur ou
deux quarts de travail d’une durée de 4 heures de façon parce qu’elle a reçu un ordre d’isolement d’une autorité
consécutive à deux quarts de travail de 12 heures : de santé publique;
1° soit rémunérée à taux double pour ces deux quarts Qu’une personne salariée ne soit pas admissible au
supplémentaires de 4 heures; montant forfaitaire prévu au cent-trente-cinquième alinéa
si elle s’absente pour un motif autre que ceux prévus au
2° accumule 4 heures de vacances qui peuvent être cent-trente-sixième alinéa;
utilisées à compter du 1er mai 2022, et ce, sans échéance;
Qu’une personne salariée à temps partiel d’un établis-
Qu e malgré le paragraphe 2° de l’alinéa précédent, sement qui effectue un quart de travail consécutif à son
la personne retraitée embauchée ou la personne salariée quart de travail soit rémunérée à taux double pour le quart
temporaire visée au paragraphe 5° du deuxième alinéa supplémentaire si, dans la même semaine, elle a effective-
reçoive plutôt un montant forfaitaire équivalent à 4 heures ment travaillé, dans un centre d’activités où des services
de vacances; sont dispensés 24 heures par jour et 7 jours par semaine,
un autre quart de travail complet de soir, de nuit ou de fin
Que, pour tout quart de travail complet effectué en sus de semaine, à taux régulier, en sus des heures normale-
de la totalité des heures prévues à sa semaine normale de ment prévues à son poste ou à son affectation temporaire,
travail, tel que mentionné à son titre d’emploi, la personne selon le cas;
retraitée embauchée ou la personne salariée temporaire
visée au paragraphe 5° du deuxième alinéa reçoive un Qu e, pour l’application de l’alinéa précédent, soient
montant forfaitaire équivalent à une demi-journée de considérés aux fins du calcul des heures normalement pré-
vacances, représentant 50 % d’un quart de travail complet; vues à son poste ou à son affectation temporaire, selon le
cas, les heures régulières, les journées de vacances, les

congés fériés, les congés mobiles, les heures de libérations d’une entente collective les concernant ou une institution
syndicales internes, les congés pour une visite médicale religieuse qui maintient une installation d’hébergement et
liée à la grossesse ainsi que les journées où la personne de soins de longue durée pour y recevoir ses membres ou
salariée s’absente parce qu’elle doit s’isoler à la demande ses adhérents et qui y exerce des fonctions équivalentes à
de son employeur ou parce qu’elle a reçu un ordre une personne salariée;
d’isolement d’une autorité de santé publique;
Qu’un cadre qui travaille pour un établissement privé
Qu’une personne salariée d’un établissement ne non conventionné, une maison de soins palliatifs au sens
puisse bénéficier de la mesure prévue au cent-trente- du paragraphe 2° de l’article 3 de la Loi concernant les
huitième alinéa plus d’une fois par semaine; soins de fin de vie et qui accepte de remplacer un cadre ou
un employé non cadre à l’extérieur de son horaire habituel
Qu’une personne salariée d’un établissement puisse de travail est rémunéré selon son salaire habituel et que
recevoir, là où le service existe, pour chaque quart de ce salaire soit majoré à 150 % pour toute heure effectuée
travail effectué en temps supplémentaire, le paiement au-delà de 40 heures par semaine;
ou le remboursement de ses frais réels et raisonnables
de déplacement en taxi entre son domicile et son lieu de Qu’un cadre d’un établissement qui accepte de rempla-
travail, soit pour l’aller, soit pour le retour, soit pour cer un cadre ou un employé non cadre à l’extérieur de son
les deux, selon le besoin de la personne salariée; horaire habituel de travail est rémunéré selon son salaire
habituel et que ce salaire soit majoré à 150 % pour toute
Qu’une personne salariée d’un établissement n’ait pas heure effectuée au-delà de 40 heures par semaine;
à payer les frais d’un espace de stationnement lorsqu’il est
disponible et géré par l’établissement pour la période du Que toutes les primes, toutes les allocations et tous les
16 janvier 2022 au 14 mai 2022; montants forfaitaires versés en vertu du présent arrêté ne
soient pas cotisables aux fins du régime de retraite;
Que les dispositions nationales et locales des conven-
tions collectives en vigueur dans le réseau de la santé et Que soient abrogés :
des services sociaux, de même que les conditions de tra-
vail applicables aux employés syndicables non syndiqués 1° le décret numéro 1276-2021 du 24 septembre 2021,
et aux employés non syndicables du réseau de la santé et modifié par les arrêtés numéros 2021-072 du 16 octobre
des services sociaux soient modifiées afin de permettre 2021 et 2021-080 du 14 novembre 2021;
la mise en œuvre des mesures prévues du cent-vingt-
septième au cent-quarante-deuxième alinéa; 2° l’arrêté numéro 2020-007 du 21 mars 2020;
Qu e les mesures prévues du cent-vingt-septième au 3° l’arrêté numéro 2020-015 du 4 avril 2020, modi-
cent-quarante-deuxième alinéa s’appliquent, avec les fié par les arrêtés numéros 2020-016 du 7 avril 2020,
adaptations nécessaires, aux conditions de travail du 2020-017 du 8 avril 2020, 2020-023 du 17 avril 2020,
personnel non visé par la Loi concernant les unités de 2020-031 du 3 mai 2020, 2020-034 du 9 mai 2020,
négociation dans le secteur des affaires sociales des éta- 2020-038 du 15 mai 2020, 2022-003 du 15 janvier 2022
blissements publics et privés conventionnés et les ententes et 2022-023 du 23 mars 2022;
conclues avec le Regroupement Les sages-femmes du
Québec soient modifiées de la même manière; 4° l’arrêté numéro 2020-017 du 8 avril 2020;
Qu e les mesures prévues aux cent-vingt-huitième, 5° l’arrêté numéro 2020-020 du 10 avril 2020, modi-
cent-vingt-neuvième, cent-trentième, cent-trente-et- fié par les arrêtés numéros 2020-044 du 12 juin 2020
unième, cent-trente-troisième, cent-trente-quatrième, et 2022-024 du 25 mars 2022;
cent-trente-cinquième, cent-trente-sixième, cent-trente-
septième, cent-trente-huitième et cent-trente-neuvième 6° l’arrêté numéro 2020-023 du 17 avril 2020;
alinéas s’appliquent, avec les adaptations nécessaires, à
la personne qui travaille pour un établissement privé non 7° l’arrêté numéro 2020-035 du 10 mai 2020, modi-
conventionné, une maison de soins palliatifs au sens du fié par les arrêtés numéros 2020-044 du 12 juin 2020,
paragraphe 2° de l’article 3 de la Loi concernant les soins 2020-064 du 17 septembre 2020, 2020-067 du 19 septem
de fin de vie, une résidence privée pour aînés, une res- bre 2020, 2021-036 du 15 mai 2021, 2021-055 du
source intermédiaire du programme de soutien à l’autono- 30 juillet 2021, 2021-071 du 16 octobre 2021, 2021-094
mie des personnes âgées non visée par la Loi sur la repré- du 30 décembre 2021, 2022-003 du 15 janvier 2022 et
sentation des ressources de type familial et de certaines 2022-008 du 23 janvier 2022;
ressources intermédiaires et sur le régime de négociation

AR02745
8° l’arrêté numéro 2020-049 du 4 juillet 2020, modi- Aide de service

fié par les arrêtés numéros 2021-054 du 16 juillet 2021,
2022-024 du 25 mars 2022 et 2022-026 du 31 mars 2022; Aide social ou aide sociale
9° l’arrêté numéro 2020-107 du 23 décembre 2020, Aide-cuisinier ou aide-cuisinière

modifié par les décrets numéros 2-2021 du 8 janvier
2021 et 799-2021 du 9 juin 2021 et par les arrêtés numé- Assistant ou assistante en pathologie
ros2021-001 du 15 janvier 2021, 2021-051 du 6 juillet 2021,
2022-023 du 23 mars 2022 et 2022-024 du 25 mars 2022; Assistant ou assistante en réadaptation
10° l’arrêté numéro 2021-017 du 26 mars 2021, modi- Assistant ou assistante technique au laboratoire ou
fié par les arrêtés numéros 2021-028 du 17 avril 2021, en radiologie
2021-036 du 15 mai 2021, 2021-039 du 28 mai 2021,
2021-040 du 5 juin 2021, 2021-071 du 16 octobre 2021 et Assistant ou assistante technique aux soins de la santé
2022-008 du 23 janvier 2022;
Assistant ou assistante technique en pharmacie
11° l’arrêté numéro 2021-032 du 30 avril 2021, modifié
par les arrêtés numéros 2021-034 du 8 mai 2021, 2021-082 Assistant ou assistante technique senior en pharmacie
du 17 novembre 2021 et 2021-093 du 23 décembre 2021;
Assistant-chef (laboratoire) ou assistante-chef
12° l’arrêté numéro 2021-081 du 14 novembre (laboratoire)
13 décembre 2021, 2021-088 du 16 décembre 2021 et Assistant-chef inhalothérapeute ou assistante-chef
2022-003 du 15 janvier 2022; inhalothérapeute;
13° l’arrêté numéro 2021-085 du 13 décembre 2021, Assistant-chef physiothérapeute ou assistante-chef

modifié par les arrêtés numéros 2021-093 du 23 décembre physiothérapeute
2021, 2022-008 du 23 janvier 2022 et 2022-026 du
31 mars 2022; Assistant-chef technicien en diététique ou assistante-
chef technicienne en diététique
14° l’arrêté numéro 2021-095 du 31 décembre 2021;
Assistant-chef technologue en électrophysiologie médi-
15° l’arrêté numéro 2022-003 du 15 janvier 2022, cale ou assistante-chef technologue en électrophysiologie
modifié par l’arrêté numéro 2022-008 du 23 janvier 2022. médicale
Annexe I Assistant-chef technologue en radiologie ou assistante-

chef technologue en radiologie
Agent ou agente de planification, de programmation
et de recherche Assistant-infirmier-chef ou assistante-infirmière-
chef ou assistant du supérieur immédiat ou assistante du
Agent ou agente de relations humaines supérieur immédiat
Agent ou agente d’intervention Audiologiste
Agent ou agente d’intervention en milieu chef d’équipe Audiologiste-orthophoniste
Agent ou agente d’intervention en milieu médico-légal Auxiliaire aux services de santé et sociaux
Agent ou agente d’intervention en milieu médico-légal Bactériologiste

chef d’équipe
Biochimiste
Biochimiste clinique
chef d’équipe Biochimiste clinique chef de laboratoire niveau I

Biochimiste clinique chef de laboratoire niveau II Diététiste-nutritionniste
Boucher ou bouchère Éducateur ou éducatrice
Brancardier ou brancardière Ergothérapeute
Buandier ou buandière Externe en inhalothérapie
Caissier ou caissière à la cafétéria Externe en soins infirmiers
Candidat à l’exercice de la profession d’infirmier ou Externe en technologie médicale

candidate à l’exercice de la profession d’infirmière
Gardien ou gardienne de résidence
Candidat à l’exercice de la profession d’infirmière
auxiliaire ou candidate à l’exercice de la profession Hygiéniste dentaire
d’infirmière auxiliaire
Infirmier auxiliaire chef d’équipe ou infirmière auxi-
Candidat infirmier praticien spécialisé ou candidate liaire chef d’équipe
infirmière praticienne spécialisée
Infirmier auxiliaire en stage d’actualisation ou infir-
Chargé ou chargée clinique de sécurité transfusionnelle mière auxiliaire en stage d’actualisation
Chargé ou chargée de l’enseignement clinique Infirmier auxiliaire ou infirmière auxiliaire

(inhalothérapie)
Infirmier chef d’équipe ou infirmière chef d’équipe
Chargé ou chargée de l’enseignement clinique
(physiothérapie) Infirmier clinicien assistant infirmier-chef ou infir-
mière clinicienne assistante infirmière-chef ou infirmier
Cha rgé ou cha rgée tech n ique de sécu r ité clinicien assistant du supérieur immédiat ou infirmière
transfusionnelle clinicienne assistante du supérieur immédiat
Chef de module Infirmier clinicien ou infirmière clinicienne
Commis surveillant d’unité (Institut Pinel) Inf ir mier clinicien ou inf ir mière clinicienne
(Institut Pinel)
Conseiller d’orientation ou conseillère d’orientation
Infirmier clinicien spécialisé ou infirmière clinicienne
Conseiller ou conseillère en soins infirmiers spécialisée
Coordon nateur ou coordon nat r ice tech nique Infirmier en dispensaire ou infirmière en dispensaire
(inhalothérapie)
Infirmier en stage d’actualisation ou infirmière en
Coordon nateur ou coordon nat r ice tech nique stage d’actualisation
(laboratoire)
Infirmier moniteur ou infirmière monitrice
Coordon nateur ou coordon nat r ice tech nique
(radiologie) Infirmier ou infirmière
Coordonnateur ou coordonnatrice technique en Infirmier ou infirmière (Institut Pinel)

électrophysiologie médicale
Infirmier praticien spécialisé ou infirmière praticienne
Criminologue spécialisée
Cuisinier ou cuisinière Infirmier premier assistant en chirurgie ou infirmière

première assistante en chirurgie
Cytologiste

AR02747
Ingénieur biomédical ou ingénieure biomédicale Préposé ou préposée au transport des bénéficiaires

handicapés physiques
Inhalothérapeute
Préposé ou préposée aux bénéficiaires
Instituteur ou institutrice clinique (laboratoire)
Préposé ou préposée aux bénéficiaires chef d’équipe
Instituteur ou institutrice clinique (radiologie)
Préposé ou préposée aux magasins
Intervenant spécialisé ou intervenante spécialisée en
pacification et en sécurité (Institut Pinel) Préposé ou préposée en établissement nordique
Magasinier ou magasinière Préposé ou préposée en physiothérapie ou ergothérapie
Moniteur ou monitrice en loisirs Préposé ou préposée en retraitement des dispositifs

médicaux
Orthophoniste
Préposé ou préposée en salle d’opération
Nettoyeur ou nettoyeuse
Presseur ou presseuse
Pâtissier-boulanger ou pâtissière-boulangère
Psychoéducateur ou psychoéducatrice
Perfusionniste clinique
Psychologue
Pharmacien
Puéricultrice / garde-bébé
Pharmacien chef I
Responsable de milieu de vie
Pharmacien chef II
Responsable des services de sage-femme
Pharmacien chef III
Réviseur ou réviseure
Pharmacien chef IV
Sage-femme
Pharmacien chef-adjoint I
Secrétaire médicale
Pharmacien chef-adjoint II
Sexologue
Physicien médical
Sexologue clinicien
Physiothérapeute
Sociothérapeute (Institut Pinel)
Préposé ou préposée à l’unité ou au pavillon
Spécialiste clinique en biologie médicale
Préposé ou préposée à la buanderie
Spécialiste en activités cliniques
Préposé ou préposée à l’accueil
Spécialiste en sciences biologiques et physiques
sanitaires
Préposé ou préposée à l’ent retien ménager
(travaux légers)
Surveillant ou surveillante en établissement
Préposé ou préposée à l’ent retien ménager Technicien de laboratoire médical diplômé ou techni-
(travaux lourds) cienne de laboratoire médical diplômée
Préposé ou préposée au service alimentaire Technicien ou technicienne classe B
Préposé ou préposée au transport Technicien ou technicienne d’intervention en loisir

Technicien ou technicienne en alimentation Agent administratif, classe 3 - secteur administration

Technicien ou technicienne en cytogénétique clinique
Technicien ou technicienne en diététique agente administrative, classe 3 - secteur secrétariat
Technicien ou technicienne en éducation spécialisée Agent administratif, classe 4 - secteur administration

Tech n icien ou tech nicien ne en physiologie
cardiorespiratoire Agent administratif, classe 4 - secteur secrétariat ou
agente administrative, classe 4 - secteur secrétariat.
Technicien ou technicienne en travail social
Annexe III
Technologiste médical ou technologiste médicale
Région sociosanitaire du Bas-Saint-Laurent;
Technologue en électrophysiologie médicale
Région sociosanitaire du Saguenay—Lac-Saint-Jean;
Technologue en imagerie médicale du domaine de la
médecine nucléaire Région sociosanitaire de la Capitale-Nationale;
Technologue en imagerie médicale du domaine Région sociosanitaire de la Mauricie et Centre-

du radiodiagnostic du-Québec;
Technologue en physiothérapie Région sociosanitaire de l’Estrie;
Technologue en radiologie (Système d’information et Région sociosanitaire de Montréal;

d’imagerie numérique)
Région sociosanitaire de Chaudière-Appalaches;
Technologue en radio-oncologie
Région sociosanitaire de Laval;
échographie - pratique autonome Région sociosanitaire de Lanaudière;
Technologue spécialisé ou technologue spécialisée en Région sociosanitaire des Laurentides;

imagerie médicale
Région sociosanitaire de la Montérégie.
radio-oncologie Annexe IV
Travailleur ou travailleuse communautaire Région sociosanitaire de l’Outaouais;
Travailleur social ou travailleuse sociale. Région sociosanitaire de l’Abitibi-Témiscamingue;
Annexe II Région sociosanitaire de la Côte-Nord;
Agent administratif, classe 1 - secteur administration Région sociosanitaire du Nord-du-Québec;

Région sociosanitaire de la Gaspésie — Îles-de-
Agent administratif, classe 1 - secteur secrétariat ou la-Madeleine;
Région sociosanitaire du Nunavik;
ou agente administrative, classe 2 - secteur administration Région sociosanitaire des Ter res-Cries-de-la-
Baie-James.

AR02749
Annexe V
Le secteur V, composé des localités de Tasiujak,

Iv ujivik, Kangiqsualujjuaq, Aupaluk, Quaqtaq,
Akulivik, Kangiqsujuaq, Kangirsuk, Salluit, Tarpangajuk
et Umiujaq;
Le secteur IV, composé des localités de Wemindji,

Eastmain, Fort Rupert (Waskaganish), Nemaska
( Nem iscau), I nu kju a k , P uvi r n it uq, Kuuj ju a k ,
Kuujjuarapik, Poste-de-la-Baleine (Whapmagoostui),
Schefferville et Kawawachikamach;
Le secteur III, composé des localités suivantes :
— celles situées sur le territoire situé au nord du

51e degré de latitude incluant Mistissini, Chisasibi, Oujé-
Bougoumou, Radisson, et Waswanipi, à l’exception de
Fermont et des localités spécifiées aux secteurs IV et V;
— Parent, Sanmaur et Clova;
— celles situées sur le territoire de la Côte-Nord,

s’étendant à l’est de Havre-St-Pierre, jusqu’à la limite du
Labrador, y compris l’Île d’Anticosti;
Le secteur II, composé des localités suivantes :
— la municipalité de Fermont;
— celles situées sur le territoire de la Côte-Nord situé

à l’est de la Rivière Moisie et s’étendant jusqu’à Havre-
St-Pierre inclusivement;
— celles des Îles-de-la-Madeleine. »

77119

AR02750
Ceci est la pièce « AAA » au soutien de


20/04/2022 11:16 Ligne du temps COVID-19 au Québec
AR02751
INSPQ
Publié sur INSPQ (https://www.inspq.qc.ca)
Centre d'expertise et de reference en sante publique
Accueil > Expertises > Maladies infectieuses > Surveillance, prévention et contrôle des maladies infectieuses >
COVID-19 (coronavirus) > Données COVID-19 au Québec > Ligne du temps
Ligne du temps COVID-19 au Québec

Cette page fournit de l’information complémentaire à la page Données COVID-19 au Québec.
Courbe des cas confirmés selon la date de déclaration des cas,

annotée des principaux événements et mesures de santé
publique liés à la COVID-19 au Québec
Les cas confirmés incluent les cas confirmés par laboratoire et, depuis le 30 mars 2020, les cas confirmés par lien
épidémiologique. Des groupes d’événements se produisant dans un intervalle de dates rapprochées peuvent faire en
sorte que certains de ceux-ci soient cachés. Il est possible de zoomer sur une période en faisant glisser la souris dans un
intervalle de dates et ainsi faire apparaître tous les événements. De plus, la version complète de la ligne du temps est
disponible de manière comprimée en dessous du graphique; il y est possible de faire glisser les poignées pour élargir (ou
rétrécir) le spectre visible de la ligne du temps du graphique et de le déplacer ensuite de gauche à droite à l’aide de la
souris.
https://www.inspq.qc.ca/print/covid-19/donnees/ligne-du-temps 1/24
AR02752
••••••••••••••••··•••••··•••••··•••••·••••••••Ill
13. Fév 20. Fév 27. Fév 6. Mar 13. Mar 20. Mar
Date de déclaration du cas
27. Mar
Mai '20 Sept '20 Jan '21 Mai '21
Un choix éditorial des événements affichés dans le graphique a été fait pour en favoriser la lecture. L’ensemble des
événements et mesures liés à la pandémie est disponible dans le tableau plus bas.
Ensemble des événements et mesures liés à la COVID-19 en

ordre chronologique
2020
Type
Date Mesures adoptées
d'événement
Événement
27 février Premier cas déclaré au Québec.
épidémiologique
Événement
29 février Début de la semaine de relâche.
épidémiologique
Isolement des voyageurs.

Mesures de
11 mars Interdiction de rassemblements de plus de 250 personnes.
santé publique
Incitation au télétravail.
Mesures de
12 mars Fermeture des casinos et des salons de jeux.
santé publique
AR02753
Type
d'événement
Événement
Urgence sanitaire déclarée.
épidémiologique
13 mars
Mesures de
Suspension des activités des tribunaux (sauf urgence).
santé publique
Interdiction de visites non essentielles dans les CHSLD, hôpitaux et centres pour personnes âgées.
Mesures de
14 mars Les personnes de 70 ans et plus sont appelées à rester à la maison.
santé publique
Les vacanciers sont priés de rentrer au pays.
Mesures de distanciation physique (1 mètre).
Fermeture de plusieurs lieux publics : les centres d’entraînements; les bars; les cabanes à sucre; les salles
de spectacles; les piscines; les arénas et les centres de ski.
Mesures de
15 mars
santé publique Réduction de moitié de la capacité maximale des restaurants.
Annulation des activités des églises, y compris les messes.
Les Québécois sont appelés à limiter leurs déplacements.
Mesures de Fermeture des garderies et des écoles jusqu’au 27 mars.

16 mars
santé publique
Fermeture de la frontière canadienne.
Mesures de
17 mars L’Assemblée nationale du Québec suspend ses travaux jusqu’au 21 avril.
santé publique
Événement en
lien avec le Augmentation de la capacité de dépistage.
dépistage
18 mars
Événement
Premier décès rapporté au Québec.
épidémiologique
Mesures de
19 mars Directive d’éviter les voyages non essentiels entre les régions sociosanitaires.
santé publique
Mesures de
21 mars Interdiction de tout rassemblement intérieur et extérieur.
santé publique
Mesures de Fermeture des centres commerciaux, salons de coiffure, salons esthétiques et autres commerces.
santé publique
Prolongation de la fermeture des écoles et des garderies jusqu’au 1er mai.
22 mars
Événement en
lien avec le Les cas testés positifs par les laboratoires hospitaliers sont maintenant considérés confirmés.
dépistage
Mesures de
Confinement obligatoire en CHSLD et résidences privées pour aînés.
santé publique
23 mars
Événement en
Les nouvelles priorités de dépistage incluent les patients, les professionnels de la santé et les résidents de
lien avec le
CHSLD symptomatiques, qui s’ajoutent aux voyageurs et leurs contacts symptomatiques.
dépistage
AR02754
Type
d'événement
Mesures de
24 mars Fermeture de tous les services à l’exception des services essentiels jusqu’au 13 avril.
santé publique
Mesures de Restriction des déplacements entre certaines régions, surtout Montréal et l’Estrie.
santé publique
La consigne de distanciation physique est portée de 1 à 2 mètres.
27 mars
Événement
La Ville de Montréal se place en état d’urgence sanitaire.     
épidémiologique
Limitation de l’accès à huit régions avec points de contrôle : le Bas-St-Laurent, l’Abitibi-Témiscamingue, la

Côte-Nord, le Saguenay–Lac-Saint-Jean, la Gaspésie–Îles-de-la-Madeleine, le Nord-du-Québec, le Nunavik,
Mesures de et les Terres-Cries-de-la-Baie-James.
28 mars
santé publique
Isolement obligatoire des voyageurs avec points de contrôle à la frontière.
La location de toute résidence touristique, comme des chalets, est interdite pour éviter les déplacements.
Événement
Ajout des cas confirmés par lien épidémiologique.
épidémiologique
Mesures de Annonce que les commerces essentiels seront fermés le dimanche pour tout le mois d’avril à l’exception des
30 mars santé publique stations-service, dépanneurs, pharmacies et comptoirs pour emporter des restaurants.   
Événement en
Nouveaux critères de priorisation de dépistage : les voyageurs ne sont plus visés en priorité. La nouvelle
lien avec le
échelle de priorisation distingue le réseau de la santé et les personnes dans la communauté.
dépistage
Points de contrôle aux abords et à l’intérieur des régions et territoires suivants : la RSS de l’Outaouais; MRC
Mesures de d'Antoine-Labelle, d'Argenteuil, des Pays-d'en-Haut et des Laurentides (RSS des Laurentides); les territoires
1er avril
santé publique d'Autray, de Joliette, de Matawinie et de Montcalm (RSS Lanaudière); l'agglomération de La Tuque (RSS
Mauricie-et-Centre-du-Québec).
Mesures de Points de contrôle aux abords et à l’intérieur des régions et territoires suivants : Rouyn-Noranda (RSS
santé publique Abitibi-Témiscamingue) et la région de Charlevoix.
4 avril
Événement
Le territoire du Québec est déclaré comme ayant de la transmission communautaire.
épidémiologique
Mesures de
5 avril Prolongation de la fermeture des services non-essentiels jusqu’au 4 mai.
santé publique
Événement
7 avril Québec atteint 10 000 cas.      
épidémiologique
Événement
8 avril Adoption de définitions nosologiques pour la surveillance de la COVID-19 au Québec.
épidémiologique
Annulation de tous les festivals et activités estivaux jusqu’au 31 août.

Mesures de
10 avril
santé publique
Annonce de la fin des transferts des patients des hôpitaux vers les CHSLD.   
Événement en
Mise à jour de la priorisation du dépistage : entre autres, les usagers et le personnel des milieux
11 avril lien avec le
d’hébergement devront se faire dépister dès qu’un nouveau cas positif non isolé est identifié.
dépistage
AR02755
Type
d'événement
Mesures de
15 avril Réouverture du secteur minier, des ateliers mécaniques, de l’aménagement et entretien paysager.
santé publique
Mesures de
20 avril Réouverture de la construction et rénovation résidentielle pour livrables le 31 juillet 2020.
santé publique
Mesures de
27 avril Reprise de la recherche universitaire.
santé publique
Réouverture des magasins avec porte extérieure à l'exception de la communauté métropolitaine de Montréal
Mesures de (CMM).
santé publique
Contrôles routiers retirés pour les régions : Chaudière-Appalaches, Lanaudière, Laurentides et la ville de
Rouyn-Noranda.
4 mai
Événement en
Révision des priorités de dépistage : toutes les personnes symptomatiques peuvent être testées, peu
lien avec le
importe leur territoire. Les DSP peuvent maintenant tester des contacts asymptomatiques à leur discrétion.
dépistage
Assouplissement aux mesures en place :
Mesures de 1. Autorisation de sortie extérieure aux personnes vivant en résidence privée pour aînés; et
6 mai
santé publique 2. Levée de l’interdiction de visites dans les unités de soins palliatifs des centres d'hébergement et de soins
de longue durée, des résidences privées pour aînés et des ressources intermédiaires et de type familial.
Autorisation de soutien de proches aidants en ressource intermédiaire et de type familial ou en résidence

privée pour aînés.
Retrait des points de contrôle suivants : RSS de l’Outaouais (sauf pour les passages d’Ottawa à Gatineau);
Mesures de RSS du Saguenay—Lac-Saint-Jean; RSS de l’Abitibi-Témiscamingue; l'agglomération de La Tuque (RSS
11 mai Mauricie-et-Centre-du-Québec).
santé publique
Réouverture des établissements préscolaires et primaires et des services de garde, à l’exception de ceux
sur le territoire de la CMM.
Réouverture complète de l'industrie de la construction et partielle de la fabrication manufacturière.
Événement en
Les résidents, symptomatiques ou non, des zones chaudes de la grande région de Montréal qui ont été en
12 mai lien avec le
contact avec des personnes infectées sont invités à se faire tester.
dépistage
Événement en
15 mai lien avec le Tous les employés des CHSLD publics et privés sont testés, incluant les employés asymptomatiques.
dépistage
Retrait des points de contrôle pour les passages d’Ottawa à Gatineau (ville de Gatineau et la MRC des
Mesures de
18 mai Collines-de-l'Outaouais); la RSS du Bas-Saint-Laurent; la RSS de la Gaspésie-Îles-de-la-Madeleine; la RSS
santé publique
de la Capitale-Nationale ainsi que pour le territoire des MRC de Charlevoix et de Charlevoix-Est.
Autorisation de pratique récréative individuelle sans contact (ex. golf, canot, randonnée) pour l’ensemble des
Mesures de
20 mai régions.
santé publique
Accès progressif à certains territoires de la SEPAQ.
Événement en
21 mai lien avec le Atteinte de l’objectif de 14 000 prélèvements par jour pour la première fois.
dépistage
Mesures de Autorisation de rassemblements extérieurs à condition que ce soit un maximum de 10 personnes provenant
santé publique d’un maximum de 3 ménages.
22 mai
Événement en
lien avec le Les personnes ayant des symptômes s’apparentant à la COVID-19 sont appelées à se faire tester.
dépistage
AR02756
Type
d'événement
Mesures de
24 mai Réouverture des commerces essentiels le dimanche.
santé publique
Mesures de Réouverture des magasins de détail avec accès direct à l’extérieur pour la CMM.
25 mai
santé publique Ouverture complète de la fabrication manufacturière.
Événement
Québec atteint 50 000 cas.
épidémiologique
29 mai
Mesures de Ouverture des musées et des comptoirs de prêts des bibliothèques pour l’ensemble du Québec.
santé publique Ouverture des cinéparcs.
Mesures de Ouverture des espaces publics extérieurs, tels que piscines extérieures et modules de jeux des parcs dont
30 mai
santé publique les jeux d'eau.
Événement en
lien avec le Nouvelle classification dans l’accès aux tests d’amplification des acides nucléiques.
dépistage
Réouverture des centres commerciaux situés en dehors de la Communauté métropolitaine de Montréal et de

la MRC de Joliette.
Réouverture des centres de soins de santé professionnels et thérapeutiques pour l’ensemble du Québec et
des centres de soins personnels et esthétiques à l’exception de la CMM.
1er juin
Réouverture des établissements de camping et de pourvoirie et des marinas pour l’ensemble du Québec.
Mesures de
Réouverture des résidences de tourisme et des établissements de résidence principale, sauf ceux de la
santé publique
Communauté métropolitaine de Montréal et de la MRC de Joliette.
Retrait des points de contrôle sur la Côte-Nord.
Réouverture des palais de justice, des salles de spectacle sans public pour captation et des studios
d’enregistrements musicaux et sonores.
Réouverture des services de garde dans la CMM.
Événement en
4 juin lien avec le Le Québec dispose d’une capacité quotidienne de plus de 20 000 analyses.
dépistage
Événement
Québec atteint 5000 décès.
épidémiologique
8 juin
Mesures de
Reprise des entraînements de sports d’équipe (soccer, baseball, hockey).
santé publique
Reprise de la restauration sur place et autorisation de rassemblements intérieurs dans des lieux privés (à
condition que ce soit un maximum de 10 personnes provenant d’un maximum de 3 ménages) sauf dans la
CMM, la MRC de Joliette et la ville de l’Épiphanie.
Mesures de Reprise des examens pratiques de la Société de l'assurance automobile du Québec.

15 juin
santé publique
Reprise des activités de sport de haut niveau et des hippodromes.
Reprise des activités des commerces de services directs à la population et aux entreprises, tels que les
agences de voyages, les cordonneries.
Réouverture des zoos, jardins, des visites d’artisans transformateurs et de fermes agrotouristiques, de lieux
Mesures de de renseignements touristiques sur l’ensemble du territoire.
19 juin
santé publique
Réouverture des centres commerciaux situés dans la CMM et la MRC de Joliette.
AR02757
Type
d'événement
Reprise de la restauration sur place et autorisation de rassemblements intérieurs dans des lieux privés (à
condition que ce soit un maximum de 10 personnes provenant d’un maximum de 3 ménages) dans la CMM,
la MRC de Joliette et la ville de l’Épiphanie.
Ouverture estivale des camps de jour.
Mesures de Les rassemblements intérieurs et extérieurs dans certains lieux publics sont permis, en respectant un
22 juin maximum de 50 personnes.
santé publique
Distanciation physique de 1 mètre entre les enfants de 16 ans et moins.
Réouverture des salles de spectacle, des théâtres et des cinémas.
Reprise des matchs de sports collectifs sous réserve des DSP.
Réouverture des infrastructures sportives intérieures ainsi que des plages publiques et privées.
Reprise du transport touristique vers les Îles-de-la-Madeline par traversier.

Mesures de
26 juin La visite des personnes proches aidantes, des accompagnateurs ou de visiteurs en centre hospitalier est
santé publique
maintenant permise.
Mesures de
1er juillet Reprise des excursions maritimes.
santé publique
Mesures de Reprise de tous les secteurs d’activité économique à l’exception des : festivals et grands événements;
3 juillet
santé publique camps de vacances réguliers avec séjour; combats en contexte sportif.
Mesures de
4 juillet Réadmission du public aux séances du conseil et aux assemblées publiques municipales.
santé publique
Événement en
Nouvelles recommandations concernant l’utilisation des tests d'amplification des acides nucléiques (TAAN) à
7 juillet lien avec le
des fin de dépistage.
dépistage
Mesures de
9 juillet Rehaussement des mesures pour les bars (restrictions des heures d’ouverture et de la capacité d’accueil).
santé publique
Événement Fin de la première vague (25 février - 11 juillet 2020), suivie d'une période intervague (12 juillet -
11 juillet
épidémiologique 22 août 2020).
Le Nouveau-Brunswick et l'Île-du-Prince-Édouard mettent en place de nouvelles modalités

Mesures de
12 juillet d'enregistrement pour les voyageurs québécois souhaitant se rendre aux Îles-de-la-Madeleine ou se
santé publique
déplacer vers le Québec continental depuis les Îles-de-la-Madeleine.
Port du couvre-visage ou du masque obligatoire dans les transports en commun et les navires de la Société
Mesures de des traversiers du Québec.
13 juillet
santé publique
Retour à la capacité maximale pour tout le réseau des services de garde éducatifs à l'enfance.
Événement en
Augmentation de la capacité d’accueil des cliniques de dépistage sans rendez-vous sur le territoire de
-------
16 juillet lien avec le
Montréal.
dépistage
Port du masque obligatoire partout au Québec dans les endroits publics fermés.
Mesures de
18 juillet Retour graduel du personnel de l'État dans les édifices gouvernementaux : taux d'occupation maximal de
santé publique
25 % de la capacité des milieux de travail. La conduite est la même pour les employeurs privés dont le
personnel travaillait à domicile.
Événement en Modification de la méthode utilisée pour le dénombrement des cas : on ne tient plus compte des résultats de
22 juillet lien avec le tests émis dans les 90 jours suivant le premier résultat positif émis, ce qui entraîne une baisse du nombre de
dépistage cas confirmés, de cas infirmés et de tests réalisés.
AR02758
Type
d'événement
Mesures de
3 août
santé publique
Le nombre maximal de personnes permis lors d'événements intérieurs et extérieurs passe de 50 à
250 personnes.
Plan de la rentrée scolaire qui inclut notamment le port du couvre-visage pour tous les élèves à partir de la
Mesures de
10 août 5e année du primaire lors de leurs déplacements à l'intérieur de l'école et dans les transports scolaires ou
santé publique
publics ainsi que des groupes-classes stables.
Événement
23 août Début de la deuxième vague.
épidémiologique
Mesures de
2 septembre Reprise des sports de combat (ex. karaté, taekwondo, boxe, judo), sans compétitions.
santé publique
Instauration d’un système d’alertes régionales selon un code de 4 couleurs : vigilance (vert), préalerte
Mesures de
8 septembre (jaune), alerte modérée (orange) et alerte maximale (rouge). Les régions de la Capitale-Nationale, Laval,
santé publique
Estrie et Outaouais se trouvent au palier jaune.
Suspension des activités de karaoké dans des lieux publics (bars, des salles louées ou des salles
Mesures de communautaires).
11 septembre
santé publique
Les tenanciers de bars ont l'obligation de tenir un registre des clients qui entrent dans leur établissement.
Mesures de Les individus qui refusent sans raison de porter un masque dans les lieux publics intérieurs pourront se voir
12 septembre
santé publique remettre un rapport d'infraction par les forces de l'ordre et seront ainsi passibles d'une amende.
Mesures de
14 septembre Reprise des activités parascolaires et des programmes spécialisés en arts et sports-études.
santé publique
Port du masque obligatoire dans les aires communes des RPA.

Mesures de
15 septembre Les régions du Bas-Saint-Laurent, de la Chaudière-Appalaches, de Montréal et de la Montérégie passent au
santé publique
niveau d'alerte régionale « préalerte » portant ainsi le nombre total de régions classées « jaunes » à huit.
Les régions de Montréal et de la Chaudière-Appalaches, ainsi qu'une portion de la région de la Capitale-

Mesures de
20 septembre Nationale passent au palier orange. Certaines parties des régions de Lanaudière et des Laurentides passent
santé publique
au palier jaune.
Nouvelles mesures pour les paliers vert et jaune : le nombre maximal de personnes permis lors
d’événements redescend à 50 personnes (plutôt que 250).
Palier orange :
Mesures de maximum 6 personnes ou 2 familles lors de rassemblements privés;

21 septembre maximum 25 personnes lors d'activités organisées dans un lieu public;
santé publique
maximum 6 personnes par table dans les bars et les restaurants;
fin de la vente d'alcool et de nourriture à 23 h et fermeture des bars à minuit; déplacements vers
d'autres régions non recommandés;
seules les visites à des fins humanitaires et de proches aidants sont autorisées dans les CHSLD;
dans les RPA, visites d’un maximum de 6 personnes, incluant le résident, dans l’unité locative.
Mesures de
22 septembre Les régions de Laval et de l’Outaouais passent au palier orange.
santé publique
Mesures de
23 septembre La MRC d'Avignon en Gaspésie passe au palier jaune.
santé publique
AR02759
Type
d'événement
La CMM, la MRC de la Rivière-du-Nord, la région de la Chaudière-Appalaches et une portion de la Capitale-

Nationale passent au palier rouge.
Mesures de Les régions qui étaient au palier jaune passent à l'orange (Bas-Saint-Laurent, Estrie, une portion de la
28 septembre
santé publique Capitale-Nationale et des secteurs de la Gaspésie, de Lanaudière, des Laurentides et de la Montérégie).
Les régions qui étaient au palier vert passent au jaune (l'Abitibi-Témiscamingue, Nord-du-Québec, Terres-
Cries-de-la-Baie-James, Nunavik, Saguenay-Lac-Saint-Jean et Côte-Nord).
Événement
29 septembre Le Québec atteint 75 000 cas.      
épidémiologique
Le ministre de la Santé et des Services sociaux demande à l'ensemble des Québécois de limiter au
maximum leurs contacts pour une période de 28 jours (du 1er au 28 octobre) afin de freiner la 2e vague.
Mesures additionnelles spécifiques au palier rouge :
Seuls les habitants d'une même adresse peuvent se rassembler.

Mesures de Les activités de groupe organisées dans un endroit public intérieur seront interdites.
1er octobre
santé publique Les lieux accueillant un auditoire (salles de spectacle, cinémas, théâtres, bibliothèques, musées)
seront fermés.
Les bars, brasseries, tavernes et casinos seront fermés ainsi que les salles à manger des
restaurants.
Les déplacements non essentiels vers une région verte, jaune ou orange et à l'extérieur du Québec
seront non recommandés.
Mesures de
5 octobre Trois municipalités de la MRC d'Avignon (en Gaspésie) passent au palier rouge.
santé publique
Mesures de Assouplissements concernant les visites en contexte de fin de vie, dans l'ensemble des milieux de soins et
7 octobre
santé publique de vie, dans toutes les régions peu importe le niveau d'alerte.
Renforcement des mesures sanitaires en zone rouge pour les réseaux de l'éducation, de l'enseignement
Mesures de supérieur et pour le milieu sportif, notamment : Port du masque obligatoire partout dans les écoles
8 octobre
santé publique secondaires en zone rouge, incluant en salle de classe et sur le terrain de l’école; Activités sportives et de
loisirs organisées non permises; Fermeture des gyms et centres de conditionnement.
Événement en
8 octobre lien avec le Révision des priorités de tests de dépistage, selon les paliers.
dépistage
Mesures de Points de contrôle policier aléatoires pour assurer le respect des consignes et limiter les déplacements non
9 octobre
santé publique essentiels entre régions.
Mesures de Secteurs qui passent au palier rouge : MRC de Portneuf, de Drummond, de Bécancour et de Nicolet-
10 octobre
santé publique Yamaska, ville de Trois-Rivières.
Mesures de
11 octobre La Ville de Gatineau et la MRC des Collines-de-l'Outaouais passent au palier rouge.
santé publique
Secteurs qui passent au palier rouge : toute la Montérégie, les MRC de Charlevoix, de Charlevoix-Est,
d'Arthabaska et de l'Érable.
Mesures de La région du Saguenay-Lac-Saint-Jean passe au palier orange.

16 octobre
santé publique
Fermeture des bars et des restaurants pour les régions en zone rouge.
Autorisation du ski alpin.
Mesures de Secteurs qui passent au palier rouge : MRC de Joliette et d'Autray.

22 octobre
santé publique Réintensification des actions de la CNESST partout au Québec.
AR02760
Type
d'événement
Événement
24 octobre Le Québec atteint 100 000 cas.
épidémiologique
L'ensemble de la Mauricie-et-Centre-du-Québec passe au palier rouge.

Mesures de
24 octobre Le gouvernement rappelle aux citoyens d'éviter les déplacements non essentiels d'une région à l'autre ou
santé publique
d'une ville à l'autre.
Prolongement des mesures en zone rouge jusqu'au 23 novembre.

Mesures de
26 octobre
santé publique
L'ensemble de la MRC de L'Assomption passe au palier rouge.
Mesures de
27 octobre Les municipalités en zone rouge peuvent à nouveau tenir des élections partielles.
santé publique
Mesures de Collecte de bonbons de maison en maison autorisée, avec consignes à suivre pour réduire les risques de
31 octobre
santé publique transmission de la COVID-19.
Mesures de
2 novembre Saguenay-Lac-Saint-Jean et Chaudière-Appalaches passent au palier rouge.
santé publique
Le territoire des Îles-de-la-Madeleine passe au palier jaune.

Mesures de
6 novembre
santé publique Activités hivernales offertes dans les centres de glisse et les centres de plein air autorisées; accès aux relais
et aux refuges du grand réseau de sentiers de motoneige.
Les municipalités de Carleton-sur-Mer, de Maria et de Nouvelle, en Gaspésie, passent du palier d'alerte

Mesures de rouge au orange. Toute la Gaspésie est au palier orange.
10 novembre
santé publique
La région du Nord-du-Québe passe du palier jaune au palier orange.
Événement en
11 novembre lien avec le Deux millions de Québécois ont été testés (23 % de la population).
dépistage
Mesures de Les marchés de Noël seront ouverts, en évitant toute forme d'animation et en évitant les dégustations dans
11 novembre
santé publique les régions aux paliers d'alerte orange et rouge.
Mesures de
12 novembre L'Estrie passe au palier d'alerte rouge.
santé publique
Proposition d'un contrat moral pour le temps des fêtes : si la situation épidémiologique se maintient, les
Mesures de
19 novembre rassemblements privés d'au maximum 10 personnes seraient autorisés du 24 au 27 décembre, avec
santé publique
confinement volontaire une semaine avant et une semaine après cette période.
Compte tenu de la situation épidémiologique, les rassemblements seront interdits dans les zones rouges,
Mesures de
3 décembre sauf pour les personnes seules, qui peuvent recevoir la visite d'une seule personne. Le confinement
santé publique
volontaire est maintenu.
Mesures de Restriction du nombre de personnes admises dans les commerces. La capacité d’accueil doit respecter le
4 décembre
santé publique ratio Superficie de plancher accessible aux clients en m2 divisé par 20 m2.
Événement
5 décembre Le Québec atteint 150 000 cas.
épidémiologique
Mesures de
7 décembre Les secteurs de l’est du Bas-Saint-Laurent passent au niveau d’alerte maximale.
santé publique
AR02761
Type
d'événement
Mesures de
14 décembre
santé publique
Les MRC des Laurentides et des Pays-d’en-Haut, ainsi que deux autres MRC de l’Outaouais passent au
niveau d’alerte maximale.
Les premiers Québécois a avoir reçu le vaccin contre la COVID-19 sont des résidents aînés et des
Événement en
travailleurs du CHSLD Centre gériatrique Maimonides Donald Berman, à Montréal, et du Centre
14 décembre lien avec la
d'hébergement Saint-Antoine, dans la Capitale-Nationale. La vaccination se poursuivra selon les groupes
vaccination
prioritaires.
Temporairement pour la période des Fêtes, toutes les régions sociosanitaires du Québec passeront au palier
Mesures de d’alerte maximale (rouge), à l’exception des régions suivantes qui seront temporairement au palier d’alerte
15 décembre
santé publique orange : Abitibi-Témiscamingue, Nord-du-Québec, Côte-Nord, Grosse-Île et Iles-de-la-Madeleine, Nunavik,
Terres-Cries-de-la Baie James.
Interdiction de se déplacer vers une région se trouvant au palier d’alerte orange en vigueur jusqu'au
11 janvier.
Mise à jour des consignes pour le temps des fêtes
Rassemblements privés (intérieurs ou extérieurs) interdits en zones rouges et orange (celles-ci sont
Mesures de considérées rouge temporairement). Seules les personnes qui résident à une même adresse
17 décembre pourront se côtoyer.
santé publique
Pour l’ensemble des zones, les personnes seules, incluant leurs enfants, peuvent se joindre à une
autre bulle familiale durant cette période.
Activités sportives, culturelles et récréatives en groupe permises à l’extérieur dans les lieux publics
(incluant les cours, entraînements et activités guidées), seules, en duo, en famille ou en groupe d’un
maximum de 8 personnes et d'un superviseur, à la condition que les personnes maintiennent entre
elles une distance de 2 mètres.
Événement en
Les personnes proches aidantes en CHSLD âgées de plus de 70 ans seront ajoutées aux clientèles
prioritaires du Programme de vaccination.
vaccination
Mesures de Les commerces non prioritaires devront fermer du 25 décembre 2020 au 10 janvier 2021

25 décembre
santé publique inclusivement.
Le Québec atteint 200 000 cas.

Événement
29 décembre
épidémiologique Détection au Québec du variant préoccupant B.1.1.7 du SRAS-CoV-2 ayant émergé au Royaume-Uni
(alpha).
Événement en
Tous les vaccins reçus seront utilisés de manière à immuniser le plus grand nombre de personnes possible
auprès des groupes prioritaires, il n’est plus nécessaire de conserver la deuxième dose en réserve.
vaccination
2021
Date Type d'événement Mesures adoptées
Prolongation de la fermeture des commerces prioritaires jusqu'au 8 février.
Les voyageurs âgés de cinq ans ou plus, quelle que soit leur citoyenneté, doivent fournir la preuve d’un
résultat négatif au dépistage de la COVID‑19 en laboratoire avant de monter à bord d’un vol à
Mesures de santé
7 janvier destination du Canada. Le dépistage doit être effectué dans les 72 heures avant le départ vers le
publique
Canada.
Port du masque de procédure obligatoire sur les terrains et dans un établissement scolaire collégial,
universitaire ou un centre d’éducation des adultes et de formation professionnelle.
Mesures de santé Couvre-feu en vigueur de 20 heures à 5 heures du matin. Interdiction de se trouver hors de son lieu de
9 janvier
publique résidence, sauf cas d’exceptions.
AR02762 Type d'événement
Mesures de santé Rentrée des élèves du primaire. Port du couvre-visage en classe obligatoire pour les élèves de 5e et 6e
11 janvier
publique année. Port d’un couvre-visage par tous les élèves en tout temps dans les corridors et les aires
communes. Port du masque de procédure obligatoire pour le personnel.
Rentrée des élèves du secondaire. Port d’un masque de procédure par tous les élèves en tout temps
Mesures de santé dans l’école et sur le terrain de l'école. Port du masque de procédure obligatoire pour le personnel dans
18 janvier
publique toutes les aires communes, sauf en classe si la distance de 2 mètres avec les élèves est maintenue.
Deux masques de procédure seront distribués quotidiennement aux élèves et enseignants.
Événement
21 janvier Le Québec atteint 250 000 cas.
épidémiologique
Événement
6 février Le Québec atteint 10 000 décès.
épidémiologique
Les régions Gaspésie−Îles-de-la-Madeleine, Bas-Saint-Laurent, Côte-Nord, Nord-du-Québec,

Abitibi-Témiscamingue et Saguenay−Lac-Saint-Jean passent au palier d’alerte orange.
Réouverture des commerces non prioritaires (y compris soins personnels et esthétiques),
centres commerciaux et bibliothèques;
Activités extérieures permises pour 4 personnes en zone rouge et 8 en zone orange;
Limite d'accueil dans les lieux de culte de 25 personnes en zone orange et 10 en zone rouge.
Mesures de santé
8 février En zone orange, réouverture des restaurants (max. 2 adultes par table, preuve de résidence et
publique
registre); des salles à manger dans les résidences pour personnes âgées; des gyms pour des
entraînements individuels et activités sportives et de loisirs intérieures (pratique individuelle, en
duo ou avec les occupants d’une même résidence privée).
Retour partiel des étudiants sur les campus collégiaux et universitaires : en zone orange, tous
les types d’activités d’enseignement, incluant les cours théoriques, peuvent être offerts en
présence; en zone rouge, le taux d’occupation des salles ne doit pas excéder 50 %.
Événement
9 février Détection du variant préoccupant B.1.351 du SRAS-CoV-2 ayant émergé en Afrique du Sud (bêta).
épidémiologique
Mesures de santé Les entreprises pourront avoir accès gratuitement à des tests rapides de détection d’antigènes de la
18 février
publique COVID-19 pour leur personnel situé au Québec.
Pour tous les voyageurs arrivant au Canada par la voie aérienne : test de dépistage moléculaire
avant de quitter l’aéroport et vers la fin de leur quarantaine, séjour de trois nuits dans un hôtel autorisé
Mesures de santé par le gouvernement fédéral. Par voie terrestre : test de dépistage moléculaire à leur arrivée et à la fin
22 février
publique de leur quarantaine.
L’Outaouais passe en zone orange.
Réouverture des cinémas et salles de spectacle. Réouverture des piscines et arénas pour pratique libre
et entrainement individuel ou en duo, avec un instructeur. 8 personnes de résidences différentes
peuvent pratiquer des activités sportives et récréatives à l’extérieur dans les lieux public (plus une
personne pour la supervision ou animation).
Mesures de santé
26 février Une personne seule (et ses enfants) peut se joindre aux personnes résidant à une seule autre adresse,
publique
à la condition de former une bulle stable.
Nouvelles consignes pour les parents : si l’enfant doit passer un test, toutes les personnes vivant sous
le même toit doivent également s’isoler, même si celles-ci n’ont pas de symptômes, au moins jusqu’à
l’obtention du résultat de test, et ensuite suivre les consignes qui leur seront données.
Événement en lien
1er mars Début de la vaccination dans la population générale, en fonction des groupes d’âge.
avec la vaccination
Événement
6 mars Détection du variant préoccupant P.1 du SRAS-CoV-2 ayant émergé au Brésil (gamma).
épidémiologique
Port du masque d'intervention pour les élèves de la 1re à la 6e année des écoles primaires en zone
rouge, en tout temps dans la classe, lors des déplacements ainsi que dans le transport scolaire (ne
concerne pas certains élèves ayant des besoins particuliers et ne s’applique pas dans la cour de
Mesures de santé
8 mars récréation).
publique
Les régions sociosanitaires Capitale-Nationale, Chaudière-Appalaches, Estrie et Mauricie–Centre-du-
Québec passent en zone orange.
11 mars Autre événement Cérémonie de commémoration nationale des victimes de la COVID-19.
En zone orange : les activités parascolaires en présentiel et les sorties scolaires peuvent reprendre
Mesures de santé
15 mars dans les établissements d’enseignement préscolaire, primaire et secondaire. Réouverture des
publique
installations intérieures et extérieures des établissements de spas.
Événement
17 mars Le Québec atteint 300 000 cas.
épidémiologique
Mesures de santé
17 mars Le couvre-feu en zone rouge sera désormais de 21 h 30 à 5 h.
publique
Événement
20 et 21 mars Fin de la deuxième vague (23 août 2020 - 20 mars 2021) et début de la troisième vague.
épidémiologique
Événement
22 mars Détection du variant d'intérêt B.1.525 du SRAS-CoV-2 ayant émergé au Nigéria (êta).
épidémiologique
Événement en lien
23 mars Un million de personnes ont été vaccinées au Québec.
avec la vaccination
Mesures de santé Réouverture des salles à manger dans les RPA en zone rouge dont les résidents ont été vaccinés
24 mars
publique depuis plus de 21 jours.
Événement en lien
25 mars Une seule dose peut être administrée aux personnes ayant eu un diagnostic confirmé de COVID-19.
avec la vaccination
En zone rouge : les lieux de culte peuvent accueillir un maximum de 25 personnes. Autorisation des
activités intérieures sans contact dans tout lieu, incluant tous les plateaux sportifs ou salles
d’entraînement, avec capacité d’accueil restreinte. Réouverture des piscines intérieures des
établissements hôteliers. Réouverture des installations intérieures et extérieures des établissements de
spas. Réouverture des salles de spectacles (mêmes consignes que les cinémas).
En zone orange : Activités extérieures sans contact permises pour des groupes de 12 personnes.
Mesures de santé Activités intérieures sans contact permises en groupe d’un maximum de 8 personnes, avec
26 mars
publique encadrement obligatoire. Autorisation des activités parascolaires intraécole pour les élèves du
préscolaire, primaire et secondaire de groupes-classes différents.
Les régions de la Gaspésie–Îles-de-la-Madeleine, la Côte-Nord et le Nord-du-Québec passent en zone

jaune. Assouplissements supplémentaires pour ces régions : réouverture des bars et microbrasseries;
levée du couvre-feu; rassemblements permis dans les domiciles et sur les terrains privés, limités aux
occupants de deux résidences; les occupants d’au plus deux résidences privées pourront partager une
table dans les restaurants.
Mesures de santé
29 mars Les élèves de 3e, 4e et 5e secondaires en zone rouge reviendront en classe à temps plein.
publique
Les régions du Bas-Saint-Laurent, de la Capitale-Nationale, de la Chaudière-Appalaches et de

l'Outaouais repassent en zone rouge.
Mesures spéciales d'urgence pour la Communauté métropolitaine de Québec (y compris Lévis), la

ville de Gatineau et la MRC des Collines-de-l'Outaouais :
Couvre-feu en vigueur de 20 h à 5 h.

Fermeture des écoles primaires et secondaires (apprentissages en ligne); des cinémas, des
Mesures de santé salles de spectacle et des musées; des restaurants (sauf pour livraison et comptoirs pour
1 avril
publique emporter); des commerces non essentiels.
Interdiction pour les commerces de vendre des produits non essentiels.
Limite de 25 personnes dans les lieux de culte.
Activités extérieures de sport ou de loisirs permises uniquement avec les personnes résidant à
la même adresse ou par un groupe de 8 personnes avec distanciation.
Les mesures spéciales d'urgence s'appliquent également dans les RPA (ex: salons de coiffure,
les piscines, les salles de conditionnement physique et les salles de cinéma devront cesser leurs
activités à l’intérieur d’une RPA).
Mesures de santé Mesures spéciales d’urgence dans plusieurs MRC de la région de la Chaudière-Appalaches : Beauce-
5 avril
publique Sartigan, Bellechasse, Les Etchemins, La Nouvelle-Beauce, Robert-Cliche.
Resserrements à certaines mesures en zone orange :
Interdiction de se déplacer vers une région au palier jaune.

Maximum de 100 personnes dans les lieux de culte (sauf pour funérailles et mariages, dont les
cérémonies sont limitées à 25 personnes).
Ajout de l'interdiction de changer de table pour la durée de la présence dans les restaurants.
Lors d'activités extérieures en groupe (maximum 12 personnes), port du masque ou du couvre-
visage obligatoire lorsque les personnes ne résident pas ensemble, sauf si elles sont assises à
2 mètres de distance.
Lors d'activités intérieures, seule la pratique individuelle, à deux ou entre les occupants d'une
même résidence est permise. Les cours individuels ou aux occupants d'une même résidence
privée peuvent être offerts.
Registre et port du masque obligatoire, en tout temps, dans les salles d'entraînement.
Activités parascolaires en groupes-classes seulement.
Resserrements à certaines mesures en zone rouge :
Interdiction de se déplacer vers une région au palier jaune.

Mesures de santé Les lieux de culte sont limités à 25 participants. Ce nombre maximal de personne s’applique
8 avril
publique
également pour les funérailles et les mariages.
Lors d'activités extérieures en groupe (maximum 8 personnes), port du masque ou du couvre-
visage obligatoire lorsque les personnes ne résident pas ensemble, sauf si elles sont assises à
2 mètres de distance.
Lieux publics intérieurs fermés pour la pratique de loisirs et de sports, sauf les piscines, les
patinoires et les lieux pour jouer au tennis et au badminton.
Port d'un masque ou couvre-visage obligatoire dans les arénas.
Gyms fermés.
Zones intérieures de spas fermés, à l’exception des bassins d’eau et des soins personnels.
Toute personne qui habite dans une zone jaune et qui se déplace dans une région qui se retrouve en
zone rouge, orange ou dans les régions de l’Abitibi-Témiscamingue ou de la Côte-Nord doit s’isoler
pendant 14 jours à son retour (exemptions pour le travail, les études, les fins humanitaires, pour obtenir
ou prodiguer des soins ou des services de santé, pour se conformer à un jugement ou comparaître
devant un tribunal ou pour l’exercice des droits de garde ou d’accès parentaux).
Prolongement des mesures spéciales d’urgence jusqu’au 18 avril dans les régions de la Capitale-
Nationale, de Chaudière-Appalaches et de l’Outaouais.
Mesures de santé
11 avril Couvre-feu devancé à 20 h dans les régions de Montréal et Laval.
publique
En zone jaune, l’accès aux milieux de vie (CHSLD, RI, RPA) est autorisé pour les personnes proches
aidantes d’une autre région de zone jaune ou orange, selon certaines conditions strictes.
En zone orange, port du masque d'intervention obligatoire en classe à compter du 12 avril pour tous les
Mesures de santé
12 avril niveaux (primaire et secondaire).
publique
En zone rouge, école en alternance une journée sur deux pour les élèves de 3e, 4e, et 5e secondaire;
activités parascolaires et sorties scolaires interdites; enseignement à distance seulement aux niveaux
collégial et universitaire (sauf pour activités qui doivent absolument se tenir en présence).
Mesures de santé Prolongement des mesures spéciales d’urgence jusqu’au 25 avril inclusivement pour les régions de la
13 avril
publique Capitale-Nationale, de la Chaudière-Appalaches et de l’Outaouais.
Événement en lien
14 avril Le quart de la population est vaccinée, soit plus de deux millions de Québécois.
avec la vaccination
Mesures spéciales d'urgence étendues à l’ensemble du territoire des régions de la

Chaudière‑Appalaches et de l’Outaouais.
La Côte-Nord passe au palier orange.
Mesures de santé Ajustements aux consignes pour les zones rouge et orange concernant le port obligatoire du
14 avril masque ou du couvre-visage lors d’activités extérieures et intérieures de loisirs ou de sports en
publique
groupe : couvre-visage est obligatoire pour les personnes de résidences différentes qui pratiquent une
activité de loisirs ou de sports ensemble pour la durée complète de l’activité,à l’intérieur comme à
l’extérieur, sauf si les personnes ne s’approchent jamais durant toute l’activité à deux mètres les unes
des autres; quand les personnes demeurent assises à deux mètres les unes des autres à l'extérieur et
pour les activités de baignade ou les sports nautiques.
Fermeture de la frontière avec l'Ontario afin d'éviter la propagation des variants; contrôles
Mesures de santé
19 avril sporadiques effectués afin de limiter les déplacements entre les deux province; quelques exceptions
publique
permises.
Mesures de santé Mesures spéciales d’urgence prolongées jusqu’au 2 mai dans les régions de l’Outaouais, de la
20 avril
publique Chaudière-Appalaches et sur le territoire de la Communauté métropolitaine de Québec.
Événement
26 avril Détection du variant préoccupant B.1.617 ayant émergé en Inde (delta).
épidémiologique
Mesures de santé Mesures spéciales d’urgence prolongées jusqu’au 9 mai dans les régions de l’Outaouais, de la
27 avril
publique Chaudière-Appalaches et sur le territoire de la Communauté métropolitaine de Québec.
Mesures de santé Mesures spéciales pour deux semaines dans la région du Bas-Saint-Laurent, à l’exception des MRC de
1ermai publique Matanie (Matane), de Matapédia et de La Mitis.
Retour en classe des élèves du préscolaire et du primaire de la Capitale-Nationale et Chaudière-

Mesures de santé Appalaches pour les centres de services scolaire des Navigateurs, des Appalaches et de la Côte-du-
3 mai Sud, à l’exception des écoles situées dans la MRC de Bellechasse.
publique
Couvre-feu à 21 h 30 pour Montréal et Laval.
Mesures de santé Mesures spéciales d’urgence sur le territoire de la MRC du Granit en Estrie. Les écoles primaires
6 mai
publique pourront rester ouvertes.
Levée des mesures spéciales d’urgence pour la Capitale-Nationale; la ville de Lévis et les municipalités
régionales de comté (MRC) de Lotbinière, de Bellechasse, de Montmagny, de L’Islet, des Appalaches et
de La Nouvelle-Beauce en Chaudière-Appalaches; les MRC de Papineau et de La Vallée-de-la-
Mesures de santé Gatineau en Outaouais.
10 mai
publique
L’Abitibi-Témiscamingue passe au palier jaune.
Réouverture des écoles primaires toujours fermées en raison des mesures spéciales d’urgence.
Levée des mesures d’urgence en Outaouais et dans la MRC de Rimouski-Neigette du Bas-Saint-

Laurent.
Mesures de santé
17 mai
publique Retour des élèves des écoles secondaires situées dans les trois MRC de la région de la Chaudière-
Appalaches (MRC des Etchemins, de Beauce-Sartigan et de Robert-Cliche), à temps plein pour les
élèves de 1er et 2e secondaire et un jour sur deux pour les élèves de 3e, 4e et 5e secondaire.
Événement en lien
18 mai La moitié de la population québécoise est vaccinée.
avec la vaccination
Retour en classe des élèves du secondaire des MRC du Bas-Saint-Laurent, à temps plein pour les
élèves de 1er et 2e secondaire et un jour sur deux pour les élèves de 3e, 4e et 5e secondaire.
Mesures de santé La Côte-Nord passe au palier jaune (le couvre-feu a été levé le 20 mai).
24 mai
publique
Mesures spéciales d'urgence levées partout au Québec, c.-à-d. MRC du Granit en Estrie, MRC des
Etchemins, de Beauce-Sartigan et de Robert-Cliche (Chaudière-Appalaches), MRC de Kamouraska, de
Témiscouata, de Rivière-du-Loup et Les Basques (Bas-Saint-Laurent).
Début des assouplissements partout au Québec, minimum 14 jours suivant la fin des mesures
d’urgence, le cas échéant.
Retrait du couvre-feu.
Ouverture des terrasses extérieures des restaurants
Palier rouge et orange : 2 adultes avec enfants mineurs de résidences différentes ou les
occupants de 1 résidence par table.
Mesures de santé Palier jaune : occupants de 2 résidences à la même table.
28 mai
publique Rassemblements permis sur les terrains privés extérieurs; Maximum 8 personnes de résidences
différentes ou les occupants de 2 résidences différentes. Distanciation physique de 2 mètres.
Levée des interdictions de déplacements.
Allègement des règles pour les grandes salles intérieures et les stades extérieurs ayant des
places assignées d’avance : maximum de 2500 personnes en plusieurs zones indépendantes de
250 personnes; entrées, sorties et toilettes distinctes pour chaque zone; zones intérieures
délimitées; surveillance des zones en tout temps; gestion des entrées répartie dans le temps.
En palier rouge, un maximum de 1000 personnes peut assister aux spectacles déambulatoires.
Régions qui passent au palier orange : Capitale-Nationale, Laurentides, Lanaudière, Montérégie et

Outaouais; Bas-Saint-Laurent, Chaudière-Appalaches et Estrie passent également au palier orange,
sauf pour certains secteurs qui demeureront au palier rouge.
Mesures de santé
31 mai
publique Des activités destinées à souligner la fin des études des élèves pourront être organisées, selon le plan
de déconfinement (à l’école et pendant les heures de classe, à l’intérieur ou à l’extérieur, sur les terrains
de l’installation; élèves et personnel scolaire; élèves répartis par bulle-classe)
Événement en lien
6 juin L'objectif de vacciner (au moins une dose) 75 % de la population de 12 ans et plus a été atteint.
avec la vaccination
Régions qui passent du palier rouge au palier orange : Montréal; Laval; MRC du Granit (Estrie); MRC de
Beauce-Sartigan, de L’Islet, de Montmagny et de Robert-Cliche (Chaudière-Appalaches); MRC de
Kamouraska, de Rivière-du-Loup, de Témiscouata et Les Basques (Bas-Saint-Laurent).
Régions qui passent au palier jaune : Saguenay–Lac-Saint-Jean; Mauricie et Centre-du-Québec; MRC

de Rimouski-Neigette, de La Mitis, de La Matapédia et de Matane (Bas-Saint-Laurent).
Régions qui passent au palier vert : Abitibi-Témiscamingue; Côte-Nord; Gaspésie – Îles-de-la-

Madeleine; Nord-du-Québec.
Port du masque non obligatoire en classe au palier orange.

Mesures de santé
7 juin
publique Allègements aux mesures dans les milieux de vie :
Palier vert : permis de recevoir 9 personnes à l’intérieur du milieu de vie, pour un total de
10 personnes incluant le résident
Palier jaune : permis de recevoir les personnes d’une autre résidence, et ce, en tenant compte
de la capacité d’accueil du milieu (par exemple : chambre, unité locative).
Palier orange : une personne à la fois pourra se rendre dans les milieux de vie.
Les visiteurs n’auront plus à prendre rendez-vous. Les personnes pourront se joindre à eux lors
des repas, selon certaines conditions qui varient en fonction des paliers d’alerte. Les résidents
d’une même résidence privée pour aînés (RPA) qui auront eu deux doses de vaccin pourront se
côtoyer à l’intérieur de leur unité locative, et ce, peu importe le palier d’alerte.
Ouverture des terrasses extérieures des bars. Palier rouge et orange : 2 adultes de résidences
différentes ou les occupants de 1 résidence par table. Palier jaune : Les occupants de 2 résidences
Mesures de santé peuvent être ensemble à la même table.
11 juin
publique
Sports et loisirs supervisés permis à l’extérieur en groupes de 25 personnes. Palier rouge et orange :
sports sans contact. Palier jaune : sports avec contacts brefs.
Régions qui passent de palier orange au palier de préalerte (jaune) : Capitale-Nationale; Chaudière-
Appalaches; Estrie; Montréal; Outaouais; Laval; Lanaudière; Laurentides; Montérégie; MRC de
Mesures de santé Kamouraska, de Rivière-du-Loup, de Témiscouata et Les Basques (Bas-Saint-Laurent).
14 juin
publique
Bars situés en zone verte et jaune pourront servir de l’alcool jusqu’à minuit (tout comme les restaurants)
et fermer à deux heures.
Spectacles et événements sportifs peuvent accueillir jusqu’à 3 500 personnes, tant à l’intérieur qu’à
l’extérieur, s'applique également aux cinéparcs en palier vert ainsi qu’aux festivals et grands
Mesures de santé événements qui seront autorisés à l’extérieur à compter du 25 juin. Sauf pour les cinéparcs, l’auditoire
17 juin
publique devra être subdivisé en sections indépendantes ayant chacune une limite maximale de 250 personnes.
Chaque section devra avoir des points d’entrée, de sortie et des installations sanitaires indépendants,
de même que des espaces de restauration distincts, si cela s’applique.
Mesures de santé Régions qui passent au palier vert : Bas-Saint-Laurent; Saguenay–Lac-Saint-Jean; Mauricie et Centre-
21 juin
publique du-Québec.
L’isolement préventif n’est plus requis pour un contact considéré comme protégé (personnes ayant reçu
Mesures de santé
22 juin les deux doses de vaccins si leur exposition à un cas s’est produite plus de 7 jours après avoir reçu la
publique
seconde dose; sinon, elles sont considérées comme partiellement protégées).
Ouverture des camps de jour et des camps de vacances. Allègements des exigences sur le port du
masque et la distanciation lors de rassemblement privés pour les personnes ayant reçu 2 doses de
Mesures de santé
25 juin vaccin. Activités et événements publics extérieurs permis selon des règles particulières. Allègement des
publique
règles pour les stades extérieurs ayant des places fixes assignées d’avance. Maximum de
2500 personnes.
Toutes les régions passent au nouveau palier vert. Nouveaux allègements au palier vert :
Rassemblements privés et terrasses extérieures : maximum 20 personnes sur des terrains

privés extérieurs, 20 personnes à la même table sur les terrasses des restaurants et des bars,
Mesures de santé 10 personnes ou les occupants de 3 résidences différentes à l’intérieur des domiciles privés.
28 juin
publique
Cinémas, salles de spectacles et stades avec des sièges assignés : Distanciation de 1,5 m entre
les sièges des personnes qui ne résident pas à une même adresse peut être calculée
latéralement (il n'est plus nécessaire de libérer un espace de 1,5 m devant et derrière les
personnes), ce qui permettra d’augmenter le nombre de spectateurs.
Mesures de santé Limite rehaussée de 3500 à 5000 personnes pour les festivals et événements extérieurs; 500
2 juillet
publique personnes par section indépendante; superficie minimale de 2 m2 par personne.
Mesures de santé Les voyageurs entièrement vaccinés entrant au Canada peuvent être admissibles à certaines
5 juillet
publique exemptions concernant la quarantaine et le dépistage.
Les bals peuvent accueillir, à l’extérieur, un maximum de 250 personnes. Il est également possible
Mesures de santé d’organiser une cérémonie de reconnaissance ou de graduation au palier vert et jaune, avec un
8 juillet
publique maximum de 250 personnes demeurant assis. Présence des parents autorisée, si le nombre maximum
de personnes est respecté.
Nouveaux assouplissements :
Distanciation abaissée de 2 mètres à 1 mètre, tant à l'extérieur qu'à l'intérieur, sauf pour activités
de chant et pratique d’exercices à intensité élevée dans les gyms.
Mesures de santé Levée des restrictions de capacité dans les commerces de détail.
12 juillet
publique
Dans les lieux intérieurs et extérieurs avec places fixes, un siège doit demeurer libre entre des
personnes de résidences différentes. La distanciation de 1 mètre doit être conservée dans les
espaces communs.
Le port du couvre-visage demeure obligatoire dans les lieux publics.
Événement
17 et 18 juillet Fin de la troisième vague (21 mars 2021 - 17 juillet 2021) et début de la quatrième vague (18 juillet).
épidémiologique
Capacité d’accueil rehaussée lors d'événements : lorsque les personnes demeurent assises à des
places déterminées (500 personnes à l'extérieur, 250 à l'intérieur); dans les stades, salles et
Mesures de santé festivals (15 000 à l'extérieur et 7 500 à l'intérieur, avec sections à 500 personnes).
1er août
publique
Vente d’alcool possible jusqu’à 1 h du matin pour les établissements tels que les bars, les restaurants et
les microbrasseries.
Le port du couvre-visage n'est plus obligatoire sur les ponts extérieurs des traversiers (distanciation
physique d'un mètre avec les autres clients ou les employés).
Mesures de santé Le masque peut être retiré à l'extérieur en période de chaleur extrême. La CNESST déclare que le port
2 août du masque n'est pas obligatoire dans les milieux extérieurs même si la distanciation physique d'un
publique
mètre ne peut être respectée, lorsqu'un avertissement de chaleur est émis par Environnement Canada.
Cette autorisation temporaire de retirer le masque se termine lorsque les températures reviennent à la
normale, c'est-à-dire sous les 30 degrés Celsius.
Les citoyens et résidents permanents entièrement vaccinés des États-Unis, qui vivent actuellement
Mesures de santé dans ce pays, pourront entrer au Canada pour un voyage discrétionnaire (non essentiel). L’obligation de
9 août
publique passer trois nuits dans un hôtel autorisé par le gouvernement est supprimée pour tous les voyageurs
arrivant par avion.
Rentrée scolaire :
Retour en classe en présence, sans restriction de groupe-classe, pour tous les élèves.
Passeport vaccinal requis pour la pratique de certaines activités parascolaires physiques et
Mesures de santé sportives pour les élèves du secondaire.
24 août
publique Port du masque d'intervention obligatoire en tout temps dans les locaux et salles de classe du
primaire et du secondaire dans 9 régions : Centre-du-Québec, Estrie, Lanaudière, Laurentides,
Laval, Mauricie, Montérégie, Montréal et Outaouais. Port du masque d'intervention en tout
temps, même en classe pour les élèves de la formation générale des adultes et de la formation
professionnelle de toutes les régions.
Mesures de santé
27 août L'agglomération de Montréal passe en mode alerte, l'état d'urgence n'a pas été renouvelé
publique
Mise en place du passeport vaccinal permettant l’accès à certains lieux ou la participation à

certaines activités uniquement aux personnes adéquatement protégées ou à celles ayant une
contre-indication clinique à la vaccination contre la COVID-19. L’utilisation de ce passeport sera
Mesures de santé limitée à des activités jugées non essentielles et qui se tiennent dans des lieux où le risque de
1er septembre
publique transmission entre individus est élevé. Ces activités incluent notamment les événements et festivals, les
salles de spectacle et les salles où se produisent des événements sportifs, les casinos, les cinémas, les
salles d’entraînement, les sports d’équipe, les bars, les restaurants et certaines activités parascolaires.
Le passeport s’appliquera aux personnes de 13 ans et plus seulement.
Mesures de santé Les ressortissants étrangers qui satisfont aux critères d’exemption pour les voyageurs entièrement
7 septembre
publique vaccinés peuvent entrer au Canada pour un voyage de nature discrétionnaire (non essentiel).
Mesures de santé La période d'isolement pour les personnes non adéquatement protégées qui ont été en contact avec un
9 septembre
publique cas confirmé passe de 14 à 10 jours.
Mesures de santé Port du masque en milieu scolaire également obligatoire dans trois MRC de la région de la Chaudière-
10 septembre
publique Appalache (Appalaches, Beauce-Sartigan et Etchemins).
Événement
14 septembre Le Québec atteint 400 000 cas.      
épidémiologique
Déploiement graduel des tests rapides de dépistage de la COVID-19 dans les établissements scolaires
de niveaux préscolaire et primaire des dix régions administratives où les risques d'éclosion sont plus
Événement en lien
17 septembre grands en raison de la situation épidémiologique (Mauricie-Centre-du-Québec; Estrie; Montréal;
avec le dépistage
Outaouais; Chaudières-Appalaches pour les MRC Beauce-Sartigan, Appalaches, et Etchemins; Laval;
Lanaudière; Laurentides; Montérégie).
Port du masque obligatoire pour tous les résidents des RPA des régions à haut taux de transmission
Mesures de santé
27 septembre communautaire, lorsqu'ils se déplacent dans la résidence, l'ascenseur et les espaces communs
publique
intérieurs.
Mesures de santé Port du masque en milieu scolaire également obligatoire dans la MRC de Robert-Cliche (Chaudière-
28 septembre
publique Appalache).
Événement en lien
28 septembre Dose de rappel du vaccin recommandée pour les usagers des CHLSD, RPA et RI-RTF.
avec la vaccination
Événement en lien
30 septembre
avec la vaccination 75 % de l'ensemble de la population du Québec est adéquatement vaccinée.
Port du masque requis dans le transport scolaire pour les élèves du préscolaire, lorsqu'ils sont avec des
élèves de différents niveaux; lors des cours d'éducation physique pour les élèves du primaire, s'il n'est
Mesures de santé
4 octobre pas possible de garder une distance de deux mètres entre les élèves ou d'organiser le cours à
publique
l'extérieur (Mauricie; Centre-du-Québec; Estrie; Montréal; Outaouais; MRC de Beauce-Sartigan,
Appalache et Etchemins; Laval; Lanaudière; Laurentides; Montérégie).
Assouplissements des mesures sanitaires pour les salles de spectacles, les auditoires sportifs et
culturels et les rassemblements publics organisés (ex. : pas de limite du nombre de participants avec
Mesures de santé passeport vaccinal et port du masque pour les événements; pour les cérémonies ou assemblées,
8 octobre
publique passeport requis si plus de 250 personnes à l'intérieur ou 500 à l'extérieur; si moins de 250 personnes
sans passeport vaccinal, distance d'1m; places assignées; 100 participants pour chorales et orchestres,
règles particulières pour les chanteurs et certains musiciens).
Port du masque d'intervention obligatoire pour tous les résidents des RPA et pour tous les élèves des
Mesures de santé
11 octobre établissements scolaires du primaire et du secondaire des MRC de Bellechasse et de Nouvelle-Beauce
publique
(Chaudière-Appalaches).
Événement en lien Déploiement des tests rapides de dépistage dans les établissements scolaires de niveaux préscolaire et
11 octobre
avec le dépistage primaire sur l'ensemble du territoire québécois.
Événement en lien Tests de détection rapide d’antigènes de la COVID-19 pour tous les élèves de la classe lorsqu’un élève
13 octobre
avec le dépistage est confirmé positif, dans trois quartiers de Montréal (Montréal-Nord, Parc-Extension, Saint-Michel).
Mesures de santé Passeport vaccinal obligatoire pour accéder aux établissements de santé et aux milieux de vie,
15 octobre
publique notamment pour les visiteurs et les proches aidants.
Preuve de vaccination répondant au nouveau standard pancanadien disponible pour les voyageurs qui
Mesures de santé
18 octobre doivent se déplacer hors du Québec; reconnue dans l’ensemble des provinces canadiennes, ainsi que
publique
dans plusieurs États américains et pays dans le monde.
Événement en lien Ajout de la région de Chaudière-Appalaches au déploiement des tests de détection rapide pour tous les
21 octobre
avec le dépistage élèves de la classe lorsqu’un élève est confirmé positif, dans les écoles préscolaires et primaires.
Port du masque d’intervention obligatoire en milieu scolaire et RPA de la MRC de La Matapédia.

Mesures de santé Nouvelles recommandations concernant les travailleuses du réseau enceintes et adéquatement
26 octobre
publique
protégées ou vaccinées, qui pourront demeurer au travail dans certains postes, en portant des
équipements de protection individuelle et en respectant certaines mesures visant à les protéger.
Vaccination obligatoire contre la COVID-19 pour les employés du secteur des transports (aérien,
Mesures de santé ferroviaire et maritime) sous réglementation fédérale et ses voyageurs. Les voyageurs en partance
30 octobre
publique d'aéroports canadiens et les passagers à bord des trains de VIA Rail et de Rocky Mountaineer devront
être entièrement vaccinés afin de voyager.
Assouplissement des mesures pour les restaurants et bars (retrait de la limite de capacité, heures
Mesures de santé
d’ouverture habituelles, 1 m entre les tables ou mesures barrières, 10 personnes par table ou les
publique
occupants de 3 résidences privées).
1er novembre
Événement en lien Intervalle recommandé de 6 mois entre la dose de rappel et la dernière dose de vaccin reçue. Intervalle
avec la vaccination optimal de 8 semaines entre les deux premières doses.
Mesures de santé
3 novembre Mesures rehaussées en milieu scolaire à Baie-Comeau (port du masque d’intervention obligatoire).
publique
Assouplissements concernant les écoles secondaires, milieux de travail, restaurants et bars, activités
sportives et récréatives hivernales extérieures, loisirs et sports et rassemblements publics, funérailles,
lieux de cultures, salles de spectacle, congrès, conférences.
Mesures de santé
15 novembre
publique Dépistage des travailleurs de la santé non vaccinés minimalement trois fois par semaine; réaffectation
du personnel non vacciné dans des secteurs à clientèles moins vulnérables; aucun intervenant
présentant des symptômes ne doit se présenter en milieu de soins.
Événement en lien Dose de rappel du vaccin offerte aux personnes de 70 ans et plus qui vivent à domicile; les personnes
16 novembre
avec la vaccination ayant reçu deux doses de vaccin à vecteur viral peuvent recevoir une dose de vaccin à ARN messager.
Événement en lien
24 novembre Début de la vaccination des 5 à 11 ans.
avec la vaccination
Mesures de santé
25 novembre Appel à la vigilance en Estrie et déploiement des tests rapides dans les écoles préscolaires et primaires.
publique
Événement
29 novembre Détection du variant préoccupant Omicron au Québec.
épidémiologique
4 et Événement Fin de la quatrième vague (18 juillet 2021 - 4 décembre 2021) et début de la cinquième vague

5 décembre épidémiologique (5 décembre 2021).
Déploiement de tests rapides de dépistage dans les services de garde; tests fournis par le service de
Événement en lien
6 décembre garde aux parents d’enfants de plus d’un an qui ont développé des symptômes s’apparentant à ceux de
avec le dépistage
la COVID-19.
Dose de rappel du vaccin offerte aux : travailleurs du réseau de la santé et des services sociaux en
Événement en lien contact avec les usagers; personnes appartenant à des communautés isolées et éloignées; personnes
7 décembre
avec la vaccination adultes qui vivent avec une maladie chronique ou un problème de santé; femmes enceintes; personnes
de 65 à 69 ans.
Tests de dépistage rapide distribués dans l’ensemble des écoles primaires du Québec (une trousse de
Événement en lien
9 décembre cinq tests par élève). Distribution élargie à l’ensemble des enfants en service de garde, même si l'enfant
avec le dépistage
ne présente pas de symptômes.
Mesures de santé
10 décembre Mesures rehaussées en milieu scolaire dans la région de la Capitale-Nationale.
publique
Mesures de santé
13 décembre Mesures rehaussées en milieu scolaire dans la MRC de Lotbinière et Lévis.
publique
Tests de dépistage rapide distribués graduellement à l’ensemble de la population, dans près de

Événement en lien
20 décembre 2000 pharmacies à travers le Québec (5 tests rapides gratuits par période de 30 jours jusqu'au
avec le dépistage
31 mars). Tests aussi distribués dans les RPA et CHSLD pour les résidents symptomatiques..
Événement en lien Dose de rappel devancée pour l'ensemble des Québécois de 60 ans et plus, l'intervalle après la
20 décembre
avec la vaccination dernière dose passe de 6 à 3 mois.
Resserrement des mesures dans les milieux de vie et centres hospitaliers (dépistage, distanciation,
masque d'intervention, interdiction d'accès aux aires communes sauf proches aidant à l'alimentation).
En RPA : maximum 5 visiteurs à la fois par jour; 4 résidents par table. En CHSLD, certaines RI-RTF et
certains milieux : un visiteur à la fois, maximum 4 personnes par jour. En centre hospitalier : une
personne proche aidante à la fois, pour un maximum de 2 personnes par jour; maximum quatre
personnes proches aidantes différentes peuvent se relayer; en cas d’éclosion dans un secteur, ce
nombre doit être abaissé à deux.
Resserrement des autres mesures
Télétravail obligatoire.
10 personnes maximum pour les rassemblements privés à l'intérieur (très fortement
recommandé que ces personnes soient adéquatement vaccinées).
Mesures de santé Écoles primaires et secondaires fermées à compter du 21 décembre (sauf pour la vaccination
20 décembre scolaire, la remise des tests rapides et les services de garde). Activités parascolaires annulées.
publique
Activités sportives, professionnelles ou amateurs, présentées à huis clos (exception pour parent
accompagnateur).
Fermeture des concessions alimentaires, des gyms, des spas et saunas (sauf soins
personnels).
Fermeture des bars, tavernes et casinos. Les restaurants demeurent ouverts, avec ouverture
des salles à manger limitée entre 5 h et 22 h.
Fermeture des cinémas, salles de spectacle, suppression des soupers-spectacles, évènements
publics et activités intérieures. Fermeture des lieux particuliers intérieurs (arcades, sites
thématiques, centres d’amusement et récréatifs, etc.).
Limite de 250 personnes, assises, avec passeport vaccinal, dans les lieux de culte et activités
publiques essentielles (assemblées, réunions). Pour les mariages et les funérailles, possibilité
de tenir une cérémonie sans passeport vaccinal avec un maximum de 25 personnes.
Capacité d'accueil des lieux réduite à 50 % dans les commerces et centres commerciaux.
Événement
22 décembre Le Québec atteint 500 000 cas.
épidémiologique
Passeport vaccinal requis pour visiter un proche dans tous les milieux de vie. Abaissement des limites
Mesures de santé
23 décembre de visiteurs : en RPA, 2 visiteurs à la fois, maximum 4 par jour; pour les autres milieux, un visiteur à la
publique
fois, maximum 2 par jour; en cas d’éclosion, personnes proches aidantes seulement.
Abaissement de la limite à six personnes (ou les occupants de deux résidences) pour les
Mesures de santé
26 décembre rassemblements dans les domiciles privés, hébergements touristiques, salles louées et tables des
publique
restaurants. Maximum 2 visiteurs par jour en RPA.
Sous plusieurs conditions, la période d’isolement pourra être réduite pour certains travailleurs de la
Mesures de santé
28 décembre santé positifs à la COVID-19, selon le type d’exposition, les résultats d’analyse de laboratoire et le du
publique
statut vaccinal du travailleur.
Événement en lien Dose de rappel offerte aux travailleurs essentiels, suivis graduellement de l'ensemble de la population,
29 décembre
avec la vaccination selon les groupes d'âge.
Aucun rassemblement privé (une personne seule avec ses enfants peut se joindre à une autre bulle
familiale). Couvre-feu de 22 h à 5 h. Fermeture des commerces le dimanche (sauf pharmacies,
Mesures de santé dépanneurs, stations d'essence). Fermeture des salles à manger des restaurants, aires de restauration
31 décembre
publique et des lieux de culte (sauf pour funérailles). Événements extérieurs avec limite de 250 personnes avec
passeport vaccinal. Sports intérieurs suspendus ou limités à deux personnes (ou personnes de la même
résidence). Rentrée scolaire en présence reportée au 17 janvier.
2022
Type
d'événement
Dans les CHSLD, RI et RPA, seules les personnes proches aidantes sont admises. En CHSLD et RI, 1 personne
Mesures de
4 janvier par jour. En RPA, 1 personne à la fois, maximum 2 par jour. Maximum 4 personnes différentes identifiées ayant
santé publique
accès à l’intérieur du milieu de vie.
AR02772
Type
d'événement
Modification des priorités de dépistage : tests PCR destinés, entre autres, aux personnes symptomatiques
présentes ou se présentant en milieu de soins ou d'hébergement, incluant les travailleurs de la santé et les
personnes en transfert ou en admission; aux personnes issues des communautés des Premières Nations et des
Inuits ou s'y rendant pour travailler; aux personnes en précarité résidentielle; aux contacts à haut risque en
Événement en contexte d’éclosions dans des milieux à haut risque.
5 janvier lien avec le
dépistage Nouvelles durées d'isolement recommandées : 5 jours pour les personnes adéquatement vaccinées (ou
10 jours si les symptômes persistent ou si non adéquatement vacciné); 7 jours pour les travailleurs de la santé
en contact avec des personnes à risque. Pour les contacts à risque élevé : 5 jours d'isolement avec la personne
suivis de 5 jours avec masque et distanciation en tout temps. Pour les contacts modérés, surveiller les
symptômes durant 10 jours.
Événement
7 janvier Le Québec atteint 750 000 cas.
épidémiologique
Événement en
Dose de rappel recommandée pour les personnes ayant récemment eu la COVID-19, après la fin des
12 janvier lien avec la
symptômes.
vaccination
Événement en
Ajout du personnel des services de garde éducatifs à l'enfance dans l'accès aux tests PCR en clinique de
dépistage.
dépistage
Fin du couvre-feu.
Nouvelle distribution d'autotests aux élèves du préscolaire et du primaire. Tests rapides maintenus au primaire.
Port du masque en classe, lors des déplacements dans l'école et durant le transport scolaire (au préscolaire,
Mesure de obligatoire uniquement dans le transport scolaire). Les espaces de restauration et cafétérias des établissements
17 janvier
santé publique d'enseignement supérieur peuvent ouvrir (6 personnes à la même table, 1 mètre entre chaque table).
Même période d'isolement de 5 jours pour le personnel et les élèves de plus de 5 ans adéquatement vaccinés
(sinon 10 jours). Seuls les contacts domiciliaires doivent s'isoler (ex. : l'enfant ou le personnel d'un service de
garde en contact avec un enfant positif ou avec un adulte positif au service de garde n'a pas à s'isoler).
Mesure de Passeport vaccinal requis pour accéder à la Société des alcools du Québec et à la Société québécoise du
18 janvier
santé publique cannabis.
Tests rapides de dépistage mis à la disposition des élèves de l’ensemble des écoles secondaires du Québec. Un
Événement en
élève qui développe des symptômes en cours de journée pourra faire un test rapide à l’école, tout comme le
personnel de ces établissements. Contrairement aux écoles primaires, il ne s’agit pas de tests rapides que les
dépistage
élèves pourront amener à la maison.
Mesure de Passeport vaccinal requis pour accéder aux commerces de vente au détail dont la superficie est supérieure à
24 janvier
santé publique 1500 m2, à l’exception de ceux dont l’activité principale est la vente de produits d’épicerie ou de pharmacie.
Plusieurs actions entreprises pour rejoindre les personnes n’ayant pas reçu leur première dose de vaccin,
Événement en
comme l'identification des quartiers d’intervention ou d'organismes communautaires appelés à contribuer ou
24 janvier lien avec la
l'ouverture d’un lien « Je contribue universitaire » pour que les étudiants de l’Université de Montréal puissent
vaccination
offrir leurs services.
Événement en
25 janvier lien avec le Mise en ligne de la plateforme d’autodéclaration des tests rapides.
dépistage
AR02773
Type
d'événement
Plusieurs assouplissements
Rassemblements privés permis pour les occupants de 2 résidences ou 4 personnes. Il est fortement
recommandé que les personnes soient adéquatement vaccinées.
Réouverture des restaurants (2 résidences ou 4 personnes par table), incluant les aires de restauration
des chalets de ski et relais. Capacité d'accueil à l'intérieur réduite à 50 % et distanciation d'un mètre
entre les tables. Fin de la vente d'alcool à 23 h et fermeture à minuit.
Activités intérieures de sports ou de loisirs permises pour les personnes de moins de 18 ans, limitées à
Mesure de 25 personnes, pour entraînement uniquement.
31 janvier
santé publique Accès aux centres récréatifs et plateaux d'entraînement pour les étudiants athlètes. Reprise des activités
parascolaires (sans matchs, compétitions ou tournois). Passeport vaccinal obligatoire pour les personnes
de 13 ans et plus.
Ouverture de certains lieux intérieurs avec 50 % de la capacité (jardins botaniques, zoos, biodôme,
planétarium, aquariums,...).
Visiteurs en RPA : 4 personnes proches aidantes par jour, possibilité de recevoir 2 personnes à la
fois. En CHSLD et ressources intermédiaires : 1 personne proche aidante à la fois, maximum
2 personnes par jour. Seules les personnes adéquatement protégées peuvent avoir accès aux milieux de
vie.
Lieux de culte ouverts à 50 % de la capacité (maximum 250 personnes, avec passeport vaccinal). Maximum
50 personnes (sans obligation de passeport vaccinal) pour les cérémonies funéraires à l'intérieur.
Mesure de
7 février Événements publics à l'intérieur (notamment cinémas et salles de spectacle) : capacité d'accueil à 50 % ou
santé publique
maximum de 500 personnes, avec passeport vaccinal. À l'extérieur : capacité d'accueil de 1 000 personnes avec
passeport vaccinal.
Les mesures de santé publique actuellement en vigueur sont disponibles sur le site de Québec.ca, section
Mesures en vigueur.
CHSLD : Centre d'hébergement de soins de longue durée
CMM : Communauté métropolitaine de Montréal
DSP : Direction de santé publique
MRC : Municipalité régionale de comté
RPA : Résidence privée pour aînés
RSS : Région sociosanitaire
Source des données :
• Compilation spéciale, INSPQ
Date de mise à jour :

15 février 2022
/nstitut national
de sante publique
-
ue ec aa- ~
© Gouvernement du Québec, 2022
AR02774
URL source (modified on 02/15/2022 - 13:09): https://www.inspq.qc.ca/covid-19/donnees/ligne-du-temps
AR02775
TAB 21
AR02776
Court File No. T-145-22
FEDERAL COURT
BETWEEN:
NABIL BEN NAOUM

Demandeur
et

Défendeur

AND BETWEEN:

Demandeur
et

Défendeur

AND BETWEEN:
AND AEDAN MACDONALD
Applicants
and

Respondent
AR02777

AND BETWEEN:
Applicants
and

Respondent
AFFIDAVIT OF CELIA LOURENCO

Department of Justice Canada
Prairie Regional Office (Winnipeg)
601 – 400 St. Mary Avenue
Winnipeg, MB R3C 4K5
Fax: (204) 983-3636
Per: Sharlene Telles-Langdon, Mariève Sirois-Vaillancourt, Robert Drummond,

Pascale-Catherine Guay, Raymond Lee, James Elford, Mahan Keramati,
Virginie Harvey, Sarah Chênevert-Beaudoin, Michaël Fortier
Tel:
Email:
Counsel for the Respondent

AR02778
FEDERAL COURT
BETWEEN:
NABIL BEN NAOUM

Demandeur
et

Défendeur

AND BETWEEN:

Demandeur
et

Défendeur

AND BETWEEN:
AND AEDAN MACDONALD
Applicants
and

Respondent
AR02779

AND BETWEEN:
Applicants
and

Respondent
AFFIDAVIT OF CELIA LOURENCO
I, CELIA LOURENCO, of the City of Ottawa, in the Province of Ontario, SOLEMNLY

AFFIRM THAT:
1. I am the Director General (DG) of the Biologic and Radiopharmaceutical Drugs

Directorate (BRDD) in the Health Products and Food Branch of Health Canada in Ottawa, Ontario.
I assumed my current position in November 2018. In my current position as DG of the Biologic
and Radiopharmaceutical Drugs Directorate, I am primarily responsible for the scientific review
and regulatory authorization of biologic and radiopharmaceutical drugs, including vaccines, for
the Canadian market. I made the decision to authorize the COVID-19 vaccines developed by
Pfizer-BioNTech, Moderna, AstraZeneca, and Janssen (Johnson & Johnson).
2. I am a pharmacologist by training, with a bachelors and PHD in Pharmacology from the

University of Toronto, Ontario, Canada. I have worked in the Health Products and Food Branch
for over 20 years, occupying various roles ranging from scientific review of new drugs to
management of various teams responsible for evaluation of clinical trials and drug submissions for
new drugs. I have participated in international initiatives focusing on developing internationally
harmonized guidelines and approaches for drug registration. During the past 20 years, I have
developed significant expertise in the application of regulations and guidelines for drug
development, registration, and post-market monitoring, including in relation to vaccines. I am also
an ex officio member of the National Advisory Committee on Immunizations. I have attached a
copy of my current curriculum vitae as Exhibit “A”.
2
AR02780
3. As a result of my position, I have personal knowledge of the facts deposed to in this

affidavit except as follows. As part of my responsibilities in the regulatory approval process for
health products, including vaccines, I necessarily receive information prepared by manufacturers,
various groups within Health Canada, or other federal government departments, agencies working
with Health Canada, and international recognized public health authorities such as the World
Health Organization (WHO). Where in this affidavit I state that I received information gathered
by others in conducting my work functions, I confirm that I trust the accuracy of that information
and believe it to be true based on the professional conduct and ability of those providing that
information. Where I otherwise state my knowledge is based on information and belief, I have
stated the source of my information and believe the same to be true.
A. HEALTH CANADA
4. The Minister of Health is responsible for maintaining and improving the health of
Canadians. This is supported by the Health Portfolio which comprises Health Canada, the Public
Health Agency of Canada, the Canadian Institutes of Health Research, the Patented Medicine
Prices Review Board, and the Canadian Food Inspection Agency. The Health Portfolio consists of
approximately 12,000 full-time equivalent employees and an annual budget of over $3.8 billion.
5. Health Canada is the Federal department responsible for helping Canadians maintain and
improve their health. Health Canada strives to:
i. prevent and reduce risks to individual health and the overall environment;
ii. promote healthier lifestyles;
iii. help ensure high quality health services that are efficient and accessible;
iv. integrate renewal of the health care system with longer term plans in the areas of
prevention, health promotion, and protection;
v. reduce health inequalities in Canadian society; and
vi. provide health information to help Canadians make informed decisions.
3
AR02781
6. One of Health Canada’s core roles is as a regulator. Health Canada has a stewardship role
that involves both protecting Canadians and facilitating the provision of products vital to the healt h
and well-being of Canadians. Health Canada regulates and authorizes the use of thousands of
products, including: biologics, consumer goods, foods, medical devices, natural health products,
pesticides, pharmaceuticals, and toxic substances.
(i.) Health Products and Food Branch (HPFB)
7. The HPFB’s mandate is to manage the health-related risks and benefits of health products
and food by: (a) minimizing health risk factors to Canadians while maximizing the safety provided
by the regulatory system for health products and food; and (b) providing information to Canadians
so they can make healthy, informed decisions about their health.
8. HPFB activities are carried out through offices that include, amongst others, the Biologic
and Radiopharmaceutical Drugs Directorate and the Marketed Health Products Directorate.
(ii.) Biologic and Radiopharmaceutical Drugs Directorate (BRDD)
9. The BRDD regulates biological drugs (products made from living sources, including
vaccines), radiopharmaceuticals (drugs that have radioactivity), blood, plasma, cells, tissues, and
organs for human use in Canada. The BRDD also regulates vaccines that are not made from living
sources such as the mRNA vaccines.
10. The BRDD provides high quality and timely risk-based decisions using currently available
scientific and clinical evidence, enabling access to safe, effective, and quality biologics and
radiopharmaceuticals for the people of Canada.
11. Before manufacturers can market a product in Canada, under the Food and Drug
Regulations, they need to obtain a Drug Identification Number (DIN) or a Notice of Compliance
(NOC), or both. To get these, manufacturers must provide strong evidence of the product's quality,
safety, and efficacy as required under Canada's Food and Drugs Act and Regulations. BRDD
assesses the submission and reviews the clinical, pre-clinical, and quality information, as required,
to determine whether the benefits of the product outweigh the risks, and if or how the risks can be
managed. BRDD also regulates clinical trials conducted in Canada to achieve high standards of
excellence in research and development and to protect clinical trial subjects.
4
AR02782
12. To determine if a drug meets Health Canada’s requirements for market authorization,
reviews are conducted based on results of pre-clinical and clinical studies whose objective is to
determine whether the drug delivers its claimed benefit with acceptable side effects.
13. The chemistry and manufacturing information about the drug is also reviewed to help to
ensure the drug meets quality standards. Since biologic drugs originate from living organisms or
cells, the manufacturing of drugs of this type is typically more complex. As such, the quality
review of a biologic can include on-site evaluations at the manufacturer’s facility and laboratory
assessments such as lot release testing within BRDD’s own laboratories.
14. BRDD applies national and international guidelines and standards in the review and
authorization of drug products, and works with international regulatory authorities and
organizations to develop harmonized evidence standards for drug regulation.
15. Once a product is authorized for sale in Canada, BRDD continues to provide regulatory
oversight, for example, by authorizing changes to the product’s use in response to new submitted
data and authorizing changes to manufacturing processes. The Marketed Health Products
Directorate, discussed below, within HPFB works to monitor the product’s safety and
effectiveness. For vaccines, this monitoring is shared with the Public Health Agency of Canada.
Health Canada’s primary source of data is the manufacturers who have a regulatory requirement
to monitor and report on the safety of their vaccines. Health Canada also accepts voluntary reports
of adverse reactions directly from Canadians. The Public Health Agency of Canada works with
the provinces and receives data from public health channels. The Marketed Health Products
Directorate’s vaccine team works closely with the Public Health Agency of Canada to bring all
sources of information together for monitoring purposes.
16. It is not necessary for a clinical trial to be conducted in Canada for an authorization to be
granted. Further, while authorization for a particular use or population is based on the data
provided in the submission for authorization, it is common for additional clinical studies to be
conducted to continue to gather more safety and efficacy information, for example, in specific
population sub-groups.
5
AR02783
17. The BRDD currently has about 415 full-time equivalent employees, with about 35
employees dedicated to the scientific review of the COVID-19 vaccines. These employees are
physicians and scientists trained in various domains such as infectious diseases, immunology,
pharmacology, toxicology, biostatistics, and biochemistry, and who have expertise in the
regulatory review of biologic drugs, including vaccines. The employees responsible for the
scientific evaluation of the COVID-19 vaccines are found within three BRDD Centres.
(iii.) Centres within the BRDD
18. BRDD contains a number of centres and supporting offices involved in the review and
authorization of biologic and radiopharmaceutical drugs for clinical trials and for the market.
19. The Centre for Biologics Evaluation is responsible for the regulatory and scientific
evaluation of vaccines, allergenic extracts, albumins, immunoglobulins, coagulation factors and
their inhibitors from human plasma or from biotechnology, heparins and heparinoids, blood and
blood components, cells and cell based medicines, gene therapies, tissues and organs for
transplantation, and sperm and ova for use in assisted human reproduction. Specifically, it
evaluates the quality (chemistry and manufacturing) data for these products, both in support of
market authorizations and clinical trials, and delivers an International Organization for
Standardization (ISO) accredited lot release program. The Centre has about 122 full-time
equivalent employees comprising scientific evaluators, research scientists, laboratory, and
administrative staff. The scientific staff have expertise in a variety of scientific disciplines
including immunology, biochemistry, microbiology, and pharmacology, among others.
20. The Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics is responsible for
the scientific evaluation of radiopharmaceuticals and a wide range of biologic products, including
biotechnology-derived products made by manipulating living organisms, such as monoclonal
antibodies, cytokines, hormones, and enzymes. The Centre evaluates the quality and clinical data
in support of these products, and is also responsible for evaluating the clinical data in support of
vaccines. The Centre contributes to the review of clinical trials by evaluating the quality data, and
delivers an ISO accredited lot release program. The Centre has about 121 full-time equivalent
employees comprising scientific evaluators, physicians, laboratory, and administrative staff. The
6
AR02784
scientific staff have expertise in a variety of disciplines including medicine, pharmacology,

toxicology, immunology, biochemistry, and microbiology, among others.
21. The Centre for Regulatory Excellence, Statistics and Trials is responsible for the review
and authorization of clinical data in support of clinical trials for radiopharmaceuticals and
biologics, including vaccines. It also provides biostatistical support to the other Centres within
BRDD in the review of submissions for market authorization, evaluates the labelling and
packaging of drug products, and supports the development and issuance of risk communications
on drug products. The Centre has about 100 fulltime equivalent employees comprising scientific
evaluators, physicians, biostatisticians, regulatory affairs, and administrative staff. The scientific
staff have expertise in a variety of scientific disciplines including medicine, pharmacology,
toxicology, immunology, biochemistry, and microbiology, among others.
(iv.) Marketed Health Products Directorate (MHPD)
22. MHPD leads an evidence-based program that works collaboratively with other
organizations to assess health product risks and makes regulatory decisions to manage those risks.
Once these risks are assessed, decisions on mitigating risks are taken, and information is
communicated openly and transparently to help Canadians make informed decisions. MHPD also
leads the development of regulations for reporting adverse reactions and works closely with
international organizations (such as the European Medicines Agency (EMA) and United States
Federal drug Administration (US FDA)) in the harmonization of regulatory systems to facilitate
the sharing of information.
23. MHPD actively monitors the post-market safety and effectiveness of all health products,
including health products for the prevention or treatment of COVID-19, including vaccines. For
example, MHPD works with industry members and health care workers to monitor safety issues,
and take the necessary steps to manage identified risks. MHPD receives a number of types of
information from industry and others for the purposes of monitoring the safety and effectiveness
of the COVID-19 vaccines. Industry provides safety summary reports, individual adverse events
following immunizations (AEFI) reports (for both Canadian and international cases), and other
information as requested. General information about post-authorization monitoring can be found
7
AR02785
here: (https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-
infection/prevention-risks/covid-19-vaccine-treatment/safety-after-authorization.html)
24. MHPD is composed of the following areas:
i. the Director General’s Office, which is responsible, among other things, for making
decisions relating to post-market surveillance;
ii. the Bureau of Biologics, Radiopharmaceuticals and Self-care Products;
iii. the Bureau of Strategic Engagement and Integrated Management Services;
iv. the Health Products Surveillance and Epidemiology Bureau;
v. the Marketed Pharmaceuticals Bureau; and
vi. the Office of Policy, Risk Advisory, and Advertising.
25. MHPD regulates human health products by:
i. collecting, monitoring, and analyzing adverse reactions, medical device, and

medication incident data, which are required to be reported by industry and by
hospitals, but can also be directly reported by health care professionals and the
general public;
ii. reviewing risk management plans as part of pre-authorization activities (a risk

management plan is a key pharmacovigilance document that identifies known and
potential risks of a health product, the proposed activities to characterize those
risks, and any risk mitigation strategies);
iii. conducting benefit-risk assessments of marketed health products (except medical

devices) and recommending risk mitigation strategies, which can include changes
to the product labelling or the conditions of use of the product;
iv. working closely with international regulatory partners to share information and
analyses on potential drug safety risks;
8
AR02786
v. communicating product-related risks to health care professionals and the public;
vi. overseeing the advertising regulatory requirements of health products; and
vii. providing policies to effectively regulate marketed health products.
26. MHPD currently monitors the following COVID-19 vaccines which have received
approval for marketing in Canada:
i. the COVID-19 vaccine manufactured by Pfizer-BioNTech sold under the brand

name Comirnaty with the international non-proprietary name tozinameran;
ii. the COVID-19 vaccine manufactured by Moderna sold under the brand name
Spikevax with the international non-proprietary name elasomeran;
iii. the COVID-19 vaccine manufactured by AstraZeneca sold under the brand name
Vaxzevria with the international non-proprietary name COVID-19 Vaccine
(ChAdOx1-S [recombinant]);
iv. the COVID-19 vaccine manufactured by Janssen sold under the brand name
Janssen COVID-19 vaccine with the international non-proprietary name COVID-
19 vaccine (Ad26.COV2-S [recombinant]);
v. the COVID-19 vaccine manufactured by Novavax sold under the brand name
Nuvaxovid with the international non-proprietary name COVID-19 Vaccine
(recombinant, adjuvanted); and
vi. the COVID-19 vaccine manufactured by Medicago sold under the brand name
Covifenz.
27. In light of the extensive national roll-out of COVID-19 vaccines, Health Canada imposed
enhanced monitoring and surveillance requirements on COVID-19 vaccine manufacturers, and
instituted additional monitoring activities in close collaboration with the Public Health Agency of
Canada. Attached as Exhibits “B” and “C”, and by way of example only, are copies of the
authorizations terms and conditions for Comirnarty (https://covid-
9
AR02787
vaccine.canada.ca/info/pdf/pfizer-biontech-covid-19-vaccine-authorisation.pdf) and Spikevax

(https://covid-vaccine.canada.ca/info/pdf/moderna-covid-19-vaccine-authorisation.pdf).
28. Additional requirements on manufacturers included the provision of detailed monthly

safety reports and a Canadian-specific risk management plan addendum. By way of example
attached as Exhibits “D” and “E” are copies of the Canadian-specific risk management plan
addendums for Comirnarty and Spikevax. Further, Health Canada maintains an online table listing
post-authorization activities related to the vaccines which lists the outcome of the review of
monthly safety reports and other post-market activities. By way of example, attached as Exhibits
"F" and “G” are copies of the Post-Authorization Activity Table for Comirnarty (https://covid-
vaccine.canada.ca/info/post-authorization-activity-table.html?linkID=SBD00510) and Spikevax
(https://covid-vaccine.canada.ca/info/post-authorization-activity-table.html?linkID=SBD00511).
29. MHPD assesses the postmarket safety data submitted by manufacturers, submitted directly
by Canadians, or received through public health channels (among other sources). MHPD issues
advisories to healthcare professionals and the public, and makes recommendations to BRDD
should changes be required to the current labelling (such as product monograph or consumer
information) of the vaccines based on the evolving safety profile of the vaccines.
B. PUBLIC HEALTH AGENCY OF CANADA (PHAC)
30. PHAC is a federal agency created by the Public Health Agency of Canada Act. It supports
the federal Minister of Health as part of the Health Portfolio.
31. PHAC’s mandate includes the prevention and control of infectious diseases, preparation
for and response to public health emergencies, strengthening intergovernmental collaboration on
public health, and facilitating national approaches to public health policy and planning.
10
AR02788
32. In the context of the COVID-19 pandemic, PHAC is notably:
i. coordinating the national surveillance system to monitor the clinical and

epidemiologic features of COVID-19, including variants of concern, to better
inform prevention and control efforts; undertaking modelling to make predictions
on the COVID-19 epidemic; and supporting diagnostic testing across Canada
through the National Microbiology Laboratory; and
ii. conducting ongoing reviews of the published scientific and medical literature on
public health measures and consulting with subject matter experts and stakeholders
in order to manage the risk of COVID-19 through the development of guidance,
documents, and recommendations.
33. In the context of the COVID-19 immunization program, PHAC is notably involved in:
i. assessing the risks and benefits of the immunization program;
ii. publishing advice from the National Advisory Committee on Immunization with
respect to the use of authorized vaccines;
iii. monitoring COVID-19 vaccination coverage rates across Canada by

Province/Territory, age group, sex, vaccine used and vaccination status ;
iv. monitoring the AEFIs and investigating potential safety signals to inform public
health and regulatory action.
v. monitoring efficacy (i.e., estimates based on experimental data from clinical trials)
and effectiveness (i.e., estimates based on non-experimental data from post-market
observational studies) in Canada and other countries; and
vi. funding research on vaccine safety and effectiveness.
C. REGULATORY FRAMEWORK GENERALLY
34. Under the Food and Drugs Act, Health Canada regulates, evaluates, and monitors the
safety, efficacy, and quality of drug products, including vaccines. Health Canada’s oversight is
11
AR02789
exercised at all stages of a product’s life cycle, as long as the product is on the Canadian market,
from early testing through clinical trials conducted in Canada, to post-market surveillance of
adverse drug reactions, and compliance monitoring.
35. Prior to selling a new drug in Canada, a manufacturer must obtain authorization in the form
of a DIN or a NOC. Under the Food and Drug Regulations that were in force at the beginning of
the pandemic, it could take several years for a manufacturer to develop the drug and generate the
information and evidence required to satisfy the regulatory requirements.
36. The Food and Drug Regulations refer to submissions being filed to, and authorizations
being issued, by the Minister. This authority is delegated to me as the DG of the BRDD.
37. Before authorizing a vaccine, I receive recommendations from specific Directors in the
scientific review areas of my Directorate. They oversee the scientific teams who review the quality,
safety and efficacy evidence provided by the manufacturers’ in their submissions, to assist me in
deciding whether the benefits of the vaccine outweigh the risks, and whether the risks can be
managed. The scientific teams review a number of aspects such as, but not limited to, the
manufacturing and quality control of the vaccine; the specifications, shelf-life and storage
conditions; review the results of all laboratory tests and non-clinical studies; and the results of all
clinical trials in humans. Following review of all the scientific data submitted, the Directors work
with their teams to finalize review reports and executive summaries with recommendations for the
disposition of the manufacturer’s submission for market authorization of the vaccine, i.e., to either
authorize or reject the submission based on the benefit-risk assessment. There is no involvement
from the Minister, his office, elected officials, or any other organizations in that process.
38. Similarly, all post-market decisions are also delegated by the Minister to officials within
Health Canada. These include, but are not limited to, decisions to change the vaccine formulation,
storage conditions, shelf-life, manufacturing sites, dosage regimens including booster doses,
conditions of use or indications, and decisions to update the information about the safety profile
of the vaccine including any warnings and precautions. My teams of scientists review the
manufacturers’ submissions to make changes to the marketed vaccines, and work with the
scientific teams in MHPD to update the information on the safety profile of the vaccines.
12
AR02790
39. Once a vaccine has been marketed in Canada, there are ongoing obligations for the
manufacturer, including lot release testing prior to lots being distributed on the Canadian market,
reporting of adverse drug reactions, preparing annual summary reports on safety, and managing
any changes in the benefit-risk profile. Health Canada also conducts analysis of adverse drug
reactions and assesses potential safety issues on an ongoing basis. This includes consideration of
information received from manufacturers, from Canadian’s voluntary reports to Canada Vigilance,
from PHAC, from our international colleagues, and from publications. Health Canada has a range
of tools to mitigate risks identified once a product has been authorized. These can include, but are
not limited to, requiring the manufacturer to do additional studies, informing the public and health
care professionals of new product safety information, recommending labelling changes or
changing the use of the product, and when warranted, removing a product from the market.
D. COVID-19
40. COVID-19 is the disease caused by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) virus and can be a severe, life-threatening respiratory disease. It was first detected
in China, in December 2019 and spread rapidly throughout the globe. The WHO declared a global
pandemic in March 2020.
41. My understanding of COVID-19 comes from information that I have received from PHAC
and from reviewing the general literature, in my role as DG of BRDD. COVID-19 is primarily
spread through respiratory droplets and aerosols (smaller droplets) created when an infected person
breathes, talks, sings, shouts, coughs, or sneezes. It can also spread through contact with objects
or surfaces contaminated by the virus.
42. A number of individuals infected with COVID-19 will remain asymptomatic, meaning that
they will show little or no symptoms and might therefore be unaware that they are infected.
Nonetheless, asymptomatic carriers can transmit COVID-19. Pre-symptomatic carriers of the
COVID-19 virus, who contracted the disease but might not yet have developed symptoms, can
also spread the disease.
13
AR02791
43. COVID-19, like any virus, changes through mutation, and new variants of the virus appear
over time. When it has been demonstrated that a variant causes an increase in transmissibility, an
increase in virulence (severity of disease), or a decrease in effectiveness of the available
diagnostics, vaccines, or treatments, this variant becomes a “variant of concern” (VOC).
44. Based on information from PHAC, the main VOC that appears to be circulating in Canada
currently is B.1.1.529 (Omicron) and its sub-variants. Other VOCs detected in Canada previously
include the B.1.1.7 (Alpha), the B.1.351 (Beta), the P.1 (Gamma), and B.1.617.2 (Delta). Attached
as Exhibit “H” is a copy of the “Figure 2. Weekly variant breakdown”, as updated on April 14,
2022 that was available online at Canada’s COVID-19 epidemiology update: (https://health-
infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html).
45. In Canada, as of April 14, 2022, there had been 3,614,450 confirmed COVID-19 infections
and 38, 207 deaths resulting from COVID-19 (representing approximately 1.06% of all infections).
Attached as Exhibit “I” is a copy of Canada’s COVID-19 epidemiology update, prepared by
PHAC, as updated on April 14, 2022 that was available online: (https://health-
infobase.canada.ca/covid-19/epidemiological-summary-covid-19-cases.html).
(i.) Interim Orders Issued
46. Section 30.1 of the Food and Drugs Act authorizes the Minister of Health to make an
interim order if the Minister believes that immediate action is required to deal with a significant
risk, direct or indirect, to health or safety.
47. To address the immediate and significant risk to the health and safety of Canadians posed
by COVID-19, the Interim Order Respecting the Importation, Sale and Advertising of Drugs for
Use in Relation to COVID-19 was made by the Minister on September 16, 2020, and further
approved by the Governor in Council on September 25, 2020 (Interim Order). A copy of the
archived Interim Order is attached as Exhibit “J”: (ARCHIVED Interim Order Respecting the
Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 - Canada.ca).
14
AR02792
48. This Interim Order was issued to provide optional flexibilities to facilitate the expedited
authorization of importation, sale, and advertising of drugs, including vaccines, to be used in the
diagnosis, treatment, mitigation, or prevention of COVID-19, as well as the pre-positioning of
such drugs. Pre-positioning refers to the early importation and placement in Canadian facilities to
facilitate the immediate distribution of the drug upon authorization.
49. This Interim Order also placed some post-market regulatory obligations for authorization
holders, manufacturers, and importers to maintain records (which may be shared with Health
Canada proactively or upon request) and to fulfill certain terms and conditions.
50. In accordance with s. 30.1(2)(d) of the Food and Drugs Act, the Interim Order would cease
to have effect one year after it came into effect. After that time, the authorizations provided under
the Interim Order would expire. The Interim Order expired on September 16, 2021.
51. Along with the Interim Order, Health Canada also published the Guidance for Market
Authorization Requirements for COVID-19 Vaccines (a copy of which is attached as Exhibit “K”).
This guidance set the minimum regulatory requirements for the initial authorization of the
vaccines. For example, Phase 3 clinical trials are required and should demonstrate, as the primary
endpoint, that the vaccine reduces the incidence of symptomatic SARS-CoV-2 infection by at least
50% in people who are vaccinated, compared to a control group of people who don't receive the
vaccine. Enough people should be enrolled so that the trial is sufficiently powered to exclude an
efficacy result below 30%. As a secondary endpoint, the trial must have a sufficient number of
participants with severe COVID-19 infection in the control group to show that the vaccine is
effective. Additionally, in line with the pre-authorization safety data requirements for preventive
vaccines for infectious diseases, the safety database for a COVID-19 vaccine should have at least
3,000 study participants. They should be vaccinated with the dosing regimen intended for
authorization. The data should come from Phase 3 randomized placebo-controlled trials that allow
for the collection of adverse events in the vaccinated (>3,000 participants) vs. the placebo (>3,000
participants) group. This enables the detection of more common adverse events, which are in the
range of at least 1 in 1,000 doses given. The median duration of safety follow-up to support
authorization should be at least 2 to 3 months after all doses in the schedule have been given. The
benefit-risk analysis for the approval of the COVID-19 vaccines under the Interim Order took into
15
AR02793
account the efficacy demonstrated in clinical trials and the potential risks based on both solicited
and unsolicited adverse events collected during the clinical trials after participants were followed
for a median of 2 to 3 months. Efficacy is measured in controlled clinical trials whereas
effectiveness is determined through observational studies in the real world use of the vaccines. All
the vaccines marketed in Canada met the minimum requirements for initial authorization based on
efficacy, safety and quality, and continue to demonstrate a positive benefit-risk balance at this time
based on real world effectiveness and ongoing monitoring of safety and quality, for all populations
for which the vaccines are authorized.
52. It should be noted that the 50% efficacy threshold is applied to the initial authorization of
a vaccine and relates to the estimated efficacy endpoint required to be demonstrated in Phase 3
clinical trials, which is test-confirmed symptomatic disease. Test-confirmed symptomatic disease
was chosen as the clinical measure of efficacy for COVID-19 vaccines because it is a more
common and rapid endpoint than severe disease, making it more feasible to design trials that can
successfully test the efficacy of the vaccines in a reasonable number of people. A similar endpoint
is used in vaccine clinical trials against influenza and other pathogens. If a vaccine prevents
symptomatic disease, then it is expected to also prevent severe disease. However, the converse
may not be true as different immune parameters contribute to prevention of severe disease as
compared to mild symptoms. Antibodies contribute an important element in the first line of
defense to prevent or reduce infection resulting in symptoms, and combined with immune cells
contribute to preventing disease that is more severe. While the level of antibodies against omicron
may wane some weeks after initial vaccination, the memory defense mechanisms resulting from
vaccine-stimulated immune cells are maintained for a longer period with effective vaccines,
contributing to prevention of severe disease over an extended time frame.
53. As described in the Federal, Provincial, Territorial Public Health Response Plan for
Ongoing Management of COVID-19, (https://www.canada.ca/en/public-
health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/federal-
provincial-territorial-public-health-response-plan-ongoing-management-covid-19.html#a5) the
goal of Canada’s COVID-19 pandemic response is to minimize serious illness and overall deaths
while minimizing societal disruption as a result of the COVID-19 pandemic. The most crucial
clinical measure to determine whether a vaccine continues to provide benefits and should therefore
16
AR02794
remain on the market, is how well the vaccine prevents severe COVID-19 disease and deaths in
real world use. The current vaccines continue to be highly effective (well over 50% effectiveness)
at preventing severe disease and deaths with the omicron variant, while continuing to demonstrate
an acceptable safety profile.
(ii.) Amendments to the Food and Drug Regulations
54. To help ensure continued and timely access to safe and effective drugs and vaccines against
COVID-19 before the Interim Order expired, amendments were brought to the Food and Drug
Regulations.
55. These regulatory amendments integrated some of the flexibilities from the Interim Order
into sections of the Food and Drug Regulations concerning the review, authorization, and
oversight processes. Attached as Exhibit “L” is a copy of the Regulatory amendments that came
into force on March 18, 2021: (Canada Gazette, Part 2, Volume 155, Number 7: Regulations
Amending the Food and Drug Regulations (Interim Order Respecting the Importation, Sale and
Advertising of Drugs for Use in Relation to COVID-19).
56. Products authorized under the Interim Order could continue to be sold without interruption
under the amended Food and Drug Regulations, and new products could be authorized with similar
flexibilities as had been provided under the Interim Order.
57. The post-market requirements that the Interim Order placed on authorization holders,
manufacturers, and importers were also continued under the amended Food and Drug Regulations
58. I am aware that foreign regulators including those in the United Kingdom, Switzerland,
Australia, and the United States have also made use of emergency pathways to authorize COVID-
19-related health products like vaccines.
59. The amendments to the Food and Drug Regulations did not include a change to the
definition of vaccines. The COVID-19 vaccines are vaccines within the Canadian regulatory
framework and there was no need to change any definition of vaccine within that framework to re-
categorize them as vaccines for approval under the Food and Drugs Act. Vaccines are considered
to be, and are regulated as, drugs under the Food and Drug Act and its regulations.
17
AR02795
E. COVID-19 Vaccines
60. Vaccination is one of the most effective ways to protect families, communities, and
individuals against COVID-19.
61. Evidence indicates that vaccines are very effective at preventing severe illness,
hospitalization, and death from COVID-19, including against VOCs. However, no vaccines
provide complete protection (i.e., no vaccine is 100% effective)--there’s a percentage of the
population who are vaccinated that will still be infected with VOCs, especially Omicron, if they
are exposed to the virus.
62. Prior to the emergence of Omicron, the evidence indicated that people who were fully
vaccinated with a messenger ribonucleic acid (mRNA) vaccine (Pfizer-BioNTech Comirnaty and
Moderna Spikevax) had high levels of vaccine protection. They were less likely to experience
illness caused by most VOCs, and were less likely to transmit COVID-19 to others. People who
were fully vaccinated with a viral vector vaccine (e.g. AstraZeneca Vaxzevria) had moderate levels
of vaccine protection, and were less likely to experience symptomatic illness caused by most
VOCs, and were less likely to spread COVID-19 to others.
63. Omicron is now the main VOC currently circulating in Canada. In order to assess the
impact of Omicron on the effectiveness of the current vaccines, Health Canada has taken
regulatory action. On November 29, 2021, Health Canada issued regulatory letters to the
manufacturers of authorized COVID-19 vaccines in Canada requesting a plan of action to address
potential risks brought on by Omicron, including effectiveness results against Omicron. By
December 6, 2021, all manufacturers responded with initial plans. Manufacturers are working on
studies to assess vaccine effectiveness and final results will be provided when available.
64. Health Canada relies on data provided by manufacturers, public health surveillance data,
and recommendations by PHAC and the World Health Organization on whether updated vaccines
are needed. The emerging evidence shows that although asymptomatic and symptomatic
infections are likely to occur with the Omicron variant in people who are vaccinated, the current
vaccines still protect against severe illness, hospitalizations, and deaths due to infection with the
Omicron variant, especially after a booster dose. While manufacturers are developing updated
vaccines targeting the VOCs such as Omicron, WHO has not yet declared a need to update the
18
AR02796
current vaccines and continues to recommend vaccination with the current vaccines, including the
use of booster doses.
65. Health Canada will continue to monitor information as it becomes available as part of the
on-going post-market monitoring process, and will continue to work with the manufacturers,
PHAC, and international partners. Health Canada will take regulatory action as needed, including
informing Canadians and working with manufacturers to update their vaccines to better address
the VOCs should formulation changes be deemed necessary in the future.
(i.) Approval of COVID Vaccines for Human Use
66. Health Canada worked closely with foreign regulators including the EMA, US FDA,
Swissmedic, Australia’s Therapeutic Goods Administration, the Health Sciences Authority in
Singapore, the United Kingdom’s Medicines and Healthcare products Regulatory Agency, and
WHO to align regulatory evidence requirements for authorization of COVID-19 vaccines.
67. In considering the evidence for the authorization of each of the vaccines, I relied on detailed
reviews and executive summaries provided by my review Centre Directors and their scientific
teams who were charged with evaluating each of the COVID-19 vaccine submissions. The
submissions contained data compiled by the manufacturers, as well as the proposed labelling.
68. The data provided in the submissions was assessed against the regulatory evidence
requirements communicated by Health Canada, aligning with other regulators as mentioned above.
Each vaccine was evaluated by a scientific team of 10 to 15 BRDD employees. The data to support
authorization of the vaccines were evaluated by the teams on a rolling basis, as data became
available from the manufacturers. Once the submission was considered complete, the review teams
integrated the quality, safety, and efficacy evidence and made a recommendation for my
consideration. The recommendation included the proposed labelling (i.e., product monograph and
vial and carton labels) as well as proposed terms and conditions on the authorization to manage
remaining uncertainties associated with the quality, safety, or efficacy of the vaccines. Examples
of these conditions include providing monthly safety reports, providing details of each lot of
vaccine before it can be released on the market, providing longer term safety and efficacy data
from the ongoing clinical trials, and providing information about vaccine effectiveness against
VOCs that emerge.
19
AR02797
69. Both scientifically and clinically, all drugs undergo development tailored to circumstances
and need. International conventions and guidelines govern that process. From discovery to
marketing, variable timelines happen, depending on how much is known about the disease,
existing drug platforms, the design of the drug development process, and the context for the drug
(preventative, diagnostic or therapeutic). The time from discovery to market authorisation varies
from as short as a couple of years to much longer time lines, up to 10 years. The timeline depends
on what happens from the clinical and manufacturing perspective. If each step is successful it can
be as short as 2 years.
70. While the Pfizer, Moderna, Astra-Zeneca and Janssen vaccines were authorised after a very
short clinical timeline, shorter even than 1-2 years, much work had gone into the technology that
enabled the rapid development of these vaccines. Scientists have been working for many years to
develop vaccines against coronaviruses, such as those that cause severe acute respiratory syndrome
(SARS) and Middle East respiratory syndrome (MERS). SARS-CoV-2, the virus that causes
COVID-19, is related to these other coronaviruses. The knowledge that was gained through past
research on coronavirus vaccines helped speed up the initial development of the current COVID-
19 vaccines.
71. The regulations make provisions for long-term safety considerations for all drugs, be they
preventative (e.g., vaccines), diagnostic, or therapeutic. Drugs are regulated on a continual, life -
cycle basis and safety regulations mandate the follow-up of all drugs following their authorisation
to market. In fact, all drugs are monitored throughout their life-cycle until lack of use or lack of
need, makes them obsolete.
72. Post-Authorization identification of adverse events for most drugs is not an unexpected or
unknown phenomenon and those are the main reasons for authorising drugs, including vaccines,
with post-market surveillance. This is because rare but serious adverse events may not be
identified until after the drug is marketed and administered to a larger number of people than the
number of people enrolled and studied in clinical trials. For the COVID-19 vaccines, rare adverse
events were identified early following authorization given the roll-out of the vaccines in many
millions of people across multiple regions. Under normal non-pandemic circumstances, it could
take many years to identify very rare adverse events for vaccines; however, with the COVID-19
20
AR02798
vaccines, the rare events were identified much more quickly due to the massive global roll-out,
which also allowed regulatory and public health authorities to take action earlier than would have
been possible for vaccines distributed to a much more limited number of individuals.
73. In my role as DG of BRDD, I review material both during the approval phase and in the
post-monitoring phase related to the effectiveness (both in respect to infection and severe
disease) and risk of the vaccines. This material includes vaccine decks prepared by MHPD. A
copy of the vaccine deck, dated April 8, 2022, is attached as Exhibit “M” by way of example.
I also receive specific summaries of new research. This information relates both to the benefits
and the risks related to the vaccines.
74. For example, the recent CDC study (mm7114e1 Cardiac Complications After SARS-
CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January
2021–January 2022 (cdc.gov)) confirms that vaccination with mRNA vaccines presents a lower
risk than SARS-CoV-2 infection in respect of cardiac complications. After this study was
released, I received a summary of this information prepared by MHPD. Attached as Exhibit
“N” is a copy of the summary I received by e-mail in respect of that study.
75. Information like the above CDC study which is received by MHPD and PHAC, is
reviewed, summarized, and incorporated into ongoing post authorization review activities.
MHPD shares this information via regular branch discussions and/or directly provides them to
BRDD as part of post-market monitoring which provides the basis for the continued benefit-
risk evaluation and consideration of additional regulatory steps in relation to the COVID-19
vaccines.
(ii.) Approved Vaccines for human use
76. There are four types of COVID-19 vaccines thus far authorized by Health Canada: mRNA
vaccines, viral vector-based vaccines, protein-subunit vaccine, and virus-like particle vaccine.
77. Two of the vaccines authorized for use in Canada are the mRNA vaccines: Pfizer-
BioNTech Comirnaty COVID-19 vaccine and Moderna Spikevax COVID-19 vaccine.
21
AR02799
78. Two of the vaccines authorized for use in Canada are viral vector-based vaccines:
AstraZeneca Vaxzevria COVID-19 vaccine and Janssen (Johnson & Johnson) COVID-19 vaccine.
79. One of the vaccines authorized for use in Canada is a protein subunit vaccine: Nuvaxovid
by Novavax.
80. One of the vaccines authorized for use in Canada is a virus-like particle vaccine: Covifenz
by Medicago.
81. Additional types of COVID-19 vaccines are under development and/or currently under
review by Health Canada. These include another protein-based vaccine and a whole-virion
inactivated vaccine. Attached as Exhibit “O” is a copy of a list of applications received for
COVID-19 drugs and vaccines as of April 14, 2022: (https://www.canada.ca/en/health-
canada/services/drugs-health-products/covid19-industry/drugs-vaccines-
treatments/authorization/applications.html).
(iii.) mRNA Vaccines
82. mRNA vaccines are a new type of vaccine. They are new in the sense that they have not
previously received regulatory authorization, but that does not mean they have not been studied or
subject to research and review. The use of mRNA to develop cancer vaccines has been under
development for many years. mRNA vaccines do not use a live virus to trigger an immune
response. Instead, they teach your cells how to make a protein that will trigger an immune
response. Once triggered, your body makes antibodies and activates immune cells. These
antibodies and immune cells help you fight the infection if the real virus does enter your body in
the future.
83. mRNA vaccines can be developed faster than traditional methods because there are few
biological steps in the manufacturing process and the remaining steps can be scaled up rapidly.
Once developed, large-scale clinical trials are carried out to show that the vaccine is safe and
effective.
22
AR02800
84. As with all vaccines, individuals gain protection from an mRNA vaccine without being
exposed to the virus that causes COVID-19 and the risk of the serious consequences of getting
sick from the virus. An individual cannot get COVID-19 from the vaccine itself.
85. mRNA is a molecule that provides cells with instructions for making proteins. mRNA
vaccines contain the instructions for making the SARS-CoV-2 spike protein. This protein is found
on the surface of the virus that causes COVID-19.
86. The mRNA molecule is essentially a recipe, telling the cells of the body how to make the
spike protein. After the spike protein is made, the cell breaks down the instructions and gets rid of
them. Our immune system recognizes that the protein doesn't belong there and begins building an
immune response and making antibodies. The mRNA never enters the central part (nucleus) of the
cell, which is where our DNA (genetic material) is found. DNA can't be altered by mRNA
vaccines.
87. COVID-19 mRNA vaccines are held to the same high standards for safety, efficacy, and
quality as all vaccines authorized for use in Canada. Only vaccines that meet those standards can
be approved. Once approved, Health Canada continues to monitor all vaccines for safety and
effectiveness in people. Attached as Exhibit “P” is a copy of the Health Canada information
page on COVID-19 mRNA vaccines that is avialable online: (https://www.canada.ca/en/health-
canada/services/drugs-health-products/covid19-industry/drugs-vaccines-
treatments/vaccines/type-mrna.html).
(iv.) Viral Vector-Based Vaccines
88. Viral vector-based vaccines approved in Canada use a non-replicating, non-pathogenic

form of a virus (in this case, the adenovirus) as a delivery system. This vector virus is not the virus
that causes COVID-19. An individual cannot get COVID-19 or any infection from the vaccine
itself.
89. Once injected into your body, the adenovirus in the vaccine produces the SARS-CoV-2
spike protein. This protein doesn't make you sick. It does its job and then goes away. Through this
process, your body can mount a strong immune response against the spike protein without being
23
AR02801
exposed to the virus that causes COVID-19 and the risk of serious consequences of getting sick
from the virus.
90. COVID-19 viral vector-based vaccines are held to high safety, efficacy, and quality
standards. Only vaccines that meet those standards can be approved. Once approved, Health
Canada continues to monitor it for safety and effectiveness. Attached as Exhibit “Q” is a copy of
the Health Canada information page on COVID-19 viral vector-based vaccines:
(https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/drugs-
vaccines-treatments/vaccines/type-viral-vector.html).
(v.) Protein Subunit-Based Vaccines
91. Protein subunit vaccines use non-infectious purified proteins from a virus (or other
pathogen), which have been specifically selected for their ability to trigger an immune response.
Protein subunit vaccines cannot cause COVID-19 because they only contain small, purified
proteins and not the virus.
92. Protein subunit vaccines are already used for other diseases, such as hepatitis B.
93. Protein subunit vaccines are made by taking a small piece of the virus’ genetic code and
inserting it into another cell. This genetic code contains instructions for the cell to start building
the virus protein which stimulates immune cells. The cell builds large quantities of the protein
which is then extracted, purified, and used as the active ingredient in the vaccine. An adjuvant may
also be used. An adjuvant is a substance that helps make a stronger and longer-lasting immune
response. Adjuvants have been used safely for decades in a number of vaccines.
94. The protein in a submit vaccine is incapable of causing disease, and the manufacturing
technology is well established.
(vi.) Plant-Based Virus-Like Particle Vaccines
95. Plant based virus-like particle vaccines use a unique plant-based technology. The
technology synthesizes the virus’ genetic code so that its genetic instructions can be read by plants.
The living plants are then used as bioreactors in the vaccine development process to produce a
non-infectious particle that copies the target virus.
24
AR02802
96. The plant-based technology uses carrier plants - such as relatives to the potato, corn,
tobacco or other plants – which can be successfully infected by a large number of plant viruses
which cannot infect humans. The technology uses the plant’s natural cell process to produce
protein virus-like particles. The code containing the genetic instructions is inserted into bacteria
which carries that information into the plant’s cells. The plants quickly produce large quantities of
these particles. The particles are then injected into a human body and there they copy the structure
of the virus which allows the immune system to recognize them as a virus that the body must
protect itself against. The virus-like particles are non-infectious.
(vii.) Comirnaty (previously Pfizer BioNTech COVID-19 Vaccine)
97. On December 9, 2020, Health Canada issued an authorization under the Interim Order to
BioNTech Manufacturing GmbH for the Pfizer‑BioNTech COVID‑19 Vaccine.
98. The interim authorization of the Pfizer‑BioNTech COVID‑19 Vaccine was based on
quality (chemistry and manufacturing), non‑clinical (pharmacology and toxicology), and clinical
(immunogenicity, safety, and efficacy) information. Following review of the available
information, Health Canada concluded that the evidence provided meets the Health Canada
standards published in the Guidance for Market Authorization Requirements for COVID-19
Vaccines (a copy of which is attached as Exhibit “K”). The evidence supports the conclusion that
the benefits associated with the Pfizer‑BioNTech COVID‑19 Vaccine outweigh the risks, having
regard to a shorter term (median of 2 months) follow up of safety and efficacy at authorization,
and the necessity of addressing the urgent public health need related to COVID‑19. Based on these
considerations, the benefit‑risk profile of the Pfizer‑BioNTech COVID‑19 Vaccine is considered
favourable for active immunization to prevent COVID‑19 caused by SARS‑CoV‑2 in individua ls
16 years of age and older. Health Canada has also authorized the use of the Pfizer-BioNTech
COVID-19 vaccine in children 5 to 11 years of age, and adolescents 12 years of age and older.
99. The interim authorization of the Pfizer‑BioNTech COVID‑19 Vaccine was subject to terms
and conditions that needed to be met by the sponsor to ascertain the continued quality, safety, and
efficacy of the product. The terms and conditions may be amended at any time. Furthermore, this
authorization may be revoked if new information does not support the safe and effective use of the
product.
25
AR02803
100. The authorization of the Pfizer‑BioNTech COVID‑19 Vaccine under the Interim Order for
use in adults 16 years of age and older was supported by results from the final efficacy analysis of
the pivotal Phase 3 study including 36,621 participants. The clinical information filed in support
of the authorization is available on Health Canada’s COVID-19 vaccines and treatments portal:
(https://covid-vaccine.canada.ca/comirnaty/product-details).
101. Based on the entirety of the data submitted to and reviewed by Health Canada to-date, the
safety and efficacy of the Pfizer‑BioNTech COVID‑19 Vaccine have been established in
participants 5 years of age and older.
102. The Canadian regulatory decision on the review of the Pfizer‑BioNTech COVID‑19
Vaccine was based on a critical assessment of the data package submitted to Health Canada. The
information submitted to Health Canada also included the Emergency Use Authorization Request
filed to the United States Food and Drug Administration, which was consulted to assist in the
review of the final efficacy analysis. A European Risk Management Plan was also submitted. The
submission milestones for the initial approval were:
Submission Milestone Date
Pre-submission meeting between sponsor and Health Canada 2020-09-08
Initial application filed by sponsor 2020-10-09
Initial non-clinical and clinical data submitted by sponsor 2020-10-09
Initial quality data submitted by sponsor 2020-11-16
Educational material submitted by sponsor 2020-11-27
Risk Management Plan submitted by sponsor 2020-12-01
Health Canada Review of Risk Management Plan complete 2020-12-06
Health Canada Quality Evaluation complete 2020-12-07
Terms and Conditions finalized by Health Canada 2020-12-08
26
AR02804
Health Canada Clinical/Medical Evaluation complete 2020-12-08
Health Canada Biostatistics Evaluation complete 2020-12-08
Final Product Monograph (English and French) submitted by

2020-12-08
sponsor
Health Canada Labelling Review complete 2020-12-08
Interim authorization issued by Director General, Biologic and

2020-12-09
Radiopharmaceutical Drugs Directorate, Health Canada
103. Attached as Exhibit “F” is a copy of the Post-Authorization Activity Table (PAAT) for
Comirnaty (previously the Pfizer-BioNTech COVID-19 Vaccine): (https://covid-
vaccine.canada.ca/).
104. The evidence, including the results of clinical trials and ongoing safety and effectiveness
data, supports the conclusion that the benefits associated with the Pfizer‑BioNTech COVID‑19
Vaccine outweigh the risks.
i. Clinical basis
105. The vaccine efficacy of Pfizer-BioNTech COVID-19 Vaccine was demonstrated in a Phase
3 randomized, placebo controlled study (Study C4591001). This is a study that will follow the
participants for up to 2 years, and hence is still ongoing. The study is conducted in the United
States, Turkey, Germany, South Africa, Brazil, and Argentina. A total of 43,651 participants
(21,823 in the Pfizer-BioNTech COVID-19 Vaccine group and 21,828 in the placebo group) were
randomised equally to receive 2 doses of Pfizer-BioNTech COVID-19 Vaccine or placebo
separated by 21 days. Randomization was stratified by age: 16 through 55 years of age or 56 years
of age and older, with a minimum of 40% of participants in the ≥ 56-year stratum.
106. Vaccine efficacy was evaluated after all study participants received 2 doses of vaccine or
placebo and were followed for a median of 2 months after the second dose. Compared to placebo,
vaccine efficacy was evaluated to be 95% (with 95% confidence interval (CI) of 90.3% to 97.6%)
27
AR02805
in subjects without prior evidence of SARS-CoV-2 infection at least 7 days after the second
administration of the vaccine.
107. In subjects 65 years of age and older without evidence of prior infections with SARS-CoV-
2, the efficacy of Pfizer-BioNTech COVID-19 Vaccine was 94.7% (95% CI: 66.7-99.9). Vaccine
efficacy was consistent across age, gender, race and ethnicity demographics. Observed vaccine
efficacy was >93% across subgroups identified by age, sex, race/ethnicity and country. A total of
10 severe cases of COVID-19 were observed in the study, with 9 of the cases occurring in the
placebo group and 1 in Pfizer-BioNTech COVID-19 Vaccine group. The confinement of the
majority of severe cases to the placebo groups suggests no evidence for vaccine-associated
enhanced respiratory disease.
108. A total of 9531 and 9536 subjects (16 years old and older) in the vaccine and placebo group
respectively, were followed for at least 2 months after the second administration to assess safety.
The most frequent adverse reactions in a random subset (N=8183) of study participants 18 years
of age and older, who received the vaccine and were monitored for reactogenicity were: injection
site pain (84.1%), fatigue (62.9%), headache (55.1%), muscle pain (38.3%), chills (31.9%), joint
pain (23.6%) and fever (14.2%) and were usually mild or moderate in intensity and resolved within
a few days after vaccine administration. The unsolicited adverse events (AEs) reported in the study
was lymphadenopathy (swollen lymph nodes) (0.3%) with no medical sequela (pathological
condition resulting from a prior disease) reported and that lasted for approximately 10 days. There
were no safety signals identified and no life-threatening AEs and deaths related to the vaccine. The
study showed that the vaccine at 30 µg was safe and well-tolerated in participants and within
demographic subgroups based on age, sex, race/ethnicity, country and baseline SARS-CoV-2
status.
ii. Non-clinical basis
109. The non‑clinical data submitted in the application for authorization of the Pfizer‑BioNTech
COVID‑19 Vaccine included pharmacodynamics studies, pharmacokinetic studies, and a pivotal
repeat‑dose toxicity study.
110. Tozinameran, the medicinal ingredient in the Pfizer‑BioNTech COVID‑19 Vaccine, was
found to elicit an immune response in mice, rats, and non‑human primates. Substantial increases
28
AR02806
in antibody titers were observed in non‑human primates after a second dose of tozinameran, which
exceeded titers measured in serum samples from patients who have recovered from COVID‑19. In
a SARS‑CoV‑2 rhesus monkey challenge model, tozinameran provided complete protection in the
lungs, and there was no evidence of vaccine‑associated enhanced respiratory disease.
111. After intramuscular administration in mice, tozinameran concentrates mainly at the

injection site with some distribution also to the liver.
112. In a pivotal toxicology study in which three once‑weekly 30 µg doses of tozinameran were
administered to rats by intramuscular injection, expected immunostimulatory responses were
observed. Full or partial resolution of all findings was observed following a three‑week recovery
period.
113. Overall, the non‑clinical pharmacology and toxicology profile of tozinameran support its
clinical use.
iii. Quality (chemistry and manufacturing) basis for decision
114. Manufacturing of the Pfizer-BioNTech COVID-19 Vaccine consists of the production of

the mRNA encoding the Spike protein for the SARS-CoV-2 virus followed by the encapsulation
of mRNA into Lipid Nano-Particles (tiny sacs of fat that envelop the mRNA molecules). Evidence
was provided to demonstrate that the vaccine is manufactured under Good Manufacturing
Practices (GMP) at all manufacturing sites providing supply to Canada and that in-process
controls, process parameters, and quality control release tests have been established to monitor
product quality throughout the process. The specifications used to evaluate key quality attributes
and consistency of production were found acceptable. This information together with the terms
and conditions supported authorization under the Interim Order.
115. The Interim Order authorization of the Pfizer-BioNTech COVID-19 vaccine was followed
by an authorization on September 16, 2021, under the Food and Drug Regulations pursuant to a
submission seeking a NOC under the amended Regulations. The NOC was issued on the basis of
the evidence submitted, the majority of which mirrored the evidence previously submitted and
reviewed under the Interim Order, including the data filed to support use of the vaccine in
adolescents 12 years of age and older. The submission also included updated longer-term safety
29
AR02807
data from the Phase 3 clinical trial participants who were followed for up to 6 months after their
second dose of vaccine. No new adverse events were identified in the updated safety dataset.
116. On November 19, 2021, on behalf of Health Canada, I authorized a Pfizer-BioNTech

Comirnaty vaccine made for children aged 5 to 11 on the basis that the safety and efficacy of a 10
g dose in children aged 5 to 11 has now been established. Furthermore, on November 9, 2021, I
also authorized the Pfizer-BioNTech Comirnaty vaccine to be used as a booster shot of 30 g in
adults 18 years of age and older. A COVID-19 booster shot is an extra dose of the vaccine given
six months after completion of the primary vaccine series. The booster shot is intended to help
people maintain their protection against COVID-19 over time.
(viii.) Moderna Spikevax (previously COVID-19 vaccine Moderna)
117. On December 23, 2020, Health Canada issued an authorization under the Interim Order
Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID -19
(described above and attached as Exhibit “J”) to Moderna Therapeutics Inc. for the Moderna
COVID‑19 Vaccine. The Interim Order, signed by the Minister of Health on September 16, 2020,
established new authorization pathways with the intent to expedite the authorization for the
importation, sale, and advertising of drugs used in relation to coronavirus disease 2019 (COVID-
19), while taking into consideration urgent public health needs caused by COVID-19.
118. The interim authorization of the Moderna COVID‑19 Vaccine was based on quality
(chemistry and manufacturing), non‑clinical (pharmacology and toxicology), and clinical
(immunogenicity, safety, and efficacy) information. Following review of the available
information, Health Canada concluded that the evidence provided met the Health Canada standards
published in the Guidance for Market Authorization Requirements for COVID-19 Vaccines (a copy
of which attached as Exhibit “K”). The evidence supported the conclusion that the benefits
associated with the Moderna COVID‑19 Vaccine outweighed the risks, having regard to a shorter
term (median of 2 months) follow up of safety and efficacy at authorization, and the necessity of
addressing the urgent public health need related to COVID‑19. Based on these considerations, the
benefit‑risk profile of the Moderna COVID‑19 Vaccine was considered favourable for active
immunization to prevent against COVID-19 caused by SARS-CoV-2 virus in individuals 18 years
30
AR02808
of age and older. Health Canada has also authorized the use of the Moderna COVID-19 vaccine
in children 6 years of age and older.
119. The interim authorization of the Moderna COVID‑19 Vaccine was subject to terms and
conditions that needed to be met by the sponsor to ascertain the continued quality, safety, and
efficacy of the product. The terms and conditions may be amended at any time. Furthermore, this
authorization may be revoked if new information does not support the safe and effective use of the
product.
120. The authorization of the Moderna COVID‑19 Vaccine under the Interim Order for use in
adults 18 years of age and older is supported by results from the efficacy analysis of the pivotal
Phase 3 study (Study mRNA‑1273‑P301 or COVE Study) which included 30,351 participants. The
clinical information filed in support of the authorization is available on Health Canada’s COVID-
19 vaccines and treatments portal: (https://covid-vaccine.canada.ca/covid-19-vaccine-
moderna/product-details).
121. Based on the entirety of the data submitted to and reviewed by Health Canada, some of
which is summarized below, the safety and efficacy of the Moderna COVID‑19 Vaccine have been
established in participants 6 years of age and older. The safety and efficacy of the Moderna
COVID‑19 Vaccine in individuals under 6 years of age have not yet been established.
122. The Canadian regulatory decision on the review of the Moderna COVID‑19 Vaccine was
based on a critical assessment of the data package submitted to Health Canada by Moderna. The
information submitted to Health Canada also included the Emergency Use Authorization Request
filed to the United States Food and Drug Administration, which was consulted in the review of the
final efficacy analysis. A European Risk Management Plan was also submitted. The submission
milestones for the initial approval were:
Initial application filed by sponsor 2020-10-12
Initial clinical data submitted by sponsor 2020-10-30
31
AR02809
Initial quality data submitted by sponsor 2020-10-30
Initial non-clinical data submitted by sponsor 2020-11-16
Educational material submitted by sponsor 2020-12-09
Risk Management Plan submitted by sponsor 2020-12-11
Health Canada Biostatistics Evaluation complete 2020-12-18
Health Canada Review of Risk Management Plan complete 2020-12-21
Health Canada Quality Evaluation complete 2020-12-21
Terms and Conditions finalized by Health Canada 2020-12-21
Health Canada Clinical/Medical Evaluation complete 2020-12-22
Final Product Monograph (English and French) submitted by

2020-12-22
sponsor
Health Canada Labelling Review complete 2020-12-22
Interim authorization issued by Director General, Biologic and

2020-12-23
Radiopharmaceutical Drugs Directorate, Health Canada
123. Attached as Exhibit “G” is a copy of the Post-Authorization Activity Table (PAAT) for
Spikevax (previously COVID-19 Vaccine Moderna): (https://covid-
vaccine.canada.ca/info/summary-basis-decision-detailTwo.html?linkID=SBD00511#paatDiv).
124. The evidence, including clinical trials and ongoing safety and effectiveness data, supports
the conclusion that the benefits associated with the Moderna COVID‑19 Vaccine outweighed the
risks.
32
AR02810
i. Clinical basis
125. The vaccine efficacy of Moderna COVID-19 Vaccine was demonstrated in a Phase 3
randomized, placebo controlled study in adults ≥ 18 years of age (Study mRNA-1273-P301). The
study is conducted in 99 sites across the United States, and is still ongoing in order to follow
participants for up to 2 years. A total of 30,351 individuals were randomly assigned to receive two
intramuscular injections of 100 µg of the vaccine (n=15,181) or placebo (n=15,170) separated by
four weeks. Participants were stratified by age and health risk into one of three groups: 18 to <65
years of age and not at risk for progression to severe COVID-19; 18 to <65 years of age and at risk
for progression to severe COVID-19; and ≥65 years of age. The proportion of participants 65 years
of age and over is 24.7%.
126. Vaccine efficacy was evaluated after all study participants received 2 doses of vaccine or
placebo and were followed for a median of 2 months after the second dose. Compared to placebo,
vaccine efficacy was evaluated to be 94.1% (95% confidence interval (CI) 89.3%, 96.8%) in
participants without prior evidence of SARS-CoV-2 infection 2 weeks after the second dose of the
vaccine. The vaccine efficacy in participants older than 65 years of age was 86.4% (95% CI:
61.4%, 95.5%). There were 30 cases of severe COVID-19 disease in the placebo group and 0 cases
in the vaccine group.
127. All participants were monitored for safety. A total of 8,163 participants in the vaccine
group and 8,111 in the placebo group were followed for at least 2 months after the second dose.
The most frequently reported adverse reactions (ARs) after any dose were: pain at the injection
site (92.0%), fatigue (70.0%), headache (64.7%), myalgia (61.5%), and chills (45.4%). The
majority of local and systemic adverse reactions were mild to moderate in severity and resolved
within 2 to 3 days. ARs were more common in younger adults (18 to < 65 years) as compared to
older adults (≥ 65 years). More ARs were reported following the second dose. The incidence and
absolute number of serious adverse events in the 28 days after vaccination was comparable
between Moderna COVID-19 Vaccine (0.5%) and placebo (0.6%) groups.
128. There were no important safety issues identified and no life-threatening adverse events
(AEs) or deaths related to the vaccine. The AEs observed showed that the vaccine at 100 µg was
33
AR02811
safe and well-tolerated in participants and within demographic subgroups based on age, sex, and
race/ethnicity.
ii. Non-clinical basis
129. The non-clinical data submitted in the application for authorization of the Moderna
COVID‑19 Vaccine included pharmacodynamic, repeat-dose toxicity, genotoxicity, and
reproductive and developmental toxicity studies.
130. The medicinal ingredient in the Moderna COVID‑19 Vaccine, known as mRNA‑1273
SARS‑CoV‑2, was found to elicit an immune response in mice, hamsters, and non-human primates
after the first and second dose of vaccine. Further, the vaccine was fully protective following viral
challenge in immunized mice and hamsters when administered as a single-dose or two-dose
schedule and in immunized non-human primates when administered as a two-dose schedule.
Finally, the vaccine did not promote vaccine-associated enhanced respiratory disease in mice,
hamsters, and non-human primates, suggesting that this unwanted side-effect may also not occur
in humans.
131. After intramuscular administration in rats, mRNA-1273 SARS-CoV-2 concentrates mainly

at the injection site, lymph nodes, and some distribution also to the spleen.
132. In repeat-dose toxicity studies, intramuscular administration of mRNA vaccines

formulated in lipid nanoparticles comparable to the Moderna COVID‑19 Vaccine were well-
tolerated in rats at doses ranging from 8.9 to 150 µg/dose once every 2 weeks for up to 6 weeks.
Effects observed were consistent with an expected immunostimulatory response and known acute
phase response following intramuscular administration of a vaccine. Full or partial recovery from
all findings was observed following a 2‑week recovery period. In addition, intramuscular
administration of mRNA‑1273 SARS‑CoV‑2 up to 100 µg/dose was well tolerated in rats with
clinical observations and pathology changes that were consistent with the results from other
studies.
133. The novel lipid, SM‑102, used in the lipid nanoparticle formulation of the Moderna
COVID‑19 Vaccine, was shown to be non-genotoxic based on results from internationally
standardized assays.
34
AR02812
134. In the reproductive and developmental toxicity study, female rats were administered 100
µg of mRNA‑1273 SARS‑CoV‑2 by intramuscular injection 28 days prior to mating, 14 days prior
to mating, and on gestation days 1 and 13. No mRNA‑1273 SARS‑CoV‑2-related maternal toxicity
or overt adverse effects on pre- and post-natal development were observed. Immunogenicity
assessment in this study also demonstrated that mRNA‑1273 SARS‑CoV‑2 elicited antibody
responses to the SARS-CoV‑2 spike 2 protein in maternal animals. High antibody titers were also
observed in fetuses and pups, indicating transfer of antibodies via placental transfer and via milk.
135. Overall, the non‑clinical pharmacology and toxicology profile of mRNA‑1273 SARS-
CoV‑2 supports its clinical use.
iii. Quality (chemistry and manufacturing) basis for decision
136. Manufacture of the Moderna COVID-19 vaccine consists of the production of the mRNA
encoding the Spike protein for the SARS-CoV-2 virus, followed by the encapsulation of this
mRNA into Lipid Nanoparticles. Evidence was provided to demonstrate that the vaccine is
manufactured under Good Manufacturing Practices (GMP) at all manufacturing sites providing
supply to Canada, and that in-process controls, process parameters, and quality control release tests
have been established to monitor product quality throughout the process. The specifications used
to evaluate key quality attributes and consistency of production were found acceptable. This
information, together with the terms and conditions imposed on the authorization, supported
authorization under the Interim Order.
137. The Interim Order authorization of the Moderna COVID-19 vaccine was followed by an
authorization on September 16, 2021, under the Food and Drug Regulations pursuant to a
submission seeking a Notice of Compliance under the amended Regulations. The NOC was issued
on the basis of the evidence submitted, the majority of which mirrored the evidence previously
submitted and reviewed under the Interim Order, including the data filed to support use of the
vaccine in adolescents 12 years of age and older. A booster shot was also authorized on November
12, 2021, as a half dose of 50 g for use in adults 18 years of age and older, to be administered 6
months after the primary series, and more recently, the vaccine has also been authorized for use in
children 6 years of age and older.
35
AR02813
138. As mentioned above, once a vaccine is authorized by Health Canada, there is continuing
regulatory oversight. Monthly safety reports have been submitted by the manufacturer and closely
reviewed to determine if any new safety signals may be arising.
139. Should new safety information be identified through ongoing surveillance, including from
adverse event reports, safety information received from the manufacturer, or through information
received from international regulatory agencies, that information is carefully assessed by scientific
and medical reviewers in order to determine if potential safety issues may be related to the vaccine,
and changes are made to the product information (product monograph) as necessary to update
relevant information for prescribers and Canadians.
F. Approval of the COVID-19 Vaccines was appropriate and the benefits continue to
outweigh the risks
140. Based on the initial evidence provided to me in my role as DG of BRDD, and the
accumulating evidence that I have received since the initial approvals, the benefits of the COVID-
19 vaccinations continue to outweigh the risks for the purpose of approval under the Food and
Drugs Act.
(i.) The authorized COVID-19 Vaccines are not experimental
141. As described in paragraph 51 above, and elsewhere in this affidavit, the COVID-19
vaccines were authorized based on a substantial initial data package provided by the manufacturers
in response to the guidelines set out by Health Canada as the regulator. Manufacturers were
required to conduct large, randomized, double-blinded Phase 3 clinical trials to measure efficacy
against test-confirmed symptomatic COVID-19 disease. Given the incidence of symptomatic
infection and severe disease, the trials were necessarily large, with tens of thousands of participants
in order to ensure that sufficient numbers of positive cases of SARS-CoV-2 could be enrolled
efficiently, including also some cases of severe disease, to assess vaccine efficacy. A sufficient
number of participants (at least 3,000 in the vaccine arm and 3,000 in the placebo arm) also needed
to be enrolled and followed for a median of 2 to 3 months to assess safety prior to authorization,
and continue to be monitored for at least 1 to 2 years after vaccine administration. As a condition
of the authorization, Health Canada requested the longer-term follow-up data of up to 2 years from
all manufacturers. These guidelines were developed, and Phase 3 trial testing commenced for the
36
AR02814
mRNA vaccines, before the emergence of the VOCs. However, Health Canada continues to
monitor the COVID-19 vaccines while they are on the market, looking for evidence regarding
efficacy and safety, including evidence of waning effectiveness.
142. While a median of 2 to 3 months of follow-up for safety assessment was a shorter
monitoring period prior to authorization than the usual 6 month timeframe for Phase 3 vaccine
trials under normal circumstances, this shorter time frame was chosen due to the context of the
pandemic and with reference to the fact that most vaccine adverse events occur within the first 2
months after administration. The standards set by Health Canada align with those chosen by other
regulators, such as the US FDA, and recommended by WHO in the same context.
143. In the post-market monitoring, with the benefit of an extended time frame and larger
exposure group, further benefits in the form of protection against severe disease can be measured
based on real world use. In post-market monitoring, protection against severe disease has become
evident in several observational studies. While there is emerging evidence of waning effectiveness
against symptomatic infection with omicron, I have not seen data indicating that the COVID-19
vaccines no longer provide benefits, including protection against severe illness that would cause
Health Canada to take regulatory action.
144. It is common practice for Phase 3 trials of many drugs, including vaccines, to continue
after regulatory authorization in order to collect longer-term efficacy and safety data that were not
required for the initial authorization. Such data can be collected in the post-market setting after
regulatory authorization. Once the regulatory threshold for authorization is met, vaccines are
considered to no longer be investigational from a regulatory perspective, although further data will
continue to be collected through clinical trials, observational studies, safety surveillance studies,
etc., to continue to inform the efficacy and safety profile of the vaccine throughout its life-cycle.
(ii.) Proven benefits are weighed against potential risks
145. Many drugs and vaccines are not 100% effective in preventing a disease, nor against
severity of illness associated with that disease. Proven benefits must be weighed against the
potential risks demonstrated by the information made available to Health Canada, and only when
the benefits outweigh the risks does Health Canada authorize the drug.
37
AR02815
146. Where there are concerns regarding effectiveness or risk related to a drug or vaccine that
is marketed in Canada, Health Canada has a variety of mechanisms available to deal with those
issues. Health Canada has the authority to request a manufacturer to conduct a benefit-risk
assessment and provide additional data to confirm the effectiveness and/or safety of the drug if
concerns arise about the drug’s benefits and/or risks. A drug may be removed from the market if
the benefits no longer outweigh the risks. Health Canada also has the authority to request changes
to the Product Monograph or labelling of a drug in order to introduce new information about the
drug’s benefits and risks. For example, in respect of the COVID-19 vaccines, multiple revisions
to the Product Monographs were made to the implicated vaccines to add updated information about
the rare risks of blood clots with low blood platelets (AstraZeneca and Janssen vaccines),
myocarditis and pericarditis (Pfizer and Moderna vaccine), capillary leak syndrome (AstraZeneca
vaccine), immune-mediated low blood platelets (AstraZeneca and Janssen), and blood clots in the
veins (AstraZeneca and Janssen). Similarly, significant waning efficacy against severe disease
leading to the need for a booster may also similarly be addressed by requiring manufacturers to
file submissions with data to update the Product Monograph and instructions for use, as applicable .
147. Should vaccine effectiveness against severe disease no longer be supported, for example,
due to loss of effectiveness against VOCs even with a booster strategy, the vaccine will no longer
be recommended by Health Canada and public health officials, and will become obsolete. Health
Canada may cancel the vaccine’s DIN at that point. Health Canada is closely monitoring the
impact of VOCs on vaccine effectiveness, and may also request that manufacturers update the
formulation of their vaccines should the current versions no longer be deemed sufficiently
efficacious for the circulating VOCs. Health Canada has updated its guidance on COVID-19
vaccines to introduce regulatory requirements should manufacturers need to update their vaccines
to address VOCs. Further guidance is under development to establish requirements for new
vaccines targeting the VOCs.
148. Although Health Canada is responsible for authorizing each vaccine based on the
demonstrated benefits weighed against the potential risks, it falls to other health authorities to
make decisions based on that information and other considerations (e.g., available supply,
differential benefits and risks amongst different vaccines, storage requirements, ease of
administration, etc.) as to how to best use the vaccines. Currently, the mRNA vaccines are
38
AR02816
preferentially recommended by the National Advisory Committee on Immunization (NACI) and

public health authorities within the Provinces and Territories. It does not mean that the other
vaccines authorized by Health Canada should be withdrawn from the market or never approved.
(iii.) Approval of the mRNA vaccines for children 5 to 11 was not based on an
unusual process
149. In respect of the approvals of the Pfizer and Moderna vaccines for children 5-11 years of
age, while the trial cohort was smaller than that for adults, this is very typical in vaccine
development for vaccines targeting all segments of the population.
150. Generally, a vaccine will be studied in the adult population and the data on efficacy will be
extrapolated for consideration of approval in children based on the immune response in a smaller
clinical trial in children as compared to the immune response in young adults up to 25 years of age
as measured in the large clinical trial in adults where vaccine efficacy was demonstrated.
Generally, large clinical trials are not repeated in children. Further, consideration of these data and
their limits is also weighed against the potential risks for children. While children are at a lower
risk of severe disease and death from COVID-19, they can still develop multi-system inflammatory
syndrome, be hospitalized, and admitted to the intensive care unit, especially children with
underlying medical conditions. Approval of COVID-19 vaccinations must take into account the
benefits of vaccination weighed against its potential risks as compared to the risks of COVID-19
infection in children. Even if similar large clinical trials as those conducted in adults had also been
conducted in children, the risk of myocarditis or pericarditis would not necessarily have been
assessed by such trials in view of the rarity of these events. Only in the post-market setting after
the vaccines are administered to hundreds of thousands or millions of children can the risk of these
events be measured. As found in the CDC post-market study referenced in paragraph 74 above,
the risk of heart complications in all populations (including children and adolescents) from the
SARS-CoV-2 infection itself is higher than the risk of myocarditis or pericarditis associated with
the mRNA vaccines. These findings support continued use of the mRNA vaccines among all
eligible individuals 5 years of age and above.
39
AR02817
(iv.) Health Canada did not receive information indicating that COVID-19
vaccines caused a toxic spike protein in recipients
151. The data provided to Health Canada for review by the manufacturers does not support the
conclusion that the spike protein contained in the COVID-19 vaccines or produced by the COVID-
19 vaccines is toxic.
152. The data Health Canada was provided with included study reports of the distribution of the
vaccine components to different tissues after intramuscular administration in rats as the animal
model. For the Pfizer vaccine for example, it is clear that when exposures are calculated as percent
dose, the exposure to the liver is up to 21% of the dose, and the remaining tissue exposures are up
to 1% of the dose. Exposures to tissues, other than those at the site of injection and in liver, are
considered small and not substantial. Further, these tissue exposures are associated with a study
dose (50 µg per 270 g rat, equal to 185 µg/kg body weight) that is 370 times greater than the
clinical dose (30 µg per 60 kg adult, equal to 0.5 µg/kg body weight).
153. Questions about possibile toxicity of the spike protein produced by intramuscular injections
of mRNA-based COVID-19 vaccines have been addressed by repeat-dose toxicity studies
conducted in rats. The reports of such studies were provided to Health Canada by the
manufacturers. Inflammation and/or toxicities were not reported in peripheral tissues. Further,
rodent developmental and reproductive toxicity studies conducted with the vaccines did not
demonstrate any toxicity concerns to the dam, fetus, or neonate. These studies investigated doses
that were at least 130 times the clinical dose in humans on a body weight basis.
154. Health Canada’s interpretation of the results of the non-clinical biodistribution and toxicity
studies took this margin of exposure into consideration in considering the benefit-risks of COVID-
19 vaccines.
(v.) Absolute risk reduction was not considered in the Food and Drug Act
approval process for the vaccines
155. COVID-19 clinical trials are designed to assess vaccine efficacy using relative risk
reduction (RRR) as the main measure of efficacy. Therefore, the use and interpretation of the
absolute risk reduction (ARR) is not appropriate with the data derived from COVID-19 clinical
trials as explained below.
40
AR02818
156. COVID-19 vaccine clinical trials are event-driven trials, and efficacy is formally evaluated
at a time point, which is determined when a sufficient number of cases of COVID-19 that are
needed to demonstrate efficacy occur in the clinical trial. As the clinical trial is blinded, we don’t
know if the COVID-19 cases occur in the vaccine or the control (placebo or unvaccinated) group.
Different subjects are enrolled in the clinical trial at different time points and are consequently
followed for different amounts of time before the decision is taken to trigger and proceed with the
efficacy assessment based on the overall accrued number of COVID-19 cases.
157. ARR is the arithmetic difference in the proportion of subjects who develop COVID-19
between the vaccinated and the control group. Scientifically, there are two major limitations to
applying this measure in COVID-19 vaccine trials. First, the ARR varies depending on the
underlying COVID-19 event rate (i.e., the incidence of COVID-19 in the communities from which
the trial subjects are enrolled from), becoming smaller when the COVID-19 event rate is low, and
larger when the event rate is high. Second, the ARR does not properly account for “at-risk”
exposure time to COVID-19 for each clinical trial subject. “At-risk” exposure time is the amount
of time a clinical trial subject was followed in the clinical trial, which starts at the time of
randomization and vaccination (with either the vaccine or placebo) to the time when the subject is
either withdrawn from the study, or efficacy is assessed at the trial level, whichever comes first.
158. Given the above two major limitations, the RRR is typically used in vaccine clinical trials
including those for COVID-19. The RRR measures how much the vaccine reduces the risk of
developing COVID-19 relative to the control group who did not have the vaccine. As such, it
measures the true benefit of the vaccine and is free of the limitations associated with ARR given
that it properly accounts for the underlying COVID-19 event rate as well as the “at-risk” exposure
time to COVID-19.
159. Given the above reasons, the RRR is considered a more relevant measure to assess vaccine
efficacy compared to the ARR for COVID-19 vaccine clinical trials.
(vi.) Adverse Events of Special Interest are monitored and considered
160. Health Canada monitors the Adverse Events of Special Interest (“AESI”) and it is not
unusual for additional AESI to appear during the post-market period. By way of background,
AESI are specific Adverse Events Following Immunization (“AEFI”) that the manufacturer will
41
AR02819
be proactively looking for using established methodologies. When Health Canada receives reports
of AESI they are reviewed using the same causality assessment that is used for all AEFI. Examples
of AESI that appeared during the post-market period include myocarditis and pericarditis with the
mRNA vaccines and the vaccine-induced immune thrombotic thrombocytopenia (VIIT) reported
with the AstraZeneca and Janssen vaccines. AESIs, as with all AEFIs, are reported after
vaccination with a COVID-19 vaccine but are not necessarily related to the vaccine.
161. With respect to adverse events of special interest that have been identified for the vaccine,
comprehensive safety assessments are done by looking at a variety of potential adverse events
using standard methodology and queries based on the Medical Dictionary for Regulatory Activities
(MedDRA) developed by the International Council for Harmonization.
162. The Canada Vigilance Program (CVP) managed by Health Canada receives serious AEFI
reports from manufacturers, Canadian hospitals, healthcare professionals, and consumers.
Similarly, the Canadian Adverse Events Following Immunization Surveillance System
(CAEFISS) managed by the PHAC, receives AEFI reports from all Provincial and Territorial
public health authorities and from federal departments, including the Department of National
Defense, Correctional Services Canada, Indigenous Services Canada, and Royal Canadian
Mounted Police.
163. Health Canada and PHAC process and review AEFI reports in their databases regularly,
and special attention is given to serious or unusual events that could signal a concern regarding
vaccine safety. Analyses are done regularly, in collaboration with provincial and territorial public
health authorities, to search for vaccine safety signals.
164. AEFI reports are not the only source of evidence used. Health Canada has imposed Terms
and Conditions for the expedited reporting of domestic and international adverse events from
manufacturers. Health Canada also assesses periodic summaries of safety information submitted
by vaccine manufacturers, reviews scientific and medical literature, and monitors activities of and
collaborates with other regulatory agencies to determine whether there is any evidence of new,
more severe, or more frequent safety concerns. Through the thorough review of all available
information, Health Canada determines whether the benefits continue to outweigh the risks or if
regulatory intervention is required.
42
AR02820
165. While the number of AEFI reports may appear elevated for the COVID-19 vaccines in
relation to that for other vaccines, it is the experience of those working in post market surveillance
that the reporting rates are significantly increased due to the heightened awareness and the desire
for reporting of any and all potential AEFI to improve our ability to understand AESI/AEFI to
improve the safety of these products for Canadians. The number of reports does not equate to
severity of these events, nor does it confirm that they were caused by the vaccine.
166. AESI are identified initially based on the data received from the clinical trials and based
on previous historical experiences with similar vaccines or in the post market space. Once those
AESI are identified, they are included in the manufacturer’s post-market risk management plan for
more deep and more focused monitoring of those particular adverse events. The manufacturers
also monitor all sorts of other potential adverse events but those are not adverse events of special
interest; rather they are adverse events of all types.
167. For example, from the information I have received in my role as DG of BRDD regarding
the risk of myocarditis/pericarditis has not changed my benefit/risk assessment. Specifically, I
have received information that up to and including March 25, 2022, there were 1,971 reports of
myocarditis/pericarditis. Of those, 1,253 reports followed vaccination with the Pfizer-BioNTech
Comirnaty COVID-19 vaccine, 676 followed vaccination with the Moderna Spikevax COVID-19
vaccine, 35 followed vaccination with the AstraZeneca Vaxzevria/COVISHIELD COVID-19
vaccine, 1 followed the Janssen COVID-19 vaccine and the vaccine name for 6 were not specified.
I also note that the reporting rate of myocarditis/pericarditis following vaccination with Moderna
Spikevax COVID-19 vaccine is higher than that of the Pfizer-BioNtech Comirnaty COVID-19
vaccine, for all ages and sexes combined.
168. However, I also note that the information I have received shows that both the Moderna
Spikevax and the Pfizer-BioNTech Comirnaty mRNA COVID-19 vaccines provide enhanced
protection against COVID-19 when offered as a booster dose. Clinical trial data show that a booster
dose produces an increased immune response and has a favourable safety profile.
169. Further, the information I have received indicates that the risk of myocarditis or pericarditis
is very rare in youths and young adults 12 to 29 years of age. Compared to older age groups, there
is a slightly increased risk after receiving an mRNA COVID-19 vaccine. The rates of myocarditis
43
AR02821
or pericarditis after receiving a booster dose with an mRNA vaccine appear to be somewhat lower
than after the second dose. Most cases have been mild and resolved quickly with medical care.
170. As noted above at paragraph 74, I have recently received a summary of an analysis
published by the CDC comparing the risk of cardiac complications (myocarditis and/or pericarditis
and cardiac complications associated with MIS) following COVID-19 infection to that following
vaccination with mRNACovid-19 vaccines. The incidence of cardiac complications following
mRNA Covid-19 vaccination is highest in males aged 12 to 17 years following the second dose.
The risk of cardiac complications in this age group is 1.8 to 5.6 times greater following COVID-
19 infection than following the second dose of an mRNA Covid-19 vaccine.
171. The risk of cardiac complications was significantly higher after COVID-19 infection than
after the first, second or unspecified dose of mRNA Covid-19 vaccine for all other groups by age
and sex.
172. In that case, once the risk of myocarditis/pericarditis was identified, Health Canada took
prompt regulatory measures to mitigate this risk including the issuance of multiple
communications to the public and changes to the Product Monographs for both mRNA vaccines.
Health Canada continues to monitor safety information stemming from all available sources,
including clinical trial data and post-market authorisation experience. Health Canada has been
working closely with international regulatory partners to monitor the safety of COVID-19 vaccines
as they are being deployed and will take action should any new safety signal be identified.
173. Another example is vaccine-induced immune thrombotic thrombocytopenia (VIIT). The

information I have received in my role as DG of BRDD regarding the risk of VIIT has not changed
my benefit-risk analysis.
174. Health Canada and the PHAC have been closely monitoring events of VIIT since they were
first identified. Up to and including March 25, 2022, there were 69 reports followed vaccination
with the AstraZeneca Vaxzevria/COVISHIELD COVID-19 vaccine, 30 followed vaccination with
the Pfizer-BioNTech Comirnaty COVID-19 vaccine, and 13 followed vaccination with the
Moderna Spikevax COVID-19 vaccine.
44
AR02822
175. Health Canada took prompt regulatory measures to mitigate this risk including the issuance
of multiple communications to the public and changes to the Product Monographs for both viral-
vector vaccines. Health Canada continues to monitor safety information stemming from all
available sources including clinical trail data and post-market authorisation experience. Health
Canada has been working closely with international regulatory partners to monitor the safety of
COVID-19 vaccines as they are being deployed and will take action should any new safety signal
be identified.
176. Finally, Health Canada medical officers have reviewed all reported death cases in the
Canada Vigilance database. These reports have been assessed for causality and there have been no
cases where there was a possible, probable, or definite causality assigned based on the accepted
WHO classification of causality. Attached as Exhibit “R” is a copy of the “WHO Causality
Assessment for Adverse Events Following Immunization (“AEFI”)”.
177. Up to and including March 25, 2022, a total of 319 reports with an outcome of death were
reported following vaccination. Although these deaths occurred after being vaccinated with a
COVID-19 vaccine, they are not necessarily related to the vaccine. Based on the medical case
review using the WHO-UMC causality assessment categories, it has been determined that: 168
reports of deaths could not be assessed due to insufficient information, 103 reports of deaths are
unlikely linked to a COVID-19 vaccine and 48 reports of death are still under investigation.
178. In comparison to the information that I have received in respect of deaths related to
COVID-19 infection, the reports of death have not changed my benefit-risk analysis nor led me to
believe that regulatory action was required.
G. Protecting Canadians against COVID-19 is in the public interest
179. Full vaccination forms a key component of Canada’s efforts to protect Canadians,
including Canadians who work in the federally regulated transportation sector or are travellers or
passengers in that sector, against the impact of COVID-19 arising from the existing SARS-CoV-
2 virus and emerging VOCs. Vaccination is one of the most effective ways to protect against
COVID-19 and the emergence of new VOCs. In the current context, with the emergence of
Omicron, the evidence continues to show that the benefits of vaccination continue to outweigh the
risks of adverse effects based on the continued protection against severe disease. Health Canada
45
AR02823
and PHAC continue to monitor the evidence as shown, by way of example, through this update
dated April 14, 2022, regarding vaccine efficacy against the Delta and Omicron VOCs that was
provided to me by PHAC and which is attached as Exhibit “S”. The information that I have
reviewed shows that:
i. vaccines are very effective at preventing severe illness, hospitalization and death
from COVID-19, including against VOCs. Effectiveness against severe illness due
to Omicron is maintained for up to at least 18 weeks, especially after a booster dose,
although more data are needed on the longer-term duration of effectiveness. PHAC
data continue to indicate that unvaccinated people are much more likely to be
admitted to hospital than fully vaccinated people;
ii. people who are fully vaccinated with an mRNA vaccine are less likely to have
COVID-19 with or without symptoms and spread COVID-19 to others based on
studies conducted prior to the emergence of the Omicron variant. With Omicron,
studies show that a booster dose is needed for effectiveness against symptomatic
disease but effectiveness wanes beyond 12 weeks;
iii. people who are fully vaccinated with a viral vector vaccine are less likely to have
COVID-19 with symptoms or spread COVID-19 to others based on studies prior to
the emergence of the Omicron variant. With Omicron, studies show that a booster
dose is needed for vaccine effectiveness against symptomatic disease but
effectiveness wanes beyond 12 weeks;
iv. to the extent that COVID-19 vaccines prevent SARS-CoV-2 infection they also
prevent post-COVID condition and there is now some evidence that vaccinated
people who do become infected are less likely to develop post-COVID condition
than unvaccinated people;
v. having as many people vaccinated as possible may reduce the risk of both the
ongoing circulation of the virus and the appearance of future variants; and
vi. having as many people vaccinated as possible may reduce the impact of COVID-
19 on the healthcare system.
46
AR02824
180. Additional information regarding this section of my affidavit, which would be considered
as a part of normal post-approval monitoring, can be found:
i. Attached as Exhibit “T” is a copy of a PDF entitled “Update on Covid-19 in

Canada: Epidemiology and Modelling” dated April 1, 2022 which can be located
on the internet at (https://www.canada.ca/content/dam/phac -
aspc/documents/services/diseases-maladies/coronavirus-disease-covid-
19/epidemiological-economic-research-data/update-covid-19-canada-
epidemiology-modelling-20220218-en.pdf) which was prepared by PHAC; and
ii. Attached as Exhibit “U” is a copy of the publically available webpage entitled
“COVID-19: Effectiveness and benefits of vaccination” which can be located at
(https://www.canada.ca/en/public-health/services/diseases/coronavirus-disease-
covid-19/vaccines/effectiveness-benefits-vaccination.html).
H. Vaccination is Effective COVID-19 Risk Management
181. As of April 1, 2022 a total of 81,932,528 vaccine doses have been administered in Canada.
Adverse effects have been reported by 43, 568 people. Of the 43, 568 individual reports, 34, 515
were considered non-serious (0.053% of all doses administered). 9, 053 were considered serious
(0.011% of all doses administered). Non-serious adverse events are mild and include soreness at
the site of injection or a slight fever. An adverse event is considered serious if it: results in death,
is life threatening (in that it is an event/reaction where the patient is at a real risk of death at the
time), requires in-patient hospitalization or prolongation of existing hospitalization, results in
persistent or significant disability/incapacity, or results in a congenital anomaly/birth defect.
Serious adverse events include anaphylaxis (a severe allergic reaction), which has been reported
825 times for all COVID-19 vaccines in Canada. This information can be found on the webpage
prepared by PHAC entitled “Reported side effects following COVID-19 vaccination in Canada”
which could be accessed under the “Weekly report” tab at (https://health-
infobase.canada.ca/covid-19/vaccine-safety/). A copy is attached to as Exhibit “V”.
182. It is important to understand the significance of the adverse effects/side effects reporting
to put the information into context.
47
AR02825
183. An adverse event is any untoward medical occurrence that follows immunization; however,
it is not necessarily caused by the vaccine. All reports of adverse events following immunizat ion
received by Health Canada and Public Health Agency of Canada are included in Health Canada
and PHAC reporting on adverse events regardless of whether they have been linked to the
vaccines; this is done to be transparent about all data available to detect any early signals of an
issue. However, expert review is required in order to determine if any reported event can be
plausibly linked to vaccination. Consideration of whether these events represent a statistically
significant variation from the usual occurrence of those same events in a similar population over a
similar timeline also requires further analysis. For example, in the Phase 3 trial of the Pfizer-
BioNTech COVID-19 vaccine, 4 reports of Bell’s Palsy occurred in the vaccine group compared
to 2 reports in the placebo group. These data alone do not mean that the vaccine increases the risk
of Bell’s Palsy. Further analysis is required to understand the background rates for this condition,
and factors that may have contributed to the adverse event in each participant. This is a process
that Health Canada undertakes as part of its benefit-risk assessment as well as during post-market
monitoring.
184. There is ongoing monitoring and reporting of adverse effects/side effects of COVID-19
vaccines. All serious events undergo medical review to determine if there are any safety issues
needing further action. These processes include meeting regularly to review the data received with
provincial and territorial partners, the regulator, research networks, and medical advisors to help
ensure that there are no safety issues that require action.
185. Health Canada maintains the Canada Vigilance adverse reaction online database, which
contains information about suspected adverse reactions (also referred to as side effects). Adverse
reaction reports are submitted by: (a) consumers and health professionals, who submit reports
voluntarily; (b) manufacturers and distributors (also known as market authorization holders) who
are required to submit reports pursuant to the Food and Drugs Act. This database, which is publicly
available, allows anyone to research adverse reaction reports submitted to Health Canada
associated with all regulated marketed health products, including COVID-19 vaccines which have
received approval for marketing in Canada. It can be located at: (https://www.canada.ca/en/health-
canada/services/drugs-health-products/medeffect-canada/adverse-reaction-database.html). In
addition, for COVID-19 vaccines, a summary of the available adverse event information reported
48
AR02826
to either Health Canada or PHAC can be located at: (https://health-infobase.canada.ca/covid-

19/vaccine-safety/).
186. Health Canada has updated the product monographs to reflect the information received and
issued a number of communications to raise awareness of this information. In addition, data on
numbers of reports received can be found on the PHAC website.
187. COVID-19 has led to a large number of individuals being hospitalized, and as of April 1,
2022, 38, 207 deaths in Canada. The hospitalizations include a large number of patients in
Intensive Care Units (ICUs) and others who have been mechanically vented. As of April 11, 2022,
Canada has detailed case report data with hospitalization status on 3,493, 909 cases. Of those, 148,
553 cases (4.3%) were hospitalized, and of those 25, 351 were admitted to the ICU. Attached to
this affidavit as Exhibit “W” is a copy of a figure prepared by the PHAC entitled “Daily Census
of Covid-19 Patients who were hospitalized, vented or in the ICU as of April 11, 2022” which
could be found as figure 6 on the webpage (https://health-infobase.canada.ca/covid-
19/epidemiological-summary-covid-19-cases.html).
188. As set out in the “Covid-19 daily epidemiological update” dated April 14, 2022, a copy of
which is Exhibit “I” and which could be located at (https://health-infobase.canada.ca/covid-
19/epidemiological-summary-covid-19-cases.html), since the start of the vaccination campaign on
December 14, 2020, PHAC received case-level vaccine history data for 72.5% of COVID-19 cases
aged 5 or older. Of those cases:
i. 932,814 (47.4%) were unvaccinated at the time of their infection;
ii. 51,668 (2.6%) were not yet protected by the vaccine, as their infection occurred
less than 14 days after their first dose;
iii. 90,925 (4.6%) were only partially vaccinated, as their infection occurred either 14
days or more after their first dose or less than 14 days after their second dose;
iv. 698,855 (35.5%) were fully vaccinated, as their infection occurred 14 days or more
after their second dose; and
49
AR02827
v. 192,656 (9.8%) were fully vaccinated with an additional dose, and in their infection
occurred 14 days or more after receipt of at least one additional dose of a COVID-
19 vaccine product after becoming fully vaccinated.
189. Attached as Exhibit “X” is a copy of a figure and a table both named “Characteristics and
severe outcomes associated unvaccinated, partially vaccinated, fully vaccinated, and fully
vaccinated with additional dose confirmed cases reported to PHAC, as of March 27, 2022” which
can be found at Figure 5 and Table 2 on the webpage (https://health-infobase.canada.ca/covid-
19/epidemiological-summary-covid-19-cases.html).
190. PHAC has also reported in the “Covid-19 daily epidemiological update” dated April 14,
2022 referenced above that among the twelve Canadian jurisdictions currently reporting case-level
vaccine history data to PHAC, a total of 25.0 million people have received at least one dose of the
COVID-19 vaccine as of March 27, 2022. Of those individuals: 25.0 million achieved at least
partial vaccination status, of which 90, 925 (0.36%) were diagnosed with COVID-19 while only
partially vaccinated; 23.9 million achieved full vaccination status, of which 698, 855(2.93%) were
diagnosed with COVID-19 while fully vaccinated; and 13.5 million achieved full vaccination with
an additional dose status, of which 192, 656 (1.42%) were diagnosed with COVID-19 while fully
accinated with an additional dose. For context, with respect to a two dose vaccine, partial
vaccination status is achieved two weeks after the first dose or less than two weeks after the second
dose. Full vaccination status is achieved two weeks after the second dose. For a single dose
vaccine (Janssen only), full vaccination is achieved two weeks after the single dose is given.
191. As of April 1, 2022, the rate of adverse event reports is not the same among different age
groups and sexes. The highest rates of adverse event reports was first amongst the 40 to 49 year
age group (74.6 reports per 100,000 doses administered) followed by those in the 50 to 59 year
age group (64.5 reports per 100,000 doses). The majority of adverse even reports were from
females (72.7%) with the reporting rate at 72.4 reports per 100,000 doses administered compared
to 28.7 per 100,000 for males (with the exception of the 12 to 17 age group). This information can
be found in the “Weekly report” tab of the webpage entitled “Reported side effects following
COVID-19 vaccination in Canada” which is Exhibit “V”.
50
AR02828
192. As part of its post-approval monitoring, Health Canada continues to work with the PHAC
to monitor Canadian and international reports of adverse effects. This includes events of special
interest: Thrombosis (blood clots) with thrombocytopenia syndrome; Guillain-Barré Syndrome;
capillary leak syndrome; inflammation of the heart muscle (myocarditis); inflammation of the
lining around the heart (pericarditis); and facial paralysis/Bell’s palsy. Attached to this affidavit as
Exhibit “Y” is a copy of a chart prepared by Public Health Agency Canada, with data up to and
including April 1, 2022, containing the number and rate (per 100,000 doses administered) of the
most frequently reported adverse events which can be located as Figure 4 under the “Weekly
report” tab on the webpage entitled “Reported side effects following COVID-19 vaccination in
Canada” referenced above. Attached to this affidavit as Exhibit “Z” is a copy of a chart prepared
by PHAC, with data from up to and including April 1, 2022, containing the number of reported
events of special interest by vaccine type which can be located as Table 1 Figure 4 under the
“Weekly report” tab on the webpage entitled “Reported side effects following COVID-19
vaccination in Canada” referenced above.
193. PHAC has also provided detailed information with respect to certain AESI as publically
reported by Health Canada:
i. Thrombosis with Thrombocytopenia Syndrome: Attached to this affidavit as

Exhibit “AA” is a copy of detailed information about thrombosis with
thrombocytopenia syndrome as of April 1, 2022 available in a dropdown tab
entitled “Thrombosis with thrombocytopenia syndrome” under the “Weekly
report” tab on the webpage entitled “Reported side effects following COVID-19
ii. Guillain-Barré Syndrome: Attached to this affidavit as Exhibit “BB” is a copy of

detailed information about Guillain-Barré Syndrome as of April 1, 2022 available
in a dropdown tab entitled “Guillain-Barré Syndrome” under the “Weekly report”
tab on the webpage entitled “Reported side effects following COVID-19
iii. Capillary Leak Syndrome: Attached to this affidavit as Exhibit “CC” is a copy of
detailed information about capillary leak syndrome as of April 1, 2022 available in
51
AR02829
a dropdown tab entitled “capillary leak syndrome” under the “Weekly report” tab
on the webpage entitled “Reported side effects following COVID-19 vaccination
in Canada” referenced above.
iv. Inflammation of the heart muscle (myocarditis)/Inflammation of the lining around

the heart (pericarditis): Attached to this affidavit as Exhibit “DD” is a copy of
detailed information about myocarditis/pericarditis as of April 1, 2022 available in
a dropdown tab entitled “Myocarditis/pericarditis” under the “Weekly report” tab
on the webpage entitled “Reported side effects following COVID-19 vaccination
in Canada” referenced above.
194. Health Canada has updated the product monographs to reflect the information received and
issued a number of communications to raise awareness of this information. In addition, data on
numbers of reports received can be found on the PHAC website.
195. Up to and including April 1, 2022, a total of 327 reports with an outcome of death were
reported following vaccination. Although these deaths occurred after being vaccinated with a
COVID-19 vaccine, they are not necessarily related to the vaccine. Attached to this affidavit as
Exhibit “EE” is a copy of detailed information about deaths as of April 1, 2022 available in a
dropdown tab entitled “Deaths” under the “Weekly report” tab on the webpage entitled “Reported
side effects following COVID-19 vaccination in Canada” referenced above. Based on the medical
case review using the World Health Organization-Uppsala Monitoring Centre (WHO-UMC)
causality assessment categories, it has been determined that:
i. 103 of these deaths are unlikely linked to a COVID-19 vaccine;
ii. 168 deaths could not be assessed due to insufficient information; and
iii. 56 of the reported deaths are still under investigation.
196. COVID-19 has led to a large number of individuals being hospitalized, and as of April 14,
2022, 38, 207 deaths in Canada. The hospitalizations include a large number of patients in
Intensive Care Units (ICUs) and others who have been mechanically vented. As of April 11, 2022,
Canada has detailed case report data with hospitalization status on 3,493, 909 cases. Of those, 148,
52
AR02830
553 cases (4.3%) were hospitalized, and of those 25,351 were admitted to the ICU. Attached to
this affidavit as Exhibit “W” is a copy of a figure prepared by the PHAC entitled “Daily number
of hospital beds and ICU beds occupied by COVID-19 patients as of April 11, 2022” which can
be found as figure 6 on the webpage (https://health-infobase.canada.ca/covid-19/epidemiological-
summary-covid-19-cases.html).
197. Further, the hospitalization, ICU admittance, and deaths attributed to COVID-19 covers all
age ranges and sexes:
i. Attached to this affidavit as Exhibit “FF” is a copy of a figure prepared by the

PHAC entitled “Age and gender distribution of COVID-19 cases hospitalized in
Canada as of April 14, 2022, 4 pm EST” which can be found as figure 7 on the
webpage (https://health-infobase.canada.ca/covid-19/epidemiological-summary-
covid-19-cases.html).
ii. Attached to this affidavit as Exhibit “GG” is a copy of a figure prepared by the
PHAC entitled “Age and gender distribution of COVID-19 cases admitted to ICU
in Canada as of April 14, 2022, 4 pm EST” which can be found as figure 7 on the
iii. Attached to this affidavit as Exhibit “HH” is a copy of a figure prepared by the
PHAC entitled “Age and gender distribution of COVID-19 cases deceased in
Canada as of April 14, 2022, 4 pm EST” which can be found as figure 7 on the
198. Attached as Exhibit “X” is a copy of a figure and a table both named “Characteristics and
severe outcomes associated unvaccinated, partially vaccinated and fully vaccinated confirmed
cases reported to PHAC, as of March 27” which can be found at Figure 5 and Table 2 on the
webpage (https://health-infobase.canada.ca/covid-19/epidemiological-summary-covid- 19-
cases.html).
53
AR02831
I. Conclusion
199. I make this affidavit bona fide in support of the Attorney General of Canada’s position in
this matter and for no other purpose.
AND I HAVE SIGNED by technological

means in the City of Ottawa, in the Province of
Ontario, this 21st day of April, 2022.
____________________________________
CELIA LOURENCO
AFFIRMED before me by technological

means, in the City of Saint-Rémi, in the
Province of Québec, this 21st day of April,
2022.
____________________________________
Commissioner for Oaths for Québec and
for outside Québec
54
AR02832
This is Exhibit “A” referred to in the

Affidavit of CELIA LOURENCO
affirmed before me by technological means
in the City of Saint-Rémi, in the Province of Québec,
this 21st day of April, 2022.

Commissioner for Oaths for Québec and for outside of Québec
AR02833
CELIA LOURENCO, Ph.D.

Ottawa, Ontario,
| (cell) 613
Second Official Language Proficiency: CBC (French)
FEDERAL REGULATORY EXECUTIVE
Executive in the federal government with strengths in directing programs in regulatory
operations, with a focus on service delivery, partnerships, and international collaboration.
Development and application of federal legislation and standards for drug regulation.
 Staff recruitment, training and

 Create a clear vision, with strategic
development
planning, execution, and reporting
 Complex change management
 Engagement of employees, partners, and
 Focus on results with high productivity
stakeholders
and positive employee engagement
 Scientific expertise in drug development
 Multidisciplinary teams in a complex risk
& regulation
management environment
 National and international collaboration
 Effective issues management and
with various stakeholders
communication
PROFESSIONAL EXPERIENCE
Executive and management roles held at the Health Products and Food Branch, Health Canada
Director General
Biologic and Radiopharmaceutical Drugs Directorate, Ottawa 11/2018 – present
• Report to the Assistant Deputy Minister, Health Products and Food Branch, in setting the
vision and strategic direction of a directorate with over 415 employees and a budget of
about $45 million
• Guide business transformation, innovation, and adaptability as the global drug
development context changes, and through challenges such as the COVID-19 pandemic
• Oversee a multidisciplinary team of directors responsible for developing and
implementing policies, guidelines, systems, and processes, and for applying the Food and
Drugs Act and associated Regulations, in regulating human biological (including blood
and blood products) and radiopharmaceutical drugs
• Provide strategic advice in setting policy and addressing complex issues related to access
to drugs by Canadians
• Build and maintain relationships with internal program partners and external stakeholders
within the health ecosystem
• Lead transformation initiatives for the Branch including the paediatric drugs action plan
and the advanced therapeutic products pathway
• Lead international collaboration initiatives under the International Coalition of Medicines
Regulatory Authorities, the International Council for Harmonization, and bilaterally with
various international regulatory authorities
AR02834
Celia Lourenco, PhD

• Represent the Department as an ex-officio member of the National Advisory Committee
on Immunization
Interim Executive Director, Therapeutic Products Directorate, Ottawa 07/2017 – 11/2018
• Supported the Director General (DG) and the Assistant Deputy Minister in setting the
vision and strategic direction of a directorate with over 520 employees and a budget of
about $60 million
• Oversaw the directorate operations by providing direction to the bureau responsible for
the directorate’s operational planning, monthly financial variance reporting, review
services & project management, stakeholder engagement, and transparency initiatives
• Supported the DG in providing direction to a multidisciplinary team of directors
responsible for developing and implementing policies, guidelines, systems, and
processes, and for applying the Food and Drugs Act and associated Regulations, in
regulating human prescription drugs and medical devices
• Provided strategic advice in setting policy and addressing complex issues related to
access to drugs and medical devices by Canadians
• Built and maintained relationships with internal program partners such as the Marketed
Health Products Directorate and the Regulatory Operations and Regions Branch, and
external stakeholders such as Industry Associations, Health Technology Assessment
agencies, health care professional associations, and the Provinces and Territories
• Led transformation initiatives for the Branch under the Regulatory Review of Drugs and
Devices, including projects on use of foreign reviews and international collaboration
• Led international collaboration initiatives as a Health Canada representative on the
Management Committee of the International Council for Harmonization
• Led international transformation initiatives such as the consolidation of the International
Pharmaceutical Regulators Forum with the International Generic Drugs Review
Programme
Director, Bureau of Gastroenterology, Infection and Viral Diseases, Ottawa 03/2014 – 07/2017
• Reporting to the Director General, directed a bureau with 41 employees and a budget of
$4.3 million, overseeing operational planning, staffing, and monthly financial variance
reporting
• Directed multidisciplinary teams in the review of industry submissions for market
authorization of human drugs for the treatment or management of gastrointestinal and
infectious diseases under the Food and Drugs Act and Regulations
• Consistently met performance targets in a collaborative environment
• Led for the Branch the policy file related to antimicrobial resistance to implement
measures to promote stewardship of human antimicrobials and incentivize innovation
• Built and maintained relationships with stakeholders including the pharmaceutical
industry and regulatory authorities such as the US Food and Drug Administration (FDA)
and the European Medicines Agency (EMA)
2
AR02835
Celia Lourenco, PhD

• Led business transformation initiatives to modernize the workplace, such as the
organizational review of the evaluation of human therapeutic products and the creation of
a central division for the review of labeling including the implementation of the new
Plain Language Labeling regulations.
• Represented Health Canada at the International Council for Harmonisation of technical
requirements for pharmaceuticals for human use
Interim Director, Bureau of Cardiology, Allergy and Neurological Sciences, Ottawa

08/2013 – 03/2014
• Reporting to the Director General, directed a bureau with 42 employees and a budget of
$5 million
• Directed multidisciplinary teams in the review of industry submissions for market
authorization of drugs for the treatment of diseases of the central nervous system,
cardiovascular and renal systems, and of allergy and respiratory diseases
• Consistently met performance targets in a collaborative environment
• Monitored and addressed emerging science and policy issues, and developed a draft
guidance document on data requirements for tamper-resistance of opioids
• Built and maintained partnerships with internal and external stakeholders
Associate Director, Bureau of Cardiology, Allergy and Neurological Sciences, Ottawa

05/2013 – 08/2013
• Assisted the Director in managing the operations of the bureau, including setting up and
monitoring contracts with external contractors
• Developed and implemented strategies to address staffing needs
• Conducted a literature review of the latest science on tamper-resistance of opioid drugs
• Addressed issues related to drug safety and drug shortages
• Monitored budget and planned spending through monthly financial situation reports
Interim Director, Office of Clinical Trials, Ottawa 04/2012 – 05/2013
• Reporting to the Director General, directed an office with a total of 70 employees and a
budget of $6.3 million
• Directed and advised on the operations and work of 6 divisions responsible for
management of clinical trial applications (CTAs), review of adverse drug reactions, and
management of the Special Access Programme (SAP)
• Monitored workload and staffing needs, and directed staffing actions to meet needs
• Directed the preparation of briefing notes, media responses, Question Period notes, and
other documents to address requests at the Assistant Deputy Minister level or above
• Directed the development of guidelines, policies, SOPs, and other documents
3
AR02836
Celia Lourenco, PhD

• Contributed to important initiatives within the Branch such as transparency and openness,
rare diseases (orphan drugs), and responses to the auditor general’s audit and Senate
Committee’s recommendations on clinical trials
• Chaired and led the working group that developed the public clinical trials database
• Participated as a scientific expert in two International Expert Working Groups of the
International Council on Harmonisation
Manager, Clinical Group 1, Office of Clinical Trials, Ottawa 08/2007 – 04/2012
• Managed the Clinical Trial Application (CTA) programme for investigational therapeutic
products
• Managed a team of 10 scientific and medical professionals
• Developed performance metrics, and managed work assigned to meet targets 100% of the
time
• Reported to the Director on the Division’s performance at bi-weekly meetings
• Established and maintained relationships with stakeholders including drug companies,
national/international research groups, Canadian university/hospital research groups,
contract research organizations, and bureaus and directorates within Health Canada
• Led meetings with clinical trial sponsors, and provided scientific and regulatory guidance
to sponsors and other stakeholders
• Monitored and kept up-to-date on trends and scientific knowledge impacting on drug
development and regulation
• Led the development and implementation of guidelines related to human clinical trials
• Represented Health Canada on working groups, national events, and international
initiatives related to clinical trials
• Addressed senior management requests, ministerial requests, media enquiries, and other
enquiries related to clinical trials, including preparing for and responding to the Auditor
General’s audit of clinical trials in 2011 and the subsequent study by the Senate
Committee on Social Affairs, Science and Technology in 2012
Other positions held at Health Canada from 02/2001 to 08/2007
 Senior Clinical Evaluator, Clinical Trials Division and Pre-market Clinical Review
Division, Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics, Biologics
and Genetic Therapies Directorate, Ottawa 06/2002 – 08/2007
 Assessment Officer, Division of Biopharmaceutics Evaluation, Bureau of Pharmaceutical
Sciences, Therapeutic Products Directorate, Ottawa 11/2001 – 06/2002
 CIHR / RxD / TPP Post-Doctoral Fellow, Biologics and Genetic Therapies
Directorate, Ottawa 2/2001 – 11/2001
• Reviewed and provided recommendations on Clinical Trial Applications, New Drug

Submissions (NDSs), supplemental NDSs, Abbreviated NDSs, and Notifiable Changes
• Provided scientific and regulatory advice to management and responded to stakeholders
• Actively involved in the development of a new regulatory framework for Positron
4
AR02837
Celia Lourenco, PhD

Emitting Radiopharmaceuticals (PERs)
• Assessed and provided recommendations related to Health Hazard Assessments
• Participated on several internal working groups
EDUCATION
Ph.D., Pharmacology (Neuroscience minor), University of Toronto (ON, Canada) 1995 – 2000
B.Sc., Pharmacology with High Distinction, University of Toronto 1991 – 1995
Awards and Achievements

2021 Health Canada Award for Excellence – COVID-19 vaccines
2021 APEX Leadership Award – COVID-19 vaccines
2019 – present Elected vice-chair of the Assembly of the International Council on
Harmonization
2017-18 Elected chair of the International Pharmaceutical Regulators Program
2013 Director General Award for developing the guidance on determination of
the “Medical Necessity” of Health Products to address drug shortages
2011 Deputy Minister Science Award for excellence in monitoring and applying
emerging science in clinical trials (e.g., adaptive clinical trial design,
science of oligonucleotide therapeutics and emerging therapies and trial
designs in the treatment of hepatitis C infection)
2009 Assistant Deputy Minister Collaborative Leadership Award for work
on H1N1 influenza
2003 Director General Award of Recognition for Efforts in Regulating Positron
Emitting Radiopharmaceuticals
5
AR02838
This is Exhibit “B” referred to in the


AR02839
Health Santé
l♦I Canada Canada
Health Products Direction générale des produits
and Food Branch de santé et des aliments
TERMS AND CONDITIONS

Company: BioNTech Manufacturing GmbH
Product: Comirnaty (COVID-19 vaccine, mRNA)
Dossier ID: HC6-024-E252736
Background:
The Food and Drug Regulations allows the Minister to impose or amend terms and conditions, and request
additional information, in relation to a COVID-19 drug submission, Drug Identification Number (DIN), or
establishment licence, at any time while it is in effect. In light of the severity of the COVID-19 pandemic, this
allows the Minister to act quickly to gather important safety information or mitigate risk in a timely manner.
Depending on the requirement, terms and conditions can be ongoing (e.g., require a monthly report), have a
defined time (e.g., a report is due to Health Canada on a specific day) or are to be completed once the data is
available (e.g., a clinical trial is completed).
The status of the Terms and Conditions will be updated on a regular basis.
Status as of November 19, 2021:
Total Number: 21
Ongoing/pending: 21
Closed: 0
Table: Terms and Conditions
Terms and Conditions Issued Status

1 Provide safety and efficacy data for all participants 12 to 15 years of age in study September Pending
C4591001 followed up for 6 months after the second dose including the blinded 16, 2021 availability
and open-label periods, and immunogenicity data 6 months after the second of data
dose in a subset of participants 12 to 15 years of age, when the data become
available.
2 Provide the immunogenicity results 6-month after the second dose from Phase 2 September Pending
of Study C4591001, when the data become available. 16, 2021 availability
of data
1
AR02840

3 Provide study C4591001 report, including safety and efficacy data up to 2 years September Pending
after the second dose for all participants, and immunogenicity data 6 months 16, 2021 availability
after the second dose in a subset of participants, when the data become of data
available.
4 Provide a Certified Product Information Document (CPID) by December 31, 2021. September Expected
16, 2021 by
December
31, 2021
5 In addition to the requirements under the Food and Drug Regulations BioNTech September Ongoing
Manufacturing GmbH, commit to the following: 16, 2021
BioNTech Manufacturing GmbH is required to treat adverse reactions associated

with COMIRNATY as priority and submit the corresponding reports to Health
Canada without delay.
2
AR02841

BioNTech Manufacturing GmbH is required to submit monthly safety reports,

unless otherwise determined by Health Canada. The monthly safety reports
should be submitted within 15 days after the last day of a month, beginning after
the first full calendar month after authorization. These reports should contain
the following:
a. Interval and cumulative number of reports (serious and non-serious),
overall and by age groups and in special populations (e.g. pregnant
women)
b. Interval and cumulative number of reports per HLT and SOC
c. Number of reports in Canada and Global
d. Exposure data, stratified by country, age groups, race and ethnicity
e. Changes to reference safety information in the interval
f. Ongoing and closed signals in the interval
g. Updated list of adverse events of special interest including the Safety
Platform for Emergency Vaccines list and Risk Management Plan (RMP)
safety concerns (including the additional missing information): reports –
numbers and relevant cases, time-to-onset and observed/expected
analyses including causality assessment
h. Fatal reports – numbers and relevant cases, including
observed/expected analyses
i. Vaccination failure / lack of efficacy (including confirmed and suspected
cases) and errors-number relevant cases
j. Potential interaction with other vaccines/concomitant treatments-
number and relevant cases
k. Summary outcomes of some of the routine pharmacovigilance activities
(as presented in the EU RMP Part III and applied in the Canadian
context) should be included for the purpose of rapid signal detection
and communication activities. Summary of all ongoing studies can be
included in the first six-month scheduled Periodic Benefit-Risk
Evaluation Report (PBRER), unless a safety signal is identified that
requires immediate regulatory action.
l. Overall risk/benefit consideration
3
AR02842

BioNTech Manufacturing GmbH is required to provide an updated Core RMP and

Canadian Addendum in a timely manner if a signal of safety issue is observed in
post-authorization surveillance. The RMP format should follow the guidance
(Guidance Document Submission of Risk Management Plans and Follow-Up
Commitments) and should include the following:
a. a safety specification that details the identified risks, potential risks, and
missing information for the COMIRNATY;
b. a pharmacovigilance plan that details specific measures to be taken to
identify and report safety issues in COVID-19 patients, including adverse
reaction reporting, periodic reporting, and ongoing/planned studies; and
c. a risk minimization plan, if applicable, to manage risks that may require
additional measures beyond those considered standard (for instance,
labelling).
8 BioNTech Manufacturing GmbH to submit final snapshots of all components of September Ongoing
the electronic platform (linked to any foreign or Canadian specific labels), 16, 2021
containing the approved Canadian-specific labelling information for COMIRNATY
in French and English for Health Canada’s records, following review and approval
by PAAB and for each subsequent update. Vaccine website (COMRINATY.ca
and/or CVDVaccine.ca) content only pertaining to drug specific information
related to a revision to the approved Product Monograph or vaccine labels will
be reviewed by Health Canada for consistency with approved labelling
information.
9 BioNTech Manufacturing GmbH are requested to develop and distribute a Health September Pending
Product Risk Communication (HPRC), in French and English, should a decision be 16, 2021
made to import, for Canadian sites, non-Canadian labelled supplies. In this case
the HPRC would need to be developed with Health Canada approval and
endorsement, to inform healthcare professionals that BioNTech Manufacturing
GmbH will delay implementation of Canadian-specific inner/outer labels
following NDS-CV approval for COMIRNATY, and that interim non Canadian
inner/outer labels will be used for the short term. Please note the following:
a. BioNTech Manufacturing GmbH should include images and texts of
these labels in the HPRC and clearly outline all deviations from
Canadian requirements
b. The HPRC should direct healthcare professionals to the electronic
platform where they can find information about the approved
Canadian-specific labelling in both official languages
c. The HPRC should include an alternative method for the health care
professionals to obtain a paper copy of the HPRC and/or Product
Monograph by mail or fax from BioNTech Manufacturing GmbH, if
they cannot access the internet
Finally, BioNTech Manufacturing GmbH should devise an appropriate

dissemination strategy to ensure the HPRC reaches the intended audience in a
timely manner.
4
AR02843

10 BioNTech Manufacturing GmbH to commit to developing Canadian specific September Expected
bilingual labelling for COMIRNATY, draft copies to be submitted in Q2 of 2022, 16, 2021 by Q2
and implementing such labelling once supplies are transitioned to Canadian 2022
dedicated supplies. Health Canada should be kept informed of estimated
timelines and proposed strategies concerning the development and
implementation of Canadian-specific bilingual labels.
a. Once Canadian-specific bilingual labeling, with the approved Brand
Name is approved by Health Canada and during the implementation
period, Canadian reference labels should be made available to
healthcare professionals.
11 Provide immunogenicity and safety data for 6 months after the booster dose November Pending
from Study C4591001, when the data become available. 9, 2021 availability
of data
12 Provide immunogenicity and safety data for 18 months after the booster dose November Pending
from Study C4591001, when the data become available. 9, 2021 availability
of data
13 Provide the results from Study C4591031, when the data become available. November Pending
9, 2021 availability
of data
14 Provide the results from the subset of Phase 3 participants receiving the 5 µg or November Pending
10 µg booster dose, when the data become available. 9, 2021 availability
of data
15 BioNTech Manufacturing GmbH is required to submit an updated Core RMP in November Expected
conjunction with the Canadian Addendum by December 3, 2021 to reflect the 9, 2021 by
use of COMIRNATY as a booster dose in Canada including any changes in the December
safety concerns, pharmacovigilance and risk minimization activities. 3, 2021
16 Provide safety data for all participants 5 to < 12 years of age in study C4591007, November Pending
6-month after Dose 2 from both initial and expansion safety cohorts when 19, 2021 availability
available. of data
17 Provide the immunogenicity data 6 months after Dose 2 in the subset of November Pending
participants 5 to < 12 years of age when available. 19, 2021 availability
of data
18 Provide the supplemental vaccine efficacy results in participants 5 to < 12 years November Pending
of age, when the pre-specified/sufficient number of cases have accrued to 19, 2021 availability
conduct the analysis. of data
19 Provide study C4591007 report including safety, efficacy and immunogenicity November Pending
data up to 2 years after Dose 2 in the participants 5 to < 12 years of age, when 19, 2021 availability
the study is completed. of data
20 BioNTech Manufacturing GmbH is required to submit an updated Core RMP in November Expected
conjunction with the RMP Canada Specific Addendum by December 3, 2021 to 19, 2021 by
address any safety concerns and additional pharmacovigilance activities and risk December
minimization measures related to the use in individuals 5 to 11 years of age. 3, 2021
5
AR02844

21 BioNTech Manufacturing GmbH will develop Canadian specific bilingual labelling November Pending
for Comirnaty. Draft copies will be submitted in sufficient time prior to 19, 2021
implementing such labelling and transitioning to Canadian dedicated supplies.
Health Canada should be kept informed of estimated timelines and proposed
strategies concerning the development and implementation of Canadian-specific
bilingual labels.
a. Once Canadian-specific bilingual labeling, with the approved Brand
Name is approved by Health Canada and during the implementation
period, Canadian reference labels should be made available to
healthcare professionals.
b. BioNTech Manufacturing GmbH to commit to labelling strategies for the
clear differentiation between product formulations, including the use of
distinguishing brand names or modifiers.
6
AR02845
This is Exhibit “C” referred to in the


AR02846
Health Santé
l♦I Canada Canada
Health Products Direction générale des produits
and Food Branch de santé et des aliments
TERMS AND CONDITIONS

Company: ModernaTx Inc.
Product: Spikevax (elasomeran mRNA vaccine)
Dossier ID: HC6-024-E252733
Background:
The Food and Drug Regulations allows the Minister to impose or amend terms and conditions, and request
additional information, in relation to a COVID-19 drug submission, Drug Identification Number (DIN), or
establishment licence, at any time while it is in effect. In light of the severity of the COVID-19 pandemic, this
allows the Minister to act quickly to gather important safety information or mitigate risk in a timely manner.
Depending on the requirement, terms and conditions can be ongoing (e.g., require a monthly report), have a
defined time (e.g., a report is due to Health Canada on a specific day) or are to be completed once the data is
available (e.g., a clinical trial is completed).
The status of the Terms and Conditions will be updated on a regular basis.
Status as of March 17, 2022:
Total Number: 20
Ongoing/pending: 20
Closed: 0
Table: Terms and Conditions

1 For the indication in adults 18 years of age and older, provide full study report September Pending
including safety, efficacy and immunogenicity, when available. 16, 2021 availability
of data
2 For the indication in adults 18 years of age and older, provide a safety update for September Pending
subjects in the Phase 3 study (mRNA-1273-P301) at the 6-month safety follow up 16, 2021 availability
when available for at least 3000 vaccinated subjects as well as for available and of data
relevant data from placebo subjects.
3 For the indication in adults 18 years of age and older, to fill data gaps, for various September Pending
sub-populations for example, provide results, when available, of all ongoing 16, 2021 availability
studies, or studies to come, conducted with the vaccine. of data
1
AR02847

4 For the indication in individuals 12 to 17 years of age, provide safety data for all September Pending
adolescents 12 through 17 years of age in study P203, 6 months after Dose 2, 16, 2021 availability
when the data become available. of data
5 For the indication in individuals 12 to 17 years of age, provide the report for September Pending
Study P203 including safety, efficacy and immunogenicity data up to 1 year after 16, 2021 availability
Dose 2 in adolescents 12 through 17 years of age, when the study is completed. of data
6 Provide an updated Certified Product Information Document (CPID) that includes September Expected
the facilities by December 31, 2021. 16, 2021 by
December
31, 2021
7 Provide final reports for ongoing drug substance (DS) and drug product (DP) PPQ September Ongoing
activities at all manufacturing sites/scales as they become available. 16, 2021
8 ModernaTX, Inc. is required to: September Ongoing
a. Treat adverse reactions associated with SPIKEVAX as priority and submit 16, 2021
the corresponding reports to Health Canada without delay;
9 ModernaTX, Inc. is required to submit monthly safety reports, unless otherwise September Ongoing
determined by Health Canada. The monthly safety reports should be submitted 16, 2021
within 15 days after the last day of a month, beginning after the first full
calendar month after authorization. These reports should contain the following:
a. Interval and cumulative number of reports (serious and non-serious),
overall and by age groups and in special populations (e.g. pregnant
women);
b. Interval and cumulative number of reports;
c. Total number of adverse event reports in Canada and Globally;
d. Exposure data stratified by country, including any available data on
age groups, race, ethnicity, on indigenous populations and remote
communities;
e. Changes to reference safety information in the interval;
f. Ongoing and closed signals in the interval;
g. Updated list of adverse events of special interest including the Safety
Platform for Emergency Vaccines (SPEAC) list and Risk Management
Plan (RMP) safety concerns (including the additional missing
information): reports – numbers and relevant cases, time-to-onset
and observed/expected analyses including causality assessment;
h. Fatal reports – numbers and relevant cases, including
observed/expected analyses;
i. Vaccination failure / lack of efficacy (including confirmed and
suspected cases) reports and vaccination errors (categories according
to preferred terms);
j. Potential interaction with other vaccines/concomitant treatments-
number and relevant cases;
k. Summary outcomes of some of the routine pharmacovigilance
activities (as presented in the EU RMP Part III and applied in the
Canadian context) should be included for the purpose of rapid signal
detection and communication activities. Summary of all ongoing
registries and studies should be included in the six-month scheduled
2
AR02848

Periodic Benefit-Risk Evaluation Reports (PBRERs), unless a safety
signal is identified that requires immediate regulatory action.; and
l. Overall risk/benefit consideration
10 ModernaTX, Inc. is required to provide an updated Core RMP and Canadian September Ongoing
Addendum in a timely manner if a signal of safety issue is observed in post- 16, 2021
authorization surveillance. The RMP format should follow the guidance
(Guidance Document Submission of Risk Management Plans and Follow-Up
Commitments) and should include the following:
a. a safety specification that details the identified risks, potential risks, and
missing information for the SPIKEVAX;
b. a pharmacovigilance plan that details specific measures to be taken to
identify and report safety issues in COVID-19 patients, including adverse
reaction reporting, periodic reporting, and ongoing/planned studies;
and
c. a risk minimization plan, if applicable, to manage risks that may require
additional measures beyond those considered standard (for instance,
labelling)
11 ModernaTX, Inc. to submit final snapshots of all components of the electronic September Ongoing
platform (linked to on the any foreign or Canadian specific labels), containing the 16, 2021
approved Canadian-specific labelling information for SPIKEVAX in French and
English for Health Canada’s review and records, prior to launch of the electronic
platform, and for each subsequent update.
12 ModernaTX, Inc. is requested to develop and distribute a Health Product Risk September Pending
Communication (HPRC), in French and English, should a decision be made to 16, 2021
import, for Canadian sites, non-Canadian labelled supplies. In this case the HPRC
would need to be developed with Health Canada approval and endorsement, to
inform healthcare professionals that ModernaTX, Inc. will delay implementation
of Canadian-specific inner/outer labels following NDS-CV approval for SPIKEVAX,
and that interim non-Canadian inner/outer labels will be used for the short term.
Please note the following:
a. ModernaTX, Inc. should include images and texts of these labels in the
HPRC and clearly outline all deviations from Canadian requirements
b. The HPRC should direct healthcare professionals to the electronic
platform where they can find information about the approved
Canadian-specific labelling in both official languages
c. The HPRC should include an alternative method for the health care
professionals to obtain a paper copy of the HPRC and/or Product
Monograph by mail or fax from ModernaTX, Inc., if they cannot access
the internet
Finally, ModernaTX, Inc. should devise an appropriate dissemination strategy to

ensure the HPRC reaches the intended audience in a timely manner.
13 ModernaTX, Inc. to commit to developing Canadian specific bilingual labelling for September Expected
SPIKEVAX, to be submitted in Q1 of 2022, and implementing such labelling once 16, 2021 by Q1
supplies are transitioned to Canadian dedicated supplies. Health Canada should 2022
be kept informed of estimated timelines and proposed strategies concerning the
development and implementation of Canadian-specific bilingual labels.
3
AR02849

a. During the period prior to implementation of the Canadian-specific
bilingual labeling, Canadian reference labels should be made available
to healthcare professionals.
14 Provide immunogenicity and safety data for 6 months following the November Pending
administration of the booster dose from Study P201, when the data become 12, 2021 availability
available. of data
15 Provide immunogenicity and safety data for 12 months following the November Pending
administration of the booster dose from Study P201, when the data become 12, 2021 availability
available. of data
16 Provide the results from the planned Study P301 Part C, in which a subset of November Pending
Phase 3 participants will receive a 50 µg booster dose, when the data become 12, 2021 availability
available. of data
17 ModernaTX, Inc. is required to submit an updated Core Risk Management Plan November Expected
(RMP) in conjunction with the Canadian Addendum by December 10, 2021 to 12, 2021 by
address any safety concerns, pharmacovigilance and risk minimization measures December
related to the use of a booster dose of Spikevax in Canada. 10, 2021
18 Provide safety data for all participants 6-11 years of age in study P204, 6-month March 17, Pending
after dose 2. 2022 availability
of data
19 Provide the immunogenicity data 6 months after dose 2 in study P204 Part 2 in March 17, Pending
participants 6-11 years of age. 2022 availability
of data
20 Provide the Clinical Study Report (CSR) for study P204 containing safety, March 17, Pending
immunogenicity and efficacy data 1 year after dose 2, in subjects 6-11 years of 2022 availability
age, when the study is completed. of data
4
AR02850
This is Exhibit “D” referred to in the


AR02851
COVID-19 mRNA Vaccine
Canada Specific Addendum to RMP
RISK MANAGEMENT PLAN
CANADA SPECIFIC ADDENDUM
for
Comirnaty ® (proposed brand name)
Pfizer-BioNTech COVID-19 Vaccine (COVID-19 mRNA Vaccine)
August 2021
Addendum to EU Risk Management Plan (RMP) Version 2.3 dated 04 August 2021
CONFIDENTIAL
Page 1
AR02852
TABLE OF CONTENTS
LIST OF TABLES.....................................................................................................................3
LIST OF FIGURES ...................................................................................................................3
LIST OF ABBREVIATIONS....................................................................................................4
1. INTRODUCTION .................................................................................................................5
2. SAFETY SPECIFICATION..................................................................................................7
2.1. Epidemiology of the indication(s) and target population(s) relevant to
Canada .........................................................................................................................7
2.2. Summary of the Safety Concerns............................................................................12
2.2.1. Canada-Specific Safety Concerns...............................................................13
2.2.2. Proposed Changes to the Canada-Specific Safety Concerns ......................13
2.3. Special population with limited information from Clinical Trials..........................13
2.4. Monitoring strategies in marginalized, remote and indigenous communities.........13
3. CLINICAL TRIAL EXPOSURE IN CANADA .................................................................14
4. NON-STUDY POST-AUTHORIZATION EXPERIENCE IN CANADA ........................14
5. PHARMACOVIGILANCE PLAN IN CANADA ..............................................................14
5.1. Canadian Routine Pharmacovigilance practices .....................................................14
5.2. Canadian Additional Pharmacovigilance Activities ...............................................15
6. RISK MINIMIZATION MEASURES IN CANADA.........................................................20
6.1. Summary Table of Risk Minimization Measures ...................................................20
6.2. Evaluation of the Effectiveness of Risk Minimization Activities...........................21
REFERENCES ........................................................................................................................22
CONFIDENTIAL
Page 2
AR02853
LIST OF TABLES
Table 1. Sections of the EU RMP.............................................................................5
Table 2. Summary of Safety Concerns in the EU RMP .........................................12
Table 3. Use in Paediatric Individuals < 12 years of Age ......................................13
Table 4. Vaccine Effectiveness...............................................................................13
Table 5. Additional Pharmacovigilance Activities for addressing Missing
Information specific for Canada ...............................................................17
Table 6. Summary Table of Risk Minimization Measures in Canada....................20
LIST OF FIGURES
Figure 1. Moving average of cases (of last 7 days) of SARS-CoV-2 in
Canada ........................................................................................................8
Figure 2. Shift in demographic characteristics of cases in Canada during the
COVID-19 pandemic..................................................................................9
Figure 3. Age distribution of severe COVID-19 cases in Canada as of July
23, 2021 (n=75,066 for hospitalization, n=14,095 for ICU
admissions, and n=26,448 for death)........................................................10
CONFIDENTIAL
Page 3
AR02854
LIST OF ABBREVIATIONS
AE adverse event
AESI adverse event of special interest
CDC centers for disease control and prevention
CIHI Canadian institute for health information
CPM Canadian product monograph
COPD chronic obstructive pulmonary disease
COVID-19 coronavirus disease 2019
CSR clinical study report
CSSE center for systems science and engineering
DCA data capture aid
EMA European medicines agency
EU European union
FDA food and drug administration
ICU intensive care unit
LTC long-term care
MIS-C multisystem inflammatory syndrome in children
mRNA messenger ribonucleic acid
OECD organization for economic co-operation and development
PHAC public health agency of Canada
PhV pharmacovigilance
POU point of use
PVP pharmacovigilance plan
RMP risk management plan
RNA ribonucleic acid
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
UK United Kingdom
US United States
VAED vaccine-associated enhanced disease
VAERD vaccine-associated enhanced respiratory disease
VOC variants of concern
WHO world health organization
CONFIDENTIAL
Page 4
AR02855
1. INTRODUCTION
The Canadian Addendum to the Pfizer-BioNTech COVID-19 Vaccine (COVID-19 mRNA
vaccine) RMP was developed based on Health Canada’s Guidance Document – Submission
of Risk Management Plans and Follow-up Commitments, effective 26 June 2015 and the
Guidance for marketing authorization requirements for COVID-19 vaccines, 20 November
2020. The Canadian Addendum should be reviewed in conjunction with the COVID-19
mRNA vaccine EU RMP Version 2.3 dated 04 August 2021.
This Canadian-specific addendum uses the data cutoff dates used in the COVID-19 mRNA
vaccine EU RMP, version 2.3, dated 04 August 2021 as follows:
12-15 years of age 13 March 2021 (Pfizer Clinical Database)

28 February 2021 (Pfizer Safety Database)
18 June 2021 (Pfizer Safety Database)
16 years and older 13 March 2021 (Pfizer Clinical Database)
23 October 2020 (BioNTech Clinical Database)
28 February 2021 (Pfizer Safety Database and Post-Authorisation
Exposure)
18 June 2021 (Pfizer Safety Database)
myocarditis/pericarditis 18 June 2021 (Pfizer Safety Database)
Pfizer-BioNTech COVID-19 Vaccine (COVID-19 mRNA Vaccine) was authorized by

Health Canada on 9 December 2020 in accordance with the Interim Order Respecting the
Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. In addition,
Notice of Authorization Amendment was issued by Health Canada on 5 May 2021 to expand
the indication to include individuals 12 to 15 years of age.
Canadian context is provided in this Addendum for the RMP sections identified in Table 1.
Table 1. Sections of the EU RMP

Part Module/Annex Canadian Context
Included
Part I See EU RMP
Product Overview
Part II SI Yes – See Section 2.1
Safety Specification Epidemiology of the Indications(s) and Target Population(s)
SII See EU RMP
Non-Clinical Part of the Safety Specification
SIII Yes – See Section 3
Clinical Trial Exposure
SIV Yes – See Section 2.3
Populations Not Studied in Clinical Trials
SV Yes – See Section 4
Post-Authorisation Experience
SVI See EU RMP
Additional EU Requirements for the Safety Specification
CONFIDENTIAL
Page 5
AR02856
Table 1. Sections of the EU RMP

Part Module/Annex Canadian Context
Included
SVII See EU RMP
Identified and Potential Risks
SVIII Yes – See Section 2.2
Summary of the Safety Concerns
Part III Yes – See Section 5
Pharmacovigilance
Plan (Including Post-
Authorisation Safety
Studies)
Part IV See EU RMP
Plan for Post-
Authorisation
Efficacy Studies
Part V Yes – See Section 6
Risk Minimisation
Measures (Including
Evaluation of the
Effectiveness of Risk
Minimisation
Activities)
Part VI See EU RMP
Summary of the
RMP
Part VII Annex 2 See EU RMP
Annexes to the Risk Tabulated Summary of Planned, On-going, and Completed
Management Plan Pharmacovigilance Study Programme
Annex 3 See EU RMP
Protocols for Proposed, On-going, and Completed Studies in
the Pharmacovigilance Plan
Annex 4 See EU RMP
Specific Adverse Drug Reaction Follow-Up Forms
Annex 5 See EU RMP
Protocols for Proposed and On-going Studies in RMP Part
IV
Annex 6 See EU RMP
Details of Proposed Additional Risk Minimisation Activities
Annex 7 See EU RMP

Other Supporting Data
Annex 8 See EU RMP
Summary of Changes to the Risk Management Plan over
Time
CONFIDENTIAL
Page 6
AR02857
2. SAFETY SPECIFICATION
2.1. Epidemiology of the indication(s) and target population(s) relevant to Canada
Indication:
Pfizer-BioNTech COVID-19 Vaccine (COVID-19 mRNA Vaccine) is indicated for active

immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. 1
Incidence:
The COVID-19 is caused by a novel coronavirus labelled as SARS-CoV-2. The disease first
emerged in December 2019, when a cluster of patients with pneumonia of unknown cause
was recognized in Wuhan City, Hubei Province, China.2 The number of infected cases
rapidly increased and spread beyond China throughout the world. On 30 January 2020, the
WHO declared COVID-19 a Public Health Emergency of International Concern and
subsequently (on March 11th) a pandemic. 3
Estimates of SARS-CoV-2 incidence change rapidly. As of July 26, 2021, the overall number
of people who have been infected with SARS-CoV-2 are over 194 million worldwide,
according to the COVID-19 Dashboard by the Center for Systems Science and Engineering
(CSSE) at Johns Hopkins University. 4,5 In Canada, the first known case of coronavirus
appeared on Jan. 25, 2020.6 As of July 26, 2021, the number of confirmed cases in Canada
has accumulated to over 1.4 million which corresponds to 3,756 cases per 100,000
population.5,7 These numbers are reported by the Public Health Agency of Canada after
Provincial/Territorial public health authorities report cases of COVID-19 within 24 hours of
their own notification. 5,8 So far 26,553 COVID-19 deaths have been reported as of July 26,
2021.7 In the US, the number of confirmed cases has reached over 34 million (10,499 cases
per 100,000 population) by July 27, 2021. 5,9 Despite, US had started witnessing a dramatic
decrease in the incidence rate (96.6 per 100,000 population) by May 06, 2021, there has been
recent increase of cases.9 In contrast, in Canada by May 06, 2021 the incidence rate was 143
per 100,000 population, showing an important decrease reporting 9 per 100,000 population in
the last 7 days as of July 26, 2021.7
The reported numbers refer only to cases that have been tested and confirmed to be carrying
the virus. There are large geographic variations in the proportion of the population tested as
well as varied quality of reporting across countries. People who carry the virus but remain
asymptomatic are less likely to be tested and therefore mild cases are likely underreported.
Because of these limitations, serological detection of antibodies against SARS-CoV-2
(seroprevalence) can better estimate the true number of infections.10 When seroprevalence
survey of New York city metro area was carried out in July 27-30, 2020, difference between
estimated number of infections based on seroprevalence were at least 6 times higher than
reported case counts.11 In order to get a broad sense of how prevalent the disease has been in
Canada, Canadian Immunity Task Force has been conducting a seroprevalence study by
testing samples left over from blood donations for SARS-CoV-2 antibodies since May
2020.12 The recent results from blood samples collected in January 2021 showed that
1.99% (95% confidence interval 1.84-2.15) donors in Canada tested positive for antibodies to
CONFIDENTIAL
Page 7
AR02858
SARS-CoV-2.13 Therefore, despite having cases that are overwhelming the health care
infrastructure, Canada remains far from herd immunity and most Canadians are still
vulnerable to SARS-CoV-2 infection.
Prevalence:
The prevalence of SARS-CoV-2 infection is defined as active cases per 100,000 people
including confirmed cases in people who have not recovered or died. On 06 May 2021, there
were over 81,000 active cases in Canada which translated to overall prevalence of 214 per
100,000 population. On July 26, 2021 there were over 5,049 active cases in Canada which
translated to overall prevalence of 13 per 100,000 population. 7 Overall, prevalence has
decreased in most provinces. There are large geographic variations as evident by low
prevalence in Prince Edward Island (0 per 100,000) and high prevalence in Yukon (178 per
100,000). 7
Demographics of the population in the proposed indication and risk factors for the
disease:
In Canada, the primary surveillance objective for COVID-19 is the detection of cases and
identification of outbreaks.8 The secondary objective is to characterize the clinical and
epidemiologic features of COVID-19 in order to better inform prevention and control
efforts.8 As of July 26, 2021 over 38 million tests have been performed in Canada. 7 This
corresponds to a test rate of 457,522 per 1 million people. Of all tests performed, 3.7% have
been found to be positive. 7
Figure 1. Moving average of cases (of last 7 days) of SARS-CoV-2 in Canada
CONFIDENTIAL
Page 8
AR02859
People of all ages can become infected with SARS-CoV-2. Detailed case report data have
been provided to the Public Health Agency of Canada (PHAC) by health authorities in the
provinces and territories on a weekly basis. 7 As of July 26, 2021, PHAC has received
detailed case report data on 1,423,778 cases. Of the cases reported in Canada so far,
about half (50.3%) were female which has remained consistent throughout the pandemic. In
April 30, 2021, about one-fifth (18.5%) were either 60 years old and over or under 19 years
old (18.3%). 7 Shift in the epidemiology, has occurred and as of July 26, 2021, adults >60
years contributed to 5.7% of the cases and ≤19 and 20-29 age groups accounted for 19.3%
and 19.1% respectively. 7
If the pandemic is roughly divided into three periods corresponding to three distinct waves of
SARS-CoV-2 infections in Canada (Figure 1), it becomes obvious that there has been a
dramatic shift in the age of cases from older to younger age groups over the course of the
pandemic (Figure 2). While by the end of August 2020 (first wave) only 8.6% of cases were
in individuals aged 19 years and under, in the period between September 01, 2020 and
February 28, 2021 (second wave), over 18% of cases were in the under 19 age group 7,14.
Between March 01, 2021 and April 30, 2021 (third wave), it further rose to 22%
(Figure 2)7,14. A notable difference among the 3 different periods is that the absolute numbers
of cases have increased dramatically in the later periods compared to the earlier one
(Figure 1).
Figure 2. Shift in demographic characteristics of cases in Canada during the

COVID-19 pandemic
□ 2021 March 01 to 2021 Apr 30

80+
60-79
- --- • 2020 Sep 01 to 2021 Feb 28
■ Until 2020 Aug 31
□ Canadian Population
Age group
40-59
.. .. ..................... .. .. .. .. .
. .. . . . . . . . . . . . . . . . .
20-39
≤19
-------
0 10 20 30 40
% proportion
CONFIDENTIAL
Page 9
AR02860
The trend of sharp increase in the proportion of cases in the younger populations over the
course of the pandemic is reversed in the older age cohorts, most notably in the 80+ age
group. While by the end of 2020 August 15% of cases were in individuals aged 80 years and
over, between 2021 March 01 and April 30, less than 2% of the cases were in that age group
(Figure 2).
Provincial dashboard provides further age breakdown in younger populations. As of July 26,
2021, based on cases reported within the province of Ontario in past 14 days, 11.1%, 16%
and 21.5% of cases were in individuals 0-9, 10-19 and 20-29 years of age, respectively.15
Figure 3. Age distribution of severe COVID-19 cases in Canada as of July 23, 2021
(n=75,066 for hospitalization, n=14,095 for ICU admissions, and n=26,448
for death)6
Symptoms of COVID-19 disease can range from very mild (or no symptoms) to severe. The
more severe cases are defined as hospitalized, admitted to ICU, or fatal. 7 As of July 12,
2021, PHAC has data on hospitalization status for 998,460 SARS-CoV-2 positive cases, of
which 72,210 (7.5%) were hospitalized. Among the hospitalized COVID-19 patients, 14,253
(19%) were admitted to the ICU and 1,923 (2.6%) needed mechanical ventilation. 7 Although
both older and younger individuals can be infected by the COVID-19 virus, risk for severe
illness with COVID-19 increases with age, with older adults being at highest risk.16 In
Canada, as of July 23, 2021, 64% of hospitalized cases, 60% of ICU admissions and 94% of
mortality were recorded in 60 years of age and older individuals (Figure 3) 7 although the age
group only represents approximately 25% of the population.16 The disproportionate
representation of severe COVID-19 is most evident in the 80+ age group7 which contributed
to over 64% of death despite being less than 5% of population 17 (Figure 3).
CONFIDENTIAL
Page 10
AR02861
Children, adolescents, and young adults are susceptible to SARS-CoV-2 infections as evident
by several reports 7,18 although they have lower incidence and fewer severe COVID-19
outcomes than adults.18 According to the US study, in 0-24 years of age groups, 2.5% were
hospitalized, 0.8% required ICU admission, and <0.1% died, compared with 16.6%, 8.6%,
and 5.0% among adults aged ≥25 years, respectively. 18 However, about 1 in 3 children
hospitalized with COVID-19 were admitted to the intensive care unit, similar to the rate
among adults. 19 Cases of Multisystem Inflammatory Syndrome in Children (MIS-C) with
severe outcomes including fatality have been reported in children with COVID-19.20
The inequalities in risk in getting COVID-19 were identified early in the pandemic as it
increasingly affects poorer neighborhoods and racialized populations. A CDC report
examined demographic trends among US COVID-19 deaths from May 01 to August 31 of
2020 and found 51.3% of decedents were non-Hispanic White (White), 24.2% were Hispanic
or Latino (Hispanic), and 18.7% were non-Hispanic Black (Black). 21 In addition, during the
observation period, the percentage of US COVID-19 deaths that were Hispanic increased
from 16.3% in May to 26.4% in August, the only racial or ethnic group among whom the
percentage of deaths increased during that time. A CDC report examining US excess deaths
found that increases in deaths compared to expectation were largest among Hispanics (53.6%
increase), Asian Americans (36.6% increase), African Americans (32.9% increase), and
Native Americans and Native Alaskans (28.9% increase), all compared to an excess 11.9%
deaths among non-Hispanic whites.22 There is a paucity of such data in Canada however a
recent seroprevalence study showed higher concentration of infections in poorer
neighborhoods and amongst racialized communities. 13 In May-June 2020, residents in the
most materially deprived neighborhoods were 1.2 times more likely to have been infected
than their counterparts from wealthy neighborhood. By January 2021, the inequality has
further deepened as residents of lower income neighborhoods were 3.45 times more likely to
have had a SARS-CoV-2 infection. 13
People living in long-term care (LTC) homes in Canada have been disproportionately
affected by COVID-19. According to a 2020 report by Canadian Institute for Health
Information (CIHI), during the first wave (as of May 25, 2020), more than 840 outbreaks had
been reported in LTC facilities and retirement homes accounting for more than 80% of all
COVID-19 deaths in the country.23 While Canada’s overall COVID-19 mortality rate was
relatively low compared with the rates in 16 countries in the Organization for Economic
Co-operation and Development (OECD), it had the highest proportion of deaths occurring in
long-term care.23 In Canada, the mortality rate for those infected with COVID-19 in LTC was
about 35% as of May 25.23 The second wave of COVID-19 in Canada (September 1, 2020, to
February 15, 2021) was bigger and broader than the first wave which resulted into a larger
number of outbreaks, infections and deaths in LTC and retirement homes.24
All viruses including SARS-CoV-2 mutate, and new variants are expected to arise over time.
Some of those mutations may change the properties of virus and create variants of concern
(VOC) which can enhance the transmission potential, make the disease more severe or lead
to sub-optimal response to the treatments/vaccines. There are currently four VOCs (Alpha,
Beta, Gamma and Delta) which are being monitored in Canada. 7 Alpha (B.1.1.7) variant was
initially detected in the UK.25,7,26 Alpha variant was the most predominant in Canada until
June 2021. 7 Delta variant (B.1.617) one of the variants that originated in India, 25,27 has
CONFIDENTIAL
Page 11
AR02862
become the most predominant variant in Canada, accounting for 70% of the cases as of
July 04, 2021 7 Gamma (P.1) variant was first identified in Japan in travelers from Brazil, in
early January. This variant accounts for 5.7% as of July 04, 2021. 7 Beta (B.1.351) variant
was initially detected in South Africa in December 2020 and it only contributes to 1.4% of
the cases.28,29
Although there was a gender balance for hospitalization and mortality in Canada,
disproportionately higher proportion of ICU admissions (63%) were male. Based on the
exposure history of nearly 1.1 million cases, 95.7% cases were acquired domestically in
Canada. Nearly half (46.8%) cases were acquired from the contact of a COVID-19 case
where as the remaining half (48.2%) were acquired from unknown source. 7
2.2. Summary of the Safety Concerns

The safety concerns proposed in the COVID-19 mRNA vaccine EU RMP (version 2.3, dated
04 August 2021) have been changed with respect to the initial version 1.0 and are presented
in Table 2.
Table 2. Summary of Safety Concerns in the EU RMP

Important Identified Risks Anaphylaxis
Myocarditis and Pericarditisa
Important Potential Risks Vaccine-associated enhanced disease (VAED) including Vaccine-
associated enhanced respiratory disease (VAERD)
Missing Information Use in pregnancy and while breast feeding
Use in immunocompromised patients
Use in frail patients with co-morbidities (e.g. chronic obstructive
pulmonary disease (COPD), diabetes, chronic neurological
disease, cardiovascular disorders)
Use in patients with autoimmune or inflammatory disorders
Interaction with other vaccines
Long term safety data
a. Newly added safety concerns in the EU RMP (version 2.3, dated 04 August 2021)
In addition to the safety concerns included in the EU RMP, Health Canada at the time of the
initial submission required the inclusion of the following 2 safety concerns as Missing
Information: “Use in paediatric individuals <16 years of age” and “Vaccine effectiveness”.
The Missing Information ‘Use in paediatric individuals <16 years of age’ was updated to
‘Use in pediatric individuals <12 years of age’ to reflect the current indication.
CONFIDENTIAL
Page 12
AR02863
2.2.1. Canada-Specific Safety Concerns

Canada Missing Information: Use in Paediatric Individuals < 12 years of Age
Table 3. Use in Paediatric Individuals < 12 years of Age

Evidence source:
Pfizer-BioNTech COVID-19 vaccine was not initially studied in paediatric individuals younger than 12 years
of age due to their exclusion from the pivotal clinical study.
Paediatric individuals may display different reactogenicity and safety profiles compared to adults, due to
lower body mass and differently matured immunological responses.
Population in need of further characterization:

The are no data in individuals less than 12 years of age; a clinical study of the safety, tolerability,
immunogenicity and efficacy of Pfizer-BioNTech COVID-19 Vaccine in individuals younger than 12 years
[C4591007 (< 12 years of age)] is ongoing. A non-interventional study (C4591009) is planned to assess the
occurrence of safety events of interest in a general US population (12 and ≥ 12 to ≤15 years of age).
Canada Missing Information: Vaccine Effectiveness
Table 4. Vaccine Effectiveness

Evidence source:
Although vaccine efficacy in a controlled clinical study is the objective of the pivotal study, real-world
vaccine effectiveness when Pfizer-BioNTech COVID-19 vaccine is used in a large and more diverse
population is unknown.
Anticipated risk/consequence of missing information:

Efficacy information obtained from clinical study data will be communicated in the product labeling. Three
post-authorization effectiveness studies in real-world use are planned: 1 non-interventional study (C4591014)
and 2 low-interventional studies (WI235284 and WI255886) to determine the effectiveness of Pfizer-
BioNTech COVID-19 Vaccine when administered outside of the clinical setting.
2.2.2. Proposed Changes to the Canada-Specific Safety Concerns

Not applicable.
2.3. Special population with limited information from Clinical Trials

Description of populations not studied in Clinical Trials are provided in the Module SIV of
the EU RMP version 2.3 (dated 04 August 2021).
2.4. Monitoring strategies in marginalized, remote and indigenous communities

Pfizer on behalf of BioNTech does not have current plans to specifically monitor these
communities. However, race information, when available, will be included in the Summary
Monthly Safety Report Appendices (see Section 5.1).
CONFIDENTIAL
Page 13
AR02864
3. CLINICAL TRIAL EXPOSURE IN CANADA

There has been no clinical trial exposure in Canada.
4. NON-STUDY POST-AUTHORIZATION EXPERIENCE IN CANADA

It is not possible to determine with certainty the number of individuals who received
COVID-19 mRNA vaccine during the period covered by the present Addendum. Estimated
shipped doses may serve as a reasonable indicator of patient exposure. With these caveats in
mind, it is estimated that approximately 29,778,060 doses of COVID-19 mRNA vaccine
were shipped to Canada.1
5. PHARMACOVIGILANCE PLAN IN CANADA

5.1. Canadian Routine Pharmacovigilance practices
All routine pharmacovigilance (PhV) activities in the EU RMP will be implemented in
Canada. Refer to Part III, Section III.1 Routine Pharmacovigilance Activities of the EU RMP
(version 2.3 dated 04 August 2021).
Please note that since the manufacturer/sponsor is BioNTech Manufacturing GmbH, Pfizer
will be submitting the relevant adverse reaction reports and conduct the pharmacovigilance
activities on behalf of BioNTech.
Pharmacovigilance and risk management processes include the ongoing timely collection,
processing, follow-up, and analysis of individual adverse event reports, with routine
surveillance measures applied to all reported Canadian and foreign adverse events. It is the
Pfizer’s policy to monitor the safety profile of its products; evaluate in a timely manner
issues potentially impacting product benefit-risk profiles such as those that may arise during
clinical development, registration and marketing; and ensure that appropriate communication
of relevant information is conveyed in a timely manner to regulatory authorities and other
interested parties as appropriate and in accordance with international principles and
prevailing regulations.
Pfizer on behalf of BioNTech conducts numerous scientific and data gathering activities for
the detection and evaluation of adverse events to provide safety monitoring commensurate
with product characteristics. Signal detection activities include medical review of reports
during individual case processing as well as periodic aggregate data review based on the
known safety profile of the drug and the life cycle for the product. Safety signal evaluation
requires the collection and assessment of information to evaluate whether there is a potential
causal link between an event and the administration of the product and also includes
subsequent qualitative and/or quantitative characterization of the identified safety risk and/or
determination that the safety risk may require further action. Signal detection activities for
the COVID-19 mRNA vaccine, will occur on a weekly basis. In addition, observed versus
1
Source: Seventh Summary Monthly Safety Report. Data available through 30 June 2021.
CONFIDENTIAL
Page 14
AR02865
expected analyses will be conducted as appropriate as part of routine signal management

activity.
Routine signal detection activities for the COVID-19 mRNA vaccine will include routine and
specific review of AEs consistent with the Adverse Events of Special Interest (AESI) list
provided in the EU RMP version 2.3 (see PART II.SVII.1.1 – Risks not considered important
for inclusion in the list of safety concerns in the RMP.)
Additional follow-up questionnaires (Data Capture Aids [DCAs]) have been created for this
vaccine. They are intended to facilitate the capture of clinical details about:
 VAED/VAERD: collection of data regarding the nature and severity of COVID-19

illness in individuals who have received the COVID-19 mRNA vaccine is anticipated
to provide insight into potential cases of VAED. The DCA was internally approved
on 18 November 2020;
 Anaphylaxis: collection of details regarding cases of potential anaphylactic reactions

in individuals who have received the COVID-19 mRNA vaccine. This DCA was
internally approved on 22 December 2020.
As stated in the CPM, to help ensure the traceability of vaccines for patient immunization
record-keeping as well as safety monitoring, health professionals should record the time and
date of administration, quantity of administered dose (if applicable), anatomical site and
route of administration, brand name and generic name of the vaccine, the product lot number
and expiry date.
Pfizer on behalf of BioNTech will submit domestic and foreign adverse reaction reports to
the Health Products and Food Branch pursuant to Part C, Division 1 (C.01.016, C.01.017)
and reports of unusual failure in efficacy pursuant to Part C, Division 8 (C.08.007, C.08.008)
of the Food and Drug Regulations, and in accordance with Health Canada’s current Guidance
Document for Industry - Reporting Adverse Reactions to Marketed Health Products and in
line with Health Canada’s Information and application requirements for drugs authorized
under the Interim Order: Guidance document. On an annual basis and whenever requested
by the Minister, Pfizer on behalf of BioNTech will conduct a concise, critical analysis of the
adverse drug reactions and serious adverse drug reactions and prepare a summary report in
respect of the reports received during the previous 12 months, in accordance with the Part C,
Division 1 (C.01.018) of the Food and Drug Regulations and as per Health Canada’s current
Guidance Document for Industry – Preparing and Submitting Summary Reports for
Marketed Drugs and Natural Health Products. In addition, Summary Monthly Safety Reports
will be compiled to support timely and continuous benefit risk evaluations. Relevant data in
the Summary Monthly Safety Report appendices will be stratified by country, including
Canada and will include information on race (when available).
5.2. Canadian Additional Pharmacovigilance Activities

The additional pharmacovigilance activities for the COVID-19 mRNA vaccine included in
Part III.2: Additional Pharmacovigilance Activities of the EU RMP (version 2.3 dated
04 August 2021) are considered to apply to Canada.
CONFIDENTIAL
Page 15
AR02866
Moreover, Health Canada previously required the addition of the following safety concerns:
 “Use in paediatric individuals < 16 years of age” that was updated to ‘Use in
paediatric individuals < 12 years of age” to reflect the current indication and for
which additional pharmacovigilance activities include the ongoing clinical study
C45910072 and the planned non-interventional study C4591009;
 “Vaccine effectiveness” for which the 3 studies C4591014, WI235284 and

WI255886 are planned.
2
Please note that Study C4591023 (reported in the previous version of the Addendum) was included into
Study C4591007 (see US-PVP version 0.5).
CONFIDENTIAL
Page 16
AR02867
Table 5. Additional Pharmacovigilance Activities for addressing Missing Information specific for Canada
Study Summary of Objectives Safety Concerns Milestones Due Dates
Status Addressed
C4591001a,b: ≥12 to ≤15 years of age: Safety compared to placebo and Use in paediatric First report with April 2021
Phase 1/2/3, placebo-controlled, randomized, observer-blind, immune-non-inferiority of individuals < 16 up to 1-month
dose-finding study to evaluate the safety, tolerability, neutralizing antibody immune years of age post dose 2
immunogenicity, and efficacy of SARS-CoV-2 RNA vaccine response compared to subjects (≥12 to ≤15 (safety)
candidates against COVID-19 in healthy individuals. 16-25 years of age. years of age)
Ongoing
Report 6-month October 2021c
post dose 2
(safety)
Report 24-month April 2023d
post dose 2
(safety)
C45910072: Dose selection. Safety Use in paediatric First report with September
<12 years of age: compared to placebo and individuals < 12 up to 1-month 2021
Phase 1 open label dose-finding study to evaluate safety, immune-non-inferiority by 3 age years of age post dose 2
tolerability, and immunogenicity and phase 2/3 placebo- cohorts of neutralizing antibody (safety) in ≥5 to
controlled, observer blinded safety, tolerability, and immune response compared to <12 years of age:
immunogenicity, study of a SARS-CoV-2 RNA vaccine subjects 16-25 years of age. Report 6-month March 2022
candidate against COVID-19 in healthy children <12 years of Efficacy if sufficient cases post dose 2
age. accrue. (safety) in ≥5
to <12 years of
age:
Ongoing (started in March 2021)
Report 24-month September
post dose 2 2023
(safety) in ≥5 to
<12 years of age:
CONFIDENTIAL
Page 17
AR02868
Status Addressed
C4591009a: A non-interventional post-approval safety study To assess the occurrence of Use in paediatric Protocol August 2021
of the Pfizer-BioNTech COVID-19 mRNA vaccine in the safety events of interest in a individuals < 12 submission to
United States. general US population (< 12 and years of age FDA:
≥ 12 to ≤15 years of age)
Planned
within selected data sources Monitoring October 2022
participating in the Sentinel report
System. submission:
Interim analysis October 2023

submission:
Final study report October 2025

submission:
C4591014a: Pfizer-BioNTech COVID-19 BNT162b2 Vaccine To estimate the effectiveness of Vaccine Final CSR June 2023
Effectiveness Study - Kaiser Permanente Southern California. 2 doses of Pfizer-BioNTech effectiveness submission:
COVID-19 mRNA vaccine
Planned (BNT162b2) against
hospitalization and emergency
department admission for acute
respiratory illness due to
SARS-CoV-2 infection.
WI235284a: Determining RSV Burden and Outcomes in To estimate the effectiveness of Vaccine Final CSR June 2023
Pregnant Women and Older Adults Requiring Hospitalization. 2 doses of Pfizer-BioNTech effectiveness submission:
Amendment for COVID VE/ Sub-study 6. COVID-19 Vaccine against
hospitalization for acute
Planned
respiratory illness due to
SARS-CoV-2 infection.
CONFIDENTIAL
Page 18
AR02869
Status Addressed
WI255886a: Avon Community Acquired Pneumonia To estimate the effectiveness of Vaccine Final CSR June 2023
Surveillance Study: A Pan-pandemic Acute Lower 2 doses of Pfizer-BioNTech effectiveness submission:
Respiratory Tract Disease Surveillance. COVID-19 Vaccine against
hospitalization for acute
respiratory illness due to SARS-
Planned CoV-2 infection.
BNT162-01 cohort 13a: Immunogenicity of Pfizer-BioNTech To assess potentially protective Vaccine First IA September
COVID-19 vaccine in immunocompromised subjects, immune responses in effectiveness submission: 2021
including assessment of antibody responses and cell-mediated immunocompromised adults.
responses
Ongoing
a. These studies are also included as additional pharmacovigilance activities in the EU RMP version 2.3 dated 04 August 2021
b. Study originally included in the PVP to address the Missing Information Use in pediatric individuals < 16 years of age
c. Due date updated from 31 July 2021 because the last subject visit for this group will not be until September 2021.
d. Due date updated from 31 January 2023 for the same reason above.
CONFIDENTIAL
Page 19
AR02870
6. RISK MINIMIZATION MEASURES IN CANADA

6.1. Summary Table of Risk Minimization Measures
The proposed Product Monograph contains detailed information for physicians and other
health care providers about the use of the COVID-19 mRNA vaccine including the risks of
adverse events as well as other information that is meant to help prevent or minimize risks
when prescribing the COVID-19 mRNA vaccine.
The Patient Medication Information section informs patients about treatment with the
COVID-19 mRNA vaccine, including adverse drug reactions and risks associated with
receiving the drug.
Table 6. Summary Table of Risk Minimization Measures in Canada

Safety Concern Routine Risk Minimization Measures Additional Risk
Minimization Measures
Important Identified Risks
Anaphylaxis Product Monograph None
Myocarditis and Product Monograph None

Pericarditis
Important Potential Risks
Vaccine-associated None None
enhanced disease
(VAED) including
Vaccine-associated
enhanced respiratory
disease (VAERD)
Missing Information
Use in pregnancy and Product Monograph None
while breast feeding
Use in Product Monograph None
immunocompromised
patients
Use in frail patients with Product Monograph None
co-morbidities (e.g.
chronic obstructive
pulmonary disease
(COPD), diabetes,
chronic neurological
disease, cardiovascular
disorders)
Use in patients with None None
autoimmune or
inflammatory disorders
Interaction with other Product Monograph None
vaccines
Long term safety data None None
Use in paediatric None None
individuals <12 years of
age
Vaccine effectiveness Product Monograph None
CONFIDENTIAL
Page 20
AR02871
In addition, educational materials have been developed for product handling and are
disseminated to points of use (POUs). A Health Product Risk Communication (dated 11
December 2020) was developed with Health Canada and disseminated to relevant healthcare
professionals and posted on CVDvaccine.ca to inform about appropriate use of the vaccine.
6.2. Evaluation of the Effectiveness of Risk Minimization Activities
Routine pharmacovigilance activities include monitoring of sources of safety information
encompasses, but is not limited to, Pfizer’s own safety databases and, when appropriate,
external databases, as well as scientific literature, accumulating data from sponsored clinical
studies, and published meta-analyses.
Pfizer on behalf of BioNTech continues to evaluate the effectiveness of the RMP by

performing routine pharmacovigilance activities to identify new information that would
suggest that the measures implemented did not adequately minimize the risk. Pfizer on behalf
of BioNTech assesses the effectiveness of the risk minimization activities and considers risk
minimization measures effective if no negative trends or worsening outcomes are identified.
CONFIDENTIAL
Page 21
AR02872
REFERENCES
1 Pfizer Canada ULC. Pfizer-BioNTech COVID-19 vaccine Product Monograph 2021
2 Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in
China, 2019. N Engl J Med. 2020;382(8):727-33.
3 World Health Organization (WHO). (2020). Listings of WHO’s response to COVID-19

Updated December 28, 2020. Available from: https://www.who.int/news/item/29-06-
2020-covidtimeline.
4 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in

real time. Lancet Infect Dis. 2020;20(5):533-34.
5 COVID-19 Map - Johns Hopkins Coronavirus Resource Center (jhu.edu)
6 Marchand-Senecal X, Kozak R, Mubareka S, et al. Diagnosis and Management of First

Case of COVID-19 in Canada: Lessons Applied From SARS-CoV-1. Clin Infect Dis.
2020;71(16):2207-10.
7 Government of Canada. (2021). Coronavirus Disease 2019 (COVID-19) Daily

Epidemiology Update. Available from: https://health-infobase.canada.ca/covid-
19/epidemiological-summary-covid-19-
cases.html?stat=rate&measure=active&map=pt#a2.
8 Government of Canada. (2021). National case definition: Coronavirus disease (COVID-

19) Updated February 17, 2021. Available from: https://www.canada.ca/en/public-
health/services/diseases/2019-novel-coronavirus-infection/health-professionals/national-
case-definition.html.
9 Centers for Disease Control and Prevention. (2021). CDC COVID Data Tracker.
Centers for Disease Control and Prevention, Updated May 06, 2020. Available from:
https://covid.cdc.gov/covid-data-tracker/#cases_casesper100k.
10 Eckerle I, Meyer B. SARS-CoV-2 seroprevalence in COVID-19 hotspots. Lancet.

2020;396(10250):514-15.
11 Centers for Disease Control and Prevention. (2020). CDC COVID Data Tracker:
Commercial Laboratory Seroprevalence Survey Data. Centers for Disease Control and
Prevention. Available from: https://covid.cdc.gov/covid-data-
tracker/?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-
ncov%2Fcases-updates%2Fcommercial-labs-interactive-serology-
dashboard.html#serology-surveillance.
12 Canadian Blood Services. COVID-19 Seroprevalence Report – August 19, 2020.
CONFIDENTIAL
Page 22
AR02873
13 COVID-19 Immunity Task Force. COVID-19 Seroprevalence Report, Report #6:

January 2021 Survey. 2021
14 Berry I, Soucy JR, Tuite A, et al. Open access epidemiologic data and an interactive
dashboard to monitor the COVID-19 outbreak in Canada. CMAJ. 2020;192(15):E420.
15 Public Health Ontario. Ontario COVID-19 Data Tool. Accessed May 08, 2021.
Available at https://www.publichealthontario.ca/en/data-and-analysis/infectious-
disease/covid-19-data-surveillance/covid-19-data-tool?tab=ageSex
16 Centers for Disease Control and Prevention. (2020). Older adults: At greater risk of
requiring hospitalization or dying if diagnosed with COVID-19. Centers for Disease
Control and Prevention, Updated April 16, 2021. Available from:
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/older-adults.html.
17 Statistics Canada. (2020). Table 17-10-0005-01 Population estimates on July 1st, by age
and sex. 2020. . Available from: https://doi.org/10.25318/1710000501-eng.
18 Leidman E, Duca LM, Omura JD, et al. COVID-19 Trends Among Persons Aged 0-24
Years - United States, March 1-December 12, 2020. MMWR Morb Mortal Wkly Rep.
2021;70(3):88-94.
19 Kim L, Whitaker M, O'Halloran A, et al. Hospitalization Rates and Characteristics of

Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 -
COVID-NET, 14 States, March 1-July 25, 2020. MMWR Morb Mortal Wkly Rep.
2020;69(32):1081-88.
20 Centers for Disease Control and Prevention. (2020). Multisystem Inflammatory

Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-
19). Centers for Disease Control and Prevention, Updated May 14, 2020. Available
from: https://emergency.cdc.gov/han/2020/han00432.asp.
21 Gold JAW, Rossen LM, Ahmad FB, et al. Race, Ethnicity, and Age Trends in Persons
Who Died from COVID-19 - United States, May-August 2020. MMWR Morb Mortal
Wkly Rep. 2020;69(42):1517-21.
22 Rossen LM, Branum AM, Ahmad FB, et al. Excess Deaths Associated with COVID-19,
by Age and Race and Ethnicity - United States, January 26-October 3, 2020. MMWR
Morb Mortal Wkly Rep. 2020;69(42):1522-27.
23 Canadian Institute for Health Information (CIHI). (June 2020). Pandemic Experience in
the Long-Term Care Sector: How Does Canada Compare With Other Countries? CIHI,
Ottawa. Available from: https://www.cihi.ca/sites/default/files/document/covid-19-
rapid-response-long-term-care-snapshot-en.pdf.
CONFIDENTIAL
Page 23
AR02874
24 Canadian Institute for Health Information. The Impact of COVID-19 on Long-Term

Care in Canada: Focus on the First 6 Months. 2021. Available from:
https://www.cihi.ca/sites/default/files/document/impact-covid-19-long-term-care-
canada-first-6-months-report-en.pdf.
25 Tracking SARS-CoV-2 variants (who.int)
26 Grint DJ, Wing K, Williamson E, et al. Case fatality risk of the SARS-CoV-2 variant of
concern B.1.1.7 in England, 16 November to 5 February. Euro Surveill. 2021;26(11).
27 BC Center for Disease Control. (2021). BC COVID-19 Data. Provincial Health

Services Authority. Available from: http://www.bccdc.ca/health-info/diseases-
conditions/covid-19/data.
28 COVID-19 daily epidemiology update - Canada.ca
29 BC Center for Disease Control. (2021). BC COVID-19 Data. Provincial Health

Services Authority. Available from: http://www.bccdc.ca/health-info/diseases-
conditions/covid-19/data.
CONFIDENTIAL
Page 24
AR02875
This is Exhibit “E” referred to in the


AR02876
ModernaTX, Inc. Module 1.3.8.2
mRNA-1273 Risk Management Plan – Canadian Addendum
Risk Management Plan for mRNA-1273

Canadian Addendum
Core RMP (EU RMP) Version number: 2.2

Core RMP (EU RMP) Data lock point: 31 May 2021
Core RMP (EU RMP) Date of final sign off: 15 July 2021
Pharmacovigilance Name: Walter Straus, VP, Clinical Safety Lead – mRNA-1273,

ModernaTX, Inc.
Pharmacovigilance Signature:
See esignature and date signed on last page of document
Confidential Page 1 of 14
AR02877
1 INTRODUCTION
This Canadian regional appendix is provided as a supplementary Annex to the European risk
management plan (RMP).
AR02878
2 THE EPIDEMIOLOGY OF THE COVID-19 DISEASE IN CANADA
As of 27 June 2021, the total number of confirmed COVID-19 cases in Canada is 1,413,203 (1).
The total number of deaths in Canada is 26,227, (1).
As of 22 June 2021, the Indigenous Services Canada (ISC) reported that on First Nations
reserves, there are a total of 31,639 confirmed positive COVID-19 cases, 673 active cases;
30,610 recovered cases and 356 deaths (2).
1. Government of Canada. 2021. COVID-19 epidemiological and economic research data.
Available at: https://www.canada.ca/en/public-health/services/diseases/2019-novel-
coronavirus-infection.html#a1
2. Government of Canada. 2021. Epidemiological summary of COVID-19 cases in First

Nations communities. Available at: https://www.sac-
isc.gc.ca/eng/1589895506010/1589895527965 and at
https://www.canada.ca/en/indigenous-services-canada/news/2021/06/government-of-
canada-covid-19-update-for-indigenous-peoples-and-communities-week-of-june-21.html
AR02879
3 PRODUCT MONOGRAPH
Please refer to current COVID-19 Vaccine Moderna Product Monograph.
AR02880
4 ANY SPECIAL CONSIDERATIONS TO GENETIC OR EXTRINSIC FACTORS

SPECIFIC TO THE CANADIAN POPULATION
ModernaTx Inc. does not anticipate any specific genetic or extrinsic factors that are different in
the Canadian population when compared to populations in other countries worldwide.

Henoch-Schonleln Purpura: HTTQSJL

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Henoch-Schonleln Purpura: HTTQSJL

Uploaded by

Copyright:

Available Formats

AR01431

3. Humoral response induced by Prime-Boost vaccination with ChAdOx1 nCoV-19 and

1. A rare case of Henoch-Sch0nlein purpura after a case report of COVID-19 vaccine:

Cutaneous Adverse Effects

1. A case series of skin reactions to COVID-19 vaccine in the Department of

Coagulopathles (Includes term: Prothrombotic)

Is often broadly defined as any derangement of hemostasis resulting in either excessive

1. Coagulopathies after SARS-CoV-2 vaccination may derive from a combined effect of

Multlsystem Inflammatory Syndrome (includes terrri: Autoantibody Release)

1. Post-vaccination multisystem inflammatory syndrome in adults without evidence of

1. Vogt-Koyanagi-Harada syndrome after COVID-19 and ChAdOx1 nCoV-19

Capillary l,.eak Syndrome (Includes Term: Systemic Capillary Extravasation

Systemic Lupus Erythematosus

1. Induction and exacerbation of subacute cutaneous lupus erythematosus

IPetechl~a (also includes: Petechial rash)

Purpura Annularls Telanglectodes

An uncommon pigmented purpuric eruption, which is characterized by symmetrical,

1. Pulmonary embolism, transient ischemic attack, and thrombocytopenia after Johnson

MIiier Fisher Syndrome

1. Miller Fisher syndrome after Pfizer COVID-19 vaccine: h11l2§iL

2. Miller Fisher syndrome after 2019 BNT162b2 mRNAcoronavirus vaccination:~

1. Nephrotic syndrome after ChAdOx1 nCoV-19 vaccine against SARScoV-2: b1tR§;Lt:

1. Hematuria, a generalized petechlal rash and headaches after Oxford AstraZeneca

2. A case of outbreak of macroscopic hematuria and lgA nephropathy after SARS-

Bullolls Drug Eruption

An aggressive and life-threatening syndrome of excessive immune activation. It most

1. Hemophagocytic lymphohistiocytosis after vaccination with ChAdOx1 nCov-19:

1. Beware of neuromyelitis optica spectrum disorder after vaccination with inactivated

2. Neuromyelitis optica in a healthy woman after vaccination against severe acute

Shingles (Includes term: Herpes zoster)

a reactivation of the chickenpox virus in the body, causing a painful rash.

1. Antiphospholipid antibodies and risk ofthrombophilia after COVID-19 vaccination:

A rare, life-threatening thrombotic microangiopathy caused by severe ADAMTS13 (a

1. First report of a de novo iTTP episode associated with a COVID-19 mRNA-based

Refractory Status Epilepticus

1. New-onset refractory status epilepticus after chadox1 ncov-19 vaccination: https://

Central Serous Retlnopathy

1. Acute-onset central serous retinopathy after Immunization with COVJD-19 mRNA

1. Late cutaneous reactions after administration of COVID-19 mRNA vaccines: ~

1. COVID-19 RNA-based vaccines and the risk of prion disease:~

See below studies.

See below studies.

1. Process-related impurities in the ChAdOx1 nCov-19 vaccine: https://

1. COVID-19 mRNA vaccine causing CNS inflammation: a case series: https:Jf

1. A systematic review of cases of CNS demyelination following COVID-19 vaccination:

Brain Haemorrhage (Includes Term: Lobar Hemorrhage)

1. Fatal brain haemorrhage after COVID-19 vaccine: https://pubroed.ocbi.olm nib gay/

Varlcella Zoster Virus

-Nerve And Muscle Adverse Events

Many different possible neurologic adverse events including encephalitis, myelopathy,

Defines the decreased strength of a muscle, which produces a reduced rotational

1. Transient oculomotor paralysis after administration of RNA-1273 messenger vaccine

Acute Macular Neuroretlnopathy

A rare, acquired retinal disorder characterised by transient or permanent visual impairment

1. Bilateral acute macular neuroretinopathy after SARS-CoV-2 vaccination: https:J/

Lipschutz ulcers (Vaginal ulcers)

1. Lipsch0tz ulcers after AstraZeneca COVID-19 vaccination: .b.tlpsJl

A disorder characterized by episodes of severe pain and muscle wasting (amyotrophy) in

1. Three cases of subacute thyroiditis after SARS-CoV-2 vaccination: post-vaccination

Keratolysls (also termed: corneal melting)

1. Bilateral immune-mediated keratolysls after immunization with SARS-CoV-2

A condition in which the thymus gland is inflamed. It isoften accompanied by autoimmune

1. Thymic hyperplasia after Covid-19 mRNA-based vaccination with Covid-19: ~

I:::::~:: papera. ___